Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.

Overview for Request: cder_mpl2p_wp057

Request ID: cder_mpl2p_wp057

Request Description: In this report we described individuals with evidence of diabetes, or diabetes and obesity, who were dispensed glucagon-like peptide-1 receptor agonists (GLP-1 RA), sodium-glucose cotransporter-2 inhibitors (SGLT-2i), or dipeptidyl peptidase-4 inhibitors (DPP-4i), and evaluated the association between these products and intentional self-harm in the Sentinel Distributed Database (SDD).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 13.0.1, with Propensity Score Analysis module and custom programming.

Data Source: We distributed this package to 10 Data Partners on May 1, 2024. These 10 Data Partners are a subset of the SDD. Data from Medicare patients having both fee-for-service medical coverage and Part D drug coverage are included. The study period included data from October 1, 2015 through September 30, 2023.

Please see Appendix A for a list of dates of available data for each Data Partner.

Study Design: We identified individuals with incident use of GLP-1 RA (exposure), SGLT-2i (comparator), or DPP-4i (comparator) and evaluated the occurrence of intentional self-harm during exposure episodes, among a cohort who were at least 18 years of age and had evidence of diabetes prior to the index date. We then conducted a Propensity Score Analysis (PSA) comparing the GLP-1 RA users to either SGLT-2i users or DPP-4i users using inverse probability of treatment weighting (IPTW) to adjust for confounding. We evaluated the occurrence of intentional self-harm[i] during exposure episodes among these cohorts and estimated hazard ratios and 95% confidence intervals of the risk of intentional self-harm in patients dispensed GLP-1 RAs compared to patients dispensed SGLT-2is or DPP-4is. We conducted subgroup analyses that divided the cohorts into patients with and without a history of (1) psychiatric diagnoses or treatments, and (2) self-harm. This study used a retrospective active comparator new-user cohort design. This is a Type 2 analysis using the Propensity Score Analysis module in the Query Request Package (QRP) documentation.

Exposures of Interest: We defined the exposure of interest, GLP-1 RA, and the comparators of interest, SGLT-2i or DPP-4i, using National Drug Codes (NDCs). Only the first qualifying dispensing of GLP-1 RA, SGLT-2i or DPP-4i (index dispensing) in any care setting was included; cohort re-entry was not allowed. We defined new use of these products as the first observed dispensing with no prior use of GLP-1 RA, SLGT-2i or DPP-4i in the 183 days prior to the index date. Please see Appendix BA for a list of medical products used to define exposures and comparators and Appendix BB for a list of medical products used to define exposure incidence criteria.

Outcome of Interest: We defined the outcome of interest as intentional self-harm[i] using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes. Please see Appendix BC for a list of the diagnosis codes used to define the outcomes.

Cohort Eligibility Criteria: We required patients included in the cohorts to be enrolled in health plans with both medical and drug coverage for at least 183 days prior to the index exposure, during which gaps in coverage of up to 45 days were allowed and treated as continuous enrollment. The following age groups were included in the cohort: 18-24, 25-44, 45-64, 65-79, and ≥80 years. We required evidence of type 2 diabetes, defined as at least one diagnosis code in any care setting and one dispensing for an oral antidiabetic agent, in the 183 days prior to and including the index date. We excluded episodes with evidence of other diabetes (i.e., type 1, gestational, or secondary diabetes) or pregnancy. We additionally excluded index episodes with both the exposure and comparator dispensed on the same day. Inclusion and exclusion criteria were defined using ICD-10-CM codes and NDCs. Please see Appendix BD for a list of generic and brand names of medical products used to define inclusion criteria. Please see Appendix BE for a list of diagnosis codes used to define inclusion criteria.

Overview for Request: cder_mpl2p_wp057

Follow-up: We determined follow-up time based on the length of the exposure episodes. Specifically, we created exposure episodes using number of days of product supplied per dispensing in outpatient pharmacy dispensing data. We bridged together exposure episodes less than 30 days apart and added 30 days at the end of each exposure episode to create continuous treatment episodes. Follow-up began on the day after exposure initiation and continued until the first occurrence of any of the following: outcome occurrence, death, Data Partner end date, disenrollment, hospitalization, initiation of the other comparator (e.g., initiation of DPP-4i for the GLP-1 RA versus SGLT-2i comparison analysis), and initiation of the other product in the comparison (i.e., initiation of SGLT-2i in the GLP-1 RA cohort). Censoring criteria were defined using NDCs and ICD-10-CM codes.

Baseline Characteristics: We assessed the following demographic characteristics on the index date: age, sex, race, ethnicity, and calendar year of index date. We assessed the following medical characteristics in the 183 days prior to and including the index date: combined comorbidity score [ii], [iii], Adapted Diabetes Complications Severity Index[iv], psychiatric drug dispensings, other psychiatric event (i.e., ADHD [Attention-deficit/hyperactivity disorder], Akathisia, Anxiety, Behavioral Disorder, Bipolar Disorder, Cerebral degenerations usually manifested in childhood, Conduct Disorder, Delirium, Depression, Electroconvulsive Therapy, Hallucination, Obsessive-Compulsive Disorder, Other Cerebral degenerations, Other mental disorders, Other Psychological Disorders, Persistent mental disorders due to conditions classified elsewhere, Personality disorders, Pervasive developmental disorders, Post-traumatic stress disorder, Psychotherapy, Psychotic Conditions, Schizophrenia, Sleep disorder, Substance abuse, Suicidal behavior, Transcranial magnetic stimulation, and Vagus nerve stimulation), Obesity diagnosis, Cardiovascular Disease, Cognitive impairment (i.e., Alzheimer's Disease and Related Disorders, Senile Dementia), Traumatic brain injury (i.e., Traumatic brain injury and nonpsychotic disorders due to brain damage), Migraine, Epilepsy, Chronic Pain, Anti-diabetic agents (i.e., Insulin, Metformin, Alpha-Glucosidase Inhibitors, Thiazolidinediones, Meglitinides [Nateglinide, Repaglinide], Amylin analogue [Pramlintide], Sulfonylureas, Bile acid sequestrants [Colesevelam]), Other weight loss agents (i.e., Benzphetamine, Combination naltrexone and bupropion, Diethylpropion, Lorcaserin, Phentermine, Phentermine-Topiramate, Phendimetrazine, Orlistat, Setmelanotide), and Other agents (i.e., Analgesic opiates, Antipsychotics, Anxiolytics/hypnotics, Lithium and other mood stabilizers, Antidepressants).

We assessed the following healthcare utilization metrics in the 183 days prior to and including the index date: number of ambulatory encounters, number of inpatient encounters, number of non-acute institutional stays, number of emergency department visits, number of dispensings, number of unique generic names dispensed, and number of unique class names dispensed.

We assessed the following characteristics in the 183 days prior to and excluding the index date: weight reduction surgeries and procedures, and lifestyle interventions.

Finally, we assessed prior self-harm in any care setting at any point in the patient's history.
Please see Appendix BF for a list of ICD-9-CM and ICD-10-CM diagnosis and procedure codes used to define baseline covariates.
Please see Appendix BG for a list of generic and brand names used to define baseline covariates.

Sensitivity Analyses: We conducted four sensitivity analyses: (1) defining the self-harm outcome as diagnosis codes recorded only in the inpatient (IP) or emergency department (ED) setting, (2) limiting the allowable episode gap and extension to 15 days, (3) requiring two or more dispensings of the study drug, and (4) evaluating a cohort with evidence of both diabetes diagnoses and obesity diagnoses.

Propensity Score Estimation: We fit a logistic regression model to estimate the propensity score (PS) based on the potential confounders outlined in Appendix CA. After PS estimation and exclusion (i.e., trimming) of patients in non-overlapping regions of the PS distributions, the PS was used to create an average treatment effect in the treated (ATT) weight for each patient.

Overview for Request: cder_mpl2p_wp057

We applied three weight truncation percentile thresholds to deal with potential extreme inverse probability of treatment weights: 0% (no truncation), 1.0%, and 2.5%. Truncation was operationalized symmetrically, in that weights smaller than the weight at the specified percentile of the weight distribution were re-assigned the value of the weight at the specified percentile of the weight distribution, while weights larger than the weight at the 100- specified percentile of the weight distribution were re-assigned the value of the weight at the 100- specified percentile of the weight distribution.

Subgroup analyses for effect estimation included (1) history of psychiatric diagnoses and treatments and (2) prior self-harm. Subgroups were formed out of the post-trimming overall population to ensure only those patients contributing to the overall analysis contributed to a subgroup analysis.

See Appendices CA and CB for the specifications of parameters used in the analyses for this request.

See Appendix CC for a diagram detailing the design of this request.

Limitations: As with all observational studies, this evaluation was limited in its ability to control for all sources of potential bias. Algorithms used to define exposures, outcomes, inclusion and exclusion criteria, and covariates are imperfect and may be misclassified. Therefore, data should be interpreted with this limitation in mind.

Notes:

Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (https://dev.sentinelsystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse).

[i] Hedegaard H, Schoenbaum M, Claassen C, Crosby A, Holland K, Proescholdbell S. Issues in Developing a Surveillance Case Definition for Nonfatal Suicide Attempt and Intentional Self-harm Using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Coded Data. Natl Health Stat Report. 2018;(108):1-19.

[ii] Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759

[iii] Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

[iv] Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

Sentinel

Table of Contents

Glossary (CIDA)	List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report
Glossary (PSA)	List of Terms to Define the Propensity Score Analysis (PSA) Found in this Report
Table 1a	Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1b	Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1c	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1d	Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Table 1e	Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Table 1f	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Table 1g	Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Table 1h	Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Table 1i	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Table 1j	Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Table 1k	Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Table 1l	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Table 1m	Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Table 1n	Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Table 1o	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

Table 1p	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1q	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Table 1r	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Table 1s	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Table 1t	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Table 1u	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1v	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Table 1w	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Table 1x	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Table 1y	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Table 1z	Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1aa	Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1ab	Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1ac	Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

Table 1ad	Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Table 1ae	Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Table 1af	Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Table 1ag	Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Table 1ah	Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Table 1ai	Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Table 1aj	Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Table 1ak	Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Table 1al	Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Table 1am	Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Table 1an	Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Table 1ao	Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1ap	Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Table 1aq	Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter

Table 1ar	Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Table 1as	Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Table 1at	Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1au	Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Table 1av	Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Table 1aw	Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Table 1ax	Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Table 1ay	Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use (observing for event in IP/ED setting) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1az	Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1ba	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1bb	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1bc	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1bd	Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use (15-day Gap & Ext) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1be	Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Table of Contents

Table 1bf	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1bg	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1bh	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1bi	Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use - Two or more dispensings in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1bj	Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1bk	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1bl	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1bm	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1bn	Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use for diabetes or obesity in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1bo	Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1bp	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1bq	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 1br	Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%), in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Table 2	Effect Estimates for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type
Table 3	Effect Estimates for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type
Table 4	Effect Estimates for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type
Table 5	Effect Estimates for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type

Table of Contents

Table 6	Effect Estimates for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type
Table 7	Effect Estimates for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type
Table 8	Effect Estimates for GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type
Table 9	Effect Estimates for GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type
Table 10	Effect Estimates for GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type
Table 11	Effect Estimates for GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type
Table 12	Effect Estimates for GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type
Table 13	Effect Estimates for GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type
Table 14	Effect Estimates for GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type
Table 15	Effect Estimates for GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type
Table 16	Effect Estimates for GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type
Table 17	Effect Estimates for GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type
Table 18	Effect Estimates for GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type
Table 19	Effect Estimates for GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type
Table 20	Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 1a	Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 1b	Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 1c	Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 1d	Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 1e	Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 2a	Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 2b	Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

Figure 2c Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 2d Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 2e Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 3a Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 3b Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 3c Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 3d Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 3e Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 4a Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 4b Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 4c Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 4d Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 4e Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 5a Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 5b Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 5c Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 5d Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i
Figure 5e Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i
Figure 6a Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i
Figure 6b Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i
Figure 6c Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i
Figure 6d Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i
Figure 6e Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i
Figure 7 Users (observing for event in IP/ED setting), 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2I
Figure 8 Users (observing for event in IP/ED setting), 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2I
Figure 9 Users (observing for event in IP/ED setting), 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i
Figure 10 Users, 15-day Gap & Ext, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i
Figure 11 Users, 15-day Gap & Ext, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i
Figure 12 Users, 15-day Gap & Ext, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i
Figure 13 Users with Two or More Dispensings, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i
Figure 14 Users with Two or More Dispensings, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i
Figure 15 Users with Two or More Dispensings, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i
Figure 16 Users with Diabetes and Obesity, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Figure 17	Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 18	Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 19a	Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Site-Adjusted Analyses in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 19b	Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Inverse Probability of Treatment Weighted Analyses in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 20a	Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 20b	Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 20c	Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 20d	Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 20e	Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 20f	Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 20g	Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 20h	Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 20i	Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 20j	Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 20k	Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 20l	Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 20m	Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter

Figure 20n Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 20o Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 20p Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 20q Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 20r Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 20s Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 20t Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 20u Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 20v Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 20w Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 20x Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 20y Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 20z Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 20aa Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 20ab Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 20ac Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest
Figure 20ad Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not
Figure 21a Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring
Figure 21b Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest
Figure 21c Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring
Figure 21d Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring
Figure 21e Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest
Figure 21f Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not
Figure 21g Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring
Figure 21h Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest
Figure 21i Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring
Figure 21j Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring
Figure 21k Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest
Figure 21l Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not
Figure 21m Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring
Figure 21n Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest
Figure 21o Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter

Figure 21p Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 21q Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 21r Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 21s Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 21t Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 21u Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 21v Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 21w Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 21x Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 21y Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 21z Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 21aa Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 21ab Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 21ac Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 21ad Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 22a Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Figure 22b Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 22c Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 22d Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 22e Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 22f Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 22g Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 22h Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 22i Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 22j Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 22k Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 22l Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 22m Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 22n Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 22o Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 22p Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 22q Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter

Figure 22r Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 22s Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 22t Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 22u Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 22v Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 22w Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 22x Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 22y Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 22z Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 22aa Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 22ab Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 22ac Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 22ad Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 23a Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 23b Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 23c Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Figure 23d Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 23e Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 23f Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 23g Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 23h Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 23i Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 23j Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 23k Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 23l Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 23m Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 23n Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 23o Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 23p Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 23q Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 23r Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 23s Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

Figure 23t Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 23u Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 23v Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 23w Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 23x Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 23y Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 23z Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 23aa Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 23ab Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 23ac Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 23ad Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 24a Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 24b Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 24c Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 24d Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 24e Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest
Figure 24f Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not
Figure 24g Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring
Figure 24h Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest
Figure 24i Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring
Figure 24j Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring
Figure 24k Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest
Figure 24l Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not
Figure 24m Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring
Figure 24n Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest
Figure 24o Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring
Figure 24p Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring
Figure 24q Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest
Figure 24r Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not
Figure 24s Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring
Figure 24t Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest
Figure 24u Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

Figure 24v Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 24w Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 24x Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 24y Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 24z Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 24aa Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 24ab Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 24ac Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 24ad Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 25a Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 25b Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 25c Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 25d Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 25e Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 25f Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 25g Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

Figure 25h Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 25i Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 25j Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 25k Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 25l Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter
Figure 25m Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 25n Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 25o Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 25p Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 25q Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 25r Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter
Figure 25s Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 25t Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 25u Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 25v Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 25w Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

Figure 25x	Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History
Figure 25y	Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 25z	Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 25aa	Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 25ab	Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 25ac	Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 25ad	Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History
Figure 26a	Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 26b	Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 26c	Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 26d	Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation (observing for event in IP/ED setting) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 26e	Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation (observing for event in IP/ED setting) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 26f	Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation (observing for event in IP/ED setting) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 27a	Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 27b	Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 27c	Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Figure 27d	Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation (observing for event in IP/ED setting) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 27e	Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation (observing for event in IP/ED setting) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 27f	Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation (observing for event in IP/ED setting) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 28a	Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 28b	Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 28c	Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 28d	Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation (observing for event in IP/ED setting) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 28e	Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation (observing for event in IP/ED setting) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 28f	Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation (observing for event in IP/ED setting) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 29a	Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 29b	Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 29c	Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 29d	Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 29e	Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 29f	Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Figure 30a Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 30b Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 30c Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 30d Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 30e Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 30f Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 31a Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 31b Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 31c Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 31d Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 31e Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 31f Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 32a Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 32b Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 32c Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 32d Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Figure 32e Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 32f Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 33a Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 33b Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 33c Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 33d Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 33e Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 33f Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 34a Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 34b Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 34c Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 34d Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 34e Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 34f Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 35a Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Figure 35b Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest
Figure 35c Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring
Figure 35d Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring
Figure 35e Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest
Figure 35f Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not
Figure 36a Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring
Figure 36b Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest
Figure 36c Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring
Figure 36d Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring
Figure 36e Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest
Figure 36f Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not
Figure 37a Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring
Figure 37b Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest
Figure 37c Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring
Figure 37d Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring
Figure 37e Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest
Figure 37f Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023
Appendix A Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (April 30, 2024)

Appendix B	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)
Appendix C	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Intentional Self-Harm Encounter, Weight: Average Treatment Effect, Stabilized (ATES)
Appendix D	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Psychiatric History, Weight: Average Treatment Effect, Stabilized (ATES)
Appendix E	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)
Appendix F	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Intentional Self-Harm Encounter, Weight: Average Treatment Effect, Stabilized (ATES)
Appendix G	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Psychiatric History, Weight: Average Treatment Effect, Stabilized (ATES)
Appendix H	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)
Appendix I	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Intentional Self-Harm Encounter, Weight: Average Treatment Effect, Stabilized (ATES)
Appendix J	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Psychiatric History, Weight: Average Treatment Effect, Stabilized (ATES)
Appendix K	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)
Appendix L	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Intentional Self-Harm Encounter, Weight: Average Treatment Effect, Stabilized (ATES)
Appendix M	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Psychiatric History, Weight: Average Treatment Effect, Stabilized (ATES)
Appendix N	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)
Appendix O	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Intentional Self-Harm Encounter, Weight: Average Treatment Effect, Stabilized (ATES)

Appendix P	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Psychiatric History, Weight: Average Treatment Effect, Stabilized (ATES)
Appendix Q	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)
Appendix R	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Intentional Self-Harm Encounter, Weight: Average Treatment Effect, Stabilized (ATES)
Appendix S	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Psychiatric History, Weight: Average Treatment Effect, Stabilized (ATES)
Appendix T	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)
Appendix U	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)
Appendix V	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)
Appendix W	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)
Appendix X	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)
Appendix Y	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)
Appendix Z	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)
Appendix AA	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)
Appendix AB	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)
Appendix AC	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)
Appendix AD	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Appendix AE	Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)
Appendix BA	List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Exposures and Comparators in this Request
Appendix BB	List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Exposure Incidence Criteria in this Request
Appendix BC	List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request
Appendix BD	List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Inclusion Criteria in this Request
Appendix BE	List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Inclusion Criteria in this Request
Appendix BF	List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Inclusion Criteria in this Request
Appendix BG	List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request
Appendix CA	Specifications Defining Parameters for Covariates for this Request
Appendix CB	Specifications Defining Parameters for this Request
Appendix CC	Design Diagrams for this Request

Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.
Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.
Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

- **Ambulatory Visit (AV) -** includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.
- **Emergency Department (ED) -** includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.
- **Inpatient Hospital Stay (IP) -** includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.
- **Non-Acute Institutional Stay (IS) -** includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.
- **Other Ambulatory Visit (OA) -** includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).
Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.
Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.
Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.
Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.
Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.
Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.
Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.
Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.
Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).
Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."
Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.
Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module*

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.
Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.
Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.
Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.
Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.
Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.
Query Period - period in which the modular program looks for exposures and outcomes of interest.
Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).
Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.
Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.
Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.
Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.
Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.
Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Glossary of Terms for Analyses Using Propensity Score Analysis (PSA) Module*

Covariate - requester defined binary variable to include in the propensity score estimation model (e.g., diabetes, heart failure, etc.) during requester-defined lookback period. Requester may also choose to add any of the following categorical, continuous, or count metrics to the propensity score estimation model:

1. Age (continuous)
2. Sex
3. Time period (i.e., monitoring period for sequential analyses)
4. Year of exposure
5. Comorbidity score
6. Medical utilization – number of inpatient stays
7. Medical utilization – number of institutional stays
8. Medical utilization – number of emergency department visits
9. Medical utilization – number of outpatient visits
10. Health care utilization – number of other ambulatory encounters (e.g., telemedicine, email consults)
11. Drug utilization – number of dispensings
12. Drug utilization – number of unique generics dispensed
13. Drug Utilization – number of unique drug classes dispensed

Covariate Evaluation Window - specified number of days relative to index date to evaluate the occurrence of covariates of interest. Note: members are required to have continuous enrollment during the covariate evaluation window, regardless of the value included in the "Continuous enrollment before exposure" field.

Individual Level Data Return - program may return individual-level, de-identified datasets to the Sentinel Operations Center (SOC). While the datasets contain a single row per patient for each specified analysis, patient identifiers such as a patient ID are not included in the output. Individual-level datasets are returned to the SOC, aggregated, and used to calculate effect estimates via Cox (proportional hazards) regression.

Mahalanobis Distance - provides a measure of balance across all variables while accounting for their correlation.

Matching Caliper - maximum allowed difference in propensity scores between treatment and control patients. Requester may select any caliper (e.g., 0.01, 0.025, and 0.05).

Matching Ratio - patients in exposed and comparator groups are nearest neighbor matched by a 1:1 or 1:n (up to 10) matching ratio.

Matched Conditional and Unconditional Analysis - in a conditional matched analysis, a Cox model, stratified by Data Partner site and matched set, is run on the matched population. This can be done for both the both 1:1 and 1:n matched cohorts. In an unconditional analysis, a Cox model, stratified by Data Partner site only, is run on the matched population. This can be done for the 1:1 matched cohort only.

Propensity Score Stratification - option to stratify propensity scores based on requester-defined percentiles in the unmatched population. In a stratified analysis, a Cox model, stratified by Data Partner site, is run on the stratified population. Note that all patients identified in exposure and comparator cohorts are used in the analysis.

PSM Tool - performs effect estimation by comparing exposure propensity-score matched parallel new user cohorts. Propensity score estimation and matching are conducted within each Sentinel Data Partner site via distributed programming code; data are returned to the SOC, aggregated, and used to calculate effect estimates.

Risk-set Level Data Return - alternative to the patient-level data return approach. In this approach, the PSM tool will produce de-identified, risk-set level datasets instead of or in addition to individual-level output. Whereas each observation in the patient-level datasets represents one patient in the cohort, each observation in the risk set dataset represents one event. Risk sets are created at the Data Partner site, returned to the SOC, aggregated, and used to calculate effect estimates via case-centered logistic regression.

Glossary of Terms for Analyses Using Propensity Score Analysis (PSA) Module*

Subgroup Analysis - may be conducted using any requester-defined covariates. Subgroup analyses may be performed in the unmatched and the matched population.

Zero Cell Correction - indicator for whether to screen variables with a zero correction added to each cell in the confounder/outcome 2x2 table. Recommended when the number of exposed outcomes is fewer than 150.

*all terms may not be used in this report

Table 1a. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	1,161,983	100.0%	1,081,155	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)*	60.7	10.5	63.7	10.2	-2.982	-0.288
Age						
18-24 years	6,141	0.5%	3,035	0.3%	0.248	0.039
25-44 years	142,618	12.3%	91,666	8.5%	3.795	0.125
45-64 years	493,305	42.5%	413,197	38.2%	4.236	0.086
65-79 years	475,370	40.9%	489,936	45.3%	-4.406	-0.089
≥ 80 years	44,549	3.8%	83,321	7.7%	-3.873	-0.167
Sex*						
Female	644,363	55.5%	470,606	43.5%	11.926	0.240
Male	517,620	44.5%	610,549	56.5%	-11.926	-0.240
Race[3]						
American Indian or Alaska Native	8,500	0.7%	5,936	0.5%	0.182	0.023
Asian	17,106	1.5%	38,594	3.6%	-2.098	-0.134
Black or African American	111,975	9.6%	100,886	9.3%	0.305	0.010
Multi-racial	6,192	0.5%	4,975	0.5%	0.073	0.010
Native Hawaiian or Other Pacific Islander	3,110	0.3%	3,770	0.3%	-0.081	-0.015
Unknown	422,235	36.3%	379,516	35.1%	1.235	0.026
White	592,865	51.0%	547,478	50.6%	0.384	0.008
Hispanic origin						
Yes	52,636	4.5%	64,463	6.0%	-1.433	-0.064
No	666,334	57.3%	633,138	58.6%	-1.217	-0.025

Table 1a. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Unknown	443,013	38.1%	383,554	35.5%	2.649	0.055
Year*						
2015	17,382	1.5%	18,309	1.7%	-0.198	-0.016
2016	84,174	7.2%	82,663	7.6%	-0.402	-0.015
2017	102,383	8.8%	101,826	9.4%	-0.607	-0.021
2018	121,376	10.4%	98,359	9.1%	1.348	0.045
2019	149,390	12.9%	137,437	12.7%	0.144	0.004
2020	162,653	14.0%	165,423	15.3%	-1.303	-0.037
2021	160,771	13.8%	166,903	15.4%	-1.602	-0.045
2022	197,489	17.0%	193,944	17.9%	-0.943	-0.025
2023	166,365	14.3%	116,291	10.8%	3.561	0.108
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,4	1.3	1.6	1.5	1.7	-0.154	-0.093
Combined comorbidity score*,5	1.6	2.1	1.8	2.4	-0.206	-0.091
Medical History						
Obesity*	549,121	47.3%	368,394	34.1%	13.183	0.271
Weight Reduction Surgery or Procedure*	668	0.1%	600	0.1%	0.002	0.001
Lifestyle intervention*	214,163	18.4%	174,914	16.2%	2.252	0.060
Cardiovascular Disease*	202,977	17.5%	246,331	22.8%	-5.316	-0.133
Cognitive Impairment*	20,942	1.8%	24,994	2.3%	-0.510	-0.036
Traumatic Brain Injury*	2,474	0.2%	1,860	0.2%	0.041	0.009
Migraine*	44,884	3.9%	28,961	2.7%	1.184	0.067
Epilepsy*	13,428	1.2%	12,015	1.1%	0.044	0.004
Chronic Pain*	243,648	21.0%	184,918	17.1%	3.865	0.099
Psychiatric History						

Table 1a. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Previous Intentional Self-Harm Ever	8,674	0.7%	5,586	0.5%	0.230	0.029
Psychiatric History Overall*	723,879	62.3%	577,496	53.4%	8.882	0.181
Psychiatric Drug Dispensings	540,526	46.5%	401,701	37.2%	9.363	0.191
Intentional Self-Harm Encounter	1,071	0.1%	751	0.1%	0.023	0.008
Any Other Psychiatric Event	587,725	50.6%	465,848	43.1%	7.491	0.151
Attention-Deficit/Hyperactivity Disorder	13,753	1.2%	6,983	0.6%	0.538	0.057
Akathisia	1,096	0.1%	779	0.1%	0.022	0.008
Anxiety	194,807	16.8%	138,389	12.8%	3.965	0.112
Behavioral Disorder	45,535	3.9%	32,021	3.0%	0.957	0.053
Bipolar Disorder	45,943	4.0%	29,136	2.7%	1.259	0.070
Cerebral Degenerations usually Manifested in Childhood	9,345	0.8%	10,891	1.0%	-0.203	-0.021
Conduct Disorder	966	0.1%	670	0.1%	0.021	0.008
Delirium	12,693	1.1%	13,600	1.3%	-0.166	-0.015
Depression	211,185	18.2%	145,446	13.5%	4.722	0.130
Electroconvulsive Therapy	187	0.0%	123	0.0%	0.005	0.004
Hallucination	1,946	0.2%	1,752	0.2%	0.005	0.001
Obsessive-Compulsive Disorder	2,210	0.2%	1,423	0.1%	0.059	0.015
Other Cerebral Degenerations	14,231	1.2%	15,774	1.5%	-0.234	-0.020
Other Mental Disorders	8,613	0.7%	7,146	0.7%	0.080	0.010
Other Psychological Disorders	97,766	8.4%	92,164	8.5%	-0.111	-0.004
Persistent Mental Disorders due to Conditions Classified Elsewhere	14,467	1.2%	16,933	1.6%	-0.321	-0.027
Personality Disorders	4,891	0.4%	2,411	0.2%	0.198	0.035
Pervasive Developmental Disorders	1,941	0.2%	1,369	0.1%	0.040	0.011

Table 1a. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Post-Traumatic Stress Disorder	21,929	1.9%	12,164	1.1%	0.762	0.063
Psychotherapy	65,814	5.7%	39,157	3.6%	2.042	0.097
Psychotic Conditions	3,853	0.3%	3,433	0.3%	0.014	0.002
Schizophrenia	18,438	1.6%	15,383	1.4%	0.164	0.013
Sleep Disorder	301,558	26.0%	220,702	20.4%	5.538	0.132
Substance Abuse	48,705	4.2%	43,505	4.0%	0.168	0.008
Suicidal Behavior	5,373	0.5%	4,149	0.4%	0.079	0.012
Transcranial Magnetic Stimulation	248	0.0%	129	0.0%	0.009	0.007
Vagus Nerve Stimulation	948	0.1%	589	0.1%	0.027	0.010
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	8,797	0.8%	0	0.0%	NaN	NaN
dulaglutide	385,520	33.2%	0	0.0%	NaN	NaN
exenatide	85,602	7.4%	0	0.0%	NaN	NaN
liraglutide	237,074	20.4%	0	0.0%	NaN	NaN
lixisenatide	15,881	1.4%	0	0.0%	NaN	NaN
semaglutide	401,755	34.6%	0	0.0%	NaN	NaN
tirzepatide	28,216	2.4%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,161,981	100.0%	1,081,154	100.0%	-0.000	-0.001
insulin*	393,030	33.8%	233,106	21.6%	12.263	0.277
metformin*	1,026,794	88.4%	967,655	89.5%	-1.136	-0.036
alpha-glucosidase inhibitors*	4,652	0.4%	4,420	0.4%	-0.008	-0.001
thiazolidinediones*	95,138	8.2%	88,494	8.2%	0.002	0.000
meglitinides*	12,589	1.1%	11,035	1.0%	0.063	0.006
amylin analogue*	154	0.0%	78	0.0%	0.006	0.006
sulfonylureas*	427,700	36.8%	426,131	39.4%	-2.607	-0.054

Table 1a. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
bile acid sequestrants*	4,319	0.4%	3,629	0.3%	0.036	0.006
Other Weight Loss Agents*	4,010	0.3%	1,229	0.1%	0.231	0.048
benzphetamine	*****	*****	*****	*****	*****	*****
Combination naltrexone and bupropion	421	0.0%	152	0.0%	0.022	0.014
diethylpropion	85	0.0%	27	0.0%	0.005	0.007
lorcaserin	181	0.0%	68	0.0%	0.009	0.009
phentermine	3,086	0.3%	920	0.1%	0.180	0.043
phentermine-topiramate	194	0.0%	46	0.0%	0.012	0.012
phendimetrazine	63	0.0%	16	0.0%	0.004	0.007
orlistat	69	0.0%	25	0.0%	0.004	0.006
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	290,140	25.0%	227,919	21.1%	3.888	0.092
Antipsychotics	77,737	6.7%	55,879	5.2%	1.522	0.064
Anxiolytics/Hypnotics	221,967	19.1%	164,506	15.2%	3.887	0.103
Lithium & Other Mood Stabilizers	67,842	5.8%	47,349	4.4%	1.459	0.066
Antidepressants	445,476	38.3%	312,762	28.9%	9.409	0.200
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	10.9	10.5	10.0	9.5	0.854	0.085
Mean number of emergency room encounters*	0.3	1.0	0.3	1.0	0.010	0.010
Mean number of inpatient hospital encounters*	0.1	0.4	0.1	0.5	-0.038	-0.087
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	-0.005	-0.027

Table 1a. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Mean number of other ambulatory encounters*	3.9	11.5	3.7	10.6	0.145	0.013
Mean number of filled prescriptions*	26.1	19.7	23.7	17.7	2.400	0.128
Mean number of generics dispensed*	10.9	5.1	10.2	4.8	0.700	0.141
Mean number of unique drug classes dispensed*	9.8	4.6	8.5	4.4	1.271	0.283

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1b. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	1,161,916	100.0%	1,080,587	99.9%	N/A	N/A
Demographic Characteristics						
Age (years)*	60.7	10.5	63.7	10.2	-2.980	-0.288
Age						
18-24 years	6,141	0.5%	*****	*****	*****	*****
25-44 years	142,604	12.3%	91,641	8.5%	3.793	0.125
45-64 years	493,263	42.5%	412,964	38.2%	4.236	0.086
65-79 years	475,359	40.9%	489,666	45.3%	-4.403	-0.089
≥ 80 years	44,549	3.8%	*****	*****	*****	*****
Sex*						
Female	*****	*****	470,479	43.5%	*****	*****
Male	*****	*****	610,108	56.5%	*****	*****
Race[3]						
American Indian or Alaska Native	*****	*****	*****	*****	*****	*****
Asian	*****	*****	38,539	3.6%	*****	*****
Black or African American	*****	*****	100,811	9.3%	*****	*****
Multi-racial	*****	*****	*****	*****	*****	*****
Native Hawaiian or Other Pacific Islander	3,110	0.3%	*****	*****	*****	*****
Unknown	422,221	36.3%	379,380	35.1%	1.230	0.026
White	592,825	51.0%	547,192	50.6%	0.383	0.008
Hispanic origin						

Table 1b. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	*****	*****	64,356	6.0%	*****	*****
No	666,310	57.3%	632,774	58.6%	-1.213	-0.025
Unknown	*****	*****	383,457	35.5%	*****	*****
Year*						
2015	17,382	1.5%	*****	*****	*****	*****
2016	*****	*****	*****	*****	*****	*****
2017	*****	*****	*****	*****	*****	*****
2018	*****	*****	*****	*****	*****	*****
2019	*****	*****	*****	*****	*****	*****
2020	*****	*****	165,399	15.3%	*****	*****
2021	160,757	13.8%	166,768	15.4%	-1.598	-0.045
2022	*****	*****	193,559	17.9%	*****	*****
2023	166,352	14.3%	*****	*****	*****	*****
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,4	1.3	1.6	1.5	1.7	-0.154	-0.093
Combined comorbidity score*,5	1.6	2.1	1.8	2.4	-0.206	-0.091
Medical History						
Obesity*	549,063	47.3%	368,314	34.1%	13.170	0.271
Weight Reduction Surgery or Procedure*	668	0.1%	*****	*****	*****	*****
Lifestyle intervention*	214,140	18.4%	174,834	16.2%	2.250	0.060
Cardiovascular Disease*	*****	*****	246,175	22.8%	*****	*****
Cognitive Impairment*	20,942	1.8%	24,982	2.3%	-0.510	-0.036
Traumatic Brain Injury*	2,474	0.2%	*****	*****	*****	*****

Table 1b. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	44,871	3.9%	28,947	2.7%	1.183	0.067
Epilepsy*	*****	*****	12,003	1.1%	*****	*****
Chronic Pain*	243,609	21.0%	184,866	17.1%	3.858	0.098
Psychiatric History						
Previous Intentional Self-Harm Ever	8,674	0.7%	*****	*****	*****	*****
Psychiatric History Overall*	723,816	62.3%	577,274	53.4%	8.873	0.180
Psychiatric Drug Dispensings	540,467	46.5%	401,574	37.2%	9.353	0.190
Intentional Self-Harm Encounter	1,071	0.1%	751	0.1%	0.023	0.008
Any Other Psychiatric Event	587,667	50.6%	465,656	43.1%	7.485	0.150
Attention-Deficit/Hyperactivity Disorder	*****	*****	*****	*****	*****	*****
Akathisia	1,096	0.1%	779	0.1%	0.022	0.008
Anxiety	194,771	16.8%	138,350	12.8%	3.960	0.112
Behavioral Disorder	*****	*****	32,001	3.0%	*****	*****
Bipolar Disorder	45,929	4.0%	*****	*****	*****	*****
Cerebral Degenerations usually Manifested in Childhood	9,345	0.8%	*****	*****	*****	*****
Conduct Disorder	*****	*****	670	0.1%	*****	*****
Delirium	12,693	1.1%	*****	*****	*****	*****
Depression	211,150	18.2%	145,387	13.5%	4.718	0.130
Electroconvulsive Therapy	187	0.0%	123	0.0%	0.005	0.004
Hallucination	1,946	0.2%	*****	*****	*****	*****
Obsessive-Compulsive Disorder	*****	*****	1,423	0.1%	*****	*****
Other Cerebral Degenerations	*****	*****	*****	*****	*****	*****

Table 1b. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Mental Disorders	*****	*****	*****	*****	*****	*****
Other Psychological Disorders	*****	*****	92,123	8.5%	*****	*****
Persistent Mental Disorders due to Conditions Classified Elsewhere	14,467	1.2%	*****	*****	*****	*****
Personality Disorders	*****	*****	*****	*****	*****	*****
Pervasive Developmental Disorders	*****	*****	1,369	0.1%	0.040	0.011
Post-Traumatic Stress Disorder	*****	*****	*****	*****	*****	*****
Psychotherapy	65,792	5.7%	*****	*****	*****	*****
Psychotic Conditions	3,853	0.3%	*****	*****	*****	*****
Schizophrenia	*****	*****	*****	*****	*****	*****
Sleep Disorder	301,515	25.9%	220,610	20.4%	5.534	0.131
Substance Abuse	48,694	4.2%	43,493	4.0%	0.166	0.008
Suicidal Behavior	5,373	0.5%	*****	*****	*****	*****
Transcranial Magnetic Stimulation	248	0.0%	129	0.0%	0.009	0.007
Vagus Nerve Stimulation	*****	*****	*****	*****	*****	*****
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	8,797	0.8%	0	0.0%	NaN	NaN
dulaglutide	385,505	33.2%	0	0.0%	NaN	NaN
exenatide	*****	*****	0	0.0%	*****	*****
liraglutide	237,053	20.4%	0	0.0%	NaN	NaN
lixisenatide	*****	*****	0	0.0%	*****	*****
semaglutide	401,733	34.6%	0	0.0%	NaN	NaN
tirzepatide	28,216	2.4%	0	0.0%	NaN	NaN

Table 1b. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Any Anti-Diabetic Agents	1,161,914	100.0%	1,080,586	100.0%	-0.000	-0.001
insulin*	392,994	33.8%	233,045	21.6%	12.256	0.276
metformin*	1,026,736	88.4%	967,152	89.5%	-1.137	-0.036
alpha-glucosidase inhibitors*	*****	*****	*****	*****	*****	*****
thiazolidinediones*	*****	*****	88,424	8.2%	*****	*****
meglitinides*	*****	*****	11,035	1.0%	*****	*****
amylin analogue*	154	0.0%	*****	*****	*****	*****
sulfonylureas*	*****	*****	*****	*****	*****	*****
bile acid sequestrants*	*****	*****	*****	*****	*****	*****
Other Weight Loss Agents*	4,008	0.3%	1,226	0.1%	0.231	0.048
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	421	0.0%	152	0.0%	0.022	0.014
diethylpropion	85	0.0%	27	0.0%	0.005	0.007
lorcaserin	181	0.0%	68	0.0%	0.009	0.009
phentermine	*****	*****	*****	*****	*****	*****
phentermine-topiramate	194	0.0%	46	0.0%	0.012	0.012
phendimetrazine	63	0.0%	*****	*****	*****	*****
orlistat	69	0.0%	25	0.0%	0.004	0.006
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	290,103	25.0%	227,831	21.1%	3.884	0.092
Antipsychotics	77,717	6.7%	55,864	5.2%	1.519	0.064
Anxiolytics/Hypnotics	221,926	19.1%	164,471	15.2%	3.879	0.103
Lithium & Other Mood Stabilizers	67,822	5.8%	47,334	4.4%	1.457	0.066

Table 1b. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Antidepressants	445,421	38.3%	312,659	28.9%	9.401	0.200
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	10.9	10.5	10.0	9.5	0.851	0.085
Mean number of emergency room encounters*	0.3	1.0	0.3	1.0	0.010	0.010
Mean number of inpatient hospital encounters*	0.1	0.4	0.1	0.5	-0.038	-0.087
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	-0.005	-0.027
Mean number of other ambulatory encounters*	3.9	11.5	3.7	10.6	0.150	0.014
Mean number of filled prescriptions*	26.1	19.7	23.7	17.7	2.397	0.128
Mean number of generics dispensed*	10.9	5.1	10.2	4.8	0.699	0.141
Mean number of unique drug classes dispensed*	9.8	4.6	8.5	4.4	1.270	0.283

Table 1b. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1c. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	1,712,503	N/A	1,192,156	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	60.5	10.3	62.0	10.8	-1.558	-0.147
Age						
18-24 years	4,860	0.3%	4,739	0.4%	-0.114	-0.020
25-44 years	163,751	9.6%	125,571	10.5%	-0.971	-0.033
45-64 years	864,974	50.5%	494,074	41.4%	9.066	0.203
65-79 years	611,896	35.7%	496,522	41.6%	-5.918	-0.142
≥ 80 years	67,022	3.9%	71,251	6.0%	-2.063	-0.096
Sex*						
Female	855,504	50.0%	612,584	51.4%	-1.428	-0.029
Male	856,999	50.0%	579,572	48.6%	1.428	0.029
Race[4]						
American Indian or Alaska Native	10,106	0.6%	6,996	0.6%	0.003	0.000
Asian	23,083	1.3%	34,103	2.9%	-1.513	-0.106
Black or African American	146,847	8.6%	122,377	10.3%	-1.690	-0.059
Multi-racial	8,955	0.5%	5,828	0.5%	0.034	0.005
Native Hawaiian or Other Pacific Islander	3,475	0.2%	3,383	0.3%	-0.081	-0.016
Unknown	785,918	45.9%	425,026	35.7%	10.241	0.360
White	734,118	42.9%	594,443	49.9%	-6.995	-0.186
Hispanic origin						
Yes	61,124	3.6%	71,252	6.0%	-2.407	-0.118
No	799,385	46.7%	690,040	57.9%	-11.202	-0.442

Table 1c. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Unknown	851,993	49.8%	430,865	36.1%	13.610	0.678
Year*						
2015	34,659	2.0%	19,969	1.7%	0.349	0.026
2016	135,489	7.9%	94,289	7.9%	0.003	0.000
2017	184,190	10.8%	112,460	9.4%	1.322	0.044
2018	163,935	9.6%	122,858	10.3%	-0.733	-0.025
2019	196,744	11.5%	154,307	12.9%	-1.455	-0.045
2020	227,612	13.3%	173,277	14.5%	-1.244	-0.036
2021	220,519	12.9%	172,544	14.5%	-1.596	-0.047
2022	333,833	19.5%	201,062	16.9%	2.628	0.069
2023	215,523	12.6%	141,390	11.9%	0.725	0.022
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,5	1.8	2.0	1.5	1.7	0.266	0.141
Combined comorbidity score*,6	2.4	3.0	1.9	2.4	0.511	0.190
Medical History						
Obesity*	840,865	49.1%	511,020	42.9%	6.236	0.127
Weight Reduction Surgery or Procedure*	3,133	0.2%	1,108	0.1%	0.090	0.024
Lifestyle intervention*	325,004	19.0%	202,524	17.0%	1.990	0.052
Cardiovascular Disease*	423,619	24.7%	256,869	21.5%	3.190	0.077
Cognitive Impairment*	60,627	3.5%	27,452	2.3%	1.238	0.074
Traumatic Brain Injury*	2,970	0.2%	2,928	0.2%	-0.072	-0.016
Migraine*	98,470	5.8%	48,167	4.0%	1.710	0.079
Epilepsy*	30,525	1.8%	15,965	1.3%	0.443	0.036
Chronic Pain*	530,150	31.0%	259,837	21.8%	9.162	0.210
Psychiatric History						

Table 1c. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Previous Intentional Self-Harm Ever	19,021	1.1%	9,838	0.8%	0.286	0.029
Psychiatric History Overall*	1,183,439	69.1%	731,315	61.3%	7.762	0.164
Psychiatric Drug Dispensings	896,153	52.3%	551,604	46.3%	6.061	0.122
Intentional Self-Harm Encounter	4,594	0.3%	1,261	0.1%	0.162	0.037
Any Other Psychiatric Event	1,005,301	58.7%	594,440	49.9%	8.841	0.179
Attention-Deficit/Hyperactivity Disorder	50,297	2.9%	11,400	1.0%	1.981	0.146
Akathisia	1,705	0.1%	1,196	0.1%	-0.001	-0.000
Anxiety	378,890	22.1%	200,597	16.8%	5.299	0.134
Behavioral Disorder	106,384	6.2%	46,249	3.9%	2.333	0.106
Bipolar Disorder	105,497	6.2%	52,533	4.4%	1.754	0.078
Cerebral Degenerations usually Manifested in Childhood	21,387	1.2%	12,601	1.1%	0.192	0.018
Conduct Disorder	955	0.1%	993	0.1%	-0.028	-0.010
Delirium	53,960	3.2%	16,876	1.4%	1.735	0.116
Depression	395,687	23.1%	209,722	17.6%	5.514	0.138
Electroconvulsive Therapy	418	0.0%	226	0.0%	0.005	0.004
Hallucination	5,809	0.3%	2,612	0.2%	0.120	0.023
Obsessive-Compulsive Disorder	7,251	0.4%	2,145	0.2%	0.243	0.044
Other Cerebral Degenerations	23,755	1.4%	17,481	1.5%	-0.079	-0.007
Other Mental Disorders	20,934	1.2%	9,704	0.8%	0.408	0.041
Other Psychological Disorders	269,208	15.7%	121,221	10.2%	5.552	0.167
Persistent Mental Disorders due to Conditions Classified Elsewhere	35,746	2.1%	18,521	1.6%	0.534	0.040
Personality Disorders	13,511	0.8%	5,340	0.4%	0.341	0.043
Pervasive Developmental Disorders	1,643	0.1%	1,860	0.2%	-0.060	-0.017
Post-Traumatic Stress Disorder	47,316	2.8%	23,501	2.0%	0.792	0.052

Table 1c. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Psychotherapy	119,367	7.0%	66,177	5.6%	1.419	0.059
Psychotic Conditions	6,147	0.4%	5,301	0.4%	-0.086	-0.014
Schizophrenia	40,254	2.4%	24,052	2.0%	0.333	0.023
Sleep Disorder	569,478	33.3%	290,371	24.4%	8.897	0.199
Substance Abuse	107,666	6.3%	59,398	5.0%	1.305	0.057
Suicidal Behavior	13,911	0.8%	5,595	0.5%	0.343	0.043
Transcranial Magnetic Stimulation	197	0.0%	368	0.0%	-0.019	-0.013
Vagus Nerve Stimulation	1,580	0.1%	1,216	0.1%	-0.010	-0.003
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	31,679	1.8%	0	0.0%	NaN	NaN
dulaglutide	618,720	36.1%	0	0.0%	NaN	NaN
exenatide	133,952	7.8%	0	0.0%	NaN	NaN
liraglutide	332,853	19.4%	0	0.0%	NaN	NaN
lixisenatide	17,604	1.0%	0	0.0%	NaN	NaN
semaglutide	537,650	31.4%	0	0.0%	NaN	NaN
tirzepatide	62,768	3.7%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,712,499	100.0%	1,192,155	100.0%	-0.000	-0.001
insulin*	710,045	41.5%	506,997	42.5%	-1.065	-0.022
metformin*	1,536,964	89.7%	1,052,151	88.3%	1.493	0.048
alpha-glucosidase inhibitors*	6,467	0.4%	5,562	0.5%	-0.089	-0.014
thiazolidinediones*	113,242	6.6%	105,092	8.8%	-2.203	-0.083
meglitinides*	17,225	1.0%	14,813	1.2%	-0.237	-0.022
amylin analogue*	315	0.0%	203	0.0%	0.001	0.001
sulfonylureas*	538,241	31.4%	462,952	38.8%	-7.403	-0.157
bile acid sequestrants*	7,384	0.4%	5,239	0.4%	-0.008	-0.001

Table 1c. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Weight Loss Agents*	4,827	0.3%	3,245	0.3%	0.010	0.002
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	1,507	0.1%	328	0.0%	0.060	0.025
diethylpropion	108	0.0%	70	0.0%	0.000	0.001
lorcaserin	143	0.0%	228	0.0%	-0.011	-0.009
phentermine	2,895	0.2%	2,358	0.2%	-0.029	-0.007
phentermine-topiramate	184	0.0%	193	0.0%	-0.005	-0.005
phendimetrazine	103	0.0%	66	0.0%	0.000	0.001
orlistat	52	0.0%	49	0.0%	-0.001	-0.002
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	720,073	42.0%	325,760	27.3%	14.723	0.314
Antipsychotics	183,799	10.7%	94,220	7.9%	2.829	0.098
Anxiolytics/Hypnotics	459,997	26.9%	248,060	20.8%	6.053	0.142
Lithium & Other Mood Stabilizers	138,313	8.1%	81,835	6.9%	1.212	0.046
Antidepressants	712,802	41.6%	444,383	37.3%	4.348	0.089
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	14.2	13.1	11.6	11.3	2.683	0.219
Mean number of emergency room encounters*	1.0	2.3	0.4	1.2	0.538	0.289
Mean number of inpatient hospital encounters*	0.3	0.8	0.1	0.5	0.189	0.293
Mean number of non-acute institutional encounters*	0.1	0.3	0.0	0.2	0.025	0.090
Mean number of other ambulatory encounters*	5.8	12.7	4.4	12.2	1.383	0.111

Table 1c. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Mean number of filled prescriptions*	38.3	32.4	27.8	21.4	10.471	0.381
Mean number of generics dispensed*	15.8	9.4	11.6	5.5	4.232	0.550
Mean number of unique drug classes dispensed*	12.1	6.8	10.2	5.3	1.968	0.322

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1d. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	1,160,845	100.0%	1,079,836	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)*	60.7	10.5	63.7	10.2	-2.976	-0.287
Age						
18-24 years	6,083	0.5%	3,017	0.3%	0.245	0.039
25-44 years	142,265	12.3%	91,461	8.5%	3.785	0.124
45-64 years	492,735	42.4%	412,592	38.2%	4.237	0.086
65-79 years	475,226	40.9%	489,513	45.3%	-4.394	-0.089
≥ 80 years	44,536	3.8%	83,253	7.7%	-3.873	-0.167
Sex*						
Female	643,586	55.4%	470,086	43.5%	11.908	0.240
Male	517,259	44.6%	609,750	56.5%	-11.908	-0.240
Race[3]						
American Indian or Alaska Native	8,473	0.7%	5,914	0.5%	0.182	0.023
Asian	*****	*****	38,522	3.6%	*****	*****
Black or African American	111,850	9.6%	100,714	9.3%	0.308	0.011
Multi-racial	*****	*****	*****	*****	*****	*****
Islander	*****	*****	*****	*****	*****	*****
Unknown	421,973	36.4%	379,214	35.1%	1.233	0.026
White	592,154	51.0%	546,748	50.6%	0.378	0.008
Hispanic origin						
Yes	52,564	4.5%	64,306	6.0%	-1.427	-0.064
No	665,522	57.3%	632,214	58.5%	-1.216	-0.025

Table 1d. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Unknown	442,759	38.1%	383,316	35.5%	2.643	0.055
Year*						
2015	17,356	1.5%	18,296	1.7%	-0.199	-0.016
2016	84,077	7.2%	82,590	7.6%	-0.406	-0.015
2017	102,256	8.8%	101,731	9.4%	-0.612	-0.021
2018	121,246	10.4%	98,287	9.1%	1.343	0.045
2019	149,203	12.9%	137,333	12.7%	0.135	0.004
2020	162,477	14.0%	165,274	15.3%	-1.309	-0.037
2021	160,628	13.8%	166,669	15.4%	-1.597	-0.045
2022	197,347	17.0%	193,424	17.9%	-0.912	-0.024
2023	166,255	14.3%	116,232	10.8%	3.558	0.108
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,4	1.3	1.6	1.5	1.7	-0.154	-0.093
Combined comorbidity score*,5	1.6	2.1	1.8	2.4	-0.206	-0.091
Medical History						
Obesity*	548,397	47.2%	367,937	34.1%	13.168	0.271
Procedure*	*****	*****	*****	*****	*****	*****
Lifestyle intervention*	213,865	18.4%	174,662	16.2%	2.248	0.059
Cardiovascular Disease*	202,725	17.5%	245,928	22.8%	-5.311	-0.133
Cognitive Impairment*	20,866	1.8%	24,896	2.3%	-0.508	-0.036
Traumatic Brain Injury*	2,461	0.2%	*****	*****	*****	*****
Migraine*	44,699	3.9%	28,857	2.7%	1.178	0.066
Epilepsy*	13,325	1.1%	11,930	1.1%	0.043	0.004
Chronic Pain*	243,151	20.9%	184,603	17.1%	3.851	0.098
Psychiatric History						

Table 1d. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Previous Intentional Self-Harm Ever	7,603	0.7%	4,833	0.4%	0.207	0.028
Psychiatric History Overall*	722,745	62.3%	576,523	53.4%	8.870	0.180
Psychiatric Drug Dispensings	539,463	46.5%	400,914	37.1%	9.344	0.190
Intentional Self-Harm Encounter	0	0.0%	0	0.0%	NaN	NaN
Any Other Psychiatric Event	586,596	50.5%	464,905	43.1%	7.479	0.150
Attention-Deficit/Hyperactivity Disorder	13,651	1.2%	6,940	0.6%	0.533	0.056
Akathisia	1,078	0.1%	*****	*****	*****	*****
Anxiety	194,042	16.7%	137,878	12.8%	3.947	0.112
Behavioral Disorder	44,559	3.8%	31,328	2.9%	0.937	0.052
Bipolar Disorder	45,450	3.9%	28,865	2.7%	1.242	0.070
Cerebral Degenerations usually Manifested in Childhood	9,316	0.8%	10,853	1.0%	-0.203	-0.021
Conduct Disorder	938	0.1%	659	0.1%	0.020	0.007
Delirium	12,535	1.1%	13,478	1.2%	-0.168	-0.016
Depression	210,296	18.1%	144,836	13.4%	4.703	0.129
Electroconvulsive Therapy	165	0.0%	*****	*****	*****	*****
Hallucination	1,867	0.2%	1,702	0.2%	0.003	0.001
Disorder	2,177	0.2%	1,412	0.1%	0.057	0.014
Other Cerebral Degenerations	14,203	1.2%	15,730	1.5%	-0.233	-0.020
Other Mental Disorders	8,522	0.7%	7,082	0.7%	0.078	0.009
Other Psychological Disorders	97,282	8.4%	91,789	8.5%	-0.120	-0.004
Persistent Mental Disorders due to Conditions Classified Elsewhere	14,431	1.2%	16,876	1.6%	-0.320	-0.027
Personality Disorders	4,626	0.4%	2,299	0.2%	0.186	0.034

Table 1d. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Disorders	1,916	0.2%	1,353	0.1%	0.040	0.010
Post-Traumatic Stress Disorder	21,571	1.9%	12,004	1.1%	0.747	0.062
Psychotherapy	65,310	5.6%	38,867	3.6%	2.027	0.097
Psychotic Conditions	3,695	0.3%	3,312	0.3%	0.012	0.002
Schizophrenia	18,205	1.6%	15,213	1.4%	0.159	0.013
Sleep Disorder	300,977	25.9%	220,301	20.4%	5.526	0.131
Substance Abuse	48,221	4.2%	43,187	4.0%	0.155	0.008
Suicidal Behavior	4,742	0.4%	3,746	0.3%	0.062	0.010
Stimulation	*****	*****	*****	*****	*****	*****
Vagus Nerve Stimulation	*****	*****	*****	*****	*****	*****
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	*****	*****	0	0.0%	*****	*****
dulaglutide	385,176	33.2%	0	0.0%	NaN	NaN
exenatide	85,471	7.4%	0	0.0%	NaN	NaN
liraglutide	236,748	20.4%	0	0.0%	NaN	NaN
lixisenatide	15,866	1.4%	0	0.0%	NaN	NaN
semaglutide	401,453	34.6%	0	0.0%	NaN	NaN
tirzepatide	28,201	2.4%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,160,843	100.0%	1,079,835	100.0%	-0.000	-0.001
insulin*	392,523	33.8%	232,788	21.6%	12.256	0.277
metformin*	1,025,791	88.4%	966,481	89.5%	-1.137	-0.036
alpha-glucosidase inhibitors*	*****	*****	*****	*****	*****	*****
thiazolidinediones*	95,063	8.2%	88,384	8.2%	0.004	0.000
meglitinides*	12,578	1.1%	*****	*****	*****	*****
amylin analogue*	153	0.0%	*****	*****	*****	*****

Table 1d. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
sulfonylureas*	427,317	36.8%	425,460	39.4%	-2.590	-0.053
bile acid sequestrants*	*****	*****	*****	*****	*****	*****
Other Weight Loss Agents*	*****	*****	*****	*****	*****	*****
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	421	0.0%	152	0.0%	0.022	0.014
diethylpropion	85	0.0%	27	0.0%	0.005	0.007
lorcaserin	181	0.0%	68	0.0%	0.009	0.009
phentermine	*****	*****	*****	*****	*****	*****
phentermine-topiramate	194	0.0%	46	0.0%	0.012	0.012
phendimetrazine	63	0.0%	*****	*****	*****	*****
orlistat	69	0.0%	25	0.0%	0.004	0.006
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	289,664	25.0%	227,578	21.1%	3.878	0.092
Antipsychotics	77,091	6.6%	55,491	5.1%	1.502	0.064
Anxiolytics/Hypnotics	221,284	19.1%	164,060	15.2%	3.869	0.103
Lithium & Other Mood Stabilizers	67,363	5.8%	47,080	4.4%	1.443	0.066
Antidepressants	444,488	38.3%	312,075	28.9%	9.390	0.200
Health Service Utilization Intensity Metrics						
encounters*	10.9	10.5	10.0	9.4	0.845	0.085
Mean number of emergency room encounters*	0.3	1.0	0.3	1.0	0.009	0.009
Mean number of inpatient hospital encounters*	0.1	0.4	0.1	0.5	-0.038	-0.089
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	-0.005	-0.028

Table 1d. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Mean number of other ambulatory encounters*	3.9	11.5	3.7	10.6	0.146	0.013
Mean number of filled prescriptions*	26.1	19.7	23.7	17.7	2.389	0.128
Mean number of generics dispensed*	10.9	5.1	10.2	4.8	0.697	0.140
Mean number of unique drug classes dispensed*	9.8	4.6	8.5	4.4	1.269	0.283

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented. N/A = Not applicable

NaN = Not a number

Table 1e. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	1,160,705	100.0%	1,079,747	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)*	60.7	10.5	63.7	10.2	-2.976	-0.287
Age						
18-24 years	6,083	0.5%	3,017	0.3%	0.245	0.039
25-44 years	142,240	12.3%	91,450	8.5%	3.785	0.124
45-64 years	492,647	42.4%	412,558	38.2%	4.235	0.086
65-79 years	475,199	40.9%	489,475	45.3%	-4.392	-0.089
≥ 80 years	44,536	3.8%	83,247	7.7%	-3.873	-0.167
Sex*						
Female	643,465	55.4%	470,056	43.5%	11.904	0.240
Male	517,240	44.6%	609,691	56.5%	-11.904	-0.240
Race[3]						
American Indian or Alaska Native	8,472	0.7%	5,914	0.5%	0.182	0.023
Asian	17,098	1.5%	38,521	3.6%	-2.095	-0.134
Black or African American	111,834	9.6%	100,709	9.3%	0.308	0.011
Multi-racial	*****	*****	4,962	0.5%	*****	*****
Islander	*****	*****	3,761	0.3%	*****	*****
Unknown	421,908	36.3%	379,184	35.1%	1.231	0.026
White	592,099	51.0%	546,696	50.6%	0.380	0.008
Hispanic origin						
Yes	52,533	4.5%	64,289	6.0%	-1.428	-0.064
No	665,454	57.3%	632,169	58.5%	-1.216	-0.025

Table 1e. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Unknown	442,718	38.1%	383,289	35.5%	2.644	0.055
Year*						
2015	17,355	1.5%	18,294	1.7%	-0.199	-0.016
2016	84,066	7.2%	82,587	7.6%	-0.406	-0.015
2017	102,189	8.8%	101,727	9.4%	-0.617	-0.021
2018	121,226	10.4%	98,284	9.1%	1.342	0.045
2019	149,202	12.9%	137,328	12.7%	0.136	0.004
2020	162,471	14.0%	165,269	15.3%	-1.309	-0.037
2021	160,621	13.8%	166,635	15.4%	-1.595	-0.045
2022	197,334	17.0%	193,397	17.9%	-0.910	-0.024
2023	166,241	14.3%	116,226	10.8%	3.558	0.108
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,4	1.3	1.6	1.5	1.7	-0.154	-0.093
Combined comorbidity score*,5	1.6	2.1	1.8	2.4	-0.206	-0.091
Medical History						
Obesity*	548,273	47.2%	367,914	34.1%	13.162	0.270
Procedure*	*****	*****	596	0.1%	*****	*****
Lifestyle intervention*	213,824	18.4%	174,649	16.2%	2.247	0.059
Cardiovascular Disease*	202,714	17.5%	245,901	22.8%	-5.309	-0.133
Cognitive Impairment*	20,865	1.8%	24,895	2.3%	-0.508	-0.036
Traumatic Brain Injury*	2,461	0.2%	1,851	0.2%	0.041	0.009
Migraine*	44,676	3.8%	28,851	2.7%	1.177	0.066
Epilepsy*	13,325	1.1%	11,930	1.1%	0.043	0.004
Chronic Pain*	243,095	20.9%	184,575	17.1%	3.849	0.098
Psychiatric History						

Table 1e. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Previous Intentional Self-Harm Ever	7,599	0.7%	4,833	0.4%	0.207	0.028
Psychiatric History Overall*	722,628	62.3%	576,467	53.4%	8.869	0.180
Psychiatric Drug Dispensings	539,365	46.5%	400,874	37.1%	9.342	0.190
Intentional Self-Harm Encounter	0	0.0%	0	0.0%	NaN	NaN
Any Other Psychiatric Event	586,490	50.5%	464,855	43.1%	7.477	0.150
Attention-Deficit/Hyperactivity Disorder	13,647	1.2%	6,940	0.6%	0.533	0.056
Akathisia	1,077	0.1%	*****	*****	*****	*****
Anxiety	193,998	16.7%	137,858	12.8%	3.946	0.111
Behavioral Disorder	44,544	3.8%	31,325	2.9%	0.937	0.052
Bipolar Disorder	45,432	3.9%	28,861	2.7%	1.241	0.070
Cerebral Degenerations usually Manifested in Childhood	9,315	0.8%	10,850	1.0%	-0.202	-0.021
Conduct Disorder	937	0.1%	658	0.1%	0.020	0.007
Delirium	12,534	1.1%	13,475	1.2%	-0.168	-0.016
Depression	210,250	18.1%	144,812	13.4%	4.702	0.129
Electroconvulsive Therapy	165	0.0%	*****	*****	*****	*****
Hallucination	1,865	0.2%	1,702	0.2%	0.003	0.001
Obsessive-Compulsive Disorder	2,176	0.2%	1,412	0.1%	0.057	0.014
Other Cerebral Degenerations	14,202	1.2%	15,730	1.5%	-0.233	-0.020
Other Mental Disorders	8,521	0.7%	7,081	0.7%	0.078	0.009
Other Psychological Disorders	97,260	8.4%	91,777	8.5%	-0.120	-0.004
Persistent Mental Disorders due to Conditions Classified Elsewhere	14,430	1.2%	16,876	1.6%	-0.320	-0.027
Personality Disorders	4,624	0.4%	2,299	0.2%	0.185	0.034

Table 1e. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Pervasive Developmental Disorders	1,916	0.2%	1,353	0.1%	0.040	0.010
Post-Traumatic Stress Disorder	21,564	1.9%	12,002	1.1%	0.746	0.062
Psychotherapy	65,291	5.6%	38,864	3.6%	2.026	0.097
Psychotic Conditions	3,695	0.3%	3,312	0.3%	0.012	0.002
Schizophrenia	18,203	1.6%	15,212	1.4%	0.159	0.013
Sleep Disorder	300,907	25.9%	220,276	20.4%	5.524	0.131
Substance Abuse	48,210	4.2%	43,175	4.0%	0.155	0.008
Suicidal Behavior	4,740	0.4%	3,746	0.3%	0.061	0.010
Transcranial Magnetic Stimulation	*****	*****	*****	*****	*****	*****
Vagus Nerve Stimulation	944	0.1%	585	0.1%	0.027	0.010
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	*****	*****	0	0.0%	*****	*****
dulaglutide	385,165	33.2%	0	0.0%	NaN	NaN
exenatide	85,377	7.4%	0	0.0%	NaN	NaN
liraglutide	236,740	20.4%	0	0.0%	NaN	NaN
lixisenatide	15,864	1.4%	0	0.0%	NaN	NaN
semaglutide	401,436	34.6%	0	0.0%	NaN	NaN
tirzepatide	28,193	2.4%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,160,703	100.0%	1,079,746	100.0%	-0.000	-0.001
insulin*	392,452	33.8%	232,769	21.6%	12.254	0.276
metformin*	1,025,661	88.4%	966,396	89.5%	-1.137	-0.036
alpha-glucosidase inhibitors*	4,643	0.4%	4,414	0.4%	-0.009	-0.001
thiazolidinediones*	95,057	8.2%	88,374	8.2%	0.005	0.000

Table 1e. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
meglitinides*	12,578	1.1%	*****	*****	*****	*****
amylin analogue*	*****	*****	77	0.0%	*****	*****
sulfonylureas*	427,246	36.8%	425,410	39.4%	-2.590	-0.053
bile acid sequestrants*	4,316	0.4%	*****	*****	*****	*****
Other Weight Loss Agents*	3,933	0.3%	*****	*****	*****	*****
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	421	0.0%	152	0.0%	0.022	0.014
diethylpropion	85	0.0%	27	0.0%	0.005	0.007
lorcaserin	181	0.0%	68	0.0%	0.009	0.009
phentermine	3,009	0.3%	916	0.1%	0.174	0.042
phentermine-topiramate	194	0.0%	46	0.0%	0.012	0.012
phendimetrazine	63	0.0%	15	0.0%	0.004	0.007
orlistat	69	0.0%	25	0.0%	0.004	0.006
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	289,599	25.0%	227,548	21.1%	3.876	0.092
Antipsychotics	77,067	6.6%	55,484	5.1%	1.501	0.064
Anxiolytics/Hypnotics	221,237	19.1%	164,038	15.2%	3.868	0.103
Lithium & Other Mood Stabilizers	67,346	5.8%	47,072	4.4%	1.443	0.066
Antidepressants	444,397	38.3%	312,042	28.9%	9.387	0.200
Health Service Utilization Intensity Metrics						
encounters*	10.9	10.5	10.0	9.4	0.845	0.085
Mean number of emergency room encounters*	0.3	1.0	0.3	1.0	0.009	0.009
Mean number of inpatient hospital encounters*	0.1	0.4	0.1	0.5	-0.038	-0.089

Table 1e. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	-0.005	-0.028
Mean number of other ambulatory encounters*	3.9	11.5	3.7	10.6	0.145	0.013
Mean number of filled prescriptions*	26.1	19.7	23.7	17.7	2.388	0.127
Mean number of generics dispensed*	10.9	5.1	10.2	4.8	0.697	0.140
Mean number of unique drug classes dispensed*	9.8	4.6	8.5	4.4	1.268	0.283

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1f. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	1,655,664	N/A	1,190,154	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	60.7	10.4	62.1	10.8	-1.389	-0.131
Age						
18-24 years	4,809	0.3%	4,693	0.4%	-0.104	-0.018
25-44 years	160,493	9.7%	124,235	10.4%	-0.745	-0.026
45-64 years	817,215	49.4%	493,671	41.5%	7.879	0.176
65-79 years	606,083	36.6%	496,295	41.7%	-5.093	-0.122
≥ 80 years	67,064	4.1%	71,259	6.0%	-1.937	-0.090
Sex*						
Female	805,963	48.7%	610,798	51.3%	-2.642	-0.053
Male	849,701	51.3%	579,356	48.7%	2.642	0.053
Race[4]						
American Indian or Alaska Native	10,077	0.6%	6,971	0.6%	0.023	0.003
Asian	23,118	1.4%	34,085	2.9%	-1.468	-0.102
Black or African American	146,942	8.9%	122,240	10.3%	-1.396	-0.049
Multi-racial	8,982	0.5%	5,824	0.5%	0.053	0.008
Islander	3,477	0.2%	3,381	0.3%	-0.074	-0.015
Unknown	741,397	44.8%	424,171	35.6%	9.139	0.320
White	721,671	43.6%	593,482	49.9%	-6.278	-0.166
Hispanic origin						
Yes	61,088	3.7%	71,213	6.0%	-2.294	-0.112
No	793,713	47.9%	689,097	57.9%	-9.961	-0.392

Table 1f. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Unknown	800,863	48.4%	429,844	36.1%	12.254	0.609
Year*						
2015	34,832	2.1%	19,949	1.7%	0.428	0.031
2016	135,579	8.2%	94,153	7.9%	0.278	0.010
2017	184,564	11.1%	112,403	9.4%	1.703	0.056
2018	162,426	9.8%	122,742	10.3%	-0.503	-0.017
2019	190,068	11.5%	153,787	12.9%	-1.442	-0.044
2020	227,050	13.7%	172,932	14.5%	-0.817	-0.024
2021	221,013	13.3%	172,114	14.5%	-1.113	-0.032
2022	283,406	17.1%	200,996	16.9%	0.229	0.006
2023	216,725	13.1%	141,078	11.9%	1.236	0.038
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,5	1.8	2.0	1.5	1.7	0.308	0.162
Combined comorbidity score*,6	2.4	2.9	1.9	2.4	0.532	0.200
Medical History						
Obesity*	792,326	47.9%	509,589	42.8%	5.038	0.103
Procedure*	3,160	0.2%	1,106	0.1%	0.098	0.026
Lifestyle intervention*	325,429	19.7%	201,928	17.0%	2.689	0.071
Cardiovascular Disease*	423,167	25.6%	256,512	21.6%	4.006	0.097
Cognitive Impairment*	58,867	3.6%	27,376	2.3%	1.255	0.075
Traumatic Brain Injury*	2,965	0.2%	2,917	0.2%	-0.066	-0.014
Migraine*	98,140	5.9%	47,621	4.0%	1.926	0.089
Epilepsy*	30,554	1.8%	15,841	1.3%	0.514	0.041
Chronic Pain*	518,691	31.3%	259,079	21.8%	9.560	0.219
Psychiatric History						

Table 1f. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Previous Intentional Self-Harm Ever	11,641	0.7%	8,585	0.7%	-0.018	-0.002
Psychiatric History Overall*	1,126,055	68.0%	729,206	61.3%	6.742	0.142
Psychiatric Drug Dispensings	884,886	53.4%	549,934	46.2%	7.239	0.146
Intentional Self-Harm Encounter	0	0.0%	0	0.0%	NaN	NaN
Any Other Psychiatric Event	947,454	57.2%	592,230	49.8%	7.464	0.151
Attention-Deficit/Hyperactivity Disorder	46,477	2.8%	11,320	1.0%	1.856	0.138
Akathisia	1,660	0.1%	1,151	0.1%	0.004	0.001
Anxiety	372,917	22.5%	199,334	16.7%	5.775	0.146
Behavioral Disorder	102,001	6.2%	45,106	3.8%	2.371	0.109
Bipolar Disorder	104,829	6.3%	51,775	4.4%	1.981	0.088
Cerebral Degenerations usually Manifested in Childhood	21,445	1.3%	12,465	1.0%	0.248	0.023
Conduct Disorder	935	0.1%	970	0.1%	-0.025	-0.010
Delirium	52,005	3.1%	16,620	1.4%	1.745	0.117
Depression	382,651	23.1%	208,515	17.5%	5.592	0.140
Electroconvulsive Therapy	349	0.0%	208	0.0%	0.004	0.003
Hallucination	5,764	0.3%	2,527	0.2%	0.136	0.026
Obsessive-Compulsive Disorder	7,299	0.4%	2,134	0.2%	0.262	0.047
Other Cerebral Degenerations	23,787	1.4%	17,442	1.5%	-0.029	-0.002
Other Mental Disorders	20,614	1.2%	9,597	0.8%	0.439	0.044
Other Psychological Disorders	217,788	13.2%	120,193	10.1%	3.055	0.096
Persistent Mental Disorders due to Conditions Classified Elsewhere	35,841	2.2%	18,494	1.6%	0.611	0.045
Personality Disorders	12,473	0.8%	5,090	0.4%	0.326	0.043

Table 1f. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Pervasive Developmental Disorders	1,622	0.1%	1,806	0.2%	-0.054	-0.015
Post-Traumatic Stress Disorder	45,027	2.7%	22,992	1.9%	0.788	0.052
Psychotherapy	116,609	7.0%	65,658	5.5%	1.526	0.063
Psychotic Conditions	5,542	0.3%	5,069	0.4%	-0.091	-0.015
Schizophrenia	40,291	2.4%	23,749	2.0%	0.438	0.030
Sleep Disorder	557,971	33.7%	289,218	24.3%	9.400	0.210
Substance Abuse	104,106	6.3%	58,623	4.9%	1.362	0.059
Suicidal Behavior	9,542	0.6%	4,875	0.4%	0.167	0.024
Transcranial Magnetic Stimulation	196	0.0%	363	0.0%	-0.019	-0.013
Vagus Nerve Stimulation	1,584	0.1%	1,213	0.1%	-0.006	-0.002
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	31,835	1.9%	0	0.0%	NaN	NaN
dulaglutide	564,052	34.1%	0	0.0%	NaN	NaN
exenatide	133,499	8.1%	0	0.0%	NaN	NaN
liraglutide	329,242	19.9%	0	0.0%	NaN	NaN
lixisenatide	17,531	1.1%	0	0.0%	NaN	NaN
semaglutide	539,297	32.6%	0	0.0%	NaN	NaN
tirzepatide	63,030	3.8%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,655,661	100.0%	1,190,153	100.0%	-0.000	-0.001
insulin*	700,390	42.3%	505,493	42.5%	-0.170	-0.003
metformin*	1,479,842	89.4%	1,050,204	88.2%	1.140	0.036
alpha-glucosidase inhibitors*	6,400	0.4%	5,560	0.5%	-0.081	-0.012
thiazolidinediones*	113,200	6.8%	104,607	8.8%	-1.952	-0.073

Table 1f. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
meglitinides*	17,277	1.0%	14,818	1.2%	-0.201	-0.019
amylin analogue*	318	0.0%	203	0.0%	0.002	0.002
sulfonylureas*	535,566	32.3%	461,896	38.8%	-6.462	-0.136
bile acid sequestrants*	7,409	0.4%	5,239	0.4%	0.007	0.001
Other Weight Loss Agents*	4,847	0.3%	3,182	0.3%	0.025	0.005
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	1,540	0.1%	329	0.0%	0.065	0.027
diethylpropion	108	0.0%	70	0.0%	0.001	0.001
lorcaserin	143	0.0%	228	0.0%	-0.011	-0.009
phentermine	2,880	0.2%	2,292	0.2%	-0.019	-0.004
phentermine-topiramate	185	0.0%	194	0.0%	-0.005	-0.004
phendimetrazine	103	0.0%	67	0.0%	0.001	0.001
orlistat	52	0.0%	49	0.0%	-0.001	-0.002
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	671,234	40.5%	324,566	27.3%	13.271	0.284
Antipsychotics	176,203	10.6%	93,342	7.8%	2.800	0.097
Anxiolytics/Hypnotics	447,708	27.0%	246,752	20.7%	6.308	0.148
Lithium & Other Mood Stabilizers	137,261	8.3%	81,021	6.8%	1.483	0.056
Antidepressants	703,418	42.5%	442,759	37.2%	5.284	0.108
Health Service Utilization Intensity Metrics						
encounters*	14.3	12.6	11.5	11.3	2.719	0.227
Mean number of emergency room encounters*	0.9	2.3	0.4	1.2	0.474	0.256
Mean number of inpatient hospital encounters*	0.3	0.8	0.1	0.5	0.192	0.298

Table 1f. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Mean number of non-acute institutional encounters*	0.1	0.3	0.0	0.2	0.025	0.092
Mean number of other ambulatory encounters*	5.8	12.8	4.4	12.2	1.395	0.111
Mean number of filled prescriptions*	38.3	32.4	27.8	21.4	10.440	0.380
Mean number of generics dispensed*	15.6	9.4	11.6	5.5	4.040	0.526
Mean number of unique drug classes dispensed*	12.1	6.9	10.1	5.3	1.961	0.321

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1g. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	1,071	100.0%	751	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)*	49.3	13.4	54.3	13.4	-5.053	-0.377
Age						
18-24 years	58	5.4%	17	2.3%	3.152	0.165
25-44 years	340	31.7%	180	24.0%	7.778	0.174
45-64 years	528	49.3%	372	49.5%	-0.234	-0.005
65-79 years	134	12.5%	153	20.4%	-7.861	-0.213
≥ 80 years	13	1.2%	29	3.9%	-2.648	-0.169
Sex*						
Female	720	67.2%	393	52.3%	14.897	0.307
Male	353	33.0%	358	47.7%	-14.710	-0.303
Race[3]						
American Indian or Alaska Native	25	2.3%	18	2.4%	-0.063	-0.004
Asian	*****	*****	17	2.3%	*****	*****
Black or African American	120	11.2%	97	12.9%	-1.712	-0.053
Multi-racial	*****	*****	*****	*****	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****	*****
Unknown	249	23.2%	166	22.1%	1.145	0.027
White	671	62.7%	444	59.1%	3.531	0.072
Hispanic origin						
Yes	67	6.3%	50	6.7%	-0.402	-0.016
No	789	73.7%	560	74.6%	-0.898	-0.020

Table 1g. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Unknown	216	20.2%	141	18.8%	1.393	0.035
Year*						
2015	26	2.4%	12	1.6%	0.830	0.059
2016	91	8.5%	71	9.5%	-0.957	-0.033
2017	117	10.9%	89	11.9%	-0.926	-0.029
2018	126	11.8%	69	9.2%	2.577	0.084
2019	179	16.7%	95	12.6%	4.064	0.115
2020	174	16.2%	125	16.6%	-0.398	-0.011
2021	130	12.1%	99	13.2%	-1.044	-0.031
2022	136	12.7%	135	18.0%	-5.278	-0.147
2023	98	9.2%	56	7.5%	1.694	0.061
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[4]	1.8	1.9	2.2	2.1	-0.446	-0.227
Combined comorbidity score*,[5]	3.9	2.5	4.4	3.0	-0.506	-0.184
Medical History						
Obesity*	667	62.3%	377	50.2%	12.079	0.245
Weight Reduction Surgery or Procedure*	*****	*****	0	0.0%	*****	*****
Lifestyle intervention*	275	25.7%	172	22.9%	2.774	0.065
Cardiovascular Disease*	245	22.9%	247	32.9%	-10.014	-0.225
Cognitive Impairment*	76	7.1%	86	11.5%	-4.355	-0.151
Traumatic Brain Injury*	13	1.2%	*****	*****	*****	*****
Migraine*	174	16.2%	90	12.0%	4.262	0.123
Epilepsy*	96	9.0%	73	9.7%	-0.757	-0.026
Chronic Pain*	458	42.8%	263	35.0%	7.744	0.159
Psychiatric History						

Table 1g. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Previous Intentional Self-Harm Ever	1,071	100.0%	751	100.0%	0.000	NaN
Psychiatric History Overall*	1,071	100.0%	751	100.0%	0.000	NaN
Psychiatric Drug Dispensings	1,004	93.7%	660	87.9%	5.861	0.204
Intentional Self-Harm Encounter	1,071	100.0%	751	100.0%	0.000	NaN
Any Other Psychiatric Event	1,071	100.0%	751	100.0%	0.000	NaN
Attention-Deficit/Hyperactivity Disorder	98	9.2%	35	4.7%	4.490	0.178
Akathisia	18	1.7%	*****	*****	*****	*****
Anxiety	729	68.1%	472	62.8%	5.218	0.110
Behavioral Disorder	968	90.4%	673	89.6%	0.769	0.026
Bipolar Disorder	480	44.8%	265	35.3%	9.532	0.195
Cerebral Degenerations usually Manifested in Childhood	29	2.7%	28	3.7%	-1.021	-0.058
Conduct Disorder	27	2.5%	11	1.5%	1.056	0.076
Delirium	160	14.9%	115	15.3%	-0.374	-0.010
Depression	854	79.7%	551	73.4%	6.370	0.151
Electroconvulsive Therapy	22	2.1%	*****	*****	*****	*****
Hallucination	80	7.5%	46	6.1%	1.344	0.053
Obsessive-Compulsive Disorder	32	3.0%	11	1.5%	1.523	0.103
Other Cerebral Degenerations	27	2.5%	34	4.5%	-2.006	-0.109
Other Mental Disorders	90	8.4%	58	7.7%	0.680	0.025
Other Psychological Disorders	478	44.6%	334	44.5%	0.157	0.003
Persistent Mental Disorders due to Conditions Classified Elsewhere	36	3.4%	47	6.3%	-2.897	-0.136
Personality Disorders	262	24.5%	111	14.8%	9.683	0.246
Pervasive Developmental Disorders	24	2.2%	16	2.1%	0.110	0.008
Post-Traumatic Stress Disorder	350	32.7%	154	20.5%	12.174	0.278

Table 1g. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Psychotherapy	485	45.3%	280	37.3%	8.001	0.163
Psychotic Conditions	158	14.8%	119	15.8%	-1.093	-0.030
Schizophrenia	230	21.5%	166	22.1%	-0.629	-0.015
Sleep Disorder	540	50.4%	309	41.1%	9.275	0.187
Substance Abuse	474	44.3%	306	40.7%	3.512	0.071
Suicidal Behavior	631	58.9%	402	53.5%	5.388	0.109
Transcranial Magnetic Stimulation	*****	*****	*****	*****	*****	*****
Vagus Nerve Stimulation	*****	*****	*****	*****	*****	*****
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	*****	*****	0	0.0%	*****	*****
dulaglutide	329	30.7%	0	0.0%	NaN	NaN
exenatide	126	11.8%	0	0.0%	NaN	NaN
liraglutide	305	28.5%	0	0.0%	NaN	NaN
lixisenatide	11	1.0%	0	0.0%	NaN	NaN
semaglutide	280	26.1%	0	0.0%	NaN	NaN
tirzepatide	15	1.4%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,071	100.0%	751	100.0%	0.000	NaN
insulin*	471	44.0%	257	34.2%	9.757	0.201
metformin*	945	88.2%	671	89.3%	-1.112	-0.035
alpha-glucosidase inhibitors*	*****	*****	*****	*****	*****	*****
thiazolidinediones*	70	6.5%	40	5.3%	1.210	0.051
meglitinides*	*****	*****	*****	*****	*****	*****
amylin analogue*	*****	*****	0	0.0%	*****	*****
sulfonylureas*	359	33.5%	247	32.9%	0.631	0.013
bile acid sequestrants*	0	0.0%	*****	*****	*****	*****

Table 1g. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Weight Loss Agents*	*****	*****	*****	*****	*****	*****
benzphetamine	0	0.0%	0	0.0%	NaN	NaN
Combination naltrexone and bupropion	0	0.0%	0	0.0%	NaN	NaN
diethylpropion	0	0.0%	0	0.0%	NaN	NaN
lorcaserin	0	0.0%	0	0.0%	NaN	NaN
phentermine	*****	*****	*****	*****	*****	*****
phentermine-topiramate	0	0.0%	0	0.0%	NaN	NaN
phendimetrazine	0	0.0%	0	0.0%	NaN	NaN
orlistat	0	0.0%	0	0.0%	NaN	NaN
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	440	41.1%	253	33.7%	7.395	0.153
Antipsychotics	628	58.6%	373	49.7%	8.970	0.181
Anxiolytics/Hypnotics	643	60.0%	411	54.7%	5.310	0.108
Lithium & Other Mood Stabilizers	460	43.0%	254	33.8%	9.129	0.189
Antidepressants	934	87.2%	584	77.8%	9.445	0.250
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	25.5	20.3	20.7	17.1	4.797	0.256
Mean number of emergency room encounters*	3.2	4.7	2.8	4.1	0.467	0.105
Mean number of inpatient hospital encounters*	1.1	1.4	1.0	1.4	0.032	0.023
Mean number of non-acute institutional encounters*	0.5	0.9	0.5	0.9	-0.060	-0.068
Mean number of other ambulatory encounters*	17.7	25.7	15.6	22.3	2.087	0.087

Table 1g. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Mean number of filled prescriptions*	50.4	33.5	44.5	31.5	5.857	0.180
Mean number of generics dispensed*	17.5	7.6	16.1	7.3	1.434	0.193
Mean number of unique drug classes dispensed*	15.5	6.5	13.7	6.3	1.777	0.278

^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1h. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	935	87.3%	664	88.4%	N/A	N/A
Demographic Characteristics						
Age (years)*	49.4	13.4	53.3	13.2	-3.911	-0.294
Age						
18-24 years	46	4.9%	17	2.6%	2.360	0.125
25-44 years	299	32.0%	168	25.3%	6.677	0.148
45-64 years	456	48.8%	338	50.9%	-2.134	-0.043
65-79 years	122	13.0%	123	18.5%	-5.476	-0.151
≥ 80 years	12	1.3%	18	2.7%	-1.427	-0.102
Sex*						
Female	623	66.6%	362	54.5%	12.113	0.250
Male	312	33.4%	302	45.5%	-12.113	-0.250
Race[3]						
American Indian or Alaska Native	*****	*****	16	2.4%	*****	*****
Asian	*****	*****	*****	*****	*****	*****
Black or African American	106	11.3%	91	13.7%	-2.368	-0.072
Multi-racial	0	0.0%	*****	*****	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****	*****
Unknown	177	18.9%	140	21.1%	-2.154	-0.054
White	622	66.5%	397	59.8%	6.735	0.140
Hispanic origin						

Table 1h. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	63	6.7%	48	7.2%	-0.491	-0.019
No	741	79.3%	516	77.7%	1.540	0.037
Unknown	131	14.0%	100	15.1%	-1.050	-0.030
Year*						
2015	24	2.6%	*****	*****	*****	*****
2016	84	9.0%	67	10.1%	-1.106	-0.038
2017	104	11.1%	84	12.7%	-1.528	-0.047
2018	114	12.2%	65	9.8%	2.403	0.077
2019	158	16.9%	91	13.7%	3.194	0.089
2020	153	16.4%	117	17.6%	-1.257	-0.033
2021	108	11.6%	85	12.8%	-1.250	-0.038
2022	116	12.4%	103	15.5%	-3.106	-0.090
2023	74	7.9%	42	6.3%	1.589	0.062
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[4]	1.8	1.9	2.1	2.0	-0.286	-0.149
Combined comorbidity score*,[5]	3.8	2.5	4.1	2.8	-0.276	-0.103
Medical History						
Obesity*	565	60.4%	339	51.1%	9.374	0.190
Weight Reduction Surgery or Procedure*	0	0.0%	0	0.0%	NaN	NaN
Lifestyle intervention*	234	25.0%	151	22.7%	2.286	0.054
Cardiovascular Disease*	213	22.8%	200	30.1%	-7.340	-0.167
Cognitive Impairment*	70	7.5%	64	9.6%	-2.152	-0.077
Traumatic Brain Injury*	*****	*****	*****	*****	*****	*****

Table 1h. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	147	15.7%	79	11.9%	3.824	0.111
Epilepsy*	83	8.9%	67	10.1%	-1.213	-0.041
Chronic Pain*	397	42.5%	237	35.7%	6.767	0.139
Psychiatric History						
Previous Intentional Self-Harm Ever	935	100.0%	664	100.0%	0.000	NaN
Psychiatric History Overall*	935	100.0%	664	100.0%	0.000	NaN
Psychiatric Drug Dispensings	877	93.8%	593	89.3%	4.490	0.162
Intentional Self-Harm Encounter	935	100.0%	664	100.0%	0.000	NaN
Any Other Psychiatric Event	935	100.0%	664	100.0%	0.000	NaN
Attention-Deficit/Hyperactivity Disorder	77	8.2%	30	4.5%	3.717	0.153
Akathisia	16	1.7%	*****	*****	*****	*****
Anxiety	630	67.4%	425	64.0%	3.374	0.071
Behavioral Disorder	844	90.3%	596	89.8%	0.508	0.017
Bipolar Disorder	423	45.2%	239	36.0%	9.247	0.189
Cerebral Degenerations usually Manifested in Childhood	25	2.7%	21	3.2%	-0.489	-0.029
Conduct Disorder	25	2.7%	11	1.7%	1.017	0.070
Delirium	144	15.4%	94	14.2%	1.244	0.035
Depression	747	79.9%	490	73.8%	6.098	0.145
Electroconvulsive Therapy	20	2.1%	*****	*****	*****	*****
Hallucination	74	7.9%	44	6.6%	1.288	0.050
Obsessive-Compulsive Disorder	27	2.9%	11	1.7%	1.231	0.083
Other Cerebral Degenerations	24	2.6%	27	4.1%	-1.499	-0.084
Other Mental Disorders	77	8.2%	53	8.0%	0.253	0.009

Table 1h. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Psychological Disorders	429	45.9%	296	44.6%	1.304	0.026
Persistent Mental Disorders due to Conditions Classified Elsewhere	34	3.6%	33	5.0%	-1.334	-0.066
Personality Disorders	230	24.6%	102	15.4%	9.237	0.233
Pervasive Developmental Disorders	23	2.5%	15	2.3%	0.201	0.013
Post-Traumatic Stress Disorder	301	32.2%	140	21.1%	11.108	0.253
Psychotherapy	417	44.6%	250	37.7%	6.948	0.142
Psychotic Conditions	145	15.5%	109	16.4%	-0.908	-0.025
Schizophrenia	212	22.7%	156	23.5%	-0.820	-0.019
Sleep Disorder	464	49.6%	279	42.0%	7.608	0.153
Substance Abuse	417	44.6%	271	40.8%	3.786	0.077
Suicidal Behavior	546	58.4%	362	54.5%	3.878	0.078
Transcranial Magnetic Stimulation	*****	*****	*****	*****	*****	*****
Vagus Nerve Stimulation	*****	*****	*****	*****	*****	*****
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	*****	*****	0	0.0%	*****	*****
dulaglutide	290	31.0%	0	0.0%	NaN	NaN
exenatide	116	12.4%	0	0.0%	NaN	NaN
liraglutide	275	29.4%	0	0.0%	NaN	NaN
lixisenatide	*****	*****	0	0.0%	*****	*****
semaglutide	231	24.7%	0	0.0%	NaN	NaN
tirzepatide	12	1.3%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	935	100.0%	664	100.0%	0.000	NaN

Table 1h. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
insulin*	410	43.9%	242	36.4%	7.404	0.151
metformin*	830	88.8%	592	89.2%	-0.387	-0.012
alpha-glucosidase inhibitors*	*****	*****	*****	*****	*****	*****
thiazolidinediones*	55	5.9%	36	5.4%	0.461	0.020
meglitinides*	*****	*****	*****	*****	*****	*****
amylin analogue*	0	0.0%	0	0.0%	NaN	NaN
sulfonylureas*	303	32.4%	216	32.5%	-0.124	-0.003
bile acid sequestrants*	0	0.0%	0	0.0%	NaN	NaN
Other Weight Loss Agents*	0	0.0%	0	0.0%	NaN	NaN
benzphetamine	0	0.0%	0	0.0%	NaN	NaN
bupropion	0	0.0%	0	0.0%	NaN	NaN
diethylpropion	0	0.0%	0	0.0%	NaN	NaN
lorcaserin	0	0.0%	0	0.0%	NaN	NaN
phentermine	0	0.0%	0	0.0%	NaN	NaN
phentermine-topiramate	0	0.0%	0	0.0%	NaN	NaN
phendimetrazine	0	0.0%	0	0.0%	NaN	NaN
orlistat	0	0.0%	0	0.0%	NaN	NaN
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	368	39.4%	232	34.9%	4.419	0.092
Antipsychotics	561	60.0%	346	52.1%	7.892	0.160
Anxiolytics/Hypnotics	559	59.8%	376	56.6%	3.160	0.064
Lithium & Other Mood Stabilizers	404	43.2%	235	35.4%	7.817	0.161
Antidepressants	812	86.8%	525	79.1%	7.779	0.208

Table 1h. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	25.6	20.1	21.2	17.5	4.359	0.231
Mean number of emergency room encounters*	3.2	4.7	2.7	3.8	0.517	0.121
Mean number of inpatient hospital encounters*	1.0	1.4	1.0	1.4	0.024	0.017
Mean number of non-acute institutional encounters*	0.5	0.9	0.5	0.9	-0.053	-0.060
Mean number of other ambulatory encounters*	18.3	26.2	16.4	23.3	1.869	0.075
Mean number of filled prescriptions*	50.7	34.1	45.4	31.8	5.246	0.159
Mean number of generics dispensed*	17.4	7.6	16.2	7.2	1.156	0.157
Mean number of unique drug classes dispensed*	15.3	6.5	13.9	6.2	1.479	0.233

^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759.

Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1i. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	956	N/A	26,663	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	50.8	13.4	47.6	11.3	3.201	0.258
Age						
18-24 years	37	3.9%	28	0.1%	3.774	0.270
25-44 years	270	28.3%	12,965	48.6%	-20.359	-0.412
45-64 years	487	50.9%	13,561	50.9%	0.023	NaN
65-79 years	145	15.2%	97	0.4%	14.805	0.597
≥ 80 years	17	1.8%	12	0.0%	1.758	0.182
Sex*						
Female	604	63.2%	11,629	43.6%	19.564	NaN
Male	352	36.8%	15,034	56.4%	-19.564	-0.384
Race[4]						
American Indian or Alaska Native	*****	*****	16	0.1%	*****	*****
Asian	*****	*****	*****	*****	*****	*****
Black or African American	101	10.6%	91	0.3%	10.270	0.458
Multi-racial	0	0.0%	*****	*****	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****	*****
Unknown	210	22.0%	26,120	98.0%	-75.989	NaN
White	614	64.2%	417	1.6%	62.611	2.021
Hispanic origin						

Table 1i. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	66	6.9%	47	0.2%	6.761	0.376
No	729	76.3%	538	2.0%	74.236	3.219
Unknown	161	16.8%	26,079	97.8%	-80.997	NaN
Year*						
2015	50	5.3%	12	0.0%	5.223	NaN
2016	90	9.4%	796	3.0%	6.461	0.262
2017	108	11.3%	690	2.6%	8.707	0.339
2018	110	11.5%	7,802	29.3%	-17.727	-0.430
2019	146	15.3%	5,527	20.7%	-5.450	-0.136
2020	163	17.1%	1,191	4.5%	12.623	0.410
2021	109	11.4%	5,840	21.9%	-10.542	-0.274
2022	117	12.2%	4,142	15.5%	-3.285	-0.092
2023	62	6.5%	664	2.5%	3.989	0.191
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.8	1.9	0.5	1.0	1.315	0.862
Combined comorbidity score*,[6]	3.9	2.6	2.0	1.1	1.927	0.960
Medical History						
Obesity*	524	54.8%	16,995	63.7%	-8.967	-0.179
Weight Reduction Surgery or Procedure*	0	0.0%	0	0.0%	NaN	NaN
Lifestyle intervention*	228	23.9%	6,092	22.8%	1.017	0.023
Cardiovascular Disease*	242	25.3%	795	3.0%	22.359	0.681
Cognitive Impairment*	81	8.5%	57	0.2%	8.262	0.411
Traumatic Brain Injury*	*****	*****	*****	*****	*****	*****

Table 1i. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	134	14.0%	92	0.3%	13.691	0.543
Epilepsy*	87	9.1%	65	0.2%	8.845	0.422
Chronic Pain*	390	40.8%	1,007	3.8%	37.048	NaN
Psychiatric History						
Previous Intentional Self-Harm Ever	956	100.0%	26,663	100.0%	0.000	NaN
Psychiatric History Overall*	956	100.0%	26,663	100.0%	0.000	NaN
Psychiatric Drug Dispensings	889	93.0%	24,571	92.2%	0.828	NaN
Intentional Self-Harm Encounter	956	100.0%	26,663	100.0%	0.000	NaN
Any Other Psychiatric Event	956	100.0%	26,663	100.0%	0.000	NaN
Attention-Deficit/Hyperactivity Disorder	66	6.9%	4,027	15.1%	-8.198	-0.250
Akathisia	18	1.9%	12	0.0%	1.871	0.187
Anxiety	641	67.1%	17,319	65.0%	2.105	NaN
Behavioral Disorder	832	87.0%	24,565	92.1%	-5.111	-0.173
Bipolar Disorder	406	42.4%	5,364	20.1%	22.303	0.481
Cerebral Degenerations usually Manifested in Childhood	31	3.2%	22	0.1%	3.165	0.245
Conduct Disorder	23	2.4%	15	0.1%	2.326	0.210
Delirium	178	18.6%	3,459	13.0%	5.651	NaN
Depression	762	79.7%	19,406	72.8%	6.891	NaN
Electroconvulsive Therapy	22	2.2%	12	0.0%	2.205	0.205
Hallucination	65	6.8%	5,803	21.8%	-14.950	-0.413
Obsessive-Compulsive Disorder	24	2.6%	13	0.0%	2.509	0.219
Other Cerebral Degenerations	28	2.9%	22	0.1%	2.851	0.232

Table 1i. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Mental Disorders	75	7.9%	1,000	3.7%	4.138	0.171
Other Psychological Disorders	419	43.8%	10,289	38.6%	5.258	0.103
Persistent Mental Disorders due to Conditions Classified Elsewhere	41	4.3%	28	0.1%	4.174	0.285
Personality Disorders	201	21.0%	5,901	22.1%	-1.138	-0.027
Pervasive Developmental Disorders	22	2.2%	22	0.1%	2.168	0.199
Post-Traumatic Stress Disorder	270	28.2%	11,640	43.7%	-15.452	-0.312
Psychotherapy	398	41.6%	15,201	57.0%	-15.385	-0.300
Psychotic Conditions	140	14.6%	1,293	4.9%	9.748	0.324
Schizophrenia	212	22.2%	5,940	22.3%	-0.081	-0.002
Sleep Disorder	482	50.4%	8,748	32.8%	17.641	NaN
Substance Abuse	448	46.8%	7,755	29.1%	17.719	NaN
Suicidal Behavior	578	60.4%	20,371	76.4%	-15.957	NaN
Transcranial Magnetic Stimulation	*****	*****	*****	*****	*****	*****
Vagus Nerve Stimulation	*****	*****	*****	*****	*****	*****
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	*****	*****	*****	*****	*****	*****
dulaglutide	299	31.2%	0	0.0%	NaN	NaN
exenatide	118	12.3%	0	0.0%	NaN	NaN
liraglutide	289	30.2%	0	0.0%	NaN	NaN
lixisenatide	*****	*****	0	0.0%	*****	*****
semaglutide	228	23.9%	0	0.0%	NaN	NaN
tirzepatide	*****	*****	0	0.0%	*****	*****
Any Anti-Diabetic Agents	956	100.0%	26,663	100.0%	0.000	NaN

Table 1i. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
insulin*	435	45.5%	7,665	28.7%	16.791	NaN
metformin*	855	89.5%	26,445	99.2%	-9.732	NaN
alpha-glucosidase inhibitors*	*****	*****	*****	*****	*****	*****
thiazolidinediones*	83	8.7%	41	0.2%	8.541	NaN
meglitinides*	*****	*****	*****	*****	*****	*****
amylin analogue*	0	0.0%	0	0.0%	NaN	NaN
sulfonylureas*	325	34.0%	3,628	13.6%	20.408	NaN
bile acid sequestrants*	0	0.0%	0	0.0%	NaN	NaN
Other Weight Loss Agents*	0	0.0%	0	0.0%	NaN	NaN
benzphetamine	0	0.0%	0	0.0%	NaN	NaN
bupropion	0	0.0%	0	0.0%	NaN	NaN
diethylpropion	0	0.0%	0	0.0%	NaN	NaN
lorcaserin	0	0.0%	0	0.0%	NaN	NaN
phentermine	0	0.0%	0	0.0%	NaN	NaN
phentermine-topiramate	0	0.0%	0	0.0%	NaN	NaN
phendimetrazine	0	0.0%	0	0.0%	NaN	NaN
orlistat	0	0.0%	0	0.0%	NaN	NaN
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	379	39.7%	15,620	58.6%	-18.895	NaN
Antipsychotics	573	59.9%	15,459	58.0%	1.963	NaN
Anxiolytics/Hypnotics	557	58.2%	22,581	84.7%	-26.453	NaN
Lithium & Other Mood Stabilizers	411	43.0%	5,358	20.1%	22.917	NaN
Antidepressants	821	85.8%	21,239	79.7%	6.179	NaN

Table 1i. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	25.4	18.8	12.8	8.6	12.561	0.857
Mean number of emergency room encounters*	3.0	4.5	2.0	1.2	1.008	0.306
Mean number of inpatient hospital encounters*	1.1	1.4	1.2	0.8	-0.190	-0.163
Mean number of non-acute institutional encounters*	0.5	0.9	0.0	0.2	0.470	0.743
Mean number of other ambulatory encounters*	17.5	25.3	1.6	4.6	15.941	0.875
Mean number of filled prescriptions*	50.3	34.5	26.0	21.7	24.263	0.841
Mean number of generics dispensed*	17.7	7.9	11.9	5.9	5.806	0.833
Mean number of unique drug classes dispensed*	15.3	6.6	10.3	5.5	5.017	0.825

Table 1i. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1j. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	438,100	100.0%	503,313	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)*	61.1	9.9	63.8	9.7	-2.690	-0.274
Age						
18-24 years	2,668	0.6%	1,517	0.3%	0.308	0.046
25-44 years	54,370	12.4%	43,600	8.7%	3.748	0.122
45-64 years	173,808	39.7%	186,956	37.1%	2.528	0.052
65-79 years	188,642	43.1%	231,996	46.1%	-3.035	-0.061
≥ 80 years	18,612	4.2%	39,244	7.8%	-3.549	-0.150
Sex*						
Female	215,165	49.1%	196,976	39.1%	9.977	0.202
Male	222,935	50.9%	306,337	60.9%	-9.977	-0.202
Race[3]						
American Indian or Alaska Native	3,085	0.7%	2,579	0.5%	0.192	0.025
Asian	10,038	2.3%	25,796	5.1%	-2.834	-0.150
Black or African American	44,605	10.2%	47,393	9.4%	0.765	0.026
Multi-racial	2,800	0.6%	2,753	0.5%	0.092	0.012
Native Hawaiian or Other Pacific Islander	1,667	0.4%	2,273	0.5%	-0.071	-0.011
Unknown	187,859	42.9%	207,599	41.2%	1.634	0.033
White	188,046	42.9%	214,920	42.7%	0.222	0.004
Hispanic origin						
Yes	23,217	5.3%	35,974	7.1%	-1.848	-0.077
No	220,998	50.4%	262,352	52.1%	-1.680	-0.034

Table 1j. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Unknown	193,885	44.3%	204,987	40.7%	3.528	0.071
Year*						
2015	6,811	1.6%	9,031	1.8%	-0.240	-0.019
2016	32,958	7.5%	40,962	8.1%	-0.616	-0.023
2017	39,353	9.0%	49,894	9.9%	-0.930	-0.032
2018	46,558	10.6%	47,690	9.5%	1.152	0.038
2019	57,124	13.0%	65,526	13.0%	0.020	0.001
2020	62,228	14.2%	77,059	15.3%	-1.106	-0.031
2021	59,930	13.7%	75,173	14.9%	-1.256	-0.036
2022	73,095	16.7%	85,867	17.1%	-0.376	-0.010
2023	60,043	13.7%	52,111	10.4%	3.352	0.103
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[4]	1.0	1.4	1.1	1.5	-0.093	-0.064
Combined comorbidity score*,[5]	1.0	1.6	1.1	1.9	-0.158	-0.090
Medical History						
Obesity*	170,293	38.9%	136,684	27.2%	11.714	0.251
Weight Reduction Surgery or Procedure*	43	0.0%	58	0.0%	-0.002	-0.002
Lifestyle intervention*	77,243	17.6%	81,082	16.1%	1.522	0.041
Cardiovascular Disease*	55,768	12.7%	84,470	16.8%	-4.053	-0.114
Cognitive Impairment*	421	0.1%	730	0.1%	-0.049	-0.014
Traumatic Brain Injury*	69	0.0%	73	0.0%	0.001	0.001
Migraine*	5,413	1.2%	4,765	0.9%	0.289	0.028
Epilepsy*	1,101	0.3%	1,364	0.3%	-0.020	-0.004
Chronic Pain*	48,950	11.2%	48,356	9.6%	1.566	0.051
Psychiatric History						

Table 1j. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Previous Intentional Self-Harm Ever	317	0.1%	257	0.1%	0.021	0.009
Psychiatric History Overall*	0	0.0%	0	0.0%	NaN	NaN
Psychiatric Drug Dispensings	0	0.0%	0	0.0%	NaN	NaN
Intentional Self-Harm Encounter	0	0.0%	0	0.0%	NaN	NaN
Any Other Psychiatric Event	0	0.0%	0	0.0%	NaN	NaN
Attention-Deficit/Hyperactivity Disorder	0	0.0%	0	0.0%	NaN	NaN
Akathisia	0	0.0%	0	0.0%	NaN	NaN
Anxiety	0	0.0%	0	0.0%	NaN	NaN
Behavioral Disorder	0	0.0%	0	0.0%	NaN	NaN
Bipolar Disorder	0	0.0%	0	0.0%	NaN	NaN
Cerebral Degenerations usually Manifested in Childhood	0	0.0%	0	0.0%	NaN	NaN
Conduct Disorder	0	0.0%	0	0.0%	NaN	NaN
Delirium	0	0.0%	0	0.0%	NaN	NaN
Depression	0	0.0%	0	0.0%	NaN	NaN
Electroconvulsive Therapy	0	0.0%	0	0.0%	NaN	NaN
Hallucination	0	0.0%	0	0.0%	NaN	NaN
Obsessive-Compulsive Disorder	0	0.0%	0	0.0%	NaN	NaN
Other Cerebral Degenerations	0	0.0%	0	0.0%	NaN	NaN
Other Mental Disorders	0	0.0%	0	0.0%	NaN	NaN
Other Psychological Disorders	0	0.0%	0	0.0%	NaN	NaN
Persistent Mental Disorders due to Conditions Classified Elsewhere	0	0.0%	0	0.0%	NaN	NaN
Personality Disorders	0	0.0%	0	0.0%	NaN	NaN
Pervasive Developmental Disorders	0	0.0%	0	0.0%	NaN	NaN

Table 1j. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Post-Traumatic Stress Disorder	0	0.0%	0	0.0%	NaN	NaN
Psychotherapy	0	0.0%	0	0.0%	NaN	NaN
Psychotic Conditions	0	0.0%	0	0.0%	NaN	NaN
Schizophrenia	0	0.0%	0	0.0%	NaN	NaN
Sleep Disorder	0	0.0%	0	0.0%	NaN	NaN
Substance Abuse	0	0.0%	0	0.0%	NaN	NaN
Suicidal Behavior	0	0.0%	0	0.0%	NaN	NaN
Transcranial Magnetic Stimulation	0	0.0%	0	0.0%	NaN	NaN
Vagus Nerve Stimulation	0	0.0%	0	0.0%	NaN	NaN
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	3,782	0.9%	0	0.0%	NaN	NaN
dulaglutide	150,590	34.4%	0	0.0%	NaN	NaN
exenatide	31,760	7.2%	0	0.0%	NaN	NaN
liraglutide	85,000	19.4%	0	0.0%	NaN	NaN
lixisenatide	6,902	1.6%	0	0.0%	NaN	NaN
semaglutide	150,869	34.4%	0	0.0%	NaN	NaN
tirzepatide	9,576	2.2%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	438,099	100.0%	503,312	100.0%	-0.000	-0.000
insulin*	143,188	32.7%	94,010	18.7%	14.006	0.325
metformin*	389,352	88.9%	455,573	90.5%	-1.642	-0.054
alpha-glucosidase inhibitors*	1,911	0.4%	2,239	0.4%	-0.009	-0.001
thiazolidinediones*	39,417	9.0%	43,352	8.6%	0.384	0.014
meglitinides*	5,429	1.2%	5,414	1.1%	0.164	0.015
amylin analogue*	35	0.0%	25	0.0%	0.003	0.004
sulfonylureas*	173,084	39.5%	206,460	41.0%	-1.512	-0.031

Table 1j. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
bile acid sequestrants*	1,260	0.3%	1,443	0.3%	0.001	0.000
Other Weight Loss Agents*	1,070	0.2%	397	0.1%	0.165	0.041
benzphetamine	*****	*****	0	0.0%	*****	*****
bupropion	0	0.0%	0	0.0%	NaN	NaN
diethylpropion	30	0.0%	*****	*****	*****	*****
lorcaserin	51	0.0%	30	0.0%	0.006	0.006
phentermine	895	0.2%	339	0.1%	0.137	0.037
phentermine-topiramate	65	0.0%	15	0.0%	0.012	0.013
phendimetrazine	24	0.0%	*****	*****	*****	*****
orlistat	19	0.0%	*****	*****	*****	*****
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	62,050	14.2%	61,534	12.2%	1.938	0.057
Antipsychotics	0	0.0%	0	0.0%	NaN	NaN
Anxiolytics/Hypnotics	0	0.0%	0	0.0%	NaN	NaN
Lithium & Other Mood Stabilizers	0	0.0%	0	0.0%	NaN	NaN
Antidepressants	116	0.0%	96	0.0%	0.007	0.005
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	7.8	7.7	7.5	6.9	0.378	0.052
Mean number of emergency room encounters*	0.2	0.6	0.2	0.6	0.007	0.012
Mean number of inpatient hospital encounters*	0.0	0.2	0.1	0.3	-0.018	-0.073
Mean number of non-acute institutional encounters*	0.0	0.1	0.0	0.1	-0.001	-0.018

Table 1j. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Mean number of other ambulatory encounters*	2.0	6.8	2.1	6.4	-0.096	-0.014
Mean number of filled prescriptions*	18.1	12.0	17.5	11.6	0.595	0.050
Mean number of generics dispensed*	8.4	3.5	8.2	3.5	0.218	0.062
Mean number of unique drug classes dispensed*	7.4	3.2	6.6	3.2	0.820	0.258

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759.

Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1k. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	438,040	100.0%	503,214	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)*	61.1	9.9	63.8	9.7	-2.688	-0.274
Age						
18-24 years	2,667	0.6%	1,517	0.3%	0.307	0.046
25-44 years	54,353	12.4%	43,598	8.7%	3.744	0.122
45-64 years	173,780	39.7%	186,930	37.1%	2.525	0.052
65-79 years	188,630	43.1%	231,938	46.1%	-3.029	-0.061
≥ 80 years	18,610	4.2%	39,231	7.8%	-3.548	-0.150
Sex*						
Female	215,116	49.1%	196,944	39.1%	9.972	0.202
Male	222,924	50.9%	306,270	60.9%	-9.972	-0.202
Race[3]						
American Indian or Alaska Native	3,084	0.7%	2,579	0.5%	0.192	0.025
Asian	10,038	2.3%	25,783	5.1%	-2.832	-0.150
Black or African American	44,597	10.2%	47,377	9.4%	0.766	0.026
Multi-racial	2,798	0.6%	2,753	0.5%	0.092	0.012
Native Hawaiian or Other Pacific Islander	1,667	0.4%	2,273	0.5%	-0.071	-0.011
Unknown	187,832	42.9%	207,580	41.3%	1.629	0.033
White	188,024	42.9%	214,869	42.7%	0.225	0.005
Hispanic origin						

Table 1k. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Yes	23,205	5.3%	35,968	7.1%	-1.850	-0.077
No	220,970	50.4%	262,284	52.1%	-1.677	-0.034
Unknown	193,865	44.3%	204,962	40.7%	3.527	0.071
Year*						
2015	6,811	1.6%	9,030	1.8%	-0.240	-0.019
2016	32,955	7.5%	40,955	8.1%	-0.615	-0.023
2017	39,331	9.0%	49,891	9.9%	-0.936	-0.032
2018	46,551	10.6%	47,684	9.5%	1.151	0.038
2019	57,120	13.0%	65,515	13.0%	0.021	0.001
2020	62,225	14.2%	77,043	15.3%	-1.105	-0.031
2021	59,924	13.7%	75,155	14.9%	-1.255	-0.036
2022	73,091	16.7%	85,834	17.1%	-0.371	-0.010
2023	60,032	13.7%	52,107	10.4%	3.350	0.103
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*[,4]	1.0	1.4	1.1	1.5	-0.092	-0.064
Combined comorbidity score*[,5]	1.0	1.6	1.1	1.9	-0.157	-0.090
Medical History						
Obesity*	170,245	38.9%	136,654	27.2%	11.709	0.251
Weight Reduction Surgery or Procedure*	42	0.0%	58	0.0%	-0.002	-0.002
Lifestyle intervention*	77,228	17.6%	81,065	16.1%	1.521	0.041

Table 1k. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Cardiovascular Disease*	55,765	12.7%	84,426	16.8%	-4.047	-0.114
Cognitive Impairment*	420	0.1%	726	0.1%	-0.048	-0.014
Traumatic Brain Injury*	68	0.0%	73	0.0%	0.001	0.001
Migraine*	5,412	1.2%	4,765	0.9%	0.289	0.028
Epilepsy*	1,101	0.3%	1,357	0.3%	-0.018	-0.004
Chronic Pain*	48,943	11.2%	48,341	9.6%	1.567	0.051
Psychiatric History						
Previous Intentional Self-Harm Ever	317	0.1%	257	0.1%	0.021	0.009
Psychiatric History Overall*	0	0.0%	0	0.0%	NaN	NaN
Psychiatric Drug Dispensings	0	0.0%	0	0.0%	NaN	NaN
Intentional Self-Harm Encounter	0	0.0%	0	0.0%	NaN	NaN
Any Other Psychiatric Event	0	0.0%	0	0.0%	NaN	NaN
Attention-Deficit/Hyperactivity Disorder	0	0.0%	0	0.0%	NaN	NaN
Akathisia	0	0.0%	0	0.0%	NaN	NaN
Anxiety	0	0.0%	0	0.0%	NaN	NaN
Behavioral Disorder	0	0.0%	0	0.0%	NaN	NaN
Bipolar Disorder	0	0.0%	0	0.0%	NaN	NaN
Cerebral Degenerations usually Manifested in Childhood	0	0.0%	0	0.0%	NaN	NaN
Conduct Disorder	0	0.0%	0	0.0%	NaN	NaN
Delirium	0	0.0%	0	0.0%	NaN	NaN

Table 1k. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Depression	0	0.0%	0	0.0%	NaN	NaN
Electroconvulsive Therapy	0	0.0%	0	0.0%	NaN	NaN
Hallucination	0	0.0%	0	0.0%	NaN	NaN
Obsessive-Compulsive Disorder	0	0.0%	0	0.0%	NaN	NaN
Other Cerebral Degenerations	0	0.0%	0	0.0%	NaN	NaN
Other Mental Disorders	0	0.0%	0	0.0%	NaN	NaN
Other Psychological Disorders	0	0.0%	0	0.0%	NaN	NaN
Persistent Mental Disorders due to Conditions Classified Elsewhere	0	0.0%	0	0.0%	NaN	NaN
Personality Disorders	0	0.0%	0	0.0%	NaN	NaN
Pervasive Developmental Disorders	0	0.0%	0	0.0%	NaN	NaN
Post-Traumatic Stress Disorder	0	0.0%	0	0.0%	NaN	NaN
Psychotherapy	0	0.0%	0	0.0%	NaN	NaN
Psychotic Conditions	0	0.0%	0	0.0%	NaN	NaN
Schizophrenia	0	0.0%	0	0.0%	NaN	NaN
Sleep Disorder	0	0.0%	0	0.0%	NaN	NaN
Substance Abuse	0	0.0%	0	0.0%	NaN	NaN
Suicidal Behavior	0	0.0%	0	0.0%	NaN	NaN
Transcranial Magnetic Stimulation	0	0.0%	0	0.0%	NaN	NaN
Vagus Nerve Stimulation	0	0.0%	0	0.0%	NaN	NaN
Medical Product Use						

Table 1k. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Index GLP-1 RA Product						
albiglutide	3,781	0.9%	0	0.0%	NaN	NaN
dulaglutide	150,586	34.4%	0	0.0%	NaN	NaN
exenatide	31,731	7.2%	0	0.0%	NaN	NaN
liraglutide	84,993	19.4%	0	0.0%	NaN	NaN
lixisenatide	6,898	1.6%	0	0.0%	NaN	NaN
semaglutide	150,858	34.4%	0	0.0%	NaN	NaN
tirzepatide	9,572	2.2%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	438,039	100.0%	503,213	100.0%	-0.000	-0.000
insulin*	143,157	32.7%	93,986	18.7%	14.004	0.325
metformin*	389,297	88.9%	455,479	90.5%	-1.641	-0.054
alpha-glucosidase inhibitors*	1,911	0.4%	2,239	0.4%	-0.009	-0.001
thiazolidinediones*	39,410	9.0%	43,342	8.6%	0.384	0.014
meglitinides*	5,429	1.2%	5,414	1.1%	0.164	0.015
amylin analogue*	32	0.0%	23	0.0%	0.003	0.004
sulfonylureas*	173,051	39.5%	206,405	41.0%	-1.512	-0.031
bile acid sequestrants*	1,259	0.3%	1,442	0.3%	0.001	0.000
Other Weight Loss Agents*	1,050	0.2%	396	0.1%	0.161	0.040
benzphetamine	*****	*****	0	0.0%	*****	*****
bupropion	0	0.0%	0	0.0%	NaN	NaN
diethylpropion	30	0.0%	*****	*****	*****	*****

Table 1k. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
lorcaserin	51	0.0%	30	0.0%	0.006	0.006
phentermine	875	0.2%	338	0.1%	0.133	0.036
phentermine-topiramate	65	0.0%	15	0.0%	0.012	0.013
phendimetrazine	24	0.0%	*****	*****	*****	*****
orlistat	19	0.0%	*****	*****	*****	*****
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	62,027	14.2%	61,510	12.2%	1.937	0.057
Antipsychotics	0	0.0%	0	0.0%	NaN	NaN
Anxiolytics/Hypnotics	0	0.0%	0	0.0%	NaN	NaN
Lithium & Other Mood Stabilizers	0	0.0%	0	0.0%	NaN	NaN
Antidepressants	115	0.0%	96	0.0%	0.007	0.005
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	7.8	7.7	7.5	6.9	0.379	0.052
Mean number of emergency room encounters*	0.2	0.6	0.2	0.6	0.007	0.013
Mean number of inpatient hospital encounters*	0.0	0.2	0.1	0.3	-0.018	-0.072
Mean number of non-acute institutional encounters*	0.0	0.1	0.0	0.1	-0.001	-0.018
Mean number of other ambulatory encounters*	2.0	6.8	2.1	6.4	-0.095	-0.014

Table 1k. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Mean number of filled prescriptions*	18.1	12.0	17.5	11.6	0.597	0.051
Mean number of generics dispensed*	8.4	3.5	8.2	3.5	0.219	0.062
Mean number of unique drug classes dispensed*	7.4	3.2	6.6	3.2	0.821	0.258

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1l. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	790,933	N/A	582,949	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.7	10.0	62.6	10.2	-0.926	-0.092
Age						
18-24 years	1,929	0.2%	2,737	0.5%	-0.226	-0.038
25-44 years	61,806	7.8%	60,730	10.4%	-2.603	-0.094
45-64 years	375,147	47.4%	223,168	38.3%	9.148	0.219
65-79 years	321,403	40.6%	259,429	44.5%	-3.867	-0.098
≥ 80 years	30,649	3.9%	36,885	6.3%	-2.452	-0.113
Sex*						
Female	372,782	47.1%	262,092	45.0%	2.172	0.044
Male	418,151	52.9%	320,857	55.0%	-2.172	-0.044
Race[4]						
American Indian or Alaska Native	3,907	0.5%	3,115	0.5%	-0.040	-0.006
Asian	18,680	2.4%	25,713	4.4%	-2.049	-0.115
Black or African American	79,208	10.0%	64,164	11.0%	-0.992	-0.034
Multi-racial	3,448	0.4%	3,557	0.6%	-0.174	-0.025
Native Hawaiian or Other Pacific Islander	2,008	0.3%	2,313	0.4%	-0.143	-0.025
Unknown	419,160	53.0%	248,408	42.6%	10.383	0.334
White	264,522	33.4%	235,679	40.4%	-6.984	-0.183
Hispanic origin						

Table 1l. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	35,574	4.5%	44,465	7.6%	-3.130	-0.138
No	307,937	38.9%	295,433	50.7%	-11.746	-0.430
Unknown	447,422	56.6%	243,051	41.7%	14.875	0.667
Year*						
2015	12,805	1.6%	10,419	1.8%	-0.168	-0.013
2016	74,185	9.4%	48,272	8.3%	1.099	0.039
2017	102,793	13.0%	56,555	9.7%	3.295	0.104
2018	92,605	11.7%	62,195	10.7%	1.039	0.033
2019	104,075	13.2%	76,525	13.1%	0.031	0.001
2020	138,792	17.5%	85,505	14.7%	2.880	0.080
2021	92,399	11.7%	82,572	14.2%	-2.482	-0.075
2022	107,609	13.6%	94,857	16.3%	-2.667	-0.076
2023	65,670	8.3%	66,049	11.3%	-3.027	-0.103
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.6	1.9	1.2	1.5	0.329	0.193
Combined comorbidity score*,[6]	1.6	2.5	1.2	1.9	0.422	0.190
Medical History						
Obesity*	299,367	37.8%	198,774	34.1%	3.752	0.079
Weight Reduction Surgery or Procedure*	44	0.0%	68	0.0%	-0.006	-0.007
Lifestyle intervention*	168,588	21.3%	95,053	16.3%	5.010	0.130
Cardiovascular Disease*	183,541	23.2%	95,010	16.3%	6.907	0.177
Cognitive Impairment*	797	0.1%	776	0.1%	-0.032	-0.009
Traumatic Brain Injury*	66	0.0%	61	0.0%	-0.002	-0.002

Table 1l. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	11,173	1.4%	7,153	1.2%	0.186	0.016
Epilepsy*	2,731	0.3%	1,519	0.3%	0.085	0.015
Chronic Pain*	170,462	21.6%	67,554	11.6%	9.964	0.273
Psychiatric History						
Previous Intentional Self-Harm Ever	492	0.1%	322	0.1%	0.007	0.003
Psychiatric History Overall*	0	0.0%	0	0.0%	NaN	NaN
Psychiatric Drug Dispensings	0	0.0%	0	0.0%	NaN	NaN
Intentional Self-Harm Encounter	0	0.0%	0	0.0%	NaN	NaN
Any Other Psychiatric Event	0	0.0%	0	0.0%	NaN	NaN
Attention-Deficit/Hyperactivity Disorder	0	0.0%	0	0.0%	NaN	NaN
Akathisia	0	0.0%	0	0.0%	NaN	NaN
Anxiety	0	0.0%	0	0.0%	NaN	NaN
Behavioral Disorder	0	0.0%	0	0.0%	NaN	NaN
Bipolar Disorder	0	0.0%	0	0.0%	NaN	NaN
Cerebral Degenerations usually Manifested in Childhood	0	0.0%	0	0.0%	NaN	NaN
Conduct Disorder	0	0.0%	0	0.0%	NaN	NaN
Delirium	0	0.0%	0	0.0%	NaN	NaN
Depression	0	0.0%	0	0.0%	NaN	NaN
Electroconvulsive Therapy	0	0.0%	0	0.0%	NaN	NaN
Hallucination	0	0.0%	0	0.0%	NaN	NaN
Obsessive-Compulsive Disorder	0	0.0%	0	0.0%	NaN	NaN
Other Cerebral Degenerations	0	0.0%	0	0.0%	NaN	NaN

Table 1l. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Mental Disorders	0	0.0%	0	0.0%	NaN	NaN
Other Psychological Disorders	0	0.0%	0	0.0%	NaN	NaN
Persistent Mental Disorders due to Conditions Classified Elsewhere	0	0.0%	0	0.0%	NaN	NaN
Personality Disorders	0	0.0%	0	0.0%	NaN	NaN
Pervasive Developmental Disorders	0	0.0%	0	0.0%	NaN	NaN
Post-Traumatic Stress Disorder	0	0.0%	0	0.0%	NaN	NaN
Psychotherapy	0	0.0%	0	0.0%	NaN	NaN
Psychotic Conditions	0	0.0%	0	0.0%	NaN	NaN
Schizophrenia	0	0.0%	0	0.0%	NaN	NaN
Sleep Disorder	0	0.0%	0	0.0%	NaN	NaN
Substance Abuse	0	0.0%	0	0.0%	NaN	NaN
Suicidal Behavior	0	0.0%	0	0.0%	NaN	NaN
Transcranial Magnetic Stimulation	0	0.0%	0	0.0%	NaN	NaN
Vagus Nerve Stimulation	0	0.0%	0	0.0%	NaN	NaN
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	6,520	0.8%	0	0.0%	NaN	NaN
dulaglutide	300,943	38.0%	0	0.0%	NaN	NaN
exenatide	52,217	6.6%	0	0.0%	NaN	NaN
liraglutide	165,736	21.0%	0	0.0%	NaN	NaN
lixisenatide	9,273	1.2%	0	0.0%	NaN	NaN
semaglutide	263,163	33.3%	0	0.0%	NaN	NaN
tirzepatide	13,927	1.8%	0	0.0%	NaN	NaN

Table 1l. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Any Anti-Diabetic Agents	790,930	100.0%	582,948	100.0%	-0.000	-0.001
insulin*	393,224	49.7%	253,705	43.5%	6.195	0.124
metformin*	671,963	85.0%	520,114	89.2%	-4.263	-0.128
alpha-glucosidase inhibitors*	2,643	0.3%	3,672	0.6%	-0.296	-0.043
thiazolidinediones*	60,284	7.6%	58,684	10.1%	-2.445	-0.086
meglitinides*	12,795	1.6%	8,972	1.5%	0.079	0.006
amylin analogue*	29	0.0%	68	0.0%	-0.008	-0.009
sulfonylureas*	312,359	39.5%	245,116	42.0%	-2.555	-0.052
bile acid sequestrants*	4,062	0.5%	2,017	0.3%	0.168	0.026
Other Weight Loss Agents*	733	0.1%	1,104	0.2%	-0.097	-0.026
benzphetamine	*****	*****	0	0.0%	*****	*****
bupropion	0	0.0%	0	0.0%	NaN	NaN
diethylpropion	19	0.0%	*****	*****	*****	*****
lorcaserin	37	0.0%	57	0.0%	-0.005	-0.006
phentermine	618	0.1%	1,003	0.2%	-0.094	-0.027
phentermine-topiramate	41	0.0%	26	0.0%	0.001	0.001
phendimetrazine	18	0.0%	*****	*****	*****	*****
orlistat	11	0.0%	12	0.0%	-0.001	-0.002
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	244,329	30.9%	91,838	15.8%	15.137	0.365
Antipsychotics	0	0.0%	0	0.0%	NaN	NaN
Anxiolytics/Hypnotics	0	0.0%	0	0.0%	NaN	NaN
Lithium & Other Mood Stabilizers	0	0.0%	0	0.0%	NaN	NaN

Table 1l. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Antidepressants	450	0.1%	110	0.0%	0.038	0.019
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	10.8	8.8	8.3	8.1	2.500	0.294
Mean number of emergency room encounters*	0.4	0.9	0.2	0.6	0.175	0.232
Mean number of inpatient hospital encounters*	0.2	0.5	0.1	0.3	0.107	0.278
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.1	0.020	0.158
Mean number of other ambulatory encounters*	2.9	7.6	2.3	6.9	0.593	0.082
Mean number of filled prescriptions*	27.6	19.1	19.2	13.2	8.395	0.511
Mean number of generics dispensed*	12.7	6.4	8.9	4.0	3.810	0.713
Mean number of unique drug classes dispensed*	9.2	4.7	7.6	3.8	1.548	0.364

Table 1l. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1m. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	723,816	100.0%	577,274	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)*	60.5	10.7	63.6	10.6	-3.135	-0.295
Age						
18-24 years	3,473	0.5%	1,517	0.3%	0.217	0.036
25-44 years	88,234	12.2%	48,041	8.3%	3.868	0.128
45-64 years	319,455	44.1%	226,008	39.2%	4.984	0.101
65-79 years	286,717	39.6%	257,670	44.6%	-5.024	-0.102
≥ 80 years	25,937	3.6%	44,038	7.6%	-4.045	-0.177
Sex*						
Female	429,141	59.3%	273,503	47.4%	11.910	0.240
Male	294,675	40.7%	303,771	52.6%	-11.910	-0.240
Race[3]						
American Indian or Alaska Native	5,413	0.7%	3,353	0.6%	0.167	0.021
Asian	7,067	1.0%	12,743	2.2%	-1.231	-0.098
Black or African American	67,364	9.3%	53,418	9.3%	0.053	0.002
Multi-racial	3,388	0.5%	2,214	0.4%	0.085	0.013
Native Hawaiian or Other Pacific Islander	1,443	0.2%	1,493	0.3%	-0.059	-0.012
Unknown	234,362	32.4%	171,781	29.8%	2.621	0.057
White	404,779	55.9%	332,272	57.6%	-1.636	-0.033
Hispanic origin						
Yes	29,414	4.1%	28,382	4.9%	-0.853	-0.041
No	445,312	61.5%	370,422	64.2%	-2.645	-0.055

Table 1m. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Unknown	249,090	34.4%	178,470	30.9%	3.497	0.075
Year*						
2015	10,571	1.5%	9,277	1.6%	-0.147	-0.012
2016	51,210	7.1%	41,699	7.2%	-0.148	-0.006
2017	63,020	8.7%	51,926	9.0%	-0.288	-0.010
2018	74,813	10.3%	50,666	8.8%	1.559	0.053
2019	92,258	12.7%	71,902	12.5%	0.291	0.009
2020	100,423	13.9%	88,340	15.3%	-1.429	-0.040
2021	100,827	13.9%	91,595	15.9%	-1.937	-0.054
2022	124,385	17.2%	107,692	18.7%	-1.471	-0.038
2023	106,309	14.7%	64,177	11.1%	3.570	0.107
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[4]	1.5	1.7	1.8	1.8	-0.279	-0.157
Combined comorbidity score*,[5]	2.0	2.3	2.4	2.7	-0.421	-0.171
Medical History						
Obesity*	378,770	52.3%	231,630	40.1%	12.205	0.247
Weight Reduction Surgery or Procedure*	625	0.1%	538	0.1%	-0.007	-0.002
Lifestyle intervention*	136,897	18.9%	93,752	16.2%	2.673	0.070
Cardiovascular Disease*	147,201	20.3%	161,705	28.0%	-7.675	-0.180
Cognitive Impairment*	20,521	2.8%	24,252	4.2%	-1.366	-0.074
Traumatic Brain Injury*	2,405	0.3%	1,784	0.3%	0.023	0.004
Migraine*	39,458	5.5%	24,182	4.2%	1.262	0.059
Epilepsy*	12,320	1.7%	10,639	1.8%	-0.141	-0.011
Chronic Pain*	194,659	26.9%	136,510	23.6%	3.246	0.075
Psychiatric History						

Table 1m. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Previous Intentional Self-Harm Ever	8,357	1.2%	5,327	0.9%	0.232	0.023
Psychiatric History Overall*	723,816	100.0%	577,274	100.0%	0.000	NaN
Psychiatric Drug Dispensings	540,467	74.7%	401,574	69.6%	5.105	0.114
Intentional Self-Harm Encounter	1,071	0.1%	751	0.1%	0.018	0.005
Any Other Psychiatric Event	587,667	81.2%	465,656	80.7%	0.525	0.013
Attention-Deficit/Hyperactivity Disorder	*****	*****	*****	*****	*****	*****
Akathisia	1,096	0.2%	779	0.1%	0.016	0.004
Anxiety	194,771	26.9%	138,350	24.0%	2.943	0.068
Behavioral Disorder	*****	*****	32,001	5.5%	*****	*****
Bipolar Disorder	45,929	6.3%	*****	*****	*****	*****
Cerebral Degenerations usually Manifested in Childhood	9,345	1.3%	*****	*****	*****	*****
Conduct Disorder	*****	*****	670	0.1%	*****	*****
Delirium	12,693	1.8%	*****	*****	*****	*****
Depression	211,150	29.2%	145,387	25.2%	3.987	0.090
Electroconvulsive Therapy	187	0.0%	123	0.0%	0.005	0.003
Hallucination	1,946	0.3%	*****	*****	*****	*****
Obsessive-Compulsive Disorder	*****	*****	1,423	0.2%	*****	*****
Other Cerebral Degenerations	*****	*****	*****	*****	*****	*****
Other Mental Disorders	*****	*****	*****	*****	*****	*****
Other Psychological Disorders	*****	*****	92,123	16.0%	*****	*****
Persistent Mental Disorders due to Conditions Classified Elsewhere	14,467	2.0%	*****	*****	*****	*****
Personality Disorders	*****	*****	*****	*****	*****	*****
Pervasive Developmental Disorders	*****	*****	1,369	0.2%	0.031	0.006

Table 1m. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Post-Traumatic Stress Disorder	*****	*****	*****	*****	*****	*****
Psychotherapy	65,792	9.1%	*****	*****	*****	*****
Psychotic Conditions	3,853	0.5%	*****	*****	*****	*****
Schizophrenia	*****	*****	*****	*****	*****	*****
Sleep Disorder	301,515	41.7%	220,610	38.2%	3.440	0.070
Substance Abuse	48,694	6.7%	43,493	7.5%	-0.807	-0.031
Suicidal Behavior	5,373	0.7%	*****	*****	*****	*****
Transcranial Magnetic Stimulation	248	0.0%	129	0.0%	0.012	0.007
Vagus Nerve Stimulation	*****	*****	*****	*****	*****	*****
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	5,015	0.7%	0	0.0%	NaN	NaN
dulaglutide	234,915	32.5%	0	0.0%	NaN	NaN
exenatide	53,837	7.4%	0	0.0%	NaN	NaN
liraglutide	152,053	21.0%	0	0.0%	NaN	NaN
lixisenatide	8,975	1.2%	0	0.0%	NaN	NaN
semaglutide	250,864	34.7%	0	0.0%	NaN	NaN
tirzepatide	18,640	2.6%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	723,815	100.0%	577,274	100.0%	-0.000	-0.002
insulin*	249,806	34.5%	139,035	24.1%	10.428	0.231
metformin*	637,384	88.1%	511,579	88.6%	-0.561	-0.017
alpha-glucosidase inhibitors*	2,740	0.4%	2,179	0.4%	0.001	0.000
thiazolidinediones*	55,716	7.7%	45,072	7.8%	-0.110	-0.004
meglitinides*	7,159	1.0%	5,621	1.0%	0.015	0.002
amylin analogue*	119	0.0%	52	0.0%	0.007	0.007
sulfonylureas*	254,590	35.2%	219,247	38.0%	-2.806	-0.058

Table 1m. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
bile acid sequestrants*	3,056	0.4%	2,183	0.4%	0.044	0.007
Other Weight Loss Agents*	2,938	0.4%	829	0.1%	0.262	0.050
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	421	0.1%	152	0.0%	0.032	0.015
diethylpropion	55	0.0%	*****	*****	*****	*****
lorcaserin	130	0.0%	38	0.0%	0.011	0.010
phentermine	2,189	0.3%	579	0.1%	0.202	0.045
phentermine-topiramate	129	0.0%	31	0.0%	0.012	0.012
phendimetrazine	39	0.0%	*****	*****	*****	*****
orlistat	50	0.0%	*****	*****	*****	*****
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	228,053	31.5%	166,297	28.8%	2.700	0.059
Antipsychotics	77,717	10.7%	55,864	9.7%	1.060	0.035
Anxiolytics/Hypnotics	221,926	30.7%	164,471	28.5%	2.170	0.048
Lithium & Other Mood Stabilizers	67,822	9.4%	47,334	8.2%	1.170	0.041
Antidepressants	445,305	61.5%	312,563	54.1%	7.377	0.150
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	12.7	11.5	12.3	10.8	0.453	0.041
Mean number of emergency room encounters*	0.5	1.2	0.5	1.3	-0.032	-0.026
Mean number of inpatient hospital encounters*	0.1	0.5	0.2	0.6	-0.070	-0.134
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.3	-0.013	-0.052

Table 1m. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Mean number of other ambulatory encounters*	5.0	13.4	5.1	13.0	-0.126	-0.010
Mean number of filled prescriptions*	31.0	21.8	29.1	20.2	1.834	0.087
Mean number of generics dispensed*	12.5	5.3	12.0	5.2	0.438	0.083
Mean number of unique drug classes dispensed*	11.2	4.8	10.2	4.6	1.022	0.218

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1n. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	723,708	100.0%	577,171	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)*	60.5	10.7	63.6	10.6	-3.134	-0.295
Age						
18-24 years	3,473	0.5%	1,517	0.3%	0.217	0.036
25-44 years	88,217	12.2%	48,032	8.3%	3.868	0.128
45-64 years	319,386	44.1%	225,973	39.2%	4.980	0.101
65-79 years	286,696	39.6%	257,619	44.6%	-5.020	-0.102
≥ 80 years	25,936	3.6%	44,030	7.6%	-4.045	-0.177
Sex*						
Female	429,050	59.3%	273,473	47.4%	11.903	0.240
Male	294,658	40.7%	303,698	52.6%	-11.903	-0.240
Race[3]						
American Indian or Alaska Native	5,413	0.7%	3,352	0.6%	0.167	0.021
Asian	7,067	1.0%	12,739	2.2%	-1.231	-0.098
Black or African American	67,352	9.3%	53,406	9.3%	0.053	0.002
Multi-racial	3,387	0.5%	2,212	0.4%	0.085	0.013
Native Hawaiian or Other Pacific Islander	1,443	0.2%	1,493	0.3%	-0.059	-0.012
Unknown	234,303	32.4%	171,756	29.8%	2.617	0.057
White	404,743	55.9%	332,213	57.6%	-1.633	-0.033
Hispanic origin						

Table 1n. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	29,394	4.1%	28,370	4.9%	-0.854	-0.041
No	445,275	61.5%	370,358	64.2%	-2.641	-0.055
Unknown	249,039	34.4%	178,443	30.9%	3.495	0.075
Year*						
2015	10,561	1.5%	9,275	1.6%	-0.148	-0.012
2016	51,200	7.1%	41,695	7.2%	-0.149	-0.006
2017	62,993	8.7%	51,923	9.0%	-0.292	-0.010
2018	74,797	10.3%	50,662	8.8%	1.558	0.053
2019	92,256	12.7%	71,896	12.5%	0.291	0.009
2020	100,418	13.9%	88,334	15.3%	-1.429	-0.040
2021	100,820	13.9%	91,543	15.9%	-1.930	-0.054
2022	124,376	17.2%	107,670	18.7%	-1.469	-0.038
2023	106,287	14.7%	64,173	11.1%	3.568	0.107
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[4]	1.5	1.7	1.8	1.8	-0.279	-0.156
Combined comorbidity score*,[5]	2.0	2.3	2.4	2.7	-0.421	-0.171
Medical History						
Obesity*	378,677	52.3%	231,610	40.1%	12.196	0.246
Weight Reduction Surgery or Procedure*	625	0.1%	538	0.1%	-0.007	-0.002
Lifestyle intervention*	136,864	18.9%	93,735	16.2%	2.671	0.070
Cardiovascular Disease*	147,189	20.3%	161,675	28.0%	-7.673	-0.180
Cognitive Impairment*	20,520	2.8%	24,247	4.2%	-1.366	-0.074
Traumatic Brain Injury*	2,405	0.3%	1,782	0.3%	0.024	0.004

Table 1n. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	39,438	5.4%	24,178	4.2%	1.260	0.059
Epilepsy*	12,320	1.7%	10,638	1.8%	-0.141	-0.011
Chronic Pain*	194,604	26.9%	136,484	23.6%	3.243	0.075
Psychiatric History						
Previous Intentional Self-Harm Ever	8,352	1.2%	5,327	0.9%	0.231	0.023
Psychiatric History Overall*	723,708	100.0%	577,171	100.0%	0.000	NaN
Psychiatric Drug Dispensings	540,370	74.7%	401,502	69.6%	5.103	0.114
Intentional Self-Harm Encounter	1,071	0.1%	751	0.1%	0.018	0.005
Any Other Psychiatric Event	587,573	81.2%	465,573	80.7%	0.525	0.013
Attention-Deficit/Hyperactivity Disorder	13,746	1.9%	6,975	1.2%	0.691	0.056
Akathisia	*****	*****	779	0.1%	*****	*****
Anxiety	194,738	26.9%	138,322	24.0%	2.943	0.068
Behavioral Disorder	45,513	6.3%	*****	*****	*****	*****
Bipolar Disorder	45,907	6.3%	*****	*****	*****	*****
Cerebral Degenerations usually Manifested in Childhood	*****	*****	*****	*****	*****	*****
Conduct Disorder	*****	*****	*****	*****	*****	*****
Delirium	*****	*****	*****	*****	*****	*****
Depression	211,109	29.2%	145,362	25.2%	3.985	0.090
Electroconvulsive Therapy	187	0.0%	123	0.0%	0.005	0.003
Hallucination	*****	*****	*****	*****	*****	*****
Obsessive-Compulsive Disorder	*****	*****	1,423	0.2%	*****	*****
Other Cerebral Degenerations	*****	*****	*****	*****	*****	*****
Other Mental Disorders	*****	*****	*****	*****	*****	*****

Table 1n. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Psychological Disorders	97,742	13.5%	92,104	16.0%	-2.452	-0.069
Persistent Mental Disorders due to Conditions Classified Elsewhere	*****	*****	*****	*****	*****	*****
Personality Disorders	*****	*****	2,410	0.4%	*****	*****
Pervasive Developmental Disorders	1,940	0.3%	1,369	0.2%	0.031	0.006
Post-Traumatic Stress Disorder	*****	*****	*****	*****	*****	*****
Psychotherapy	65,770	9.1%	*****	*****	*****	*****
Psychotic Conditions	3,853	0.5%	*****	*****	*****	*****
Schizophrenia	*****	*****	*****	*****	*****	*****
Sleep Disorder	301,451	41.7%	220,574	38.2%	3.437	0.070
Substance Abuse	48,683	6.7%	43,480	7.5%	-0.806	-0.031
Suicidal Behavior	*****	*****	*****	*****	*****	*****
Transcranial Magnetic Stimulation	248	0.0%	129	0.0%	0.012	0.007
Vagus Nerve Stimulation	947	0.1%	588	0.1%	0.029	0.008
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	5,015	0.7%	0	0.0%	NaN	NaN
dulaglutide	234,905	32.5%	0	0.0%	NaN	NaN
exenatide	53,792	7.4%	0	0.0%	NaN	NaN
liraglutide	152,032	21.0%	0	0.0%	NaN	NaN
lixisenatide	8,974	1.2%	0	0.0%	NaN	NaN
semaglutide	250,841	34.7%	0	0.0%	NaN	NaN
tirzepatide	18,632	2.6%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	723,707	100.0%	577,171	100.0%	-0.000	-0.002

Table 1n. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
insulin*	249,748	34.5%	139,018	24.1%	10.423	0.231
metformin*	637,286	88.1%	511,490	88.6%	-0.562	-0.018
alpha-glucosidase inhibitors*	2,737	0.4%	2,175	0.4%	0.001	0.000
thiazolidinediones*	55,711	7.7%	45,064	7.8%	-0.110	-0.004
meglitinides*	7,159	1.0%	5,613	1.0%	0.017	0.002
amylin analogue*	119	0.0%	52	0.0%	0.007	0.007
sulfonylureas*	254,540	35.2%	219,195	38.0%	-2.806	-0.058
bile acid sequestrants*	3,055	0.4%	2,183	0.4%	0.044	0.007
Other Weight Loss Agents*	2,902	0.4%	829	0.1%	0.257	0.049
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	421	0.1%	152	0.0%	0.032	0.015
diethylpropion	55	0.0%	*****	*****	*****	*****
lorcaserin	130	0.0%	38	0.0%	0.011	0.010
phentermine	2,154	0.3%	579	0.1%	0.197	0.044
phentermine-topiramate	128	0.0%	31	0.0%	0.012	0.011
phendimetrazine	39	0.0%	*****	*****	*****	*****
orlistat	50	0.0%	*****	*****	*****	*****
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	227,999	31.5%	166,276	28.8%	2.695	0.059
Antipsychotics	77,691	10.7%	*****	*****	*****	*****
Anxiolytics/Hypnotics	221,872	30.7%	164,441	28.5%	2.167	0.047
Lithium & Other Mood Stabilizers	67,802	9.4%	47,323	8.2%	1.170	0.041
Antidepressants	445,217	61.5%	312,504	54.1%	7.375	0.150

Table 1n. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	12.7	11.5	12.3	10.8	0.452	0.040
Mean number of emergency room encounters*	0.5	1.2	0.5	1.3	-0.032	-0.026
Mean number of inpatient hospital encounters*	0.1	0.5	0.2	0.6	-0.070	-0.134
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.3	-0.013	-0.053
Mean number of other ambulatory encounters*	5.0	13.4	5.1	13.0	-0.128	-0.010
Mean number of filled prescriptions*	31.0	21.8	29.1	20.2	1.831	0.087
Mean number of generics dispensed*	12.5	5.3	12.0	5.1	0.437	0.083
Mean number of unique drug classes dispensed*	11.2	4.8	10.2	4.6	1.021	0.218

Table 1n. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1o. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	828,024	N/A	612,480	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.2	10.6	62.0	11.0	-0.822	-0.076
Age						
18-24 years	2,795	0.3%	2,197	0.4%	-0.021	-0.004
25-44 years	85,000	10.3%	62,795	10.3%	0.013	0.000
45-64 years	380,652	46.0%	259,879	42.4%	3.541	0.077
65-79 years	323,402	39.1%	251,674	41.1%	-2.034	-0.047
≥ 80 years	36,175	4.4%	35,936	5.9%	-1.499	-0.069
Sex*						
Female	447,373	54.0%	337,388	55.1%	-1.056	-0.021
Male	380,651	46.0%	275,092	44.9%	1.056	0.021
Race[4]						
American Indian or Alaska Native	5,850	0.7%	3,831	0.6%	0.081	0.010
Asian	8,833	1.1%	11,293	1.8%	-0.777	-0.065
Black or African American	75,659	9.1%	62,182	10.2%	-1.015	-0.035
Multi-racial	3,992	0.5%	2,487	0.4%	0.076	0.012
Native Hawaiian or Other Pacific Islander	1,598	0.2%	1,312	0.2%	-0.021	-0.005
Unknown	294,636	35.6%	183,181	29.9%	5.675	0.204
White	437,455	52.8%	348,195	56.8%	-4.019	-0.105
Hispanic origin						

Table 1o. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	31,582	3.8%	31,089	5.1%	-1.262	-0.063
No	477,669	57.7%	392,353	64.1%	-6.372	-0.253
Unknown	318,772	38.5%	189,038	30.9%	7.634	0.391
Year*						
2015	14,829	1.8%	9,903	1.6%	0.174	0.013
2016	63,666	7.7%	46,862	7.7%	0.038	0.001
2017	81,780	9.9%	56,648	9.2%	0.628	0.021
2018	82,775	10.0%	62,235	10.2%	-0.164	-0.005
2019	102,698	12.4%	78,444	12.8%	-0.405	-0.012
2020	116,755	14.1%	88,247	14.4%	-0.308	-0.009
2021	116,314	14.0%	89,902	14.7%	-0.631	-0.018
2022	149,132	18.0%	105,393	17.2%	0.803	0.021
2023	100,075	12.1%	74,845	12.2%	-0.134	-0.004
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.8	2.0	1.7	1.8	0.071	0.037
Combined comorbidity score*,[6]	2.5	2.8	2.4	2.5	0.160	0.060
Medical History						
Obesity*	414,319	50.0%	295,184	48.2%	1.842	0.037
Weight Reduction Surgery or Procedure*	1,274	0.2%	769	0.1%	0.028	0.008
Lifestyle intervention*	151,368	18.3%	105,240	17.2%	1.098	0.029
Cardiovascular Disease*	218,967	26.4%	154,690	25.3%	1.188	0.028
Cognitive Impairment*	34,237	4.1%	22,968	3.7%	0.385	0.020
Traumatic Brain Injury*	2,570	0.3%	2,278	0.4%	-0.062	-0.011

Table 1o. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	49,318	6.0%	33,619	5.5%	0.467	0.020
Epilepsy*	17,969	2.2%	12,053	2.0%	0.202	0.014
Chronic Pain*	252,478	30.5%	170,198	27.8%	2.703	0.060
Psychiatric History						
Previous Intentional Self-Harm Ever	10,419	1.3%	7,632	1.2%	0.012	0.001
Psychiatric History Overall*	828,024	100.0%	612,480	100.0%	0.000	NaN
Psychiatric Drug Dispensings	613,623	74.1%	455,725	74.4%	-0.300	-0.007
Intentional Self-Harm Encounter	1,985	0.2%	1,007	0.2%	0.075	0.017
Any Other Psychiatric Event	683,336	82.5%	496,494	81.1%	1.463	0.038
Attention-Deficit/Hyperactivity Disorder	18,155	2.2%	9,096	1.5%	0.707	0.053
Akathisia	1,316	0.2%	967	0.2%	0.001	0.000
Anxiety	233,029	28.1%	164,178	26.8%	1.337	0.030
Behavioral Disorder	58,184	7.0%	37,538	6.1%	0.898	0.036
Bipolar Disorder	55,637	6.7%	41,093	6.7%	0.010	0.000
Cerebral Degenerations usually Manifested in Childhood	14,481	1.7%	10,444	1.7%	0.044	0.003
Conduct Disorder	922	0.1%	796	0.1%	-0.019	-0.005
Delirium	26,289	3.2%	13,747	2.2%	0.930	0.057
Depression	252,080	30.4%	171,491	28.0%	2.444	0.054
Electroconvulsive Therapy	261	0.0%	186	0.0%	0.001	0.001
Hallucination	3,307	0.4%	2,097	0.3%	0.057	0.009
Obsessive-Compulsive Disorder	3,138	0.4%	1,775	0.3%	0.089	0.015
Other Cerebral Degenerations	19,094	2.3%	15,027	2.5%	-0.148	-0.010
Other Mental Disorders	12,441	1.5%	8,028	1.3%	0.192	0.016

Table 1o. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Psychological Disorders	134,389	16.2%	99,692	16.3%	-0.047	-0.001
Persistent Mental Disorders due to Conditions Classified Elsewhere	23,547	2.8%	15,898	2.6%	0.248	0.015
Personality Disorders	6,682	0.8%	4,079	0.7%	0.141	0.016
Pervasive Developmental Disorders	1,696	0.2%	1,568	0.3%	-0.051	-0.011
Post-Traumatic Stress Disorder	25,602	3.1%	18,135	3.0%	0.131	0.008
Psychotherapy	75,111	9.1%	52,569	8.6%	0.488	0.017
Psychotic Conditions	4,945	0.6%	4,261	0.7%	-0.099	-0.012
Schizophrenia	22,523	2.7%	19,492	3.2%	-0.462	-0.027
Sleep Disorder	361,867	43.7%	240,716	39.3%	4.401	0.090
Substance Abuse	65,900	8.0%	48,267	7.9%	0.078	0.003
Suicidal Behavior	7,806	0.9%	4,642	0.8%	0.185	0.020
Transcranial Magnetic Stimulation	202	0.0%	233	0.0%	-0.014	-0.008
Vagus Nerve Stimulation	1,140	0.1%	880	0.1%	-0.006	-0.002
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	9,734	1.2%	0	0.0%	NaN	NaN
dulaglutide	286,055	34.5%	0	0.0%	NaN	NaN
exenatide	63,660	7.7%	0	0.0%	NaN	NaN
liraglutide	173,583	21.0%	0	0.0%	NaN	NaN
lixisenatide	8,842	1.1%	0	0.0%	NaN	NaN
semaglutide	273,075	33.0%	0	0.0%	NaN	NaN
tirzepatide	17,853	2.2%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	828,023	100.0%	612,480	100.0%	-0.000	-0.002

Table 1o. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
insulin*	313,935	37.9%	258,752	42.2%	-4.333	-0.089
metformin*	732,237	88.4%	536,848	87.7%	0.780	0.024
alpha-glucosidase inhibitors*	3,218	0.4%	2,543	0.4%	-0.027	-0.004
thiazolidinediones*	60,439	7.3%	50,278	8.2%	-0.910	-0.034
meglitinides*	8,526	1.0%	6,865	1.1%	-0.091	-0.009
amylin analogue*	153	0.0%	128	0.0%	-0.002	-0.002
sulfonylureas*	285,511	34.5%	227,551	37.2%	-2.671	-0.056
bile acid sequestrants*	3,971	0.5%	3,008	0.5%	-0.012	-0.002
Other Weight Loss Agents*	2,599	0.3%	1,793	0.3%	0.021	0.004
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	564	0.1%	277	0.0%	0.023	0.010
diethylpropion	58	0.0%	48	0.0%	-0.001	-0.001
lorcaserin	103	0.0%	117	0.0%	-0.007	-0.005
phentermine	1,765	0.2%	1,222	0.2%	0.014	0.003
phentermine-topiramate	108	0.0%	97	0.0%	-0.003	-0.002
phendimetrazine	50	0.0%	38	0.0%	-0.000	-0.000
orlistat	42	0.0%	30	0.0%	0.000	0.000
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	320,971	38.8%	208,262	34.0%	4.760	0.099
Antipsychotics	96,202	11.6%	74,822	12.2%	-0.598	-0.019
Anxiolytics/Hypnotics	269,012	32.5%	200,610	32.8%	-0.265	-0.006
Lithium & Other Mood Stabilizers	80,163	9.7%	64,464	10.5%	-0.844	-0.028
Antidepressants	496,291	59.9%	365,513	59.7%	0.259	0.005

Table 1o. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	14.2	12.4	13.4	12.0	0.813	0.067
Mean number of emergency room encounters*	0.8	2.0	0.5	1.4	0.214	0.123
Mean number of inpatient hospital encounters*	0.3	0.7	0.2	0.5	0.087	0.136
Mean number of non-acute institutional encounters*	0.1	0.3	0.0	0.3	0.010	0.035
Mean number of other ambulatory encounters*	6.0	13.9	5.6	14.1	0.417	0.030
Mean number of filled prescriptions*	36.1	28.1	32.6	22.9	3.497	0.136
Mean number of generics dispensed*	14.6	7.6	13.1	5.5	1.418	0.213
Mean number of unique drug classes dispensed*	12.1	5.8	11.6	5.2	0.547	0.099

Table 1o. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*] Covariate included in the propensity score logistic regression model.

[1] Covariates in blue show a standardized difference greater than 0.1.

[2] Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3] Value represents standard deviation where no % follows the value.

[4] Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5] Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6] Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1p. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	1,154,786	N/A	1,118,691	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.6	10.3	62.4	10.7	-0.849	-0.081
Age						
18-24 years	4,638	0.4%	4,378	0.4%	0.010	0.002
25-44 years	123,031	10.7%	112,473	10.1%	0.600	0.021
45-64 years	492,529	42.7%	453,322	40.5%	2.129	0.048
65-79 years	480,868	41.6%	478,848	42.8%	-1.163	-0.028
≥ 80 years	53,721	4.7%	69,670	6.2%	-1.576	-0.071
Sex*						
Female	589,853	51.1%	558,058	49.9%	1.194	0.024
Male	564,932	48.9%	560,633	50.1%	-1.194	-0.024
Race[4]						
American Indian or Alaska Native	8,291	0.7%	6,747	0.6%	0.115	0.014
Asian	18,497	1.6%	33,426	3.0%	-1.386	-0.093
Black or African American	109,076	9.4%	114,761	10.3%	-0.813	-0.028
Multi-racial	5,987	0.5%	5,347	0.5%	0.040	0.006
Native Hawaiian or Other Pacific Islander	3,255	0.3%	3,344	0.3%	-0.017	-0.003
Unknown	426,884	37.0%	389,218	34.8%	2.174	0.073
White	582,796	50.5%	565,850	50.6%	-0.114	-0.003
Hispanic origin						
Yes	52,382	4.5%	68,494	6.1%	-1.587	-0.074
No	652,618	56.5%	658,580	58.9%	-2.356	-0.088

Table 1p. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Unknown	449,786	38.9%	391,617	35.0%	3.943	0.185
Year*						
2015	19,412	1.7%	18,840	1.7%	-0.003	-0.000
2016	90,717	7.9%	87,976	7.9%	-0.008	-0.000
2017	110,273	9.5%	106,174	9.5%	0.058	0.002
2018	118,089	10.2%	113,633	10.2%	0.068	0.002
2019	150,483	13.0%	146,062	13.1%	-0.025	-0.001
2020	167,300	14.5%	165,118	14.8%	-0.272	-0.008
2021	162,513	14.1%	163,065	14.6%	-0.503	-0.015
2022	194,465	16.8%	188,637	16.9%	-0.022	-0.001
2023	141,533	12.3%	129,185	11.5%	0.708	0.022
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.5	1.7	1.5	1.7	-0.034	-0.019
Combined comorbidity score*,[6]	1.8	2.3	1.9	2.4	-0.033	-0.014
Medical History						
Obesity*	500,059	43.3%	460,838	41.2%	2.109	0.043
Weight Reduction Surgery or Procedure*	816	0.1%	834	0.1%	-0.004	-0.001
Lifestyle intervention*	204,401	17.7%	186,328	16.7%	1.044	0.028
Cardiovascular Disease*	243,859	21.1%	242,374	21.7%	-0.549	-0.014
Cognitive Impairment*	26,503	2.3%	25,974	2.3%	-0.027	-0.002
Traumatic Brain Injury*	2,486	0.2%	2,455	0.2%	-0.004	-0.001
Migraine*	43,603	3.8%	39,770	3.6%	0.221	0.012
Epilepsy*	15,005	1.3%	14,233	1.3%	0.027	0.002
Chronic Pain*	246,286	21.3%	230,378	20.6%	0.734	0.018
Psychiatric History						

Table 1p. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Previous Intentional Self-Harm Ever	8,645	0.7%	8,281	0.7%	0.008	0.001
Psychiatric History Overall*	706,011	61.1%	668,215	59.7%	1.406	0.029
Psychiatric Drug Dispensings	517,241	44.8%	495,448	44.3%	0.503	0.010
Intentional Self-Harm Encounter	1,201	0.1%	1,060	0.1%	0.009	0.003
Any Other Psychiatric Event	578,447	50.1%	540,035	48.3%	1.818	0.037
Attention-Deficit/Hyperactivity Disorder	12,293	1.1%	9,763	0.9%	0.192	0.020
Akathisia	1,123	0.1%	1,040	0.1%	0.004	0.001
Anxiety	188,823	16.4%	176,387	15.8%	0.584	0.016
Behavioral Disorder	45,704	4.0%	39,978	3.6%	0.384	0.020
Bipolar Disorder	43,722	3.8%	42,718	3.8%	-0.032	-0.002
Cerebral Degenerations usually Manifested in Childhood	11,396	1.0%	11,401	1.0%	-0.032	-0.003
Conduct Disorder	873	0.1%	861	0.1%	-0.001	-0.000
Delirium	17,653	1.5%	15,115	1.4%	0.178	0.015
Depression	207,665	18.0%	184,838	16.5%	1.460	0.039
Electroconvulsive Therapy	194	0.0%	196	0.0%	-0.001	-0.001
Hallucination	2,367	0.2%	2,173	0.2%	0.011	0.002
Obsessive-Compulsive Disorder	2,057	0.2%	1,924	0.2%	0.006	0.001
Other Cerebral Degenerations	16,575	1.4%	16,515	1.5%	-0.041	-0.003
Other Mental Disorders	9,308	0.8%	8,713	0.8%	0.027	0.003
Other Psychological Disorders	103,147	8.9%	107,682	9.6%	-0.694	-0.024
Persistent Mental Disorders due to Conditions Classified Elsewhere	18,638	1.6%	17,431	1.6%	0.056	0.004
Personality Disorders	4,636	0.4%	3,953	0.4%	0.048	0.008
Pervasive Developmental Disorders	1,602	0.1%	1,721	0.2%	-0.015	-0.004

Table 1p. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Post-Traumatic Stress Disorder	20,193	1.7%	18,577	1.7%	0.088	0.007
Psychotherapy	60,930	5.3%	55,383	5.0%	0.326	0.015
Psychotic Conditions	4,416	0.4%	4,511	0.4%	-0.021	-0.003
Schizophrenia	18,050	1.6%	20,563	1.8%	-0.275	-0.021
Sleep Disorder	298,346	25.8%	260,239	23.3%	2.573	0.060
Substance Abuse	52,736	4.6%	52,222	4.7%	-0.101	-0.005
Suicidal Behavior	6,045	0.5%	5,073	0.5%	0.070	0.010
Transcranial Magnetic Stimulation	194	0.0%	185	0.0%	0.000	0.000
Vagus Nerve Stimulation	1,007	0.1%	804	0.1%	0.015	0.005
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	10,077	0.9%	0	0.0%	NaN	NaN
dulaglutide	396,604	34.3%	0	0.0%	NaN	NaN
exenatide	87,648	7.6%	0	0.0%	NaN	NaN
liraglutide	238,660	20.7%	0	0.0%	NaN	NaN
lixisenatide	13,554	1.2%	0	0.0%	NaN	NaN
semaglutide	386,265	33.4%	0	0.0%	NaN	NaN
tirzepatide	24,406	2.1%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,154,783	100.0%	1,118,690	100.0%	-0.000	-0.001
insulin*	419,616	36.3%	439,493	39.3%	-2.949	-0.061
metformin*	1,023,028	88.6%	988,826	88.4%	0.199	0.006
alpha-glucosidase inhibitors*	4,812	0.4%	4,941	0.4%	-0.025	-0.004
thiazolidinediones*	93,706	8.1%	95,314	8.5%	-0.406	-0.015
meglitinides*	12,732	1.1%	13,303	1.2%	-0.087	-0.008
amylin analogue*	146	0.0%	179	0.0%	-0.003	-0.003
sulfonylureas*	428,853	37.1%	432,254	38.6%	-1.502	-0.031

Table 1p. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
bile acid sequestrants*	5,159	0.4%	4,685	0.4%	0.028	0.004
Other Weight Loss Agents*	2,956	0.3%	2,233	0.2%	0.056	0.012
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	332	0.0%	290	0.0%	0.003	0.002
diethylpropion	74	0.0%	41	0.0%	0.003	0.004
lorcaserin	143	0.0%	121	0.0%	0.002	0.001
phentermine	2,238	0.2%	1,671	0.1%	0.044	0.011
phentermine-topiramate	144	0.0%	78	0.0%	0.005	0.006
phendimetrazine	59	0.0%	31	0.0%	0.002	0.004
orlistat	52	0.0%	42	0.0%	0.001	0.001
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	310,342	26.9%	287,908	25.7%	1.138	0.026
Antipsychotics	74,028	6.4%	79,285	7.1%	-0.677	-0.027
Anxiolytics/Hypnotics	215,275	18.6%	214,861	19.2%	-0.564	-0.014
Lithium & Other Mood Stabilizers	62,919	5.4%	67,618	6.0%	-0.596	-0.026
Antidepressants	420,861	36.4%	396,405	35.4%	1.010	0.021
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	11.3	10.6	11.1	10.6	0.165	0.016
Mean number of emergency room encounters*	0.4	1.2	0.4	1.1	0.022	0.019
Mean number of inpatient hospital encounters*	0.1	0.5	0.1	0.5	0.007	0.014
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	0.001	0.003

Table 1p. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Mean number of other ambulatory encounters*	4.2	11.7	4.2	11.7	-0.005	-0.000
Mean number of filled prescriptions*	27.5	21.4	26.7	19.9	0.742	0.036
Mean number of generics dispensed*	11.5	5.7	11.2	5.2	0.279	0.051
Mean number of unique drug classes dispensed*	9.8	4.8	9.7	4.9	0.134	0.028

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759.
Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.
*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
N/A = Not applicable
NaN = Not a number

Table 1q. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	1,153,680	N/A	1,117,909	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.6	10.3	62.4	10.7	-0.849	-0.081
Age						
18-24 years	4,587	0.4%	4,345	0.4%	0.009	0.001
25-44 years	122,705	10.6%	112,175	10.0%	0.602	0.021
45-64 years	491,961	42.6%	452,920	40.5%	2.128	0.048
65-79 years	480,729	41.7%	478,805	42.8%	-1.161	-0.028
≥ 80 years	53,698	4.7%	69,665	6.2%	-1.577	-0.071
Sex*						
Female	589,173	51.1%	557,544	49.9%	1.195	0.024
Male	564,506	48.9%	560,365	50.1%	-1.195	-0.024
Race[4]						
American Indian or Alaska Native	8,259	0.7%	6,722	0.6%	0.115	0.014
Asian	18,486	1.6%	33,416	3.0%	-1.387	-0.093
Black or African American	108,982	9.4%	114,666	10.3%	-0.811	-0.028
Multi-racial	5,986	0.5%	5,337	0.5%	0.041	0.006
Native Hawaiian or Other Pacific Islander	3,255	0.3%	3,341	0.3%	-0.017	-0.003
Unknown	426,598	37.0%	389,035	34.8%	2.177	0.073
White	582,114	50.5%	565,392	50.6%	-0.119	-0.003
Hispanic origin						
Yes	52,278	4.5%	68,451	6.1%	-1.592	-0.074
No	651,835	56.5%	658,023	58.9%	-2.361	-0.088

Table 1q. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Unknown	449,567	39.0%	391,436	35.0%	3.953	0.185
Year*						
2015	19,382	1.7%	18,817	1.7%	-0.003	-0.000
2016	90,606	7.9%	87,907	7.9%	-0.010	-0.000
2017	110,145	9.5%	106,099	9.5%	0.056	0.002
2018	117,978	10.2%	113,540	10.2%	0.070	0.002
2019	150,305	13.0%	145,936	13.1%	-0.026	-0.001
2020	167,118	14.5%	164,994	14.8%	-0.273	-0.008
2021	162,377	14.1%	162,943	14.6%	-0.501	-0.014
2022	194,290	16.8%	188,545	16.9%	-0.025	-0.001
2023	141,479	12.3%	129,128	11.6%	0.712	0.022
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.5	1.7	1.5	1.7	-0.034	-0.019
Combined comorbidity score*,[6]	1.8	2.3	1.9	2.4	-0.033	-0.014
Medical History						
Obesity*	499,426	43.3%	460,315	41.2%	2.113	0.043
Weight Reduction Surgery or Procedure*	815	0.1%	832	0.1%	-0.004	-0.001
Lifestyle intervention*	204,126	17.7%	186,084	16.6%	1.048	0.028
Cardiovascular Disease*	243,586	21.1%	242,110	21.7%	-0.544	-0.014
Cognitive Impairment*	26,427	2.3%	25,892	2.3%	-0.026	-0.002
Traumatic Brain Injury*	2,476	0.2%	2,445	0.2%	-0.004	-0.001
Migraine*	43,429	3.8%	39,604	3.5%	0.222	0.012
Epilepsy*	14,897	1.3%	14,124	1.3%	0.028	0.002
Chronic Pain*	245,797	21.3%	229,969	20.6%	0.734	0.018
Psychiatric History						

Table 1q. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Previous Intentional Self-Harm Ever	7,437	0.6%	7,223	0.6%	-0.001	-0.000
Psychiatric History Overall*	704,924	61.1%	667,311	59.7%	1.409	0.029
Psychiatric Drug Dispensings	516,220	44.7%	494,602	44.2%	0.502	0.010
Intentional Self-Harm Encounter	0	0.0%	0	0.0%	NaN	NaN
Any Other Psychiatric Event	577,358	50.0%	539,074	48.2%	1.823	0.037
Attention-Deficit/Hyperactivity Disorder	12,181	1.1%	9,709	0.9%	0.187	0.019
Akathisia	1,100	0.1%	1,021	0.1%	0.004	0.001
Anxiety	188,043	16.3%	175,668	15.7%	0.585	0.016
Behavioral Disorder	44,617	3.9%	39,009	3.5%	0.378	0.020
Bipolar Disorder	43,206	3.7%	42,287	3.8%	-0.038	-0.002
Cerebral Degenerations usually Manifested in Childhood	11,366	1.0%	11,357	1.0%	-0.031	-0.003
Conduct Disorder	851	0.1%	838	0.1%	-0.001	-0.000
Delirium	17,466	1.5%	14,952	1.3%	0.176	0.015
Depression	206,742	17.9%	184,040	16.5%	1.457	0.039
Electroconvulsive Therapy	163	0.0%	177	0.0%	-0.002	-0.001
Hallucination	2,281	0.2%	2,098	0.2%	0.010	0.002
Obsessive-Compulsive Disorder	2,021	0.2%	1,912	0.2%	0.004	0.001
Other Cerebral Degenerations	16,546	1.4%	16,482	1.5%	-0.040	-0.003
Other Mental Disorders	9,224	0.8%	8,612	0.8%	0.029	0.003
Other Psychological Disorders	102,613	8.9%	107,198	9.6%	-0.695	-0.024
Persistent Mental Disorders due to Conditions Classified Elsewhere	18,598	1.6%	17,398	1.6%	0.056	0.004
Personality Disorders	4,375	0.4%	3,747	0.3%	0.044	0.007
Pervasive Developmental Disorders	1,581	0.1%	1,683	0.2%	-0.014	-0.004

Table 1q. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Post-Traumatic Stress Disorder	19,814	1.7%	18,284	1.6%	0.082	0.006
Psychotherapy	60,381	5.2%	54,953	4.9%	0.318	0.015
Psychotic Conditions	4,219	0.4%	4,323	0.4%	-0.021	-0.003
Schizophrenia	17,788	1.5%	20,300	1.8%	-0.274	-0.021
Sleep Disorder	297,768	25.8%	259,800	23.2%	2.570	0.060
Substance Abuse	52,184	4.5%	51,785	4.6%	-0.109	-0.005
Suicidal Behavior	5,272	0.5%	4,481	0.4%	0.056	0.009
Transcranial Magnetic Stimulation	194	0.0%	180	0.0%	0.001	0.001
Vagus Nerve Stimulation	1,003	0.1%	798	0.1%	0.016	0.006
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	10,075	0.9%	0	0.0%	NaN	NaN
dulaglutide	396,268	34.3%	0	0.0%	NaN	NaN
exenatide	87,471	7.6%	0	0.0%	NaN	NaN
liraglutide	238,355	20.7%	0	0.0%	NaN	NaN
lixisenatide	13,532	1.2%	0	0.0%	NaN	NaN
semaglutide	386,012	33.5%	0	0.0%	NaN	NaN
tirzepatide	24,397	2.1%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,153,677	100.0%	1,117,908	100.0%	-0.000	-0.001
insulin*	419,172	36.3%	439,203	39.3%	-2.954	-0.061
metformin*	1,022,030	88.6%	988,115	88.4%	0.199	0.006
alpha-glucosidase inhibitors*	4,796	0.4%	4,937	0.4%	-0.026	-0.004
thiazolidinediones*	93,614	8.1%	95,276	8.5%	-0.408	-0.015
meglitinides*	12,726	1.1%	13,301	1.2%	-0.087	-0.008
amylin analogue*	146	0.0%	179	0.0%	-0.003	-0.003
sulfonylureas*	428,486	37.1%	432,039	38.6%	-1.506	-0.031

Table 1q. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
bile acid sequestrants*	5,161	0.4%	4,682	0.4%	0.028	0.004
Other Weight Loss Agents*	2,932	0.3%	2,235	0.2%	0.054	0.011
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	332	0.0%	291	0.0%	0.003	0.002
diethylpropion	74	0.0%	41	0.0%	0.003	0.004
lorcaserin	143	0.0%	121	0.0%	0.002	0.001
phentermine	2,215	0.2%	1,672	0.1%	0.042	0.010
phentermine-topiramate	144	0.0%	78	0.0%	0.005	0.006
phendimetrazine	59	0.0%	31	0.0%	0.002	0.004
orlistat	52	0.0%	42	0.0%	0.001	0.001
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	309,900	26.9%	287,545	25.7%	1.140	0.026
Antipsychotics	73,352	6.4%	78,714	7.0%	-0.683	-0.027
Anxiolytics/Hypnotics	214,598	18.6%	214,264	19.2%	-0.565	-0.014
Lithium & Other Mood Stabilizers	62,415	5.4%	67,210	6.0%	-0.602	-0.026
Antidepressants	419,896	36.4%	395,627	35.4%	1.006	0.021
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	11.2	10.5	11.1	10.6	0.164	0.016
Mean number of emergency room encounters*	0.4	1.2	0.4	1.1	0.022	0.019
Mean number of inpatient hospital encounters*	0.1	0.5	0.1	0.5	0.007	0.014
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	0.001	0.003

Table 1q. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Mean number of other ambulatory encounters*	4.2	11.7	4.2	11.7	-0.008	-0.001
Mean number of filled prescriptions*	27.4	21.4	26.7	19.9	0.741	0.036
Mean number of generics dispensed*	11.5	5.7	11.2	5.2	0.279	0.051
Mean number of unique drug classes dispensed*	9.8	4.8	9.7	4.9	0.134	0.028

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1r. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	954	N/A	26,643	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	50.7	13.4	47.6	11.3	3.168	0.255
Age						
18-24 years	37	3.9%	24	0.1%	3.796	0.272
25-44 years	270	28.3%	12,961	48.6%	-20.334	-0.412
45-64 years	486	51.0%	13,549	50.9%	0.116	NaN
65-79 years	143	15.0%	97	0.4%	14.661	0.593
≥ 80 years	17	1.8%	12	0.0%	1.761	0.182
Sex*						
Female	604	63.3%	11,611	43.6%	19.709	NaN
Male	350	36.7%	15,032	56.4%	-19.709	-0.387
Race[4]						
American Indian or Alaska Native	*****	*****	16	0.1%	*****	*****
Asian	*****	*****	*****	*****	*****	*****
Black or African American	101	10.6%	90	0.3%	10.296	0.459
Multi-racial	0	0.0%	*****	*****	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****	*****
Unknown	208	21.8%	26,114	98.0%	-76.181	NaN
White	614	64.3%	404	1.5%	62.771	2.031
Hispanic origin						

Table 1r. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	66	6.9%	47	0.2%	6.768	0.376
No	729	76.4%	523	2.0%	74.425	3.251
Unknown	159	16.7%	26,073	97.9%	-81.193	NaN
Year*						
2015	50	5.3%	12	0.0%	5.228	NaN
2016	90	9.5%	795	3.0%	6.479	0.263
2017	108	11.3%	690	2.6%	8.725	0.339
2018	110	11.6%	7,799	29.3%	-17.715	-0.429
2019	146	15.3%	5,519	20.7%	-5.410	-0.135
2020	162	16.9%	1,188	4.5%	12.485	0.407
2021	109	11.4%	5,838	21.9%	-10.533	-0.274
2022	117	12.3%	4,142	15.5%	-3.273	-0.091
2023	62	6.5%	660	2.5%	4.014	0.192
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.8	1.9	0.5	1.0	1.316	0.862
Combined comorbidity score*,[6]	3.9	2.6	2.0	1.1	1.925	0.958
Medical History						
Obesity*	524	54.9%	16,981	63.7%	-8.863	-0.177
Weight Reduction Surgery or Procedure*	0	0.0%	0	0.0%	NaN	NaN
Lifestyle intervention*	228	23.9%	6,079	22.8%	1.086	0.025
Cardiovascular Disease*	241	25.2%	790	3.0%	22.246	0.679
Cognitive Impairment*	81	8.5%	56	0.2%	8.280	0.411
Traumatic Brain Injury*	*****	*****	*****	*****	*****	*****

Table 1r. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	134	14.1%	91	0.3%	13.718	0.543
Epilepsy*	87	9.1%	65	0.2%	8.857	0.423
Chronic Pain*	390	40.9%	998	3.7%	37.155	NaN
Psychiatric History						
Previous Intentional Self-Harm Ever	954	100.0%	26,643	100.0%	0.000	NaN
Psychiatric History Overall*	954	100.0%	26,643	100.0%	0.000	NaN
Psychiatric Drug Dispensings	887	93.0%	24,550	92.1%	0.822	NaN
Intentional Self-Harm Encounter	954	100.0%	26,643	100.0%	0.000	NaN
Any Other Psychiatric Event	954	100.0%	26,643	100.0%	0.000	NaN
Attention-Deficit/Hyperactivity Disorder	66	6.9%	4,020	15.1%	-8.170	-0.249
Akathisia	17	1.7%	12	0.0%	1.704	0.178
Anxiety	640	67.0%	17,302	64.9%	2.067	NaN
Behavioral Disorder	830	87.0%	24,548	92.1%	-5.141	-0.174
Bipolar Disorder	404	42.3%	5,348	20.1%	22.247	0.480
Cerebral Degenerations usually Manifested in Childhood	31	3.3%	21	0.1%	3.173	0.246
Conduct Disorder	23	2.4%	15	0.1%	2.330	0.210
Delirium	176	18.5%	3,459	13.0%	5.498	NaN
Depression	760	79.6%	19,387	72.8%	6.869	NaN
Electroconvulsive Therapy	20	2.1%	12	0.0%	2.038	0.196
Hallucination	65	6.8%	5,803	21.8%	-14.954	-0.413
Obsessive-Compulsive Disorder	24	2.6%	13	0.0%	2.514	0.220
Other Cerebral Degenerations	28	2.9%	23	0.1%	2.856	0.232

Table 1r. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Mental Disorders	75	7.9%	1,000	3.8%	4.149	0.172
Other Psychological Disorders	419	43.9%	10,283	38.6%	5.326	0.105
Persistent Mental Disorders due to Conditions Classified Elsewhere	41	4.3%	28	0.1%	4.185	0.285
Personality Disorders	201	21.0%	5,896	22.1%	-1.096	-0.026
Pervasive Developmental Disorders	22	2.3%	22	0.1%	2.172	0.199
Post-Traumatic Stress Disorder	270	28.2%	11,626	43.6%	-15.385	-0.311
Psychotherapy	396	41.5%	15,194	57.0%	-15.498	-0.302
Psychotic Conditions	140	14.6%	1,289	4.8%	9.787	0.325
Schizophrenia	212	22.2%	5,932	22.3%	-0.030	-0.001
Sleep Disorder	481	50.4%	8,741	32.8%	17.558	NaN
Substance Abuse	447	46.9%	7,750	29.1%	17.790	NaN
Suicidal Behavior	576	60.4%	20,357	76.4%	-16.035	NaN
Transcranial Magnetic Stimulation	*****	*****	*****	*****	*****	*****
Vagus Nerve Stimulation	*****	*****	*****	*****	*****	*****
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	*****	*****	0	0.0%	*****	*****
dulaglutide	299	31.3%	0	0.0%	NaN	NaN
exenatide	118	12.3%	0	0.0%	NaN	NaN
liraglutide	289	30.3%	0	0.0%	NaN	NaN
lixisenatide	*****	*****	0	0.0%	*****	*****
semaglutide	227	23.8%	0	0.0%	NaN	NaN
tirzepatide	*****	*****	0	0.0%	*****	*****

Table 1r. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Any Anti-Diabetic Agents	954	100.0%	26,643	100.0%	0.000	NaN
insulin*	434	45.4%	7,645	28.7%	16.748	NaN
metformin*	854	89.4%	26,430	99.2%	-9.768	NaN
alpha-glucosidase inhibitors*	*****	*****	*****	*****	*****	*****
thiazolidinediones*	83	8.7%	41	0.2%	8.557	NaN
meglitinides*	*****	*****	*****	*****	*****	*****
amylin analogue*	0	0.0%	0	0.0%	NaN	NaN
sulfonylureas*	325	34.1%	3,614	13.6%	20.511	NaN
bile acid sequestrants*	0	0.0%	0	0.0%	NaN	NaN
Other Weight Loss Agents*	0	0.0%	0	0.0%	NaN	NaN
benzphetamine	0	0.0%	0	0.0%	NaN	NaN
bupropion	0	0.0%	0	0.0%	NaN	NaN
diethylpropion	0	0.0%	0	0.0%	NaN	NaN
lorcaserin	0	0.0%	0	0.0%	NaN	NaN
phentermine	0	0.0%	0	0.0%	NaN	NaN
phentermine-topiramate	0	0.0%	0	0.0%	NaN	NaN
phendimetrazine	0	0.0%	0	0.0%	NaN	NaN
orlistat	0	0.0%	0	0.0%	NaN	NaN
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	379	39.8%	15,609	58.6%	-18.831	NaN
Antipsychotics	573	60.0%	15,438	57.9%	2.094	NaN
Anxiolytics/Hypnotics	557	58.3%	22,562	84.7%	-26.348	NaN
Lithium & Other Mood Stabilizers	411	43.1%	5,338	20.0%	23.053	NaN

Table 1r. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Antidepressants	819	85.8%	21,218	79.6%	6.169	NaN
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	25.4	18.9	12.8	8.6	12.572	0.858
Mean number of emergency room encounters*	3.0	4.5	2.0	1.2	1.011	0.307
Mean number of inpatient hospital encounters*	1.1	1.4	1.2	0.8	-0.192	-0.165
Mean number of non-acute institutional encounters*	0.5	0.9	0.0	0.2	0.468	0.742
Mean number of other ambulatory encounters*	17.5	25.3	1.6	4.4	15.898	0.876
Mean number of filled prescriptions*	50.3	34.5	26.0	21.6	24.336	0.845
Mean number of generics dispensed*	17.7	7.9	11.9	5.8	5.818	0.835
Mean number of unique drug classes dispensed*	15.3	6.6	10.3	5.5	5.033	0.828

Table 1r. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759.
Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1s. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	440,776	N/A	533,512	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	62.0	9.8	62.9	10.1	-0.869	-0.088
Age						
18-24 years	1,900	0.4%	2,385	0.4%	-0.016	-0.002
25-44 years	46,152	10.5%	53,581	10.0%	0.427	0.015
45-64 years	178,889	40.6%	201,546	37.8%	2.808	0.069
65-79 years	191,520	43.5%	240,792	45.1%	-1.683	-0.044
≥ 80 years	22,315	5.1%	35,208	6.6%	-1.537	-0.067
Sex*						
Female	198,169	45.0%	233,025	43.7%	1.282	0.026
Male	242,606	55.0%	300,487	56.3%	-1.282	-0.026
Race[4]						
American Indian or Alaska Native	3,101	0.7%	2,982	0.6%	0.145	0.018
Asian	10,810	2.5%	24,428	4.6%	-2.126	-0.117
Black or African American	43,575	9.9%	57,118	10.7%	-0.820	-0.028
Multi-racial	2,768	0.6%	3,083	0.6%	0.050	0.007
Native Hawaiian or Other Pacific Islander	1,716	0.4%	2,234	0.4%	-0.029	-0.005
Unknown	191,876	43.5%	222,201	41.6%	1.883	0.059
White	186,930	42.4%	221,466	41.5%	0.898	0.023
Hispanic origin						

Table 1s. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	23,127	5.2%	40,964	7.7%	-2.431	-0.105
No	218,435	49.6%	276,300	51.8%	-2.232	-0.079
Unknown	199,213	45.2%	216,248	40.5%	4.663	0.201
Year*						
2015	7,996	1.8%	9,503	1.8%	0.033	0.002
2016	37,278	8.5%	44,400	8.3%	0.135	0.005
2017	44,490	10.1%	52,592	9.9%	0.236	0.008
2018	46,825	10.6%	55,483	10.4%	0.224	0.007
2019	58,434	13.3%	70,988	13.3%	-0.049	-0.001
2020	63,207	14.3%	79,590	14.9%	-0.578	-0.017
2021	59,537	13.5%	75,954	14.2%	-0.729	-0.021
2022	71,879	16.3%	86,545	16.2%	0.085	0.002
2023	51,130	11.6%	58,456	11.0%	0.643	0.021
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*[,5]	1.2	1.5	1.2	1.5	0.003	0.002
Combined comorbidity score*[,6]	1.1	1.8	1.2	1.9	-0.012	-0.007
Medical History						
Obesity*	155,549	35.3%	173,068	32.4%	2.851	0.061
Weight Reduction Surgery or Procedure*	44	0.0%	59	0.0%	-0.001	-0.001
Lifestyle intervention*	75,619	17.2%	85,737	16.1%	1.086	0.030
Cardiovascular Disease*	71,028	16.1%	86,371	16.2%	-0.075	-0.002
Cognitive Impairment*	583	0.1%	749	0.1%	-0.008	-0.002
Traumatic Brain Injury*	59	0.0%	61	0.0%	0.002	0.002

Table 1s. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	5,244	1.2%	5,778	1.1%	0.107	0.010
Epilepsy*	1,343	0.3%	1,501	0.3%	0.023	0.004
Chronic Pain*	51,744	11.7%	58,316	10.9%	0.809	0.026
Psychiatric History						
Previous Intentional Self-Harm Ever	344	0.1%	310	0.1%	0.020	0.008
Psychiatric History Overall*	0	0.0%	0	0.0%	NaN	NaN
Psychiatric Drug Dispensings	0	0.0%	0	0.0%	NaN	NaN
Intentional Self-Harm Encounter	0	0.0%	0	0.0%	NaN	NaN
Any Other Psychiatric Event	0	0.0%	0	0.0%	NaN	NaN
Attention-Deficit/Hyperactivity Disorder	0	0.0%	0	0.0%	NaN	NaN
Akathisia	0	0.0%	0	0.0%	NaN	NaN
Anxiety	0	0.0%	0	0.0%	NaN	NaN
Behavioral Disorder	0	0.0%	0	0.0%	NaN	NaN
Bipolar Disorder	0	0.0%	0	0.0%	NaN	NaN
Cerebral Degenerations usually Manifested in Childhood	0	0.0%	0	0.0%	NaN	NaN
Conduct Disorder	0	0.0%	0	0.0%	NaN	NaN
Delirium	0	0.0%	0	0.0%	NaN	NaN
Depression	0	0.0%	0	0.0%	NaN	NaN
Electroconvulsive Therapy	0	0.0%	0	0.0%	NaN	NaN
Hallucination	0	0.0%	0	0.0%	NaN	NaN
Obsessive-Compulsive Disorder	0	0.0%	0	0.0%	NaN	NaN
Other Cerebral Degenerations	0	0.0%	0	0.0%	NaN	NaN

Table 1s. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Mental Disorders	0	0.0%	0	0.0%	NaN	NaN
Other Psychological Disorders	0	0.0%	0	0.0%	NaN	NaN
Persistent Mental Disorders due to Conditions Classified Elsewhere	0	0.0%	0	0.0%	NaN	NaN
Personality Disorders	0	0.0%	0	0.0%	NaN	NaN
Pervasive Developmental Disorders	0	0.0%	0	0.0%	NaN	NaN
Post-Traumatic Stress Disorder	0	0.0%	0	0.0%	NaN	NaN
Psychotherapy	0	0.0%	0	0.0%	NaN	NaN
Psychotic Conditions	0	0.0%	0	0.0%	NaN	NaN
Schizophrenia	0	0.0%	0	0.0%	NaN	NaN
Sleep Disorder	0	0.0%	0	0.0%	NaN	NaN
Substance Abuse	0	0.0%	0	0.0%	NaN	NaN
Suicidal Behavior	0	0.0%	0	0.0%	NaN	NaN
Transcranial Magnetic Stimulation	0	0.0%	0	0.0%	NaN	NaN
Vagus Nerve Stimulation	0	0.0%	0	0.0%	NaN	NaN
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	4,517	1.0%	0	0.0%	NaN	NaN
dulaglutide	156,561	35.5%	0	0.0%	NaN	NaN
exenatide	33,457	7.6%	0	0.0%	NaN	NaN
liraglutide	88,030	20.0%	0	0.0%	NaN	NaN
lixisenatide	5,898	1.3%	0	0.0%	NaN	NaN
semaglutide	145,276	33.0%	0	0.0%	NaN	NaN
tirzepatide	8,410	1.9%	0	0.0%	NaN	NaN

Table 1s. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Any Anti-Diabetic Agents	440,772	100.0%	533,510	100.0%	-0.001	-0.002
insulin*	171,032	38.8%	207,248	38.8%	-0.044	-0.001
metformin*	393,186	89.2%	476,867	89.4%	-0.179	-0.006
alpha-glucosidase inhibitors*	2,137	0.5%	2,780	0.5%	-0.036	-0.005
thiazolidinediones*	38,464	8.7%	49,371	9.3%	-0.528	-0.018
meglitinides*	5,623	1.3%	7,237	1.4%	-0.081	-0.007
amylin analogue*	29	0.0%	56	0.0%	-0.004	-0.004
sulfonylureas*	170,998	38.8%	218,430	40.9%	-2.147	-0.044
bile acid sequestrants*	1,800	0.4%	1,829	0.3%	0.065	0.011
Other Weight Loss Agents*	709	0.2%	665	0.1%	0.036	0.010
benzphetamine	*****	*****	0	0.0%	*****	*****
bupropion	0	0.0%	0	0.0%	NaN	NaN
diethylpropion	19	0.0%	*****	*****	*****	*****
lorcaserin	37	0.0%	43	0.0%	0.000	0.000
phentermine	593	0.1%	580	0.1%	0.026	0.007
phentermine-topiramate	41	0.0%	26	0.0%	0.004	0.005
phendimetrazine	18	0.0%	*****	*****	*****	*****
orlistat	11	0.0%	*****	*****	*****	*****
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	72,555	16.5%	78,383	14.7%	1.769	0.049
Antipsychotics	0	0.0%	0	0.0%	NaN	NaN
Anxiolytics/Hypnotics	0	0.0%	0	0.0%	NaN	NaN
Lithium & Other Mood Stabilizers	0	0.0%	0	0.0%	NaN	NaN

Table 1s. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Antidepressants	162	0.0%	108	0.0%	0.016	0.010
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	8.4	7.8	8.0	7.7	0.311	0.040
Mean number of emergency room encounters*	0.2	0.6	0.2	0.6	0.022	0.035
Mean number of inpatient hospital encounters*	0.1	0.3	0.1	0.3	0.008	0.028
Mean number of non-acute institutional encounters*	0.0	0.1	0.0	0.1	0.001	0.007
Mean number of other ambulatory encounters*	2.3	7.1	2.3	6.9	-0.003	-0.000
Mean number of filled prescriptions*	19.9	13.2	18.8	12.5	1.101	0.085
Mean number of generics dispensed*	9.2	4.0	8.7	3.7	0.476	0.122
Mean number of unique drug classes dispensed*	7.6	3.3	7.3	3.5	0.232	0.068

Table 1s. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1t. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	720,398	N/A	587,499	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.3	10.6	62.3	10.9	-0.953	-0.089
Age						
18-24 years	2,742	0.4%	2,073	0.4%	0.028	0.005
25-44 years	77,588	10.8%	58,218	9.9%	0.861	0.029
45-64 years	316,072	43.9%	245,619	41.8%	2.067	0.045
65-79 years	292,253	40.6%	246,093	41.9%	-1.320	-0.031
≥ 80 years	31,743	4.4%	35,495	6.0%	-1.635	-0.074
Sex*						
Female	395,911	55.0%	317,580	54.1%	0.901	0.018
Male	324,486	45.0%	269,919	45.9%	-0.901	-0.018
Race[4]						
American Indian or Alaska Native	5,295	0.7%	3,735	0.6%	0.099	0.012
Asian	7,696	1.1%	11,114	1.9%	-0.823	-0.068
Black or African American	65,997	9.2%	59,469	10.1%	-0.961	-0.033
Multi-racial	3,264	0.5%	2,343	0.4%	0.054	0.009
Native Hawaiian or Other Pacific Islander	1,517	0.2%	1,304	0.2%	-0.011	-0.002
Unknown	236,529	32.8%	172,813	29.4%	3.418	0.121
White	400,099	55.5%	336,721	57.3%	-1.776	-0.046
Hispanic origin						

Table 1t. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	29,294	4.1%	30,178	5.1%	-1.070	-0.053
No	438,764	60.9%	379,603	64.6%	-3.708	-0.144
Unknown	252,340	35.0%	177,718	30.2%	4.778	0.240
Year*						
2015	11,521	1.6%	9,510	1.6%	-0.019	-0.002
2016	54,056	7.5%	44,543	7.6%	-0.078	-0.003
2017	66,512	9.2%	54,373	9.3%	-0.022	-0.001
2018	72,284	10.0%	58,828	10.0%	0.021	0.001
2019	93,003	12.9%	75,751	12.9%	0.016	0.000
2020	104,673	14.5%	85,686	14.6%	-0.055	-0.002
2021	103,300	14.3%	86,818	14.8%	-0.438	-0.013
2022	123,641	17.2%	101,546	17.3%	-0.122	-0.003
2023	91,408	12.7%	70,444	12.0%	0.698	0.022
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.7	1.8	1.7	1.8	-0.083	-0.045
Combined comorbidity score*,[6]	2.3	2.5	2.4	2.5	-0.103	-0.041
Medical History						
Obesity*	348,798	48.4%	276,557	47.1%	1.344	0.027
Weight Reduction Surgery or Procedure*	743	0.1%	663	0.1%	-0.010	-0.003
Lifestyle intervention*	130,226	18.1%	99,476	16.9%	1.145	0.031
Cardiovascular Disease*	174,146	24.2%	149,891	25.5%	-1.340	-0.032
Cognitive Impairment*	25,598	3.6%	22,395	3.8%	-0.259	-0.014
Traumatic Brain Injury*	2,417	0.3%	2,069	0.4%	-0.017	-0.003

Table 1t. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	38,107	5.3%	30,131	5.1%	0.161	0.007
Epilepsy*	13,539	1.9%	11,333	1.9%	-0.050	-0.004
Chronic Pain*	194,622	27.0%	158,534	27.0%	0.031	0.001
Psychiatric History						
Previous Intentional Self-Harm Ever	8,224	1.1%	6,917	1.2%	-0.036	-0.003
Psychiatric History Overall*	720,398	100.0%	587,499	100.0%	0.000	NaN
Psychiatric Drug Dispensings	526,513	73.1%	433,101	73.7%	-0.633	-0.014
Intentional Self-Harm Encounter	1,166	0.2%	909	0.2%	0.007	0.002
Any Other Psychiatric Event	588,224	81.7%	474,850	80.8%	0.827	0.021
Attention-Deficit/Hyperactivity Disorder	12,516	1.7%	8,397	1.4%	0.308	0.025
Akathisia	1,113	0.2%	897	0.2%	0.002	0.000
Anxiety	189,746	26.3%	154,146	26.2%	0.101	0.002
Behavioral Disorder	45,805	6.4%	34,904	5.9%	0.417	0.017
Bipolar Disorder	43,839	6.1%	36,893	6.3%	-0.194	-0.008
Cerebral Degenerations usually Manifested in Childhood	11,292	1.6%	10,015	1.7%	-0.137	-0.011
Conduct Disorder	897	0.1%	748	0.1%	-0.003	-0.001
Delirium	16,890	2.3%	13,121	2.2%	0.111	0.007
Depression	209,631	29.1%	161,288	27.5%	1.646	0.037
Electroconvulsive Therapy	187	0.0%	168	0.0%	-0.003	-0.002
Hallucination	2,286	0.3%	1,891	0.3%	-0.004	-0.001
Obsessive-Compulsive Disorder	2,069	0.3%	1,677	0.3%	0.002	0.000
Other Cerebral Degenerations	16,560	2.3%	14,647	2.5%	-0.194	-0.013
Other Mental Disorders	9,204	1.3%	7,611	1.3%	-0.018	-0.002

Table 1t. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Psychological Disorders	103,213	14.3%	94,229	16.0%	-1.712	-0.048
Persistent Mental Disorders due to Conditions Classified Elsewhere	18,351	2.5%	15,464	2.6%	-0.085	-0.005
Personality Disorders	4,586	0.6%	3,416	0.6%	0.055	0.007
Pervasive Developmental Disorders	1,688	0.2%	1,505	0.3%	-0.022	-0.004
Post-Traumatic Stress Disorder	20,319	2.8%	16,024	2.7%	0.093	0.006
Psychotherapy	61,786	8.6%	47,891	8.2%	0.425	0.015
Psychotic Conditions	4,316	0.6%	3,902	0.7%	-0.065	-0.008
Schizophrenia	18,150	2.5%	17,922	3.1%	-0.531	-0.032
Sleep Disorder	301,551	41.9%	228,736	38.9%	2.925	0.060
Substance Abuse	52,448	7.3%	45,430	7.7%	-0.452	-0.017
Suicidal Behavior	5,917	0.8%	4,413	0.8%	0.070	0.008
Transcranial Magnetic Stimulation	202	0.0%	160	0.0%	0.001	0.000
Vagus Nerve Stimulation	973	0.1%	701	0.1%	0.016	0.004
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	5,590	0.8%	0	0.0%	NaN	NaN
dulaglutide	242,054	33.6%	0	0.0%	NaN	NaN
exenatide	54,682	7.6%	0	0.0%	NaN	NaN
liraglutide	152,483	21.2%	0	0.0%	NaN	NaN
lixisenatide	7,864	1.1%	0	0.0%	NaN	NaN
semaglutide	242,609	33.7%	0	0.0%	NaN	NaN
tirzepatide	16,215	2.3%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	720,397	100.0%	587,499	100.0%	-0.000	-0.002

Table 1t. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
insulin*	258,942	35.9%	235,719	40.1%	-4.178	-0.087
metformin*	634,986	88.1%	515,361	87.7%	0.423	0.013
alpha-glucosidase inhibitors*	2,767	0.4%	2,348	0.4%	-0.016	-0.002
thiazolidinediones*	55,542	7.7%	47,422	8.1%	-0.362	-0.013
meglitinides*	7,284	1.0%	6,474	1.1%	-0.091	-0.009
amylin analogue*	108	0.0%	112	0.0%	-0.004	-0.003
sulfonylureas*	258,454	35.9%	218,094	37.1%	-1.246	-0.026
bile acid sequestrants*	3,404	0.5%	2,760	0.5%	0.003	0.000
Other Weight Loss Agents*	2,220	0.3%	1,442	0.2%	0.063	0.012
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	335	0.0%	256	0.0%	0.003	0.001
diethylpropion	50	0.0%	32	0.0%	0.002	0.002
lorcaserin	103	0.0%	69	0.0%	0.003	0.002
phentermine	1,625	0.2%	1,018	0.2%	0.052	0.012
phentermine-topiramate	98	0.0%	49	0.0%	0.005	0.005
phendimetrazine	39	0.0%	23	0.0%	0.002	0.002
orlistat	42	0.0%	26	0.0%	0.001	0.002
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	238,393	33.1%	193,725	33.0%	0.117	0.003
Antipsychotics	74,452	10.3%	68,520	11.7%	-1.328	-0.043
Anxiolytics/Hypnotics	216,221	30.0%	186,962	31.8%	-1.809	-0.039
Lithium & Other Mood Stabilizers	63,603	8.8%	58,396	9.9%	-1.111	-0.038
Antidepressants	428,731	59.5%	345,917	58.9%	0.633	0.013

Table 1t. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	13.0	11.5	13.1	11.7	-0.075	-0.006
Mean number of emergency room encounters*	0.5	1.4	0.5	1.3	0.006	0.004
Mean number of inpatient hospital encounters*	0.2	0.6	0.2	0.5	-0.003	-0.005
Mean number of non-acute institutional encounters*	0.0	0.3	0.0	0.3	-0.002	-0.008
Mean number of other ambulatory encounters*	5.4	13.7	5.4	13.7	-0.090	-0.007
Mean number of filled prescriptions*	32.0	23.2	31.9	21.9	0.134	0.006
Mean number of generics dispensed*	12.9	5.8	12.9	5.3	0.033	0.006
Mean number of unique drug classes dispensed*	11.3	4.9	11.3	5.0	-0.032	-0.007

Table 1t. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1u. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	1,106,389	N/A	1,065,932	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.5	10.3	62.6	10.6	-1.093	-0.104
Age						
18-24 years	4,595	0.4%	4,037	0.4%	0.037	0.006
25-44 years	119,433	10.8%	104,705	9.8%	0.972	0.033
45-64 years	468,562	42.4%	425,915	40.0%	2.394	0.055
65-79 years	462,982	41.8%	462,917	43.4%	-1.582	-0.038
≥ 80 years	50,816	4.6%	68,358	6.4%	-1.820	-0.081
Sex*						
Female	568,146	51.4%	522,457	49.0%	2.337	0.047
Male	538,242	48.6%	543,475	51.0%	-2.337	-0.047
Race[4]						
American Indian or Alaska Native	8,058	0.7%	6,445	0.6%	0.124	0.015
Asian	17,784	1.6%	32,811	3.1%	-1.471	-0.098
Black or African American	104,888	9.5%	108,891	10.2%	-0.735	-0.025
Multi-racial	5,619	0.5%	4,986	0.5%	0.040	0.006
Native Hawaiian or Other Pacific Islander	3,163	0.3%	3,284	0.3%	-0.022	-0.004
Unknown	404,330	36.5%	366,548	34.4%	2.157	0.072
White	562,547	50.8%	542,967	50.9%	-0.093	-0.002
Hispanic origin						

Table 1u. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	50,692	4.6%	66,020	6.2%	-1.612	-0.075
No	632,072	57.1%	632,671	59.4%	-2.224	-0.082
Unknown	423,625	38.3%	367,241	34.5%	3.836	0.179
Year*						
2015	18,227	1.6%	17,934	1.7%	-0.035	-0.003
2016	85,722	7.7%	83,539	7.8%	-0.089	-0.003
2017	104,375	9.4%	101,274	9.5%	-0.067	-0.002
2018	113,055	10.2%	106,880	10.0%	0.191	0.006
2019	144,081	13.0%	139,231	13.1%	-0.039	-0.001
2020	160,817	14.5%	158,887	14.9%	-0.371	-0.011
2021	155,977	14.1%	156,141	14.6%	-0.550	-0.016
2022	186,645	16.9%	180,443	16.9%	-0.058	-0.002
2023	137,490	12.4%	121,603	11.4%	1.019	0.032
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.5	1.7	1.5	1.7	-0.063	-0.037
Combined comorbidity score*,[6]	1.8	2.3	1.9	2.4	-0.074	-0.032
Medical History						
Obesity*	478,476	43.2%	427,660	40.1%	3.126	0.064
Weight Reduction Surgery or Procedure*	736	0.1%	735	0.1%	-0.002	-0.001
Lifestyle intervention*	195,841	17.7%	175,948	16.5%	1.194	0.032
Cardiovascular Disease*	226,014	20.4%	232,263	21.8%	-1.362	-0.034
Cognitive Impairment*	24,203	2.2%	24,799	2.3%	-0.139	-0.009
Traumatic Brain Injury*	2,331	0.2%	2,212	0.2%	0.003	0.001

Table 1u. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	40,656	3.7%	35,862	3.4%	0.310	0.017
Epilepsy*	13,839	1.3%	13,264	1.2%	0.006	0.001
Chronic Pain*	230,070	20.8%	212,661	20.0%	0.844	0.021
Psychiatric History						
Previous Intentional Self-Harm Ever	8,064	0.7%	7,437	0.7%	0.031	0.004
Psychiatric History Overall*	671,479	60.7%	626,809	58.8%	1.887	0.039
Psychiatric Drug Dispensings	491,310	44.4%	460,507	43.2%	1.204	0.024
Intentional Self-Harm Encounter	1,085	0.1%	945	0.1%	0.009	0.003
Any Other Psychiatric Event	548,487	49.6%	505,608	47.4%	2.141	0.043
Attention-Deficit/Hyperactivity Disorder	11,603	1.0%	8,818	0.8%	0.221	0.023
Akathisia	1,047	0.1%	943	0.1%	0.006	0.002
Anxiety	177,510	16.0%	162,135	15.2%	0.833	0.023
Behavioral Disorder	42,720	3.9%	36,792	3.5%	0.410	0.022
Bipolar Disorder	41,140	3.7%	38,429	3.6%	0.113	0.006
Cerebral Degenerations usually Manifested in Childhood	10,455	0.9%	10,812	1.0%	-0.069	-0.007
Conduct Disorder	835	0.1%	806	0.1%	-0.000	-0.000
Delirium	15,596	1.4%	14,182	1.3%	0.079	0.007
Depression	195,792	17.7%	170,610	16.0%	1.691	0.045
Electroconvulsive Therapy	171	0.0%	172	0.0%	-0.001	-0.000
Hallucination	2,110	0.2%	2,007	0.2%	0.002	0.001
Obsessive-Compulsive Disorder	1,935	0.2%	1,755	0.2%	0.010	0.002
Other Cerebral Degenerations	15,367	1.4%	15,744	1.5%	-0.088	-0.007
Other Mental Disorders	8,572	0.8%	8,038	0.8%	0.021	0.002

Table 1u. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Psychological Disorders	96,175	8.7%	100,292	9.4%	-0.716	-0.025
Persistent Mental Disorders due to Conditions Classified Elsewhere	16,998	1.5%	16,688	1.6%	-0.029	-0.002
Personality Disorders	4,304	0.4%	3,471	0.3%	0.063	0.011
Pervasive Developmental Disorders	1,562	0.1%	1,627	0.2%	-0.011	-0.003
Post-Traumatic Stress Disorder	19,062	1.7%	16,597	1.6%	0.166	0.013
Psychotherapy	57,648	5.2%	50,148	4.7%	0.506	0.023
Psychotic Conditions	4,033	0.4%	4,129	0.4%	-0.023	-0.004
Schizophrenia	17,010	1.5%	18,924	1.8%	-0.238	-0.019
Sleep Disorder	281,455	25.4%	242,443	22.7%	2.694	0.063
Substance Abuse	48,869	4.4%	48,445	4.5%	-0.128	-0.006
Suicidal Behavior	5,557	0.5%	4,710	0.4%	0.060	0.009
Transcranial Magnetic Stimulation	190	0.0%	167	0.0%	0.002	0.001
Vagus Nerve Stimulation	928	0.1%	702	0.1%	0.018	0.007
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	9,477	0.9%	0	0.0%	NaN	NaN
dulaglutide	378,914	34.2%	0	0.0%	NaN	NaN
exenatide	83,821	7.6%	0	0.0%	NaN	NaN
liraglutide	228,219	20.6%	0	0.0%	NaN	NaN
lixisenatide	13,024	1.2%	0	0.0%	NaN	NaN
semaglutide	371,184	33.5%	0	0.0%	NaN	NaN
tirzepatide	23,568	2.1%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,106,386	100.0%	1,065,931	100.0%	-0.000	-0.001

Table 1u. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
insulin*	393,545	35.6%	392,931	36.9%	-1.292	-0.027
metformin*	980,445	88.6%	943,598	88.5%	0.093	0.003
alpha-glucosidase inhibitors*	4,579	0.4%	4,613	0.4%	-0.019	-0.003
thiazolidinediones*	90,197	8.2%	89,753	8.4%	-0.268	-0.010
meglitinides*	12,126	1.1%	12,296	1.2%	-0.058	-0.005
amylin analogue*	137	0.0%	149	0.0%	-0.002	-0.001
sulfonylureas*	411,919	37.2%	411,779	38.6%	-1.400	-0.029
bile acid sequestrants*	4,703	0.4%	4,320	0.4%	0.020	0.003
Other Weight Loss Agents*	2,850	0.3%	1,920	0.2%	0.077	0.017
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	319	0.0%	246	0.0%	0.006	0.004
diethylpropion	66	0.0%	36	0.0%	0.003	0.004
lorcaserin	141	0.0%	104	0.0%	0.003	0.003
phentermine	2,161	0.2%	1,439	0.1%	0.060	0.015
phentermine-topiramate	135	0.0%	71	0.0%	0.006	0.006
phendimetrazine	53	0.0%	27	0.0%	0.002	0.004
orlistat	51	0.0%	35	0.0%	0.001	0.002
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	286,734	25.9%	265,478	24.9%	1.010	0.023
Antipsychotics	69,541	6.3%	72,013	6.8%	-0.470	-0.019
Anxiolytics/Hypnotics	202,194	18.3%	196,881	18.5%	-0.195	-0.005
Lithium & Other Mood Stabilizers	59,470	5.4%	61,163	5.7%	-0.363	-0.016
Antidepressants	400,513	36.2%	367,119	34.4%	1.759	0.037

Table 1u. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	11.0	10.4	10.9	10.4	0.150	0.014
Mean number of emergency room encounters*	0.4	1.1	0.4	1.1	0.009	0.008
Mean number of inpatient hospital encounters*	0.1	0.5	0.1	0.5	-0.005	-0.011
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	-0.001	-0.005
Mean number of other ambulatory encounters*	4.1	11.7	4.1	11.6	-0.042	-0.004
Mean number of filled prescriptions*	26.8	20.8	26.2	19.5	0.628	0.031
Mean number of generics dispensed*	11.3	5.5	11.1	5.1	0.204	0.038
Mean number of unique drug classes dispensed*	9.7	4.7	9.5	4.7	0.212	0.045

Table 1u. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1v. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	1,105,253	N/A	1,065,182	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.5	10.3	62.6	10.6	-1.091	-0.104
Age						
18-24 years	4,549	0.4%	4,009	0.4%	0.035	0.006
25-44 years	119,117	10.8%	104,451	9.8%	0.971	0.033
45-64 years	467,988	42.3%	425,529	39.9%	2.393	0.055
65-79 years	462,806	41.9%	462,844	43.5%	-1.579	-0.038
≥ 80 years	50,793	4.6%	68,349	6.4%	-1.821	-0.081
Sex*						
Female	567,449	51.3%	521,984	49.0%	2.337	0.047
Male	537,804	48.7%	543,198	51.0%	-2.337	-0.047
Race[4]						
American Indian or Alaska Native	8,032	0.7%	6,423	0.6%	0.124	0.015
Asian	17,772	1.6%	32,802	3.1%	-1.471	-0.098
Black or African American	104,778	9.5%	108,791	10.2%	-0.733	-0.025
Multi-racial	5,618	0.5%	4,980	0.5%	0.041	0.006
Native Hawaiian or Other Pacific Islander	3,162	0.3%	3,281	0.3%	-0.022	-0.004
Unknown	404,033	36.6%	366,382	34.4%	2.160	0.072
White	561,857	50.8%	542,523	50.9%	-0.097	-0.002
Hispanic origin						

Table 1v. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	50,596	4.6%	65,977	6.2%	-1.616	-0.075
No	631,273	57.1%	632,127	59.3%	-2.229	-0.082
Unknown	423,383	38.3%	367,078	34.5%	3.845	0.179
Year*						
2015	18,197	1.6%	17,916	1.7%	-0.036	-0.003
2016	85,617	7.7%	83,473	7.8%	-0.090	-0.003
2017	104,243	9.4%	101,194	9.5%	-0.069	-0.002
2018	112,935	10.2%	106,798	10.0%	0.192	0.006
2019	143,907	13.0%	139,115	13.1%	-0.040	-0.001
2020	160,628	14.5%	158,773	14.9%	-0.373	-0.011
2021	155,831	14.1%	156,027	14.6%	-0.549	-0.016
2022	186,478	16.9%	180,340	16.9%	-0.058	-0.002
2023	137,417	12.4%	121,546	11.4%	1.022	0.032
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.4	1.7	1.5	1.7	-0.063	-0.037
Combined comorbidity score*,[6]	1.8	2.3	1.9	2.4	-0.074	-0.032
Medical History						
Obesity*	477,833	43.2%	427,186	40.1%	3.128	0.064
Weight Reduction Surgery or Procedure*	734	0.1%	734	0.1%	-0.002	-0.001
Lifestyle intervention*	195,564	17.7%	175,736	16.5%	1.196	0.032
Cardiovascular Disease*	225,732	20.4%	232,018	21.8%	-1.358	-0.034
Cognitive Impairment*	24,128	2.2%	24,721	2.3%	-0.138	-0.009
Traumatic Brain Injury*	2,322	0.2%	2,204	0.2%	0.003	0.001

Table 1v. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	40,493	3.7%	35,726	3.4%	0.310	0.017
Epilepsy*	13,738	1.2%	13,171	1.2%	0.006	0.001
Chronic Pain*	229,610	20.8%	212,301	19.9%	0.843	0.021
Psychiatric History						
Previous Intentional Self-Harm Ever	6,976	0.6%	6,493	0.6%	0.022	0.003
Psychiatric History Overall*	670,400	60.7%	625,970	58.8%	1.889	0.039
Psychiatric Drug Dispensings	490,314	44.4%	459,729	43.2%	1.202	0.024
Intentional Self-Harm Encounter	0	0.0%	0	0.0%	NaN	NaN
Any Other Psychiatric Event	547,419	49.5%	504,729	47.4%	2.145	0.043
Attention-Deficit/Hyperactivity Disorder	11,506	1.0%	8,772	0.8%	0.218	0.023
Akathisia	1,026	0.1%	929	0.1%	0.006	0.002
Anxiety	176,785	16.0%	161,499	15.2%	0.833	0.023
Behavioral Disorder	41,735	3.8%	35,929	3.4%	0.403	0.022
Bipolar Disorder	40,660	3.7%	38,056	3.6%	0.106	0.006
Cerebral Degenerations usually Manifested in Childhood	10,424	0.9%	10,774	1.0%	-0.068	-0.007
Conduct Disorder	813	0.1%	785	0.1%	-0.000	-0.000
Delirium	15,429	1.4%	14,040	1.3%	0.078	0.007
Depression	194,935	17.6%	169,900	16.0%	1.687	0.045
Electroconvulsive Therapy	147	0.0%	158	0.0%	-0.002	-0.001
Hallucination	2,028	0.2%	1,941	0.2%	0.001	0.000
Obsessive-Compulsive Disorder	1,901	0.2%	1,742	0.2%	0.008	0.002
Other Cerebral Degenerations	15,336	1.4%	15,713	1.5%	-0.088	-0.007
Other Mental Disorders	8,487	0.8%	7,953	0.7%	0.021	0.002

Table 1v. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Psychological Disorders	95,682	8.7%	99,865	9.4%	-0.718	-0.025
Persistent Mental Disorders due to Conditions Classified Elsewhere	16,958	1.5%	16,654	1.6%	-0.029	-0.002
Personality Disorders	4,063	0.4%	3,294	0.3%	0.058	0.010
Pervasive Developmental Disorders	1,540	0.1%	1,597	0.1%	-0.011	-0.003
Post-Traumatic Stress Disorder	18,718	1.7%	16,357	1.5%	0.158	0.013
Psychotherapy	57,155	5.2%	49,767	4.7%	0.499	0.023
Psychotic Conditions	3,859	0.3%	3,961	0.4%	-0.023	-0.004
Schizophrenia	16,773	1.5%	18,689	1.8%	-0.237	-0.019
Sleep Disorder	280,903	25.4%	242,054	22.7%	2.691	0.063
Substance Abuse	48,370	4.4%	48,054	4.5%	-0.135	-0.007
Suicidal Behavior	4,869	0.4%	4,184	0.4%	0.048	0.007
Transcranial Magnetic Stimulation	189	0.0%	162	0.0%	0.002	0.002
Vagus Nerve Stimulation	923	0.1%	697	0.1%	0.018	0.007
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	9,473	0.9%	0	0.0%	NaN	NaN
dulaglutide	378,567	34.3%	0	0.0%	NaN	NaN
exenatide	83,648	7.6%	0	0.0%	NaN	NaN
liraglutide	227,918	20.6%	0	0.0%	NaN	NaN
lixisenatide	13,009	1.2%	0	0.0%	NaN	NaN
semaglutide	370,902	33.6%	0	0.0%	NaN	NaN
tirzepatide	23,555	2.1%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,105,250	100.0%	1,065,181	100.0%	-0.000	-0.001

Table 1v. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
insulin*	393,106	35.6%	392,663	36.9%	-1.296	-0.027
metformin*	979,422	88.6%	942,921	88.5%	0.093	0.003
alpha-glucosidase inhibitors*	4,569	0.4%	4,608	0.4%	-0.019	-0.003
thiazolidinediones*	90,111	8.2%	89,713	8.4%	-0.269	-0.010
meglitinides*	12,118	1.1%	12,291	1.2%	-0.058	-0.005
amylin analogue*	137	0.0%	149	0.0%	-0.002	-0.001
sulfonylureas*	411,535	37.2%	411,561	38.6%	-1.403	-0.029
bile acid sequestrants*	4,704	0.4%	4,319	0.4%	0.020	0.003
Other Weight Loss Agents*	2,826	0.3%	1,921	0.2%	0.075	0.016
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	319	0.0%	246	0.0%	0.006	0.004
diethylpropion	66	0.0%	36	0.0%	0.003	0.004
lorcaserin	141	0.0%	104	0.0%	0.003	0.003
phentermine	2,137	0.2%	1,439	0.1%	0.058	0.014
phentermine-topiramate	135	0.0%	71	0.0%	0.006	0.006
phendimetrazine	53	0.0%	27	0.0%	0.002	0.004
orlistat	51	0.0%	35	0.0%	0.001	0.002
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	286,299	25.9%	265,151	24.9%	1.011	0.023
Antipsychotics	68,916	6.2%	71,504	6.7%	-0.478	-0.020
Anxiolytics/Hypnotics	201,557	18.2%	196,347	18.4%	-0.197	-0.005
Lithium & Other Mood Stabilizers	59,009	5.3%	60,808	5.7%	-0.370	-0.016
Antidepressants	399,582	36.2%	366,414	34.4%	1.754	0.037

Table 1v. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	11.0	10.4	10.9	10.3	0.148	0.014
Mean number of emergency room encounters*	0.4	1.1	0.4	1.1	0.009	0.008
Mean number of inpatient hospital encounters*	0.1	0.5	0.1	0.5	-0.005	-0.011
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	-0.001	-0.005
Mean number of other ambulatory encounters*	4.1	11.7	4.1	11.6	-0.045	-0.004
Mean number of filled prescriptions*	26.8	20.7	26.2	19.4	0.626	0.031
Mean number of generics dispensed*	11.3	5.5	11.1	5.1	0.203	0.038
Mean number of unique drug classes dispensed*	9.7	4.7	9.5	4.7	0.212	0.045

Table 1v. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1w. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	951	N/A	26,627	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	50.7	13.4	47.6	11.3	3.151	0.254
Age						
18-24 years	37	3.9%	23	0.1%	3.816	0.273
25-44 years	270	28.3%	12,954	48.6%	-20.316	-0.411
45-64 years	485	51.0%	13,541	50.9%	0.122	NaN
65-79 years	142	15.0%	98	0.4%	14.611	0.592
≥ 80 years	17	1.8%	12	0.0%	1.767	0.182
Sex*						
Female	603	63.4%	11,597	43.6%	19.799	NaN
Male	349	36.6%	15,030	56.4%	-19.799	-0.389
Race[4]						
American Indian or Alaska Native	*****	*****	16	0.1%	*****	*****
Asian	*****	*****	*****	*****	*****	*****
Black or African American	101	10.7%	88	0.3%	10.337	0.460
Multi-racial	0	0.0%	*****	*****	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****	*****
Unknown	206	21.7%	26,112	98.1%	-76.383	NaN
White	613	64.4%	393	1.5%	62.915	2.040
Hispanic origin						

Table 1w. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	66	6.9%	46	0.2%	6.720	0.375
No	728	76.5%	509	1.9%	74.621	3.280
Unknown	158	16.6%	26,072	97.9%	-81.341	NaN
Year*						
2015	50	5.2%	12	0.0%	5.172	NaN
2016	90	9.5%	792	3.0%	6.519	0.264
2017	108	11.3%	689	2.6%	8.749	0.340
2018	110	11.6%	7,795	29.3%	-17.693	-0.429
2019	146	15.4%	5,516	20.7%	-5.357	-0.134
2020	160	16.8%	1,187	4.5%	12.311	0.402
2021	109	11.4%	5,837	21.9%	-10.504	-0.273
2022	117	12.3%	4,140	15.5%	-3.235	-0.090
2023	62	6.5%	659	2.5%	4.038	0.193
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.8	1.9	0.5	1.0	1.318	0.862
Combined comorbidity score*,[6]	3.9	2.6	2.0	1.1	1.923	0.957
Medical History						
Obesity*	524	55.1%	16,968	63.7%	-8.670	-0.174
Weight Reduction Surgery or Procedure*	0	0.0%	0	0.0%	NaN	NaN
Lifestyle intervention*	227	23.9%	6,073	22.8%	1.089	0.025
Cardiovascular Disease*	239	25.1%	788	3.0%	22.162	0.677
Cognitive Impairment*	*****	*****	*****	*****	*****	*****
Traumatic Brain Injury*	*****	*****	*****	*****	*****	*****

Table 1w. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	133	14.0%	88	0.3%	13.640	0.542
Epilepsy*	86	9.0%	64	0.2%	8.758	0.420
Chronic Pain*	390	41.0%	988	3.7%	37.325	NaN
Psychiatric History						
Previous Intentional Self-Harm Ever	951	100.0%	26,627	100.0%	0.000	NaN
Psychiatric History Overall*	951	100.0%	26,627	100.0%	0.000	NaN
Psychiatric Drug Dispensings	884	92.9%	24,534	92.1%	0.805	NaN
Intentional Self-Harm Encounter	951	100.0%	26,627	100.0%	0.000	NaN
Any Other Psychiatric Event	951	100.0%	26,627	100.0%	0.000	NaN
Attention-Deficit/Hyperactivity Disorder	66	6.9%	4,018	15.1%	-8.147	-0.248
Akathisia	16	1.7%	*****	*****	*****	*****
Anxiety	637	67.0%	17,289	64.9%	2.038	NaN
Behavioral Disorder	828	87.0%	24,533	92.1%	-5.108	-0.173
Bipolar Disorder	402	42.2%	5,336	20.0%	22.190	0.479
Cerebral Degenerations usually Manifested in Childhood	31	3.3%	21	0.1%	3.187	0.247
Conduct Disorder	23	2.4%	14	0.1%	2.341	0.211
Delirium	174	18.3%	3,457	13.0%	5.320	NaN
Depression	757	79.6%	19,374	72.8%	6.822	NaN
Electroconvulsive Therapy	19	2.0%	11	0.0%	1.958	0.192
Hallucination	65	6.8%	5,802	21.8%	-14.943	-0.412
Obsessive-Compulsive Disorder	24	2.6%	13	0.0%	2.523	0.220
Other Cerebral Degenerations	28	3.0%	23	0.1%	2.865	0.233
Other Mental Disorders	75	7.9%	999	3.8%	4.178	0.173

Table 1w. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Psychological Disorders	418	43.9%	10,278	38.6%	5.324	0.105
Persistent Mental Disorders due to Conditions Classified Elsewhere	41	4.3%	27	0.1%	4.202	0.286
Personality Disorders	200	21.0%	5,888	22.1%	-1.073	-0.025
Pervasive Developmental Disorders	22	2.3%	20	0.1%	2.186	0.201
Post-Traumatic Stress Disorder	268	28.2%	11,615	43.6%	-15.413	-0.312
Psychotherapy	396	41.6%	15,186	57.0%	-15.452	-0.301
Psychotic Conditions	139	14.6%	1,286	4.8%	9.784	0.325
Schizophrenia	212	22.2%	5,925	22.3%	-0.017	-0.000
Sleep Disorder	479	50.4%	8,734	32.8%	17.568	NaN
Substance Abuse	445	46.8%	7,745	29.1%	17.718	NaN
Suicidal Behavior	573	60.3%	20,347	76.4%	-16.162	NaN
Transcranial Magnetic Stimulation	*****	*****	*****	*****	*****	*****
Vagus Nerve Stimulation	*****	*****	*****	*****	*****	*****
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	*****	*****	0	0.0%	*****	*****
dulaglutide	298	31.3%	0	0.0%	NaN	NaN
exenatide	118	12.4%	0	0.0%	NaN	NaN
liraglutide	288	30.2%	0	0.0%	NaN	NaN
lixisenatide	*****	*****	0	0.0%	*****	*****
semaglutide	226	23.8%	0	0.0%	NaN	NaN
tirzepatide	*****	*****	0	0.0%	*****	*****
Any Anti-Diabetic Agents	951	100.0%	26,627	100.0%	0.000	NaN

Table 1w. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
insulin*	431	45.3%	7,630	28.7%	16.691	NaN
metformin*	850	89.4%	26,417	99.2%	-9.813	NaN
alpha-glucosidase inhibitors*	*****	*****	*****	*****	*****	*****
thiazolidinediones*	83	8.7%	41	0.2%	8.588	NaN
meglitinides*	*****	*****	*****	*****	*****	*****
amylin analogue*	0	0.0%	0	0.0%	NaN	NaN
sulfonylureas*	325	34.1%	3,609	13.6%	20.564	NaN
bile acid sequestrants*	0	0.0%	0	0.0%	NaN	NaN
Other Weight Loss Agents*	0	0.0%	0	0.0%	NaN	NaN
benzphetamine	0	0.0%	0	0.0%	NaN	NaN
bupropion	0	0.0%	0	0.0%	NaN	NaN
diethylpropion	0	0.0%	0	0.0%	NaN	NaN
lorcaserin	0	0.0%	0	0.0%	NaN	NaN
phentermine	0	0.0%	0	0.0%	NaN	NaN
phentermine-topiramate	0	0.0%	0	0.0%	NaN	NaN
phendimetrazine	0	0.0%	0	0.0%	NaN	NaN
orlistat	0	0.0%	0	0.0%	NaN	NaN
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	378	39.8%	15,601	58.6%	-18.838	NaN
Antipsychotics	571	60.0%	15,425	57.9%	2.075	NaN
Anxiolytics/Hypnotics	555	58.4%	22,548	84.7%	-26.307	NaN
Lithium & Other Mood Stabilizers	411	43.2%	5,327	20.0%	23.158	NaN
Antidepressants	816	85.8%	21,203	79.6%	6.158	NaN

Table 1w. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	25.4	18.9	12.8	8.6	12.588	0.858
Mean number of emergency room encounters*	3.0	4.5	2.0	1.2	1.010	0.306
Mean number of inpatient hospital encounters*	1.0	1.4	1.2	0.8	-0.193	-0.166
Mean number of non-acute institutional encounters*	0.5	0.9	0.0	0.2	0.467	0.740
Mean number of other ambulatory encounters*	17.4	25.3	1.6	4.3	15.868	0.874
Mean number of filled prescriptions*	50.2	34.4	25.9	21.6	24.232	0.844
Mean number of generics dispensed*	17.6	7.9	11.8	5.8	5.790	0.836
Mean number of unique drug classes dispensed*	15.3	6.5	10.3	5.5	5.018	0.828

Table 1w. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1x. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	407,392	N/A	500,796	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.9	9.8	63.0	10.0	-1.159	-0.117
Age						
18-24 years	1,878	0.5%	2,111	0.4%	0.039	0.006
25-44 years	43,918	10.8%	49,197	9.8%	0.956	0.033
45-64 years	164,233	40.3%	187,506	37.4%	2.872	0.071
65-79 years	177,195	43.5%	227,997	45.5%	-2.032	-0.053
≥ 80 years	20,169	5.0%	33,985	6.8%	-1.835	-0.080
Sex*						
Female	185,140	45.4%	215,616	43.1%	2.390	0.048
Male	222,252	54.6%	285,179	56.9%	-2.390	-0.048
Race[4]						
American Indian or Alaska Native	2,917	0.7%	2,826	0.6%	0.152	0.019
Asian	9,949	2.4%	23,530	4.7%	-2.256	-0.123
Black or African American	40,540	10.0%	53,047	10.6%	-0.641	-0.022
Multi-racial	2,486	0.6%	2,825	0.6%	0.046	0.006
Native Hawaiian or Other Pacific Islander	1,623	0.4%	2,153	0.4%	-0.031	-0.005
Unknown	175,492	43.1%	205,694	41.1%	2.004	0.062
White	174,384	42.8%	210,720	42.1%	0.728	0.019
Hispanic origin						

Table 1x. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	21,736	5.3%	38,697	7.7%	-2.392	-0.103
No	204,630	50.2%	262,576	52.4%	-2.202	-0.077
Unknown	181,026	44.4%	199,524	39.8%	4.594	0.196
Year*						
2015	7,198	1.8%	8,866	1.8%	-0.004	-0.000
2016	33,659	8.3%	41,492	8.3%	-0.023	-0.001
2017	40,235	9.9%	49,455	9.9%	0.001	0.000
2018	43,129	10.6%	51,412	10.3%	0.321	0.011
2019	53,928	13.2%	66,720	13.3%	-0.085	-0.003
2020	59,011	14.5%	75,544	15.1%	-0.600	-0.017
2021	55,498	13.6%	71,579	14.3%	-0.670	-0.020
2022	66,546	16.3%	81,555	16.3%	0.050	0.001
2023	48,188	11.8%	54,172	10.8%	1.011	0.032
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*[,5]	1.2	1.5	1.2	1.5	-0.028	-0.018
Combined comorbidity score*[,6]	1.1	1.7	1.1	1.8	-0.048	-0.027
Medical History						
Obesity*	144,033	35.4%	157,924	31.5%	3.820	0.082
Weight Reduction Surgery or Procedure*	43	0.0%	55	0.0%	-0.000	-0.000
Lifestyle intervention*	70,040	17.2%	80,100	16.0%	1.198	0.033
Cardiovascular Disease*	62,226	15.3%	81,371	16.2%	-0.974	-0.027
Cognitive Impairment*	518	0.1%	693	0.1%	-0.011	-0.003
Traumatic Brain Injury*	55	0.0%	61	0.0%	0.001	0.001

Table 1x. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	4,778	1.2%	5,267	1.1%	0.121	0.012
Epilepsy*	1,172	0.3%	1,418	0.3%	0.004	0.001
Chronic Pain*	46,337	11.4%	53,357	10.7%	0.720	0.023
Psychiatric History						
Previous Intentional Self-Harm Ever	303	0.1%	293	0.1%	0.016	0.006
Psychiatric History Overall*	0	0.0%	0	0.0%	NaN	NaN
Psychiatric Drug Dispensings	0	0.0%	0	0.0%	NaN	NaN
Intentional Self-Harm Encounter	0	0.0%	0	0.0%	NaN	NaN
Any Other Psychiatric Event	0	0.0%	0	0.0%	NaN	NaN
Attention-Deficit/Hyperactivity Disorder	0	0.0%	0	0.0%	NaN	NaN
Akathisia	0	0.0%	0	0.0%	NaN	NaN
Anxiety	0	0.0%	0	0.0%	NaN	NaN
Behavioral Disorder	0	0.0%	0	0.0%	NaN	NaN
Bipolar Disorder	0	0.0%	0	0.0%	NaN	NaN
Cerebral Degenerations usually Manifested in Childhood	0	0.0%	0	0.0%	NaN	NaN
Conduct Disorder	0	0.0%	0	0.0%	NaN	NaN
Delirium	0	0.0%	0	0.0%	NaN	NaN
Depression	0	0.0%	0	0.0%	NaN	NaN
Electroconvulsive Therapy	0	0.0%	0	0.0%	NaN	NaN
Hallucination	0	0.0%	0	0.0%	NaN	NaN
Obsessive-Compulsive Disorder	0	0.0%	0	0.0%	NaN	NaN
Other Cerebral Degenerations	0	0.0%	0	0.0%	NaN	NaN
Other Mental Disorders	0	0.0%	0	0.0%	NaN	NaN

Table 1x. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Psychological Disorders	0	0.0%	0	0.0%	NaN	NaN
Persistent Mental Disorders due to Conditions Classified Elsewhere	0	0.0%	0	0.0%	NaN	NaN
Personality Disorders	0	0.0%	0	0.0%	NaN	NaN
Pervasive Developmental Disorders	0	0.0%	0	0.0%	NaN	NaN
Post-Traumatic Stress Disorder	0	0.0%	0	0.0%	NaN	NaN
Psychotherapy	0	0.0%	0	0.0%	NaN	NaN
Psychotic Conditions	0	0.0%	0	0.0%	NaN	NaN
Schizophrenia	0	0.0%	0	0.0%	NaN	NaN
Sleep Disorder	0	0.0%	0	0.0%	NaN	NaN
Substance Abuse	0	0.0%	0	0.0%	NaN	NaN
Suicidal Behavior	0	0.0%	0	0.0%	NaN	NaN
Transcranial Magnetic Stimulation	0	0.0%	0	0.0%	NaN	NaN
Vagus Nerve Stimulation	0	0.0%	0	0.0%	NaN	NaN
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	4,094	1.0%	0	0.0%	NaN	NaN
dulaglutide	144,050	35.4%	0	0.0%	NaN	NaN
exenatide	30,761	7.6%	0	0.0%	NaN	NaN
liraglutide	81,069	19.9%	0	0.0%	NaN	NaN
lixisenatide	5,493	1.3%	0	0.0%	NaN	NaN
semaglutide	134,984	33.1%	0	0.0%	NaN	NaN
tirzepatide	7,885	1.9%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	407,389	100.0%	500,795	100.0%	-0.001	-0.003
insulin*	151,477	37.2%	177,797	35.5%	1.679	0.035

Table 1x. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
metformin*	363,670	89.3%	448,192	89.5%	-0.228	-0.007
alpha-glucosidase inhibitors*	1,931	0.5%	2,475	0.5%	-0.020	-0.003
thiazolidinediones*	35,787	8.8%	45,280	9.0%	-0.257	-0.009
meglitinides*	5,118	1.3%	6,448	1.3%	-0.031	-0.003
amylin analogue*	29	0.0%	43	0.0%	-0.001	-0.002
sulfonylureas*	159,050	39.0%	203,836	40.7%	-1.661	-0.034
bile acid sequestrants*	1,506	0.4%	1,650	0.3%	0.040	0.007
Other Weight Loss Agents*	694	0.2%	574	0.1%	0.056	0.015
benzphetamine	*****	*****	0	0.0%	*****	*****
bupropion	0	0.0%	0	0.0%	NaN	NaN
diethylpropion	19	0.0%	*****	*****	*****	*****
lorcaserin	37	0.0%	36	0.0%	0.002	0.002
phentermine	578	0.1%	498	0.1%	0.042	0.012
phentermine-topiramate	42	0.0%	26	0.0%	0.005	0.006
phendimetrazine	18	0.0%	*****	*****	*****	*****
orlistat	11	0.0%	*****	*****	*****	*****
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	63,186	15.5%	71,086	14.2%	1.315	0.037
Antipsychotics	0	0.0%	0	0.0%	NaN	NaN
Anxiolytics/Hypnotics	0	0.0%	0	0.0%	NaN	NaN
Lithium & Other Mood Stabilizers	0	0.0%	0	0.0%	NaN	NaN
Antidepressants	134	0.0%	101	0.0%	0.013	0.008
Health Service Utilization Intensity Metrics						

Table 1x. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Mean number of ambulatory encounters*	8.1	7.7	7.9	7.5	0.209	0.028
Mean number of emergency room encounters*	0.2	0.6	0.2	0.6	0.012	0.021
Mean number of inpatient hospital encounters*	0.1	0.3	0.1	0.3	0.000	0.000
Mean number of non-acute institutional encounters*	0.0	0.1	0.0	0.1	-0.000	-0.001
Mean number of other ambulatory encounters*	2.2	7.1	2.2	6.9	-0.055	-0.008
Mean number of filled prescriptions*	19.3	12.8	18.6	12.3	0.691	0.055
Mean number of generics dispensed*	8.9	3.9	8.6	3.7	0.289	0.077
Mean number of unique drug classes dispensed*	7.4	3.3	7.2	3.4	0.255	0.077

Table 1x. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1y. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	700,217	N/A	565,961	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.3	10.5	62.5	10.9	-1.175	-0.110
Age						
18-24 years	2,723	0.4%	1,952	0.3%	0.044	0.007
25-44 years	76,142	10.9%	54,939	9.7%	1.167	0.040
45-64 years	306,234	43.7%	233,906	41.3%	2.405	0.053
65-79 years	284,720	40.7%	240,066	42.4%	-1.756	-0.041
≥ 80 years	30,398	4.3%	35,098	6.2%	-1.860	-0.084
Sex*						
Female	386,678	55.2%	301,521	53.3%	1.947	0.039
Male	313,539	44.8%	264,441	46.7%	-1.947	-0.039
Race[4]						
American Indian or Alaska Native	5,187	0.7%	3,607	0.6%	0.103	0.013
Asian	7,464	1.1%	10,935	1.9%	-0.866	-0.072
Black or African American	64,213	9.2%	56,991	10.1%	-0.899	-0.031
Multi-racial	3,122	0.4%	2,214	0.4%	0.055	0.009
Islander	1,479	0.2%	1,284	0.2%	-0.016	-0.003
Unknown	227,937	32.6%	164,663	29.1%	3.458	0.122
White	390,815	55.8%	326,268	57.6%	-1.835	-0.048
Hispanic origin						

Table 1y. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	28,637	4.1%	29,265	5.2%	-1.081	-0.053
No	429,348	61.3%	367,757	65.0%	-3.663	-0.142
Unknown	242,232	34.6%	168,940	29.9%	4.744	0.237
Year*						
2015	11,028	1.6%	9,148	1.6%	-0.041	-0.003
2016	52,080	7.4%	42,689	7.5%	-0.105	-0.004
2017	64,157	9.2%	52,331	9.2%	-0.084	-0.003
2018	70,262	10.0%	55,906	9.9%	0.156	0.005
2019	90,350	12.9%	72,968	12.9%	0.010	0.000
2020	101,784	14.5%	83,353	14.7%	-0.192	-0.006
2021	100,402	14.3%	84,198	14.9%	-0.538	-0.015
2022	120,359	17.2%	98,273	17.4%	-0.175	-0.005
2023	89,796	12.8%	67,095	11.9%	0.969	0.030
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.6	1.8	1.7	1.8	-0.114	-0.062
Combined comorbidity score*,[6]	2.2	2.4	2.4	2.6	-0.151	-0.061
Medical History						
Obesity*	339,222	48.4%	261,440	46.2%	2.251	0.046
Weight Reduction Surgery or Procedure*	692	0.1%	606	0.1%	-0.008	-0.003
Lifestyle intervention*	126,770	18.1%	94,993	16.8%	1.320	0.035
Cardiovascular Disease*	165,393	23.6%	145,832	25.8%	-2.147	-0.051
Cognitive Impairment*	24,133	3.4%	21,859	3.9%	-0.416	-0.022
Traumatic Brain Injury*	2,331	0.3%	1,941	0.3%	-0.010	-0.002

Table 1y. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	36,525	5.2%	28,025	5.0%	0.264	0.012
Epilepsy*	12,876	1.8%	10,833	1.9%	-0.075	-0.006
Chronic Pain*	186,468	26.6%	149,782	26.5%	0.165	0.004
Psychiatric History						
Previous Intentional Self-Harm Ever	7,894	1.1%	6,436	1.1%	-0.010	-0.001
Psychiatric History Overall*	700,217	100.0%	565,961	100.0%	0.000	NaN
Psychiatric Drug Dispensings	511,493	73.0%	414,572	73.3%	-0.203	-0.005
Intentional Self-Harm Encounter	1,093	0.2%	846	0.1%	0.007	0.002
Any Other Psychiatric Event	570,648	81.5%	456,783	80.7%	0.787	0.020
Attention-Deficit/Hyperactivity Disorder	12,116	1.7%	7,871	1.4%	0.340	0.027
Akathisia	1,072	0.2%	848	0.1%	0.003	0.001
Anxiety	183,179	26.2%	146,351	25.9%	0.302	0.007
Behavioral Disorder	44,034	6.3%	33,134	5.9%	0.434	0.018
Bipolar Disorder	42,345	6.0%	34,459	6.1%	-0.041	-0.002
Cerebral Degenerations usually Manifested in Childhood	10,682	1.5%	9,732	1.7%	-0.194	-0.015
Conduct Disorder	874	0.1%	723	0.1%	-0.003	-0.001
Delirium	15,579	2.2%	12,696	2.2%	-0.018	-0.001
Depression	202,634	28.9%	153,618	27.1%	1.796	0.040
Electroconvulsive Therapy	173	0.0%	154	0.0%	-0.002	-0.002
Hallucination	2,119	0.3%	1,803	0.3%	-0.016	-0.003
Obsessive-Compulsive Disorder	2,000	0.3%	1,584	0.3%	0.006	0.001
Other Cerebral Degenerations	15,788	2.3%	14,275	2.5%	-0.267	-0.018
Other Mental Disorders	8,760	1.3%	7,259	1.3%	-0.031	-0.003

Table 1y. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Psychological Disorders	99,044	14.1%	90,323	16.0%	-1.814	-0.051
Persistent Mental Disorders due to Conditions Classified Elsewhere	17,288	2.5%	15,115	2.7%	-0.202	-0.013
Personality Disorders	4,384	0.6%	3,119	0.6%	0.075	0.010
Disorders	1,670	0.2%	1,457	0.3%	-0.019	-0.004
Post-Traumatic Stress Disorder	19,669	2.8%	14,868	2.6%	0.182	0.011
Psychotherapy	59,893	8.6%	44,936	7.9%	0.614	0.022
Psychotic Conditions	4,083	0.6%	3,694	0.7%	-0.070	-0.009
Schizophrenia	17,553	2.5%	17,010	3.0%	-0.499	-0.031
Sleep Disorder	291,697	41.7%	219,266	38.7%	2.916	0.060
Substance Abuse	50,098	7.2%	43,441	7.7%	-0.521	-0.020
Suicidal Behavior	5,627	0.8%	4,224	0.7%	0.057	0.007
Transcranial Magnetic Stimulation	200	0.0%	149	0.0%	0.002	0.001
Vagus Nerve Stimulation	928	0.1%	644	0.1%	0.019	0.005
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	5,357	0.8%	0	0.0%	NaN	NaN
dulaglutide	234,614	33.5%	0	0.0%	NaN	NaN
exenatide	53,147	7.6%	0	0.0%	NaN	NaN
liraglutide	148,097	21.2%	0	0.0%	NaN	NaN
lixisenatide	7,634	1.1%	0	0.0%	NaN	NaN
semaglutide	236,383	33.8%	0	0.0%	NaN	NaN
tirzepatide	15,877	2.3%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	700,216	100.0%	565,961	100.0%	-0.000	-0.002

Table 1y. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
insulin*	248,405	35.5%	216,400	38.2%	-2.760	-0.058
metformin*	617,368	88.2%	497,069	87.8%	0.341	0.011
alpha-glucosidase inhibitors*	2,666	0.4%	2,228	0.4%	-0.013	-0.002
thiazolidinediones*	54,062	7.7%	45,295	8.0%	-0.282	-0.011
meglitinides*	7,031	1.0%	6,074	1.1%	-0.069	-0.007
amylin analogue*	105	0.0%	94	0.0%	-0.002	-0.001
sulfonylureas*	251,243	35.9%	210,212	37.1%	-1.262	-0.026
bile acid sequestrants*	3,217	0.5%	2,585	0.5%	0.003	0.000
Other Weight Loss Agents*	2,175	0.3%	1,271	0.2%	0.086	0.017
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	329	0.0%	226	0.0%	0.007	0.003
diethylpropion	46	0.0%	28	0.0%	0.002	0.002
lorcaserin	103	0.0%	62	0.0%	0.004	0.003
phentermine	1,591	0.2%	895	0.2%	0.069	0.016
phentermine-topiramate	95	0.0%	45	0.0%	0.006	0.005
phendimetrazine	35	0.0%	20	0.0%	0.001	0.002
orlistat	41	0.0%	24	0.0%	0.002	0.002
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	226,888	32.4%	182,984	32.3%	0.071	0.002
Antipsychotics	71,828	10.3%	64,472	11.4%	-1.134	-0.037
Anxiolytics/Hypnotics	208,648	29.8%	177,130	31.3%	-1.500	-0.033
Lithium & Other Mood Stabilizers	61,632	8.8%	54,784	9.7%	-0.878	-0.030
Antidepressants	417,036	59.6%	330,217	58.3%	1.212	0.025

Table 1y. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	12.9	11.5	13.0	11.5	-0.082	-0.007
Mean number of emergency room encounters*	0.5	1.3	0.5	1.3	-0.008	-0.006
Mean number of inpatient hospital encounters*	0.2	0.5	0.2	0.5	-0.015	-0.028
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.3	-0.004	-0.016
Mean number of other ambulatory encounters*	5.3	13.6	5.4	13.7	-0.133	-0.010
Mean number of filled prescriptions*	31.6	22.7	31.5	21.6	0.087	0.004
Mean number of generics dispensed*	12.8	5.7	12.8	5.3	-0.012	-0.002
Mean number of unique drug classes dispensed*	11.2	4.9	11.1	4.9	0.039	0.008

Table 1y. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1z. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	1,150,636	100.0%	1,396,382	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)*	60.6	10.5	64.9	10.9	-4.304	-0.403
Age						
18-24 years	6,118	0.5%	4,450	0.3%	0.213	0.033
25-44 years	141,761	12.3%	115,688	8.3%	4.035	0.133
45-64 years	490,847	42.7%	504,188	36.1%	6.552	0.134
65-79 years	469,828	40.8%	598,153	42.8%	-2.004	-0.041
≥ 80 years	42,082	3.7%	173,903	12.5%	-8.797	-0.328
Sex*						
Female	636,705	55.3%	723,456	51.8%	3.526	0.071
Male	513,931	44.7%	672,926	48.2%	-3.526	-0.071
Race[3]						
American Indian or Alaska Native	8,294	0.7%	10,784	0.8%	-0.051	-0.006
Asian	16,616	1.4%	67,225	4.8%	-3.370	-0.194
Black or African American	110,002	9.6%	170,466	12.2%	-2.648	-0.085
Multi-racial	6,198	0.5%	4,008	0.3%	0.252	0.039
Islander	3,036	0.3%	5,359	0.4%	-0.120	-0.021
Unknown	420,355	36.5%	433,448	31.0%	5.492	0.116
White	586,135	50.9%	705,092	50.5%	0.446	0.009
Hispanic origin						
Yes	51,536	4.5%	117,749	8.4%	-3.954	-0.161
No	656,736	57.1%	904,410	64.8%	-7.692	-0.158
Unknown	442,364	38.4%	374,223	26.8%	11.646	0.250

Table 1z. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Year*						
2015	17,382	1.5%	61,581	4.4%	-2.899	-0.172
2016	83,994	7.3%	264,769	19.0%	-11.661	-0.351
2017	101,341	8.8%	260,737	18.7%	-9.865	-0.290
2018	119,464	10.4%	224,550	16.1%	-5.698	-0.169
2019	145,809	12.7%	201,109	14.4%	-1.730	-0.051
2020	159,197	13.8%	169,538	12.1%	1.694	0.050
2021	158,828	13.8%	104,824	7.5%	6.297	0.205
2022	197,149	17.1%	75,284	5.4%	11.743	0.378
2023	167,472	14.6%	33,990	2.4%	12.121	0.445
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[4]	1.3	1.6	1.5	1.8	-0.213	-0.125
Combined comorbidity score*,[5]	1.6	2.1	1.9	2.6	-0.290	-0.124
Medical History						
Obesity*	546,395	47.5%	371,603	26.6%	20.875	0.443
Procedure*	658	0.1%	1,619	0.1%	-0.059	-0.020
Lifestyle intervention*	212,960	18.5%	189,165	13.5%	4.961	0.136
Cardiovascular Disease*	200,238	17.4%	303,532	21.7%	-4.335	-0.109
Cognitive Impairment*	20,200	1.8%	67,792	4.9%	-3.099	-0.174
Traumatic Brain Injury*	2,457	0.2%	3,307	0.2%	-0.023	-0.005
Migraine*	44,619	3.9%	35,587	2.5%	1.329	0.075
Epilepsy*	13,184	1.1%	20,637	1.5%	-0.332	-0.029
Chronic Pain*	241,582	21.0%	226,408	16.2%	4.782	0.123
Psychiatric History						
Previous Intentional Self-Harm Ever	8,465	0.7%	8,428	0.6%	0.132	0.016
Psychiatric History Overall*	717,513	62.4%	736,620	52.8%	9.606	0.195

Table 1z. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Psychiatric Drug Dispensings	535,562	46.5%	534,443	38.3%	8.271	0.168
Intentional Self-Harm Encounter	1,053	0.1%	1,461	0.1%	-0.013	-0.004
Any Other Psychiatric Event	582,621	50.6%	584,603	41.9%	8.769	0.177
Attention-Deficit/Hyperactivity Disorder	13,744	1.2%	6,519	0.5%	0.728	0.080
Akathisia	1,083	0.1%	1,485	0.1%	-0.012	-0.004
Anxiety	193,091	16.8%	177,940	12.7%	4.038	0.114
Behavioral Disorder	45,104	3.9%	48,345	3.5%	0.458	0.024
Bipolar Disorder	45,404	3.9%	44,132	3.2%	0.786	0.042
Cerebral Degenerations usually Manifested in Childhood	9,137	0.8%	19,965	1.4%	-0.636	-0.061
Conduct Disorder	976	0.1%	1,289	0.1%	-0.007	-0.003
Delirium	12,357	1.1%	33,548	2.4%	-1.329	-0.102
Depression	208,985	18.2%	204,997	14.7%	3.482	0.094
Electroconvulsive Therapy	183	0.0%	267	0.0%	-0.003	-0.002
Hallucination	1,905	0.2%	4,003	0.3%	-0.121	-0.025
Disorder	2,205	0.2%	1,674	0.1%	0.072	0.018
Other Cerebral Degenerations	13,852	1.2%	36,025	2.6%	-1.376	-0.101
Other Mental Disorders	8,518	0.7%	13,182	0.9%	-0.204	-0.022
Other Psychological Disorders	96,823	8.4%	119,229	8.5%	-0.124	-0.004
Persistent Mental Disorders due to Conditions Classified Elsewhere	13,935	1.2%	51,711	3.7%	-2.492	-0.161
Personality Disorders	4,809	0.4%	4,159	0.3%	0.120	0.020
Pervasive Developmental Disorders	1,910	0.2%	1,903	0.1%	0.030	0.008

Table 1z. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Post-Traumatic Stress Disorder	21,766	1.9%	15,613	1.1%	0.774	0.064
Psychotherapy	65,156	5.7%	59,300	4.2%	1.416	0.065
Psychotic Conditions	3,769	0.3%	10,450	0.7%	-0.421	-0.058
Schizophrenia	17,993	1.6%	29,569	2.1%	-0.554	-0.041
Sleep Disorder	299,805	26.1%	227,159	16.3%	9.788	0.241
Substance Abuse	48,195	4.2%	55,355	4.0%	0.224	0.011
Suicidal Behavior	5,326	0.5%	7,330	0.5%	-0.062	-0.009
Transcranial Magnetic Stimulation	244	0.0%	88	0.0%	0.015	0.013
Vagus Nerve Stimulation	949	0.1%	791	0.1%	0.026	0.010
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	8,774	0.8%	0	0.0%	NaN	NaN
dulaglutide	379,591	33.0%	0	0.0%	NaN	NaN
exenatide	84,591	7.4%	0	0.0%	NaN	NaN
liraglutide	233,989	20.3%	0	0.0%	NaN	NaN
lixisenatide	15,644	1.4%	0	0.0%	NaN	NaN
semaglutide	400,289	34.8%	0	0.0%	NaN	NaN
tirzepatide	28,620	2.5%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,150,634	100.0%	1,396,382	100.0%	-0.000	-0.002
insulin*	387,616	33.7%	247,290	17.7%	15.978	0.372
metformin*	1,020,020	88.6%	1,212,924	86.9%	1.786	0.055
alpha-glucosidase inhibitors*	4,538	0.4%	7,298	0.5%	-0.128	-0.019
thiazolidinediones*	93,820	8.2%	97,103	7.0%	1.200	0.045
meglitinides*	12,033	1.0%	21,207	1.5%	-0.473	-0.042
amylin analogue*	153	0.0%	40	0.0%	0.010	0.012
sulfonylureas*	418,499	36.4%	631,438	45.2%	-8.848	-0.181

Table 1z. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
bile acid sequestrants*	4,272	0.4%	5,536	0.4%	-0.025	-0.004
Other Weight Loss Agents*	4,064	0.4%	752	0.1%	0.299	0.066
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	427	0.0%	116	0.0%	0.029	0.019
diethylpropion	84	0.0%	14	0.0%	0.006	0.010
lorcaserin	183	0.0%	69	0.0%	0.011	0.011
phentermine	3,127	0.3%	484	0.0%	0.237	0.061
phentermine-topiramate	199	0.0%	29	0.0%	0.015	0.015
phendimetrazine	63	0.0%	19	0.0%	0.004	0.007
orlistat	71	0.0%	38	0.0%	0.003	0.005
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	287,623	25.0%	335,304	24.0%	0.985	0.023
Antipsychotics	76,709	6.7%	92,942	6.7%	0.011	0.000
Anxiolytics/Hypnotics	220,069	19.1%	232,274	16.6%	2.492	0.065
Lithium & Other Mood Stabilizers	67,049	5.8%	72,652	5.2%	0.624	0.027
Antidepressants	441,539	38.4%	409,252	29.3%	9.065	0.192
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	10.9	10.5	10.4	11.3	0.479	0.044
Mean number of emergency room encounters*	0.3	1.0	0.4	1.1	-0.041	-0.039
Mean number of inpatient hospital encounters*	0.1	0.4	0.2	0.6	-0.081	-0.168
Mean number of non-acute institutional encounters*	0.0	0.2	0.1	0.3	-0.039	-0.144

Table 1z. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Mean number of other ambulatory encounters*	3.9	11.4	5.1	14.2	-1.258	-0.098
Mean number of filled prescriptions*	26.1	19.7	25.4	20.2	0.685	0.034
Mean number of generics dispensed*	10.9	5.1	10.4	5.1	0.545	0.107
Mean number of unique drug classes dispensed*	9.8	4.6	8.7	4.6	1.094	0.239

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1aa. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	1,150,446	100.0%	1,396,159	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)*	60.6	10.5	64.9	10.9	-4.302	-0.403
Age						
18-24 years	*****	*****	*****	*****	*****	*****
25-44 years	141,712	12.3%	*****	*****	*****	*****
45-64 years	490,730	42.7%	504,135	36.1%	6.547	0.134
65-79 years	469,807	40.8%	598,043	42.8%	-1.998	-0.041
≥ 80 years	*****	*****	173,847	12.5%	*****	*****
Sex*						
Female	636,559	55.3%	723,347	51.8%	3.522	0.071
Male	513,887	44.7%	672,812	48.2%	-3.522	-0.071
Race[3]						
American Indian or Alaska Native	*****	*****	*****	*****	*****	*****
Asian	*****	*****	67,196	4.8%	*****	*****
Black or African American	109,989	9.6%	170,410	12.2%	-2.645	-0.085
Multi-racial	*****	*****	*****	*****	*****	*****
Native Hawaiian or Other Pacific Islander	3,036	0.3%	5,359	0.4%	-0.120	-0.021
Unknown	420,269	36.5%	433,396	31.0%	5.489	0.116
White	586,050	50.9%	705,010	50.5%	0.445	0.009
Hispanic origin						
Yes	51,525	4.5%	117,731	8.4%	-3.954	-0.161
No	656,664	57.1%	904,311	64.8%	-7.692	-0.158

Table 1aa. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Unknown	442,257	38.4%	374,117	26.8%	11.646	0.250
Year*						
2015	17,382	1.5%	61,562	4.4%	-2.898	-0.172
2016	*****	*****	264,694	19.0%	*****	*****
2017	101,324	8.8%	260,703	18.7%	-9.866	-0.290
2018	*****	*****	224,518	16.1%	*****	*****
2019	*****	*****	201,074	14.4%	*****	*****
2020	*****	*****	169,524	12.1%	*****	*****
2021	158,802	13.8%	*****	*****	*****	*****
2022	197,103	17.1%	*****	*****	*****	*****
2023	167,395	14.6%	33,990	2.4%	12.116	0.445
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[4]	1.3	1.6	1.5	1.8	-0.213	-0.125
Combined comorbidity score*,[5]	1.6	2.1	1.9	2.6	-0.290	-0.124
Medical History						
Obesity*	546,225	47.5%	371,569	26.6%	20.866	0.443
Weight Reduction Surgery or Procedure*	*****	*****	*****	*****	*****	*****
Lifestyle intervention*	212,909	18.5%	189,120	13.5%	4.961	0.136
Cardiovascular Disease*	200,204	17.4%	303,443	21.7%	-4.332	-0.109
Cognitive Impairment*	*****	*****	67,738	4.9%	*****	*****
Traumatic Brain Injury*	*****	*****	*****	*****	*****	*****
Migraine*	44,580	3.9%	35,574	2.5%	1.327	0.075
Epilepsy*	*****	*****	*****	*****	*****	*****
Chronic Pain*	241,496	21.0%	226,343	16.2%	4.780	0.123
Psychiatric History						

Table 1aa. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Previous Intentional Self-Harm Ever	*****	*****	*****	*****	*****	*****
Psychiatric History Overall*	717,336	62.4%	736,472	52.7%	9.603	0.195
Psychiatric Drug Dispensings	535,398	46.5%	534,344	38.3%	8.266	0.168
Intentional Self-Harm Encounter	*****	*****	*****	*****	*****	*****
Any Other Psychiatric Event	582,470	50.6%	584,463	41.9%	8.768	0.177
Attention-Deficit/Hyperactivity Disorder	13,733	1.2%	*****	*****	*****	*****
Akathisia	*****	*****	1,485	0.1%	*****	*****
Anxiety	193,008	16.8%	177,897	12.7%	4.035	0.114
Behavioral Disorder	45,087	3.9%	48,325	3.5%	0.458	0.024
Bipolar Disorder	45,377	3.9%	44,119	3.2%	0.784	0.042
Cerebral Degenerations usually Manifested in Childhood	*****	*****	19,951	1.4%	*****	*****
Conduct Disorder	*****	*****	*****	*****	*****	*****
Delirium	*****	*****	33,527	2.4%	*****	*****
Depression	208,909	18.2%	204,942	14.7%	*****	*****
Electroconvulsive Therapy	*****	*****	267	0.0%	*****	*****
Hallucination	*****	*****	*****	*****	*****	*****
Obsessive-Compulsive Disorder	*****	*****	*****	*****	*****	*****
Other Cerebral Degenerations	*****	*****	35,999	2.6%	*****	*****
Other Mental Disorders	*****	*****	*****	*****	*****	*****
Other Psychological Disorders	96,786	8.4%	119,197	8.5%	-0.125	-0.004
Persistent Mental Disorders due to Conditions Classified Elsewhere	13,935	1.2%	51,664	3.7%	-2.489	-0.161
Personality Disorders	*****	*****	*****	*****	*****	*****
Pervasive Developmental Disorders	1,910	0.2%	1,903	0.1%	0.030	0.008
Post-Traumatic Stress Disorder	21,750	1.9%	*****	*****	*****	*****

Table 1aa. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Psychotherapy	65,113	5.7%	59,283	4.2%	1.414	0.065
Psychotic Conditions	3,769	0.3%	*****	*****	*****	*****
Schizophrenia	*****	*****	29,558	2.1%	*****	*****
Sleep Disorder	299,704	26.1%	227,103	16.3%	9.785	0.241
Substance Abuse	48,171	4.2%	55,340	4.0%	0.223	0.011
Suicidal Behavior	*****	*****	*****	*****	*****	*****
Transcranial Magnetic Stimulation	244	0.0%	88	0.0%	0.015	0.013
Vagus Nerve Stimulation	*****	*****	791	0.1%	*****	*****
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	8,774	0.8%	0	0.0%	NaN	NaN
dulaglutide	379,555	33.0%	0	0.0%	NaN	NaN
exenatide	84,569	7.4%	0	0.0%	NaN	NaN
liraglutide	233,962	20.3%	0	0.0%	NaN	NaN
lixisenatide	15,631	1.4%	0	0.0%	NaN	NaN
semaglutide	400,213	34.8%	0	0.0%	NaN	NaN
tirzepatide	28,604	2.5%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,150,444	100.0%	1,396,159	100.0%	-0.000	-0.002
insulin*	387,482	33.7%	247,269	17.7%	15.970	0.372
metformin*	1,019,852	88.6%	1,212,760	86.9%	1.784	0.054
alpha-glucosidase inhibitors*	*****	*****	*****	*****	*****	*****
thiazolidinediones*	93,790	8.2%	97,076	7.0%	1.199	0.045
meglitinides*	12,033	1.0%	*****	*****	*****	*****
amylin analogue*	153	0.0%	40	0.0%	0.010	0.012
sulfonylureas*	418,421	36.4%	631,269	45.2%	-8.844	-0.181
bile acid sequestrants*	*****	*****	*****	*****	*****	*****

Table 1aa. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Other Weight Loss Agents*	4,040	0.4%	752	0.1%	0.297	0.066
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	427	0.0%	116	0.0%	0.029	0.019
diethylpropion	84	0.0%	14	0.0%	0.006	0.010
lorcaserin	183	0.0%	69	0.0%	0.011	0.011
phentermine	3,104	0.3%	484	0.0%	0.235	0.060
phentermine-topiramate	199	0.0%	29	0.0%	0.015	0.015
phendimetrazine	63	0.0%	19	0.0%	0.004	0.007
orlistat	*****	*****	38	0.0%	*****	*****
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	287,525	25.0%	335,215	24.0%	0.983	0.023
Antipsychotics	76,670	6.7%	92,912	6.7%	0.010	0.000
Anxiolytics/Hypnotics	219,981	19.1%	232,223	16.6%	2.488	0.065
Lithium & Other Mood Stabilizers	67,012	5.8%	72,634	5.2%	0.622	0.027
Antidepressants	441,389	38.4%	409,180	29.3%	9.059	0.192
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	10.9	10.5	10.4	11.3	0.478	0.044
Mean number of emergency room encounters*	0.3	1.0	0.4	1.1	-0.041	-0.039
Mean number of inpatient hospital encounters*	0.1	0.4	0.2	0.6	-0.080	-0.168
Mean number of non-acute institutional encounters*	0.0	0.2	0.1	0.3	-0.038	-0.145
Mean number of other ambulatory encounters*	3.8	11.4	5.1	14.2	-1.258	-0.098

Table 1aa. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Mean number of filled prescriptions*	26.1	19.7	25.4	20.2	0.683	0.034
Mean number of generics dispensed*	10.9	5.1	10.4	5.1	0.544	0.107
Mean number of unique drug classes dispensed*	9.8	4.6	8.7	4.6	1.093	0.239

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1ab. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	1,313,982	N/A	1,539,090	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.8	10.4	62.7	11.6	-0.908	-0.082
Age						
18-24 years	3,880	0.3%	8,486	0.6%	-0.256	-0.040
25-44 years	122,533	9.3%	170,003	11.0%	-1.720	-0.059
45-64 years	591,767	45.0%	604,211	39.3%	5.779	0.131
65-79 years	521,168	39.7%	613,997	39.9%	-0.230	-0.005
≥ 80 years	74,633	5.7%	142,394	9.3%	-3.572	-0.139
Sex*						
Female	726,622	55.3%	846,329	55.0%	0.310	0.006
Male	587,360	44.7%	692,761	45.0%	-0.310	-0.006
Race[4]						
American Indian or Alaska Native	8,403	0.6%	13,230	0.9%	-0.220	-0.026
Asian	22,742	1.7%	61,305	4.0%	-2.252	-0.137
Black or African American	123,930	9.4%	201,718	13.1%	-3.675	-0.119
Multi-racial	31,352	2.4%	4,951	0.3%	2.064	0.198
Native Hawaiian or Other Pacific Islander	3,204	0.2%	4,996	0.3%	-0.081	-0.015
Unknown	488,262	37.2%	499,459	32.5%	4.707	0.154
White	636,088	48.4%	753,431	49.0%	-0.544	-0.014
Hispanic origin						

Table 1ab. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Yes	78,454	6.0%	130,709	8.5%	-2.522	-0.103
No	717,485	54.6%	966,354	62.8%	-8.183	-0.292
Unknown	518,043	39.4%	442,027	28.7%	10.705	0.469
Year*						
2015	40,488	3.1%	46,346	3.0%	0.070	0.004
2016	175,963	13.4%	206,911	13.4%	-0.052	-0.002
2017	179,629	13.7%	219,234	14.2%	-0.574	-0.017
2018	172,082	13.1%	211,120	13.7%	-0.621	-0.018
2019	178,806	13.6%	216,794	14.1%	-0.478	-0.014
2020	152,852	11.6%	207,324	13.5%	-1.838	-0.056
2021	142,583	10.9%	158,571	10.3%	0.548	0.018
2022	169,931	12.9%	161,031	10.5%	2.470	0.078
2023	101,648	7.7%	111,758	7.3%	0.475	0.018
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*[,5]	1.7	2.0	1.5	1.8	0.192	0.101
Combined comorbidity score*[,6]	2.4	2.9	1.9	2.4	0.458	0.170
Medical History						
Obesity*	542,168	41.3%	569,000	37.0%	4.292	0.089
Weight Reduction Surgery or Procedure*	2,058	0.2%	1,557	0.1%	0.055	0.015
Lifestyle intervention*	245,957	18.7%	234,461	15.2%	3.485	0.095
Cardiovascular Disease*	310,549	23.6%	322,151	20.9%	2.703	0.067
Cognitive Impairment*	77,438	5.9%	54,158	3.5%	2.375	0.113
Traumatic Brain Injury*	3,706	0.3%	3,899	0.3%	0.029	0.006

Table 1ab. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Migraine*	84,850	6.5%	55,715	3.6%	2.838	0.132
Epilepsy*	31,818	2.4%	23,041	1.5%	0.924	0.067
Chronic Pain*	345,436	26.3%	312,386	20.3%	5.992	0.143
Psychiatric History						
Previous Intentional Self-Harm Ever	17,122	1.3%	13,676	0.9%	0.414	0.040
Psychiatric History Overall*	856,696	65.2%	919,873	59.8%	5.431	0.113
Psychiatric Drug Dispensings	660,035	50.2%	704,261	45.8%	4.473	0.090
Intentional Self-Harm Encounter	6,714	0.5%	1,779	0.1%	0.395	0.071
Any Other Psychiatric Event	720,454	54.8%	737,957	47.9%	6.882	0.139
Attention-Deficit/Hyperactivity Disorder	18,021	1.4%	12,800	0.8%	0.540	0.052
Akathisia	1,663	0.1%	2,054	0.1%	-0.007	-0.002
Anxiety	271,276	20.6%	254,762	16.6%	4.093	0.106
Behavioral Disorder	89,892	6.8%	62,221	4.0%	2.798	0.124
Bipolar Disorder	71,381	5.4%	69,900	4.5%	0.891	0.041
Cerebral Degenerations usually Manifested in Childhood	21,379	1.6%	19,733	1.3%	0.345	0.029
Conduct Disorder	1,154	0.1%	1,797	0.1%	-0.029	-0.009
Delirium	52,013	4.0%	32,592	2.1%	1.841	0.108
Depression	298,374	22.7%	272,107	17.7%	5.028	0.126
Electroconvulsive Therapy	661	0.1%	360	0.0%	0.027	0.014
Hallucination	5,243	0.4%	4,391	0.3%	0.114	0.019
Obsessive-Compulsive Disorder	2,501	0.2%	2,979	0.2%	-0.003	-0.001
Other Cerebral Degenerations	33,241	2.5%	31,829	2.1%	0.462	0.031

Table 1ab. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Other Mental Disorders	19,646	1.5%	15,230	1.0%	0.506	0.046
Other Psychological Disorders	142,186	10.8%	155,925	10.1%	0.690	0.023
Persistent Mental Disorders due to Conditions Classified Elsewhere	52,954	4.0%	40,738	2.6%	1.383	0.078
Personality Disorders	11,361	0.9%	7,777	0.5%	0.359	0.044
Pervasive Developmental Disorders	1,264	0.1%	3,840	0.2%	-0.153	-0.037
Post-Traumatic Stress Disorder	26,709	2.0%	29,569	1.9%	0.112	0.008
Psychotherapy	85,240	6.5%	88,607	5.8%	0.730	0.030
Psychotic Conditions	16,219	1.2%	10,900	0.7%	0.526	0.054
Schizophrenia	37,582	2.9%	41,725	2.7%	0.149	0.009
Sleep Disorder	386,101	29.4%	308,702	20.1%	9.327	0.219
Substance Abuse	69,035	5.3%	76,025	4.9%	0.314	0.014
Suicidal Behavior	15,142	1.2%	8,322	0.5%	0.612	0.067
Transcranial Magnetic Stimulation	164	0.0%	155	0.0%	0.002	0.002
Vagus Nerve Stimulation	1,034	0.1%	1,066	0.1%	0.009	0.003
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	22,379	1.7%	0	0.0%	NaN	NaN
dulaglutide	475,806	36.2%	0	0.0%	NaN	NaN
exenatide	129,295	9.8%	0	0.0%	NaN	NaN
liraglutide	344,442	26.2%	0	0.0%	NaN	NaN
lixisenatide	12,041	0.9%	0	0.0%	NaN	NaN
semaglutide	316,101	24.1%	0	0.0%	NaN	NaN
tirzepatide	19,442	1.5%	0	0.0%	NaN	NaN

Table 1ab. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Any Anti-Diabetic Agents	1,313,980	100.0%	1,539,090	100.0%	-0.000	-0.002
insulin*	464,698	35.4%	579,887	37.7%	-2.312	-0.048
metformin*	1,140,546	86.8%	1,343,116	87.3%	-0.466	-0.014
alpha-glucosidase inhibitors*	7,008	0.5%	8,298	0.5%	-0.006	-0.001
thiazolidinediones*	90,414	6.9%	125,078	8.1%	-1.246	-0.047
meglitinides*	17,460	1.3%	22,318	1.5%	-0.121	-0.010
amylin analogue*	109	0.0%	239	0.0%	-0.007	-0.007
sulfonylureas*	528,462	40.2%	645,916	42.0%	-1.749	-0.036
bile acid sequestrants*	6,510	0.5%	6,618	0.4%	0.065	0.010
Other Weight Loss Agents*	3,074	0.2%	2,895	0.2%	0.046	0.010
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	595	0.0%	362	0.0%	0.022	0.012
diethylpropion	65	0.0%	44	0.0%	0.002	0.003
lorcaserin	136	0.0%	198	0.0%	-0.003	-0.002
phentermine	2,133	0.2%	2,137	0.1%	0.024	0.006
phentermine-topiramate	134	0.0%	77	0.0%	0.005	0.006
phendimetrazine	57	0.0%	43	0.0%	0.002	0.003
orlistat	39	0.0%	81	0.0%	-0.002	-0.004
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	467,222	35.6%	422,778	27.5%	8.088	0.175
Antipsychotics	117,322	8.9%	141,089	9.2%	-0.238	-0.008
Anxiolytics/Hypnotics	287,728	21.9%	323,937	21.0%	0.850	0.021
Lithium & Other Mood Stabilizers	99,825	7.6%	111,602	7.3%	0.346	0.013

Table 1ab. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Antidepressants	545,539	41.5%	557,237	36.2%	5.312	0.109
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	13.5	12.7	11.5	13.2	1.911	0.148
Mean number of emergency room encounters*	0.9	2.5	0.4	1.1	0.483	0.249
Mean number of inpatient hospital encounters*	0.4	1.9	0.2	0.5	0.273	0.201
Mean number of non-acute institutional encounters*	0.2	1.0	0.0	0.3	0.122	0.165
Mean number of other ambulatory encounters*	7.1	16.5	5.1	13.9	1.953	0.128
Mean number of filled prescriptions*	34.7	30.8	28.3	22.5	6.327	0.234
Mean number of generics dispensed*	13.9	8.9	11.5	5.6	2.400	0.322
Mean number of unique drug classes dispensed*	11.2	6.4	10.0	5.3	1.171	0.199

Table 1ab. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	DPP-4 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1ac. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) (SDD) (SDD) (SDD) (SDD) (SDD) (SDD) (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	1,149,394	100.0%	1,394,699	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)*	60.6	10.4	64.9	10.9	-4.303	-0.403
Age						
18-24 years	6,057	0.5%	4,410	0.3%	0.211	0.033
25-44 years	141,386	12.3%	115,355	8.3%	4.030	0.133
45-64 years	490,212	42.6%	503,376	36.1%	6.558	0.135
65-79 years	469,671	40.9%	597,766	42.9%	-1.997	-0.040
≥ 80 years	42,068	3.7%	173,792	12.5%	-8.801	-0.328
Sex*						
Female	635,860	55.3%	722,536	51.8%	3.515	0.071
Male	513,534	44.7%	672,163	48.2%	-3.515	-0.071
Race[3]						
American Indian or Alaska Native	8,270	0.7%	10,761	0.8%	-0.052	-0.006
Asian	*****	*****	67,164	4.8%	*****	*****
Black or African American	109,872	9.6%	170,212	12.2%	-2.645	-0.085
Multi-racial	*****	*****	*****	*****	*****	*****
Native Hawaiian or Other Pacific Islander	3,036	0.3%	*****	*****	*****	*****
Unknown	420,022	36.5%	433,088	31.1%	5.490	0.116
White	585,390	50.9%	704,118	50.5%	0.445	0.009
Hispanic origin						

Table 1ac. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) (SDD) (SDD) (SDD) (SDD) (SDD) (SDD) (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Yes	51,456	4.5%	117,608	8.4%	-3.956	-0.162
No	655,893	57.1%	903,190	64.8%	-7.695	-0.158
Unknown	442,045	38.5%	373,901	26.8%	11.650	0.250
Year*						
2015	17,356	1.5%	61,501	4.4%	-2.900	-0.172
2016	83,899	7.3%	264,416	19.0%	-11.659	-0.350
2017	101,209	8.8%	260,425	18.7%	-9.867	-0.290
2018	119,336	10.4%	224,271	16.1%	-5.698	-0.169
2019	145,628	12.7%	200,854	14.4%	-1.731	-0.051
2020	159,025	13.8%	169,335	12.1%	1.694	0.050
2021	158,676	13.8%	104,723	7.5%	6.297	0.205
2022	196,965	17.1%	75,215	5.4%	11.744	0.378
2023	167,300	14.6%	33,959	2.4%	12.121	0.445
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[4]	1.3	1.6	1.5	1.8	-0.213	-0.125
Combined comorbidity score*,[5]	1.6	2.1	1.9	2.6	-0.289	-0.124
Medical History						
Obesity*	545,570	47.5%	370,920	26.6%	20.871	0.443
Weight Reduction Surgery or Procedure*	*****	*****	*****	*****	*****	*****
Lifestyle intervention*	212,633	18.5%	188,850	13.5%	4.959	0.136
Cardiovascular Disease*	199,960	17.4%	302,987	21.7%	-4.327	-0.109
Cognitive Impairment*	20,123	1.8%	67,512	4.8%	-3.090	-0.174
Traumatic Brain Injury*	2,443	0.2%	3,285	0.2%	-0.023	-0.005

Table 1ac. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) (SDD) (SDD) (SDD) (SDD) (SDD) (SDD) (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Migraine*	44,411	3.9%	35,402	2.5%	1.326	0.075
Epilepsy*	13,089	1.1%	20,468	1.5%	-0.329	-0.029
Chronic Pain*	241,048	21.0%	225,797	16.2%	4.782	0.123
Psychiatric History						
Previous Intentional Self-Harm Ever	7,409	0.6%	6,963	0.5%	0.145	0.019
Psychiatric History Overall*	716,284	62.3%	735,012	52.7%	9.618	0.195
Psychiatric Drug Dispensings	534,414	46.5%	533,003	38.2%	8.279	0.168
Intentional Self-Harm Encounter	0	0.0%	0	0.0%	NaN	NaN
Any Other Psychiatric Event	581,418	50.6%	583,003	41.8%	8.783	0.177
Attention-Deficit/Hyperactivity Disorder	13,638	1.2%	6,459	0.5%	0.723	0.080
Akathisia	1,065	0.1%	1,469	0.1%	-0.013	-0.004
Anxiety	192,297	16.7%	176,999	12.7%	4.039	0.114
Behavioral Disorder	44,136	3.8%	47,013	3.4%	0.469	0.025
Bipolar Disorder	44,909	3.9%	43,481	3.1%	0.790	0.043
Cerebral Degenerations usually Manifested in Childhood	9,106	0.8%	19,888	1.4%	-0.634	-0.061
Conduct Disorder	948	0.1%	1,254	0.1%	-0.007	-0.003
Delirium	12,194	1.1%	33,224	2.4%	-1.321	-0.102
Depression	208,070	18.1%	203,787	14.6%	3.491	0.094
Electroconvulsive Therapy	161	0.0%	243	0.0%	-0.003	-0.003
Hallucination	1,824	0.2%	3,878	0.3%	-0.119	-0.026
Obsessive-Compulsive Disorder	2,173	0.2%	1,651	0.1%	0.071	0.018
Other Cerebral Degenerations	13,823	1.2%	35,893	2.6%	-1.371	-0.101

Table 1ac. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) (SDD) (SDD) (SDD) (SDD) (SDD) (SDD) (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Other Mental Disorders	8,428	0.7%	13,042	0.9%	-0.202	-0.022
Other Psychological Disorders	96,316	8.4%	118,491	8.5%	-0.116	-0.004
Persistent Mental Disorders due to Conditions Classified Elsewhere	13,899	1.2%	51,529	3.7%	-2.485	-0.161
Personality Disorders	4,552	0.4%	3,919	0.3%	0.115	0.020
Pervasive Developmental Disorders	1,887	0.2%	1,872	0.1%	0.030	0.008
Post-Traumatic Stress Disorder	21,410	1.9%	15,337	1.1%	0.763	0.063
Psychotherapy	64,649	5.6%	58,701	4.2%	1.416	0.066
Psychotic Conditions	3,617	0.3%	10,105	0.7%	-0.410	-0.057
Schizophrenia	17,763	1.5%	29,155	2.1%	-0.545	-0.041
Sleep Disorder	299,173	26.0%	226,535	16.2%	9.786	0.241
Substance Abuse	47,706	4.2%	54,687	3.9%	0.229	0.012
Suicidal Behavior	4,704	0.4%	6,443	0.5%	-0.053	-0.008
Transcranial Magnetic Stimulation	*****	*****	88	0.0%	*****	*****
Vagus Nerve Stimulation	*****	*****	*****	*****	*****	*****
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	*****	*****	0	0.0%	*****	*****
dulaglutide	379,232	33.0%	0	0.0%	NaN	NaN
exenatide	84,447	7.3%	0	0.0%	NaN	NaN
liraglutide	233,657	20.3%	0	0.0%	NaN	NaN
lixisenatide	15,619	1.4%	0	0.0%	NaN	NaN
semaglutide	399,943	34.8%	0	0.0%	NaN	NaN
tirzepatide	28,589	2.5%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,149,392	100.0%	1,394,699	100.0%	-0.000	-0.002

Table 1ac. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) (SDD) (SDD) (SDD) (SDD) (SDD) (SDD) (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
insulin*	387,021	33.7%	246,822	17.7%	15.975	0.372
metformin*	1,018,928	88.6%	1,211,450	86.9%	1.788	0.055
alpha-glucosidase inhibitors*	*****	*****	*****	*****	*****	*****
thiazolidinediones*	93,718	8.2%	96,999	7.0%	1.199	0.045
meglitinides*	12,022	1.0%	21,187	1.5%	-0.473	-0.042
amylin analogue*	*****	*****	40	0.0%	*****	*****
sulfonylureas*	418,077	36.4%	630,715	45.2%	-8.849	-0.181
bile acid sequestrants*	*****	*****	*****	*****	*****	*****
Other Weight Loss Agents*	4,037	0.4%	752	0.1%	0.297	0.066
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	427	0.0%	116	0.0%	0.029	0.019
diethylpropion	84	0.0%	14	0.0%	0.006	0.010
lorcaserin	183	0.0%	69	0.0%	0.011	0.011
phentermine	3,101	0.3%	484	0.0%	0.235	0.060
phentermine-topiramate	199	0.0%	29	0.0%	0.015	0.015
phendimetrazine	63	0.0%	19	0.0%	0.004	0.007
orlistat	*****	*****	38	0.0%	*****	*****
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	287,097	25.0%	334,627	24.0%	0.985	0.023
Antipsychotics	76,056	6.6%	92,066	6.6%	0.016	0.001
Anxiolytics/Hypnotics	219,357	19.1%	231,357	16.6%	2.496	0.065
Lithium & Other Mood Stabilizers	66,569	5.8%	71,994	5.2%	0.630	0.028
Antidepressants	440,476	38.3%	407,977	29.3%	9.070	0.193

Table 1ac. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) (SDD) (SDD) (SDD) (SDD) (SDD) (SDD) (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	10.8	10.4	10.4	11.3	0.477	0.044
Mean number of emergency room encounters*	0.3	1.0	0.4	1.1	-0.041	-0.039
Mean number of inpatient hospital encounters*	0.1	0.4	0.2	0.6	-0.080	-0.169
Mean number of non-acute institutional encounters*	0.0	0.2	0.1	0.3	-0.038	-0.146
Mean number of other ambulatory encounters*	3.8	11.4	5.1	14.1	-1.251	-0.097
Mean number of filled prescriptions*	26.1	19.6	25.4	20.2	0.682	0.034
Mean number of generics dispensed*	10.9	5.1	10.4	5.1	0.545	0.107
Mean number of unique drug classes dispensed*	9.8	4.6	8.7	4.6	1.094	0.239

Table 1ac. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) (SDD) (SDD) (SDD) (SDD) (SDD) (SDD) (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	DPP-4 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759.

Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1ad. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	1,149,285	100.0%	1,394,653	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)*	60.6	10.4	64.9	10.9	-4.302	-0.403
Age						
18-24 years	6,057	0.5%	4,410	0.3%	0.211	0.033
25-44 years	141,350	12.3%	115,352	8.3%	4.028	0.133
45-64 years	490,152	42.6%	503,364	36.1%	6.556	0.134
65-79 years	469,659	40.9%	597,745	42.9%	-1.994	-0.040
≥ 80 years	42,067	3.7%	173,782	12.5%	-8.800	-0.328
Sex*						
Female	635,780	55.3%	722,512	51.8%	3.514	0.070
Male	513,505	44.7%	672,141	48.2%	-3.514	-0.070
Race[3]						
American Indian or Alaska Native	8,270	0.7%	10,761	0.8%	-0.052	-0.006
Asian	*****	*****	67,161	4.8%	*****	*****
Black or African American	109,863	9.6%	170,204	12.2%	-2.645	-0.085
Multi-racial	*****	*****	*****	*****	*****	*****
Native Hawaiian or Other Pacific Islander	3,036	0.3%	*****	*****	*****	*****
Unknown	419,956	36.5%	433,084	31.1%	5.487	0.116
White	585,359	50.9%	704,087	50.5%	0.448	0.009
Hispanic origin						

Table 1ad. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Yes	51,451	4.5%	117,607	8.4%	-3.956	-0.162
No	655,863	57.1%	903,156	64.8%	-7.691	-0.158
Unknown	441,971	38.5%	373,890	26.8%	11.647	0.250
Year[*]						
2015	17,356	1.5%	61,495	4.4%	-2.899	-0.172
2016	83,898	7.3%	264,406	19.0%	-11.659	-0.350
2017	101,206	8.8%	260,411	18.7%	-9.866	-0.290
2018	119,334	10.4%	224,266	16.1%	-5.697	-0.169
2019	145,626	12.7%	200,853	14.4%	-1.731	-0.051
2020	159,022	13.8%	169,330	12.1%	1.695	0.050
2021	158,656	13.8%	104,721	7.5%	6.296	0.205
2022	196,933	17.1%	75,213	5.4%	11.742	0.378
2023	167,254	14.6%	33,958	2.4%	12.118	0.445
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)[*,4]	1.3	1.6	1.5	1.8	-0.212	-0.125
Combined comorbidity score[*,5]	1.6	2.1	1.9	2.6	-0.289	-0.124
Medical History						
Obesity[*]	545,479	47.5%	370,905	26.6%	20.868	0.443
Weight Reduction Surgery or Procedure[*]	648	0.1%	1,611	0.1%	-0.059	-0.020
Lifestyle intervention[*]	212,596	18.5%	188,841	13.5%	4.958	0.135
Cardiovascular Disease[*]	199,945	17.4%	302,968	21.7%	-4.326	-0.109
Cognitive Impairment[*]	20,123	1.8%	67,507	4.8%	-3.090	-0.174
Traumatic Brain Injury[*]	2,440	0.2%	3,285	0.2%	-0.023	-0.005

Table 1ad. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Migraine*	44,391	3.9%	35,400	2.5%	1.324	0.075
Epilepsy*	13,089	1.1%	20,465	1.5%	-0.329	-0.029
Chronic Pain*	241,004	21.0%	225,780	16.2%	4.781	0.123
Psychiatric History						
Previous Intentional Self-Harm Ever	7,403	0.6%	6,962	0.5%	0.145	0.019
Psychiatric History Overall*	716,186	62.3%	734,982	52.7%	9.616	0.195
Psychiatric Drug Dispensings	534,327	46.5%	532,980	38.2%	8.276	0.168
Intentional Self-Harm Encounter	0	0.0%	0	0.0%	NaN	NaN
Any Other Psychiatric Event	581,329	50.6%	582,977	41.8%	8.781	0.177
Attention-Deficit/Hyperactivity Disorder	13,631	1.2%	6,459	0.5%	0.723	0.080
Akathisia	1,065	0.1%	1,468	0.1%	-0.013	-0.004
Anxiety	192,245	16.7%	176,986	12.7%	4.037	0.114
Behavioral Disorder	44,124	3.8%	47,012	3.4%	0.468	0.025
Bipolar Disorder	44,887	3.9%	43,479	3.1%	0.788	0.043
Cerebral Degenerations usually Manifested in Childhood	9,106	0.8%	19,888	1.4%	-0.634	-0.061
Conduct Disorder	948	0.1%	1,254	0.1%	-0.007	-0.003
Delirium	12,193	1.1%	33,218	2.4%	-1.321	-0.102
Depression	208,025	18.1%	203,773	14.6%	3.489	0.094
Electroconvulsive Therapy	161	0.0%	243	0.0%	-0.003	-0.003
Hallucination	1,823	0.2%	3,877	0.3%	-0.119	-0.026
Obsessive-Compulsive Disorder	2,172	0.2%	1,651	0.1%	0.071	0.018
Other Cerebral Degenerations	13,823	1.2%	35,891	2.6%	-1.371	-0.101

Table 1ad. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Other Mental Disorders	8,424	0.7%	13,042	0.9%	-0.202	-0.022
Other Psychological Disorders	96,303	8.4%	118,485	8.5%	-0.116	-0.004
Persistent Mental Disorders due to Conditions Classified Elsewhere	13,899	1.2%	51,525	3.7%	-2.485	-0.161
Personality Disorders	4,550	0.4%	3,919	0.3%	0.115	0.020
Pervasive Developmental Disorders	1,887	0.2%	1,872	0.1%	0.030	0.008
Post-Traumatic Stress Disorder	21,397	1.9%	15,335	1.1%	0.762	0.063
Psychotherapy	64,623	5.6%	58,696	4.2%	1.414	0.065
Psychotic Conditions	3,615	0.3%	10,103	0.7%	-0.410	-0.057
Schizophrenia	17,759	1.5%	29,155	2.1%	-0.545	-0.041
Sleep Disorder	299,116	26.0%	226,523	16.2%	9.784	0.241
Substance Abuse	47,697	4.2%	54,684	3.9%	0.229	0.012
Suicidal Behavior	4,704	0.4%	6,443	0.5%	-0.053	-0.008
Transcranial Magnetic Stimulation	*****	*****	88	0.0%	0.015	0.013
Vagus Nerve Stimulation	*****	*****	*****	*****	*****	*****
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	*****	*****	0	0.0%	*****	*****
dulaglutide	379,207	33.0%	0	0.0%	NaN	NaN
exenatide	84,443	7.3%	0	0.0%	NaN	NaN
liraglutide	233,648	20.3%	0	0.0%	NaN	NaN
lixisenatide	15,611	1.4%	0	0.0%	NaN	NaN
semaglutide	399,893	34.8%	0	0.0%	NaN	NaN
tirzepatide	28,577	2.5%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,149,283	100.0%	1,394,653	100.0%	-0.000	-0.002

Table 1ad. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
insulin*	386,947	33.7%	246,811	17.7%	15.972	0.372
metformin*	1,018,833	88.6%	1,211,417	86.9%	1.788	0.055
alpha-glucosidase inhibitors*	*****	*****	*****	*****	*****	*****
thiazolidinediones*	93,704	8.2%	96,998	7.0%	1.198	0.045
meglitinides*	12,021	1.0%	21,187	1.5%	-0.473	-0.042
amylin analogue*	*****	*****	40	0.0%	*****	*****
sulfonylureas*	418,034	36.4%	630,683	45.2%	-8.848	-0.181
bile acid sequestrants*	*****	*****	*****	*****	*****	*****
Other Weight Loss Agents*	*****	*****	*****	*****	*****	*****
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	*****	*****	116	0.0%	*****	*****
diethylpropion	84	0.0%	14	0.0%	0.006	0.010
lorcaserin	183	0.0%	69	0.0%	0.011	0.011
phentermine	*****	*****	*****	*****	*****	*****
phentermine-topiramate	199	0.0%	29	0.0%	0.015	0.015
phendimetrazine	63	0.0%	19	0.0%	0.004	0.007
orlistat	70	0.0%	38	0.0%	0.003	0.005
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	287,051	25.0%	334,607	24.0%	0.984	0.023
Antipsychotics	76,021	6.6%	92,061	6.6%	0.014	0.001
Anxiolytics/Hypnotics	219,301	19.1%	231,340	16.6%	2.494	0.065
Lithium & Other Mood Stabilizers	66,540	5.8%	71,990	5.2%	0.628	0.028
Antidepressants	440,398	38.3%	407,957	29.3%	9.068	0.193

Table 1ad. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	10.8	10.4	10.4	11.3	0.477	0.044
Mean number of emergency room encounters*	0.3	1.0	0.4	1.1	-0.041	-0.039
Mean number of inpatient hospital encounters*	0.1	0.4	0.2	0.6	-0.080	-0.169
Mean number of non-acute institutional encounters*	0.0	0.2	0.1	0.3	-0.038	-0.147
Mean number of other ambulatory encounters*	3.8	11.4	5.1	14.1	-1.251	-0.097
Mean number of filled prescriptions*	26.1	19.6	25.4	20.2	0.680	0.034
Mean number of generics dispensed*	10.9	5.1	10.4	5.1	0.544	0.107
Mean number of unique drug classes dispensed*	9.8	4.6	8.7	4.6	1.093	0.239

Table 1ad. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	DPP-4 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1ae. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	1,257,828	N/A	1,536,134	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	62.1	10.5	62.7	11.6	-0.607	-0.055
Age						
18-24 years	3,840	0.3%	8,387	0.5%	-0.241	-0.037
25-44 years	122,117	9.7%	169,362	11.0%	-1.317	-0.045
45-64 years	545,432	43.4%	602,026	39.2%	4.172	0.094
65-79 years	511,670	40.7%	613,983	40.0%	0.710	0.017
≥ 80 years	74,771	5.9%	142,378	9.3%	-3.324	-0.128
Sex*						
Female	683,602	54.3%	844,569	55.0%	-0.632	-0.013
Male	574,227	45.7%	691,565	45.0%	0.632	0.013
Race[4]						
American Indian or Alaska Native	8,356	0.7%	13,207	0.9%	-0.195	-0.023
Asian	18,525	1.5%	61,295	4.0%	-2.517	-0.156
Black or African American	121,932	9.7%	201,223	13.1%	-3.405	-0.110
Multi-racial	6,035	0.5%	4,949	0.3%	0.158	0.025
Native Hawaiian or Other Pacific Islander	3,206	0.3%	4,994	0.3%	-0.070	-0.013
Unknown	474,487	37.7%	498,912	32.5%	5.244	0.171
White	625,288	49.7%	751,555	48.9%	0.787	0.020
Hispanic origin						

Table 1ae. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Yes	52,611	4.2%	130,626	8.5%	-4.321	-0.186
No	700,459	55.7%	964,695	62.8%	-7.112	-0.253
Unknown	504,758	40.1%	440,813	28.7%	11.433	0.534
Year*						
2015	40,510	3.2%	46,058	3.0%	0.222	0.013
2016	173,850	13.8%	206,697	13.5%	0.366	0.011
2017	175,035	13.9%	219,003	14.3%	-0.341	-0.010
2018	166,683	13.3%	210,919	13.7%	-0.479	-0.014
2019	168,758	13.4%	216,611	14.1%	-0.684	-0.020
2020	152,862	12.2%	207,022	13.5%	-1.324	-0.040
2021	133,866	10.6%	157,982	10.3%	0.358	0.012
2022	144,602	11.5%	160,556	10.5%	1.044	0.034
2023	101,661	8.1%	111,288	7.2%	0.838	0.032
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*[,5]	1.7	2.0	1.5	1.8	0.194	0.103
Combined comorbidity score*[,6]	2.3	2.9	1.9	2.4	0.383	0.143
Medical History						
Obesity*	520,169	41.4%	566,802	36.9%	4.457	0.093
Weight Reduction Surgery or Procedure*	2,061	0.2%	1,549	0.1%	0.063	0.017
Lifestyle intervention*	212,812	16.9%	234,177	15.2%	1.674	0.046
Cardiovascular Disease*	296,957	23.6%	321,343	20.9%	2.690	0.066
Cognitive Impairment*	76,301	6.1%	53,983	3.5%	2.552	0.121
Traumatic Brain Injury*	3,704	0.3%	3,891	0.3%	0.041	0.008

Table 1ae. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Migraine*	58,100	4.6%	55,317	3.6%	1.018	0.051
Epilepsy*	31,755	2.5%	22,660	1.5%	1.049	0.075
Chronic Pain*	303,469	24.1%	310,789	20.2%	3.895	0.094
Psychiatric History						
Previous Intentional Self-Harm Ever	10,528	0.8%	11,646	0.8%	0.079	0.009
Psychiatric History Overall*	800,702	63.7%	916,951	59.7%	3.965	0.082
Psychiatric Drug Dispensings	603,880	48.0%	701,363	45.7%	2.352	0.047
Intentional Self-Harm Encounter	0	0.0%	0	0.0%	NaN	NaN
Any Other Psychiatric Event	668,758	53.2%	735,023	47.8%	5.319	0.107
Attention-Deficit/Hyperactivity Disorder	17,817	1.4%	12,735	0.8%	0.587	0.056
Akathisia	1,593	0.1%	1,793	0.1%	0.010	0.003
Anxiety	240,840	19.1%	252,479	16.4%	2.711	0.071
Behavioral Disorder	69,703	5.5%	60,611	3.9%	1.596	0.075
Bipolar Disorder	63,107	5.0%	68,818	4.5%	0.537	0.025
Cerebral Degenerations usually Manifested in Childhood	20,364	1.6%	19,675	1.3%	0.338	0.028
Conduct Disorder	1,130	0.1%	1,763	0.1%	-0.025	-0.008
Delirium	50,470	4.0%	32,055	2.1%	1.926	0.113
Depression	271,442	21.6%	270,013	17.6%	4.003	0.102
Electroconvulsive Therapy	586	0.0%	335	0.0%	0.025	0.013
Hallucination	5,103	0.4%	4,244	0.3%	0.129	0.022
Obsessive-Compulsive Disorder	2,472	0.2%	2,943	0.2%	0.005	0.001
Other Cerebral Degenerations	33,396	2.7%	31,721	2.1%	0.590	0.039
Other Mental Disorders	19,662	1.6%	15,094	1.0%	0.581	0.052

Table 1ae. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Other Psychological Disorders	139,703	11.1%	154,533	10.1%	1.047	0.034
Persistent Mental Disorders due to Conditions Classified Elsewhere	53,047	4.2%	40,385	2.6%	1.588	0.088
Personality Disorders	7,713	0.6%	7,445	0.5%	0.129	0.017
Pervasive Developmental Disorders	1,240	0.1%	3,759	0.2%	-0.146	-0.035
Post-Traumatic Stress Disorder	25,047	2.0%	29,048	1.9%	0.100	0.007
Psychotherapy	80,171	6.4%	87,079	5.7%	0.705	0.030
Psychotic Conditions	8,474	0.7%	10,266	0.7%	0.005	0.001
Schizophrenia	29,953	2.4%	41,176	2.7%	-0.299	-0.019
Sleep Disorder	346,706	27.6%	306,796	20.0%	7.592	0.180
Substance Abuse	65,070	5.2%	75,304	4.9%	0.271	0.012
Suicidal Behavior	9,321	0.7%	7,273	0.5%	0.268	0.034
Transcranial Magnetic Stimulation	163	0.0%	155	0.0%	0.003	0.003
Vagus Nerve Stimulation	1,035	0.1%	1,064	0.1%	0.013	0.005
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	17,971	1.4%	0	0.0%	NaN	NaN
dulaglutide	438,405	34.9%	0	0.0%	NaN	NaN
exenatide	126,845	10.1%	0	0.0%	NaN	NaN
liraglutide	332,567	26.4%	0	0.0%	NaN	NaN
lixisenatide	11,978	1.0%	0	0.0%	NaN	NaN
semaglutide	316,163	25.1%	0	0.0%	NaN	NaN
tirzepatide	19,442	1.5%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,257,827	100.0%	1,536,134	100.0%	-0.000	-0.002
insulin*	443,561	35.3%	577,879	37.6%	-2.355	-0.049

Table 1ae. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
metformin*	1,102,130	87.6%	1,340,284	87.3%	0.371	0.011
alpha-glucosidase inhibitors*	6,622	0.5%	8,293	0.5%	-0.013	-0.002
thiazolidinediones*	89,936	7.2%	125,039	8.1%	-0.990	-0.037
meglitinides*	17,490	1.4%	22,315	1.5%	-0.062	-0.005
amylin analogue*	108	0.0%	239	0.0%	-0.007	-0.006
sulfonylureas*	484,467	38.5%	644,641	42.0%	-3.449	-0.071
bile acid sequestrants*	6,522	0.5%	6,619	0.4%	0.088	0.013
Other Weight Loss Agents*	3,081	0.2%	2,827	0.2%	0.061	0.013
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	603	0.0%	363	0.0%	0.024	0.013
diethylpropion	65	0.0%	44	0.0%	0.002	0.004
lorcaserin	136	0.0%	199	0.0%	-0.002	-0.002
phentermine	2,132	0.2%	2,067	0.1%	0.035	0.009
phentermine-topiramate	134	0.0%	77	0.0%	0.006	0.006
phendimetrazine	57	0.0%	43	0.0%	0.002	0.003
orlistat	39	0.0%	81	0.0%	-0.002	-0.003
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	415,400	33.0%	421,153	27.4%	5.609	0.123
Antipsychotics	109,088	8.7%	138,999	9.0%	-0.376	-0.013
Anxiolytics/Hypnotics	278,563	22.1%	321,386	20.9%	1.225	0.030
Lithium & Other Mood Stabilizers	91,556	7.3%	110,297	7.2%	0.099	0.004
Antidepressants	489,107	38.9%	554,509	36.1%	2.787	0.058
Health Service Utilization Intensity Metrics						

Table 1ae. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Mean number of ambulatory encounters*	12.5	11.9	11.5	13.2	1.017	0.081
Mean number of emergency room encounters*	0.7	2.1	0.4	1.1	0.288	0.172
Mean number of inpatient hospital encounters*	0.3	0.8	0.2	0.5	0.146	0.210
Mean number of non-acute institutional encounters*	0.1	0.9	0.0	0.3	0.090	0.138
Mean number of other ambulatory encounters*	6.7	16.3	5.1	13.9	1.577	0.104
Mean number of filled prescriptions*	32.2	27.9	28.3	22.5	3.912	0.154
Mean number of generics dispensed*	13.0	7.7	11.5	5.6	1.546	0.229
Mean number of unique drug classes dispensed*	10.7	5.8	10.0	5.3	0.698	0.125

Table 1ae. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	DPP-4 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1af. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	1,052	100.0%	1,460	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)*	50.2	14.2	54.2	12.9	-4.028	-0.296
Age						
18-24 years	58	5.5%	39	2.7%	2.821	0.143
25-44 years	326	30.9%	330	22.6%	8.268	0.188
45-64 years	522	49.4%	759	52.0%	-2.554	-0.051
65-79 years	142	13.4%	277	19.0%	-5.526	-0.150
≥ 80 years	19	1.8%	55	3.8%	-1.968	-0.120
Sex*						
Female	699	66.4%	811	55.5%	10.645	0.219
Male	364	34.6%	649	44.5%	-9.982	-0.205
Race[3]						
American Indian or Alaska Native	*****	*****	*****	*****	*****	*****
Asian	*****	*****	32	2.2%	*****	*****
Black or African American	117	11.1%	198	13.6%	-2.482	-0.076
Multi-racial	*****	*****	*****	*****	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%	*****	*****	*****	*****
Unknown	252	24.0%	308	21.1%	2.768	0.066
White	660	62.7%	892	61.1%	1.404	0.029
Hispanic origin						
Yes	71	6.7%	123	8.4%	-1.701	-0.064
No	771	73.3%	1,121	76.8%	-3.769	-0.087

Table 1af. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Unknown	214	20.3%	216	14.8%	5.471	0.144
Year*						
2015	29	2.7%	61	4.2%	-1.432	-0.078
2016	98	9.3%	278	19.0%	-9.761	-0.283
2017	118	11.2%	278	19.0%	-7.867	-0.221
2018	128	12.1%	247	16.9%	-4.797	-0.136
2019	178	16.9%	220	15.1%	1.788	0.049
2020	166	15.7%	189	12.9%	2.774	0.079
2021	126	11.9%	92	6.3%	5.630	0.197
2022	138	13.1%	64	4.4%	8.685	0.311
2023	95	9.0%	31	2.1%	6.873	0.303
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,4	1.8	1.9	2.2	2.2	-0.310	-0.152
Combined comorbidity score*,5	3.9	2.5	4.3	2.8	-0.415	-0.154
Medical History						
Obesity*	655	62.0%	649	44.5%	17.574	0.358
Weight Reduction Surgery or Procedure*	*****	*****	*****	*****	*****	*****
Lifestyle intervention*	276	26.1%	270	18.5%	7.643	0.184
Cardiovascular Disease*	250	23.7%	456	31.2%	-7.559	-0.170
Cognitive Impairment*	82	7.8%	226	15.5%	-7.714	-0.242
Traumatic Brain Injury*	13	1.2%	18	1.2%	-0.002	-0.000
Migraine*	169	16.0%	172	11.8%	4.223	0.122
Epilepsy*	96	9.1%	160	11.0%	-1.868	-0.062
Chronic Pain*	449	42.5%	546	37.4%	5.122	0.105
Psychiatric History						

Table 1af. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Previous Intentional Self-Harm Ever	1,056	100.0%	1,460	100.0%	0.000	NaN
Psychiatric History Overall*	1,056	100.0%	1,460	100.0%	0.000	NaN
Psychiatric Drug Dispensings	984	93.2%	1,341	91.8%	1.333	0.051
Intentional Self-Harm Encounter	*****	*****	*****	*****	*****	*****
Any Other Psychiatric Event	1,056	100.0%	1,460	100.0%	0.000	NaN
Attention-Deficit/Hyperactivity Disorder	95	9.0%	54	3.7%	5.298	0.219
Akathisia	19	1.8%	16	1.1%	0.703	0.059
Anxiety	711	67.3%	898	61.5%	5.823	0.122
Behavioral Disorder	951	90.1%	1,312	89.9%	0.194	0.006
Bipolar Disorder	468	44.3%	638	43.7%	0.620	0.012
Cerebral Degenerations usually Manifested in Childhood	31	2.9%	63	4.3%	-1.379	-0.074
Conduct Disorder	26	2.5%	34	2.3%	0.133	0.009
Delirium	162	15.3%	303	20.8%	-5.413	-0.141
Depression	839	79.5%	1,155	79.1%	0.341	0.008
Electroconvulsive Therapy	22	2.1%	24	1.6%	0.439	0.033
Hallucination	80	7.6%	124	8.5%	-0.917	-0.034
Obsessive-Compulsive Disorder	31	2.9%	22	1.5%	1.429	0.097
Other Cerebral Degenerations	32	3.0%	106	7.3%	-4.230	-0.192
Other Mental Disorders	88	8.3%	133	9.1%	-0.776	-0.028
Other Psychological Disorders	477	45.2%	706	48.4%	-3.186	-0.064
Persistent Mental Disorders due to Conditions Classified Elsewhere	36	3.4%	135	9.2%	-5.837	-0.242
Personality Disorders	254	24.1%	238	16.3%	7.752	0.194
Pervasive Developmental Disorders	24	2.3%	31	2.1%	0.149	0.010

Table 1af. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Post-Traumatic Stress Disorder	340	32.2%	271	18.6%	13.635	0.317
Psychotherapy	464	43.9%	582	39.9%	4.076	0.083
Psychotic Conditions	159	15.1%	342	23.4%	-8.368	-0.213
Schizophrenia	226	21.4%	403	27.6%	-6.201	-0.145
Sleep Disorder	531	50.3%	568	38.9%	11.380	0.230
Substance Abuse	466	44.1%	653	44.7%	-0.597	-0.012
Suicidal Behavior	623	59.0%	885	60.6%	-1.620	-0.033
Transcranial Magnetic Stimulation	*****	*****	0	0.0%	*****	*****
Vagus Nerve Stimulation	*****	*****	*****	*****	*****	*****
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	*****	*****	0	0.0%	*****	*****
dulaglutide	323	30.6%	0	0.0%	NaN	NaN
exenatide	122	11.6%	0	0.0%	NaN	NaN
liraglutide	305	28.9%	0	0.0%	NaN	NaN
lixisenatide	12	1.1%	0	0.0%	NaN	NaN
semaglutide	270	25.6%	0	0.0%	NaN	NaN
tirzepatide	15	1.4%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,056	100.0%	1,460	100.0%	0.000	NaN
insulin*	461	43.7%	447	30.6%	13.039	0.272
metformin*	930	88.1%	1,310	89.7%	-1.658	-0.053
alpha-glucosidase inhibitors*	*****	*****	*****	*****	*****	*****
thiazolidinediones*	73	6.9%	77	5.3%	1.639	0.069
meglitinides*	12	1.1%	15	1.0%	0.109	0.011
amylin analogue*	*****	*****	0	0.0%	*****	*****
sulfonylureas*	350	33.1%	554	37.9%	-4.801	-0.100

Table 1af. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
bile acid sequestrants*	0	0.0%	*****	*****	*****	*****
Other Weight Loss Agents*	*****	*****	0	0.0%	*****	*****
benzphetamine	0	0.0%	0	0.0%	NaN	NaN
bupropion	0	0.0%	0	0.0%	NaN	NaN
diethylpropion	0	0.0%	0	0.0%	NaN	NaN
lorcaserin	0	0.0%	0	0.0%	NaN	NaN
phentermine	*****	*****	0	0.0%	*****	*****
phentermine-topiramate	0	0.0%	0	0.0%	NaN	NaN
phendimetrazine	0	0.0%	0	0.0%	NaN	NaN
orlistat	0	0.0%	0	0.0%	NaN	NaN
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	428	40.5%	588	40.3%	0.256	0.005
Antipsychotics	614	58.1%	846	57.9%	0.199	0.004
Anxiolytics/Hypnotics	627	59.4%	866	59.3%	0.060	0.001
Lithium & Other Mood Stabilizers	443	42.0%	640	43.8%	-1.885	-0.038
Antidepressants	913	86.5%	1,203	82.4%	4.061	0.112
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	25.2	20.3	21.8	19.4	3.487	0.176
Mean number of emergency room encounters*	3.3	4.7	3.1	5.0	0.139	0.029
Mean number of inpatient hospital encounters*	1.0	1.4	1.3	1.6	-0.300	-0.198
Mean number of non-acute institutional encounters*	0.5	0.9	0.8	1.2	-0.274	-0.265

Table 1af. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Mean number of other ambulatory encounters*	17.5	25.8	23.2	28.6	-5.638	-0.207
Mean number of filled prescriptions*	49.8	33.3	45.5	30.3	4.332	0.136
Mean number of generics dispensed*	17.4	7.7	16.5	7.2	0.975	0.131
Mean number of unique drug classes dispensed*	15.4	6.6	14.1	6.3	1.326	0.206

^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1ag. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	898	85.4%	1,232	84.4%	N/A	N/A
Demographic Characteristics						
Age (years)*	49.8	13.4	52.8	12.7	-3.040	-0.233
Age						
18-24 years	43	4.8%	36	2.9%	1.866	0.097
25-44 years	283	31.5%	309	25.1%	6.433	0.143
45-64 years	433	48.2%	647	52.5%	-4.298	-0.086
65-79 years	126	14.0%	209	17.0%	-2.933	-0.081
≥ 80 years	13	1.4%	31	2.5%	-1.069	-0.077
Sex*						
Female	594	66.1%	712	57.8%	8.355	0.173
Male	304	33.9%	520	42.2%	-8.355	-0.173
Race[3]						
American Indian or Alaska Native	*****	*****	*****	*****	*****	*****
Asian	*****	*****	26	2.1%	*****	*****
Black or African American	107	11.9%	181	14.7%	-2.776	-0.082
Multi-racial	0	0.0%	*****	*****	*****	*****
Islander	0	0.0%	*****	*****	*****	*****
Unknown	157	17.5%	217	17.6%	-0.130	-0.003
White	608	67.7%	780	63.3%	4.394	0.093
Hispanic origin						

Table 1ag. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Yes	67	7.5%	115	9.3%	-1.873	-0.068
No	741	82.5%	1,016	82.5%	0.049	0.001
Unknown	90	10.0%	101	8.2%	1.824	0.063
Year*						
2015	24	2.7%	45	3.7%	-0.980	-0.056
2016	85	9.5%	214	17.4%	-7.905	-0.233
2017	105	11.7%	253	20.5%	-8.843	-0.242
2018	115	12.8%	204	16.6%	-3.752	-0.106
2019	158	17.6%	196	15.9%	1.686	0.045
2020	144	16.0%	163	13.2%	2.805	0.079
2021	96	10.7%	73	5.9%	4.765	0.173
2022	107	11.9%	56	4.5%	7.370	0.271
2023	64	7.1%	28	2.3%	4.854	0.231
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[4]	1.8	1.9	2.0	2.1	-0.200	-0.101
Combined comorbidity score*,[5]	3.9	2.6	4.1	2.7	-0.226	-0.085
Medical History						
Obesity*	546	60.8%	569	46.2%	14.617	0.296
Procedure*	*****	*****	*****	*****	*****	*****
Lifestyle intervention*	228	25.4%	238	19.3%	6.072	0.146
Cardiovascular Disease*	216	24.1%	353	28.7%	-4.599	-0.105
Cognitive Impairment*	71	7.9%	166	13.5%	-5.568	-0.181
Traumatic Brain Injury*	*****	*****	12	1.0%	*****	*****

Table 1ag. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Migraine*	145	16.1%	157	12.7%	3.403	0.097
Epilepsy*	80	8.9%	130	10.6%	-1.643	-0.055
Chronic Pain*	375	41.8%	466	37.8%	3.935	0.080
Psychiatric History						
Previous Intentional Self-Harm Ever	898	100.0%	1,232	100.0%	0.000	NaN
Psychiatric History Overall*	898	100.0%	1,232	100.0%	0.000	NaN
Psychiatric Drug Dispensings	840	93.5%	1,148	93.2%	0.359	0.014
Intentional Self-Harm Encounter	898	100.0%	1,232	100.0%	0.000	NaN
Any Other Psychiatric Event	898	100.0%	1,232	100.0%	0.000	NaN
Attention-Deficit/Hyperactivity Disorder	72	8.0%	46	3.7%	4.284	0.183
Akathisia	16	1.8%	12	1.0%	0.808	0.069
Anxiety	600	66.8%	767	62.3%	4.559	0.095
Behavioral Disorder	807	89.9%	1,105	89.7%	0.175	0.006
Bipolar Disorder	406	45.2%	574	46.6%	-1.379	-0.028
Cerebral Degenerations usually Manifested in Childhood	25	2.8%	41	3.3%	-0.544	-0.032
Conduct Disorder	24	2.7%	29	2.4%	0.319	0.020
Delirium	140	15.6%	235	19.1%	-3.484	-0.092
Depression	718	80.0%	969	78.7%	1.303	0.032
Electroconvulsive Therapy	19	2.1%	19	1.5%	0.574	0.043
Hallucination	73	8.1%	102	8.3%	-0.150	-0.005
Obsessive-Compulsive Disorder	24	2.7%	18	1.5%	1.212	0.085

Table 1ag. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Other Cerebral Degenerations	25	2.8%	75	6.1%	-3.304	-0.161
Other Mental Disorders	76	8.5%	108	8.8%	-0.303	-0.011
Other Psychological Disorders	418	46.5%	603	48.9%	-2.397	-0.048
Persistent Mental Disorders due to Conditions Classified Elsewhere	33	3.7%	96	7.8%	-4.117	-0.178
Personality Disorders	224	24.9%	211	17.1%	7.818	0.193
Disorders	20	2.2%	30	2.4%	-0.208	-0.014
Post-Traumatic Stress Disorder	280	31.2%	250	20.3%	10.888	0.251
Psychotherapy	388	43.2%	493	40.0%	3.191	0.065
Psychotic Conditions	137	15.3%	285	23.1%	-7.877	-0.201
Schizophrenia	208	23.2%	365	29.6%	-6.464	-0.147
Sleep Disorder	450	50.1%	465	37.7%	12.368	0.251
Substance Abuse	403	44.9%	555	45.0%	-0.171	-0.003
Suicidal Behavior	531	59.1%	750	60.9%	-1.745	-0.036
Transcranial Magnetic Stimulation	*****	*****	0	0.0%	*****	*****
Vagus Nerve Stimulation	*****	*****	*****	*****	*****	*****
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	*****	*****	0	0.0%	*****	*****
dulaglutide	279	31.1%	0	0.0%	NaN	NaN
exenatide	114	12.7%	0	0.0%	NaN	NaN
liraglutide	278	31.0%	0	0.0%	NaN	NaN
lixisenatide	*****	*****	0	0.0%	*****	*****

Table 1ag. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
semaglutide	202	22.5%	0	0.0%	NaN	NaN
tirzepatide	13	1.4%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	898	100.0%	1,232	100.0%	0.000	NaN
insulin*	393	43.8%	405	32.9%	10.891	0.225
metformin*	791	88.1%	1,110	90.1%	-2.013	-0.065
alpha-glucosidase inhibitors*	*****	*****	*****	*****	*****	*****
thiazolidinediones*	56	6.2%	68	5.5%	0.717	0.030
meglitinides*	*****	*****	11	0.9%	*****	*****
amylin analogue*	0	0.0%	0	0.0%	NaN	NaN
sulfonylureas*	297	33.1%	452	36.7%	-3.615	-0.076
bile acid sequestrants*	0	0.0%	0	0.0%	NaN	NaN
Other Weight Loss Agents*	0	0.0%	0	0.0%	NaN	NaN
benzphetamine	0	0.0%	0	0.0%	NaN	NaN
bupropion	0	0.0%	0	0.0%	NaN	NaN
diethylpropion	0	0.0%	0	0.0%	NaN	NaN
lorcaserin	0	0.0%	0	0.0%	NaN	NaN
phentermine	0	0.0%	0	0.0%	NaN	NaN
phentermine-topiramate	0	0.0%	0	0.0%	NaN	NaN
phendimetrazine	0	0.0%	0	0.0%	NaN	NaN
orlistat	0	0.0%	0	0.0%	NaN	NaN
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	362	40.3%	501	40.7%	-0.354	-0.007
Antipsychotics	542	60.4%	749	60.8%	-0.439	-0.009

Table 1ag. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Anxiolytics/Hypnotics	535	59.6%	743	60.3%	-0.732	-0.015
Lithium & Other Mood Stabilizers	384	42.8%	567	46.0%	-3.261	-0.066
Antidepressants	772	86.0%	1,025	83.2%	2.771	0.077
Health Service Utilization Intensity Metrics						
encounters*	25.9	20.1	22.3	20.0	3.607	0.180
Mean number of emergency room encounters*	3.3	4.7	3.1	5.1	0.199	0.041
Mean number of inpatient hospital encounters*	1.1	1.4	1.3	1.5	-0.238	-0.161
Mean number of non-acute institutional encounters*	0.5	0.9	0.7	1.0	-0.173	-0.184
Mean number of other ambulatory encounters*	19.2	27.5	23.8	29.4	-4.666	-0.164
Mean number of filled prescriptions*	50.9	34.0	47.2	31.0	3.714	0.114
Mean number of generics dispensed*	17.6	7.6	16.7	7.3	0.870	0.117
Mean number of unique drug classes dispensed*	15.5	6.5	14.4	6.4	1.149	0.178

Table 1ag. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	DPP-4 Inhibitors	

^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759.

Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1ah. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	897	N/A	1,274	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	52.2	13.4	50.9	13.1	1.313	0.099
Age						
18-24 years	33	3.6%	47	3.7%	-0.055	-0.003
25-44 years	236	26.3%	379	29.7%	-3.399	-0.077
45-64 years	453	50.6%	647	50.7%	-0.191	-0.004
65-79 years	155	17.3%	178	13.9%	3.333	0.096
≥ 80 years	20	2.2%	24	1.9%	0.312	0.022
Sex*						
Female	562	62.7%	769	60.3%	2.386	0.049
Male	334	37.3%	506	39.7%	-2.386	-0.049
Race[4]						
American Indian or Alaska Native	*****	*****	22	1.7%	*****	*****
Asian	*****	*****	*****	*****	*****	*****
Black or African American	96	10.7%	188	14.7%	-4.033	-0.121
Multi-racial	0	0.0%	*****	*****	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%	*****	*****	*****	*****
Unknown	178	19.9%	227	17.8%	2.043	0.062
White	590	65.8%	811	63.7%	2.092	0.048
Hispanic origin						

Table 1ah. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Yes	74	8.3%	118	9.3%	-0.976	-0.036
No	719	80.1%	1,048	82.2%	-2.108	-0.064
Unknown	104	11.6%	108	8.5%	3.084	0.135
Year*						
2015	30	3.3%	40	3.2%	0.156	0.009
2016	133	14.8%	182	14.3%	0.518	0.015
2017	154	17.2%	214	16.8%	0.390	0.010
2018	125	14.0%	196	15.4%	-1.425	-0.041
2019	134	15.0%	205	16.1%	-1.099	-0.030
2020	129	14.4%	207	16.2%	-1.802	-0.051
2021	79	8.8%	96	7.6%	1.272	0.047
2022	70	7.8%	87	6.8%	0.989	0.039
2023	42	4.7%	47	3.7%	1.001	0.051
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.9	1.9	1.8	2.0	0.066	0.033
Combined comorbidity score*,[6]	4.1	2.7	3.9	2.7	0.140	0.052
Medical History						
Obesity*	470	52.4%	675	53.0%	-0.593	-0.012
Weight Reduction Surgery or Procedure*	*****	*****	*****	*****	*****	*****
Lifestyle intervention*	192	21.4%	311	24.4%	-3.027	-0.074
Cardiovascular Disease*	244	27.2%	310	24.3%	2.842	0.066
Cognitive Impairment*	104	11.6%	132	10.4%	1.217	0.039
Traumatic Brain Injury*	*****	*****	*****	*****	*****	*****

Table 1ah. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Migraine*	135	15.0%	175	13.7%	1.316	0.038
Epilepsy*	85	9.5%	123	9.7%	-0.188	-0.006
Chronic Pain*	364	40.6%	490	38.5%	2.116	0.044
Psychiatric History						
Previous Intentional Self-Harm Ever	897	100.0%	1,274	100.0%	0.000	NaN
Psychiatric History Overall*	897	100.0%	1,274	100.0%	0.000	NaN
Psychiatric Drug Dispensings	840	93.6%	1,201	94.2%	-0.605	-0.025
Intentional Self-Harm Encounter	897	100.0%	1,274	100.0%	0.000	NaN
Any Other Psychiatric Event	897	100.0%	1,274	100.0%	0.000	NaN
Attention-Deficit/Hyperactivity Disorder	65	7.2%	49	3.8%	3.420	0.150
Akathisia	21	2.4%	12	0.9%	1.472	0.116
Anxiety	586	65.3%	830	65.1%	0.184	0.004
Behavioral Disorder	800	89.2%	1,148	90.1%	-0.850	-0.028
Bipolar Disorder	405	45.2%	639	50.1%	-4.951	-0.099
Cerebral Degenerations usually Manifested in Childhood	34	3.8%	38	3.0%	0.872	0.048
Conduct Disorder	23	2.5%	30	2.3%	0.225	0.015
Delirium	174	19.4%	197	15.5%	3.953	0.105
Depression	721	80.4%	1,001	78.6%	1.831	0.046
Electroconvulsive Therapy	30	3.4%	20	1.6%	1.812	0.117
Hallucination	72	8.0%	96	7.5%	0.479	0.018
Obsessive-Compulsive Disorder	18	2.0%	20	1.6%	0.390	0.029
Other Cerebral Degenerations	32	3.6%	61	4.8%	-1.184	-0.060

Table 1ah. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Other Mental Disorders	74	8.2%	107	8.4%	-0.210	-0.008
Other Psychological Disorders	396	44.1%	616	48.4%	-4.257	-0.086
Persistent Mental Disorders due to Conditions Classified Elsewhere	48	5.4%	79	6.2%	-0.814	-0.035
Personality Disorders	202	22.5%	235	18.5%	3.996	0.100
Pervasive Developmental Disorders	15	1.7%	42	3.3%	-1.578	-0.101
Post-Traumatic Stress Disorder	254	28.3%	275	21.6%	6.716	0.156
Psychotherapy	376	41.9%	537	42.2%	-0.273	-0.006
Psychotic Conditions	141	15.7%	276	21.7%	-5.985	-0.154
Schizophrenia	204	22.8%	403	31.6%	-8.849	-0.202
Sleep Disorder	432	48.2%	491	38.5%	9.642	0.202
Substance Abuse	415	46.2%	539	42.3%	3.934	0.080
Suicidal Behavior	544	60.6%	789	61.9%	-1.292	-0.027
Transcranial Magnetic Stimulation	*****	*****	0	0.0%	*****	*****
Vagus Nerve Stimulation	*****	*****	*****	*****	*****	*****
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	*****	*****	0	0.0%	*****	*****
dulaglutide	284	31.7%	0	0.0%	NaN	NaN
exenatide	128	14.2%	0	0.0%	NaN	NaN
liraglutide	308	34.4%	0	0.0%	NaN	NaN
lixisenatide	*****	*****	0	0.0%	*****	*****
semaglutide	154	17.2%	0	0.0%	NaN	NaN
tirzepatide	*****	*****	0	0.0%	*****	*****
Any Anti-Diabetic Agents	897	100.0%	1,274	100.0%	0.000	NaN

Table 1ah. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
insulin*	361	40.2%	519	40.7%	-0.483	-0.010
metformin*	804	89.6%	1,155	90.6%	-1.017	-0.034
alpha-glucosidase inhibitors*	*****	*****	*****	*****	*****	*****
thiazolidinediones*	48	5.4%	70	5.5%	-0.141	-0.006
meglitinides*	*****	*****	*****	*****	*****	*****
amylin analogue*	0	0.0%	0	0.0%	NaN	NaN
sulfonylureas*	306	34.1%	429	33.7%	0.378	0.008
bile acid sequestrants*	0	0.0%	0	0.0%	NaN	NaN
Other Weight Loss Agents*	0	0.0%	0	0.0%	NaN	NaN
benzphetamine	0	0.0%	0	0.0%	NaN	NaN
bupropion	0	0.0%	0	0.0%	NaN	NaN
diethylpropion	0	0.0%	0	0.0%	NaN	NaN
lorcaserin	0	0.0%	0	0.0%	NaN	NaN
phentermine	0	0.0%	0	0.0%	NaN	NaN
phentermine-topiramate	0	0.0%	0	0.0%	NaN	NaN
phendimetrazine	0	0.0%	0	0.0%	NaN	NaN
orlistat	0	0.0%	0	0.0%	NaN	NaN
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	375	41.8%	503	39.4%	2.330	0.047
Antipsychotics	519	57.9%	828	65.0%	-7.088	-0.147
Anxiolytics/Hypnotics	512	57.0%	819	64.3%	-7.230	-0.148
Lithium & Other Mood Stabilizers	378	42.2%	644	50.5%	-8.341	-0.169
Antidepressants	770	85.9%	1,082	84.9%	0.978	0.028

Table 1ah. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	24.0	18.5	24.6	23.8	-0.598	-0.028
Mean number of emergency room encounters*	3.2	4.6	3.1	4.9	0.059	0.012
Mean number of inpatient hospital encounters*	1.2	1.7	1.2	1.4	-0.006	-0.004
Mean number of non-acute institutional encounters*	0.6	1.0	0.6	0.9	0.057	0.060
Mean number of other ambulatory encounters*	20.5	27.4	22.3	28.1	-1.797	-0.065
Mean number of filled prescriptions*	48.2	33.4	49.8	31.4	-1.637	-0.051
Mean number of generics dispensed*	17.2	7.9	17.2	7.3	-0.064	-0.008
Mean number of unique drug classes dispensed*	14.9	6.6	15.0	6.5	-0.074	-0.011

Table 1ah. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	DPP-4 Inhibitors	

^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1ai. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	433,110	100.0%	659,687	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)*	61.0	9.9	64.7	10.2	-3.760	-0.374
Age						
18-24 years	2,658	0.6%	2,274	0.3%	0.269	0.039
25-44 years	53,983	12.5%	55,894	8.5%	3.991	0.131
45-64 years	172,777	39.9%	235,156	35.6%	4.246	0.088
65-79 years	186,219	43.0%	290,288	44.0%	-1.008	-0.020
≥ 80 years	17,473	4.0%	76,075	11.5%	-7.498	-0.283
Sex*						
Female	212,087	49.0%	309,822	47.0%	2.003	0.040
Male	221,023	51.0%	349,865	53.0%	-2.003	-0.040
Race[3]						
American Indian or Alaska Native	3,014	0.7%	4,761	0.7%	-0.026	-0.003
Asian	9,754	2.3%	45,411	6.9%	-4.632	-0.223
Black or African American	43,680	10.1%	81,482	12.4%	-2.266	-0.072
Multi-racial	2,796	0.6%	2,290	0.3%	0.298	0.042
Native Hawaiian or Other Pacific Islander	1,626	0.4%	3,401	0.5%	-0.140	-0.021
Unknown	186,736	43.1%	246,997	37.4%	5.674	0.116
White	185,504	42.8%	275,345	41.7%	1.092	0.022
Hispanic origin						
Yes	22,665	5.2%	67,600	10.2%	-5.014	-0.188
No	217,133	50.1%	382,484	58.0%	-7.846	-0.158

Table 1ai. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Unknown	193,312	44.6%	209,603	31.8%	12.860	0.267
Year*						
2015	6,811	1.6%	29,583	4.5%	-2.912	-0.171
2016	32,872	7.6%	129,112	19.6%	-11.982	-0.355
2017	38,840	9.0%	126,515	19.2%	-10.210	-0.297
2018	45,726	10.6%	107,286	16.3%	-5.706	-0.168
2019	55,630	12.8%	94,460	14.3%	-1.475	-0.043
2020	60,735	14.0%	78,787	11.9%	2.080	0.062
2021	59,084	13.6%	45,765	6.9%	6.704	0.222
2022	72,979	16.8%	32,966	5.0%	11.853	0.387
2023	60,433	14.0%	15,213	2.3%	11.647	0.436
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[4]	1.0	1.4	1.2	1.5	-0.117	-0.080
Combined comorbidity score*,[5]	0.9	1.6	1.1	1.9	-0.127	-0.072
Medical History						
Obesity*	169,307	39.1%	137,499	20.8%	18.248	0.406
Weight Reduction Surgery or Procedure*	42	0.0%	127	0.0%	-0.010	-0.008
Lifestyle intervention*	76,716	17.7%	90,309	13.7%	4.023	0.111
Cardiovascular Disease*	54,798	12.7%	99,984	15.2%	-2.504	-0.072
Cognitive Impairment*	407	0.1%	1,175	0.2%	-0.084	-0.023
Traumatic Brain Injury*	69	0.0%	118	0.0%	-0.002	-0.002
Migraine*	5,381	1.2%	5,724	0.9%	0.375	0.037
Epilepsy*	1,088	0.3%	2,112	0.3%	-0.069	-0.013
Chronic Pain*	48,320	11.2%	58,449	8.9%	2.296	0.077
Psychiatric History						

Table 1ai. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Previous Intentional Self-Harm Ever	307	0.1%	314	0.0%	0.023	0.010
Psychiatric History Overall*	0	0.0%	0	0.0%	NaN	NaN
Psychiatric Drug Dispensings	0	0.0%	0	0.0%	NaN	NaN
Intentional Self-Harm Encounter	0	0.0%	0	0.0%	NaN	NaN
Any Other Psychiatric Event	0	0.0%	0	0.0%	NaN	NaN
Attention-Deficit/Hyperactivity Disorder	0	0.0%	0	0.0%	NaN	NaN
Akathisia	0	0.0%	0	0.0%	NaN	NaN
Anxiety	0	0.0%	0	0.0%	NaN	NaN
Behavioral Disorder	0	0.0%	0	0.0%	NaN	NaN
Bipolar Disorder	0	0.0%	0	0.0%	NaN	NaN
Cerebral Degenerations usually Manifested in Childhood	0	0.0%	0	0.0%	NaN	NaN
Conduct Disorder	0	0.0%	0	0.0%	NaN	NaN
Delirium	0	0.0%	0	0.0%	NaN	NaN
Depression	0	0.0%	0	0.0%	NaN	NaN
Electroconvulsive Therapy	0	0.0%	0	0.0%	NaN	NaN
Hallucination	0	0.0%	0	0.0%	NaN	NaN
Obsessive-Compulsive Disorder	0	0.0%	0	0.0%	NaN	NaN
Other Cerebral Degenerations	0	0.0%	0	0.0%	NaN	NaN
Other Mental Disorders	0	0.0%	0	0.0%	NaN	NaN
Other Psychological Disorders	0	0.0%	0	0.0%	NaN	NaN
Persistent Mental Disorders due to Conditions Classified Elsewhere	0	0.0%	0	0.0%	NaN	NaN
Personality Disorders	0	0.0%	0	0.0%	NaN	NaN
Pervasive Developmental Disorders	0	0.0%	0	0.0%	NaN	NaN

Table 1ai. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Post-Traumatic Stress Disorder	0	0.0%	0	0.0%	NaN	NaN
Psychotherapy	0	0.0%	0	0.0%	NaN	NaN
Psychotic Conditions	0	0.0%	0	0.0%	NaN	NaN
Schizophrenia	0	0.0%	0	0.0%	NaN	NaN
Sleep Disorder	0	0.0%	0	0.0%	NaN	NaN
Substance Abuse	0	0.0%	0	0.0%	NaN	NaN
Suicidal Behavior	0	0.0%	0	0.0%	NaN	NaN
Transcranial Magnetic Stimulation	0	0.0%	0	0.0%	NaN	NaN
Vagus Nerve Stimulation	0	0.0%	0	0.0%	NaN	NaN
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	3,758	0.9%	0	0.0%	NaN	NaN
dulaglutide	148,024	34.2%	0	0.0%	NaN	NaN
exenatide	31,364	7.2%	0	0.0%	NaN	NaN
liraglutide	83,747	19.3%	0	0.0%	NaN	NaN
lixisenatide	6,803	1.6%	0	0.0%	NaN	NaN
semaglutide	150,057	34.6%	0	0.0%	NaN	NaN
tirzepatide	9,738	2.2%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	433,109	100.0%	659,687	100.0%	-0.000	-0.002
insulin*	141,040	32.6%	97,801	14.8%	17.739	0.427
metformin*	386,322	89.2%	582,255	88.3%	0.935	0.030
alpha-glucosidase inhibitors*	1,858	0.4%	3,881	0.6%	-0.159	-0.022
thiazolidinediones*	38,834	9.0%	48,260	7.3%	1.651	0.060
meglitinides*	5,173	1.2%	9,809	1.5%	-0.293	-0.025
amylin analogue*	35	0.0%	*****	*****	*****	*****
sulfonylureas*	168,971	39.0%	307,995	46.7%	-7.675	-0.156

Table 1ai. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
bile acid sequestrants*	1,243	0.3%	2,153	0.3%	-0.039	-0.007
Other Weight Loss Agents*	1,083	0.3%	232	0.0%	0.215	0.057
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	0	0.0%	0	0.0%	NaN	NaN
diethylpropion	29	0.0%	*****	*****	*****	*****
lorcaserin	50	0.0%	20	0.0%	0.009	0.010
phentermine	911	0.2%	178	0.0%	0.183	0.053
phentermine-topiramate	65	0.0%	14	0.0%	0.013	0.014
phendimetrazine	24	0.0%	*****	*****	*****	*****
orlistat	18	0.0%	12	0.0%	0.002	0.004
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	61,291	14.2%	95,151	14.4%	-0.272	-0.008
Antipsychotics	0	0.0%	0	0.0%	NaN	NaN
Anxiolytics/Hypnotics	0	0.0%	0	0.0%	NaN	NaN
Lithium & Other Mood Stabilizers	0	0.0%	0	0.0%	NaN	NaN
Antidepressants	115	0.0%	219	0.0%	-0.007	-0.004
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	7.8	7.7	7.7	8.7	0.082	0.010
Mean number of emergency room encounters*	0.2	0.6	0.2	0.6	-0.021	-0.036
Mean number of inpatient hospital encounters*	0.0	0.2	0.1	0.3	-0.029	-0.109
Mean number of non-acute institutional encounters*	0.0	0.1	0.0	0.1	-0.007	-0.070

Table 1ai. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Mean number of other ambulatory encounters*	2.0	6.7	2.5	8.5	-0.471	-0.062
Mean number of filled prescriptions*	18.1	12.0	18.3	13.0	-0.172	-0.014
Mean number of generics dispensed*	8.4	3.5	8.2	3.7	0.165	0.046
Mean number of unique drug classes dispensed*	7.4	3.2	6.7	3.3	0.719	0.222

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1aj. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	432,910	100.0%	659,458	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)*	61.0	9.9	64.7	10.2	-3.753	-0.373
Age						
18-24 years	2,656	0.6%	2,274	0.3%	0.269	0.039
25-44 years	53,942	12.5%	55,894	8.5%	3.985	0.130
45-64 years	172,656	39.9%	235,102	35.7%	4.232	0.087
65-79 years	186,186	43.0%	290,182	44.0%	-0.995	-0.020
≥ 80 years	17,470	4.0%	76,006	11.5%	-7.490	-0.282
Sex*						
Female	211,959	49.0%	309,714	47.0%	1.997	0.040
Male	220,951	51.0%	349,744	53.0%	-1.997	-0.040
Race[3]						
American Indian or Alaska Native	3,014	0.7%	4,759	0.7%	-0.025	-0.003
Asian	9,753	2.3%	45,381	6.9%	-4.629	-0.223
Black or African American	43,665	10.1%	81,431	12.3%	-2.262	-0.072
Multi-racial	2,793	0.6%	2,288	0.3%	0.298	0.042
Native Hawaiian or Other Pacific Islander	1,626	0.4%	3,399	0.5%	-0.140	-0.021
Unknown	186,633	43.1%	246,963	37.4%	5.662	0.116
White	185,426	42.8%	275,237	41.7%	1.096	0.022
Hispanic origin						
Yes	22,625	5.2%	67,590	10.2%	-5.023	-0.189
No	217,045	50.1%	382,332	58.0%	-7.840	-0.158

Table 1aj. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Unknown	193,240	44.6%	209,536	31.8%	12.863	0.267
Year*						
2015	6,809	1.6%	29,564	4.5%	-2.910	-0.170
2016	32,860	7.6%	129,038	19.6%	-11.977	-0.355
2017	38,797	9.0%	126,468	19.2%	-10.216	-0.297
2018	45,702	10.6%	107,251	16.3%	-5.707	-0.168
2019	55,622	12.8%	94,441	14.3%	-1.473	-0.043
2020	60,724	14.0%	78,767	11.9%	2.083	0.062
2021	59,049	13.6%	45,756	6.9%	6.702	0.222
2022	72,943	16.8%	32,962	5.0%	11.851	0.387
2023	60,404	14.0%	15,211	2.3%	11.646	0.436
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[4]	1.0	1.4	1.2	1.5	-0.117	-0.080
Combined comorbidity score*,[5]	0.9	1.6	1.1	1.9	-0.126	-0.072
Medical History						
Obesity*	169,162	39.1%	137,461	20.8%	18.231	0.406
Weight Reduction Surgery or Procedure*	40	0.0%	126	0.0%	-0.010	-0.008
Lifestyle intervention*	76,672	17.7%	90,266	13.7%	4.023	0.111
Cardiovascular Disease*	54,783	12.7%	99,902	15.1%	-2.495	-0.072
Cognitive Impairment*	407	0.1%	1,171	0.2%	-0.084	-0.023
Traumatic Brain Injury*	69	0.0%	117	0.0%	-0.002	-0.001
Migraine*	5,371	1.2%	5,723	0.9%	0.373	0.037
Epilepsy*	1,088	0.3%	2,108	0.3%	-0.068	-0.013
Chronic Pain*	48,297	11.2%	58,415	8.9%	2.298	0.077
Psychiatric History						

Table 1aj. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Previous Intentional Self-Harm Ever	307	0.1%	314	0.0%	0.023	0.010
Psychiatric History Overall*	0	0.0%	0	0.0%	NaN	NaN
Psychiatric Drug Dispensings	0	0.0%	0	0.0%	NaN	NaN
Intentional Self-Harm Encounter	0	0.0%	0	0.0%	NaN	NaN
Any Other Psychiatric Event	0	0.0%	0	0.0%	NaN	NaN
Attention-Deficit/Hyperactivity Disorder	0	0.0%	0	0.0%	NaN	NaN
Akathisia	0	0.0%	0	0.0%	NaN	NaN
Anxiety	0	0.0%	0	0.0%	NaN	NaN
Behavioral Disorder	0	0.0%	0	0.0%	NaN	NaN
Bipolar Disorder	0	0.0%	0	0.0%	NaN	NaN
Cerebral Degenerations usually Manifested in Childhood	0	0.0%	0	0.0%	NaN	NaN
Conduct Disorder	0	0.0%	0	0.0%	NaN	NaN
Delirium	0	0.0%	0	0.0%	NaN	NaN
Depression	0	0.0%	0	0.0%	NaN	NaN
Electroconvulsive Therapy	0	0.0%	0	0.0%	NaN	NaN
Hallucination	0	0.0%	0	0.0%	NaN	NaN
Obsessive-Compulsive Disorder	0	0.0%	0	0.0%	NaN	NaN
Other Cerebral Degenerations	0	0.0%	0	0.0%	NaN	NaN
Other Mental Disorders	0	0.0%	0	0.0%	NaN	NaN
Other Psychological Disorders	0	0.0%	0	0.0%	NaN	NaN
Persistent Mental Disorders due to Conditions Classified Elsewhere	0	0.0%	0	0.0%	NaN	NaN
Personality Disorders	0	0.0%	0	0.0%	NaN	NaN
Pervasive Developmental Disorders	0	0.0%	0	0.0%	NaN	NaN

Table 1aj. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Post-Traumatic Stress Disorder	0	0.0%	0	0.0%	NaN	NaN
Psychotherapy	0	0.0%	0	0.0%	NaN	NaN
Psychotic Conditions	0	0.0%	0	0.0%	NaN	NaN
Schizophrenia	0	0.0%	0	0.0%	NaN	NaN
Sleep Disorder	0	0.0%	0	0.0%	NaN	NaN
Substance Abuse	0	0.0%	0	0.0%	NaN	NaN
Suicidal Behavior	0	0.0%	0	0.0%	NaN	NaN
Transcranial Magnetic Stimulation	0	0.0%	0	0.0%	NaN	NaN
Vagus Nerve Stimulation	0	0.0%	0	0.0%	NaN	NaN
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	3,757	0.9%	0	0.0%	NaN	NaN
dulaglutide	147,996	34.2%	0	0.0%	NaN	NaN
exenatide	31,291	7.2%	0	0.0%	NaN	NaN
liraglutide	83,727	19.3%	0	0.0%	NaN	NaN
lixisenatide	6,788	1.6%	0	0.0%	NaN	NaN
semaglutide	150,002	34.6%	0	0.0%	NaN	NaN
tirzepatide	9,730	2.2%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	432,909	100.0%	659,458	100.0%	-0.000	-0.002
insulin*	140,892	32.5%	97,782	14.8%	17.718	0.426
metformin*	386,147	89.2%	582,074	88.3%	0.932	0.029
alpha-glucosidase inhibitors*	1,856	0.4%	3,879	0.6%	-0.159	-0.022
thiazolidinediones*	38,812	9.0%	48,224	7.3%	1.653	0.060
meglitinides*	5,171	1.2%	9,799	1.5%	-0.291	-0.025
amylin analogue*	24	0.0%	*****	*****	*****	*****
sulfonylureas*	168,865	39.0%	307,839	46.7%	-7.674	-0.156

Table 1aj. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
bile acid sequestrants*	1,239	0.3%	2,151	0.3%	-0.040	-0.007
Other Weight Loss Agents*	1,027	0.2%	232	0.0%	0.202	0.055
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	0	0.0%	0	0.0%	NaN	NaN
diethylpropion	29	0.0%	*****	*****	*****	*****
lorcaserin	50	0.0%	20	0.0%	0.009	0.010
phentermine	856	0.2%	178	0.0%	0.171	0.051
phentermine-topiramate	64	0.0%	14	0.0%	0.013	0.014
phendimetrazine	24	0.0%	*****	*****	*****	*****
orlistat	18	0.0%	12	0.0%	0.002	0.004
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	61,246	14.1%	95,065	14.4%	-0.268	-0.008
Antipsychotics	0	0.0%	0	0.0%	NaN	NaN
Anxiolytics/Hypnotics	0	0.0%	0	0.0%	NaN	NaN
Lithium & Other Mood Stabilizers	0	0.0%	0	0.0%	NaN	NaN
Antidepressants	115	0.0%	219	0.0%	-0.007	-0.004
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	7.8	7.7	7.7	8.7	0.082	0.010
Mean number of emergency room encounters*	0.2	0.6	0.2	0.6	-0.021	-0.036
Mean number of inpatient hospital encounters*	0.0	0.2	0.1	0.3	-0.029	-0.108
Mean number of non-acute institutional encounters*	0.0	0.1	0.0	0.1	-0.007	-0.070

Table 1aj. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Mean number of other ambulatory encounters*	2.0	6.7	2.5	8.5	-0.472	-0.062
Mean number of filled prescriptions*	18.1	12.0	18.3	13.0	-0.172	-0.014
Mean number of generics dispensed*	8.4	3.5	8.2	3.7	0.166	0.046
Mean number of unique drug classes dispensed*	7.4	3.2	6.7	3.3	0.718	0.222

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1ak. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	506,601	N/A	749,664	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	62.3	9.6	63.2	10.8	-0.889	-0.087
Age						
18-24 years	1,480	0.3%	3,993	0.5%	-0.241	-0.038
25-44 years	45,017	8.9%	79,615	10.6%	-1.734	-0.061
45-64 years	217,806	43.0%	277,588	37.0%	5.965	0.147
65-79 years	214,919	42.4%	320,168	42.7%	-0.284	-0.007
≥ 80 years	27,378	5.4%	68,301	9.1%	-3.707	-0.147
Sex*						
Female	241,972	47.8%	366,540	48.9%	-1.130	-0.023
Male	264,629	52.2%	383,125	51.1%	1.130	0.023
Race[4]						
American Indian or Alaska Native	2,696	0.5%	5,799	0.8%	-0.241	-0.030
Asian	11,016	2.2%	45,549	6.1%	-3.901	-0.200
Black or African American	52,303	10.3%	103,453	13.8%	-3.476	-0.110
Multi-racial	2,391	0.5%	3,051	0.4%	0.065	0.010
Native Hawaiian or Other Pacific Islander	1,705	0.3%	3,496	0.5%	-0.130	-0.021
Unknown	226,144	44.6%	297,699	39.7%	4.929	0.150
White	210,346	41.5%	290,618	38.8%	2.755	0.069
Hispanic origin						
Yes	24,581	4.9%	78,033	10.4%	-5.557	-0.224
No	245,849	48.5%	413,778	55.2%	-6.666	-0.224
Unknown	236,171	46.6%	257,854	34.4%	12.223	0.522

Table 1ak. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Year*						
2015	16,562	3.3%	23,629	3.2%	0.117	0.007
2016	78,612	15.5%	107,367	14.3%	1.196	0.034
2017	76,460	15.1%	112,369	15.0%	0.104	0.003
2018	79,675	15.7%	105,233	14.0%	1.690	0.048
2019	61,542	12.1%	106,228	14.2%	-2.022	-0.060
2020	58,675	11.6%	100,073	13.3%	-1.767	-0.054
2021	46,914	9.3%	72,639	9.7%	-0.429	-0.015
2022	48,038	9.5%	72,161	9.6%	-0.143	-0.005
2023	40,124	7.9%	49,965	6.7%	1.255	0.049
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.4	1.7	1.2	1.6	0.182	0.111
Combined comorbidity score*,[6]	1.3	2.1	1.1	1.9	0.199	0.099
Medical History						
Obesity*	166,507	32.9%	216,192	28.8%	4.029	0.088
Weight Reduction Surgery or Procedure*	60	0.0%	148	0.0%	-0.008	-0.006
Lifestyle intervention*	89,446	17.7%	109,172	14.6%	3.093	0.085
Cardiovascular Disease*	90,730	17.9%	115,744	15.4%	2.470	0.068
Cognitive Impairment*	1,064	0.2%	1,225	0.2%	0.047	0.011
Traumatic Brain Injury*	67	0.0%	106	0.0%	-0.001	-0.001
Migraine*	6,807	1.3%	7,668	1.0%	0.321	0.030
Epilepsy*	2,113	0.4%	2,291	0.3%	0.112	0.019
Chronic Pain*	75,386	14.9%	81,173	10.8%	4.053	0.122
Psychiatric History						
Previous Intentional Self-Harm Ever	351	0.1%	626	0.1%	-0.014	-0.005

Table 1ak. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Psychiatric History Overall*	0	0.0%	0	0.0%	NaN	NaN
Psychiatric Drug Dispensings	0	0.0%	0	0.0%	NaN	NaN
Intentional Self-Harm Encounter	0	0.0%	0	0.0%	NaN	NaN
Any Other Psychiatric Event	0	0.0%	0	0.0%	NaN	NaN
Attention-Deficit/Hyperactivity Disorder	0	0.0%	0	0.0%	NaN	NaN
Akathisia	0	0.0%	0	0.0%	NaN	NaN
Anxiety	0	0.0%	0	0.0%	NaN	NaN
Behavioral Disorder	0	0.0%	0	0.0%	NaN	NaN
Bipolar Disorder	0	0.0%	0	0.0%	NaN	NaN
Cerebral Degenerations usually Manifested in Childhood	0	0.0%	0	0.0%	NaN	NaN
Conduct Disorder	0	0.0%	0	0.0%	NaN	NaN
Delirium	0	0.0%	0	0.0%	NaN	NaN
Depression	0	0.0%	0	0.0%	NaN	NaN
Electroconvulsive Therapy	0	0.0%	0	0.0%	NaN	NaN
Hallucination	0	0.0%	0	0.0%	NaN	NaN
Obsessive-Compulsive Disorder	0	0.0%	0	0.0%	NaN	NaN
Other Cerebral Degenerations	0	0.0%	0	0.0%	NaN	NaN
Other Mental Disorders	0	0.0%	0	0.0%	NaN	NaN
Other Psychological Disorders	0	0.0%	0	0.0%	NaN	NaN
Persistent Mental Disorders due to Conditions Classified Elsewhere	0	0.0%	0	0.0%	NaN	NaN
Personality Disorders	0	0.0%	0	0.0%	NaN	NaN
Pervasive Developmental Disorders	0	0.0%	0	0.0%	NaN	NaN
Post-Traumatic Stress Disorder	0	0.0%	0	0.0%	NaN	NaN

Table 1ak. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Psychotherapy	0	0.0%	0	0.0%	NaN	NaN
Psychotic Conditions	0	0.0%	0	0.0%	NaN	NaN
Schizophrenia	0	0.0%	0	0.0%	NaN	NaN
Sleep Disorder	0	0.0%	0	0.0%	NaN	NaN
Substance Abuse	0	0.0%	0	0.0%	NaN	NaN
Suicidal Behavior	0	0.0%	0	0.0%	NaN	NaN
Transcranial Magnetic Stimulation	0	0.0%	0	0.0%	NaN	NaN
Vagus Nerve Stimulation	0	0.0%	0	0.0%	NaN	NaN
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	8,369	1.7%	0	0.0%	NaN	NaN
dulaglutide	178,398	35.2%	0	0.0%	NaN	NaN
exenatide	53,124	10.5%	0	0.0%	NaN	NaN
liraglutide	135,383	26.7%	0	0.0%	NaN	NaN
lixisenatide	5,083	1.0%	0	0.0%	NaN	NaN
semaglutide	117,867	23.3%	0	0.0%	NaN	NaN
tirzepatide	12,844	2.5%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	506,600	100.0%	749,664	100.0%	-0.000	-0.002
insulin*	192,330	38.0%	276,816	36.9%	1.039	0.022
metformin*	444,163	87.7%	663,351	88.5%	-0.811	-0.025
alpha-glucosidase inhibitors*	2,452	0.5%	4,462	0.6%	-0.111	-0.015
thiazolidinediones*	39,197	7.7%	65,810	8.8%	-1.041	-0.038
meglitinides*	11,924	2.4%	11,669	1.6%	0.797	0.058
amylin analogue*	11	0.0%	33	0.0%	-0.002	-0.004
sulfonylureas*	215,215	42.5%	331,733	44.3%	-1.769	-0.036
bile acid sequestrants*	2,540	0.5%	2,375	0.3%	0.185	0.029

Table 1ak. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Other Weight Loss Agents*	595	0.1%	1,161	0.2%	-0.037	-0.010
benzphetamine	0	0.0%	*****	*****	*****	*****
bupropion	0	0.0%	0	0.0%	NaN	NaN
diethylpropion	16	0.0%	16	0.0%	0.001	0.002
lorcaserin	33	0.0%	100	0.0%	-0.007	-0.007
phentermine	493	0.1%	971	0.1%	-0.032	-0.010
phentermine-topiramate	38	0.0%	56	0.0%	-0.000	-0.000
phendimetrazine	17	0.0%	*****	*****	*****	*****
orlistat	*****	*****	16	0.0%	*****	*****
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	116,934	23.1%	122,047	16.3%	6.802	0.172
Antipsychotics	0	0.0%	0	0.0%	NaN	NaN
Anxiolytics/Hypnotics	0	0.0%	0	0.0%	NaN	NaN
Lithium & Other Mood Stabilizers	0	0.0%	0	0.0%	NaN	NaN
Antidepressants	884	0.2%	256	0.0%	0.140	0.044
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	9.6	8.8	8.5	11.2	1.134	0.113
Mean number of emergency room encounters*	0.5	1.8	0.2	0.6	0.312	0.229
Mean number of inpatient hospital encounters*	0.1	0.5	0.1	0.3	0.072	0.185
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.1	0.020	0.129
Mean number of other ambulatory encounters*	3.0	8.8	2.5	8.4	0.402	0.047

Table 1ak. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Mean number of filled prescriptions*	23.7	17.9	19.5	14.4	4.164	0.257
Mean number of generics dispensed*	10.7	5.9	8.8	4.0	1.895	0.377
Mean number of unique drug classes dispensed*	8.2	4.0	7.5	3.8	0.643	0.166

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1al. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	717,336	100.0%	736,472	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)*	60.4	10.6	65.1	11.4	-4.683	-0.425
Age						
18-24 years	3,457	0.5%	2,175	0.3%	0.187	0.030
25-44 years	87,729	12.2%	59,791	8.1%	4.111	0.136
45-64 years	317,953	44.3%	268,979	36.5%	7.802	0.159
65-79 years	283,588	39.5%	307,755	41.8%	-2.254	-0.046
≥ 80 years	24,609	3.4%	97,772	13.3%	-9.845	-0.362
Sex*						
Female	424,472	59.2%	413,525	56.1%	3.024	0.061
Male	292,864	40.8%	322,947	43.9%	-3.024	-0.061
Race[3]						
American Indian or Alaska Native	5,278	0.7%	6,022	0.8%	-0.082	-0.009
Asian	6,860	1.0%	21,785	3.0%	-2.002	-0.145
Black or African American	66,309	9.2%	88,928	12.1%	-2.831	-0.092
Multi-racial	3,400	0.5%	1,715	0.2%	0.241	0.041
Islander	1,410	0.2%	1,958	0.3%	-0.069	-0.014
Unknown	233,533	32.6%	186,399	25.3%	7.246	0.160
White	400,546	55.8%	429,665	58.3%	-2.503	-0.051
Hispanic origin						
Yes	28,860	4.0%	50,131	6.8%	-2.784	-0.123
No	439,531	61.3%	521,827	70.9%	-9.582	-0.203

Table 1al. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Unknown	248,945	34.7%	164,514	22.3%	12.366	0.276
Year*						
2015	10,571	1.5%	31,979	4.3%	-2.869	-0.171
2016	51,118	7.1%	135,582	18.4%	-11.284	-0.343
2017	62,484	8.7%	134,188	18.2%	-9.510	-0.281
2018	73,733	10.3%	117,232	15.9%	-5.639	-0.168
2019	90,172	12.6%	106,614	14.5%	-1.906	-0.056
2020	98,454	13.7%	90,737	12.3%	1.404	0.042
2021	99,718	13.9%	59,050	8.0%	5.883	0.189
2022	124,124	17.3%	42,313	5.7%	11.558	0.368
2023	106,962	14.9%	18,777	2.5%	12.361	0.449
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[4]	1.5	1.7	1.9	2.0	-0.378	-0.205
Combined comorbidity score*,[5]	2.0	2.2	2.6	2.9	-0.626	-0.243
Medical History						
Obesity*	376,918	52.5%	234,070	31.8%	20.762	0.430
Procedure*	613	0.1%	1,490	0.2%	-0.117	-0.031
Lifestyle intervention*	136,193	19.0%	98,811	13.4%	5.569	0.152
Cardiovascular Disease*	145,406	20.3%	203,459	27.6%	-7.356	-0.173
Cognitive Impairment*	19,792	2.8%	66,563	9.0%	-6.279	-0.269
Traumatic Brain Injury*	2,386	0.3%	3,185	0.4%	-0.100	-0.016
Migraine*	39,199	5.5%	29,850	4.1%	1.411	0.066
Epilepsy*	12,095	1.7%	18,516	2.5%	-0.828	-0.058
Chronic Pain*	193,176	26.9%	167,894	22.8%	4.133	0.096
Psychiatric History						

Table 1al. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Previous Intentional Self-Harm Ever	8,154	1.1%	8,109	1.1%	0.036	0.003
Psychiatric History Overall*	717,336	100.0%	736,472	100.0%	0.000	NaN
Psychiatric Drug Dispensings	535,398	74.6%	534,344	72.6%	2.082	0.047
Intentional Self-Harm Encounter	*****	*****	*****	*****	*****	*****
Any Other Psychiatric Event	582,470	81.2%	584,463	79.4%	1.839	0.046
Attention-Deficit/Hyperactivity Disorder	13,733	1.9%	*****	*****	*****	*****
Akathisia	*****	*****	1,485	0.2%	*****	*****
Anxiety	193,008	26.9%	177,897	24.2%	2.751	0.063
Behavioral Disorder	45,087	6.3%	48,325	6.6%	-0.276	-0.011
Bipolar Disorder	45,377	6.3%	44,119	6.0%	0.335	0.014
Cerebral Degenerations usually Manifested in Childhood	*****	*****	19,951	2.7%	*****	*****
Conduct Disorder	*****	*****	*****	*****	*****	*****
Delirium	*****	*****	33,527	4.6%	*****	*****
Depression	208,909	29.1%	204,942	27.8%	1.295	0.029
Electroconvulsive Therapy	*****	*****	267	0.0%	*****	*****
Hallucination	*****	*****	*****	*****	*****	*****
Obsessive-Compulsive Disorder	*****	*****	*****	*****	*****	*****
Other Cerebral Degenerations	*****	*****	35,999	4.9%	*****	*****
Other Mental Disorders	*****	*****	*****	*****	*****	*****
Other Psychological Disorders	96,786	13.5%	119,197	16.2%	-2.692	-0.076

Table 1al. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Persistent Mental Disorders due to Conditions Classified Elsewhere	13,935	1.9%	51,664	7.0%	-5.072	-0.247
Personality Disorders	*****	*****	*****	*****	*****	*****
Disorders	1,910	0.3%	1,903	0.3%	0.008	0.002
Disorder	21,750	3.0%	*****	*****	*****	*****
Psychotherapy	65,113	9.1%	59,283	8.0%	1.027	0.037
Psychotic Conditions	3,769	0.5%	*****	*****	*****	*****
Schizophrenia	*****	*****	29,558	4.0%	*****	*****
Sleep Disorder	299,704	41.8%	227,103	30.8%	10.944	0.229
Substance Abuse	48,171	6.7%	55,340	7.5%	-0.799	-0.031
Suicidal Behavior	*****	*****	*****	*****	*****	*****
Transcranial Magnetic Stimulation	244	0.0%	88	0.0%	0.022	0.015
Vagus Nerve Stimulation	*****	*****	791	0.1%	*****	*****
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	5,016	0.7%	0	0.0%	NaN	NaN
dulaglutide	231,531	32.3%	0	0.0%	NaN	NaN
exenatide	53,205	7.4%	0	0.0%	NaN	NaN
liraglutide	150,215	20.9%	0	0.0%	NaN	NaN
lixisenatide	8,828	1.2%	0	0.0%	NaN	NaN
semaglutide	250,156	34.9%	0	0.0%	NaN	NaN
tirzepatide	18,866	2.6%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	717,335	100.0%	736,472	100.0%	-0.000	-0.002
insulin*	246,442	34.4%	149,468	20.3%	14.060	0.320

Table 1al. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
metformin*	633,530	88.3%	630,505	85.6%	2.706	0.080
alpha-glucosidase inhibitors*	2,679	0.4%	3,413	0.5%	-0.090	-0.014
thiazolidinediones*	54,956	7.7%	48,816	6.6%	1.033	0.040
meglitinides*	6,860	1.0%	11,393	1.5%	-0.591	-0.053
amylin analogue*	118	0.0%	*****	*****	*****	*****
sulfonylureas*	249,450	34.8%	323,274	43.9%	-9.120	-0.188
bile acid sequestrants*	3,028	0.4%	3,380	0.5%	-0.037	-0.006
Other Weight Loss Agents*	2,957	0.4%	520	0.1%	0.342	0.070
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	427	0.1%	116	0.0%	0.044	0.023
diethylpropion	55	0.0%	*****	*****	*****	*****
lorcaserin	133	0.0%	49	0.0%	0.012	0.011
phentermine	2,193	0.3%	306	0.0%	0.264	0.063
phentermine-topiramate	134	0.0%	15	0.0%	0.017	0.016
phendimetrazine	39	0.0%	*****	*****	*****	*****
orlistat	52	0.0%	26	0.0%	0.004	0.005
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	226,234	31.5%	240,064	32.6%	-1.058	-0.023
Antipsychotics	76,670	10.7%	92,912	12.6%	-1.928	-0.060
Anxiolytics/Hypnotics	219,981	30.7%	232,223	31.5%	-0.865	-0.019
Stabilizers	67,012	9.3%	72,634	9.9%	-0.521	-0.018
Antidepressants	441,274	61.5%	408,961	55.5%	5.986	0.122
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	12.7	11.5	12.7	12.8	-0.055	-0.005

Table 1al. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Mean number of emergency room encounters*	0.5	1.2	0.6	1.4	-0.108	-0.084
Mean number of inpatient hospital encounters*	0.1	0.5	0.3	0.7	-0.143	-0.245
Mean number of non-acute institutional encounters*	0.0	0.2	0.1	0.4	-0.071	-0.207
Mean number of other ambulatory encounters*	5.0	13.3	7.4	17.4	-2.495	-0.161
Mean number of filled prescriptions*	30.9	21.8	31.8	23.1	-0.886	-0.040
Mean number of generics dispensed*	12.5	5.3	12.3	5.4	0.136	0.025
Mean number of unique drug classes dispensed*	11.2	4.7	10.5	4.8	0.727	0.152

Table 1al. Aggregated Unadjusted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	DPP-4 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1am. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	717,153	100.0%	736,409	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)*	60.4	10.6	65.1	11.4	-4.680	-0.424
Age						
18-24 years	3,456	0.5%	2,175	0.3%	0.187	0.030
25-44 years	87,665	12.2%	59,790	8.1%	4.105	0.136
45-64 years	317,855	44.3%	268,964	36.5%	7.798	0.159
65-79 years	283,570	39.5%	307,726	41.8%	-2.246	-0.046
≥ 80 years	24,607	3.4%	97,754	13.3%	-9.843	-0.362
Sex*						
Female	424,334	59.2%	413,492	56.1%	3.019	0.061
Male	292,819	40.8%	322,917	43.9%	-3.019	-0.061
Race[3]						
American Indian or Alaska Native	5,278	0.7%	6,022	0.8%	-0.082	-0.009
Asian	6,859	1.0%	21,780	3.0%	-2.001	-0.145
Black or African American	66,294	9.2%	88,919	12.1%	-2.831	-0.092
Multi-racial	3,398	0.5%	1,714	0.2%	0.241	0.041
Native Hawaiian or Other Pacific Islander	1,410	0.2%	1,958	0.3%	-0.069	-0.014
Unknown	233,432	32.5%	186,386	25.3%	7.240	0.160
White	400,482	55.8%	429,630	58.3%	-2.498	-0.050
Hispanic origin						
Yes	28,849	4.0%	50,128	6.8%	-2.784	-0.123
No	439,466	61.3%	521,793	70.9%	-9.577	-0.203

Table 1am. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Unknown	248,838	34.7%	164,488	22.3%	12.362	0.276
Year*						
2015	10,571	1.5%	31,973	4.3%	-2.868	-0.171
2016	51,117	7.1%	135,569	18.4%	-11.282	-0.343
2017	62,480	8.7%	134,172	18.2%	-9.508	-0.281
2018	73,730	10.3%	117,223	15.9%	-5.637	-0.168
2019	90,168	12.6%	106,609	14.5%	-1.904	-0.056
2020	98,449	13.7%	90,729	12.3%	1.407	0.042
2021	99,696	13.9%	59,046	8.0%	5.884	0.189
2022	124,076	17.3%	42,311	5.7%	11.556	0.368
2023	106,866	14.9%	18,777	2.5%	12.352	0.449
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[4]	1.5	1.7	1.9	2.0	-0.378	-0.205
Combined comorbidity score*,[5]	2.0	2.2	2.6	2.9	-0.626	-0.243
Medical History						
Obesity*	376,757	52.5%	234,051	31.8%	20.752	0.430
Weight Reduction Surgery or Procedure*	612	0.1%	1,488	0.2%	-0.117	-0.031
Lifestyle intervention*	136,125	19.0%	98,802	13.4%	5.565	0.151
Cardiovascular Disease*	145,380	20.3%	203,425	27.6%	-7.352	-0.173
Cognitive Impairment*	19,789	2.8%	66,539	9.0%	-6.276	-0.269
Traumatic Brain Injury*	2,383	0.3%	3,185	0.4%	-0.100	-0.016
Migraine*	39,168	5.5%	29,848	4.1%	1.408	0.066
Epilepsy*	12,092	1.7%	18,512	2.5%	-0.828	-0.058
Chronic Pain*	193,088	26.9%	167,872	22.8%	4.128	0.096
Psychiatric History						

Table 1am. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Previous Intentional Self-Harm Ever	8,146	1.1%	8,108	1.1%	0.035	0.003
Psychiatric History Overall*	717,153	100.0%	736,409	100.0%	0.000	NaN
Psychiatric Drug Dispensings	535,240	74.6%	534,296	72.6%	2.080	0.047
Intentional Self-Harm Encounter	1,052	0.1%	1,460	0.2%	-0.052	-0.012
Any Other Psychiatric Event	582,305	81.2%	584,403	79.4%	1.838	0.046
Attention-Deficit/Hyperactivity Disorder	13,720	1.9%	6,513	0.9%	1.029	0.088
Akathisia	1,082	0.2%	1,485	0.2%	-0.051	-0.012
Anxiety	192,917	26.9%	177,874	24.2%	2.746	0.063
Behavioral Disorder	45,064	6.3%	*****	*****	*****	*****
Bipolar Disorder	45,346	6.3%	*****	*****	*****	*****
Cerebral Degenerations usually Manifested in Childhood	*****	*****	*****	*****	*****	*****
Conduct Disorder	973	0.1%	1,288	0.2%	-0.039	-0.010
Delirium	*****	*****	33,512	4.6%	*****	*****
Depression	208,836	29.1%	204,916	27.8%	1.294	0.029
Electroconvulsive Therapy	*****	*****	267	0.0%	*****	*****
Hallucination	*****	*****	*****	*****	*****	*****
Obsessive-Compulsive Disorder	*****	*****	1,673	0.2%	*****	*****
Other Cerebral Degenerations	*****	*****	35,987	4.9%	*****	*****
Other Mental Disorders	*****	*****	*****	*****	*****	*****
Other Psychological Disorders	96,756	13.5%	119,182	16.2%	-2.693	-0.076
Persistent Mental Disorders due to Conditions Classified Elsewhere	*****	*****	51,647	7.0%	*****	*****
Personality Disorders	*****	*****	*****	*****	*****	*****
Pervasive Developmental Disorders	*****	*****	*****	*****	*****	*****

Table 1am. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Post-Traumatic Stress Disorder	21,732	3.0%	*****	*****	*****	*****
Psychotherapy	65,078	9.1%	*****	*****	*****	*****
Psychotic Conditions	3,769	0.5%	*****	*****	*****	*****
Schizophrenia	*****	*****	*****	*****	*****	*****
Sleep Disorder	299,596	41.8%	227,080	30.8%	10.940	0.229
Substance Abuse	48,153	6.7%	*****	*****	*****	*****
Suicidal Behavior	5,321	0.7%	7,328	1.0%	-0.253	-0.027
Transcranial Magnetic Stimulation	244	0.0%	88	0.0%	0.022	0.015
Vagus Nerve Stimulation	948	0.1%	791	0.1%	0.025	0.007
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	5,015	0.7%	0	0.0%	NaN	NaN
dulaglutide	231,499	32.3%	0	0.0%	NaN	NaN
exenatide	53,197	7.4%	0	0.0%	NaN	NaN
liraglutide	150,193	20.9%	0	0.0%	NaN	NaN
lixisenatide	8,812	1.2%	0	0.0%	NaN	NaN
semaglutide	250,076	34.9%	0	0.0%	NaN	NaN
tirzepatide	18,842	2.6%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	717,152	100.0%	736,409	100.0%	-0.000	-0.002
insulin*	246,315	34.3%	149,455	20.3%	14.051	0.319
metformin*	633,361	88.3%	630,462	85.6%	2.703	0.080
alpha-glucosidase inhibitors*	2,677	0.4%	3,411	0.5%	-0.090	-0.014
thiazolidinediones*	54,941	7.7%	48,812	6.6%	1.033	0.040
meglitinides*	6,858	1.0%	11,391	1.5%	-0.591	-0.053
amylin analogue*	117	0.0%	*****	*****	*****	*****
sulfonylureas*	249,396	34.8%	323,234	43.9%	-9.117	-0.187

Table 1am. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
bile acid sequestrants*	3,026	0.4%	3,380	0.5%	-0.037	-0.006
Other Weight Loss Agents*	2,945	0.4%	519	0.1%	0.340	0.069
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	*****	*****	116	0.0%	*****	*****
diethylpropion	55	0.0%	*****	*****	*****	*****
lorcaserin	133	0.0%	49	0.0%	0.012	0.011
phentermine	2,183	0.3%	305	0.0%	0.263	0.063
phentermine-topiramate	134	0.0%	15	0.0%	0.017	0.016
phendimetrazine	39	0.0%	*****	*****	*****	*****
orlistat	52	0.0%	26	0.0%	0.004	0.005
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	226,150	31.5%	240,039	32.6%	-1.061	-0.023
Antipsychotics	76,619	10.7%	*****	*****	*****	*****
Anxiolytics/Hypnotics	219,883	30.7%	232,195	31.5%	-0.870	-0.019
Lithium & Other Mood Stabilizers	66,982	9.3%	*****	*****	*****	*****
Antidepressants	441,136	61.5%	408,924	55.5%	5.983	0.122
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	12.7	11.5	12.7	12.8	-0.056	-0.005
Mean number of emergency room encounters*	0.5	1.2	0.6	1.4	-0.108	-0.084
Mean number of inpatient hospital encounters*	0.1	0.5	0.3	0.7	-0.143	-0.245
Mean number of non-acute institutional encounters*	0.0	0.2	0.1	0.4	-0.071	-0.210
Mean number of other ambulatory encounters*	4.9	13.3	7.4	17.4	-2.496	-0.161

Table 1am. Aggregated Unweighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Mean number of filled prescriptions*	30.9	21.8	31.8	23.1	-0.890	-0.040
Mean number of generics dispensed*	12.5	5.3	12.3	5.4	0.135	0.025
Mean number of unique drug classes dispensed*	11.2	4.7	10.5	4.8	0.725	0.152

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1an. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	754,821	N/A	787,051	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.9	10.7	62.7	12.0	-0.751	-0.066
Age						
18-24 years	2,362	0.3%	4,168	0.5%	-0.217	-0.034
25-44 years	74,335	9.8%	86,721	11.0%	-1.170	-0.040
45-64 years	331,041	43.9%	313,290	39.8%	4.051	0.089
65-79 years	302,727	40.1%	307,330	39.0%	1.058	0.024
≥ 80 years	44,355	5.9%	75,543	9.6%	-3.722	-0.142
Sex*						
Female	436,864	57.9%	462,280	58.7%	-0.859	-0.017
Male	317,956	42.1%	324,771	41.3%	0.859	0.017
Race[4]						
American Indian or Alaska Native	5,315	0.7%	7,257	0.9%	-0.218	-0.024
Asian	10,005	1.3%	19,762	2.5%	-1.185	-0.087
Black or African American	70,813	9.4%	102,113	13.0%	-3.593	-0.116
Multi-racial	3,294	0.4%	1,997	0.3%	0.183	0.032
Native Hawaiian or Other Pacific Islander	1,452	0.2%	1,806	0.2%	-0.037	-0.008
Unknown	249,268	33.0%	206,834	26.3%	6.744	0.231
White	414,674	54.9%	447,282	56.8%	-1.893	-0.047
Hispanic origin						
Yes	29,822	4.0%	55,970	7.1%	-3.161	-0.143
No	457,951	60.7%	547,673	69.6%	-8.915	-0.329

Table 1an. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Unknown	267,048	35.4%	183,408	23.3%	12.076	0.603
Year*						
2015	21,811	2.9%	23,054	2.9%	-0.040	-0.002
2016	95,864	12.7%	102,046	13.0%	-0.265	-0.008
2017	98,520	13.1%	108,677	13.8%	-0.756	-0.022
2018	101,170	13.4%	106,431	13.5%	-0.120	-0.004
2019	100,718	13.3%	110,761	14.1%	-0.730	-0.021
2020	93,658	12.4%	106,043	13.5%	-1.065	-0.032
2021	85,797	11.4%	83,993	10.7%	0.695	0.022
2022	90,427	12.0%	85,619	10.9%	1.102	0.035
2023	66,855	8.9%	60,426	7.7%	1.180	0.043
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.8	2.0	1.8	1.9	0.064	0.033
Combined comorbidity score*,[6]	2.6	2.9	2.5	2.7	0.171	0.061
Medical History						
Obesity*	341,863	45.3%	331,464	42.1%	3.176	0.065
Weight Reduction Surgery or Procedure*	1,489	0.2%	1,236	0.2%	0.040	0.010
Lifestyle intervention*	128,631	17.0%	121,408	15.4%	1.616	0.045
Cardiovascular Disease*	196,651	26.1%	198,845	25.3%	0.788	0.018
Cognitive Impairment*	57,611	7.6%	48,530	6.2%	1.466	0.059
Traumatic Brain Injury*	3,220	0.4%	3,213	0.4%	0.018	0.003
Migraine*	42,688	5.7%	40,218	5.1%	0.545	0.024
Epilepsy*	21,620	2.9%	18,185	2.3%	0.554	0.035
Chronic Pain*	212,857	28.2%	208,230	26.5%	1.743	0.039
Psychiatric History						

Table 1an. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Previous Intentional Self-Harm Ever	11,506	1.5%	10,877	1.4%	0.142	0.012
Psychiatric History Overall*	754,821	100.0%	787,051	100.0%	0.000	NaN
Psychiatric Drug Dispensings	562,398	74.5%	595,807	75.7%	-1.194	-0.028
Intentional Self-Harm Encounter	3,324	0.4%	1,536	0.2%	0.245	0.044
Any Other Psychiatric Event	620,824	82.2%	630,317	80.1%	2.162	0.056
Attention-Deficit/Hyperactivity Disorder	13,196	1.7%	10,057	1.3%	0.470	0.039
Akathisia	1,492	0.2%	1,637	0.2%	-0.010	-0.002
Anxiety	208,707	27.6%	211,882	26.9%	0.729	0.016
Behavioral Disorder	60,776	8.1%	52,890	6.7%	1.332	0.051
Bipolar Disorder	54,586	7.2%	57,630	7.3%	-0.091	-0.004
Cerebral Degenerations usually Manifested in Childhood	17,668	2.3%	17,509	2.2%	0.116	0.008
Conduct Disorder	1,065	0.1%	1,542	0.2%	-0.055	-0.013
Delirium	35,776	4.7%	28,612	3.6%	1.104	0.055
Depression	242,355	32.1%	229,150	29.1%	2.993	0.065
Electroconvulsive Therapy	408	0.1%	312	0.0%	0.015	0.007
Hallucination	3,897	0.5%	3,841	0.5%	0.028	0.004
Obsessive-Compulsive Disorder	2,119	0.3%	2,475	0.3%	-0.034	-0.006
Other Cerebral Degenerations	27,170	3.6%	28,805	3.7%	-0.060	-0.003
Other Mental Disorders	14,048	1.9%	13,187	1.7%	0.186	0.014
Other Psychological Disorders	115,953	15.4%	132,242	16.8%	-1.441	-0.039
Persistent Mental Disorders due to Conditions Classified Elsewhere	41,848	5.5%	37,146	4.7%	0.824	0.038
Personality Disorders	7,235	1.0%	6,165	0.8%	0.175	0.019
Pervasive Developmental Disorders	1,371	0.2%	3,110	0.4%	-0.214	-0.040

Table 1an. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Post-Traumatic Stress Disorder	21,887	2.9%	23,643	3.0%	-0.104	-0.006
Psychotherapy	71,364	9.5%	72,994	9.3%	0.180	0.006
Psychotic Conditions	10,901	1.4%	9,497	1.2%	0.238	0.021
Schizophrenia	25,916	3.4%	35,456	4.5%	-1.072	-0.055
Sleep Disorder	311,942	41.3%	259,998	33.0%	8.292	0.174
Substance Abuse	57,442	7.6%	64,063	8.1%	-0.530	-0.020
Suicidal Behavior	10,009	1.3%	7,267	0.9%	0.403	0.038
Transcranial Magnetic Stimulation	176	0.0%	130	0.0%	0.007	0.005
Vagus Nerve Stimulation	963	0.1%	906	0.1%	0.013	0.004
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	8,973	1.2%	0	0.0%	NaN	NaN
dulaglutide	258,605	34.3%	0	0.0%	NaN	NaN
exenatide	74,777	9.9%	0	0.0%	NaN	NaN
liraglutide	197,787	26.2%	0	0.0%	NaN	NaN
lixisenatide	6,931	0.9%	0	0.0%	NaN	NaN
semaglutide	196,827	26.1%	0	0.0%	NaN	NaN
tirzepatide	12,535	1.7%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	754,820	100.0%	787,051	100.0%	-0.000	-0.001
insulin*	260,833	34.6%	302,245	38.4%	-3.847	-0.080
metformin*	656,636	87.0%	680,622	86.5%	0.515	0.015
alpha-glucosidase inhibitors*	3,239	0.4%	3,838	0.5%	-0.059	-0.009
thiazolidinediones*	52,408	6.9%	60,531	7.7%	-0.748	-0.029
meglitinides*	9,667	1.3%	10,924	1.4%	-0.107	-0.009
amylin analogue*	85	0.0%	158	0.0%	-0.009	-0.007
sulfonylureas*	285,391	37.8%	317,974	40.4%	-2.592	-0.053

Table 1an. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
bile acid sequestrants*	4,030	0.5%	3,873	0.5%	0.042	0.006
Other Weight Loss Agents*	2,222	0.3%	1,628	0.2%	0.088	0.018
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	417	0.1%	264	0.0%	0.022	0.010
diethylpropion	43	0.0%	25	0.0%	0.003	0.004
lorcaserin	103	0.0%	105	0.0%	0.000	0.000
phentermine	1,560	0.2%	1,151	0.1%	0.060	0.014
phentermine-topiramate	97	0.0%	33	0.0%	0.009	0.009
phendimetrazine	34	0.0%	29	0.0%	0.001	0.001
orlistat	34	0.0%	53	0.0%	-0.002	-0.003
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	278,901	36.9%	273,810	34.8%	2.160	0.045
Antipsychotics	89,812	11.9%	116,729	14.8%	-2.933	-0.087
Anxiolytics/Hypnotics	240,461	31.9%	269,303	34.2%	-2.360	-0.050
Lithium & Other Mood Stabilizers	77,145	10.2%	91,798	11.7%	-1.443	-0.046
Antidepressants	458,181	60.7%	468,795	59.6%	1.137	0.023
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	13.7	12.3	13.6	14.1	0.154	0.012
Mean number of emergency room encounters*	0.7	2.1	0.6	1.3	0.179	0.100
Mean number of inpatient hospital encounters*	0.4	1.8	0.2	0.6	0.191	0.142
Mean number of non-acute institutional encounters*	0.2	1.0	0.1	0.4	0.086	0.113

Table 1an. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Mean number of other ambulatory encounters*	7.7	17.5	6.9	16.4	0.766	0.045
Mean number of filled prescriptions*	35.2	27.8	33.8	24.2	1.391	0.053
Mean number of generics dispensed*	13.8	7.0	13.2	5.7	0.604	0.095
Mean number of unique drug classes dispensed*	11.7	5.5	11.6	5.3	0.153	0.028

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1ao. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	1,075,535	N/A	1,409,027	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.9	10.3	63.3	11.4	-1.336	-0.123
Age						
18-24 years	3,833	0.4%	6,857	0.5%	-0.130	-0.020
25-44 years	109,541	10.2%	145,551	10.3%	-0.145	-0.005
45-64 years	456,146	42.4%	538,246	38.2%	4.211	0.097
65-79 years	449,288	41.8%	579,134	41.1%	0.672	0.016
≥ 80 years	56,728	5.3%	139,239	9.9%	-4.608	-0.179
Sex*						
Female	577,303	53.7%	760,170	54.0%	-0.274	-0.006
Male	498,232	46.3%	648,856	46.0%	0.274	0.006
Race[4]						
Native	7,177	0.7%	12,378	0.9%	-0.211	-0.024
Asian	16,817	1.6%	59,968	4.3%	-2.692	-0.162
Black or African American	100,690	9.4%	185,444	13.2%	-3.799	-0.123
Multi-racial	5,422	0.5%	4,275	0.3%	0.201	0.032
Pacific Islander	3,029	0.3%	4,850	0.3%	-0.063	-0.011
Unknown	397,919	37.0%	436,425	31.0%	6.024	0.193
White	544,482	50.6%	705,687	50.1%	0.541	0.013
Hispanic origin						

Table 1ao. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Yes	46,570	4.3%	124,015	8.8%	-4.472	-0.190
No	607,851	56.5%	912,354	64.8%	-8.235	-0.286
Unknown	421,115	39.2%	372,658	26.4%	12.706	0.578
Year*						
2015	30,218	2.8%	45,587	3.2%	-0.426	-0.025
2016	134,710	12.5%	204,358	14.5%	-1.979	-0.058
2017	140,680	13.1%	215,729	15.3%	-2.230	-0.064
2018	137,981	12.8%	205,268	14.6%	-1.739	-0.051
2019	142,605	13.3%	207,154	14.7%	-1.443	-0.042
2020	136,157	12.7%	192,674	13.7%	-1.015	-0.030
2021	122,886	11.4%	137,205	9.7%	1.688	0.056
2022	132,282	12.3%	124,944	8.9%	3.432	0.113
2023	98,016	9.1%	76,108	5.4%	3.712	0.145
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*[,5]	1.5	1.7	1.5	1.8	-0.066	-0.038
Combined comorbidity score*[,6]	1.8	2.4	1.9	2.5	-0.076	-0.031
Medical History						
Obesity*	431,513	40.1%	480,619	34.1%	6.011	0.126
Procedure*	1,058	0.1%	1,402	0.1%	-0.001	-0.000
Lifestyle intervention*	182,902	17.0%	206,033	14.6%	2.383	0.066
Cardiovascular Disease*	216,404	20.1%	297,679	21.1%	-1.006	-0.025
Cognitive Impairment*	35,577	3.3%	53,207	3.8%	-0.468	-0.026
Traumatic Brain Injury*	2,570	0.2%	3,410	0.2%	-0.003	-0.001

Table 1ao. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Migraine*	38,931	3.6%	45,236	3.2%	0.409	0.023
Epilepsy*	15,494	1.4%	20,741	1.5%	-0.031	-0.003
Chronic Pain*	218,129	20.3%	268,482	19.1%	1.227	0.031
Psychiatric History						
Previous Intentional Self-Harm Ever	7,735	0.7%	11,034	0.8%	-0.064	-0.007
Psychiatric History Overall*	642,470	59.7%	815,221	57.9%	1.878	0.038
Psychiatric Drug Dispensings	472,784	44.0%	613,433	43.5%	0.422	0.009
Intentional Self-Harm Encounter	1,285	0.1%	1,635	0.1%	0.003	0.001
Any Other Psychiatric Event	523,576	48.7%	650,149	46.1%	2.539	0.051
Attention-Deficit/Hyperactivity Disorder	10,666	1.0%	9,510	0.7%	0.317	0.035
Akathisia	1,143	0.1%	1,667	0.1%	-0.012	-0.004
Anxiety	170,664	15.9%	212,421	15.1%	0.792	0.022
Behavioral Disorder	43,411	4.0%	53,822	3.8%	0.216	0.011
Bipolar Disorder	39,894	3.7%	58,056	4.1%	-0.411	-0.021
Cerebral Degenerations usually Manifested in Childhood	11,365	1.1%	18,582	1.3%	-0.262	-0.024
Conduct Disorder	851	0.1%	1,556	0.1%	-0.031	-0.010
Delirium	20,102	1.9%	29,902	2.1%	-0.253	-0.018
Depression	193,049	17.9%	234,972	16.7%	1.273	0.034
Electroconvulsive Therapy	202	0.0%	329	0.0%	-0.005	-0.003

Table 1ao. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Hallucination	2,642	0.2%	4,016	0.3%	-0.039	-0.008
Obsessive-Compulsive Disorder	1,788	0.2%	2,298	0.2%	0.003	0.001
Degenerations	18,957	1.8%	30,631	2.2%	-0.411	-0.030
Other Mental Disorders	9,380	0.9%	13,547	1.0%	-0.089	-0.009
Other Psychological Disorders	92,773	8.6%	135,287	9.6%	-0.976	-0.034
Persistent Mental Disorders due to Conditions Classified Elsewhere	25,534	2.4%	39,956	2.8%	-0.462	-0.029
Personality Disorders	4,331	0.4%	5,683	0.4%	-0.001	-0.000
Pervasive Developmental Disorders	1,232	0.1%	2,798	0.2%	-0.084	-0.021
Post-Traumatic Stress Disorder	17,381	1.6%	22,604	1.6%	0.012	0.001
Psychotherapy	56,171	5.2%	73,674	5.2%	-0.006	-0.000
Psychotic Conditions	5,216	0.5%	9,995	0.7%	-0.224	-0.029
Schizophrenia	16,162	1.5%	36,280	2.6%	-1.072	-0.076
Sleep Disorder	263,727	24.5%	263,945	18.7%	5.788	0.142
Substance Abuse	45,919	4.3%	65,835	4.7%	-0.403	-0.020
Suicidal Behavior	6,042	0.6%	7,717	0.5%	0.014	0.002
Transcranial Magnetic Stimulation	164	0.0%	144	0.0%	0.005	0.004
Vagus Nerve Stimulation	891	0.1%	888	0.1%	0.020	0.007
Medical Product Use						
Index GLP-1 RA Product						

Table 1ao. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
albiglutide	13,173	1.2%	0	0.0%	NaN	NaN
dulaglutide	369,726	34.4%	0	0.0%	NaN	NaN
exenatide	100,903	9.4%	0	0.0%	NaN	NaN
liraglutide	272,281	25.3%	0	0.0%	NaN	NaN
lixisenatide	11,025	1.0%	0	0.0%	NaN	NaN
semaglutide	292,490	27.2%	0	0.0%	NaN	NaN
tirzepatide	17,876	1.7%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,075,534	100.0%	1,409,027	100.0%	-0.000	-0.002
insulin*	345,609	32.1%	462,155	32.8%	-0.666	-0.014
metformin*	944,499	87.8%	1,228,725	87.2%	0.613	0.019
alpha-glucosidase inhibitors*	4,980	0.5%	7,245	0.5%	-0.051	-0.007
thiazolidinediones*	82,699	7.7%	108,533	7.7%	-0.014	-0.001
meglitinides*	13,810	1.3%	20,392	1.4%	-0.163	-0.014
amylin analogue*	96	0.0%	142	0.0%	-0.001	-0.001
sulfonylureas*	424,710	39.5%	598,625	42.5%	-2.997	-0.061
bile acid sequestrants*	5,079	0.5%	5,954	0.4%	0.050	0.007
Other Weight Loss Agents*	2,704	0.3%	1,751	0.1%	0.127	0.029
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	313	0.0%	241	0.0%	0.012	0.008
diethylpropion	63	0.0%	38	0.0%	0.003	0.005
lorcaserin	136	0.0%	120	0.0%	0.004	0.004
phentermine	2,044	0.2%	1,216	0.1%	0.104	0.028
phentermine-topiramate	134	0.0%	64	0.0%	0.008	0.009
phendimetrazine	55	0.0%	40	0.0%	0.002	0.004

Table 1ao. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
orlistat	39	0.0%	67	0.0%	-0.001	-0.002
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	289,964	27.0%	372,238	26.4%	0.542	0.012
Antipsychotics	66,266	6.2%	117,634	8.3%	-2.187	-0.085
Anxiolytics/Hypnotics	197,242	18.3%	273,835	19.4%	-1.095	-0.028
Stabilizers	57,555	5.4%	92,706	6.6%	-1.228	-0.052
Antidepressants	384,137	35.7%	480,743	34.1%	1.597	0.034
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	11.0	10.5	11.1	12.6	-0.124	-0.011
Mean number of emergency room encounters*	0.4	1.3	0.4	1.1	0.014	0.011
Mean number of inpatient hospital encounters*	0.2	0.5	0.2	0.5	-0.005	-0.010
Mean number of non-acute institutional encounters*	0.0	0.3	0.0	0.3	-0.004	-0.013
Mean number of other ambulatory encounters*	4.5	12.7	5.1	14.2	-0.645	-0.048
Mean number of filled prescriptions*	27.0	21.6	27.3	21.5	-0.339	-0.016
Mean number of generics dispensed*	11.2	5.6	11.1	5.3	0.061	0.011
Mean number of unique drug classes dispensed*	9.7	4.7	9.6	5.0	0.068	0.014

Table 1ao. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	DPP-4 Inhibitors	

[*] Covariate included in the propensity score logistic regression model.

[1] Covariates in blue show a standardized difference greater than 0.1.

[2] Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3] Value represents standard deviation where no % follows the value.

[4] Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5] Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6] Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1ap. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	1,074,433	N/A	1,407,629	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.9	10.3	63.3	11.4	-1.337	-0.123
Age						
18-24 years	3,792	0.4%	6,797	0.5%	-0.130	-0.020
25-44 years	109,205	10.2%	145,133	10.3%	-0.147	-0.005
45-64 years	455,554	42.4%	537,485	38.2%	4.216	0.097
65-79 years	449,174	41.8%	579,004	41.1%	0.672	0.016
≥ 80 years	56,709	5.3%	139,210	9.9%	-4.612	-0.179
Sex*						
Female	576,595	53.7%	759,331	53.9%	-0.279	-0.006
Male	497,838	46.3%	648,298	46.1%	0.279	0.006
Race[4]						
American Indian or Alaska Native	7,152	0.7%	12,353	0.9%	-0.212	-0.024
Asian	16,805	1.6%	59,949	4.3%	-2.695	-0.162
Black or African American	100,599	9.4%	185,237	13.2%	-3.797	-0.123
Multi-racial	5,413	0.5%	4,272	0.3%	0.200	0.032
Native Hawaiian or Other Pacific Islander	3,029	0.3%	4,847	0.3%	-0.062	-0.011
Unknown	397,615	37.0%	436,220	31.0%	6.017	0.192
White	543,820	50.6%	704,751	50.1%	0.548	0.014
Hispanic origin						

Table 1ap. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Yes	46,488	4.3%	123,915	8.8%	-4.476	-0.190
No	607,095	56.5%	911,196	64.7%	-8.229	-0.286
Unknown	420,850	39.2%	372,518	26.5%	12.705	0.578
Year*						
2015	30,164	2.8%	45,532	3.2%	-0.427	-0.025
2016	134,544	12.5%	204,134	14.5%	-1.980	-0.058
2017	140,522	13.1%	215,499	15.3%	-2.231	-0.064
2018	137,850	12.8%	205,052	14.6%	-1.737	-0.051
2019	142,436	13.3%	206,942	14.7%	-1.445	-0.042
2020	136,017	12.7%	192,474	13.7%	-1.014	-0.030
2021	122,780	11.4%	137,090	9.7%	1.688	0.056
2022	132,175	12.3%	124,841	8.9%	3.433	0.113
2023	97,946	9.1%	76,066	5.4%	3.712	0.145
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.5	1.7	1.5	1.8	-0.066	-0.038
Combined comorbidity score*,[6]	1.8	2.4	1.9	2.5	-0.076	-0.031
Medical History						
Obesity*	430,869	40.1%	479,839	34.1%	6.014	0.126
Weight Reduction Surgery or Procedure*	1,052	0.1%	1,395	0.1%	-0.001	-0.000
Lifestyle intervention*	182,624	17.0%	205,724	14.6%	2.382	0.066
Cardiovascular Disease*	216,144	20.1%	297,301	21.1%	-1.004	-0.025
Cognitive Impairment*	35,475	3.3%	53,029	3.8%	-0.465	-0.025
Traumatic Brain Injury*	2,560	0.2%	3,394	0.2%	-0.003	-0.001

Table 1ap. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Migraine*	38,728	3.6%	45,005	3.2%	0.407	0.022
Epilepsy*	15,360	1.4%	20,555	1.5%	-0.031	-0.003
Chronic Pain*	217,608	20.3%	267,864	19.0%	1.224	0.031
Psychiatric History						
Previous Intentional Self-Harm Ever	6,459	0.6%	9,388	0.7%	-0.066	-0.008
Psychiatric History Overall*	641,345	59.7%	813,730	57.8%	1.883	0.038
Psychiatric Drug Dispensings	471,699	43.9%	612,012	43.5%	0.424	0.009
Intentional Self-Harm Encounter	0	0.0%	0	0.0%	NaN	NaN
Any Other Psychiatric Event	522,461	48.6%	648,603	46.1%	2.549	0.051
Attention-Deficit/Hyperactivity Disorder	10,566	1.0%	9,442	0.7%	0.313	0.035
Akathisia	1,113	0.1%	1,643	0.1%	-0.013	-0.004
Anxiety	169,841	15.8%	211,373	15.0%	0.791	0.022
Behavioral Disorder	42,266	3.9%	52,335	3.7%	0.216	0.011
Bipolar Disorder	39,292	3.7%	57,259	4.1%	-0.411	-0.021
Cerebral Degenerations usually Manifested in Childhood	11,325	1.1%	18,514	1.3%	-0.261	-0.024
Conduct Disorder	823	0.1%	1,522	0.1%	-0.031	-0.010
Delirium	19,856	1.8%	29,605	2.1%	-0.255	-0.018
Depression	192,080	17.9%	233,700	16.6%	1.275	0.034
Electroconvulsive Therapy	162	0.0%	304	0.0%	-0.007	-0.005
Hallucination	2,521	0.2%	3,886	0.3%	-0.041	-0.008
Obsessive-Compulsive Disorder	1,758	0.2%	2,267	0.2%	0.003	0.001
Other Cerebral Degenerations	18,921	1.8%	30,535	2.2%	-0.408	-0.030
Other Mental Disorders	9,272	0.9%	13,413	1.0%	-0.090	-0.009

Table 1ap. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Other Psychological Disorders	92,233	8.6%	134,463	9.6%	-0.968	-0.034
Persistent Mental Disorders due to Conditions Classified Elsewhere	25,489	2.4%	39,838	2.8%	-0.458	-0.029
Personality Disorders	4,030	0.4%	5,393	0.4%	-0.008	-0.001
Pervasive Developmental Disorders	1,208	0.1%	2,751	0.2%	-0.083	-0.021
Post-Traumatic Stress Disorder	16,980	1.6%	22,274	1.6%	-0.002	-0.000
Psychotherapy	55,584	5.2%	72,982	5.2%	-0.011	-0.001
Psychotic Conditions	4,968	0.5%	9,626	0.7%	-0.221	-0.029
Schizophrenia	15,856	1.5%	35,805	2.5%	-1.068	-0.076
Sleep Disorder	263,128	24.5%	263,306	18.7%	5.784	0.142
Substance Abuse	45,325	4.2%	65,129	4.6%	-0.408	-0.020
Suicidal Behavior	5,202	0.5%	6,719	0.5%	0.007	0.001
Transcranial Magnetic Stimulation	163	0.0%	144	0.0%	0.005	0.004
Vagus Nerve Stimulation	890	0.1%	885	0.1%	0.020	0.007
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	13,159	1.2%	0	0.0%	NaN	NaN
dulaglutide	369,385	34.4%	0	0.0%	NaN	NaN
exenatide	100,738	9.4%	0	0.0%	NaN	NaN
liraglutide	271,943	25.3%	0	0.0%	NaN	NaN
lixisenatide	10,999	1.0%	0	0.0%	NaN	NaN
semaglutide	292,290	27.2%	0	0.0%	NaN	NaN
tirzepatide	17,862	1.7%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,074,431	100.0%	1,407,629	100.0%	-0.000	-0.002

Table 1ap. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
insulin*	345,207	32.1%	461,676	32.8%	-0.669	-0.014
metformin*	943,529	87.8%	1,227,463	87.2%	0.616	0.019
alpha-glucosidase inhibitors*	4,967	0.5%	7,241	0.5%	-0.052	-0.007
thiazolidinediones*	82,608	7.7%	108,464	7.7%	-0.017	-0.001
meglitinides*	13,805	1.3%	20,383	1.4%	-0.163	-0.014
amylin analogue*	95	0.0%	142	0.0%	-0.001	-0.001
sulfonylureas*	424,339	39.5%	598,128	42.5%	-2.998	-0.061
bile acid sequestrants*	5,081	0.5%	5,954	0.4%	0.050	0.007
Other Weight Loss Agents*	2,701	0.3%	1,746	0.1%	0.127	0.030
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	312	0.0%	241	0.0%	0.012	0.008
diethylpropion	63	0.0%	39	0.0%	0.003	0.005
lorcaserin	136	0.0%	120	0.0%	0.004	0.004
phentermine	2,042	0.2%	1,210	0.1%	0.104	0.028
phentermine-topiramate	134	0.0%	64	0.0%	0.008	0.009
phendimetrazine	56	0.0%	40	0.0%	0.002	0.004
orlistat	39	0.0%	67	0.0%	-0.001	-0.002
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	289,479	26.9%	371,597	26.4%	0.544	0.012
Antipsychotics	65,515	6.1%	116,586	8.3%	-2.185	-0.085
Anxiolytics/Hypnotics	196,519	18.3%	272,808	19.4%	-1.090	-0.028
Lithium & Other Mood Stabilizers	56,981	5.3%	91,893	6.5%	-1.225	-0.052
Antidepressants	383,106	35.7%	479,462	34.1%	1.595	0.034

Table 1ap. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	11.0	10.4	11.1	12.6	-0.125	-0.011
Mean number of emergency room encounters*	0.4	1.3	0.4	1.1	0.014	0.012
Mean number of inpatient hospital encounters*	0.2	0.5	0.2	0.5	-0.006	-0.011
Mean number of non-acute institutional encounters*	0.0	0.3	0.0	0.3	-0.004	-0.013
Mean number of other ambulatory encounters*	4.5	12.7	5.1	14.1	-0.643	-0.048
Mean number of filled prescriptions*	27.0	21.5	27.3	21.4	-0.341	-0.016
Mean number of generics dispensed*	11.2	5.6	11.1	5.3	0.061	0.011
Mean number of unique drug classes dispensed*	9.6	4.7	9.6	5.0	0.068	0.014

Table 1ap. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	DPP-4 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1aq. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	877	N/A	1,247	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	51.9	13.3	51.2	12.9	0.714	0.055
Age						
18-24 years	33	3.7%	46	3.7%	0.020	0.001
25-44 years	236	26.9%	354	28.4%	-1.450	-0.033
45-64 years	446	50.8%	645	51.7%	-0.914	-0.018
65-79 years	143	16.3%	178	14.3%	2.074	0.061
≥ 80 years	19	2.2%	24	1.9%	0.271	0.019
Sex*						
Female	548	62.5%	763	61.2%	1.255	0.026
Male	329	37.5%	484	38.8%	-1.255	-0.026
Race[4]						
American Indian or Alaska Native	*****	*****	22	1.7%	*****	*****
Asian	*****	*****	*****	*****	*****	*****
Black or African American	94	10.7%	186	14.9%	-4.156	-0.125
Multi-racial	0	0.0%	*****	*****	*****	*****
Islander	0	0.0%	*****	*****	*****	*****
Unknown	168	19.2%	224	18.0%	1.191	0.036
White	585	66.7%	789	63.3%	3.413	0.078
Hispanic origin						

Table 1aq. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Yes	65	7.4%	115	9.2%	-1.832	-0.069
No	709	80.8%	1,023	82.1%	-1.258	-0.038
Unknown	103	11.8%	108	8.7%	3.090	0.135
Year*						
2015	30	3.4%	40	3.2%	0.163	0.009
2016	128	14.6%	182	14.6%	-0.019	-0.001
2017	140	16.0%	214	17.2%	-1.210	-0.033
2018	125	14.3%	194	15.5%	-1.277	-0.036
2019	134	15.3%	204	16.4%	-1.062	-0.029
2020	129	14.7%	186	14.9%	-0.267	-0.008
2021	79	9.0%	96	7.7%	1.313	0.049
2022	70	8.0%	83	6.6%	1.329	0.052
2023	42	4.8%	47	3.8%	1.030	0.052
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.9	1.9	1.9	2.0	0.023	0.012
Combined comorbidity score*,[6]	4.1	2.7	4.0	2.6	0.083	0.031
Medical History						
Obesity*	464	53.0%	648	52.0%	0.981	0.020
Procedure*	*****	*****	*****	*****	*****	*****
Lifestyle intervention*	192	21.9%	289	23.2%	-1.363	-0.033
Cardiovascular Disease*	238	27.1%	309	24.8%	2.305	0.054
Cognitive Impairment*	97	11.1%	133	10.6%	0.444	0.014
Traumatic Brain Injury*	*****	*****	*****	*****	*****	*****

Table 1aq. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Migraine*	131	15.0%	172	13.8%	1.185	0.034
Epilepsy*	85	9.7%	123	9.9%	-0.206	-0.007
Chronic Pain*	357	40.7%	487	39.1%	1.611	0.033
Psychiatric History						
Previous Intentional Self-Harm Ever	877	100.0%	1,247	100.0%	0.000	NaN
Psychiatric History Overall*	877	100.0%	1,247	100.0%	0.000	NaN
Psychiatric Drug Dispensings	820	93.5%	1,173	94.1%	-0.623	-0.026
Intentional Self-Harm Encounter	877	100.0%	1,247	100.0%	0.000	NaN
Any Other Psychiatric Event	877	100.0%	1,247	100.0%	0.000	NaN
Attention-Deficit/Hyperactivity Disorder	65	7.4%	49	3.9%	3.474	0.151
Akathisia	21	2.4%	12	0.9%	1.434	0.113
Anxiety	574	65.4%	806	64.6%	0.799	0.017
Behavioral Disorder	783	89.3%	1,121	89.9%	-0.639	-0.021
Bipolar Disorder	392	44.7%	615	49.3%	-4.602	-0.093
Cerebral Degenerations usually Manifested in Childhood	34	3.9%	38	3.0%	0.895	0.049
Conduct Disorder	23	2.6%	30	2.4%	0.233	0.015
Delirium	167	19.0%	197	15.8%	3.174	0.084
Depression	705	80.4%	994	79.7%	0.709	0.018
Electroconvulsive Therapy	30	3.4%	20	1.6%	1.782	0.114
Hallucination	71	8.2%	96	7.7%	0.474	0.018
Obsessive-Compulsive Disorder	18	2.0%	20	1.6%	0.401	0.030
Other Cerebral Degenerations	29	3.3%	61	4.9%	-1.560	-0.079
Other Mental Disorders	71	8.0%	107	8.6%	-0.560	-0.020

Table 1aq. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Other Psychological Disorders	393	44.8%	612	49.1%	-4.216	-0.085
Persistent Mental Disorders due to Conditions Classified Elsewhere	45	5.1%	79	6.3%	-1.229	-0.054
Personality Disorders	199	22.7%	233	18.7%	4.014	0.100
Pervasive Developmental Disorders	15	1.7%	41	3.3%	-1.547	-0.099
Post-Traumatic Stress Disorder	250	28.5%	272	21.8%	6.720	0.156
Psychotherapy	363	41.4%	532	42.6%	-1.202	-0.025
Psychotic Conditions	139	15.8%	274	22.0%	-6.146	-0.158
Schizophrenia	199	22.7%	382	30.6%	-7.963	-0.183
Sleep Disorder	426	48.6%	489	39.2%	9.372	0.196
Substance Abuse	406	46.3%	536	43.0%	3.354	0.068
Suicidal Behavior	538	61.3%	765	61.4%	-0.060	-0.001
Transcranial Magnetic Stimulation	*****	*****	0	0.0%	*****	*****
Vagus Nerve Stimulation	*****	*****	*****	*****	*****	*****
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	*****	*****	0	0.0%	*****	*****
dulaglutide	271	30.9%	0	0.0%	NaN	NaN
exenatide	126	14.3%	0	0.0%	NaN	NaN
liraglutide	304	34.7%	0	0.0%	NaN	NaN
lixisenatide	*****	*****	0	0.0%	*****	*****
semaglutide	153	17.5%	0	0.0%	NaN	NaN

Table 1aq. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
tirzepatide	*****	*****	0	0.0%	*****	*****
Any Anti-Diabetic Agents	877	100.0%	1,247	100.0%	0.000	NaN
insulin*	348	39.7%	495	39.7%	-0.001	-0.000
metformin*	785	89.5%	1,128	90.4%	-0.966	-0.032
alpha-glucosidase inhibitors*	*****	*****	*****	*****	*****	*****
thiazolidinediones*	48	5.5%	70	5.6%	-0.136	-0.006
meglitinides*	*****	*****	*****	*****	*****	*****
amylin analogue*	0	0.0%	0	0.0%	NaN	NaN
sulfonylureas*	297	33.9%	429	34.4%	-0.500	-0.011
bile acid sequestrants*	0	0.0%	0	0.0%	NaN	NaN
Other Weight Loss Agents*	0	0.0%	0	0.0%	NaN	NaN
benzphetamine	0	0.0%	0	0.0%	NaN	NaN
bupropion	0	0.0%	0	0.0%	NaN	NaN
diethylpropion	0	0.0%	0	0.0%	NaN	NaN
lorcaserin	0	0.0%	0	0.0%	NaN	NaN
phentermine	0	0.0%	0	0.0%	NaN	NaN
phentermine-topiramate	0	0.0%	0	0.0%	NaN	NaN
phendimetrazine	0	0.0%	0	0.0%	NaN	NaN
orlistat	0	0.0%	0	0.0%	NaN	NaN
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	367	41.9%	502	40.3%	1.606	0.033
Antipsychotics	508	58.0%	801	64.3%	-6.308	-0.131
Anxiolytics/Hypnotics	504	57.5%	792	63.5%	-5.985	-0.123

Table 1aq. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Lithium & Other Mood Stabilizers	369	42.0%	617	49.5%	-7.491	-0.152
Antidepressants	754	86.0%	1,055	84.6%	1.395	0.039
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	24.3	18.5	24.6	23.1	-0.281	-0.013
Mean number of emergency room encounters*	3.1	4.6	3.1	4.9	0.013	0.003
Mean number of inpatient hospital encounters*	1.2	1.7	1.2	1.5	-0.045	-0.029
Mean number of non-acute institutional encounters*	0.6	1.0	0.6	0.9	0.025	0.027
Mean number of other ambulatory encounters*	20.4	27.6	22.6	28.3	-2.287	-0.082
Mean number of filled prescriptions*	48.5	33.1	49.3	31.3	-0.818	-0.025
Mean number of generics dispensed*	17.2	7.8	17.2	7.3	0.009	0.001
Mean number of unique drug classes dispensed*	15.0	6.5	14.9	6.5	0.034	0.005

Table 1aq. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	DPP-4 Inhibitors	

^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1ar. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	393,016	N/A	677,738	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	62.2	9.7	63.6	10.6	-1.364	-0.134
Age						
18-24 years	1,478	0.4%	3,494	0.5%	-0.139	-0.021
25-44 years	39,829	10.1%	68,426	10.1%	0.038	0.001
45-64 years	159,977	40.7%	245,993	36.3%	4.409	0.109
65-79 years	170,484	43.4%	293,946	43.4%	0.007	0.000
≥ 80 years	21,248	5.4%	65,880	9.7%	-4.314	-0.168
Sex*						
Female	187,007	47.6%	327,206	48.3%	-0.697	-0.014
Male	206,010	52.4%	350,532	51.7%	0.697	0.014
Race[4]						
American Indian or Alaska Native	2,433	0.6%	5,504	0.8%	-0.193	-0.023
Asian	9,111	2.3%	43,549	6.4%	-4.107	-0.205
Black or African American	38,089	9.7%	92,191	13.6%	-3.911	-0.125
Multi-racial	2,294	0.6%	2,562	0.4%	0.206	0.030
Native Hawaiian or Other Pacific Islander	1,533	0.4%	3,314	0.5%	-0.099	-0.015
Unknown	171,770	43.7%	258,018	38.1%	5.635	0.169
White	167,786	42.7%	272,601	40.2%	2.470	0.062
Hispanic origin						

Table 1ar. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Yes	19,295	4.9%	73,448	10.8%	-5.928	-0.236
No	194,140	49.4%	388,209	57.3%	-7.883	-0.260
Unknown	179,581	45.7%	216,082	31.9%	13.810	0.576
Year*						
2015	11,979	3.0%	23,171	3.4%	-0.371	-0.021
2016	53,173	13.5%	104,946	15.5%	-1.955	-0.056
2017	54,023	13.7%	109,456	16.2%	-2.404	-0.068
2018	51,811	13.2%	101,825	15.0%	-1.841	-0.053
2019	52,049	13.2%	100,040	14.8%	-1.517	-0.044
2020	48,559	12.4%	91,358	13.5%	-1.124	-0.034
2021	42,599	10.8%	60,366	8.9%	1.932	0.066
2022	45,887	11.7%	54,222	8.0%	3.675	0.125
2023	32,937	8.4%	32,355	4.8%	3.607	0.147
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.2	1.5	1.2	1.5	-0.030	-0.020
Combined comorbidity score*,[6]	1.1	1.8	1.1	1.9	-0.036	-0.020
Medical History						
Obesity*	127,185	32.4%	177,771	26.2%	6.131	0.136
Weight Reduction Surgery or Procedure*	54	0.0%	111	0.0%	-0.003	-0.002
Lifestyle intervention*	65,536	16.7%	96,128	14.2%	2.491	0.070
Cardiovascular Disease*	57,905	14.7%	102,560	15.1%	-0.399	-0.011
Cognitive Impairment*	540	0.1%	1,068	0.2%	-0.020	-0.005
Traumatic Brain Injury*	57	0.0%	106	0.0%	-0.001	-0.001

Table 1ar. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Migraine*	4,470	1.1%	6,562	1.0%	0.169	0.017
Epilepsy*	1,253	0.3%	2,171	0.3%	-0.001	-0.000
Chronic Pain*	42,899	10.9%	67,608	10.0%	0.940	0.031
Psychiatric History						
Previous Intentional Self-Harm Ever	254	0.1%	394	0.1%	0.006	0.003
Psychiatric History Overall*	0	0.0%	0	0.0%	NaN	NaN
Psychiatric Drug Dispensings	0	0.0%	0	0.0%	NaN	NaN
Intentional Self-Harm Encounter	0	0.0%	0	0.0%	NaN	NaN
Any Other Psychiatric Event	0	0.0%	0	0.0%	NaN	NaN
Attention-Deficit/Hyperactivity Disorder	0	0.0%	0	0.0%	NaN	NaN
Akathisia	0	0.0%	0	0.0%	NaN	NaN
Anxiety	0	0.0%	0	0.0%	NaN	NaN
Behavioral Disorder	0	0.0%	0	0.0%	NaN	NaN
Bipolar Disorder	0	0.0%	0	0.0%	NaN	NaN
Cerebral Degenerations usually Manifested in Childhood	0	0.0%	0	0.0%	NaN	NaN
Conduct Disorder	0	0.0%	0	0.0%	NaN	NaN
Delirium	0	0.0%	0	0.0%	NaN	NaN
Depression	0	0.0%	0	0.0%	NaN	NaN
Electroconvulsive Therapy	0	0.0%	0	0.0%	NaN	NaN
Hallucination	0	0.0%	0	0.0%	NaN	NaN
Obsessive-Compulsive Disorder	0	0.0%	0	0.0%	NaN	NaN
Other Cerebral Degenerations	0	0.0%	0	0.0%	NaN	NaN
Other Mental Disorders	0	0.0%	0	0.0%	NaN	NaN

Table 1ar. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Other Psychological Disorders	0	0.0%	0	0.0%	NaN	NaN
Persistent Mental Disorders due to Conditions Classified Elsewhere	0	0.0%	0	0.0%	NaN	NaN
Personality Disorders	0	0.0%	0	0.0%	NaN	NaN
Pervasive Developmental Disorders	0	0.0%	0	0.0%	NaN	NaN
Post-Traumatic Stress Disorder	0	0.0%	0	0.0%	NaN	NaN
Psychotherapy	0	0.0%	0	0.0%	NaN	NaN
Psychotic Conditions	0	0.0%	0	0.0%	NaN	NaN
Schizophrenia	0	0.0%	0	0.0%	NaN	NaN
Sleep Disorder	0	0.0%	0	0.0%	NaN	NaN
Substance Abuse	0	0.0%	0	0.0%	NaN	NaN
Suicidal Behavior	0	0.0%	0	0.0%	NaN	NaN
Transcranial Magnetic Stimulation	0	0.0%	0	0.0%	NaN	NaN
Vagus Nerve Stimulation	0	0.0%	0	0.0%	NaN	NaN
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	5,684	1.4%	0	0.0%	NaN	NaN
dulaglutide	139,509	35.5%	0	0.0%	NaN	NaN
exenatide	37,141	9.5%	0	0.0%	NaN	NaN
liraglutide	97,356	24.8%	0	0.0%	NaN	NaN
lixisenatide	4,485	1.1%	0	0.0%	NaN	NaN
semaglutide	104,185	26.5%	0	0.0%	NaN	NaN
tirzepatide	5,783	1.5%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	393,015	100.0%	677,738	100.0%	-0.000	-0.003
insulin*	128,522	32.7%	208,253	30.7%	1.974	0.043

Table 1ar. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
metformin*	348,829	88.8%	598,847	88.4%	0.397	0.013
alpha-glucosidase inhibitors*	2,107	0.5%	3,982	0.6%	-0.051	-0.007
thiazolidinediones*	32,390	8.2%	55,387	8.2%	0.069	0.003
meglitinides*	5,547	1.4%	10,314	1.5%	-0.111	-0.009
amylin analogue*	11	0.0%	25	0.0%	-0.001	-0.001
sulfonylureas*	161,735	41.2%	301,892	44.5%	-3.392	-0.069
bile acid sequestrants*	1,640	0.4%	2,246	0.3%	0.086	0.014
Other Weight Loss Agents*	596	0.2%	516	0.1%	0.076	0.022
benzphetamine	0	0.0%	*****	*****	*****	*****
bupropion	0	0.0%	0	0.0%	NaN	NaN
diethylpropion	16	0.0%	13	0.0%	0.002	0.004
lorcaserin	33	0.0%	35	0.0%	0.003	0.004
phentermine	494	0.1%	423	0.1%	0.063	0.021
phentermine-topiramate	38	0.0%	26	0.0%	0.006	0.007
phendimetrazine	17	0.0%	*****	*****	*****	*****
orlistat	*****	*****	16	0.0%	*****	*****
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	64,264	16.4%	104,751	15.5%	0.895	0.025
Antipsychotics	0	0.0%	0	0.0%	NaN	NaN
Anxiolytics/Hypnotics	0	0.0%	0	0.0%	NaN	NaN
Lithium & Other Mood Stabilizers	0	0.0%	0	0.0%	NaN	NaN
Antidepressants	143	0.0%	247	0.0%	-0.000	-0.000
Health Service Utilization Intensity Metrics						

Table 1ar. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Mean number of ambulatory encounters*	8.2	7.8	8.1	9.9	0.020	0.002
Mean number of emergency room encounters*	0.2	0.7	0.2	0.6	0.007	0.010
Mean number of inpatient hospital encounters*	0.1	0.3	0.1	0.3	0.003	0.010
Mean number of non-acute institutional encounters*	0.0	0.1	0.0	0.1	-0.001	-0.005
Mean number of other ambulatory encounters*	2.2	7.4	2.5	8.5	-0.319	-0.040
Mean number of filled prescriptions*	18.9	12.7	19.1	13.7	-0.104	-0.008
Mean number of generics dispensed*	8.7	3.9	8.6	3.9	0.139	0.036
Mean number of unique drug classes dispensed*	7.3	3.2	7.2	3.6	0.110	0.032

Table 1ar. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	DPP-4 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1as. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	683,663	N/A	734,504	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.7	10.6	63.2	11.8	-1.507	-0.135
Age						
18-24 years	2,349	0.3%	3,354	0.5%	-0.113	-0.018
25-44 years	70,532	10.3%	76,059	10.4%	-0.038	-0.001
45-64 years	299,018	43.7%	287,493	39.1%	4.597	0.102
65-79 years	276,400	40.4%	293,334	39.9%	0.493	0.011
≥ 80 years	35,364	5.2%	74,264	10.1%	-4.938	-0.190
Sex*						
Female	394,842	57.8%	426,470	58.1%	-0.308	-0.006
Male	288,820	42.2%	308,034	41.9%	0.308	0.006
Race[4]						
American Indian or Alaska Native	4,748	0.7%	6,835	0.9%	-0.236	-0.026
Asian	7,103	1.0%	19,331	2.6%	-1.593	-0.119
Black or African American	62,106	9.1%	95,382	13.0%	-3.902	-0.127
Multi-racial	3,089	0.5%	1,781	0.2%	0.209	0.036
Native Hawaiian or Other Pacific Islander	1,387	0.2%	1,764	0.2%	-0.037	-0.008
Unknown	225,024	32.9%	185,053	25.2%	7.720	0.262
White	380,204	55.6%	424,358	57.8%	-2.162	-0.054
Hispanic origin						

Table 1as. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Yes	26,707	3.9%	53,277	7.3%	-3.347	-0.151
No	415,655	60.8%	521,372	71.0%	-10.185	-0.372
Unknown	241,301	35.3%	159,855	21.8%	13.532	0.665
Year*						
2015	17,964	2.6%	22,864	3.1%	-0.485	-0.029
2016	80,535	11.8%	101,446	13.8%	-2.032	-0.061
2017	85,987	12.6%	107,811	14.7%	-2.101	-0.062
2018	86,134	12.6%	104,601	14.2%	-1.642	-0.048
2019	90,814	13.3%	107,571	14.6%	-1.362	-0.039
2020	88,074	12.9%	101,023	13.8%	-0.871	-0.026
2021	80,745	11.8%	75,935	10.3%	1.472	0.048
2022	87,330	12.8%	70,013	9.5%	3.242	0.105
2023	66,080	9.7%	43,239	5.9%	3.779	0.143
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.7	1.9	1.8	1.9	-0.134	-0.071
Combined comorbidity score*,[6]	2.3	2.6	2.5	2.7	-0.192	-0.073
Medical History						
Obesity*	310,214	45.4%	292,843	39.9%	5.506	0.113
Weight Reduction Surgery or Procedure*	988	0.1%	1,177	0.2%	-0.016	-0.004
Lifestyle intervention*	118,743	17.4%	109,004	14.8%	2.528	0.070
Cardiovascular Disease*	161,060	23.6%	188,734	25.7%	-2.137	-0.051
Cognitive Impairment*	35,945	5.3%	48,152	6.6%	-1.298	-0.056
Traumatic Brain Injury*	2,604	0.4%	3,002	0.4%	-0.028	-0.004

Table 1as. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Migraine*	35,528	5.2%	35,232	4.8%	0.400	0.018
Epilepsy*	14,581	2.1%	17,101	2.3%	-0.195	-0.013
Chronic Pain*	179,276	26.2%	188,673	25.7%	0.536	0.012
Psychiatric History						
Previous Intentional Self-Harm Ever	7,741	1.1%	9,623	1.3%	-0.178	-0.016
Psychiatric History Overall*	683,663	100.0%	734,504	100.0%	0.000	NaN
Psychiatric Drug Dispensings	503,198	73.6%	550,816	75.0%	-1.388	-0.032
Intentional Self-Harm Encounter	1,312	0.2%	1,466	0.2%	-0.008	-0.002
Any Other Psychiatric Event	554,956	81.2%	586,086	79.8%	1.380	0.035
Attention-Deficit/Hyperactivity Disorder	11,358	1.7%	8,359	1.1%	0.523	0.045
Akathisia	1,190	0.2%	1,501	0.2%	-0.030	-0.007
Anxiety	179,196	26.2%	191,046	26.0%	0.201	0.005
Behavioral Disorder	45,334	6.6%	48,553	6.6%	0.021	0.001
Bipolar Disorder	41,996	6.1%	51,730	7.0%	-0.900	-0.036
Cerebral Degenerations usually Manifested in Childhood	11,677	1.7%	16,965	2.3%	-0.602	-0.043
Conduct Disorder	905	0.1%	1,403	0.2%	-0.059	-0.015
Delirium	20,123	2.9%	27,282	3.7%	-0.771	-0.043
Depression	203,464	29.8%	211,043	28.7%	1.028	0.023
Electroconvulsive Therapy	206	0.0%	293	0.0%	-0.010	-0.005
Hallucination	2,658	0.4%	3,650	0.5%	-0.108	-0.016
Obsessive-Compulsive Disorder	1,880	0.3%	2,063	0.3%	-0.006	-0.001
Other Cerebral Degenerations	19,623	2.9%	28,195	3.8%	-0.968	-0.054

Table 1as. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Other Mental Disorders	9,663	1.4%	12,294	1.7%	-0.260	-0.021
Other Psychological Disorders	96,995	14.2%	121,814	16.6%	-2.397	-0.067
Persistent Mental Disorders due to Conditions Classified Elsewhere	26,254	3.8%	36,861	5.0%	-1.178	-0.058
Personality Disorders	4,494	0.7%	5,094	0.7%	-0.036	-0.004
Pervasive Developmental Disorders	1,351	0.2%	2,519	0.3%	-0.145	-0.028
Post-Traumatic Stress Disorder	18,416	2.7%	20,117	2.7%	-0.045	-0.003
Psychotherapy	59,712	8.7%	65,920	9.0%	-0.241	-0.009
Psychotic Conditions	5,325	0.8%	9,081	1.2%	-0.458	-0.046
Schizophrenia	17,103	2.5%	32,675	4.4%	-1.947	-0.107
Sleep Disorder	277,863	40.6%	237,796	32.4%	8.268	0.174
Substance Abuse	47,829	7.0%	59,068	8.0%	-1.046	-0.040
Suicidal Behavior	6,198	0.9%	6,961	0.9%	-0.041	-0.004
Transcranial Magnetic Stimulation	176	0.0%	127	0.0%	0.008	0.006
Vagus Nerve Stimulation	906	0.1%	807	0.1%	0.023	0.007
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	7,364	1.1%	0	0.0%	NaN	NaN
dulaglutide	229,670	33.6%	0	0.0%	NaN	NaN
exenatide	63,658	9.3%	0	0.0%	NaN	NaN
liraglutide	175,263	25.6%	0	0.0%	NaN	NaN
lixisenatide	6,579	1.0%	0	0.0%	NaN	NaN
semaglutide	189,639	27.7%	0	0.0%	NaN	NaN
tirzepatide	12,352	1.8%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	683,662	100.0%	734,504	100.0%	-0.000	-0.001

Table 1as. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
insulin*	223,323	32.7%	255,240	34.7%	-2.084	-0.044
metformin*	596,669	87.3%	634,244	86.3%	0.925	0.027
alpha-glucosidase inhibitors*	2,868	0.4%	3,408	0.5%	-0.044	-0.007
thiazolidinediones*	49,859	7.3%	54,098	7.4%	-0.072	-0.003
meglitinides*	8,227	1.2%	10,306	1.4%	-0.200	-0.018
amylin analogue*	83	0.0%	103	0.0%	-0.002	-0.002
sulfonylureas*	260,126	38.0%	300,409	40.9%	-2.851	-0.059
bile acid sequestrants*	3,485	0.5%	3,569	0.5%	0.024	0.003
Other Weight Loss Agents*	2,118	0.3%	1,120	0.2%	0.157	0.033
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	332	0.0%	204	0.0%	0.021	0.011
diethylpropion	43	0.0%	24	0.0%	0.003	0.004
lorcaserin	104	0.0%	79	0.0%	0.004	0.004
phentermine	1,540	0.2%	731	0.1%	0.126	0.031
phentermine-topiramate	97	0.0%	33	0.0%	0.010	0.010
phendimetrazine	34	0.0%	29	0.0%	0.001	0.002
orlistat	34	0.0%	47	0.0%	-0.001	-0.002
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	230,959	33.8%	252,219	34.3%	-0.556	-0.012
Antipsychotics	70,190	10.3%	105,157	14.3%	-4.050	-0.124
Anxiolytics/Hypnotics	208,094	30.4%	245,076	33.4%	-2.928	-0.063
Lithium & Other Mood Stabilizers	61,157	8.9%	82,524	11.2%	-2.290	-0.076
Antidepressants	409,224	59.9%	430,915	58.7%	1.190	0.024

Table 1as. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	12.9	11.5	13.3	13.8	-0.439	-0.035
Mean number of emergency room encounters*	0.6	1.5	0.6	1.3	-0.005	-0.004
Mean number of inpatient hospital encounters*	0.2	0.6	0.2	0.6	-0.025	-0.040
Mean number of non-acute institutional encounters*	0.1	0.4	0.1	0.4	-0.013	-0.036
Mean number of other ambulatory encounters*	6.0	15.1	7.0	16.8	-1.068	-0.067
Mean number of filled prescriptions*	32.2	23.9	33.3	23.8	-1.110	-0.047
Mean number of generics dispensed*	12.8	5.8	12.9	5.5	-0.169	-0.030
Mean number of unique drug classes dispensed*	11.2	4.9	11.3	5.1	-0.121	-0.024

Table 1as. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	DPP-4 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1at. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	1,033,798	N/A	1,338,423	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.8	10.3	63.5	11.3	-1.734	-0.161
Age						
18-24 years	3,832	0.4%	6,233	0.5%	-0.095	-0.015
25-44 years	107,461	10.4%	134,480	10.0%	0.347	0.012
45-64 years	439,160	42.5%	505,469	37.8%	4.714	0.109
65-79 years	431,635	41.8%	555,604	41.5%	0.241	0.006
≥ 80 years	51,709	5.0%	136,636	10.2%	-5.207	-0.202
Sex*						
Female	555,211	53.7%	718,156	53.7%	0.049	0.001
Male	478,587	46.3%	620,267	46.3%	-0.049	-0.001
Race[4]						
American Indian or Alaska Native	6,960	0.7%	11,750	0.9%	-0.205	-0.023
Asian	16,107	1.6%	58,769	4.4%	-2.833	-0.169
Black or African American	96,579	9.3%	175,865	13.1%	-3.798	-0.123
Multi-racial	5,237	0.5%	3,924	0.3%	0.213	0.035
Native Hawaiian or Other Pacific Islander	2,943	0.3%	4,731	0.4%	-0.069	-0.012
Unknown	382,903	37.0%	407,297	30.4%	6.607	0.210
White	523,068	50.6%	676,087	50.5%	0.083	0.002
Hispanic origin						

Table 1at. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Yes	45,007	4.4%	119,597	8.9%	-4.582	-0.194
No	584,213	56.5%	876,209	65.5%	-8.954	-0.309
Unknown	404,578	39.1%	342,616	25.6%	13.537	0.611
Year*						
2015	27,527	2.7%	44,984	3.4%	-0.698	-0.041
2016	124,129	12.0%	201,880	15.1%	-3.076	-0.090
2017	131,700	12.7%	212,048	15.8%	-3.104	-0.089
2018	131,233	12.7%	199,932	14.9%	-2.244	-0.065
2019	137,450	13.3%	198,646	14.8%	-1.546	-0.045
2020	132,861	12.9%	182,435	13.6%	-0.779	-0.023
2021	120,613	11.7%	125,176	9.4%	2.314	0.076
2022	130,699	12.6%	109,612	8.2%	4.453	0.148
2023	97,587	9.4%	63,710	4.8%	4.680	0.185
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.4	1.7	1.5	1.8	-0.106	-0.061
Combined comorbidity score*,[6]	1.7	2.3	1.9	2.5	-0.140	-0.059
Medical History						
Obesity*	418,147	40.4%	438,983	32.8%	7.649	0.161
Weight Reduction Surgery or Procedure*	871	0.1%	1,349	0.1%	-0.017	-0.005
Lifestyle intervention*	177,357	17.2%	192,640	14.4%	2.763	0.077
Cardiovascular Disease*	200,305	19.4%	283,545	21.2%	-1.809	-0.046
Cognitive Impairment*	30,134	2.9%	52,268	3.9%	-0.990	-0.055
Traumatic Brain Injury*	2,348	0.2%	3,225	0.2%	-0.014	-0.003

Table 1at. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Migraine*	36,658	3.5%	41,096	3.1%	0.475	0.027
Epilepsy*	13,855	1.3%	19,687	1.5%	-0.131	-0.011
Chronic Pain*	205,380	19.9%	247,787	18.5%	1.353	0.035
Psychiatric History						
Previous Intentional Self-Harm Ever	7,124	0.7%	10,074	0.8%	-0.064	-0.008
Psychiatric History Overall*	613,455	59.3%	763,565	57.0%	2.290	0.047
Psychiatric Drug Dispensings	450,840	43.6%	571,330	42.7%	0.923	0.019
Intentional Self-Harm Encounter	1,114	0.1%	1,546	0.1%	-0.008	-0.002
Any Other Psychiatric Event	498,052	48.2%	607,618	45.4%	2.779	0.056
Attention-Deficit/Hyperactivity Disorder	10,245	1.0%	8,421	0.6%	0.362	0.040
Akathisia	1,061	0.1%	1,556	0.1%	-0.014	-0.004
Anxiety	160,752	15.5%	195,347	14.6%	0.954	0.027
Behavioral Disorder	40,121	3.9%	50,114	3.7%	0.137	0.007
Bipolar Disorder	37,374	3.6%	52,854	3.9%	-0.334	-0.018
Cerebral Degenerations usually Manifested in Childhood	10,116	1.0%	17,790	1.3%	-0.351	-0.033
Conduct Disorder	791	0.1%	1,444	0.1%	-0.031	-0.010
Delirium	16,814	1.6%	28,695	2.1%	-0.517	-0.038
Depression	181,593	17.6%	218,436	16.3%	1.245	0.033
Electroconvulsive Therapy	178	0.0%	305	0.0%	-0.006	-0.004
Hallucination	2,240	0.2%	3,802	0.3%	-0.067	-0.013
Obsessive-Compulsive Disorder	1,703	0.2%	2,051	0.2%	0.011	0.003
Other Cerebral Degenerations	16,661	1.6%	29,686	2.2%	-0.606	-0.044

Table 1at. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Other Mental Disorders	8,391	0.8%	12,792	1.0%	-0.144	-0.015
Other Psychological Disorders	86,605	8.4%	125,782	9.4%	-1.020	-0.036
Persistent Mental Disorders due to Conditions Classified Elsewhere	21,515	2.1%	39,333	2.9%	-0.858	-0.055
Personality Disorders	3,962	0.4%	5,108	0.4%	0.002	0.000
Pervasive Developmental Disorders	1,203	0.1%	2,548	0.2%	-0.074	-0.019
Post-Traumatic Stress Disorder	16,532	1.6%	20,331	1.5%	0.080	0.006
Psychotherapy	52,930	5.1%	67,827	5.1%	0.052	0.002
Psychotic Conditions	4,463	0.4%	9,599	0.7%	-0.285	-0.038
Schizophrenia	15,098	1.5%	33,780	2.5%	-1.063	-0.076
Sleep Disorder	251,102	24.3%	244,366	18.3%	6.032	0.149
Substance Abuse	42,644	4.1%	60,903	4.6%	-0.425	-0.021
Suicidal Behavior	5,454	0.5%	7,328	0.5%	-0.020	-0.003
Transcranial Magnetic Stimulation	164	0.0%	124	0.0%	0.007	0.006
Vagus Nerve Stimulation	836	0.1%	829	0.1%	0.019	0.007
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	12,131	1.2%	0	0.0%	NaN	NaN
dulaglutide	354,230	34.3%	0	0.0%	NaN	NaN
exenatide	95,300	9.2%	0	0.0%	NaN	NaN
liraglutide	257,592	24.9%	0	0.0%	NaN	NaN
lixisenatide	10,793	1.0%	0	0.0%	NaN	NaN
semaglutide	287,503	27.8%	0	0.0%	NaN	NaN
tirzepatide	17,747	1.7%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,033,796	100.0%	1,338,423	100.0%	-0.000	-0.002

Table 1at. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
insulin*	328,656	31.8%	403,704	30.2%	1.628	0.035
metformin*	909,513	88.0%	1,166,735	87.2%	0.805	0.025
alpha-glucosidase inhibitors*	4,690	0.5%	6,886	0.5%	-0.061	-0.009
thiazolidinediones*	80,018	7.7%	101,129	7.6%	0.184	0.007
meglitinides*	12,935	1.3%	19,449	1.5%	-0.202	-0.018
amylin analogue*	94	0.0%	105	0.0%	0.001	0.001
sulfonylureas*	406,073	39.3%	573,259	42.8%	-3.551	-0.073
bile acid sequestrants*	4,616	0.4%	5,568	0.4%	0.030	0.005
Other Weight Loss Agents*	2,666	0.3%	1,391	0.1%	0.154	0.036
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	305	0.0%	194	0.0%	0.015	0.010
diethylpropion	59	0.0%	30	0.0%	0.004	0.006
lorcaserin	135	0.0%	96	0.0%	0.006	0.006
phentermine	2,016	0.2%	955	0.1%	0.124	0.034
phentermine-topiramate	133	0.0%	54	0.0%	0.009	0.010
phendimetrazine	49	0.0%	32	0.0%	0.002	0.004
orlistat	39	0.0%	60	0.0%	-0.001	-0.001
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	269,273	26.0%	347,767	26.0%	0.064	0.001
Antipsychotics	62,112	6.0%	108,099	8.1%	-2.068	-0.081
Anxiolytics/Hypnotics	186,080	18.0%	253,416	18.9%	-0.934	-0.024
Lithium & Other Mood Stabilizers	54,419	5.3%	84,962	6.3%	-1.084	-0.046
Antidepressants	366,903	35.5%	446,287	33.3%	2.146	0.045

Table 1at. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	10.8	10.3	11.0	12.4	-0.184	-0.016
Mean number of emergency room encounters*	0.4	1.2	0.4	1.1	-0.010	-0.009
Mean number of inpatient hospital encounters*	0.1	0.5	0.2	0.5	-0.025	-0.049
Mean number of non-acute institutional encounters*	0.0	0.3	0.0	0.3	-0.012	-0.044
Mean number of other ambulatory encounters*	4.3	12.3	5.2	14.3	-0.915	-0.069
Mean number of filled prescriptions*	26.4	20.8	27.1	21.2	-0.644	-0.031
Mean number of generics dispensed*	11.0	5.4	11.0	5.3	-0.018	-0.003
Mean number of unique drug classes dispensed*	9.5	4.7	9.4	4.9	0.114	0.024

Table 1at. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	DPP-4 Inhibitors	

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1au. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	1,032,667	N/A	1,336,948	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.8	10.3	63.5	11.3	-1.736	-0.161
Age						
18-24 years	3,790	0.4%	6,177	0.5%	-0.095	-0.015
25-44 years	107,148	10.4%	134,074	10.0%	0.348	0.012
45-64 years	438,573	42.5%	504,690	37.7%	4.721	0.109
65-79 years	431,468	41.8%	555,408	41.5%	0.239	0.006
≥ 80 years	51,687	5.0%	136,598	10.2%	-5.212	-0.202
Sex*						
Female	554,500	53.7%	717,276	53.7%	0.046	0.001
Male	478,167	46.3%	619,671	46.3%	-0.046	-0.001
Race[4]						
American Indian or Alaska Native	6,938	0.7%	11,726	0.9%	-0.205	-0.023
Asian	16,094	1.6%	58,746	4.4%	-2.835	-0.169
Black or African American	96,477	9.3%	175,655	13.1%	-3.796	-0.123
Multi-racial	5,233	0.5%	3,921	0.3%	0.214	0.035
Native Hawaiian or Other Pacific Islander	2,943	0.3%	4,728	0.4%	-0.069	-0.012
Unknown	382,586	37.0%	407,021	30.4%	6.604	0.210
White	522,395	50.6%	675,152	50.5%	0.088	0.002
Hispanic origin						

Table 1au. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Yes	44,930	4.4%	119,486	8.9%	-4.586	-0.194
No	583,441	56.5%	875,044	65.5%	-8.952	-0.309
Unknown	404,296	39.2%	342,417	25.6%	13.539	0.611
Year*						
2015	27,481	2.7%	44,931	3.4%	-0.700	-0.041
2016	123,971	12.0%	201,654	15.1%	-3.078	-0.090
2017	131,538	12.7%	211,816	15.8%	-3.106	-0.089
2018	131,086	12.7%	199,705	14.9%	-2.243	-0.065
2019	137,273	13.3%	198,411	14.8%	-1.548	-0.045
2020	132,715	12.9%	182,222	13.6%	-0.778	-0.023
2021	120,504	11.7%	125,053	9.4%	2.316	0.076
2022	130,590	12.6%	109,506	8.2%	4.455	0.148
2023	97,510	9.4%	63,650	4.8%	4.682	0.185
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.4	1.7	1.5	1.8	-0.106	-0.061
Combined comorbidity score*,[6]	1.7	2.3	1.9	2.5	-0.140	-0.059
Medical History						
Obesity*	417,523	40.4%	438,195	32.8%	7.656	0.161
Weight Reduction Surgery or Procedure*	865	0.1%	1,343	0.1%	-0.017	-0.006
Lifestyle intervention*	177,089	17.1%	192,315	14.4%	2.764	0.077
Cardiovascular Disease*	200,035	19.4%	283,143	21.2%	-1.808	-0.046
Cognitive Impairment*	30,036	2.9%	52,090	3.9%	-0.988	-0.055
Traumatic Brain Injury*	2,336	0.2%	3,207	0.2%	-0.014	-0.003

Table 1au. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Migraine*	36,480	3.5%	40,878	3.1%	0.475	0.027
Epilepsy*	13,744	1.3%	19,519	1.5%	-0.129	-0.011
Chronic Pain*	204,905	19.8%	247,183	18.5%	1.354	0.035
Psychiatric History						
Previous Intentional Self-Harm Ever	6,013	0.6%	8,521	0.6%	-0.055	-0.007
Psychiatric History Overall*	612,354	59.3%	762,047	57.0%	2.299	0.047
Psychiatric Drug Dispensings	449,807	43.6%	569,907	42.6%	0.930	0.019
Intentional Self-Harm Encounter	0	0.0%	0	0.0%	NaN	NaN
Any Other Psychiatric Event	496,974	48.1%	606,070	45.3%	2.793	0.056
Attention-Deficit/Hyperactivity Disorder	10,152	1.0%	8,355	0.6%	0.358	0.040
Akathisia	1,037	0.1%	1,537	0.1%	-0.015	-0.004
Anxiety	160,008	15.5%	194,348	14.5%	0.958	0.027
Behavioral Disorder	39,117	3.8%	48,706	3.6%	0.145	0.008
Bipolar Disorder	36,852	3.6%	52,115	3.9%	-0.329	-0.017
Cerebral Degenerations usually Manifested in Childhood	10,081	1.0%	17,726	1.3%	-0.350	-0.033
Conduct Disorder	766	0.1%	1,411	0.1%	-0.031	-0.010
Delirium	16,607	1.6%	28,409	2.1%	-0.517	-0.038
Depression	180,707	17.5%	217,203	16.2%	1.253	0.034
Electroconvulsive Therapy	145	0.0%	280	0.0%	-0.007	-0.005
Hallucination	2,140	0.2%	3,678	0.3%	-0.068	-0.014
Obsessive-Compulsive Disorder	1,673	0.2%	2,024	0.2%	0.011	0.003
Other Cerebral Degenerations	16,627	1.6%	29,593	2.2%	-0.603	-0.044
Other Mental Disorders	8,295	0.8%	12,660	0.9%	-0.144	-0.015

Table 1au. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Other Psychological Disorders	86,116	8.3%	125,003	9.3%	-1.011	-0.036
Persistent Mental Disorders due to Conditions Classified Elsewhere	21,469	2.1%	39,221	2.9%	-0.855	-0.055
Personality Disorders	3,702	0.4%	4,840	0.4%	-0.004	-0.001
Pervasive Developmental Disorders	1,181	0.1%	2,505	0.2%	-0.073	-0.019
Post-Traumatic Stress Disorder	16,182	1.6%	20,017	1.5%	0.070	0.006
Psychotherapy	52,420	5.1%	67,172	5.0%	0.052	0.002
Psychotic Conditions	4,261	0.4%	9,253	0.7%	-0.279	-0.038
Schizophrenia	14,838	1.4%	33,340	2.5%	-1.057	-0.076
Sleep Disorder	250,543	24.3%	243,744	18.2%	6.030	0.149
Substance Abuse	42,125	4.1%	60,222	4.5%	-0.425	-0.021
Suicidal Behavior	4,738	0.5%	6,385	0.5%	-0.019	-0.003
Transcranial Magnetic Stimulation	162	0.0%	124	0.0%	0.006	0.006
Vagus Nerve Stimulation	834	0.1%	826	0.1%	0.019	0.007
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	12,119	1.2%	0	0.0%	NaN	NaN
dulaglutide	353,876	34.3%	0	0.0%	NaN	NaN
exenatide	95,140	9.2%	0	0.0%	NaN	NaN
liraglutide	257,244	24.9%	0	0.0%	NaN	NaN
lixisenatide	10,773	1.0%	0	0.0%	NaN	NaN
semaglutide	287,281	27.8%	0	0.0%	NaN	NaN
tirzepatide	17,731	1.7%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,032,665	100.0%	1,336,948	100.0%	-0.000	-0.002
insulin*	328,241	31.8%	403,166	30.2%	1.630	0.035

Table 1au. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
metformin*	908,510	88.0%	1,165,411	87.2%	0.807	0.025
alpha-glucosidase inhibitors*	4,682	0.5%	6,881	0.5%	-0.061	-0.009
thiazolidinediones*	79,935	7.7%	101,048	7.6%	0.183	0.007
meglitinides*	12,927	1.3%	19,438	1.5%	-0.202	-0.018
amylin analogue*	93	0.0%	105	0.0%	0.001	0.001
sulfonylureas*	405,674	39.3%	572,728	42.8%	-3.554	-0.073
bile acid sequestrants*	4,615	0.4%	5,566	0.4%	0.031	0.005
Other Weight Loss Agents*	2,663	0.3%	1,388	0.1%	0.154	0.036
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	305	0.0%	194	0.0%	0.015	0.010
diethylpropion	59	0.0%	30	0.0%	0.004	0.006
lorcaserin	135	0.0%	96	0.0%	0.006	0.006
phentermine	2,014	0.2%	952	0.1%	0.124	0.034
phentermine-topiramate	133	0.0%	54	0.0%	0.009	0.010
phendimetrazine	49	0.0%	32	0.0%	0.002	0.004
orlistat	39	0.0%	60	0.0%	-0.001	-0.001
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	268,803	26.0%	347,124	26.0%	0.066	0.002
Antipsychotics	61,449	6.0%	107,119	8.0%	-2.062	-0.081
Anxiolytics/Hypnotics	185,413	18.0%	252,429	18.9%	-0.926	-0.024
Lithium & Other Mood Stabilizers	53,926	5.2%	84,207	6.3%	-1.076	-0.046
Antidepressants	365,934	35.4%	445,013	33.3%	2.150	0.045
Health Service Utilization Intensity Metrics						

Table 1au. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Mean number of ambulatory encounters*	10.8	10.3	11.0	12.3	-0.183	-0.016
Mean number of emergency room encounters*	0.4	1.2	0.4	1.1	-0.010	-0.009
Mean number of inpatient hospital encounters*	0.1	0.5	0.2	0.5	-0.025	-0.049
Mean number of non-acute institutional encounters*	0.0	0.3	0.0	0.3	-0.012	-0.044
Mean number of other ambulatory encounters*	4.2	12.3	5.2	14.3	-0.912	-0.068
Mean number of filled prescriptions*	26.4	20.8	27.0	21.2	-0.645	-0.031
Mean number of generics dispensed*	11.0	5.4	11.0	5.3	-0.018	-0.003
Mean number of unique drug classes dispensed*	9.5	4.6	9.4	4.9	0.115	0.024

Table 1au. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	DPP-4 Inhibitors	

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1av. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	859	N/A	1,218	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	51.6	13.3	51.2	12.8	0.409	0.031
Age						
18-24 years	33	3.8%	44	3.6%	0.219	0.012
25-44 years	235	27.4%	342	28.1%	-0.663	-0.015
45-64 years	436	50.8%	635	52.2%	-1.374	-0.028
65-79 years	137	16.0%	173	14.2%	1.754	0.052
≥ 80 years	17	2.0%	24	1.9%	0.063	0.005
Sex*						
Female	539	62.8%	746	61.3%	1.470	0.030
Male	320	37.2%	471	38.7%	-1.470	-0.030
Race[4]						
American Indian or Alaska Native	*****	*****	22	1.8%	*****	*****
Asian	*****	*****	*****	*****	*****	*****
Black or African American	92	10.8%	179	14.7%	-3.944	-0.119
Multi-racial	0	0.0%	*****	*****	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%	*****	*****	*****	*****
Unknown	164	19.1%	221	18.2%	0.905	0.028
White	575	67.0%	770	63.2%	3.758	0.086
Hispanic origin						

Table 1av. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Yes	63	7.3%	114	9.4%	-2.028	-0.076
No	695	80.9%	997	81.9%	-0.973	-0.030
Unknown	101	11.7%	107	8.7%	3.001	0.131
Year*						
2015	30	3.5%	40	3.3%	0.157	0.009
2016	121	14.1%	182	14.9%	-0.813	-0.023
2017	134	15.6%	214	17.6%	-1.971	-0.053
2018	122	14.2%	192	15.7%	-1.511	-0.043
2019	134	15.6%	203	16.6%	-1.045	-0.028
2020	126	14.7%	178	14.7%	0.065	0.002
2021	79	9.2%	92	7.6%	1.622	0.060
2022	70	8.1%	75	6.1%	2.011	0.080
2023	42	4.9%	42	3.4%	1.484	0.076
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.9	1.9	1.9	2.0	0.008	0.004
Combined comorbidity score*,[6]	4.0	2.7	4.0	2.7	0.025	0.010
Medical History						
Obesity*	460	53.5%	623	51.2%	2.338	0.048
Weight Reduction Surgery or Procedure*	*****	*****	*****	*****	*****	*****
Lifestyle intervention*	192	22.3%	275	22.6%	-0.266	-0.007
Cardiovascular Disease*	229	26.7%	306	25.1%	1.509	0.035
Cognitive Impairment*	90	10.4%	132	10.8%	-0.415	-0.014
Traumatic Brain Injury*	*****	*****	*****	*****	*****	*****

Table 1av. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Migraine*	128	14.9%	168	13.8%	1.126	0.032
Epilepsy*	*****	*****	121	9.9%	*****	*****
Chronic Pain*	349	40.7%	473	38.8%	1.813	0.038
Psychiatric History						
Previous Intentional Self-Harm Ever	859	100.0%	1,218	100.0%	0.000	NaN
Psychiatric History Overall*	859	100.0%	1,218	100.0%	0.000	NaN
Psychiatric Drug Dispensings	802	93.4%	1,144	94.0%	-0.599	-0.025
Intentional Self-Harm Encounter	859	100.0%	1,218	100.0%	0.000	NaN
Any Other Psychiatric Event	859	100.0%	1,218	100.0%	0.000	NaN
Attention-Deficit/Hyperactivity Disorder	64	7.5%	49	4.0%	3.478	0.150
Akathisia	19	2.2%	*****	*****	*****	*****
Anxiety	559	65.0%	782	64.2%	0.823	0.017
Behavioral Disorder	768	89.3%	1,094	89.8%	-0.460	-0.015
Bipolar Disorder	383	44.6%	596	48.9%	-4.328	-0.087
Cerebral Degenerations usually Manifested in Childhood	33	3.8%	37	3.1%	0.773	0.042
Conduct Disorder	22	2.6%	28	2.3%	0.281	0.018
Delirium	157	18.3%	197	16.2%	2.160	0.058
Depression	691	80.5%	970	79.6%	0.814	0.020
Electroconvulsive Therapy	27	3.1%	20	1.7%	1.470	0.096
Hallucination	70	8.1%	95	7.8%	0.295	0.011
Obsessive-Compulsive Disorder	18	2.1%	20	1.7%	0.414	0.031
Other Cerebral Degenerations	27	3.2%	61	5.0%	-1.814	-0.093
Other Mental Disorders	68	8.0%	106	8.7%	-0.709	-0.026

Table 1av. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Other Psychological Disorders	388	45.2%	598	49.1%	-3.882	-0.079
Persistent Mental Disorders due to Conditions Classified Elsewhere	41	4.8%	79	6.5%	-1.689	-0.074
Personality Disorders	194	22.6%	227	18.7%	3.957	0.099
Pervasive Developmental Disorders	*****	*****	38	3.1%	*****	*****
Post-Traumatic Stress Disorder	246	28.6%	267	21.9%	6.714	0.156
Psychotherapy	355	41.3%	513	42.1%	-0.831	-0.017
Psychotic Conditions	136	15.9%	271	22.3%	-6.400	-0.164
Schizophrenia	193	22.4%	368	30.2%	-7.784	-0.180
Sleep Disorder	416	48.5%	473	38.8%	9.649	0.202
Substance Abuse	397	46.2%	529	43.4%	2.784	0.056
Suicidal Behavior	526	61.2%	751	61.7%	-0.414	-0.009
Transcranial Magnetic Stimulation	*****	*****	0	0.0%	*****	*****
Vagus Nerve Stimulation	*****	*****	*****	*****	*****	*****
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	*****	*****	0	0.0%	NaN	NaN
dulaglutide	264	30.8%	0	0.0%	NaN	NaN
exenatide	123	14.3%	0	0.0%	NaN	NaN
liraglutide	300	34.9%	0	0.0%	NaN	NaN
lixisenatide	*****	*****	0	0.0%	*****	*****
semaglutide	152	17.7%	0	0.0%	NaN	NaN
tirzepatide	*****	*****	0	0.0%	*****	*****
Any Anti-Diabetic Agents	859	100.0%	1,218	100.0%	0.000	NaN
insulin*	341	39.7%	477	39.2%	0.477	0.010

Table 1av. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
metformin*	769	89.4%	1,099	90.2%	-0.768	-0.025
alpha-glucosidase inhibitors*	*****	*****	*****	*****	*****	*****
thiazolidinediones*	48	5.6%	66	5.4%	0.197	0.009
meglitinides*	*****	*****	*****	*****	*****	*****
amylin analogue*	0	0.0%	0	0.0%	NaN	NaN
sulfonylureas*	292	33.9%	425	34.9%	-0.992	-0.021
bile acid sequestrants*	0	0.0%	0	0.0%	NaN	NaN
Other Weight Loss Agents*	0	0.0%	0	0.0%	NaN	NaN
benzphetamine	0	0.0%	0	0.0%	NaN	NaN
bupropion	0	0.0%	0	0.0%	NaN	NaN
diethylpropion	0	0.0%	0	0.0%	NaN	NaN
lorcaserin	0	0.0%	0	0.0%	NaN	NaN
phentermine	0	0.0%	0	0.0%	NaN	NaN
phentermine-topiramate	0	0.0%	0	0.0%	NaN	NaN
phendimetrazine	0	0.0%	0	0.0%	NaN	NaN
orlistat	0	0.0%	0	0.0%	NaN	NaN
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	358	41.7%	495	40.7%	0.990	0.020
Antipsychotics	499	58.1%	776	63.7%	-5.589	-0.116
Anxiolytics/Hypnotics	495	57.6%	769	63.1%	-5.469	-0.112
Lithium & Other Mood Stabilizers	361	42.1%	599	49.2%	-7.129	-0.145
Antidepressants	739	86.0%	1,026	84.2%	1.761	0.049
Health Service Utilization Intensity Metrics						

Table 1av. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Mean number of ambulatory encounters*	24.4	18.7	24.3	22.6	0.059	0.003
Mean number of emergency room encounters*	3.1	4.6	3.1	4.9	-0.005	-0.001
Mean number of inpatient hospital encounters*	1.2	1.6	1.2	1.5	-0.076	-0.050
Mean number of non-acute institutional encounters*	0.6	1.0	0.6	0.9	-0.006	-0.007
Mean number of other ambulatory encounters*	20.1	27.6	22.8	28.3	-2.682	-0.096
Mean number of filled prescriptions*	48.5	33.0	49.1	31.4	-0.573	-0.018
Mean number of generics dispensed*	17.2	7.8	17.2	7.3	0.026	0.003
Mean number of unique drug classes dispensed*	15.0	6.5	14.9	6.5	0.095	0.015

Table 1av. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter^

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	DPP-4 Inhibitors	

^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1aw. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	372,672	N/A	641,017	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	62.0	9.7	63.8	10.5	-1.741	-0.172
Age						
18-24 years	1,488	0.4%	3,158	0.5%	-0.093	-0.014
25-44 years	38,836	10.4%	63,103	9.8%	0.577	0.020
45-64 years	151,965	40.8%	231,152	36.1%	4.717	0.117
65-79 years	161,057	43.2%	279,504	43.6%	-0.386	-0.010
≥ 80 years	19,326	5.2%	64,100	10.0%	-4.814	-0.188
Sex*						
Female	177,680	47.7%	308,694	48.2%	-0.479	-0.010
Male	194,991	52.3%	332,323	51.8%	0.479	0.010
Race[4]						
American Indian or Alaska Native	2,357	0.6%	5,212	0.8%	-0.181	-0.021
Asian	8,563	2.3%	42,297	6.6%	-4.301	-0.213
Black or African American	36,013	9.7%	86,552	13.5%	-3.839	-0.123
Multi-racial	2,214	0.6%	2,280	0.4%	0.238	0.035
Native Hawaiian or Other Pacific Islander	1,456	0.4%	3,213	0.5%	-0.111	-0.017
Unknown	163,063	43.8%	239,890	37.4%	6.332	0.189
White	159,006	42.7%	261,572	40.8%	1.861	0.047
Hispanic origin						

Table 1aw. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Yes	18,443	4.9%	70,504	11.0%	-6.050	-0.239
No	183,977	49.4%	372,521	58.1%	-8.747	-0.287
Unknown	170,251	45.7%	197,991	30.9%	14.797	0.613
Year*						
2015	10,720	2.9%	22,696	3.5%	-0.664	-0.038
2016	47,825	12.8%	103,131	16.1%	-3.256	-0.093
2017	49,571	13.3%	106,951	16.7%	-3.383	-0.095
2018	48,500	13.0%	98,465	15.4%	-2.347	-0.068
2019	49,567	13.3%	95,080	14.8%	-1.532	-0.044
2020	47,019	12.6%	85,798	13.4%	-0.768	-0.023
2021	41,639	11.2%	54,557	8.5%	2.662	0.091
2022	45,128	12.1%	47,256	7.4%	4.737	0.162
2023	32,702	8.8%	27,083	4.2%	4.550	0.187
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.1	1.5	1.2	1.5	-0.057	-0.038
Combined comorbidity score*,[6]	1.0	1.7	1.1	1.9	-0.065	-0.036
Medical History						
Obesity*	122,115	32.8%	160,934	25.1%	7.661	0.171
Weight Reduction Surgery or Procedure*	44	0.0%	104	0.0%	-0.004	-0.004
Lifestyle intervention*	62,675	16.8%	89,917	14.0%	2.791	0.079
Cardiovascular Disease*	52,538	14.1%	96,788	15.1%	-1.002	-0.029
Cognitive Impairment*	474	0.1%	1,008	0.2%	-0.030	-0.008
Traumatic Brain Injury*	54	0.0%	106	0.0%	-0.002	-0.002

Table 1aw. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Migraine*	4,218	1.1%	6,105	1.0%	0.180	0.018
Epilepsy*	1,112	0.3%	2,045	0.3%	-0.021	-0.004
Chronic Pain*	39,818	10.7%	62,436	9.7%	0.944	0.031
Psychiatric History						
Previous Intentional Self-Harm Ever	239	0.1%	367	0.1%	0.007	0.003
Psychiatric History Overall*	0	0.0%	0	0.0%	NaN	NaN
Psychiatric Drug Dispensings	0	0.0%	0	0.0%	NaN	NaN
Intentional Self-Harm Encounter	0	0.0%	0	0.0%	NaN	NaN
Any Other Psychiatric Event	0	0.0%	0	0.0%	NaN	NaN
Attention-Deficit/Hyperactivity Disorder	0	0.0%	0	0.0%	NaN	NaN
Akathisia	0	0.0%	0	0.0%	NaN	NaN
Anxiety	0	0.0%	0	0.0%	NaN	NaN
Behavioral Disorder	0	0.0%	0	0.0%	NaN	NaN
Bipolar Disorder	0	0.0%	0	0.0%	NaN	NaN
Cerebral Degenerations usually Manifested in Childhood	0	0.0%	0	0.0%	NaN	NaN
Conduct Disorder	0	0.0%	0	0.0%	NaN	NaN
Delirium	0	0.0%	0	0.0%	NaN	NaN
Depression	0	0.0%	0	0.0%	NaN	NaN
Electroconvulsive Therapy	0	0.0%	0	0.0%	NaN	NaN
Hallucination	0	0.0%	0	0.0%	NaN	NaN
Obsessive-Compulsive Disorder	0	0.0%	0	0.0%	NaN	NaN
Other Cerebral Degenerations	0	0.0%	0	0.0%	NaN	NaN

Table 1aw. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Other Mental Disorders	0	0.0%	0	0.0%	NaN	NaN
Other Psychological Disorders	0	0.0%	0	0.0%	NaN	NaN
Persistent Mental Disorders due to Conditions Classified Elsewhere	0	0.0%	0	0.0%	NaN	NaN
Personality Disorders	0	0.0%	0	0.0%	NaN	NaN
Pervasive Developmental Disorders	0	0.0%	0	0.0%	NaN	NaN
Post-Traumatic Stress Disorder	0	0.0%	0	0.0%	NaN	NaN
Psychotherapy	0	0.0%	0	0.0%	NaN	NaN
Psychotic Conditions	0	0.0%	0	0.0%	NaN	NaN
Schizophrenia	0	0.0%	0	0.0%	NaN	NaN
Sleep Disorder	0	0.0%	0	0.0%	NaN	NaN
Substance Abuse	0	0.0%	0	0.0%	NaN	NaN
Suicidal Behavior	0	0.0%	0	0.0%	NaN	NaN
Transcranial Magnetic Stimulation	0	0.0%	0	0.0%	NaN	NaN
Vagus Nerve Stimulation	0	0.0%	0	0.0%	NaN	NaN
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	5,126	1.4%	0	0.0%	NaN	NaN
dulaglutide	131,943	35.4%	0	0.0%	NaN	NaN
exenatide	34,377	9.2%	0	0.0%	NaN	NaN
liraglutide	90,346	24.2%	0	0.0%	NaN	NaN
lixisenatide	4,379	1.2%	0	0.0%	NaN	NaN
semaglutide	101,598	27.3%	0	0.0%	NaN	NaN
tirzepatide	5,704	1.5%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	372,670	100.0%	641,017	100.0%	-0.000	-0.003

Table 1aw. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
insulin*	119,370	32.0%	176,248	27.5%	4.536	0.100
metformin*	331,301	88.9%	566,378	88.4%	0.543	0.017
alpha-glucosidase inhibitors*	1,940	0.5%	3,745	0.6%	-0.064	-0.009
thiazolidinediones*	30,945	8.3%	51,150	8.0%	0.324	0.012
meglitinides*	5,095	1.4%	9,685	1.5%	-0.144	-0.012
amylin analogue*	11	0.0%	19	0.0%	0.000	0.000
sulfonylureas*	152,757	41.0%	287,552	44.9%	-3.869	-0.079
bile acid sequestrants*	1,406	0.4%	2,120	0.3%	0.046	0.008
Other Weight Loss Agents*	598	0.2%	408	0.1%	0.097	0.029
benzphetamine	0	0.0%	*****	*****	*****	*****
bupropion	0	0.0%	0	0.0%	NaN	NaN
diethylpropion	16	0.0%	*****	*****	*****	*****
lorcaserin	34	0.0%	25	0.0%	0.005	0.006
phentermine	495	0.1%	334	0.1%	0.081	0.027
phentermine-topiramate	38	0.0%	20	0.0%	0.007	0.009
phendimetrazine	17	0.0%	*****	*****	*****	*****
orlistat	*****	*****	16	0.0%	*****	*****
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	57,803	15.5%	97,655	15.2%	0.276	0.008
Antipsychotics	0	0.0%	0	0.0%	NaN	NaN
Anxiolytics/Hypnotics	0	0.0%	0	0.0%	NaN	NaN
Lithium & Other Mood Stabilizers	0	0.0%	0	0.0%	NaN	NaN
Antidepressants	124	0.0%	238	0.0%	-0.004	-0.002

Table 1aw. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	8.0	7.6	8.0	9.6	-0.067	-0.008
Mean number of emergency room encounters*	0.2	0.6	0.2	0.6	-0.005	-0.008
Mean number of inpatient hospital encounters*	0.1	0.3	0.1	0.3	-0.006	-0.021
Mean number of non-acute institutional encounters*	0.0	0.1	0.0	0.1	-0.002	-0.021
Mean number of other ambulatory encounters*	2.1	7.2	2.6	8.6	-0.413	-0.052
Mean number of filled prescriptions*	18.6	12.4	18.9	13.6	-0.386	-0.030
Mean number of generics dispensed*	8.6	3.8	8.5	3.8	0.027	0.007
Mean number of unique drug classes dispensed*	7.3	3.2	7.1	3.5	0.137	0.041

Table 1aw. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	DPP-4 Inhibitors	

[*] Covariate included in the propensity score logistic regression model.

[1] Covariates in blue show a standardized difference greater than 0.1.

[2] Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3] Value represents standard deviation where no % follows the value.

[4] Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5] Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6] Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1ax. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	661,762	N/A	701,327	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.5	10.5	63.4	11.7	-1.911	-0.172
Age						
18-24 years	2,347	0.4%	3,058	0.4%	-0.081	-0.013
25-44 years	69,570	10.5%	70,711	10.1%	0.430	0.015
45-64 years	290,753	43.9%	271,838	38.8%	5.176	0.115
65-79 years	267,030	40.4%	282,588	40.3%	0.058	0.001
≥ 80 years	32,062	4.8%	73,132	10.4%	-5.583	-0.215
Sex*						
Female	382,635	57.8%	405,517	57.8%	-0.001	-0.000
Male	279,127	42.2%	295,810	42.2%	0.001	0.000
Race[4]						
American Indian or Alaska Native	4,606	0.7%	6,515	0.9%	-0.233	-0.026
Asian	6,822	1.0%	18,954	2.7%	-1.672	-0.124
Black or African American	59,867	9.0%	90,847	13.0%	-3.907	-0.127
Multi-racial	3,001	0.5%	1,672	0.2%	0.215	0.037
Native Hawaiian or Other Pacific Islander	1,357	0.2%	1,719	0.2%	-0.040	-0.008
Unknown	218,436	33.0%	173,358	24.7%	8.290	0.281
White	367,673	55.6%	408,261	58.2%	-2.653	-0.066
Hispanic origin						

Table 1ax. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Yes	25,933	3.9%	51,332	7.3%	-3.400	-0.153
No	401,791	60.7%	502,057	71.6%	-10.871	-0.395
Unknown	234,038	35.4%	147,938	21.1%	14.272	0.697
Year*						
2015	16,554	2.5%	22,683	3.2%	-0.733	-0.044
2016	75,153	11.4%	100,600	14.3%	-2.988	-0.090
2017	81,336	12.3%	106,559	15.2%	-2.903	-0.085
2018	82,467	12.5%	102,456	14.6%	-2.147	-0.063
2019	88,001	13.3%	103,961	14.8%	-1.526	-0.044
2020	86,250	13.0%	96,451	13.8%	-0.719	-0.021
2021	79,482	12.0%	70,206	10.0%	2.000	0.065
2022	86,586	13.1%	62,088	8.9%	4.231	0.138
2023	65,933	10.0%	36,323	5.2%	4.784	0.184
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.6	1.8	1.8	1.9	-0.182	-0.098
Combined comorbidity score*,[6]	2.2	2.5	2.5	2.7	-0.279	-0.108
Medical History						
Obesity*	302,947	45.8%	271,141	38.7%	7.118	0.146
Weight Reduction Surgery or Procedure*	843	0.1%	1,148	0.2%	-0.036	-0.010
Lifestyle intervention*	116,114	17.5%	102,384	14.6%	2.948	0.082
Cardiovascular Disease*	150,900	22.8%	181,556	25.9%	-3.085	-0.074
Cognitive Impairment*	31,069	4.7%	47,667	6.8%	-2.102	-0.091
Traumatic Brain Injury*	2,425	0.4%	2,882	0.4%	-0.045	-0.007

Table 1ax. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Migraine*	34,025	5.1%	32,659	4.7%	0.485	0.022
Epilepsy*	13,322	2.0%	16,463	2.3%	-0.334	-0.023
Chronic Pain*	171,437	25.9%	176,808	25.2%	0.696	0.016
Psychiatric History						
Previous Intentional Self-Harm Ever	7,291	1.1%	8,981	1.3%	-0.179	-0.017
Psychiatric History Overall*	661,762	100.0%	701,327	100.0%	0.000	NaN
Psychiatric Drug Dispensings	486,797	73.6%	523,786	74.7%	-1.124	-0.026
Intentional Self-Harm Encounter	1,175	0.2%	1,409	0.2%	-0.023	-0.005
Any Other Psychiatric Event	535,658	80.9%	558,620	79.7%	1.292	0.033
Attention-Deficit/Hyperactivity Disorder	11,088	1.7%	7,632	1.1%	0.587	0.050
Akathisia	1,123	0.2%	1,434	0.2%	-0.035	-0.008
Anxiety	171,873	26.0%	179,734	25.6%	0.344	0.008
Behavioral Disorder	42,781	6.5%	46,115	6.6%	-0.111	-0.004
Bipolar Disorder	40,088	6.1%	48,346	6.9%	-0.836	-0.034
Cerebral Degenerations usually Manifested in Childhood	10,613	1.6%	16,497	2.4%	-0.749	-0.054
Conduct Disorder	855	0.1%	1,327	0.2%	-0.060	-0.015
Delirium	17,333	2.6%	26,550	3.8%	-1.166	-0.067
Depression	194,728	29.4%	200,443	28.6%	0.845	0.019
Electroconvulsive Therapy	186	0.0%	280	0.0%	-0.012	-0.006
Hallucination	2,331	0.4%	3,521	0.5%	-0.150	-0.023
Obsessive-Compulsive Disorder	1,823	0.3%	1,892	0.3%	0.006	0.001
Other Cerebral Degenerations	17,574	2.7%	27,595	3.9%	-1.279	-0.072
Other Mental Disorders	8,866	1.3%	11,807	1.7%	-0.344	-0.028

Table 1ax. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Other Psychological Disorders	92,308	13.9%	115,608	16.5%	-2.535	-0.071
Persistent Mental Disorders due to Conditions Classified Elsewhere	22,592	3.4%	36,530	5.2%	-1.795	-0.089
Personality Disorders	4,215	0.6%	4,695	0.7%	-0.032	-0.004
Pervasive Developmental Disorders	1,325	0.2%	2,345	0.3%	-0.134	-0.026
Post-Traumatic Stress Disorder	17,826	2.7%	18,609	2.7%	0.040	0.003
Psychotherapy	57,245	8.7%	62,112	8.9%	-0.206	-0.007
Psychotic Conditions	4,692	0.7%	8,826	1.3%	-0.549	-0.056
Schizophrenia	16,245	2.5%	31,026	4.4%	-1.969	-0.109
Sleep Disorder	268,717	40.6%	224,970	32.1%	8.529	0.179
Substance Abuse	45,392	6.9%	55,865	8.0%	-1.106	-0.042
Suicidal Behavior	5,749	0.9%	6,721	1.0%	-0.090	-0.009
Transcranial Magnetic Stimulation	175	0.0%	113	0.0%	0.010	0.007
Vagus Nerve Stimulation	871	0.1%	771	0.1%	0.022	0.006
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	6,881	1.0%	0	0.0%	NaN	NaN
dulaglutide	221,296	33.4%	0	0.0%	NaN	NaN
exenatide	60,774	9.2%	0	0.0%	NaN	NaN
liraglutide	167,528	25.3%	0	0.0%	NaN	NaN
lixisenatide	6,444	1.0%	0	0.0%	NaN	NaN
semaglutide	187,255	28.3%	0	0.0%	NaN	NaN
tirzepatide	12,309	1.9%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	661,761	100.0%	701,327	100.0%	-0.000	-0.001
insulin*	214,618	32.4%	228,236	32.5%	-0.112	-0.002

Table 1ax. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
metformin*	578,742	87.5%	605,150	86.3%	1.168	0.035
alpha-glucosidase inhibitors*	2,725	0.4%	3,252	0.5%	-0.052	-0.008
thiazolidinediones*	48,472	7.3%	50,680	7.2%	0.098	0.004
meglitinides*	7,719	1.2%	9,936	1.4%	-0.250	-0.022
amylin analogue*	81	0.0%	77	0.0%	0.001	0.001
sulfonylureas*	250,061	37.8%	289,123	41.2%	-3.438	-0.071
bile acid sequestrants*	3,260	0.5%	3,370	0.5%	0.012	0.002
Other Weight Loss Agents*	2,100	0.3%	921	0.1%	0.186	0.039
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	327	0.0%	174	0.0%	0.025	0.013
diethylpropion	42	0.0%	20	0.0%	0.004	0.005
lorcaserin	104	0.0%	65	0.0%	0.006	0.006
phentermine	1,527	0.2%	588	0.1%	0.147	0.037
phentermine-topiramate	97	0.0%	29	0.0%	0.010	0.011
phendimetrazine	33	0.0%	25	0.0%	0.001	0.002
orlistat	34	0.0%	42	0.0%	-0.001	-0.001
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	218,755	33.1%	238,868	34.1%	-1.003	-0.021
Antipsychotics	67,004	10.1%	98,958	14.1%	-3.985	-0.123
Anxiolytics/Hypnotics	199,881	30.2%	231,985	33.1%	-2.874	-0.062
Lithium & Other Mood Stabilizers	58,770	8.9%	77,568	11.1%	-2.179	-0.073
Antidepressants	396,368	59.9%	408,789	58.3%	1.608	0.033
Health Service Utilization Intensity Metrics						

Table 1ax. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		DPP-4 Inhibitors			
Mean number of ambulatory encounters*	12.7	11.4	13.3	13.6	-0.503	-0.040
Mean number of emergency room encounters*	0.5	1.4	0.6	1.3	-0.033	-0.024
Mean number of inpatient hospital encounters*	0.2	0.6	0.2	0.6	-0.049	-0.081
Mean number of non-acute institutional encounters*	0.1	0.3	0.1	0.4	-0.025	-0.072
Mean number of other ambulatory encounters*	5.7	14.7	7.1	17.0	-1.443	-0.091
Mean number of filled prescriptions*	31.7	23.2	33.1	23.6	-1.478	-0.063
Mean number of generics dispensed*	12.6	5.7	12.9	5.5	-0.244	-0.044
Mean number of unique drug classes dispensed*	11.1	4.8	11.2	5.0	-0.087	-0.018

Table 1ax. Aggregated Weighted Characteristics of GLP-1RA or DPP-4i Users, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	DPP-4 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1ay. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use (observing for event in IP/ED setting) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	1,162,009	100.0%	1,081,183	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)*	60.7	10.5	63.7	10.2	-2.982	-0.288
Age						
18-24 years	6,143	0.5%	3,035	0.3%	0.248	0.039
25-44 years	142,626	12.3%	91,671	8.5%	3.795	0.125
45-64 years	493,317	42.5%	413,209	38.2%	4.236	0.086
65-79 years	475,373	40.9%	489,947	45.3%	-4.406	-0.089
≥ 80 years	44,550	3.8%	83,321	7.7%	-3.873	-0.167
Sex*						
Female	644,380	55.5%	470,614	43.5%	11.926	0.240
Male	517,629	44.5%	610,569	56.5%	-11.926	-0.240
Race[3]						
Native	8,501	0.7%	5,936	0.5%	0.183	0.023
Asian	17,107	1.5%	38,595	3.6%	-2.098	-0.134
Black or African American	111,979	9.6%	100,894	9.3%	0.305	0.010
Multi-racial	6,192	0.5%	4,975	0.5%	0.073	0.010
Pacific Islander	3,110	0.3%	3,770	0.3%	-0.081	-0.015
Unknown	422,242	36.3%	379,521	35.1%	1.235	0.026
White	592,878	51.0%	547,492	50.6%	0.384	0.008
Hispanic origin						

Table 1ay. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use (observing for event in IP/ED setting) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	52,636	4.5%	64,465	6.0%	-1.433	-0.064
No	666,351	57.3%	633,156	58.6%	-1.217	-0.025
Unknown	443,022	38.1%	383,562	35.5%	2.649	0.055
Year*						
2015	17,383	1.5%	18,309	1.7%	-0.197	-0.016
2016	84,175	7.2%	82,666	7.6%	-0.402	-0.015
2017	102,387	8.8%	101,829	9.4%	-0.607	-0.021
2018	121,379	10.4%	98,360	9.1%	1.348	0.045
2019	149,396	12.9%	137,439	12.7%	0.145	0.004
2020	162,652	14.0%	165,424	15.3%	-1.303	-0.037
2021	160,777	13.8%	166,912	15.4%	-1.602	-0.045
2022	197,488	17.0%	193,950	17.9%	-0.943	-0.025
2023	166,372	14.3%	116,294	10.8%	3.561	0.108
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[4]	1.3	1.6	1.5	1.7	-0.154	-0.093
Combined comorbidity score*,[5]	1.6	2.1	1.8	2.4	-0.206	-0.091
Medical History						
Obesity*	549,136	47.3%	368,407	34.1%	13.183	0.271
Procedure*	668	0.1%	600	0.1%	0.002	0.001
Lifestyle intervention*	214,167	18.4%	174,917	16.2%	2.252	0.060
Cardiovascular Disease*	202,978	17.5%	246,343	22.8%	-5.317	-0.133
Cognitive Impairment*	20,943	1.8%	24,996	2.3%	-0.510	-0.036
Traumatic Brain Injury*	2,474	0.2%	1,860	0.2%	0.041	0.009
Migraine*	44,887	3.9%	28,961	2.7%	1.184	0.067

Table 1ay. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use (observing for event in IP/ED setting) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Epilepsy*	13,430	1.2%	12,017	1.1%	0.044	0.004
Chronic Pain*	243,659	21.0%	184,928	17.1%	3.865	0.099
Psychiatric History						
Previous Intentional Self-Harm Ever	8,691	0.7%	5,604	0.5%	0.230	0.029
Psychiatric History Overall*	723,905	62.3%	577,524	53.4%	8.882	0.181
Psychiatric Drug Dispensings	540,549	46.5%	401,716	37.2%	9.363	0.191
Intentional Self-Harm Encounter	1,087	0.1%	770	0.1%	0.022	0.008
Any Other Psychiatric Event	587,752	50.6%	465,876	43.1%	7.491	0.151
Attention-Deficit/Hyperactivity Disorder	13,757	1.2%	6,986	0.6%	0.538	0.056
Akathisia	1,096	0.1%	779	0.1%	0.022	0.008
Anxiety	194,821	16.8%	138,397	12.8%	3.965	0.112
Behavioral Disorder	45,562	3.9%	32,045	3.0%	0.957	0.053
Bipolar Disorder	45,948	4.0%	29,141	2.7%	1.259	0.070
Cerebral Degenerations usually Manifested in Childhood	9,345	0.8%	10,891	1.0%	-0.203	-0.021
Conduct Disorder	967	0.1%	669	0.1%	0.021	0.008
Delirium	12,694	1.1%	13,603	1.3%	-0.166	-0.015
Depression	211,198	18.2%	145,458	13.5%	4.722	0.130
Electroconvulsive Therapy	187	0.0%	123	0.0%	0.005	0.004
Hallucination	1,947	0.2%	1,755	0.2%	0.005	0.001

Table 1ay. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use (observing for event in IP/ED setting) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Obsessive-Compulsive Disorder	2,211	0.2%	1,423	0.1%	0.059	0.015
Other Cerebral Degenerations	14,231	1.2%	15,775	1.5%	-0.234	-0.020
Other Mental Disorders	8,614	0.7%	7,146	0.7%	0.080	0.010
Other Psychological Disorders	97,778	8.4%	92,175	8.5%	-0.111	-0.004
Persistent Mental Disorders due to Conditions Classified Elsewhere	14,468	1.2%	16,934	1.6%	-0.321	-0.027
Personality Disorders	4,892	0.4%	2,413	0.2%	0.198	0.035
Pervasive Developmental Disorders	1,941	0.2%	1,369	0.1%	0.040	0.011
Post-Traumatic Stress Disorder	21,931	1.9%	12,168	1.1%	0.762	0.063
Psychotherapy	65,819	5.7%	39,164	3.6%	2.042	0.097
Psychotic Conditions	3,856	0.3%	3,435	0.3%	0.014	0.002
Schizophrenia	18,442	1.6%	15,388	1.4%	0.164	0.013
Sleep Disorder	301,569	26.0%	220,706	20.4%	5.539	0.132
Substance Abuse	48,712	4.2%	43,513	4.0%	0.167	0.008
Suicidal Behavior	5,387	0.5%	4,165	0.4%	0.078	0.012
Transcranial Magnetic Stimulation	248	0.0%	129	0.0%	0.009	0.007
Vagus Nerve Stimulation	948	0.1%	589	0.1%	0.027	0.010
Medical Product Use						
Index GLP-1 RA Product						

Table 1ay. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use (observing for event in IP/ED setting) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
albiglutide	8,797	0.8%	0	0.0%	NaN	NaN
dulaglutide	385,528	33.2%	0	0.0%	NaN	NaN
exenatide	85,604	7.4%	0	0.0%	NaN	NaN
liraglutide	237,081	20.4%	0	0.0%	NaN	NaN
lixisenatide	15,881	1.4%	0	0.0%	NaN	NaN
semaglutide	401,762	34.6%	0	0.0%	NaN	NaN
tirzepatide	28,218	2.4%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,162,007	100.0%	1,081,182	100.0%	-0.000	-0.001
insulin*	393,036	33.8%	233,117	21.6%	12.263	0.277
metformin*	1,026,818	88.4%	967,679	89.5%	-1.136	-0.036
alpha-glucosidase inhibitors*	4,653	0.4%	4,420	0.4%	-0.008	-0.001
thiazolidinediones*	95,140	8.2%	88,497	8.2%	0.002	0.000
meglitinides*	12,589	1.1%	11,036	1.0%	0.063	0.006
amylin analogue*	154	0.0%	78	0.0%	0.006	0.006
sulfonylureas*	427,707	36.8%	426,143	39.4%	-2.607	-0.054
bile acid sequestrants*	4,319	0.4%	3,629	0.3%	0.036	0.006
Other Weight Loss Agents*	4,010	0.3%	1,229	0.1%	0.231	0.048
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	421	0.0%	152	0.0%	0.022	0.014
diethylpropion	85	0.0%	27	0.0%	0.005	0.007
lorcaserin	181	0.0%	68	0.0%	0.009	0.009
phentermine	3,086	0.3%	920	0.1%	0.180	0.043
phentermine-topiramate	194	0.0%	46	0.0%	0.012	0.012
phendimetrazine	63	0.0%	16	0.0%	0.004	0.007

Table 1ay. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use (observing for event in IP/ED setting) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
orlistat	69	0.0%	25	0.0%	0.004	0.006
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	290,151	25.0%	227,925	21.1%	3.889	0.092
Antipsychotics	77,747	6.7%	55,889	5.2%	1.521	0.064
Anxiolytics/Hypnotics	221,984	19.1%	164,511	15.2%	3.888	0.103
Stabilizers	67,849	5.8%	47,354	4.4%	1.459	0.066
Antidepressants	445,496	38.3%	312,775	28.9%	9.409	0.200
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	10.9	10.5	10.0	9.5	0.854	0.085
Mean number of emergency room encounters*	0.3	1.0	0.3	1.0	0.010	0.010
Mean number of inpatient hospital encounters*	0.1	0.4	0.1	0.5	-0.038	-0.087
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	-0.005	-0.027
Mean number of other ambulatory encounters*	3.9	11.5	3.7	10.6	0.145	0.013
Mean number of filled prescriptions*	26.1	19.7	23.7	17.7	2.401	0.128
Mean number of generics dispensed*	10.9	5.1	10.2	4.8	0.700	0.141
Mean number of unique drug classes dispensed*	9.8	4.6	8.5	4.4	1.271	0.283

Table 1ay. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use (observing for event in IP/ED setting) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759.

Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1az. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	1,161,942	100.0%	1,080,616	99.9%	N/A	N/A
Demographic Characteristics						
Age (years)*	60.7	10.5	63.7	10.2	-2.980	-0.288
Age						
18-24 years	6,143	0.5%	*****	*****	*****	*****
25-44 years	142,611	12.3%	91,645	8.5%	3.793	0.125
45-64 years	493,276	42.5%	412,978	38.2%	4.236	0.086
65-79 years	475,362	40.9%	489,677	45.3%	-4.404	-0.089
≥ 80 years	44,550	3.8%	*****	*****	*****	*****
Sex*						
Female	*****	*****	470,488	43.5%	*****	*****
Male	*****	*****	610,128	56.5%	*****	*****
Race[3]						
American Indian or Alaska Native	*****	*****	*****	*****	*****	*****
Asian	*****	*****	38,540	3.6%	*****	*****
Black or African American	*****	*****	100,819	9.3%	*****	*****
Multi-racial	*****	*****	*****	*****	*****	*****
Native Hawaiian or Other Pacific Islander	3,110	0.3%	*****	*****	*****	*****
Unknown	422,228	36.3%	379,386	35.1%	1.230	0.026
White	592,837	51.0%	547,206	50.6%	0.383	0.008
Hispanic origin						

Table 1az. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	*****	*****	64,358	6.0%	*****	*****
No	666,326	57.3%	632,791	58.6%	-1.212	-0.025
Unknown	*****	*****	383,467	35.5%	*****	*****
Year*						
2015	17,383	1.5%	*****	*****	*****	*****
2016	*****	*****	*****	*****	*****	*****
2017	*****	*****	*****	*****	*****	*****
2018	*****	*****	*****	*****	*****	*****
2019	*****	*****	*****	*****	*****	*****
2020	*****	*****	165,400	15.3%	*****	*****
2021	*****	*****	166,777	15.4%	*****	*****
2022	197,480	17.0%	193,566	17.9%	-0.917	-0.024
2023	166,359	14.3%	*****	*****	*****	*****
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,4	1.3	1.6	1.5	1.7	-0.154	-0.093
Combined comorbidity score*,5	1.6	2.1	1.8	2.4	-0.206	-0.091
Medical History						
Obesity*	549,078	47.3%	368,327	34.1%	13.170	0.271
Weight Reduction Surgery or Procedure*	668	0.1%	*****	*****	*****	*****
Lifestyle intervention*	214,144	18.4%	174,837	16.2%	2.250	0.060
Cardiovascular Disease*	*****	*****	246,188	22.8%	*****	*****
Cognitive Impairment*	20,943	1.8%	24,984	2.3%	-0.510	-0.036
Traumatic Brain Injury*	2,474	0.2%	*****	*****	*****	*****

Table 1az. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	44,874	3.9%	28,947	2.7%	1.183	0.067
Epilepsy*	*****	*****	12,005	1.1%	*****	*****
Chronic Pain*	243,621	21.0%	184,877	17.1%	3.858	0.098
Psychiatric History						
Previous Intentional Self-Harm Ever	8,691	0.7%	*****	*****	*****	*****
Psychiatric History Overall*	723,842	62.3%	577,303	53.4%	8.872	0.180
Psychiatric Drug Dispensings	540,490	46.5%	401,590	37.2%	9.353	0.190
Intentional Self-Harm Encounter	1,087	0.1%	770	0.1%	0.022	0.008
Any Other Psychiatric Event	587,694	50.6%	465,685	43.1%	7.484	0.150
Attention-Deficit/Hyperactivity Disorder	*****	*****	*****	*****	*****	*****
Akathisia	1,096	0.1%	779	0.1%	0.022	0.008
Anxiety	194,785	16.8%	138,359	12.8%	3.960	0.112
Behavioral Disorder	*****	*****	32,025	3.0%	*****	*****
Bipolar Disorder	45,933	4.0%	*****	*****	*****	*****
Cerebral Degenerations usually Manifested in Childhood	9,345	0.8%	*****	*****	*****	*****
Conduct Disorder	*****	*****	669	0.1%	*****	*****
Delirium	12,694	1.1%	*****	*****	*****	*****
Depression	211,162	18.2%	145,399	13.5%	4.718	0.130
Electroconvulsive Therapy	187	0.0%	123	0.0%	0.005	0.004
Hallucination	1,947	0.2%	*****	*****	*****	*****
Obsessive-Compulsive Disorder	*****	*****	1,423	0.1%	*****	*****
Other Cerebral Degenerations	*****	*****	*****	*****	*****	*****
Other Mental Disorders	*****	*****	*****	*****	*****	*****

Table 1az. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Psychological Disorders	*****	*****	92,133	8.5%	*****	*****
Persistent Mental Disorders due to Conditions Classified Elsewhere	14,468	1.2%	*****	*****	*****	*****
Personality Disorders	*****	*****	*****	*****	*****	*****
Pervasive Developmental Disorders	*****	*****	1,369	0.1%	*****	*****
Post-Traumatic Stress Disorder	*****	*****	*****	*****	*****	*****
Psychotherapy	65,797	5.7%	*****	*****	*****	*****
Psychotic Conditions	3,856	0.3%	*****	*****	*****	*****
Schizophrenia	*****	*****	*****	*****	*****	*****
Sleep Disorder	301,526	26.0%	220,615	20.4%	5.535	0.131
Substance Abuse	48,700	4.2%	43,500	4.0%	0.166	0.008
Suicidal Behavior	5,387	0.5%	*****	*****	*****	*****
Transcranial Magnetic Stimulation	248	0.0%	*****	*****	*****	*****
Vagus Nerve Stimulation	*****	*****	*****	*****	*****	*****
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	8,797	0.8%	0	0.0%	NaN	NaN
dulaglutide	385,514	33.2%	0	0.0%	NaN	NaN
exenatide	*****	*****	0	0.0%	*****	*****
liraglutide	237,060	20.4%	0	0.0%	NaN	NaN
lixisenatide	*****	*****	0	0.0%	*****	*****
semaglutide	401,740	34.6%	0	0.0%	NaN	NaN
tirzepatide	28,218	2.4%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,161,940	100.0%	1,080,615	100.0%	-0.000	-0.001
insulin*	393,000	33.8%	233,057	21.6%	12.256	0.276

Table 1az. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
metformin*	1,026,760	88.4%	967,175	89.5%	-1.136	-0.036
alpha-glucosidase inhibitors*	*****	*****	*****	*****	*****	*****
thiazolidinediones*	*****	*****	88,429	8.2%	*****	*****
meglitinides*	*****	*****	11,036	1.0%	*****	*****
amylin analogue*	154	0.0%	*****	*****	*****	*****
sulfonylureas*	427,682	36.8%	425,719	39.4%	-2.588	-0.053
bile acid sequestrants*	*****	*****	*****	*****	*****	*****
Other Weight Loss Agents*	*****	*****	*****	*****	*****	*****
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	421	0.0%	152	0.0%	0.022	0.014
diethylpropion	85	0.0%	27	0.0%	0.005	0.007
lorcaserin	181	0.0%	68	0.0%	0.009	0.009
phentermine	*****	*****	*****	*****	*****	*****
phentermine-topiramate	194	0.0%	46	0.0%	0.012	0.012
phendimetrazine	63	0.0%	*****	*****	*****	*****
orlistat	69	0.0%	25	0.0%	0.004	0.006
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	290,114	25.0%	227,837	21.1%	3.884	0.092
Antipsychotics	77,726	6.7%	55,873	5.2%	1.519	0.064
Anxiolytics/Hypnotics	221,942	19.1%	164,475	15.2%	3.880	0.103
Lithium & Other Mood Stabilizers	67,828	5.8%	47,338	4.4%	1.457	0.066
Antidepressants	445,441	38.3%	312,673	28.9%	9.401	0.200
Health Service Utilization Intensity Metrics						

Table 1az. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Mean number of ambulatory encounters*	10.9	10.5	10.0	9.5	0.851	0.085
Mean number of emergency room encounters*	0.3	1.0	0.3	1.0	0.010	0.010
Mean number of inpatient hospital encounters*	0.1	0.4	0.1	0.5	-0.038	-0.087
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	-0.005	-0.027
Mean number of other ambulatory encounters*	3.9	11.5	3.7	10.6	0.150	0.014
Mean number of filled prescriptions*	26.1	19.7	23.7	17.7	2.397	0.128
Mean number of generics dispensed*	10.9	5.1	10.2	4.8	0.699	0.141
Mean number of unique drug classes dispensed*	9.8	4.6	8.5	4.4	1.270	0.283

Table 1az. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1ba. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	2,651,987	N/A	1,192,250	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	57.2	10.3	62.1	10.8	-4.827	-0.457
Age						
18-24 years	4,861	0.2%	4,739	0.4%	-0.214	-0.037
25-44 years	163,195	6.2%	125,345	10.5%	-4.360	-0.153
45-64 years	1,805,023	68.1%	494,389	41.5%	26.596	0.592
65-79 years	611,886	23.1%	496,528	41.6%	-18.574	-0.447
≥ 80 years	67,022	2.5%	71,250	6.0%	-3.449	-0.164
Sex*						
Female	1,795,045	67.7%	612,663	51.4%	16.300	0.324
Male	856,942	32.3%	579,587	48.6%	-16.300	-0.324
Race[4]						
American Indian or Alaska Native	10,107	0.4%	6,996	0.6%	-0.206	-0.027
Asian	23,085	0.9%	34,104	2.9%	-1.990	-0.141
Black or African American	146,852	5.5%	122,390	10.3%	-4.728	-0.169
Multi-racial	949,165	35.8%	5,829	0.5%	35.302	1.794
Native Hawaiian or Other Pacific Islander	3,475	0.1%	3,383	0.3%	-0.153	-0.032
Unknown	785,703	29.6%	425,110	35.7%	-6.029	-0.212
White	733,600	27.7%	594,438	49.9%	-22.196	-0.574
Hispanic origin						

Table 1ba. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	1,001,333	37.8%	71,258	6.0%	31.781	1.165
No	798,854	30.1%	689,822	57.9%	-27.736	-1.112
Unknown	851,799	32.1%	431,171	36.2%	-4.045	-0.150
Year*						
2015	34,656	1.3%	19,969	1.7%	-0.368	-0.028
2016	135,482	5.1%	94,288	7.9%	-2.800	-0.105
2017	184,170	6.9%	112,470	9.4%	-2.489	-0.084
2018	163,917	6.2%	122,858	10.3%	-4.124	-0.140
2019	196,739	7.4%	154,311	12.9%	-5.524	-0.172
2020	227,060	8.6%	173,117	14.5%	-5.958	-0.178
2021	220,513	8.3%	172,551	14.5%	-6.158	-0.183
2022	1,273,973	48.0%	201,291	16.9%	31.155	0.767
2023	215,476	8.1%	141,395	11.9%	-3.734	-0.117
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.2	2.0	1.5	1.7	-0.375	-0.198
Combined comorbidity score*,[6]	2.6	2.8	1.9	2.4	0.714	0.273
Medical History						
Obesity*	840,715	31.7%	510,874	42.8%	-11.148	-0.226
Weight Reduction Surgery or Procedure*	3,135	0.1%	1,108	0.1%	0.025	0.007
Lifestyle intervention*	1,264,617	47.7%	202,512	17.0%	30.700	0.766
Cardiovascular Disease*	423,596	16.0%	257,106	21.6%	-5.592	-0.137
Cognitive Impairment*	60,614	2.3%	27,452	2.3%	-0.017	-0.001
Traumatic Brain Injury*	2,970	0.1%	2,929	0.2%	-0.134	-0.030

Table 1ba. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	1,038,102	39.1%	48,175	4.0%	35.104	1.245
Epilepsy*	30,521	1.2%	15,968	1.3%	-0.188	-0.016
Chronic Pain*	1,470,286	55.4%	260,074	21.8%	33.627	0.755
Psychiatric History						
Previous Intentional Self-Harm Ever	19,047	0.7%	9,866	0.8%	-0.109	-0.011
Psychiatric History Overall*	2,122,958	80.1%	731,411	61.3%	18.705	0.398
Psychiatric Drug Dispensings	1,835,706	69.2%	551,693	46.3%	22.947	0.462
Intentional Self-Harm Encounter	4,620	0.2%	1,294	0.1%	0.066	0.015
Any Other Psychiatric Event	1,944,836	73.3%	594,538	49.9%	23.468	0.477
Attention-Deficit/Hyperactivity Disorder	50,266	1.9%	11,403	1.0%	0.939	0.071
Akathisia	1,705	0.1%	1,196	0.1%	-0.036	-0.012
Anxiety	1,318,490	49.7%	200,688	16.8%	32.884	0.791
Behavioral Disorder	105,840	4.0%	46,284	3.9%	0.109	0.005
Bipolar Disorder	104,912	4.0%	52,304	4.4%	-0.431	-0.020
Cerebral Degenerations usually Manifested in Childhood	21,385	0.8%	12,601	1.1%	-0.251	-0.024
Conduct Disorder	956	0.0%	991	0.1%	-0.047	-0.018
Delirium	53,947	2.0%	16,877	1.4%	0.619	0.042
Depression	395,099	14.9%	209,575	17.6%	-2.680	-0.068
Electroconvulsive Therapy	418	0.0%	226	0.0%	-0.003	-0.002
Hallucination	5,809	0.2%	2,614	0.2%	-0.000	-0.000
Obsessive-Compulsive Disorder	7,263	0.3%	2,145	0.2%	0.094	0.018
Other Cerebral Degenerations	23,755	0.9%	17,482	1.5%	-0.571	-0.049
Other Mental Disorders	20,933	0.8%	9,704	0.8%	-0.025	-0.003

Table 1ba. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Psychological Disorders	268,602	10.1%	121,002	10.1%	-0.021	-0.001
Persistent Mental Disorders due to Conditions Classified Elsewhere	35,750	1.3%	18,522	1.6%	-0.205	-0.016
Personality Disorders	12,965	0.5%	5,346	0.4%	0.040	0.005
Pervasive Developmental Disorders	1,643	0.1%	1,860	0.2%	-0.094	-0.027
Post-Traumatic Stress Disorder	46,759	1.8%	23,580	2.0%	-0.215	-0.014
Psychotherapy	119,350	4.5%	66,261	5.6%	-1.057	-0.045
Psychotic Conditions	6,151	0.2%	5,308	0.4%	-0.213	-0.034
Schizophrenia	40,249	1.5%	24,060	2.0%	-0.500	-0.035
Sleep Disorder	1,509,059	56.9%	290,591	24.4%	32.530	0.716
Substance Abuse	107,118	4.0%	59,173	5.0%	-0.924	-0.041
Suicidal Behavior	13,931	0.5%	5,615	0.5%	0.054	0.007
Transcranial Magnetic Stimulation	197	0.0%	368	0.0%	-0.023	-0.016
Vagus Nerve Stimulation	1,580	0.1%	1,216	0.1%	-0.042	-0.014
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	31,669	1.2%	0	0.0%	NaN	NaN
dulaglutide	1,558,855	58.8%	0	0.0%	NaN	NaN
exenatide	133,392	5.0%	0	0.0%	NaN	NaN
liraglutide	332,847	12.6%	0	0.0%	NaN	NaN
lixisenatide	17,603	0.7%	0	0.0%	NaN	NaN
semaglutide	537,596	20.3%	0	0.0%	NaN	NaN
tirzepatide	62,741	2.4%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	2,651,984	100.0%	1,192,249	100.0%	-0.000	-0.000

Table 1ba. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
insulin*	709,956	26.8%	507,068	42.5%	-15.760	-0.320
metformin*	2,476,453	93.4%	1,051,947	88.2%	5.149	0.168
alpha-glucosidase inhibitors*	6,467	0.2%	5,562	0.5%	-0.223	-0.035
thiazolidinediones*	113,243	4.3%	105,395	8.8%	-4.570	-0.174
meglitinides*	17,224	0.6%	14,813	1.2%	-0.593	-0.057
amylin analogue*	315	0.0%	203	0.0%	-0.005	-0.004
sulfonylureas*	1,478,443	55.7%	462,952	38.8%	16.918	0.351
bile acid sequestrants*	7,383	0.3%	5,239	0.4%	-0.161	-0.025
Other Weight Loss Agents*	4,826	0.2%	3,244	0.3%	-0.090	-0.017
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	1,505	0.1%	328	0.0%	0.029	0.012
diethylpropion	108	0.0%	70	0.0%	-0.002	-0.002
lorcaserin	143	0.0%	228	0.0%	-0.014	-0.012
phentermine	2,895	0.1%	2,358	0.2%	-0.089	-0.021
phentermine-topiramate	184	0.0%	193	0.0%	-0.009	-0.008
phendimetrazine	103	0.0%	66	0.0%	-0.002	-0.002
orlistat	52	0.0%	49	0.0%	-0.002	-0.004
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	1,659,573	62.6%	325,615	27.3%	35.268	0.744
Antipsychotics	183,229	6.9%	93,999	7.9%	-0.975	-0.034
Anxiolytics/Hypnotics	459,375	17.3%	247,839	20.8%	-3.466	-0.083
Lithium & Other Mood Stabilizers	137,733	5.2%	81,620	6.8%	-1.652	-0.064
Antidepressants	1,652,375	62.3%	444,467	37.3%	25.027	0.508

Table 1ba. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	23.0	13.8	11.6	11.3	11.450	0.909
Mean number of emergency room encounters*	3.8	3.0	0.4	1.2	3.383	1.466
Mean number of inpatient hospital encounters*	0.2	0.8	0.1	0.5	0.072	0.113
Mean number of non-acute institutional encounters*	0.0	0.3	0.0	0.2	0.006	0.023
Mean number of other ambulatory encounters*	5.1	12.2	4.4	12.2	0.738	0.060
Mean number of filled prescriptions*	59.1	35.7	27.9	21.5	31.239	1.060
Mean number of generics dispensed*	25.8	12.0	11.6	5.5	14.199	1.524
Mean number of unique drug classes dispensed*	18.5	8.3	10.2	5.3	8.298	1.195

Table 1ba. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*] Covariate included in the propensity score logistic regression model.

[1] Covariates in blue show a standardized difference greater than 0.1.

[2] Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3] Value represents standard deviation where no % follows the value.

[4] Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5] Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6] Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759.
Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.
*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
N/A = Not applicable
NaN = Not a number

Table 1bb. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	1,154,818	N/A	1,118,721	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.6	10.3	62.4	10.7	-0.849	-0.081
Age						
18-24 years	4,639	0.4%	4,378	0.4%	0.010	0.002
25-44 years	123,038	10.7%	112,475	10.1%	0.600	0.021
45-64 years	492,548	42.7%	453,346	40.5%	2.128	0.048
65-79 years	480,870	41.6%	478,854	42.8%	-1.163	-0.028
≥ 80 years	53,722	4.7%	69,669	6.2%	-1.576	-0.071
Sex*						
Female	589,866	51.1%	558,073	49.9%	1.194	0.024
Male	564,951	48.9%	560,648	50.1%	-1.194	-0.024
Race[4]						
American Indian or Alaska Native	8,292	0.7%	6,747	0.6%	0.115	0.014
Asian	18,498	1.6%	33,426	3.0%	-1.386	-0.093
Black or African American	109,080	9.4%	114,768	10.3%	-0.813	-0.028
Multi-racial	5,995	0.5%	5,347	0.5%	0.041	0.006
Islander	3,255	0.3%	3,344	0.3%	-0.017	-0.003
Unknown	426,893	37.0%	389,228	34.8%	2.174	0.073
White	582,805	50.5%	565,861	50.6%	-0.114	-0.003
Hispanic origin						

Table 1bb. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	52,390	4.5%	68,500	6.1%	-1.586	-0.074
No	652,628	56.5%	658,584	58.9%	-2.356	-0.088
Unknown	449,800	38.9%	391,638	35.0%	3.942	0.185
Year*						
2015	19,413	1.7%	18,840	1.7%	-0.003	-0.000
2016	90,718	7.9%	87,977	7.9%	-0.008	-0.000
2017	110,283	9.5%	106,179	9.5%	0.059	0.002
2018	118,090	10.2%	113,634	10.2%	0.068	0.002
2019	150,486	13.0%	146,066	13.1%	-0.025	-0.001
2020	167,296	14.5%	165,114	14.8%	-0.272	-0.008
2021	162,520	14.1%	163,072	14.6%	-0.503	-0.015
2022	194,473	16.8%	188,651	16.9%	-0.023	-0.001
2023	141,538	12.3%	129,189	11.5%	0.708	0.022
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.5	1.7	1.5	1.7	-0.034	-0.019
Combined comorbidity score*,[6]	1.8	2.3	1.9	2.4	-0.033	-0.014
Medical History						
Obesity*	500,068	43.3%	460,848	41.2%	2.109	0.043
Weight Reduction Surgery or Procedure*	816	0.1%	834	0.1%	-0.004	-0.001
Lifestyle intervention*	204,407	17.7%	186,331	16.7%	1.045	0.028
Cardiovascular Disease*	243,866	21.1%	242,391	21.7%	-0.550	-0.014
Cognitive Impairment*	26,503	2.3%	25,975	2.3%	-0.027	-0.002
Traumatic Brain Injury*	2,486	0.2%	2,455	0.2%	-0.004	-0.001

Table 1bb. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	43,614	3.8%	39,774	3.6%	0.221	0.012
Epilepsy*	15,006	1.3%	14,235	1.3%	0.027	0.002
Chronic Pain*	246,310	21.3%	230,396	20.6%	0.734	0.018
Psychiatric History						
Previous Intentional Self-Harm Ever	8,669	0.8%	8,303	0.7%	0.008	0.001
Psychiatric History Overall*	706,043	61.1%	668,247	59.7%	1.406	0.029
Psychiatric Drug Dispensings	517,267	44.8%	495,473	44.3%	0.503	0.010
Intentional Self-Harm Encounter	1,226	0.1%	1,086	0.1%	0.009	0.003
Any Other Psychiatric Event	578,481	50.1%	540,068	48.3%	1.817	0.037
Attention-Deficit/Hyperactivity Disorder	12,296	1.1%	9,766	0.9%	0.192	0.020
Akathisia	1,123	0.1%	1,040	0.1%	0.004	0.001
Anxiety	188,846	16.4%	176,404	15.8%	0.584	0.016
Behavioral Disorder	45,732	4.0%	40,008	3.6%	0.384	0.020
Bipolar Disorder	43,722	3.8%	42,717	3.8%	-0.032	-0.002
Cerebral Degenerations usually Manifested in Childhood	11,396	1.0%	11,400	1.0%	-0.032	-0.003
Conduct Disorder	874	0.1%	858	0.1%	-0.001	-0.000
Delirium	17,655	1.5%	15,116	1.4%	0.178	0.015
Depression	207,678	18.0%	184,846	16.5%	1.461	0.039
Electroconvulsive Therapy	194	0.0%	196	0.0%	-0.001	-0.001
Hallucination	2,369	0.2%	2,174	0.2%	0.011	0.002
Obsessive-Compulsive Disorder	2,065	0.2%	1,924	0.2%	0.007	0.002
Other Cerebral Degenerations	16,575	1.4%	16,516	1.5%	-0.041	-0.003
Other Mental Disorders	9,309	0.8%	8,713	0.8%	0.027	0.003

Table 1bb. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Psychological Disorders	103,158	8.9%	107,690	9.6%	-0.693	-0.024
Persistent Mental Disorders due to Conditions Classified Elsewhere	18,639	1.6%	17,431	1.6%	0.056	0.004
Personality Disorders	4,633	0.4%	3,958	0.4%	0.047	0.008
Pervasive Developmental Disorders	1,602	0.1%	1,721	0.2%	-0.015	-0.004
Post-Traumatic Stress Disorder	20,189	1.7%	18,584	1.7%	0.087	0.007
Psychotherapy	60,939	5.3%	55,393	5.0%	0.326	0.015
Psychotic Conditions	4,419	0.4%	4,517	0.4%	-0.021	-0.003
Schizophrenia	18,054	1.6%	20,571	1.8%	-0.275	-0.021
Sleep Disorder	298,367	25.8%	260,247	23.3%	2.574	0.060
Substance Abuse	52,738	4.6%	52,225	4.7%	-0.101	-0.005
Suicidal Behavior	6,064	0.5%	5,092	0.5%	0.070	0.010
Transcranial Magnetic Stimulation	194	0.0%	185	0.0%	0.000	0.000
Vagus Nerve Stimulation	1,007	0.1%	804	0.1%	0.015	0.005
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	10,077	0.9%	0	0.0%	NaN	NaN
dulaglutide	396,619	34.3%	0	0.0%	NaN	NaN
exenatide	87,645	7.6%	0	0.0%	NaN	NaN
liraglutide	238,672	20.7%	0	0.0%	NaN	NaN
lixisenatide	13,554	1.2%	0	0.0%	NaN	NaN
semaglutide	386,270	33.4%	0	0.0%	NaN	NaN
tirzepatide	24,408	2.1%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,154,815	100.0%	1,118,720	100.0%	-0.000	-0.001

Table 1bb. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
insulin*	419,620	36.3%	439,501	39.3%	-2.950	-0.061
metformin*	1,023,058	88.6%	988,843	88.4%	0.200	0.006
alpha-glucosidase inhibitors*	4,812	0.4%	4,942	0.4%	-0.025	-0.004
thiazolidinediones*	93,709	8.1%	95,332	8.5%	-0.407	-0.015
meglitinides*	12,732	1.1%	13,303	1.2%	-0.087	-0.008
amylin analogue*	146	0.0%	179	0.0%	-0.003	-0.003
sulfonylureas*	428,869	37.1%	432,266	38.6%	-1.502	-0.031
bile acid sequestrants*	5,159	0.4%	4,684	0.4%	0.028	0.004
Other Weight Loss Agents*	2,956	0.3%	2,233	0.2%	0.056	0.012
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	332	0.0%	290	0.0%	0.003	0.002
diethylpropion	74	0.0%	41	0.0%	0.003	0.004
lorcaserin	143	0.0%	121	0.0%	0.002	0.001
phentermine	2,238	0.2%	1,671	0.1%	0.044	0.011
phentermine-topiramate	144	0.0%	78	0.0%	0.005	0.006
phendimetrazine	59	0.0%	31	0.0%	0.002	0.004
orlistat	52	0.0%	42	0.0%	0.001	0.001
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	310,352	26.9%	287,912	25.7%	1.139	0.026
Antipsychotics	74,040	6.4%	79,291	7.1%	-0.676	-0.027
Anxiolytics/Hypnotics	215,289	18.6%	214,862	19.2%	-0.563	-0.014
Lithium & Other Mood Stabilizers	62,918	5.4%	67,624	6.0%	-0.596	-0.026
Antidepressants	420,886	36.4%	396,424	35.4%	1.011	0.021

Table 1bb. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	11.3	10.6	11.1	10.6	0.165	0.016
Mean number of emergency room encounters*	0.4	1.2	0.4	1.1	0.022	0.019
Mean number of inpatient hospital encounters*	0.1	0.5	0.1	0.5	0.007	0.014
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	0.001	0.003
Mean number of other ambulatory encounters*	4.2	11.7	4.2	11.7	-0.006	-0.000
Mean number of filled prescriptions*	27.5	21.4	26.7	19.9	0.741	0.036
Mean number of generics dispensed*	11.5	5.7	11.2	5.2	0.278	0.051
Mean number of unique drug classes dispensed*	9.8	4.8	9.7	4.9	0.133	0.028

Table 1bb. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*] Covariate included in the propensity score logistic regression model.

[1] Covariates in blue show a standardized difference greater than 0.1.

[2] Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3] Value represents standard deviation where no % follows the value.

[4] Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5] Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6] Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1bc. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	1,106,420	N/A	1,065,963	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.5	10.3	62.6	10.6	-1.093	-0.104
Age						
18-24 years	4,597	0.4%	4,037	0.4%	0.037	0.006
25-44 years	119,438	10.8%	104,707	9.8%	0.972	0.033
45-64 years	468,580	42.4%	425,935	40.0%	2.393	0.055
65-79 years	462,987	41.8%	462,926	43.4%	-1.582	-0.038
≥ 80 years	50,818	4.6%	68,358	6.4%	-1.820	-0.081
Sex*						
Female	568,160	51.4%	522,472	49.0%	2.337	0.047
Male	538,260	48.6%	543,491	51.0%	-2.337	-0.047
Race[4]						
American Indian or Alaska Native	8,058	0.7%	6,445	0.6%	0.124	0.015
Asian	17,786	1.6%	32,811	3.1%	-1.471	-0.098
Black or African American	104,892	9.5%	108,899	10.2%	-0.736	-0.025
Multi-racial	5,623	0.5%	4,986	0.5%	0.040	0.006
Native Hawaiian or Other Pacific Islander	3,163	0.3%	3,284	0.3%	-0.022	-0.004
Unknown	404,338	36.5%	366,557	34.4%	2.157	0.072
White	562,559	50.8%	542,981	50.9%	-0.093	-0.002
Hispanic origin						

Table 1bc. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	50,696	4.6%	66,024	6.2%	-1.612	-0.075
No	632,088	57.1%	632,682	59.4%	-2.224	-0.082
Unknown	423,636	38.3%	367,257	34.5%	3.836	0.179
Year*						
2015	18,227	1.6%	17,934	1.7%	-0.035	-0.003
2016	85,724	7.7%	83,540	7.8%	-0.089	-0.003
2017	104,382	9.4%	101,279	9.5%	-0.067	-0.002
2018	113,056	10.2%	106,882	10.0%	0.191	0.006
2019	144,085	13.0%	139,236	13.1%	-0.039	-0.001
2020	160,814	14.5%	158,885	14.9%	-0.371	-0.011
2021	155,986	14.1%	156,148	14.6%	-0.550	-0.016
2022	186,650	16.9%	180,452	16.9%	-0.059	-0.002
2023	137,495	12.4%	121,608	11.4%	1.019	0.032
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.5	1.7	1.5	1.7	-0.063	-0.037
Combined comorbidity score*,[6]	1.8	2.3	1.9	2.4	-0.074	-0.032
Medical History						
Obesity*	478,488	43.2%	427,674	40.1%	3.126	0.064
Weight Reduction Surgery or Procedure*	736	0.1%	735	0.1%	-0.002	-0.001
Lifestyle intervention*	195,845	17.7%	175,951	16.5%	1.195	0.032
Cardiovascular Disease*	226,022	20.4%	232,277	21.8%	-1.362	-0.034
Cognitive Impairment*	24,203	2.2%	24,800	2.3%	-0.139	-0.009
Traumatic Brain Injury*	2,331	0.2%	2,212	0.2%	0.003	0.001

Table 1bc. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	40,661	3.7%	35,864	3.4%	0.311	0.017
Epilepsy*	13,841	1.3%	13,266	1.2%	0.006	0.001
Chronic Pain*	230,088	20.8%	212,676	20.0%	0.844	0.021
Psychiatric History						
Previous Intentional Self-Harm Ever	8,084	0.7%	7,456	0.7%	0.031	0.004
Psychiatric History Overall*	671,509	60.7%	626,839	58.8%	1.887	0.039
Psychiatric Drug Dispensings	491,332	44.4%	460,529	43.2%	1.204	0.024
Intentional Self-Harm Encounter	1,105	0.1%	968	0.1%	0.009	0.003
Any Other Psychiatric Event	548,517	49.6%	505,639	47.4%	2.141	0.043
Attention-Deficit/Hyperactivity Disorder	11,607	1.0%	8,821	0.8%	0.222	0.023
Akathisia	1,047	0.1%	943	0.1%	0.006	0.002
Anxiety	177,528	16.0%	162,151	15.2%	0.834	0.023
Behavioral Disorder	42,745	3.9%	36,818	3.5%	0.409	0.022
Bipolar Disorder	41,141	3.7%	38,429	3.6%	0.113	0.006
Cerebral Degenerations usually Manifested in Childhood	10,455	0.9%	10,812	1.0%	-0.069	-0.007
Conduct Disorder	836	0.1%	804	0.1%	0.000	0.000
Delirium	15,599	1.4%	14,184	1.3%	0.079	0.007
Depression	195,804	17.7%	170,621	16.0%	1.691	0.045
Electroconvulsive Therapy	171	0.0%	172	0.0%	-0.001	-0.000
Hallucination	2,112	0.2%	2,009	0.2%	0.002	0.001
Obsessive-Compulsive Disorder	1,939	0.2%	1,755	0.2%	0.011	0.003
Other Cerebral Degenerations	15,367	1.4%	15,745	1.5%	-0.088	-0.007
Other Mental Disorders	8,573	0.8%	8,038	0.8%	0.021	0.002

Table 1bc. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Psychological Disorders	96,184	8.7%	100,302	9.4%	-0.716	-0.025
Persistent Mental Disorders due to Conditions Classified Elsewhere	16,998	1.5%	16,689	1.6%	-0.029	-0.002
Personality Disorders	4,302	0.4%	3,473	0.3%	0.063	0.011
Pervasive Developmental Disorders	1,562	0.1%	1,626	0.2%	-0.011	-0.003
Post-Traumatic Stress Disorder	19,059	1.7%	16,603	1.6%	0.165	0.013
Psychotherapy	57,653	5.2%	50,157	4.7%	0.505	0.023
Psychotic Conditions	4,037	0.4%	4,133	0.4%	-0.023	-0.004
Schizophrenia	17,014	1.5%	18,930	1.8%	-0.238	-0.019
Sleep Disorder	281,470	25.4%	242,448	22.7%	2.695	0.063
Substance Abuse	48,873	4.4%	48,448	4.5%	-0.128	-0.006
Suicidal Behavior	5,571	0.5%	4,727	0.4%	0.060	0.009
Transcranial Magnetic Stimulation	190	0.0%	167	0.0%	0.002	0.001
Vagus Nerve Stimulation	928	0.1%	702	0.1%	0.018	0.007
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	9,477	0.9%	0	0.0%	NaN	NaN
dulaglutide	378,927	34.2%	0	0.0%	NaN	NaN
exenatide	83,820	7.6%	0	0.0%	NaN	NaN
liraglutide	228,228	20.6%	0	0.0%	NaN	NaN
lixisenatide	13,024	1.2%	0	0.0%	NaN	NaN
semaglutide	371,191	33.5%	0	0.0%	NaN	NaN
tirzepatide	23,570	2.1%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,106,416	100.0%	1,065,962	100.0%	-0.000	-0.001
insulin*	393,552	35.6%	392,942	36.9%	-1.293	-0.027

Table 1bc. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
metformin*	980,474	88.6%	943,620	88.5%	0.094	0.003
alpha-glucosidase inhibitors*	4,579	0.4%	4,613	0.4%	-0.019	-0.003
thiazolidinediones*	90,200	8.2%	89,765	8.4%	-0.269	-0.010
meglitinides*	12,126	1.1%	12,296	1.2%	-0.058	-0.005
amylin analogue*	137	0.0%	149	0.0%	-0.002	-0.001
sulfonylureas*	411,933	37.2%	411,791	38.6%	-1.400	-0.029
bile acid sequestrants*	4,703	0.4%	4,320	0.4%	0.020	0.003
Other Weight Loss Agents*	2,850	0.3%	1,920	0.2%	0.077	0.017
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	319	0.0%	246	0.0%	0.006	0.004
diethylpropion	66	0.0%	36	0.0%	0.003	0.004
lorcaserin	141	0.0%	104	0.0%	0.003	0.003
phentermine	2,161	0.2%	1,439	0.1%	0.060	0.015
phentermine-topiramate	135	0.0%	71	0.0%	0.006	0.006
phendimetrazine	53	0.0%	27	0.0%	0.002	0.004
orlistat	51	0.0%	35	0.0%	0.001	0.002
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	286,744	25.9%	265,485	24.9%	1.011	0.023
Antipsychotics	69,551	6.3%	72,020	6.8%	-0.470	-0.019
Anxiolytics/Hypnotics	202,206	18.3%	196,885	18.5%	-0.194	-0.005
Lithium & Other Mood Stabilizers	59,470	5.4%	61,169	5.7%	-0.363	-0.016
Antidepressants	400,533	36.2%	367,138	34.4%	1.759	0.037
Health Service Utilization Intensity Metrics						

Table 1bc. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Mean number of ambulatory encounters*	11.0	10.4	10.9	10.4	0.150	0.014
Mean number of emergency room encounters*	0.4	1.1	0.4	1.1	0.009	0.008
Mean number of inpatient hospital encounters*	0.1	0.5	0.1	0.5	-0.005	-0.011
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	-0.001	-0.005
Mean number of other ambulatory encounters*	4.1	11.7	4.1	11.6	-0.042	-0.004
Mean number of filled prescriptions*	26.8	20.8	26.2	19.5	0.627	0.031
Mean number of generics dispensed*	11.3	5.5	11.1	5.1	0.203	0.038
Mean number of unique drug classes dispensed*	9.7	4.7	9.5	4.7	0.212	0.045

Table 1bc. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1bd. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use (15-day Gap & Ext) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	1,162,008	100.0%	1,081,164	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)*	60.7	10.5	63.7	10.2	-2.982	-0.288
Age						
18-24 years	6,141	0.5%	3,035	0.3%	0.248	0.039
25-44 years	142,620	12.3%	91,667	8.5%	3.795	0.125
45-64 years	493,312	42.5%	413,202	38.2%	4.235	0.086
65-79 years	475,385	40.9%	489,939	45.3%	-4.405	-0.089
≥ 80 years	44,550	3.8%	83,321	7.7%	-3.873	-0.167
Sex*						
Female	644,372	55.5%	470,612	43.5%	11.925	0.240
Male	517,636	44.5%	610,552	56.5%	-11.925	-0.240
Race[3]						
American Indian or Alaska Native	8,500	0.7%	5,936	0.5%	0.182	0.023
Asian	17,106	1.5%	38,595	3.6%	-2.098	-0.134
Black or African American	111,977	9.6%	100,887	9.3%	0.305	0.010
Multi-racial	6,193	0.5%	4,975	0.5%	0.073	0.010
Native Hawaiian or Other Pacific Islander	3,110	0.3%	3,770	0.3%	-0.081	-0.015
Unknown	422,244	36.3%	379,520	35.1%	1.235	0.026
White	592,878	51.0%	547,481	50.6%	0.384	0.008
Hispanic origin						

Table 1bd. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use (15-day Gap & Ext) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	52,638	4.5%	64,465	6.0%	-1.433	-0.064
No	666,348	57.3%	633,141	58.6%	-1.217	-0.025
Unknown	443,022	38.1%	383,558	35.5%	2.649	0.055
Year*						
2015	17,382	1.5%	18,309	1.7%	-0.198	-0.016
2016	84,177	7.2%	82,664	7.6%	-0.402	-0.015
2017	102,385	8.8%	101,827	9.4%	-0.607	-0.021
2018	121,378	10.4%	98,359	9.1%	1.348	0.045
2019	149,393	12.9%	137,437	12.7%	0.145	0.004
2020	162,658	14.0%	165,426	15.3%	-1.303	-0.037
2021	160,776	13.8%	166,905	15.4%	-1.601	-0.045
2022	197,492	17.0%	193,945	17.9%	-0.943	-0.025
2023	166,367	14.3%	116,292	10.8%	3.561	0.108
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[4]	1.3	1.6	1.5	1.7	-0.154	-0.093
Combined comorbidity score*,[5]	1.6	2.1	1.8	2.4	-0.206	-0.091
Medical History						
Obesity*	549,129	47.3%	368,396	34.1%	13.183	0.271
Weight Reduction Surgery or Procedure*	668	0.1%	600	0.1%	0.002	0.001
Lifestyle intervention*	214,168	18.4%	174,916	16.2%	2.252	0.060
Cardiovascular Disease*	202,982	17.5%	246,331	22.8%	-5.316	-0.133
Cognitive Impairment*	20,942	1.8%	24,994	2.3%	-0.510	-0.036
Traumatic Brain Injury*	2,474	0.2%	1,860	0.2%	0.041	0.009

Table 1bd. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use (15-day Gap & Ext) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	44,884	3.9%	28,961	2.7%	1.184	0.067
Epilepsy*	13,428	1.2%	12,016	1.1%	0.044	0.004
Chronic Pain*	243,651	21.0%	184,919	17.1%	3.864	0.099
Psychiatric History						
Previous Intentional Self-Harm Ever	8,674	0.7%	5,586	0.5%	0.230	0.029
Psychiatric History Overall*	723,890	62.3%	577,499	53.4%	8.882	0.181
Psychiatric Drug Dispensings	540,530	46.5%	401,704	37.2%	9.362	0.191
Intentional Self-Harm Encounter	1,071	0.1%	751	0.1%	0.023	0.008
Any Other Psychiatric Event	587,735	50.6%	465,851	43.1%	7.491	0.151
Disorder	13,753	1.2%	6,983	0.6%	0.538	0.056
Akathisia	1,096	0.1%	779	0.1%	0.022	0.008
Anxiety	194,810	16.8%	138,390	12.8%	3.965	0.112
Behavioral Disorder	45,535	3.9%	32,021	3.0%	0.957	0.053
Bipolar Disorder	45,943	4.0%	29,136	2.7%	1.259	0.070
Cerebral Degenerations usually Manifested in Childhood	9,345	0.8%	10,891	1.0%	-0.203	-0.021
Conduct Disorder	966	0.1%	670	0.1%	0.021	0.008
Delirium	12,693	1.1%	13,600	1.3%	-0.166	-0.015
Depression	211,185	18.2%	145,448	13.5%	4.721	0.130
Electroconvulsive Therapy	187	0.0%	123	0.0%	0.005	0.004
Hallucination	1,946	0.2%	1,752	0.2%	0.005	0.001
Obsessive-Compulsive Disorder	2,210	0.2%	1,423	0.1%	0.059	0.015
Other Cerebral Degenerations	14,231	1.2%	15,774	1.5%	-0.234	-0.020
Other Mental Disorders	8,613	0.7%	7,146	0.7%	0.080	0.010

Table 1bd. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use (15-day Gap & Ext) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Psychological Disorders	97,769	8.4%	92,164	8.5%	-0.111	-0.004
Persistent Mental Disorders due to Conditions Classified Elsewhere	14,467	1.2%	16,933	1.6%	-0.321	-0.027
Personality Disorders	4,891	0.4%	2,411	0.2%	0.198	0.035
Pervasive Developmental Disorders	1,941	0.2%	1,369	0.1%	0.040	0.011
Post-Traumatic Stress Disorder	21,929	1.9%	12,164	1.1%	0.762	0.063
Psychotherapy	65,814	5.7%	39,158	3.6%	2.042	0.097
Psychotic Conditions	3,853	0.3%	3,433	0.3%	0.014	0.002
Schizophrenia	18,438	1.6%	15,383	1.4%	0.164	0.013
Sleep Disorder	301,561	26.0%	220,702	20.4%	5.538	0.132
Substance Abuse	48,705	4.2%	43,505	4.0%	0.168	0.008
Suicidal Behavior	5,374	0.5%	4,149	0.4%	0.079	0.012
Transcranial Magnetic Stimulation	248	0.0%	129	0.0%	0.009	0.007
Vagus Nerve Stimulation	949	0.1%	589	0.1%	0.027	0.010
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	8,797	0.8%	0	0.0%	NaN	NaN
dulaglutide	385,530	33.2%	0	0.0%	NaN	NaN
exenatide	85,605	7.4%	0	0.0%	NaN	NaN
liraglutide	237,081	20.4%	0	0.0%	NaN	NaN
lixisenatide	15,881	1.4%	0	0.0%	NaN	NaN
semaglutide	401,760	34.6%	0	0.0%	NaN	NaN
tirzepatide	28,216	2.4%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,162,006	100.0%	1,081,163	100.0%	-0.000	-0.001
insulin*	393,037	33.8%	233,108	21.6%	12.263	0.277

Table 1bd. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use (15-day Gap & Ext) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
metformin*	1,026,815	88.4%	967,663	89.5%	-1.136	-0.036
alpha-glucosidase inhibitors*	4,652	0.4%	4,420	0.4%	-0.008	-0.001
thiazolidinediones*	95,142	8.2%	88,495	8.2%	0.003	0.000
meglitinides*	12,590	1.1%	11,036	1.0%	0.063	0.006
amylin analogue*	154	0.0%	78	0.0%	0.006	0.006
sulfonylureas*	427,711	36.8%	426,135	39.4%	-2.607	-0.054
bile acid sequestrants*	4,319	0.4%	3,629	0.3%	0.036	0.006
Other Weight Loss Agents*	4,010	0.3%	1,229	0.1%	0.231	0.048
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	421	0.0%	152	0.0%	0.022	0.014
diethylpropion	85	0.0%	27	0.0%	0.005	0.007
lorcaserin	181	0.0%	68	0.0%	0.009	0.009
phentermine	3,086	0.3%	920	0.1%	0.180	0.043
phentermine-topiramate	194	0.0%	46	0.0%	0.012	0.012
phendimetrazine	63	0.0%	16	0.0%	0.004	0.007
orlistat	69	0.0%	25	0.0%	0.004	0.006
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	290,145	25.0%	227,920	21.1%	3.888	0.092
Antipsychotics	77,737	6.7%	55,879	5.2%	1.521	0.064
Anxiolytics/Hypnotics	221,969	19.1%	164,507	15.2%	3.886	0.103
Lithium & Other Mood Stabilizers	67,842	5.8%	47,349	4.4%	1.459	0.066
Antidepressants	445,479	38.3%	312,764	28.9%	9.409	0.200
Health Service Utilization Intensity Metrics						

Table 1bd. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use (15-day Gap & Ext) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Mean number of ambulatory encounters*	10.9	10.5	10.0	9.5	0.854	0.085
Mean number of emergency room encounters*	0.3	1.0	0.3	1.0	0.010	0.010
Mean number of inpatient hospital encounters*	0.1	0.4	0.1	0.5	-0.038	-0.087
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	-0.005	-0.027
Mean number of other ambulatory encounters*	3.9	11.5	3.7	10.6	0.145	0.013
Mean number of filled prescriptions*	26.1	19.7	23.7	17.7	2.400	0.128
Mean number of generics dispensed*	10.9	5.1	10.2	4.8	0.699	0.141
Mean number of unique drug classes dispensed*	9.8	4.6	8.5	4.4	1.271	0.283

Table 1bd. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use (15-day Gap & Ext) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1be. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	1,161,940	100.0%	1,080,595	99.9%	N/A	N/A
Demographic Characteristics						
Age (years)*	60.7	10.5	63.7	10.2	-2.980	-0.288
Age						
18-24 years	6,141	0.5%	*****	*****	*****	*****
25-44 years	142,605	12.3%	91,642	8.5%	3.792	0.125
45-64 years	493,270	42.5%	412,968	38.2%	4.236	0.086
65-79 years	475,374	40.9%	489,669	45.3%	-4.403	-0.089
≥ 80 years	44,550	3.8%	*****	*****	*****	*****
Sex*						
Female	*****	*****	470,484	43.5%	*****	*****
Male	*****	*****	610,111	56.5%	*****	*****
Race[3]						
American Indian or Alaska Native	*****	*****	*****	*****	*****	*****
Asian	*****	*****	38,540	3.6%	*****	*****
Black or African American	*****	*****	100,812	9.3%	*****	*****
Multi-racial	*****	*****	*****	*****	*****	*****
Islander	3,110	0.3%	*****	*****	*****	*****
Unknown	422,230	36.3%	379,384	35.1%	1.230	0.026
White	592,837	51.0%	547,195	50.6%	0.383	0.008
Hispanic origin						
Yes	*****	*****	64,358	6.0%	*****	*****

Table 1be. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
No	666,323	57.3%	632,776	58.6%	-1.212	-0.025
Unknown	*****	*****	383,461	35.5%	*****	*****
Year*						
2015	17,382	1.5%	*****	*****	*****	*****
2016	*****	*****	*****	*****	*****	*****
2017	*****	*****	*****	*****	*****	*****
2018	*****	*****	*****	*****	*****	*****
2019	*****	*****	*****	*****	*****	*****
2020	*****	*****	165,401	15.3%	*****	*****
2021	160,762	13.8%	166,770	15.4%	-1.598	-0.045
2022	*****	*****	193,560	17.9%	*****	*****
2023	166,354	14.3%	*****	*****	*****	*****
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[4]	1.3	1.6	1.5	1.7	-0.154	-0.093
Combined comorbidity score*,[5]	1.6	2.1	1.8	2.4	-0.206	-0.091
Medical History						
Obesity*	549,070	47.3%	368,316	34.1%	13.170	0.271
Procedure*	668	0.1%	*****	*****	*****	*****
Lifestyle intervention*	214,145	18.4%	174,836	16.2%	2.250	0.060
Cardiovascular Disease*	*****	*****	246,175	22.8%	*****	*****
Cognitive Impairment*	20,942	1.8%	24,982	2.3%	-0.510	-0.036
Traumatic Brain Injury*	2,474	0.2%	*****	*****	*****	*****
Migraine*	44,871	3.9%	28,947	2.7%	1.183	0.067
Epilepsy*	*****	*****	12,004	1.1%	*****	*****

Table 1be. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Chronic Pain*	243,611	21.0%	184,866	17.1%	3.858	0.098
Psychiatric History						
Previous Intentional Self-Harm Ever	*****	*****	*****	*****	*****	*****
Psychiatric History Overall*	723,826	62.3%	577,276	53.4%	8.873	0.180
Psychiatric Drug Dispensings	540,470	46.5%	401,576	37.2%	9.352	0.190
Intentional Self-Harm Encounter	1,071	0.1%	751	0.1%	0.023	0.008
Any Other Psychiatric Event	587,676	50.6%	465,658	43.1%	7.484	0.150
Attention-Deficit/Hyperactivity Disorder	*****	*****	*****	*****	*****	*****
Akathisia	1,096	0.1%	779	0.1%	0.022	0.008
Anxiety	194,773	16.8%	138,351	12.8%	3.960	0.112
Behavioral Disorder	*****	*****	32,000	3.0%	*****	*****
Bipolar Disorder	45,929	4.0%	*****	*****	*****	*****
Cerebral Degenerations usually Manifested in Childhood	9,345	0.8%	*****	*****	*****	*****
Conduct Disorder	*****	*****	670	0.1%	*****	*****
Delirium	12,693	1.1%	*****	*****	*****	*****
Depression	211,149	18.2%	145,388	13.5%	4.718	0.130
Electroconvulsive Therapy	187	0.0%	123	0.0%	0.005	0.004
Hallucination	1,946	0.2%	*****	*****	*****	*****
Obsessive-Compulsive Disorder	*****	*****	1,423	0.1%	*****	*****
Other Cerebral Degenerations	*****	*****	*****	*****	*****	*****
Other Mental Disorders	*****	*****	*****	*****	*****	*****
Other Psychological Disorders	*****	*****	92,123	8.5%	*****	*****

Table 1be. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Persistent Mental Disorders due to Conditions Classified Elsewhere	14,467	1.2%	*****	*****	*****	*****
Personality Disorders	*****	*****	*****	*****	*****	*****
Pervasive Developmental Disorders	*****	*****	1,369	0.1%	0.040	0.011
Post-Traumatic Stress Disorder	*****	*****	*****	*****	*****	*****
Psychotherapy	65,792	5.7%	39,147	3.6%	2.040	0.097
Psychotic Conditions	3,853	0.3%	*****	*****	*****	*****
Schizophrenia	*****	*****	*****	*****	*****	*****
Sleep Disorder	301,517	25.9%	220,610	20.4%	5.534	0.131
Substance Abuse	48,694	4.2%	43,492	4.0%	0.166	0.008
Suicidal Behavior	5,374	0.5%	*****	*****	*****	*****
Transcranial Magnetic Stimulation	248	0.0%	129	0.0%	0.009	0.007
Vagus Nerve Stimulation	*****	*****	*****	*****	*****	*****
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	8,797	0.8%	0	0.0%	NaN	NaN
dulaglutide	385,514	33.2%	0	0.0%	NaN	NaN
exenatide	*****	*****	0	0.0%	*****	*****
liraglutide	237,060	20.4%	0	0.0%	NaN	NaN
lixisenatide	*****	*****	0	0.0%	*****	*****
semaglutide	401,738	34.6%	0	0.0%	NaN	NaN
tirzepatide	28,216	2.4%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,161,938	100.0%	1,080,594	100.0%	-0.000	-0.001
insulin*	393,000	33.8%	233,046	21.6%	12.256	0.276

Table 1be. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
metformin*	1,026,756	88.4%	967,159	89.5%	-1.137	-0.036
alpha-glucosidase inhibitors*	*****	*****	*****	*****	*****	*****
thiazolidinediones*	*****	*****	88,425	8.2%	*****	*****
meglitinides*	*****	*****	11,036	1.0%	*****	*****
amylin analogue*	154	0.0%	*****	*****	*****	*****
sulfonylureas*	427,684	36.8%	425,711	39.4%	-2.588	-0.053
bile acid sequestrants*	*****	*****	*****	*****	*****	*****
Other Weight Loss Agents*	*****	*****	*****	*****	*****	*****
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	421	0.0%	152	0.0%	0.022	0.014
diethylpropion	85	0.0%	27	0.0%	0.005	0.007
lorcaserin	181	0.0%	68	0.0%	0.009	0.009
phentermine	*****	*****	*****	*****	*****	*****
phentermine-topiramate	194	0.0%	46	0.0%	0.012	0.012
phendimetrazine	63	0.0%	*****	*****	*****	*****
orlistat	69	0.0%	25	0.0%	0.004	0.006
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	290,107	25.0%	227,832	21.1%	3.884	0.092
Antipsychotics	77,717	6.7%	55,863	5.2%	1.519	0.064
Anxiolytics/Hypnotics	221,927	19.1%	164,471	15.2%	3.879	0.103
Lithium & Other Mood Stabilizers	67,822	5.8%	47,334	4.4%	1.457	0.066
Antidepressants	445,424	38.3%	312,660	28.9%	9.400	0.200
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	10.9	10.5	10.0	9.5	0.851	0.085

Table 1be. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Mean number of emergency room encounters*	0.3	1.0	0.3	1.0	0.010	0.010
Mean number of inpatient hospital encounters*	0.1	0.4	0.1	0.5	-0.038	-0.087
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	-0.005	-0.027
Mean number of other ambulatory encounters*	3.9	11.5	3.7	10.6	0.150	0.014
Mean number of filled prescriptions*	26.1	19.7	23.7	17.7	2.397	0.128
Mean number of generics dispensed*	10.9	5.1	10.2	4.8	0.699	0.141
Mean number of unique drug classes dispensed*	9.8	4.6	8.5	4.4	1.270	0.283

Table 1be. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1bf. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	1,709,551	N/A	1,192,050	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	60.5	10.3	62.0	10.8	-1.519	-0.144
Age						
18-24 years	4,860	0.3%	4,739	0.4%	-0.113	-0.019
25-44 years	160,906	9.4%	125,569	10.5%	-1.122	-0.039
45-64 years	864,861	50.6%	493,967	41.4%	9.152	0.205
65-79 years	611,902	35.8%	496,525	41.7%	-5.860	-0.141
≥ 80 years	67,022	3.9%	71,251	6.0%	-2.057	-0.096
Sex*						
Female	852,613	49.9%	612,474	51.4%	-1.506	-0.030
Male	856,939	50.1%	579,576	48.6%	1.506	0.030
Race[4]						
American Indian or Alaska Native	10,107	0.6%	6,996	0.6%	0.004	0.001
Asian	23,083	1.4%	34,104	2.9%	-1.511	-0.106
Black or African American	146,851	8.6%	122,378	10.3%	-1.676	-0.059
Multi-racial	8,956	0.5%	5,719	0.5%	0.044	0.006
Islander	3,475	0.2%	3,383	0.3%	-0.081	-0.016
Unknown	785,786	46.0%	425,022	35.7%	10.310	0.362
White	731,294	42.8%	594,447	49.9%	-7.091	-0.188
Hispanic origin						

Table 1bf. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	61,127	3.6%	71,253	6.0%	-2.402	-0.117
No	796,576	46.6%	689,935	57.9%	-11.282	-0.446
Unknown	851,849	49.8%	430,862	36.1%	13.684	0.683
Year*						
2015	34,657	2.0%	19,969	1.7%	0.352	0.026
2016	135,490	7.9%	94,290	7.9%	0.016	0.001
2017	184,173	10.8%	112,459	9.4%	1.339	0.045
2018	163,932	9.6%	122,858	10.3%	-0.717	-0.024
2019	196,739	11.5%	154,307	12.9%	-1.436	-0.044
2020	227,607	13.3%	173,171	14.5%	-1.213	-0.036
2021	220,515	12.9%	172,546	14.5%	-1.576	-0.046
2022	330,942	19.4%	201,060	16.9%	2.492	0.066
2023	215,497	12.6%	141,390	11.9%	0.744	0.023
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.8	2.0	1.5	1.7	0.269	0.142
Combined comorbidity score*,[6]	2.4	3.0	1.9	2.4	0.508	0.189
Medical History						
Obesity*	837,951	49.0%	511,018	42.9%	6.147	0.125
Procedure*	3,133	0.2%	1,108	0.1%	0.090	0.024
Lifestyle intervention*	324,976	19.0%	202,526	17.0%	2.020	0.053
Cardiovascular Disease*	423,607	24.8%	256,869	21.5%	3.230	0.078
Cognitive Impairment*	60,619	3.5%	27,451	2.3%	1.243	0.074
Traumatic Brain Injury*	2,970	0.2%	2,928	0.2%	-0.072	-0.016

Table 1bf. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	98,459	5.8%	48,166	4.0%	1.719	0.080
Epilepsy*	30,530	1.8%	15,964	1.3%	0.447	0.036
Chronic Pain*	527,262	30.8%	259,726	21.8%	9.054	0.208
Psychiatric History						
Previous Intentional Self-Harm Ever	16,182	0.9%	9,729	0.8%	0.130	0.014
Psychiatric History Overall*	1,180,510	69.1%	731,204	61.3%	7.714	0.163
Psychiatric Drug Dispensings	893,252	52.3%	551,492	46.3%	5.987	0.121
Intentional Self-Harm Encounter	4,595	0.3%	1,261	0.1%	0.163	0.038
Any Other Psychiatric Event	1,002,391	58.6%	594,329	49.9%	8.777	0.177
Attention-Deficit/Hyperactivity Disorder	47,450	2.8%	11,400	1.0%	1.819	0.136
Akathisia	1,705	0.1%	1,196	0.1%	-0.001	-0.000
Anxiety	376,029	22.0%	200,595	16.8%	5.168	0.131
Behavioral Disorder	106,372	6.2%	46,139	3.9%	2.352	0.107
Bipolar Disorder	105,489	6.2%	52,423	4.4%	1.773	0.079
Cerebral Degenerations usually Manifested in Childhood	21,388	1.3%	12,601	1.1%	0.194	0.018
Conduct Disorder	955	0.1%	993	0.1%	-0.027	-0.010
Delirium	53,953	3.2%	16,876	1.4%	1.740	0.116
Depression	392,833	23.0%	209,612	17.6%	5.395	0.135
Electroconvulsive Therapy	418	0.0%	226	0.0%	0.005	0.004
Hallucination	5,810	0.3%	2,612	0.2%	0.121	0.023
Obsessive-Compulsive Disorder	7,252	0.4%	2,145	0.2%	0.244	0.044
Other Cerebral Degenerations	23,755	1.4%	17,481	1.5%	-0.077	-0.006
Other Mental Disorders	20,935	1.2%	9,704	0.8%	0.411	0.041

Table 1bf. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Psychological Disorders	266,326	15.6%	121,220	10.2%	5.410	0.162
Persistent Mental Disorders due to Conditions Classified Elsewhere	35,745	2.1%	18,521	1.6%	0.537	0.040
Personality Disorders	13,512	0.8%	5,340	0.4%	0.342	0.044
Disorders	1,643	0.1%	1,860	0.2%	-0.060	-0.017
Post-Traumatic Stress Disorder	47,320	2.8%	23,392	2.0%	0.806	0.053
Psychotherapy	119,366	7.0%	66,068	5.5%	1.440	0.059
Psychotic Conditions	6,147	0.4%	5,301	0.4%	-0.085	-0.013
Schizophrenia	40,256	2.4%	24,052	2.0%	0.337	0.023
Sleep Disorder	566,601	33.1%	290,367	24.4%	8.785	0.197
Substance Abuse	107,668	6.3%	59,289	5.0%	1.324	0.058
Suicidal Behavior	13,913	0.8%	5,595	0.5%	0.345	0.043
Transcranial Magnetic Stimulation	197	0.0%	368	0.0%	-0.019	-0.013
Vagus Nerve Stimulation	1,581	0.1%	1,216	0.1%	-0.010	-0.003
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	31,668	1.9%	0	0.0%	NaN	NaN
dulaglutide	615,828	36.0%	0	0.0%	NaN	NaN
exenatide	133,944	7.8%	0	0.0%	NaN	NaN
liraglutide	332,859	19.5%	0	0.0%	NaN	NaN
lixisenatide	17,604	1.0%	0	0.0%	NaN	NaN
semaglutide	537,620	31.4%	0	0.0%	NaN	NaN
tirzepatide	62,742	3.7%	0	0.0%	NaN	NaN

Table 1bf. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Any Anti-Diabetic Agents	1,709,548	100.0%	1,192,049	100.0%	-0.000	-0.001
insulin*	707,158	41.4%	506,887	42.5%	-1.157	-0.023
metformin*	1,534,017	89.7%	1,052,044	88.3%	1.477	0.047
alpha-glucosidase inhibitors*	6,467	0.4%	5,562	0.5%	-0.088	-0.014
thiazolidinediones*	113,241	6.6%	105,095	8.8%	-2.192	-0.082
meglitinides*	17,228	1.0%	14,814	1.2%	-0.235	-0.022
amylin analogue*	316	0.0%	203	0.0%	0.001	0.001
sulfonylureas*	535,397	31.3%	462,954	38.8%	-7.519	-0.159
bile acid sequestrants*	7,384	0.4%	5,239	0.4%	-0.008	-0.001
Other Weight Loss Agents*	4,827	0.3%	3,244	0.3%	0.010	0.002
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	1,507	0.1%	328	0.0%	0.061	0.025
diethylpropion	108	0.0%	70	0.0%	0.000	0.001
lorcaserin	143	0.0%	228	0.0%	-0.011	-0.009
phentermine	2,895	0.2%	2,358	0.2%	-0.028	-0.007
phentermine-topiramate	184	0.0%	193	0.0%	-0.005	-0.005
phendimetrazine	103	0.0%	66	0.0%	0.000	0.001
orlistat	52	0.0%	49	0.0%	-0.001	-0.002
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	717,137	41.9%	325,760	27.3%	14.621	0.312
Antipsychotics	183,789	10.8%	94,109	7.9%	2.856	0.098
Anxiolytics/Hypnotics	457,115	26.7%	247,948	20.8%	5.939	0.140
Lithium & Other Mood Stabilizers	138,302	8.1%	81,832	6.9%	1.225	0.047

Table 1bf. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Antidepressants	712,764	41.7%	444,271	37.3%	4.424	0.091
Health Service Utilization Intensity Metrics						
encounters*	14.2	13.2	11.6	11.3	2.677	0.218
Mean number of emergency room encounters*	1.0	2.3	0.4	1.2	0.531	0.286
Mean number of inpatient hospital encounters*	0.3	0.8	0.1	0.5	0.188	0.291
Mean number of non-acute institutional encounters*	0.1	0.3	0.0	0.2	0.025	0.090
Mean number of other ambulatory encounters*	5.8	12.7	4.4	12.2	1.381	0.111
Mean number of filled prescriptions*	38.3	32.5	27.8	21.4	10.457	0.380
Mean number of generics dispensed*	15.8	9.4	11.6	5.5	4.210	0.547
Mean number of unique drug classes dispensed*	12.1	6.8	10.2	5.3	1.957	0.320

Table 1bf. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1bg. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	1,154,805	N/A	1,118,689	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.6	10.3	62.4	10.7	-0.849	-0.081
Age						
18-24 years	4,638	0.4%	4,377	0.4%	0.010	0.002
25-44 years	123,024	10.7%	112,474	10.1%	0.599	0.021
45-64 years	492,533	42.7%	453,317	40.5%	2.129	0.048
65-79 years	480,889	41.6%	478,851	42.8%	-1.162	-0.028
≥ 80 years	53,721	4.7%	69,670	6.2%	-1.576	-0.071
Sex*						
Female	589,854	51.1%	558,052	49.9%	1.194	0.024
Male	564,951	48.9%	560,638	50.1%	-1.194	-0.024
Race[4]						
American Indian or Alaska Native	8,291	0.7%	6,747	0.6%	0.115	0.014
Asian	18,497	1.6%	33,426	3.0%	-1.386	-0.093
Black or African American	109,078	9.4%	114,761	10.3%	-0.813	-0.028
Multi-racial	5,987	0.5%	5,337	0.5%	0.041	0.006
Native Hawaiian or Other Pacific Islander	3,255	0.3%	3,344	0.3%	-0.017	-0.003
Unknown	426,899	37.0%	389,222	34.8%	2.175	0.073
White	582,799	50.5%	565,853	50.6%	-0.114	-0.003
Hispanic origin						

Table 1bg. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	52,383	4.5%	68,496	6.1%	-1.587	-0.074
No	652,623	56.5%	658,573	58.9%	-2.356	-0.088
Unknown	449,799	39.0%	391,621	35.0%	3.943	0.185
Year*						
2015	19,412	1.7%	18,840	1.7%	-0.003	-0.000
2016	90,726	7.9%	87,978	7.9%	-0.008	-0.000
2017	110,275	9.5%	106,174	9.5%	0.058	0.002
2018	118,091	10.2%	113,633	10.2%	0.068	0.002
2019	150,485	13.0%	146,062	13.1%	-0.025	-0.001
2020	167,305	14.5%	165,112	14.8%	-0.272	-0.008
2021	162,518	14.1%	163,068	14.6%	-0.503	-0.015
2022	194,457	16.8%	188,636	16.9%	-0.023	-0.001
2023	141,535	12.3%	129,186	11.5%	0.708	0.022
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.5	1.7	1.5	1.7	-0.034	-0.019
Combined comorbidity score*,[6]	1.8	2.3	1.9	2.4	-0.033	-0.014
Medical History						
Obesity*	500,063	43.3%	460,840	41.2%	2.108	0.043
Weight Reduction Surgery or Procedure*	816	0.1%	834	0.1%	-0.004	-0.001
Lifestyle intervention*	204,406	17.7%	186,330	16.7%	1.044	0.028
Cardiovascular Disease*	243,863	21.1%	242,375	21.7%	-0.549	-0.014
Cognitive Impairment*	26,503	2.3%	25,974	2.3%	-0.027	-0.002
Traumatic Brain Injury*	2,486	0.2%	2,455	0.2%	-0.004	-0.001

Table 1bg. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	43,603	3.8%	39,770	3.6%	0.221	0.012
Epilepsy*	15,006	1.3%	14,233	1.3%	0.027	0.002
Chronic Pain*	246,278	21.3%	230,368	20.6%	0.734	0.018
Psychiatric History						
Previous Intentional Self-Harm Ever	8,635	0.7%	8,272	0.7%	0.008	0.001
Psychiatric History Overall*	706,017	61.1%	668,207	59.7%	1.406	0.029
Psychiatric Drug Dispensings	517,234	44.8%	495,440	44.3%	0.502	0.010
Intentional Self-Harm Encounter	1,201	0.1%	1,060	0.1%	0.009	0.003
Any Other Psychiatric Event	578,453	50.1%	540,027	48.3%	1.818	0.037
Attention-Deficit/Hyperactivity Disorder	12,283	1.1%	9,763	0.9%	0.191	0.020
Akathisia	1,123	0.1%	1,040	0.1%	0.004	0.001
Anxiety	188,816	16.4%	176,386	15.8%	0.583	0.016
Behavioral Disorder	45,704	4.0%	39,968	3.6%	0.385	0.020
Bipolar Disorder	43,723	3.8%	42,708	3.8%	-0.032	-0.002
Cerebral Degenerations usually Manifested in Childhood	11,396	1.0%	11,401	1.0%	-0.032	-0.003
Conduct Disorder	873	0.1%	861	0.1%	-0.001	-0.000
Delirium	17,653	1.5%	15,115	1.4%	0.177	0.015
Depression	207,655	18.0%	184,829	16.5%	1.460	0.039
Electroconvulsive Therapy	194	0.0%	196	0.0%	-0.001	-0.001
Hallucination	2,367	0.2%	2,173	0.2%	0.011	0.002
Obsessive-Compulsive Disorder	2,057	0.2%	1,924	0.2%	0.006	0.001
Other Cerebral Degenerations	16,575	1.4%	16,515	1.5%	-0.041	-0.003
Other Mental Disorders	9,308	0.8%	8,713	0.8%	0.027	0.003

Table 1bg. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Psychological Disorders	103,140	8.9%	107,681	9.6%	-0.694	-0.024
Persistent Mental Disorders due to Conditions Classified Elsewhere	18,638	1.6%	17,430	1.6%	0.056	0.004
Personality Disorders	4,636	0.4%	3,953	0.4%	0.048	0.008
Pervasive Developmental Disorders	1,602	0.1%	1,721	0.2%	-0.015	-0.004
Post-Traumatic Stress Disorder	20,193	1.7%	18,567	1.7%	0.089	0.007
Psychotherapy	60,930	5.3%	55,373	4.9%	0.326	0.015
Psychotic Conditions	4,416	0.4%	4,511	0.4%	-0.021	-0.003
Schizophrenia	18,050	1.6%	20,562	1.8%	-0.275	-0.021
Sleep Disorder	298,345	25.8%	260,239	23.3%	2.572	0.060
Substance Abuse	52,736	4.6%	52,212	4.7%	-0.101	-0.005
Suicidal Behavior	6,046	0.5%	5,073	0.5%	0.070	0.010
Transcranial Magnetic Stimulation	194	0.0%	185	0.0%	0.000	0.000
Vagus Nerve Stimulation	1,008	0.1%	804	0.1%	0.015	0.005
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	10,077	0.9%	0	0.0%	NaN	NaN
dulaglutide	396,601	34.3%	0	0.0%	NaN	NaN
exenatide	87,651	7.6%	0	0.0%	NaN	NaN
liraglutide	238,675	20.7%	0	0.0%	NaN	NaN
lixisenatide	13,554	1.2%	0	0.0%	NaN	NaN
semaglutide	386,268	33.4%	0	0.0%	NaN	NaN
tirzepatide	24,406	2.1%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,154,802	100.0%	1,118,688	100.0%	-0.000	-0.001

Table 1bg. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
insulin*	419,617	36.3%	439,486	39.3%	-2.949	-0.061
metformin*	1,023,043	88.6%	988,823	88.4%	0.199	0.006
alpha-glucosidase inhibitors*	4,812	0.4%	4,941	0.4%	-0.025	-0.004
thiazolidinediones*	93,709	8.1%	95,317	8.5%	-0.406	-0.015
meglitinides*	12,733	1.1%	13,303	1.2%	-0.087	-0.008
amylin analogue*	146	0.0%	179	0.0%	-0.003	-0.003
sulfonylureas*	428,852	37.1%	432,258	38.6%	-1.503	-0.031
bile acid sequestrants*	5,159	0.4%	4,684	0.4%	0.028	0.004
Other Weight Loss Agents*	2,956	0.3%	2,233	0.2%	0.056	0.012
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	332	0.0%	290	0.0%	0.003	0.002
diethylpropion	74	0.0%	41	0.0%	0.003	0.004
lorcaserin	143	0.0%	121	0.0%	0.002	0.001
phentermine	2,238	0.2%	1,671	0.1%	0.044	0.011
phentermine-topiramate	144	0.0%	78	0.0%	0.005	0.006
phendimetrazine	59	0.0%	31	0.0%	0.002	0.004
orlistat	52	0.0%	42	0.0%	0.001	0.001
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	310,337	26.9%	287,910	25.7%	1.137	0.026
Antipsychotics	74,029	6.4%	79,274	7.1%	-0.676	-0.027
Anxiolytics/Hypnotics	215,268	18.6%	214,851	19.2%	-0.565	-0.014
Lithium & Other Mood Stabilizers	62,920	5.4%	67,617	6.0%	-0.596	-0.026
Antidepressants	420,863	36.4%	396,396	35.4%	1.011	0.021

Table 1bg. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	11.3	10.6	11.1	10.6	0.165	0.016
Mean number of emergency room encounters*	0.4	1.2	0.4	1.1	0.022	0.019
Mean number of inpatient hospital encounters*	0.1	0.5	0.1	0.5	0.007	0.014
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	0.001	0.003
Mean number of other ambulatory encounters*	4.2	11.7	4.2	11.7	-0.005	-0.000
Mean number of filled prescriptions*	27.5	21.4	26.7	19.9	0.741	0.036
Mean number of generics dispensed*	11.5	5.7	11.2	5.2	0.278	0.051
Mean number of unique drug classes dispensed*	9.8	4.8	9.7	4.9	0.134	0.028

Table 1bg. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1bh. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	1,106,400	N/A	1,065,923	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.5	10.3	62.6	10.6	-1.092	-0.104
Age						
18-24 years	4,595	0.4%	4,037	0.4%	0.037	0.006
25-44 years	119,430	10.8%	104,703	9.8%	0.972	0.033
45-64 years	468,561	42.4%	425,907	40.0%	2.393	0.055
65-79 years	462,997	41.8%	462,918	43.4%	-1.582	-0.038
≥ 80 years	50,816	4.6%	68,358	6.4%	-1.820	-0.081
Sex*						
Female	568,148	51.4%	522,449	49.0%	2.337	0.047
Male	538,252	48.6%	543,474	51.0%	-2.337	-0.047
Race[4]						
American Indian or Alaska Native	8,058	0.7%	6,445	0.6%	0.124	0.015
Asian	17,784	1.6%	32,811	3.1%	-1.471	-0.098
Black or African American	104,889	9.5%	108,891	10.2%	-0.735	-0.025
Multi-racial	5,619	0.5%	4,980	0.5%	0.041	0.006
Islander	3,163	0.3%	3,284	0.3%	-0.022	-0.004
Unknown	404,338	36.5%	366,548	34.4%	2.158	0.072
White	562,550	50.8%	542,964	50.9%	-0.093	-0.002
Hispanic origin						

Table 1bh. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	50,693	4.6%	66,021	6.2%	-1.612	-0.075
No	632,078	57.1%	632,663	59.4%	-2.224	-0.082
Unknown	423,629	38.3%	367,239	34.5%	3.836	0.179
Year*						
2015	18,226	1.6%	17,933	1.7%	-0.035	-0.003
2016	85,726	7.7%	83,539	7.8%	-0.089	-0.003
2017	104,376	9.4%	101,273	9.5%	-0.067	-0.002
2018	113,055	10.2%	106,878	10.0%	0.191	0.006
2019	144,082	13.0%	139,230	13.1%	-0.039	-0.001
2020	160,821	14.5%	158,884	14.9%	-0.370	-0.011
2021	155,982	14.1%	156,142	14.6%	-0.550	-0.016
2022	186,641	16.9%	180,441	16.9%	-0.059	-0.002
2023	137,491	12.4%	121,603	11.4%	1.019	0.032
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*[,5]	1.5	1.7	1.5	1.7	-0.063	-0.037
Combined comorbidity score*[,6]	1.8	2.3	1.9	2.4	-0.074	-0.032
Medical History						
Obesity*	478,477	43.2%	427,655	40.1%	3.126	0.064
Weight Reduction Surgery or Procedure*	736	0.1%	735	0.1%	-0.002	-0.001
Lifestyle intervention*	195,844	17.7%	175,947	16.5%	1.194	0.032
Cardiovascular Disease*	226,015	20.4%	232,262	21.8%	-1.362	-0.034
Cognitive Impairment*	24,202	2.2%	24,798	2.3%	-0.139	-0.009
Traumatic Brain Injury*	2,331	0.2%	2,212	0.2%	0.003	0.001

Table 1bh. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	40,655	3.7%	35,861	3.4%	0.310	0.017
Epilepsy*	13,840	1.3%	13,264	1.2%	0.006	0.001
Chronic Pain*	230,065	20.8%	212,653	20.0%	0.844	0.021
Psychiatric History						
Previous Intentional Self-Harm Ever	8,060	0.7%	7,433	0.7%	0.031	0.004
Psychiatric History Overall*	671,480	60.7%	626,797	58.8%	1.887	0.039
Psychiatric Drug Dispensings	491,304	44.4%	460,496	43.2%	1.204	0.024
Intentional Self-Harm Encounter	1,085	0.1%	945	0.1%	0.009	0.003
Any Other Psychiatric Event	548,487	49.6%	505,598	47.4%	2.141	0.043
Attention-Deficit/Hyperactivity Disorder	11,598	1.0%	8,818	0.8%	0.221	0.023
Akathisia	1,047	0.1%	943	0.1%	0.006	0.002
Anxiety	177,506	16.0%	162,132	15.2%	0.833	0.023
Behavioral Disorder	42,719	3.9%	36,786	3.5%	0.410	0.022
Bipolar Disorder	41,139	3.7%	38,423	3.6%	0.114	0.006
Cerebral Degenerations usually Manifested in Childhood	10,455	0.9%	10,812	1.0%	-0.069	-0.007
Conduct Disorder	835	0.1%	806	0.1%	-0.000	-0.000
Delirium	15,596	1.4%	14,182	1.3%	0.079	0.007
Depression	195,785	17.7%	170,603	16.0%	1.690	0.045
Electroconvulsive Therapy	171	0.0%	172	0.0%	-0.001	-0.000
Hallucination	2,110	0.2%	2,007	0.2%	0.002	0.001
Obsessive-Compulsive Disorder	1,935	0.2%	1,755	0.2%	0.010	0.002
Other Cerebral Degenerations	15,367	1.4%	15,744	1.5%	-0.088	-0.007
Other Mental Disorders	8,572	0.8%	8,038	0.8%	0.021	0.002

Table 1bh. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Psychological Disorders	96,171	8.7%	100,290	9.4%	-0.717	-0.025
Persistent Mental Disorders due to Conditions Classified Elsewhere	16,997	1.5%	16,688	1.6%	-0.029	-0.002
Personality Disorders	4,304	0.4%	3,471	0.3%	0.063	0.011
Pervasive Developmental Disorders	1,562	0.1%	1,626	0.2%	-0.011	-0.003
Post-Traumatic Stress Disorder	19,061	1.7%	16,592	1.6%	0.166	0.013
Psychotherapy	57,647	5.2%	50,143	4.7%	0.506	0.023
Psychotic Conditions	4,033	0.4%	4,129	0.4%	-0.023	-0.004
Schizophrenia	17,010	1.5%	18,924	1.8%	-0.238	-0.019
Sleep Disorder	281,451	25.4%	242,439	22.7%	2.694	0.063
Substance Abuse	48,868	4.4%	48,440	4.5%	-0.127	-0.006
Suicidal Behavior	5,557	0.5%	4,710	0.4%	0.060	0.009
Transcranial Magnetic Stimulation	190	0.0%	167	0.0%	0.002	0.001
Vagus Nerve Stimulation	929	0.1%	702	0.1%	0.018	0.007
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	9,477	0.9%	0	0.0%	NaN	NaN
dulaglutide	378,914	34.2%	0	0.0%	NaN	NaN
exenatide	83,823	7.6%	0	0.0%	NaN	NaN
liraglutide	228,228	20.6%	0	0.0%	NaN	NaN
lixisenatide	13,024	1.2%	0	0.0%	NaN	NaN
semaglutide	371,185	33.5%	0	0.0%	NaN	NaN
tirzepatide	23,568	2.1%	0	0.0%	NaN	NaN

Table 1bh. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Any Anti-Diabetic Agents	1,106,397	100.0%	1,065,922	100.0%	-0.000	-0.001
insulin*	393,542	35.6%	392,918	36.9%	-1.292	-0.027
metformin*	980,454	88.6%	943,589	88.5%	0.093	0.003
alpha-glucosidase inhibitors*	4,579	0.4%	4,612	0.4%	-0.019	-0.003
thiazolidinediones*	90,200	8.2%	89,754	8.4%	-0.268	-0.010
meglitinides*	12,127	1.1%	12,296	1.2%	-0.058	-0.005
amylin analogue*	137	0.0%	149	0.0%	-0.002	-0.001
sulfonylureas*	411,921	37.2%	411,778	38.6%	-1.400	-0.029
bile acid sequestrants*	4,703	0.4%	4,320	0.4%	0.020	0.003
Other Weight Loss Agents*	2,850	0.3%	1,920	0.2%	0.077	0.017
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	319	0.0%	246	0.0%	0.006	0.004
diethylpropion	66	0.0%	36	0.0%	0.003	0.004
lorcaserin	141	0.0%	104	0.0%	0.003	0.003
phentermine	2,161	0.2%	1,439	0.1%	0.060	0.015
phentermine-topiramate	135	0.0%	71	0.0%	0.006	0.006
phendimetrazine	53	0.0%	27	0.0%	0.002	0.004
orlistat	51	0.0%	35	0.0%	0.001	0.002
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	286,731	25.9%	265,476	24.9%	1.010	0.023
Antipsychotics	69,541	6.3%	72,006	6.8%	-0.470	-0.019
Anxiolytics/Hypnotics	202,189	18.3%	196,873	18.5%	-0.195	-0.005
Lithium & Other Mood Stabilizers	59,470	5.4%	61,161	5.7%	-0.363	-0.016

Table 1bh. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Antidepressants	400,511	36.2%	367,109	34.4%	1.759	0.037
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	11.0	10.4	10.9	10.4	0.150	0.014
Mean number of emergency room encounters*	0.4	1.1	0.4	1.1	0.009	0.008
Mean number of inpatient hospital encounters*	0.1	0.5	0.1	0.5	-0.005	-0.011
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	-0.001	-0.005
Mean number of other ambulatory encounters*	4.1	11.7	4.1	11.6	-0.042	-0.004
Mean number of filled prescriptions*	26.8	20.8	26.2	19.5	0.627	0.031
Mean number of generics dispensed*	11.3	5.5	11.1	5.1	0.203	0.038
Mean number of unique drug classes dispensed*	9.7	4.7	9.5	4.7	0.212	0.045

Table 1bh. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759.
Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.
*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
N/A = Not applicable
NaN = Not a number

Table 1bi. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use - Two or more dispensings in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	824,408	100.0%	752,899	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)*	60.4	10.4	63.6	10.1	-3.175	-0.309
Age						
18-24 years	4,047	0.5%	1,854	0.2%	0.245	0.040
25-44 years	103,048	12.5%	62,401	8.3%	4.212	0.138
45-64 years	361,104	43.8%	295,040	39.2%	4.614	0.094
65-79 years	326,648	39.6%	338,446	45.0%	-5.330	-0.108
≥ 80 years	29,561	3.6%	55,158	7.3%	-3.740	-0.165
Sex*						
Female	458,670	55.6%	321,106	42.6%	12.987	0.262
Male	365,738	44.4%	431,793	57.4%	-12.987	-0.262
Race[3]						
American Indian or Alaska Native	5,954	0.7%	4,103	0.5%	0.177	0.022
Asian	11,727	1.4%	27,375	3.6%	-2.213	-0.141
Black or African American	74,833	9.1%	64,044	8.5%	0.571	0.020
Multi-racial	4,676	0.6%	3,597	0.5%	0.089	0.012
Islander	2,017	0.2%	2,434	0.3%	-0.079	-0.015
Unknown	307,726	37.3%	268,527	35.7%	1.661	0.035
White	417,475	50.6%	382,819	50.8%	-0.207	-0.004
Hispanic origin						

Table 1bi. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use - Two or more dispensings in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	36,553	4.4%	43,090	5.7%	-1.289	-0.059
No	464,013	56.3%	436,917	58.0%	-1.747	-0.035
Unknown	323,842	39.3%	272,892	36.2%	3.036	0.063
Year*						
2015	6,266	0.8%	7,418	1.0%	-0.225	-0.024
2016	52,494	6.4%	54,551	7.2%	-0.878	-0.035
2017	69,671	8.5%	70,748	9.4%	-0.946	-0.033
2018	85,611	10.4%	69,460	9.2%	1.159	0.039
2019	107,369	13.0%	95,113	12.6%	0.391	0.012
2020	120,277	14.6%	118,880	15.8%	-1.200	-0.033
2021	116,034	14.1%	116,998	15.5%	-1.465	-0.041
2022	143,381	17.4%	139,123	18.5%	-1.086	-0.028
2023	123,305	15.0%	80,608	10.7%	4.250	0.127
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[4]	1.3	1.6	1.4	1.7	-0.161	-0.099
Combined comorbidity score*,[5]	1.6	2.0	1.8	2.3	-0.188	-0.086
Medical History						
Obesity*	394,018	47.8%	255,953	34.0%	13.798	0.283
Weight Reduction Surgery or Procedure*	420	0.1%	382	0.1%	0.000	0.000
Lifestyle intervention*	155,164	18.8%	122,423	16.3%	2.561	0.067
Cardiovascular Disease*	137,170	16.6%	167,391	22.2%	-5.594	-0.142
Cognitive Impairment*	14,554	1.8%	17,419	2.3%	-0.548	-0.039
Traumatic Brain Injury*	1,755	0.2%	1,335	0.2%	0.036	0.008

Table 1bi. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use - Two or more dispensings in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	32,080	3.9%	19,749	2.6%	1.268	0.071
Epilepsy*	9,485	1.2%	8,269	1.1%	0.052	0.005
Chronic Pain*	171,753	20.8%	125,479	16.7%	4.167	0.107
Psychiatric History						
Previous Intentional Self-Harm Ever	6,235	0.8%	3,807	0.5%	0.251	0.032
Psychiatric History Overall*	517,191	62.7%	402,356	53.4%	9.294	0.189
Psychiatric Drug Dispensings	388,285	47.1%	281,814	37.4%	9.668	0.197
Intentional Self-Harm Encounter	724	0.1%	482	0.1%	0.024	0.009
Any Other Psychiatric Event	419,742	50.9%	323,419	43.0%	7.958	0.160
Attention-Deficit/Hyperactivity Disorder	10,167	1.2%	4,941	0.7%	0.577	0.060
Akathisia	785	0.1%	568	0.1%	0.020	0.007
Anxiety	139,100	16.9%	94,671	12.6%	4.299	0.122
Behavioral Disorder	32,486	3.9%	22,029	2.9%	1.015	0.056
Bipolar Disorder	33,214	4.0%	20,500	2.7%	1.306	0.072
Cerebral Degenerations usually Manifested in Childhood	6,193	0.8%	7,079	0.9%	-0.189	-0.021
Conduct Disorder	737	0.1%	529	0.1%	0.019	0.007
Delirium	8,451	1.0%	8,810	1.2%	-0.145	-0.014
Depression	150,845	18.3%	100,993	13.4%	4.883	0.134
Electroconvulsive Therapy	132	0.0%	91	0.0%	0.004	0.003
Hallucination	1,345	0.2%	1,183	0.2%	0.006	0.002
Obsessive-Compulsive Disorder	1,623	0.2%	1,066	0.1%	0.055	0.013
Other Cerebral Degenerations	9,840	1.2%	10,955	1.5%	-0.261	-0.023
Other Mental Disorders	6,080	0.7%	4,830	0.6%	0.096	0.012

Table 1bi. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use - Two or more dispensings in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Psychological Disorders	68,071	8.3%	62,341	8.3%	-0.023	-0.001
Persistent Mental Disorders due to Conditions Classified Elsewhere	10,166	1.2%	12,016	1.6%	-0.363	-0.031
Personality Disorders	3,525	0.4%	1,674	0.2%	0.205	0.036
Pervasive Developmental Disorders	1,504	0.2%	1,084	0.1%	0.038	0.010
Post-Traumatic Stress Disorder	16,098	2.0%	8,342	1.1%	0.845	0.069
Psychotherapy	48,447	5.9%	28,010	3.7%	2.156	0.101
Psychotic Conditions	2,601	0.3%	2,386	0.3%	-0.001	-0.000
Schizophrenia	13,707	1.7%	11,615	1.5%	0.120	0.010
Sleep Disorder	217,621	26.4%	154,958	20.6%	5.816	0.138
Substance Abuse	33,627	4.1%	28,604	3.8%	0.280	0.014
Suicidal Behavior	3,733	0.5%	2,801	0.4%	0.081	0.013
Transcranial Magnetic Stimulation	184	0.0%	80	0.0%	0.012	0.009
Vagus Nerve Stimulation	701	0.1%	384	0.1%	0.034	0.013
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	6,423	0.8%	0	0.0%	NaN	NaN
dulaglutide	298,709	36.2%	0	0.0%	NaN	NaN
exenatide	58,912	7.1%	0	0.0%	NaN	NaN
liraglutide	154,578	18.8%	0	0.0%	NaN	NaN
lixisenatide	10,541	1.3%	0	0.0%	NaN	NaN
semaglutide	273,621	33.2%	0	0.0%	NaN	NaN
tirzepatide	22,248	2.7%	0	0.0%	NaN	NaN

Table 1bi. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use - Two or more dispensings in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Any Anti-Diabetic Agents	824,407	100.0%	752,898	100.0%	0.000	0.000
insulin*	274,430	33.3%	161,101	21.4%	11.891	0.269
metformin*	732,748	88.9%	677,382	90.0%	-1.088	-0.035
alpha-glucosidase inhibitors*	3,305	0.4%	3,171	0.4%	-0.020	-0.003
thiazolidinediones*	66,560	8.1%	62,009	8.2%	-0.162	-0.006
meglitinides*	8,812	1.1%	7,809	1.0%	0.032	0.003
amylin analogue*	116	0.0%	59	0.0%	0.006	0.006
sulfonylureas*	303,503	36.8%	297,374	39.5%	-2.683	-0.055
bile acid sequestrants*	3,057	0.4%	2,591	0.3%	0.027	0.004
Other Weight Loss Agents*	2,971	0.4%	823	0.1%	0.251	0.052
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	308	0.0%	121	0.0%	0.021	0.013
diethylpropion	65	0.0%	18	0.0%	0.005	0.008
lorcaserin	130	0.0%	43	0.0%	0.010	0.010
phentermine	2,281	0.3%	609	0.1%	0.196	0.046
phentermine-topiramate	154	0.0%	26	0.0%	0.015	0.014
phendimetrazine	50	0.0%	*****	*****	*****	*****
orlistat	53	0.0%	14	0.0%	0.005	0.007
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	203,311	24.7%	155,282	20.6%	4.037	0.097
Antipsychotics	57,379	7.0%	40,811	5.4%	1.540	0.064
Anxiolytics/Hypnotics	159,191	19.3%	114,796	15.2%	4.063	0.108
Lithium & Other Mood Stabilizers	49,496	6.0%	34,215	4.5%	1.459	0.065

Table 1bi. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use - Two or more dispensings in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Antidepressants	321,459	39.0%	220,325	29.3%	9.729	0.206
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	10.8	10.4	10.0	9.4	0.872	0.088
Mean number of emergency room encounters*	0.3	0.9	0.3	0.9	0.020	0.021
Mean number of inpatient hospital encounters*	0.1	0.4	0.1	0.4	-0.033	-0.083
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	-0.005	-0.029
Mean number of other ambulatory encounters*	3.9	11.7	3.7	10.8	0.177	0.016
Mean number of filled prescriptions*	26.9	20.3	24.7	18.5	2.191	0.113
Mean number of generics dispensed*	11.0	5.1	10.3	4.8	0.708	0.143
Mean number of unique drug classes dispensed*	9.8	4.6	8.5	4.4	1.288	0.287

Table 1bi. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use - Two or more dispensings in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1bj. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	824,321	100.0%	752,456	99.9%	N/A	N/A
Demographic Characteristics						
Age (years)*	60.4	10.4	63.6	10.1	-3.173	-0.309
Age						
18-24 years	4,047	0.5%	1,854	0.2%	0.245	0.040
25-44 years	103,026	12.5%	62,383	8.3%	4.208	0.138
45-64 years	361,051	43.8%	294,865	39.2%	4.613	0.094
65-79 years	326,636	39.6%	338,227	44.9%	-5.325	-0.108
≥ 80 years	29,561	3.6%	55,127	7.3%	-3.740	-0.165
Sex*						
Female	458,597	55.6%	321,015	42.7%	12.971	0.262
Male	365,724	44.4%	431,441	57.3%	-12.971	-0.262
Race[3]						
American Indian or Alaska Native	*****	*****	*****	*****	*****	*****
Asian	*****	*****	27,341	3.6%	*****	*****
Black or African American	74,820	9.1%	63,996	8.5%	0.572	0.020
Multi-racial	*****	*****	*****	*****	*****	*****
Islander	2,017	0.2%	*****	*****	*****	*****
Unknown	307,710	37.3%	268,419	35.7%	1.657	0.034
White	417,422	50.6%	382,584	50.8%	-0.206	-0.004
Hispanic origin						

Table 1bj. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	*****	*****	43,005	5.7%	*****	*****
No	463,972	56.3%	436,621	58.0%	-1.741	-0.035
Unknown	*****	*****	272,830	36.3%	*****	*****
Year*						
2015	*****	*****	7,418	1.0%	*****	*****
2016	*****	*****	*****	*****	*****	*****
2017	69,658	8.5%	*****	*****	*****	*****
2018	*****	*****	*****	*****	*****	*****
2019	*****	*****	*****	*****	*****	*****
2020	*****	*****	*****	*****	*****	*****
2021	*****	*****	116,893	15.5%	*****	*****
2022	*****	*****	138,812	18.4%	*****	*****
2023	123,288	15.0%	*****	*****	*****	*****
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[4]	1.3	1.6	1.4	1.7	-0.161	-0.099
Combined comorbidity score*,[5]	1.6	2.0	1.8	2.3	-0.188	-0.086
Medical History						
Obesity*	393,943	47.8%	255,892	34.0%	13.782	0.283
Procedure*	420	0.1%	*****	*****	*****	*****
Lifestyle intervention*	155,135	18.8%	122,361	16.3%	2.558	0.067
Cardiovascular Disease*	*****	*****	167,247	22.2%	*****	*****
Cognitive Impairment*	14,554	1.8%	17,405	2.3%	-0.548	-0.039
Traumatic Brain Injury*	1,755	0.2%	*****	*****	*****	*****

Table 1bj. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	32,064	3.9%	19,734	2.6%	1.267	0.071
Epilepsy*	*****	*****	8,254	1.1%	*****	*****
Chronic Pain*	171,709	20.8%	125,450	16.7%	4.158	0.107
Psychiatric History						
Previous Intentional Self-Harm Ever	*****	*****	*****	*****	*****	*****
Psychiatric History Overall*	517,113	62.7%	402,160	53.4%	9.286	0.189
Psychiatric Drug Dispensings	388,212	47.1%	281,699	37.4%	9.657	0.196
Encounter	724	0.1%	482	0.1%	0.024	0.009
Any Other Psychiatric Event	419,676	50.9%	323,248	43.0%	7.953	0.160
Attention-Deficit/Hyperactivity Disorder	*****	*****	*****	*****	*****	*****
Akathisia	785	0.1%	568	0.1%	0.020	0.007
Anxiety	139,062	16.9%	94,633	12.6%	4.293	0.121
Behavioral Disorder	32,474	3.9%	22,016	2.9%	1.014	0.056
Bipolar Disorder	33,197	4.0%	*****	*****	*****	*****
Cerebral Degenerations usually Manifested in Childhood	6,193	0.8%	*****	*****	*****	*****
Conduct Disorder	*****	*****	529	0.1%	*****	*****
Delirium	8,451	1.0%	*****	*****	*****	*****
Depression	150,805	18.3%	100,940	13.4%	4.880	0.134
Electroconvulsive Therapy	132	0.0%	91	0.0%	0.004	0.003
Hallucination	1,345	0.2%	*****	*****	*****	*****
Obsessive-Compulsive Disorder	1,623	0.2%	1,066	0.1%	0.055	0.013

Table 1bj. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Degenerations	*****	*****	*****	*****	*****	*****
Other Mental Disorders	*****	*****	*****	*****	*****	*****
Other Psychological Disorders	68,059	8.3%	62,316	8.3%	-0.025	-0.001
Persistent Mental Disorders due to Conditions Classified Elsewhere	10,166	1.2%	12,003	1.6%	-0.362	-0.031
Personality Disorders	*****	*****	*****	*****	*****	*****
Pervasive Developmental Disorders	1,504	0.2%	1,084	0.1%	0.038	0.010
Disorder	*****	*****	*****	*****	*****	*****
Psychotherapy	48,421	5.9%	27,998	3.7%	2.153	0.101
Psychotic Conditions	*****	*****	*****	*****	*****	*****
Schizophrenia	*****	*****	*****	*****	*****	*****
Sleep Disorder	217,578	26.4%	154,869	20.6%	5.813	0.137
Substance Abuse	*****	*****	*****	*****	*****	*****
Suicidal Behavior	3,733	0.5%	*****	*****	*****	*****
Transcranial Magnetic Stimulation	184	0.0%	80	0.0%	0.012	0.009
Vagus Nerve Stimulation	*****	*****	*****	*****	*****	*****
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	*****	*****	0	0.0%	*****	*****
dulaglutide	298,698	36.2%	0	0.0%	NaN	NaN
exenatide	58,896	7.1%	0	0.0%	NaN	NaN
liraglutide	154,551	18.7%	0	0.0%	NaN	NaN

Table 1bj. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
lixisenatide	*****	*****	0	0.0%	*****	*****
semaglutide	273,597	33.2%	0	0.0%	NaN	NaN
tirzepatide	*****	*****	0	0.0%	*****	*****
Any Anti-Diabetic Agents	824,320	100.0%	752,455	100.0%	0.000	0.000
insulin*	274,377	33.3%	161,044	21.4%	11.883	0.269
metformin*	732,673	88.9%	676,983	90.0%	-1.088	-0.035
alpha-glucosidase inhibitors*	*****	*****	*****	*****	*****	*****
thiazolidinediones*	*****	*****	61,959	8.2%	*****	*****
meglitinides*	*****	*****	7,809	1.0%	*****	*****
amylin analogue*	*****	*****	*****	*****	*****	*****
sulfonylureas*	303,464	36.8%	297,064	39.5%	-2.665	-0.055
bile acid sequestrants*	*****	*****	*****	*****	*****	*****
Other Weight Loss Agents*	*****	*****	*****	*****	*****	*****
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	308	0.0%	121	0.0%	0.021	0.013
diethylpropion	65	0.0%	18	0.0%	0.005	0.008
lorcaserin	130	0.0%	43	0.0%	0.010	0.010
phentermine	*****	*****	*****	*****	*****	*****
phentermine-topiramate	154	0.0%	26	0.0%	0.015	0.014
phendimetrazine	50	0.0%	*****	*****	*****	*****
orlistat	53	0.0%	14	0.0%	0.005	0.007
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	203,265	24.7%	155,218	20.6%	4.030	0.096

Table 1bj. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Antipsychotics	57,358	7.0%	40,795	5.4%	1.537	0.064
Anxiolytics/Hypnotics	159,141	19.3%	114,769	15.3%	4.053	0.107
Stabilizers	49,476	6.0%	34,200	4.5%	1.457	0.065
Antidepressants	321,391	39.0%	220,227	29.3%	9.721	0.206
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	10.8	10.4	10.0	9.4	0.869	0.088
Mean number of emergency room encounters*	0.3	0.9	0.3	0.9	0.020	0.021
Mean number of inpatient hospital encounters*	0.1	0.4	0.1	0.4	-0.033	-0.083
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	-0.005	-0.029
Mean number of other ambulatory encounters*	3.9	11.7	3.7	10.8	0.182	0.016
Mean number of filled prescriptions*	26.9	20.3	24.7	18.5	2.185	0.113
Mean number of generics dispensed*	11.0	5.1	10.3	4.8	0.707	0.142
Mean number of unique drug classes dispensed*	9.8	4.6	8.5	4.4	1.286	0.287

Table 1bj. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759.

Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1bk. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	1,193,550	N/A	835,111	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	60.8	10.8	61.9	10.7	-1.028	-0.096
Age						
18-24 years	3,017	0.3%	3,019	0.4%	-0.109	-0.020
25-44 years	117,824	9.9%	87,425	10.5%	-0.597	-0.020
45-64 years	579,606	48.6%	354,734	42.5%	6.084	0.134
65-79 years	447,227	37.5%	342,676	41.0%	-3.563	-0.084
≥ 80 years	45,876	3.8%	47,258	5.7%	-1.815	-0.087
Sex*						
Female	593,780	49.7%	428,450	51.3%	-1.556	-0.031
Male	599,770	50.3%	406,661	48.7%	1.556	0.031
Race[4]						
American Indian or Alaska Native	6,701	0.6%	4,852	0.6%	-0.020	-0.003
Asian	16,088	1.3%	23,973	2.9%	-1.523	-0.107
Black or African American	98,585	8.3%	79,239	9.5%	-1.229	-0.044
Multi-racial	6,311	0.5%	4,095	0.5%	0.038	0.006
Native Hawaiian or Other Pacific Islander	2,178	0.2%	2,189	0.3%	-0.080	-0.017
Unknown	515,406	43.2%	304,502	36.5%	6.720	0.237
White	548,281	45.9%	416,261	49.8%	-3.908	-0.104
Hispanic origin						

Table 1bk. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	42,187	3.5%	48,165	5.8%	-2.233	-0.111
No	573,285	48.0%	476,748	57.1%	-9.056	-0.355
Unknown	578,079	48.4%	310,198	37.1%	11.289	0.556
Year*						
2015	12,704	1.1%	7,688	0.9%	0.144	0.015
2016	86,751	7.3%	60,639	7.3%	0.007	0.000
2017	132,965	11.1%	76,423	9.2%	1.989	0.066
2018	114,937	9.6%	86,993	10.4%	-0.787	-0.026
2019	147,798	12.4%	108,235	13.0%	-0.578	-0.018
2020	159,933	13.4%	126,590	15.2%	-1.759	-0.051
2021	175,893	14.7%	121,620	14.6%	0.174	0.005
2022	220,418	18.5%	144,179	17.3%	1.203	0.032
2023	142,151	11.9%	102,743	12.3%	-0.393	-0.012
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.9	2.1	1.5	1.7	0.431	0.224
Combined comorbidity score*,[6]	2.7	3.1	1.9	2.3	0.817	0.295
Medical History						
Obesity*	594,899	49.8%	361,637	43.3%	6.539	0.133
Weight Reduction Surgery or Procedure*	938	0.1%	652	0.1%	0.000	0.000
Lifestyle intervention*	234,210	19.6%	145,887	17.5%	2.154	0.056
Cardiovascular Disease*	297,108	24.9%	174,010	20.8%	4.056	0.099
Cognitive Impairment*	46,984	3.9%	19,430	2.3%	1.610	0.093
Traumatic Brain Injury*	2,297	0.2%	2,173	0.3%	-0.068	-0.014

Table 1bk. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	72,819	6.1%	33,811	4.0%	2.052	0.094
Epilepsy*	27,193	2.3%	11,312	1.4%	0.924	0.069
Chronic Pain*	395,083	33.1%	182,906	21.9%	11.199	0.254
Psychiatric History						
Previous Intentional Self-Harm Ever	15,943	1.3%	6,789	0.8%	0.523	0.052
Psychiatric History Overall*	837,841	70.2%	516,528	61.9%	8.346	0.177
Psychiatric Drug Dispensings	668,783	56.0%	393,324	47.1%	8.935	0.180
Intentional Self-Harm Encounter	2,060	0.2%	841	0.1%	0.072	0.019
Any Other Psychiatric Event	714,878	59.9%	418,199	50.1%	9.818	0.199
Attention-Deficit/Hyperactivity Disorder	50,857	4.3%	7,886	0.9%	3.317	0.215
Akathisia	1,490	0.1%	833	0.1%	0.025	0.007
Anxiety	304,877	25.5%	141,509	16.9%	8.599	0.212
Behavioral Disorder	83,953	7.0%	33,745	4.0%	2.993	0.131
Bipolar Disorder	90,213	7.6%	37,786	4.5%	3.034	0.128
Cerebral Degenerations usually Manifested in Childhood	12,344	1.0%	8,279	1.0%	0.043	0.004
Conduct Disorder	700	0.1%	821	0.1%	-0.040	-0.014
Delirium	42,028	3.5%	11,371	1.4%	2.160	0.141
Depression	325,204	27.2%	149,283	17.9%	9.371	0.227
Electroconvulsive Therapy	342	0.0%	159	0.0%	0.010	0.006
Hallucination	4,417	0.4%	1,584	0.2%	0.180	0.034
Obsessive-Compulsive Disorder	7,075	0.6%	1,623	0.2%	0.398	0.064
Other Cerebral Degenerations	16,485	1.4%	12,231	1.5%	-0.083	-0.007
Other Mental Disorders	16,733	1.4%	6,622	0.8%	0.609	0.059

Table 1bk. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Psychological Disorders	163,103	13.7%	83,859	10.0%	3.624	0.113
Persistent Mental Disorders due to Conditions Classified Elsewhere	28,125	2.4%	13,368	1.6%	0.756	0.055
Personality Disorders	12,070	1.0%	3,732	0.4%	0.564	0.066
Pervasive Developmental Disorders	1,298	0.1%	1,514	0.2%	-0.073	-0.019
Post-Traumatic Stress Disorder	44,124	3.7%	16,238	1.9%	1.752	0.106
Psychotherapy	95,002	8.0%	47,364	5.7%	2.288	0.091
Psychotic Conditions	4,471	0.4%	3,753	0.4%	-0.075	-0.012
Schizophrenia	37,956	3.2%	17,586	2.1%	1.074	0.067
Sleep Disorder	427,450	35.8%	205,464	24.6%	11.210	0.248
Substance Abuse	90,273	7.6%	39,960	4.8%	2.778	0.116
Suicidal Behavior	9,597	0.8%	3,957	0.5%	0.330	0.041
Transcranial Magnetic Stimulation	152	0.0%	318	0.0%	-0.025	-0.016
Vagus Nerve Stimulation	919	0.1%	774	0.1%	-0.016	-0.005
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	11,176	0.9%	0	0.0%	NaN	NaN
dulaglutide	479,047	40.1%	0	0.0%	NaN	NaN
exenatide	95,095	8.0%	0	0.0%	NaN	NaN
liraglutide	216,876	18.2%	0	0.0%	NaN	NaN
lixisenatide	12,126	1.0%	0	0.0%	NaN	NaN
semaglutide	362,369	30.4%	0	0.0%	NaN	NaN
tirzepatide	22,512	1.9%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	1,193,548	100.0%	835,110	100.0%	-0.000	-0.001
insulin*	529,641	44.4%	358,770	43.0%	1.414	0.029

Table 1bk. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
metformin*	1,076,359	90.2%	741,209	88.8%	1.425	0.047
alpha-glucosidase inhibitors*	4,904	0.4%	3,806	0.5%	-0.045	-0.007
thiazolidinediones*	81,955	6.9%	74,202	8.9%	-2.019	-0.075
meglitinides*	12,557	1.1%	10,216	1.2%	-0.171	-0.016
amylin analogue*	103	0.0%	141	0.0%	-0.008	-0.007
sulfonylureas*	389,840	32.7%	326,002	39.0%	-6.375	-0.134
bile acid sequestrants*	5,528	0.5%	3,700	0.4%	0.020	0.003
Other Weight Loss Agents*	4,127	0.3%	3,755	0.4%	-0.104	-0.017
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	1,624	0.1%	302	0.0%	0.100	0.034
diethylpropion	88	0.0%	21	0.0%	0.005	0.007
lorcaserin	99	0.0%	85	0.0%	-0.002	-0.002
phentermine	2,176	0.2%	1,385	0.2%	0.016	0.004
phentermine-topiramate	156	0.0%	198	0.0%	-0.011	-0.008
phendimetrazine	81	0.0%	1,776	0.2%	-0.206	-0.063
orlistat	40	0.0%	31	0.0%	-0.000	-0.001
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	493,070	41.3%	226,355	27.1%	14.206	0.304
Antipsychotics	160,515	13.4%	68,794	8.2%	5.211	0.168
Anxiolytics/Hypnotics	349,035	29.2%	177,137	21.2%	8.032	0.186
Lithium & Other Mood Stabilizers	102,694	8.6%	59,790	7.2%	1.445	0.054
Antidepressants	557,241	46.7%	318,766	38.2%	8.517	0.173
Health Service Utilization Intensity Metrics						

Table 1bk. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Mean number of ambulatory encounters*	15.0	13.3	11.6	11.3	3.416	0.277
Mean number of emergency room encounters*	1.0	2.3	0.4	1.2	0.599	0.329
Mean number of inpatient hospital encounters*	0.4	0.8	0.1	0.4	0.238	0.374
Mean number of non-acute institutional encounters*	0.1	0.3	0.0	0.2	0.032	0.120
Mean number of other ambulatory encounters*	6.5	13.5	4.5	12.6	2.055	0.158
Mean number of filled prescriptions*	42.7	37.5	29.0	21.9	13.609	0.443
Mean number of generics dispensed*	16.5	10.2	11.8	5.6	4.732	0.574
Mean number of unique drug classes dispensed*	12.8	7.4	10.3	5.4	2.530	0.391

Table 1bk. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1bl. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	820,303	N/A	776,910	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.3	10.3	62.3	10.6	-0.955	-0.092
Age						
18-24 years	2,980	0.4%	2,780	0.4%	0.005	0.001
25-44 years	87,875	10.7%	77,402	10.0%	0.750	0.026
45-64 years	361,483	44.1%	321,885	41.4%	2.636	0.060
65-79 years	331,498	40.4%	328,894	42.3%	-1.922	-0.047
≥ 80 years	36,467	4.4%	45,950	5.9%	-1.469	-0.067
Sex*						
Female	416,902	50.8%	384,650	49.5%	1.313	0.026
Male	403,402	49.2%	392,260	50.5%	-1.313	-0.026
Race[4]						
American Indian or Alaska Native	5,769	0.7%	4,706	0.6%	0.098	0.012
Asian	12,797	1.6%	23,566	3.0%	-1.473	-0.099
Black or African American	72,767	8.9%	73,584	9.5%	-0.601	-0.021
Multi-racial	4,554	0.6%	3,827	0.5%	0.063	0.009
Islander	2,083	0.3%	2,162	0.3%	-0.024	-0.005
Unknown	310,877	37.9%	274,241	35.3%	2.599	0.088
White	411,456	50.2%	394,823	50.8%	-0.661	-0.017
Hispanic origin						

Table 1bl. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	36,110	4.4%	46,234	6.0%	-1.549	-0.073
No	455,128	55.5%	453,527	58.4%	-2.893	-0.109
Unknown	329,065	40.1%	277,149	35.7%	4.442	0.209
Year*						
2015	7,629	0.9%	7,229	0.9%	-0.000	-0.000
2016	58,820	7.2%	55,770	7.2%	-0.008	-0.000
2017	76,589	9.3%	72,278	9.3%	0.033	0.001
2018	84,235	10.3%	79,460	10.2%	0.041	0.001
2019	107,419	13.1%	102,133	13.1%	-0.051	-0.002
2020	123,582	15.1%	119,628	15.4%	-0.333	-0.009
2021	116,790	14.2%	114,724	14.8%	-0.529	-0.015
2022	141,436	17.2%	134,405	17.3%	-0.058	-0.002
2023	103,803	12.7%	91,283	11.7%	0.905	0.028
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*[,5]	1.4	1.7	1.5	1.7	-0.043	-0.025
Combined comorbidity score*[,6]	1.8	2.3	1.8	2.3	-0.045	-0.020
Medical History						
Obesity*	357,931	43.6%	321,314	41.4%	2.276	0.047
Procedure*	514	0.1%	527	0.1%	-0.005	-0.002
Lifestyle intervention*	147,472	18.0%	130,713	16.8%	1.153	0.031
Cardiovascular Disease*	166,859	20.3%	163,365	21.0%	-0.686	-0.017
Cognitive Impairment*	18,800	2.3%	18,238	2.3%	-0.056	-0.004
Traumatic Brain Injury*	1,824	0.2%	1,713	0.2%	0.002	0.000

Table 1bl. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	30,751	3.7%	27,408	3.5%	0.221	0.012
Epilepsy*	10,552	1.3%	9,867	1.3%	0.016	0.001
Chronic Pain*	172,589	21.0%	158,554	20.4%	0.631	0.016
Psychiatric History						
Previous Intentional Self-Harm Ever	6,152	0.7%	5,735	0.7%	0.012	0.001
Psychiatric History Overall*	503,714	61.4%	466,189	60.0%	1.400	0.029
Psychiatric Drug Dispensings	371,460	45.3%	348,095	44.8%	0.478	0.010
Intentional Self-Harm Encounter	770	0.1%	704	0.1%	0.003	0.001
Any Other Psychiatric Event	412,212	50.3%	375,622	48.3%	1.903	0.038
Attention-Deficit/Hyperactivity Disorder	9,036	1.1%	6,894	0.9%	0.214	0.022
Akathisia	841	0.1%	762	0.1%	0.005	0.001
Anxiety	134,108	16.3%	121,819	15.7%	0.669	0.018
Behavioral Disorder	32,362	3.9%	27,645	3.6%	0.387	0.020
Bipolar Disorder	31,465	3.8%	30,254	3.9%	-0.058	-0.003
Cerebral Degenerations usually Manifested in Childhood	7,505	0.9%	7,483	1.0%	-0.048	-0.005
Conduct Disorder	661	0.1%	695	0.1%	-0.009	-0.003
Delirium	11,706	1.4%	9,972	1.3%	0.144	0.012
Depression	147,849	18.0%	129,216	16.6%	1.392	0.037
Electroconvulsive Therapy	126	0.0%	131	0.0%	-0.002	-0.001
Hallucination	1,604	0.2%	1,459	0.2%	0.008	0.002
Obsessive-Compulsive Disorder	1,521	0.2%	1,467	0.2%	-0.003	-0.001

Table 1bl. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Cerebral Degenerations	11,527	1.4%	11,443	1.5%	-0.068	-0.006
Other Mental Disorders	6,461	0.8%	5,911	0.8%	0.027	0.003
Other Psychological Disorders	71,390	8.7%	73,505	9.5%	-0.758	-0.026
Persistent Mental Disorders due to Conditions Classified Elsewhere	13,446	1.6%	12,489	1.6%	0.032	0.003
Personality Disorders	3,321	0.4%	2,775	0.4%	0.048	0.008
Pervasive Developmental Disorders	1,248	0.2%	1,365	0.2%	-0.024	-0.006
Disorder	14,592	1.8%	12,954	1.7%	0.112	0.009
Psychotherapy	44,954	5.5%	39,715	5.1%	0.368	0.016
Psychotic Conditions	2,988	0.4%	3,191	0.4%	-0.047	-0.007
Schizophrenia	13,610	1.7%	15,328	2.0%	-0.314	-0.024
Sleep Disorder	215,307	26.2%	182,701	23.5%	2.731	0.064
Substance Abuse	36,001	4.4%	34,733	4.5%	-0.082	-0.004
Suicidal Behavior	4,163	0.5%	3,510	0.5%	0.056	0.008
Transcranial Magnetic Stimulation	149	0.0%	118	0.0%	0.003	0.002
Vagus Nerve Stimulation	747	0.1%	522	0.1%	0.024	0.008
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	7,468	0.9%	0	0.0%	NaN	NaN
dulaglutide	307,662	37.5%	0	0.0%	NaN	NaN
exenatide	60,660	7.4%	0	0.0%	NaN	NaN
liraglutide	156,912	19.1%	0	0.0%	NaN	NaN

Table 1bl. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
lixisenatide	9,170	1.1%	0	0.0%	NaN	NaN
semaglutide	261,193	31.8%	0	0.0%	NaN	NaN
tirzepatide	18,871	2.3%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	820,301	100.0%	776,909	100.0%	-0.000	-0.001
insulin*	296,342	36.1%	305,327	39.3%	-3.174	-0.066
metformin*	730,734	89.1%	690,049	88.8%	0.261	0.008
alpha-glucosidase inhibitors*	3,431	0.4%	3,459	0.4%	-0.027	-0.004
thiazolidinediones*	65,892	8.0%	65,984	8.5%	-0.460	-0.017
meglitinides*	9,104	1.1%	9,299	1.2%	-0.087	-0.008
amylin analogue*	100	0.0%	118	0.0%	-0.003	-0.003
sulfonylureas*	304,560	37.1%	301,499	38.8%	-1.680	-0.035
bile acid sequestrants*	3,700	0.5%	3,289	0.4%	0.028	0.004
Other Weight Loss Agents*	2,140	0.3%	1,517	0.2%	0.066	0.014
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	255	0.0%	247	0.0%	-0.001	-0.000
diethylpropion	53	0.0%	21	0.0%	0.004	0.006
lorcaserin	99	0.0%	75	0.0%	0.002	0.002
phentermine	1,598	0.2%	1,101	0.1%	0.053	0.013
phentermine-topiramate	116	0.0%	52	0.0%	0.007	0.007
phendimetrazine	46	0.0%	28	0.0%	0.002	0.003
orlistat	40	0.0%	27	0.0%	0.001	0.002
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	217,250	26.5%	197,732	25.5%	1.033	0.024

Table 1bl. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Antipsychotics	54,656	6.7%	57,716	7.4%	-0.766	-0.030
Anxiolytics/Hypnotics	154,251	18.8%	150,158	19.3%	-0.523	-0.013
Lithium & Other Mood Stabilizers	45,843	5.6%	48,996	6.3%	-0.718	-0.030
Antidepressants	303,516	37.0%	279,883	36.0%	0.975	0.020
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	11.2	10.4	11.1	10.5	0.117	0.011
Mean number of emergency room encounters*	0.4	1.1	0.4	1.1	0.017	0.016
Mean number of inpatient hospital encounters*	0.1	0.5	0.1	0.4	0.005	0.011
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	0.000	0.002
Mean number of other ambulatory encounters*	4.2	11.9	4.2	12.0	-0.032	-0.003
Mean number of filled prescriptions*	28.5	22.4	27.8	20.5	0.678	0.032
Mean number of generics dispensed*	11.6	5.7	11.3	5.2	0.243	0.044
Mean number of unique drug classes dispensed*	9.9	4.8	9.8	4.9	0.106	0.022

Table 1bl. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759.
Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.
*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
N/A = Not applicable
NaN = Not a number

Table 1bm. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	785,057	N/A	738,843	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	61.3	10.3	62.5	10.5	-1.216	-0.117
Age						
18-24 years	2,963	0.4%	2,551	0.3%	0.032	0.005
25-44 years	85,442	10.9%	71,826	9.7%	1.162	0.040
45-64 years	343,447	43.7%	301,882	40.9%	2.889	0.066
65-79 years	318,830	40.6%	317,540	43.0%	-2.366	-0.058
≥ 80 years	34,375	4.4%	45,043	6.1%	-1.718	-0.078
Sex*						
Female	401,618	51.2%	358,797	48.6%	2.596	0.052
Male	383,440	48.8%	380,046	51.4%	-2.596	-0.052
Race[4]						
American Indian or Alaska Native	5,610	0.7%	4,497	0.6%	0.106	0.013
Asian	12,261	1.6%	23,133	3.1%	-1.569	-0.105
Black or African American	69,918	8.9%	69,586	9.4%	-0.512	-0.018
Multi-racial	4,261	0.5%	3,563	0.5%	0.060	0.009
Native Hawaiian or Other Pacific Islander	2,035	0.3%	2,120	0.3%	-0.028	-0.005
Unknown	294,306	37.5%	257,638	34.9%	2.618	0.088
White	396,668	50.5%	378,306	51.2%	-0.675	-0.018
Hispanic origin						

Table 1bm. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	34,953	4.5%	44,439	6.0%	-1.562	-0.073
No	440,425	56.1%	435,158	58.9%	-2.796	-0.104
Unknown	309,679	39.4%	259,246	35.1%	4.359	0.204
Year*						
2015	7,043	0.9%	6,894	0.9%	-0.036	-0.004
2016	55,237	7.0%	53,091	7.2%	-0.150	-0.006
2017	72,298	9.2%	68,982	9.3%	-0.127	-0.004
2018	80,491	10.3%	74,618	10.1%	0.154	0.005
2019	102,873	13.1%	97,035	13.1%	-0.030	-0.001
2020	118,633	15.1%	114,625	15.5%	-0.403	-0.011
2021	111,998	14.3%	109,651	14.8%	-0.575	-0.017
2022	135,678	17.3%	128,442	17.4%	-0.102	-0.003
2023	100,806	12.8%	85,504	11.6%	1.268	0.039
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.4	1.7	1.5	1.7	-0.071	-0.042
Combined comorbidity score*,[6]	1.7	2.2	1.8	2.3	-0.081	-0.036
Medical History						
Obesity*	342,274	43.6%	297,271	40.2%	3.364	0.069
Weight Reduction Surgery or Procedure*	465	0.1%	460	0.1%	-0.003	-0.001
Lifestyle intervention*	141,258	18.0%	122,993	16.6%	1.347	0.036
Cardiovascular Disease*	154,202	19.6%	156,368	21.2%	-1.522	-0.039
Cognitive Impairment*	17,148	2.2%	17,349	2.3%	-0.164	-0.011
Traumatic Brain Injury*	1,695	0.2%	1,550	0.2%	0.006	0.001

Table 1bm. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	28,746	3.7%	24,637	3.3%	0.327	0.018
Epilepsy*	9,736	1.2%	9,178	1.2%	-0.002	-0.000
Chronic Pain*	161,169	20.5%	145,581	19.7%	0.826	0.021
Psychiatric History						
Previous Intentional Self-Harm Ever	5,744	0.7%	5,140	0.7%	0.036	0.004
Psychiatric History Overall*	478,837	61.0%	436,305	59.1%	1.941	0.040
Psychiatric Drug Dispensings	352,539	44.9%	322,795	43.7%	1.217	0.025
Intentional Self-Harm Encounter	709	0.1%	628	0.1%	0.005	0.002
Any Other Psychiatric Event	390,686	49.8%	350,867	47.5%	2.276	0.046
Attention-Deficit/Hyperactivity Disorder	8,533	1.1%	6,232	0.8%	0.243	0.025
Akathisia	767	0.1%	696	0.1%	0.004	0.001
Anxiety	126,043	16.1%	111,487	15.1%	0.966	0.027
Behavioral Disorder	30,294	3.9%	25,424	3.4%	0.418	0.022
Bipolar Disorder	29,619	3.8%	27,159	3.7%	0.097	0.005
Cerebral Degenerations usually Manifested in Childhood	6,917	0.9%	7,058	1.0%	-0.074	-0.008
Conduct Disorder	636	0.1%	643	0.1%	-0.006	-0.002
Delirium	10,351	1.3%	9,311	1.3%	0.058	0.005
Depression	139,314	17.7%	118,833	16.1%	1.662	0.045
Electroconvulsive Therapy	116	0.0%	119	0.0%	-0.001	-0.001
Hallucination	1,450	0.2%	1,351	0.2%	0.002	0.000
Obsessive-Compulsive Disorder	1,429	0.2%	1,330	0.2%	0.002	0.000
Other Cerebral Degenerations	10,699	1.4%	10,860	1.5%	-0.107	-0.009
Other Mental Disorders	5,994	0.8%	5,447	0.7%	0.026	0.003

Table 1bm. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Psychological Disorders	66,582	8.5%	68,125	9.2%	-0.739	-0.026
Persistent Mental Disorders due to Conditions Classified Elsewhere	12,219	1.6%	11,894	1.6%	-0.053	-0.004
Personality Disorders	3,085	0.4%	2,437	0.3%	0.063	0.011
Pervasive Developmental Disorders	1,207	0.2%	1,293	0.2%	-0.021	-0.005
Post-Traumatic Stress Disorder	13,815	1.8%	11,486	1.6%	0.205	0.016
Psychotherapy	42,494	5.4%	35,926	4.9%	0.550	0.025
Psychotic Conditions	2,725	0.3%	2,921	0.4%	-0.048	-0.008
Schizophrenia	12,807	1.6%	14,162	1.9%	-0.285	-0.022
Sleep Disorder	203,025	25.9%	169,839	23.0%	2.874	0.067
Substance Abuse	33,374	4.3%	32,049	4.3%	-0.087	-0.004
Suicidal Behavior	3,830	0.5%	3,256	0.4%	0.047	0.007
Transcranial Magnetic Stimulation	145	0.0%	107	0.0%	0.004	0.003
Vagus Nerve Stimulation	682	0.1%	459	0.1%	0.025	0.009
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	7,038	0.9%	0	0.0%	NaN	NaN
dulaglutide	293,573	37.4%	0	0.0%	NaN	NaN
exenatide	57,996	7.4%	0	0.0%	NaN	NaN
liraglutide	149,710	19.1%	0	0.0%	NaN	NaN
lixisenatide	8,771	1.1%	0	0.0%	NaN	NaN
semaglutide	250,978	32.0%	0	0.0%	NaN	NaN
tirzepatide	18,260	2.3%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	785,055	100.0%	738,842	100.0%	-0.000	-0.001
insulin*	276,942	35.3%	272,061	36.8%	-1.546	-0.032

Table 1bm. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
metformin*	699,481	89.1%	657,307	89.0%	0.135	0.004
alpha-glucosidase inhibitors*	3,265	0.4%	3,242	0.4%	-0.023	-0.004
thiazolidinediones*	63,393	8.1%	62,099	8.4%	-0.330	-0.012
meglitinides*	8,639	1.1%	8,603	1.2%	-0.064	-0.006
amylin analogue*	97	0.0%	101	0.0%	-0.001	-0.001
sulfonylureas*	292,402	37.2%	286,588	38.8%	-1.543	-0.032
bile acid sequestrants*	3,359	0.4%	3,037	0.4%	0.017	0.003
Other Weight Loss Agents*	2,070	0.3%	1,302	0.2%	0.087	0.019
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	237	0.0%	197	0.0%	0.004	0.002
diethylpropion	49	0.0%	21	0.0%	0.003	0.005
lorcaserin	99	0.0%	69	0.0%	0.003	0.003
phentermine	1,554	0.2%	956	0.1%	0.069	0.017
phentermine-topiramate	107	0.0%	45	0.0%	0.008	0.008
phendimetrazine	42	0.0%	18	0.0%	0.003	0.005
orlistat	40	0.0%	22	0.0%	0.002	0.003
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	200,554	25.5%	181,680	24.6%	0.957	0.022
Antipsychotics	51,323	6.5%	52,423	7.1%	-0.558	-0.022
Anxiolytics/Hypnotics	144,785	18.4%	137,288	18.6%	-0.139	-0.004
Lithium & Other Mood Stabilizers	43,335	5.5%	44,230	6.0%	-0.466	-0.020
Antidepressants	288,668	36.8%	258,550	35.0%	1.776	0.037
Health Service Utilization Intensity Metrics						

Table 1bm. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Mean number of ambulatory encounters*	11.0	10.3	10.9	10.3	0.119	0.012
Mean number of emergency room encounters*	0.4	1.0	0.4	1.0	0.008	0.008
Mean number of inpatient hospital encounters*	0.1	0.4	0.1	0.4	-0.005	-0.012
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	-0.001	-0.007
Mean number of other ambulatory encounters*	4.1	11.8	4.2	11.9	-0.056	-0.005
Mean number of filled prescriptions*	27.8	21.7	27.3	20.1	0.530	0.025
Mean number of generics dispensed*	11.3	5.5	11.1	5.1	0.177	0.033
Mean number of unique drug classes dispensed*	9.8	4.7	9.6	4.7	0.195	0.041

Table 1bm. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1bn. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use for diabetes or obesity in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	576,208	100.0%	384,900	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)*	60.0	10.7	62.6	10.5	-2.580	-0.244
Age						
18-24 years	3,341	0.6%	1,318	0.3%	0.237	0.035
25-44 years	77,817	13.5%	38,246	9.9%	3.568	0.111
45-64 years	244,405	42.4%	148,363	38.5%	3.870	0.079
65-79 years	235,522	40.9%	176,972	46.0%	-5.104	-0.103
≥ 80 years	15,123	2.6%	20,001	5.2%	-2.572	-0.133
Sex*						
Female	333,627	57.9%	178,241	46.3%	11.592	0.234
Male	242,581	42.1%	206,659	53.7%	-11.592	-0.234
Race[3]						
American Indian or Alaska Native	2,983	0.5%	1,522	0.4%	0.122	0.018
Asian	4,239	0.7%	4,546	1.2%	-0.445	-0.046
Black or African American	58,961	10.2%	39,983	10.4%	-0.155	-0.005
Multi-racial	3,339	0.6%	1,870	0.5%	0.094	0.013
Native Hawaiian or Other Pacific Islander	1,171	0.2%	820	0.2%	-0.010	-0.002
Unknown	208,200	36.1%	130,607	33.9%	2.200	0.046
White	297,315	51.6%	205,552	53.4%	-1.805	-0.036
Hispanic origin						
Yes	20,647	3.6%	17,980	4.7%	-1.088	-0.055

Table 1bn. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use for diabetes or obesity in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
No	327,626	56.9%	226,770	58.9%	-2.058	-0.042
Unknown	227,935	39.6%	140,150	36.4%	3.146	0.065
Year*						
2015	6,704	1.2%	5,027	1.3%	-0.143	-0.013
2016	33,648	5.8%	24,165	6.3%	-0.439	-0.018
2017	44,715	7.8%	32,935	8.6%	-0.797	-0.029
2018	56,239	9.8%	34,593	9.0%	0.773	0.027
2019	69,615	12.1%	48,254	12.5%	-0.455	-0.014
2020	72,326	12.6%	55,812	14.5%	-1.948	-0.057
2021	85,704	14.9%	65,389	17.0%	-2.115	-0.058
2022	110,020	19.1%	75,039	19.5%	-0.402	-0.010
2023	97,237	16.9%	43,686	11.3%	5.525	0.159
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[4]	1.5	1.7	1.7	1.8	-0.272	-0.154
Combined comorbidity score*,[5]	1.9	2.2	2.3	2.6	-0.371	-0.154
Medical History						
Obesity*	576,208	100.0%	384,900	100.0%	0.000	NaN
Weight Reduction Surgery or Procedure*	563	0.1%	386	0.1%	-0.003	-0.001
Lifestyle intervention*	127,882	22.2%	76,156	19.8%	2.408	0.059
Cardiovascular Disease*	111,602	19.4%	100,907	26.2%	-6.848	-0.164
Cognitive Impairment*	8,619	1.5%	7,791	2.0%	-0.528	-0.040
Traumatic Brain Injury*	1,276	0.2%	758	0.2%	0.025	0.005
Migraine*	27,055	4.7%	13,378	3.5%	1.220	0.062
Epilepsy*	7,543	1.3%	5,186	1.3%	-0.038	-0.003

Table 1bn. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use for diabetes or obesity in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Chronic Pain*	144,145	25.0%	83,099	21.6%	3.426	0.081
Psychiatric History						
Previous Intentional Self-Harm Ever	5,009	0.9%	2,494	0.6%	0.221	0.026
Psychiatric History Overall*	396,971	68.9%	241,856	62.8%	6.058	0.128
Psychiatric Drug Dispensings	285,821	49.6%	159,641	41.5%	8.128	0.164
Intentional Self-Harm Encounter	692	0.1%	390	0.1%	0.019	0.006
Any Other Psychiatric Event	343,122	59.5%	210,165	54.6%	4.946	0.100
Attention-Deficit/Hyperactivity Disorder	8,116	1.4%	3,191	0.8%	0.579	0.055
Akathisia	612	0.1%	339	0.1%	0.018	0.006
Anxiety	116,329	20.2%	63,137	16.4%	3.785	0.098
Behavioral Disorder	27,769	4.8%	14,390	3.7%	1.081	0.053
Bipolar Disorder	27,749	4.8%	14,166	3.7%	1.135	0.056
Cerebral Degenerations usually Manifested in Childhood	4,997	0.9%	4,350	1.1%	-0.263	-0.026
Conduct Disorder	555	0.1%	304	0.1%	0.017	0.006
Delirium	7,455	1.3%	6,259	1.6%	-0.332	-0.028
Depression	125,441	21.8%	67,619	17.6%	4.202	0.106
Electroconvulsive Therapy	139	0.0%	74	0.0%	0.005	0.003
Hallucination	1,184	0.2%	824	0.2%	-0.009	-0.002
Obsessive-Compulsive Disorder	1,477	0.3%	692	0.2%	0.077	0.016
Other Cerebral Degenerations	6,547	1.1%	5,174	1.3%	-0.208	-0.019
Other Mental Disorders	4,725	0.8%	3,000	0.8%	0.041	0.005
Other Psychological Disorders	55,140	9.6%	39,364	10.2%	-0.658	-0.022

Table 1bn. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use for diabetes or obesity in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Persistent Mental Disorders due to Conditions Classified Elsewhere	5,329	0.9%	4,769	1.2%	-0.314	-0.030
Personality Disorders	3,197	0.6%	1,319	0.3%	0.212	0.032
Pervasive Developmental Disorders	1,225	0.2%	655	0.2%	0.042	0.010
Post-Traumatic Stress Disorder	12,996	2.3%	5,856	1.5%	0.734	0.054
Psychotherapy	38,030	6.6%	17,441	4.5%	2.069	0.090
Psychotic Conditions	2,062	0.4%	1,466	0.4%	-0.023	-0.004
Schizophrenia	10,245	1.8%	6,696	1.7%	0.038	0.003
Sleep Disorder	204,222	35.4%	122,841	31.9%	3.527	0.075
Substance Abuse	27,888	4.8%	19,201	5.0%	-0.149	-0.007
Suicidal Behavior	3,051	0.5%	1,802	0.5%	0.061	0.009
Transcranial Magnetic Stimulation	178	0.0%	64	0.0%	0.014	0.009
Vagus Nerve Stimulation	628	0.1%	307	0.1%	0.029	0.010
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	3,014	0.5%	0	0.0%	NaN	NaN
dulaglutide	178,936	31.1%	0	0.0%	NaN	NaN
exenatide	35,206	6.1%	0	0.0%	NaN	NaN
liraglutide	109,943	19.1%	0	0.0%	NaN	NaN
lixisenatide	7,109	1.2%	0	0.0%	NaN	NaN
semaglutide	224,075	38.9%	0	0.0%	NaN	NaN
tirzepatide	18,348	3.2%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	576,206	100.0%	384,900	100.0%	-0.000	-0.003
insulin*	186,162	32.3%	91,883	23.9%	8.436	0.189
metformin*	509,810	88.5%	342,209	88.9%	-0.432	-0.014

Table 1bn. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use for diabetes or obesity in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
alpha-glucosidase inhibitors*	2,109	0.4%	1,416	0.4%	-0.002	-0.000
thiazolidinediones*	46,746	8.1%	33,072	8.6%	-0.480	-0.017
meglitinides*	5,431	0.9%	3,410	0.9%	0.057	0.006
amylin analogue*	87	0.0%	36	0.0%	0.006	0.005
sulfonylureas*	197,200	34.2%	146,099	38.0%	-3.734	-0.078
bile acid sequestrants*	2,303	0.4%	1,378	0.4%	0.042	0.007
Other Weight Loss Agents*	3,255	0.6%	932	0.2%	0.323	0.051
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	329	0.1%	112	0.0%	0.028	0.013
diethylpropion	61	0.0%	18	0.0%	0.006	0.007
lorcaserin	146	0.0%	54	0.0%	0.011	0.008
phentermine	2,540	0.4%	710	0.2%	0.256	0.046
phentermine-topiramate	157	0.0%	34	0.0%	0.018	0.014
phendimetrazine	44	0.0%	*****	*****	*****	*****
orlistat	48	0.0%	17	0.0%	0.004	0.005
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	162,109	28.1%	97,924	25.4%	2.692	0.061
Antipsychotics	42,531	7.4%	23,426	6.1%	1.295	0.052
Anxiolytics/Hypnotics	118,997	20.7%	65,777	17.1%	3.562	0.091
Lithium & Other Mood Stabilizers	36,845	6.4%	19,917	5.2%	1.220	0.052
Antidepressants	237,208	41.2%	126,551	32.9%	8.288	0.172
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	12.2	10.8	11.7	10.0	0.588	0.057

Table 1bn. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use for diabetes or obesity in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Mean number of emergency room encounters*	0.4	1.1	0.4	1.2	-0.029	-0.024
Mean number of inpatient hospital encounters*	0.1	0.5	0.2	0.6	-0.068	-0.130
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	-0.010	-0.044
Mean number of other ambulatory encounters*	4.1	10.6	4.2	9.9	-0.091	-0.009
Mean number of filled prescriptions*	27.2	20.1	25.6	18.5	1.539	0.080
Mean number of generics dispensed*	11.6	5.3	11.2	5.2	0.370	0.070
Mean number of unique drug classes dispensed*	10.4	4.8	9.4	4.7	0.998	0.212

Table 1bn. Aggregated Unadjusted Characteristics of GLP-1RA or SGLT-2i Use for diabetes or obesity in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

[*]Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759.

Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1bo. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1]	Number/ Mean	Percent/ Standard Deviation[2]	Number/ Mean	Percent/ Standard Deviation[2]	Absolute Difference	Standardized Difference
Unique patients	576,119	100.0%	384,759	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)*	60.0	10.7	62.6	10.5	-2.580	-0.244
Age						
18-24 years	3,341	0.6%	*****	*****	*****	*****
25-44 years	77,797	13.5%	38,230	9.9%	3.568	0.111
45-64 years	244,352	42.4%	148,298	38.5%	3.870	0.079
65-79 years	235,506	40.9%	176,916	46.0%	-5.103	-0.103
≥ 80 years	15,123	2.6%	*****	*****	*****	*****
Sex*						
Female	333,556	57.9%	178,178	46.3%	11.588	0.234
Male	242,563	42.1%	206,581	53.7%	-11.588	-0.234
Race[3]						
Native	*****	*****	*****	*****	*****	*****
Asian	*****	*****	*****	*****	*****	*****
Black or African American	58,950	10.2%	39,962	10.4%	-0.154	-0.005
Multi-racial	*****	*****	*****	*****	*****	*****
Islander	*****	*****	*****	*****	*****	*****
Unknown	208,175	36.1%	130,579	33.9%	2.196	0.046
White	297,266	51.6%	205,468	53.4%	-1.804	-0.036
Hispanic origin						

Table 1bo. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	*****	*****	17,959	4.7%	*****	*****
No	327,586	56.9%	226,698	58.9%	-2.059	-0.042
Unknown	*****	*****	140,102	36.4%	*****	*****
Year*						
2015	*****	*****	5,027	1.3%	*****	*****
2016	*****	*****	*****	*****	*****	*****
2017	*****	*****	*****	*****	*****	*****
2018	*****	*****	*****	*****	*****	*****
2019	*****	*****	*****	*****	*****	*****
2020	*****	*****	55,801	14.5%	*****	*****
2021	85,689	14.9%	65,360	17.0%	-2.114	-0.058
2022	110,006	19.1%	74,951	19.5%	-0.386	-0.010
2023	97,219	16.9%	*****	*****	*****	*****
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[4]	1.5	1.7	1.7	1.8	-0.272	-0.154
Combined comorbidity score*,[5]	1.9	2.2	2.3	2.6	-0.371	-0.154
Medical History						
Obesity*	576,119	100.0%	384,759	100.0%	0.000	NaN
Procedure*	563	0.1%	*****	*****	*****	*****
Lifestyle intervention*	127,850	22.2%	76,122	19.8%	2.407	0.059
Cardiovascular Disease*	111,590	19.4%	100,859	26.2%	-6.844	-0.164
Cognitive Impairment*	*****	*****	*****	*****	*****	*****
Traumatic Brain Injury*	*****	*****	758	0.2%	*****	*****

Table 1bo. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	27,036	4.7%	13,360	3.5%	1.220	0.062
Epilepsy*	*****	*****	*****	*****	*****	*****
Chronic Pain*	144,092	25.0%	83,074	21.6%	3.420	0.081
Psychiatric History						
Previous Intentional Self-Harm Ever	*****	*****	*****	*****	*****	*****
Psychiatric History Overall*	396,885	68.9%	241,760	62.8%	6.055	0.128
Psychiatric Drug Dispensings	285,742	49.6%	159,589	41.5%	8.120	0.164
Encounter	692	0.1%	390	0.1%	0.019	0.006
Any Other Psychiatric Event	343,044	59.5%	210,073	54.6%	4.945	0.100
Attention-Deficit/Hyperactivity Disorder	*****	*****	*****	*****	*****	*****
Akathisia	612	0.1%	339	0.1%	0.018	0.006
Anxiety	116,282	20.2%	63,115	16.4%	3.780	0.098
Behavioral Disorder	27,756	4.8%	*****	*****	*****	*****
Bipolar Disorder	27,727	4.8%	*****	*****	*****	*****
Cerebral Degenerations usually Manifested in Childhood	*****	*****	*****	*****	*****	*****
Conduct Disorder	*****	*****	304	0.1%	*****	*****
Delirium	*****	*****	*****	*****	*****	*****
Depression	125,396	21.8%	67,591	17.6%	4.199	0.106
Electroconvulsive Therapy	139	0.0%	74	0.0%	0.005	0.003
Hallucination	*****	*****	*****	*****	*****	*****

Table 1bo. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Obsessive-Compulsive Disorder	*****	*****	692	0.2%	*****	*****
Other Cerebral Degenerations	*****	*****	*****	*****	*****	*****
Other Mental Disorders	*****	*****	*****	*****	*****	*****
Other Psychological Disorders	55,127	9.6%	39,350	10.2%	-0.658	-0.022
Persistent Mental Disorders due to Conditions Classified Elsewhere	*****	*****	*****	*****	*****	*****
Personality Disorders	*****	*****	*****	*****	*****	*****
Pervasive Developmental Disorders	*****	*****	655	0.2%	*****	*****
Post-Traumatic Stress Disorder	12,984	2.3%	*****	*****	*****	*****
Psychotherapy	38,001	6.6%	*****	*****	*****	*****
Psychotic Conditions	2,062	0.4%	1,466	0.4%	-0.023	-0.004
Schizophrenia	*****	*****	*****	*****	*****	*****
Sleep Disorder	204,163	35.4%	122,779	31.9%	3.527	0.075
Substance Abuse	27,876	4.8%	19,185	5.0%	-0.148	-0.007
Suicidal Behavior	3,051	0.5%	*****	*****	*****	*****
Transcranial Magnetic Stimulation	178	0.0%	64	0.0%	0.014	0.009
Vagus Nerve Stimulation	*****	*****	307	0.1%	*****	*****
Medical Product Use						
Index GLP-1 RA Product						

Table 1bo. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
albiglutide	3,014	0.5%	0	0.0%	NaN	NaN
dulaglutide	178,914	31.1%	0	0.0%	NaN	NaN
exenatide	35,195	6.1%	0	0.0%	NaN	NaN
liraglutide	109,923	19.1%	0	0.0%	NaN	NaN
lixisenatide	*****	*****	0	0.0%	*****	*****
semaglutide	224,050	38.9%	0	0.0%	NaN	NaN
tirzepatide	*****	*****	0	0.0%	*****	*****
Any Anti-Diabetic Agents	576,117	100.0%	384,759	100.0%	-0.000	-0.003
insulin*	186,112	32.3%	91,855	23.9%	8.431	0.188
metformin*	509,735	88.5%	342,083	88.9%	-0.431	-0.014
alpha-glucosidase inhibitors*	*****	*****	*****	*****	*****	*****
thiazolidinediones*	*****	*****	33,054	8.6%	-0.478	-0.017
meglitinides*	*****	*****	3,410	0.9%	0.056	0.006
amylin analogue*	87	0.0%	*****	*****	*****	*****
sulfonylureas*	197,170	34.2%	145,994	37.9%	-3.720	-0.078
bile acid sequestrants*	*****	*****	*****	*****	*****	*****
Other Weight Loss Agents*	*****	*****	*****	*****	*****	*****
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	329	0.1%	112	0.0%	0.028	0.013
diethylpropion	61	0.0%	18	0.0%	0.006	0.007
lorcaserin	146	0.0%	54	0.0%	0.011	0.008
phentermine	*****	*****	*****	*****	*****	*****
phentermine-topiramate	157	0.0%	34	0.0%	0.018	0.014
phendimetrazine	44	0.0%	*****	*****	*****	*****

Table 1bo. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
orlistat	48	0.0%	17	0.0%	0.004	0.005
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	162,058	28.1%	97,887	25.4%	2.688	0.061
Antipsychotics	42,503	7.4%	*****	*****	*****	*****
Anxiolytics/Hypnotics	118,943	20.6%	65,764	17.1%	3.553	0.091
Stabilizers	36,823	6.4%	*****	*****	*****	*****
Antidepressants	237,134	41.2%	126,510	32.9%	8.280	0.172
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	12.2	10.8	11.7	10.0	0.585	0.056
Mean number of emergency room encounters*	0.4	1.1	0.4	1.2	-0.028	-0.024
Mean number of inpatient hospital encounters*	0.1	0.5	0.2	0.6	-0.068	-0.130
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	-0.010	-0.044
Mean number of other ambulatory encounters*	4.1	10.6	4.2	9.9	-0.088	-0.009
Mean number of filled prescriptions*	27.2	20.1	25.6	18.5	1.535	0.079
Mean number of generics dispensed*	11.6	5.3	11.2	5.2	0.370	0.070
Mean number of unique drug classes dispensed*	10.4	4.8	9.4	4.7	0.997	0.211

Table 1bo. Aggregated Unweighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation (Unweighted, Trimmed) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1bp. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	689,137	N/A	418,293	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	60.2	10.5	61.1	10.9	-0.878	-0.082
Age						
18-24 years	2,884	0.4%	1,891	0.5%	-0.033	-0.005
25-44 years	80,216	11.6%	49,234	11.8%	-0.130	-0.004
45-64 years	320,672	46.5%	176,569	42.2%	4.321	0.094
65-79 years	265,679	38.6%	173,890	41.6%	-3.019	-0.071
≥ 80 years	19,686	2.9%	16,709	4.0%	-1.138	-0.063
Sex*						
Female	372,510	54.1%	229,023	54.8%	-0.697	-0.014
Male	316,627	45.9%	189,269	45.2%	0.697	0.014
Race[4]						
American Indian or Alaska Native	3,169	0.5%	1,838	0.4%	0.020	0.003
Asian	4,505	0.7%	4,242	1.0%	-0.360	-0.040
Black or African American	64,339	9.3%	46,699	11.2%	-1.828	-0.062
Multi-racial	3,763	0.5%	2,140	0.5%	0.034	0.005
Native Hawaiian or Other Pacific Islander	1,283	0.2%	746	0.2%	0.008	0.002
Unknown	283,796	41.2%	145,551	34.8%	6.385	0.237
White	328,283	47.6%	217,077	51.9%	-4.259	-0.115
Hispanic origin						

Table 1bp. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	22,348	3.2%	19,505	4.7%	-1.420	-0.075
No	352,362	51.1%	242,399	57.9%	-6.819	-0.293
Unknown	314,428	45.6%	156,389	37.4%	8.239	0.435
Year*						
2015	11,453	1.7%	5,485	1.3%	0.351	0.029
2016	44,581	6.5%	27,079	6.5%	-0.005	-0.000
2017	61,369	8.9%	35,504	8.5%	0.417	0.015
2018	67,030	9.7%	41,638	10.0%	-0.228	-0.008
2019	80,455	11.7%	51,958	12.4%	-0.747	-0.023
2020	91,417	13.3%	55,408	13.2%	0.019	0.001
2021	101,373	14.7%	65,213	15.6%	-0.880	-0.025
2022	139,946	20.3%	77,370	18.5%	1.811	0.046
2023	91,513	13.3%	58,638	14.0%	-0.739	-0.022
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.8	2.0	1.8	1.8	0.062	0.032
Combined comorbidity score*,[6]	2.5	2.8	2.3	2.5	0.193	0.072
Medical History						
Obesity*	689,137	100.0%	418,293	100.0%	0.000	NaN
Weight Reduction Surgery or Procedure*	1,398	0.2%	591	0.1%	0.062	0.015
Lifestyle intervention*	151,863	22.0%	86,928	20.8%	1.255	0.031
Cardiovascular Disease*	172,988	25.1%	100,135	23.9%	1.163	0.028
Cognitive Impairment*	17,922	2.6%	8,009	1.9%	0.686	0.046
Traumatic Brain Injury*	1,356	0.2%	1,043	0.2%	-0.052	-0.011

Table 1bp. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	39,020	5.7%	21,480	5.1%	0.527	0.023
Epilepsy*	11,029	1.6%	6,390	1.5%	0.073	0.006
Chronic Pain*	207,417	30.1%	112,384	26.9%	3.231	0.072
Psychiatric History						
Previous Intentional Self-Harm Ever	7,379	1.1%	4,074	1.0%	0.097	0.010
Psychiatric History Overall*	496,973	72.1%	291,233	69.6%	2.491	0.055
Psychiatric Drug Dispensings	359,516	52.2%	213,017	50.9%	1.244	0.025
Intentional Self-Harm Encounter	1,808	0.3%	599	0.1%	0.119	0.026
Any Other Psychiatric Event	440,547	63.9%	252,198	60.3%	3.635	0.075
Attention-Deficit/Hyperactivity Disorder	15,488	2.2%	5,008	1.2%	1.050	0.081
Akathisia	856	0.1%	482	0.1%	0.009	0.003
Anxiety	161,557	23.4%	88,206	21.1%	2.356	0.057
Behavioral Disorder	43,644	6.3%	20,902	5.0%	1.336	0.058
Bipolar Disorder	41,413	6.0%	23,549	5.6%	0.380	0.016
Cerebral Degenerations usually Manifested in Childhood	8,196	1.2%	4,803	1.1%	0.041	0.004
Conduct Disorder	589	0.1%	427	0.1%	-0.017	-0.005
Delirium	17,128	2.5%	6,878	1.6%	0.841	0.059
Depression	168,369	24.4%	91,489	21.9%	2.560	0.061
Electroconvulsive Therapy	142	0.0%	135	0.0%	-0.012	-0.007
Hallucination	2,261	0.3%	1,162	0.3%	0.050	0.009
Obsessive-Compulsive Disorder	2,512	0.4%	1,054	0.3%	0.112	0.020
Other Cerebral Degenerations	8,971	1.3%	5,592	1.3%	-0.035	-0.003
Other Mental Disorders	6,754	1.0%	3,947	0.9%	0.037	0.004

Table 1bp. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Psychological Disorders	94,325	13.7%	49,066	11.7%	1.957	0.059
Persistent Mental Disorders due to Conditions Classified Elsewhere	9,711	1.4%	4,951	1.2%	0.226	0.020
Personality Disorders	4,823	0.7%	2,707	0.6%	0.053	0.006
Pervasive Developmental Disorders	1,107	0.2%	810	0.2%	-0.033	-0.008
Post-Traumatic Stress Disorder	17,859	2.6%	10,518	2.5%	0.077	0.005
Psychotherapy	51,743	7.5%	28,221	6.7%	0.762	0.030
Psychotic Conditions	2,662	0.4%	2,128	0.5%	-0.123	-0.018
Schizophrenia	14,377	2.1%	9,775	2.3%	-0.251	-0.017
Sleep Disorder	272,147	39.5%	145,666	34.8%	4.667	0.097
Substance Abuse	43,121	6.3%	24,178	5.8%	0.477	0.020
Suicidal Behavior	5,560	0.8%	2,327	0.6%	0.250	0.030
Transcranial Magnetic Stimulation	203	0.0%	207	0.0%	-0.020	-0.010
Vagus Nerve Stimulation	849	0.1%	629	0.2%	-0.027	-0.007
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	4,143	0.6%	0	0.0%	NaN	NaN
dulaglutide	230,805	33.5%	0	0.0%	NaN	NaN
exenatide	45,537	6.6%	0	0.0%	NaN	NaN
liraglutide	133,211	19.3%	0	0.0%	NaN	NaN
lixisenatide	7,191	1.0%	0	0.0%	NaN	NaN
semaglutide	253,555	36.8%	0	0.0%	NaN	NaN
tirzepatide	17,885	2.6%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	689,134	100.0%	418,293	100.0%	-0.000	-0.003
insulin*	254,209	36.9%	185,943	44.5%	-7.565	-0.155

Table 1bp. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
metformin*	613,255	89.0%	367,659	87.9%	1.094	0.034
alpha-glucosidase inhibitors*	2,390	0.3%	1,764	0.4%	-0.075	-0.012
thiazolidinediones*	51,886	7.5%	36,976	8.8%	-1.311	-0.048
meglitinides*	6,056	0.9%	4,645	1.1%	-0.232	-0.023
amylin analogue*	127	0.0%	72	0.0%	0.001	0.001
sulfonylureas*	228,951	33.2%	152,548	36.5%	-3.246	-0.069
bile acid sequestrants*	3,021	0.4%	2,060	0.5%	-0.054	-0.008
Other Weight Loss Agents*	3,213	0.5%	2,853	0.7%	-0.216	-0.029
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	628	0.1%	195	0.0%	0.044	0.017
diethylpropion	47	0.0%	41	0.0%	-0.003	-0.003
lorcaserin	123	0.0%	127	0.0%	-0.013	-0.008
phentermine	2,244	0.3%	1,428	0.3%	-0.016	-0.003
phentermine-topiramate	151	0.0%	112	0.0%	-0.005	-0.003
phendimetrazine	44	0.0%	964	0.2%	-0.224	-0.066
orlistat	42	0.0%	30	0.0%	-0.001	-0.001
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	264,727	38.4%	133,108	31.8%	6.592	0.139
Antipsychotics	62,970	9.1%	37,311	8.9%	0.218	0.008
Anxiolytics/Hypnotics	169,104	24.5%	97,659	23.3%	1.192	0.028
Lithium & Other Mood Stabilizers	52,698	7.6%	32,840	7.9%	-0.204	-0.008
Antidepressants	288,797	41.9%	173,963	41.6%	0.318	0.006
Health Service Utilization Intensity Metrics						

Table 1bp. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Mean number of ambulatory encounters*	14.1	12.0	13.4	12.1	0.666	0.055
Mean number of emergency room encounters*	0.8	2.1	0.5	1.4	0.276	0.156
Mean number of inpatient hospital encounters*	0.3	0.7	0.2	0.6	0.098	0.151
Mean number of non-acute institutional encounters*	0.0	0.3	0.0	0.3	0.012	0.041
Mean number of other ambulatory encounters*	5.3	11.7	4.7	11.4	0.607	0.052
Mean number of filled prescriptions*	33.8	28.3	29.9	22.3	3.867	0.152
Mean number of generics dispensed*	14.3	8.2	12.6	5.8	1.667	0.234
Mean number of unique drug classes dispensed*	11.7	6.1	11.1	5.6	0.561	0.096

Table 1bp. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 0%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product		Covariate Balance
	GLP-1 Receptor Agonists	SGLT-2 Inhibitors	

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1bq. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	577,644	N/A	393,157	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	60.6	10.6	61.4	10.9	-0.819	-0.076
Age						
18-24 years	2,784	0.5%	1,763	0.4%	0.034	0.005
25-44 years	70,830	12.3%	44,679	11.4%	0.898	0.029
45-64 years	245,639	42.5%	161,367	41.0%	1.480	0.032
65-79 years	240,930	41.7%	168,849	42.9%	-1.238	-0.029
≥ 80 years	17,461	3.0%	16,499	4.2%	-1.174	-0.063
Sex*						
Female	312,650	54.1%	209,631	53.3%	0.805	0.016
Male	264,994	45.9%	183,526	46.7%	-0.805	-0.016
Race[4]						
Native	2,950	0.5%	1,772	0.5%	0.060	0.009
Asian	4,363	0.8%	4,167	1.1%	-0.305	-0.032
Black or African American	58,109	10.1%	44,317	11.3%	-1.212	-0.040
Multi-racial	3,218	0.6%	1,996	0.5%	0.049	0.007
Pacific Islander	1,225	0.2%	742	0.2%	0.023	0.005
Unknown	210,678	36.5%	132,122	33.6%	2.867	0.104
White	297,101	51.4%	208,041	52.9%	-1.482	-0.039
Hispanic origin						

Table 1bq. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Yes	20,596	3.6%	18,806	4.8%	-1.218	-0.063
No	325,497	56.3%	233,001	59.3%	-2.915	-0.121
Unknown	231,551	40.1%	141,349	36.0%	4.133	0.212
Year*						
2015	7,420	1.3%	5,191	1.3%	-0.036	-0.003
2016	36,493	6.3%	25,443	6.5%	-0.154	-0.006
2017	48,626	8.4%	33,630	8.6%	-0.136	-0.005
2018	56,278	9.7%	38,913	9.9%	-0.155	-0.005
2019	72,019	12.5%	49,760	12.7%	-0.189	-0.006
2020	76,757	13.3%	53,138	13.5%	-0.228	-0.007
2021	88,376	15.3%	61,910	15.7%	-0.448	-0.012
2022	108,419	18.8%	72,980	18.6%	0.207	0.005
2023	83,256	14.4%	52,192	13.3%	1.138	0.033
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*,[5]	1.7	1.8	1.8	1.8	-0.106	-0.058
Combined comorbidity score*,[6]	2.1	2.4	2.3	2.5	-0.124	-0.050
Medical History						
Obesity*	577,644	100.0%	393,157	100.0%	0.000	NaN
Procedure*	647	0.1%	489	0.1%	-0.013	-0.004
Lifestyle intervention*	123,744	21.4%	79,758	20.3%	1.136	0.028
Cardiovascular Disease*	131,670	22.8%	95,415	24.3%	-1.475	-0.036
Cognitive Impairment*	10,637	1.8%	7,684	2.0%	-0.113	-0.008
Traumatic Brain Injury*	1,306	0.2%	944	0.2%	-0.014	-0.003

Table 1bq. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Migraine*	26,489	4.6%	18,032	4.6%	-0.001	-0.000
Epilepsy*	8,269	1.4%	5,806	1.5%	-0.045	-0.004
Chronic Pain*	145,607	25.2%	100,581	25.6%	-0.376	-0.009
Psychiatric History						
Previous Intentional Self-Harm Ever	5,010	0.9%	3,566	0.9%	-0.040	-0.004
Psychiatric History Overall*	394,079	68.2%	268,543	68.3%	-0.082	-0.002
Psychiatric Drug Dispensings	277,635	48.1%	192,511	49.0%	-0.902	-0.018
Intentional Self-Harm Encounter	759	0.1%	527	0.1%	-0.002	-0.001
Any Other Psychiatric Event	343,374	59.4%	231,947	59.0%	0.448	0.009
Attention-Deficit/Hyperactivity Disorder	7,481	1.3%	4,328	1.1%	0.194	0.018
Akathisia	644	0.1%	426	0.1%	0.003	0.001
Anxiety	114,448	19.8%	77,719	19.8%	0.045	0.001
Behavioral Disorder	27,826	4.8%	17,623	4.5%	0.335	0.016
Bipolar Disorder	26,892	4.7%	19,746	5.0%	-0.367	-0.017
Cerebral Degenerations usually Manifested in Childhood	5,873	1.0%	4,421	1.1%	-0.108	-0.010
Conduct Disorder	518	0.1%	360	0.1%	-0.002	-0.001
Delirium	9,867	1.7%	6,384	1.6%	0.084	0.007
Depression	125,151	21.7%	81,547	20.7%	0.924	0.023
Electroconvulsive Therapy	132	0.0%	115	0.0%	-0.007	-0.004

Table 1bq. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Hallucination	1,377	0.2%	974	0.2%	-0.009	-0.002
Obsessive-Compulsive Disorder	1,396	0.2%	921	0.2%	0.008	0.002
Other Cerebral Degenerations	7,334	1.3%	5,352	1.4%	-0.092	-0.008
Other Mental Disorders	5,051	0.9%	3,562	0.9%	-0.032	-0.003
Other Psychological Disorders	57,979	10.0%	44,273	11.3%	-1.224	-0.040
Persistent Mental Disorders due to Conditions Classified Elsewhere	6,689	1.2%	4,717	1.2%	-0.042	-0.004
Personality Disorders	3,081	0.5%	2,077	0.5%	0.005	0.001
Pervasive Developmental Disorders	1,092	0.2%	763	0.2%	-0.005	-0.001
Post-Traumatic Stress Disorder	12,208	2.1%	8,563	2.2%	-0.065	-0.004
Psychotherapy	35,850	6.2%	23,980	6.1%	0.107	0.004
Psychotic Conditions	2,265	0.4%	1,883	0.5%	-0.087	-0.013
Schizophrenia	10,061	1.7%	8,588	2.2%	-0.443	-0.032
Sleep Disorder	207,412	35.9%	134,001	34.1%	1.823	0.038
Substance Abuse	29,926	5.2%	21,883	5.6%	-0.385	-0.017
Suicidal Behavior	3,419	0.6%	2,113	0.5%	0.054	0.007
Transcranial Magnetic Stimulation	148	0.0%	97	0.0%	0.001	0.001
Vagus Nerve Stimulation	666	0.1%	414	0.1%	0.010	0.003

Table 1bq. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	3,425	0.6%	0	0.0%	NaN	NaN
dulaglutide	185,259	32.1%	0	0.0%	NaN	NaN
exenatide	36,612	6.3%	0	0.0%	NaN	NaN
liraglutide	112,964	19.6%	0	0.0%	NaN	NaN
lixisenatide	6,303	1.1%	0	0.0%	NaN	NaN
semaglutide	217,816	37.7%	0	0.0%	NaN	NaN
tirzepatide	16,154	2.8%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	577,641	100.0%	393,157	100.0%	-0.001	-0.003
insulin*	199,321	34.5%	163,052	41.5%	-6.967	-0.145
metformin*	510,950	88.5%	345,755	87.9%	0.511	0.016
inhibitors*	2,188	0.4%	1,596	0.4%	-0.027	-0.004
thiazolidinediones*	47,394	8.2%	34,217	8.7%	-0.498	-0.018
meglitinides*	5,466	0.9%	4,199	1.1%	-0.122	-0.012
amylin analogue*	83	0.0%	65	0.0%	-0.002	-0.002
sulfonylureas*	202,830	35.1%	143,968	36.6%	-1.505	-0.032
bile acid sequestrants*	2,579	0.4%	1,831	0.5%	-0.019	-0.003
Other Weight Loss Agents*	2,601	0.5%	1,460	0.4%	0.079	0.012
benzphetamine	*****	*****	*****	*****	*****	*****
and bupropion	277	0.0%	183	0.0%	0.001	0.001
diethylpropion	47	0.0%	26	0.0%	0.001	0.002
lorcaserin	123	0.0%	83	0.0%	0.000	0.000
phentermine	2,004	0.3%	1,107	0.3%	0.065	0.012

Table 1bq. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
phentermine-topiramate	130	0.0%	54	0.0%	0.009	0.006
phendimetrazine	39	0.0%	19	0.0%	0.002	0.003
orlistat	42	0.0%	27	0.0%	0.000	0.000
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	171,994	29.8%	119,347	30.4%	-0.581	-0.013
Antipsychotics	40,842	7.1%	32,210	8.2%	-1.122	-0.043
Anxiolytics/Hypnotics	116,606	20.2%	84,679	21.5%	-1.352	-0.033
Stabilizers	34,806	6.0%	27,871	7.1%	-1.064	-0.043
Antidepressants	228,175	39.5%	156,266	39.7%	-0.245	-0.005
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	12.6	10.8	12.8	11.1	-0.253	-0.023
Mean number of emergency room encounters*	0.5	1.3	0.5	1.3	-0.012	-0.009
Mean number of inpatient hospital encounters*	0.2	0.6	0.2	0.6	-0.007	-0.012
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.3	-0.002	-0.010
Mean number of other ambulatory encounters*	4.4	10.8	4.6	11.0	-0.159	-0.015
Mean number of filled prescriptions*	28.3	21.5	28.7	20.5	-0.364	-0.017
Mean number of generics dispensed*	12.1	5.9	12.2	5.4	-0.146	-0.026

Table 1bq. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 1%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Mean number of unique drug classes dispensed*	10.5	5.0	10.7	5.1	-0.184	-0.037

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 1br. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Patient Characteristics[1,2]	Number/ Mean	Percent/ Standard Deviation[3]	Number/ Mean	Percent/ Standard Deviation[3]	Absolute Difference	Standardized Difference
Weighted patients	561,559	N/A	374,743	N/A	N/A	N/A
Demographic Characteristics						
Age (years)*	60.6	10.6	61.7	10.8	-1.038	-0.097
Age						
18-24 years	2,765	0.5%	1,623	0.4%	0.059	0.009
25-44 years	69,358	12.4%	41,740	11.1%	1.213	0.039
45-64 years	237,248	42.2%	151,387	40.4%	1.850	0.041
65-79 years	235,327	41.9%	163,760	43.7%	-1.793	-0.042
≥ 80 years	16,861	3.0%	16,233	4.3%	-1.329	-0.071
Sex*						
Female	305,118	54.3%	196,445	52.4%	1.913	0.038
Male	256,441	45.7%	178,298	47.6%	-1.913	-0.038
Race[4]						
American Indian or Alaska Native	2,891	0.5%	1,695	0.5%	0.062	0.009
Asian	4,252	0.8%	4,067	1.1%	-0.328	-0.034
Black or African American	56,673	10.1%	42,161	11.3%	-1.158	-0.039
Multi-racial	3,082	0.5%	1,856	0.5%	0.054	0.008
Native Hawaiian or Other Pacific Islander	1,201	0.2%	730	0.2%	0.019	0.004
Unknown	203,097	36.2%	123,906	33.1%	3.102	0.112
White	290,362	51.7%	200,328	53.5%	-1.751	-0.046
Hispanic origin						
Yes	20,100	3.6%	18,119	4.8%	-1.256	-0.065
No	318,956	56.8%	224,433	59.9%	-3.092	-0.128

Table 1br. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Unknown	222,502	39.6%	132,191	35.3%	4.347	0.222
Year*						
2015	7,104	1.3%	4,940	1.3%	-0.053	-0.005
2016	35,021	6.2%	24,222	6.5%	-0.227	-0.009
2017	46,724	8.3%	32,093	8.6%	-0.244	-0.009
2018	54,584	9.7%	36,702	9.8%	-0.074	-0.002
2019	69,850	12.4%	47,525	12.7%	-0.243	-0.007
2020	74,522	13.3%	51,286	13.7%	-0.415	-0.012
2021	86,045	15.3%	59,509	15.9%	-0.557	-0.015
2022	105,759	18.8%	69,731	18.6%	0.226	0.006
2023	81,949	14.6%	48,736	13.0%	1.588	0.047
Health Characteristics						
Adapted Diabetes Complications Severity Index (aDCSI)*[,5]	1.6	1.8	1.8	1.8	-0.136	-0.075
Combined comorbidity score*[,6]	2.1	2.4	2.3	2.5	-0.167	-0.068
Medical History						
Obesity*	561,559	100.0%	374,743	100.0%	0.000	NaN
Weight Reduction Surgery or Procedure*	603	0.1%	443	0.1%	-0.011	-0.003
Lifestyle intervention*	120,500	21.5%	75,427	20.1%	1.331	0.033
Cardiovascular Disease*	125,150	22.3%	91,888	24.5%	-2.234	-0.054
Cognitive Impairment*	9,929	1.8%	7,396	2.0%	-0.205	-0.015
Traumatic Brain Injury*	1,246	0.2%	866	0.2%	-0.009	-0.002
Migraine*	25,318	4.5%	16,315	4.4%	0.155	0.008
Epilepsy*	7,854	1.4%	5,481	1.5%	-0.064	-0.005
Chronic Pain*	139,372	24.8%	93,454	24.9%	-0.119	-0.003
Psychiatric History						

Table 1br. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Previous Intentional Self-Harm Ever	4,776	0.9%	3,212	0.9%	-0.006	-0.001
Psychiatric History Overall*	381,451	67.9%	253,168	67.6%	0.369	0.008
Psychiatric Drug Dispensings	268,417	47.8%	179,516	47.9%	-0.105	-0.002
Intentional Self-Harm Encounter	711	0.1%	474	0.1%	0.000	0.000
Any Other Psychiatric Event	331,843	59.1%	218,611	58.3%	0.757	0.015
Attention-Deficit/Hyperactivity Disorder	7,182	1.3%	3,924	1.0%	0.232	0.022
Akathisia	609	0.1%	393	0.1%	0.004	0.001
Anxiety	109,844	19.6%	71,908	19.2%	0.372	0.009
Behavioral Disorder	26,626	4.7%	16,226	4.3%	0.412	0.020
Bipolar Disorder	25,815	4.6%	17,938	4.8%	-0.190	-0.009
Cerebral Degenerations usually Manifested in Childhood	5,539	1.0%	4,198	1.1%	-0.134	-0.013
Conduct Disorder	501	0.1%	344	0.1%	-0.003	-0.001
Delirium	9,058	1.6%	6,090	1.6%	-0.012	-0.001
Depression	120,414	21.4%	75,976	20.3%	1.169	0.029
Electroconvulsive Therapy	125	0.0%	101	0.0%	-0.005	-0.003
Hallucination	1,271	0.2%	907	0.2%	-0.016	-0.003
Obsessive-Compulsive Disorder	1,341	0.2%	841	0.2%	0.014	0.003
Other Cerebral Degenerations	6,967	1.2%	5,107	1.4%	-0.122	-0.011
Other Mental Disorders	4,767	0.8%	3,317	0.9%	-0.036	-0.004
Other Psychological Disorders	55,304	9.8%	41,509	11.1%	-1.228	-0.040
Persistent Mental Disorders due to Conditions Classified Elsewhere	6,225	1.1%	4,537	1.2%	-0.102	-0.010
Personality Disorders	2,928	0.5%	1,834	0.5%	0.032	0.005
Pervasive Developmental Disorders	1,071	0.2%	728	0.2%	-0.004	-0.001
Post-Traumatic Stress Disorder	11,758	2.1%	7,715	2.1%	0.035	0.002

Table 1br. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Psychotherapy	34,530	6.1%	21,811	5.8%	0.329	0.014
Psychotic Conditions	2,137	0.4%	1,736	0.5%	-0.083	-0.013
Schizophrenia	9,684	1.7%	7,958	2.1%	-0.399	-0.029
Sleep Disorder	199,879	35.6%	126,289	33.7%	1.893	0.040
Substance Abuse	28,448	5.1%	20,437	5.5%	-0.388	-0.017
Suicidal Behavior	3,211	0.6%	1,960	0.5%	0.049	0.007
Transcranial Magnetic Stimulation	145	0.0%	86	0.0%	0.003	0.002
Vagus Nerve Stimulation	627	0.1%	366	0.1%	0.014	0.004
Medical Product Use						
Index GLP-1 RA Product						
albiglutide	3,265	0.6%	0	0.0%	NaN	NaN
dulaglutide	179,700	32.0%	0	0.0%	NaN	NaN
exenatide	35,418	6.3%	0	0.0%	NaN	NaN
liraglutide	109,505	19.5%	0	0.0%	NaN	NaN
lixisenatide	6,121	1.1%	0	0.0%	NaN	NaN
semaglutide	212,452	37.8%	0	0.0%	NaN	NaN
tirzepatide	15,838	2.8%	0	0.0%	NaN	NaN
Any Anti-Diabetic Agents	561,556	100.0%	374,743	100.0%	-0.001	-0.003
insulin*	190,589	33.9%	146,717	39.2%	-5.212	-0.109
metformin*	496,901	88.5%	329,951	88.0%	0.439	0.014
alpha-glucosidase inhibitors*	2,108	0.4%	1,488	0.4%	-0.022	-0.004
thiazolidinediones*	46,159	8.2%	32,408	8.6%	-0.428	-0.015
meglitinides*	5,302	0.9%	3,873	1.0%	-0.089	-0.009
amylin analogue*	81	0.0%	60	0.0%	-0.002	-0.001
sulfonylureas*	197,239	35.1%	137,499	36.7%	-1.568	-0.033
bile acid sequestrants*	2,438	0.4%	1,691	0.5%	-0.017	-0.003

Table 1br. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Other Weight Loss Agents*	2,541	0.5%	1,291	0.3%	0.108	0.017
benzphetamine	*****	*****	*****	*****	*****	*****
bupropion	269	0.0%	159	0.0%	0.006	0.003
diethylpropion	47	0.0%	23	0.0%	0.002	0.003
lorcaserin	122	0.0%	73	0.0%	0.002	0.002
phentermine	1,959	0.3%	980	0.3%	0.087	0.016
phentermine-topiramate	124	0.0%	50	0.0%	0.009	0.007
phendimetrazine	37	0.0%	16	0.0%	0.002	0.003
orlistat	41	0.0%	24	0.0%	0.001	0.001
setmelanotide	0	0.0%	0	0.0%	NaN	NaN
Other Agents						
Analgesic Opiates*	163,136	29.1%	110,698	29.5%	-0.489	-0.011
Antipsychotics	39,149	7.0%	29,440	7.9%	-0.885	-0.034
Anxiolytics/Hypnotics	111,792	19.9%	77,823	20.8%	-0.860	-0.021
Lithium & Other Mood Stabilizers	33,508	6.0%	25,367	6.8%	-0.802	-0.033
Antidepressants	220,884	39.3%	145,323	38.8%	0.555	0.011
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters*	12.4	10.7	12.6	10.9	-0.207	-0.019
Mean number of emergency room encounters*	0.5	1.3	0.5	1.3	-0.023	-0.018
Mean number of inpatient hospital encounters*	0.2	0.5	0.2	0.6	-0.019	-0.035
Mean number of non-acute institutional encounters*	0.0	0.2	0.0	0.2	-0.004	-0.018
Mean number of other ambulatory encounters*	4.3	10.7	4.5	10.8	-0.195	-0.018

Table 1br. Aggregated Weighted Characteristics of GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation (Inverse Probability of Treatment Weighted, Trimmed, Weight: Average Treatment Effect, Stabilized (ATES), Truncation: 2.5%) in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	Medical Product				Covariate Balance	
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors			
Mean number of filled prescriptions*	27.9	20.9	28.2	20.1	-0.343	-0.017
Mean number of generics dispensed*	11.9	5.7	12.0	5.4	-0.167	-0.030
Mean number of unique drug classes dispensed*	10.4	4.9	10.4	5.0	-0.079	-0.016

*Covariate included in the propensity score logistic regression model.

[1]Covariates in blue show a standardized difference greater than 0.1.

[2]Weighted patient characteristics tables facilitate the assessment of covariate balance after inverse probability weighting and should not be interpreted as a description of the unweighted population. Treated patients are weighted by the proportion of treated patients in the trimmed population divided by the inverse of their propensity score (PS). Reference patients are weighted by 1 minus the proportion of treated patients in the trimmed population divided by 1 minus their PS.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[5]Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-726.

[6]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A = Not applicable

NaN = Not a number

Table 2a. Effect Estimates for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,161,983	691,293.97	217.30	0.59	840	1.22	0.72	0.35	0.16	1.38 (1.25, 1.54)	<0.001
SGLT-2 Inhibitors	1,081,155	702,556.73	237.35	0.65	609	0.87	0.56				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,161,916	691,251.98	217.30	0.59	840	1.22	0.72	0.35	0.16	N/A	N/A
SGLT-2 Inhibitors	1,080,587	702,281.31	237.38	0.65	609	0.87	0.56				
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]											
GLP-1 Receptor Agonists	1,712,503	927,221.32	197.76	0.54	1,313	1.42	0.77	-0.10	-0.16	1.03 (0.51, 2.07)	N/A
SGLT-2 Inhibitors	1,192,156	730,416.24	223.78	0.61	1,108	1.52	0.93				

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A= Not Applicable

Table 2b. Effect Estimates for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Intentional Self-Harm Encounter^

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1RA or SGLT-2i Users, 30-day Gap & Ext, No truncation											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,161,983	691,293.97	217.30	0.59	840	1.22	0.72	0.35	0.16	1.38 (1.25, 1.54)	<0.001
SGLT-2 Inhibitors	1,081,155	702,556.73	237.35	0.65	609	0.87	0.56				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,161,916	691,251.98	217.30	0.59	840	1.22	0.72	0.35	0.16	N/A	N/A
SGLT-2 Inhibitors	1,080,587	702,281.31	237.38	0.65	609	0.87	0.56				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	1,712,503	927,221.32	197.76	0.54	1,313	1.42	0.77	-0.10	-0.16	1.03 (0.51, 2.07)	N/A
SGLT-2 Inhibitors	1,192,156	730,416.24	223.78	0.61	1,108	1.52	0.93				
GLP-1RA or SGLT-2i Users, 30-day Gap & Ext, No truncation, Subgroup: No Prior Intentional Self-Harm Encounter											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,160,845	690,801.18	217.35	0.60	714	1.03	0.62	0.29	0.13	1.38 (1.23, 1.55)	<0.001
SGLT-2 Inhibitors	1,079,836	702,002.11	237.45	0.65	522	0.74	0.48				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,160,705	690,707.96	217.35	0.60	714	1.03	0.62	0.29	0.13	N/A	N/A
SGLT-2 Inhibitors	1,079,747	701,947.34	237.45	0.65	522	0.74	0.48				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	1,655,664	924,388.31	203.93	0.56	689	0.75	0.42	-0.48	-0.34	0.65 (0.50, 0.86)	N/A
SGLT-2 Inhibitors	1,190,154	729,806.26	223.97	0.61	898	1.23	0.75				
GLP-1RA or SGLT-2i Users, 30-day Gap & Ext, No truncation, Subgroup: Prior Intentional Self-Harm Encounter											
Site-Adjusted Analysis, Unweighted											

Table 2b. Effect Estimates for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Intentional Self-Harm Encounter^

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1 Receptor Agonists	791	336.32	155.30	0.43	90	267.60	113.78	-46.09	-2.58	0.88 (0.64, 1.22)	0.45
SGLT-2 Inhibitors	550	204.02	135.49	0.37	64	313.69	116.36				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	767	330.98	157.62	0.43	85	256.81	110.82	-64.21	-7.16	N/A	N/A
SGLT-2 Inhibitors	534	196.25	134.23	0.37	63	321.02	117.98				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	757	323.70	156.16	0.43	81	251.59	107.57	-183.02	-47.38	0.62 (0.42, 0.92)	N/A
SGLT-2 Inhibitors	562	200.50	130.22	0.36	87	434.61	154.95				

^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A=Not Applicable

Table 2c. Effect Estimates for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Psychiatric History Overall

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1RA or SGLT-2i Users, 30-day Gap & Ext, No truncation											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,161,983	691,293.97	217.30	0.59	840	1.22	0.72	0.35	0.16	1.38 (1.25, 1.54)	<0.001
SGLT-2 Inhibitors	1,081,155	702,556.73	237.35	0.65	609	0.87	0.56				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,161,916	691,251.98	217.30	0.59	840	1.22	0.72	0.35	0.16	N/A	N/A
SGLT-2 Inhibitors	1,080,587	702,281.31	237.38	0.65	609	0.87	0.56				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	1,712,503	927,221.32	197.76	0.54	1,313	1.42	0.77	-0.10	-0.16	1.03 (0.51, 2.07)	N/A
SGLT-2 Inhibitors	1,192,156	730,416.24	223.78	0.61	1,108	1.52	0.93				
GLP-1RA or SGLT-2i Users, 30-day Gap & Ext, No truncation, Subgroup: No Prior Psychiatric History											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	438,100	269,782.09	224.92	0.62	43	0.16	0.10	-0.02	-0.03	0.89 (0.60, 1.31)	0.54
SGLT-2 Inhibitors	503,313	344,849.45	250.25	0.69	63	0.18	0.13				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	438,040	269,742.80	224.92	0.62	43	0.16	0.10	-0.02	-0.03	N/A	N/A
SGLT-2 Inhibitors	503,214	344,776.52	250.25	0.69	63	0.18	0.13				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	790,933	472,475.98	218.19	0.60	42	0.09	0.05	-0.10	-0.07	0.53 (0.29, 0.97)	N/A
SGLT-2 Inhibitors	582,949	374,511.79	234.65	0.64	72	0.19	0.12				
GLP-1RA or SGLT-2i Users, 30-day Gap & Ext, No truncation, Subgroup: Prior Psychiatric History											
Site-Adjusted Analysis, Unweighted											

Table 2c. Effect Estimates for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Psychiatric History Overall

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1 Receptor Agonists	723,816	421,469.89	212.68	0.58	797	1.89	1.10	0.36	0.16	1.22 (1.10, 1.36)	<0.001
SGLT-2 Inhibitors	577,274	357,431.86	226.15	0.62	546	1.53	0.95				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	723,708	421,407.18	212.68	0.58	797	1.89	1.10	0.36	0.16	N/A	N/A
SGLT-2 Inhibitors	577,171	357,362.02	226.15	0.62	546	1.53	0.95				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	828,024	468,934.63	206.85	0.57	889	1.90	1.07	-0.31	-0.23	0.89 (0.65, 1.23)	N/A
SGLT-2 Inhibitors	612,480	363,514.55	216.78	0.59	801	2.20	1.31				

^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A=Not Applicable

Table 3a. Effect Estimates for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,161,983	691,293.97	217.30	0.59	840	1.22	0.72	0.35	0.16	1.38 (1.25, 1.54)	<0.001
SGLT-2 Inhibitors	1,081,155	702,556.73	237.35	0.65	609	0.87	0.56				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,161,916	691,251.98	217.30	0.59	840	1.22	0.72	0.35	0.16	N/A	N/A
SGLT-2 Inhibitors	1,080,587	702,281.31	237.38	0.65	609	0.87	0.56				
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]											
GLP-1 Receptor Agonists	1,154,786	689,333.89	218.03	0.60	777	1.13	0.67	-0.10	-0.09	0.93 (0.81, 1.08)	N/A
SGLT-2 Inhibitors	1,118,691	694,791.33	226.85	0.62	850	1.22	0.76				

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A= Not Applicable

Table 3b. Effect Estimates for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Intentional Self-Harm Encounter^

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1RA or SGLT-2i Users, 30-day Gap & Ext, 1% truncation											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,161,983	691,293.97	217.30	0.59	840	1.22	0.72	0.35	0.16	1.38 (1.25, 1.54)	<0.001
SGLT-2 Inhibitors	1,081,155	702,556.73	237.35	0.65	609	0.87	0.56				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,161,916	691,251.98	217.30	0.59	840	1.22	0.72	0.35	0.16	N/A	N/A
SGLT-2 Inhibitors	1,080,587	702,281.31	237.38	0.65	609	0.87	0.56				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	1,154,786	689,333.89	218.03	0.60	777	1.13	0.67	-0.10	-0.09	0.93 (0.81, 1.08)	N/A
SGLT-2 Inhibitors	1,118,691	694,791.33	226.85	0.62	850	1.22	0.76				
GLP-1RA or SGLT-2i Users, 30-day Gap & Ext, 1% truncation, Subgroup: No Prior Intentional Self-Harm Encounter											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,160,845	690,801.18	217.35	0.60	714	1.03	0.62	0.29	0.13	1.38 (1.23, 1.55)	<0.001
SGLT-2 Inhibitors	1,079,836	702,002.11	237.45	0.65	522	0.74	0.48				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,160,705	690,707.96	217.35	0.60	714	1.03	0.62	0.29	0.13	N/A	N/A
SGLT-2 Inhibitors	1,079,747	701,947.34	237.45	0.65	522	0.74	0.48				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	1,153,680	688,906.67	218.10	0.60	645	0.94	0.56	-0.07	-0.07	0.94 (0.81, 1.10)	N/A
SGLT-2 Inhibitors	1,117,909	694,561.53	226.93	0.62	702	1.01	0.63				
GLP-1RA or SGLT-2i Users, 30-day Gap & Ext, 1% truncation, Subgroup: Prior Intentional Self-Harm Encounter											
Site-Adjusted Analysis, Unweighted											

Table 3b. Effect Estimates for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Intentional Self-Harm Encounter^

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1 Receptor Agonists	791	336.32	155.30	0.43	90	267.60	113.78	-46.09	-2.58	0.88 (0.64, 1.22)	0.45
SGLT-2 Inhibitors	550	204.02	135.49	0.37	64	313.69	116.36				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	767	330.98	157.62	0.43	85	256.81	110.82	-64.21	-7.16	N/A	N/A
SGLT-2 Inhibitors	534	196.25	134.23	0.37	63	321.02	117.98				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	755	323.43	156.39	0.43	81	251.80	107.81	-146.11	-36.91	0.67 (0.47, 0.97)	N/A
SGLT-2 Inhibitors	546	198.64	132.84	0.36	79	397.91	144.72				

^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A=Not Applicable

Table 3c. Effect Estimates for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Psychiatric History Overall

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1RA or SGLT-2i Users, 30-day Gap & Ext, 1% truncation											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,161,983	691,293.97	217.30	0.59	840	1.22	0.72	0.35	0.16	1.38 (1.25, 1.54)	<0.001
SGLT-2 Inhibitors	1,081,155	702,556.73	237.35	0.65	609	0.87	0.56				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,161,916	691,251.98	217.30	0.59	840	1.22	0.72	0.35	0.16	N/A	N/A
SGLT-2 Inhibitors	1,080,587	702,281.31	237.38	0.65	609	0.87	0.56				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	1,154,786	689,333.89	218.03	0.60	777	1.13	0.67	-0.10	-0.09	0.93 (0.81, 1.08)	N/A
SGLT-2 Inhibitors	1,118,691	694,791.33	226.85	0.62	850	1.22	0.76				
GLP-1RA or SGLT-2i Users, 30-day Gap & Ext, 1% truncation, Subgroup: No Prior Psychiatric History											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	438,100	269,782.09	224.92	0.62	43	0.16	0.10	-0.02	-0.03	0.89 (0.60, 1.31)	0.54
SGLT-2 Inhibitors	503,313	344,849.45	250.25	0.69	63	0.18	0.13				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	438,040	269,742.80	224.92	0.62	43	0.16	0.10	-0.02	-0.03	N/A	N/A
SGLT-2 Inhibitors	503,214	344,776.52	250.25	0.69	63	0.18	0.13				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	440,776	275,000.17	227.88	0.62	41	0.15	0.09	-0.06	-0.04	0.75 (0.44, 1.27)	N/A
SGLT-2 Inhibitors	533,512	348,014.36	238.26	0.65	72	0.21	0.13				
GLP-1RA or SGLT-2i Users, 30-day Gap & Ext, 1% truncation, Subgroup: Prior Psychiatric History											
Site-Adjusted Analysis, Unweighted											

Table 3c. Effect Estimates for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Psychiatric History Overall

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1 Receptor Agonists	723,816	421,469.89	212.68	0.58	797	1.89	1.10	0.36	0.16	1.22 (1.10, 1.36)	<0.001
SGLT-2 Inhibitors	577,274	357,431.86	226.15	0.62	546	1.53	0.95				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	723,708	421,407.18	212.68	0.58	797	1.89	1.10	0.36	0.16	N/A	N/A
SGLT-2 Inhibitors	577,171	357,362.02	226.15	0.62	546	1.53	0.95				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	720,398	419,109.51	212.49	0.58	745	1.78	1.03	-0.16	-0.13	0.92 (0.80, 1.06)	N/A
SGLT-2 Inhibitors	587,499	351,657.56	218.63	0.60	683	1.94	1.16				

^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A=Not Applicable

Table 4a. Effect Estimates for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,161,983	691,293.97	217.30	0.59	840	1.22	0.72	0.35	0.16	1.38 (1.25, 1.54)	<0.001
SGLT-2 Inhibitors	1,081,155	702,556.73	237.35	0.65	609	0.87	0.56				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,161,916	691,251.98	217.30	0.59	840	1.22	0.72	0.35	0.16	N/A	N/A
SGLT-2 Inhibitors	1,080,587	702,281.31	237.38	0.65	609	0.87	0.56				
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]											
GLP-1 Receptor Agonists	1,106,389	661,769.28	218.47	0.60	735	1.11	0.66	-0.04	-0.06	0.97 (0.86, 1.10)	N/A
SGLT-2 Inhibitors	1,065,932	666,982.99	228.55	0.63	770	1.15	0.72				

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A= Not Applicable

Table 4b. Effect Estimates for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Intentional Self-Harm Encounter^

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1RA or SGLT-2i Users, 30-day Gap & Ext, 2.5% truncation											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,161,983	691,293.97	217.30	0.59	840	1.22	0.72	0.35	0.16	1.38 (1.25, 1.54)	<0.001
SGLT-2 Inhibitors	1,081,155	702,556.73	237.35	0.65	609	0.87	0.56				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,161,916	691,251.98	217.30	0.59	840	1.22	0.72	0.35	0.16	N/A	N/A
SGLT-2 Inhibitors	1,080,587	702,281.31	237.38	0.65	609	0.87	0.56				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	1,106,389	661,769.28	218.47	0.60	735	1.11	0.66	-0.04	-0.06	0.97 (0.86, 1.10)	N/A
SGLT-2 Inhibitors	1,065,932	666,982.99	228.55	0.63	770	1.15	0.72				
GLP-1RA or SGLT-2i Users, 30-day Gap & Ext, 2.5% truncation,Subgroup: No Prior Intentional Self-Harm Encounter											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,160,845	690,801.18	217.35	0.60	714	1.03	0.62	0.29	0.13	1.38 (1.23, 1.55)	<0.001
SGLT-2 Inhibitors	1,079,836	702,002.11	237.45	0.65	522	0.74	0.48				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,160,705	690,707.96	217.35	0.60	714	1.03	0.62	0.29	0.13	N/A	N/A
SGLT-2 Inhibitors	1,079,747	701,947.34	237.45	0.65	522	0.74	0.48				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	1,105,253	661,287.45	218.53	0.60	615	0.93	0.56	-0.04	-0.05	0.98 (0.85, 1.12)	N/A
SGLT-2 Inhibitors	1,065,182	666,742.86	228.63	0.63	644	0.97	0.60				
GLP-1RA or SGLT-2i Users, 30-day Gap & Ext, 2.5% truncation, Subgroup: Prior Intentional Self-Harm Encounter											
Site-Adjusted Analysis, Unweighted											

Table 4b. Effect Estimates for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Intentional Self-Harm Encounter^

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1 Receptor Agonists	791	336.32	155.30	0.43	90	267.60	113.78	-46.09	-2.58	0.88 (0.64, 1.22)	0.45
SGLT-2 Inhibitors	550	204.02	135.49	0.37	64	313.69	116.36				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	767	330.98	157.62	0.43	85	256.81	110.82	-64.21	-7.16	N/A	N/A
SGLT-2 Inhibitors	534	196.25	134.23	0.37	63	321.02	117.98				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	752	322.82	156.73	0.43	81	252.27	108.25	-134.25	-33.02	0.69 (0.48, 0.99)	N/A
SGLT-2 Inhibitors	531	193.91	133.49	0.37	75	386.52	141.27				

^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A=Not Applicable

Table 4c. Effect Estimates for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Psychiatric History Overall

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1RA or SGLT-2i Users, 30-day Gap & Ext, 2.5% truncation											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,161,983	691,293.97	217.30	0.59	840	1.22	0.72	0.35	0.16	1.38 (1.25, 1.54)	<0.001
SGLT-2 Inhibitors	1,081,155	702,556.73	237.35	0.65	609	0.87	0.56				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,161,916	691,251.98	217.30	0.59	840	1.22	0.72	0.35	0.16	N/A	N/A
SGLT-2 Inhibitors	1,080,587	702,281.31	237.38	0.65	609	0.87	0.56				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	1,106,389	661,769.28	218.47	0.60	735	1.11	0.66	-0.04	-0.06	0.97 (0.86, 1.10)	N/A
SGLT-2 Inhibitors	1,065,932	666,982.99	228.55	0.63	770	1.15	0.72				
GLP-1RA or SGLT-2i Users, 30-day Gap & Ext, 2.5% truncation, Subgroup: No Prior Psychiatric History											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	438,100	269,782.09	224.92	0.62	43	0.16	0.10	-0.02	-0.03	0.89 (0.60, 1.31)	0.54
SGLT-2 Inhibitors	503,313	344,849.45	250.25	0.69	63	0.18	0.13				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	438,040	269,742.80	224.92	0.62	43	0.16	0.10	-0.02	-0.03	N/A	N/A
SGLT-2 Inhibitors	503,214	344,776.52	250.25	0.69	63	0.18	0.13				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	407,392	253,831.29	227.57	0.62	39	0.15	0.10	-0.05	-0.04	0.77 (0.47, 1.26)	N/A
SGLT-2 Inhibitors	500,796	330,009.84	240.69	0.66	67	0.20	0.13				
GLP-1RA or SGLT-2i Users, 30-day Gap & Ext, 2.5% truncation, Subgroup: Prior Psychiatric History											
Site-Adjusted Analysis, Unweighted											

Table 4c. Effect Estimates for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Psychiatric History Overall

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1 Receptor Agonists	723,816	421,469.89	212.68	0.58	797	1.89	1.10	0.36	0.16	1.22 (1.10, 1.36)	<0.001
SGLT-2 Inhibitors	577,274	357,431.86	226.15	0.62	546	1.53	0.95				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	723,708	421,407.18	212.68	0.58	797	1.89	1.10	0.36	0.16	N/A	N/A
SGLT-2 Inhibitors	577,171	357,362.02	226.15	0.62	546	1.53	0.95				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	700,217	408,273.13	212.96	0.58	721	1.77	1.03	-0.10	-0.09	0.95 (0.84, 1.08)	N/A
SGLT-2 Inhibitors	565,961	340,495.91	219.74	0.60	637	1.87	1.13				

^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A=Not Applicable

Table 5a. Effect Estimates for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,150,636	684,043.14	217.14	0.59	827	1.21	0.72				
								0.15	-0.06	1.23 (1.12, 1.35)	<0.001
DPP-4 Inhibitors	1,396,382	1,024,858.64	268.07	0.73	1,088	1.06	0.78				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,150,446	683,967.93	217.15	0.59	826	1.21	0.72				
								0.15	-0.06	N/A	N/A
DPP-4 Inhibitors	1,396,159	1,024,703.54	268.07	0.73	1,088	1.06	0.78				
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]											
GLP-1 Receptor Agonists	1,313,982	767,849.36	213.44	0.58	1,917	2.50	1.46				
								1.00	0.48	1.90 (0.70, 5.18)	N/A
DPP-4 Inhibitors	1,539,090	1,004,859.60	238.47	0.65	1,506	1.50	0.98				

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A= Not Applicable

Table 5b. Effect Estimates for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Intentional Self-Harm Encounter^

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1RA or DPP-4i Users, 30-day Gap & Ext, No truncation											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,150,636	684,043.14	217.14	0.59	827	1.21	0.72	0.15	-0.06	1.23 (1.12, 1.35)	<0.001
DPP-4 Inhibitors	1,396,382	1,024,858.64	268.07	0.73	1,088	1.06	0.78				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,150,446	683,967.93	217.15	0.59	826	1.21	0.72	0.15	-0.06	N/A	N/A
DPP-4 Inhibitors	1,396,159	1,024,703.54	268.07	0.73	1,088	1.06	0.78				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	1,313,982	767,849.36	213.44	0.58	1,917	2.50	1.46	1.00	0.48	1.90 (0.70, 5.18)	N/A
DPP-4 Inhibitors	1,539,090	1,004,859.60	238.47	0.65	1,506	1.50	0.98				
GLP-1RA or DPP-4i Users, 30-day Gap & Ext, No truncation, Subgroup: No Prior Intentional Self-Harm Encounter											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,149,394	683,521.15	217.21	0.59	702	1.03	0.61	0.09	-0.08	1.20 (1.09, 1.33)	<0.001
DPP-4 Inhibitors	1,394,699	1,024,140.62	268.21	0.73	957	0.93	0.69				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,149,285	683,473.78	217.21	0.59	702	1.03	0.61	0.09	-0.08	N/A	N/A
DPP-4 Inhibitors	1,394,653	1,024,115.26	268.21	0.73	957	0.93	0.69				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											

Table 5b. Effect Estimates for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Intentional Self-Harm Encounter^

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1 Receptor Agonists	1,257,828	755,789.00	219.47	0.60	639	0.85	0.51	-0.48	-0.36	0.74 (0.61, 0.91)	N/A
DPP-4 Inhibitors	1,536,134	1,004,049.51	238.74	0.65	1,326	1.32	0.86				
GLP-1RA or DPP-4i Users, 30-day Gap & Ext, No truncation, Subgroup: Prior Intentional Self-Harm Encounter											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	882	382.42	158.37	0.43	103	269.34	116.78	36.45	26.01	1.16 (0.89, 1.51)	0.278
DPP-4 Inhibitors	1,311	510.97	142.36	0.39	119	232.89	90.77				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	855	371.93	158.89	0.44	97	260.80	113.45	16.94	18.45	N/A	N/A
DPP-4 Inhibitors	1,200	467.48	142.29	0.39	114	243.86	95.00				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	846	385.82	166.56	0.46	95	247.19	112.73	15.12	23.24	1.08 (0.78, 1.51)	N/A
DPP-4 Inhibitors	1,236	476.66	140.84	0.39	111	232.07	89.49				

^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A=Not Applicable

Table 5c. Effect Estimates for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Psychiatric History Overall

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1RA or DPP-4i Users, 30-day Gap & Ext, No truncation											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,150,636	684,043.14	217.14	0.59	827	1.21	0.72	0.15	-0.06	1.23 (1.12, 1.35)	<0.001
DPP-4 Inhibitors	1,396,382	1,024,858.64	268.07	0.73	1,088	1.06	0.78				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,150,446	683,967.93	217.15	0.59	826	1.21	0.72	0.15	-0.06	N/A	N/A
DPP-4 Inhibitors	1,396,159	1,024,703.54	268.07	0.73	1,088	1.06	0.78				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	1,313,982	767,849.36	213.44	0.58	1,917	2.50	1.46	1.00	0.48	1.90 (0.70, 5.18)	N/A
DPP-4 Inhibitors	1,539,090	1,004,859.60	238.47	0.65	1,506	1.50	0.98				
GLP-1RA or DPP-4i Users, 30-day Gap & Ext, No truncation, Subgroup: No Prior Psychiatric History											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	432,783	266,096.73	224.57	0.61	43	0.16	0.10	-0.04	-0.05	0.85 (0.59, 1.23)	0.394
DPP-4 Inhibitors	659,529	506,845.31	280.69	0.77	101	0.20	0.15				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	432,670	266,039.71	224.58	0.61	43	0.16	0.10	-0.04	-0.05	N/A	N/A
DPP-4 Inhibitors	659,305	506,674.03	280.69	0.77	101	0.20	0.15				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	506,393	318,498.96	229.73	0.63	40	0.13	0.08	-0.10	-0.07	0.65 (0.39, 1.07)	N/A
DPP-4 Inhibitors	749,486	509,084.03	248.09	0.68	114	0.22	0.15				

Table 5c. Effect Estimates for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Psychiatric History Overall

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1RA or DPP-4i Users, 30-day Gap & Ext, No truncation, Subgroup: Prior Psychiatric History											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	717,336	417,574.64	212.62	0.58	783	1.88	1.09	-0.03	-0.25	1.05 (0.95, 1.15)	0.341
DPP-4 Inhibitors	736,472	517,727.32	256.76	0.70	987	1.91	1.34				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	717,153	417,509.56	212.64	0.58	783	1.88	1.09	-0.03	-0.25	N/A	N/A
DPP-4 Inhibitors	736,409	517,691.22	256.77	0.70	987	1.91	1.34				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	754,821	444,822.37	215.24	0.59	1,187	2.67	1.57	0.31	0.08	1.28 (0.70, 2.33)	N/A
DPP-4 Inhibitors	787,051	498,417.36	231.30	0.63	1,176	2.36	1.49				

^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A=Not Applicable

Table 6a. Effect Estimates for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,150,636	684,043.14	217.14	0.59	827	1.21	0.72	0.15	-0.06	1.23 (1.12, 1.35)	<0.001
DPP-4 Inhibitors	1,396,382	1,024,858.64	268.07	0.73	1,088	1.06	0.78				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,150,446	683,967.93	217.15	0.59	826	1.21	0.72	0.15	-0.06	N/A	N/A
DPP-4 Inhibitors	1,396,159	1,024,703.54	268.07	0.73	1,088	1.06	0.78				
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]											
GLP-1 Receptor Agonists	1,075,535	674,135.53	228.94	0.63	756	1.12	0.70	-0.25	-0.22	0.94 (0.82, 1.07)	N/A
DPP-4 Inhibitors	1,409,027	949,968.95	246.25	0.67	1,305	1.37	0.93				

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A= Not Applicable

Table 6b. Effect Estimates for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Intentional Self-Harm Encounter^

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1RA or DPP-4i Users, 30-day Gap & Ext, 1% truncation											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,150,636	684,043.14	217.14	0.59	827	1.21	0.72	0.15	-0.06	1.23 (1.12, 1.35)	<0.001
DPP-4 Inhibitors	1,396,382	1,024,858.64	268.07	0.73	1,088	1.06	0.78				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,150,446	683,967.93	217.15	0.59	826	1.21	0.72	0.15	-0.06	N/A	N/A
DPP-4 Inhibitors	1,396,159	1,024,703.54	268.07	0.73	1,088	1.06	0.78				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	1,075,535	674,135.53	228.94	0.63	756	1.12	0.70	-0.25	-0.22	0.94 (0.82, 1.07)	N/A
DPP-4 Inhibitors	1,409,027	949,968.95	246.25	0.67	1,305	1.37	0.93				
GLP-1RA or DPP-4i Users, 30-day Gap & Ext, 1% truncation, Subgroup: No Prior Intentional Self-Harm Encounter											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,149,394	683,521.15	217.21	0.59	702	1.03	0.61	0.09	-0.08	1.20 (1.09, 1.33)	<0.001
DPP-4 Inhibitors	1,394,699	1,024,140.62	268.21	0.73	957	0.93	0.69				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,149,285	683,473.78	217.21	0.59	702	1.03	0.61	0.09	-0.08	N/A	N/A
DPP-4 Inhibitors	1,394,653	1,024,115.26	268.21	0.73	957	0.93	0.69				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											

Table 6b. Effect Estimates for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Intentional Self-Harm Encounter^

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1 Receptor Agonists	1,074,433	673,724.94	229.03	0.63	602	0.89	0.56	-0.31	-0.25	0.85 (0.74, 0.98)	N/A
DPP-4 Inhibitors	1,407,629	949,498.19	246.37	0.67	1,148	1.21	0.82				
GLP-1RA or DPP-4i Users, 30-day Gap & Ext, 1% truncation, Subgroup: Prior Intentional Self-Harm Encounter											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	882	382.42	158.37	0.43	103	269.34	116.78	36.45	26.01	1.16 (0.89, 1.51)	0.278
DPP-4 Inhibitors	1,311	510.97	142.36	0.39	119	232.89	90.77				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	855	371.93	158.89	0.44	97	260.80	113.45	16.94	18.45	N/A	N/A
DPP-4 Inhibitors	1,200	467.48	142.29	0.39	114	243.86	95.00				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	826	378.55	167.40	0.46	95	251.63	115.32	17.31	24.56	1.08 (0.78, 1.49)	N/A
DPP-4 Inhibitors	1,209	468.11	141.47	0.39	110	234.32	90.76				

^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A=Not Applicable

Table 6c. Effect Estimates for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Psychiatric History Overall

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1RA or DPP-4i Users, 30-day Gap & Ext, 1% truncation											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,150,636	684,043.14	217.14	0.59	827	1.21	0.72	0.15	-0.06	1.23 (1.12, 1.35)	<0.001
DPP-4 Inhibitors	1,396,382	1,024,858.64	268.07	0.73	1,088	1.06	0.78				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,150,446	683,967.93	217.15	0.59	826	1.21	0.72	0.15	-0.06	N/A	N/A
DPP-4 Inhibitors	1,396,159	1,024,703.54	268.07	0.73	1,088	1.06	0.78				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	1,075,535	674,135.53	228.94	0.63	756	1.12	0.70	-0.25	-0.22	0.94 (0.82, 1.07)	N/A
DPP-4 Inhibitors	1,409,027	949,968.95	246.25	0.67	1,305	1.37	0.93				
GLP-1RA or DPP-4i Users, 30-day Gap & Ext, 1% truncation, Subgroup: No Prior Psychiatric History											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	432,783	266,096.73	224.57	0.61	43	0.16	0.10	-0.04	-0.05	0.85 (0.59, 1.23)	0.394
DPP-4 Inhibitors	659,529	506,845.31	280.69	0.77	101	0.20	0.15				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	432,670	266,039.71	224.58	0.61	43	0.16	0.10	-0.04	-0.05	N/A	N/A
DPP-4 Inhibitors	659,305	506,674.03	280.69	0.77	101	0.20	0.15				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	392,808	258,405.07	240.28	0.66	39	0.15	0.10	-0.08	-0.07	0.74 (0.45, 1.20)	N/A
DPP-4 Inhibitors	677,581	478,738.11	258.06	0.71	112	0.23	0.17				
GLP-1RA or DPP-4i Users, 30-day Gap & Ext, 1% truncation, Subgroup: Prior Psychiatric History											
Site-Adjusted Analysis, Unweighted											

Table 6c. Effect Estimates for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Psychiatric History Overall

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1 Receptor Agonists	717,336	417,574.64	212.62	0.58	783	1.88	1.09	-0.03	-0.25	1.05 (0.95, 1.15)	0.341
DPP-4 Inhibitors	736,472	517,727.32	256.76	0.70	987	1.91	1.34				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	717,153	417,509.56	212.64	0.58	783	1.88	1.09	-0.03	-0.25	N/A	N/A
DPP-4 Inhibitors	736,409	517,691.22	256.77	0.70	987	1.91	1.34				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	683,663	414,631.96	221.52	0.61	752	1.81	1.10	-0.43	-0.36	0.91 (0.80, 1.04)	N/A
DPP-4 Inhibitors	734,504	477,712.28	237.55	0.65	1,072	2.24	1.46				

^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A=Not Applicable

Table 7a. Effect Estimates for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,150,636	684,043.14	217.14	0.59	827	1.21	0.72	0.15	-0.06	1.23 (1.12, 1.35)	<0.001
DPP-4 Inhibitors	1,396,382	1,024,858.64	268.07	0.73	1,088	1.06	0.78				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,150,446	683,967.93	217.15	0.59	826	1.21	0.72	0.15	-0.06	N/A	N/A
DPP-4 Inhibitors	1,396,159	1,024,703.54	268.07	0.73	1,088	1.06	0.78				
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]											
GLP-1 Receptor Agonists	1,033,798	649,020.71	229.30	0.63	706	1.09	0.68	-0.24	-0.23	0.94 (0.83, 1.05)	N/A
DPP-4 Inhibitors	1,338,423	915,625.37	249.87	0.68	1,220	1.33	0.91				

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A= Not Applicable

Table 7b. Effect Estimates for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Intentional Self-Harm Encounter^

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1RA or DPP-4i Users, 30-day Gap & Ext, 2.5% truncation											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,150,636	684,043.14	217.14	0.59	827	1.21	0.72	0.15	-0.06	1.23 (1.12, 1.35)	<0.001
DPP-4 Inhibitors	1,396,382	1,024,858.64	268.07	0.73	1,088	1.06	0.78				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,150,446	683,967.93	217.15	0.59	826	1.21	0.72	0.15	-0.06	N/A	N/A
DPP-4 Inhibitors	1,396,159	1,024,703.54	268.07	0.73	1,088	1.06	0.78				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	1,033,798	649,020.71	229.30	0.63	706	1.09	0.68	-0.24	-0.23	0.94 (0.83, 1.05)	N/A
DPP-4 Inhibitors	1,338,423	915,625.37	249.87	0.68	1,220	1.33	0.91				
GLP-1RA or DPP-4i Users, 30-day Gap & Ext, 2.5% truncation, Subgroup: No Prior Intentional Self-Harm Encounter											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,149,394	683,521.15	217.21	0.59	702	1.03	0.61	0.09	-0.08	1.20 (1.09, 1.33)	<0.001
DPP-4 Inhibitors	1,394,699	1,024,140.62	268.21	0.73	957	0.93	0.69				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,149,285	683,473.78	217.21	0.59	702	1.03	0.61	0.09	-0.08	N/A	N/A
DPP-4 Inhibitors	1,394,653	1,024,115.26	268.21	0.73	957	0.93	0.69				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	1,032,667	648,539.36	229.39	0.63	580	0.89	0.56	-0.28	-0.24	0.88 (0.78, 1.00)	N/A
DPP-4 Inhibitors	1,336,948	915,105.60	250.00	0.68	1,074	1.17	0.80				
GLP-1RA or DPP-4i Users, 30-day Gap & Ext, 2.5% truncation, Subgroup: Prior Intentional Self-Harm Encounter											
Site-Adjusted Analysis, Unweighted											

Table 7b. Effect Estimates for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Intentional Self-Harm Encounter^

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1 Receptor Agonists	882	382.42	158.37	0.43	103	269.34	116.78	36.45	26.01	1.16 (0.89, 1.51)	0.278
DPP-4 Inhibitors	1,311	510.97	142.36	0.39	119	232.89	90.77				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	855	371.93	158.89	0.44	97	260.80	113.45	16.94	18.45	N/A	N/A
DPP-4 Inhibitors	1,200	467.48	142.29	0.39	114	243.86	95.00				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	808	369.63	166.99	0.46	93	251.60	115.03	17.57	24.22	1.08 (0.79, 1.48)	N/A
DPP-4 Inhibitors	1,181	458.06	141.72	0.39	107	234.03	90.81				

^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A=Not Applicable

Table 7c. Effect Estimates for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Psychiatric History Overall

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1RA or DPP-4i Users, 30-day Gap & Ext, 2.5% truncation											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,150,636	684,043.14	217.14	0.59	827	1.21	0.72	0.15	-0.06	1.23 (1.12, 1.35)	<0.001
DPP-4 Inhibitors	1,396,382	1,024,858.64	268.07	0.73	1,088	1.06	0.78				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,150,446	683,967.93	217.15	0.59	826	1.21	0.72	0.15	-0.06	N/A	N/A
DPP-4 Inhibitors	1,396,159	1,024,703.54	268.07	0.73	1,088	1.06	0.78				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	1,033,798	649,020.71	229.30	0.63	706	1.09	0.68	-0.24	-0.23	0.94 (0.83, 1.05)	N/A
DPP-4 Inhibitors	1,338,423	915,625.37	249.87	0.68	1,220	1.33	0.91				
GLP-1RA or DPP-4i Users, 30-day Gap & Ext, 2.5% truncation, Subgroup: No Prior Psychiatric History											
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	432,783	266,096.73	224.57	0.61	43	0.16	0.10	-0.04	-0.05	0.85 (0.59, 1.23)	0.394
DPP-4 Inhibitors	659,529	506,845.31	280.69	0.77	101	0.20	0.15				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	432,670	266,039.71	224.58	0.61	43	0.16	0.10	-0.04	-0.05	N/A	N/A
DPP-4 Inhibitors	659,305	506,674.03	280.69	0.77	101	0.20	0.15				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	372,463	244,332.74	239.60	0.66	38	0.16	0.10	-0.08	-0.06	0.74 (0.47, 1.18)	N/A
DPP-4 Inhibitors	640,886	459,819.83	262.06	0.72	107	0.23	0.17				
GLP-1RA or DPP-4i Users, 30-day Gap & Ext, 2.5% truncation, Subgroup: Prior Psychiatric History											
Site-Adjusted Analysis, Unweighted											

Table 7c. Effect Estimates for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type and Psychiatric History Overall

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
GLP-1 Receptor Agonists	717,336	417,574.64	212.62	0.58	783	1.88	1.09	-0.03	-0.25	1.05 (0.95, 1.15)	0.341
DPP-4 Inhibitors	736,472	517,727.32	256.76	0.70	987	1.91	1.34				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	717,153	417,509.56	212.64	0.58	783	1.88	1.09	-0.03	-0.25	N/A	N/A
DPP-4 Inhibitors	736,409	517,691.22	256.77	0.70	987	1.91	1.34				
Inverse Probability of Treatment Weighted Analysis [1]; Weight = ATES, Trimmed [2]											
GLP-1 Receptor Agonists	661,762	402,384.76	222.09	0.61	713	1.77	1.08	-0.44	-0.38	0.90 (0.80, 1.01)	N/A
DPP-4 Inhibitors	701,327	462,184.15	240.70	0.66	1,023	2.21	1.46				

^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A=Not Applicable

Table 8. Effect Estimates for GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,162,009	691,422.78	217.33	0.60	546	0.79	0.47	0.25	0.12	1.45 (1.27, 1.65)	<0.001
SGLT-2 Inhibitors	1,081,183	702,663.01	237.38	0.65	379	0.54	0.35				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,161,942	691,380.52	217.33	0.60	546	0.79	0.47	0.25	0.12	N/A	N/A
SGLT-2 Inhibitors	1,080,616	702,387.81	237.41	0.65	379	0.54	0.35				
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]											
GLP-1 Receptor Agonists	2,651,987	1,073,763.25	147.89	0.40	627	0.58	0.24	-0.28	-0.29	0.84 (0.60, 1.18)	N/A
SGLT-2 Inhibitors	1,192,250	730,669.74	223.84	0.61	632	0.87	0.53				

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A= Not Applicable

Table 9. Effect Estimates for GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,162,009	691,422.78	217.33	0.60	546	0.79	0.47	0.25	0.12	1.45 (1.27, 1.65)	<0.001
SGLT-2 Inhibitors	1,081,183	702,663.01	237.38	0.65	379	0.54	0.35				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,161,942	691,380.52	217.33	0.60	546	0.79	0.47	0.25	0.12	N/A	N/A
SGLT-2 Inhibitors	1,080,616	702,387.81	237.41	0.65	379	0.54	0.35				
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]											
GLP-1 Receptor Agonists	1,154,818	689,440.68	218.06	0.60	513	0.74	0.44	-0.05	-0.05	0.95 (0.79, 1.14)	N/A
SGLT-2 Inhibitors	1,118,721	694,920.25	226.88	0.62	554	0.80	0.49				

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A= Not Applicable

Table 10. Effect Estimates for GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,162,009	691,422.78	217.33	0.60	546	0.79	0.47	0.25	0.12	1.45 (1.27, 1.65)	<0.001
SGLT-2 Inhibitors	1,081,183	702,663.01	237.38	0.65	379	0.54	0.35				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,161,942	691,380.52	217.33	0.60	546	0.79	0.47	0.25	0.12	N/A	N/A
SGLT-2 Inhibitors	1,080,616	702,387.81	237.41	0.65	379	0.54	0.35				
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]											
GLP-1 Receptor Agonists	1,106,420	661,878.68	218.50	0.60	477	0.72	0.43	-0.03	-0.04	0.97 (0.83, 1.14)	N/A
SGLT-2 Inhibitors	1,065,963	667,097.84	228.58	0.63	502	0.75	0.47				

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A= Not Applicable

Table 11. Effect Estimates for GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,162,008	555,417.45	174.58	0.48	701	1.26	0.60	0.41	0.13	1.44 (1.29, 1.62)	<0.001
SGLT-2 Inhibitors	1,081,164	595,121.03	201.05	0.55	509	0.86	0.47				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,161,940	555,382.57	174.58	0.48	701	1.26	0.60	0.41	0.13	N/A	N/A
SGLT-2 Inhibitors	1,080,595	594,868.07	201.07	0.55	509	0.86	0.47				
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]											
GLP-1 Receptor Agonists	1,709,551	748,043.07	159.82	0.44	1,159	1.55	0.68	0.01	-0.12	1.08 (0.51, 2.32)	N/A
SGLT-2 Inhibitors	1,192,050	619,124.84	189.70	0.52	954	1.54	0.80				

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A= Not Applicable

Table 12. Effect Estimates for GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,162,008	555,417.45	174.58	0.48	701	1.26	0.60	0.41	0.13	1.44 (1.29, 1.62)	<0.001
SGLT-2 Inhibitors	1,081,164	595,121.03	201.05	0.55	509	0.86	0.47				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,161,940	555,382.57	174.58	0.48	701	1.26	0.60	0.41	0.13	N/A	N/A
SGLT-2 Inhibitors	1,080,595	594,868.07	201.07	0.55	509	0.86	0.47				
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]											
GLP-1 Receptor Agonists	1,154,805	553,793.76	175.16	0.48	641	1.16	0.55	-0.06	-0.09	0.95 (0.81, 1.11)	N/A
SGLT-2 Inhibitors	1,118,689	587,935.60	191.96	0.53	717	1.22	0.64				

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A= Not Applicable

Table 13. Effect Estimates for GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	1,162,008	555,417.45	174.58	0.48	701	1.26	0.60	0.41	0.13	1.44 (1.29, 1.62)	<0.001
SGLT-2 Inhibitors	1,081,164	595,121.03	201.05	0.55	509	0.86	0.47				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	1,161,940	555,382.57	174.58	0.48	701	1.26	0.60	0.41	0.13	N/A	N/A
SGLT-2 Inhibitors	1,080,595	594,868.07	201.07	0.55	509	0.86	0.47				
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]											
GLP-1 Receptor Agonists	1,106,400	531,494.56	175.46	0.48	605	1.14	0.55	-0.01	-0.06	0.99 (0.86, 1.14)	N/A
SGLT-2 Inhibitors	1,065,923	564,256.00	193.35	0.53	649	1.15	0.61				

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A= Not Applicable

Table 14. Effect Estimates for GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	824,408	571,427.59	253.17	0.69	658	1.15	0.80	0.35	0.19	1.42 (1.26, 1.60)	<0.001
SGLT-2 Inhibitors	752,899	571,568.67	277.28	0.76	458	0.80	0.61				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	824,321	571,357.99	253.16	0.69	658	1.15	0.80	0.35	0.19	N/A	N/A
SGLT-2 Inhibitors	752,456	571,352.76	277.34	0.76	458	0.80	0.61				
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]											
GLP-1 Receptor Agonists	1,193,550	803,691.64	245.95	0.67	1,180	1.47	0.99	0.08	0.00	1.17 (0.51, 2.68)	N/A
SGLT-2 Inhibitors	835,111	593,887.19	259.75	0.71	823	1.39	0.99				

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A= Not Applicable

Table 15. Effect Estimates for GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	824,408	571,427.59	253.17	0.69	658	1.15	0.80	0.35	0.19	1.42 (1.26, 1.60)	<0.001
SGLT-2 Inhibitors	752,899	571,568.67	277.28	0.76	458	0.80	0.61				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	824,321	571,357.99	253.16	0.69	658	1.15	0.80	0.35	0.19	N/A	N/A
SGLT-2 Inhibitors	752,456	571,352.76	277.34	0.76	458	0.80	0.61				
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]											
GLP-1 Receptor Agonists	820,303	575,926.15	256.44	0.70	597	1.04	0.73	-0.10	-0.10	0.93 (0.79, 1.10)	N/A
SGLT-2 Inhibitors	776,910	562,918.34	264.65	0.72	640	1.14	0.82				

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A= Not Applicable

Table 16. Effect Estimates for GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	824,408	571,427.59	253.17	0.69	658	1.15	0.80	0.35	0.19	1.42 (1.26, 1.60)	<0.001
SGLT-2 Inhibitors	752,899	571,568.67	277.28	0.76	458	0.80	0.61				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	824,321	571,357.99	253.16	0.69	658	1.15	0.80	0.35	0.19	N/A	N/A
SGLT-2 Inhibitors	752,456	571,352.76	277.34	0.76	458	0.80	0.61				
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]											
GLP-1 Receptor Agonists	785,057	551,432.05	256.56	0.70	565	1.02	0.72	-0.05	-0.07	0.97 (0.84, 1.12)	N/A
SGLT-2 Inhibitors	738,843	539,571.87	266.74	0.73	582	1.08	0.79				

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A= Not Applicable

Table 17. Effect Estimates for GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	576,208	335,359.88	212.58	0.58	478	1.43	0.83	0.39	0.18	1.36 (1.17, 1.58)	<0.001
SGLT-2 Inhibitors	384,900	241,351.15	229.03	0.63	251	1.04	0.65				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	576,119	335,301.03	212.58	0.58	478	1.43	0.83	0.39	0.18	N/A	N/A
SGLT-2 Inhibitors	384,759	241,281.69	229.05	0.63	251	1.04	0.65				
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]											
GLP-1 Receptor Agonists	689,137	386,384.64	204.79	0.56	605	1.57	0.88	-0.13	-0.11	0.99 (0.61, 1.63)	N/A
SGLT-2 Inhibitors	418,293	244,256.34	213.28	0.58	414	1.69	0.99				

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A= Not Applicable

Table 18. Effect Estimates for GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	576,208	335,359.88	212.58	0.58	478	1.43	0.83	0.39	0.18	1.36 (1.17, 1.58)	<0.001
SGLT-2 Inhibitors	384,900	241,351.15	229.03	0.63	251	1.04	0.65				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	576,119	335,301.03	212.58	0.58	478	1.43	0.83	0.39	0.18	N/A	N/A
SGLT-2 Inhibitors	384,759	241,281.69	229.05	0.63	251	1.04	0.65				
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]											
GLP-1 Receptor Agonists	577,644	338,687.95	214.16	0.59	456	1.35	0.79	-0.12	-0.08	0.94 (0.77, 1.14)	N/A
SGLT-2 Inhibitors	393,157	233,111.68	216.57	0.59	342	1.47	0.87				

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A= Not Applicable

Table 19. Effect Estimates for GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Risk Difference per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analysis, Unweighted											
GLP-1 Receptor Agonists	576,208	335,359.88	212.58	0.58	478	1.43	0.83	0.39	0.18	1.36 (1.17, 1.58)	<0.001
SGLT-2 Inhibitors	384,900	241,351.15	229.03	0.63	251	1.04	0.65				
Inverse Probability of Treatment Weighted Analysis; Unweighted, Trimmed											
GLP-1 Receptor Agonists	576,119	335,301.03	212.58	0.58	478	1.43	0.83	0.39	0.18	N/A	N/A
SGLT-2 Inhibitors	384,759	241,281.69	229.05	0.63	251	1.04	0.65				
Inverse Probability of Treatment Weighted Analysis[1]; Weight = ATES, Trimmed[2]											
GLP-1 Receptor Agonists	561,559	329,976.78	214.62	0.59	438	1.33	0.78	-0.07	-0.05	0.97 (0.81, 1.17)	N/A
SGLT-2 Inhibitors	374,743	224,138.01	218.46	0.60	312	1.39	0.83				

[1]All values in this section are weighted.

[2]ATES = Average Treatment Effect, Stabilized.

N/A= Not Applicable

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	GLP-1RA or SGLT-2i Users, 0% truncation				GLP-1RA or SGLT-2i Users, 1% truncation			
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	368,537,023	N/A	368,537,023	N/A	368,537,023	N/A	368,537,023	N/A
Had required coverage type (medical and/or drug coverage)	275,209,277	93,327,746	275,209,277	93,327,746	275,209,277	93,327,746	275,209,277	93,327,746
Enrolled during specified age range	214,507,877	60,701,400	214,507,877	60,701,400	214,507,877	60,701,400	214,507,877	60,701,400
Had requestable medical charts	214,507,877	0	214,507,877	0	214,507,877	0	214,507,877	0
Met demographic requirements (sex, race, and Hispanic origin)	214,437,809	70,068	214,437,809	70,068	214,437,809	70,068	214,437,809	70,068
Members with a valid index event								
Had any cohort-defining claim during the query period	4,478,687	209,959,122	3,745,127	210,692,682	4,478,687	209,959,122	3,745,127	210,692,682
Claim recorded during specified age range	4,477,327	1,360	3,744,791	336	4,477,327	1,360	3,744,791	336
Episode defining index claim recorded during the query period	4,398,159	79,168	3,658,687	86,104	4,398,159	79,168	3,658,687	86,104
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	3,446,512	951,647	2,815,355	843,332	3,446,512	951,647	2,815,355	843,332
Met inclusion and exclusion criteria[1]	1,208,954	2,237,558	1,119,398	1,695,957	1,208,954	2,237,558	1,119,398	1,695,957
Evidence of dpp_washout	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Evidence of gest_diabetes	N/A	3,092	N/A	960	N/A	3,092	N/A	960
Evidence of glp_washout	N/A	865,965	N/A	N/A	N/A	865,965	N/A	N/A
Evidence of insulin_noad	N/A	387,969	N/A	229,292	N/A	387,969	N/A	229,292

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	GLP-1RA or SGLT-2i Users, 0% truncation				GLP-1RA or SGLT-2i Users, 1% truncation			
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Evidence of no_glpdpp	N/A	N/A	N/A	1,020,964	N/A	N/A	N/A	1,020,964
Evidence of no_glpsglt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Evidence of no_sgltdpp	N/A	992,184	N/A	N/A	N/A	992,184	N/A	N/A
Evidence of pregnancy	N/A	54,654	N/A	32,420	N/A	54,654	N/A	32,420
Evidence of secondary_diabetes	N/A	196,708	N/A	158,010	N/A	196,708	N/A	158,010
Evidence of sglt_washout	N/A	N/A	N/A	556,211	N/A	N/A	N/A	556,211
Evidence of type1_diabetes	N/A	174,097	N/A	118,846	N/A	174,097	N/A	118,846
No evidence of dm_and_obes	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of type2_Diabetes	N/A	1,286,625	N/A	763,011	N/A	1,286,625	N/A	763,011
Met event incidence criteria	1,208,954	0	1,119,398	0	1,208,954	0	1,119,398	0
Had sufficient post-index continuous enrollment	1,208,954	0	1,119,398	0	1,208,954	0	1,119,398	0
Had minimum days' supply on index date	1,208,954	0	1,119,398	0	1,208,954	0	1,119,398	0
Had index episode of at least required length	1,208,954	0	1,119,398	0	1,208,954	0	1,119,398	0
Had index episode longer than blackout period	1,206,816	2,138	1,117,215	2,183	1,206,816	2,138	1,117,215	2,183
Did not have an event during blackout period	1,206,786	30	1,117,178	37	1,206,786	30	1,117,178	37
Final cohort								
Number of members	1,206,786	N/A	1,117,178	N/A	1,206,786	N/A	1,117,178	N/A
Number of episodes	1,206,786	N/A	1,117,178	N/A	1,206,786	N/A	1,117,178	N/A
Members meeting comparative cohort eligibility requirements								
Excluded due to same-day initition of both exposure groups	1,206,786	0	1,117,178	0	1,206,786	0	1,117,178	0

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

	GLP-1RA or SGLT-2i Users, 0% truncation				GLP-1RA or SGLT-2i Users, 1% truncation			
	GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Excluded due to prior initiation of other exposure group	1,161,983	44,803	1,081,155	36,023	1,161,983	44,803	1,081,155	36,023
Excluded due to propensity score trimming	1,161,916	67	1,080,587	568	1,161,916	67	1,080,587	568
Included in comparative analysis	1,161,916	0	1,080,587	0	1,161,916	0	1,080,587	0
Additional information								
Number of events in comparative analysis	840	N/A	609	N/A	840	N/A	609	N/A
Number of patients with a truncated inverse probability of treatment weight	N/A	N/A	N/A	N/A	14,756	N/A	30,098	N/A

[1]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.
*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
N/A= Not Applicable

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

GLP-1RA or SGLT-2i Users, 2.5% truncation				GLP-1RA or DPP-4i Users, 0% truncation				GLP-1RA or DPP-4i Users, 1% truncation			
GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		DPP-4 Inhibitors		GLP-1 Receptor Agonists		DPP-4 Inhibitors	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements											
368,537,023	N/A	368,537,023	N/A	368,537,023	N/A	368,537,023	N/A	368,537,023	N/A	368,537,023	N/A
275,209,277	93,327,746	275,209,277	93,327,746	275,209,277	93,327,746	275,209,277	93,327,746	275,209,277	93,327,746	275,209,277	93,327,746
214,507,877	60,701,400	214,507,877	60,701,400	214,507,877	60,701,400	214,507,877	60,701,400	214,507,877	60,701,400	214,507,877	60,701,400
214,507,877	0	214,507,877	0	214,507,877	0	214,507,877	0	214,507,877	0	214,507,877	0
214,437,809	70,068	214,437,809	70,068	214,437,809	70,068	214,437,809	70,068	214,437,809	70,068	214,437,809	70,068
Members with a valid index event											
4,478,687	209,959,122	3,745,127	210,692,682	4,478,687	209,959,122	4,088,866	210,348,943	4,478,687	209,959,122	4,088,866	210,348,943
4,477,327	1,360	3,744,791	336	4,477,327	1,360	4,088,288	578	4,477,327	1,360	4,088,288	578
4,398,159	79,168	3,658,687	86,104	4,398,159	79,168	3,669,861	418,427	4,398,159	79,168	3,669,861	418,427
Members with required pre-index history											
3,446,512	951,647	2,815,355	843,332	3,446,512	951,647	2,729,381	940,480	3,446,512	951,647	2,729,381	940,480
1,208,954	2,237,558	1,119,398	1,695,957	1,208,954	2,237,558	1,414,140	1,315,241	1,208,954	2,237,558	1,414,140	1,315,241
N/A	N/A	N/A	N/A	N/A	N/A	N/A	755,102	N/A	N/A	N/A	755,102
N/A	3,092	N/A	960	N/A	3,092	N/A	1,039	N/A	3,092	N/A	1,039
N/A	865,965	N/A	N/A	N/A	865,965	N/A	N/A	N/A	865,965	N/A	N/A
N/A	387,969	N/A	229,292	N/A	387,969	N/A	178,413	N/A	387,969	N/A	178,413

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

GLP-1RA or SGLT-2i Users, 2.5% truncation				GLP-1RA or DPP-4i Users, 0% truncation				GLP-1RA or DPP-4i Users, 1% truncation			
GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		DPP-4 Inhibitors		GLP-1 Receptor Agonists		DPP-4 Inhibitors	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
N/A	N/A	N/A	1,020,964	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A	N/A	425,575	N/A	N/A	N/A	425,575
N/A	992,184	N/A	N/A	N/A	992,184	N/A	N/A	N/A	992,184	N/A	N/A
N/A	54,654	N/A	32,420	N/A	54,654	N/A	37,261	N/A	54,654	N/A	37,261
N/A	196,708	N/A	158,010	N/A	196,708	N/A	198,623	N/A	196,708	N/A	198,623
N/A	N/A	N/A	556,211	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	174,097	N/A	118,846	N/A	174,097	N/A	133,673	N/A	174,097	N/A	133,673
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	1,286,625	N/A	763,011	N/A	1,286,625	N/A	588,479	N/A	1,286,625	N/A	588,479
1,208,954	0	1,119,398	0	1,208,954	0	1,414,140	0	1,208,954	0	1,414,140	0
1,208,954	0	1,119,398	0	1,208,954	0	1,414,140	0	1,208,954	0	1,414,140	0
1,208,954	0	1,119,398	0	1,208,954	0	1,414,140	0	1,208,954	0	1,414,140	0
1,208,954	0	1,119,398	0	1,208,954	0	1,414,140	0	1,208,954	0	1,414,140	0
1,206,816	2,138	1,117,215	2,183	1,206,816	2,138	1,411,305	2,835	1,206,816	2,138	1,411,305	2,835
1,206,786	30	1,117,178	37	1,206,786	30	1,411,252	53	1,206,786	30	1,411,252	53
Final cohort											
1,206,786	N/A	1,117,178	N/A	1,206,786	N/A	1,411,252	N/A	1,206,786	N/A	1,411,252	N/A
1,206,786	N/A	1,117,178	N/A	1,206,786	N/A	1,411,252	N/A	1,206,786	N/A	1,411,252	N/A

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

GLP-1RA or SGLT-2i Users, 2.5% truncation				GLP-1RA or DPP-4i Users, 0% truncation				GLP-1RA or DPP-4i Users, 1% truncation			
GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		DPP-4 Inhibitors		GLP-1 Receptor Agonists		DPP-4 Inhibitors	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting comparative cohort eligibility requirements											
1,206,786	0	1,117,178	0	1,206,786	0	1,411,252	0	1,206,786	0	1,411,252	0
1,161,983	44,803	1,081,155	36,023	1,150,636	56,150	1,396,382	14,870	1,150,636	56,150	1,396,382	14,870
1,161,916	67	1,080,587	568	1,150,446	190	1,396,159	223	1,150,446	190	1,396,159	223
1,161,916	0	1,080,587	0	1,150,446	0	1,396,159	0	1,150,446	0	1,396,159	0
Additional information											
840	N/A	609	N/A	826	N/A	1,088	N/A	826	N/A	1,088	N/A
35,794	N/A	76,331	N/A	N/A	N/A	N/A	N/A	25,311	N/A	25,618	N/A

[1]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.
*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
N/A=Not Applicable

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

GLP-1RA or DPP-4i Users, 2.5% truncation				GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation			
GLP-1 Receptor Agonists		DPP-4 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements							
368,537,023	N/A	368,537,023	N/A	368,537,023	N/A	368,537,023	N/A
275,209,277	93,327,746	275,209,277	93,327,746	275,209,277	93,327,746	275,209,277	93,327,746
214,507,877	60,701,400	214,507,877	60,701,400	214,507,877	60,701,400	214,507,877	60,701,400
214,507,877	0	214,507,877	0	214,507,877	0	214,507,877	0
214,437,809	70,068	214,437,809	70,068	214,437,809	70,068	214,437,809	70,068
Members with a valid index event							
4,478,687	209,959,122	4,088,866	210,348,943	4,478,687	209,959,122	3,745,127	210,692,682
4,477,327	1,360	4,088,288	578	4,477,327	1,360	3,744,791	336
4,398,159	79,168	3,669,861	418,427	4,398,159	79,168	3,658,687	86,104
Members with required pre-index history							
3,446,512	951,647	2,729,381	940,480	3,446,512	951,647	2,815,355	843,332
1,208,954	2,237,558	1,414,140	1,315,241	1,208,954	2,237,558	1,119,398	1,695,957
N/A	N/A	N/A	755,102	N/A	N/A	N/A	N/A
N/A	3,092	N/A	1,039	N/A	3,092	N/A	960
N/A	865,965	N/A	N/A	N/A	865,965	N/A	N/A
N/A	387,969	N/A	178,413	N/A	387,969	N/A	229,292

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

GLP-1RA or DPP-4i Users, 2.5% truncation				GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation			
GLP-1 Receptor Agonists		DPP-4 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
N/A	N/A	N/A	N/A	N/A	N/A	N/A	1,020,964
N/A	N/A	N/A	425,575	N/A	N/A	N/A	N/A
N/A	992,184	N/A	N/A	N/A	992,184	N/A	N/A
N/A	54,654	N/A	37,261	N/A	54,654	N/A	32,420
N/A	196,708	N/A	198,623	N/A	196,708	N/A	158,010
N/A	N/A	N/A	N/A	N/A	N/A	N/A	556,211
N/A	174,097	N/A	133,673	N/A	174,097	N/A	118,846
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	1,286,625	N/A	588,479	N/A	1,286,625	N/A	763,011
1,208,954	0	1,414,140	0	1,208,954	0	1,119,398	0
1,208,954	0	1,414,140	0	1,208,954	0	1,119,398	0
1,208,954	0	1,414,140	0	1,208,954	0	1,119,398	0
1,208,954	0	1,414,140	0	1,208,954	0	1,119,398	0
1,206,816	2,138	1,411,305	2,835	*****	*****	*****	*****
1,206,786	30	1,411,252	53	1,206,814	*****	1,117,212	*****
Final cohort							
1,206,786	N/A	1,411,252	N/A	1,206,814	N/A	1,117,212	N/A
1,206,786	N/A	1,411,252	N/A	1,206,814	N/A	1,117,212	N/A

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

GLP-1RA or DPP-4i Users, 2.5% truncation				GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation			
GLP-1 Receptor Agonists		DPP-4 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting comparative cohort eligibility requirements							
1,206,786	0	1,411,252	0	1,206,814	0	1,117,212	0
1,150,636	56,150	1,396,382	14,870	1,162,009	44,805	1,081,183	36,029
1,150,446	190	1,396,159	223	1,161,942	67	1,080,616	567
1,150,446	0	1,396,159	0	1,161,942	0	1,080,616	0
Additional information							
826	N/A	1,088	N/A	546	N/A	379	N/A
63,421	N/A	63,914	N/A	N/A	N/A	N/A	N/A

[1]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
N/A= Not Applicable

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation				GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation			
GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements							
368,537,023	N/A	368,537,023	N/A	368,537,023	N/A	368,537,023	N/A
275,209,277	93,327,746	275,209,277	93,327,746	275,209,277	93,327,746	275,209,277	93,327,746
214,507,877	60,701,400	214,507,877	60,701,400	214,507,877	60,701,400	214,507,877	60,701,400
214,507,877	0	214,507,877	0	214,507,877	0	214,507,877	0
214,437,809	70,068	214,437,809	70,068	214,437,809	70,068	214,437,809	70,068
Members with a valid index event							
4,478,687	209,959,122	3,745,127	210,692,682	4,478,687	209,959,122	3,745,127	210,692,682
4,477,327	1,360	3,744,791	336	4,477,327	1,360	3,744,791	336
4,398,159	79,168	3,658,687	86,104	4,398,159	79,168	3,658,687	86,104
Members with required pre-index history							
3,446,512	951,647	2,815,355	843,332	3,446,512	951,647	2,815,355	843,332
1,208,954	2,237,558	1,119,398	1,695,957	1,208,954	2,237,558	1,119,398	1,695,957
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	3,092	N/A	960	N/A	3,092	N/A	960
N/A	865,965	N/A	N/A	N/A	865,965	N/A	N/A
N/A	387,969	N/A	229,292	N/A	387,969	N/A	229,292

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation				GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation			
GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
N/A	N/A	N/A	1,020,964	N/A	N/A	N/A	1,020,964
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	992,184	N/A	N/A	N/A	992,184	N/A	N/A
N/A	54,654	N/A	32,420	N/A	54,654	N/A	32,420
N/A	196,708	N/A	158,010	N/A	196,708	N/A	158,010
N/A	N/A	N/A	556,211	N/A	N/A	N/A	556,211
N/A	174,097	N/A	118,846	N/A	174,097	N/A	118,846
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	1,286,625	N/A	763,011	N/A	1,286,625	N/A	763,011
1,208,954	0	1,119,398	0	1,208,954	0	1,119,398	0
1,208,954	0	1,119,398	0	1,208,954	0	1,119,398	0
1,208,954	0	1,119,398	0	1,208,954	0	1,119,398	0
1,208,954	0	1,119,398	0	1,208,954	0	1,119,398	0
*****	*****	*****	*****	*****	*****	1,117,215	2,183
1,206,814	*****	1,117,212	*****	1,206,814	*****	1,117,212	*****
Final cohort							
1,206,814	N/A	1,117,212	N/A	1,206,814	N/A	1,117,212	N/A
1,206,814	N/A	1,117,212	N/A	1,206,814	N/A	1,117,212	N/A
Members meeting comparative cohort eligibility requirements							

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation				GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation			
GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
1,206,814	0	1,117,212	0	1,206,814	0	1,117,212	0
1,162,009	44,805	1,081,183	36,029	1,162,009	44,805	1,081,183	36,029
1,161,942	67	1,080,616	567	1,161,942	67	1,080,616	567
1,161,942	0	1,080,616	0	1,161,942	0	1,080,616	0
Additional information							
546	N/A	379	N/A	546	N/A	379	N/A
14,752	N/A	30,103	N/A	35,793	N/A	76,335	N/A

[1]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A= Not Applicable

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation				GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation			
GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements							
368,537,023	N/A	368,537,023	N/A	368,537,023	N/A	368,537,023	N/A
275,209,277	93,327,746	275,209,277	93,327,746	275,209,277	93,327,746	275,209,277	93,327,746
214,507,877	60,701,400	214,507,877	60,701,400	214,507,877	60,701,400	214,507,877	60,701,400
214,507,877	0	214,507,877	0	214,507,877	0	214,507,877	0
214,437,809	70,068	214,437,809	70,068	214,437,809	70,068	214,437,809	70,068
Members with a valid index event							
4,478,687	209,959,122	3,745,127	210,692,682	4,478,687	209,959,122	3,745,127	210,692,682
4,477,327	1,360	3,744,791	336	4,477,327	1,360	3,744,791	336
4,422,793	54,534	3,679,841	64,950	4,422,793	54,534	3,679,841	64,950
Members with required pre-index history							
3,575,241	847,552	2,919,686	760,155	3,575,241	847,552	2,919,686	760,155
1,208,980	2,366,261	1,119,407	1,800,279	1,208,980	2,366,261	1,119,407	1,800,279
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	3,138	N/A	986	N/A	3,138	N/A	986
N/A	1,222,119	N/A	N/A	N/A	1,222,119	N/A	N/A
N/A	417,455	N/A	244,475	N/A	417,455	N/A	244,475

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation				GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation			
GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
N/A	N/A	N/A	1,082,447	N/A	N/A	N/A	1,082,447
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	1,048,289	N/A	N/A	N/A	1,048,289	N/A	N/A
N/A	61,906	N/A	36,440	N/A	61,906	N/A	36,440
N/A	218,638	N/A	172,505	N/A	218,638	N/A	172,505
N/A	N/A	N/A	816,598	N/A	N/A	N/A	816,598
N/A	193,753	N/A	130,492	N/A	193,753	N/A	130,492
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	1,359,387	N/A	811,299	N/A	1,359,387	N/A	811,299
1,208,980	0	1,119,407	0	1,208,980	0	1,119,407	0
1,208,980	0	1,119,407	0	1,208,980	0	1,119,407	0
1,208,980	0	1,119,407	0	1,208,980	0	1,119,407	0
1,208,980	0	1,119,407	0	1,208,980	0	1,119,407	0
1,206,842	2,138	1,117,224	2,183	1,206,842	2,138	1,117,224	2,183
1,206,812	30	1,117,187	37	1,206,812	30	1,117,187	37
Final cohort							
1,206,812	N/A	1,117,187	N/A	1,206,812	N/A	1,117,187	N/A
1,206,812	N/A	1,117,187	N/A	1,206,812	N/A	1,117,187	N/A
Members meeting comparative cohort eligibility requirements							

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation				GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation			
GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
1,206,812	0	1,117,187	0	1,206,812	0	1,117,187	0
1,162,008	44,804	1,081,164	36,023	1,162,008	44,804	1,081,164	36,023
1,161,940	68	1,080,595	569	1,161,940	68	1,080,595	569
1,161,940	0	1,080,595	0	1,161,940	0	1,080,595	0
Additional information							
701	N/A	509	N/A	701	N/A	509	N/A
N/A	N/A	N/A	N/A	14,754	N/A	30,098	N/A

[1]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A=Not Applicable

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation				GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation			
GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements							
368,537,023	N/A	368,537,023	N/A	368,537,023	N/A	368,537,023	N/A
275,209,277	93,327,746	275,209,277	93,327,746	275,209,277	93,327,746	275,209,277	93,327,746
214,507,877	60,701,400	214,507,877	60,701,400	214,507,877	60,701,400	214,507,877	60,701,400
214,507,877	0	214,507,877	0	214,507,877	0	214,507,877	0
214,437,809	70,068	214,437,809	70,068	214,437,809	70,068	214,437,809	70,068
Members with a valid index event							
4,478,687	209,959,122	3,745,127	210,692,682	4,478,687	209,959,122	3,745,127	210,692,682
4,477,327	1,360	3,744,791	336	4,477,327	1,360	3,744,791	336
4,422,793	54,534	3,679,841	64,950	4,398,159	79,168	3,658,687	86,104
Members with required pre-index history							
3,575,241	847,552	2,919,686	760,155	3,446,512	951,647	2,815,355	843,332
1,208,980	2,366,261	1,119,407	1,800,279	1,208,954	2,237,558	1,119,398	1,695,957
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	3,138	N/A	986	N/A	3,092	N/A	960
N/A	1,222,119	N/A	N/A	N/A	865,965	N/A	N/A
N/A	417,455	N/A	244,475	N/A	387,969	N/A	229,292

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation				GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation			
GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
N/A	N/A	N/A	1,082,447	N/A	N/A	N/A	1,020,964
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	1,048,289	N/A	N/A	N/A	992,184	N/A	N/A
N/A	61,906	N/A	36,440	N/A	54,654	N/A	32,420
N/A	218,638	N/A	172,505	N/A	196,708	N/A	158,010
N/A	N/A	N/A	816,598	N/A	N/A	N/A	556,211
N/A	193,753	N/A	130,492	N/A	174,097	N/A	118,846
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	1,359,387	N/A	811,299	N/A	1,286,625	N/A	763,011
1,208,980	0	1,119,407	0	1,208,954	0	1,119,398	0
1,208,980	0	1,119,407	0	1,208,954	0	1,119,398	0
1,208,980	0	1,119,407	0	1,208,954	0	1,119,398	0
1,208,980	0	1,119,407	0	1,208,954	0	1,119,398	0
1,206,842	2,138	1,117,224	2,183	1,206,816	2,138	1,117,215	2,183
1,206,812	30	1,117,187	37	1,206,816	0	1,117,215	0
Final cohort							
1,206,812	N/A	1,117,187	N/A	1,206,816	N/A	1,117,215	N/A
1,206,812	N/A	1,117,187	N/A	1,206,816	N/A	1,117,215	N/A

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation				GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation			
GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting comparative cohort eligibility requirements							
1,206,812	0	1,117,187	0	841,467	0	765,102	0
1,162,008	44,804	1,081,164	36,023	824,408	17,059	752,899	12,203
1,161,940	68	1,080,595	569	824,321	87	752,456	443
1,161,940	0	1,080,595	0	824,321	0	752,456	0
Additional information							
701	N/A	509	N/A	658	N/A	458	N/A
35,793	N/A	76,329	N/A	N/A	N/A	N/A	N/A

[1]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
N/A=Not Applicable

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation				GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation			
GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements							
368,537,023	N/A	368,537,023	N/A	368,537,023	N/A	368,537,023	N/A
275,209,277	93,327,746	275,209,277	93,327,746	275,209,277	93,327,746	275,209,277	93,327,746
214,507,877	60,701,400	214,507,877	60,701,400	214,507,877	60,701,400	214,507,877	60,701,400
214,507,877	0	214,507,877	0	214,507,877	0	214,507,877	0
214,437,809	70,068	214,437,809	70,068	214,437,809	70,068	214,437,809	70,068
Members with a valid index event							
4,478,687	209,959,122	3,745,127	210,692,682	4,478,687	209,959,122	3,745,127	210,692,682
4,477,327	1,360	3,744,791	336	4,477,327	1,360	3,744,791	336
4,398,159	79,168	3,658,687	86,104	4,398,159	79,168	3,658,687	86,104
Members with required pre-index history							
3,446,512	951,647	2,815,355	843,332	3,446,512	951,647	2,815,355	843,332
1,208,954	2,237,558	1,119,398	1,695,957	1,208,954	2,237,558	1,119,398	1,695,957
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	3,092	N/A	960	N/A	3,092	N/A	960
N/A	865,965	N/A	N/A	N/A	865,965	N/A	N/A
N/A	387,969	N/A	229,292	N/A	387,969	N/A	229,292

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation				GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation			
GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
N/A	N/A	N/A	1,020,964	N/A	N/A	N/A	1,020,964
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	992,184	N/A	N/A	N/A	992,184	N/A	N/A
N/A	54,654	N/A	32,420	N/A	54,654	N/A	32,420
N/A	196,708	N/A	158,010	N/A	196,708	N/A	158,010
N/A	N/A	N/A	556,211	N/A	N/A	N/A	556,211
N/A	174,097	N/A	118,846	N/A	174,097	N/A	118,846
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	1,286,625	N/A	763,011	N/A	1,286,625	N/A	763,011
1,208,954	0	1,119,398	0	1,208,954	0	1,119,398	0
1,208,954	0	1,119,398	0	1,208,954	0	1,119,398	0
1,208,954	0	1,119,398	0	1,208,954	0	1,119,398	0
1,208,954	0	1,119,398	0	1,208,954	0	1,119,398	0
1,206,816	2,138	1,117,215	2,183	1,206,816	2,138	1,117,215	2,183
1,206,816	0	1,117,215	0	1,206,816	0	1,117,215	0
Final cohort							
1,206,816	N/A	1,117,215	N/A	1,206,816	N/A	1,117,215	N/A
1,206,816	N/A	1,117,215	N/A	1,206,816	N/A	1,117,215	N/A

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation				GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation			
GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting comparative cohort eligibility requirements							
841,467	0	765,102	0	841,467	0	765,102	0
824,408	17,059	752,899	12,203	824,408	17,059	752,899	12,203
824,321	87	752,456	443	824,321	87	752,456	443
824,321	0	752,456	0	824,321	0	752,456	0
Additional information							
658	N/A	458	N/A	658	N/A	458	N/A
9,683	N/A	21,859	N/A	23,975	N/A	54,864	N/A

[1]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
N/A= Not Applicable

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation				GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation				GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation			
GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements											
368,537,023	N/A	368,537,023	N/A	368,537,023	N/A	368,537,023	N/A	368,537,023	N/A	368,537,023	N/A
275,209,277	93,327,746	275,209,277	93,327,746	275,209,277	93,327,746	275,209,277	93,327,746	275,209,277	93,327,746	275,209,277	93,327,746
214,507,877	60,701,400	214,507,877	60,701,400	214,507,877	60,701,400	214,507,877	60,701,400	214,507,877	60,701,400	214,507,877	60,701,400
214,507,877	0	214,507,877	0	214,507,877	0	214,507,877	0	214,507,877	0	214,507,877	0
214,437,809	70,068	214,437,809	70,068	214,437,809	70,068	214,437,809	70,068	214,437,809	70,068	214,437,809	70,068
Members with a valid index event											
4,478,687	209,959,122	3,745,127	210,692,682	4,478,687	209,959,122	3,745,127	210,692,682	4,478,687	209,959,122	3,745,127	210,692,682
4,477,327	1,360	3,744,791	336	4,477,327	1,360	3,744,791	336	4,477,327	1,360	3,744,791	336
4,398,159	79,168	3,658,687	86,104	4,398,159	79,168	3,658,687	86,104	4,398,159	79,168	3,658,687	86,104
Members with required pre-index history											
3,446,512	951,647	2,815,355	843,332	3,446,512	951,647	2,815,355	843,332	3,446,512	951,647	2,815,355	843,332
591,008	2,855,504	397,295	2,418,060	591,008	2,855,504	397,295	2,418,060	591,008	2,855,504	397,295	2,418,060
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	3,291	N/A	1,031	N/A	3,291	N/A	1,031	N/A	3,291	N/A	1,031
N/A	1,070,423	N/A	N/A	N/A	1,070,423	N/A	N/A	N/A	1,070,423	N/A	N/A
N/A	412,047	N/A	239,784	N/A	412,047	N/A	239,784	N/A	412,047	N/A	239,784

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation				GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation				GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation			
GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
N/A	N/A	N/A	1,087,421	N/A	N/A	N/A	1,087,421	N/A	N/A	N/A	1,087,421
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
N/A	1,055,044	N/A	N/A	N/A	1,055,044	N/A	N/A	N/A	1,055,044	N/A	N/A
N/A	59,672	N/A	35,675	N/A	59,672	N/A	35,675	N/A	59,672	N/A	35,675
N/A	213,976	N/A	171,128	N/A	213,976	N/A	171,128	N/A	213,976	N/A	171,128
N/A	N/A	N/A	736,211	N/A	N/A	N/A	736,211	N/A	N/A	N/A	736,211
N/A	187,598	N/A	127,341	N/A	187,598	N/A	127,341	N/A	187,598	N/A	127,341
N/A	2,499,681	N/A	2,108,150	N/A	2,499,681	N/A	2,108,150	N/A	2,499,681	N/A	2,108,150
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
591,008	0	397,295	0	591,008	0	397,295	0	591,008	0	397,295	0
591,008	0	397,295	0	591,008	0	397,295	0	591,008	0	397,295	0
591,008	0	397,295	0	591,008	0	397,295	0	591,008	0	397,295	0
591,008	0	397,295	0	591,008	0	397,295	0	591,008	0	397,295	0
589,799	1,209	396,400	895	589,799	1,209	396,400	895	589,799	1,209	396,400	895
589,780	19	396,380	20	589,780	19	396,380	20	589,780	19	396,380	20
Final cohort											
589,780	N/A	396,380	N/A	589,780	N/A	396,380	N/A	589,780	N/A	396,380	N/A
589,780	N/A	396,380	N/A	589,780	N/A	396,380	N/A	589,780	N/A	396,380	N/A

Table 20. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation				GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation				GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation			
GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors		GLP-1 Receptor Agonists		SGLT-2 Inhibitors	
Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting comparative cohort eligibility requirements											
589,780	0	396,380	0	589,780	0	396,380	0	589,780	0	396,380	0
576,208	13,572	384,900	11,480	576,208	13,572	384,900	11,480	576,208	13,572	384,900	11,480
576,119	89	384,759	141	576,119	89	384,759	141	576,119	89	384,759	141
576,119	0	384,759	0	576,119	0	384,759	0	576,119	0	384,759	0
Additional information											
478	N/A	251	N/A	478	N/A	251	N/A	478	N/A	251	N/A
N/A	N/A	N/A	N/A	4,605	N/A	14,614	N/A	10,183	N/A	37,867	N/A

[1]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
N/A=Not Applicable

Figure 1a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 1a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 1b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 1b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 1c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming

Figure 1c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



[1]Results in these figures are provided for the subset of Data Partners with a propensity score model that converged.

Figure 1d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 1d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 1e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 1e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 2a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 2a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 2b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 2b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 2c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 2c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



[1]Results in these figures are provided for the subset of Data Partners with a propensity score model that converged.

Figure 2d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 2d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 2e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 2e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 3a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 3a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 3b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 3b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 3c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 3c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



[1]Results in these figures are provided for the subset of Data Partners with a propensity score model that converged.

Figure 3d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 3d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 3e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 3e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 4a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 4a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 4b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 4b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 4c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 4c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



[1]Results in these figures are provided for the subset of Data Partners with a propensity score model that converged.

Figure 4d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 4d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 4e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 4e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 5a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 5a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 5b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 5b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 5c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 5c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



[1]Results in these figures are provided for the subset of Data Partners with a propensity score model that converged.

Figure 5d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 5d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 5e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 5e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 6a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 6a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 6b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 6b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 6c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 6c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



[1]Results in these figures are provided for the subset of Data Partners with a propensity score model that converged.

Figure 6d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 6d. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 6e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 6e. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 7. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 7. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 8. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 8. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 9. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 9. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 10. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming

Figure 10. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 11. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 11. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 12. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 12. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 13. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 13. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 14. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 14. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 15. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 15. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 16. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 16. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 17. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 17. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 18. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Unweighted Propensity Score Distribution Before Trimming



Unweighted Propensity Score Distribution After Trimming



Figure 18. Histograms Depicting Propensity Score Distributions Before and After Adjustment for GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023

Weighted Propensity Score Distribution After Trimming, Inverse Probability of Treatment Weighted, Average Treatment Effect Stabilized (ATES)



Figure 19a. Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Site-Adjusted Analyses in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 19a. Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Site-Adjusted Analyses in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



For the Intentional Self-Harm subgroup in the figure provided, results are among the subset of Data Partners with a propensity score model that converged.

Figure 19b. Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Inverse Probability of Treatment Weighted Analyses in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 19b. Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Inverse Probability of Treatment Weighted Analyses in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



For the Intentional Self-Harm subgroup in the figure provided, results are among the subset of Data Partners with a propensity score model that converged.

Figure 20a. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 20b. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 20c. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 20d. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 20e. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 20f. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 20g. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 20h. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 20i. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 20j. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 20k. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 20l. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 20m. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this figure are provided for the subset of Data Partners with a propensity score model that converged.

Figure 20n. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this figure are provided for the subset of Data Partners with a propensity score model that converged.

Figure 20o. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this figure are provided for the subset of Data Partners with a propensity score model that converged.

Figure 20p. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this figure are provided for the subset of Data Partners with a propensity score model that converged.

Figure 20q. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this figure are provided for the subset of Data Partners with a propensity score model that converged.

Figure 20r. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this figure are provided for the subset of Data Partners with a propensity score model that converged.

Figure 20s. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 20t. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 20u. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 20v. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 20w. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 20x. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 20y. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 20z. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 20aa. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 20ab. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 20ac. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 20ad. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 21a. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 21b. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 21c. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 21d. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 21e. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 21f. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 21g. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 21h. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 21i. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 21j. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 21k. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 21l. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 21m. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this figure are provided for the subset of Data Partners with a propensity score model that converged.

Figure 21n. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this figure are provided for the subset of Data Partners with a propensity score model that converged.

Figure 21o. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this figure are provided for the subset of Data Partners with a propensity score model that converged.

Figure 21p. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this figure are provided for the subset of Data Partners with a propensity score model that converged.

Figure 21q. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this figure are provided for the subset of Data Partners with a propensity score model that converged.

Figure 21r. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this figure are provided for the subset of Data Partners with a propensity score model that converged.

Figure 21s. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 21t. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 21u. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 21v. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 21w. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 21x. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 21y. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 21z. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 21aa. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 21ab. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 21ac. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 21ad. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 22a. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 22b. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 22c. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 22d. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 22e. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 22f. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 22g. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 22h. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 22i. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 22j. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 22k. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 22l. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 22m. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 22n. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 22o. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 22p. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 22q. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 22r. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 22s. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 22t. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 22u. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 22v. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 22w. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 22x. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 22y. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 22z. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 22aa. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 22ab. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 22ac. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 22ad. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 23a. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 23b. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 23c. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 23d. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 23e. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 23f. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 23g. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 23h. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 23i. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 23j. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 23k. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 23l. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 23m. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 23n. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 23o. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 23p. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 23q. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 23r. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 23s. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 23t. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 23u. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 23v. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 23w. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 23x. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 23y. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 23z. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 23aa. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 23ab. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 23ac. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 23ad. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 24a. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 24b. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 24c. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 24d. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 24e. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 24f. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 24g. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 24h. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 24i. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 24j. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 24k. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 24l. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 24m. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 24n. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 24o. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 24p. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 24q. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 24r. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 24s. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 24t. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 24u. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 24v. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 24w. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 24x. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 24y. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 24z. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 24aa. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 24ab. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 24ac. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 24ad. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 25a. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 25b. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 25c. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 25d. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 25e. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 25f. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 25g. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 25h. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 25i. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 25j. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 25k. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 25l. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Intentional Self-Harm Encounter



Figure 25m. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 25n. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 25o. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 25p. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 25q. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter[1]



[1]Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 25r. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Intentional Self-Harm Encounter



^Results in this table are provided for the subset of Data Partners with a propensity score model that converged.

Figure 25s. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 25t. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 25u. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 25v. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 25w. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 25x. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: No Prior Psychiatric History



Figure 25y. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 25z. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 25aa. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 25ab. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 25ac. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 25ad. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, Subgroup: Prior Psychiatric History



Figure 26a. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 26b. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 26c. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 26d. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 26e. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 26f. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 27a. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 27b. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 27c. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 27d. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 27e. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 27f. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 28a. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 28b. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 28c. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 28d. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 28e. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 28f. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 29a. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 29b. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 29c. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 29d. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 29e. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 29f. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 30a. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 30b. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 30c. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 30d. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 30e. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 30f. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 31a. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 31b. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 31c. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 31d. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 31e. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 31f. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 32a. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 32b. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 32c. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 32d. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 32e. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 32f. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 33a. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 33b. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 33c. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 33d. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 33e. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 33f. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 34a. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 34b. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 34c. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 34d. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 34e. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 34f. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 35a. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 35b. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 35c. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 35d. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 35e. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 35f. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 36a. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 36b. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 36c. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 36d. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 36e. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 36f. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 37a. Aggregated Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 37b. Aggregated Unadjusted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 37c. Aggregated Unadjusted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 37d. Aggregated Weighted Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Not Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 37e. Aggregated Weighted 1-Kaplan-Meier Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Figure 37f. Aggregated Weighted Log of Negative Log of Estimate and 95% Confidence Interval of Event of Interest Occurring Among GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023



Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (May 1, 2024)

Masked DP ID[1]	DP Start Date	DP End Date[2]
DP01	01/01/2000	10/31/2022
DP02	01/01/2007	06/30/2023
DP03	01/01/2005	07/31/2022
DP04	01/01/2008	04/30/2023
DP05	01/01/2000	08/31/2022
DP06	01/01/2000	04/30/2023
DP07	01/01/2010	06/30/2023
DP08	01/01/2014	12/31/2020
DP09	01/01/2008	09/30/2023
DP10	01/01/2006	06/30/2023

[1]Participating Data Partner(s) include(s) CVS Health/Aetna; and Center for Medicare and Medicaid Services - Medicaid Data; and Carelon Research; and Humana, Inc., Healthcare Research; and OptumInsight, Inc.; and Center for Medicare and Medicaid Services - Medicare Fee-for-Service data; and HealthPartners Institute for Education and Research; and Marshfield Clinic Research Foundation; and Kaiser Permanente Colorado; and Kaiser Permanente Mid-Atlantic.

[2]End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Aggregated	2,242,503	0.118	46473.13	1.295	45.205
DP01	3,541	0.262	14.415	0.989	1.054
DP02	263,952	0.477	1608.190	1.118	5.307
DP03	6,358	0.118	75.247	1.008	1.177
DP04	185,206	0.440	46473.13	1.920	137.295
DP05	1,688	0.419	86.475	1.143	2.737
DP06	13,100	0.358	2840.735	1.698	30.352
DP07	954,668	0.500	4468.129	1.164	11.752
DP08	267,075	0.479	544.079	1.038	2.135
DP09	192,100	0.489	6854.116	1.387	22.729
DP10	354,815	0.449	13612.46	1.592	48.645

Appendix C. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Intentional Self-Harm Encounter, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	2,242,503	0.118	46473.13	1.295	45.205
DP01	3,541	0.262	14.415	0.989	1.054
DP02	263,952	0.477	1608.190	1.118	5.307
DP03	6,358	0.118	75.247	1.008	1.177
DP04	185,206	0.440	46473.13	1.920	137.295
DP05	1,688	0.419	86.475	1.143	2.737
DP06	13,100	0.358	2840.735	1.698	30.352
DP07	954,668	0.500	4468.129	1.164	11.752
DP08	267,075	0.479	544.079	1.038	2.135
DP09	192,100	0.489	6854.116	1.387	22.729
DP10	354,815	0.449	13612.46	1.592	48.645
No Intentional Self-Harm Encounter					
Aggregated	2,240,452	0.118	31116.99	1.270	32.857
DP01	3,400	0.260	12.069	0.997	0.957
DP02	263,756	0.477	1643.211	1.118	5.330
DP03	6,349	0.118	19.615	0.994	0.680
DP04	185,126	0.440	31116.99	1.672	85.401
DP05	1,681	0.419	120.869	1.196	3.591
DP06	13,080	0.358	776.374	1.352	9.170
DP07	953,796	0.500	4516.229	1.165	11.917
DP08	266,599	0.479	402.477	1.035	1.611
DP09	192,002	0.489	4268.028	1.352	16.595
DP10	354,663	0.449	13738.51	1.595	49.555

Appendix C. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Intentional Self-Harm Encounter, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Intentional Self-Harm Encounter					
Aggregated	1,301	0.433	8.242	1.014	0.610
DP01	0	.	.	.	.
DP02	N/A	N/A	N/A	N/A	N/A
DP03	N/A	N/A	N/A	N/A	N/A
DP04	N/A	N/A	N/A	N/A	N/A
DP05	0	.	.	.	.
DP06	N/A	N/A	N/A	N/A	N/A
DP07	843	0.482	8.242	1.020	0.663
DP08	458	0.433	5.340	1.003	0.497
DP09	N/A	N/A	N/A	N/A	N/A
DP10	N/A	N/A	N/A	N/A	N/A

Note: N/A represent PS models that did not reach convergence.

Appendix D. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Psychiatric History, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	2,242,503	0.118	46473.13	1.295	45.205
DP01	3,541	0.262	14.415	0.989	1.054
DP02	263,952	0.477	1608.190	1.118	5.307
DP03	6,358	0.118	75.247	1.008	1.177
DP04	185,206	0.440	46473.13	1.920	137.295
DP05	1,688	0.419	86.475	1.143	2.737
DP06	13,100	0.358	2840.735	1.698	30.352
DP07	954,668	0.500	4468.129	1.164	11.752
DP08	267,075	0.479	544.079	1.038	2.135
DP09	192,100	0.489	6854.116	1.387	22.729
DP10	354,815	0.449	13612.46	1.592	48.645
No Psychiatric History Overall					
Aggregated	941,254	0.092	25999.69	1.460	45.803
DP01	1,442	0.212	22.219	1.001	1.113
DP02	98,032	0.473	1415.956	1.230	8.034
DP03	3,951	0.092	22.555	0.991	0.570
DP04	94,708	0.488	4873.362	1.604	27.864
DP05	712	0.453	116.696	1.212	4.584
DP06	5,422	0.405	1250.297	1.687	19.874
DP07	363,599	0.443	3842.318	1.317	16.345
DP08	115,235	0.460	472.203	1.069	2.517
DP09	91,920	0.464	5528.644	1.587	27.596
DP10	166,233	0.499	25999.69	2.034	101.861

Appendix D. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Psychiatric History, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Psychiatric History Overall					
Aggregated	1,300,879	0.164	4718.048	1.107	6.875
DP01	1,964	0.301	12.415	0.996	1.045
DP02	165,894	0.447	441.886	1.063	2.183
DP03	2,361	0.164	13.386	0.987	0.672
DP04	90,476	0.389	4718.048	1.263	19.174
DP05	960	0.399	44.069	1.106	1.960
DP06	7,668	0.325	332.836	1.229	5.845
DP07	591,028	0.467	898.928	1.076	3.142
DP08	151,825	0.430	104.902	1.017	0.728
DP09	100,163	0.446	812.188	1.160	5.379
DP10	188,540	0.404	1915.206	1.213	9.868

Appendix E. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Aggregated	2,242,503	0.138	9.520	1.014	0.886
DP01	3,541	0.271	5.879	0.966	0.879
DP02	263,952	0.502	5.678	1.006	0.764
DP03	6,358	0.138	3.004	0.967	0.348
DP04	185,206	0.455	8.681	1.025	1.115
DP05	1,688	0.436	8.506	1.028	1.061
DP06	13,100	0.373	9.520	1.045	1.219
DP07	954,668	0.518	5.979	1.011	0.805
DP08	267,075	0.539	3.894	0.999	0.550
DP09	192,100	0.502	8.281	1.025	1.074
DP10	354,815	0.464	8.531	1.026	1.099

Appendix F. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Intentional Self-Harm Encounter, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	2,242,503	0.138	9.520	1.014	0.886
DP01	3,541	0.271	5.879	0.966	0.879
DP02	263,952	0.502	5.678	1.006	0.764
DP03	6,358	0.138	3.004	0.967	0.348
DP04	185,206	0.455	8.681	1.025	1.115
DP05	1,688	0.436	8.506	1.028	1.061
DP06	13,100	0.373	9.520	1.045	1.219
DP07	954,668	0.518	5.979	1.011	0.805
DP08	267,075	0.539	3.894	0.999	0.550
DP09	192,100	0.502	8.281	1.025	1.074
DP10	354,815	0.464	8.531	1.026	1.099
No Intentional Self-Harm Encounter					
Aggregated	2,240,452	0.138	9.417	1.014	0.886
DP01	3,400	0.263	5.522	0.978	0.824
DP02	263,756	0.502	5.694	1.006	0.766
DP03	6,349	0.138	2.952	0.966	0.343
DP04	185,126	0.455	8.687	1.025	1.116
DP05	1,681	0.436	8.844	1.041	1.123
DP06	13,080	0.373	9.417	1.043	1.206
DP07	953,796	0.518	5.981	1.011	0.806
DP08	266,599	0.539	3.899	0.999	0.550
DP09	192,002	0.502	8.287	1.025	1.075
DP10	354,663	0.464	8.527	1.026	1.099

Appendix F. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Intentional Self-Harm Encounter, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Intentional Self-Harm Encounter					
Aggregated	1,301	0.481	3.638	1.000	0.511
DP01	0	.	.	.	.
DP02	N/A	N/A	N/A	N/A	N/A
DP03	N/A	N/A	N/A	N/A	N/A
DP04	N/A	N/A	N/A	N/A	N/A
DP05	0	.	.	.	.
DP06	N/A	N/A	N/A	N/A	N/A
DP07	843	0.499	3.638	1.004	0.547
DP08	458	0.481	2.973	0.994	0.438
DP09	N/A	N/A	N/A	N/A	N/A
DP10	N/A	N/A	N/A	N/A	N/A

Note: N/A represent PS models that did not reach convergence.

Appendix G. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Psychiatric History, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	2,242,503	0.138	9.520	1.014	0.886
DP01	3,541	0.271	5.879	0.966	0.879
DP02	263,952	0.502	5.678	1.006	0.764
DP03	6,358	0.138	3.004	0.967	0.348
DP04	185,206	0.455	8.681	1.025	1.115
DP05	1,688	0.436	8.506	1.028	1.061
DP06	13,100	0.373	9.520	1.045	1.219
DP07	954,668	0.518	5.979	1.011	0.805
DP08	267,075	0.539	3.894	0.999	0.550
DP09	192,100	0.502	8.281	1.025	1.074
DP10	354,815	0.464	8.531	1.026	1.099
No Psychiatric History Overall					
Aggregated	941,254	0.123	12.822	1.035	1.165
DP01	1,442	0.215	5.089	0.960	0.704
DP02	98,032	0.498	7.750	1.027	1.022
DP03	3,951	0.123	2.317	0.967	0.265
DP04	94,708	0.497	10.421	1.041	1.330
DP05	712	0.463	7.155	1.000	0.999
DP06	5,422	0.412	12.822	1.081	1.624
DP07	363,599	0.468	8.322	1.033	1.085
DP08	115,235	0.507	4.999	1.006	0.701
DP09	91,920	0.480	10.739	1.050	1.356
DP10	166,233	0.506	11.316	1.055	1.424

Appendix G. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Psychiatric History, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Psychiatric History Overall					
Aggregated	1,300,879	0.174	7.778	1.005	0.726
DP01	1,964	0.303	5.863	0.978	0.918
DP02	165,894	0.479	4.807	1.000	0.659
DP03	2,361	0.174	3.471	0.962	0.412
DP04	90,476	0.413	6.883	1.010	0.897
DP05	960	0.420	7.316	1.025	0.957
DP06	7,668	0.348	7.778	1.027	0.984
DP07	591,028	0.500	4.970	1.005	0.684
DP08	151,825	0.519	3.207	1.000	0.448
DP09	100,163	0.464	6.600	1.010	0.874
DP10	188,540	0.427	6.775	1.011	0.884

Appendix H. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Aggregated	2,242,503	0.182	4.575	0.969	0.634
DP01	3,541	0.276	4.034	0.933	0.722
DP02	263,952	0.524	3.377	0.970	0.586
DP03	6,358	0.182	1.932	0.952	0.271
DP04	185,206	0.473	4.237	0.956	0.732
DP05	1,688	0.457	3.831	0.958	0.666
DP06	13,100	0.395	4.575	0.968	0.775
DP07	954,668	0.532	3.511	0.973	0.610
DP08	267,075	0.561	2.723	0.981	0.467
DP09	192,100	0.516	4.132	0.960	0.721
DP10	354,815	0.481	4.204	0.959	0.728

Appendix I. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Intentional Self-Harm Encounter, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	2,242,503	0.182	4.575	0.969	0.634
DP01	3,541	0.276	4.034	0.933	0.722
DP02	263,952	0.524	3.377	0.970	0.586
DP03	6,358	0.182	1.932	0.952	0.271
DP04	185,206	0.473	4.237	0.956	0.732
DP05	1,688	0.457	3.831	0.958	0.666
DP06	13,100	0.395	4.575	0.968	0.775
DP07	954,668	0.532	3.511	0.973	0.610
DP08	267,075	0.561	2.723	0.981	0.467
DP09	192,100	0.516	4.132	0.960	0.721
DP10	354,815	0.481	4.204	0.959	0.728
No Intentional Self-Harm Encounter					
Aggregated	2,240,452	0.181	4.538	0.969	0.634
DP01	3,400	0.269	3.927	0.952	0.697
DP02	263,756	0.524	3.380	0.971	0.586
DP03	6,349	0.181	1.917	0.951	0.269
DP04	185,126	0.473	4.240	0.956	0.732
DP05	1,681	0.456	4.098	0.967	0.711
DP06	13,080	0.395	4.538	0.966	0.769
DP07	953,796	0.532	3.513	0.973	0.610
DP08	266,599	0.561	2.726	0.981	0.467
DP09	192,002	0.516	4.133	0.960	0.721
DP10	354,663	0.481	4.205	0.959	0.728

Appendix I. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Intentional Self-Harm Encounter, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Intentional Self-Harm Encounter					
Aggregated	1,301	0.523	2.791	0.986	0.449
DP01	0	.	.	.	.
DP02	N/A	N/A	N/A	N/A	N/A
DP03	N/A	N/A	N/A	N/A	N/A
DP04	N/A	N/A	N/A	N/A	N/A
DP05	0	.	.	.	.
DP06	N/A	N/A	N/A	N/A	N/A
DP07	843	0.526	2.791	0.989	0.483
DP08	458	0.523	2.273	0.980	0.381
DP09	N/A	N/A	N/A	N/A	N/A
DP10	N/A	N/A	N/A	N/A	N/A

Note: N/A represent PS models that did not reach convergence.

Appendix J. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Psychiatric History, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	2,242,503	0.182	4.575	0.969	0.634
DP01	3,541	0.276	4.034	0.933	0.722
DP02	263,952	0.524	3.377	0.970	0.586
DP03	6,358	0.182	1.932	0.952	0.271
DP04	185,206	0.473	4.237	0.956	0.732
DP05	1,688	0.457	3.831	0.958	0.666
DP06	13,100	0.395	4.575	0.968	0.775
DP07	954,668	0.532	3.511	0.973	0.610
DP08	267,075	0.561	2.723	0.981	0.467
DP09	192,100	0.516	4.132	0.960	0.721
DP10	354,815	0.481	4.204	0.959	0.728
No Psychiatric History Overall					
Aggregated	941,254	0.217	5.549	0.965	0.754
DP01	1,442	0.227	3.250	0.928	0.549
DP02	98,032	0.517	4.092	0.969	0.713
DP03	3,951	0.217	1.659	0.958	0.217
DP04	94,708	0.508	4.753	0.953	0.823
DP05	712	0.475	3.850	0.947	0.736
DP06	5,422	0.421	5.549	0.971	0.979
DP07	363,599	0.490	4.191	0.969	0.738
DP08	115,235	0.533	3.228	0.978	0.568
DP09	91,920	0.495	4.737	0.958	0.824
DP10	166,233	0.512	4.833	0.955	0.842

Appendix J. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Psychiatric History, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Psychiatric History Overall					
Aggregated	1,300,879	0.200	4.412	0.973	0.556
DP01	1,964	0.307	4.412	0.954	0.808
DP02	165,894	0.505	3.049	0.973	0.527
DP03	2,361	0.200	2.088	0.942	0.315
DP04	90,476	0.438	3.696	0.961	0.633
DP05	960	0.438	3.825	0.969	0.647
DP06	7,668	0.379	3.941	0.968	0.653
DP07	591,028	0.527	3.172	0.977	0.547
DP08	151,825	0.555	2.375	0.987	0.393
DP09	100,163	0.485	3.652	0.964	0.634
DP10	188,540	0.451	3.653	0.963	0.628

Appendix K. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Aggregated	2,546,605	0.272	25322.46	1.120	19.350
DP01	1,281	0.289	131.209	1.243	4.723
DP02	268,019	0.489	886.221	1.070	3.079
DP03	2,740	0.280	15.887	0.998	1.027
DP04	164,557	0.366	4418.915	1.246	17.576
DP05	1,666	0.422	51.198	1.109	2.528
DP06	11,560	0.272	361.137	1.237	5.998
DP07	1,160,380	0.404	9783.208	1.088	11.167
DP08	405,127	0.343	4210.003	1.029	7.049
DP09	183,943	0.466	25322.46	1.298	59.343
DP10	347,332	0.439	7649.842	1.216	15.830

Appendix L. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Intentional Self-Harm Encounter, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	2,546,605	0.272	25322.46	1.120	19.350
DP01	1,281	0.289	131.209	1.243	4.723
DP02	268,019	0.489	886.221	1.070	3.079
DP03	2,740	0.280	15.887	0.998	1.027
DP04	164,557	0.366	4418.915	1.246	17.576
DP05	1,666	0.422	51.198	1.109	2.528
DP06	11,560	0.272	361.137	1.237	5.998
DP07	1,160,380	0.404	9783.208	1.088	11.167
DP08	405,127	0.343	4210.003	1.029	7.049
DP09	183,943	0.466	25322.46	1.298	59.343
DP10	347,332	0.439	7649.842	1.216	15.830
No Intentional Self-Harm Encounter					
Aggregated	2,543,938	0.272	3625.220	1.098	6.696
DP01	1,278	0.290	120.627	1.208	4.372
DP02	267,816	0.489	910.556	1.070	3.109
DP03	2,721	0.281	16.177	1.003	1.036
DP04	164,436	0.366	3598.996	1.216	13.676
DP05	1,648	0.421	66.061	1.122	2.725
DP06	11,546	0.272	380.449	1.208	5.440
DP07	1,159,130	0.405	3625.220	1.078	6.211
DP08	404,346	0.343	797.881	1.017	1.989
DP09	183,849	0.466	986.159	1.157	5.878
DP10	347,168	0.439	2776.115	1.192	8.927

Appendix L. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Intentional Self-Harm Encounter, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Intentional Self-Harm Encounter					
Aggregated	2,055	0.420	27.778	1.013	0.926
DP02	153	0.420	27.778	1.112	2.296
DP03	0	.	.	.	.
DP04	N/A	N/A	N/A	N/A	N/A
DP05	0	.	.	.	.
DP06	N/A	N/A	N/A	N/A	N/A
DP07	1,144	0.451	8.569	1.008	0.796
DP08	758	0.429	10.183	1.002	0.553
DP09	N/A	N/A	N/A	N/A	N/A
DP10	N/A	N/A	N/A	N/A	N/A

Note: N/A represent PS models that did not reach convergence.

Appendix M. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Psychiatric History, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	2,546,605	0.272	25322.46	1.120	19.350
DP01	1,281	0.289	131.209	1.243	4.723
DP02	268,019	0.489	886.221	1.070	3.079
DP03	2,740	0.280	15.887	0.998	1.027
DP04	164,557	0.366	4418.915	1.246	17.576
DP05	1,666	0.422	51.198	1.109	2.528
DP06	11,560	0.272	361.137	1.237	5.998
DP07	1,160,380	0.404	9783.208	1.088	11.167
DP08	405,127	0.343	4210.003	1.029	7.049
DP09	183,943	0.466	25322.46	1.298	59.343
DP10	347,332	0.439	7649.842	1.216	15.830
No Psychiatric History Overall					
Aggregated	1,091,975	0.222	7147.275	1.150	13.925
DP01	N/A	N/A	N/A	N/A	N/A
DP02	102,760	0.445	315.355	1.103	3.306
DP03	1,648	0.222	30.538	1.003	1.150
DP04	84,673	0.425	6755.169	1.312	24.241
DP05	683	0.462	24.501	1.074	1.998
DP06	4,815	0.328	472.942	1.397	8.623
DP07	448,776	0.352	5747.079	1.112	11.520
DP08	192,812	0.270	7147.275	1.067	16.597
DP09	90,095	0.473	962.563	1.208	6.971
DP10	165,713	0.499	5197.953	1.258	16.195

Appendix M. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Psychiatric History, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Psychiatric History Overall					
Aggregated	1,453,562	0.234	2281.169	1.061	3.785
DP01	785	0.254	51.061	1.127	2.827
DP02	165,151	0.448	137.225	1.044	1.776
DP03	1,008	0.400	12.716	1.019	1.003
DP04	79,756	0.305	726.800	1.108	4.455
DP05	892	0.388	26.775	1.038	1.570
DP06	6,720	0.234	100.145	1.089	2.429
DP07	711,555	0.439	1234.692	1.051	3.134
DP08	212,306	0.413	2281.169	1.027	5.618
DP09	93,815	0.407	330.693	1.096	3.349
DP10	181,574	0.383	1105.445	1.111	4.654

Note: N/A represent PS models that did not reach convergence.

Appendix N. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Aggregated	2,546,605	0.286	11.439	0.976	0.868
DP01	1,281	0.293	11.439	1.007	1.272
DP02	268,019	0.501	6.620	0.979	0.894
DP03	2,740	0.290	5.398	0.962	0.708
DP04	164,557	0.381	8.252	0.977	1.045
DP05	1,666	0.426	9.957	0.996	1.293
DP06	11,560	0.286	8.310	0.995	1.024
DP07	1,160,380	0.421	6.174	0.972	0.837
DP08	405,127	0.394	3.907	0.982	0.557
DP09	183,943	0.476	7.904	0.979	1.029
DP10	347,332	0.449	8.003	0.974	1.038

Appendix O. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Intentional Self-Harm Encounter, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	2,546,605	0.286	11.439	0.976	0.868
DP01	1,281	0.293	11.439	1.007	1.272
DP02	268,019	0.501	6.620	0.979	0.894
DP03	2,740	0.290	5.398	0.962	0.708
DP04	164,557	0.381	8.252	0.977	1.045
DP05	1,666	0.426	9.957	0.996	1.293
DP06	11,560	0.286	8.310	0.995	1.024
DP07	1,160,380	0.421	6.174	0.972	0.837
DP08	405,127	0.394	3.907	0.982	0.557
DP09	183,943	0.476	7.904	0.979	1.029
DP10	347,332	0.449	8.003	0.974	1.038
No Intentional Self-Harm Encounter					
Aggregated	2,543,938	0.285	9.956	0.976	0.869
DP01	1,278	0.295	9.398	0.977	1.066
DP02	267,816	0.501	6.631	0.979	0.895
DP03	2,721	0.291	5.584	0.967	0.725
DP04	164,436	0.381	8.265	0.977	1.046
DP05	1,648	0.426	9.956	1.002	1.305
DP06	11,546	0.285	8.214	0.993	1.018
DP07	1,159,130	0.421	6.181	0.973	0.837
DP08	404,346	0.394	3.910	0.982	0.558
DP09	183,849	0.476	7.909	0.979	1.030
DP10	347,168	0.449	8.014	0.974	1.039

Appendix O. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Intentional Self-Harm Encounter, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Intentional Self-Harm Encounter					
Aggregated	2,055	0.424	7.369	0.990	0.633
DP02	153	0.424	7.369	0.979	0.912
DP03	0	.	.	.	.
DP04	N/A	N/A	N/A	N/A	N/A
DP05	0	.	.	.	.
DP06	N/A	N/A	N/A	N/A	N/A
DP07	1,144	0.460	5.015	0.995	0.709
DP08	758	0.467	2.846	0.985	0.399
DP09	N/A	N/A	N/A	N/A	N/A
DP10	N/A	N/A	N/A	N/A	N/A

Note: N/A represent PS models that did not reach convergence.

Appendix P. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Psychiatric History, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	2,546,605	0.286	11.439	0.976	0.868
DP01	1,281	0.293	11.439	1.007	1.272
DP02	268,019	0.501	6.620	0.979	0.894
DP03	2,740	0.290	5.398	0.962	0.708
DP04	164,557	0.381	8.252	0.977	1.045
DP05	1,666	0.426	9.957	0.996	1.293
DP06	11,560	0.286	8.310	0.995	1.024
DP07	1,160,380	0.421	6.174	0.972	0.837
DP08	405,127	0.394	3.907	0.982	0.557
DP09	183,943	0.476	7.904	0.979	1.029
DP10	347,332	0.449	8.003	0.974	1.038
No Psychiatric History Overall					
Aggregated	1,091,975	0.231	12.177	0.980	0.959
DP01	N/A	N/A	N/A	N/A	N/A
DP02	102,760	0.458	7.337	0.983	0.980
DP03	1,648	0.231	4.744	0.958	0.625
DP04	84,673	0.434	9.772	0.991	1.235
DP05	683	0.463	11.804	1.025	1.592
DP06	4,815	0.334	12.177	1.034	1.498
DP07	448,776	0.370	6.775	0.976	0.894
DP08	192,812	0.330	4.018	0.979	0.549
DP09	90,095	0.481	8.896	0.986	1.143
DP10	165,713	0.504	9.093	0.981	1.172

Appendix P. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Psychiatric History, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Psychiatric History Overall					
Aggregated	1,453,562	0.249	8.280	0.976	0.805
DP01	785	0.259	7.923	0.968	0.949
DP02	165,151	0.460	6.085	0.978	0.836
DP03	1,008	0.410	5.617	0.990	0.784
DP04	79,756	0.325	6.652	0.971	0.850
DP05	892	0.394	8.280	0.985	1.057
DP06	6,720	0.249	5.929	0.977	0.745
DP07	711,555	0.455	5.913	0.973	0.814
DP08	212,306	0.468	3.654	0.988	0.532
DP09	93,815	0.418	6.905	0.976	0.913
DP10	181,574	0.394	7.044	0.972	0.919

Note: N/A represent PS models that did not reach convergence.

Appendix Q. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Aggregated	2,546,605	0.301	4.603	0.932	0.628
DP01	1,281	0.302	3.414	0.900	0.583
DP02	268,019	0.511	3.711	0.933	0.661
DP03	2,740	0.308	3.056	0.927	0.532
DP04	164,557	0.393	3.865	0.910	0.666
DP05	1,666	0.434	4.603	0.910	0.807
DP06	11,560	0.301	3.740	0.924	0.617
DP07	1,160,380	0.433	3.532	0.931	0.627
DP08	405,127	0.426	2.738	0.964	0.475
DP09	183,943	0.485	3.958	0.918	0.696
DP10	347,332	0.459	3.982	0.911	0.697

Appendix R. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Intentional Self-Harm Encounter, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	2,546,605	0.301	4.603	0.932	0.628
DP01	1,281	0.302	3.414	0.900	0.583
DP02	268,019	0.511	3.711	0.933	0.661
DP03	2,740	0.308	3.056	0.927	0.532
DP04	164,557	0.393	3.865	0.910	0.666
DP05	1,666	0.434	4.603	0.910	0.807
DP06	11,560	0.301	3.740	0.924	0.617
DP07	1,160,380	0.433	3.532	0.931	0.627
DP08	405,127	0.426	2.738	0.964	0.475
DP09	183,943	0.485	3.958	0.918	0.696
DP10	347,332	0.459	3.982	0.911	0.697
No Intentional Self-Harm Encounter					
Aggregated	2,543,938	0.301	4.775	0.931	0.628
DP01	1,278	0.305	3.440	0.898	0.576
DP02	267,816	0.511	3.714	0.933	0.661
DP03	2,721	0.309	3.088	0.931	0.536
DP04	164,436	0.393	3.869	0.910	0.667
DP05	1,648	0.433	4.775	0.918	0.833
DP06	11,546	0.301	3.721	0.923	0.615
DP07	1,159,130	0.433	3.533	0.931	0.628
DP08	404,346	0.426	2.737	0.963	0.475
DP09	183,849	0.485	3.959	0.918	0.696

Appendix R. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Intentional Self-Harm Encounter, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
DP10	347,168	0.459	3.981	0.911	0.697
Intentional Self-Harm Encounter					
Aggregated	2,055	0.430	3.241	0.968	0.515
DP02	153	0.430	3.156	0.923	0.590
DP03	0	.	.	.	.
DP04	N/A	N/A	N/A	N/A	N/A
DP05	0	.	.	.	.
DP06	N/A	N/A	N/A	N/A	N/A
DP07	1,144	0.478	3.241	0.969	0.589
DP08	758	0.532	2.227	0.975	0.353
DP09	N/A	N/A	N/A	N/A	N/A
DP10	N/A	N/A	N/A	N/A	N/A

Note: N/A represent PS models that did not reach convergence.

Appendix S. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Psychiatric History, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Overall					
Aggregated	2,546,605	0.301	4.603	0.932	0.628
DP01	1,281	0.302	3.414	0.900	0.583
DP02	268,019	0.511	3.711	0.933	0.661
DP03	2,740	0.308	3.056	0.927	0.532
DP04	164,557	0.393	3.865	0.910	0.666
DP05	1,666	0.434	4.603	0.910	0.807
DP06	11,560	0.301	3.740	0.924	0.617
DP07	1,160,380	0.433	3.532	0.931	0.627
DP08	405,127	0.426	2.738	0.964	0.475
DP09	183,943	0.485	3.958	0.918	0.696
DP10	347,332	0.459	3.982	0.911	0.697
No Psychiatric History Overall					
Aggregated	1,091,975	0.247	6.286	0.928	0.658
DP01	N/A	N/A	N/A	N/A	N/A
DP02	102,760	0.469	3.971	0.931	0.699
DP03	1,648	0.247	2.870	0.930	0.483
DP04	84,673	0.444	4.467	0.910	0.766
DP05	683	0.466	6.286	0.937	1.081
DP06	4,815	0.343	5.158	0.930	0.865
DP07	448,776	0.384	3.688	0.928	0.641
DP08	192,812	0.367	2.691	0.959	0.451
DP09	90,095	0.489	4.222	0.914	0.737
DP10	165,713	0.508	4.358	0.908	0.759

Appendix S. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or DPP-4i Users, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Subgroup: Prior Psychiatric History, Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Psychiatric History Overall					
Aggregated	1,453,562	0.267	3.972	0.938	0.607
DP01	785	0.267	3.235	0.896	0.519
DP02	165,151	0.472	3.577	0.938	0.637
DP03	1,008	0.426	3.571	0.959	0.629
DP04	79,756	0.343	3.406	0.921	0.581
DP05	892	0.401	3.972	0.918	0.688
DP06	6,720	0.270	3.164	0.934	0.511
DP07	711,555	0.466	3.503	0.935	0.626
DP08	212,306	0.498	2.650	0.972	0.464
DP09	93,815	0.430	3.734	0.928	0.653
DP10	181,574	0.408	3.681	0.921	0.642

Note: N/A represent PS models that did not reach convergence.

Appendix T. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users (observing for event in IP/ED setting), 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Aggregated	2,242,558	0.118	940209.1	1.714	629.467
DP01	3,541	0.262	14.415	0.989	1.054
DP02	263,957	0.477	1608.791	1.118	5.308
DP03	6,358	0.118	75.247	1.008	1.177
DP04	185,208	0.440	46434.27	1.920	137.178
DP05	1,688	0.419	86.475	1.143	2.737
DP06	13,100	0.358	2840.735	1.698	30.352
DP07	954,695	0.500	4471.586	1.164	11.750
DP08	267,081	0.479	499.210	1.037	1.864
DP09	192,109	0.489	940209.1	6.282	2145.232
DP10	354,821	0.449	13611.46	1.591	48.618

Appendix U. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Aggregated	2,242,558	0.138	9.520	1.014	0.886
DP01	3,541	0.271	5.879	0.966	0.879
DP02	263,957	0.502	5.677	1.006	0.764
DP03	6,358	0.138	3.004	0.967	0.348
DP04	185,208	0.455	8.678	1.024	1.115
DP05	1,688	0.436	8.506	1.028	1.061
DP06	13,100	0.373	9.520	1.045	1.219
DP07	954,695	0.518	5.979	1.011	0.805
DP08	267,081	0.539	3.895	0.999	0.550
DP09	192,109	0.502	8.285	1.025	1.074
DP10	354,821	0.464	8.531	1.026	1.099

Appendix V. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2I Users (observing for event in IP/ED setting), 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Aggregated	2,242,558	0.182	4.575	0.969	0.634
DP01	3,541	0.276	4.034	0.933	0.722
DP02	263,957	0.524	3.377	0.970	0.586
DP03	6,358	0.182	1.932	0.952	0.271
DP04	185,208	0.473	4.238	0.956	0.732
DP05	1,688	0.457	3.831	0.958	0.666
DP06	13,100	0.395	4.575	0.968	0.775
DP07	954,695	0.532	3.511	0.973	0.610
DP08	267,081	0.561	2.723	0.981	0.467
DP09	192,109	0.516	4.133	0.960	0.721
DP10	354,821	0.481	4.204	0.959	0.728

Appendix W. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Aggregated	2,242,535	0.118	46437.88	1.294	45.136
DP01	3,541	0.262	14.415	0.989	1.054
DP02	263,952	0.477	1608.190	1.118	5.307
DP03	6,358	0.118	75.247	1.008	1.177
DP04	185,209	0.440	46437.88	1.920	137.189
DP05	1,688	0.419	86.475	1.143	2.737
DP06	13,099	0.358	1700.254	1.474	17.479
DP07	954,684	0.500	4468.088	1.164	11.754
DP08	267,079	0.479	544.080	1.038	2.135
DP09	192,103	0.489	6850.743	1.387	22.720
DP10	354,822	0.449	13605.93	1.591	48.631

Appendix X. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Aggregated	2,242,535	0.138	9.492	1.014	0.886
DP01	3,541	0.271	5.879	0.966	0.879
DP02	263,952	0.502	5.678	1.006	0.764
DP03	6,358	0.138	3.004	0.967	0.348
DP04	185,209	0.455	8.684	1.025	1.116
DP05	1,688	0.436	8.506	1.028	1.061
DP06	13,099	0.373	9.492	1.044	1.212
DP07	954,684	0.518	5.980	1.011	0.805
DP08	267,079	0.539	3.894	0.999	0.550
DP09	192,103	0.502	8.280	1.025	1.074
DP10	354,822	0.464	8.530	1.026	1.099

Appendix Y. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users, 15-day Gap & Ext, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Aggregated	2,242,535	0.182	4.522	0.969	0.634
DP01	3,541	0.276	4.034	0.933	0.722
DP02	263,952	0.524	3.377	0.970	0.586
DP03	6,358	0.182	1.932	0.952	0.271
DP04	185,209	0.473	4.238	0.956	0.732
DP05	1,688	0.457	3.831	0.958	0.666
DP06	13,099	0.395	4.522	0.966	0.767
DP07	954,684	0.532	3.511	0.973	0.610
DP08	267,079	0.561	2.723	0.981	0.467
DP09	192,103	0.516	4.131	0.960	0.721
DP10	354,822	0.481	4.204	0.959	0.728

Appendix Z. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users with Two or More Dispensings, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Aggregated	1,576,777	0.124	13724.12	1.287	27.032
DP01	2,642	0.286	15.884	0.995	1.117
DP02	169,314	0.476	3373.926	1.156	10.729
DP03	4,148	0.124	15.189	0.993	0.623
DP04	141,006	0.429	8738.251	1.438	31.243
DP05	1,320	0.398	37.366	1.155	2.330
DP06	9,913	0.347	4681.538	1.964	49.673
DP07	669,793	0.499	5496.403	1.186	14.459
DP08	189,548	0.476	331.708	1.032	1.450
DP09	133,317	0.480	8808.471	1.479	33.388
DP10	255,776	0.445	13724.12	1.623	51.620

Appendix AA. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users with Two or More Dispensings, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Aggregated	1,576,777	0.151	9.822	1.013	0.904
DP01	2,642	0.292	6.640	0.975	0.964
DP02	169,314	0.501	5.802	1.005	0.785
DP03	4,148	0.151	3.215	0.970	0.372
DP04	141,006	0.444	8.504	1.020	1.097
DP05	1,320	0.416	8.443	1.030	1.087
DP06	9,913	0.362	9.822	1.047	1.257
DP07	669,793	0.517	6.078	1.011	0.817
DP08	189,548	0.534	3.925	0.999	0.556
DP09	133,317	0.492	8.644	1.026	1.121
DP10	255,776	0.459	8.706	1.024	1.120

Appendix AB. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users with Two or More Dispensings, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Aggregated	1,576,777	0.195	4.688	0.966	0.644
DP01	2,642	0.295	4.184	0.934	0.763
DP02	169,314	0.521	3.458	0.969	0.600
DP03	4,148	0.195	1.990	0.952	0.282
DP04	141,006	0.462	4.233	0.953	0.729
DP05	1,320	0.441	4.383	0.968	0.739
DP06	9,913	0.381	4.688	0.965	0.785
DP07	669,793	0.531	3.537	0.971	0.615
DP08	189,548	0.557	2.737	0.980	0.472
DP09	133,317	0.506	4.300	0.958	0.748
DP10	255,776	0.476	4.229	0.954	0.735

Appendix AC. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 0% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Aggregated	960,878	0.200	9760.428	1.153	13.404
DP01	1,565	0.371	60.094	1.011	1.931
DP02	133,438	0.408	437.792	1.067	2.303
DP03	2,061	0.200	11.120	0.982	0.621
DP04	86,200	0.362	9760.428	1.331	34.745
DP05	866	0.366	92.636	1.158	3.467
DP06	5,833	0.285	395.818	1.269	6.577
DP07	412,803	0.418	919.850	1.077	3.066
DP08	66,260	0.395	43.788	1.022	0.716
DP09	89,803	0.409	1171.802	1.208	7.259
DP10	162,049	0.368	3701.881	1.343	19.074

Appendix AD. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 1% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Aggregated	960,878	0.215	8.256	1.010	0.761
DP01	1,565	0.377	6.883	0.951	1.050
DP02	133,438	0.448	4.744	1.003	0.645
DP03	2,061	0.215	3.509	0.962	0.453
DP04	86,200	0.389	7.334	1.016	0.941
DP05	866	0.384	7.070	1.011	0.887
DP06	5,833	0.313	8.256	1.030	1.007
DP07	412,803	0.460	4.948	1.008	0.669
DP08	66,260	0.491	3.347	1.002	0.457
DP09	89,803	0.430	7.149	1.019	0.933
DP10	162,049	0.394	7.172	1.017	0.925

Appendix AE. Distribution of Inverse Probability of Treatment Weights After Trimming for GLP-1RA or SGLT-2i Users with Diabetes and Obesity, 2.5% truncation in the Sentinel Distributed Database (SDD) from October 1, 2015 to September 30, 2023, by Data Partner (DP), Weight: Average Treatment Effect, Stabilized (ATES)

Masked DP ID	Number of Patients	Minimum	Maximum	Mean	Standard Deviation
Aggregated	960,878	0.243	5.008	0.974	0.564
DP01	1,565	0.382	5.008	0.921	0.902
DP02	133,438	0.480	3.034	0.977	0.515
DP03	2,061	0.243	2.322	0.944	0.365
DP04	86,200	0.416	3.772	0.962	0.641
DP05	866	0.411	3.270	0.953	0.573
DP06	5,833	0.342	3.895	0.967	0.637
DP07	412,803	0.494	3.108	0.980	0.528
DP08	66,260	0.532	2.417	0.987	0.392
DP09	89,803	0.454	3.822	0.967	0.655
DP10	162,049	0.421	3.765	0.965	0.640

Appendix BA. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Exposures and Comparators in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
GLP-1 Receptor Agonists	
albiglutide	Tanzeum
dulaglutide	Trulicity
exenatide	Byetta
exenatide microspheres	Bydureon
exenatide microspheres	Bydureon BCise
insulin degludec/liraglutide	Xultophy 100/3.6
insulin glargine,human recombinant analog/lixisenatide	Soliqua 100/33
liraglutide	Saxenda
liraglutide	Victoza 2-Pak
liraglutide	Victoza 3-Pak
lixisenatide	Adlyxin
semaglutide	Ozempic
semaglutide	Rybelsus
semaglutide	Wegovy
tirzepatide	Mounjaro
DPP4 Inhibitors	
alogliptin benzoate	Nesina
alogliptin benzoate	alogliptin
alogliptin benzoate/metformin HCl	Kazano
alogliptin benzoate/metformin HCl	alogliptin-metformin
alogliptin benzoate/pioglitazone HCl	Oseni
alogliptin benzoate/pioglitazone HCl	alogliptin-pioglitazone
linagliptin	Tradjenta
linagliptin/metformin HCl	Jentadueto
linagliptin/metformin HCl	Jentadueto XR
saxagliptin HCl	Onglyza
saxagliptin HCl	saxagliptin
saxagliptin HCl/metformin HCl	Kombiglyze XR
saxagliptin HCl/metformin HCl	saxagliptin-metformin
sitagliptin phosphate	Januvia
sitagliptin phosphate/metformin HCl	Janumet
sitagliptin phosphate/metformin HCl	Janumet XR
SGLT-2 Inhibitors	

Appendix BA. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Exposures and Comparators in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
bexagliflozin	Brenzavvy
bexagliflozin	bexagliflozin
canagliflozin	Invokana
canagliflozin/metformin HCl	Invokamet
canagliflozin/metformin HCl	Invokamet XR
dapagliflozin propanediol	Farxiga
dapagliflozin propanediol/metformin HCl	Xigduo XR
empagliflozin	Jardiance
empagliflozin/metformin HCl	Synjardy
empagliflozin/metformin HCl	Synjardy XR
ertugliflozin pidolate	Steglatro
ertugliflozin pidolate/metformin HCl	Segluromet
sotagliflozin	Inpefa

Appendix BB. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Exposure Incidence Criteria in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
GLP-1 Receptor Agonists	
albiglutide	Tanzeum
dulaglutide	Trulicity
exenatide	Byetta
exenatide microspheres	Bydureon
exenatide microspheres	Bydureon BCise
insulin degludec/liraglutide	Xultophy 100/3.6
insulin glargine,human recombinant analog/lixisenatide	Soliqua 100/33
liraglutide	Saxenda
liraglutide	Victoza 2-Pak
liraglutide	Victoza 3-Pak
lixisenatide	Adlyxin
semaglutide	Ozempic
semaglutide	Rybelsus
semaglutide	Wegovy
tirzepatide	Mounjaro
DPP4 Inhibitors	
alogliptin benzoate	Nesina
alogliptin benzoate	alogliptin
alogliptin benzoate/metformin HCl	Kazano
alogliptin benzoate/metformin HCl	alogliptin-metformin
alogliptin benzoate/pioglitazone HCl	Oseni
alogliptin benzoate/pioglitazone HCl	alogliptin-pioglitazone
linagliptin	Tradjenta
linagliptin/metformin HCl	Jentadueto
linagliptin/metformin HCl	Jentadueto XR
saxagliptin HCl	Onglyza
saxagliptin HCl	saxagliptin
saxagliptin HCl/metformin HCl	Kombiglyze XR
saxagliptin HCl/metformin HCl	saxagliptin-metformin
sitagliptin phosphate	Januvia
sitagliptin phosphate/metformin HCl	Janumet
sitagliptin phosphate/metformin HCl	Janumet XR
SGLT-2 Inhibitors	
bexagliflozin	Brenzavvy

Appendix BB. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Exposure Incidence Criteria in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
bexagliflozin	bexagliflozin
canagliflozin	Invokana
canagliflozin/metformin HCl	Invokamet
canagliflozin/metformin HCl	Invokamet XR
dapagliflozin propanediol	Farxiga
dapagliflozin propanediol/metformin HCl	Xigduo XR
empagliflozin	Jardiance
empagliflozin/metformin HCl	Synjardy
empagliflozin/metformin HCl	Synjardy XR
ertugliflozin pidolate	Steglatro
ertugliflozin pidolate/metformin HCl	Segluromet
sotagliflozin	Inpefa

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
	Intentional Self-Harm (Outcome)		
T14.91	Suicide attempt	Diagnosis	ICD-10-CM
T14.91XA	Suicide attempt, initial encounter	Diagnosis	ICD-10-CM
T14.91XD	Suicide attempt, subsequent encounter	Diagnosis	ICD-10-CM
T14.91XS	Suicide attempt, sequela	Diagnosis	ICD-10-CM
T36.0X2	Poisoning by penicillins, intentional self-harm	Diagnosis	ICD-10-CM
T36.0X2A	Poisoning by penicillins, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.0X2D	Poisoning by penicillins, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.0X2S	Poisoning by penicillins, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.1X2	Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm	Diagnosis	ICD-10-CM
T36.1X2A	Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.1X2D	Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.1X2S	Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.2X2	Poisoning by chloramphenicol group, intentional self-harm	Diagnosis	ICD-10-CM
T36.2X2A	Poisoning by chloramphenicol group, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.2X2D	Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.2X2S	Poisoning by chloramphenicol group, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.3X2	Poisoning by macrolides, intentional self-harm	Diagnosis	ICD-10-CM
T36.3X2A	Poisoning by macrolides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.3X2D	Poisoning by macrolides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.3X2S	Poisoning by macrolides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.4X2	Poisoning by tetracyclines, intentional self-harm	Diagnosis	ICD-10-CM
T36.4X2A	Poisoning by tetracyclines, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.4X2D	Poisoning by tetracyclines, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.4X2S	Poisoning by tetracyclines, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.5X2	Poisoning by aminoglycosides, intentional self-harm	Diagnosis	ICD-10-CM
T36.5X2A	Poisoning by aminoglycosides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.5X2D	Poisoning by aminoglycosides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.5X2S	Poisoning by aminoglycosides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.6X2	Poisoning by rifampicins, intentional self-harm	Diagnosis	ICD-10-CM
T36.6X2A	Poisoning by rifampicins, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.6X2D	Poisoning by rifampicins, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.6X2S	Poisoning by rifampicins, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T36.7X2	Poisoning by antifungal antibiotics, systemically used, intentional self-harm	Diagnosis	ICD-10-CM
T36.7X2A	Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.7X2D	Poisoning by antifungal antibiotics, systemically used, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.7X2S	Poisoning by antifungal antibiotics, systemically used, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.8X2	Poisoning by other systemic antibiotics, intentional self-harm	Diagnosis	ICD-10-CM
T36.8X2A	Poisoning by other systemic antibiotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.8X2D	Poisoning by other systemic antibiotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.8X2S	Poisoning by other systemic antibiotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.92	Poisoning by unspecified systemic antibiotic, intentional self-harm	Diagnosis	ICD-10-CM
T36.92XA	Poisoning by unspecified systemic antibiotic, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.92XD	Poisoning by unspecified systemic antibiotic, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.92XS	Poisoning by unspecified systemic antibiotic, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T37.0X2	Poisoning by sulfonamides, intentional self-harm	Diagnosis	ICD-10-CM
T37.0X2A	Poisoning by sulfonamides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.0X2D	Poisoning by sulfonamides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.0X2S	Poisoning by sulfonamides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T37.1X2	Poisoning by antimycobacterial drugs, intentional self-harm	Diagnosis	ICD-10-CM
T37.1X2A	Poisoning by antimycobacterial drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.1X2D	Poisoning by antimycobacterial drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.1X2S	Poisoning by antimycobacterial drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T37.2X2	Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm	Diagnosis	ICD-10-CM
T37.2X2A	Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.2X2D	Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.2X2S	Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T37.3X2	Poisoning by other antiprotozoal drugs, intentional self-harm	Diagnosis	ICD-10-CM
T37.3X2A	Poisoning by other antiprotozoal drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.3X2D	Poisoning by other antiprotozoal drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.3X2S	Poisoning by other antiprotozoal drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T37.4X2	Poisoning by anthelminthics, intentional self-harm	Diagnosis	ICD-10-CM
T37.4X2A	Poisoning by anthelminthics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.4X2D	Poisoning by anthelminthics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.4X2S	Poisoning by anthelminthics, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T37.5X2	Poisoning by antiviral drugs, intentional self-harm	Diagnosis	ICD-10-CM
T37.5X2A	Poisoning by antiviral drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.5X2D	Poisoning by antiviral drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.5X2S	Poisoning by antiviral drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T37.8X2	Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm	Diagnosis	ICD-10-CM
T37.8X2A	Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.8X2D	Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.8X2S	Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T37.92	Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm	Diagnosis	ICD-10-CM
T37.92XA	Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.92XD	Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.92XS	Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.0X2	Poisoning by glucocorticoids and synthetic analogues, intentional self-harm	Diagnosis	ICD-10-CM
T38.0X2A	Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.0X2D	Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.0X2S	Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.1X2	Poisoning by thyroid hormones and substitutes, intentional self-harm	Diagnosis	ICD-10-CM
T38.1X2A	Poisoning by thyroid hormones and substitutes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.1X2D	Poisoning by thyroid hormones and substitutes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.1X2S	Poisoning by thyroid hormones and substitutes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.2X2	Poisoning by antithyroid drugs, intentional self-harm	Diagnosis	ICD-10-CM
T38.2X2A	Poisoning by antithyroid drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.2X2D	Poisoning by antithyroid drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.2X2S	Poisoning by antithyroid drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.3X2	Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm	Diagnosis	ICD-10-CM
T38.3X2A	Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.3X2D	Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.3X2S	Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.4X2	Poisoning by oral contraceptives, intentional self-harm	Diagnosis	ICD-10-CM
T38.4X2A	Poisoning by oral contraceptives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T38.4X2D	Poisoning by oral contraceptives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.4X2S	Poisoning by oral contraceptives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.5X2	Poisoning by other estrogens and progestogens, intentional self-harm	Diagnosis	ICD-10-CM
T38.5X2A	Poisoning by other estrogens and progestogens, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.5X2D	Poisoning by other estrogens and progestogens, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.5X2S	Poisoning by other estrogens and progestogens, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.6X2	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm	Diagnosis	ICD-10-CM
T38.6X2A	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.6X2D	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.6X2S	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.7X2	Poisoning by androgens and anabolic congeners, intentional self-harm	Diagnosis	ICD-10-CM
T38.7X2A	Poisoning by androgens and anabolic congeners, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.7X2D	Poisoning by androgens and anabolic congeners, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.7X2S	Poisoning by androgens and anabolic congeners, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.802	Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm	Diagnosis	ICD-10-CM
T38.802A	Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.802D	Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.802S	Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.812	Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm	Diagnosis	ICD-10-CM
T38.812A	Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.812D	Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.812S	Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.892	Poisoning by other hormones and synthetic substitutes, intentional self-harm	Diagnosis	ICD-10-CM
T38.892A	Poisoning by other hormones and synthetic substitutes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.892D	Poisoning by other hormones and synthetic substitutes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.892S	Poisoning by other hormones and synthetic substitutes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.902	Poisoning by unspecified hormone antagonists, intentional self-harm	Diagnosis	ICD-10-CM
T38.902A	Poisoning by unspecified hormone antagonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.902D	Poisoning by unspecified hormone antagonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.902S	Poisoning by unspecified hormone antagonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T38.992	Poisoning by other hormone antagonists, intentional self-harm	Diagnosis	ICD-10-CM
T38.992A	Poisoning by other hormone antagonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.992D	Poisoning by other hormone antagonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.992S	Poisoning by other hormone antagonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.012	Poisoning by aspirin, intentional self-harm	Diagnosis	ICD-10-CM
T39.012A	Poisoning by aspirin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.012D	Poisoning by aspirin, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.012S	Poisoning by aspirin, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.092	Poisoning by salicylates, intentional self-harm	Diagnosis	ICD-10-CM
T39.092A	Poisoning by salicylates, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.092D	Poisoning by salicylates, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.092S	Poisoning by salicylates, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.1X2	Poisoning by 4-Aminophenol derivatives, intentional self-harm	Diagnosis	ICD-10-CM
T39.1X2A	Poisoning by 4-Aminophenol derivatives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.1X2D	Poisoning by 4-Aminophenol derivatives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.1X2S	Poisoning by 4-Aminophenol derivatives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.2X2	Poisoning by pyrazolone derivatives, intentional self-harm	Diagnosis	ICD-10-CM
T39.2X2A	Poisoning by pyrazolone derivatives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.2X2D	Poisoning by pyrazolone derivatives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.2X2S	Poisoning by pyrazolone derivatives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.312	Poisoning by propionic acid derivatives, intentional self-harm	Diagnosis	ICD-10-CM
T39.312A	Poisoning by propionic acid derivatives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.312D	Poisoning by propionic acid derivatives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.312S	Poisoning by propionic acid derivatives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.392	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm	Diagnosis	ICD-10-CM
T39.392A	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.392D	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.392S	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.4X2	Poisoning by antirheumatics, not elsewhere classified, intentional self-harm	Diagnosis	ICD-10-CM
T39.4X2A	Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.4X2D	Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.4X2S	Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.8X2	Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T39.8X2A	Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.8X2D	Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.8X2S	Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.92	Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm	Diagnosis	ICD-10-CM
T39.92XA	Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.92XD	Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.92XS	Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.0X2	Poisoning by opium, intentional self-harm	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X2D	Poisoning by opium, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.0X2S	Poisoning by opium, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.1X2	Poisoning by heroin, intentional self-harm	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X2D	Poisoning by heroin, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.1X2S	Poisoning by heroin, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.2X2	Poisoning by other opioids, intentional self-harm	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X2D	Poisoning by other opioids, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.2X2S	Poisoning by other opioids, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.3X2	Poisoning by methadone, intentional self-harm	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X2D	Poisoning by methadone, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.3X2S	Poisoning by methadone, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.412	Poisoning by fentanyl or fentanyl analogs, intentional self-harm	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.412D	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.412S	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.422	Poisoning by tramadol, intentional self-harm	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.422D	Poisoning by tramadol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.422S	Poisoning by tramadol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.492	Poisoning by other synthetic narcotics, intentional self-harm	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.492D	Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.492S	Poisoning by other synthetic narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.4X2	Poisoning by other synthetic narcotics, intentional self-harm	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X2D	Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.4X2S	Poisoning by other synthetic narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.5X2	Poisoning by cocaine, intentional self-harm	Diagnosis	ICD-10-CM
T40.5X2A	Poisoning by cocaine, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.5X2D	Poisoning by cocaine, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.5X2S	Poisoning by cocaine, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.602	Poisoning by unspecified narcotics, intentional self-harm	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.602D	Poisoning by unspecified narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.602S	Poisoning by unspecified narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.692	Poisoning by other narcotics, intentional self-harm	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.692D	Poisoning by other narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.692S	Poisoning by other narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.712	Poisoning by cannabis, intentional self-harm	Diagnosis	ICD-10-CM
T40.712A	Poisoning by cannabis, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.712D	Poisoning by cannabis, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.712S	Poisoning by cannabis, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.722	Poisoning by synthetic cannabinoids, intentional self-harm	Diagnosis	ICD-10-CM
T40.722A	Poisoning by synthetic cannabinoids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.722D	Poisoning by synthetic cannabinoids, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.722S	Poisoning by synthetic cannabinoids, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.7X2	Poisoning by cannabis (derivatives), intentional self-harm	Diagnosis	ICD-10-CM
T40.7X2A	Poisoning by cannabis (derivatives), intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.7X2D	Poisoning by cannabis (derivatives), intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T40.7X2S	Poisoning by cannabis (derivatives), intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.8X2	Poisoning by lysergide [LSD], intentional self-harm	Diagnosis	ICD-10-CM
T40.8X2A	Poisoning by lysergide [LSD], intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.8X2D	Poisoning by lysergide [LSD], intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.8X2S	Poisoning by lysergide [LSD], intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.902	Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm	Diagnosis	ICD-10-CM
T40.902A	Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.902D	Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.902S	Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.992	Poisoning by other psychodysleptics [hallucinogens], intentional self-harm	Diagnosis	ICD-10-CM
T40.992A	Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.992D	Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.992S	Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, sequela	Diagnosis	ICD-10-CM
T41.0X2	Poisoning by inhaled anesthetics, intentional self-harm	Diagnosis	ICD-10-CM
T41.0X2A	Poisoning by inhaled anesthetics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T41.0X2D	Poisoning by inhaled anesthetics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T41.0X2S	Poisoning by inhaled anesthetics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T41.1X2	Poisoning by intravenous anesthetics, intentional self-harm	Diagnosis	ICD-10-CM
T41.1X2A	Poisoning by intravenous anesthetics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T41.1X2D	Poisoning by intravenous anesthetics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T41.1X2S	Poisoning by intravenous anesthetics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T41.202	Poisoning by unspecified general anesthetics, intentional self-harm	Diagnosis	ICD-10-CM
T41.202A	Poisoning by unspecified general anesthetics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T41.202D	Poisoning by unspecified general anesthetics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T41.202S	Poisoning by unspecified general anesthetics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T41.292	Poisoning by other general anesthetics, intentional self-harm	Diagnosis	ICD-10-CM
T41.292A	Poisoning by other general anesthetics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T41.292D	Poisoning by other general anesthetics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T41.292S	Poisoning by other general anesthetics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T41.3X2	Poisoning by local anesthetics, intentional self-harm	Diagnosis	ICD-10-CM
T41.3X2A	Poisoning by local anesthetics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T41.3X2D	Poisoning by local anesthetics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T41.3X2S	Poisoning by local anesthetics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T41.42	Poisoning by unspecified anesthetic, intentional self-harm	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T41.42XA	Poisoning by unspecified anesthetic, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T41.42XD	Poisoning by unspecified anesthetic, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T41.42XS	Poisoning by unspecified anesthetic, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T41.5X2	Poisoning by therapeutic gases, intentional self-harm	Diagnosis	ICD-10-CM
T41.5X2A	Poisoning by therapeutic gases, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T41.5X2D	Poisoning by therapeutic gases, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T41.5X2S	Poisoning by therapeutic gases, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.0X2	Poisoning by hydantoin derivatives, intentional self-harm	Diagnosis	ICD-10-CM
T42.0X2A	Poisoning by hydantoin derivatives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.0X2D	Poisoning by hydantoin derivatives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.0X2S	Poisoning by hydantoin derivatives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.1X2	Poisoning by iminostilbenes, intentional self-harm	Diagnosis	ICD-10-CM
T42.1X2A	Poisoning by iminostilbenes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.1X2D	Poisoning by iminostilbenes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.1X2S	Poisoning by iminostilbenes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.2X2	Poisoning by succinimides and oxazolidinediones, intentional self-harm	Diagnosis	ICD-10-CM
T42.2X2A	Poisoning by succinimides and oxazolidinediones, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.2X2D	Poisoning by succinimides and oxazolidinediones, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.2X2S	Poisoning by succinimides and oxazolidinediones, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.3X2	Poisoning by barbiturates, intentional self-harm	Diagnosis	ICD-10-CM
T42.3X2A	Poisoning by barbiturates, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.3X2D	Poisoning by barbiturates, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.3X2S	Poisoning by barbiturates, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.4X2	Poisoning by benzodiazepines, intentional self-harm	Diagnosis	ICD-10-CM
T42.4X2A	Poisoning by benzodiazepines, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.4X2D	Poisoning by benzodiazepines, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.4X2S	Poisoning by benzodiazepines, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.5X2	Poisoning by mixed antiepileptics, intentional self-harm	Diagnosis	ICD-10-CM
T42.5X2A	Poisoning by mixed antiepileptics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.5X2D	Poisoning by mixed antiepileptics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.5X2S	Poisoning by mixed antiepileptics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.6X2	Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm	Diagnosis	ICD-10-CM
T42.6X2A	Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.6X2D	Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T42.6X2S	Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.72	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm	Diagnosis	ICD-10-CM
T42.72XA	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.72XD	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.72XS	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.8X2	Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm	Diagnosis	ICD-10-CM
T42.8X2A	Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.8X2D	Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.8X2S	Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.012	Poisoning by tricyclic antidepressants, intentional self-harm	Diagnosis	ICD-10-CM
T43.012A	Poisoning by tricyclic antidepressants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.012D	Poisoning by tricyclic antidepressants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.012S	Poisoning by tricyclic antidepressants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.022	Poisoning by tetracyclic antidepressants, intentional self-harm	Diagnosis	ICD-10-CM
T43.022A	Poisoning by tetracyclic antidepressants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.022D	Poisoning by tetracyclic antidepressants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.022S	Poisoning by tetracyclic antidepressants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.1X2	Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm	Diagnosis	ICD-10-CM
T43.1X2A	Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.1X2D	Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.1X2S	Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.202	Poisoning by unspecified antidepressants, intentional self-harm	Diagnosis	ICD-10-CM
T43.202A	Poisoning by unspecified antidepressants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.202D	Poisoning by unspecified antidepressants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.202S	Poisoning by unspecified antidepressants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.212	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm	Diagnosis	ICD-10-CM
T43.212A	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.212D	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T43.212S	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.222	Poisoning by selective serotonin reuptake inhibitors, intentional self-harm	Diagnosis	ICD-10-CM
T43.222A	Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.222D	Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.222S	Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.292	Poisoning by other antidepressants, intentional self-harm	Diagnosis	ICD-10-CM
T43.292A	Poisoning by other antidepressants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.292D	Poisoning by other antidepressants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.292S	Poisoning by other antidepressants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.3X2	Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm	Diagnosis	ICD-10-CM
T43.3X2A	Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.3X2D	Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.3X2S	Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.4X2	Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm	Diagnosis	ICD-10-CM
T43.4X2A	Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.4X2D	Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.4X2S	Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.502	Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm	Diagnosis	ICD-10-CM
T43.502A	Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.502D	Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.502S	Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.592	Poisoning by other antipsychotics and neuroleptics, intentional self-harm	Diagnosis	ICD-10-CM
T43.592A	Poisoning by other antipsychotics and neuroleptics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.592D	Poisoning by other antipsychotics and neuroleptics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.592S	Poisoning by other antipsychotics and neuroleptics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.602	Poisoning by unspecified psychostimulants, intentional self-harm	Diagnosis	ICD-10-CM
T43.602A	Poisoning by unspecified psychostimulants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.602D	Poisoning by unspecified psychostimulants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.602S	Poisoning by unspecified psychostimulants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.612	Poisoning by caffeine, intentional self-harm	Diagnosis	ICD-10-CM
T43.612A	Poisoning by caffeine, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.612D	Poisoning by caffeine, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.612S	Poisoning by caffeine, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.622	Poisoning by amphetamines, intentional self-harm	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T43.622A	Poisoning by amphetamines, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.622D	Poisoning by amphetamines, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.622S	Poisoning by amphetamines, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.632	Poisoning by methylphenidate, intentional self-harm	Diagnosis	ICD-10-CM
T43.632A	Poisoning by methylphenidate, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.632D	Poisoning by methylphenidate, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.632S	Poisoning by methylphenidate, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.642	Poisoning by ecstasy, intentional self-harm	Diagnosis	ICD-10-CM
T43.642A	Poisoning by ecstasy, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.642D	Poisoning by ecstasy, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.642S	Poisoning by ecstasy, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.692	Poisoning by other psychostimulants, intentional self-harm	Diagnosis	ICD-10-CM
T43.692A	Poisoning by other psychostimulants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.692D	Poisoning by other psychostimulants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.692S	Poisoning by other psychostimulants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.8X2	Poisoning by other psychotropic drugs, intentional self-harm	Diagnosis	ICD-10-CM
T43.8X2A	Poisoning by other psychotropic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.8X2D	Poisoning by other psychotropic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.8X2S	Poisoning by other psychotropic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.92	Poisoning by unspecified psychotropic drug, intentional self-harm	Diagnosis	ICD-10-CM
T43.92XA	Poisoning by unspecified psychotropic drug, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.92XD	Poisoning by unspecified psychotropic drug, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.92XS	Poisoning by unspecified psychotropic drug, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.0X2	Poisoning by anticholinesterase agents, intentional self-harm	Diagnosis	ICD-10-CM
T44.0X2A	Poisoning by anticholinesterase agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.0X2D	Poisoning by anticholinesterase agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.0X2S	Poisoning by anticholinesterase agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.1X2	Poisoning by other parasympathomimetics [cholinergics], intentional self-harm	Diagnosis	ICD-10-CM
T44.1X2A	Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.1X2D	Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.1X2S	Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.2X2	Poisoning by ganglionic blocking drugs, intentional self-harm	Diagnosis	ICD-10-CM
T44.2X2A	Poisoning by ganglionic blocking drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.2X2D	Poisoning by ganglionic blocking drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T44.2X2S	Poisoning by ganglionic blocking drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.3X2	Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm	Diagnosis	ICD-10-CM
T44.3X2A	Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.3X2D	Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.3X2S	Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.4X2	Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm	Diagnosis	ICD-10-CM
T44.4X2A	Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.4X2D	Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.4X2S	Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.5X2	Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm	Diagnosis	ICD-10-CM
T44.5X2A	Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.5X2D	Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.5X2S	Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.6X2	Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm	Diagnosis	ICD-10-CM
T44.6X2A	Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.6X2D	Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.6X2S	Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.7X2	Poisoning by beta-adrenoreceptor antagonists, intentional self-harm	Diagnosis	ICD-10-CM
T44.7X2A	Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.7X2D	Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.7X2S	Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.8X2	Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm	Diagnosis	ICD-10-CM
T44.8X2A	Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.8X2D	Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.8X2S	Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.902	Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm	Diagnosis	ICD-10-CM
T44.902A	Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T44.902D	Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.902S	Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.992	Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm	Diagnosis	ICD-10-CM
T44.992A	Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.992D	Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.992S	Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.0X2	Poisoning by antiallergic and antiemetic drugs, intentional self-harm	Diagnosis	ICD-10-CM
T45.0X2A	Poisoning by antiallergic and antiemetic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.0X2D	Poisoning by antiallergic and antiemetic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.0X2S	Poisoning by antiallergic and antiemetic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.1X2	Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm	Diagnosis	ICD-10-CM
T45.1X2A	Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.1X2D	Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.1X2S	Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.2X2	Poisoning by vitamins, intentional self-harm	Diagnosis	ICD-10-CM
T45.2X2A	Poisoning by vitamins, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.2X2D	Poisoning by vitamins, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.2X2S	Poisoning by vitamins, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.3X2	Poisoning by enzymes, intentional self-harm	Diagnosis	ICD-10-CM
T45.3X2A	Poisoning by enzymes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.3X2D	Poisoning by enzymes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.3X2S	Poisoning by enzymes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.4X2	Poisoning by iron and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T45.4X2A	Poisoning by iron and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.4X2D	Poisoning by iron and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.4X2S	Poisoning by iron and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.512	Poisoning by anticoagulants, intentional self-harm	Diagnosis	ICD-10-CM
T45.512A	Poisoning by anticoagulants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.512D	Poisoning by anticoagulants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.512S	Poisoning by anticoagulants, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T45.522	Poisoning by antithrombotic drugs, intentional self-harm	Diagnosis	ICD-10-CM
T45.522A	Poisoning by antithrombotic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.522D	Poisoning by antithrombotic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.522S	Poisoning by antithrombotic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.602	Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm	Diagnosis	ICD-10-CM
T45.602A	Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.602D	Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.602S	Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.612	Poisoning by thrombolytic drug, intentional self-harm	Diagnosis	ICD-10-CM
T45.612A	Poisoning by thrombolytic drug, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.612D	Poisoning by thrombolytic drug, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.612S	Poisoning by thrombolytic drug, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.622	Poisoning by hemostatic drug, intentional self-harm	Diagnosis	ICD-10-CM
T45.622A	Poisoning by hemostatic drug, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.622D	Poisoning by hemostatic drug, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.622S	Poisoning by hemostatic drug, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.692	Poisoning by other fibrinolysis-affecting drugs, intentional self-harm	Diagnosis	ICD-10-CM
T45.692A	Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.692D	Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.692S	Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.7X2	Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm	Diagnosis	ICD-10-CM
T45.7X2A	Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.7X2D	Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.7X2S	Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.8X2	Poisoning by other primarily systemic and hematological agents, intentional self-harm	Diagnosis	ICD-10-CM
T45.8X2A	Poisoning by other primarily systemic and hematological agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.8X2D	Poisoning by other primarily systemic and hematological agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.8X2S	Poisoning by other primarily systemic and hematological agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.92	Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm	Diagnosis	ICD-10-CM
T45.92XA	Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T45.92XD	Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.92XS	Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.0X2	Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm	Diagnosis	ICD-10-CM
T46.0X2A	Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.0X2D	Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.0X2S	Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.1X2	Poisoning by calcium-channel blockers, intentional self-harm	Diagnosis	ICD-10-CM
T46.1X2A	Poisoning by calcium-channel blockers, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.1X2D	Poisoning by calcium-channel blockers, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.1X2S	Poisoning by calcium-channel blockers, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.2X2	Poisoning by other antidysrhythmic drugs, intentional self-harm	Diagnosis	ICD-10-CM
T46.2X2A	Poisoning by other antidysrhythmic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.2X2D	Poisoning by other antidysrhythmic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.2X2S	Poisoning by other antidysrhythmic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.3X2	Poisoning by coronary vasodilators, intentional self-harm	Diagnosis	ICD-10-CM
T46.3X2A	Poisoning by coronary vasodilators, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.3X2D	Poisoning by coronary vasodilators, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.3X2S	Poisoning by coronary vasodilators, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.4X2	Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm	Diagnosis	ICD-10-CM
T46.4X2A	Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.4X2D	Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.4X2S	Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.5X2	Poisoning by other antihypertensive drugs, intentional self-harm	Diagnosis	ICD-10-CM
T46.5X2A	Poisoning by other antihypertensive drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.5X2D	Poisoning by other antihypertensive drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.5X2S	Poisoning by other antihypertensive drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.6X2	Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm	Diagnosis	ICD-10-CM
T46.6X2A	Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.6X2D	Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.6X2S	Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T46.7X2	Poisoning by peripheral vasodilators, intentional self-harm	Diagnosis	ICD-10-CM
T46.7X2A	Poisoning by peripheral vasodilators, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.7X2D	Poisoning by peripheral vasodilators, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.7X2S	Poisoning by peripheral vasodilators, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.8X2	Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm	Diagnosis	ICD-10-CM
T46.8X2A	Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.8X2D	Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.8X2S	Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.902	Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm	Diagnosis	ICD-10-CM
T46.902A	Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.902D	Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.902S	Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.992	Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm	Diagnosis	ICD-10-CM
T46.992A	Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.992D	Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.992S	Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.0X2	Poisoning by histamine H2-receptor blockers, intentional self-harm	Diagnosis	ICD-10-CM
T47.0X2A	Poisoning by histamine H2-receptor blockers, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.0X2D	Poisoning by histamine H2-receptor blockers, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.0X2S	Poisoning by histamine H2-receptor blockers, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.1X2	Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm	Diagnosis	ICD-10-CM
T47.1X2A	Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.1X2D	Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.1X2S	Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.2X2	Poisoning by stimulant laxatives, intentional self-harm	Diagnosis	ICD-10-CM
T47.2X2A	Poisoning by stimulant laxatives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.2X2D	Poisoning by stimulant laxatives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.2X2S	Poisoning by stimulant laxatives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.3X2	Poisoning by saline and osmotic laxatives, intentional self-harm	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T47.3X2A	Poisoning by saline and osmotic laxatives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.3X2D	Poisoning by saline and osmotic laxatives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.3X2S	Poisoning by saline and osmotic laxatives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.4X2	Poisoning by other laxatives, intentional self-harm	Diagnosis	ICD-10-CM
T47.4X2A	Poisoning by other laxatives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.4X2D	Poisoning by other laxatives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.4X2S	Poisoning by other laxatives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.5X2	Poisoning by digestants, intentional self-harm	Diagnosis	ICD-10-CM
T47.5X2A	Poisoning by digestants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.5X2D	Poisoning by digestants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.5X2S	Poisoning by digestants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.6X2	Poisoning by antidiarrheal drugs, intentional self-harm	Diagnosis	ICD-10-CM
T47.6X2A	Poisoning by antidiarrheal drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.6X2D	Poisoning by antidiarrheal drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.6X2S	Poisoning by antidiarrheal drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.7X2	Poisoning by emetics, intentional self-harm	Diagnosis	ICD-10-CM
T47.7X2A	Poisoning by emetics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.7X2D	Poisoning by emetics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.7X2S	Poisoning by emetics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.8X2	Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm	Diagnosis	ICD-10-CM
T47.8X2A	Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.8X2D	Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.8X2S	Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.92	Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm	Diagnosis	ICD-10-CM
T47.92XA	Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.92XD	Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.92XS	Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.0X2	Poisoning by oxytocic drugs, intentional self-harm	Diagnosis	ICD-10-CM
T48.0X2A	Poisoning by oxytocic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T48.0X2D	Poisoning by oxytocic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.0X2S	Poisoning by oxytocic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.1X2	Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm	Diagnosis	ICD-10-CM
T48.1X2A	Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.1X2D	Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.1X2S	Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.202	Poisoning by unspecified drugs acting on muscles, intentional self-harm	Diagnosis	ICD-10-CM
T48.202A	Poisoning by unspecified drugs acting on muscles, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.202D	Poisoning by unspecified drugs acting on muscles, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.202S	Poisoning by unspecified drugs acting on muscles, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.292	Poisoning by other drugs acting on muscles, intentional self-harm	Diagnosis	ICD-10-CM
T48.292A	Poisoning by other drugs acting on muscles, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.292D	Poisoning by other drugs acting on muscles, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.292S	Poisoning by other drugs acting on muscles, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.3X2	Poisoning by antitussives, intentional self-harm	Diagnosis	ICD-10-CM
T48.3X2A	Poisoning by antitussives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.3X2D	Poisoning by antitussives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.3X2S	Poisoning by antitussives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.4X2	Poisoning by expectorants, intentional self-harm	Diagnosis	ICD-10-CM
T48.4X2A	Poisoning by expectorants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.4X2D	Poisoning by expectorants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.4X2S	Poisoning by expectorants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.5X2	Poisoning by other anti-common-cold drugs, intentional self-harm	Diagnosis	ICD-10-CM
T48.5X2A	Poisoning by other anti-common-cold drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.5X2D	Poisoning by other anti-common-cold drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.5X2S	Poisoning by other anti-common-cold drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.6X2	Poisoning by antiasthmatics, intentional self-harm	Diagnosis	ICD-10-CM
T48.6X2A	Poisoning by antiasthmatics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.6X2D	Poisoning by antiasthmatics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.6X2S	Poisoning by antiasthmatics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.902	Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T48.902A	Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.902D	Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.902S	Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.992	Poisoning by other agents primarily acting on the respiratory system, intentional self-harm	Diagnosis	ICD-10-CM
T48.992A	Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.992D	Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.992S	Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.0X2	Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm	Diagnosis	ICD-10-CM
T49.0X2A	Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.0X2D	Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.0X2S	Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.1X2	Poisoning by antipruritics, intentional self-harm	Diagnosis	ICD-10-CM
T49.1X2A	Poisoning by antipruritics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.1X2D	Poisoning by antipruritics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.1X2S	Poisoning by antipruritics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.2X2	Poisoning by local astringents and local detergents, intentional self-harm	Diagnosis	ICD-10-CM
T49.2X2A	Poisoning by local astringents and local detergents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.2X2D	Poisoning by local astringents and local detergents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.2X2S	Poisoning by local astringents and local detergents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.3X2	Poisoning by emollients, demulcents and protectants, intentional self-harm	Diagnosis	ICD-10-CM
T49.3X2A	Poisoning by emollients, demulcents and protectants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.3X2D	Poisoning by emollients, demulcents and protectants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.3X2S	Poisoning by emollients, demulcents and protectants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.4X2	Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm	Diagnosis	ICD-10-CM
T49.4X2A	Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T49.4X2D	Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.4X2S	Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.5X2	Poisoning by ophthalmological drugs and preparations, intentional self-harm	Diagnosis	ICD-10-CM
T49.5X2A	Poisoning by ophthalmological drugs and preparations, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.5X2D	Poisoning by ophthalmological drugs and preparations, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.5X2S	Poisoning by ophthalmological drugs and preparations, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.6X2	Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm	Diagnosis	ICD-10-CM
T49.6X2A	Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.6X2D	Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.6X2S	Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.7X2	Poisoning by dental drugs, topically applied, intentional self-harm	Diagnosis	ICD-10-CM
T49.7X2A	Poisoning by dental drugs, topically applied, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.7X2D	Poisoning by dental drugs, topically applied, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.7X2S	Poisoning by dental drugs, topically applied, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.8X2	Poisoning by other topical agents, intentional self-harm	Diagnosis	ICD-10-CM
T49.8X2A	Poisoning by other topical agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.8X2D	Poisoning by other topical agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.8X2S	Poisoning by other topical agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.92	Poisoning by unspecified topical agent, intentional self-harm	Diagnosis	ICD-10-CM
T49.92XA	Poisoning by unspecified topical agent, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.92XD	Poisoning by unspecified topical agent, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.92XS	Poisoning by unspecified topical agent, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.0X2	Poisoning by mineralocorticoids and their antagonists, intentional self-harm	Diagnosis	ICD-10-CM
T50.0X2A	Poisoning by mineralocorticoids and their antagonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.0X2D	Poisoning by mineralocorticoids and their antagonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.0X2S	Poisoning by mineralocorticoids and their antagonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.1X2	Poisoning by loop [high-ceiling] diuretics, intentional self-harm	Diagnosis	ICD-10-CM
T50.1X2A	Poisoning by loop [high-ceiling] diuretics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.1X2D	Poisoning by loop [high-ceiling] diuretics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.1X2S	Poisoning by loop [high-ceiling] diuretics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.2X2	Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T50.2X2A	Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.2X2D	Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.2X2S	Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.3X2	Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm	Diagnosis	ICD-10-CM
T50.3X2A	Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.3X2D	Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.3X2S	Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.4X2	Poisoning by drugs affecting uric acid metabolism, intentional self-harm	Diagnosis	ICD-10-CM
T50.4X2A	Poisoning by drugs affecting uric acid metabolism, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.4X2D	Poisoning by drugs affecting uric acid metabolism, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.4X2S	Poisoning by drugs affecting uric acid metabolism, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.5X2	Poisoning by appetite depressants, intentional self-harm	Diagnosis	ICD-10-CM
T50.5X2A	Poisoning by appetite depressants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.5X2D	Poisoning by appetite depressants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.5X2S	Poisoning by appetite depressants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.6X2	Poisoning by antidotes and chelating agents, intentional self-harm	Diagnosis	ICD-10-CM
T50.6X2A	Poisoning by antidotes and chelating agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.6X2D	Poisoning by antidotes and chelating agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.6X2S	Poisoning by antidotes and chelating agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.7X2	Poisoning by analeptics and opioid receptor antagonists, intentional self-harm	Diagnosis	ICD-10-CM
T50.7X2A	Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.7X2D	Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.7X2S	Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.8X2	Poisoning by diagnostic agents, intentional self-harm	Diagnosis	ICD-10-CM
T50.8X2A	Poisoning by diagnostic agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.8X2D	Poisoning by diagnostic agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.8X2S	Poisoning by diagnostic agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.902	Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm	Diagnosis	ICD-10-CM
T50.902A	Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T50.902D	Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.902S	Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.912	Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm	Diagnosis	ICD-10-CM
T50.912A	Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.912D	Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.912S	Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.992	Poisoning by other drugs, medicaments and biological substances, intentional self-harm	Diagnosis	ICD-10-CM
T50.992A	Poisoning by other drugs, medicaments and biological substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.992D	Poisoning by other drugs, medicaments and biological substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.992S	Poisoning by other drugs, medicaments and biological substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.A12	Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm	Diagnosis	ICD-10-CM
T50.A12A	Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.A12D	Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.A12S	Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.A22	Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm	Diagnosis	ICD-10-CM
T50.A22A	Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.A22D	Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.A22S	Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.A92	Poisoning by other bacterial vaccines, intentional self-harm	Diagnosis	ICD-10-CM
T50.A92A	Poisoning by other bacterial vaccines, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.A92D	Poisoning by other bacterial vaccines, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.A92S	Poisoning by other bacterial vaccines, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.B12	Poisoning by smallpox vaccines, intentional self-harm	Diagnosis	ICD-10-CM
T50.B12A	Poisoning by smallpox vaccines, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T50.B12D	Poisoning by smallpox vaccines, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.B12S	Poisoning by smallpox vaccines, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.B92	Poisoning by other viral vaccines, intentional self-harm	Diagnosis	ICD-10-CM
T50.B92A	Poisoning by other viral vaccines, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.B92D	Poisoning by other viral vaccines, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.B92S	Poisoning by other viral vaccines, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.Z12	Poisoning by immunoglobulin, intentional self-harm	Diagnosis	ICD-10-CM
T50.Z12A	Poisoning by immunoglobulin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.Z12D	Poisoning by immunoglobulin, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.Z12S	Poisoning by immunoglobulin, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.Z92	Poisoning by other vaccines and biological substances, intentional self-harm	Diagnosis	ICD-10-CM
T50.Z92A	Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.Z92D	Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.Z92S	Poisoning by other vaccines and biological substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.0X2	Toxic effect of ethanol, intentional self-harm	Diagnosis	ICD-10-CM
T51.0X2A	Toxic effect of ethanol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.0X2D	Toxic effect of ethanol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.0X2S	Toxic effect of ethanol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.1X2	Toxic effect of methanol, intentional self-harm	Diagnosis	ICD-10-CM
T51.1X2A	Toxic effect of methanol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.1X2D	Toxic effect of methanol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.1X2S	Toxic effect of methanol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.2X2	Toxic effect of 2-Propanol, intentional self-harm	Diagnosis	ICD-10-CM
T51.2X2A	Toxic effect of 2-Propanol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.2X2D	Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.2X2S	Toxic effect of 2-Propanol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.3X2	Toxic effect of fusel oil, intentional self-harm	Diagnosis	ICD-10-CM
T51.3X2A	Toxic effect of fusel oil, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.3X2D	Toxic effect of fusel oil, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.3X2S	Toxic effect of fusel oil, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.8X2	Toxic effect of other alcohols, intentional self-harm	Diagnosis	ICD-10-CM
T51.8X2A	Toxic effect of other alcohols, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.8X2D	Toxic effect of other alcohols, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.8X2S	Toxic effect of other alcohols, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T51.92	Toxic effect of unspecified alcohol, intentional self-harm	Diagnosis	ICD-10-CM
T51.92XA	Toxic effect of unspecified alcohol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.92XD	Toxic effect of unspecified alcohol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.92XS	Toxic effect of unspecified alcohol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T52.0X2	Toxic effect of petroleum products, intentional self-harm	Diagnosis	ICD-10-CM
T52.0X2A	Toxic effect of petroleum products, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T52.0X2D	Toxic effect of petroleum products, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T52.0X2S	Toxic effect of petroleum products, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T52.1X2	Toxic effect of benzene, intentional self-harm	Diagnosis	ICD-10-CM
T52.1X2A	Toxic effect of benzene, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T52.1X2D	Toxic effect of benzene, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T52.1X2S	Toxic effect of benzene, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T52.2X2	Toxic effect of homologues of benzene, intentional self-harm	Diagnosis	ICD-10-CM
T52.2X2A	Toxic effect of homologues of benzene, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T52.2X2D	Toxic effect of homologues of benzene, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T52.2X2S	Toxic effect of homologues of benzene, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T52.3X2	Toxic effect of glycols, intentional self-harm	Diagnosis	ICD-10-CM
T52.3X2A	Toxic effect of glycols, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T52.3X2D	Toxic effect of glycols, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T52.3X2S	Toxic effect of glycols, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T52.4X2	Toxic effect of ketones, intentional self-harm	Diagnosis	ICD-10-CM
T52.4X2A	Toxic effect of ketones, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T52.4X2D	Toxic effect of ketones, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T52.4X2S	Toxic effect of ketones, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T52.8X2	Toxic effect of other organic solvents, intentional self-harm	Diagnosis	ICD-10-CM
T52.8X2A	Toxic effect of other organic solvents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T52.8X2D	Toxic effect of other organic solvents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T52.8X2S	Toxic effect of other organic solvents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T52.92	Toxic effect of unspecified organic solvent, intentional self-harm	Diagnosis	ICD-10-CM
T52.92XA	Toxic effect of unspecified organic solvent, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T52.92XD	Toxic effect of unspecified organic solvent, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T52.92XS	Toxic effect of unspecified organic solvent, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.0X2	Toxic effect of carbon tetrachloride, intentional self-harm	Diagnosis	ICD-10-CM
T53.0X2A	Toxic effect of carbon tetrachloride, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T53.0X2D	Toxic effect of carbon tetrachloride, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.0X2S	Toxic effect of carbon tetrachloride, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.1X2	Toxic effect of chloroform, intentional self-harm	Diagnosis	ICD-10-CM
T53.1X2A	Toxic effect of chloroform, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.1X2D	Toxic effect of chloroform, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.1X2S	Toxic effect of chloroform, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.2X2	Toxic effect of trichloroethylene, intentional self-harm	Diagnosis	ICD-10-CM
T53.2X2A	Toxic effect of trichloroethylene, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.2X2D	Toxic effect of trichloroethylene, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.2X2S	Toxic effect of trichloroethylene, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.3X2	Toxic effect of tetrachloroethylene, intentional self-harm	Diagnosis	ICD-10-CM
T53.3X2A	Toxic effect of tetrachloroethylene, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.3X2D	Toxic effect of tetrachloroethylene, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.3X2S	Toxic effect of tetrachloroethylene, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.4X2	Toxic effect of dichloromethane, intentional self-harm	Diagnosis	ICD-10-CM
T53.4X2A	Toxic effect of dichloromethane, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.4X2D	Toxic effect of dichloromethane, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.4X2S	Toxic effect of dichloromethane, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.5X2	Toxic effect of chlorofluorocarbons, intentional self-harm	Diagnosis	ICD-10-CM
T53.5X2A	Toxic effect of chlorofluorocarbons, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.5X2D	Toxic effect of chlorofluorocarbons, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.5X2S	Toxic effect of chlorofluorocarbons, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.6X2	Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm	Diagnosis	ICD-10-CM
T53.6X2A	Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.6X2D	Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.6X2S	Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.7X2	Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm	Diagnosis	ICD-10-CM
T53.7X2A	Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.7X2D	Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.7X2S	Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.92	Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T53.92XA	Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.92XD	Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.92XS	Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T54.0X2	Toxic effect of phenol and phenol homologues, intentional self-harm	Diagnosis	ICD-10-CM
T54.0X2A	Toxic effect of phenol and phenol homologues, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T54.0X2D	Toxic effect of phenol and phenol homologues, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T54.0X2S	Toxic effect of phenol and phenol homologues, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T54.1X2	Toxic effect of other corrosive organic compounds, intentional self-harm	Diagnosis	ICD-10-CM
T54.1X2A	Toxic effect of other corrosive organic compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T54.1X2D	Toxic effect of other corrosive organic compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T54.1X2S	Toxic effect of other corrosive organic compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T54.2X2	Toxic effect of corrosive acids and acid-like substances, intentional self-harm	Diagnosis	ICD-10-CM
T54.2X2A	Toxic effect of corrosive acids and acid-like substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T54.2X2D	Toxic effect of corrosive acids and acid-like substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T54.2X2S	Toxic effect of corrosive acids and acid-like substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T54.3X2	Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm	Diagnosis	ICD-10-CM
T54.3X2A	Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T54.3X2D	Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T54.3X2S	Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T54.92	Toxic effect of unspecified corrosive substance, intentional self-harm	Diagnosis	ICD-10-CM
T54.92XA	Toxic effect of unspecified corrosive substance, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T54.92XD	Toxic effect of unspecified corrosive substance, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T54.92XS	Toxic effect of unspecified corrosive substance, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T55.0X2	Toxic effect of soaps, intentional self-harm	Diagnosis	ICD-10-CM
T55.0X2A	Toxic effect of soaps, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T55.0X2D	Toxic effect of soaps, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T55.0X2S	Toxic effect of soaps, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T55.1X2	Toxic effect of detergents, intentional self-harm	Diagnosis	ICD-10-CM
T55.1X2A	Toxic effect of detergents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T55.1X2D	Toxic effect of detergents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T55.1X2S	Toxic effect of detergents, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T56.0X2	Toxic effect of lead and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T56.0X2A	Toxic effect of lead and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.0X2D	Toxic effect of lead and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.0X2S	Toxic effect of lead and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.1X2	Toxic effect of mercury and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T56.1X2A	Toxic effect of mercury and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.1X2D	Toxic effect of mercury and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.1X2S	Toxic effect of mercury and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.2X2	Toxic effect of chromium and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T56.2X2A	Toxic effect of chromium and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.2X2D	Toxic effect of chromium and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.2X2S	Toxic effect of chromium and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.3X2	Toxic effect of cadmium and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T56.3X2A	Toxic effect of cadmium and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.3X2D	Toxic effect of cadmium and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.3X2S	Toxic effect of cadmium and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.4X2	Toxic effect of copper and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T56.4X2A	Toxic effect of copper and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.4X2D	Toxic effect of copper and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.4X2S	Toxic effect of copper and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.5X2	Toxic effect of zinc and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T56.5X2A	Toxic effect of zinc and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.5X2D	Toxic effect of zinc and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.5X2S	Toxic effect of zinc and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.6X2	Toxic effect of tin and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T56.6X2A	Toxic effect of tin and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.6X2D	Toxic effect of tin and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.6X2S	Toxic effect of tin and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.7X2	Toxic effect of beryllium and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T56.7X2A	Toxic effect of beryllium and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.7X2D	Toxic effect of beryllium and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.7X2S	Toxic effect of beryllium and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.812	Toxic effect of thallium, intentional self-harm	Diagnosis	ICD-10-CM
T56.812A	Toxic effect of thallium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T56.812D	Toxic effect of thallium, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.812S	Toxic effect of thallium, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.892	Toxic effect of other metals, intentional self-harm	Diagnosis	ICD-10-CM
T56.892A	Toxic effect of other metals, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.892D	Toxic effect of other metals, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.892S	Toxic effect of other metals, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.92	Toxic effect of unspecified metal, intentional self-harm	Diagnosis	ICD-10-CM
T56.92XA	Toxic effect of unspecified metal, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.92XD	Toxic effect of unspecified metal, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.92XS	Toxic effect of unspecified metal, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T57.0X2	Toxic effect of arsenic and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T57.0X2A	Toxic effect of arsenic and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T57.0X2D	Toxic effect of arsenic and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T57.0X2S	Toxic effect of arsenic and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T57.1X2	Toxic effect of phosphorus and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T57.1X2A	Toxic effect of phosphorus and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T57.1X2D	Toxic effect of phosphorus and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T57.1X2S	Toxic effect of phosphorus and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T57.2X2	Toxic effect of manganese and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T57.2X2A	Toxic effect of manganese and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T57.2X2D	Toxic effect of manganese and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T57.2X2S	Toxic effect of manganese and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T57.3X2	Toxic effect of hydrogen cyanide, intentional self-harm	Diagnosis	ICD-10-CM
T57.3X2A	Toxic effect of hydrogen cyanide, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T57.3X2D	Toxic effect of hydrogen cyanide, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T57.3X2S	Toxic effect of hydrogen cyanide, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T57.8X2	Toxic effect of other specified inorganic substances, intentional self-harm	Diagnosis	ICD-10-CM
T57.8X2A	Toxic effect of other specified inorganic substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T57.8X2D	Toxic effect of other specified inorganic substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T57.8X2S	Toxic effect of other specified inorganic substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T57.92	Toxic effect of unspecified inorganic substance, intentional self-harm	Diagnosis	ICD-10-CM
T57.92XA	Toxic effect of unspecified inorganic substance, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T57.92XD	Toxic effect of unspecified inorganic substance, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T57.92XS	Toxic effect of unspecified inorganic substance, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T58.02	Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm	Diagnosis	ICD-10-CM
T58.02XA	Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T58.02XD	Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T58.02XS	Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T58.12	Toxic effect of carbon monoxide from utility gas, intentional self-harm	Diagnosis	ICD-10-CM
T58.12XA	Toxic effect of carbon monoxide from utility gas, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T58.12XD	Toxic effect of carbon monoxide from utility gas, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T58.12XS	Toxic effect of carbon monoxide from utility gas, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T58.2X2	Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm	Diagnosis	ICD-10-CM
T58.2X2A	Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T58.2X2D	Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T58.2X2S	Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T58.8X2	Toxic effect of carbon monoxide from other source, intentional self-harm	Diagnosis	ICD-10-CM
T58.8X2A	Toxic effect of carbon monoxide from other source, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T58.8X2D	Toxic effect of carbon monoxide from other source, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T58.8X2S	Toxic effect of carbon monoxide from other source, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T58.92	Toxic effect of carbon monoxide from unspecified source, intentional self-harm	Diagnosis	ICD-10-CM
T58.92XA	Toxic effect of carbon monoxide from unspecified source, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T58.92XD	Toxic effect of carbon monoxide from unspecified source, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T58.92XS	Toxic effect of carbon monoxide from unspecified source, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.0X2	Toxic effect of nitrogen oxides, intentional self-harm	Diagnosis	ICD-10-CM
T59.0X2A	Toxic effect of nitrogen oxides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.0X2D	Toxic effect of nitrogen oxides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.0X2S	Toxic effect of nitrogen oxides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.1X2	Toxic effect of sulfur dioxide, intentional self-harm	Diagnosis	ICD-10-CM
T59.1X2A	Toxic effect of sulfur dioxide, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.1X2D	Toxic effect of sulfur dioxide, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.1X2S	Toxic effect of sulfur dioxide, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.2X2	Toxic effect of formaldehyde, intentional self-harm	Diagnosis	ICD-10-CM
T59.2X2A	Toxic effect of formaldehyde, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.2X2D	Toxic effect of formaldehyde, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T59.2X2S	Toxic effect of formaldehyde, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.3X2	Toxic effect of lacrimogenic gas, intentional self-harm	Diagnosis	ICD-10-CM
T59.3X2A	Toxic effect of lacrimogenic gas, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.3X2D	Toxic effect of lacrimogenic gas, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.3X2S	Toxic effect of lacrimogenic gas, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.4X2	Toxic effect of chlorine gas, intentional self-harm	Diagnosis	ICD-10-CM
T59.4X2A	Toxic effect of chlorine gas, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.4X2D	Toxic effect of chlorine gas, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.4X2S	Toxic effect of chlorine gas, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.5X2	Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm	Diagnosis	ICD-10-CM
T59.5X2A	Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.5X2D	Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.5X2S	Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.6X2	Toxic effect of hydrogen sulfide, intentional self-harm	Diagnosis	ICD-10-CM
T59.6X2A	Toxic effect of hydrogen sulfide, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.6X2D	Toxic effect of hydrogen sulfide, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.6X2S	Toxic effect of hydrogen sulfide, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.7X2	Toxic effect of carbon dioxide, intentional self-harm	Diagnosis	ICD-10-CM
T59.7X2A	Toxic effect of carbon dioxide, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.7X2D	Toxic effect of carbon dioxide, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.7X2S	Toxic effect of carbon dioxide, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.812	Toxic effect of smoke, intentional self-harm	Diagnosis	ICD-10-CM
T59.812A	Toxic effect of smoke, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.812D	Toxic effect of smoke, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.812S	Toxic effect of smoke, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.892	Toxic effect of other specified gases, fumes and vapors, intentional self-harm	Diagnosis	ICD-10-CM
T59.892A	Toxic effect of other specified gases, fumes and vapors, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.892D	Toxic effect of other specified gases, fumes and vapors, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.892S	Toxic effect of other specified gases, fumes and vapors, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.92	Toxic effect of unspecified gases, fumes and vapors, intentional self-harm	Diagnosis	ICD-10-CM
T59.92XA	Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.92XD	Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.92XS	Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T60.0X2	Toxic effect of organophosphate and carbamate insecticides, intentional self-harm	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T60.0X2A	Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T60.0X2D	Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T60.0X2S	Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T60.1X2	Toxic effect of halogenated insecticides, intentional self-harm	Diagnosis	ICD-10-CM
T60.1X2A	Toxic effect of halogenated insecticides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T60.1X2D	Toxic effect of halogenated insecticides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T60.1X2S	Toxic effect of halogenated insecticides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T60.2X2	Toxic effect of other insecticides, intentional self-harm	Diagnosis	ICD-10-CM
T60.2X2A	Toxic effect of other insecticides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T60.2X2D	Toxic effect of other insecticides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T60.2X2S	Toxic effect of other insecticides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T60.3X2	Toxic effect of herbicides and fungicides, intentional self-harm	Diagnosis	ICD-10-CM
T60.3X2A	Toxic effect of herbicides and fungicides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T60.3X2D	Toxic effect of herbicides and fungicides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T60.3X2S	Toxic effect of herbicides and fungicides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T60.4X2	Toxic effect of rodenticides, intentional self-harm	Diagnosis	ICD-10-CM
T60.4X2A	Toxic effect of rodenticides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T60.4X2D	Toxic effect of rodenticides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T60.4X2S	Toxic effect of rodenticides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T60.8X2	Toxic effect of other pesticides, intentional self-harm	Diagnosis	ICD-10-CM
T60.8X2A	Toxic effect of other pesticides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T60.8X2D	Toxic effect of other pesticides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T60.8X2S	Toxic effect of other pesticides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T60.92	Toxic effect of unspecified pesticide, intentional self-harm	Diagnosis	ICD-10-CM
T60.92XA	Toxic effect of unspecified pesticide, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T60.92XD	Toxic effect of unspecified pesticide, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T60.92XS	Toxic effect of unspecified pesticide, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T61.02	Ciguatera fish poisoning, intentional self-harm	Diagnosis	ICD-10-CM
T61.02XA	Ciguatera fish poisoning, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T61.02XD	Ciguatera fish poisoning, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T61.02XS	Ciguatera fish poisoning, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T61.12	Scombroid fish poisoning, intentional self-harm	Diagnosis	ICD-10-CM
T61.12XA	Scombroid fish poisoning, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T61.12XD	Scombroid fish poisoning, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T61.12XS	Scombroid fish poisoning, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T61.772	Other fish poisoning, intentional self-harm	Diagnosis	ICD-10-CM
T61.772A	Other fish poisoning, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T61.772D	Other fish poisoning, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T61.772S	Other fish poisoning, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T61.782	Other shellfish poisoning, intentional self-harm	Diagnosis	ICD-10-CM
T61.782A	Other shellfish poisoning, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T61.782D	Other shellfish poisoning, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T61.782S	Other shellfish poisoning, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T61.8X2	Toxic effect of other seafood, intentional self-harm	Diagnosis	ICD-10-CM
T61.8X2A	Toxic effect of other seafood, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T61.8X2D	Toxic effect of other seafood, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T61.8X2S	Toxic effect of other seafood, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T61.92	Toxic effect of unspecified seafood, intentional self-harm	Diagnosis	ICD-10-CM
T61.92XA	Toxic effect of unspecified seafood, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T61.92XD	Toxic effect of unspecified seafood, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T61.92XS	Toxic effect of unspecified seafood, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T62.0X2	Toxic effect of ingested mushrooms, intentional self-harm	Diagnosis	ICD-10-CM
T62.0X2A	Toxic effect of ingested mushrooms, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T62.0X2D	Toxic effect of ingested mushrooms, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T62.0X2S	Toxic effect of ingested mushrooms, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T62.1X2	Toxic effect of ingested berries, intentional self-harm	Diagnosis	ICD-10-CM
T62.1X2A	Toxic effect of ingested berries, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T62.1X2D	Toxic effect of ingested berries, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T62.1X2S	Toxic effect of ingested berries, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T62.2X2	Toxic effect of other ingested (parts of) plant(s), intentional self-harm	Diagnosis	ICD-10-CM
T62.2X2A	Toxic effect of other ingested (parts of) plant(s), intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T62.2X2D	Toxic effect of other ingested (parts of) plant(s), intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T62.2X2S	Toxic effect of other ingested (parts of) plant(s), intentional self-harm, sequela	Diagnosis	ICD-10-CM
T62.8X2	Toxic effect of other specified noxious substances eaten as food, intentional self-harm	Diagnosis	ICD-10-CM
T62.8X2A	Toxic effect of other specified noxious substances eaten as food, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T62.8X2D	Toxic effect of other specified noxious substances eaten as food, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T62.8X2S	Toxic effect of other specified noxious substances eaten as food, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T62.92	Toxic effect of unspecified noxious substance eaten as food, intentional self-harm	Diagnosis	ICD-10-CM
T62.92XA	Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T62.92XD	Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T62.92XS	Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.002	Toxic effect of unspecified snake venom, intentional self-harm	Diagnosis	ICD-10-CM
T63.002A	Toxic effect of unspecified snake venom, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.002D	Toxic effect of unspecified snake venom, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.002S	Toxic effect of unspecified snake venom, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.012	Toxic effect of rattlesnake venom, intentional self-harm	Diagnosis	ICD-10-CM
T63.012A	Toxic effect of rattlesnake venom, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.012D	Toxic effect of rattlesnake venom, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.012S	Toxic effect of rattlesnake venom, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.022	Toxic effect of coral snake venom, intentional self-harm	Diagnosis	ICD-10-CM
T63.022A	Toxic effect of coral snake venom, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.022D	Toxic effect of coral snake venom, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.022S	Toxic effect of coral snake venom, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.032	Toxic effect of taipan venom, intentional self-harm	Diagnosis	ICD-10-CM
T63.032A	Toxic effect of taipan venom, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.032D	Toxic effect of taipan venom, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.032S	Toxic effect of taipan venom, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.042	Toxic effect of cobra venom, intentional self-harm	Diagnosis	ICD-10-CM
T63.042A	Toxic effect of cobra venom, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.042D	Toxic effect of cobra venom, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.042S	Toxic effect of cobra venom, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.062	Toxic effect of venom of other North and South American snake, intentional self-harm	Diagnosis	ICD-10-CM
T63.062A	Toxic effect of venom of other North and South American snake, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.062D	Toxic effect of venom of other North and South American snake, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.062S	Toxic effect of venom of other North and South American snake, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.072	Toxic effect of venom of other Australian snake, intentional self-harm	Diagnosis	ICD-10-CM
T63.072A	Toxic effect of venom of other Australian snake, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.072D	Toxic effect of venom of other Australian snake, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.072S	Toxic effect of venom of other Australian snake, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.082	Toxic effect of venom of other African and Asian snake, intentional self-harm	Diagnosis	ICD-10-CM
T63.082A	Toxic effect of venom of other African and Asian snake, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T63.082D	Toxic effect of venom of other African and Asian snake, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.082S	Toxic effect of venom of other African and Asian snake, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.092	Toxic effect of venom of other snake, intentional self-harm	Diagnosis	ICD-10-CM
T63.092A	Toxic effect of venom of other snake, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.092D	Toxic effect of venom of other snake, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.092S	Toxic effect of venom of other snake, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.112	Toxic effect of venom of gila monster, intentional self-harm	Diagnosis	ICD-10-CM
T63.112A	Toxic effect of venom of gila monster, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.112D	Toxic effect of venom of gila monster, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.112S	Toxic effect of venom of gila monster, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.122	Toxic effect of venom of other venomous lizard, intentional self-harm	Diagnosis	ICD-10-CM
T63.122A	Toxic effect of venom of other venomous lizard, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.122D	Toxic effect of venom of other venomous lizard, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.122S	Toxic effect of venom of other venomous lizard, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.192	Toxic effect of venom of other reptiles, intentional self-harm	Diagnosis	ICD-10-CM
T63.192A	Toxic effect of venom of other reptiles, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.192D	Toxic effect of venom of other reptiles, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.192S	Toxic effect of venom of other reptiles, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.2X2	Toxic effect of venom of scorpion, intentional self-harm	Diagnosis	ICD-10-CM
T63.2X2A	Toxic effect of venom of scorpion, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.2X2D	Toxic effect of venom of scorpion, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.2X2S	Toxic effect of venom of scorpion, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.302	Toxic effect of unspecified spider venom, intentional self-harm	Diagnosis	ICD-10-CM
T63.302A	Toxic effect of unspecified spider venom, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.302D	Toxic effect of unspecified spider venom, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.302S	Toxic effect of unspecified spider venom, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.312	Toxic effect of venom of black widow spider, intentional self-harm	Diagnosis	ICD-10-CM
T63.312A	Toxic effect of venom of black widow spider, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.312D	Toxic effect of venom of black widow spider, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.312S	Toxic effect of venom of black widow spider, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.322	Toxic effect of venom of tarantula, intentional self-harm	Diagnosis	ICD-10-CM
T63.322A	Toxic effect of venom of tarantula, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.322D	Toxic effect of venom of tarantula, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.322S	Toxic effect of venom of tarantula, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T63.332	Toxic effect of venom of brown recluse spider, intentional self-harm	Diagnosis	ICD-10-CM
T63.332A	Toxic effect of venom of brown recluse spider, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.332D	Toxic effect of venom of brown recluse spider, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.332S	Toxic effect of venom of brown recluse spider, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.392	Toxic effect of venom of other spider, intentional self-harm	Diagnosis	ICD-10-CM
T63.392A	Toxic effect of venom of other spider, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.392D	Toxic effect of venom of other spider, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.392S	Toxic effect of venom of other spider, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.412	Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm	Diagnosis	ICD-10-CM
T63.412A	Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.412D	Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.412S	Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.422	Toxic effect of venom of ants, intentional self-harm	Diagnosis	ICD-10-CM
T63.422A	Toxic effect of venom of ants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.422D	Toxic effect of venom of ants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.422S	Toxic effect of venom of ants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.432	Toxic effect of venom of caterpillars, intentional self-harm	Diagnosis	ICD-10-CM
T63.432A	Toxic effect of venom of caterpillars, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.432D	Toxic effect of venom of caterpillars, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.432S	Toxic effect of venom of caterpillars, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.442	Toxic effect of venom of bees, intentional self-harm	Diagnosis	ICD-10-CM
T63.442A	Toxic effect of venom of bees, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.442D	Toxic effect of venom of bees, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.442S	Toxic effect of venom of bees, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.452	Toxic effect of venom of hornets, intentional self-harm	Diagnosis	ICD-10-CM
T63.452A	Toxic effect of venom of hornets, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.452D	Toxic effect of venom of hornets, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.452S	Toxic effect of venom of hornets, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.462	Toxic effect of venom of wasps, intentional self-harm	Diagnosis	ICD-10-CM
T63.462A	Toxic effect of venom of wasps, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.462D	Toxic effect of venom of wasps, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.462S	Toxic effect of venom of wasps, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.482	Toxic effect of venom of other arthropod, intentional self-harm	Diagnosis	ICD-10-CM
T63.482A	Toxic effect of venom of other arthropod, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T63.482D	Toxic effect of venom of other arthropod, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.482S	Toxic effect of venom of other arthropod, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.512	Toxic effect of contact with stingray, intentional self-harm	Diagnosis	ICD-10-CM
T63.512A	Toxic effect of contact with stingray, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.512D	Toxic effect of contact with stingray, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.512S	Toxic effect of contact with stingray, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.592	Toxic effect of contact with other venomous fish, intentional self-harm	Diagnosis	ICD-10-CM
T63.592A	Toxic effect of contact with other venomous fish, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.592D	Toxic effect of contact with other venomous fish, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.592S	Toxic effect of contact with other venomous fish, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.612	Toxic effect of contact with Portuguese Man-o-war, intentional self-harm	Diagnosis	ICD-10-CM
T63.612A	Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.612D	Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.612S	Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.622	Toxic effect of contact with other jellyfish, intentional self-harm	Diagnosis	ICD-10-CM
T63.622A	Toxic effect of contact with other jellyfish, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.622D	Toxic effect of contact with other jellyfish, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.622S	Toxic effect of contact with other jellyfish, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.632	Toxic effect of contact with sea anemone, intentional self-harm	Diagnosis	ICD-10-CM
T63.632A	Toxic effect of contact with sea anemone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.632D	Toxic effect of contact with sea anemone, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.632S	Toxic effect of contact with sea anemone, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.692	Toxic effect of contact with other venomous marine animals, intentional self-harm	Diagnosis	ICD-10-CM
T63.692A	Toxic effect of contact with other venomous marine animals, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.692D	Toxic effect of contact with other venomous marine animals, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.692S	Toxic effect of contact with other venomous marine animals, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.712	Toxic effect of contact with venomous marine plant, intentional self-harm	Diagnosis	ICD-10-CM
T63.712A	Toxic effect of contact with venomous marine plant, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.712D	Toxic effect of contact with venomous marine plant, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.712S	Toxic effect of contact with venomous marine plant, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.792	Toxic effect of contact with other venomous plant, intentional self-harm	Diagnosis	ICD-10-CM
T63.792A	Toxic effect of contact with other venomous plant, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.792D	Toxic effect of contact with other venomous plant, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.792S	Toxic effect of contact with other venomous plant, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T63.812	Toxic effect of contact with venomous frog, intentional self-harm	Diagnosis	ICD-10-CM
T63.812A	Toxic effect of contact with venomous frog, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.812D	Toxic effect of contact with venomous frog, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.812S	Toxic effect of contact with venomous frog, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.822	Toxic effect of contact with venomous toad, intentional self-harm	Diagnosis	ICD-10-CM
T63.822A	Toxic effect of contact with venomous toad, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.822D	Toxic effect of contact with venomous toad, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.822S	Toxic effect of contact with venomous toad, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.832	Toxic effect of contact with other venomous amphibian, intentional self-harm	Diagnosis	ICD-10-CM
T63.832A	Toxic effect of contact with other venomous amphibian, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.832D	Toxic effect of contact with other venomous amphibian, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.832S	Toxic effect of contact with other venomous amphibian, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.892	Toxic effect of contact with other venomous animals, intentional self-harm	Diagnosis	ICD-10-CM
T63.892A	Toxic effect of contact with other venomous animals, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.892D	Toxic effect of contact with other venomous animals, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.892S	Toxic effect of contact with other venomous animals, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.92	Toxic effect of contact with unspecified venomous animal, intentional self-harm	Diagnosis	ICD-10-CM
T63.92XA	Toxic effect of contact with unspecified venomous animal, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.92XD	Toxic effect of contact with unspecified venomous animal, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.92XS	Toxic effect of contact with unspecified venomous animal, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T64.02	Toxic effect of aflatoxin, intentional self-harm	Diagnosis	ICD-10-CM
T64.02XA	Toxic effect of aflatoxin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T64.02XD	Toxic effect of aflatoxin, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T64.02XS	Toxic effect of aflatoxin, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T64.82	Toxic effect of other mycotoxin food contaminants, intentional self-harm	Diagnosis	ICD-10-CM
T64.82XA	Toxic effect of other mycotoxin food contaminants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T64.82XD	Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T64.82XS	Toxic effect of other mycotoxin food contaminants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.0X2	Toxic effect of cyanides, intentional self-harm	Diagnosis	ICD-10-CM
T65.0X2A	Toxic effect of cyanides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.0X2D	Toxic effect of cyanides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.0X2S	Toxic effect of cyanides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.1X2	Toxic effect of strychnine and its salts, intentional self-harm	Diagnosis	ICD-10-CM
T65.1X2A	Toxic effect of strychnine and its salts, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T65.1X2D	Toxic effect of strychnine and its salts, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.1X2S	Toxic effect of strychnine and its salts, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.212	Toxic effect of chewing tobacco, intentional self-harm	Diagnosis	ICD-10-CM
T65.212A	Toxic effect of chewing tobacco, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.212D	Toxic effect of chewing tobacco, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.212S	Toxic effect of chewing tobacco, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.222	Toxic effect of tobacco cigarettes, intentional self-harm	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.222D	Toxic effect of tobacco cigarettes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.222S	Toxic effect of tobacco cigarettes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.292	Toxic effect of other tobacco and nicotine, intentional self-harm	Diagnosis	ICD-10-CM
T65.292A	Toxic effect of other tobacco and nicotine, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.292D	Toxic effect of other tobacco and nicotine, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.292S	Toxic effect of other tobacco and nicotine, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.3X2	Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm	Diagnosis	ICD-10-CM
T65.3X2A	Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.3X2D	Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.3X2S	Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.4X2	Toxic effect of carbon disulfide, intentional self-harm	Diagnosis	ICD-10-CM
T65.4X2A	Toxic effect of carbon disulfide, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.4X2D	Toxic effect of carbon disulfide, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.4X2S	Toxic effect of carbon disulfide, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.5X2	Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm	Diagnosis	ICD-10-CM
T65.5X2A	Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.5X2D	Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.5X2S	Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.6X2	Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm	Diagnosis	ICD-10-CM
T65.6X2A	Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.6X2D	Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.6X2S	Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.812	Toxic effect of latex, intentional self-harm	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T65.812A	Toxic effect of latex, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.812D	Toxic effect of latex, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.812S	Toxic effect of latex, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.822	Toxic effect of harmful algae and algae toxins, intentional self-harm	Diagnosis	ICD-10-CM
T65.822A	Toxic effect of harmful algae and algae toxins, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.822D	Toxic effect of harmful algae and algae toxins, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.822S	Toxic effect of harmful algae and algae toxins, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.832	Toxic effect of fiberglass, intentional self-harm	Diagnosis	ICD-10-CM
T65.832A	Toxic effect of fiberglass, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.832D	Toxic effect of fiberglass, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.832S	Toxic effect of fiberglass, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.892	Toxic effect of other specified substances, intentional self-harm	Diagnosis	ICD-10-CM
T65.892A	Toxic effect of other specified substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.892D	Toxic effect of other specified substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.892S	Toxic effect of other specified substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.92	Toxic effect of unspecified substance, intentional self-harm	Diagnosis	ICD-10-CM
T65.92XA	Toxic effect of unspecified substance, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.92XD	Toxic effect of unspecified substance, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.92XS	Toxic effect of unspecified substance, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.112	Asphyxiation due to smothering under pillow, intentional self-harm	Diagnosis	ICD-10-CM
T71.112A	Asphyxiation due to smothering under pillow, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.112D	Asphyxiation due to smothering under pillow, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T71.112S	Asphyxiation due to smothering under pillow, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.122	Asphyxiation due to plastic bag, intentional self-harm	Diagnosis	ICD-10-CM
T71.122A	Asphyxiation due to plastic bag, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.122D	Asphyxiation due to plastic bag, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T71.122S	Asphyxiation due to plastic bag, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.132	Asphyxiation due to being trapped in bed linens, intentional self-harm	Diagnosis	ICD-10-CM
T71.132A	Asphyxiation due to being trapped in bed linens, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.132D	Asphyxiation due to being trapped in bed linens, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T71.132S	Asphyxiation due to being trapped in bed linens, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.152	Asphyxiation due to smothering in furniture, intentional self-harm	Diagnosis	ICD-10-CM
T71.152A	Asphyxiation due to smothering in furniture, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.152D	Asphyxiation due to smothering in furniture, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
T71.152S	Asphyxiation due to smothering in furniture, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.162	Asphyxiation due to hanging, intentional self-harm	Diagnosis	ICD-10-CM
T71.162A	Asphyxiation due to hanging, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.162D	Asphyxiation due to hanging, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T71.162S	Asphyxiation due to hanging, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.192	Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm	Diagnosis	ICD-10-CM
T71.192A	Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.192D	Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T71.192S	Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.222	Asphyxiation due to being trapped in a car trunk, intentional self-harm	Diagnosis	ICD-10-CM
T71.222A	Asphyxiation due to being trapped in a car trunk, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.222D	Asphyxiation due to being trapped in a car trunk, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T71.222S	Asphyxiation due to being trapped in a car trunk, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.232	Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm	Diagnosis	ICD-10-CM
T71.232A	Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.232D	Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T71.232S	Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, sequela	Diagnosis	ICD-10-CM
X71	Intentional self-harm by drowning and submersion	Diagnosis	ICD-10-CM
X71.0	Intentional self-harm by drowning and submersion while in bathtub	Diagnosis	ICD-10-CM
X71.0XXA	Intentional self-harm by drowning and submersion while in bathtub, initial encounter	Diagnosis	ICD-10-CM
X71.0XXD	Intentional self-harm by drowning and submersion while in bathtub, subsequent encounter	Diagnosis	ICD-10-CM
X71.0XXS	Intentional self-harm by drowning and submersion while in bathtub, sequela	Diagnosis	ICD-10-CM
X71.1	Intentional self-harm by drowning and submersion while in swimming pool	Diagnosis	ICD-10-CM
X71.1XXA	Intentional self-harm by drowning and submersion while in swimming pool, initial encounter	Diagnosis	ICD-10-CM
X71.1XXD	Intentional self-harm by drowning and submersion while in swimming pool, subsequent encounter	Diagnosis	ICD-10-CM
X71.1XXS	Intentional self-harm by drowning and submersion while in swimming pool, sequela	Diagnosis	ICD-10-CM
X71.2	Intentional self-harm by drowning and submersion after jump into swimming pool	Diagnosis	ICD-10-CM
X71.2XXA	Intentional self-harm by drowning and submersion after jump into swimming pool, initial encounter	Diagnosis	ICD-10-CM
X71.2XXD	Intentional self-harm by drowning and submersion after jump into swimming pool, subsequent encounter	Diagnosis	ICD-10-CM
X71.2XXS	Intentional self-harm by drowning and submersion after jump into swimming pool, sequela	Diagnosis	ICD-10-CM
X71.3	Intentional self-harm by drowning and submersion in natural water	Diagnosis	ICD-10-CM
X71.3XXA	Intentional self-harm by drowning and submersion in natural water, initial encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
X71.3XXD	Intentional self-harm by drowning and submersion in natural water, subsequent encounter	Diagnosis	ICD-10-CM
X71.3XXS	Intentional self-harm by drowning and submersion in natural water, sequela	Diagnosis	ICD-10-CM
X71.8	Other intentional self-harm by drowning and submersion	Diagnosis	ICD-10-CM
X71.8XXA	Other intentional self-harm by drowning and submersion, initial encounter	Diagnosis	ICD-10-CM
X71.8XXD	Other intentional self-harm by drowning and submersion, subsequent encounter	Diagnosis	ICD-10-CM
X71.8XXS	Other intentional self-harm by drowning and submersion, sequela	Diagnosis	ICD-10-CM
X71.9	Intentional self-harm by drowning and submersion, unspecified	Diagnosis	ICD-10-CM
X71.9XXA	Intentional self-harm by drowning and submersion, unspecified, initial encounter	Diagnosis	ICD-10-CM
X71.9XXD	Intentional self-harm by drowning and submersion, unspecified, subsequent encounter	Diagnosis	ICD-10-CM
X71.9XXS	Intentional self-harm by drowning and submersion, unspecified, sequela	Diagnosis	ICD-10-CM
X72	Intentional self-harm by handgun discharge	Diagnosis	ICD-10-CM
X72.XXXA	Intentional self-harm by handgun discharge, initial encounter	Diagnosis	ICD-10-CM
X72.XXXD	Intentional self-harm by handgun discharge, subsequent encounter	Diagnosis	ICD-10-CM
X72.XXXS	Intentional self-harm by handgun discharge, sequela	Diagnosis	ICD-10-CM
X73	Intentional self-harm by rifle, shotgun and larger firearm discharge	Diagnosis	ICD-10-CM
X73.0	Intentional self-harm by shotgun discharge	Diagnosis	ICD-10-CM
X73.0XXA	Intentional self-harm by shotgun discharge, initial encounter	Diagnosis	ICD-10-CM
X73.0XXD	Intentional self-harm by shotgun discharge, subsequent encounter	Diagnosis	ICD-10-CM
X73.0XXS	Intentional self-harm by shotgun discharge, sequela	Diagnosis	ICD-10-CM
X73.1	Intentional self-harm by hunting rifle discharge	Diagnosis	ICD-10-CM
X73.1XXA	Intentional self-harm by hunting rifle discharge, initial encounter	Diagnosis	ICD-10-CM
X73.1XXD	Intentional self-harm by hunting rifle discharge, subsequent encounter	Diagnosis	ICD-10-CM
X73.1XXS	Intentional self-harm by hunting rifle discharge, sequela	Diagnosis	ICD-10-CM
X73.2	Intentional self-harm by machine gun discharge	Diagnosis	ICD-10-CM
X73.2XXA	Intentional self-harm by machine gun discharge, initial encounter	Diagnosis	ICD-10-CM
X73.2XXD	Intentional self-harm by machine gun discharge, subsequent encounter	Diagnosis	ICD-10-CM
X73.2XXS	Intentional self-harm by machine gun discharge, sequela	Diagnosis	ICD-10-CM
X73.8	Intentional self-harm by other larger firearm discharge	Diagnosis	ICD-10-CM
X73.8XXA	Intentional self-harm by other larger firearm discharge, initial encounter	Diagnosis	ICD-10-CM
X73.8XXD	Intentional self-harm by other larger firearm discharge, subsequent encounter	Diagnosis	ICD-10-CM
X73.8XXS	Intentional self-harm by other larger firearm discharge, sequela	Diagnosis	ICD-10-CM
X73.9	Intentional self-harm by unspecified larger firearm discharge	Diagnosis	ICD-10-CM
X73.9XXA	Intentional self-harm by unspecified larger firearm discharge, initial encounter	Diagnosis	ICD-10-CM
X73.9XXD	Intentional self-harm by unspecified larger firearm discharge, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
X73.9XXS	Intentional self-harm by unspecified larger firearm discharge, sequela	Diagnosis	ICD-10-CM
X74	Intentional self-harm by other and unspecified firearm and gun discharge	Diagnosis	ICD-10-CM
X74.0	Intentional self-harm by gas, air or spring-operated guns	Diagnosis	ICD-10-CM
X74.01	Intentional self-harm by airgun	Diagnosis	ICD-10-CM
X74.01XA	Intentional self-harm by airgun, initial encounter	Diagnosis	ICD-10-CM
X74.01XD	Intentional self-harm by airgun, subsequent encounter	Diagnosis	ICD-10-CM
X74.01XS	Intentional self-harm by airgun, sequela	Diagnosis	ICD-10-CM
X74.02	Intentional self-harm by paintball gun	Diagnosis	ICD-10-CM
X74.02XA	Intentional self-harm by paintball gun, initial encounter	Diagnosis	ICD-10-CM
X74.02XD	Intentional self-harm by paintball gun, subsequent encounter	Diagnosis	ICD-10-CM
X74.02XS	Intentional self-harm by paintball gun, sequela	Diagnosis	ICD-10-CM
X74.09	Intentional self-harm by other gas, air or spring-operated gun	Diagnosis	ICD-10-CM
X74.09XA	Intentional self-harm by other gas, air or spring-operated gun, initial encounter	Diagnosis	ICD-10-CM
X74.09XD	Intentional self-harm by other gas, air or spring-operated gun, subsequent encounter	Diagnosis	ICD-10-CM
X74.09XS	Intentional self-harm by other gas, air or spring-operated gun, sequela	Diagnosis	ICD-10-CM
X74.8	Intentional self-harm by other firearm discharge	Diagnosis	ICD-10-CM
X74.8XXA	Intentional self-harm by other firearm discharge, initial encounter	Diagnosis	ICD-10-CM
X74.8XXD	Intentional self-harm by other firearm discharge, subsequent encounter	Diagnosis	ICD-10-CM
X74.8XXS	Intentional self-harm by other firearm discharge, sequela	Diagnosis	ICD-10-CM
X74.9	Intentional self-harm by unspecified firearm discharge	Diagnosis	ICD-10-CM
X74.9XXA	Intentional self-harm by unspecified firearm discharge, initial encounter	Diagnosis	ICD-10-CM
X74.9XXD	Intentional self-harm by unspecified firearm discharge, subsequent encounter	Diagnosis	ICD-10-CM
X74.9XXS	Intentional self-harm by unspecified firearm discharge, sequela	Diagnosis	ICD-10-CM
X75	Intentional self-harm by explosive material	Diagnosis	ICD-10-CM
X75.XXXA	Intentional self-harm by explosive material, initial encounter	Diagnosis	ICD-10-CM
X75.XXXD	Intentional self-harm by explosive material, subsequent encounter	Diagnosis	ICD-10-CM
X75.XXXS	Intentional self-harm by explosive material, sequela	Diagnosis	ICD-10-CM
X76	Intentional self-harm by smoke, fire and flames	Diagnosis	ICD-10-CM
X76.XXXA	Intentional self-harm by smoke, fire and flames, initial encounter	Diagnosis	ICD-10-CM
X76.XXXD	Intentional self-harm by smoke, fire and flames, subsequent encounter	Diagnosis	ICD-10-CM
X76.XXXS	Intentional self-harm by smoke, fire and flames, sequela	Diagnosis	ICD-10-CM
X77	Intentional self-harm by steam, hot vapors and hot objects	Diagnosis	ICD-10-CM
X77.0	Intentional self-harm by steam or hot vapors	Diagnosis	ICD-10-CM
X77.0XXA	Intentional self-harm by steam or hot vapors, initial encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
X77.0XXD	Intentional self-harm by steam or hot vapors, subsequent encounter	Diagnosis	ICD-10-CM
X77.0XXS	Intentional self-harm by steam or hot vapors, sequela	Diagnosis	ICD-10-CM
X77.1	Intentional self-harm by hot tap water	Diagnosis	ICD-10-CM
X77.1XXA	Intentional self-harm by hot tap water, initial encounter	Diagnosis	ICD-10-CM
X77.1XXD	Intentional self-harm by hot tap water, subsequent encounter	Diagnosis	ICD-10-CM
X77.1XXS	Intentional self-harm by hot tap water, sequela	Diagnosis	ICD-10-CM
X77.2	Intentional self-harm by other hot fluids	Diagnosis	ICD-10-CM
X77.2XXA	Intentional self-harm by other hot fluids, initial encounter	Diagnosis	ICD-10-CM
X77.2XXD	Intentional self-harm by other hot fluids, subsequent encounter	Diagnosis	ICD-10-CM
X77.2XXS	Intentional self-harm by other hot fluids, sequela	Diagnosis	ICD-10-CM
X77.3	Intentional self-harm by hot household appliances	Diagnosis	ICD-10-CM
X77.3XXA	Intentional self-harm by hot household appliances, initial encounter	Diagnosis	ICD-10-CM
X77.3XXD	Intentional self-harm by hot household appliances, subsequent encounter	Diagnosis	ICD-10-CM
X77.3XXS	Intentional self-harm by hot household appliances, sequela	Diagnosis	ICD-10-CM
X77.8	Intentional self-harm by other hot objects	Diagnosis	ICD-10-CM
X77.8XXA	Intentional self-harm by other hot objects, initial encounter	Diagnosis	ICD-10-CM
X77.8XXD	Intentional self-harm by other hot objects, subsequent encounter	Diagnosis	ICD-10-CM
X77.8XXS	Intentional self-harm by other hot objects, sequela	Diagnosis	ICD-10-CM
X77.9	Intentional self-harm by unspecified hot objects	Diagnosis	ICD-10-CM
X77.9XXA	Intentional self-harm by unspecified hot objects, initial encounter	Diagnosis	ICD-10-CM
X77.9XXD	Intentional self-harm by unspecified hot objects, subsequent encounter	Diagnosis	ICD-10-CM
X77.9XXS	Intentional self-harm by unspecified hot objects, sequela	Diagnosis	ICD-10-CM
X78	Intentional self-harm by sharp object	Diagnosis	ICD-10-CM
X78.0	Intentional self-harm by sharp glass	Diagnosis	ICD-10-CM
X78.0XXA	Intentional self-harm by sharp glass, initial encounter	Diagnosis	ICD-10-CM
X78.0XXD	Intentional self-harm by sharp glass, subsequent encounter	Diagnosis	ICD-10-CM
X78.0XXS	Intentional self-harm by sharp glass, sequela	Diagnosis	ICD-10-CM
X78.1	Intentional self-harm by knife	Diagnosis	ICD-10-CM
X78.1XXA	Intentional self-harm by knife, initial encounter	Diagnosis	ICD-10-CM
X78.1XXD	Intentional self-harm by knife, subsequent encounter	Diagnosis	ICD-10-CM
X78.1XXS	Intentional self-harm by knife, sequela	Diagnosis	ICD-10-CM
X78.2	Intentional self-harm by sword or dagger	Diagnosis	ICD-10-CM
X78.2XXA	Intentional self-harm by sword or dagger, initial encounter	Diagnosis	ICD-10-CM
X78.2XXD	Intentional self-harm by sword or dagger, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
X78.2XXS	Intentional self-harm by sword or dagger, sequela	Diagnosis	ICD-10-CM
X78.8	Intentional self-harm by other sharp object	Diagnosis	ICD-10-CM
X78.8XXA	Intentional self-harm by other sharp object, initial encounter	Diagnosis	ICD-10-CM
X78.8XXD	Intentional self-harm by other sharp object, subsequent encounter	Diagnosis	ICD-10-CM
X78.8XXS	Intentional self-harm by other sharp object, sequela	Diagnosis	ICD-10-CM
X78.9	Intentional self-harm by unspecified sharp object	Diagnosis	ICD-10-CM
X78.9XXA	Intentional self-harm by unspecified sharp object, initial encounter	Diagnosis	ICD-10-CM
X78.9XXD	Intentional self-harm by unspecified sharp object, subsequent encounter	Diagnosis	ICD-10-CM
X78.9XXS	Intentional self-harm by unspecified sharp object, sequela	Diagnosis	ICD-10-CM
X79	Intentional self-harm by blunt object	Diagnosis	ICD-10-CM
X79.XXXA	Intentional self-harm by blunt object, initial encounter	Diagnosis	ICD-10-CM
X79.XXXD	Intentional self-harm by blunt object, subsequent encounter	Diagnosis	ICD-10-CM
X79.XXXS	Intentional self-harm by blunt object, sequela	Diagnosis	ICD-10-CM
X80	Intentional self-harm by jumping from a high place	Diagnosis	ICD-10-CM
X80.XXXA	Intentional self-harm by jumping from a high place, initial encounter	Diagnosis	ICD-10-CM
X80.XXXD	Intentional self-harm by jumping from a high place, subsequent encounter	Diagnosis	ICD-10-CM
X80.XXXS	Intentional self-harm by jumping from a high place, sequela	Diagnosis	ICD-10-CM
X81	Intentional self-harm by jumping or lying in front of moving object	Diagnosis	ICD-10-CM
X81.0	Intentional self-harm by jumping or lying in front of motor vehicle	Diagnosis	ICD-10-CM
X81.0XXA	Intentional self-harm by jumping or lying in front of motor vehicle, initial encounter	Diagnosis	ICD-10-CM
X81.0XXD	Intentional self-harm by jumping or lying in front of motor vehicle, subsequent encounter	Diagnosis	ICD-10-CM
X81.0XXS	Intentional self-harm by jumping or lying in front of motor vehicle, sequela	Diagnosis	ICD-10-CM
X81.1	Intentional self-harm by jumping or lying in front of (subway) train	Diagnosis	ICD-10-CM
X81.1XXA	Intentional self-harm by jumping or lying in front of (subway) train, initial encounter	Diagnosis	ICD-10-CM
X81.1XXD	Intentional self-harm by jumping or lying in front of (subway) train, subsequent encounter	Diagnosis	ICD-10-CM
X81.1XXS	Intentional self-harm by jumping or lying in front of (subway) train, sequela	Diagnosis	ICD-10-CM
X81.8	Intentional self-harm by jumping or lying in front of other moving object	Diagnosis	ICD-10-CM
X81.8XXA	Intentional self-harm by jumping or lying in front of other moving object, initial encounter	Diagnosis	ICD-10-CM
X81.8XXD	Intentional self-harm by jumping or lying in front of other moving object, subsequent encounter	Diagnosis	ICD-10-CM
X81.8XXS	Intentional self-harm by jumping or lying in front of other moving object, sequela	Diagnosis	ICD-10-CM
X82	Intentional self-harm by crashing of motor vehicle	Diagnosis	ICD-10-CM
X82.0	Intentional collision of motor vehicle with other motor vehicle	Diagnosis	ICD-10-CM
X82.0XXA	Intentional collision of motor vehicle with other motor vehicle, initial encounter	Diagnosis	ICD-10-CM
X82.0XXD	Intentional collision of motor vehicle with other motor vehicle, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BC. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
X82.0XXS	Intentional collision of motor vehicle with other motor vehicle, sequela	Diagnosis	ICD-10-CM
X82.1	Intentional collision of motor vehicle with train	Diagnosis	ICD-10-CM
X82.1XXA	Intentional collision of motor vehicle with train, initial encounter	Diagnosis	ICD-10-CM
X82.1XXD	Intentional collision of motor vehicle with train, subsequent encounter	Diagnosis	ICD-10-CM
X82.1XXS	Intentional collision of motor vehicle with train, sequela	Diagnosis	ICD-10-CM
X82.2	Intentional collision of motor vehicle with tree	Diagnosis	ICD-10-CM
X82.2XXA	Intentional collision of motor vehicle with tree, initial encounter	Diagnosis	ICD-10-CM
X82.2XXD	Intentional collision of motor vehicle with tree, subsequent encounter	Diagnosis	ICD-10-CM
X82.2XXS	Intentional collision of motor vehicle with tree, sequela	Diagnosis	ICD-10-CM
X82.8	Other intentional self-harm by crashing of motor vehicle	Diagnosis	ICD-10-CM
X82.8XXA	Other intentional self-harm by crashing of motor vehicle, initial encounter	Diagnosis	ICD-10-CM
X82.8XXD	Other intentional self-harm by crashing of motor vehicle, subsequent encounter	Diagnosis	ICD-10-CM
X82.8XXS	Other intentional self-harm by crashing of motor vehicle, sequela	Diagnosis	ICD-10-CM
X83	Intentional self-harm by other specified means	Diagnosis	ICD-10-CM
X83.0	Intentional self-harm by crashing of aircraft	Diagnosis	ICD-10-CM
X83.0XXA	Intentional self-harm by crashing of aircraft, initial encounter	Diagnosis	ICD-10-CM
X83.0XXD	Intentional self-harm by crashing of aircraft, subsequent encounter	Diagnosis	ICD-10-CM
X83.0XXS	Intentional self-harm by crashing of aircraft, sequela	Diagnosis	ICD-10-CM
X83.1	Intentional self-harm by electrocution	Diagnosis	ICD-10-CM
X83.1XXA	Intentional self-harm by electrocution, initial encounter	Diagnosis	ICD-10-CM
X83.1XXD	Intentional self-harm by electrocution, subsequent encounter	Diagnosis	ICD-10-CM
X83.1XXS	Intentional self-harm by electrocution, sequela	Diagnosis	ICD-10-CM
X83.2	Intentional self-harm by exposure to extremes of cold	Diagnosis	ICD-10-CM
X83.2XXA	Intentional self-harm by exposure to extremes of cold, initial encounter	Diagnosis	ICD-10-CM
X83.2XXD	Intentional self-harm by exposure to extremes of cold, subsequent encounter	Diagnosis	ICD-10-CM
X83.2XXS	Intentional self-harm by exposure to extremes of cold, sequela	Diagnosis	ICD-10-CM
X83.8	Intentional self-harm by other specified means	Diagnosis	ICD-10-CM
X83.8XXA	Intentional self-harm by other specified means, initial encounter	Diagnosis	ICD-10-CM
X83.8XXD	Intentional self-harm by other specified means, subsequent encounter	Diagnosis	ICD-10-CM
X83.8XXS	Intentional self-harm by other specified means, sequela	Diagnosis	ICD-10-CM

Appendix BD. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Inclusion Criteria in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
Oral Anti-diabetic Medications	
acarbose	Precose
acarbose	acarbose
alogliptin benzoate/metformin HCl	Kazano
alogliptin benzoate/metformin HCl	alogliptin-metformin
canagliflozin/metformin HCl	Invokamet
canagliflozin/metformin HCl	Invokamet XR
chlorpropamide	chlorpropamide
colesevelam HCl	WelChol
colesevelam HCl	colesevelam
dapagliflozin propanediol/metformin HCl	Xigduo XR
empagliflozin/linagliptin/metformin HCl	Trijardy XR
empagliflozin/metformin HCl	Synjardy
empagliflozin/metformin HCl	Synjardy XR
ertugliflozin pidolate/metformin HCl	Segluromet
glimepiride	Amaryl
glimepiride	glimepiride
glipizide	Glucotrol
glipizide	Glucotrol XL
glipizide	glipizide
glipizide/metformin HCl	glipizide-metformin
glyburide	Diabeta
glyburide	glyburide
glyburide,micronized	Glynase
glyburide,micronized	glyburide micronized
glyburide/metformin HCl	Glucovance
glyburide/metformin HCl	glyburide-metformin
linagliptin/metformin HCl	Jentadueto
linagliptin/metformin HCl	Jentadueto XR
metformin HCl	Fortamet
metformin HCl	Glucophage
metformin HCl	Glucophage XR
metformin HCl	Glumetza
metformin HCl	Riomet
metformin HCl	Riomet ER
metformin HCl	metformin

Appendix BD. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Inclusion Criteria in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
miglitol	Glyset
miglitol	miglitol
nateglinide	Starlix
nateglinide	nateglinide
pioglitazone HCl	Actos
pioglitazone HCl	pioglitazone
pioglitazone HCl/glimepiride	DUETACT
pioglitazone HCl/glimepiride	pioglitazone-glimepiride
pioglitazone HCl/metformin HCl	Actoplus MET
pioglitazone HCl/metformin HCl	Actoplus Met XR
pioglitazone HCl/metformin HCl	pioglitazone-metformin
repaglinide	Prandin
repaglinide	repaglinide
repaglinide/metformin HCl	Prandimet
repaglinide/metformin HCl	repaglinide-metformin
rosiglitazone maleate	Avandia
rosiglitazone maleate/glimepiride	Avandaryl
rosiglitazone maleate/metformin HCl	Avandamet
saxagliptin HCl/metformin HCl	Kombiglyze XR
saxagliptin HCl/metformin HCl	saxagliptin-metformin
sitagliptin phosphate/metformin HCl	Janumet
sitagliptin phosphate/metformin HCl	Janumet XR
tolazamide	tolazamide
tolbutamide	tolbutamide
Insulin	
insulin NPH human isophane	Humulin N NPH Insulin KwikPen
insulin NPH human isophane	Humulin N NPH U-100 Insulin
insulin NPH human isophane	Novolin N FlexPen
insulin NPH human isophane	Novolin N NPH U-100 Insulin
insulin NPH human isophane/insulin regular, human	Humulin 70/30 U-100 Insulin
insulin NPH human isophane/insulin regular, human	Humulin 70/30 U-100 KwikPen
insulin NPH human isophane/insulin regular, human	Novolin 70-30 FlexPen U-100
insulin NPH human isophane/insulin regular, human	Novolin 70/30 U-100 Insulin
insulin aspart	Novolog FlexPen U-100 Insulin
insulin aspart	Novolog PenFill U-100 Insulin
insulin aspart	Novolog U-100 Insulin aspart

Appendix BD. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Inclusion Criteria in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
insulin aspart	insulin aspart U-100
insulin aspart (niacinamide)	Fiasp FlexTouch U-100 Insulin
insulin aspart (niacinamide)	Fiasp Penfill U-100 Insulin
insulin aspart (niacinamide)	Fiasp U-100 Insulin
insulin aspart (niacinamide)/pump cartridge	Fiasp Pumpcart
insulin aspart protamine human/insulin aspart	Novolog Mix 70-30 U-100 Insuln
insulin aspart protamine human/insulin aspart	Novolog Mix 70-30FlexPen U-100
insulin aspart protamine human/insulin aspart	insulin asp prt-insulin aspart
insulin degludec	Tresiba FlexTouch U-100
insulin degludec	Tresiba FlexTouch U-200
insulin degludec	Tresiba U-100 Insulin
insulin degludec	insulin degludec
insulin degludec/liraglutide	Xultophy 100/3.6
insulin detemir	Levemir FlexPen
insulin detemir	Levemir FlexTouch U100 Insulin
insulin detemir	Levemir U-100 Insulin
insulin glargine,human recombinant analog	Basaglar KwikPen U-100 Insulin
insulin glargine,human recombinant analog	Basaglar Tempo Pen(U-100)Insln
insulin glargine,human recombinant analog	Lantus Solostar U-100 Insulin
insulin glargine,human recombinant analog	Lantus U-100 Insulin
insulin glargine,human recombinant analog	Semglee U-100 Insulin
insulin glargine,human recombinant analog	Toujeo Max U-300 SoloStar
insulin glargine,human recombinant analog	Toujeo SoloStar U-300 Insulin
insulin glargine,human recombinant analog	insulin glargine
insulin glargine,human recombinant analog/lixisenatide	Soliqua 100/33
insulin glargine-aglr	Rezvoglar KwikPen
insulin glargine-yfgn	insulin glargine-yfgn
insulin glulisine	Apidra SoloStar U-100 Insulin
insulin glulisine	Apidra U-100 Insulin
insulin lispro	Admelog SoloStar U-100 Insulin
insulin lispro	Admelog U-100 Insulin lispro
insulin lispro	Humalog Junior KwikPen U-100
insulin lispro	Humalog KwikPen Insulin
insulin lispro	Humalog Tempo Pen(U-100)Insuln
insulin lispro	Humalog U-100 Insulin
insulin lispro	insulin lispro

Appendix BD. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Inclusion Criteria in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
insulin lispro protamine and insulin lispro	Humalog Mix 50-50 Insuln U-100
insulin lispro protamine and insulin lispro	Humalog Mix 50-50 KwikPen
insulin lispro protamine and insulin lispro	Humalog Mix 75-25 KwikPen
insulin lispro protamine and insulin lispro	Humalog Mix 75-25(U-100)Insuln
insulin lispro protamine and insulin lispro	insulin lispro protamin-lispro
insulin lispro-aabc	Lyumjev KwikPen U-100 Insulin
insulin lispro-aabc	Lyumjev KwikPen U-200 Insulin
insulin lispro-aabc	Lyumjev Tempo Pen(U-100)Insuln
insulin lispro-aabc	Lyumjev U-100 Insulin
insulin regular, human	Afrezza
insulin regular, human	Humulin R Regular U-100 Insuln
insulin regular, human	Humulin R U-500 (Conc) Insulin
insulin regular, human	Humulin R U-500 (Conc) Kwikpen
insulin regular, human	Novolin R FlexPen
insulin regular, human	Novolin R Regular U100 Insulin
insulin regular, human in 0.9 % sodium chloride	Myxredlin
Anti-diabetic Medications	
acarbose	Precose
acarbose	acarbose
alogliptin benzoate/metformin HCl	Kazano
alogliptin benzoate/metformin HCl	alogliptin-metformin
canagliflozin/metformin HCl	Invokamet
canagliflozin/metformin HCl	Invokamet XR
chlorpropamide	chlorpropamide
colesevelam HCl	WelChol
colesevelam HCl	colesevelam
dapagliflozin propanediol/metformin HCl	Xigduo XR
empagliflozin/linagliptin/metformin HCl	Trijardy XR
empagliflozin/metformin HCl	Synjardy
empagliflozin/metformin HCl	Synjardy XR
ertugliflozin pidolate/metformin HCl	Segluromet
glimepiride	Amaryl
glimepiride	glimepiride
glipizide	Glucotrol
glipizide	Glucotrol XL
glipizide	glipizide

Appendix BD. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Inclusion Criteria in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
glipizide/metformin HCl	glipizide-metformin
glyburide	Diabeta
glyburide	glyburide
glyburide,micronized	Glynase
glyburide,micronized	glyburide micronized
glyburide/metformin HCl	Glucovance
glyburide/metformin HCl	glyburide-metformin
linagliptin/metformin HCl	Jentadueto
linagliptin/metformin HCl	Jentadueto XR
metformin HCl	Fortamet
metformin HCl	Glucophage
metformin HCl	Glucophage XR
metformin HCl	Glumetza
metformin HCl	Riomet
metformin HCl	Riomet ER
metformin HCl	metformin
metformin HCl/blood sugar diagnostic	DM2
miglitol	Glyset
miglitol	miglitol
nateglinide	Starlix
nateglinide	nateglinide
pioglitazone HCl	Actos
pioglitazone HCl	pioglitazone
pioglitazone HCl/glimepiride	DUETACT
pioglitazone HCl/glimepiride	pioglitazone-glimepiride
pioglitazone HCl/metformin HCl	Actoplus MET
pioglitazone HCl/metformin HCl	Actoplus Met XR
pioglitazone HCl/metformin HCl	pioglitazone-metformin
pramlintide acetate	SymlinPen 120
pramlintide acetate	SymlinPen 60
repaglinide	Prandin
repaglinide	repaglinide
repaglinide/metformin HCl	Prandimet
repaglinide/metformin HCl	repaglinide-metformin
rosiglitazone maleate	Avandia
rosiglitazone maleate/glimepiride	Avandaryl

Appendix BD. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Inclusion Criteria in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
rosiglitazone maleate/metformin HCl	Avandamet
saxagliptin HCl/metformin HCl	Kombiglyze XR
saxagliptin HCl/metformin HCl	saxagliptin-metformin
sitagliptin phosphate/metformin HCl	Janumet
sitagliptin phosphate/metformin HCl	Janumet XR
tolazamide	tolazamide
tolbutamide	tolbutamide

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
	Type 2 Diabetes Mellitus		
250.00	Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.02	Diabetes mellitus without mention of complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.10	Diabetes with ketoacidosis, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.12	Diabetes with ketoacidosis, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.20	Diabetes with hyperosmolarity, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.22	Diabetes with hyperosmolarity, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.30	Diabetes with other coma, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.32	Diabetes with other coma, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.50	Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.52	Diabetes with ophthalmic manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.60	Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.62	Diabetes with neurological manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.70	Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.72	Diabetes with peripheral circulatory disorders, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.80	Diabetes with other specified manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.82	Diabetes with other specified manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.90	Diabetes with unspecified complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.92	Diabetes with unspecified complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
E11	Type 2 diabetes mellitus	Diagnosis	ICD-10-CM
E11.0	Type 2 diabetes mellitus with hyperosmolarity	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.1	Type 2 diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.2	Type 2 diabetes mellitus with kidney complications	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.3	Type 2 diabetes mellitus with ophthalmic complications	Diagnosis	ICD-10-CM
E11.31	Type 2 diabetes mellitus with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.32	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.33	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.34	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.35	Type 2 diabetes mellitus with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.352	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.353	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.354	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.355	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.4	Type 2 diabetes mellitus with neurological complications	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.5	Type 2 diabetes mellitus with circulatory complications	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.6	Type 2 diabetes mellitus with other specified complications	Diagnosis	ICD-10-CM
E11.61	Type 2 diabetes mellitus with diabetic arthropathy	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.62	Type 2 diabetes mellitus with skin complications	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.63	Type 2 diabetes mellitus with oral complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.64	Type 2 diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
	Type 1 Diabetes Mellitus		
250.01	Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.03	Diabetes mellitus without mention of complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.11	Diabetes with ketoacidosis, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.13	Diabetes with ketoacidosis, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.21	Diabetes with hyperosmolarity, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.23	Diabetes with hyperosmolarity, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.31	Diabetes with other coma, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.33	Diabetes with other coma, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.51	Diabetes with ophthalmic manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.53	Diabetes with ophthalmic manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.61	Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.63	Diabetes with neurological manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.71	Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.73	Diabetes with peripheral circulatory disorders, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.81	Diabetes with other specified manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.83	Diabetes with other specified manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.91	Diabetes with unspecified complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.93	Diabetes with unspecified complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
E10	Type 1 diabetes mellitus	Diagnosis	ICD-10-CM
E10.1	Type 1 diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.2	Type 1 diabetes mellitus with kidney complications	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.3	Type 1 diabetes mellitus with ophthalmic complications	Diagnosis	ICD-10-CM
E10.31	Type 1 diabetes mellitus with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.32	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.33	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.34	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E10.35	Type 1 diabetes mellitus with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.352	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.353	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.354	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.355	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.4	Type 1 diabetes mellitus with neurological complications	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.5	Type 1 diabetes mellitus with circulatory complications	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.6	Type 1 diabetes mellitus with other specified complications	Diagnosis	ICD-10-CM
E10.61	Type 1 diabetes mellitus with diabetic arthropathy	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.62	Type 1 diabetes mellitus with skin complications	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.63	Type 1 diabetes mellitus with oral complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.64	Type 1 diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
	Gestational Diabetes		
648.81	Abnormal maternal glucose tolerance, with delivery	Diagnosis	ICD-9-CM
648.82	Abnormal maternal glucose tolerance, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
648.83	Abnormal maternal glucose tolerance, antepartum	Diagnosis	ICD-9-CM
648.84	Abnormal maternal glucose tolerance complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication	Diagnosis	ICD-9-CM
O24.4	Gestational diabetes mellitus	Diagnosis	ICD-10-CM
O24.41	Gestational diabetes mellitus in pregnancy	Diagnosis	ICD-10-CM
O24.410	Gestational diabetes mellitus in pregnancy, diet controlled	Diagnosis	ICD-10-CM
O24.414	Gestational diabetes mellitus in pregnancy, insulin controlled	Diagnosis	ICD-10-CM
O24.415	Gestational diabetes mellitus in pregnancy, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM
O24.419	Gestational diabetes mellitus in pregnancy, unspecified control	Diagnosis	ICD-10-CM
O24.42	Gestational diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
O24.420	Gestational diabetes mellitus in childbirth, diet controlled	Diagnosis	ICD-10-CM
O24.424	Gestational diabetes mellitus in childbirth, insulin controlled	Diagnosis	ICD-10-CM
O24.425	Gestational diabetes mellitus in childbirth, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM
O24.429	Gestational diabetes mellitus in childbirth, unspecified control	Diagnosis	ICD-10-CM
O24.43	Gestational diabetes mellitus in the puerperium	Diagnosis	ICD-10-CM
O24.430	Gestational diabetes mellitus in the puerperium, diet controlled	Diagnosis	ICD-10-CM
O24.434	Gestational diabetes mellitus in the puerperium, insulin controlled	Diagnosis	ICD-10-CM
O24.435	Gestational diabetes mellitus in puerperium, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O24.439	Gestational diabetes mellitus in the puerperium, unspecified control	Diagnosis	ICD-10-CM
	Secondary Diabetes		
249.00	Secondary diabetes mellitus without mention of complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.01	Secondary diabetes mellitus without mention of complication, uncontrolled	Diagnosis	ICD-9-CM
249.10	Secondary diabetes mellitus with ketoacidosis, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.11	Secondary diabetes mellitus with ketoacidosis, uncontrolled	Diagnosis	ICD-9-CM
249.20	Secondary diabetes mellitus with hyperosmolarity, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.21	Secondary diabetes mellitus with hyperosmolarity, uncontrolled	Diagnosis	ICD-9-CM
249.30	Secondary diabetes mellitus with other coma, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.31	Secondary diabetes mellitus with other coma, uncontrolled	Diagnosis	ICD-9-CM
249.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.50	Secondary diabetes mellitus with ophthalmic manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.51	Secondary diabetes mellitus with ophthalmic manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.60	Secondary diabetes mellitus with neurological manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.61	Secondary diabetes mellitus with neurological manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.70	Secondary diabetes mellitus with peripheral circulatory disorders, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.71	Secondary diabetes mellitus with peripheral circulatory disorders, uncontrolled	Diagnosis	ICD-9-CM
249.80	Secondary diabetes mellitus with other specified manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.81	Secondary diabetes mellitus with other specified manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.90	Secondary diabetes mellitus with unspecified complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.91	Secondary diabetes mellitus with unspecified complication, uncontrolled	Diagnosis	ICD-9-CM
E08	Diabetes mellitus due to underlying condition	Diagnosis	ICD-10-CM
E08.0	Diabetes mellitus due to underlying condition with hyperosmolarity	Diagnosis	ICD-10-CM
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.1	Diabetes mellitus due to underlying condition with ketoacidosis	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.2	Diabetes mellitus due to underlying condition with kidney complications	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.3	Diabetes mellitus due to underlying condition with ophthalmic complications	Diagnosis	ICD-10-CM
E08.31	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.32	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.33	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.34	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E08.35	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.352	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.353	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.354	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.355	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.4	Diabetes mellitus due to underlying condition with neurological complications	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.5	Diabetes mellitus due to underlying condition with circulatory complications	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.6	Diabetes mellitus due to underlying condition with other specified complications	Diagnosis	ICD-10-CM
E08.61	Diabetes mellitus due to underlying condition with diabetic arthropathy	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.62	Diabetes mellitus due to underlying condition with skin complications	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.63	Diabetes mellitus due to underlying condition with oral complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.64	Diabetes mellitus due to underlying condition with hypoglycemia	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E09	Drug or chemical induced diabetes mellitus	Diagnosis	ICD-10-CM
E09.0	Drug or chemical induced diabetes mellitus with hyperosmolarity	Diagnosis	ICD-10-CM
E09.00	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E09.1	Drug or chemical induced diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E09.2	Drug or chemical induced diabetes mellitus with kidney complications	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.3	Drug or chemical induced diabetes mellitus with ophthalmic complications	Diagnosis	ICD-10-CM
E09.31	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.32	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.33	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.34	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.35	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.352	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula	Diagnosis	ICD-10-CM
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.353	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.354	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E09.355	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E09.37	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment	Diagnosis	ICD-10-CM
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E09.4	Drug or chemical induced diabetes mellitus with neurological complications	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM
E09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM
E09.5	Drug or chemical induced diabetes mellitus with circulatory complications	Diagnosis	ICD-10-CM
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E09.6	Drug or chemical induced diabetes mellitus with other specified complications	Diagnosis	ICD-10-CM
E09.61	Drug or chemical induced diabetes mellitus with diabetic arthropathy	Diagnosis	ICD-10-CM
E09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.62	Drug or chemical induced diabetes mellitus with skin complications	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E09.63	Drug or chemical induced diabetes mellitus with oral complications	Diagnosis	ICD-10-CM
E09.630	Drug or chemical induced diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E09.64	Drug or chemical induced diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E09.69	Drug or chemical induced diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13	Other specified diabetes mellitus	Diagnosis	ICD-10-CM
E13.0	Other specified diabetes mellitus with hyperosmolarity	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.1	Other specified diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.2	Other specified diabetes mellitus with kidney complications	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.3	Other specified diabetes mellitus with ophthalmic complications	Diagnosis	ICD-10-CM
E13.31	Other specified diabetes mellitus with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.32	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.33	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.34	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.35	Other specified diabetes mellitus with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.352	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.353	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.354	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.355	Other specified diabetes mellitus with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.37	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment	Diagnosis	ICD-10-CM
E13.37X1	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E13.37X2	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E13.37X3	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E13.37X9	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.4	Other specified diabetes mellitus with neurological complications	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.5	Other specified diabetes mellitus with circulatory complications	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.6	Other specified diabetes mellitus with other specified complications	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
E13.61	Other specified diabetes mellitus with diabetic arthropathy	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.62	Other specified diabetes mellitus with skin complications	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.63	Other specified diabetes mellitus with oral complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.64	Other specified diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
	Obesity		
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-9-CM
278.0	Overweight and obesity	Diagnosis	ICD-9-CM
278.00	Obesity, unspecified	Diagnosis	ICD-9-CM
278.01	Morbid obesity	Diagnosis	ICD-9-CM
278.03	Obesity hypoventilation syndrome	Diagnosis	ICD-9-CM
539.0	Complications of gastric band procedure	Diagnosis	ICD-9-CM
539.01	Infection due to gastric band procedure	Diagnosis	ICD-9-CM
539.09	Other complications of gastric band procedure	Diagnosis	ICD-9-CM
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
O99.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
V45.86	Bariatric surgery status	Diagnosis	ICD-9-CM
V85.3	Body Mass Index Between 30-39, adult	Diagnosis	ICD-9-CM
V85.30	Body Mass Index 30.0-30.9, adult	Diagnosis	ICD-9-CM
V85.31	Body Mass Index 31.0-31.9, adult	Diagnosis	ICD-9-CM
V85.32	Body Mass Index 32.0-32.9, adult	Diagnosis	ICD-9-CM
V85.33	Body Mass Index 33.0-33.9, adult	Diagnosis	ICD-9-CM
V85.34	Body Mass Index 34.0-34.9, adult	Diagnosis	ICD-9-CM
V85.35	Body Mass Index 35.0-35.9, adult	Diagnosis	ICD-9-CM
V85.36	Body Mass Index 36.0-36.9, adult	Diagnosis	ICD-9-CM
V85.37	Body Mass Index 37.0-37.9, adult	Diagnosis	ICD-9-CM
V85.38	Body Mass Index 38.0-38.9, adult	Diagnosis	ICD-9-CM
V85.39	Body Mass Index 39.0-39.9, adult	Diagnosis	ICD-9-CM
V85.4	Body Mass Index 40 and over, adult	Diagnosis	ICD-9-CM
V85.41	Body Mass Index 40.0-44.9, adult	Diagnosis	ICD-9-CM
V85.42	Body Mass Index 45.0-49.9, adult	Diagnosis	ICD-9-CM
V85.43	Body Mass Index 50.0-59.9, adult	Diagnosis	ICD-9-CM
V85.44	Body Mass Index 60.0-69.9, adult	Diagnosis	ICD-9-CM
V85.45	Body Mass Index 70 and over, adult	Diagnosis	ICD-9-CM
Z68.30	Body mass index [BMI] 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index [BMI] 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index [BMI] 32.0-32.9, adult	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
Z68.33	Body mass index [BMI] 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index [BMI] 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index [BMI] 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index [BMI] 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index [BMI] 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index [BMI] 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index [BMI] 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index [BMI] 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index [BMI] 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index [BMI] 50.0-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index [BMI] 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index [BMI] 70 or greater, adult	Diagnosis	ICD-10-CM
	Pregnancy		
01964	ANESTHESIA FOR ABORTION PROCEDURES	Procedure	CPT-4
01965	Anesthesia for incomplete or missed abortion procedures	Procedure	CPT-4
01966	Anesthesia for induced abortion procedures	Procedure	CPT-4
0W8NXZZ	Division of Female Perineum, External Approach	Procedure	ICD-10-PCS
10900ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Open Approach	Procedure	ICD-10-PCS
10903ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Percutaneous Approach	Procedure	ICD-10-PCS
10904ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
10907ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10908ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
10A00ZZ	Abortion of Products of Conception, Open Approach	Procedure	ICD-10-PCS
10A03ZZ	Abortion of Products of Conception, Percutaneous Approach	Procedure	ICD-10-PCS
10A04ZZ	Abortion of Products of Conception, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
10A07Z6	Abortion of Products of Conception, Vacuum, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10A07ZW	Abortion of Products of Conception, Laminaria, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10A07ZX	Abortion of Products of Conception, Abortifacient, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10A07ZZ	Abortion of Products of Conception, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10A08ZZ	Abortion of Products of Conception, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
10D00Z0	Extraction of Products of Conception, Classical, Open Approach	Procedure	ICD-10-PCS
10D00Z1	Extraction of Products of Conception, Low Cervical, Open Approach	Procedure	ICD-10-PCS
10D00Z2	Extraction of Products of Conception, Extraperitoneal, Open Approach	Procedure	ICD-10-PCS
10D07Z3	Extraction of Products of Conception, Low Forceps, Via Natural or Artificial Opening	Procedure	ICD-10-PCS

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
10D07Z4	Extraction of Products of Conception, Mid Forceps, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z5	Extraction of Products of Conception, High Forceps, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z6	Extraction of Products of Conception, Vacuum, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z7	Extraction of Products of Conception, Internal Version, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z8	Extraction of Products of Conception, Other, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D27ZZ	Extraction of products of conception, ectopic, via natural or artificial opening	Procedure	ICD-10-PCS
10D28ZZ	Extraction of products of conception, ectopic, via natural or artificial opening endoscopic	Procedure	ICD-10-PCS
10E0XZZ	Delivery of Products of Conception, External Approach	Procedure	ICD-10-PCS
10S07ZZ	Reposition Products of Conception, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10T20ZZ	Resection of products of conception, ectopic, open approach	Procedure	ICD-10-PCS
10T23ZZ	Resection of products of conception, ectopic, percutaneous approach	Procedure	ICD-10-PCS
10T24ZZ	Resection of products of conception, ectopic, percutaneous endoscopic approach	Procedure	ICD-10-PCS
10T27ZZ	Resection of products of conception, ectopic, via natural or artificial opening	Procedure	ICD-10-PCS
10T28ZZ	Resection of products of conception, ectopic, via natural or artificial opening endoscopic	Procedure	ICD-10-PCS
58321	ARTIFICIAL INSEMINATION; INTRA-CERVICAL	Procedure	CPT-4
58322	ARTIFICIAL INSEMINATION	Procedure	CPT-4
58974	TRANSFER OF EMBRYO	Procedure	CPT-4
58976	Gamete, zygote, or embryo intrafallopian transfer	Procedure	CPT-4
59015	Chorionic villus sampling, any method	Procedure	CPT-4
59100	Surgical treatment of ectopic pregnancy: tubal or ovarian, requiring salpingectomy and/or oophorectomy, abdominal or vaginal approach	Procedure	CPT-4
59120	Surgical treatment of ectopic pregnancy; tubal or ovarian, requiring salpingectomy and/or oophorectomy, abdominal or vaginal approach	Procedure	CPT-4
59121	Surgical treatment of ectopic pregnancy; tubal or ovarian, without salpingectomy and/or oophorectomy	Procedure	CPT-4
59125	Surgical Treatment Of Ectopic Pregnancy	Procedure	CPT-4
59126	Surgical Treatment Of Ectopic Pregnancy	Procedure	CPT-4
59130	Surgical treatment of ectopic pregnancy; abdominal pregnancy	Procedure	CPT-4
59135	Surgical treatment of ectopic pregnancy; interstitial, uterine pregnancy requiring total hysterectomy	Procedure	CPT-4
59136	Surgical treatment of ectopic pregnancy; interstitial, uterine pregnancy with partial resection of uterus	Procedure	CPT-4
59140	Surgical treatment of ectopic pregnancy; cervical, with evacuation	Procedure	CPT-4
59150	Laparoscopic treatment of ectopic pregnancy; without salpingectomy and/or oophorectomy	Procedure	CPT-4
59151	Laparoscopic treatment of ectopic pregnancy; with salpingectomy and/or oophorectomy	Procedure	CPT-4
59400	Routine obstetric care including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartum care	Procedure	CPT-4
59409	Vaginal delivery only (with or without episiotomy and/or forceps);	Procedure	CPT-4

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
59410	Vaginal delivery only (with or without episiotomy and/or forceps); including postpartum care	Procedure	CPT-4
59510	Routine obstetric care including antepartum care, cesarean delivery, and postpartum care	Procedure	CPT-4
59514	Cesarean delivery only;	Procedure	CPT-4
59515	Cesarean delivery only; including postpartum care	Procedure	CPT-4
59610	Routine obstetric care including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartum care, after previous cesarean delivery	Procedure	CPT-4
59612	Vaginal delivery only, after previous cesarean delivery (with or without episiotomy and/or forceps);	Procedure	CPT-4
59614	Vaginal delivery only, after previous cesarean delivery (with or without episiotomy and/or forceps); including postpartum care	Procedure	CPT-4
59618	Routine obstetric care including antepartum care, cesarean delivery, and postpartum care, following attempted vaginal delivery after previous cesarean delivery	Procedure	CPT-4
59620	Cesarean delivery only, following attempted vaginal delivery after previous cesarean delivery;	Procedure	CPT-4
59622	Cesarean delivery only, following attempted vaginal delivery after previous cesarean delivery; including postpartum care	Procedure	CPT-4
59812	Treatment of incomplete abortion, any trimester, completed surgically	Procedure	CPT-4
59820	Treatment of incomplete abortion completed surgically, first trimester	Procedure	CPT-4
59821	Treatment of incomplete abortion completed surgically, second trimester	Procedure	CPT-4
59830	Treatment of septic abortion, completed surgically	Procedure	CPT-4
59840	INDUCED ABORTION, BY DILATION AND CURETTAGE	Procedure	CPT-4
59841	INDUCED ABORTION, BY DILATION AND EVACUATION	Procedure	CPT-4
59850	INDUCED ABORTION, BY ONE OR MORE INTRAAMNIOTIC INJECTIONS	Procedure	CPT-4
59851	INDUCED ABORTION, BY ONE OR MORE INTRAAMNIOTIC INJECTIONS, WITH DILATION AND CURETTAGE AND/OR EVACUATION	Procedure	CPT-4
59852	INDUCED ABORTION, BY ONE OR MORE INTRAAMNIOTIC INJECTIONS, WITH HYSTEROTOMY	Procedure	CPT-4
59855	INDUCED ABORTION, BY ONE OR MORE VAGINAL SUPPOSITORIES	Procedure	CPT-4
59856	INDUCED ABORTION, BY ONE OR MORE VAGINAL SUPPOSITORIES, WITH DILATION AND CURETTAGE AND/OR EVACUATION	Procedure	CPT-4
59857	INDUCED ABORTION, BY ONE OR MORE VAGINAL SUPPOSITORIES, WITH HYSTEROTOMY	Procedure	CPT-4
59870	Evacuation and curettage of uterus for hydatidiform mole	Procedure	CPT-4
630	Hydatidiform mole	Diagnosis	ICD-9-CM
6318	Other abnormal products of conception	Diagnosis	ICD-9-CM
632	Missed abortion	Diagnosis	ICD-9-CM
633	Ectopic pregnancy	Diagnosis	ICD-9-CM
6330	633.0(ABDOMINAL PREGNANCY)	Diagnosis	ICD-9-CM
63300	633.00(ABD PREG W/O INTRAU PREG)	Diagnosis	ICD-9-CM

Code	Description	Code Category	Code Type
63301	633.01(ABD PREG W INTRAUT PREG)	Diagnosis	ICD-9-CM
6331	Tubal pregnancy	Diagnosis	ICD-9-CM
63310	Tubal pregnancy without intrauterine pregnancy	Diagnosis	ICD-9-CM
63311	Tubal pregnancy with intrauterine pregnancy	Diagnosis	ICD-9-CM
6332	Ovarian pregnancy	Diagnosis	ICD-9-CM
63320	Ovarian pregnancy without intrauterine pregnancy	Diagnosis	ICD-9-CM
63321	Ovarian pregnancy with intrauterine pregnancy	Diagnosis	ICD-9-CM
6338	Other ectopic pregnancy	Diagnosis	ICD-9-CM
63380	Other ectopic pregnancy without intrauterine pregnancy	Diagnosis	ICD-9-CM
63381	Other ectopic pregnancy with intrauterine pregnancy	Diagnosis	ICD-9-CM
6339	Unspecified ectopic pregnancy	Diagnosis	ICD-9-CM
63390	Unspecified ectopic pregnancy without intrauterine pregnancy	Diagnosis	ICD-9-CM
63391	Unspecified ectopic pregnancy with intrauterine pregnancy	Diagnosis	ICD-9-CM
634	Spontaneous abortion	Diagnosis	ICD-9-CM
6340	Spontaneous abortion complicated by genital tract and pelvic infection	Diagnosis	ICD-9-CM
63400	Unspecified spontaneous abortion complicated by genital tract and pelvic infection	Diagnosis	ICD-9-CM
63401	Incomplete spontaneous abortion complicated by genital tract and pelvic infection	Diagnosis	ICD-9-CM
63402	Complete spontaneous abortion complicated by genital tract and pelvic infection	Diagnosis	ICD-9-CM
6341	Spontaneous abortion complicated by delayed or excessive hemorrhage	Diagnosis	ICD-9-CM
63410	Unspecified spontaneous abortion complicated by delayed or excessive hemorrhage	Diagnosis	ICD-9-CM
63411	Incomplete spontaneous abortion complicated by delayed or excessive hemorrhage	Diagnosis	ICD-9-CM
63412	Complete spontaneous abortion complicated by delayed or excessive hemorrhage	Diagnosis	ICD-9-CM
6342	Spontaneous abortion complicated by damage to pelvic organs or tissues	Diagnosis	ICD-9-CM
63420	Unspecified spontaneous abortion complicated by damage to pelvic organs or tissues	Diagnosis	ICD-9-CM
63421	Incomplete spontaneous abortion complicated by damage to pelvic organs or tissues	Diagnosis	ICD-9-CM
63422	Complete spontaneous abortion complicated by damage to pelvic organs or tissues	Diagnosis	ICD-9-CM
6343	Spontaneous abortion complicated by renal failure	Diagnosis	ICD-9-CM
63430	Unspecified spontaneous abortion complicated by renal failure	Diagnosis	ICD-9-CM
63431	Incomplete spontaneous abortion complicated by renal failure	Diagnosis	ICD-9-CM
63432	Complete spontaneous abortion complicated by renal failure	Diagnosis	ICD-9-CM
6344	Spontaneous abortion complicated by metabolic disorder	Diagnosis	ICD-9-CM
63440	Unspecified spontaneous abortion complicated by metabolic disorder	Diagnosis	ICD-9-CM
63441	Incomplete spontaneous abortion complicated by metabolic disorder	Diagnosis	ICD-9-CM
63442	Complete spontaneous abortion complicated by metabolic disorder	Diagnosis	ICD-9-CM
6345	Spontaneous abortion complicated by shock	Diagnosis	ICD-9-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
63450	Unspecified spontaneous abortion complicated by shock	Diagnosis	ICD-9-CM
63451	Incomplete spontaneous abortion complicated by shock	Diagnosis	ICD-9-CM
63452	Complete spontaneous abortion complicated by shock	Diagnosis	ICD-9-CM
6346	Spontaneous abortion complicated by embolism	Diagnosis	ICD-9-CM
63460	Unspecified spontaneous abortion complicated by embolism	Diagnosis	ICD-9-CM
63461	Incomplete spontaneous abortion complicated by embolism	Diagnosis	ICD-9-CM
63462	Complete spontaneous abortion complicated by embolism	Diagnosis	ICD-9-CM
6347	Spontaneous abortion with other specified complications	Diagnosis	ICD-9-CM
63470	Unspecified spontaneous abortion with other specified complications	Diagnosis	ICD-9-CM
63471	Incomplete spontaneous abortion with other specified complications	Diagnosis	ICD-9-CM
63472	Complete spontaneous abortion with other specified complications	Diagnosis	ICD-9-CM
6348	Spontaneous abortion with unspecified complication	Diagnosis	ICD-9-CM
63480	Unspecified spontaneous abortion with unspecified complication	Diagnosis	ICD-9-CM
63481	Incomplete spontaneous abortion with unspecified complication	Diagnosis	ICD-9-CM
63482	Complete spontaneous abortion with unspecified complication	Diagnosis	ICD-9-CM
6349	Spontaneous abortion without mention of complication	Diagnosis	ICD-9-CM
63490	Unspecified spontaneous abortion without mention of complication	Diagnosis	ICD-9-CM
63491	Incomplete spontaneous abortion without mention of complication	Diagnosis	ICD-9-CM
63492	Complete spontaneous abortion without mention of complication	Diagnosis	ICD-9-CM
635	Legally induced abortion	Diagnosis	ICD-9-CM
6350	Legally induced abortion complicated by genital tract and pelvic infection	Diagnosis	ICD-9-CM
63500	Unspecified legally induced abortion complicated by genital tract and pelvic infection	Diagnosis	ICD-9-CM
63501	Incomplete legally induced abortion complicated by genital tract and pelvic infection	Diagnosis	ICD-9-CM
63502	Complete legally induced abortion complicated by genital tract and pelvic infection	Diagnosis	ICD-9-CM
6351	Legally induced abortion complicated by delayed or excessive hemorrhage	Diagnosis	ICD-9-CM
63510	Unspecified legally induced abortion complicated by delayed or excessive hemorrhage	Diagnosis	ICD-9-CM
63511	Incomplete legally induced abortion complicated by delayed or excessive hemorrhage	Diagnosis	ICD-9-CM
63512	Complete legally induced abortion complicated by delayed or excessive hemorrhage	Diagnosis	ICD-9-CM
6352	Legally induced abortion complicated by damage to pelvic organs or tissues	Diagnosis	ICD-9-CM
63520	Unspecified legally induced abortion complicated by damage to pelvic organs or tissues	Diagnosis	ICD-9-CM
63521	Legally induced abortion complicated by damage to pelvic organs or tissues, incomplete	Diagnosis	ICD-9-CM
63522	Complete legally induced abortion complicated by damage to pelvic organs or tissues	Diagnosis	ICD-9-CM
6353	Legally induced abortion complicated by renal failure	Diagnosis	ICD-9-CM
63530	Unspecified legally induced abortion complicated by renal failure	Diagnosis	ICD-9-CM
63531	Incomplete legally induced abortion complicated by renal failure	Diagnosis	ICD-9-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
63532	Complete legally induced abortion complicated by renal failure	Diagnosis	ICD-9-CM
6354	Legally induced abortion complicated by metabolic disorder	Diagnosis	ICD-9-CM
63540	Unspecified legally induced abortion complicated by metabolic disorder	Diagnosis	ICD-9-CM
63541	Incomplete legally induced abortion complicated by metabolic disorder	Diagnosis	ICD-9-CM
63542	Complete legally induced abortion complicated by metabolic disorder	Diagnosis	ICD-9-CM
6355	Legally induced abortion complicated by shock	Diagnosis	ICD-9-CM
63550	Unspecified legally induced abortion complicated by shock	Diagnosis	ICD-9-CM
63551	Legally induced abortion, complicated by shock, incomplete	Diagnosis	ICD-9-CM
63552	Complete legally induced abortion complicated by shock	Diagnosis	ICD-9-CM
6356	Legally induced abortion complicated by embolism	Diagnosis	ICD-9-CM
63560	Unspecified legally induced abortion complicated by embolism	Diagnosis	ICD-9-CM
63561	Incomplete legally induced abortion complicated by embolism	Diagnosis	ICD-9-CM
63562	Complete legally induced abortion complicated by embolism	Diagnosis	ICD-9-CM
6357	Legally induced abortion with other specified complications	Diagnosis	ICD-9-CM
63570	Unspecified legally induced abortion with other specified complications	Diagnosis	ICD-9-CM
63571	Incomplete legally induced abortion with other specified complications	Diagnosis	ICD-9-CM
63572	Complete legally induced abortion with other specified complications	Diagnosis	ICD-9-CM
6358	Legally induced abortion with unspecified complication	Diagnosis	ICD-9-CM
63580	Unspecified legally induced abortion with unspecified complication	Diagnosis	ICD-9-CM
63581	Incomplete legally induced abortion with unspecified complication	Diagnosis	ICD-9-CM
63582	Complete legally induced abortion with unspecified complication	Diagnosis	ICD-9-CM
6359	Legally induced abortion without mention of complication	Diagnosis	ICD-9-CM
63590	Unspecified legally induced abortion without mention of complication	Diagnosis	ICD-9-CM
63591	Incomplete legally induced abortion without mention of complication	Diagnosis	ICD-9-CM
63592	Complete legally induced abortion without mention of complication	Diagnosis	ICD-9-CM
636	Illegal abortion	Diagnosis	ICD-9-CM
6360	Illegal abortion complicated by genital tract and pelvic infection	Diagnosis	ICD-9-CM
63600	Unspecified illegally induced abortion complicated by genital tract and pelvic infection	Diagnosis	ICD-9-CM
63601	Incomplete illegally induced abortion complicated by genital tract and pelvic infection	Diagnosis	ICD-9-CM
63602	Complete illegally induced abortion complicated by genital tract and pelvic infection	Diagnosis	ICD-9-CM
6361	Illegal abortion complicated by delayed or excessive hemorrhage	Diagnosis	ICD-9-CM
63610	Unspecified illegally induced abortion complicated by delayed or excessive hemorrhage	Diagnosis	ICD-9-CM
63611	Incomplete illegally induced abortion complicated by delayed or excessive hemorrhage	Diagnosis	ICD-9-CM
63612	Complete illegally induced abortion complicated by delayed or excessive hemorrhage	Diagnosis	ICD-9-CM
6362	Illegal abortion complicated by damage to pelvic organs or tissues	Diagnosis	ICD-9-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
63620	Unspecified illegally induced abortion complicated by damage to pelvic organs or tissues	Diagnosis	ICD-9-CM
63621	Incomplete illegally induced abortion complicated by damage to pelvic organs or tissues	Diagnosis	ICD-9-CM
63622	Complete illegally induced abortion complicated by damage to pelvic organs or tissues	Diagnosis	ICD-9-CM
6363	Illegal abortion complicated by renal failure	Diagnosis	ICD-9-CM
63630	Unspecified illegally induced abortion complicated by renal failure	Diagnosis	ICD-9-CM
63631	Incomplete illegally induced abortion complicated by renal failure	Diagnosis	ICD-9-CM
63632	Complete illegally induced abortion complicated by renal failure	Diagnosis	ICD-9-CM
6364	Illegal abortion complicated by metabolic disorder	Diagnosis	ICD-9-CM
63640	Unspecified illegally induced abortion complicated by metabolic disorder	Diagnosis	ICD-9-CM
63641	Incomplete illegally induced abortion complicated by metabolic disorder	Diagnosis	ICD-9-CM
63642	Complete illegally induced abortion complicated by metabolic disorder	Diagnosis	ICD-9-CM
6365	636.5(ILLEGAL ABORTION W SHOCK)	Diagnosis	ICD-9-CM
63650	Unspecified illegally induced abortion complicated by shock	Diagnosis	ICD-9-CM
63651	Incomplete illegally induced abortion complicated by shock	Diagnosis	ICD-9-CM
63652	Complete illegally induced abortion complicated by shock	Diagnosis	ICD-9-CM
6366	Illegal abortion complicated by embolism	Diagnosis	ICD-9-CM
63660	Unspecified illegally induced abortion complicated by embolism	Diagnosis	ICD-9-CM
63661	Incomplete illegally induced abortion complicated by embolism	Diagnosis	ICD-9-CM
63662	Complete illegally induced abortion complicated by embolism	Diagnosis	ICD-9-CM
6367	Illegal abortion with other specified complications	Diagnosis	ICD-9-CM
63670	Unspecified illegally induced abortion with other specified complications	Diagnosis	ICD-9-CM
63671	Incomplete illegally induced abortion with other specified complications	Diagnosis	ICD-9-CM
63672	Complete illegally induced abortion with other specified complications	Diagnosis	ICD-9-CM
6368	Illegal abortion with unspecified complication	Diagnosis	ICD-9-CM
63680	Unspecified illegally induced abortion with unspecified complication	Diagnosis	ICD-9-CM
63681	Incomplete illegally induced abortion with unspecified complication	Diagnosis	ICD-9-CM
63682	Complete illegally induced abortion with unspecified complication	Diagnosis	ICD-9-CM
6369	Illegal abortion without mention of complication	Diagnosis	ICD-9-CM
63690	Unspecified illegally induced abortion without mention of complication	Diagnosis	ICD-9-CM
63691	Incomplete illegally induced abortion without mention of complication	Diagnosis	ICD-9-CM
63692	Complete illegally induced abortion without mention of complication	Diagnosis	ICD-9-CM
637	637(UNSPECIFIED ABORTION)	Diagnosis	ICD-9-CM
6370	Unspecified abortion complicated by genital tract and pelvic infection	Diagnosis	ICD-9-CM
63700	Abortion, unspecified as to completion or legality, complicated by genital tract and pelvic infection	Diagnosis	ICD-9-CM
63701	Abortion, unspecified as to legality, incomplete, complicated by genital tract and pelvic infection	Diagnosis	ICD-9-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
63702	Abortion, unspecified as to legality, complete, complicated by genital tract and pelvic infection	Diagnosis	ICD-9-CM
6371	Unspecified abortion complicated by delayed or excessive hemorrhage	Diagnosis	ICD-9-CM
63710	Abortion, unspecified as to completion or legality, complicated by delayed or excessive hemorrhage	Diagnosis	ICD-9-CM
63711	Abortion, unspecified as to legality, incomplete, complicated by delayed or excessive hemorrhage	Diagnosis	ICD-9-CM
63712	Abortion, unspecified as to legality, complete, complicated by delayed or excessive hemorrhage	Diagnosis	ICD-9-CM
6372	637.2(ABORT NOS W PELVIC DAMAG)	Diagnosis	ICD-9-CM
63720	Abortion, unspecified as to completion or legality, complicated by damage to pelvic organs or tissues	Diagnosis	ICD-9-CM
63721	Abortion, unspecified as to legality, incomplete, complicated by damage to pelvic organs or tissues	Diagnosis	ICD-9-CM
63722	Abortion, unspecified as to legality, complete, complicated by damage to pelvic organs or tissues	Diagnosis	ICD-9-CM
6373	637.3(ABORT NOS W RENAL FAIL)	Diagnosis	ICD-9-CM
63730	Abortion, unspecified as to completion or legality, complicated by renal failure	Diagnosis	ICD-9-CM
63731	Abortion, unspecified as to legality, incomplete, complicated by renal failure	Diagnosis	ICD-9-CM
63732	Abortion, unspecified as to legality, complete, complicated by renal failure	Diagnosis	ICD-9-CM
6374	637.4(ABORT NOS W METABOL DIS)	Diagnosis	ICD-9-CM
63740	Abortion, unspecified as to completion or legality, complicated by metabolic disorder	Diagnosis	ICD-9-CM
63741	Abortion, unspecified as to legality, incomplete, complicated by metabolic disorder	Diagnosis	ICD-9-CM
63742	Abortion, unspecified as to legality, complete, complicated by metabolic disorder	Diagnosis	ICD-9-CM
6375	637.5(ABORTION NOS W SHOCK)	Diagnosis	ICD-9-CM
63750	Abortion, unspecified as to completion or legality, complicated by shock	Diagnosis	ICD-9-CM
63751	Abortion, unspecified as to legality, incomplete, complicated by shock	Diagnosis	ICD-9-CM
63752	Abortion, unspecified as to legality, complete, complicated by shock	Diagnosis	ICD-9-CM
6376	637.6(ABORTION NOS W EMBOLISM)	Diagnosis	ICD-9-CM
63760	Abortion, unspecified as to completion or legality, complicated by embolism	Diagnosis	ICD-9-CM
63761	Abortion, unspecified as to legality, incomplete, complicated by embolism	Diagnosis	ICD-9-CM
63762	Abortion, unspecified as to legality, complete, complicated by embolism	Diagnosis	ICD-9-CM
6377	637.7(ABORTION NOS W COMPL NEC)	Diagnosis	ICD-9-CM
63770	Abortion, unspecified as to completion or legality, with other specified complications	Diagnosis	ICD-9-CM
63771	Abortion, unspecified as to legality, incomplete, with other specified complications	Diagnosis	ICD-9-CM
63772	Abortion, unspecified as to legality, complete, with other specified complications	Diagnosis	ICD-9-CM
6378	637.8(ABORTION NOS W COMPL NOS)	Diagnosis	ICD-9-CM
63780	Abortion, unspecified as to completion or legality, with unspecified complication	Diagnosis	ICD-9-CM
63781	Abortion, unspecified as to legality, incomplete, with unspecified complication	Diagnosis	ICD-9-CM
63782	Abortion, unspecified as to legality, complete, with unspecified complication	Diagnosis	ICD-9-CM
6379	637.9(ABORTION NOS UNCOMPLICAT)	Diagnosis	ICD-9-CM
63790	Unspecified type of abortion, unspecified as to completion or legality, without mention of complication	Diagnosis	ICD-9-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
63791	Abortion, unspecified as to legality, incomplete, without mention of complication	Diagnosis	ICD-9-CM
63792	Abortion, unspecified as to legality, complete, without mention of complication	Diagnosis	ICD-9-CM
6398	Other specified complications following abortion or ectopic and molar pregnancy	Diagnosis	ICD-9-CM
64101	Placenta previa without hemorrhage, with delivery	Diagnosis	ICD-9-CM
64111	Hemorrhage from placenta previa, with delivery	Diagnosis	ICD-9-CM
64121	Premature separation of placenta, with delivery	Diagnosis	ICD-9-CM
64131	Antepartum hemorrhage associated with coagulation defects, with delivery	Diagnosis	ICD-9-CM
64181	Other antepartum hemorrhage, with delivery	Diagnosis	ICD-9-CM
64191	Unspecified antepartum hemorrhage, with delivery	Diagnosis	ICD-9-CM
64201	Benign essential hypertension with delivery	Diagnosis	ICD-9-CM
64202	Benign essential hypertension, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64211	Hypertension secondary to renal disease, with delivery	Diagnosis	ICD-9-CM
64212	Hypertension secondary to renal disease, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64221	Other pre-existing hypertension, with delivery	Diagnosis	ICD-9-CM
64222	Other pre-existing hypertension, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64231	Transient hypertension of pregnancy, with delivery	Diagnosis	ICD-9-CM
64232	Transient hypertension of pregnancy, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64241	Mild or unspecified pre-eclampsia, with delivery	Diagnosis	ICD-9-CM
64242	Mild or unspecified pre-eclampsia, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64251	Severe pre-eclampsia, with delivery	Diagnosis	ICD-9-CM
64252	Severe pre-eclampsia, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64261	Eclampsia, with delivery	Diagnosis	ICD-9-CM
64262	Eclampsia, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64271	Pre-eclampsia or eclampsia superimposed on pre-existing hypertension, with delivery	Diagnosis	ICD-9-CM
64272	Pre-eclampsia or eclampsia superimposed on pre-existing hypertension, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64291	Unspecified hypertension, with delivery	Diagnosis	ICD-9-CM
64292	Unspecified hypertension, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64301	Mild hyperemesis gravidarum, delivered	Diagnosis	ICD-9-CM
64311	Hyperemesis gravidarum with metabolic disturbance, delivered	Diagnosis	ICD-9-CM
64321	Late vomiting of pregnancy, delivered	Diagnosis	ICD-9-CM
64381	Other vomiting complicating pregnancy, delivered	Diagnosis	ICD-9-CM
64391	Unspecified vomiting of pregnancy, delivered	Diagnosis	ICD-9-CM
64421	Early onset of delivery, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
64501	Prolonged pregnancy, with delivery	Diagnosis	ICD-9-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
64510	Post term pregnancy	Diagnosis	ICD-9-CM
64511	Post term pregnancy, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
64511	Post term pregnancy	Diagnosis	ICD-9-CM
64513	Post term pregnancy	Diagnosis	ICD-9-CM
64520	Prolonged pregnancy	Diagnosis	ICD-9-CM
64521	Prolonged pregnancy, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
64521	Prolonged pregnancy	Diagnosis	ICD-9-CM
64523	Prolonged pregnancy, antepartum condition or complication	Diagnosis	ICD-9-CM
64523	Prolonged pregnancy	Diagnosis	ICD-9-CM
64601	PAPYRACEOUS FETUS, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND	Diagnosis	ICD-9-CM
64611	Edema or excessive weight gain in pregnancy, with delivery, with or without mention of antepartum complication	Diagnosis	ICD-9-CM
64612	Edema or excessive weight gain in pregnancy, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64621	Unspecified renal disease in pregnancy, with delivery	Diagnosis	ICD-9-CM
64622	Unspecified renal disease in pregnancy, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64641	Peripheral neuritis in pregnancy, with delivery	Diagnosis	ICD-9-CM
64642	Peripheral neuritis in pregnancy, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64651	Asymptomatic bacteriuria in pregnancy, with delivery	Diagnosis	ICD-9-CM
64652	Asymptomatic bacteriuria in pregnancy, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64661	Infections of genitourinary tract in pregnancy, with delivery	Diagnosis	ICD-9-CM
64662	Infections of genitourinary tract in pregnancy, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64671	Liver and biliary tract disorders in pregnancy, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
64681	Other specified complication of pregnancy, with delivery	Diagnosis	ICD-9-CM
64682	Other specified complications of pregnancy, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64691	Unspecified complication of pregnancy, with delivery	Diagnosis	ICD-9-CM
64701	Maternal syphilis, complicating pregnancy, with delivery	Diagnosis	ICD-9-CM
64702	Maternal syphilis, complicating pregnancy, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64711	Maternal gonorrhea with delivery	Diagnosis	ICD-9-CM
64712	Maternal gonorrhea, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64721	Other maternal venereal diseases with delivery	Diagnosis	ICD-9-CM
64722	Other maternal venereal diseases with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64731	Maternal tuberculosis with delivery	Diagnosis	ICD-9-CM
64732	Maternal tuberculosis with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64741	Maternal malaria with delivery	Diagnosis	ICD-9-CM
64742	Maternal malaria with delivery, with current postpartum complication	Diagnosis	ICD-9-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
64751	Maternal rubella with delivery	Diagnosis	ICD-9-CM
64752	Maternal rubella with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64761	Other maternal viral disease with delivery	Diagnosis	ICD-9-CM
64762	Other maternal viral disease with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64781	Other specified maternal infectious and parasitic disease with delivery	Diagnosis	ICD-9-CM
64782	Other specified maternal infectious and parasitic disease with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64791	Unspecified maternal infection or infestation with delivery	Diagnosis	ICD-9-CM
64792	Unspecified maternal infection or infestation with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64801	Maternal diabetes mellitus with delivery	Diagnosis	ICD-9-CM
64802	Maternal diabetes mellitus with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64811	Maternal thyroid dysfunction with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
64812	Maternal thyroid dysfunction with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64821	Maternal anemia, with delivery	Diagnosis	ICD-9-CM
64822	Maternal anemia with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64831	Maternal drug dependence, with delivery	Diagnosis	ICD-9-CM
64832	Maternal drug dependence, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64841	Maternal mental disorders, with delivery	Diagnosis	ICD-9-CM
64842	Maternal mental disorders, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64851	Maternal congenital cardiovascular disorders, with delivery	Diagnosis	ICD-9-CM
64852	Maternal congenital cardiovascular disorders, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64861	Other maternal cardiovascular diseases, with delivery	Diagnosis	ICD-9-CM
64862	Other maternal cardiovascular diseases, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64871	Bone and joint disorders of maternal back, pelvis, and lower limbs, with delivery	Diagnosis	ICD-9-CM
64872	Bone and joint disorders of maternal back, pelvis, and lower limbs, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64881	Abnormal maternal glucose tolerance, with delivery	Diagnosis	ICD-9-CM
64882	Abnormal maternal glucose tolerance, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64891	Other current maternal conditions classifiable elsewhere, with delivery	Diagnosis	ICD-9-CM
64892	Other current maternal conditions classifiable elsewhere, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
64901	Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
64902	Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
64911	Obesity complicating pregnancy, childbirth, or the puerperium, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
64912	Obesity complicating pregnancy, childbirth, or the puerperium, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
64921	Bariatric surgery status complicating pregnancy, childbirth, or the puerperium, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
64922	Bariatric surgery status complicating pregnancy, childbirth, or the puerperium, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
64931	Coagulation defects complicating pregnancy, childbirth, or the puerperium, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
64932	Coagulation defects complicating pregnancy, childbirth, or the puerperium, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
64941	Epilepsy complicating pregnancy, childbirth, or the puerperium, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
64942	Epilepsy complicating pregnancy, childbirth, or the puerperium, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
64951	Spotting complicating pregnancy, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
64961	Uterine size date discrepancy, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
64962	Uterine size date discrepancy, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
64971	Cervical shortening, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
64981	Onset (spontaneous) of labor after 37 completed weeks of gestation but before 39 completed weeks gestation, with delivery by (planned) cesarean section, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
64982	Onset (spontaneous) of labor after 37 completed weeks of gestation but before 39 completed weeks gestation, with delivery by (planned) cesarean section, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
650	Normal delivery	Diagnosis	ICD-9-CM
65101	Twin pregnancy, delivered	Diagnosis	ICD-9-CM
65111	Triplet pregnancy, delivered	Diagnosis	ICD-9-CM
65121	Quadruplet pregnancy, delivered	Diagnosis	ICD-9-CM
65130	Twin pregnancy with fetal loss and retention of one fetus, unspecified as to episode of care or not applicable	Diagnosis	ICD-9-CM
65131	Twin pregnancy with fetal loss and retention of one fetus, delivered	Diagnosis	ICD-9-CM
65133	Twin pregnancy with fetal loss and retention of one fetus, antepartum	Diagnosis	ICD-9-CM
65140	Triplet pregnancy with fetal loss and retention of one or more, unspecified as to episode of care or not applicable	Diagnosis	ICD-9-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
65141	Triplet pregnancy with fetal loss and retention of one or more, delivered	Diagnosis	ICD-9-CM
65143	Triplet pregnancy with fetal loss and retention of one or more, antepartum	Diagnosis	ICD-9-CM
65150	Quadruplet pregnancy with fetal loss and retention of one or more, unspecified as to episode of care or not applicable	Diagnosis	ICD-9-CM
65151	Quadruplet pregnancy with fetal loss and retention of one or more, delivered	Diagnosis	ICD-9-CM
65153	Quadruplet pregnancy with fetal loss and retention of one or more, antepartum	Diagnosis	ICD-9-CM
65160	Other multiple pregnancy with fetal loss and retention of one or more fetus(es), unspecified as to episode of care or not applicable	Diagnosis	ICD-9-CM
65161	Other multiple pregnancy with fetal loss and retention of one or more fetus(es), delivered	Diagnosis	ICD-9-CM
65163	Other multiple pregnancy with fetal loss and retention of one or more fetus(es), antepartum	Diagnosis	ICD-9-CM
65171	Multiple gestation following (elective) fetal reduction, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
65181	Other specified multiple gestation, delivered	Diagnosis	ICD-9-CM
65191	Unspecified multiple gestation, delivered	Diagnosis	ICD-9-CM
65201	Unstable lie of fetus, delivered	Diagnosis	ICD-9-CM
65211	Breech or other malpresentation successfully converted to cephalic presentation, delivered	Diagnosis	ICD-9-CM
65221	Breech presentation without mention of version, delivered	Diagnosis	ICD-9-CM
65231	Transverse or oblique fetal presentation, delivered	Diagnosis	ICD-9-CM
65241	Fetal face or brow presentation, delivered	Diagnosis	ICD-9-CM
65251	High fetal head at term, delivered	Diagnosis	ICD-9-CM
65261	Multiple gestation with malpresentation of one fetus or more, delivered	Diagnosis	ICD-9-CM
65271	Prolapsed arm of fetus, delivered	Diagnosis	ICD-9-CM
65281	Other specified malposition or malpresentation of fetus, delivered	Diagnosis	ICD-9-CM
65291	Unspecified malposition or malpresentation of fetus, delivered	Diagnosis	ICD-9-CM
65301	Major abnormality of bony pelvis, not further specified, delivered	Diagnosis	ICD-9-CM
65311	Generally contracted pelvis in pregnancy, delivered	Diagnosis	ICD-9-CM
65321	Inlet contraction of pelvis in pregnancy, delivered	Diagnosis	ICD-9-CM
65331	Outlet contraction of pelvis in pregnancy, delivered	Diagnosis	ICD-9-CM
65341	Fetopelvic disproportion, delivered	Diagnosis	ICD-9-CM
65351	Unusually large fetus causing disproportion, delivered	Diagnosis	ICD-9-CM
65361	Hydrocephalic fetus causing disproportion, delivered	Diagnosis	ICD-9-CM
65371	Other fetal abnormality causing disproportion, delivered	Diagnosis	ICD-9-CM
65381	Fetal disproportion of other origin, delivered	Diagnosis	ICD-9-CM
65391	Unspecified fetal disproportion, delivered	Diagnosis	ICD-9-CM
65401	Congenital abnormalities of pregnant uterus, delivered	Diagnosis	ICD-9-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
65402	Congenital abnormalities of pregnant uterus, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
65411	Tumors of body of uterus, delivered	Diagnosis	ICD-9-CM
65412	Tumors of body of uterus, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
65421	Previous cesarean delivery, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
65431	Retroverted and incarcerated gravid uterus, delivered	Diagnosis	ICD-9-CM
65432	Retroverted and incarcerated gravid uterus, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
65441	Other abnormalities in shape or position of gravid uterus and of neighboring structures, delivered	Diagnosis	ICD-9-CM
65442	Other abnormalities in shape or position of gravid uterus and of neighboring structures, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
65451	Cervical incompetence, delivered	Diagnosis	ICD-9-CM
65452	Cervical incompetence, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
65461	Other congenital or acquired abnormality of cervix, with delivery	Diagnosis	ICD-9-CM
65462	Other congenital or acquired abnormality of cervix, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
65471	Congenital or acquired abnormality of vagina, with delivery	Diagnosis	ICD-9-CM
65472	Congenital or acquired abnormality of vagina, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
65481	Congenital or acquired abnormality of vulva, with delivery	Diagnosis	ICD-9-CM
65482	Congenital or acquired abnormality of vulva, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
65491	Other and unspecified abnormality of organs and soft tissues of pelvis, with delivery	Diagnosis	ICD-9-CM
65492	Other and unspecified abnormality of organs and soft tissues of pelvis, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
65501	Central nervous system malformation in fetus, with delivery	Diagnosis	ICD-9-CM
65511	Chromosomal abnormality in fetus, affecting management of mother, with delivery	Diagnosis	ICD-9-CM
65521	Hereditary disease in family possibly affecting fetus, affecting management of mother, with delivery	Diagnosis	ICD-9-CM
65531	Suspected damage to fetus from viral disease in mother, affecting management of mother, with delivery	Diagnosis	ICD-9-CM
65541	Suspected damage to fetus from other disease in mother, affecting management of mother, with delivery	Diagnosis	ICD-9-CM
65551	Suspected damage to fetus from drugs, affecting management of mother, delivered	Diagnosis	ICD-9-CM
65561	Suspected damage to fetus from radiation, affecting management of mother, delivered	Diagnosis	ICD-9-CM
65571	Decreased fetal movements, affecting management of mother, delivered	Diagnosis	ICD-9-CM
65581	Other known or suspected fetal abnormality, not elsewhere classified, affecting management of mother, delivery	Diagnosis	ICD-9-CM
65591	Unspecified fetal abnormality affecting management of mother, delivery	Diagnosis	ICD-9-CM
65601	Fetal-maternal hemorrhage, with delivery	Diagnosis	ICD-9-CM
65611	Rhesus isoimmunization affecting management of mother, delivered	Diagnosis	ICD-9-CM
65621	Isoimmunization from other and unspecified blood-group incompatibility, affecting management of mother, delivered	Diagnosis	ICD-9-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
65631	Fetal distress affecting management of mother, delivered	Diagnosis	ICD-9-CM
65640	Intrauterine death affecting management of mother unspecified as to episode of care	Diagnosis	ICD-9-CM
65641	Intrauterine death, affecting management of mother, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
65643	Intrauterine death affecting management of mother antepartum	Diagnosis	ICD-9-CM
65651	Poor fetal growth, affecting management of mother, delivered	Diagnosis	ICD-9-CM
65661	Excessive fetal growth affecting management of mother, delivered	Diagnosis	ICD-9-CM
65671	Other placental conditions affecting management of mother, delivered	Diagnosis	ICD-9-CM
65681	Other specified fetal and placental problems affecting management of mother, delivered	Diagnosis	ICD-9-CM
65691	Unspecified fetal and placental problem affecting management of mother, delivered	Diagnosis	ICD-9-CM
65701	Polyhydramnios, with delivery	Diagnosis	ICD-9-CM
65801	Oligohydramnios, delivered	Diagnosis	ICD-9-CM
65811	Premature rupture of membranes in pregnancy, delivered	Diagnosis	ICD-9-CM
65821	Delayed delivery after spontaneous or unspecified rupture of membranes, delivered	Diagnosis	ICD-9-CM
65831	Delayed delivery after artificial rupture of membranes, delivered	Diagnosis	ICD-9-CM
65841	Infection of amniotic cavity, delivered	Diagnosis	ICD-9-CM
65881	Other problem associated with amniotic cavity and membranes, delivered	Diagnosis	ICD-9-CM
65891	Unspecified problem associated with amniotic cavity and membranes, delivered	Diagnosis	ICD-9-CM
65901	Failed mechanical induction of labor, delivered	Diagnosis	ICD-9-CM
65911	Failed medical or unspecified induction of labor, delivered	Diagnosis	ICD-9-CM
65921	Unspecified maternal pyrexia during labor, delivered	Diagnosis	ICD-9-CM
65931	Generalized infection during labor, delivered	Diagnosis	ICD-9-CM
65941	Grand multiparity, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
65951	Elderly primigravida, delivered	Diagnosis	ICD-9-CM
65961	Elderly multigravida, delivered, with mention of antepartum condition	Diagnosis	ICD-9-CM
65971	Abnormality in fetal heart rate or rhythm, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
65981	Other specified indication for care or intervention related to labor and delivery, delivered	Diagnosis	ICD-9-CM
65991	Unspecified indication for care or intervention related to labor and delivery, delivered	Diagnosis	ICD-9-CM
66001	Obstruction caused by malposition of fetus at onset of labor, delivered	Diagnosis	ICD-9-CM
66011	Obstruction by bony pelvis during labor and delivery, delivered	Diagnosis	ICD-9-CM
66021	Obstruction by abnormal pelvic soft tissues during labor and delivery, delivered	Diagnosis	ICD-9-CM
66031	Deep transverse arrest and persistent occipitoposterior position during labor and deliver, delivered	Diagnosis	ICD-9-CM
66041	Shoulder (girdle) dystocia during labor and deliver, delivered	Diagnosis	ICD-9-CM
66051	Locked twins, delivered	Diagnosis	ICD-9-CM
66061	Unspecified failed trial of labor, delivered	Diagnosis	ICD-9-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
66071	Unspecified failed forceps or vacuum extractor, delivered	Diagnosis	ICD-9-CM
66081	Other causes of obstructed labor, delivered	Diagnosis	ICD-9-CM
66091	Unspecified obstructed labor, with delivery	Diagnosis	ICD-9-CM
66101	Primary uterine inertia, with delivery	Diagnosis	ICD-9-CM
66111	Secondary uterine inertia, with delivery	Diagnosis	ICD-9-CM
66121	Other and unspecified uterine inertia, with delivery	Diagnosis	ICD-9-CM
66131	Precipitate labor, with delivery	Diagnosis	ICD-9-CM
66141	Hypertonic, incoordinate, or prolonged uterine contractions, with delivery	Diagnosis	ICD-9-CM
66191	Unspecified abnormality of labor, with delivery	Diagnosis	ICD-9-CM
66201	Prolonged first stage of labor, delivered	Diagnosis	ICD-9-CM
66211	Unspecified prolonged labor, delivered	Diagnosis	ICD-9-CM
66221	Prolonged second stage of labor, delivered	Diagnosis	ICD-9-CM
66231	Delayed delivery of second twin, triplet, etc., delivered	Diagnosis	ICD-9-CM
66301	Prolapse of cord, complicating labor and delivery, delivered	Diagnosis	ICD-9-CM
66311	Cord around neck, with compression, complicating labor and delivery, delivered	Diagnosis	ICD-9-CM
66321	Other and unspecified cord entanglement, with compression, complicating labor and delivery, delivered	Diagnosis	ICD-9-CM
66331	Other and unspecified cord entanglement, without mention of compression, complicating labor and delivery, delivered	Diagnosis	ICD-9-CM
66341	Short cord complicating labor and delivery, delivered	Diagnosis	ICD-9-CM
66351	Vasa previa complicating labor and delivery, delivered	Diagnosis	ICD-9-CM
66361	Vascular lesions of cord complicating labor and delivery, delivered	Diagnosis	ICD-9-CM
66381	Other umbilical cord complications during labor and delivery, delivered	Diagnosis	ICD-9-CM
66391	Unspecified umbilical cord complication during labor and delivery, delivered	Diagnosis	ICD-9-CM
66401	First-degree perineal laceration, with delivery	Diagnosis	ICD-9-CM
66411	Second-degree perineal laceration, with delivery	Diagnosis	ICD-9-CM
66421	Third-degree perineal laceration, with delivery	Diagnosis	ICD-9-CM
66431	Fourth-degree perineal laceration, with delivery	Diagnosis	ICD-9-CM
66441	Unspecified perineal laceration, with delivery	Diagnosis	ICD-9-CM
66451	Vulvar and perineal hematoma, with delivery	Diagnosis	ICD-9-CM
66461	Anal sphincter tear complicating delivery, not associated with third-degree perineal laceration, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
66481	Other specified trauma to perineum and vulva, with delivery	Diagnosis	ICD-9-CM
66491	Unspecified trauma to perineum and vulva, with delivery	Diagnosis	ICD-9-CM
66501	Rupture of uterus before onset of labor, with delivery	Diagnosis	ICD-9-CM
66511	Rupture of uterus during labor, with delivery	Diagnosis	ICD-9-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
66522	Inversion of uterus, delivered with postpartum complication	Diagnosis	ICD-9-CM
66531	Laceration of cervix, with delivery	Diagnosis	ICD-9-CM
66541	High vaginal laceration, with delivery	Diagnosis	ICD-9-CM
66551	Other injury to pelvic organs, with delivery	Diagnosis	ICD-9-CM
66561	Damage to pelvic joints and ligaments, with delivery	Diagnosis	ICD-9-CM
66571	Pelvic hematoma, with delivery	Diagnosis	ICD-9-CM
66572	Pelvic hematoma, delivered with postpartum complication	Diagnosis	ICD-9-CM
66581	Other specified obstetrical trauma, with delivery	Diagnosis	ICD-9-CM
66582	Other specified obstetrical trauma, delivered, with postpartum	Diagnosis	ICD-9-CM
66591	Unspecified obstetrical trauma, with delivery	Diagnosis	ICD-9-CM
66592	Unspecified obstetrical trauma, delivered, with postpartum complication	Diagnosis	ICD-9-CM
66602	Third-stage postpartum hemorrhage, with delivery	Diagnosis	ICD-9-CM
66612	Other immediate postpartum hemorrhage, with delivery	Diagnosis	ICD-9-CM
6662	REMOV TUBE ECTOP PREG	Procedure	ICD-9-CM
66622	Delayed and secondary postpartum hemorrhage, with delivery	Diagnosis	ICD-9-CM
66632	Postpartum coagulation defects, with delivery	Diagnosis	ICD-9-CM
66702	Retained placenta without hemorrhage, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
66712	Retained portions of placenta or membranes, without hemorrhage, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
66801	Pulmonary complications of the administration of anesthesia or other sedation in labor and delivery, delivered	Diagnosis	ICD-9-CM
66802	Pulmonary complications of the administration of anesthesia or other sedation in labor and delivery, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
66811	Cardiac complications of the administration of anesthesia or other sedation in labor and delivery, delivered	Diagnosis	ICD-9-CM
66812	Cardiac complications of the administration of anesthesia or other sedation in labor and delivery, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
66821	Central nervous system complications of the administration of anesthesia or other sedation in labor and delivery, delivered	Diagnosis	ICD-9-CM
66822	Central nervous system complications of the administration of anesthesia or other sedation in labor and delivery, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
66881	Other complications of the administration of anesthesia or other sedation in labor and delivery, delivered	Diagnosis	ICD-9-CM
66882	Other complications of the administration of anesthesia or other sedation in labor and delivery, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
66891	Unspecified complication of the administration of anesthesia or other sedation in labor and delivery, delivered	Diagnosis	ICD-9-CM
66892	Unspecified complication of the administration of anesthesia or other sedation in labor and delivery, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
66901	Maternal distress, with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
66902	Maternal distress, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
66911	Shock during or following labor and delivery, with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
66912	Shock during or following labor and delivery, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
66921	Maternal hypotension syndrome, with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
66922	Maternal hypotension syndrome, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
66932	Acute kidney failure following labor and delivery, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
66941	Other complications of obstetrical surgery and PRs, with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
66942	Other complications of obstetrical surgery and PRs, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
66951	Forceps or vacuum extractor delivery without mention of indication, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
66961	Breech extraction, without mention of indication, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
66971	Cesarean delivery, without mention of indication, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
66981	Other complication of labor and delivery, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
66982	Other complication of labor and delivery, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
66991	Unspecified complication of labor and delivery, with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
66992	Unspecified complication of labor and delivery, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67002	Major puerperal infection, unspecified, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
67012	Puerperal endometritis, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
67022	Puerperal sepsis, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
67032	Puerperal septic thrombophlebitis, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
67082	Other major puerperal infection, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
67101	Varicose veins of legs, with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67102	Varicose veins of legs, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67111	Varicose veins of vulva and perineum, with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
67112	Varicose veins of vulva and perineum, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67121	Superficial thrombophlebitis with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67122	Superficial thrombophlebitis with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67131	Deep phlebothrombosis, antepartum, with delivery	Diagnosis	ICD-9-CM
67142	Deep phlebothrombosis, postpartum, with delivery	Diagnosis	ICD-9-CM
67151	Other phlebitis and thrombosis with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67152	Other phlebitis and thrombosis with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67181	Other venous complication, with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67182	Other venous complication, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67191	Unspecified venous complication, with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67192	Unspecified venous complication, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67202	Puerperal pyrexia of unknown origin, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
67301	Obstetrical air embolism, with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67302	Obstetrical air embolism, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67311	Amniotic fluid embolism, with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67312	Amniotic fluid embolism, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67321	Obstetrical blood-clot embolism, with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67322	Obstetrical blood-clot embolism, with mention of postpartum complication	Diagnosis	ICD-9-CM
67331	Obstetrical pyemic and septic embolism, with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67332	Obstetrical pyemic and septic embolism, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67381	Other obstetrical pulmonary embolism, with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67382	Other obstetrical pulmonary embolism, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67401	Cerebrovascular disorder, with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67402	Cerebrovascular disorder, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67412	Disruption of cesarean wound, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67422	Disruption of perineal wound, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67432	Other complication of obstetrical surgical wounds, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67442	Placental polyp, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67451	Peripartum cardiomyopathy, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67452	Peripartum cardiomyopathy, delivered, with mention of postpartum condition	Diagnosis	ICD-9-CM
67482	Other complication of puerperium, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67492	Unspecified complications of puerperium, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67501	Infection of nipple associated with childbirth, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67502	Infection of nipple associated with childbirth, delivered with mention of postpartum complication	Diagnosis	ICD-9-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
67511	Abscess of breast associated with childbirth, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67512	Abscess of breast associated with childbirth, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
67521	Nonpurulent mastitis, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67522	Nonpurulent mastitis, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
67581	Other specified infection of the breast and nipple associated with childbirth, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67582	Other specified infection of the breast and nipple associated with childbirth, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
67591	Unspecified infection of the breast and nipple, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67592	Unspecified infection of the breast and nipple, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
67601	Retracted nipple, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67602	Retracted nipple, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
67611	Cracked nipple, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67612	Cracked nipple, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
67621	Engorgement of breasts, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67622	Engorgement of breasts, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
67631	Other and unspecified disorder of breast associated with childbirth, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67632	Other and unspecified disorder of breast associated with childbirth, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
67641	Failure of lactation, with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67642	Failure of lactation, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67651	Suppressed lactation, with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67652	Suppressed lactation, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67661	Galactorrhea, with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67662	Galactorrhea, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67681	Other disorder of lactation, with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67682	Other disorder of lactation, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67691	Unspecified disorder of lactation, with delivery, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67692	Unspecified disorder of lactation, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
67801	Fetal hematologic conditions, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67811	Fetal conjoined twins, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67901	Maternal complications from in utero PR, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67902	Maternal complications from in utero PR, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
67911	Fetal complications from in utero PR, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
67912	Fetal complications from in utero PR, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
6901	Dilation and curettage for termination of pregnancy	Procedure	ICD-9-CM
6951	Aspiration curettage of uterus for termination of pregnancy	Procedure	ICD-9-CM
72	Forceps, vacuum, and breech delivery	Procedure	ICD-9-CM
720	Low forceps operation	Procedure	ICD-9-CM
721	Low forceps operation with episiotomy	Procedure	ICD-9-CM
722	Mid forceps operation	Procedure	ICD-9-CM
7221	Mid forceps operation with episiotomy	Procedure	ICD-9-CM
7229	Other mid forceps operation	Procedure	ICD-9-CM
723	High forceps operation	Procedure	ICD-9-CM
7231	High forceps operation with episiotomy	Procedure	ICD-9-CM
7239	Other high forceps operation	Procedure	ICD-9-CM
724	Forceps rotation of fetal head	Procedure	ICD-9-CM
725	Breech extraction	Procedure	ICD-9-CM
7251	Partial breech extraction with forceps to aftercoming head	Procedure	ICD-9-CM
7252	Other partial breech extraction	Procedure	ICD-9-CM
7253	Total breech extraction with forceps to aftercoming head	Procedure	ICD-9-CM
7254	Other total breech extraction	Procedure	ICD-9-CM
726	Forceps application to aftercoming head	Procedure	ICD-9-CM
727	Vacuum extraction	Procedure	ICD-9-CM
7271	Vacuum extraction with episiotomy	Procedure	ICD-9-CM
7279	Other vacuum extraction	Procedure	ICD-9-CM
728	Other specified instrumental delivery	Procedure	ICD-9-CM
729	Unspecified instrumental delivery	Procedure	ICD-9-CM
73	Other PRs inducing or assisting delivery	Procedure	ICD-9-CM
730	Artificial rupture of membranes	Procedure	ICD-9-CM
7301	Induction of labor by artificial rupture of membranes	Procedure	ICD-9-CM
7309	Other artificial rupture of membranes	Procedure	ICD-9-CM
731	Other surgical induction of labor	Procedure	ICD-9-CM
732	Internal and combined version and extraction	Procedure	ICD-9-CM
7321	Internal and combined version without extraction	Procedure	ICD-9-CM
7322	Internal and combined version with extraction	Procedure	ICD-9-CM
733	Failed forceps	Procedure	ICD-9-CM
734	Medical induction of labor	Procedure	ICD-9-CM
735	Manually assisted delivery	Procedure	ICD-9-CM

Code	Description	Code Category	Code Type
7351	Manual rotation of fetal head	Procedure	ICD-9-CM
7359	Other manually assisted delivery	Procedure	ICD-9-CM
736	Episiotomy	Procedure	ICD-9-CM
738	Operations on fetus to facilitate delivery	Procedure	ICD-9-CM
739	Other operations assisting delivery	Procedure	ICD-9-CM
7391	External version to assist delivery	Procedure	ICD-9-CM
7392	Replacement of prolapsed umbilical cord	Procedure	ICD-9-CM
7393	Incision of cervix to assist delivery	Procedure	ICD-9-CM
7394	Pubiotomy to assist delivery	Procedure	ICD-9-CM
7399	Other operations to assist delivery	Procedure	ICD-9-CM
740	Classical cesarean section	Procedure	ICD-9-CM
741	Low cervical cesarean section	Procedure	ICD-9-CM
742	Extraperitoneal cesarean section	Procedure	ICD-9-CM
743	REMOV INTRAPERIT FETUS	Procedure	ICD-9-CM
744	Cesarean section of other specified type	Procedure	ICD-9-CM
749	Cesarean section of unspecified type	Procedure	ICD-9-CM
7491	Hysterotomy to terminate pregnancy	Procedure	ICD-9-CM
7499	Other cesarean section of unspecified type	Procedure	ICD-9-CM
750	Intra-amniotic injection for abortion	Procedure	ICD-9-CM
7630	Fetus or newborn affected by breech delivery and extraction	Diagnosis	ICD-9-CM
7632	Fetus or newborn affected by forceps delivery	Diagnosis	ICD-9-CM
7633	Fetus or newborn affected by delivery by vacuum extractor	Diagnosis	ICD-9-CM
7634	Fetus or newborn affected by cesarean delivery	Diagnosis	ICD-9-CM
7636	Fetus or newborn affected by precipitate delivery	Diagnosis	ICD-9-CM
76500	Extreme immaturity, unspecified [weight]	Diagnosis	ICD-9-CM
76501	Extreme immaturity, less than 500 grams	Diagnosis	ICD-9-CM
76502	Extreme immaturity, 500-749 grams	Diagnosis	ICD-9-CM
76503	Extreme immaturity, 750-999 grams	Diagnosis	ICD-9-CM
76504	Extreme immaturity, 1,000-1,249 grams	Diagnosis	ICD-9-CM
76505	Extreme immaturity, 1,250-1,499 grams	Diagnosis	ICD-9-CM
76506	Extreme immaturity, 1,500-1,749 grams	Diagnosis	ICD-9-CM
76507	Extreme immaturity, 1,750-1,999 grams	Diagnosis	ICD-9-CM
76508	Extreme immaturity, 2,000-2,499 grams	Diagnosis	ICD-9-CM
76509	Extreme immaturity, 2,500 grams and over	Diagnosis	ICD-9-CM
76510	Other preterm infants, unspecified [weight]	Diagnosis	ICD-9-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
76511	Other preterm infants, less than 500 grams	Diagnosis	ICD-9-CM
76512	Other preterm infants, 500-749 grams	Diagnosis	ICD-9-CM
76513	Other preterm infants, 750-999 grams	Diagnosis	ICD-9-CM
76514	Other preterm infants, 1,000-1,249 grams	Diagnosis	ICD-9-CM
76515	Other preterm infants, 1,250-1,499 grams	Diagnosis	ICD-9-CM
76516	Other preterm infants, 1,500-1,749 grams	Diagnosis	ICD-9-CM
76517	Other preterm infants, 1,750-1,999 grams	Diagnosis	ICD-9-CM
76518	Other preterm infants, 2,000-2,499 grams	Diagnosis	ICD-9-CM
76519	Other preterm infants, 2,500 grams and over	Diagnosis	ICD-9-CM
76520	Unspecified weeks of gestation	Diagnosis	ICD-9-CM
76521	Less than 24 completed weeks of gestation	Diagnosis	ICD-9-CM
76522	24 completed weeks of gestation	Diagnosis	ICD-9-CM
76523	25-26 completed weeks of gestation	Diagnosis	ICD-9-CM
76524	27-28 completed weeks of gestation	Diagnosis	ICD-9-CM
76525	29-30 completed weeks of gestation	Diagnosis	ICD-9-CM
76526	31-32 completed weeks of gestation	Diagnosis	ICD-9-CM
76527	33-34 completed weeks of gestation	Diagnosis	ICD-9-CM
76528	35-36 completed weeks of gestation	Diagnosis	ICD-9-CM
76529	37+ completed weeks of gestation	Diagnosis	ICD-9-CM
76621	Post-term infant	Diagnosis	ICD-9-CM
76622	Prolonged gestation of infant	Diagnosis	ICD-9-CM
7680	Fetal death from asphyxia or anoxia before onset of labor or at unspecified time	Diagnosis	ICD-9-CM
76801	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, first trimester (< 14 weeks 0 days), transabdominal approach; single or first gestation	Procedure	CPT-4
76802	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, first trimester (< 14 weeks 0 days), transabdominal approach; each additional gestation	Procedure	CPT-4
76805	Complete Ultrasounds (Maternal and Fetal Evaluation); Second and Third Trimesters (Single or First Gestation)	Procedure	CPT-4
7681	Fetal death from asphyxia or anoxia during labor	Diagnosis	ICD-9-CM
76810	Complete Ultrasounds (Maternal and Fetal Evaluation); Second and Third Trimesters (Each Additional Gestation)	Procedure	CPT-4
76811	Detailed fetal anatomic examination (single or first gestation)	Procedure	CPT-4
76812	Detailed fetal anatomic examination (Each additional Gestation)	Procedure	CPT-4
76813	Nuchal Translucency Measurement (Single or First Gestation)	Procedure	CPT-4
76814	Nuchal Translucency Measurement (Each Additional Gestation)	Procedure	CPT-4

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
7796	Termination of pregnancy (fetus)	Diagnosis	ICD-9-CM
81420	Fetal aneuploidy genomic sequence analysis, cell-free fetal DNA	Procedure	CPT-4
81507	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma algorithm reported as a risk score for each trisomy	Procedure	CPT-4
82106	Alpha-fetoprotein, amniotic	Procedure	CPT-4
82677	Assay of estriol	Procedure	CPT-4
82950	Glucose; post glucose dose (includes glucose)	Procedure	CPT-4
82951	Glucose; tolerance test (GTT), 3 specimens (includes glucose)	Procedure	CPT-4
82952	Glucose tolerance test, additional beyond 3 specimens	Procedure	CPT-4
84163	PAPP-A serum test	Procedure	CPT-4
86336	Inhibin A	Procedure	CPT-4
87081	Group B streptococcus screening (genital)	Procedure	CPT-4
88016	Necropsy (autopsy), gross examination only; macerated stillborn	Procedure	CPT-4
O00	Ectopic pregnancy	Diagnosis	ICD-10-CM
O000	Abdominal pregnancy	Diagnosis	ICD-10-CM
O0000	Abdominal pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O0001	Abdominal pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O001	Tubal pregnancy	Diagnosis	ICD-10-CM
O0010	Tubal pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00101	Right tubal pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00102	Left tubal pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00109	Unspecified tubal pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O0011	Tubal pregnancy wit intrauterine pregnancy	Diagnosis	ICD-10-CM
O00111	Right tubal pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O00112	Left tubal pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O00119	Unspecified tubal pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O002	Ovarian pregnancy	Diagnosis	ICD-10-CM
O0020	Ovarian pregnancy WITHOUT INTRAUTERINE PREGNANCY	Diagnosis	ICD-10-CM
O00201	Right ovarian pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00202	Left ovarian pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00209	Unspecified ovarian pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O0021	Ovarian pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O00211	Right ovarian pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O00212	Left ovarian pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00219	Unspecified ovarian pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O008	Other ectopic pregnancy	Diagnosis	ICD-10-CM
O0080	Other ectopic pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O0081	Other ectopic pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O009	Ectopic pregnancy, unspecified	Diagnosis	ICD-10-CM
O0090	Unspecified ectopic pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O0091	Unspecified ectopic pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O01	Hydatidiform mole	Diagnosis	ICD-10-CM
O010	Classical hydatidiform mole	Diagnosis	ICD-10-CM
O011	Incomplete and partial hydatidiform mole	Diagnosis	ICD-10-CM
O019	Hydatidiform mole, unspecified	Diagnosis	ICD-10-CM
O020	Blighted ovum and nonhydatidiform mole	Diagnosis	ICD-10-CM
O021	Missed abortion	Diagnosis	ICD-10-CM
O0289	Other abnormal products of conception	Diagnosis	ICD-10-CM
O029	Abnormal products of conception, unspecified	Diagnosis	ICD-10-CM
O03	Spontaneous abortion	Diagnosis	ICD-10-CM
O030	Genital tract and pelvic infection following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
O031	Delayed or excessive hemorrhage following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
O032	Embolism following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
O0330	Unspecified complication following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
O0331	Shock following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
O0332	Renal failure following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
O0333	Metabolic disorder following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
O0334	Damage to pelvic organs following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
O0335	Other venous complications following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
O0336	Cardiac arrest following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
O0337	Sepsis following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
O0338	Urinary tract infection following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
O0339	Incomplete spontaneous abortion with other complications	Diagnosis	ICD-10-CM
O034	Incomplete spontaneous abortion without complication	Diagnosis	ICD-10-CM
O035	Genital tract and pelvic infection following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
O036	Delayed or excessive hemorrhage following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
O037	Embolism following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
O0380	Unspecified complication following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
O0381	Shock following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
O0382	Renal failure following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O0383	Metabolic disorder following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
O0384	Damage to pelvic organs following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
O0385	Other venous complications following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
O0386	Cardiac arrest following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
O0387	Sepsis following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
O0388	Urinary tract infection following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
O0389	Complete or unspecified spontaneous abortion with other complications	Diagnosis	ICD-10-CM
O039	Complete or unspecified spontaneous abortion without complication	Diagnosis	ICD-10-CM
O04	Complications following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
O045	Genital tract and pelvic infection following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
O046	Delayed or excessive hemorrhage following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
O047	Embolism following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
O048	(Induced) termination of pregnancy with other and unspecified complications	Diagnosis	ICD-10-CM
O0480	(Induced) termination of pregnancy with unspecified complications	Diagnosis	ICD-10-CM
O0481	Shock following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
O0482	Renal failure following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
O0483	Metabolic disorder following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
O0484	Damage to pelvic organs following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
O0485	Other venous complications following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
O0486	Cardiac arrest following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
O0487	Sepsis following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
O0488	Urinary tract infection following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
O0489	(Induced) termination of pregnancy with other complications	Diagnosis	ICD-10-CM
O080	Genitl trct and pelvic infct fol ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O081	Delayed or excess hemor fol ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O082	Embolism following ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O083	Shock following ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O084	Renal failure following ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O085	Metabolic disorders following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O086	Damage to pelvic organs and tiss fol an ect and molar preg	Diagnosis	ICD-10-CM
O087	Oth venous comp following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O0881	Cardiac arrest following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O0882	Sepsis following ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O0883	Urinary tract infection fol an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O0889	Other complications following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O089	Unsp complication following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O0901	Supervision of pregnancy with history of infertility, first trimester	Diagnosis	ICD-10-CM
O0902	Supervision of pregnancy with history of infertility, second trimester	Diagnosis	ICD-10-CM
O0903	Supervision of pregnancy with history of infertility, third trimester	Diagnosis	ICD-10-CM
O0911	Supervision of pregnancy with history of ectopic pregnancy, first trimester	Diagnosis	ICD-10-CM
O0912	Supervision of pregnancy with history of ectopic pregnancy, second trimester	Diagnosis	ICD-10-CM
O0913	Supervision of pregnancy with history of ectopic pregnancy, third trimester	Diagnosis	ICD-10-CM
O09211	Supervision of pregnancy with history of pre-term labor, first trimester	Diagnosis	ICD-10-CM
O09212	Supervision of pregnancy with history of pre-term labor, second trimester	Diagnosis	ICD-10-CM
O09213	Supervision of pregnancy with history of pre-term labor, third trimester	Diagnosis	ICD-10-CM
O09291	Supervision of pregnancy with other poor reproductive or obstetric history, first trimester	Diagnosis	ICD-10-CM
O09292	Supervision of pregnancy with other poor reproductive or obstetric history, second trimester	Diagnosis	ICD-10-CM
O09293	Supervision of pregnancy with other poor reproductive or obstetric history, third trimester	Diagnosis	ICD-10-CM
O0931	Supervision of pregnancy with insufficient antenatal care, first trimester	Diagnosis	ICD-10-CM
O0932	Supervision of pregnancy with insufficient antenatal care, second trimester	Diagnosis	ICD-10-CM
O0933	Supervision of pregnancy with insufficient antenatal care, third trimester	Diagnosis	ICD-10-CM
O0941	Supervision of pregnancy with grand multiparity, first trimester	Diagnosis	ICD-10-CM
O0942	Supervision of pregnancy with grand multiparity, second trimester	Diagnosis	ICD-10-CM
O0943	Supervision of pregnancy with grand multiparity, third trimester	Diagnosis	ICD-10-CM
O09511	Supervision of elderly primigravida, first trimester	Diagnosis	ICD-10-CM
O09512	Supervision of elderly primigravida, second trimester	Diagnosis	ICD-10-CM
O09513	Supervision of elderly primigravida, third trimester	Diagnosis	ICD-10-CM
O09521	Supervision of elderly multigravida, first trimester	Diagnosis	ICD-10-CM
O09522	Supervision of elderly multigravida, second trimester	Diagnosis	ICD-10-CM
O09523	Supervision of elderly multigravida, third trimester	Diagnosis	ICD-10-CM
O09611	Supervision of young primigravida, first trimester	Diagnosis	ICD-10-CM
O09612	Supervision of young primigravida, second trimester	Diagnosis	ICD-10-CM
O09613	Supervision of young primigravida, third trimester	Diagnosis	ICD-10-CM
O09621	Supervision of young multigravida, first trimester	Diagnosis	ICD-10-CM
O09622	Supervision of young multigravida, second trimester	Diagnosis	ICD-10-CM
O09623	Supervision of young multigravida, third trimester	Diagnosis	ICD-10-CM
O0971	Supervision of high risk pregnancy due to social problems, first trimester	Diagnosis	ICD-10-CM
O0972	Supervision of high risk pregnancy due to social problems, second trimester	Diagnosis	ICD-10-CM
O0973	Supervision of high risk pregnancy due to social problems, third trimester	Diagnosis	ICD-10-CM
O09811	Supervision of pregnancy resulting from assisted reproductive technology, first trimester	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O09812	Supervision of pregnancy resulting from assisted reproductive technology, second trimester	Diagnosis	ICD-10-CM
O09813	Supervision of pregnancy resulting from assisted reproductive technology, third trimester	Diagnosis	ICD-10-CM
O09821	Supervision of pregnancy with history of in utero procedure during previous pregnancy, first trimester	Diagnosis	ICD-10-CM
O09822	Supervision of pregnancy with history of in utero procedure during previous pregnancy, second trimester	Diagnosis	ICD-10-CM
O09823	Supervision of pregnancy with history of in utero procedure during previous pregnancy, third trimester	Diagnosis	ICD-10-CM
O09891	Supervision of other high risk pregnancies, first trimester	Diagnosis	ICD-10-CM
O09892	Supervision of other high risk pregnancies, second trimester	Diagnosis	ICD-10-CM
O09893	Supervision of other high risk pregnancies, third trimester	Diagnosis	ICD-10-CM
O0991	Supervision of high risk pregnancy, unspecified, first trimester	Diagnosis	ICD-10-CM
O0992	Supervision of high risk pregnancy, unspecified, second trimester	Diagnosis	ICD-10-CM
O0993	Supervision of high risk pregnancy, unspecified, third trimester	Diagnosis	ICD-10-CM
O09A1	Supervision of pregnancy with history of molar pregnancy, first trimester	Diagnosis	ICD-10-CM
O09A2	Supervision of pregnancy with history of molar pregnancy, second trimester	Diagnosis	ICD-10-CM
O09A3	Supervision of pregnancy with history of molar pregnancy, third trimester	Diagnosis	ICD-10-CM
O10011	Pre-existing essential hypertension complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O10012	Pre-existing essential hypertension complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O10013	Pre-existing essential hypertension complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O1002	Pre-existing essential hypertension complicating childbirth	Diagnosis	ICD-10-CM
O10111	Pre-existing hypertensive heart disease complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O10112	Pre-existing hypertensive heart disease complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O10113	Pre-existing hypertensive heart disease complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O1012	Pre-existing hypertensive heart disease complicating childbirth	Diagnosis	ICD-10-CM
O10211	Pre-existing hypertensive chronic kidney disease complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O10212	Pre-existing hypertensive chronic kidney disease complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O10213	Pre-existing hypertensive chronic kidney disease complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O1022	Pre-existing hypertensive chronic kidney disease complicating childbirth	Diagnosis	ICD-10-CM
O10311	Pre-existing hypertensive heart and chronic kidney disease complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O10312	Pre-existing hypertensive heart and chronic kidney disease complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O10313	Pre-existing hypertensive heart and chronic kidney disease complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O1032	Pre-existing hypertensive heart and chronic kidney disease complicating childbirth	Diagnosis	ICD-10-CM
O10411	Pre-existing secondary hypertension complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O10412	Pre-existing secondary hypertension complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O10413	Pre-existing secondary hypertension complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O1042	Pre-existing secondary hypertension complicating childbirth	Diagnosis	ICD-10-CM
O10911	Unspecified pre-existing hypertension complicating pregnancy, first trimester	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O10912	Unspecified pre-existing hypertension complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O10913	Unspecified pre-existing hypertension complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O1092	Unspecified pre-existing hypertension complicating childbirth	Diagnosis	ICD-10-CM
O111	Pre-existing hypertension with pre-eclampsia, first trimester	Diagnosis	ICD-10-CM
O112	Pre-existing hypertension with pre-eclampsia, second trimester	Diagnosis	ICD-10-CM
O113	Pre-existing hypertension with pre-eclampsia, third trimester	Diagnosis	ICD-10-CM
O114	Pre-existing hypertension with pre-eclampsia, complicating childbirth	Diagnosis	ICD-10-CM
O1201	Gestational edema, first trimester	Diagnosis	ICD-10-CM
O1202	Gestational edema, second trimester	Diagnosis	ICD-10-CM
O1203	Gestational edema, third trimester	Diagnosis	ICD-10-CM
O1204	Gestational edema, complicating childbirth	Diagnosis	ICD-10-CM
O1211	Gestational proteinuria, first trimester	Diagnosis	ICD-10-CM
O1212	Gestational proteinuria, second trimester	Diagnosis	ICD-10-CM
O1213	Gestational proteinuria, third trimester	Diagnosis	ICD-10-CM
O1214	Gestational proteinuria, complicating childbirth	Diagnosis	ICD-10-CM
O1221	Gestational edema with proteinuria, first trimester	Diagnosis	ICD-10-CM
O1222	Gestational edema with proteinuria, second trimester	Diagnosis	ICD-10-CM
O1223	Gestational edema with proteinuria, third trimester	Diagnosis	ICD-10-CM
O1224	Gestational edema with proteinuria, complicating childbirth	Diagnosis	ICD-10-CM
O131	Gestational [pregnancy-induced] hypertension without significant proteinuria, first trimester	Diagnosis	ICD-10-CM
O132	Gestational [pregnancy-induced] hypertension without significant proteinuria, second trimester	Diagnosis	ICD-10-CM
O133	Gestational [pregnancy-induced] hypertension without significant proteinuria, third trimester	Diagnosis	ICD-10-CM
O134	Gestational [pregnancy-induced] hypertension without significant proteinuria, complicating childbirth	Diagnosis	ICD-10-CM
O1402	Mild to moderate pre-eclampsia, second trimester	Diagnosis	ICD-10-CM
O1403	Mild to moderate pre-eclampsia, third trimester	Diagnosis	ICD-10-CM
O1404	Mild to moderate pre-eclampsia, complicating childbirth	Diagnosis	ICD-10-CM
O1412	Severe pre-eclampsia, second trimester	Diagnosis	ICD-10-CM
O1413	Severe pre-eclampsia, third trimester	Diagnosis	ICD-10-CM
O1414	Severe pre-eclampsia complicating childbirth	Diagnosis	ICD-10-CM
O1422	HELLP syndrome (HELLP), second trimester	Diagnosis	ICD-10-CM
O1423	HELLP syndrome (HELLP), third trimester	Diagnosis	ICD-10-CM
O1424	HELLP syndrome, complicating childbirth	Diagnosis	ICD-10-CM
O1492	Unspecified pre-eclampsia, second trimester	Diagnosis	ICD-10-CM
O1493	Unspecified pre-eclampsia, third trimester	Diagnosis	ICD-10-CM
O1494	Unspecified pre-eclampsia, complicating childbirth	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O1502	Eclampsia complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O1503	Eclampsia complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O161	Unspecified maternal hypertension, first trimester	Diagnosis	ICD-10-CM
O162	Unspecified maternal hypertension, second trimester	Diagnosis	ICD-10-CM
O163	Unspecified maternal hypertension, third trimester	Diagnosis	ICD-10-CM
O164	Unspecified maternal hypertension, complicating childbirth	Diagnosis	ICD-10-CM
O2201	Varicose veins of lower extremity in pregnancy, first trimester	Diagnosis	ICD-10-CM
O2202	Varicose veins of lower extremity in pregnancy, second trimester	Diagnosis	ICD-10-CM
O2203	Varicose veins of lower extremity in pregnancy, third trimester	Diagnosis	ICD-10-CM
O2211	Genital varices in pregnancy, first trimester	Diagnosis	ICD-10-CM
O2212	Genital varices in pregnancy, second trimester	Diagnosis	ICD-10-CM
O2213	Genital varices in pregnancy, third trimester	Diagnosis	ICD-10-CM
O2221	Superficial thrombophlebitis in pregnancy, first trimester	Diagnosis	ICD-10-CM
O2222	Superficial thrombophlebitis in pregnancy, second trimester	Diagnosis	ICD-10-CM
O2223	Superficial thrombophlebitis in pregnancy, third trimester	Diagnosis	ICD-10-CM
O2231	Deep phlebothrombosis in pregnancy, first trimester	Diagnosis	ICD-10-CM
O2232	Deep phlebothrombosis in pregnancy, second trimester	Diagnosis	ICD-10-CM
O2233	Deep phlebothrombosis in pregnancy, third trimester	Diagnosis	ICD-10-CM
O2241	Hemorrhoids in pregnancy, first trimester	Diagnosis	ICD-10-CM
O2242	Hemorrhoids in pregnancy, second trimester	Diagnosis	ICD-10-CM
O2243	Hemorrhoids in pregnancy, third trimester	Diagnosis	ICD-10-CM
O2251	Cerebral venous thrombosis in pregnancy, first trimester	Diagnosis	ICD-10-CM
O2252	Cerebral venous thrombosis in pregnancy, second trimester	Diagnosis	ICD-10-CM
O2253	Cerebral venous thrombosis in pregnancy, third trimester	Diagnosis	ICD-10-CM
O228X1	Other venous complications in pregnancy, first trimester	Diagnosis	ICD-10-CM
O228X2	Other venous complications in pregnancy, second trimester	Diagnosis	ICD-10-CM
O228X3	Other venous complications in pregnancy, third trimester	Diagnosis	ICD-10-CM
O2291	Venous complication in pregnancy, unspecified, first trimester	Diagnosis	ICD-10-CM
O2292	Venous complication in pregnancy, unspecified, second trimester	Diagnosis	ICD-10-CM
O2293	Venous complication in pregnancy, unspecified, third trimester	Diagnosis	ICD-10-CM
O2301	Infections of kidney in pregnancy, first trimester	Diagnosis	ICD-10-CM
O2302	Infections of kidney in pregnancy, second trimester	Diagnosis	ICD-10-CM
O2303	Infections of kidney in pregnancy, third trimester	Diagnosis	ICD-10-CM
O2311	Infections of bladder in pregnancy, first trimester	Diagnosis	ICD-10-CM
O2312	Infections of bladder in pregnancy, second trimester	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O2313	Infections of bladder in pregnancy, third trimester	Diagnosis	ICD-10-CM
O2321	Infections of urethra in pregnancy, first trimester	Diagnosis	ICD-10-CM
O2322	Infections of urethra in pregnancy, second trimester	Diagnosis	ICD-10-CM
O2323	Infections of urethra in pregnancy, third trimester	Diagnosis	ICD-10-CM
O2331	Infections of other parts of urinary tract in pregnancy, first trimester	Diagnosis	ICD-10-CM
O2332	Infections of other parts of urinary tract in pregnancy, second trimester	Diagnosis	ICD-10-CM
O2333	Infections of other parts of urinary tract in pregnancy, third trimester	Diagnosis	ICD-10-CM
O2341	Unspecified infection of urinary tract in pregnancy, first trimester	Diagnosis	ICD-10-CM
O2342	Unspecified infection of urinary tract in pregnancy, second trimester	Diagnosis	ICD-10-CM
O2343	Unspecified infection of urinary tract in pregnancy, third trimester	Diagnosis	ICD-10-CM
O23511	Infections of cervix in pregnancy, first trimester	Diagnosis	ICD-10-CM
O23512	Infections of cervix in pregnancy, second trimester	Diagnosis	ICD-10-CM
O23513	Infections of cervix in pregnancy, third trimester	Diagnosis	ICD-10-CM
O23521	Salpingo-oophoritis in pregnancy, first trimester	Diagnosis	ICD-10-CM
O23522	Salpingo-oophoritis in pregnancy, second trimester	Diagnosis	ICD-10-CM
O23523	Salpingo-oophoritis in pregnancy, third trimester	Diagnosis	ICD-10-CM
O23591	Infection of other part of genital tract in pregnancy, first trimester	Diagnosis	ICD-10-CM
O23592	Infection of other part of genital tract in pregnancy, second trimester	Diagnosis	ICD-10-CM
O23593	Infection of other part of genital tract in pregnancy, third trimester	Diagnosis	ICD-10-CM
O2391	Unspecified genitourinary tract infection in pregnancy, first trimester	Diagnosis	ICD-10-CM
O2392	Unspecified genitourinary tract infection in pregnancy, second trimester	Diagnosis	ICD-10-CM
O2393	Unspecified genitourinary tract infection in pregnancy, third trimester	Diagnosis	ICD-10-CM
O24011	Pre-existing type 1 diabetes mellitus, in pregnancy, first trimester	Diagnosis	ICD-10-CM
O24012	Pre-existing type 1 diabetes mellitus, in pregnancy, second trimester	Diagnosis	ICD-10-CM
O24013	Pre-existing type 1 diabetes mellitus, in pregnancy, third trimester	Diagnosis	ICD-10-CM
O2402	Pre-existing type 1 diabetes mellitus, in childbirth	Diagnosis	ICD-10-CM
O24111	Pre-existing type 2 diabetes mellitus, in pregnancy, first trimester	Diagnosis	ICD-10-CM
O24112	Pre-existing type 2 diabetes mellitus, in pregnancy, second trimester	Diagnosis	ICD-10-CM
O24113	Pre-existing type 2 diabetes mellitus, in pregnancy, third trimester	Diagnosis	ICD-10-CM
O2412	Pre-existing type 2 diabetes mellitus, in childbirth	Diagnosis	ICD-10-CM
O24311	Unspecified pre-existing diabetes mellitus in pregnancy, first trimester	Diagnosis	ICD-10-CM
O24312	Unspecified pre-existing diabetes mellitus in pregnancy, second trimester	Diagnosis	ICD-10-CM
O24313	Unspecified pre-existing diabetes mellitus in pregnancy, third trimester	Diagnosis	ICD-10-CM
O2432	Unspecified pre-existing diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
O24420	Gestational diabetes mellitus in childbirth, diet controlled	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O24424	Gestational diabetes mellitus in childbirth, insulin controlled	Diagnosis	ICD-10-CM
O24425	Gestational diabetes mellitus in childbirth, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM
O24429	Gestational diabetes mellitus in childbirth, unspecified control	Diagnosis	ICD-10-CM
O24811	Other pre-existing diabetes mellitus in pregnancy, first trimester	Diagnosis	ICD-10-CM
O24812	Other pre-existing diabetes mellitus in pregnancy, second trimester	Diagnosis	ICD-10-CM
O24813	Other pre-existing diabetes mellitus in pregnancy, third trimester	Diagnosis	ICD-10-CM
O2482	Other pre-existing diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
O24911	Unspecified diabetes mellitus in pregnancy, first trimester	Diagnosis	ICD-10-CM
O24912	Unspecified diabetes mellitus in pregnancy, second trimester	Diagnosis	ICD-10-CM
O24913	Unspecified diabetes mellitus in pregnancy, third trimester	Diagnosis	ICD-10-CM
O2492	Unspecified diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
O2511	Malnutrition in pregnancy, first trimester	Diagnosis	ICD-10-CM
O2512	Malnutrition in pregnancy, second trimester	Diagnosis	ICD-10-CM
O2513	Malnutrition in pregnancy, third trimester	Diagnosis	ICD-10-CM
O252	Malnutrition in childbirth	Diagnosis	ICD-10-CM
O2601	Excessive weight gain in pregnancy, first trimester	Diagnosis	ICD-10-CM
O2602	Excessive weight gain in pregnancy, second trimester	Diagnosis	ICD-10-CM
O2603	Excessive weight gain in pregnancy, third trimester	Diagnosis	ICD-10-CM
O2611	Low weight gain in pregnancy, first trimester	Diagnosis	ICD-10-CM
O2612	Low weight gain in pregnancy, second trimester	Diagnosis	ICD-10-CM
O2613	Low weight gain in pregnancy, third trimester	Diagnosis	ICD-10-CM
O2621	Pregnancy care for patient with recurrent pregnancy loss, first trimester	Diagnosis	ICD-10-CM
O2622	Pregnancy care for patient with recurrent pregnancy loss, second trimester	Diagnosis	ICD-10-CM
O2623	Pregnancy care for patient with recurrent pregnancy loss, third trimester	Diagnosis	ICD-10-CM
O2631	Retained intrauterine contraceptive device in pregnancy, first trimester	Diagnosis	ICD-10-CM
O2632	Retained intrauterine contraceptive device in pregnancy, second trimester	Diagnosis	ICD-10-CM
O2633	Retained intrauterine contraceptive device in pregnancy, third trimester	Diagnosis	ICD-10-CM
O2641	Herpes gestationis, first trimester	Diagnosis	ICD-10-CM
O2642	Herpes gestationis, second trimester	Diagnosis	ICD-10-CM
O2643	Herpes gestationis, third trimester	Diagnosis	ICD-10-CM
O2651	Maternal hypotension syndrome, first trimester	Diagnosis	ICD-10-CM
O2652	Maternal hypotension syndrome, second trimester	Diagnosis	ICD-10-CM
O2653	Maternal hypotension syndrome, third trimester	Diagnosis	ICD-10-CM
O26611	Liver and biliary tract disorders in pregnancy, first trimester	Diagnosis	ICD-10-CM
O26612	Liver and biliary tract disorders in pregnancy, second trimester	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O26613	Liver and biliary tract disorders in pregnancy, third trimester	Diagnosis	ICD-10-CM
O2662	Liver and biliary tract disorders in childbirth	Diagnosis	ICD-10-CM
O26711	Subluxation of symphysis (pubis) in pregnancy, first trimester	Diagnosis	ICD-10-CM
O26712	Subluxation of symphysis (pubis) in pregnancy, second trimester	Diagnosis	ICD-10-CM
O26713	Subluxation of symphysis (pubis) in pregnancy, third trimester	Diagnosis	ICD-10-CM
O2672	Subluxation of symphysis (pubis) in childbirth	Diagnosis	ICD-10-CM
O26811	Pregnancy related exhaustion and fatigue, first trimester	Diagnosis	ICD-10-CM
O26812	Pregnancy related exhaustion and fatigue, second trimester	Diagnosis	ICD-10-CM
O26813	Pregnancy related exhaustion and fatigue, third trimester	Diagnosis	ICD-10-CM
O26821	Pregnancy related peripheral neuritis, first trimester	Diagnosis	ICD-10-CM
O26822	Pregnancy related peripheral neuritis, second trimester	Diagnosis	ICD-10-CM
O26823	Pregnancy related peripheral neuritis, third trimester	Diagnosis	ICD-10-CM
O26831	Pregnancy related renal disease, first trimester	Diagnosis	ICD-10-CM
O26832	Pregnancy related renal disease, second trimester	Diagnosis	ICD-10-CM
O26833	Pregnancy related renal disease, third trimester	Diagnosis	ICD-10-CM
O26841	Uterine size-date discrepancy, first trimester	Diagnosis	ICD-10-CM
O26842	Uterine size-date discrepancy, second trimester	Diagnosis	ICD-10-CM
O26843	Uterine size-date discrepancy, third trimester	Diagnosis	ICD-10-CM
O26851	Spotting complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O26852	Spotting complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O26853	Spotting complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O26872	Cervical shortening, second trimester	Diagnosis	ICD-10-CM
O26873	Cervical shortening, third trimester	Diagnosis	ICD-10-CM
O26891	Other specified pregnancy related conditions, first trimester	Diagnosis	ICD-10-CM
O26892	Other specified pregnancy related conditions, second trimester	Diagnosis	ICD-10-CM
O26893	Other specified pregnancy related conditions, third trimester	Diagnosis	ICD-10-CM
O2691	Pregnancy related conditions, unspecified, first trimester	Diagnosis	ICD-10-CM
O2692	Pregnancy related conditions, unspecified, second trimester	Diagnosis	ICD-10-CM
O2693	Pregnancy related conditions, unspecified, third trimester	Diagnosis	ICD-10-CM
O29011	Aspiration pneumonitis due to anesthesia during pregnancy, first trimester	Diagnosis	ICD-10-CM
O29012	Aspiration pneumonitis due to anesthesia during pregnancy, second trimester	Diagnosis	ICD-10-CM
O29013	Aspiration pneumonitis due to anesthesia during pregnancy, third trimester	Diagnosis	ICD-10-CM
O29021	Pressure collapse of lung due to anesthesia during pregnancy, first trimester	Diagnosis	ICD-10-CM
O29022	Pressure collapse of lung due to anesthesia during pregnancy, second trimester	Diagnosis	ICD-10-CM
O29023	Pressure collapse of lung due to anesthesia during pregnancy, third trimester	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O29091	Other pulmonary complications of anesthesia during pregnancy, first trimester	Diagnosis	ICD-10-CM
O29092	Other pulmonary complications of anesthesia during pregnancy, second trimester	Diagnosis	ICD-10-CM
O29093	Other pulmonary complications of anesthesia during pregnancy, third trimester	Diagnosis	ICD-10-CM
O29111	Cardiac arrest due to anesthesia during pregnancy, first trimester	Diagnosis	ICD-10-CM
O29112	Cardiac arrest due to anesthesia during pregnancy, second trimester	Diagnosis	ICD-10-CM
O29113	Cardiac arrest due to anesthesia during pregnancy, third trimester	Diagnosis	ICD-10-CM
O29121	Cardiac failure due to anesthesia during pregnancy, first trimester	Diagnosis	ICD-10-CM
O29122	Cardiac failure due to anesthesia during pregnancy, second trimester	Diagnosis	ICD-10-CM
O29123	Cardiac failure due to anesthesia during pregnancy, third trimester	Diagnosis	ICD-10-CM
O29191	Other cardiac complications of anesthesia during pregnancy, first trimester	Diagnosis	ICD-10-CM
O29192	Other cardiac complications of anesthesia during pregnancy, second trimester	Diagnosis	ICD-10-CM
O29193	Other cardiac complications of anesthesia during pregnancy, third trimester	Diagnosis	ICD-10-CM
O29211	Cerebral anoxia due to anesthesia during pregnancy, first trimester	Diagnosis	ICD-10-CM
O29212	Cerebral anoxia due to anesthesia during pregnancy, second trimester	Diagnosis	ICD-10-CM
O29213	Cerebral anoxia due to anesthesia during pregnancy, third trimester	Diagnosis	ICD-10-CM
O29291	Other central nervous system complications of anesthesia during pregnancy, first trimester	Diagnosis	ICD-10-CM
O29292	Other central nervous system complications of anesthesia during pregnancy, second trimester	Diagnosis	ICD-10-CM
O29293	Other central nervous system complications of anesthesia during pregnancy, third trimester	Diagnosis	ICD-10-CM
O293X1	Toxic reaction to local anesthesia during pregnancy, first trimester	Diagnosis	ICD-10-CM
O293X2	Toxic reaction to local anesthesia during pregnancy, second trimester	Diagnosis	ICD-10-CM
O293X3	Toxic reaction to local anesthesia during pregnancy, third trimester	Diagnosis	ICD-10-CM
O2941	Spinal and epidural anesthesia induced headache during pregnancy, first trimester	Diagnosis	ICD-10-CM
O2942	Spinal and epidural anesthesia induced headache during pregnancy, second trimester	Diagnosis	ICD-10-CM
O2943	Spinal and epidural anesthesia induced headache during pregnancy, third trimester	Diagnosis	ICD-10-CM
O295X1	Other complications of spinal and epidural anesthesia during pregnancy, first trimester	Diagnosis	ICD-10-CM
O295X2	Other complications of spinal and epidural anesthesia during pregnancy, second trimester	Diagnosis	ICD-10-CM
O295X3	Other complications of spinal and epidural anesthesia during pregnancy, third trimester	Diagnosis	ICD-10-CM
O2961	Failed or difficult intubation for anesthesia during pregnancy, first trimester	Diagnosis	ICD-10-CM
O2962	Failed or difficult intubation for anesthesia during pregnancy, second trimester	Diagnosis	ICD-10-CM
O2963	Failed or difficult intubation for anesthesia during pregnancy, third trimester	Diagnosis	ICD-10-CM
O298X1	Other complications of anesthesia during pregnancy, first trimester	Diagnosis	ICD-10-CM
O298X2	Other complications of anesthesia during pregnancy, second trimester	Diagnosis	ICD-10-CM
O298X3	Other complications of anesthesia during pregnancy, third trimester	Diagnosis	ICD-10-CM
O2991	Unspecified complication of anesthesia during pregnancy, first trimester	Diagnosis	ICD-10-CM
O2992	Unspecified complication of anesthesia during pregnancy, second trimester	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O2993	Unspecified complication of anesthesia during pregnancy, third trimester	Diagnosis	ICD-10-CM
O30001	Twin pregnancy, unspecified number of placenta and unspecified number of amniotic sacs, first trimester	Diagnosis	ICD-10-CM
O30002	Twin pregnancy, unspecified number of placenta and unspecified number of amniotic sacs, second trimester	Diagnosis	ICD-10-CM
O30003	Twin pregnancy, unspecified number of placenta and unspecified number of amniotic sacs, third trimester	Diagnosis	ICD-10-CM
O30011	Twin pregnancy, monochorionic/monoamniotic, first trimester	Diagnosis	ICD-10-CM
O30012	Twin pregnancy, monochorionic/monoamniotic, second trimester	Diagnosis	ICD-10-CM
O30013	Twin pregnancy, monochorionic/monoamniotic, third trimester	Diagnosis	ICD-10-CM
O30021	Conjoined twin pregnancy, first trimester	Diagnosis	ICD-10-CM
O30022	Conjoined twin pregnancy, second trimester	Diagnosis	ICD-10-CM
O30023	Conjoined twin pregnancy, third trimester	Diagnosis	ICD-10-CM
O30031	Twin pregnancy, monochorionic/diamniotic, first trimester	Diagnosis	ICD-10-CM
O30032	Twin pregnancy, monochorionic/diamniotic, second trimester	Diagnosis	ICD-10-CM
O30033	Twin pregnancy, monochorionic/diamniotic, third trimester	Diagnosis	ICD-10-CM
O30041	Twin pregnancy, dichorionic/diamniotic, first trimester	Diagnosis	ICD-10-CM
O30042	Twin pregnancy, dichorionic/diamniotic, second trimester	Diagnosis	ICD-10-CM
O30043	Twin pregnancy, dichorionic/diamniotic, third trimester	Diagnosis	ICD-10-CM
O30091	Twin pregnancy, unable to determine number of placenta and number of amniotic sacs, first trimester	Diagnosis	ICD-10-CM
O30092	Twin pregnancy, unable to determine number of placenta and number of amniotic sacs, second trimester	Diagnosis	ICD-10-CM
O30093	Twin pregnancy, unable to determine number of placenta and number of amniotic sacs, third trimester	Diagnosis	ICD-10-CM
O30101	Triplet pregnancy, unspecified number of placenta and unspecified number of amniotic sacs, first trimester	Diagnosis	ICD-10-CM
O30102	Triplet pregnancy, unspecified number of placenta and unspecified number of amniotic sacs, second trimester	Diagnosis	ICD-10-CM
O30103	Triplet pregnancy, unspecified number of placenta and unspecified number of amniotic sacs, third trimester	Diagnosis	ICD-10-CM
O30111	Triplet pregnancy with two or more monochorionic fetuses, first trimester	Diagnosis	ICD-10-CM
O30112	Triplet pregnancy with two or more monochorionic fetuses, second trimester	Diagnosis	ICD-10-CM
O30113	Triplet pregnancy with two or more monochorionic fetuses, third trimester	Diagnosis	ICD-10-CM
O30121	Triplet pregnancy with two or more monoamniotic fetuses, first trimester	Diagnosis	ICD-10-CM
O30122	Triplet pregnancy with two or more monoamniotic fetuses, second trimester	Diagnosis	ICD-10-CM
O30123	Triplet pregnancy with two or more monoamniotic fetuses, third trimester	Diagnosis	ICD-10-CM
O30131	Triplet pregnancy, trichorionic/triamniotic, first trimester	Diagnosis	ICD-10-CM
O30132	Triplet pregnancy, trichorionic/triamniotic, second trimester	Diagnosis	ICD-10-CM
O30133	Triplet pregnancy, trichorionic/triamniotic, third trimester	Diagnosis	ICD-10-CM
O30191	Triplet pregnancy, unable to determine number of placenta and number of amniotic sacs, first trimester	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O30192	Triplet pregnancy, unable to determine number of placenta and number of amniotic sacs, second trimester	Diagnosis	ICD-10-CM
O30193	Triplet pregnancy, unable to determine number of placenta and number of amniotic sacs, third trimester	Diagnosis	ICD-10-CM
O30201	Quadruplet pregnancy, unspecified number of placenta and unspecified number of amniotic sacs, first trimester	Diagnosis	ICD-10-CM
O30202	Quadruplet pregnancy, unspecified number of placenta and unspecified number of amniotic sacs, second trimester	Diagnosis	ICD-10-CM
O30203	Quadruplet pregnancy, unspecified number of placenta and unspecified number of amniotic sacs, third trimester	Diagnosis	ICD-10-CM
O30211	Quadruplet pregnancy with two or more monochorionic fetuses, first trimester	Diagnosis	ICD-10-CM
O30212	Quadruplet pregnancy with two or more monochorionic fetuses, second trimester	Diagnosis	ICD-10-CM
O30213	Quadruplet pregnancy with two or more monochorionic fetuses, third trimester	Diagnosis	ICD-10-CM
O30221	Quadruplet pregnancy with two or more monoamniotic fetuses, first trimester	Diagnosis	ICD-10-CM
O30222	Quadruplet pregnancy with two or more monoamniotic fetuses, second trimester	Diagnosis	ICD-10-CM
O30223	Quadruplet pregnancy with two or more monoamniotic fetuses, third trimester	Diagnosis	ICD-10-CM
O30231	Quadruplet pregnancy, quadrachorionic/quadra-amniotic, first trimester	Diagnosis	ICD-10-CM
O30232	Quadruplet pregnancy, quadrachorionic/quadra-amniotic, second trimester	Diagnosis	ICD-10-CM
O30233	Quadruplet pregnancy, quadrachorionic/quadra-amniotic, third trimester	Diagnosis	ICD-10-CM
O30291	Quadruplet pregnancy, unable to determine number of placenta and number of amniotic sacs, first trimester	Diagnosis	ICD-10-CM
O30292	Quadruplet pregnancy, unable to determine number of placenta and number of amniotic sacs, second trimester	Diagnosis	ICD-10-CM
O30293	Quadruplet pregnancy, unable to determine number of placenta and number of amniotic sacs, third trimester	Diagnosis	ICD-10-CM
O30801	Other specified multiple gestation, unspecified number of placenta and unspecified number of amniotic sacs, first trimester	Diagnosis	ICD-10-CM
O30802	Other specified multiple gestation, unspecified number of placenta and unspecified number of amniotic sacs, second trimester	Diagnosis	ICD-10-CM
O30803	Other specified multiple gestation, unspecified number of placenta and unspecified number of amniotic sacs, third trimester	Diagnosis	ICD-10-CM
O30811	Other specified multiple gestation with two or more monochorionic fetuses, first trimester	Diagnosis	ICD-10-CM
O30812	Other specified multiple gestation with two or more monochorionic fetuses, second trimester	Diagnosis	ICD-10-CM
O30813	Other specified multiple gestation with two or more monochorionic fetuses, third trimester	Diagnosis	ICD-10-CM
O30821	Other specified multiple gestation with two or more monoamniotic fetuses, first trimester	Diagnosis	ICD-10-CM
O30822	Other specified multiple gestation with two or more monoamniotic fetuses, second trimester	Diagnosis	ICD-10-CM
O30823	Other specified multiple gestation with two or more monoamniotic fetuses, third trimester	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O30831	Other specified multiple gestation, number of chorions and amnions are both equal to the number of fetuses, first trimester	Diagnosis	ICD-10-CM
O30832	Other specified multiple gestation, number of chorions and amnions are both equal to the number of fetuses, second trimester	Diagnosis	ICD-10-CM
O30833	Other specified multiple gestation, number of chorions and amnions are both equal to the number of fetuses, third trimester	Diagnosis	ICD-10-CM
O30891	Other specified multiple gestation, unable to determine number of placenta and number of amniotic sacs, first trimester	Diagnosis	ICD-10-CM
O30892	Other specified multiple gestation, unable to determine number of placenta and number of amniotic sacs, second trimester	Diagnosis	ICD-10-CM
O30893	Other specified multiple gestation, unable to determine number of placenta and number of amniotic sacs, third trimester	Diagnosis	ICD-10-CM
O3091	Multiple gestation, unspecified, first trimester	Diagnosis	ICD-10-CM
O3092	Multiple gestation, unspecified, second trimester	Diagnosis	ICD-10-CM
O3093	Multiple gestation, unspecified, third trimester	Diagnosis	ICD-10-CM
O3100X0	Papyraceous fetus, unspecified trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3100X1	Papyraceous fetus, unspecified trimester, fetus 1	Diagnosis	ICD-10-CM
O3100X2	Papyraceous fetus, unspecified trimester, fetus 2	Diagnosis	ICD-10-CM
O3100X3	Papyraceous fetus, unspecified trimester, fetus 3	Diagnosis	ICD-10-CM
O3100X4	Papyraceous fetus, unspecified trimester, fetus 4	Diagnosis	ICD-10-CM
O3100X5	Papyraceous fetus, unspecified trimester, fetus 5	Diagnosis	ICD-10-CM
O3100X9	Papyraceous fetus, unspecified trimester, other fetus	Diagnosis	ICD-10-CM
O3101X0	Papyraceous fetus, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3101X1	Papyraceous fetus, first trimester, fetus 1	Diagnosis	ICD-10-CM
O3101X2	Papyraceous fetus, first trimester, fetus 2	Diagnosis	ICD-10-CM
O3101X3	Papyraceous fetus, first trimester, fetus 3	Diagnosis	ICD-10-CM
O3101X4	Papyraceous fetus, first trimester, fetus 4	Diagnosis	ICD-10-CM
O3101X5	Papyraceous fetus, first trimester, fetus 5	Diagnosis	ICD-10-CM
O3101X9	Papyraceous fetus, first trimester, other fetus	Diagnosis	ICD-10-CM
O3102X0	Papyraceous fetus, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3102X1	Papyraceous fetus, second trimester, fetus 1	Diagnosis	ICD-10-CM
O3102X2	Papyraceous fetus, second trimester, fetus 2	Diagnosis	ICD-10-CM
O3102X3	Papyraceous fetus, second trimester, fetus 3	Diagnosis	ICD-10-CM
O3102X4	Papyraceous fetus, second trimester, fetus 4	Diagnosis	ICD-10-CM
O3102X5	Papyraceous fetus, second trimester, fetus 5	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O3102X9	Papyraceous fetus, second trimester, other fetus	Diagnosis	ICD-10-CM
O3103X0	Papyraceous fetus, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3103X1	Papyraceous fetus, third trimester, fetus 1	Diagnosis	ICD-10-CM
O3103X2	Papyraceous fetus, third trimester, fetus 2	Diagnosis	ICD-10-CM
O3103X3	Papyraceous fetus, third trimester, fetus 3	Diagnosis	ICD-10-CM
O3103X4	Papyraceous fetus, third trimester, fetus 4	Diagnosis	ICD-10-CM
O3103X5	Papyraceous fetus, third trimester, fetus 5	Diagnosis	ICD-10-CM
O3103X9	Papyraceous fetus, third trimester, other fetus	Diagnosis	ICD-10-CM
O3110X0	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3110X1	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, fetus 1	Diagnosis	ICD-10-CM
O3110X2	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, fetus 2	Diagnosis	ICD-10-CM
O3110X3	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, fetus 3	Diagnosis	ICD-10-CM
O3110X4	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, fetus 4	Diagnosis	ICD-10-CM
O3110X5	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, fetus 5	Diagnosis	ICD-10-CM
O3110X9	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, other fetus	Diagnosis	ICD-10-CM
O3111X0	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3111X1	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, fetus 1	Diagnosis	ICD-10-CM
O3111X2	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, fetus 2	Diagnosis	ICD-10-CM
O3111X3	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, fetus 3	Diagnosis	ICD-10-CM
O3111X4	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, fetus 4	Diagnosis	ICD-10-CM
O3111X5	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, fetus 5	Diagnosis	ICD-10-CM
O3111X9	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, other fetus	Diagnosis	ICD-10-CM
O3112X0	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3112X1	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, fetus 1	Diagnosis	ICD-10-CM
O3112X2	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, fetus 2	Diagnosis	ICD-10-CM
O3112X3	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, fetus 3	Diagnosis	ICD-10-CM
O3112X4	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, fetus 4	Diagnosis	ICD-10-CM
O3112X5	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, fetus 5	Diagnosis	ICD-10-CM
O3112X9	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, other fetus	Diagnosis	ICD-10-CM
O3113X0	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3113X1	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, fetus 1	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O3113X2	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, fetus 2	Diagnosis	ICD-10-CM
O3113X3	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, fetus 3	Diagnosis	ICD-10-CM
O3113X4	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, fetus 4	Diagnosis	ICD-10-CM
O3113X5	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, fetus 5	Diagnosis	ICD-10-CM
O3113X9	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, other fetus	Diagnosis	ICD-10-CM
O312	Continuing pregnancy after intrauterine death of one fetus or more	Diagnosis	ICD-10-CM
O3120X0	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3120X1	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 1	Diagnosis	ICD-10-CM
O3120X2	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 2	Diagnosis	ICD-10-CM
O3120X3	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 3	Diagnosis	ICD-10-CM
O3120X4	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 4	Diagnosis	ICD-10-CM
O3120X5	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 5	Diagnosis	ICD-10-CM
O3120X9	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, other fetus	Diagnosis	ICD-10-CM
O3121X0	Continuing pregnancy after intrauterine death of one fetus or more, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3121X1	Continuing pregnancy after intrauterine death of one fetus or more, first trimester, fetus 1	Diagnosis	ICD-10-CM
O3121X2	Continuing pregnancy after intrauterine death of one fetus or more, first trimester, fetus 2	Diagnosis	ICD-10-CM
O3121X3	Continuing pregnancy after intrauterine death of one fetus or more, first trimester, fetus 3	Diagnosis	ICD-10-CM
O3121X4	Continuing pregnancy after intrauterine death of one fetus or more, first trimester, fetus 4	Diagnosis	ICD-10-CM
O3121X5	Continuing pregnancy after intrauterine death of one fetus or more, first trimester, fetus 5	Diagnosis	ICD-10-CM
O3121X9	Continuing pregnancy after intrauterine death of one fetus or more, first trimester, other fetus	Diagnosis	ICD-10-CM
O3122X0	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3122X1	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 1	Diagnosis	ICD-10-CM
O3122X2	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 2	Diagnosis	ICD-10-CM
O3122X3	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 3	Diagnosis	ICD-10-CM
O3122X4	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 4	Diagnosis	ICD-10-CM
O3122X5	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 5	Diagnosis	ICD-10-CM
O3122X9	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, other fetus	Diagnosis	ICD-10-CM
O3123X0	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3123X1	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus 1	Diagnosis	ICD-10-CM
O3123X2	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus 2	Diagnosis	ICD-10-CM
O3123X3	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus 3	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O3123X4	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus 4	Diagnosis	ICD-10-CM
O3123X5	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus 5	Diagnosis	ICD-10-CM
O3123X9	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, other fetus	Diagnosis	ICD-10-CM
O3131X0	Continuing pregnancy after elective fetal reduction of one fetus or more, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3131X1	Continuing pregnancy after elective fetal reduction of one fetus or more, first trimester, fetus 1	Diagnosis	ICD-10-CM
O3131X2	Continuing pregnancy after elective fetal reduction of one fetus or more, first trimester, fetus 2	Diagnosis	ICD-10-CM
O3131X3	Continuing pregnancy after elective fetal reduction of one fetus or more, first trimester, fetus 3	Diagnosis	ICD-10-CM
O3131X4	Continuing pregnancy after elective fetal reduction of one fetus or more, first trimester, fetus 4	Diagnosis	ICD-10-CM
O3131X5	Continuing pregnancy after elective fetal reduction of one fetus or more, first trimester, fetus 5	Diagnosis	ICD-10-CM
O3131X9	Continuing pregnancy after elective fetal reduction of one fetus or more, first trimester, other fetus	Diagnosis	ICD-10-CM
O3132X0	Continuing pregnancy after elective fetal reduction of one fetus or more, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3132X1	Continuing pregnancy after elective fetal reduction of one fetus or more, second trimester, fetus 1	Diagnosis	ICD-10-CM
O3132X2	Continuing pregnancy after elective fetal reduction of one fetus or more, second trimester, fetus 2	Diagnosis	ICD-10-CM
O3132X3	Continuing pregnancy after elective fetal reduction of one fetus or more, second trimester, fetus 3	Diagnosis	ICD-10-CM
O3132X4	Continuing pregnancy after elective fetal reduction of one fetus or more, second trimester, fetus 4	Diagnosis	ICD-10-CM
O3132X5	Continuing pregnancy after elective fetal reduction of one fetus or more, second trimester, fetus 5	Diagnosis	ICD-10-CM
O3132X9	Continuing pregnancy after elective fetal reduction of one fetus or more, second trimester, other fetus	Diagnosis	ICD-10-CM
O3133X0	Continuing pregnancy after elective fetal reduction of one fetus or more, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3133X1	Continuing pregnancy after elective fetal reduction of one fetus or more, third trimester, fetus 1	Diagnosis	ICD-10-CM
O3133X2	Continuing pregnancy after elective fetal reduction of one fetus or more, third trimester, fetus 2	Diagnosis	ICD-10-CM
O3133X3	Continuing pregnancy after elective fetal reduction of one fetus or more, third trimester, fetus 3	Diagnosis	ICD-10-CM
O3133X4	Continuing pregnancy after elective fetal reduction of one fetus or more, third trimester, fetus 4	Diagnosis	ICD-10-CM
O3133X5	Continuing pregnancy after elective fetal reduction of one fetus or more, third trimester, fetus 5	Diagnosis	ICD-10-CM
O3133X9	Continuing pregnancy after elective fetal reduction of one fetus or more, third trimester, other fetus	Diagnosis	ICD-10-CM
O318X10	Other complications specific to multiple gestation, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O318X11	Other complications specific to multiple gestation, first trimester, fetus 1	Diagnosis	ICD-10-CM
O318X12	Other complications specific to multiple gestation, first trimester, fetus 2	Diagnosis	ICD-10-CM
O318X13	Other complications specific to multiple gestation, first trimester, fetus 3	Diagnosis	ICD-10-CM
O318X14	Other complications specific to multiple gestation, first trimester, fetus 4	Diagnosis	ICD-10-CM
O318X15	Other complications specific to multiple gestation, first trimester, fetus 5	Diagnosis	ICD-10-CM
O318X19	Other complications specific to multiple gestation, first trimester, other fetus	Diagnosis	ICD-10-CM
O318X20	Other complications specific to multiple gestation, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O318X21	Other complications specific to multiple gestation, second trimester, fetus 1	Diagnosis	ICD-10-CM
O318X22	Other complications specific to multiple gestation, second trimester, fetus 2	Diagnosis	ICD-10-CM
O318X23	Other complications specific to multiple gestation, second trimester, fetus 3	Diagnosis	ICD-10-CM
O318X24	Other complications specific to multiple gestation, second trimester, fetus 4	Diagnosis	ICD-10-CM
O318X25	Other complications specific to multiple gestation, second trimester, fetus 5	Diagnosis	ICD-10-CM
O318X29	Other complications specific to multiple gestation, second trimester, other fetus	Diagnosis	ICD-10-CM
O318X30	Other complications specific to multiple gestation, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O318X31	Other complications specific to multiple gestation, third trimester, fetus 1	Diagnosis	ICD-10-CM
O318X32	Other complications specific to multiple gestation, third trimester, fetus 2	Diagnosis	ICD-10-CM
O318X33	Other complications specific to multiple gestation, third trimester, fetus 3	Diagnosis	ICD-10-CM
O318X34	Other complications specific to multiple gestation, third trimester, fetus 4	Diagnosis	ICD-10-CM
O318X35	Other complications specific to multiple gestation, third trimester, fetus 5	Diagnosis	ICD-10-CM
O318X39	Other complications specific to multiple gestation, third trimester, other fetus	Diagnosis	ICD-10-CM
O3401	Maternal care for unspecified congenital malformation of uterus, first trimester	Diagnosis	ICD-10-CM
O3402	Maternal care for unspecified congenital malformation of uterus, second trimester	Diagnosis	ICD-10-CM
O3403	Maternal care for unspecified congenital malformation of uterus, third trimester	Diagnosis	ICD-10-CM
O3411	Maternal care for benign tumor of corpus uteri, first trimester	Diagnosis	ICD-10-CM
O3412	Maternal care for benign tumor of corpus uteri, second trimester	Diagnosis	ICD-10-CM
O3413	Maternal care for benign tumor of corpus uteri, third trimester	Diagnosis	ICD-10-CM
O3431	Maternal care for cervical incompetence, first trimester	Diagnosis	ICD-10-CM
O3432	Maternal care for cervical incompetence, second trimester	Diagnosis	ICD-10-CM
O3433	Maternal care for cervical incompetence, third trimester	Diagnosis	ICD-10-CM
O3441	Maternal care for other abnormalities of cervix, first trimester	Diagnosis	ICD-10-CM
O3442	Maternal care for other abnormalities of cervix, second trimester	Diagnosis	ICD-10-CM
O3443	Maternal care for other abnormalities of cervix, third trimester	Diagnosis	ICD-10-CM
O34511	Maternal care for incarceration of gravid uterus, first trimester	Diagnosis	ICD-10-CM
O34512	Maternal care for incarceration of gravid uterus, second trimester	Diagnosis	ICD-10-CM
O34513	Maternal care for incarceration of gravid uterus, third trimester	Diagnosis	ICD-10-CM
O34521	Maternal care for prolapse of gravid uterus, first trimester	Diagnosis	ICD-10-CM
O34522	Maternal care for prolapse of gravid uterus, second trimester	Diagnosis	ICD-10-CM
O34523	Maternal care for prolapse of gravid uterus, third trimester	Diagnosis	ICD-10-CM
O34531	Maternal care for retroversion of gravid uterus, first trimester	Diagnosis	ICD-10-CM
O34532	Maternal care for retroversion of gravid uterus, second trimester	Diagnosis	ICD-10-CM
O34533	Maternal care for retroversion of gravid uterus, third trimester	Diagnosis	ICD-10-CM
O34591	Maternal care for other abnormalities of gravid uterus, first trimester	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O34592	Maternal care for other abnormalities of gravid uterus, second trimester	Diagnosis	ICD-10-CM
O34593	Maternal care for other abnormalities of gravid uterus, third trimester	Diagnosis	ICD-10-CM
O3461	Maternal care for abnormality of vagina, first trimester	Diagnosis	ICD-10-CM
O3462	Maternal care for abnormality of vagina, second trimester	Diagnosis	ICD-10-CM
O3463	Maternal care for abnormality of vagina, third trimester	Diagnosis	ICD-10-CM
O3471	Maternal care for abnormality of vulva and perineum, first trimester	Diagnosis	ICD-10-CM
O3472	Maternal care for abnormality of vulva and perineum, second trimester	Diagnosis	ICD-10-CM
O3473	Maternal care for abnormality of vulva and perineum, third trimester	Diagnosis	ICD-10-CM
O3481	Maternal care for other abnormalities of pelvic organs, first trimester	Diagnosis	ICD-10-CM
O3482	Maternal care for other abnormalities of pelvic organs, second trimester	Diagnosis	ICD-10-CM
O3483	Maternal care for other abnormalities of pelvic organs, third trimester	Diagnosis	ICD-10-CM
O3491	Maternal care for abnormality of pelvic organ, unspecified, first trimester	Diagnosis	ICD-10-CM
O3492	Maternal care for abnormality of pelvic organ, unspecified, second trimester	Diagnosis	ICD-10-CM
O3493	Maternal care for abnormality of pelvic organ, unspecified, third trimester	Diagnosis	ICD-10-CM
O360110	Maternal care for anti-D [Rh] antibodies, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O360111	Maternal care for anti-D [Rh] antibodies, first trimester, fetus 1	Diagnosis	ICD-10-CM
O360112	Maternal care for anti-D [Rh] antibodies, first trimester, fetus 2	Diagnosis	ICD-10-CM
O360113	Maternal care for anti-D [Rh] antibodies, first trimester, fetus 3	Diagnosis	ICD-10-CM
O360114	Maternal care for anti-D [Rh] antibodies, first trimester, fetus 4	Diagnosis	ICD-10-CM
O360115	Maternal care for anti-D [Rh] antibodies, first trimester, fetus 5	Diagnosis	ICD-10-CM
O360119	Maternal care for anti-D [Rh] antibodies, first trimester, other fetus	Diagnosis	ICD-10-CM
O360120	Maternal care for anti-D [Rh] antibodies, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O360121	Maternal care for anti-D [Rh] antibodies, second trimester, fetus 1	Diagnosis	ICD-10-CM
O360122	Maternal care for anti-D [Rh] antibodies, second trimester, fetus 2	Diagnosis	ICD-10-CM
O360123	Maternal care for anti-D [Rh] antibodies, second trimester, fetus 3	Diagnosis	ICD-10-CM
O360124	Maternal care for anti-D [Rh] antibodies, second trimester, fetus 4	Diagnosis	ICD-10-CM
O360125	Maternal care for anti-D [Rh] antibodies, second trimester, fetus 5	Diagnosis	ICD-10-CM
O360129	Maternal care for anti-D [Rh] antibodies, second trimester, other fetus	Diagnosis	ICD-10-CM
O360130	Maternal care for anti-D [Rh] antibodies, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O360131	Maternal care for anti-D [Rh] antibodies, third trimester, fetus 1	Diagnosis	ICD-10-CM
O360132	Maternal care for anti-D [Rh] antibodies, third trimester, fetus 2	Diagnosis	ICD-10-CM
O360133	Maternal care for anti-D [Rh] antibodies, third trimester, fetus 3	Diagnosis	ICD-10-CM
O360134	Maternal care for anti-D [Rh] antibodies, third trimester, fetus 4	Diagnosis	ICD-10-CM
O360135	Maternal care for anti-D [Rh] antibodies, third trimester, fetus 5	Diagnosis	ICD-10-CM
O360139	Maternal care for anti-D [Rh] antibodies, third trimester, other fetus	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O360910	Maternal care for other rhesus isoimmunization, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O360911	Maternal care for other rhesus isoimmunization, first trimester, fetus 1	Diagnosis	ICD-10-CM
O360912	Maternal care for other rhesus isoimmunization, first trimester, fetus 2	Diagnosis	ICD-10-CM
O360913	Maternal care for other rhesus isoimmunization, first trimester, fetus 3	Diagnosis	ICD-10-CM
O360914	Maternal care for other rhesus isoimmunization, first trimester, fetus 4	Diagnosis	ICD-10-CM
O360915	Maternal care for other rhesus isoimmunization, first trimester, fetus 5	Diagnosis	ICD-10-CM
O360919	Maternal care for other rhesus isoimmunization, first trimester, other fetus	Diagnosis	ICD-10-CM
O360920	Maternal care for other rhesus isoimmunization, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O360921	Maternal care for other rhesus isoimmunization, second trimester, fetus 1	Diagnosis	ICD-10-CM
O360922	Maternal care for other rhesus isoimmunization, second trimester, fetus 2	Diagnosis	ICD-10-CM
O360923	Maternal care for other rhesus isoimmunization, second trimester, fetus 3	Diagnosis	ICD-10-CM
O360924	Maternal care for other rhesus isoimmunization, second trimester, fetus 4	Diagnosis	ICD-10-CM
O360925	Maternal care for other rhesus isoimmunization, second trimester, fetus 5	Diagnosis	ICD-10-CM
O360929	Maternal care for other rhesus isoimmunization, second trimester, other fetus	Diagnosis	ICD-10-CM
O360930	Maternal care for other rhesus isoimmunization, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O360931	Maternal care for other rhesus isoimmunization, third trimester, fetus 1	Diagnosis	ICD-10-CM
O360932	Maternal care for other rhesus isoimmunization, third trimester, fetus 2	Diagnosis	ICD-10-CM
O360933	Maternal care for other rhesus isoimmunization, third trimester, fetus 3	Diagnosis	ICD-10-CM
O360934	Maternal care for other rhesus isoimmunization, third trimester, fetus 4	Diagnosis	ICD-10-CM
O360935	Maternal care for other rhesus isoimmunization, third trimester, fetus 5	Diagnosis	ICD-10-CM
O360939	Maternal care for other rhesus isoimmunization, third trimester, other fetus	Diagnosis	ICD-10-CM
O361110	Maternal care for Anti-A sensitization, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O361111	Maternal care for Anti-A sensitization, first trimester, fetus 1	Diagnosis	ICD-10-CM
O361112	Maternal care for Anti-A sensitization, first trimester, fetus 2	Diagnosis	ICD-10-CM
O361113	Maternal care for Anti-A sensitization, first trimester, fetus 3	Diagnosis	ICD-10-CM
O361114	Maternal care for Anti-A sensitization, first trimester, fetus 4	Diagnosis	ICD-10-CM
O361115	Maternal care for Anti-A sensitization, first trimester, fetus 5	Diagnosis	ICD-10-CM
O361119	Maternal care for Anti-A sensitization, first trimester, other fetus	Diagnosis	ICD-10-CM
O361120	Maternal care for Anti-A sensitization, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O361121	Maternal care for Anti-A sensitization, second trimester, fetus 1	Diagnosis	ICD-10-CM
O361122	Maternal care for Anti-A sensitization, second trimester, fetus 2	Diagnosis	ICD-10-CM
O361123	Maternal care for Anti-A sensitization, second trimester, fetus 3	Diagnosis	ICD-10-CM
O361124	Maternal care for Anti-A sensitization, second trimester, fetus 4	Diagnosis	ICD-10-CM
O361125	Maternal care for Anti-A sensitization, second trimester, fetus 5	Diagnosis	ICD-10-CM
O361129	Maternal care for Anti-A sensitization, second trimester, other fetus	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O361130	Maternal care for Anti-A sensitization, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O361131	Maternal care for Anti-A sensitization, third trimester, fetus 1	Diagnosis	ICD-10-CM
O361132	Maternal care for Anti-A sensitization, third trimester, fetus 2	Diagnosis	ICD-10-CM
O361133	Maternal care for Anti-A sensitization, third trimester, fetus 3	Diagnosis	ICD-10-CM
O361134	Maternal care for Anti-A sensitization, third trimester, fetus 4	Diagnosis	ICD-10-CM
O361135	Maternal care for Anti-A sensitization, third trimester, fetus 5	Diagnosis	ICD-10-CM
O361139	Maternal care for Anti-A sensitization, third trimester, other fetus	Diagnosis	ICD-10-CM
O361910	Maternal care for other isoimmunization, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O361911	Maternal care for other isoimmunization, first trimester, fetus 1	Diagnosis	ICD-10-CM
O361912	Maternal care for other isoimmunization, first trimester, fetus 2	Diagnosis	ICD-10-CM
O361913	Maternal care for other isoimmunization, first trimester, fetus 3	Diagnosis	ICD-10-CM
O361914	Maternal care for other isoimmunization, first trimester, fetus 4	Diagnosis	ICD-10-CM
O361915	Maternal care for other isoimmunization, first trimester, fetus 5	Diagnosis	ICD-10-CM
O361919	Maternal care for other isoimmunization, first trimester, other fetus	Diagnosis	ICD-10-CM
O361920	Maternal care for other isoimmunization, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O361921	Maternal care for other isoimmunization, second trimester, fetus 1	Diagnosis	ICD-10-CM
O361922	Maternal care for other isoimmunization, second trimester, fetus 2	Diagnosis	ICD-10-CM
O361923	Maternal care for other isoimmunization, second trimester, fetus 3	Diagnosis	ICD-10-CM
O361924	Maternal care for other isoimmunization, second trimester, fetus 4	Diagnosis	ICD-10-CM
O361925	Maternal care for other isoimmunization, second trimester, fetus 5	Diagnosis	ICD-10-CM
O361929	Maternal care for other isoimmunization, second trimester, other fetus	Diagnosis	ICD-10-CM
O361930	Maternal care for other isoimmunization, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O361931	Maternal care for other isoimmunization, third trimester, fetus 1	Diagnosis	ICD-10-CM
O361932	Maternal care for other isoimmunization, third trimester, fetus 2	Diagnosis	ICD-10-CM
O361933	Maternal care for other isoimmunization, third trimester, fetus 3	Diagnosis	ICD-10-CM
O361934	Maternal care for other isoimmunization, third trimester, fetus 4	Diagnosis	ICD-10-CM
O361935	Maternal care for other isoimmunization, third trimester, fetus 5	Diagnosis	ICD-10-CM
O361939	Maternal care for other isoimmunization, third trimester, other fetus	Diagnosis	ICD-10-CM
O3621X0	Maternal care for hydrops fetalis, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3621X1	Maternal care for hydrops fetalis, first trimester, fetus 1	Diagnosis	ICD-10-CM
O3621X2	Maternal care for hydrops fetalis, first trimester, fetus 2	Diagnosis	ICD-10-CM
O3621X3	Maternal care for hydrops fetalis, first trimester, fetus 3	Diagnosis	ICD-10-CM
O3621X4	Maternal care for hydrops fetalis, first trimester, fetus 4	Diagnosis	ICD-10-CM
O3621X5	Maternal care for hydrops fetalis, first trimester, fetus 5	Diagnosis	ICD-10-CM
O3621X9	Maternal care for hydrops fetalis, first trimester, other fetus	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O3622X0	Maternal care for hydrops fetalis, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3622X1	Maternal care for hydrops fetalis, second trimester, fetus 1	Diagnosis	ICD-10-CM
O3622X2	Maternal care for hydrops fetalis, second trimester, fetus 2	Diagnosis	ICD-10-CM
O3622X3	Maternal care for hydrops fetalis, second trimester, fetus 3	Diagnosis	ICD-10-CM
O3622X4	Maternal care for hydrops fetalis, second trimester, fetus 4	Diagnosis	ICD-10-CM
O3622X5	Maternal care for hydrops fetalis, second trimester, fetus 5	Diagnosis	ICD-10-CM
O3622X9	Maternal care for hydrops fetalis, second trimester, other fetus	Diagnosis	ICD-10-CM
O3623X0	Maternal care for hydrops fetalis, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3623X1	Maternal care for hydrops fetalis, third trimester, fetus 1	Diagnosis	ICD-10-CM
O3623X2	Maternal care for hydrops fetalis, third trimester, fetus 2	Diagnosis	ICD-10-CM
O3623X3	Maternal care for hydrops fetalis, third trimester, fetus 3	Diagnosis	ICD-10-CM
O3623X4	Maternal care for hydrops fetalis, third trimester, fetus 4	Diagnosis	ICD-10-CM
O3623X5	Maternal care for hydrops fetalis, third trimester, fetus 5	Diagnosis	ICD-10-CM
O3623X9	Maternal care for hydrops fetalis, third trimester, other fetus	Diagnosis	ICD-10-CM
O364	Maternal care for intrauterine death	Diagnosis	ICD-10-CM
O364XX0	Maternal care for intrauterine death, not applicable or unspecified	Diagnosis	ICD-10-CM
O364XX1	Maternal care for intrauterine death, fetus 1	Diagnosis	ICD-10-CM
O364XX2	Maternal care for intrauterine death, fetus 2	Diagnosis	ICD-10-CM
O364XX3	Maternal care for intrauterine death, fetus 3	Diagnosis	ICD-10-CM
O364XX4	Maternal care for intrauterine death, fetus 4	Diagnosis	ICD-10-CM
O364XX5	Maternal care for intrauterine death, fetus 5	Diagnosis	ICD-10-CM
O364XX9	Maternal care for intrauterine death, other fetus	Diagnosis	ICD-10-CM
O365110	Maternal care for known or suspected placental insufficiency, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O365111	Maternal care for known or suspected placental insufficiency, first trimester, fetus 1	Diagnosis	ICD-10-CM
O365112	Maternal care for known or suspected placental insufficiency, first trimester, fetus 2	Diagnosis	ICD-10-CM
O365113	Maternal care for known or suspected placental insufficiency, first trimester, fetus 3	Diagnosis	ICD-10-CM
O365114	Maternal care for known or suspected placental insufficiency, first trimester, fetus 4	Diagnosis	ICD-10-CM
O365115	Maternal care for known or suspected placental insufficiency, first trimester, fetus 5	Diagnosis	ICD-10-CM
O365119	Maternal care for known or suspected placental insufficiency, first trimester, other fetus	Diagnosis	ICD-10-CM
O365120	Maternal care for known or suspected placental insufficiency, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O365121	Maternal care for known or suspected placental insufficiency, second trimester, fetus 1	Diagnosis	ICD-10-CM
O365122	Maternal care for known or suspected placental insufficiency, second trimester, fetus 2	Diagnosis	ICD-10-CM
O365123	Maternal care for known or suspected placental insufficiency, second trimester, fetus 3	Diagnosis	ICD-10-CM
O365124	Maternal care for known or suspected placental insufficiency, second trimester, fetus 4	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O365125	Maternal care for known or suspected placental insufficiency, second trimester, fetus 5	Diagnosis	ICD-10-CM
O365129	Maternal care for known or suspected placental insufficiency, second trimester, other fetus	Diagnosis	ICD-10-CM
O365130	Maternal care for known or suspected placental insufficiency, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O365131	Maternal care for known or suspected placental insufficiency, third trimester, fetus 1	Diagnosis	ICD-10-CM
O365132	Maternal care for known or suspected placental insufficiency, third trimester, fetus 2	Diagnosis	ICD-10-CM
O365133	Maternal care for known or suspected placental insufficiency, third trimester, fetus 3	Diagnosis	ICD-10-CM
O365134	Maternal care for known or suspected placental insufficiency, third trimester, fetus 4	Diagnosis	ICD-10-CM
O365135	Maternal care for known or suspected placental insufficiency, third trimester, fetus 5	Diagnosis	ICD-10-CM
O365139	Maternal care for known or suspected placental insufficiency, third trimester, other fetus	Diagnosis	ICD-10-CM
O365910	Maternal care for other known or suspected poor fetal growth, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O365911	Maternal care for other known or suspected poor fetal growth, first trimester, fetus 1	Diagnosis	ICD-10-CM
O365912	Maternal care for other known or suspected poor fetal growth, first trimester, fetus 2	Diagnosis	ICD-10-CM
O365913	Maternal care for other known or suspected poor fetal growth, first trimester, fetus 3	Diagnosis	ICD-10-CM
O365914	Maternal care for other known or suspected poor fetal growth, first trimester, fetus 4	Diagnosis	ICD-10-CM
O365915	Maternal care for other known or suspected poor fetal growth, first trimester, fetus 5	Diagnosis	ICD-10-CM
O365919	Maternal care for other known or suspected poor fetal growth, first trimester, other fetus	Diagnosis	ICD-10-CM
O365920	Maternal care for other known or suspected poor fetal growth, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O365921	Maternal care for other known or suspected poor fetal growth, second trimester, fetus 1	Diagnosis	ICD-10-CM
O365922	Maternal care for other known or suspected poor fetal growth, second trimester, fetus 2	Diagnosis	ICD-10-CM
O365923	Maternal care for other known or suspected poor fetal growth, second trimester, fetus 3	Diagnosis	ICD-10-CM
O365924	Maternal care for other known or suspected poor fetal growth, second trimester, fetus 4	Diagnosis	ICD-10-CM
O365925	Maternal care for other known or suspected poor fetal growth, second trimester, fetus 5	Diagnosis	ICD-10-CM
O365929	Maternal care for other known or suspected poor fetal growth, second trimester, other fetus	Diagnosis	ICD-10-CM
O365930	Maternal care for other known or suspected poor fetal growth, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O365931	Maternal care for other known or suspected poor fetal growth, third trimester, fetus 1	Diagnosis	ICD-10-CM
O365932	Maternal care for other known or suspected poor fetal growth, third trimester, fetus 2	Diagnosis	ICD-10-CM
O365933	Maternal care for other known or suspected poor fetal growth, third trimester, fetus 3	Diagnosis	ICD-10-CM
O365934	Maternal care for other known or suspected poor fetal growth, third trimester, fetus 4	Diagnosis	ICD-10-CM
O365935	Maternal care for other known or suspected poor fetal growth, third trimester, fetus 5	Diagnosis	ICD-10-CM
O365939	Maternal care for other known or suspected poor fetal growth, third trimester, other fetus	Diagnosis	ICD-10-CM
O3661X0	Maternal care for excessive fetal growth, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O3661X1	Maternal care for excessive fetal growth, first trimester, fetus 1	Diagnosis	ICD-10-CM
O3661X2	Maternal care for excessive fetal growth, first trimester, fetus 2	Diagnosis	ICD-10-CM
O3661X3	Maternal care for excessive fetal growth, first trimester, fetus 3	Diagnosis	ICD-10-CM
O3661X4	Maternal care for excessive fetal growth, first trimester, fetus 4	Diagnosis	ICD-10-CM
O3661X5	Maternal care for excessive fetal growth, first trimester, fetus 5	Diagnosis	ICD-10-CM
O3661X9	Maternal care for excessive fetal growth, first trimester, other fetus	Diagnosis	ICD-10-CM
O3662X0	Maternal care for excessive fetal growth, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3662X1	Maternal care for excessive fetal growth, second trimester, fetus 1	Diagnosis	ICD-10-CM
O3662X2	Maternal care for excessive fetal growth, second trimester, fetus 2	Diagnosis	ICD-10-CM
O3662X3	Maternal care for excessive fetal growth, second trimester, fetus 3	Diagnosis	ICD-10-CM
O3662X4	Maternal care for excessive fetal growth, second trimester, fetus 4	Diagnosis	ICD-10-CM
O3662X5	Maternal care for excessive fetal growth, second trimester, fetus 5	Diagnosis	ICD-10-CM
O3662X9	Maternal care for excessive fetal growth, second trimester, other fetus	Diagnosis	ICD-10-CM
O3663X0	Maternal care for excessive fetal growth, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3663X1	Maternal care for excessive fetal growth, third trimester, fetus 1	Diagnosis	ICD-10-CM
O3663X2	Maternal care for excessive fetal growth, third trimester, fetus 2	Diagnosis	ICD-10-CM
O3663X3	Maternal care for excessive fetal growth, third trimester, fetus 3	Diagnosis	ICD-10-CM
O3663X4	Maternal care for excessive fetal growth, third trimester, fetus 4	Diagnosis	ICD-10-CM
O3663X5	Maternal care for excessive fetal growth, third trimester, fetus 5	Diagnosis	ICD-10-CM
O3663X9	Maternal care for excessive fetal growth, third trimester, other fetus	Diagnosis	ICD-10-CM
O3671X0	Maternal care for viable fetus in abdominal pregnancy, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3671X1	Maternal care for viable fetus in abdominal pregnancy, first trimester, fetus 1	Diagnosis	ICD-10-CM
O3671X2	Maternal care for viable fetus in abdominal pregnancy, first trimester, fetus 2	Diagnosis	ICD-10-CM
O3671X3	Maternal care for viable fetus in abdominal pregnancy, first trimester, fetus 3	Diagnosis	ICD-10-CM
O3671X4	Maternal care for viable fetus in abdominal pregnancy, first trimester, fetus 4	Diagnosis	ICD-10-CM
O3671X5	Maternal care for viable fetus in abdominal pregnancy, first trimester, fetus 5	Diagnosis	ICD-10-CM
O3671X9	Maternal care for viable fetus in abdominal pregnancy, first trimester, other fetus	Diagnosis	ICD-10-CM
O3672X0	Maternal care for viable fetus in abdominal pregnancy, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3672X1	Maternal care for viable fetus in abdominal pregnancy, second trimester, fetus 1	Diagnosis	ICD-10-CM
O3672X2	Maternal care for viable fetus in abdominal pregnancy, second trimester, fetus 2	Diagnosis	ICD-10-CM
O3672X3	Maternal care for viable fetus in abdominal pregnancy, second trimester, fetus 3	Diagnosis	ICD-10-CM
O3672X4	Maternal care for viable fetus in abdominal pregnancy, second trimester, fetus 4	Diagnosis	ICD-10-CM
O3672X5	Maternal care for viable fetus in abdominal pregnancy, second trimester, fetus 5	Diagnosis	ICD-10-CM
O3672X9	Maternal care for viable fetus in abdominal pregnancy, second trimester, other fetus	Diagnosis	ICD-10-CM
O3673X0	Maternal care for viable fetus in abdominal pregnancy, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O3673X1	Maternal care for viable fetus in abdominal pregnancy, third trimester, fetus 1	Diagnosis	ICD-10-CM
O3673X2	Maternal care for viable fetus in abdominal pregnancy, third trimester, fetus 2	Diagnosis	ICD-10-CM
O3673X3	Maternal care for viable fetus in abdominal pregnancy, third trimester, fetus 3	Diagnosis	ICD-10-CM
O3673X4	Maternal care for viable fetus in abdominal pregnancy, third trimester, fetus 4	Diagnosis	ICD-10-CM
O3673X5	Maternal care for viable fetus in abdominal pregnancy, third trimester, fetus 5	Diagnosis	ICD-10-CM
O3673X9	Maternal care for viable fetus in abdominal pregnancy, third trimester, other fetus	Diagnosis	ICD-10-CM
O368120	Decreased fetal movements, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O368121	Decreased fetal movements, second trimester, fetus 1	Diagnosis	ICD-10-CM
O368122	Decreased fetal movements, second trimester, fetus 2	Diagnosis	ICD-10-CM
O368123	Decreased fetal movements, second trimester, fetus 3	Diagnosis	ICD-10-CM
O368124	Decreased fetal movements, second trimester, fetus 4	Diagnosis	ICD-10-CM
O368125	Decreased fetal movements, second trimester, fetus 5	Diagnosis	ICD-10-CM
O368129	Decreased fetal movements, second trimester, other fetus	Diagnosis	ICD-10-CM
O368130	Decreased fetal movements, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O368131	Decreased fetal movements, third trimester, fetus 1	Diagnosis	ICD-10-CM
O368132	Decreased fetal movements, third trimester, fetus 2	Diagnosis	ICD-10-CM
O368133	Decreased fetal movements, third trimester, fetus 3	Diagnosis	ICD-10-CM
O368134	Decreased fetal movements, third trimester, fetus 4	Diagnosis	ICD-10-CM
O368135	Decreased fetal movements, third trimester, fetus 5	Diagnosis	ICD-10-CM
O368139	Decreased fetal movements, third trimester, other fetus	Diagnosis	ICD-10-CM
O368210	Fetal anemia and thrombocytopenia, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O368211	Fetal anemia and thrombocytopenia, first trimester, fetus 1	Diagnosis	ICD-10-CM
O368212	Fetal anemia and thrombocytopenia, first trimester, fetus 2	Diagnosis	ICD-10-CM
O368213	Fetal anemia and thrombocytopenia, first trimester, fetus 3	Diagnosis	ICD-10-CM
O368214	Fetal anemia and thrombocytopenia, first trimester, fetus 4	Diagnosis	ICD-10-CM
O368215	Fetal anemia and thrombocytopenia, first trimester, fetus 5	Diagnosis	ICD-10-CM
O368219	Fetal anemia and thrombocytopenia, first trimester, other fetus	Diagnosis	ICD-10-CM
O368220	Fetal anemia and thrombocytopenia, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O368221	Fetal anemia and thrombocytopenia, second trimester, fetus 1	Diagnosis	ICD-10-CM
O368222	Fetal anemia and thrombocytopenia, second trimester, fetus 2	Diagnosis	ICD-10-CM
O368223	Fetal anemia and thrombocytopenia, second trimester, fetus 3	Diagnosis	ICD-10-CM
O368224	Fetal anemia and thrombocytopenia, second trimester, fetus 4	Diagnosis	ICD-10-CM
O368225	Fetal anemia and thrombocytopenia, second trimester, fetus 5	Diagnosis	ICD-10-CM
O368229	Fetal anemia and thrombocytopenia, second trimester, other fetus	Diagnosis	ICD-10-CM
O368230	Fetal anemia and thrombocytopenia, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O368231	Fetal anemia and thrombocytopenia, third trimester, fetus 1	Diagnosis	ICD-10-CM
O368232	Fetal anemia and thrombocytopenia, third trimester, fetus 2	Diagnosis	ICD-10-CM
O368233	Fetal anemia and thrombocytopenia, third trimester, fetus 3	Diagnosis	ICD-10-CM
O368234	Fetal anemia and thrombocytopenia, third trimester, fetus 4	Diagnosis	ICD-10-CM
O368235	Fetal anemia and thrombocytopenia, third trimester, fetus 5	Diagnosis	ICD-10-CM
O368239	Fetal anemia and thrombocytopenia, third trimester, other fetus	Diagnosis	ICD-10-CM
O368310	Maternal care for abnormalities of the fetal heart rate or rhythm, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O368311	Maternal care for abnormalities of the fetal heart rate or rhythm, first trimester, fetus 1	Diagnosis	ICD-10-CM
O368312	Maternal care for abnormalities of the fetal heart rate or rhythm, first trimester, fetus 2	Diagnosis	ICD-10-CM
O368313	Maternal care for abnormalities of the fetal heart rate or rhythm, first trimester, fetus 3	Diagnosis	ICD-10-CM
O368314	Maternal care for abnormalities of the fetal heart rate or rhythm, first trimester, fetus 4	Diagnosis	ICD-10-CM
O368315	Maternal care for abnormalities of the fetal heart rate or rhythm, first trimester, fetus 5	Diagnosis	ICD-10-CM
O368320	Maternal care for abnormalities of the fetal heart rate or rhythm, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O368321	Maternal care for abnormalities of the fetal heart rate or rhythm, second trimester, fetus 1	Diagnosis	ICD-10-CM
O368322	Maternal care for abnormalities of the fetal heart rate or rhythm, second trimester, fetus 2	Diagnosis	ICD-10-CM
O368323	Maternal care for abnormalities of the fetal heart rate or rhythm, second trimester, fetus 3	Diagnosis	ICD-10-CM
O368324	Maternal care for abnormalities of the fetal heart rate or rhythm, second trimester, fetus 4	Diagnosis	ICD-10-CM
O368325	Maternal care for abnormalities of the fetal heart rate or rhythm, second trimester, fetus 5	Diagnosis	ICD-10-CM
O368329	Maternal care for abnormalities of the fetal heart rate or rhythm, second trimester, other fetus	Diagnosis	ICD-10-CM
O368330	Maternal care for abnormalities of the fetal heart rate or rhythm, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O368331	Maternal care for abnormalities of the fetal heart rate or rhythm, third trimester, fetus 1	Diagnosis	ICD-10-CM
O368332	Maternal care for abnormalities of the fetal heart rate or rhythm, third trimester, fetus 2	Diagnosis	ICD-10-CM
O368333	Maternal care for abnormalities of the fetal heart rate or rhythm, third trimester, fetus 3	Diagnosis	ICD-10-CM
O368334	Maternal care for abnormalities of the fetal heart rate or rhythm, third trimester, fetus 4	Diagnosis	ICD-10-CM
O368335	Maternal care for abnormalities of the fetal heart rate or rhythm, third trimester, fetus 5	Diagnosis	ICD-10-CM
O368339	Maternal care for abnormalities of the fetal heart rate or rhythm, third trimester, other fetus	Diagnosis	ICD-10-CM
O368910	Maternal care for other specified fetal problems, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O368911	Maternal care for other specified fetal problems, first trimester, fetus 1	Diagnosis	ICD-10-CM
O368912	Maternal care for other specified fetal problems, first trimester, fetus 2	Diagnosis	ICD-10-CM
O368913	Maternal care for other specified fetal problems, first trimester, fetus 3	Diagnosis	ICD-10-CM
O368914	Maternal care for other specified fetal problems, first trimester, fetus 4	Diagnosis	ICD-10-CM
O368915	Maternal care for other specified fetal problems, first trimester, fetus 5	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O368919	Maternal care for other specified fetal problems, first trimester, other fetus	Diagnosis	ICD-10-CM
O368920	Maternal care for other specified fetal problems, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O368921	Maternal care for other specified fetal problems, second trimester, fetus 1	Diagnosis	ICD-10-CM
O368922	Maternal care for other specified fetal problems, second trimester, fetus 2	Diagnosis	ICD-10-CM
O368923	Maternal care for other specified fetal problems, second trimester, fetus 3	Diagnosis	ICD-10-CM
O368924	Maternal care for other specified fetal problems, second trimester, fetus 4	Diagnosis	ICD-10-CM
O368925	Maternal care for other specified fetal problems, second trimester, fetus 5	Diagnosis	ICD-10-CM
O368929	Maternal care for other specified fetal problems, second trimester, other fetus	Diagnosis	ICD-10-CM
O368930	Maternal care for other specified fetal problems, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O368931	Maternal care for other specified fetal problems, third trimester, fetus 1	Diagnosis	ICD-10-CM
O368932	Maternal care for other specified fetal problems, third trimester, fetus 2	Diagnosis	ICD-10-CM
O368933	Maternal care for other specified fetal problems, third trimester, fetus 3	Diagnosis	ICD-10-CM
O368934	Maternal care for other specified fetal problems, third trimester, fetus 4	Diagnosis	ICD-10-CM
O368935	Maternal care for other specified fetal problems, third trimester, fetus 5	Diagnosis	ICD-10-CM
O368939	Maternal care for other specified fetal problems, third trimester, other fetus	Diagnosis	ICD-10-CM
O3691X0	Maternal care for fetal problem, unspecified, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3691X1	Maternal care for fetal problem, unspecified, first trimester, fetus 1	Diagnosis	ICD-10-CM
O3691X2	Maternal care for fetal problem, unspecified, first trimester, fetus 2	Diagnosis	ICD-10-CM
O3691X3	Maternal care for fetal problem, unspecified, first trimester, fetus 3	Diagnosis	ICD-10-CM
O3691X4	Maternal care for fetal problem, unspecified, first trimester, fetus 4	Diagnosis	ICD-10-CM
O3691X5	Maternal care for fetal problem, unspecified, first trimester, fetus 5	Diagnosis	ICD-10-CM
O3691X9	Maternal care for fetal problem, unspecified, first trimester, other fetus	Diagnosis	ICD-10-CM
O3692X0	Maternal care for fetal problem, unspecified, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3692X1	Maternal care for fetal problem, unspecified, second trimester, fetus 1	Diagnosis	ICD-10-CM
O3692X2	Maternal care for fetal problem, unspecified, second trimester, fetus 2	Diagnosis	ICD-10-CM
O3692X3	Maternal care for fetal problem, unspecified, second trimester, fetus 3	Diagnosis	ICD-10-CM
O3692X4	Maternal care for fetal problem, unspecified, second trimester, fetus 4	Diagnosis	ICD-10-CM
O3692X5	Maternal care for fetal problem, unspecified, second trimester, fetus 5	Diagnosis	ICD-10-CM
O3692X9	Maternal care for fetal problem, unspecified, second trimester, other fetus	Diagnosis	ICD-10-CM
O3693X0	Maternal care for fetal problem, unspecified, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O3693X1	Maternal care for fetal problem, unspecified, third trimester, fetus 1	Diagnosis	ICD-10-CM
O3693X2	Maternal care for fetal problem, unspecified, third trimester, fetus 2	Diagnosis	ICD-10-CM
O3693X3	Maternal care for fetal problem, unspecified, third trimester, fetus 3	Diagnosis	ICD-10-CM
O3693X4	Maternal care for fetal problem, unspecified, third trimester, fetus 4	Diagnosis	ICD-10-CM
O3693X5	Maternal care for fetal problem, unspecified, third trimester, fetus 5	Diagnosis	ICD-10-CM

Code	Description	Code Category	Code Type
O3693X9	Maternal care for fetal problem, unspecified, third trimester, other fetus	Diagnosis	ICD-10-CM
O401XX0	Polyhydramnios, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O401XX1	Polyhydramnios, first trimester, fetus 1	Diagnosis	ICD-10-CM
O401XX2	Polyhydramnios, first trimester, fetus 2	Diagnosis	ICD-10-CM
O401XX3	Polyhydramnios, first trimester, fetus 3	Diagnosis	ICD-10-CM
O401XX4	Polyhydramnios, first trimester, fetus 4	Diagnosis	ICD-10-CM
O401XX5	Polyhydramnios, first trimester, fetus 5	Diagnosis	ICD-10-CM
O401XX9	Polyhydramnios, first trimester, other fetus	Diagnosis	ICD-10-CM
O402XX0	Polyhydramnios, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O402XX1	Polyhydramnios, second trimester, fetus 1	Diagnosis	ICD-10-CM
O402XX2	Polyhydramnios, second trimester, fetus 2	Diagnosis	ICD-10-CM
O402XX3	Polyhydramnios, second trimester, fetus 3	Diagnosis	ICD-10-CM
O402XX4	Polyhydramnios, second trimester, fetus 4	Diagnosis	ICD-10-CM
O402XX5	Polyhydramnios, second trimester, fetus 5	Diagnosis	ICD-10-CM
O402XX9	Polyhydramnios, second trimester, other fetus	Diagnosis	ICD-10-CM
O403XX0	Polyhydramnios, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O403XX1	Polyhydramnios, third trimester, fetus 1	Diagnosis	ICD-10-CM
O403XX2	Polyhydramnios, third trimester, fetus 2	Diagnosis	ICD-10-CM
O403XX3	Polyhydramnios, third trimester, fetus 3	Diagnosis	ICD-10-CM
O403XX4	Polyhydramnios, third trimester, fetus 4	Diagnosis	ICD-10-CM
O403XX5	Polyhydramnios, third trimester, fetus 5	Diagnosis	ICD-10-CM
O403XX9	Polyhydramnios, third trimester, other fetus	Diagnosis	ICD-10-CM
O4101X0	Oligohydramnios, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O4101X1	Oligohydramnios, first trimester, fetus 1	Diagnosis	ICD-10-CM
O4101X2	Oligohydramnios, first trimester, fetus 2	Diagnosis	ICD-10-CM
O4101X3	Oligohydramnios, first trimester, fetus 3	Diagnosis	ICD-10-CM
O4101X4	Oligohydramnios, first trimester, fetus 4	Diagnosis	ICD-10-CM
O4101X5	Oligohydramnios, first trimester, fetus 5	Diagnosis	ICD-10-CM
O4101X9	Oligohydramnios, first trimester, other fetus	Diagnosis	ICD-10-CM
O4102X0	Oligohydramnios, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O4102X1	Oligohydramnios, second trimester, fetus 1	Diagnosis	ICD-10-CM
O4102X2	Oligohydramnios, second trimester, fetus 2	Diagnosis	ICD-10-CM
O4102X3	Oligohydramnios, second trimester, fetus 3	Diagnosis	ICD-10-CM
O4102X4	Oligohydramnios, second trimester, fetus 4	Diagnosis	ICD-10-CM
O4102X5	Oligohydramnios, second trimester, fetus 5	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O4102X9	Oligohydramnios, second trimester, other fetus	Diagnosis	ICD-10-CM
O4103X0	Oligohydramnios, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O4103X1	Oligohydramnios, third trimester, fetus 1	Diagnosis	ICD-10-CM
O4103X2	Oligohydramnios, third trimester, fetus 2	Diagnosis	ICD-10-CM
O4103X3	Oligohydramnios, third trimester, fetus 3	Diagnosis	ICD-10-CM
O4103X4	Oligohydramnios, third trimester, fetus 4	Diagnosis	ICD-10-CM
O4103X5	Oligohydramnios, third trimester, fetus 5	Diagnosis	ICD-10-CM
O4103X9	Oligohydramnios, third trimester, other fetus	Diagnosis	ICD-10-CM
O411010	Infection of amniotic sac and membranes, unspecified, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O411011	Infection of amniotic sac and membranes, unspecified, first trimester, fetus 1	Diagnosis	ICD-10-CM
O411012	Infection of amniotic sac and membranes, unspecified, first trimester, fetus 2	Diagnosis	ICD-10-CM
O411013	Infection of amniotic sac and membranes, unspecified, first trimester, fetus 3	Diagnosis	ICD-10-CM
O411014	Infection of amniotic sac and membranes, unspecified, first trimester, fetus 4	Diagnosis	ICD-10-CM
O411015	Infection of amniotic sac and membranes, unspecified, first trimester, fetus 5	Diagnosis	ICD-10-CM
O411019	Infection of amniotic sac and membranes, unspecified, first trimester, other fetus	Diagnosis	ICD-10-CM
O411020	Infection of amniotic sac and membranes, unspecified, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O411021	Infection of amniotic sac and membranes, unspecified, second trimester, fetus 1	Diagnosis	ICD-10-CM
O411022	Infection of amniotic sac and membranes, unspecified, second trimester, fetus 2	Diagnosis	ICD-10-CM
O411023	Infection of amniotic sac and membranes, unspecified, second trimester, fetus 3	Diagnosis	ICD-10-CM
O411024	Infection of amniotic sac and membranes, unspecified, second trimester, fetus 4	Diagnosis	ICD-10-CM
O411025	Infection of amniotic sac and membranes, unspecified, second trimester, fetus 5	Diagnosis	ICD-10-CM
O411029	Infection of amniotic sac and membranes, unspecified, second trimester, other fetus	Diagnosis	ICD-10-CM
O411030	Infection of amniotic sac and membranes, unspecified, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O411031	Infection of amniotic sac and membranes, unspecified, third trimester, fetus 1	Diagnosis	ICD-10-CM
O411032	Infection of amniotic sac and membranes, unspecified, third trimester, fetus 2	Diagnosis	ICD-10-CM
O411033	Infection of amniotic sac and membranes, unspecified, third trimester, fetus 3	Diagnosis	ICD-10-CM
O411034	Infection of amniotic sac and membranes, unspecified, third trimester, fetus 4	Diagnosis	ICD-10-CM
O411035	Infection of amniotic sac and membranes, unspecified, third trimester, fetus 5	Diagnosis	ICD-10-CM
O411039	Infection of amniotic sac and membranes, unspecified, third trimester, other fetus	Diagnosis	ICD-10-CM
O411210	Chorioamnionitis, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O411211	Chorioamnionitis, first trimester, fetus 1	Diagnosis	ICD-10-CM
O411212	Chorioamnionitis, first trimester, fetus 2	Diagnosis	ICD-10-CM
O411213	Chorioamnionitis, first trimester, fetus 3	Diagnosis	ICD-10-CM
O411214	Chorioamnionitis, first trimester, fetus 4	Diagnosis	ICD-10-CM
O411215	Chorioamnionitis, first trimester, fetus 5	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O411219	Chorioamnionitis, first trimester, other fetus	Diagnosis	ICD-10-CM
O411220	Chorioamnionitis, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O411221	Chorioamnionitis, second trimester, fetus 1	Diagnosis	ICD-10-CM
O411222	Chorioamnionitis, second trimester, fetus 2	Diagnosis	ICD-10-CM
O411223	Chorioamnionitis, second trimester, fetus 3	Diagnosis	ICD-10-CM
O411224	Chorioamnionitis, second trimester, fetus 4	Diagnosis	ICD-10-CM
O411225	Chorioamnionitis, second trimester, fetus 5	Diagnosis	ICD-10-CM
O411229	Chorioamnionitis, second trimester, other fetus	Diagnosis	ICD-10-CM
O411230	Chorioamnionitis, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O411231	Chorioamnionitis, third trimester, fetus 1	Diagnosis	ICD-10-CM
O411232	Chorioamnionitis, third trimester, fetus 2	Diagnosis	ICD-10-CM
O411233	Chorioamnionitis, third trimester, fetus 3	Diagnosis	ICD-10-CM
O411234	Chorioamnionitis, third trimester, fetus 4	Diagnosis	ICD-10-CM
O411235	Chorioamnionitis, third trimester, fetus 5	Diagnosis	ICD-10-CM
O411239	Chorioamnionitis, third trimester, other fetus	Diagnosis	ICD-10-CM
O411410	Placentitis, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O411411	Placentitis, first trimester, fetus 1	Diagnosis	ICD-10-CM
O411412	Placentitis, first trimester, fetus 2	Diagnosis	ICD-10-CM
O411413	Placentitis, first trimester, fetus 3	Diagnosis	ICD-10-CM
O411414	Placentitis, first trimester, fetus 4	Diagnosis	ICD-10-CM
O411415	Placentitis, first trimester, fetus 5	Diagnosis	ICD-10-CM
O411419	Placentitis, first trimester, other fetus	Diagnosis	ICD-10-CM
O411420	Placentitis, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O411421	Placentitis, second trimester, fetus 1	Diagnosis	ICD-10-CM
O411422	Placentitis, second trimester, fetus 2	Diagnosis	ICD-10-CM
O411423	Placentitis, second trimester, fetus 3	Diagnosis	ICD-10-CM
O411424	Placentitis, second trimester, fetus 4	Diagnosis	ICD-10-CM
O411425	Placentitis, second trimester, fetus 5	Diagnosis	ICD-10-CM
O411429	Placentitis, second trimester, other fetus	Diagnosis	ICD-10-CM
O411430	Placentitis, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O411431	Placentitis, third trimester, fetus 1	Diagnosis	ICD-10-CM
O411432	Placentitis, third trimester, fetus 2	Diagnosis	ICD-10-CM
O411433	Placentitis, third trimester, fetus 3	Diagnosis	ICD-10-CM
O411434	Placentitis, third trimester, fetus 4	Diagnosis	ICD-10-CM
O411435	Placentitis, third trimester, fetus 5	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O411439	Placentitis, third trimester, other fetus	Diagnosis	ICD-10-CM
O418X10	Other specified disorders of amniotic fluid and membranes, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O418X11	Other specified disorders of amniotic fluid and membranes, first trimester, fetus 1	Diagnosis	ICD-10-CM
O418X12	Other specified disorders of amniotic fluid and membranes, first trimester, fetus 2	Diagnosis	ICD-10-CM
O418X13	Other specified disorders of amniotic fluid and membranes, first trimester, fetus 3	Diagnosis	ICD-10-CM
O418X14	Other specified disorders of amniotic fluid and membranes, first trimester, fetus 4	Diagnosis	ICD-10-CM
O418X15	Other specified disorders of amniotic fluid and membranes, first trimester, fetus 5	Diagnosis	ICD-10-CM
O418X19	Other specified disorders of amniotic fluid and membranes, first trimester, other fetus	Diagnosis	ICD-10-CM
O418X20	Other specified disorders of amniotic fluid and membranes, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O418X21	Other specified disorders of amniotic fluid and membranes, second trimester, fetus 1	Diagnosis	ICD-10-CM
O418X22	Other specified disorders of amniotic fluid and membranes, second trimester, fetus 2	Diagnosis	ICD-10-CM
O418X23	Other specified disorders of amniotic fluid and membranes, second trimester, fetus 3	Diagnosis	ICD-10-CM
O418X24	Other specified disorders of amniotic fluid and membranes, second trimester, fetus 4	Diagnosis	ICD-10-CM
O418X25	Other specified disorders of amniotic fluid and membranes, second trimester, fetus 5	Diagnosis	ICD-10-CM
O418X29	Other specified disorders of amniotic fluid and membranes, second trimester, other fetus	Diagnosis	ICD-10-CM
O418X30	Other specified disorders of amniotic fluid and membranes, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O418X31	Other specified disorders of amniotic fluid and membranes, third trimester, fetus 1	Diagnosis	ICD-10-CM
O418X32	Other specified disorders of amniotic fluid and membranes, third trimester, fetus 2	Diagnosis	ICD-10-CM
O418X33	Other specified disorders of amniotic fluid and membranes, third trimester, fetus 3	Diagnosis	ICD-10-CM
O418X34	Other specified disorders of amniotic fluid and membranes, third trimester, fetus 4	Diagnosis	ICD-10-CM
O418X35	Other specified disorders of amniotic fluid and membranes, third trimester, fetus 5	Diagnosis	ICD-10-CM
O418X39	Other specified disorders of amniotic fluid and membranes, third trimester, other fetus	Diagnosis	ICD-10-CM
O4191X0	Disorder of amniotic fluid and membranes, unspecified, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O4191X1	Disorder of amniotic fluid and membranes, unspecified, first trimester, fetus 1	Diagnosis	ICD-10-CM
O4191X2	Disorder of amniotic fluid and membranes, unspecified, first trimester, fetus 2	Diagnosis	ICD-10-CM
O4191X3	Disorder of amniotic fluid and membranes, unspecified, first trimester, fetus 3	Diagnosis	ICD-10-CM
O4191X4	Disorder of amniotic fluid and membranes, unspecified, first trimester, fetus 4	Diagnosis	ICD-10-CM
O4191X5	Disorder of amniotic fluid and membranes, unspecified, first trimester, fetus 5	Diagnosis	ICD-10-CM
O4191X9	Disorder of amniotic fluid and membranes, unspecified, first trimester, other fetus	Diagnosis	ICD-10-CM
O4192X0	Disorder of amniotic fluid and membranes, unspecified, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O4192X1	Disorder of amniotic fluid and membranes, unspecified, second trimester, fetus 1	Diagnosis	ICD-10-CM
O4192X2	Disorder of amniotic fluid and membranes, unspecified, second trimester, fetus 2	Diagnosis	ICD-10-CM
O4192X3	Disorder of amniotic fluid and membranes, unspecified, second trimester, fetus 3	Diagnosis	ICD-10-CM
O4192X4	Disorder of amniotic fluid and membranes, unspecified, second trimester, fetus 4	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O4192X5	Disorder of amniotic fluid and membranes, unspecified, second trimester, fetus 5	Diagnosis	ICD-10-CM
O4192X9	Disorder of amniotic fluid and membranes, unspecified, second trimester, other fetus	Diagnosis	ICD-10-CM
O4193X0	Disorder of amniotic fluid and membranes, unspecified, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O4193X1	Disorder of amniotic fluid and membranes, unspecified, third trimester, fetus 1	Diagnosis	ICD-10-CM
O4193X2	Disorder of amniotic fluid and membranes, unspecified, third trimester, fetus 2	Diagnosis	ICD-10-CM
O4193X3	Disorder of amniotic fluid and membranes, unspecified, third trimester, fetus 3	Diagnosis	ICD-10-CM
O4193X4	Disorder of amniotic fluid and membranes, unspecified, third trimester, fetus 4	Diagnosis	ICD-10-CM
O4193X5	Disorder of amniotic fluid and membranes, unspecified, third trimester, fetus 5	Diagnosis	ICD-10-CM
O4193X9	Disorder of amniotic fluid and membranes, unspecified, third trimester, other fetus	Diagnosis	ICD-10-CM
O42011	Preterm premature rupture of membranes, onset of labor within 24 hours of rupture, first trimester	Diagnosis	ICD-10-CM
O42012	Preterm premature rupture of membranes, onset of labor within 24 hours of rupture, second trimester	Diagnosis	ICD-10-CM
O42013	Preterm premature rupture of membranes, onset of labor within 24 hours of rupture, third trimester	Diagnosis	ICD-10-CM
O42019	Preterm premature rupture of membranes, onset of labor within 24 hours of rupture, unspecified trimester	Diagnosis	ICD-10-CM
O4202	Full-term premature rupture of membranes, onset of labor within 24 hours of rupture	Diagnosis	ICD-10-CM
O42111	Preterm premature rupture of membranes, onset of labor more than 24 hours following rupture, first trimester	Diagnosis	ICD-10-CM
O42112	Preterm premature rupture of membranes, onset of labor more than 24 hours following rupture, second trimester	Diagnosis	ICD-10-CM
O42113	Preterm premature rupture of membranes, onset of labor more than 24 hours following rupture, third trimester	Diagnosis	ICD-10-CM
O42119	Preterm premature rupture of membranes, onset of labor more than 24 hours following rupture, unspecified trimester	Diagnosis	ICD-10-CM
O4212	Full-term premature rupture of membranes, onset of labor more than 24 hours following rupture	Diagnosis	ICD-10-CM
O42911	Preterm premature rupture of membranes, unspecified as to length of time between rupture and onset of labor, first trimester	Diagnosis	ICD-10-CM
O42912	Preterm premature rupture of membranes, unspecified as to length of time between rupture and onset of labor, second trimester	Diagnosis	ICD-10-CM
O42913	Preterm premature rupture of membranes, unspecified as to length of time between rupture and onset of labor, third trimester	Diagnosis	ICD-10-CM
O42919	Preterm premature rupture of membranes, unspecified as to length of time between rupture and onset of labor, unspecified trimester	Diagnosis	ICD-10-CM
O4292	Full-term premature rupture of membranes, unspecified as to length of time between rupture and onset of labor	Diagnosis	ICD-10-CM
O43011	Fetomaternal placental transfusion syndrome, first trimester	Diagnosis	ICD-10-CM
O43012	Fetomaternal placental transfusion syndrome, second trimester	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O43013	Fetomaternal placental transfusion syndrome, third trimester	Diagnosis	ICD-10-CM
O43021	Fetus-to-fetus placental transfusion syndrome, first trimester	Diagnosis	ICD-10-CM
O43022	Fetus-to-fetus placental transfusion syndrome, second trimester	Diagnosis	ICD-10-CM
O43023	Fetus-to-fetus placental transfusion syndrome, third trimester	Diagnosis	ICD-10-CM
O43101	Malformation of placenta, unspecified, first trimester	Diagnosis	ICD-10-CM
O43102	Malformation of placenta, unspecified, second trimester	Diagnosis	ICD-10-CM
O43103	Malformation of placenta, unspecified, third trimester	Diagnosis	ICD-10-CM
O43111	Circumvallate placenta, first trimester	Diagnosis	ICD-10-CM
O43112	Circumvallate placenta, second trimester	Diagnosis	ICD-10-CM
O43113	Circumvallate placenta, third trimester	Diagnosis	ICD-10-CM
O43121	Velamentous insertion of umbilical cord, first trimester	Diagnosis	ICD-10-CM
O43122	Velamentous insertion of umbilical cord, second trimester	Diagnosis	ICD-10-CM
O43123	Velamentous insertion of umbilical cord, third trimester	Diagnosis	ICD-10-CM
O43191	Other malformation of placenta, first trimester	Diagnosis	ICD-10-CM
O43192	Other malformation of placenta, second trimester	Diagnosis	ICD-10-CM
O43193	Other malformation of placenta, third trimester	Diagnosis	ICD-10-CM
O43211	Placenta accreta, first trimester	Diagnosis	ICD-10-CM
O43212	Placenta accreta, second trimester	Diagnosis	ICD-10-CM
O43213	Placenta accreta, third trimester	Diagnosis	ICD-10-CM
O43221	Placenta increta, first trimester	Diagnosis	ICD-10-CM
O43222	Placenta increta, second trimester	Diagnosis	ICD-10-CM
O43223	Placenta increta, third trimester	Diagnosis	ICD-10-CM
O43231	Placenta percreta, first trimester	Diagnosis	ICD-10-CM
O43232	Placenta percreta, second trimester	Diagnosis	ICD-10-CM
O43233	Placenta percreta, third trimester	Diagnosis	ICD-10-CM
O43811	Placental infarction, first trimester	Diagnosis	ICD-10-CM
O43812	Placental infarction, second trimester	Diagnosis	ICD-10-CM
O43813	Placental infarction, third trimester	Diagnosis	ICD-10-CM
O43891	Other placental disorders, first trimester	Diagnosis	ICD-10-CM
O43892	Other placental disorders, second trimester	Diagnosis	ICD-10-CM
O43893	Other placental disorders, third trimester	Diagnosis	ICD-10-CM
O4391	Unspecified placental disorder, first trimester	Diagnosis	ICD-10-CM
O4392	Unspecified placental disorder, second trimester	Diagnosis	ICD-10-CM
O4393	Unspecified placental disorder, third trimester	Diagnosis	ICD-10-CM
O4401	Complete placenta previa NOS or without hemorrhage, first trimester	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O4402	Complete placenta previa NOS or without hemorrhage, second trimester	Diagnosis	ICD-10-CM
O4403	Complete placenta previa NOS or without hemorrhage, third trimester	Diagnosis	ICD-10-CM
O4411	Complete placenta previa with hemorrhage, first trimester	Diagnosis	ICD-10-CM
O4412	Complete placenta previa with hemorrhage, second trimester	Diagnosis	ICD-10-CM
O4413	Complete placenta previa with hemorrhage, third trimester	Diagnosis	ICD-10-CM
O4421	Partial placenta previa NOS or without hemorrhage, first trimester	Diagnosis	ICD-10-CM
O4422	Partial placenta previa NOS or without hemorrhage, second trimester	Diagnosis	ICD-10-CM
O4423	Partial placenta previa NOS or without hemorrhage, third trimester	Diagnosis	ICD-10-CM
O4431	Partial placenta previa with hemorrhage, first trimester	Diagnosis	ICD-10-CM
O4432	Partial placenta previa with hemorrhage, second trimester	Diagnosis	ICD-10-CM
O4433	Partial placenta previa with hemorrhage, third trimester	Diagnosis	ICD-10-CM
O4441	Low lying placenta NOS or without hemorrhage, first trimester	Diagnosis	ICD-10-CM
O4442	Low lying placenta NOS or without hemorrhage, second trimester	Diagnosis	ICD-10-CM
O4443	Low lying placenta NOS or without hemorrhage, third trimester	Diagnosis	ICD-10-CM
O4451	Low lying placenta with hemorrhage, first trimester	Diagnosis	ICD-10-CM
O4452	Low lying placenta with hemorrhage, second trimester	Diagnosis	ICD-10-CM
O4453	Low lying placenta with hemorrhage, third trimester	Diagnosis	ICD-10-CM
O45001	Premature separation of placenta with coagulation defect, unspecified, first trimester	Diagnosis	ICD-10-CM
O45002	Premature separation of placenta with coagulation defect, unspecified, second trimester	Diagnosis	ICD-10-CM
O45003	Premature separation of placenta with coagulation defect, unspecified, third trimester	Diagnosis	ICD-10-CM
O45011	Premature separation of placenta with afibrinogenemia, first trimester	Diagnosis	ICD-10-CM
O45012	Premature separation of placenta with afibrinogenemia, second trimester	Diagnosis	ICD-10-CM
O45013	Premature separation of placenta with afibrinogenemia, third trimester	Diagnosis	ICD-10-CM
O45021	Premature separation of placenta with disseminated intravascular coagulation, first trimester	Diagnosis	ICD-10-CM
O45022	Premature separation of placenta with disseminated intravascular coagulation, second trimester	Diagnosis	ICD-10-CM
O45023	Premature separation of placenta with disseminated intravascular coagulation, third trimester	Diagnosis	ICD-10-CM
O45091	Premature separation of placenta with other coagulation defect, first trimester	Diagnosis	ICD-10-CM
O45092	Premature separation of placenta with other coagulation defect, second trimester	Diagnosis	ICD-10-CM
O45093	Premature separation of placenta with other coagulation defect, third trimester	Diagnosis	ICD-10-CM
O458X1	Other premature separation of placenta, first trimester	Diagnosis	ICD-10-CM
O458X2	Other premature separation of placenta, second trimester	Diagnosis	ICD-10-CM
O458X3	Other premature separation of placenta, third trimester	Diagnosis	ICD-10-CM
O4591	Premature separation of placenta, unspecified, first trimester	Diagnosis	ICD-10-CM
O4592	Premature separation of placenta, unspecified, second trimester	Diagnosis	ICD-10-CM
O4593	Premature separation of placenta, unspecified, third trimester	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O46001	Antepartum hemorrhage with coagulation defect, unspecified, first trimester	Diagnosis	ICD-10-CM
O46002	Antepartum hemorrhage with coagulation defect, unspecified, second trimester	Diagnosis	ICD-10-CM
O46003	Antepartum hemorrhage with coagulation defect, unspecified, third trimester	Diagnosis	ICD-10-CM
O46011	Antepartum hemorrhage with afibrinogenemia, first trimester	Diagnosis	ICD-10-CM
O46012	Antepartum hemorrhage with afibrinogenemia, second trimester	Diagnosis	ICD-10-CM
O46013	Antepartum hemorrhage with afibrinogenemia, third trimester	Diagnosis	ICD-10-CM
O46021	Antepartum hemorrhage with disseminated intravascular coagulation, first trimester	Diagnosis	ICD-10-CM
O46022	Antepartum hemorrhage with disseminated intravascular coagulation, second trimester	Diagnosis	ICD-10-CM
O46023	Antepartum hemorrhage with disseminated intravascular coagulation, third trimester	Diagnosis	ICD-10-CM
O46091	Antepartum hemorrhage with other coagulation defect, first trimester	Diagnosis	ICD-10-CM
O46092	Antepartum hemorrhage with other coagulation defect, second trimester	Diagnosis	ICD-10-CM
O46093	Antepartum hemorrhage with other coagulation defect, third trimester	Diagnosis	ICD-10-CM
O468X1	Other antepartum hemorrhage, first trimester	Diagnosis	ICD-10-CM
O468X2	Other antepartum hemorrhage, second trimester	Diagnosis	ICD-10-CM
O468X3	Other antepartum hemorrhage, third trimester	Diagnosis	ICD-10-CM
O4691	Antepartum hemorrhage, unspecified, first trimester	Diagnosis	ICD-10-CM
O4692	Antepartum hemorrhage, unspecified, second trimester	Diagnosis	ICD-10-CM
O4693	Antepartum hemorrhage, unspecified, third trimester	Diagnosis	ICD-10-CM
O4702	False labor before 37 completed weeks of gestation, second trimester	Diagnosis	ICD-10-CM
O4703	False labor before 37 completed weeks of gestation, third trimester	Diagnosis	ICD-10-CM
O471	False labor at or after 37 completed weeks of gestation	Diagnosis	ICD-10-CM
O480	Post-term pregnancy	Diagnosis	ICD-10-CM
O481	Prolonged pregnancy	Diagnosis	ICD-10-CM
O6002	Preterm labor without delivery, second trimester	Diagnosis	ICD-10-CM
O6003	Preterm labor without delivery, third trimester	Diagnosis	ICD-10-CM
O6010X0	Preterm labor with preterm delivery, unspecified trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O6010X1	Preterm labor with preterm delivery, unspecified trimester, fetus 1	Diagnosis	ICD-10-CM
O6010X2	Preterm labor with preterm delivery, unspecified trimester, fetus 2	Diagnosis	ICD-10-CM
O6010X3	Preterm labor with preterm delivery, unspecified trimester, fetus 3	Diagnosis	ICD-10-CM
O6010X4	Preterm labor with preterm delivery, unspecified trimester, fetus 4	Diagnosis	ICD-10-CM
O6010X5	Preterm labor with preterm delivery, unspecified trimester, fetus 5	Diagnosis	ICD-10-CM
O6010X9	Preterm labor with preterm delivery, unspecified trimester, other fetus	Diagnosis	ICD-10-CM
O6012X0	Preterm labor second trimester with preterm delivery second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O6012X1	Preterm labor second trimester with preterm delivery second trimester, fetus 1	Diagnosis	ICD-10-CM
O6012X2	Preterm labor second trimester with preterm delivery second trimester, fetus 2	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O6012X3	Preterm labor second trimester with preterm delivery second trimester, fetus 3	Diagnosis	ICD-10-CM
O6012X4	Preterm labor second trimester with preterm delivery second trimester, fetus 4	Diagnosis	ICD-10-CM
O6012X5	Preterm labor second trimester with preterm delivery second trimester, fetus 5	Diagnosis	ICD-10-CM
O6012X9	Preterm labor second trimester with preterm delivery second trimester, other fetus	Diagnosis	ICD-10-CM
O6013X0	Preterm labor second trimester with preterm delivery third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O6013X1	Preterm labor second trimester with preterm delivery third trimester, fetus 1	Diagnosis	ICD-10-CM
O6013X2	Preterm labor second trimester with preterm delivery third trimester, fetus 2	Diagnosis	ICD-10-CM
O6013X3	Preterm labor second trimester with preterm delivery third trimester, fetus 3	Diagnosis	ICD-10-CM
O6013X4	Preterm labor second trimester with preterm delivery third trimester, fetus 4	Diagnosis	ICD-10-CM
O6013X5	Preterm labor second trimester with preterm delivery third trimester, fetus 5	Diagnosis	ICD-10-CM
O6013X9	Preterm labor second trimester with preterm delivery third trimester, other fetus	Diagnosis	ICD-10-CM
O6014X0	Preterm labor third trimester with preterm delivery third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O6014X1	Preterm labor third trimester with preterm delivery third trimester, fetus 1	Diagnosis	ICD-10-CM
O6014X2	Preterm labor third trimester with preterm delivery third trimester, fetus 2	Diagnosis	ICD-10-CM
O6014X3	Preterm labor third trimester with preterm delivery third trimester, fetus 3	Diagnosis	ICD-10-CM
O6014X4	Preterm labor third trimester with preterm delivery third trimester, fetus 4	Diagnosis	ICD-10-CM
O6014X5	Preterm labor third trimester with preterm delivery third trimester, fetus 5	Diagnosis	ICD-10-CM
O6014X9	Preterm labor third trimester with preterm delivery third trimester, other fetus	Diagnosis	ICD-10-CM
O6020X0	Term delivery with preterm labor, unspecified trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O6020X1	Term delivery with preterm labor, unspecified trimester, fetus 1	Diagnosis	ICD-10-CM
O6020X2	Term delivery with preterm labor, unspecified trimester, fetus 2	Diagnosis	ICD-10-CM
O6020X3	Term delivery with preterm labor, unspecified trimester, fetus 3	Diagnosis	ICD-10-CM
O6020X4	Term delivery with preterm labor, unspecified trimester, fetus 4	Diagnosis	ICD-10-CM
O6020X5	Term delivery with preterm labor, unspecified trimester, fetus 5	Diagnosis	ICD-10-CM
O6020X9	Term delivery with preterm labor, unspecified trimester, other fetus	Diagnosis	ICD-10-CM
O6022X0	Term delivery with preterm labor, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O6022X1	Term delivery with preterm labor, second trimester, fetus 1	Diagnosis	ICD-10-CM
O6022X2	Term delivery with preterm labor, second trimester, fetus 2	Diagnosis	ICD-10-CM
O6022X3	Term delivery with preterm labor, second trimester, fetus 3	Diagnosis	ICD-10-CM
O6022X4	Term delivery with preterm labor, second trimester, fetus 4	Diagnosis	ICD-10-CM
O6022X5	Term delivery with preterm labor, second trimester, fetus 5	Diagnosis	ICD-10-CM
O6022X9	Term delivery with preterm labor, second trimester, other fetus	Diagnosis	ICD-10-CM
O6023X0	Term delivery with preterm labor, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O6023X1	Term delivery with preterm labor, third trimester, fetus 1	Diagnosis	ICD-10-CM
O6023X2	Term delivery with preterm labor, third trimester, fetus 2	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O6023X3	Term delivery with preterm labor, third trimester, fetus 3	Diagnosis	ICD-10-CM
O6023X4	Term delivery with preterm labor, third trimester, fetus 4	Diagnosis	ICD-10-CM
O6023X5	Term delivery with preterm labor, third trimester, fetus 5	Diagnosis	ICD-10-CM
O6023X9	Term delivery with preterm labor, third trimester, other fetus	Diagnosis	ICD-10-CM
O632	Delayed delivery of second twin, triplet, etc	Diagnosis	ICD-10-CM
O670	Intrapartum hemorrhage with coagulation defect	Diagnosis	ICD-10-CM
O678	Other intrapartum hemorrhage	Diagnosis	ICD-10-CM
O679	Intrapartum hemorrhage, unspecified	Diagnosis	ICD-10-CM
O68	Labor and delivery complicated by abnormality of fetal acid-base balance	Diagnosis	ICD-10-CM
O690XX0	Labor and delivery complicated by prolapse of cord, not applicable or unspecified	Diagnosis	ICD-10-CM
O690XX1	Labor and delivery complicated by prolapse of cord, fetus 1	Diagnosis	ICD-10-CM
O690XX2	Labor and delivery complicated by prolapse of cord, fetus 2	Diagnosis	ICD-10-CM
O690XX3	Labor and delivery complicated by prolapse of cord, fetus 3	Diagnosis	ICD-10-CM
O690XX4	Labor and delivery complicated by prolapse of cord, fetus 4	Diagnosis	ICD-10-CM
O690XX5	Labor and delivery complicated by prolapse of cord, fetus 5	Diagnosis	ICD-10-CM
O690XX9	Labor and delivery complicated by prolapse of cord, other fetus	Diagnosis	ICD-10-CM
O691XX0	Labor and delivery complicated by cord around neck, with compression, not applicable or unspecified	Diagnosis	ICD-10-CM
O691XX1	Labor and delivery complicated by cord around neck, with compression, fetus 1	Diagnosis	ICD-10-CM
O691XX2	Labor and delivery complicated by cord around neck, with compression, fetus 2	Diagnosis	ICD-10-CM
O691XX3	Labor and delivery complicated by cord around neck, with compression, fetus 3	Diagnosis	ICD-10-CM
O691XX4	Labor and delivery complicated by cord around neck, with compression, fetus 4	Diagnosis	ICD-10-CM
O691XX5	Labor and delivery complicated by cord around neck, with compression, fetus 5	Diagnosis	ICD-10-CM
O691XX9	Labor and delivery complicated by cord around neck, with compression, other fetus	Diagnosis	ICD-10-CM
O692XX0	Labor and delivery complicated by other cord entanglement, with compression, not applicable or unspecified	Diagnosis	ICD-10-CM
O692XX1	Labor and delivery complicated by other cord entanglement, with compression, fetus 1	Diagnosis	ICD-10-CM
O692XX2	Labor and delivery complicated by other cord entanglement, with compression, fetus 2	Diagnosis	ICD-10-CM
O692XX3	Labor and delivery complicated by other cord entanglement, with compression, fetus 3	Diagnosis	ICD-10-CM
O692XX4	Labor and delivery complicated by other cord entanglement, with compression, fetus 4	Diagnosis	ICD-10-CM
O692XX5	Labor and delivery complicated by other cord entanglement, with compression, fetus 5	Diagnosis	ICD-10-CM
O692XX9	Labor and delivery complicated by other cord entanglement, with compression, other fetus	Diagnosis	ICD-10-CM
O693XX0	Labor and delivery complicated by short cord, not applicable or unspecified	Diagnosis	ICD-10-CM
O693XX1	Labor and delivery complicated by short cord, fetus 1	Diagnosis	ICD-10-CM
O693XX2	Labor and delivery complicated by short cord, fetus 2	Diagnosis	ICD-10-CM
O693XX3	Labor and delivery complicated by short cord, fetus 3	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O693XX4	Labor and delivery complicated by short cord, fetus 4	Diagnosis	ICD-10-CM
O693XX5	Labor and delivery complicated by short cord, fetus 5	Diagnosis	ICD-10-CM
O693XX9	Labor and delivery complicated by short cord, other fetus	Diagnosis	ICD-10-CM
O694XX0	Labor and delivery complicated by vasa previa, not applicable or unspecified	Diagnosis	ICD-10-CM
O694XX1	Labor and delivery complicated by vasa previa, fetus 1	Diagnosis	ICD-10-CM
O694XX2	Labor and delivery complicated by vasa previa, fetus 2	Diagnosis	ICD-10-CM
O694XX3	Labor and delivery complicated by vasa previa, fetus 3	Diagnosis	ICD-10-CM
O694XX4	Labor and delivery complicated by vasa previa, fetus 4	Diagnosis	ICD-10-CM
O694XX5	Labor and delivery complicated by vasa previa, fetus 5	Diagnosis	ICD-10-CM
O694XX9	Labor and delivery complicated by vasa previa, other fetus	Diagnosis	ICD-10-CM
O695XX0	Labor and delivery complicated by vascular lesion of cord, not applicable or unspecified	Diagnosis	ICD-10-CM
O695XX1	Labor and delivery complicated by vascular lesion of cord, fetus 1	Diagnosis	ICD-10-CM
O695XX2	Labor and delivery complicated by vascular lesion of cord, fetus 2	Diagnosis	ICD-10-CM
O695XX3	Labor and delivery complicated by vascular lesion of cord, fetus 3	Diagnosis	ICD-10-CM
O695XX4	Labor and delivery complicated by vascular lesion of cord, fetus 4	Diagnosis	ICD-10-CM
O695XX5	Labor and delivery complicated by vascular lesion of cord, fetus 5	Diagnosis	ICD-10-CM
O695XX9	Labor and delivery complicated by vascular lesion of cord, other fetus	Diagnosis	ICD-10-CM
O6981X0	Labor and delivery complicated by cord around neck, without compression, not applicable or unspecified	Diagnosis	ICD-10-CM
O6981X1	Labor and delivery complicated by cord around neck, without compression, fetus 1	Diagnosis	ICD-10-CM
O6981X2	Labor and delivery complicated by cord around neck, without compression, fetus 2	Diagnosis	ICD-10-CM
O6981X3	Labor and delivery complicated by cord around neck, without compression, fetus 3	Diagnosis	ICD-10-CM
O6981X4	Labor and delivery complicated by cord around neck, without compression, fetus 4	Diagnosis	ICD-10-CM
O6981X5	Labor and delivery complicated by cord around neck, without compression, fetus 5	Diagnosis	ICD-10-CM
O6981X9	Labor and delivery complicated by cord around neck, without compression, other fetus	Diagnosis	ICD-10-CM
O6982X0	Labor and delivery complicated by other cord entanglement, without compression, not applicable or unspecified	Diagnosis	ICD-10-CM
O6982X1	Labor and delivery complicated by other cord entanglement, without compression, fetus 1	Diagnosis	ICD-10-CM
O6982X2	Labor and delivery complicated by other cord entanglement, without compression, fetus 2	Diagnosis	ICD-10-CM
O6982X3	Labor and delivery complicated by other cord entanglement, without compression, fetus 3	Diagnosis	ICD-10-CM
O6982X4	Labor and delivery complicated by other cord entanglement, without compression, fetus 4	Diagnosis	ICD-10-CM
O6982X5	Labor and delivery complicated by other cord entanglement, without compression, fetus 5	Diagnosis	ICD-10-CM
O6982X9	Labor and delivery complicated by other cord entanglement, without compression, other fetus	Diagnosis	ICD-10-CM
O6989X0	Labor and delivery complicated by other cord complications, not applicable or unspecified	Diagnosis	ICD-10-CM
O6989X1	Labor and delivery complicated by other cord complications, fetus 1	Diagnosis	ICD-10-CM
O6989X2	Labor and delivery complicated by other cord complications, fetus 2	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O6989X3	Labor and delivery complicated by other cord complications, fetus 3	Diagnosis	ICD-10-CM
O6989X4	Labor and delivery complicated by other cord complications, fetus 4	Diagnosis	ICD-10-CM
O6989X5	Labor and delivery complicated by other cord complications, fetus 5	Diagnosis	ICD-10-CM
O6989X9	Labor and delivery complicated by other cord complications, other fetus	Diagnosis	ICD-10-CM
O699XX0	Labor and delivery complicated by cord complication, unspecified, not applicable or unspecified	Diagnosis	ICD-10-CM
O699XX1	Labor and delivery complicated by cord complication, unspecified, fetus 1	Diagnosis	ICD-10-CM
O699XX2	Labor and delivery complicated by cord complication, unspecified, fetus 2	Diagnosis	ICD-10-CM
O699XX3	Labor and delivery complicated by cord complication, unspecified, fetus 3	Diagnosis	ICD-10-CM
O699XX4	Labor and delivery complicated by cord complication, unspecified, fetus 4	Diagnosis	ICD-10-CM
O699XX5	Labor and delivery complicated by cord complication, unspecified, fetus 5	Diagnosis	ICD-10-CM
O699XX9	Labor and delivery complicated by cord complication, unspecified, other fetus	Diagnosis	ICD-10-CM
O700	First degree perineal laceration during delivery	Diagnosis	ICD-10-CM
O701	Second degree perineal laceration during delivery	Diagnosis	ICD-10-CM
O7020	Third degree perineal laceration during delivery, unspecified	Diagnosis	ICD-10-CM
O7021	Third degree perineal laceration during delivery, IIIa	Diagnosis	ICD-10-CM
O7022	Third degree perineal laceration during delivery, IIIb	Diagnosis	ICD-10-CM
O7023	Third degree perineal laceration during delivery, IIIc	Diagnosis	ICD-10-CM
O703	Fourth degree perineal laceration during delivery	Diagnosis	ICD-10-CM
O704	Anal sphincter tear complicating delivery, not associated with third degree laceration	Diagnosis	ICD-10-CM
O709	Perineal laceration during delivery, unspecified	Diagnosis	ICD-10-CM
O7102	Rupture of uterus before onset of labor, second trimester	Diagnosis	ICD-10-CM
O7103	Rupture of uterus before onset of labor, third trimester	Diagnosis	ICD-10-CM
O740	Aspiration pneumonitis due to anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O741	Other pulmonary complications of anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O742	Cardiac complications of anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O743	Central nervous system complications of anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O744	Toxic reaction to local anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O745	Spinal and epidural anesthesia-induced headache during labor and delivery	Diagnosis	ICD-10-CM
O746	Other complications of spinal and epidural anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O747	Failed or difficult intubation for anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O748	Other complications of anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O749	Complication of anesthesia during labor and delivery, unspecified	Diagnosis	ICD-10-CM
O750	Maternal distress during labor and delivery	Diagnosis	ICD-10-CM
O751	Shock during or following labor and delivery	Diagnosis	ICD-10-CM
O755	Delayed delivery after artificial rupture of membranes	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O7581	Maternal exhaustion complicating labor and delivery	Diagnosis	ICD-10-CM
O7582	Onset (spontaneous) of labor after 37 completed weeks of gestation but before 39 completed weeks gestation, with delivery by (planned) cesarean section	Diagnosis	ICD-10-CM
O7589	Other specified complications of labor and delivery	Diagnosis	ICD-10-CM
O759	Complication of labor and delivery, unspecified	Diagnosis	ICD-10-CM
O76	Abnormality in fetal heart rate and rhythm complicating labor and delivery	Diagnosis	ICD-10-CM
O770	Labor and delivery complicated by meconium in amniotic fluid	Diagnosis	ICD-10-CM
O778	Labor and delivery complicated by other evidence of fetal stress	Diagnosis	ICD-10-CM
O779	Labor and delivery complicated by fetal stress, unspecified	Diagnosis	ICD-10-CM
O80	Encounter for full-term uncomplicated delivery	Diagnosis	ICD-10-CM
O82	Encounter for cesarean delivery without indication	Diagnosis	ICD-10-CM
O88011	Air embolism in pregnancy, first trimester	Diagnosis	ICD-10-CM
O88012	Air embolism in pregnancy, second trimester	Diagnosis	ICD-10-CM
O88013	Air embolism in pregnancy, third trimester	Diagnosis	ICD-10-CM
O8802	Air embolism in childbirth	Diagnosis	ICD-10-CM
O88111	Amniotic fluid embolism in pregnancy, first trimester	Diagnosis	ICD-10-CM
O88112	Amniotic fluid embolism in pregnancy, second trimester	Diagnosis	ICD-10-CM
O88113	Amniotic fluid embolism in pregnancy, third trimester	Diagnosis	ICD-10-CM
O8812	Amniotic fluid embolism in childbirth	Diagnosis	ICD-10-CM
O88211	Thromboembolism in pregnancy, first trimester	Diagnosis	ICD-10-CM
O88212	Thromboembolism in pregnancy, second trimester	Diagnosis	ICD-10-CM
O88213	Thromboembolism in pregnancy, third trimester	Diagnosis	ICD-10-CM
O8822	Thromboembolism in childbirth	Diagnosis	ICD-10-CM
O88311	Pyemic and septic embolism in pregnancy, first trimester	Diagnosis	ICD-10-CM
O88312	Pyemic and septic embolism in pregnancy, second trimester	Diagnosis	ICD-10-CM
O88313	Pyemic and septic embolism in pregnancy, third trimester	Diagnosis	ICD-10-CM
O8832	Pyemic and septic embolism in childbirth	Diagnosis	ICD-10-CM
O88811	Other embolism in pregnancy, first trimester	Diagnosis	ICD-10-CM
O88812	Other embolism in pregnancy, second trimester	Diagnosis	ICD-10-CM
O88813	Other embolism in pregnancy, third trimester	Diagnosis	ICD-10-CM
O8882	Other embolism in childbirth	Diagnosis	ICD-10-CM
O91011	Infection of nipple associated with pregnancy, first trimester	Diagnosis	ICD-10-CM
O91012	Infection of nipple associated with pregnancy, second trimester	Diagnosis	ICD-10-CM
O91013	Infection of nipple associated with pregnancy, third trimester	Diagnosis	ICD-10-CM
O91111	Abscess of breast associated with pregnancy, first trimester	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O91112	Abscess of breast associated with pregnancy, second trimester	Diagnosis	ICD-10-CM
O91113	Abscess of breast associated with pregnancy, third trimester	Diagnosis	ICD-10-CM
O91211	Nonpurulent mastitis associated with pregnancy, first trimester	Diagnosis	ICD-10-CM
O91212	Nonpurulent mastitis associated with pregnancy, second trimester	Diagnosis	ICD-10-CM
O91213	Nonpurulent mastitis associated with pregnancy, third trimester	Diagnosis	ICD-10-CM
O92011	Retracted nipple associated with pregnancy, first trimester	Diagnosis	ICD-10-CM
O92012	Retracted nipple associated with pregnancy, second trimester	Diagnosis	ICD-10-CM
O92013	Retracted nipple associated with pregnancy, third trimester	Diagnosis	ICD-10-CM
O92111	Cracked nipple associated with pregnancy, first trimester	Diagnosis	ICD-10-CM
O92112	Cracked nipple associated with pregnancy, second trimester	Diagnosis	ICD-10-CM
O92113	Cracked nipple associated with pregnancy, third trimester	Diagnosis	ICD-10-CM
O98011	Tuberculosis complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O98012	Tuberculosis complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O98013	Tuberculosis complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9802	Tuberculosis complicating childbirth	Diagnosis	ICD-10-CM
O98111	Syphilis complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O98112	Syphilis complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O98113	Syphilis complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9812	Syphilis complicating childbirth	Diagnosis	ICD-10-CM
O98211	Gonorrhea complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O98212	Gonorrhea complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O98213	Gonorrhea complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9822	Gonorrhea complicating childbirth	Diagnosis	ICD-10-CM
O98311	Other infections with a predominantly sexual mode of transmission complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O98312	Other infections with a predominantly sexual mode of transmission complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O98313	Other infections with a predominantly sexual mode of transmission complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9832	Other infections with a predominantly sexual mode of transmission complicating childbirth	Diagnosis	ICD-10-CM
O98411	Viral hepatitis complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O98412	Viral hepatitis complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O98413	Viral hepatitis complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9842	Viral hepatitis complicating childbirth	Diagnosis	ICD-10-CM
O98511	Other viral diseases complicating pregnancy, first trimester	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O98512	Other viral diseases complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O98513	Other viral diseases complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9852	Other viral diseases complicating childbirth	Diagnosis	ICD-10-CM
O98611	Protozoal diseases complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O98612	Protozoal diseases complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O98613	Protozoal diseases complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9862	Protozoal diseases complicating childbirth	Diagnosis	ICD-10-CM
O98711	Human immunodeficiency virus [HIV] disease complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O98712	Human immunodeficiency virus [HIV] disease complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O98713	Human immunodeficiency virus [HIV] disease complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9872	Human immunodeficiency virus [HIV] disease complicating childbirth	Diagnosis	ICD-10-CM
O98811	Other maternal infectious and parasitic diseases complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O98812	Other maternal infectious and parasitic diseases complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O98813	Other maternal infectious and parasitic diseases complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9882	Other maternal infectious and parasitic diseases complicating childbirth	Diagnosis	ICD-10-CM
O98911	Unspecified maternal infectious and parasitic disease complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O98912	Unspecified maternal infectious and parasitic disease complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O98913	Unspecified maternal infectious and parasitic disease complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9892	Unspecified maternal infectious and parasitic disease complicating childbirth	Diagnosis	ICD-10-CM
O99011	Anemia complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99012	Anemia complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99013	Anemia complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9902	Anemia complicating childbirth	Diagnosis	ICD-10-CM
O99111	Other diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99112	Other diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99113	Other diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9912	Other diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism complicating childbirth	Diagnosis	ICD-10-CM
O99211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99214	Obesity complicating childbirth	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O99281	Endocrine, nutritional and metabolic diseases complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99282	Endocrine, nutritional and metabolic diseases complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99283	Endocrine, nutritional and metabolic diseases complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99284	Endocrine, nutritional and metabolic diseases complicating childbirth	Diagnosis	ICD-10-CM
O99311	Alcohol use complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99312	Alcohol use complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99313	Alcohol use complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99314	Alcohol use complicating childbirth	Diagnosis	ICD-10-CM
O99321	Drug use complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99322	Drug use complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99323	Drug use complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99324	Drug use complicating childbirth	Diagnosis	ICD-10-CM
O99331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99341	Other mental disorders complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99342	Other mental disorders complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99343	Other mental disorders complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99344	Other mental disorders complicating childbirth	Diagnosis	ICD-10-CM
O99351	Diseases of the nervous system complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99352	Diseases of the nervous system complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99353	Diseases of the nervous system complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99354	Diseases of the nervous system complicating childbirth	Diagnosis	ICD-10-CM
O99411	Diseases of the circulatory system complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99412	Diseases of the circulatory system complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99413	Diseases of the circulatory system complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9942	Diseases of the circulatory system complicating childbirth	Diagnosis	ICD-10-CM
O99511	Diseases of the respiratory system complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99512	Diseases of the respiratory system complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99513	Diseases of the respiratory system complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9952	Diseases of the respiratory system complicating childbirth	Diagnosis	ICD-10-CM
O99611	Diseases of the digestive system complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99612	Diseases of the digestive system complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99613	Diseases of the digestive system complicating pregnancy, third trimester	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
O9962	Diseases of the digestive system complicating childbirth	Diagnosis	ICD-10-CM
O99711	Diseases of the skin and subcutaneous tissue complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99712	Diseases of the skin and subcutaneous tissue complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99713	Diseases of the skin and subcutaneous tissue complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9972	Diseases of the skin and subcutaneous tissue complicating childbirth	Diagnosis	ICD-10-CM
O99814	Abnormal glucose complicating childbirth	Diagnosis	ICD-10-CM
O99824	Streptococcus B carrier state complicating childbirth	Diagnosis	ICD-10-CM
O99834	Other infection carrier state complicating childbirth	Diagnosis	ICD-10-CM
O99841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O9A111	Malignant neoplasm complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O9A112	Malignant neoplasm complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O9A113	Malignant neoplasm complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9A12	Malignant neoplasm complicating childbirth	Diagnosis	ICD-10-CM
O9A211	Injury, poisoning and certain other consequences of external causes complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O9A212	Injury, poisoning and certain other consequences of external causes complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O9A213	Injury, poisoning and certain other consequences of external causes complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9A22	Injury, poisoning and certain other consequences of external causes complicating childbirth	Diagnosis	ICD-10-CM
O9A311	Physical abuse complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O9A312	Physical abuse complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O9A313	Physical abuse complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9A32	Physical abuse complicating childbirth	Diagnosis	ICD-10-CM
O9A411	Sexual abuse complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O9A412	Sexual abuse complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O9A413	Sexual abuse complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9A42	Sexual abuse complicating childbirth	Diagnosis	ICD-10-CM
O9A511	Psychological abuse complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O9A512	Psychological abuse complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O9A513	Psychological abuse complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9A52	Psychological abuse complicating childbirth	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
P030	Newborn affected by breech delivery and extraction	Diagnosis	ICD-10-CM
P032	Newborn affected by forceps delivery	Diagnosis	ICD-10-CM
P033	Newborn affected by delivery by vacuum extractor [ventouse]	Diagnosis	ICD-10-CM
P034	Newborn affected by Cesarean delivery	Diagnosis	ICD-10-CM
P035	Newborn affected by precipitate delivery	Diagnosis	ICD-10-CM
P0700	Extremely low birth weight newborn, unspecified weight	Diagnosis	ICD-10-CM
P0701	Extremely low birth weight newborn, less than 500 grams	Diagnosis	ICD-10-CM
P0702	Extremely low birth weight newborn, 500-749 grams	Diagnosis	ICD-10-CM
P0703	Extremely low birth weight newborn, 750-999 grams	Diagnosis	ICD-10-CM
P0710	Other low birth weight newborn, unspecified weight	Diagnosis	ICD-10-CM
P0714	Other low birth weight newborn, 1000-1249 grams	Diagnosis	ICD-10-CM
P0715	Other low birth weight newborn, 1250-1499 grams	Diagnosis	ICD-10-CM
P0716	Other low birth weight newborn, 1500-1749 grams	Diagnosis	ICD-10-CM
P0717	Other low birth weight newborn, 1750-1999 grams	Diagnosis	ICD-10-CM
P0718	Other low birth weight newborn, 2000-2499 grams	Diagnosis	ICD-10-CM
P0720	Extreme immaturity of newborn, unspecified weeks of gestation	Diagnosis	ICD-10-CM
P0721	Extreme immaturity of newborn, gestational age less than 23 completed weeks	Diagnosis	ICD-10-CM
P0722	Extreme immaturity of newborn, gestational age 23 completed weeks	Diagnosis	ICD-10-CM
P0723	Extreme immaturity of newborn, gestational age 24 completed weeks	Diagnosis	ICD-10-CM
P0724	Extreme immaturity of newborn, gestational age 25 completed weeks	Diagnosis	ICD-10-CM
P0725	Extreme immaturity of newborn, gestational age 26 completed weeks	Diagnosis	ICD-10-CM
P0726	Extreme immaturity of newborn, gestational age 27 completed weeks	Diagnosis	ICD-10-CM
P0730	Preterm newborn, unspecified weeks of gestation	Diagnosis	ICD-10-CM
P0731	Preterm newborn, gestational age 28 completed weeks	Diagnosis	ICD-10-CM
P0732	Preterm newborn, gestational age 29 completed weeks	Diagnosis	ICD-10-CM
P0733	Preterm newborn, gestational age 30 completed weeks	Diagnosis	ICD-10-CM
P0734	Preterm newborn, gestational age 31 completed weeks	Diagnosis	ICD-10-CM
P0735	Preterm newborn, gestational age 32 completed weeks	Diagnosis	ICD-10-CM
P0736	Preterm newborn, gestational age 33 completed weeks	Diagnosis	ICD-10-CM
P0737	Preterm newborn, gestational age 34 completed weeks	Diagnosis	ICD-10-CM
P0738	Preterm newborn, gestational age 35 completed weeks	Diagnosis	ICD-10-CM
P0739	Preterm newborn, gestational age 36 completed weeks	Diagnosis	ICD-10-CM
P0821	Post-term newborn	Diagnosis	ICD-10-CM
P0822	Prolonged gestation of newborn	Diagnosis	ICD-10-CM
P95	Stillbirth	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
S0190	Mifepristone, oral, 200 mg	Procedure	HCPCS
S0191	Misoprostol, oral, 200 mcg	Procedure	HCPCS
S0199	Medically induced abortion by oral ingestion of medication including all associated services and supplies (e.g., patient counseling, office visits, confirmation of pregnancy by HCG, ultrasound to confirm duration of pregnancy, ultrasound to confirm completion of abortion) except drugs	Procedure	HCPCS
S2260	Induced abortion, 17 to 24 weeks	Procedure	HCPCS
S2262	Abortion for maternal indication, 25 weeks or greater	Procedure	HCPCS
S2265	Induced abortion, 25 to 28 weeks	Procedure	HCPCS
S2266	Induced abortion, 29 to 31 weeks	Procedure	HCPCS
S2267	Induced abortion, 32 weeks or greater	Procedure	HCPCS
S4011	IN VITRO FERTILIZATION;	Procedure	HCPCS
S4013	COMPLETE CYCLE GIFT CASE RATE	Procedure	HCPCS
S4014	COMPLETE CYCLE ZIFT CASE RATE	Procedure	HCPCS
S4015	COMPLETE IVF CYCLE CASE RATE NOS	Procedure	HCPCS
S4016	FROZEN IVF CYCLE CASE RATE	Procedure	HCPCS
S4035	STIMULATED INTRAUTERINE INSEMINATION (IUI), CASE RATE	Procedure	HCPCS
S4037	Cryopreserved embryo transfer, case rate	Procedure	HCPCS
V27	Outcome of delivery	Diagnosis	ICD-9-CM
V270	Outcome of delivery, single liveborn	Diagnosis	ICD-9-CM
V271	Outcome of delivery, single stillborn	Diagnosis	ICD-9-CM
V272	Outcome of delivery, twins, both liveborn	Diagnosis	ICD-9-CM
V273	Outcome of delivery, twins, one liveborn and one stillborn	Diagnosis	ICD-9-CM
V274	Outcome of delivery, twins, both stillborn	Diagnosis	ICD-9-CM
V275	Outcome of delivery, other multiple birth, all liveborn	Diagnosis	ICD-9-CM
V276	Outcome of delivery, other multiple birth, some liveborn	Diagnosis	ICD-9-CM
V277	Outcome of delivery, other multiple birth, all stillborn	Diagnosis	ICD-9-CM
V279	Outcome of delivery, unspecified	Diagnosis	ICD-9-CM
V30	Single liveborn	Diagnosis	ICD-9-CM
V300	Single liveborn, born in hospital	Diagnosis	ICD-9-CM
V3000	Single liveborn, born in hospital, delivered without mention of cesarean delivery	Diagnosis	ICD-9-CM
V3001	Single liveborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V301	Single liveborn, born before admission to hospital	Diagnosis	ICD-9-CM
V302	Single liveborn, born outside hospital and not hospitalized	Diagnosis	ICD-9-CM
V31	Twin birth, mate liveborn	Diagnosis	ICD-9-CM
V310	Twin, mate liveborn, born in hospital	Diagnosis	ICD-9-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
V3100	Twin, mate liveborn, born in hospital, delivered without mention of cesarean delivery	Diagnosis	ICD-9-CM
V3101	Twin, mate liveborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V311	Twin birth, mate liveborn, born before admission to hospital	Diagnosis	ICD-9-CM
V312	Twin birth, mate liveborn, born outside hospital and not hospitalized	Diagnosis	ICD-9-CM
V32	Twin birth, mate stillborn	Diagnosis	ICD-9-CM
V320	Twin, mate stillborn, born in hospital	Diagnosis	ICD-9-CM
V3200	Twin, mate stillborn, born in hospital, delivered without mention of cesarean delivery	Diagnosis	ICD-9-CM
V3201	Twin, mate stillborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V321	Twin birth, mate stillborn, born before admission to hospital	Diagnosis	ICD-9-CM
V322	Twin birth, mate stillborn, born outside hospital and not hospitalized	Diagnosis	ICD-9-CM
V33	Twin birth, unspecified whether mate liveborn or stillborn	Diagnosis	ICD-9-CM
V330	Twin, unspecified, born in hospital	Diagnosis	ICD-9-CM
V3300	Twin, unspecified whether mate stillborn or liveborn, born in hospital, delivered without mention of cesarean delivery	Diagnosis	ICD-9-CM
V3301	Twin, unspecified whether mate stillborn or liveborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V331	Twin birth, unspecified whether mate liveborn or stillborn, born before admission to hospital	Diagnosis	ICD-9-CM
V332	Twin birth, unspecified whether mate liveborn or stillborn, born outside hospital and not hospitalized	Diagnosis	ICD-9-CM
V34	Other multiple birth (three or more), mates all liveborn	Diagnosis	ICD-9-CM
V340	Other multiple, mates all liveborn, born in hospital	Diagnosis	ICD-9-CM
V3400	Other multiple, mates all liveborn, born in hospital, delivered without mention of cesarean delivery	Diagnosis	ICD-9-CM
V3401	Other multiple, mates all liveborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V341	Other multiple birth (three or more), mates all liveborn, born before admission to hospital	Diagnosis	ICD-9-CM
V342	Other multiple birth (three or more), mates all liveborn, born outside hospital and not hospitalized	Diagnosis	ICD-9-CM
V35	Other multiple birth (three or more), mates all stillborn	Diagnosis	ICD-9-CM
V350	Other multiple, mates all stillborn, born in hospital	Diagnosis	ICD-9-CM
V3500	Other multiple birth (three or more), mates all still born, born in hospital, delivered without mention of cesarean section	Diagnosis	ICD-9-CM
V3501	Other multiple birth (three or more), mates all still born, born in hospital, delivered by cesarean section	Diagnosis	ICD-9-CM
V351	Other multiple birth (three or more), mates all stillborn, born before admission to hospital	Diagnosis	ICD-9-CM
V352	Other multiple birth (three or more), mates all stillborn, born outside of hospital and not hospitalized	Diagnosis	ICD-9-CM
V36	Other multiple birth (three or more), mates liveborn and stillborn	Diagnosis	ICD-9-CM
V360	Other multiple, mates liveborn and stillborn, born in hospital	Diagnosis	ICD-9-CM
V3600	Other multiple, mates liveborn and stillborn, born in hospital, delivered without mention of cesarean delivery	Diagnosis	ICD-9-CM
V3601	Other multiple, mates liveborn and stillborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
V361	Other multiple birth (three or more), mates liveborn and stillborn, born before admission to hospital	Diagnosis	ICD-9-CM
V362	Other multiple birth (three or more), mates liveborn and stillborn, born outside hospital and not hospitalized	Diagnosis	ICD-9-CM
V37	Other multiple birth (three or more), unspecified whether mates liveborn or stillborn	Diagnosis	ICD-9-CM
V370	Other multiple, unspecified whether mates stillborn or liveborn, born in hospital	Diagnosis	ICD-9-CM
V3700	Other multiple, unspecified whether mates stillborn or liveborn, born in hospital, delivered without mention of cesarean delivery	Diagnosis	ICD-9-CM
V3701	Other multiple, unspecified whether mates stillborn or liveborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V371	Other multiple birth (three or more), unspecified whether mates liveborn or stillborn, born before admission to hospital	Diagnosis	ICD-9-CM
V372	Other multiple birth (three or more), unspecified whether mates liveborn or stillborn, born outside of hospital	Diagnosis	ICD-9-CM
V39	Liveborn, unspecified whether single, twin, or multiple	Diagnosis	ICD-9-CM
V390	Other liveborn, unspecified whether single, twin, or multiple, born in hospital	Diagnosis	ICD-9-CM
V3900	Liveborn infant, unspecified whether single, twin, or multiple, born in hospital, delivered without mention of cesarean delivery	Diagnosis	ICD-9-CM
V3901	Liveborn infant, unspecified whether single, twin, or multiple, born in hospital, delivered by cesarean	Diagnosis	ICD-9-CM
V391	Liveborn, unspecified whether single, twin or multiple, born before admission to hospital	Diagnosis	ICD-9-CM
V392	Liveborn, unspecified whether single, twin or multiple, born outside hospital and not hospitalized	Diagnosis	ICD-9-CM
Z332	Encounter for elective termination of pregnancy	Diagnosis	ICD-10-CM
Z3401	Encounter for supervision of normal first pregnancy, first trimester	Diagnosis	ICD-10-CM
Z3402	Encounter for supervision of normal first pregnancy, second trimester	Diagnosis	ICD-10-CM
Z3403	Encounter for supervision of normal first pregnancy, third trimester	Diagnosis	ICD-10-CM
Z3481	Encounter for supervision of other normal pregnancy, first trimester	Diagnosis	ICD-10-CM
Z3482	Encounter for supervision of other normal pregnancy, second trimester	Diagnosis	ICD-10-CM
Z3483	Encounter for supervision of other normal pregnancy, third trimester	Diagnosis	ICD-10-CM
Z3491	Encounter for supervision of normal pregnancy, unspecified, first trimester	Diagnosis	ICD-10-CM
Z3492	Encounter for supervision of normal pregnancy, unspecified, second trimester	Diagnosis	ICD-10-CM
Z3493	Encounter for supervision of normal pregnancy, unspecified, third trimester	Diagnosis	ICD-10-CM
Z370	Single live birth	Diagnosis	ICD-10-CM
Z371	Single stillbirth	Diagnosis	ICD-10-CM
Z372	Twins, both liveborn	Diagnosis	ICD-10-CM
Z373	Twins, one liveborn and one stillborn	Diagnosis	ICD-10-CM
Z374	Twins, both stillborn	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
Z3750	Multiple births, unspecified, all liveborn	Diagnosis	ICD-10-CM
Z3751	Triplets, all liveborn	Diagnosis	ICD-10-CM
Z3752	Quadruplets, all liveborn	Diagnosis	ICD-10-CM
Z3753	Quintuplets, all liveborn	Diagnosis	ICD-10-CM
Z3754	Sextuplets, all liveborn	Diagnosis	ICD-10-CM
Z3759	Other multiple births, all liveborn	Diagnosis	ICD-10-CM
Z3760	Multiple births, unspecified, some liveborn	Diagnosis	ICD-10-CM
Z3761	Triplets, some liveborn	Diagnosis	ICD-10-CM
Z3762	Quadruplets, some liveborn	Diagnosis	ICD-10-CM
Z3763	Quintuplets, some liveborn	Diagnosis	ICD-10-CM
Z3764	Sextuplets, some liveborn	Diagnosis	ICD-10-CM
Z3769	Other multiple births, some liveborn	Diagnosis	ICD-10-CM
Z377	Other multiple births, all stillborn	Diagnosis	ICD-10-CM
Z379	Outcome of delivery, unspecified	Diagnosis	ICD-10-CM
Z3800	Single liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3801	Single liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z381	Single liveborn infant, born outside hospital	Diagnosis	ICD-10-CM
Z382	Single liveborn infant, unspecified as to place of birth	Diagnosis	ICD-10-CM
Z3830	Twin liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3831	Twin liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z384	Twin liveborn infant, born outside hospital	Diagnosis	ICD-10-CM
Z385	Twin liveborn infant, unspecified as to place of birth	Diagnosis	ICD-10-CM
Z3861	Triplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3862	Triplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z3863	Quadruplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3864	Quadruplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z3865	Quintuplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3866	Quintuplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z3868	Other multiple liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3869	Other multiple liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z387	Other multiple liveborn infant, born outside hospital	Diagnosis	ICD-10-CM
Z388	Other multiple liveborn infant, unspecified as to place of birth	Diagnosis	ICD-10-CM
Z3A01	Less than 8 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A08	8 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A09	9 weeks gestation of pregnancy	Diagnosis	ICD-10-CM

Appendix BE. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of

Code	Description	Code Category	Code Type
Z3A10	10 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A11	11 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A12	12 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A13	13 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A14	14 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A15	15 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A16	16 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A17	17 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A18	18 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A19	19 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A20	20 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A21	21 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A22	22 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A23	23 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A24	24 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A25	25 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A26	26 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A27	27 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A28	28 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A29	29 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A30	30 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A31	31 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A32	32 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A33	33 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A34	34 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A35	35 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A36	36 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A37	37 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A38	38 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A39	39 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A40	40 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A41	41 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A42	42 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A49	Greater than 42 weeks gestation of pregnancy	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
	Intentional Self-Harm (Covariate)		
293.83	Mood disorder in conditions classified elsewhere	Diagnosis	ICD-9-CM
296.0	Bipolar I disorder, single manic episode	Diagnosis	ICD-9-CM
296.00	Bipolar I disorder, single manic episode, unspecified	Diagnosis	ICD-9-CM
296.01	Bipolar I disorder, single manic episode, mild	Diagnosis	ICD-9-CM
296.02	Bipolar I disorder, single manic episode, moderate	Diagnosis	ICD-9-CM
296.03	Bipolar I disorder, single manic episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.04	Bipolar I disorder, single manic episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.05	Bipolar I disorder, single manic episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.06	Bipolar I disorder, single manic episode, in full remission	Diagnosis	ICD-9-CM
296.1	Manic disorder, recurrent episode	Diagnosis	ICD-9-CM
296.10	Manic disorder, recurrent episode, unspecified	Diagnosis	ICD-9-CM
296.11	Manic disorder, recurrent episode, mild	Diagnosis	ICD-9-CM
296.12	Manic disorder, recurrent episode, moderate	Diagnosis	ICD-9-CM
296.13	Manic disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.14	Manic disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.15	Manic disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.16	Manic disorder, recurrent episode, in full remission	Diagnosis	ICD-9-CM
296.2	Major depressive disorder, single episode	Diagnosis	ICD-9-CM
296.20	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-9-CM
296.21	Major depressive disorder, single episode, mild	Diagnosis	ICD-9-CM
296.22	Major depressive disorder, single episode, moderate	Diagnosis	ICD-9-CM
296.23	Major depressive disorder, single episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.24	Major depressive disorder, single episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.25	Major depressive disorder, single episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.26	Major depressive disorder, single episode in full remission	Diagnosis	ICD-9-CM
296.3	Major depressive disorder, recurrent episode	Diagnosis	ICD-9-CM
296.30	Major depressive disorder, recurrent episode, unspecified	Diagnosis	ICD-9-CM
296.31	Major depressive disorder, recurrent episode, mild	Diagnosis	ICD-9-CM
296.32	Major depressive disorder, recurrent episode, moderate	Diagnosis	ICD-9-CM
296.33	Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.34	Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.35	Major depressive disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.36	Major depressive disorder, recurrent episode, in full remission	Diagnosis	ICD-9-CM
296.4	Bipolar I disorder, most recent episode (or current) manic	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
296.40	Bipolar I disorder, most recent episode (or current) manic, unspecified	Diagnosis	ICD-9-CM
296.41	Bipolar I disorder, most recent episode (or current) manic, mild	Diagnosis	ICD-9-CM
296.42	Bipolar I disorder, most recent episode (or current) manic, moderate	Diagnosis	ICD-9-CM
296.43	Bipolar I disorder, most recent episode (or current) manic, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.44	Bipolar I disorder, most recent episode (or current) manic, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.45	Bipolar I disorder, most recent episode (or current) manic, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.46	Bipolar I disorder, most recent episode (or current) manic, in full remission	Diagnosis	ICD-9-CM
296.5	Bipolar I disorder, most recent episode (or current), depressed	Diagnosis	ICD-9-CM
296.50	Bipolar I disorder, most recent episode (or current) depressed, unspecified	Diagnosis	ICD-9-CM
296.51	Bipolar I disorder, most recent episode (or current) depressed, mild	Diagnosis	ICD-9-CM
296.52	Bipolar I disorder, most recent episode (or current) depressed, moderate	Diagnosis	ICD-9-CM
296.53	Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.54	Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.55	Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.56	Bipolar I disorder, most recent episode (or current) depressed, in full remission	Diagnosis	ICD-9-CM
296.6	Bipolar I disorder, most recent episode (or current), mixed	Diagnosis	ICD-9-CM
296.60	Bipolar I disorder, most recent episode (or current) mixed, unspecified	Diagnosis	ICD-9-CM
296.61	Bipolar I disorder, most recent episode (or current) mixed, mild	Diagnosis	ICD-9-CM
296.62	Bipolar I disorder, most recent episode (or current) mixed, moderate	Diagnosis	ICD-9-CM
296.63	Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.64	Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.65	Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.66	Bipolar I disorder, most recent episode (or current) mixed, in full remission	Diagnosis	ICD-9-CM
296.7	Bipolar I disorder, most recent episode (or current) unspecified	Diagnosis	ICD-9-CM
296.8	Other and unspecified bipolar disorders	Diagnosis	ICD-9-CM
296.80	Bipolar disorder, unspecified	Diagnosis	ICD-9-CM
296.81	Atypical manic disorder	Diagnosis	ICD-9-CM
296.82	Atypical depressive disorder	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
296.89	Other and unspecified bipolar disorders	Diagnosis	ICD-9-CM
296.90	Unspecified episodic mood disorder	Diagnosis	ICD-9-CM
296.99	Other specified episodic mood disorder	Diagnosis	ICD-9-CM
298.0	Depressive type psychosis	Diagnosis	ICD-9-CM
300.4	Dysthymic disorder	Diagnosis	ICD-9-CM
300.9	Unspecified nonpsychotic mental disorder	Diagnosis	ICD-9-CM
301.0	Paranoid personality disorder	Diagnosis	ICD-9-CM
301.1	Affective personality disorder	Diagnosis	ICD-9-CM
301.10	Affective personality disorder, unspecified	Diagnosis	ICD-9-CM
301.11	Chronic hypomanic personality disorder	Diagnosis	ICD-9-CM
301.12	Chronic depressive personality disorder	Diagnosis	ICD-9-CM
301.13	Cyclothymic disorder	Diagnosis	ICD-9-CM
301.2	Schizoid personality disorder	Diagnosis	ICD-9-CM
301.20	Schizoid personality disorder, unspecified	Diagnosis	ICD-9-CM
301.21	Introverted personality	Diagnosis	ICD-9-CM
301.22	Schizotypal personality disorder	Diagnosis	ICD-9-CM
301.3	Explosive personality disorder	Diagnosis	ICD-9-CM
301.4	Obsessive-compulsive personality disorder	Diagnosis	ICD-9-CM
301.5	Histrionic personality disorder	Diagnosis	ICD-9-CM
301.50	Histrionic personality disorder, unspecified	Diagnosis	ICD-9-CM
301.51	Chronic factitious illness with physical symptoms	Diagnosis	ICD-9-CM
301.59	Other histrionic personality disorder	Diagnosis	ICD-9-CM
301.6	Dependent personality disorder	Diagnosis	ICD-9-CM
301.7	Antisocial personality disorder	Diagnosis	ICD-9-CM
301.8	Other personality disorders	Diagnosis	ICD-9-CM
301.81	Narcissistic personality disorder	Diagnosis	ICD-9-CM
301.82	Avoidant personality disorder	Diagnosis	ICD-9-CM
301.83	Borderline personality disorder	Diagnosis	ICD-9-CM
301.84	Passive-aggressive personality	Diagnosis	ICD-9-CM
301.89	Other personality disorder	Diagnosis	ICD-9-CM
301.9	Unspecified personality disorder	Diagnosis	ICD-9-CM
309.0	Adjustment disorder with depressed mood	Diagnosis	ICD-9-CM
309.1	Prolonged depressive reaction as adjustment reaction	Diagnosis	ICD-9-CM
309.2	Predominant disturbance of other emotions as adjustment reaction	Diagnosis	ICD-9-CM
309.21	Separation anxiety disorder	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
309.22	Emancipation disorder of adolescence and early adult life	Diagnosis	ICD-9-CM
309.23	Specific academic or work inhibition as adjustment reaction	Diagnosis	ICD-9-CM
309.24	Adjustment disorder with anxiety	Diagnosis	ICD-9-CM
309.28	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-9-CM
309.29	Other adjustment reaction with predominant disturbance of other emotions	Diagnosis	ICD-9-CM
309.3	Adjustment disorder with disturbance of conduct	Diagnosis	ICD-9-CM
309.4	Adjustment disorder with mixed disturbance of emotions and conduct	Diagnosis	ICD-9-CM
309.8	Other specified adjustment reactions	Diagnosis	ICD-9-CM
309.81	Posttraumatic stress disorder	Diagnosis	ICD-9-CM
309.82	Adjustment reaction with physical symptoms	Diagnosis	ICD-9-CM
309.83	Adjustment reaction with withdrawal	Diagnosis	ICD-9-CM
309.89	Other specified adjustment reaction	Diagnosis	ICD-9-CM
309.9	Unspecified adjustment reaction	Diagnosis	ICD-9-CM
311	Depressive disorder, not elsewhere classified	Diagnosis	ICD-9-CM
E950	Suicide and self-inflicted poisoning by solid or liquid substances	Diagnosis	ICD-9-CM
E951	Suicide and self-inflicted poisoning by gases in domestic use	Diagnosis	ICD-9-CM
E952	Suicide and self-inflicted poisoning by other gases and vapors	Diagnosis	ICD-9-CM
E953	Suicide and self-inflicted injury by hanging strangulation and suffocation	Diagnosis	ICD-9-CM
E954	Suicide and self-inflicted injury by submersion [drowning]	Diagnosis	ICD-9-CM
E955	Suicide and self-inflicted injury by firearms air guns and explosives	Diagnosis	ICD-9-CM
E956	Suicide and self-inflicted injury by cutting and piercing instrument	Diagnosis	ICD-9-CM
E957	Suicide and self-inflicted injuries by jumping from high place	Diagnosis	ICD-9-CM
E958	Suicide and self-inflicted injury by other and unspecified means	Diagnosis	ICD-9-CM
T14.91	Suicide attempt	Diagnosis	ICD-10-CM
T14.91XA	Suicide attempt, initial encounter	Diagnosis	ICD-10-CM
T14.91XD	Suicide attempt, subsequent encounter	Diagnosis	ICD-10-CM
T14.91XS	Suicide attempt, sequela	Diagnosis	ICD-10-CM
T36.0X2	Poisoning by penicillins, intentional self-harm	Diagnosis	ICD-10-CM
T36.0X2A	Poisoning by penicillins, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.0X2D	Poisoning by penicillins, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.0X2S	Poisoning by penicillins, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.1X2	Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm	Diagnosis	ICD-10-CM
T36.1X2A	Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T36.1X2D	Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.1X2S	Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.2X2	Poisoning by chloramphenicol group, intentional self-harm	Diagnosis	ICD-10-CM
T36.2X2A	Poisoning by chloramphenicol group, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.2X2D	Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.2X2S	Poisoning by chloramphenicol group, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.3X2	Poisoning by macrolides, intentional self-harm	Diagnosis	ICD-10-CM
T36.3X2A	Poisoning by macrolides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.3X2D	Poisoning by macrolides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.3X2S	Poisoning by macrolides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.4X2	Poisoning by tetracyclines, intentional self-harm	Diagnosis	ICD-10-CM
T36.4X2A	Poisoning by tetracyclines, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.4X2D	Poisoning by tetracyclines, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.4X2S	Poisoning by tetracyclines, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.5X2	Poisoning by aminoglycosides, intentional self-harm	Diagnosis	ICD-10-CM
T36.5X2A	Poisoning by aminoglycosides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.5X2D	Poisoning by aminoglycosides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.5X2S	Poisoning by aminoglycosides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.6X2	Poisoning by rifampicins, intentional self-harm	Diagnosis	ICD-10-CM
T36.6X2A	Poisoning by rifampicins, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.6X2D	Poisoning by rifampicins, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.6X2S	Poisoning by rifampicins, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.7X2	Poisoning by antifungal antibiotics, systemically used, intentional self-harm	Diagnosis	ICD-10-CM
T36.7X2A	Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.7X2D	Poisoning by antifungal antibiotics, systemically used, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.7X2S	Poisoning by antifungal antibiotics, systemically used, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.8X2	Poisoning by other systemic antibiotics, intentional self-harm	Diagnosis	ICD-10-CM
T36.8X2A	Poisoning by other systemic antibiotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.8X2D	Poisoning by other systemic antibiotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.8X2S	Poisoning by other systemic antibiotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.92	Poisoning by unspecified systemic antibiotic, intentional self-harm	Diagnosis	ICD-10-CM
T36.92XA	Poisoning by unspecified systemic antibiotic, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.92XD	Poisoning by unspecified systemic antibiotic, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T36.92XS	Poisoning by unspecified systemic antibiotic, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T37.0X2	Poisoning by sulfonamides, intentional self-harm	Diagnosis	ICD-10-CM
T37.0X2A	Poisoning by sulfonamides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.0X2D	Poisoning by sulfonamides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.0X2S	Poisoning by sulfonamides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T37.1X2	Poisoning by antimycobacterial drugs, intentional self-harm	Diagnosis	ICD-10-CM
T37.1X2A	Poisoning by antimycobacterial drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.1X2D	Poisoning by antimycobacterial drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.1X2S	Poisoning by antimycobacterial drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T37.2X2	Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm	Diagnosis	ICD-10-CM
T37.2X2A	Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.2X2D	Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.2X2S	Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T37.3X2	Poisoning by other antiprotozoal drugs, intentional self-harm	Diagnosis	ICD-10-CM
T37.3X2A	Poisoning by other antiprotozoal drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.3X2D	Poisoning by other antiprotozoal drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.3X2S	Poisoning by other antiprotozoal drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T37.4X2	Poisoning by anthelminthics, intentional self-harm	Diagnosis	ICD-10-CM
T37.4X2A	Poisoning by anthelminthics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.4X2D	Poisoning by anthelminthics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.4X2S	Poisoning by anthelminthics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T37.5X2	Poisoning by antiviral drugs, intentional self-harm	Diagnosis	ICD-10-CM
T37.5X2A	Poisoning by antiviral drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.5X2D	Poisoning by antiviral drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.5X2S	Poisoning by antiviral drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T37.8X2	Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm	Diagnosis	ICD-10-CM
T37.8X2A	Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.8X2D	Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.8X2S	Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T37.92	Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm	Diagnosis	ICD-10-CM
T37.92XA	Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.92XD	Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.92XS	Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.0X2	Poisoning by glucocorticoids and synthetic analogues, intentional self-harm	Diagnosis	ICD-10-CM
T38.0X2A	Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.0X2D	Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.0X2S	Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.1X2	Poisoning by thyroid hormones and substitutes, intentional self-harm	Diagnosis	ICD-10-CM
T38.1X2A	Poisoning by thyroid hormones and substitutes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.1X2D	Poisoning by thyroid hormones and substitutes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.1X2S	Poisoning by thyroid hormones and substitutes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.2X2	Poisoning by antithyroid drugs, intentional self-harm	Diagnosis	ICD-10-CM
T38.2X2A	Poisoning by antithyroid drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.2X2D	Poisoning by antithyroid drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.2X2S	Poisoning by antithyroid drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.3X2	Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm	Diagnosis	ICD-10-CM
T38.3X2A	Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.3X2D	Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.3X2S	Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.4X2	Poisoning by oral contraceptives, intentional self-harm	Diagnosis	ICD-10-CM
T38.4X2A	Poisoning by oral contraceptives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.4X2D	Poisoning by oral contraceptives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.4X2S	Poisoning by oral contraceptives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.5X2	Poisoning by other estrogens and progestogens, intentional self-harm	Diagnosis	ICD-10-CM
T38.5X2A	Poisoning by other estrogens and progestogens, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.5X2D	Poisoning by other estrogens and progestogens, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.5X2S	Poisoning by other estrogens and progestogens, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T38.6X2	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm	Diagnosis	ICD-10-CM
T38.6X2A	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.6X2D	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.6X2S	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.7X2	Poisoning by androgens and anabolic congeners, intentional self-harm	Diagnosis	ICD-10-CM
T38.7X2A	Poisoning by androgens and anabolic congeners, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.7X2D	Poisoning by androgens and anabolic congeners, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.7X2S	Poisoning by androgens and anabolic congeners, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.802	Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm	Diagnosis	ICD-10-CM
T38.802A	Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.802D	Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.802S	Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.812	Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm	Diagnosis	ICD-10-CM
T38.812A	Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.812D	Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.812S	Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.892	Poisoning by other hormones and synthetic substitutes, intentional self-harm	Diagnosis	ICD-10-CM
T38.892A	Poisoning by other hormones and synthetic substitutes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.892D	Poisoning by other hormones and synthetic substitutes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.892S	Poisoning by other hormones and synthetic substitutes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.902	Poisoning by unspecified hormone antagonists, intentional self-harm	Diagnosis	ICD-10-CM
T38.902A	Poisoning by unspecified hormone antagonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.902D	Poisoning by unspecified hormone antagonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.902S	Poisoning by unspecified hormone antagonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.992	Poisoning by other hormone antagonists, intentional self-harm	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T38.992A	Poisoning by other hormone antagonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.992D	Poisoning by other hormone antagonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.992S	Poisoning by other hormone antagonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.012	Poisoning by aspirin, intentional self-harm	Diagnosis	ICD-10-CM
T39.012A	Poisoning by aspirin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.012D	Poisoning by aspirin, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.012S	Poisoning by aspirin, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.092	Poisoning by salicylates, intentional self-harm	Diagnosis	ICD-10-CM
T39.092A	Poisoning by salicylates, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.092D	Poisoning by salicylates, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.092S	Poisoning by salicylates, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.1X2	Poisoning by 4-Aminophenol derivatives, intentional self-harm	Diagnosis	ICD-10-CM
T39.1X2A	Poisoning by 4-Aminophenol derivatives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.1X2D	Poisoning by 4-Aminophenol derivatives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.1X2S	Poisoning by 4-Aminophenol derivatives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.2X2	Poisoning by pyrazolone derivatives, intentional self-harm	Diagnosis	ICD-10-CM
T39.2X2A	Poisoning by pyrazolone derivatives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.2X2D	Poisoning by pyrazolone derivatives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.2X2S	Poisoning by pyrazolone derivatives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.312	Poisoning by propionic acid derivatives, intentional self-harm	Diagnosis	ICD-10-CM
T39.312A	Poisoning by propionic acid derivatives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.312D	Poisoning by propionic acid derivatives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.312S	Poisoning by propionic acid derivatives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.392	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm	Diagnosis	ICD-10-CM
T39.392A	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.392D	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.392S	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.4X2	Poisoning by antirheumatics, not elsewhere classified, intentional self-harm	Diagnosis	ICD-10-CM
T39.4X2A	Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.4X2D	Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.4X2S	Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T39.8X2	Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm	Diagnosis	ICD-10-CM
T39.8X2A	Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.8X2D	Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.8X2S	Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.92	Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm	Diagnosis	ICD-10-CM
T39.92XA	Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.92XD	Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.92XS	Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.0X2	Poisoning by opium, intentional self-harm	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X2D	Poisoning by opium, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.0X2S	Poisoning by opium, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.1X2	Poisoning by heroin, intentional self-harm	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X2D	Poisoning by heroin, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.1X2S	Poisoning by heroin, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.2X2	Poisoning by other opioids, intentional self-harm	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X2D	Poisoning by other opioids, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.2X2S	Poisoning by other opioids, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.3X2	Poisoning by methadone, intentional self-harm	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X2D	Poisoning by methadone, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.3X2S	Poisoning by methadone, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.412	Poisoning by fentanyl or fentanyl analogs, intentional self-harm	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.412D	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T40.412S	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.422	Poisoning by tramadol, intentional self-harm	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.422D	Poisoning by tramadol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.422S	Poisoning by tramadol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.492	Poisoning by other synthetic narcotics, intentional self-harm	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.492D	Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.492S	Poisoning by other synthetic narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.4X2	Poisoning by other synthetic narcotics, intentional self-harm	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X2D	Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.4X2S	Poisoning by other synthetic narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.5X2	Poisoning by cocaine, intentional self-harm	Diagnosis	ICD-10-CM
T40.5X2A	Poisoning by cocaine, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.5X2D	Poisoning by cocaine, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.5X2S	Poisoning by cocaine, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.602	Poisoning by unspecified narcotics, intentional self-harm	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.602D	Poisoning by unspecified narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.602S	Poisoning by unspecified narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.692	Poisoning by other narcotics, intentional self-harm	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.692D	Poisoning by other narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.692S	Poisoning by other narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.712	Poisoning by cannabis, intentional self-harm	Diagnosis	ICD-10-CM
T40.712A	Poisoning by cannabis, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.712D	Poisoning by cannabis, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.712S	Poisoning by cannabis, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.722	Poisoning by synthetic cannabinoids, intentional self-harm	Diagnosis	ICD-10-CM
T40.722A	Poisoning by synthetic cannabinoids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.722D	Poisoning by synthetic cannabinoids, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.722S	Poisoning by synthetic cannabinoids, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.7X2	Poisoning by cannabis (derivatives), intentional self-harm	Diagnosis	ICD-10-CM
T40.7X2A	Poisoning by cannabis (derivatives), intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T40.7X2D	Poisoning by cannabis (derivatives), intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.7X2S	Poisoning by cannabis (derivatives), intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.8X2	Poisoning by lysergide [LSD], intentional self-harm	Diagnosis	ICD-10-CM
T40.8X2A	Poisoning by lysergide [LSD], intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.8X2D	Poisoning by lysergide [LSD], intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.8X2S	Poisoning by lysergide [LSD], intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.902	Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm	Diagnosis	ICD-10-CM
T40.902A	Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.902D	Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.902S	Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.992	Poisoning by other psychodysleptics [hallucinogens], intentional self-harm	Diagnosis	ICD-10-CM
T40.992A	Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.992D	Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.992S	Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, sequela	Diagnosis	ICD-10-CM
T41.0X2	Poisoning by inhaled anesthetics, intentional self-harm	Diagnosis	ICD-10-CM
T41.0X2A	Poisoning by inhaled anesthetics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T41.0X2D	Poisoning by inhaled anesthetics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T41.0X2S	Poisoning by inhaled anesthetics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T41.1X2	Poisoning by intravenous anesthetics, intentional self-harm	Diagnosis	ICD-10-CM
T41.1X2A	Poisoning by intravenous anesthetics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T41.1X2D	Poisoning by intravenous anesthetics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T41.1X2S	Poisoning by intravenous anesthetics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T41.202	Poisoning by unspecified general anesthetics, intentional self-harm	Diagnosis	ICD-10-CM
T41.202A	Poisoning by unspecified general anesthetics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T41.202D	Poisoning by unspecified general anesthetics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T41.202S	Poisoning by unspecified general anesthetics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T41.292	Poisoning by other general anesthetics, intentional self-harm	Diagnosis	ICD-10-CM
T41.292A	Poisoning by other general anesthetics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T41.292D	Poisoning by other general anesthetics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T41.292S	Poisoning by other general anesthetics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T41.3X2	Poisoning by local anesthetics, intentional self-harm	Diagnosis	ICD-10-CM
T41.3X2A	Poisoning by local anesthetics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T41.3X2D	Poisoning by local anesthetics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T41.3X2S	Poisoning by local anesthetics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T41.42	Poisoning by unspecified anesthetic, intentional self-harm	Diagnosis	ICD-10-CM
T41.42XA	Poisoning by unspecified anesthetic, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T41.42XD	Poisoning by unspecified anesthetic, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T41.42XS	Poisoning by unspecified anesthetic, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T41.5X2	Poisoning by therapeutic gases, intentional self-harm	Diagnosis	ICD-10-CM
T41.5X2A	Poisoning by therapeutic gases, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T41.5X2D	Poisoning by therapeutic gases, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T41.5X2S	Poisoning by therapeutic gases, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.0X2	Poisoning by hydantoin derivatives, intentional self-harm	Diagnosis	ICD-10-CM
T42.0X2A	Poisoning by hydantoin derivatives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.0X2D	Poisoning by hydantoin derivatives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.0X2S	Poisoning by hydantoin derivatives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.1X2	Poisoning by iminostilbenes, intentional self-harm	Diagnosis	ICD-10-CM
T42.1X2A	Poisoning by iminostilbenes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.1X2D	Poisoning by iminostilbenes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.1X2S	Poisoning by iminostilbenes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.2X2	Poisoning by succinimides and oxazolidinediones, intentional self-harm	Diagnosis	ICD-10-CM
T42.2X2A	Poisoning by succinimides and oxazolidinediones, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.2X2D	Poisoning by succinimides and oxazolidinediones, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.2X2S	Poisoning by succinimides and oxazolidinediones, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.3X2	Poisoning by barbiturates, intentional self-harm	Diagnosis	ICD-10-CM
T42.3X2A	Poisoning by barbiturates, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.3X2D	Poisoning by barbiturates, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.3X2S	Poisoning by barbiturates, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.4X2	Poisoning by benzodiazepines, intentional self-harm	Diagnosis	ICD-10-CM
T42.4X2A	Poisoning by benzodiazepines, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.4X2D	Poisoning by benzodiazepines, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.4X2S	Poisoning by benzodiazepines, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.5X2	Poisoning by mixed antiepileptics, intentional self-harm	Diagnosis	ICD-10-CM
T42.5X2A	Poisoning by mixed antiepileptics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.5X2D	Poisoning by mixed antiepileptics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.5X2S	Poisoning by mixed antiepileptics, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T42.6X2	Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm	Diagnosis	ICD-10-CM
T42.6X2A	Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.6X2D	Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.6X2S	Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.72	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm	Diagnosis	ICD-10-CM
T42.72XA	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.72XD	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.72XS	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.8X2	Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm	Diagnosis	ICD-10-CM
T42.8X2A	Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.8X2D	Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.8X2S	Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.012	Poisoning by tricyclic antidepressants, intentional self-harm	Diagnosis	ICD-10-CM
T43.012A	Poisoning by tricyclic antidepressants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.012D	Poisoning by tricyclic antidepressants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.012S	Poisoning by tricyclic antidepressants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.022	Poisoning by tetracyclic antidepressants, intentional self-harm	Diagnosis	ICD-10-CM
T43.022A	Poisoning by tetracyclic antidepressants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.022D	Poisoning by tetracyclic antidepressants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.022S	Poisoning by tetracyclic antidepressants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.1X2	Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm	Diagnosis	ICD-10-CM
T43.1X2A	Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.1X2D	Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.1X2S	Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T43.202	Poisoning by unspecified antidepressants, intentional self-harm	Diagnosis	ICD-10-CM
T43.202A	Poisoning by unspecified antidepressants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.202D	Poisoning by unspecified antidepressants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.202S	Poisoning by unspecified antidepressants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.212	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm	Diagnosis	ICD-10-CM
T43.212A	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.212D	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.212S	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.222	Poisoning by selective serotonin reuptake inhibitors, intentional self-harm	Diagnosis	ICD-10-CM
T43.222A	Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.222D	Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.222S	Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.292	Poisoning by other antidepressants, intentional self-harm	Diagnosis	ICD-10-CM
T43.292A	Poisoning by other antidepressants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.292D	Poisoning by other antidepressants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.292S	Poisoning by other antidepressants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.3X2	Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm	Diagnosis	ICD-10-CM
T43.3X2A	Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.3X2D	Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.3X2S	Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.4X2	Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm	Diagnosis	ICD-10-CM
T43.4X2A	Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.4X2D	Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.4X2S	Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.502	Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T43.502A	Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.502D	Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.502S	Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.592	Poisoning by other antipsychotics and neuroleptics, intentional self-harm	Diagnosis	ICD-10-CM
T43.592A	Poisoning by other antipsychotics and neuroleptics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.592D	Poisoning by other antipsychotics and neuroleptics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.592S	Poisoning by other antipsychotics and neuroleptics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.602	Poisoning by unspecified psychostimulants, intentional self-harm	Diagnosis	ICD-10-CM
T43.602A	Poisoning by unspecified psychostimulants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.602D	Poisoning by unspecified psychostimulants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.602S	Poisoning by unspecified psychostimulants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.612	Poisoning by caffeine, intentional self-harm	Diagnosis	ICD-10-CM
T43.612A	Poisoning by caffeine, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.612D	Poisoning by caffeine, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.612S	Poisoning by caffeine, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.622	Poisoning by amphetamines, intentional self-harm	Diagnosis	ICD-10-CM
T43.622A	Poisoning by amphetamines, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.622D	Poisoning by amphetamines, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.622S	Poisoning by amphetamines, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.632	Poisoning by methylphenidate, intentional self-harm	Diagnosis	ICD-10-CM
T43.632A	Poisoning by methylphenidate, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.632D	Poisoning by methylphenidate, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.632S	Poisoning by methylphenidate, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.642	Poisoning by ecstasy, intentional self-harm	Diagnosis	ICD-10-CM
T43.642A	Poisoning by ecstasy, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.642D	Poisoning by ecstasy, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.642S	Poisoning by ecstasy, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.692	Poisoning by other psychostimulants, intentional self-harm	Diagnosis	ICD-10-CM
T43.692A	Poisoning by other psychostimulants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.692D	Poisoning by other psychostimulants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.692S	Poisoning by other psychostimulants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.8X2	Poisoning by other psychotropic drugs, intentional self-harm	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T43.8X2A	Poisoning by other psychotropic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.8X2D	Poisoning by other psychotropic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.8X2S	Poisoning by other psychotropic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.92	Poisoning by unspecified psychotropic drug, intentional self-harm	Diagnosis	ICD-10-CM
T43.92XA	Poisoning by unspecified psychotropic drug, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.92XD	Poisoning by unspecified psychotropic drug, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.92XS	Poisoning by unspecified psychotropic drug, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.0X2	Poisoning by anticholinesterase agents, intentional self-harm	Diagnosis	ICD-10-CM
T44.0X2A	Poisoning by anticholinesterase agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.0X2D	Poisoning by anticholinesterase agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.0X2S	Poisoning by anticholinesterase agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.1X2	Poisoning by other parasympathomimetics [cholinergics], intentional self-harm	Diagnosis	ICD-10-CM
T44.1X2A	Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.1X2D	Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.1X2S	Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.2X2	Poisoning by ganglionic blocking drugs, intentional self-harm	Diagnosis	ICD-10-CM
T44.2X2A	Poisoning by ganglionic blocking drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.2X2D	Poisoning by ganglionic blocking drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.2X2S	Poisoning by ganglionic blocking drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.3X2	Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm	Diagnosis	ICD-10-CM
T44.3X2A	Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.3X2D	Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.3X2S	Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.4X2	Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm	Diagnosis	ICD-10-CM
T44.4X2A	Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.4X2D	Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.4X2S	Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T44.5X2	Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm	Diagnosis	ICD-10-CM
T44.5X2A	Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.5X2D	Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.5X2S	Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.6X2	Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm	Diagnosis	ICD-10-CM
T44.6X2A	Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.6X2D	Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.6X2S	Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.7X2	Poisoning by beta-adrenoreceptor antagonists, intentional self-harm	Diagnosis	ICD-10-CM
T44.7X2A	Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.7X2D	Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.7X2S	Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.8X2	Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm	Diagnosis	ICD-10-CM
T44.8X2A	Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.8X2D	Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.8X2S	Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.902	Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm	Diagnosis	ICD-10-CM
T44.902A	Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.902D	Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.902S	Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.992	Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm	Diagnosis	ICD-10-CM
T44.992A	Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.992D	Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T44.992S	Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.0X2	Poisoning by antiallergic and antiemetic drugs, intentional self-harm	Diagnosis	ICD-10-CM
T45.0X2A	Poisoning by antiallergic and antiemetic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.0X2D	Poisoning by antiallergic and antiemetic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.0X2S	Poisoning by antiallergic and antiemetic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.1X2	Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm	Diagnosis	ICD-10-CM
T45.1X2A	Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.1X2D	Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.1X2S	Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.2X2	Poisoning by vitamins, intentional self-harm	Diagnosis	ICD-10-CM
T45.2X2A	Poisoning by vitamins, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.2X2D	Poisoning by vitamins, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.2X2S	Poisoning by vitamins, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.3X2	Poisoning by enzymes, intentional self-harm	Diagnosis	ICD-10-CM
T45.3X2A	Poisoning by enzymes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.3X2D	Poisoning by enzymes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.3X2S	Poisoning by enzymes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.4X2	Poisoning by iron and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T45.4X2A	Poisoning by iron and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.4X2D	Poisoning by iron and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.4X2S	Poisoning by iron and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.512	Poisoning by anticoagulants, intentional self-harm	Diagnosis	ICD-10-CM
T45.512A	Poisoning by anticoagulants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.512D	Poisoning by anticoagulants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.512S	Poisoning by anticoagulants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.522	Poisoning by antithrombotic drugs, intentional self-harm	Diagnosis	ICD-10-CM
T45.522A	Poisoning by antithrombotic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.522D	Poisoning by antithrombotic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.522S	Poisoning by antithrombotic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.602	Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm	Diagnosis	ICD-10-CM
T45.602A	Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T45.602D	Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.602S	Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.612	Poisoning by thrombolytic drug, intentional self-harm	Diagnosis	ICD-10-CM
T45.612A	Poisoning by thrombolytic drug, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.612D	Poisoning by thrombolytic drug, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.612S	Poisoning by thrombolytic drug, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.622	Poisoning by hemostatic drug, intentional self-harm	Diagnosis	ICD-10-CM
T45.622A	Poisoning by hemostatic drug, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.622D	Poisoning by hemostatic drug, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.622S	Poisoning by hemostatic drug, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.692	Poisoning by other fibrinolysis-affecting drugs, intentional self-harm	Diagnosis	ICD-10-CM
T45.692A	Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.692D	Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.692S	Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.7X2	Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm	Diagnosis	ICD-10-CM
T45.7X2A	Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.7X2D	Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.7X2S	Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.8X2	Poisoning by other primarily systemic and hematological agents, intentional self-harm	Diagnosis	ICD-10-CM
T45.8X2A	Poisoning by other primarily systemic and hematological agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.8X2D	Poisoning by other primarily systemic and hematological agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.8X2S	Poisoning by other primarily systemic and hematological agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.92	Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm	Diagnosis	ICD-10-CM
T45.92XA	Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.92XD	Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T45.92XS	Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.0X2	Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm	Diagnosis	ICD-10-CM
T46.0X2A	Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.0X2D	Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.0X2S	Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.1X2	Poisoning by calcium-channel blockers, intentional self-harm	Diagnosis	ICD-10-CM
T46.1X2A	Poisoning by calcium-channel blockers, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.1X2D	Poisoning by calcium-channel blockers, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.1X2S	Poisoning by calcium-channel blockers, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.2X2	Poisoning by other antidysrhythmic drugs, intentional self-harm	Diagnosis	ICD-10-CM
T46.2X2A	Poisoning by other antidysrhythmic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.2X2D	Poisoning by other antidysrhythmic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.2X2S	Poisoning by other antidysrhythmic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.3X2	Poisoning by coronary vasodilators, intentional self-harm	Diagnosis	ICD-10-CM
T46.3X2A	Poisoning by coronary vasodilators, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.3X2D	Poisoning by coronary vasodilators, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.3X2S	Poisoning by coronary vasodilators, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.4X2	Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm	Diagnosis	ICD-10-CM
T46.4X2A	Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.4X2D	Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.4X2S	Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.5X2	Poisoning by other antihypertensive drugs, intentional self-harm	Diagnosis	ICD-10-CM
T46.5X2A	Poisoning by other antihypertensive drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.5X2D	Poisoning by other antihypertensive drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.5X2S	Poisoning by other antihypertensive drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.6X2	Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm	Diagnosis	ICD-10-CM
T46.6X2A	Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T46.6X2D	Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.6X2S	Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.7X2	Poisoning by peripheral vasodilators, intentional self-harm	Diagnosis	ICD-10-CM
T46.7X2A	Poisoning by peripheral vasodilators, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.7X2D	Poisoning by peripheral vasodilators, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.7X2S	Poisoning by peripheral vasodilators, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.8X2	Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm	Diagnosis	ICD-10-CM
T46.8X2A	Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.8X2D	Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.8X2S	Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.902	Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm	Diagnosis	ICD-10-CM
T46.902A	Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.902D	Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.902S	Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.992	Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm	Diagnosis	ICD-10-CM
T46.992A	Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.992D	Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.992S	Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.0X2	Poisoning by histamine H2-receptor blockers, intentional self-harm	Diagnosis	ICD-10-CM
T47.0X2A	Poisoning by histamine H2-receptor blockers, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.0X2D	Poisoning by histamine H2-receptor blockers, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.0X2S	Poisoning by histamine H2-receptor blockers, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.1X2	Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm	Diagnosis	ICD-10-CM
T47.1X2A	Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T47.1X2D	Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.1X2S	Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.2X2	Poisoning by stimulant laxatives, intentional self-harm	Diagnosis	ICD-10-CM
T47.2X2A	Poisoning by stimulant laxatives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.2X2D	Poisoning by stimulant laxatives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.2X2S	Poisoning by stimulant laxatives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.3X2	Poisoning by saline and osmotic laxatives, intentional self-harm	Diagnosis	ICD-10-CM
T47.3X2A	Poisoning by saline and osmotic laxatives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.3X2D	Poisoning by saline and osmotic laxatives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.3X2S	Poisoning by saline and osmotic laxatives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.4X2	Poisoning by other laxatives, intentional self-harm	Diagnosis	ICD-10-CM
T47.4X2A	Poisoning by other laxatives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.4X2D	Poisoning by other laxatives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.4X2S	Poisoning by other laxatives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.5X2	Poisoning by digestants, intentional self-harm	Diagnosis	ICD-10-CM
T47.5X2A	Poisoning by digestants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.5X2D	Poisoning by digestants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.5X2S	Poisoning by digestants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.6X2	Poisoning by antidiarrheal drugs, intentional self-harm	Diagnosis	ICD-10-CM
T47.6X2A	Poisoning by antidiarrheal drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.6X2D	Poisoning by antidiarrheal drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.6X2S	Poisoning by antidiarrheal drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.7X2	Poisoning by emetics, intentional self-harm	Diagnosis	ICD-10-CM
T47.7X2A	Poisoning by emetics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.7X2D	Poisoning by emetics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.7X2S	Poisoning by emetics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.8X2	Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm	Diagnosis	ICD-10-CM
T47.8X2A	Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.8X2D	Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.8X2S	Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T47.92	Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm	Diagnosis	ICD-10-CM
T47.92XA	Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.92XD	Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.92XS	Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.0X2	Poisoning by oxytocic drugs, intentional self-harm	Diagnosis	ICD-10-CM
T48.0X2A	Poisoning by oxytocic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.0X2D	Poisoning by oxytocic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.0X2S	Poisoning by oxytocic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.1X2	Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm	Diagnosis	ICD-10-CM
T48.1X2A	Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.1X2D	Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.1X2S	Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.202	Poisoning by unspecified drugs acting on muscles, intentional self-harm	Diagnosis	ICD-10-CM
T48.202A	Poisoning by unspecified drugs acting on muscles, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.202D	Poisoning by unspecified drugs acting on muscles, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.202S	Poisoning by unspecified drugs acting on muscles, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.292	Poisoning by other drugs acting on muscles, intentional self-harm	Diagnosis	ICD-10-CM
T48.292A	Poisoning by other drugs acting on muscles, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.292D	Poisoning by other drugs acting on muscles, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.292S	Poisoning by other drugs acting on muscles, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.3X2	Poisoning by antitussives, intentional self-harm	Diagnosis	ICD-10-CM
T48.3X2A	Poisoning by antitussives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.3X2D	Poisoning by antitussives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.3X2S	Poisoning by antitussives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.4X2	Poisoning by expectorants, intentional self-harm	Diagnosis	ICD-10-CM
T48.4X2A	Poisoning by expectorants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.4X2D	Poisoning by expectorants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T48.4X2S	Poisoning by expectorants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.5X2	Poisoning by other anti-common-cold drugs, intentional self-harm	Diagnosis	ICD-10-CM
T48.5X2A	Poisoning by other anti-common-cold drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.5X2D	Poisoning by other anti-common-cold drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.5X2S	Poisoning by other anti-common-cold drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.6X2	Poisoning by antiasthmatics, intentional self-harm	Diagnosis	ICD-10-CM
T48.6X2A	Poisoning by antiasthmatics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.6X2D	Poisoning by antiasthmatics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.6X2S	Poisoning by antiasthmatics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.902	Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm	Diagnosis	ICD-10-CM
T48.902A	Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.902D	Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.902S	Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.992	Poisoning by other agents primarily acting on the respiratory system, intentional self-harm	Diagnosis	ICD-10-CM
T48.992A	Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.992D	Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.992S	Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.0X2	Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm	Diagnosis	ICD-10-CM
T49.0X2A	Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.0X2D	Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.0X2S	Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.1X2	Poisoning by antipruritics, intentional self-harm	Diagnosis	ICD-10-CM
T49.1X2A	Poisoning by antipruritics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.1X2D	Poisoning by antipruritics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T49.1X2S	Poisoning by antipruritics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.2X2	Poisoning by local astringents and local detergents, intentional self-harm	Diagnosis	ICD-10-CM
T49.2X2A	Poisoning by local astringents and local detergents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.2X2D	Poisoning by local astringents and local detergents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.2X2S	Poisoning by local astringents and local detergents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.3X2	Poisoning by emollients, demulcents and protectants, intentional self-harm	Diagnosis	ICD-10-CM
T49.3X2A	Poisoning by emollients, demulcents and protectants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.3X2D	Poisoning by emollients, demulcents and protectants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.3X2S	Poisoning by emollients, demulcents and protectants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.4X2	Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm	Diagnosis	ICD-10-CM
T49.4X2A	Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.4X2D	Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.4X2S	Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.5X2	Poisoning by ophthalmological drugs and preparations, intentional self-harm	Diagnosis	ICD-10-CM
T49.5X2A	Poisoning by ophthalmological drugs and preparations, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.5X2D	Poisoning by ophthalmological drugs and preparations, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.5X2S	Poisoning by ophthalmological drugs and preparations, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.6X2	Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm	Diagnosis	ICD-10-CM
T49.6X2A	Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.6X2D	Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.6X2S	Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.7X2	Poisoning by dental drugs, topically applied, intentional self-harm	Diagnosis	ICD-10-CM
T49.7X2A	Poisoning by dental drugs, topically applied, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.7X2D	Poisoning by dental drugs, topically applied, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.7X2S	Poisoning by dental drugs, topically applied, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T49.8X2	Poisoning by other topical agents, intentional self-harm	Diagnosis	ICD-10-CM
T49.8X2A	Poisoning by other topical agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.8X2D	Poisoning by other topical agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.8X2S	Poisoning by other topical agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.92	Poisoning by unspecified topical agent, intentional self-harm	Diagnosis	ICD-10-CM
T49.92XA	Poisoning by unspecified topical agent, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.92XD	Poisoning by unspecified topical agent, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.92XS	Poisoning by unspecified topical agent, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.0X2	Poisoning by mineralocorticoids and their antagonists, intentional self-harm	Diagnosis	ICD-10-CM
T50.0X2A	Poisoning by mineralocorticoids and their antagonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.0X2D	Poisoning by mineralocorticoids and their antagonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.0X2S	Poisoning by mineralocorticoids and their antagonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.1X2	Poisoning by loop [high-ceiling] diuretics, intentional self-harm	Diagnosis	ICD-10-CM
T50.1X2A	Poisoning by loop [high-ceiling] diuretics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.1X2D	Poisoning by loop [high-ceiling] diuretics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.1X2S	Poisoning by loop [high-ceiling] diuretics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.2X2	Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm	Diagnosis	ICD-10-CM
T50.2X2A	Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.2X2D	Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.2X2S	Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.3X2	Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm	Diagnosis	ICD-10-CM
T50.3X2A	Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.3X2D	Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.3X2S	Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.4X2	Poisoning by drugs affecting uric acid metabolism, intentional self-harm	Diagnosis	ICD-10-CM
T50.4X2A	Poisoning by drugs affecting uric acid metabolism, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T50.4X2D	Poisoning by drugs affecting uric acid metabolism, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.4X2S	Poisoning by drugs affecting uric acid metabolism, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.5X2	Poisoning by appetite depressants, intentional self-harm	Diagnosis	ICD-10-CM
T50.5X2A	Poisoning by appetite depressants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.5X2D	Poisoning by appetite depressants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.5X2S	Poisoning by appetite depressants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.6X2	Poisoning by antidotes and chelating agents, intentional self-harm	Diagnosis	ICD-10-CM
T50.6X2A	Poisoning by antidotes and chelating agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.6X2D	Poisoning by antidotes and chelating agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.6X2S	Poisoning by antidotes and chelating agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.7X2	Poisoning by analeptics and opioid receptor antagonists, intentional self-harm	Diagnosis	ICD-10-CM
T50.7X2A	Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.7X2D	Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.7X2S	Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.8X2	Poisoning by diagnostic agents, intentional self-harm	Diagnosis	ICD-10-CM
T50.8X2A	Poisoning by diagnostic agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.8X2D	Poisoning by diagnostic agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.8X2S	Poisoning by diagnostic agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.902	Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm	Diagnosis	ICD-10-CM
T50.902A	Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.902D	Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.902S	Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.912	Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm	Diagnosis	ICD-10-CM
T50.912A	Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.912D	Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T50.912S	Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.992	Poisoning by other drugs, medicaments and biological substances, intentional self-harm	Diagnosis	ICD-10-CM
T50.992A	Poisoning by other drugs, medicaments and biological substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.992D	Poisoning by other drugs, medicaments and biological substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.992S	Poisoning by other drugs, medicaments and biological substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.A12	Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm	Diagnosis	ICD-10-CM
T50.A12A	Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.A12D	Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.A12S	Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.A22	Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm	Diagnosis	ICD-10-CM
T50.A22A	Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.A22D	Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.A22S	Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.A92	Poisoning by other bacterial vaccines, intentional self-harm	Diagnosis	ICD-10-CM
T50.A92A	Poisoning by other bacterial vaccines, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.A92D	Poisoning by other bacterial vaccines, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.A92S	Poisoning by other bacterial vaccines, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.B12	Poisoning by smallpox vaccines, intentional self-harm	Diagnosis	ICD-10-CM
T50.B12A	Poisoning by smallpox vaccines, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.B12D	Poisoning by smallpox vaccines, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.B12S	Poisoning by smallpox vaccines, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.B92	Poisoning by other viral vaccines, intentional self-harm	Diagnosis	ICD-10-CM
T50.B92A	Poisoning by other viral vaccines, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.B92D	Poisoning by other viral vaccines, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T50.B92S	Poisoning by other viral vaccines, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.Z12	Poisoning by immunoglobulin, intentional self-harm	Diagnosis	ICD-10-CM
T50.Z12A	Poisoning by immunoglobulin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.Z12D	Poisoning by immunoglobulin, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.Z12S	Poisoning by immunoglobulin, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.Z92	Poisoning by other vaccines and biological substances, intentional self-harm	Diagnosis	ICD-10-CM
T50.Z92A	Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.Z92D	Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.Z92S	Poisoning by other vaccines and biological substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.0X2	Toxic effect of ethanol, intentional self-harm	Diagnosis	ICD-10-CM
T51.0X2A	Toxic effect of ethanol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.0X2D	Toxic effect of ethanol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.0X2S	Toxic effect of ethanol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.1X2	Toxic effect of methanol, intentional self-harm	Diagnosis	ICD-10-CM
T51.1X2A	Toxic effect of methanol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.1X2D	Toxic effect of methanol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.1X2S	Toxic effect of methanol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.2X2	Toxic effect of 2-Propanol, intentional self-harm	Diagnosis	ICD-10-CM
T51.2X2A	Toxic effect of 2-Propanol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.2X2D	Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.2X2S	Toxic effect of 2-Propanol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.3X2	Toxic effect of fusel oil, intentional self-harm	Diagnosis	ICD-10-CM
T51.3X2A	Toxic effect of fusel oil, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.3X2D	Toxic effect of fusel oil, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.3X2S	Toxic effect of fusel oil, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.8X2	Toxic effect of other alcohols, intentional self-harm	Diagnosis	ICD-10-CM
T51.8X2A	Toxic effect of other alcohols, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.8X2D	Toxic effect of other alcohols, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.8X2S	Toxic effect of other alcohols, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.92	Toxic effect of unspecified alcohol, intentional self-harm	Diagnosis	ICD-10-CM
T51.92XA	Toxic effect of unspecified alcohol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.92XD	Toxic effect of unspecified alcohol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.92XS	Toxic effect of unspecified alcohol, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T52.0X2	Toxic effect of petroleum products, intentional self-harm	Diagnosis	ICD-10-CM
T52.0X2A	Toxic effect of petroleum products, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T52.0X2D	Toxic effect of petroleum products, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T52.0X2S	Toxic effect of petroleum products, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T52.1X2	Toxic effect of benzene, intentional self-harm	Diagnosis	ICD-10-CM
T52.1X2A	Toxic effect of benzene, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T52.1X2D	Toxic effect of benzene, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T52.1X2S	Toxic effect of benzene, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T52.2X2	Toxic effect of homologues of benzene, intentional self-harm	Diagnosis	ICD-10-CM
T52.2X2A	Toxic effect of homologues of benzene, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T52.2X2D	Toxic effect of homologues of benzene, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T52.2X2S	Toxic effect of homologues of benzene, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T52.3X2	Toxic effect of glycols, intentional self-harm	Diagnosis	ICD-10-CM
T52.3X2A	Toxic effect of glycols, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T52.3X2D	Toxic effect of glycols, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T52.3X2S	Toxic effect of glycols, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T52.4X2	Toxic effect of ketones, intentional self-harm	Diagnosis	ICD-10-CM
T52.4X2A	Toxic effect of ketones, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T52.4X2D	Toxic effect of ketones, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T52.4X2S	Toxic effect of ketones, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T52.8X2	Toxic effect of other organic solvents, intentional self-harm	Diagnosis	ICD-10-CM
T52.8X2A	Toxic effect of other organic solvents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T52.8X2D	Toxic effect of other organic solvents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T52.8X2S	Toxic effect of other organic solvents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T52.92	Toxic effect of unspecified organic solvent, intentional self-harm	Diagnosis	ICD-10-CM
T52.92XA	Toxic effect of unspecified organic solvent, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T52.92XD	Toxic effect of unspecified organic solvent, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T52.92XS	Toxic effect of unspecified organic solvent, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.0X2	Toxic effect of carbon tetrachloride, intentional self-harm	Diagnosis	ICD-10-CM
T53.0X2A	Toxic effect of carbon tetrachloride, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.0X2D	Toxic effect of carbon tetrachloride, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.0X2S	Toxic effect of carbon tetrachloride, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.1X2	Toxic effect of chloroform, intentional self-harm	Diagnosis	ICD-10-CM
T53.1X2A	Toxic effect of chloroform, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.1X2D	Toxic effect of chloroform, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T53.1X2S	Toxic effect of chloroform, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.2X2	Toxic effect of trichloroethylene, intentional self-harm	Diagnosis	ICD-10-CM
T53.2X2A	Toxic effect of trichloroethylene, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.2X2D	Toxic effect of trichloroethylene, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.2X2S	Toxic effect of trichloroethylene, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.3X2	Toxic effect of tetrachloroethylene, intentional self-harm	Diagnosis	ICD-10-CM
T53.3X2A	Toxic effect of tetrachloroethylene, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.3X2D	Toxic effect of tetrachloroethylene, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.3X2S	Toxic effect of tetrachloroethylene, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.4X2	Toxic effect of dichloromethane, intentional self-harm	Diagnosis	ICD-10-CM
T53.4X2A	Toxic effect of dichloromethane, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.4X2D	Toxic effect of dichloromethane, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.4X2S	Toxic effect of dichloromethane, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.5X2	Toxic effect of chlorofluorocarbons, intentional self-harm	Diagnosis	ICD-10-CM
T53.5X2A	Toxic effect of chlorofluorocarbons, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.5X2D	Toxic effect of chlorofluorocarbons, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.5X2S	Toxic effect of chlorofluorocarbons, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.6X2	Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm	Diagnosis	ICD-10-CM
T53.6X2A	Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.6X2D	Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.6X2S	Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.7X2	Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm	Diagnosis	ICD-10-CM
T53.7X2A	Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.7X2D	Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.7X2S	Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.92	Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm	Diagnosis	ICD-10-CM
T53.92XA	Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T53.92XD	Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.92XS	Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T54.0X2	Toxic effect of phenol and phenol homologues, intentional self-harm	Diagnosis	ICD-10-CM
T54.0X2A	Toxic effect of phenol and phenol homologues, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T54.0X2D	Toxic effect of phenol and phenol homologues, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T54.0X2S	Toxic effect of phenol and phenol homologues, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T54.1X2	Toxic effect of other corrosive organic compounds, intentional self-harm	Diagnosis	ICD-10-CM
T54.1X2A	Toxic effect of other corrosive organic compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T54.1X2D	Toxic effect of other corrosive organic compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T54.1X2S	Toxic effect of other corrosive organic compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T54.2X2	Toxic effect of corrosive acids and acid-like substances, intentional self-harm	Diagnosis	ICD-10-CM
T54.2X2A	Toxic effect of corrosive acids and acid-like substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T54.2X2D	Toxic effect of corrosive acids and acid-like substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T54.2X2S	Toxic effect of corrosive acids and acid-like substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T54.3X2	Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm	Diagnosis	ICD-10-CM
T54.3X2A	Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T54.3X2D	Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T54.3X2S	Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T54.92	Toxic effect of unspecified corrosive substance, intentional self-harm	Diagnosis	ICD-10-CM
T54.92XA	Toxic effect of unspecified corrosive substance, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T54.92XD	Toxic effect of unspecified corrosive substance, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T54.92XS	Toxic effect of unspecified corrosive substance, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T55.0X2	Toxic effect of soaps, intentional self-harm	Diagnosis	ICD-10-CM
T55.0X2A	Toxic effect of soaps, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T55.0X2D	Toxic effect of soaps, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T55.0X2S	Toxic effect of soaps, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T55.1X2	Toxic effect of detergents, intentional self-harm	Diagnosis	ICD-10-CM
T55.1X2A	Toxic effect of detergents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T55.1X2D	Toxic effect of detergents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T55.1X2S	Toxic effect of detergents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.0X2	Toxic effect of lead and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T56.0X2A	Toxic effect of lead and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.0X2D	Toxic effect of lead and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.0X2S	Toxic effect of lead and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.1X2	Toxic effect of mercury and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T56.1X2A	Toxic effect of mercury and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.1X2D	Toxic effect of mercury and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.1X2S	Toxic effect of mercury and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.2X2	Toxic effect of chromium and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T56.2X2A	Toxic effect of chromium and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.2X2D	Toxic effect of chromium and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.2X2S	Toxic effect of chromium and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.3X2	Toxic effect of cadmium and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T56.3X2A	Toxic effect of cadmium and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.3X2D	Toxic effect of cadmium and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.3X2S	Toxic effect of cadmium and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.4X2	Toxic effect of copper and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T56.4X2A	Toxic effect of copper and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.4X2D	Toxic effect of copper and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.4X2S	Toxic effect of copper and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.5X2	Toxic effect of zinc and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T56.5X2A	Toxic effect of zinc and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.5X2D	Toxic effect of zinc and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.5X2S	Toxic effect of zinc and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.6X2	Toxic effect of tin and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T56.6X2A	Toxic effect of tin and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.6X2D	Toxic effect of tin and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.6X2S	Toxic effect of tin and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.7X2	Toxic effect of beryllium and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T56.7X2A	Toxic effect of beryllium and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.7X2D	Toxic effect of beryllium and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.7X2S	Toxic effect of beryllium and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.812	Toxic effect of thallium, intentional self-harm	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T56.812A	Toxic effect of thallium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.812D	Toxic effect of thallium, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.812S	Toxic effect of thallium, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.892	Toxic effect of other metals, intentional self-harm	Diagnosis	ICD-10-CM
T56.892A	Toxic effect of other metals, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.892D	Toxic effect of other metals, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.892S	Toxic effect of other metals, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.92	Toxic effect of unspecified metal, intentional self-harm	Diagnosis	ICD-10-CM
T56.92XA	Toxic effect of unspecified metal, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.92XD	Toxic effect of unspecified metal, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.92XS	Toxic effect of unspecified metal, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T57.0X2	Toxic effect of arsenic and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T57.0X2A	Toxic effect of arsenic and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T57.0X2D	Toxic effect of arsenic and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T57.0X2S	Toxic effect of arsenic and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T57.1X2	Toxic effect of phosphorus and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T57.1X2A	Toxic effect of phosphorus and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T57.1X2D	Toxic effect of phosphorus and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T57.1X2S	Toxic effect of phosphorus and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T57.2X2	Toxic effect of manganese and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T57.2X2A	Toxic effect of manganese and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T57.2X2D	Toxic effect of manganese and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T57.2X2S	Toxic effect of manganese and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T57.3X2	Toxic effect of hydrogen cyanide, intentional self-harm	Diagnosis	ICD-10-CM
T57.3X2A	Toxic effect of hydrogen cyanide, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T57.3X2D	Toxic effect of hydrogen cyanide, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T57.3X2S	Toxic effect of hydrogen cyanide, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T57.8X2	Toxic effect of other specified inorganic substances, intentional self-harm	Diagnosis	ICD-10-CM
T57.8X2A	Toxic effect of other specified inorganic substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T57.8X2D	Toxic effect of other specified inorganic substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T57.8X2S	Toxic effect of other specified inorganic substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T57.92	Toxic effect of unspecified inorganic substance, intentional self-harm	Diagnosis	ICD-10-CM
T57.92XA	Toxic effect of unspecified inorganic substance, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T57.92XD	Toxic effect of unspecified inorganic substance, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T57.92XS	Toxic effect of unspecified inorganic substance, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T58.02	Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm	Diagnosis	ICD-10-CM
T58.02XA	Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T58.02XD	Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T58.02XS	Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T58.12	Toxic effect of carbon monoxide from utility gas, intentional self-harm	Diagnosis	ICD-10-CM
T58.12XA	Toxic effect of carbon monoxide from utility gas, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T58.12XD	Toxic effect of carbon monoxide from utility gas, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T58.12XS	Toxic effect of carbon monoxide from utility gas, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T58.2X2	Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm	Diagnosis	ICD-10-CM
T58.2X2A	Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T58.2X2D	Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T58.2X2S	Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T58.8X2	Toxic effect of carbon monoxide from other source, intentional self-harm	Diagnosis	ICD-10-CM
T58.8X2A	Toxic effect of carbon monoxide from other source, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T58.8X2D	Toxic effect of carbon monoxide from other source, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T58.8X2S	Toxic effect of carbon monoxide from other source, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T58.92	Toxic effect of carbon monoxide from unspecified source, intentional self-harm	Diagnosis	ICD-10-CM
T58.92XA	Toxic effect of carbon monoxide from unspecified source, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T58.92XD	Toxic effect of carbon monoxide from unspecified source, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T58.92XS	Toxic effect of carbon monoxide from unspecified source, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.0X2	Toxic effect of nitrogen oxides, intentional self-harm	Diagnosis	ICD-10-CM
T59.0X2A	Toxic effect of nitrogen oxides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.0X2D	Toxic effect of nitrogen oxides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.0X2S	Toxic effect of nitrogen oxides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.1X2	Toxic effect of sulfur dioxide, intentional self-harm	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T59.1X2A	Toxic effect of sulfur dioxide, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.1X2D	Toxic effect of sulfur dioxide, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.1X2S	Toxic effect of sulfur dioxide, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.2X2	Toxic effect of formaldehyde, intentional self-harm	Diagnosis	ICD-10-CM
T59.2X2A	Toxic effect of formaldehyde, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.2X2D	Toxic effect of formaldehyde, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.2X2S	Toxic effect of formaldehyde, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.3X2	Toxic effect of lacrimogenic gas, intentional self-harm	Diagnosis	ICD-10-CM
T59.3X2A	Toxic effect of lacrimogenic gas, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.3X2D	Toxic effect of lacrimogenic gas, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.3X2S	Toxic effect of lacrimogenic gas, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.4X2	Toxic effect of chlorine gas, intentional self-harm	Diagnosis	ICD-10-CM
T59.4X2A	Toxic effect of chlorine gas, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.4X2D	Toxic effect of chlorine gas, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.4X2S	Toxic effect of chlorine gas, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.5X2	Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm	Diagnosis	ICD-10-CM
T59.5X2A	Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.5X2D	Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.5X2S	Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.6X2	Toxic effect of hydrogen sulfide, intentional self-harm	Diagnosis	ICD-10-CM
T59.6X2A	Toxic effect of hydrogen sulfide, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.6X2D	Toxic effect of hydrogen sulfide, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.6X2S	Toxic effect of hydrogen sulfide, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.7X2	Toxic effect of carbon dioxide, intentional self-harm	Diagnosis	ICD-10-CM
T59.7X2A	Toxic effect of carbon dioxide, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.7X2D	Toxic effect of carbon dioxide, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.7X2S	Toxic effect of carbon dioxide, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.812	Toxic effect of smoke, intentional self-harm	Diagnosis	ICD-10-CM
T59.812A	Toxic effect of smoke, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.812D	Toxic effect of smoke, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.812S	Toxic effect of smoke, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.892	Toxic effect of other specified gases, fumes and vapors, intentional self-harm	Diagnosis	ICD-10-CM
T59.892A	Toxic effect of other specified gases, fumes and vapors, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.892D	Toxic effect of other specified gases, fumes and vapors, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T59.892S	Toxic effect of other specified gases, fumes and vapors, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.92	Toxic effect of unspecified gases, fumes and vapors, intentional self-harm	Diagnosis	ICD-10-CM
T59.92XA	Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.92XD	Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.92XS	Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T60.0X2	Toxic effect of organophosphate and carbamate insecticides, intentional self-harm	Diagnosis	ICD-10-CM
T60.0X2A	Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T60.0X2D	Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T60.0X2S	Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T60.1X2	Toxic effect of halogenated insecticides, intentional self-harm	Diagnosis	ICD-10-CM
T60.1X2A	Toxic effect of halogenated insecticides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T60.1X2D	Toxic effect of halogenated insecticides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T60.1X2S	Toxic effect of halogenated insecticides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T60.2X2	Toxic effect of other insecticides, intentional self-harm	Diagnosis	ICD-10-CM
T60.2X2A	Toxic effect of other insecticides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T60.2X2D	Toxic effect of other insecticides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T60.2X2S	Toxic effect of other insecticides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T60.3X2	Toxic effect of herbicides and fungicides, intentional self-harm	Diagnosis	ICD-10-CM
T60.3X2A	Toxic effect of herbicides and fungicides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T60.3X2D	Toxic effect of herbicides and fungicides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T60.3X2S	Toxic effect of herbicides and fungicides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T60.4X2	Toxic effect of rodenticides, intentional self-harm	Diagnosis	ICD-10-CM
T60.4X2A	Toxic effect of rodenticides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T60.4X2D	Toxic effect of rodenticides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T60.4X2S	Toxic effect of rodenticides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T60.8X2	Toxic effect of other pesticides, intentional self-harm	Diagnosis	ICD-10-CM
T60.8X2A	Toxic effect of other pesticides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T60.8X2D	Toxic effect of other pesticides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T60.8X2S	Toxic effect of other pesticides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T60.92	Toxic effect of unspecified pesticide, intentional self-harm	Diagnosis	ICD-10-CM
T60.92XA	Toxic effect of unspecified pesticide, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T60.92XD	Toxic effect of unspecified pesticide, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T60.92XS	Toxic effect of unspecified pesticide, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T61.02	Ciguatera fish poisoning, intentional self-harm	Diagnosis	ICD-10-CM
T61.02XA	Ciguatera fish poisoning, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T61.02XD	Ciguatera fish poisoning, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T61.02XS	Ciguatera fish poisoning, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T61.12	Scombroid fish poisoning, intentional self-harm	Diagnosis	ICD-10-CM
T61.12XA	Scombroid fish poisoning, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T61.12XD	Scombroid fish poisoning, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T61.12XS	Scombroid fish poisoning, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T61.772	Other fish poisoning, intentional self-harm	Diagnosis	ICD-10-CM
T61.772A	Other fish poisoning, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T61.772D	Other fish poisoning, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T61.772S	Other fish poisoning, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T61.782	Other shellfish poisoning, intentional self-harm	Diagnosis	ICD-10-CM
T61.782A	Other shellfish poisoning, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T61.782D	Other shellfish poisoning, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T61.782S	Other shellfish poisoning, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T61.8X2	Toxic effect of other seafood, intentional self-harm	Diagnosis	ICD-10-CM
T61.8X2A	Toxic effect of other seafood, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T61.8X2D	Toxic effect of other seafood, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T61.8X2S	Toxic effect of other seafood, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T61.92	Toxic effect of unspecified seafood, intentional self-harm	Diagnosis	ICD-10-CM
T61.92XA	Toxic effect of unspecified seafood, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T61.92XD	Toxic effect of unspecified seafood, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T61.92XS	Toxic effect of unspecified seafood, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T62.0X2	Toxic effect of ingested mushrooms, intentional self-harm	Diagnosis	ICD-10-CM
T62.0X2A	Toxic effect of ingested mushrooms, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T62.0X2D	Toxic effect of ingested mushrooms, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T62.0X2S	Toxic effect of ingested mushrooms, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T62.1X2	Toxic effect of ingested berries, intentional self-harm	Diagnosis	ICD-10-CM
T62.1X2A	Toxic effect of ingested berries, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T62.1X2D	Toxic effect of ingested berries, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T62.1X2S	Toxic effect of ingested berries, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T62.2X2	Toxic effect of other ingested (parts of) plant(s), intentional self-harm	Diagnosis	ICD-10-CM
T62.2X2A	Toxic effect of other ingested (parts of) plant(s), intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T62.2X2D	Toxic effect of other ingested (parts of) plant(s), intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T62.2X2S	Toxic effect of other ingested (parts of) plant(s), intentional self-harm, sequela	Diagnosis	ICD-10-CM
T62.8X2	Toxic effect of other specified noxious substances eaten as food, intentional self-harm	Diagnosis	ICD-10-CM
T62.8X2A	Toxic effect of other specified noxious substances eaten as food, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T62.8X2D	Toxic effect of other specified noxious substances eaten as food, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T62.8X2S	Toxic effect of other specified noxious substances eaten as food, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T62.92	Toxic effect of unspecified noxious substance eaten as food, intentional self-harm	Diagnosis	ICD-10-CM
T62.92XA	Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T62.92XD	Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T62.92XS	Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.002	Toxic effect of unspecified snake venom, intentional self-harm	Diagnosis	ICD-10-CM
T63.002A	Toxic effect of unspecified snake venom, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.002D	Toxic effect of unspecified snake venom, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.002S	Toxic effect of unspecified snake venom, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.012	Toxic effect of rattlesnake venom, intentional self-harm	Diagnosis	ICD-10-CM
T63.012A	Toxic effect of rattlesnake venom, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.012D	Toxic effect of rattlesnake venom, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.012S	Toxic effect of rattlesnake venom, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.022	Toxic effect of coral snake venom, intentional self-harm	Diagnosis	ICD-10-CM
T63.022A	Toxic effect of coral snake venom, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.022D	Toxic effect of coral snake venom, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.022S	Toxic effect of coral snake venom, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.032	Toxic effect of taipan venom, intentional self-harm	Diagnosis	ICD-10-CM
T63.032A	Toxic effect of taipan venom, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.032D	Toxic effect of taipan venom, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.032S	Toxic effect of taipan venom, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.042	Toxic effect of cobra venom, intentional self-harm	Diagnosis	ICD-10-CM
T63.042A	Toxic effect of cobra venom, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.042D	Toxic effect of cobra venom, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.042S	Toxic effect of cobra venom, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T63.062	Toxic effect of venom of other North and South American snake, intentional self-harm	Diagnosis	ICD-10-CM
T63.062A	Toxic effect of venom of other North and South American snake, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.062D	Toxic effect of venom of other North and South American snake, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.062S	Toxic effect of venom of other North and South American snake, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.072	Toxic effect of venom of other Australian snake, intentional self-harm	Diagnosis	ICD-10-CM
T63.072A	Toxic effect of venom of other Australian snake, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.072D	Toxic effect of venom of other Australian snake, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.072S	Toxic effect of venom of other Australian snake, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.082	Toxic effect of venom of other African and Asian snake, intentional self-harm	Diagnosis	ICD-10-CM
T63.082A	Toxic effect of venom of other African and Asian snake, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.082D	Toxic effect of venom of other African and Asian snake, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.082S	Toxic effect of venom of other African and Asian snake, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.092	Toxic effect of venom of other snake, intentional self-harm	Diagnosis	ICD-10-CM
T63.092A	Toxic effect of venom of other snake, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.092D	Toxic effect of venom of other snake, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.092S	Toxic effect of venom of other snake, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.112	Toxic effect of venom of gila monster, intentional self-harm	Diagnosis	ICD-10-CM
T63.112A	Toxic effect of venom of gila monster, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.112D	Toxic effect of venom of gila monster, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.112S	Toxic effect of venom of gila monster, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.122	Toxic effect of venom of other venomous lizard, intentional self-harm	Diagnosis	ICD-10-CM
T63.122A	Toxic effect of venom of other venomous lizard, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.122D	Toxic effect of venom of other venomous lizard, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.122S	Toxic effect of venom of other venomous lizard, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.192	Toxic effect of venom of other reptiles, intentional self-harm	Diagnosis	ICD-10-CM
T63.192A	Toxic effect of venom of other reptiles, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.192D	Toxic effect of venom of other reptiles, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.192S	Toxic effect of venom of other reptiles, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.2X2	Toxic effect of venom of scorpion, intentional self-harm	Diagnosis	ICD-10-CM
T63.2X2A	Toxic effect of venom of scorpion, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.2X2D	Toxic effect of venom of scorpion, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.2X2S	Toxic effect of venom of scorpion, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T63.302	Toxic effect of unspecified spider venom, intentional self-harm	Diagnosis	ICD-10-CM
T63.302A	Toxic effect of unspecified spider venom, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.302D	Toxic effect of unspecified spider venom, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.302S	Toxic effect of unspecified spider venom, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.312	Toxic effect of venom of black widow spider, intentional self-harm	Diagnosis	ICD-10-CM
T63.312A	Toxic effect of venom of black widow spider, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.312D	Toxic effect of venom of black widow spider, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.312S	Toxic effect of venom of black widow spider, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.322	Toxic effect of venom of tarantula, intentional self-harm	Diagnosis	ICD-10-CM
T63.322A	Toxic effect of venom of tarantula, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.322D	Toxic effect of venom of tarantula, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.322S	Toxic effect of venom of tarantula, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.332	Toxic effect of venom of brown recluse spider, intentional self-harm	Diagnosis	ICD-10-CM
T63.332A	Toxic effect of venom of brown recluse spider, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.332D	Toxic effect of venom of brown recluse spider, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.332S	Toxic effect of venom of brown recluse spider, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.392	Toxic effect of venom of other spider, intentional self-harm	Diagnosis	ICD-10-CM
T63.392A	Toxic effect of venom of other spider, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.392D	Toxic effect of venom of other spider, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.392S	Toxic effect of venom of other spider, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.412	Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm	Diagnosis	ICD-10-CM
T63.412A	Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.412D	Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.412S	Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.422	Toxic effect of venom of ants, intentional self-harm	Diagnosis	ICD-10-CM
T63.422A	Toxic effect of venom of ants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.422D	Toxic effect of venom of ants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.422S	Toxic effect of venom of ants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.432	Toxic effect of venom of caterpillars, intentional self-harm	Diagnosis	ICD-10-CM
T63.432A	Toxic effect of venom of caterpillars, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.432D	Toxic effect of venom of caterpillars, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.432S	Toxic effect of venom of caterpillars, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.442	Toxic effect of venom of bees, intentional self-harm	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T63.442A	Toxic effect of venom of bees, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.442D	Toxic effect of venom of bees, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.442S	Toxic effect of venom of bees, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.452	Toxic effect of venom of hornets, intentional self-harm	Diagnosis	ICD-10-CM
T63.452A	Toxic effect of venom of hornets, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.452D	Toxic effect of venom of hornets, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.452S	Toxic effect of venom of hornets, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.462	Toxic effect of venom of wasps, intentional self-harm	Diagnosis	ICD-10-CM
T63.462A	Toxic effect of venom of wasps, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.462D	Toxic effect of venom of wasps, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.462S	Toxic effect of venom of wasps, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.482	Toxic effect of venom of other arthropod, intentional self-harm	Diagnosis	ICD-10-CM
T63.482A	Toxic effect of venom of other arthropod, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.482D	Toxic effect of venom of other arthropod, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.482S	Toxic effect of venom of other arthropod, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.512	Toxic effect of contact with stingray, intentional self-harm	Diagnosis	ICD-10-CM
T63.512A	Toxic effect of contact with stingray, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.512D	Toxic effect of contact with stingray, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.512S	Toxic effect of contact with stingray, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.592	Toxic effect of contact with other venomous fish, intentional self-harm	Diagnosis	ICD-10-CM
T63.592A	Toxic effect of contact with other venomous fish, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.592D	Toxic effect of contact with other venomous fish, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.592S	Toxic effect of contact with other venomous fish, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.612	Toxic effect of contact with Portuguese Man-o-war, intentional self-harm	Diagnosis	ICD-10-CM
T63.612A	Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.612D	Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.612S	Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.622	Toxic effect of contact with other jellyfish, intentional self-harm	Diagnosis	ICD-10-CM
T63.622A	Toxic effect of contact with other jellyfish, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.622D	Toxic effect of contact with other jellyfish, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.622S	Toxic effect of contact with other jellyfish, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.632	Toxic effect of contact with sea anemone, intentional self-harm	Diagnosis	ICD-10-CM
T63.632A	Toxic effect of contact with sea anemone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.632D	Toxic effect of contact with sea anemone, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T63.632S	Toxic effect of contact with sea anemone, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.692	Toxic effect of contact with other venomous marine animals, intentional self-harm	Diagnosis	ICD-10-CM
T63.692A	Toxic effect of contact with other venomous marine animals, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.692D	Toxic effect of contact with other venomous marine animals, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.692S	Toxic effect of contact with other venomous marine animals, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.712	Toxic effect of contact with venomous marine plant, intentional self-harm	Diagnosis	ICD-10-CM
T63.712A	Toxic effect of contact with venomous marine plant, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.712D	Toxic effect of contact with venomous marine plant, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.712S	Toxic effect of contact with venomous marine plant, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.792	Toxic effect of contact with other venomous plant, intentional self-harm	Diagnosis	ICD-10-CM
T63.792A	Toxic effect of contact with other venomous plant, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.792D	Toxic effect of contact with other venomous plant, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.792S	Toxic effect of contact with other venomous plant, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.812	Toxic effect of contact with venomous frog, intentional self-harm	Diagnosis	ICD-10-CM
T63.812A	Toxic effect of contact with venomous frog, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.812D	Toxic effect of contact with venomous frog, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.812S	Toxic effect of contact with venomous frog, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.822	Toxic effect of contact with venomous toad, intentional self-harm	Diagnosis	ICD-10-CM
T63.822A	Toxic effect of contact with venomous toad, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.822D	Toxic effect of contact with venomous toad, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.822S	Toxic effect of contact with venomous toad, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.832	Toxic effect of contact with other venomous amphibian, intentional self-harm	Diagnosis	ICD-10-CM
T63.832A	Toxic effect of contact with other venomous amphibian, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.832D	Toxic effect of contact with other venomous amphibian, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.832S	Toxic effect of contact with other venomous amphibian, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.892	Toxic effect of contact with other venomous animals, intentional self-harm	Diagnosis	ICD-10-CM
T63.892A	Toxic effect of contact with other venomous animals, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.892D	Toxic effect of contact with other venomous animals, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.892S	Toxic effect of contact with other venomous animals, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T63.92	Toxic effect of contact with unspecified venomous animal, intentional self-harm	Diagnosis	ICD-10-CM
T63.92XA	Toxic effect of contact with unspecified venomous animal, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.92XD	Toxic effect of contact with unspecified venomous animal, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.92XS	Toxic effect of contact with unspecified venomous animal, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T64.02	Toxic effect of aflatoxin, intentional self-harm	Diagnosis	ICD-10-CM
T64.02XA	Toxic effect of aflatoxin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T64.02XD	Toxic effect of aflatoxin, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T64.02XS	Toxic effect of aflatoxin, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T64.82	Toxic effect of other mycotoxin food contaminants, intentional self-harm	Diagnosis	ICD-10-CM
T64.82XA	Toxic effect of other mycotoxin food contaminants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T64.82XD	Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T64.82XS	Toxic effect of other mycotoxin food contaminants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.0X2	Toxic effect of cyanides, intentional self-harm	Diagnosis	ICD-10-CM
T65.0X2A	Toxic effect of cyanides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.0X2D	Toxic effect of cyanides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.0X2S	Toxic effect of cyanides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.1X2	Toxic effect of strychnine and its salts, intentional self-harm	Diagnosis	ICD-10-CM
T65.1X2A	Toxic effect of strychnine and its salts, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.1X2D	Toxic effect of strychnine and its salts, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.1X2S	Toxic effect of strychnine and its salts, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.212	Toxic effect of chewing tobacco, intentional self-harm	Diagnosis	ICD-10-CM
T65.212A	Toxic effect of chewing tobacco, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.212D	Toxic effect of chewing tobacco, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.212S	Toxic effect of chewing tobacco, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.222	Toxic effect of tobacco cigarettes, intentional self-harm	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.222D	Toxic effect of tobacco cigarettes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.222S	Toxic effect of tobacco cigarettes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.292	Toxic effect of other tobacco and nicotine, intentional self-harm	Diagnosis	ICD-10-CM
T65.292A	Toxic effect of other tobacco and nicotine, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.292D	Toxic effect of other tobacco and nicotine, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.292S	Toxic effect of other tobacco and nicotine, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T65.3X2	Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm	Diagnosis	ICD-10-CM
T65.3X2A	Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.3X2D	Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.3X2S	Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.4X2	Toxic effect of carbon disulfide, intentional self-harm	Diagnosis	ICD-10-CM
T65.4X2A	Toxic effect of carbon disulfide, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.4X2D	Toxic effect of carbon disulfide, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.4X2S	Toxic effect of carbon disulfide, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.5X2	Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm	Diagnosis	ICD-10-CM
T65.5X2A	Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.5X2D	Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.5X2S	Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.6X2	Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm	Diagnosis	ICD-10-CM
T65.6X2A	Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.6X2D	Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.6X2S	Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.812	Toxic effect of latex, intentional self-harm	Diagnosis	ICD-10-CM
T65.812A	Toxic effect of latex, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.812D	Toxic effect of latex, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.812S	Toxic effect of latex, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.822	Toxic effect of harmful algae and algae toxins, intentional self-harm	Diagnosis	ICD-10-CM
T65.822A	Toxic effect of harmful algae and algae toxins, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.822D	Toxic effect of harmful algae and algae toxins, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.822S	Toxic effect of harmful algae and algae toxins, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.832	Toxic effect of fiberglass, intentional self-harm	Diagnosis	ICD-10-CM
T65.832A	Toxic effect of fiberglass, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.832D	Toxic effect of fiberglass, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T65.832S	Toxic effect of fiberglass, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.892	Toxic effect of other specified substances, intentional self-harm	Diagnosis	ICD-10-CM
T65.892A	Toxic effect of other specified substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.892D	Toxic effect of other specified substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.892S	Toxic effect of other specified substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.92	Toxic effect of unspecified substance, intentional self-harm	Diagnosis	ICD-10-CM
T65.92XA	Toxic effect of unspecified substance, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.92XD	Toxic effect of unspecified substance, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.92XS	Toxic effect of unspecified substance, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.112	Asphyxiation due to smothering under pillow, intentional self-harm	Diagnosis	ICD-10-CM
T71.112A	Asphyxiation due to smothering under pillow, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.112D	Asphyxiation due to smothering under pillow, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T71.112S	Asphyxiation due to smothering under pillow, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.122	Asphyxiation due to plastic bag, intentional self-harm	Diagnosis	ICD-10-CM
T71.122A	Asphyxiation due to plastic bag, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.122D	Asphyxiation due to plastic bag, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T71.122S	Asphyxiation due to plastic bag, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.132	Asphyxiation due to being trapped in bed linens, intentional self-harm	Diagnosis	ICD-10-CM
T71.132A	Asphyxiation due to being trapped in bed linens, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.132D	Asphyxiation due to being trapped in bed linens, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T71.132S	Asphyxiation due to being trapped in bed linens, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.152	Asphyxiation due to smothering in furniture, intentional self-harm	Diagnosis	ICD-10-CM
T71.152A	Asphyxiation due to smothering in furniture, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.152D	Asphyxiation due to smothering in furniture, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T71.152S	Asphyxiation due to smothering in furniture, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.162	Asphyxiation due to hanging, intentional self-harm	Diagnosis	ICD-10-CM
T71.162A	Asphyxiation due to hanging, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.162D	Asphyxiation due to hanging, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T71.162S	Asphyxiation due to hanging, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.192	Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm	Diagnosis	ICD-10-CM
T71.192A	Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.192D	Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T71.192S	Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.222	Asphyxiation due to being trapped in a car trunk, intentional self-harm	Diagnosis	ICD-10-CM
T71.222A	Asphyxiation due to being trapped in a car trunk, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.222D	Asphyxiation due to being trapped in a car trunk, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T71.222S	Asphyxiation due to being trapped in a car trunk, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.232	Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm	Diagnosis	ICD-10-CM
T71.232A	Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.232D	Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T71.232S	Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, sequela	Diagnosis	ICD-10-CM
X71	Intentional self-harm by drowning and submersion	Diagnosis	ICD-10-CM
X71.0	Intentional self-harm by drowning and submersion while in bathtub	Diagnosis	ICD-10-CM
X71.0XXA	Intentional self-harm by drowning and submersion while in bathtub, initial encounter	Diagnosis	ICD-10-CM
X71.0XXD	Intentional self-harm by drowning and submersion while in bathtub, subsequent encounter	Diagnosis	ICD-10-CM
X71.0XXS	Intentional self-harm by drowning and submersion while in bathtub, sequela	Diagnosis	ICD-10-CM
X71.1	Intentional self-harm by drowning and submersion while in swimming pool	Diagnosis	ICD-10-CM
X71.1XXA	Intentional self-harm by drowning and submersion while in swimming pool, initial encounter	Diagnosis	ICD-10-CM
X71.1XXD	Intentional self-harm by drowning and submersion while in swimming pool, subsequent encounter	Diagnosis	ICD-10-CM
X71.1XXS	Intentional self-harm by drowning and submersion while in swimming pool, sequela	Diagnosis	ICD-10-CM
X71.2	Intentional self-harm by drowning and submersion after jump into swimming pool	Diagnosis	ICD-10-CM
X71.2XXA	Intentional self-harm by drowning and submersion after jump into swimming pool, initial encounter	Diagnosis	ICD-10-CM
X71.2XXD	Intentional self-harm by drowning and submersion after jump into swimming pool, subsequent encounter	Diagnosis	ICD-10-CM
X71.2XXS	Intentional self-harm by drowning and submersion after jump into swimming pool, sequela	Diagnosis	ICD-10-CM
X71.3	Intentional self-harm by drowning and submersion in natural water	Diagnosis	ICD-10-CM
X71.3XXA	Intentional self-harm by drowning and submersion in natural water, initial encounter	Diagnosis	ICD-10-CM
X71.3XXD	Intentional self-harm by drowning and submersion in natural water, subsequent encounter	Diagnosis	ICD-10-CM
X71.3XXS	Intentional self-harm by drowning and submersion in natural water, sequela	Diagnosis	ICD-10-CM
X71.8	Other intentional self-harm by drowning and submersion	Diagnosis	ICD-10-CM
X71.8XXA	Other intentional self-harm by drowning and submersion, initial encounter	Diagnosis	ICD-10-CM
X71.8XXD	Other intentional self-harm by drowning and submersion, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
X71.8XXS	Other intentional self-harm by drowning and submersion, sequela	Diagnosis	ICD-10-CM
X71.9	Intentional self-harm by drowning and submersion, unspecified	Diagnosis	ICD-10-CM
X71.9XXA	Intentional self-harm by drowning and submersion, unspecified, initial encounter	Diagnosis	ICD-10-CM
X71.9XXD	Intentional self-harm by drowning and submersion, unspecified, subsequent encounter	Diagnosis	ICD-10-CM
X71.9XXS	Intentional self-harm by drowning and submersion, unspecified, sequela	Diagnosis	ICD-10-CM
X72	Intentional self-harm by handgun discharge	Diagnosis	ICD-10-CM
X72.XXXA	Intentional self-harm by handgun discharge, initial encounter	Diagnosis	ICD-10-CM
X72.XXXD	Intentional self-harm by handgun discharge, subsequent encounter	Diagnosis	ICD-10-CM
X72.XXXS	Intentional self-harm by handgun discharge, sequela	Diagnosis	ICD-10-CM
X73	Intentional self-harm by rifle, shotgun and larger firearm discharge	Diagnosis	ICD-10-CM
X73.0	Intentional self-harm by shotgun discharge	Diagnosis	ICD-10-CM
X73.0XXA	Intentional self-harm by shotgun discharge, initial encounter	Diagnosis	ICD-10-CM
X73.0XXD	Intentional self-harm by shotgun discharge, subsequent encounter	Diagnosis	ICD-10-CM
X73.0XXS	Intentional self-harm by shotgun discharge, sequela	Diagnosis	ICD-10-CM
X73.1	Intentional self-harm by hunting rifle discharge	Diagnosis	ICD-10-CM
X73.1XXA	Intentional self-harm by hunting rifle discharge, initial encounter	Diagnosis	ICD-10-CM
X73.1XXD	Intentional self-harm by hunting rifle discharge, subsequent encounter	Diagnosis	ICD-10-CM
X73.1XXS	Intentional self-harm by hunting rifle discharge, sequela	Diagnosis	ICD-10-CM
X73.2	Intentional self-harm by machine gun discharge	Diagnosis	ICD-10-CM
X73.2XXA	Intentional self-harm by machine gun discharge, initial encounter	Diagnosis	ICD-10-CM
X73.2XXD	Intentional self-harm by machine gun discharge, subsequent encounter	Diagnosis	ICD-10-CM
X73.2XXS	Intentional self-harm by machine gun discharge, sequela	Diagnosis	ICD-10-CM
X73.8	Intentional self-harm by other larger firearm discharge	Diagnosis	ICD-10-CM
X73.8XXA	Intentional self-harm by other larger firearm discharge, initial encounter	Diagnosis	ICD-10-CM
X73.8XXD	Intentional self-harm by other larger firearm discharge, subsequent encounter	Diagnosis	ICD-10-CM
X73.8XXS	Intentional self-harm by other larger firearm discharge, sequela	Diagnosis	ICD-10-CM
X73.9	Intentional self-harm by unspecified larger firearm discharge	Diagnosis	ICD-10-CM
X73.9XXA	Intentional self-harm by unspecified larger firearm discharge, initial encounter	Diagnosis	ICD-10-CM
X73.9XXD	Intentional self-harm by unspecified larger firearm discharge, subsequent encounter	Diagnosis	ICD-10-CM
X73.9XXS	Intentional self-harm by unspecified larger firearm discharge, sequela	Diagnosis	ICD-10-CM
X74	Intentional self-harm by other and unspecified firearm and gun discharge	Diagnosis	ICD-10-CM
X74.0	Intentional self-harm by gas, air or spring-operated guns	Diagnosis	ICD-10-CM
X74.01	Intentional self-harm by airgun	Diagnosis	ICD-10-CM
X74.01XA	Intentional self-harm by airgun, initial encounter	Diagnosis	ICD-10-CM
X74.01XD	Intentional self-harm by airgun, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
X74.01XS	Intentional self-harm by airgun, sequela	Diagnosis	ICD-10-CM
X74.02	Intentional self-harm by paintball gun	Diagnosis	ICD-10-CM
X74.02XA	Intentional self-harm by paintball gun, initial encounter	Diagnosis	ICD-10-CM
X74.02XD	Intentional self-harm by paintball gun, subsequent encounter	Diagnosis	ICD-10-CM
X74.02XS	Intentional self-harm by paintball gun, sequela	Diagnosis	ICD-10-CM
X74.09	Intentional self-harm by other gas, air or spring-operated gun	Diagnosis	ICD-10-CM
X74.09XA	Intentional self-harm by other gas, air or spring-operated gun, initial encounter	Diagnosis	ICD-10-CM
X74.09XD	Intentional self-harm by other gas, air or spring-operated gun, subsequent encounter	Diagnosis	ICD-10-CM
X74.09XS	Intentional self-harm by other gas, air or spring-operated gun, sequela	Diagnosis	ICD-10-CM
X74.8	Intentional self-harm by other firearm discharge	Diagnosis	ICD-10-CM
X74.8XXA	Intentional self-harm by other firearm discharge, initial encounter	Diagnosis	ICD-10-CM
X74.8XXD	Intentional self-harm by other firearm discharge, subsequent encounter	Diagnosis	ICD-10-CM
X74.8XXS	Intentional self-harm by other firearm discharge, sequela	Diagnosis	ICD-10-CM
X74.9	Intentional self-harm by unspecified firearm discharge	Diagnosis	ICD-10-CM
X74.9XXA	Intentional self-harm by unspecified firearm discharge, initial encounter	Diagnosis	ICD-10-CM
X74.9XXD	Intentional self-harm by unspecified firearm discharge, subsequent encounter	Diagnosis	ICD-10-CM
X74.9XXS	Intentional self-harm by unspecified firearm discharge, sequela	Diagnosis	ICD-10-CM
X75	Intentional self-harm by explosive material	Diagnosis	ICD-10-CM
X75.XXXA	Intentional self-harm by explosive material, initial encounter	Diagnosis	ICD-10-CM
X75.XXXD	Intentional self-harm by explosive material, subsequent encounter	Diagnosis	ICD-10-CM
X75.XXXS	Intentional self-harm by explosive material, sequela	Diagnosis	ICD-10-CM
X76	Intentional self-harm by smoke, fire and flames	Diagnosis	ICD-10-CM
X76.XXXA	Intentional self-harm by smoke, fire and flames, initial encounter	Diagnosis	ICD-10-CM
X76.XXXD	Intentional self-harm by smoke, fire and flames, subsequent encounter	Diagnosis	ICD-10-CM
X76.XXXS	Intentional self-harm by smoke, fire and flames, sequela	Diagnosis	ICD-10-CM
X77	Intentional self-harm by steam, hot vapors and hot objects	Diagnosis	ICD-10-CM
X77.0	Intentional self-harm by steam or hot vapors	Diagnosis	ICD-10-CM
X77.0XXA	Intentional self-harm by steam or hot vapors, initial encounter	Diagnosis	ICD-10-CM
X77.0XXD	Intentional self-harm by steam or hot vapors, subsequent encounter	Diagnosis	ICD-10-CM
X77.0XXS	Intentional self-harm by steam or hot vapors, sequela	Diagnosis	ICD-10-CM
X77.1	Intentional self-harm by hot tap water	Diagnosis	ICD-10-CM
X77.1XXA	Intentional self-harm by hot tap water, initial encounter	Diagnosis	ICD-10-CM
X77.1XXD	Intentional self-harm by hot tap water, subsequent encounter	Diagnosis	ICD-10-CM
X77.1XXS	Intentional self-harm by hot tap water, sequela	Diagnosis	ICD-10-CM
X77.2	Intentional self-harm by other hot fluids	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
X77.2XXA	Intentional self-harm by other hot fluids, initial encounter	Diagnosis	ICD-10-CM
X77.2XXD	Intentional self-harm by other hot fluids, subsequent encounter	Diagnosis	ICD-10-CM
X77.2XXS	Intentional self-harm by other hot fluids, sequela	Diagnosis	ICD-10-CM
X77.3	Intentional self-harm by hot household appliances	Diagnosis	ICD-10-CM
X77.3XXA	Intentional self-harm by hot household appliances, initial encounter	Diagnosis	ICD-10-CM
X77.3XXD	Intentional self-harm by hot household appliances, subsequent encounter	Diagnosis	ICD-10-CM
X77.3XXS	Intentional self-harm by hot household appliances, sequela	Diagnosis	ICD-10-CM
X77.8	Intentional self-harm by other hot objects	Diagnosis	ICD-10-CM
X77.8XXA	Intentional self-harm by other hot objects, initial encounter	Diagnosis	ICD-10-CM
X77.8XXD	Intentional self-harm by other hot objects, subsequent encounter	Diagnosis	ICD-10-CM
X77.8XXS	Intentional self-harm by other hot objects, sequela	Diagnosis	ICD-10-CM
X77.9	Intentional self-harm by unspecified hot objects	Diagnosis	ICD-10-CM
X77.9XXA	Intentional self-harm by unspecified hot objects, initial encounter	Diagnosis	ICD-10-CM
X77.9XXD	Intentional self-harm by unspecified hot objects, subsequent encounter	Diagnosis	ICD-10-CM
X77.9XXS	Intentional self-harm by unspecified hot objects, sequela	Diagnosis	ICD-10-CM
X78	Intentional self-harm by sharp object	Diagnosis	ICD-10-CM
X78.0	Intentional self-harm by sharp glass	Diagnosis	ICD-10-CM
X78.0XXA	Intentional self-harm by sharp glass, initial encounter	Diagnosis	ICD-10-CM
X78.0XXD	Intentional self-harm by sharp glass, subsequent encounter	Diagnosis	ICD-10-CM
X78.0XXS	Intentional self-harm by sharp glass, sequela	Diagnosis	ICD-10-CM
X78.1	Intentional self-harm by knife	Diagnosis	ICD-10-CM
X78.1XXA	Intentional self-harm by knife, initial encounter	Diagnosis	ICD-10-CM
X78.1XXD	Intentional self-harm by knife, subsequent encounter	Diagnosis	ICD-10-CM
X78.1XXS	Intentional self-harm by knife, sequela	Diagnosis	ICD-10-CM
X78.2	Intentional self-harm by sword or dagger	Diagnosis	ICD-10-CM
X78.2XXA	Intentional self-harm by sword or dagger, initial encounter	Diagnosis	ICD-10-CM
X78.2XXD	Intentional self-harm by sword or dagger, subsequent encounter	Diagnosis	ICD-10-CM
X78.2XXS	Intentional self-harm by sword or dagger, sequela	Diagnosis	ICD-10-CM
X78.8	Intentional self-harm by other sharp object	Diagnosis	ICD-10-CM
X78.8XXA	Intentional self-harm by other sharp object, initial encounter	Diagnosis	ICD-10-CM
X78.8XXD	Intentional self-harm by other sharp object, subsequent encounter	Diagnosis	ICD-10-CM
X78.8XXS	Intentional self-harm by other sharp object, sequela	Diagnosis	ICD-10-CM
X78.9	Intentional self-harm by unspecified sharp object	Diagnosis	ICD-10-CM
X78.9XXA	Intentional self-harm by unspecified sharp object, initial encounter	Diagnosis	ICD-10-CM
X78.9XXD	Intentional self-harm by unspecified sharp object, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
X78.9XXS	Intentional self-harm by unspecified sharp object, sequela	Diagnosis	ICD-10-CM
X79	Intentional self-harm by blunt object	Diagnosis	ICD-10-CM
X79.XXXA	Intentional self-harm by blunt object, initial encounter	Diagnosis	ICD-10-CM
X79.XXXD	Intentional self-harm by blunt object, subsequent encounter	Diagnosis	ICD-10-CM
X79.XXXS	Intentional self-harm by blunt object, sequela	Diagnosis	ICD-10-CM
X80	Intentional self-harm by jumping from a high place	Diagnosis	ICD-10-CM
X80.XXXA	Intentional self-harm by jumping from a high place, initial encounter	Diagnosis	ICD-10-CM
X80.XXXD	Intentional self-harm by jumping from a high place, subsequent encounter	Diagnosis	ICD-10-CM
X80.XXXS	Intentional self-harm by jumping from a high place, sequela	Diagnosis	ICD-10-CM
X81	Intentional self-harm by jumping or lying in front of moving object	Diagnosis	ICD-10-CM
X81.0	Intentional self-harm by jumping or lying in front of motor vehicle	Diagnosis	ICD-10-CM
X81.0XXA	Intentional self-harm by jumping or lying in front of motor vehicle, initial encounter	Diagnosis	ICD-10-CM
X81.0XXD	Intentional self-harm by jumping or lying in front of motor vehicle, subsequent encounter	Diagnosis	ICD-10-CM
X81.0XXS	Intentional self-harm by jumping or lying in front of motor vehicle, sequela	Diagnosis	ICD-10-CM
X81.1	Intentional self-harm by jumping or lying in front of (subway) train	Diagnosis	ICD-10-CM
X81.1XXA	Intentional self-harm by jumping or lying in front of (subway) train, initial encounter	Diagnosis	ICD-10-CM
X81.1XXD	Intentional self-harm by jumping or lying in front of (subway) train, subsequent encounter	Diagnosis	ICD-10-CM
X81.1XXS	Intentional self-harm by jumping or lying in front of (subway) train, sequela	Diagnosis	ICD-10-CM
X81.8	Intentional self-harm by jumping or lying in front of other moving object	Diagnosis	ICD-10-CM
X81.8XXA	Intentional self-harm by jumping or lying in front of other moving object, initial encounter	Diagnosis	ICD-10-CM
X81.8XXD	Intentional self-harm by jumping or lying in front of other moving object, subsequent encounter	Diagnosis	ICD-10-CM
X81.8XXS	Intentional self-harm by jumping or lying in front of other moving object, sequela	Diagnosis	ICD-10-CM
X82	Intentional self-harm by crashing of motor vehicle	Diagnosis	ICD-10-CM
X82.0	Intentional collision of motor vehicle with other motor vehicle	Diagnosis	ICD-10-CM
X82.0XXA	Intentional collision of motor vehicle with other motor vehicle, initial encounter	Diagnosis	ICD-10-CM
X82.0XXD	Intentional collision of motor vehicle with other motor vehicle, subsequent encounter	Diagnosis	ICD-10-CM
X82.0XXS	Intentional collision of motor vehicle with other motor vehicle, sequela	Diagnosis	ICD-10-CM
X82.1	Intentional collision of motor vehicle with train	Diagnosis	ICD-10-CM
X82.1XXA	Intentional collision of motor vehicle with train, initial encounter	Diagnosis	ICD-10-CM
X82.1XXD	Intentional collision of motor vehicle with train, subsequent encounter	Diagnosis	ICD-10-CM
X82.1XXS	Intentional collision of motor vehicle with train, sequela	Diagnosis	ICD-10-CM
X82.2	Intentional collision of motor vehicle with tree	Diagnosis	ICD-10-CM
X82.2XXA	Intentional collision of motor vehicle with tree, initial encounter	Diagnosis	ICD-10-CM
X82.2XXD	Intentional collision of motor vehicle with tree, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
X82.2XXS	Intentional collision of motor vehicle with tree, sequela	Diagnosis	ICD-10-CM
X82.8	Other intentional self-harm by crashing of motor vehicle	Diagnosis	ICD-10-CM
X82.8XXA	Other intentional self-harm by crashing of motor vehicle, initial encounter	Diagnosis	ICD-10-CM
X82.8XXD	Other intentional self-harm by crashing of motor vehicle, subsequent encounter	Diagnosis	ICD-10-CM
X82.8XXS	Other intentional self-harm by crashing of motor vehicle, sequela	Diagnosis	ICD-10-CM
X83	Intentional self-harm by other specified means	Diagnosis	ICD-10-CM
X83.0	Intentional self-harm by crashing of aircraft	Diagnosis	ICD-10-CM
X83.0XXA	Intentional self-harm by crashing of aircraft, initial encounter	Diagnosis	ICD-10-CM
X83.0XXD	Intentional self-harm by crashing of aircraft, subsequent encounter	Diagnosis	ICD-10-CM
X83.0XXS	Intentional self-harm by crashing of aircraft, sequela	Diagnosis	ICD-10-CM
X83.1	Intentional self-harm by electrocution	Diagnosis	ICD-10-CM
X83.1XXA	Intentional self-harm by electrocution, initial encounter	Diagnosis	ICD-10-CM
X83.1XXD	Intentional self-harm by electrocution, subsequent encounter	Diagnosis	ICD-10-CM
X83.1XXS	Intentional self-harm by electrocution, sequela	Diagnosis	ICD-10-CM
X83.2	Intentional self-harm by exposure to extremes of cold	Diagnosis	ICD-10-CM
X83.2XXA	Intentional self-harm by exposure to extremes of cold, initial encounter	Diagnosis	ICD-10-CM
X83.2XXD	Intentional self-harm by exposure to extremes of cold, subsequent encounter	Diagnosis	ICD-10-CM
X83.2XXS	Intentional self-harm by exposure to extremes of cold, sequela	Diagnosis	ICD-10-CM
X83.8	Intentional self-harm by other specified means	Diagnosis	ICD-10-CM
X83.8XXA	Intentional self-harm by other specified means, initial encounter	Diagnosis	ICD-10-CM
X83.8XXD	Intentional self-harm by other specified means, subsequent encounter	Diagnosis	ICD-10-CM
X83.8XXS	Intentional self-harm by other specified means, sequela	Diagnosis	ICD-10-CM
Psychiatric drug dispensings			
80184	Phenobarbital	Procedure	CPT-4
C9035	Injection, aripiprazole lauroxil (Aristada Initio), 1 mg	Procedure	HCPCS
C9037	Injection, risperidone (Perseris), 0.5 mg	Procedure	HCPCS
C9055	Injection, brexanolone, 1 mg	Procedure	HCPCS
C9470	Injection, aripiprazole lauroxil, 1 mg	Procedure	HCPCS
C9497	Loxapine, inhalation powder, 10 mg	Procedure	HCPCS
G2082	Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of up to 56 mg of esketamine nasal self administration, includes 2 hours post administration observation	Procedure	HCPCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
G2083	Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self administration, includes 2 hours post administration observation	Procedure	HCPCS
J0400	Injection, aripiprazole, intramuscular, 0.25 mg	Procedure	HCPCS
J0401	Injection, aripiprazole, extended release, 1 mg	Procedure	HCPCS
J1320	Injection, amitriptyline HCl, up to 20 mg	Procedure	HCPCS
J1630	Injection, haloperidol, up to 5 mg	Procedure	HCPCS
J1631	Injection, haloperidol decanoate, per 50 mg	Procedure	HCPCS
J1632	Injection, brexanolone, 1 mg	Procedure	HCPCS
J1790	Injection, droperidol, up to 5 mg	Procedure	HCPCS
J1810	Injection, droperidol and fentanyl citrate, up to 2 ml ampule	Procedure	HCPCS
J1942	Injection, aripiprazole lauroxil, 1 mg	Procedure	HCPCS
J1990	Injection, chlordiazepoxide HCl, up to 100 mg	Procedure	HCPCS
J2060	Injection, lorazepam, 2 mg	Procedure	HCPCS
J2062	Loxapine for inhalation, 1 mg	Procedure	HCPCS
J2358	Injection, olanzapine, long-acting, 1 mg	Procedure	HCPCS
J2426	Injection, paliperidone palmitate extended release, 1 mg	Procedure	HCPCS
J2515	Injection, pentobarbital sodium, per 50 mg	Procedure	HCPCS
J2560	Injection, phenobarbital sodium, up to 120 mg	Procedure	HCPCS
J2561	Injection, phenobarbital sodium (Sezaby), 1 mg	Procedure	HCPCS
J2680	Injection, fluphenazine decanoate, up to 25 mg	Procedure	HCPCS
J2794	Injection, risperidone (RISPERDAL CONSTA), 0.5 mg	Procedure	HCPCS
J3230	Injection, chlorpromazine HCl, up to 50 mg	Procedure	HCPCS
J3310	Injection, perphenazine, up to 5 mg	Procedure	HCPCS
J3360	Injection, diazepam, up to 5 mg	Procedure	HCPCS
J3486	Injection, ziprasidone mesylate, 10 mg	Procedure	HCPCS
S0013	Esketamine, nasal spray, 1 mg	Procedure	HCPCS
S0136	Clozapine, 25 mg	Procedure	HCPCS
S0160	Dextroamphetamine sulfate, 5 mg	Procedure	HCPCS
S0166	Injection, olanzapine, 2.5 mg	Procedure	HCPCS
S0183	Prochlorperazine maleate, oral, 5 mg (for circumstances falling under the Medicare statute, use Q0164)	Procedure	HCPCS
Attention deficit hyperactivity disorder			
314	Hyperkinetic syndrome of childhood	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
314.0	Attention deficit disorder of childhood	Diagnosis	ICD-9-CM
314.00	Attention deficit disorder of childhood without mention of hyperactivity	Diagnosis	ICD-9-CM
314.01	Attention deficit disorder of childhood with hyperactivity	Diagnosis	ICD-9-CM
314.1	Hyperkinesis of childhood with developmental delay	Diagnosis	ICD-9-CM
314.2	Hyperkinetic conduct disorder of childhood	Diagnosis	ICD-9-CM
314.8	Other specified manifestations of hyperkinetic syndrome of childhood	Diagnosis	ICD-9-CM
314.9	Unspecified hyperkinetic syndrome of childhood	Diagnosis	ICD-9-CM
F90.0	Attention-deficit hyperactivity disorder, predominantly inattentive type	Diagnosis	ICD-10-CM
F90.1	Attention-deficit hyperactivity disorder, predominantly hyperactive type	Diagnosis	ICD-10-CM
F90.2	Attention-deficit hyperactivity disorder, combined type	Diagnosis	ICD-10-CM
F90.8	Attention-deficit hyperactivity disorder, other type	Diagnosis	ICD-10-CM
F90.9	Attention-deficit hyperactivity disorder, unspecified type	Diagnosis	ICD-10-CM
Akathisia			
333.99	Other extrapyramidal disease and abnormal movement disorder	Diagnosis	ICD-9-CM
G25.70	Drug induced movement disorder, unspecified	Diagnosis	ICD-10-CM
G25.71	Drug induced akathisia	Diagnosis	ICD-10-CM
G25.79	Other drug induced movement disorders	Diagnosis	ICD-10-CM
G25.89	Other specified extrapyramidal and movement disorders	Diagnosis	ICD-10-CM
G25.9	Extrapyramidal and movement disorder, unspecified	Diagnosis	ICD-10-CM
G26	Extrapyramidal and movement disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
Anxiety			
293.84	Anxiety disorder in conditions classified elsewhere	Diagnosis	ICD-9-CM
300.0	Anxiety states	Diagnosis	ICD-9-CM
300.00	Anxiety state, unspecified	Diagnosis	ICD-9-CM
300.01	Panic disorder without agoraphobia	Diagnosis	ICD-9-CM
300.02	Generalized anxiety disorder	Diagnosis	ICD-9-CM
300.09	Other anxiety states	Diagnosis	ICD-9-CM
300.10	Hysteria, unspecified	Diagnosis	ICD-9-CM
300.2	Phobic disorders	Diagnosis	ICD-9-CM
300.20	Phobia, unspecified	Diagnosis	ICD-9-CM
300.21	Agoraphobia with panic disorder	Diagnosis	ICD-9-CM
300.22	Agoraphobia without mention of panic attacks	Diagnosis	ICD-9-CM
300.23	Social phobia	Diagnosis	ICD-9-CM
300.29	Other isolated or specific phobias	Diagnosis	ICD-9-CM
300.5	Neurasthenia	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
300.89	Other somatoform disorders	Diagnosis	ICD-9-CM
300.9	Unspecified nonpsychotic mental disorder	Diagnosis	ICD-9-CM
308.0	Predominant disturbance of emotions	Diagnosis	ICD-9-CM
308.1	Predominant disturbance of consciousness as reaction to stress	Diagnosis	ICD-9-CM
308.2	Predominant psychomotor disturbance as reaction to stress	Diagnosis	ICD-9-CM
308.3	Other acute reactions to stress	Diagnosis	ICD-9-CM
308.4	Mixed disorders as reaction to stress	Diagnosis	ICD-9-CM
308.9	Unspecified acute reaction to stress	Diagnosis	ICD-9-CM
313.0	Overanxious disorder specific to childhood and adolescence	Diagnosis	ICD-9-CM
313.1	Misery and unhappiness disorder specific to childhood and adolescence	Diagnosis	ICD-9-CM
313.21	Shyness disorder of childhood	Diagnosis	ICD-9-CM
313.22	Introverted disorder of childhood	Diagnosis	ICD-9-CM
313.3	Relationship problems specific to childhood and adolescence	Diagnosis	ICD-9-CM
313.82	Identity disorder of childhood or adolescence	Diagnosis	ICD-9-CM
313.83	Academic underachievement disorder of childhood or adolescence	Diagnosis	ICD-9-CM
F06.4	Anxiety disorder due to known physiological condition	Diagnosis	ICD-10-CM
F40.00	Agoraphobia, unspecified	Diagnosis	ICD-10-CM
F40.01	Agoraphobia with panic disorder	Diagnosis	ICD-10-CM
F40.02	Agoraphobia without panic disorder	Diagnosis	ICD-10-CM
F40.10	Social phobia, unspecified	Diagnosis	ICD-10-CM
F40.11	Social phobia, generalized	Diagnosis	ICD-10-CM
F40.210	Arachnophobia	Diagnosis	ICD-10-CM
F40.218	Other animal type phobia	Diagnosis	ICD-10-CM
F40.220	Fear of thunderstorms	Diagnosis	ICD-10-CM
F40.228	Other natural environment type phobia	Diagnosis	ICD-10-CM
F40.230	Fear of blood	Diagnosis	ICD-10-CM
F40.231	Fear of injections and transfusions	Diagnosis	ICD-10-CM
F40.232	Fear of other medical care	Diagnosis	ICD-10-CM
F40.233	Fear of injury	Diagnosis	ICD-10-CM
F40.240	Claustrophobia	Diagnosis	ICD-10-CM
F40.241	Acrophobia	Diagnosis	ICD-10-CM
F40.242	Fear of bridges	Diagnosis	ICD-10-CM
F40.243	Fear of flying	Diagnosis	ICD-10-CM
F40.248	Other situational type phobia	Diagnosis	ICD-10-CM
F40.290	Androphobia	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F40.291	Gynephobia	Diagnosis	ICD-10-CM
F40.298	Other specified phobia	Diagnosis	ICD-10-CM
F40.8	Other phobic anxiety disorders	Diagnosis	ICD-10-CM
F40.9	Phobic anxiety disorder, unspecified	Diagnosis	ICD-10-CM
F41.0	Panic disorder [episodic paroxysmal anxiety]	Diagnosis	ICD-10-CM
F41.1	Generalized anxiety disorder	Diagnosis	ICD-10-CM
F41.3	Other mixed anxiety disorders	Diagnosis	ICD-10-CM
F41.8	Other specified anxiety disorders	Diagnosis	ICD-10-CM
F41.9	Anxiety disorder, unspecified	Diagnosis	ICD-10-CM
F42	Obsessive-compulsive disorder	Diagnosis	ICD-10-CM
F42.2	Mixed obsessional thoughts and acts	Diagnosis	ICD-10-CM
F42.3	Hoarding disorder	Diagnosis	ICD-10-CM
F42.4	Excoriation (skin-picking) disorder	Diagnosis	ICD-10-CM
F43.0	Acute stress reaction	Diagnosis	ICD-10-CM
F44.9	Dissociative and conversion disorder, unspecified	Diagnosis	ICD-10-CM
F45.8	Other somatoform disorders	Diagnosis	ICD-10-CM
F48.8	Other specified nonpsychotic mental disorders	Diagnosis	ICD-10-CM
F48.9	Nonpsychotic mental disorder, unspecified	Diagnosis	ICD-10-CM
F93.8	Other childhood emotional disorders	Diagnosis	ICD-10-CM
F99	Mental disorder, not otherwise specified	Diagnosis	ICD-10-CM
R45.2	Unhappiness	Diagnosis	ICD-10-CM
R45.5	Hostility	Diagnosis	ICD-10-CM
R45.6	Violent behavior	Diagnosis	ICD-10-CM
R45.7	State of emotional shock and stress, unspecified	Diagnosis	ICD-10-CM
Behavioral Disorder			
300.11	Conversion disorder	Diagnosis	ICD-9-CM
300.12	Dissociative amnesia	Diagnosis	ICD-9-CM
300.13	Dissociative fugue	Diagnosis	ICD-9-CM
300.14	Dissociative identity disorder	Diagnosis	ICD-9-CM
300.15	Dissociative disorder or reaction, unspecified	Diagnosis	ICD-9-CM
300.16	Factitious disorder with predominantly psychological signs and symptoms	Diagnosis	ICD-9-CM
300.19	Other and unspecified factitious illness	Diagnosis	ICD-9-CM
300.6	Depersonalization disorder	Diagnosis	ICD-9-CM
300.7	Hypochondriasis	Diagnosis	ICD-9-CM
300.81	Somatization disorder	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
300.82	Undifferentiated somatoform disorder	Diagnosis	ICD-9-CM
301.10	Affective personality disorder, unspecified	Diagnosis	ICD-9-CM
302.1	Zoophilia	Diagnosis	ICD-9-CM
302.2	Pedophilia	Diagnosis	ICD-9-CM
302.3	Transvestic fetishism	Diagnosis	ICD-9-CM
302.4	Exhibitionism	Diagnosis	ICD-9-CM
302.50	Trans-sexualism with unspecified sexual history	Diagnosis	ICD-9-CM
302.51	Trans-sexualism with asexual history	Diagnosis	ICD-9-CM
302.52	Trans-sexualism with homosexual history	Diagnosis	ICD-9-CM
302.53	Trans-sexualism with heterosexual history	Diagnosis	ICD-9-CM
302.6	Gender identity disorder in children	Diagnosis	ICD-9-CM
302.70	Psychosexual dysfunction, unspecified	Diagnosis	ICD-9-CM
302.71	Hypoactive sexual desire disorder	Diagnosis	ICD-9-CM
302.72	Psychosexual dysfunction with inhibited sexual excitement	Diagnosis	ICD-9-CM
302.73	Female orgasmic disorder	Diagnosis	ICD-9-CM
302.74	Male orgasmic disorder	Diagnosis	ICD-9-CM
302.75	Premature ejaculation	Diagnosis	ICD-9-CM
302.76	Dyspareunia, psychogenic	Diagnosis	ICD-9-CM
302.79	Psychosexual dysfunction with other specified psychosexual dysfunctions	Diagnosis	ICD-9-CM
302.81	Fetishism	Diagnosis	ICD-9-CM
302.82	Voyeurism	Diagnosis	ICD-9-CM
302.83	Sexual masochism	Diagnosis	ICD-9-CM
302.84	Sexual sadism	Diagnosis	ICD-9-CM
302.85	Gender identity disorder in adolescents or adults	Diagnosis	ICD-9-CM
302.89	Other specified psychosexual disorder	Diagnosis	ICD-9-CM
302.9	Unspecified psychosexual disorder	Diagnosis	ICD-9-CM
306.0	Musculoskeletal malfunction arising from mental factors	Diagnosis	ICD-9-CM
306.1	Respiratory malfunction arising from mental factors	Diagnosis	ICD-9-CM
306.2	Cardiovascular malfunction arising from mental factors	Diagnosis	ICD-9-CM
306.3	Skin malfunction arising from mental factors	Diagnosis	ICD-9-CM
306.4	Gastrointestinal malfunction arising from mental factors	Diagnosis	ICD-9-CM
306.50	Psychogenic genitourinary malfunction, unspecified	Diagnosis	ICD-9-CM
306.51	Psychogenic vaginismus	Diagnosis	ICD-9-CM
306.52	Psychogenic dysmenorrhea	Diagnosis	ICD-9-CM
306.53	Psychogenic dysuria	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
306.59	Other genitourinary malfunction arising from mental factors	Diagnosis	ICD-9-CM
306.6	Endocrine malfunction arising from mental factors	Diagnosis	ICD-9-CM
306.7	Malfunction of organs of special sense arising from mental factors	Diagnosis	ICD-9-CM
306.8	Other specified psychophysiological malfunction	Diagnosis	ICD-9-CM
306.9	Unspecified psychophysiological malfunction	Diagnosis	ICD-9-CM
307.1	Anorexia nervosa	Diagnosis	ICD-9-CM
307.50	Eating disorder, unspecified	Diagnosis	ICD-9-CM
307.51	Bulimia nervosa	Diagnosis	ICD-9-CM
307.52	Pica	Diagnosis	ICD-9-CM
307.53	Rumination disorder	Diagnosis	ICD-9-CM
307.54	Psychogenic vomiting	Diagnosis	ICD-9-CM
307.59	Other disorder of eating	Diagnosis	ICD-9-CM
307.80	Psychogenic pain, site unspecified	Diagnosis	ICD-9-CM
307.81	Tension headache	Diagnosis	ICD-9-CM
307.89	Other pain disorder related to psychological factors	Diagnosis	ICD-9-CM
309.22	Emancipation disorder of adolescence and early adult life	Diagnosis	ICD-9-CM
309.23	Specific academic or work inhibition as adjustment reaction	Diagnosis	ICD-9-CM
309.24	Adjustment disorder with anxiety	Diagnosis	ICD-9-CM
309.28	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-9-CM
309.29	Other adjustment reaction with predominant disturbance of other emotions	Diagnosis	ICD-9-CM
309.3	Adjustment disorder with disturbance of conduct	Diagnosis	ICD-9-CM
309.4	Adjustment disorder with mixed disturbance of emotions and conduct	Diagnosis	ICD-9-CM
309.82	Adjustment reaction with physical symptoms	Diagnosis	ICD-9-CM
309.83	Adjustment reaction with withdrawal	Diagnosis	ICD-9-CM
309.89	Other specified adjustment reaction	Diagnosis	ICD-9-CM
309.9	Unspecified adjustment reaction	Diagnosis	ICD-9-CM
310.1	Personality change due to conditions classified elsewhere	Diagnosis	ICD-9-CM
312.32	Kleptomania	Diagnosis	ICD-9-CM
312.81	Conduct disorder, childhood onset type	Diagnosis	ICD-9-CM
312.82	Conduct disorder, adolescent onset type	Diagnosis	ICD-9-CM
313.81	Oppositional defiant disorder	Diagnosis	ICD-9-CM
316	Psychic factors associated with diseases classified elsewhere	Diagnosis	ICD-9-CM
E952.8	Suicide and self-inflicted poisoning by other specified gases and vapors	Diagnosis	ICD-9-CM
E952.9	Suicide and self-inflicted poisoning by unspecified gases and vapors	Diagnosis	ICD-9-CM
E953.0	Suicide and self-inflicted injury by hanging	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
E953.1	Suicide and self-inflicted injury by suffocation by plastic bag	Diagnosis	ICD-9-CM
E953.8	Suicide and self-inflicted injury by other specified means	Diagnosis	ICD-9-CM
E953.9	Suicide and self-inflicted injury by unspecified means	Diagnosis	ICD-9-CM
E955.1	Suicide and self-inflicted injury by shotgun	Diagnosis	ICD-9-CM
E955.2	Suicide and self-inflicted injury by hunting rifle	Diagnosis	ICD-9-CM
E955.3	Suicide and self-inflicted injury by military firearms	Diagnosis	ICD-9-CM
E955.4	Suicide and self-inflicted injury by other and unspecified firearm	Diagnosis	ICD-9-CM
E955.5	Suicide and self-inflicted injury by explosives	Diagnosis	ICD-9-CM
E955.6	Suicide and self-inflicted injury by air gun	Diagnosis	ICD-9-CM
E955.7	Suicide and self-inflicted injury by paintball gun	Diagnosis	ICD-9-CM
E955.9	Suicide and self-inflicted injury by firearms and explosives, unspecified	Diagnosis	ICD-9-CM
E957.0	Suicide and self-inflicted injuries by jumping from residential premises	Diagnosis	ICD-9-CM
E957.1	Suicide and self-inflicted injuries by jumping from other man-made structures	Diagnosis	ICD-9-CM
E957.2	Suicide and self-inflicted injuries by jumping from natural sites	Diagnosis	ICD-9-CM
E957.9	Suicide and self-inflicted injuries by jumping from unspecified site	Diagnosis	ICD-9-CM
E958.0	Suicide and self-inflicted injury by jumping or lying before moving object	Diagnosis	ICD-9-CM
E958.1	Suicide and self-inflicted injury by burns, fire	Diagnosis	ICD-9-CM
E958.2	Suicide and self-inflicted injury by scald	Diagnosis	ICD-9-CM
E958.3	Suicide and self-inflicted injury by extremes of cold	Diagnosis	ICD-9-CM
E958.4	Suicide and self-inflicted injury by electrocution	Diagnosis	ICD-9-CM
E958.5	Suicide and self-inflicted injury by crashing of motor vehicle	Diagnosis	ICD-9-CM
E958.6	Suicide and self-inflicted injury by crashing of aircraft	Diagnosis	ICD-9-CM
E958.7	Suicide and self-inflicted injury by caustic substances, except poisoning	Diagnosis	ICD-9-CM
E958.8	Suicide and self-inflicted injury by other specified means	Diagnosis	ICD-9-CM
E958.9	Suicide and self-inflicted injury by unspecified means	Diagnosis	ICD-9-CM
E959	Late effects of self-inflicted injury	Diagnosis	ICD-9-CM
F22	Delusional disorders	Diagnosis	ICD-10-CM
F23	Brief psychotic disorder	Diagnosis	ICD-10-CM
F32.8	Other depressive episodes	Diagnosis	ICD-10-CM
F32.81	Premenstrual dysphoric disorder	Diagnosis	ICD-10-CM
F34.8	Other persistent mood [affective] disorders	Diagnosis	ICD-10-CM
F43.20	Adjustment disorder, unspecified	Diagnosis	ICD-10-CM
F43.22	Adjustment disorder with anxiety	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
F43.24	Adjustment disorder with disturbance of conduct	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F43.25	Adjustment disorder with mixed disturbance of emotions and conduct	Diagnosis	ICD-10-CM
F43.29	Adjustment disorder with other symptoms	Diagnosis	ICD-10-CM
F43.8	Other reactions to severe stress	Diagnosis	ICD-10-CM
F43.9	Reaction to severe stress, unspecified	Diagnosis	ICD-10-CM
F44.0	Dissociative amnesia	Diagnosis	ICD-10-CM
F44.1	Dissociative fugue	Diagnosis	ICD-10-CM
F44.2	Dissociative stupor	Diagnosis	ICD-10-CM
F44.4	Conversion disorder with motor symptom or deficit	Diagnosis	ICD-10-CM
F44.5	Conversion disorder with seizures or convulsions	Diagnosis	ICD-10-CM
F44.6	Conversion disorder with sensory symptom or deficit	Diagnosis	ICD-10-CM
F44.7	Conversion disorder with mixed symptom presentation	Diagnosis	ICD-10-CM
F44.81	Dissociative identity disorder	Diagnosis	ICD-10-CM
F45.0	Somatization disorder	Diagnosis	ICD-10-CM
F45.1	Undifferentiated somatoform disorder	Diagnosis	ICD-10-CM
F45.20	Hypochondriacal disorder, unspecified	Diagnosis	ICD-10-CM
F45.21	Hypochondriasis	Diagnosis	ICD-10-CM
F45.22	Body dysmorphic disorder	Diagnosis	ICD-10-CM
F45.29	Other hypochondriacal disorders	Diagnosis	ICD-10-CM
F45.41	Pain disorder exclusively related to psychological factors	Diagnosis	ICD-10-CM
F45.42	Pain disorder with related psychological factors	Diagnosis	ICD-10-CM
F45.9	Somatoform disorder, unspecified	Diagnosis	ICD-10-CM
F48.1	Depersonalization-derealization syndrome	Diagnosis	ICD-10-CM
F50.00	Anorexia nervosa, unspecified	Diagnosis	ICD-10-CM
F50.01	Anorexia nervosa, restricting type	Diagnosis	ICD-10-CM
F50.02	Anorexia nervosa, binge eating/purging type	Diagnosis	ICD-10-CM
F50.2	Bulimia nervosa	Diagnosis	ICD-10-CM
F50.8	Other eating disorders	Diagnosis	ICD-10-CM
F50.81	Binge eating disorder	Diagnosis	ICD-10-CM
F50.82	Avoidant/restrictive food intake disorder	Diagnosis	ICD-10-CM
F50.89	Other specified eating disorder	Diagnosis	ICD-10-CM
F50.9	Eating disorder, unspecified	Diagnosis	ICD-10-CM
F52.0	Hypoactive sexual desire disorder	Diagnosis	ICD-10-CM
F52.1	Sexual aversion disorder	Diagnosis	ICD-10-CM
F52.21	Male erectile disorder	Diagnosis	ICD-10-CM
F52.22	Female sexual arousal disorder	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F52.31	Female orgasmic disorder	Diagnosis	ICD-10-CM
F52.32	Male orgasmic disorder	Diagnosis	ICD-10-CM
F52.4	Premature ejaculation	Diagnosis	ICD-10-CM
F52.5	Vaginismus not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F52.6	Dyspareunia not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F52.8	Other sexual dysfunction not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F52.9	Unspecified sexual dysfunction not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F53.0	Postpartum depression	Diagnosis	ICD-10-CM
F53.1	Puerperal psychosis	Diagnosis	ICD-10-CM
F54	Psychological and behavioral factors associated with disorders or diseases classified elsewhere	Diagnosis	ICD-10-CM
F59	Unspecified behavioral syndromes associated with physiological disturbances and physical factors	Diagnosis	ICD-10-CM
F60.1	Schizoid personality disorder	Diagnosis	ICD-10-CM
F60.7	Dependent personality disorder	Diagnosis	ICD-10-CM
F60.9	Personality disorder, unspecified	Diagnosis	ICD-10-CM
F63.0	Pathological gambling	Diagnosis	ICD-10-CM
F63.2	Kleptomania	Diagnosis	ICD-10-CM
F63.3	Trichotillomania	Diagnosis	ICD-10-CM
F63.9	Impulse disorder, unspecified	Diagnosis	ICD-10-CM
F64.0	Transsexualism	Diagnosis	ICD-10-CM
F64.1	Dual role transvestism	Diagnosis	ICD-10-CM
F64.8	Other gender identity disorders	Diagnosis	ICD-10-CM
F64.9	Gender identity disorder, unspecified	Diagnosis	ICD-10-CM
F65.0	Fetishism	Diagnosis	ICD-10-CM
F65.1	Transvestic fetishism	Diagnosis	ICD-10-CM
F65.2	Exhibitionism	Diagnosis	ICD-10-CM
F65.3	Voyeurism	Diagnosis	ICD-10-CM
F65.4	Pedophilia	Diagnosis	ICD-10-CM
F65.50	Sadomasochism, unspecified	Diagnosis	ICD-10-CM
F65.51	Sexual masochism	Diagnosis	ICD-10-CM
F65.52	Sexual sadism	Diagnosis	ICD-10-CM
F65.81	Frotteurism	Diagnosis	ICD-10-CM
F65.89	Other paraphilias	Diagnosis	ICD-10-CM
F65.9	Paraphilia, unspecified	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F68.10	Factitious disorder imposed on self, unspecified	Diagnosis	ICD-10-CM
F68.11	Factitious disorder imposed on self, with predominantly psychological signs and symptoms	Diagnosis	ICD-10-CM
F68.12	Factitious disorder imposed on self, with predominantly physical signs and symptoms	Diagnosis	ICD-10-CM
F68.13	Factitious disorder imposed on self, with combined psychological and physical signs and symptoms	Diagnosis	ICD-10-CM
F68.8	Other specified disorders of adult personality and behavior	Diagnosis	ICD-10-CM
F68.A	Factitious disorder imposed on another	Diagnosis	ICD-10-CM
F69	Unspecified disorder of adult personality and behavior	Diagnosis	ICD-10-CM
F91.0	Conduct disorder confined to family context	Diagnosis	ICD-10-CM
F91.1	Conduct disorder, childhood-onset type	Diagnosis	ICD-10-CM
F91.2	Conduct disorder, adolescent-onset type	Diagnosis	ICD-10-CM
F91.3	Oppositional defiant disorder	Diagnosis	ICD-10-CM
F91.8	Other conduct disorders	Diagnosis	ICD-10-CM
F91.9	Conduct disorder, unspecified	Diagnosis	ICD-10-CM
O90.6	Postpartum mood disturbance	Diagnosis	ICD-10-CM
R37	Sexual dysfunction, unspecified	Diagnosis	ICD-10-CM
R45.3	Demoralization and apathy	Diagnosis	ICD-10-CM
R45.4	Irritability and anger	Diagnosis	ICD-10-CM
R45.81	Low self-esteem	Diagnosis	ICD-10-CM
R45.82	Worries	Diagnosis	ICD-10-CM
R45.83	Excessive crying of child, adolescent or adult	Diagnosis	ICD-10-CM
R45.84	Anhedonia	Diagnosis	ICD-10-CM
R45.850	Homicidal ideations	Diagnosis	ICD-10-CM
R45.851	Suicidal ideations	Diagnosis	ICD-10-CM
R45.86	Emotional lability	Diagnosis	ICD-10-CM
R45.89	Other symptoms and signs involving emotional state	Diagnosis	ICD-10-CM
R46.0	Very low level of personal hygiene	Diagnosis	ICD-10-CM
R46.1	Bizarre personal appearance	Diagnosis	ICD-10-CM
R46.2	Strange and inexplicable behavior	Diagnosis	ICD-10-CM
R46.3	Overactivity	Diagnosis	ICD-10-CM
R46.4	Slowness and poor responsiveness	Diagnosis	ICD-10-CM
R46.5	Suspiciousness and marked evasiveness	Diagnosis	ICD-10-CM
R46.6	Undue concern and preoccupation with stressful events	Diagnosis	ICD-10-CM
R46.7	Verbosity and circumstantial detail obscuring reason for contact	Diagnosis	ICD-10-CM
R46.81	Obsessive-compulsive behavior	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
R46.89	Other symptoms and signs involving appearance and behavior	Diagnosis	ICD-10-CM
T14.91	Suicide attempt	Diagnosis	ICD-10-CM
T14.91XA	Suicide attempt, initial encounter	Diagnosis	ICD-10-CM
T14.91XD	Suicide attempt, subsequent encounter	Diagnosis	ICD-10-CM
T14.91XS	Suicide attempt, sequela	Diagnosis	ICD-10-CM
T36.0X2D	Poisoning by penicillins, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.0X2S	Poisoning by penicillins, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.1X2D	Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.1X2S	Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.2X2D	Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.2X2S	Poisoning by chloramphenicol group, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.3X2D	Poisoning by macrolides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.3X2S	Poisoning by macrolides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.4X2D	Poisoning by tetracyclines, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.4X2S	Poisoning by tetracyclines, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.5X2D	Poisoning by aminoglycosides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.5X2S	Poisoning by aminoglycosides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.6X2D	Poisoning by rifampicins, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.6X2S	Poisoning by rifampicins, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.7X2D	Poisoning by antifungal antibiotics, systemically used, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.7X2S	Poisoning by antifungal antibiotics, systemically used, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.8X2D	Poisoning by other systemic antibiotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.8X2S	Poisoning by other systemic antibiotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T36.92XD	Poisoning by unspecified systemic antibiotic, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T36.92XS	Poisoning by unspecified systemic antibiotic, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T37.0X2D	Poisoning by sulfonamides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.0X2S	Poisoning by sulfonamides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T37.1X2D	Poisoning by antimycobacterial drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.1X2S	Poisoning by antimycobacterial drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T37.2X2D	Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.2X2S	Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T37.3X2D	Poisoning by other antiprotozoal drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.3X2S	Poisoning by other antiprotozoal drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T37.4X2D	Poisoning by anthelminthics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.4X2S	Poisoning by anthelminthics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T37.5X2D	Poisoning by antiviral drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.5X2S	Poisoning by antiviral drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T37.8X2D	Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.8X2S	Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T37.92XD	Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T37.92XS	Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.0X2D	Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.0X2S	Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.1X2D	Poisoning by thyroid hormones and substitutes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.1X2S	Poisoning by thyroid hormones and substitutes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.2X2D	Poisoning by antithyroid drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.2X2S	Poisoning by antithyroid drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.3X2D	Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.3X2S	Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.4X2D	Poisoning by oral contraceptives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.4X2S	Poisoning by oral contraceptives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.5X2D	Poisoning by other estrogens and progestogens, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.5X2S	Poisoning by other estrogens and progestogens, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.6X2D	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.6X2S	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.7X2D	Poisoning by androgens and anabolic congeners, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.7X2S	Poisoning by androgens and anabolic congeners, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T38.802D	Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.802S	Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.812D	Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.812S	Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.892D	Poisoning by other hormones and synthetic substitutes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.892S	Poisoning by other hormones and synthetic substitutes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.902D	Poisoning by unspecified hormone antagonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.902S	Poisoning by unspecified hormone antagonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T38.992D	Poisoning by other hormone antagonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T38.992S	Poisoning by other hormone antagonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.012D	Poisoning by aspirin, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.012S	Poisoning by aspirin, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.092D	Poisoning by salicylates, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.092S	Poisoning by salicylates, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.1X2D	Poisoning by 4-Aminophenol derivatives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.1X2S	Poisoning by 4-Aminophenol derivatives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.2X2D	Poisoning by pyrazolone derivatives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.2X2S	Poisoning by pyrazolone derivatives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.312D	Poisoning by propionic acid derivatives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.312S	Poisoning by propionic acid derivatives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.392D	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.392S	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.4X2D	Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.4X2S	Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T39.8X2D	Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.8X2S	Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T39.92XD	Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T39.92XS	Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.0X2D	Poisoning by opium, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.0X2S	Poisoning by opium, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.1X2D	Poisoning by heroin, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.1X2S	Poisoning by heroin, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.2X2D	Poisoning by other opioids, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.2X2S	Poisoning by other opioids, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.3X2D	Poisoning by methadone, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.3X2S	Poisoning by methadone, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.4X2D	Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.4X2S	Poisoning by other synthetic narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.5X2A	Poisoning by cocaine, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.5X2D	Poisoning by cocaine, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.5X2S	Poisoning by cocaine, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.602D	Poisoning by unspecified narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.602S	Poisoning by unspecified narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.692D	Poisoning by other narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.692S	Poisoning by other narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.7X2D	Poisoning by cannabis (derivatives), intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.7X2S	Poisoning by cannabis (derivatives), intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.8X2D	Poisoning by lysergide [LSD], intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.8X2S	Poisoning by lysergide [LSD], intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.902D	Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.902S	Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.992D	Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.992S	Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, sequela	Diagnosis	ICD-10-CM
T41.0X2D	Poisoning by inhaled anesthetics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T41.0X2S	Poisoning by inhaled anesthetics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T41.1X2D	Poisoning by intravenous anesthetics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T41.1X2S	Poisoning by intravenous anesthetics, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T41.202D	Poisoning by unspecified general anesthetics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T41.202S	Poisoning by unspecified general anesthetics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T41.292D	Poisoning by other general anesthetics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T41.292S	Poisoning by other general anesthetics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T41.3X2D	Poisoning by local anesthetics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T41.3X2S	Poisoning by local anesthetics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T41.42XD	Poisoning by unspecified anesthetic, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T41.42XS	Poisoning by unspecified anesthetic, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T41.5X2A	Poisoning by therapeutic gases, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T41.5X2D	Poisoning by therapeutic gases, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T41.5X2S	Poisoning by therapeutic gases, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.0X2D	Poisoning by hydantoin derivatives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.0X2S	Poisoning by hydantoin derivatives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.1X2D	Poisoning by iminostilbenes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.1X2S	Poisoning by iminostilbenes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.2X2D	Poisoning by succinimides and oxazolidinediones, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.2X2S	Poisoning by succinimides and oxazolidinediones, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.3X2D	Poisoning by barbiturates, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.3X2S	Poisoning by barbiturates, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.4X2D	Poisoning by benzodiazepines, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.4X2S	Poisoning by benzodiazepines, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.5X2D	Poisoning by mixed antiepileptics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.5X2S	Poisoning by mixed antiepileptics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.6X2D	Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.6X2S	Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.72XD	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.72XS	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T42.8X2D	Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T42.8X2S	Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T43.012D	Poisoning by tricyclic antidepressants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.012S	Poisoning by tricyclic antidepressants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.022D	Poisoning by tetracyclic antidepressants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.022S	Poisoning by tetracyclic antidepressants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.1X2D	Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.1X2S	Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.202D	Poisoning by unspecified antidepressants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.202S	Poisoning by unspecified antidepressants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.212D	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.212S	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.222D	Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.222S	Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.292D	Poisoning by other antidepressants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.292S	Poisoning by other antidepressants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.3X2D	Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.3X2S	Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.4X2D	Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.4X2S	Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.502D	Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.502S	Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.592D	Poisoning by other antipsychotics and neuroleptics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.592S	Poisoning by other antipsychotics and neuroleptics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.602D	Poisoning by unspecified psychostimulants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.602S	Poisoning by unspecified psychostimulants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.612D	Poisoning by caffeine, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.612S	Poisoning by caffeine, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.622D	Poisoning by amphetamines, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T43.622S	Poisoning by amphetamines, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.632D	Poisoning by methylphenidate, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.632S	Poisoning by methylphenidate, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.692D	Poisoning by other psychostimulants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.692S	Poisoning by other psychostimulants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.8X2D	Poisoning by other psychotropic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.8X2S	Poisoning by other psychotropic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T43.92XD	Poisoning by unspecified psychotropic drug, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T43.92XS	Poisoning by unspecified psychotropic drug, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.0X2A	Poisoning by anticholinesterase agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.0X2D	Poisoning by anticholinesterase agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.0X2S	Poisoning by anticholinesterase agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.1X2A	Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.1X2D	Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.1X2S	Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.2X2A	Poisoning by ganglionic blocking drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.2X2D	Poisoning by ganglionic blocking drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.2X2S	Poisoning by ganglionic blocking drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.3X2A	Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.3X2D	Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.3X2S	Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.4X2A	Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.4X2D	Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.4X2S	Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.5X2A	Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.5X2D	Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T44.5X2S	Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.6X2A	Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.6X2D	Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.6X2S	Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.7X2A	Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.7X2D	Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.7X2S	Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.8X2A	Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.8X2D	Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.8X2S	Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.902A	Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.902D	Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.902S	Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T44.992A	Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T44.992D	Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T44.992S	Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.0X2D	Poisoning by antiallergic and antiemetic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.0X2S	Poisoning by antiallergic and antiemetic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.1X2D	Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.1X2S	Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.2X2D	Poisoning by vitamins, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.2X2S	Poisoning by vitamins, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.3X2D	Poisoning by enzymes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.3X2S	Poisoning by enzymes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.4X2D	Poisoning by iron and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T45.4X2S	Poisoning by iron and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.512D	Poisoning by anticoagulants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.512S	Poisoning by anticoagulants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.522D	Poisoning by antithrombotic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.522S	Poisoning by antithrombotic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.602D	Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.602S	Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.612D	Poisoning by thrombolytic drug, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.612S	Poisoning by thrombolytic drug, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.622D	Poisoning by hemostatic drug, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.622S	Poisoning by hemostatic drug, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.692D	Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.692S	Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.7X2D	Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.7X2S	Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.8X2D	Poisoning by other primarily systemic and hematological agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.8X2S	Poisoning by other primarily systemic and hematological agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T45.92XD	Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T45.92XS	Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.0X2A	Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.0X2D	Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.0X2S	Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.1X2A	Poisoning by calcium-channel blockers, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.1X2D	Poisoning by calcium-channel blockers, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.1X2S	Poisoning by calcium-channel blockers, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T46.2X2A	Poisoning by other antidysrhythmic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.2X2D	Poisoning by other antidysrhythmic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.2X2S	Poisoning by other antidysrhythmic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.3X2A	Poisoning by coronary vasodilators, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.3X2D	Poisoning by coronary vasodilators, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.3X2S	Poisoning by coronary vasodilators, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.4X2A	Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.4X2D	Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.4X2S	Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.5X2A	Poisoning by other antihypertensive drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.5X2D	Poisoning by other antihypertensive drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.5X2S	Poisoning by other antihypertensive drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.6X2A	Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.6X2D	Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.6X2S	Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.7X2A	Poisoning by peripheral vasodilators, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.7X2D	Poisoning by peripheral vasodilators, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.7X2S	Poisoning by peripheral vasodilators, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.8X2A	Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.8X2D	Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.8X2S	Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.902A	Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T46.902D	Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.902S	Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T46.992A	Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T46.992D	Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T46.992S	Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.0X2A	Poisoning by histamine H2-receptor blockers, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.0X2D	Poisoning by histamine H2-receptor blockers, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.0X2S	Poisoning by histamine H2-receptor blockers, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.1X2A	Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.1X2D	Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.1X2S	Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.2X2A	Poisoning by stimulant laxatives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.2X2D	Poisoning by stimulant laxatives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.2X2S	Poisoning by stimulant laxatives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.3X2A	Poisoning by saline and osmotic laxatives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.3X2D	Poisoning by saline and osmotic laxatives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.3X2S	Poisoning by saline and osmotic laxatives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.4X2A	Poisoning by other laxatives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.4X2D	Poisoning by other laxatives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.4X2S	Poisoning by other laxatives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.5X2A	Poisoning by digestants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.5X2D	Poisoning by digestants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.5X2S	Poisoning by digestants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.6X2A	Poisoning by antidiarrheal drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.6X2D	Poisoning by antidiarrheal drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.6X2S	Poisoning by antidiarrheal drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.7X2A	Poisoning by emetics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.7X2D	Poisoning by emetics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.7X2S	Poisoning by emetics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.8X2A	Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.8X2D	Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T47.8X2S	Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T47.92XA	Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T47.92XD	Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T47.92XS	Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.0X2A	Poisoning by oxytocic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.0X2D	Poisoning by oxytocic drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.0X2S	Poisoning by oxytocic drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.1X2A	Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.1X2D	Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.1X2S	Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.202A	Poisoning by unspecified drugs acting on muscles, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.202D	Poisoning by unspecified drugs acting on muscles, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.202S	Poisoning by unspecified drugs acting on muscles, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.292A	Poisoning by other drugs acting on muscles, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.292D	Poisoning by other drugs acting on muscles, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.292S	Poisoning by other drugs acting on muscles, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.3X2A	Poisoning by antitussives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.3X2D	Poisoning by antitussives, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.3X2S	Poisoning by antitussives, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.4X2A	Poisoning by expectorants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.4X2D	Poisoning by expectorants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.4X2S	Poisoning by expectorants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.5X2A	Poisoning by other anti-common-cold drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.5X2D	Poisoning by other anti-common-cold drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.5X2S	Poisoning by other anti-common-cold drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.6X2A	Poisoning by antiasthmatics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.6X2D	Poisoning by antiasthmatics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T48.6X2S	Poisoning by antiasthmatics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.902A	Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.902D	Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.902S	Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T48.992A	Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T48.992D	Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T48.992S	Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.0X2A	Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.0X2D	Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.0X2S	Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.1X2A	Poisoning by antipruritics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.1X2D	Poisoning by antipruritics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.1X2S	Poisoning by antipruritics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.2X2A	Poisoning by local astringents and local detergents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.2X2D	Poisoning by local astringents and local detergents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.2X2S	Poisoning by local astringents and local detergents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.3X2A	Poisoning by emollients, demulcents and protectants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.3X2D	Poisoning by emollients, demulcents and protectants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.3X2S	Poisoning by emollients, demulcents and protectants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.4X2A	Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.4X2D	Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T49.4X2S	Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.5X2A	Poisoning by ophthalmological drugs and preparations, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.5X2D	Poisoning by ophthalmological drugs and preparations, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.5X2S	Poisoning by ophthalmological drugs and preparations, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.6X2A	Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.6X2D	Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.6X2S	Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.7X2A	Poisoning by dental drugs, topically applied, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.7X2D	Poisoning by dental drugs, topically applied, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.7X2S	Poisoning by dental drugs, topically applied, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.8X2A	Poisoning by other topical agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.8X2D	Poisoning by other topical agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.8X2S	Poisoning by other topical agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T49.92XA	Poisoning by unspecified topical agent, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T49.92XD	Poisoning by unspecified topical agent, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T49.92XS	Poisoning by unspecified topical agent, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.0X2D	Poisoning by mineralocorticoids and their antagonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.0X2S	Poisoning by mineralocorticoids and their antagonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.1X2A	Poisoning by loop [high-ceiling] diuretics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.1X2D	Poisoning by loop [high-ceiling] diuretics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.1X2S	Poisoning by loop [high-ceiling] diuretics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.2X2A	Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.2X2D	Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.2X2S	Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.3X2A	Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T50.3X2D	Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.3X2S	Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.4X2A	Poisoning by drugs affecting uric acid metabolism, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.4X2D	Poisoning by drugs affecting uric acid metabolism, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.4X2S	Poisoning by drugs affecting uric acid metabolism, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.5X2A	Poisoning by appetite depressants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.5X2D	Poisoning by appetite depressants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.5X2S	Poisoning by appetite depressants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.6X2A	Poisoning by antidotes and chelating agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.6X2D	Poisoning by antidotes and chelating agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.6X2S	Poisoning by antidotes and chelating agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.7X2A	Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.7X2D	Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.7X2S	Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.8X2A	Poisoning by diagnostic agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.8X2D	Poisoning by diagnostic agents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.8X2S	Poisoning by diagnostic agents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.902A	Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.902D	Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.902S	Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.992A	Poisoning by other drugs, medicaments and biological substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.992D	Poisoning by other drugs, medicaments and biological substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.992S	Poisoning by other drugs, medicaments and biological substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.A12A	Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T50.A12D	Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.A12S	Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.A22A	Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.A22D	Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.A22S	Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.A92A	Poisoning by other bacterial vaccines, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.A92D	Poisoning by other bacterial vaccines, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.A92S	Poisoning by other bacterial vaccines, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.B12A	Poisoning by smallpox vaccines, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.B12D	Poisoning by smallpox vaccines, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.B12S	Poisoning by smallpox vaccines, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.B92A	Poisoning by other viral vaccines, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.B92D	Poisoning by other viral vaccines, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.B92S	Poisoning by other viral vaccines, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.Z12D	Poisoning by immunoglobulin, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.Z12S	Poisoning by immunoglobulin, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T50.Z92A	Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.Z92D	Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T50.Z92S	Poisoning by other vaccines and biological substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.0X2D	Toxic effect of ethanol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.0X2S	Toxic effect of ethanol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.1X2D	Toxic effect of methanol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.1X2S	Toxic effect of methanol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.2X2A	Toxic effect of 2-Propanol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.2X2D	Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.2X2S	Toxic effect of 2-Propanol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.3X2D	Toxic effect of fusel oil, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.3X2S	Toxic effect of fusel oil, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T51.8X2D	Toxic effect of other alcohols, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.8X2S	Toxic effect of other alcohols, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.92XD	Toxic effect of unspecified alcohol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.92XS	Toxic effect of unspecified alcohol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T52.0X2D	Toxic effect of petroleum products, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T52.0X2S	Toxic effect of petroleum products, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T52.1X2D	Toxic effect of benzene, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T52.1X2S	Toxic effect of benzene, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T52.2X2D	Toxic effect of homologues of benzene, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T52.2X2S	Toxic effect of homologues of benzene, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T52.3X2D	Toxic effect of glycols, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T52.3X2S	Toxic effect of glycols, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T52.4X2D	Toxic effect of ketones, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T52.4X2S	Toxic effect of ketones, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T52.8X2D	Toxic effect of other organic solvents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T52.8X2S	Toxic effect of other organic solvents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T52.92XD	Toxic effect of unspecified organic solvent, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T52.92XS	Toxic effect of unspecified organic solvent, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.0X2D	Toxic effect of carbon tetrachloride, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.0X2S	Toxic effect of carbon tetrachloride, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.1X2D	Toxic effect of chloroform, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.1X2S	Toxic effect of chloroform, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.2X2D	Toxic effect of trichloroethylene, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.2X2S	Toxic effect of trichloroethylene, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.3X2D	Toxic effect of tetrachloroethylene, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.3X2S	Toxic effect of tetrachloroethylene, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.4X2D	Toxic effect of dichloromethane, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.4X2S	Toxic effect of dichloromethane, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.5X2D	Toxic effect of chlorofluorocarbons, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.5X2S	Toxic effect of chlorofluorocarbons, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.6X2D	Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.6X2S	Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T53.7X2D	Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.7X2S	Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T53.92XD	Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T53.92XS	Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T54.0X2D	Toxic effect of phenol and phenol homologues, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T54.0X2S	Toxic effect of phenol and phenol homologues, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T54.1X2D	Toxic effect of other corrosive organic compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T54.1X2S	Toxic effect of other corrosive organic compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T54.2X2D	Toxic effect of corrosive acids and acid-like substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T54.2X2S	Toxic effect of corrosive acids and acid-like substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T54.3X2D	Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T54.3X2S	Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T54.92XD	Toxic effect of unspecified corrosive substance, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T54.92XS	Toxic effect of unspecified corrosive substance, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T55.0X2D	Toxic effect of soaps, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T55.0X2S	Toxic effect of soaps, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T55.1X2D	Toxic effect of detergents, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T55.1X2S	Toxic effect of detergents, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.0X2D	Toxic effect of lead and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.0X2S	Toxic effect of lead and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.1X2D	Toxic effect of mercury and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.1X2S	Toxic effect of mercury and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.2X2D	Toxic effect of chromium and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.2X2S	Toxic effect of chromium and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.3X2D	Toxic effect of cadmium and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.3X2S	Toxic effect of cadmium and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.4X2D	Toxic effect of copper and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.4X2S	Toxic effect of copper and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T56.5X2D	Toxic effect of zinc and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.5X2S	Toxic effect of zinc and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.6X2D	Toxic effect of tin and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.6X2S	Toxic effect of tin and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.7X2D	Toxic effect of beryllium and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.7X2S	Toxic effect of beryllium and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.812D	Toxic effect of thallium, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.812S	Toxic effect of thallium, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.892D	Toxic effect of other metals, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.892S	Toxic effect of other metals, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T56.92XD	Toxic effect of unspecified metal, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T56.92XS	Toxic effect of unspecified metal, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T57.0X2D	Toxic effect of arsenic and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T57.0X2S	Toxic effect of arsenic and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T57.1X2D	Toxic effect of phosphorus and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T57.1X2S	Toxic effect of phosphorus and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T57.2X2D	Toxic effect of manganese and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T57.2X2S	Toxic effect of manganese and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T57.3X2D	Toxic effect of hydrogen cyanide, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T57.3X2S	Toxic effect of hydrogen cyanide, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T57.8X2D	Toxic effect of other specified inorganic substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T57.8X2S	Toxic effect of other specified inorganic substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T57.92XD	Toxic effect of unspecified inorganic substance, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T57.92XS	Toxic effect of unspecified inorganic substance, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T58.02XD	Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T58.02XS	Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T58.12XD	Toxic effect of carbon monoxide from utility gas, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T58.12XS	Toxic effect of carbon monoxide from utility gas, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T58.2X2D	Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T58.2X2S	Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T58.8X2D	Toxic effect of carbon monoxide from other source, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T58.8X2S	Toxic effect of carbon monoxide from other source, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T58.92XD	Toxic effect of carbon monoxide from unspecified source, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T58.92XS	Toxic effect of carbon monoxide from unspecified source, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.0X2D	Toxic effect of nitrogen oxides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.0X2S	Toxic effect of nitrogen oxides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.1X2D	Toxic effect of sulfur dioxide, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.1X2S	Toxic effect of sulfur dioxide, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.2X2D	Toxic effect of formaldehyde, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.2X2S	Toxic effect of formaldehyde, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.3X2D	Toxic effect of lacrimogenic gas, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.3X2S	Toxic effect of lacrimogenic gas, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.4X2D	Toxic effect of chlorine gas, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.4X2S	Toxic effect of chlorine gas, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.5X2D	Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.5X2S	Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.6X2D	Toxic effect of hydrogen sulfide, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.6X2S	Toxic effect of hydrogen sulfide, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.7X2D	Toxic effect of carbon dioxide, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.7X2S	Toxic effect of carbon dioxide, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.812D	Toxic effect of smoke, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.812S	Toxic effect of smoke, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.892D	Toxic effect of other specified gases, fumes and vapors, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.892S	Toxic effect of other specified gases, fumes and vapors, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T59.92XD	Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T59.92XS	Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T60.0X2D	Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T60.0X2S	Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T60.1X2D	Toxic effect of halogenated insecticides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T60.1X2S	Toxic effect of halogenated insecticides, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T60.2X2D	Toxic effect of other insecticides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T60.2X2S	Toxic effect of other insecticides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T60.3X2D	Toxic effect of herbicides and fungicides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T60.3X2S	Toxic effect of herbicides and fungicides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T60.4X2D	Toxic effect of rodenticides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T60.4X2S	Toxic effect of rodenticides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T60.8X2D	Toxic effect of other pesticides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T60.8X2S	Toxic effect of other pesticides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T60.92XD	Toxic effect of unspecified pesticide, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T60.92XS	Toxic effect of unspecified pesticide, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T61.02XD	Ciguatera fish poisoning, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T61.02XS	Ciguatera fish poisoning, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T61.12XD	Scombroid fish poisoning, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T61.12XS	Scombroid fish poisoning, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T61.772D	Other fish poisoning, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T61.772S	Other fish poisoning, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T61.782D	Other shellfish poisoning, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T61.782S	Other shellfish poisoning, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T61.8X2D	Toxic effect of other seafood, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T61.8X2S	Toxic effect of other seafood, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T61.92XD	Toxic effect of unspecified seafood, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T61.92XS	Toxic effect of unspecified seafood, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T62.0X2D	Toxic effect of ingested mushrooms, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T62.0X2S	Toxic effect of ingested mushrooms, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T62.1X2D	Toxic effect of ingested berries, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T62.1X2S	Toxic effect of ingested berries, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T62.2X2D	Toxic effect of other ingested (parts of) plant(s), intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T62.2X2S	Toxic effect of other ingested (parts of) plant(s), intentional self-harm, sequela	Diagnosis	ICD-10-CM
T62.8X2D	Toxic effect of other specified noxious substances eaten as food, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T62.8X2S	Toxic effect of other specified noxious substances eaten as food, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T62.92XD	Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T62.92XS	Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T63.002D	Toxic effect of unspecified snake venom, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.002S	Toxic effect of unspecified snake venom, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.012D	Toxic effect of rattlesnake venom, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.012S	Toxic effect of rattlesnake venom, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.022D	Toxic effect of coral snake venom, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.022S	Toxic effect of coral snake venom, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.032D	Toxic effect of taipan venom, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.032S	Toxic effect of taipan venom, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.042D	Toxic effect of cobra venom, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.042S	Toxic effect of cobra venom, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.062D	Toxic effect of venom of other North and South American snake, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.062S	Toxic effect of venom of other North and South American snake, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.072D	Toxic effect of venom of other Australian snake, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.072S	Toxic effect of venom of other Australian snake, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.082D	Toxic effect of venom of other African and Asian snake, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.082S	Toxic effect of venom of other African and Asian snake, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.092D	Toxic effect of venom of other snake, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.092S	Toxic effect of venom of other snake, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.112D	Toxic effect of venom of gila monster, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.112S	Toxic effect of venom of gila monster, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.122D	Toxic effect of venom of other venomous lizard, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.122S	Toxic effect of venom of other venomous lizard, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.192D	Toxic effect of venom of other reptiles, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.192S	Toxic effect of venom of other reptiles, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.2X2D	Toxic effect of venom of scorpion, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.2X2S	Toxic effect of venom of scorpion, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.302D	Toxic effect of unspecified spider venom, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.302S	Toxic effect of unspecified spider venom, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.312D	Toxic effect of venom of black widow spider, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.312S	Toxic effect of venom of black widow spider, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.322D	Toxic effect of venom of tarantula, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.322S	Toxic effect of venom of tarantula, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.332D	Toxic effect of venom of brown recluse spider, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T63.332S	Toxic effect of venom of brown recluse spider, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.392D	Toxic effect of venom of other spider, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.392S	Toxic effect of venom of other spider, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.412D	Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.412S	Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.422D	Toxic effect of venom of ants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.422S	Toxic effect of venom of ants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.432D	Toxic effect of venom of caterpillars, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.432S	Toxic effect of venom of caterpillars, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.442D	Toxic effect of venom of bees, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.442S	Toxic effect of venom of bees, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.452D	Toxic effect of venom of hornets, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.452S	Toxic effect of venom of hornets, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.462D	Toxic effect of venom of wasps, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.462S	Toxic effect of venom of wasps, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.482D	Toxic effect of venom of other arthropod, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.482S	Toxic effect of venom of other arthropod, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.512D	Toxic effect of contact with stingray, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.512S	Toxic effect of contact with stingray, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.592D	Toxic effect of contact with other venomous fish, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.592S	Toxic effect of contact with other venomous fish, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.612D	Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.612S	Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.622D	Toxic effect of contact with other jellyfish, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.622S	Toxic effect of contact with other jellyfish, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.632D	Toxic effect of contact with sea anemone, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.632S	Toxic effect of contact with sea anemone, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.692D	Toxic effect of contact with other venomous marine animals, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.692S	Toxic effect of contact with other venomous marine animals, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.712D	Toxic effect of contact with venomous marine plant, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.712S	Toxic effect of contact with venomous marine plant, intentional self-harm, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T63.792D	Toxic effect of contact with other venomous plant, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.792S	Toxic effect of contact with other venomous plant, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.812D	Toxic effect of contact with venomous frog, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.812S	Toxic effect of contact with venomous frog, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.822D	Toxic effect of contact with venomous toad, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.822S	Toxic effect of contact with venomous toad, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.832D	Toxic effect of contact with other venomous amphibian, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.832S	Toxic effect of contact with other venomous amphibian, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.892D	Toxic effect of contact with other venomous animals, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.892S	Toxic effect of contact with other venomous animals, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T63.92XD	Toxic effect of contact with unspecified venomous animal, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T63.92XS	Toxic effect of contact with unspecified venomous animal, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T64.02XD	Toxic effect of aflatoxin, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T64.02XS	Toxic effect of aflatoxin, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T64.82XD	Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T64.82XS	Toxic effect of other mycotoxin food contaminants, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.0X2D	Toxic effect of cyanides, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.0X2S	Toxic effect of cyanides, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.1X2D	Toxic effect of strychnine and its salts, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.1X2S	Toxic effect of strychnine and its salts, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.212D	Toxic effect of chewing tobacco, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.212S	Toxic effect of chewing tobacco, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.222D	Toxic effect of tobacco cigarettes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.222S	Toxic effect of tobacco cigarettes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.292D	Toxic effect of other tobacco and nicotine, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.292S	Toxic effect of other tobacco and nicotine, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.3X2D	Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.3X2S	Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.4X2D	Toxic effect of carbon disulfide, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T65.4X2S	Toxic effect of carbon disulfide, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.5X2D	Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.5X2S	Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.6X2D	Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.6X2S	Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.812D	Toxic effect of latex, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.812S	Toxic effect of latex, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.822D	Toxic effect of harmful algae and algae toxins, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.822S	Toxic effect of harmful algae and algae toxins, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.832D	Toxic effect of fiberglass, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.832S	Toxic effect of fiberglass, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.892D	Toxic effect of other specified substances, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.892S	Toxic effect of other specified substances, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.92XD	Toxic effect of unspecified substance, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.92XS	Toxic effect of unspecified substance, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.112D	Asphyxiation due to smothering under pillow, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T71.112S	Asphyxiation due to smothering under pillow, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.122D	Asphyxiation due to plastic bag, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T71.122S	Asphyxiation due to plastic bag, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.132D	Asphyxiation due to being trapped in bed linens, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T71.132S	Asphyxiation due to being trapped in bed linens, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.152D	Asphyxiation due to smothering in furniture, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T71.152S	Asphyxiation due to smothering in furniture, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.162D	Asphyxiation due to hanging, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T71.162S	Asphyxiation due to hanging, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.192D	Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T71.192S	Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.222D	Asphyxiation due to being trapped in a car trunk, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T71.222S	Asphyxiation due to being trapped in a car trunk, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T71.232D	Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T71.232S	Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, sequela	Diagnosis	ICD-10-CM
V40.2	Other mental problems	Diagnosis	ICD-9-CM
V40.3	Other behavioral problems	Diagnosis	ICD-9-CM
V40.31	Wandering in diseases classified elsewhere	Diagnosis	ICD-9-CM
V40.39	Other specified behavioral problem	Diagnosis	ICD-9-CM
V40.9	Unspecified mental or behavioral problem	Diagnosis	ICD-9-CM
V62.84	Suicidal ideation	Diagnosis	ICD-9-CM
V67.3	Psychotherapy and other treatment for mental disorder follow-up examination	Diagnosis	ICD-9-CM
X71.0XXA	Intentional self-harm by drowning and submersion while in bathtub, initial encounter	Diagnosis	ICD-10-CM
X71.0XXD	Intentional self-harm by drowning and submersion while in bathtub, subsequent encounter	Diagnosis	ICD-10-CM
X71.0XXS	Intentional self-harm by drowning and submersion while in bathtub, sequela	Diagnosis	ICD-10-CM
X71.1XXA	Intentional self-harm by drowning and submersion while in swimming pool, initial encounter	Diagnosis	ICD-10-CM
X71.1XXD	Intentional self-harm by drowning and submersion while in swimming pool, subsequent encounter	Diagnosis	ICD-10-CM
X71.1XXS	Intentional self-harm by drowning and submersion while in swimming pool, sequela	Diagnosis	ICD-10-CM
X71.2XXA	Intentional self-harm by drowning and submersion after jump into swimming pool, initial encounter	Diagnosis	ICD-10-CM
X71.2XXD	Intentional self-harm by drowning and submersion after jump into swimming pool, subsequent encounter	Diagnosis	ICD-10-CM
X71.2XXS	Intentional self-harm by drowning and submersion after jump into swimming pool, sequela	Diagnosis	ICD-10-CM
X71.3XXA	Intentional self-harm by drowning and submersion in natural water, initial encounter	Diagnosis	ICD-10-CM
X71.3XXD	Intentional self-harm by drowning and submersion in natural water, subsequent encounter	Diagnosis	ICD-10-CM
X71.3XXS	Intentional self-harm by drowning and submersion in natural water, sequela	Diagnosis	ICD-10-CM
X71.8XXA	Other intentional self-harm by drowning and submersion, initial encounter	Diagnosis	ICD-10-CM
X71.8XXD	Other intentional self-harm by drowning and submersion, subsequent encounter	Diagnosis	ICD-10-CM
X71.8XXS	Other intentional self-harm by drowning and submersion, sequela	Diagnosis	ICD-10-CM
X71.9XXA	Intentional self-harm by drowning and submersion, unspecified, initial encounter	Diagnosis	ICD-10-CM
X71.9XXD	Intentional self-harm by drowning and submersion, unspecified, subsequent encounter	Diagnosis	ICD-10-CM
X71.9XXS	Intentional self-harm by drowning and submersion, unspecified, sequela	Diagnosis	ICD-10-CM
X72.XXXA	Intentional self-harm by handgun discharge, initial encounter	Diagnosis	ICD-10-CM
X72.XXXD	Intentional self-harm by handgun discharge, subsequent encounter	Diagnosis	ICD-10-CM
X72.XXXS	Intentional self-harm by handgun discharge, sequela	Diagnosis	ICD-10-CM
X73.0XXA	Intentional self-harm by shotgun discharge, initial encounter	Diagnosis	ICD-10-CM
X73.0XXD	Intentional self-harm by shotgun discharge, subsequent encounter	Diagnosis	ICD-10-CM
X73.0XXS	Intentional self-harm by shotgun discharge, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
X73.1XXA	Intentional self-harm by hunting rifle discharge, initial encounter	Diagnosis	ICD-10-CM
X73.1XXD	Intentional self-harm by hunting rifle discharge, subsequent encounter	Diagnosis	ICD-10-CM
X73.1XXS	Intentional self-harm by hunting rifle discharge, sequela	Diagnosis	ICD-10-CM
X73.2XXA	Intentional self-harm by machine gun discharge, initial encounter	Diagnosis	ICD-10-CM
X73.2XXD	Intentional self-harm by machine gun discharge, subsequent encounter	Diagnosis	ICD-10-CM
X73.2XXS	Intentional self-harm by machine gun discharge, sequela	Diagnosis	ICD-10-CM
X73.8XXA	Intentional self-harm by other larger firearm discharge, initial encounter	Diagnosis	ICD-10-CM
X73.8XXD	Intentional self-harm by other larger firearm discharge, subsequent encounter	Diagnosis	ICD-10-CM
X73.8XXS	Intentional self-harm by other larger firearm discharge, sequela	Diagnosis	ICD-10-CM
X73.9XXA	Intentional self-harm by unspecified larger firearm discharge, initial encounter	Diagnosis	ICD-10-CM
X73.9XXD	Intentional self-harm by unspecified larger firearm discharge, subsequent encounter	Diagnosis	ICD-10-CM
X73.9XXS	Intentional self-harm by unspecified larger firearm discharge, sequela	Diagnosis	ICD-10-CM
X74.01XA	Intentional self-harm by airgun, initial encounter	Diagnosis	ICD-10-CM
X74.01XD	Intentional self-harm by airgun, subsequent encounter	Diagnosis	ICD-10-CM
X74.01XS	Intentional self-harm by airgun, sequela	Diagnosis	ICD-10-CM
X74.02XA	Intentional self-harm by paintball gun, initial encounter	Diagnosis	ICD-10-CM
X74.02XD	Intentional self-harm by paintball gun, subsequent encounter	Diagnosis	ICD-10-CM
X74.02XS	Intentional self-harm by paintball gun, sequela	Diagnosis	ICD-10-CM
X74.09XA	Intentional self-harm by other gas, air or spring-operated gun, initial encounter	Diagnosis	ICD-10-CM
X74.09XD	Intentional self-harm by other gas, air or spring-operated gun, subsequent encounter	Diagnosis	ICD-10-CM
X74.09XS	Intentional self-harm by other gas, air or spring-operated gun, sequela	Diagnosis	ICD-10-CM
X74.8XXA	Intentional self-harm by other firearm discharge, initial encounter	Diagnosis	ICD-10-CM
X74.8XXD	Intentional self-harm by other firearm discharge, subsequent encounter	Diagnosis	ICD-10-CM
X74.8XXS	Intentional self-harm by other firearm discharge, sequela	Diagnosis	ICD-10-CM
X74.9XXA	Intentional self-harm by unspecified firearm discharge, initial encounter	Diagnosis	ICD-10-CM
X74.9XXD	Intentional self-harm by unspecified firearm discharge, subsequent encounter	Diagnosis	ICD-10-CM
X74.9XXS	Intentional self-harm by unspecified firearm discharge, sequela	Diagnosis	ICD-10-CM
X75.XXXA	Intentional self-harm by explosive material, initial encounter	Diagnosis	ICD-10-CM
X75.XXXD	Intentional self-harm by explosive material, subsequent encounter	Diagnosis	ICD-10-CM
X75.XXXS	Intentional self-harm by explosive material, sequela	Diagnosis	ICD-10-CM
X76.XXXA	Intentional self-harm by smoke, fire and flames, initial encounter	Diagnosis	ICD-10-CM
X76.XXXD	Intentional self-harm by smoke, fire and flames, subsequent encounter	Diagnosis	ICD-10-CM
X76.XXXS	Intentional self-harm by smoke, fire and flames, sequela	Diagnosis	ICD-10-CM
X77.0XXA	Intentional self-harm by steam or hot vapors, initial encounter	Diagnosis	ICD-10-CM
X77.0XXD	Intentional self-harm by steam or hot vapors, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
X77.0XXS	Intentional self-harm by steam or hot vapors, sequela	Diagnosis	ICD-10-CM
X77.1XXA	Intentional self-harm by hot tap water, initial encounter	Diagnosis	ICD-10-CM
X77.1XXD	Intentional self-harm by hot tap water, subsequent encounter	Diagnosis	ICD-10-CM
X77.1XXS	Intentional self-harm by hot tap water, sequela	Diagnosis	ICD-10-CM
X77.2XXA	Intentional self-harm by other hot fluids, initial encounter	Diagnosis	ICD-10-CM
X77.2XXD	Intentional self-harm by other hot fluids, subsequent encounter	Diagnosis	ICD-10-CM
X77.2XXS	Intentional self-harm by other hot fluids, sequela	Diagnosis	ICD-10-CM
X77.3XXA	Intentional self-harm by hot household appliances, initial encounter	Diagnosis	ICD-10-CM
X77.3XXD	Intentional self-harm by hot household appliances, subsequent encounter	Diagnosis	ICD-10-CM
X77.3XXS	Intentional self-harm by hot household appliances, sequela	Diagnosis	ICD-10-CM
X77.8XXA	Intentional self-harm by other hot objects, initial encounter	Diagnosis	ICD-10-CM
X77.8XXD	Intentional self-harm by other hot objects, subsequent encounter	Diagnosis	ICD-10-CM
X77.8XXS	Intentional self-harm by other hot objects, sequela	Diagnosis	ICD-10-CM
X77.9XXA	Intentional self-harm by unspecified hot objects, initial encounter	Diagnosis	ICD-10-CM
X77.9XXD	Intentional self-harm by unspecified hot objects, subsequent encounter	Diagnosis	ICD-10-CM
X77.9XXS	Intentional self-harm by unspecified hot objects, sequela	Diagnosis	ICD-10-CM
X78.0XXA	Intentional self-harm by sharp glass, initial encounter	Diagnosis	ICD-10-CM
X78.0XXD	Intentional self-harm by sharp glass, subsequent encounter	Diagnosis	ICD-10-CM
X78.0XXS	Intentional self-harm by sharp glass, sequela	Diagnosis	ICD-10-CM
X78.1XXA	Intentional self-harm by knife, initial encounter	Diagnosis	ICD-10-CM
X78.1XXD	Intentional self-harm by knife, subsequent encounter	Diagnosis	ICD-10-CM
X78.1XXS	Intentional self-harm by knife, sequela	Diagnosis	ICD-10-CM
X78.2XXA	Intentional self-harm by sword or dagger, initial encounter	Diagnosis	ICD-10-CM
X78.2XXD	Intentional self-harm by sword or dagger, subsequent encounter	Diagnosis	ICD-10-CM
X78.2XXS	Intentional self-harm by sword or dagger, sequela	Diagnosis	ICD-10-CM
X78.8XXA	Intentional self-harm by other sharp object, initial encounter	Diagnosis	ICD-10-CM
X78.8XXD	Intentional self-harm by other sharp object, subsequent encounter	Diagnosis	ICD-10-CM
X78.8XXS	Intentional self-harm by other sharp object, sequela	Diagnosis	ICD-10-CM
X78.9XXA	Intentional self-harm by unspecified sharp object, initial encounter	Diagnosis	ICD-10-CM
X78.9XXD	Intentional self-harm by unspecified sharp object, subsequent encounter	Diagnosis	ICD-10-CM
X78.9XXS	Intentional self-harm by unspecified sharp object, sequela	Diagnosis	ICD-10-CM
X79.XXXA	Intentional self-harm by blunt object, initial encounter	Diagnosis	ICD-10-CM
X79.XXXD	Intentional self-harm by blunt object, subsequent encounter	Diagnosis	ICD-10-CM
X79.XXXS	Intentional self-harm by blunt object, sequela	Diagnosis	ICD-10-CM
X80.XXXA	Intentional self-harm by jumping from a high place, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
X80.XXXD	Intentional self-harm by jumping from a high place, subsequent encounter	Diagnosis	ICD-10-CM
X80.XXXS	Intentional self-harm by jumping from a high place, sequela	Diagnosis	ICD-10-CM
X81.0XXA	Intentional self-harm by jumping or lying in front of motor vehicle, initial encounter	Diagnosis	ICD-10-CM
X81.0XXD	Intentional self-harm by jumping or lying in front of motor vehicle, subsequent encounter	Diagnosis	ICD-10-CM
X81.0XXS	Intentional self-harm by jumping or lying in front of motor vehicle, sequela	Diagnosis	ICD-10-CM
X81.1XXA	Intentional self-harm by jumping or lying in front of (subway) train, initial encounter	Diagnosis	ICD-10-CM
X81.1XXD	Intentional self-harm by jumping or lying in front of (subway) train, subsequent encounter	Diagnosis	ICD-10-CM
X81.1XXS	Intentional self-harm by jumping or lying in front of (subway) train, sequela	Diagnosis	ICD-10-CM
X81.8XXA	Intentional self-harm by jumping or lying in front of other moving object, initial encounter	Diagnosis	ICD-10-CM
X81.8XXD	Intentional self-harm by jumping or lying in front of other moving object, subsequent encounter	Diagnosis	ICD-10-CM
X81.8XXS	Intentional self-harm by jumping or lying in front of other moving object, sequela	Diagnosis	ICD-10-CM
X82.0XXA	Intentional collision of motor vehicle with other motor vehicle, initial encounter	Diagnosis	ICD-10-CM
X82.0XXD	Intentional collision of motor vehicle with other motor vehicle, subsequent encounter	Diagnosis	ICD-10-CM
X82.0XXS	Intentional collision of motor vehicle with other motor vehicle, sequela	Diagnosis	ICD-10-CM
X82.1XXA	Intentional collision of motor vehicle with train, initial encounter	Diagnosis	ICD-10-CM
X82.1XXD	Intentional collision of motor vehicle with train, subsequent encounter	Diagnosis	ICD-10-CM
X82.1XXS	Intentional collision of motor vehicle with train, sequela	Diagnosis	ICD-10-CM
X82.2XXA	Intentional collision of motor vehicle with tree, initial encounter	Diagnosis	ICD-10-CM
X82.2XXD	Intentional collision of motor vehicle with tree, subsequent encounter	Diagnosis	ICD-10-CM
X82.2XXS	Intentional collision of motor vehicle with tree, sequela	Diagnosis	ICD-10-CM
X82.8XXA	Other intentional self-harm by crashing of motor vehicle, initial encounter	Diagnosis	ICD-10-CM
X82.8XXD	Other intentional self-harm by crashing of motor vehicle, subsequent encounter	Diagnosis	ICD-10-CM
X82.8XXS	Other intentional self-harm by crashing of motor vehicle, sequela	Diagnosis	ICD-10-CM
X83.0XXA	Intentional self-harm by crashing of aircraft, initial encounter	Diagnosis	ICD-10-CM
X83.0XXD	Intentional self-harm by crashing of aircraft, subsequent encounter	Diagnosis	ICD-10-CM
X83.0XXS	Intentional self-harm by crashing of aircraft, sequela	Diagnosis	ICD-10-CM
X83.1XXA	Intentional self-harm by electrocution, initial encounter	Diagnosis	ICD-10-CM
X83.1XXD	Intentional self-harm by electrocution, subsequent encounter	Diagnosis	ICD-10-CM
X83.1XXS	Intentional self-harm by electrocution, sequela	Diagnosis	ICD-10-CM
X83.2XXA	Intentional self-harm by exposure to extremes of cold, initial encounter	Diagnosis	ICD-10-CM
X83.2XXD	Intentional self-harm by exposure to extremes of cold, subsequent encounter	Diagnosis	ICD-10-CM
X83.2XXS	Intentional self-harm by exposure to extremes of cold, sequela	Diagnosis	ICD-10-CM
X83.8XXA	Intentional self-harm by other specified means, initial encounter	Diagnosis	ICD-10-CM
X83.8XXD	Intentional self-harm by other specified means, subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
X83.8XXS	Intentional self-harm by other specified means, sequela	Diagnosis	ICD-10-CM
Z87.890	Personal history of sex reassignment	Diagnosis	ICD-10-CM
Z91.5	Personal history of self-harm	Diagnosis	ICD-10-CM
Z91.83	Wandering in diseases classified elsewhere	Diagnosis	ICD-10-CM
Bipolar Disorder			
296.0	Bipolar I disorder, single manic episode	Diagnosis	ICD-9-CM
296.00	Bipolar I disorder, single manic episode, unspecified	Diagnosis	ICD-9-CM
296.01	Bipolar I disorder, single manic episode, mild	Diagnosis	ICD-9-CM
296.02	Bipolar I disorder, single manic episode, moderate	Diagnosis	ICD-9-CM
296.03	Bipolar I disorder, single manic episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.04	Bipolar I disorder, single manic episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.05	Bipolar I disorder, single manic episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.06	Bipolar I disorder, single manic episode, in full remission	Diagnosis	ICD-9-CM
296.1	Manic disorder, recurrent episode	Diagnosis	ICD-9-CM
296.10	Manic disorder, recurrent episode, unspecified	Diagnosis	ICD-9-CM
296.11	Manic disorder, recurrent episode, mild	Diagnosis	ICD-9-CM
296.12	Manic disorder, recurrent episode, moderate	Diagnosis	ICD-9-CM
296.13	Manic disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.14	Manic disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.15	Manic disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.16	Manic disorder, recurrent episode, in full remission	Diagnosis	ICD-9-CM
296.4	Bipolar I disorder, most recent episode (or current) manic	Diagnosis	ICD-9-CM
296.40	Bipolar I disorder, most recent episode (or current) manic, unspecified	Diagnosis	ICD-9-CM
296.41	Bipolar I disorder, most recent episode (or current) manic, mild	Diagnosis	ICD-9-CM
296.42	Bipolar I disorder, most recent episode (or current) manic, moderate	Diagnosis	ICD-9-CM
296.43	Bipolar I disorder, most recent episode (or current) manic, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.44	Bipolar I disorder, most recent episode (or current) manic, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.45	Bipolar I disorder, most recent episode (or current) manic, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.46	Bipolar I disorder, most recent episode (or current) manic, in full remission	Diagnosis	ICD-9-CM
296.5	Bipolar I disorder, most recent episode (or current), depressed	Diagnosis	ICD-9-CM
296.50	Bipolar I disorder, most recent episode (or current) depressed, unspecified	Diagnosis	ICD-9-CM
296.51	Bipolar I disorder, most recent episode (or current) depressed, mild	Diagnosis	ICD-9-CM
296.52	Bipolar I disorder, most recent episode (or current) depressed, moderate	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
296.53	Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.54	Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.55	Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.56	Bipolar I disorder, most recent episode (or current) depressed, in full remission	Diagnosis	ICD-9-CM
296.6	Bipolar I disorder, most recent episode (or current), mixed	Diagnosis	ICD-9-CM
296.60	Bipolar I disorder, most recent episode (or current) mixed, unspecified	Diagnosis	ICD-9-CM
296.61	Bipolar I disorder, most recent episode (or current) mixed, mild	Diagnosis	ICD-9-CM
296.62	Bipolar I disorder, most recent episode (or current) mixed, moderate	Diagnosis	ICD-9-CM
296.63	Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.64	Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.65	Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.66	Bipolar I disorder, most recent episode (or current) mixed, in full remission	Diagnosis	ICD-9-CM
296.7	Bipolar I disorder, most recent episode (or current) unspecified	Diagnosis	ICD-9-CM
296.8	Other and unspecified bipolar disorders	Diagnosis	ICD-9-CM
296.80	Bipolar disorder, unspecified	Diagnosis	ICD-9-CM
296.81	Atypical manic disorder	Diagnosis	ICD-9-CM
296.82	Atypical depressive disorder	Diagnosis	ICD-9-CM
296.89	Other and unspecified bipolar disorders	Diagnosis	ICD-9-CM
296.99	Other specified episodic mood disorder	Diagnosis	ICD-9-CM
F30.10	Manic episode without psychotic symptoms, unspecified	Diagnosis	ICD-10-CM
F30.11	Manic episode without psychotic symptoms, mild	Diagnosis	ICD-10-CM
F30.12	Manic episode without psychotic symptoms, moderate	Diagnosis	ICD-10-CM
F30.13	Manic episode, severe, without psychotic symptoms	Diagnosis	ICD-10-CM
F30.2	Manic episode, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F30.3	Manic episode in partial remission	Diagnosis	ICD-10-CM
F30.4	Manic episode in full remission	Diagnosis	ICD-10-CM
F30.8	Other manic episodes	Diagnosis	ICD-10-CM
F30.9	Manic episode, unspecified	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.70	Bipolar disorder, currently in remission, most recent episode unspecified	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.72	Bipolar disorder, in full remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.74	Bipolar disorder, in full remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F34.81	Disruptive mood dysregulation disorder	Diagnosis	ICD-10-CM
F34.89	Other specified persistent mood disorders	Diagnosis	ICD-10-CM
F34.9	Persistent mood [affective] disorder, unspecified	Diagnosis	ICD-10-CM
	Cerebral Degenerations		
330	Cerebral degenerations usually manifest in childhood	Diagnosis	ICD-9-CM
330.0	Leukodystrophy	Diagnosis	ICD-9-CM
330.1	Cerebral lipidoses	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
330.2	Cerebral degeneration in generalized lipidoses	Diagnosis	ICD-9-CM
330.3	Cerebral degeneration of childhood in other diseases classified elsewhere	Diagnosis	ICD-9-CM
330.8	Other specified cerebral degenerations in childhood	Diagnosis	ICD-9-CM
330.9	Unspecified cerebral degeneration in childhood	Diagnosis	ICD-9-CM
E75.00	GM2 gangliosidosis, unspecified	Diagnosis	ICD-10-CM
E75.01	Sandhoff disease	Diagnosis	ICD-10-CM
E75.02	Tay-Sachs disease	Diagnosis	ICD-10-CM
E75.09	Other GM2 gangliosidosis	Diagnosis	ICD-10-CM
E75.10	Unspecified gangliosidosis	Diagnosis	ICD-10-CM
E75.11	Mucolipidosis IV	Diagnosis	ICD-10-CM
E75.19	Other gangliosidosis	Diagnosis	ICD-10-CM
E75.23	Krabbe disease	Diagnosis	ICD-10-CM
E75.25	Metachromatic leukodystrophy	Diagnosis	ICD-10-CM
E75.29	Other sphingolipidosis	Diagnosis	ICD-10-CM
E75.4	Neuronal ceroid lipofuscinosis	Diagnosis	ICD-10-CM
F84.2	Rett's syndrome	Diagnosis	ICD-10-CM
G31.81	Alpers disease	Diagnosis	ICD-10-CM
G31.82	Leigh's disease	Diagnosis	ICD-10-CM
G31.9	Degenerative disease of nervous system, unspecified	Diagnosis	ICD-10-CM
G93.89	Other specified disorders of brain	Diagnosis	ICD-10-CM
G93.9	Disorder of brain, unspecified	Diagnosis	ICD-10-CM
	Conduct Disorder		
312	Disturbance of conduct, not elsewhere classified	Diagnosis	ICD-9-CM
312.0	Undersocialized conduct disorder, aggressive type	Diagnosis	ICD-9-CM
312.00	Undersocialized conduct disorder, aggressive type, unspecified	Diagnosis	ICD-9-CM
312.01	Undersocialized conduct disorder, aggressive type, mild	Diagnosis	ICD-9-CM
312.02	Undersocialized conduct disorder, aggressive type, moderate	Diagnosis	ICD-9-CM
312.03	Undersocialized conduct disorder, aggressive type, severe	Diagnosis	ICD-9-CM
312.1	Undersocialized conduct disorder, unaggressive type	Diagnosis	ICD-9-CM
312.10	Undersocialized conduct disorder, unaggressive type, unspecified	Diagnosis	ICD-9-CM
312.11	Undersocialized conduct disorder, unaggressive type, mild	Diagnosis	ICD-9-CM
312.12	Undersocialized conduct disorder, unaggressive type, moderate	Diagnosis	ICD-9-CM
312.13	Undersocialized conduct disorder, unaggressive type, severe	Diagnosis	ICD-9-CM
312.2	Socialized conduct disorder	Diagnosis	ICD-9-CM
312.20	Socialized conduct disorder, unspecified	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
312.21	Socialized conduct disorder, mild	Diagnosis	ICD-9-CM
312.22	Socialized conduct disorder, moderate	Diagnosis	ICD-9-CM
312.23	Socialized conduct disorder, severe	Diagnosis	ICD-9-CM
312.3	Disorders of impulse control, not elsewhere classified	Diagnosis	ICD-9-CM
312.30	Impulse control disorder, unspecified	Diagnosis	ICD-9-CM
312.31	Pathological gambling	Diagnosis	ICD-9-CM
312.33	Pyromania	Diagnosis	ICD-9-CM
312.34	Intermittent explosive disorder	Diagnosis	ICD-9-CM
312.35	Isolated explosive disorder	Diagnosis	ICD-9-CM
312.39	Other disorder of impulse control	Diagnosis	ICD-9-CM
312.4	Mixed disturbance of conduct and emotions	Diagnosis	ICD-9-CM
312.8	Other specified disturbances of conduct, not elsewhere classified	Diagnosis	ICD-9-CM
312.89	Other specified disturbance of conduct, not elsewhere classified	Diagnosis	ICD-9-CM
312.9	Unspecified disturbance of conduct	Diagnosis	ICD-9-CM
F63.1	Pyromania	Diagnosis	ICD-10-CM
F63.81	Intermittent explosive disorder	Diagnosis	ICD-10-CM
F63.89	Other impulse disorders	Diagnosis	ICD-10-CM
	Delirium		
292.81	Drug-induced delirium	Diagnosis	ICD-9-CM
293	Transient mental disorders due to conditions classified elsewhere	Diagnosis	ICD-9-CM
293.0	Delirium due to conditions classified elsewhere	Diagnosis	ICD-9-CM
293.1	Subacute delirium	Diagnosis	ICD-9-CM
293.8	Other specified transient mental disorders due to conditions classified elsewhere	Diagnosis	ICD-9-CM
293.81	Psychotic disorder with delusions in conditions classified elsewhere	Diagnosis	ICD-9-CM
293.82	Psychotic disorder with hallucinations in conditions classified elsewhere	Diagnosis	ICD-9-CM
293.83	Mood disorder in conditions classified elsewhere	Diagnosis	ICD-9-CM
293.89	Other transient mental disorders due to conditions classified elsewhere	Diagnosis	ICD-9-CM
293.9	Unspecified transient mental disorder in conditions classified elsewhere	Diagnosis	ICD-9-CM
348.3	Encephalopathy, not elsewhere classified	Diagnosis	ICD-9-CM
348.30	Encephalopathy, unspecified	Diagnosis	ICD-9-CM
348.31	Metabolic encephalopathy	Diagnosis	ICD-9-CM
348.39	Other encephalopathy	Diagnosis	ICD-9-CM
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
F06.0	Psychotic disorder with hallucinations due to known physiological condition	Diagnosis	ICD-10-CM
F06.1	Catatonic disorder due to known physiological condition	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F06.2	Psychotic disorder with delusions due to known physiological condition	Diagnosis	ICD-10-CM
F06.30	Mood disorder due to known physiological condition, unspecified	Diagnosis	ICD-10-CM
F06.31	Mood disorder due to known physiological condition with depressive features	Diagnosis	ICD-10-CM
F06.32	Mood disorder due to known physiological condition with major depressive-like episode	Diagnosis	ICD-10-CM
F06.33	Mood disorder due to known physiological condition with manic features	Diagnosis	ICD-10-CM
F06.34	Mood disorder due to known physiological condition with mixed features	Diagnosis	ICD-10-CM
F06.8	Other specified mental disorders due to known physiological condition	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F53	Mental and behavioral disorders associated with the puerperium, not elsewhere classified	Diagnosis	ICD-10-CM
G93.40	Encephalopathy, unspecified	Diagnosis	ICD-10-CM
G93.41	Metabolic encephalopathy	Diagnosis	ICD-10-CM
G93.49	Other encephalopathy	Diagnosis	ICD-10-CM
I67.83	Posterior reversible encephalopathy syndrome	Diagnosis	ICD-10-CM
	Depression		
296.2	Major depressive disorder, single episode	Diagnosis	ICD-9-CM
296.20	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-9-CM
296.21	Major depressive disorder, single episode, mild	Diagnosis	ICD-9-CM
296.22	Major depressive disorder, single episode, moderate	Diagnosis	ICD-9-CM
296.23	Major depressive disorder, single episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.24	Major depressive disorder, single episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.25	Major depressive disorder, single episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.26	Major depressive disorder, single episode in full remission	Diagnosis	ICD-9-CM
296.3	Major depressive disorder, recurrent episode	Diagnosis	ICD-9-CM
296.30	Major depressive disorder, recurrent episode, unspecified	Diagnosis	ICD-9-CM
296.31	Major depressive disorder, recurrent episode, mild	Diagnosis	ICD-9-CM
296.32	Major depressive disorder, recurrent episode, moderate	Diagnosis	ICD-9-CM
296.33	Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.34	Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.35	Major depressive disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.36	Major depressive disorder, recurrent episode, in full remission	Diagnosis	ICD-9-CM
296.90	Unspecified episodic mood disorder	Diagnosis	ICD-9-CM
300.4	Dysthymic disorder	Diagnosis	ICD-9-CM
309.0	Adjustment disorder with depressed mood	Diagnosis	ICD-9-CM
309.1	Prolonged depressive reaction as adjustment reaction	Diagnosis	ICD-9-CM
311	Depressive disorder, not elsewhere classified	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F39	Unspecified mood [affective] disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
	Electroconvulsive Therapy		
90870	Electroconvulsive therapy (includes necessary monitoring)	Procedure	CPT-4
90871	Electroconvulsive therapy (includes necessary monitoring); multiple seizures, per day	Procedure	CPT-4
	Hallucination		
780.1	Hallucinations	Diagnosis	ICD-9-CM
R44.0	Auditory hallucinations	Diagnosis	ICD-10-CM
R44.2	Other hallucinations	Diagnosis	ICD-10-CM
R44.3	Hallucinations, unspecified	Diagnosis	ICD-10-CM
	Obsessive-Compulsive Disorder		
300.3	Obsessive-compulsive disorders	Diagnosis	ICD-9-CM
F42.8	Other obsessive-compulsive disorder	Diagnosis	ICD-10-CM
F42.9	Obsessive-compulsive disorder, unspecified	Diagnosis	ICD-10-CM
	Other Cerebral Degenerations		
331	Other cerebral degenerations	Diagnosis	ICD-9-CM
331.0	Alzheimer's disease	Diagnosis	ICD-9-CM
331.1	Frontotemporal dementia	Diagnosis	ICD-9-CM
331.11	Pick's disease	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
331.19	Other frontotemporal dementia	Diagnosis	ICD-9-CM
331.2	Senile degeneration of brain	Diagnosis	ICD-9-CM
331.3	Communicating hydrocephalus	Diagnosis	ICD-9-CM
331.4	Obstructive hydrocephalus	Diagnosis	ICD-9-CM
331.5	Idiopathic normal pressure hydrocephalus [INPH]	Diagnosis	ICD-9-CM
331.6	Corticobasal degeneration	Diagnosis	ICD-9-CM
331.7	Cerebral degeneration in diseases classified elsewhere	Diagnosis	ICD-9-CM
331.8	Other cerebral degeneration	Diagnosis	ICD-9-CM
331.81	Reye's syndrome	Diagnosis	ICD-9-CM
331.82	Dementia with Lewy bodies	Diagnosis	ICD-9-CM
331.83	Mild cognitive impairment, so stated	Diagnosis	ICD-9-CM
331.89	Other cerebral degeneration	Diagnosis	ICD-9-CM
331.9	Unspecified cerebral degeneration	Diagnosis	ICD-9-CM
G13.2	Systemic atrophy primarily affecting the central nervous system in myxedema	Diagnosis	ICD-10-CM
G13.8	Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere	Diagnosis	ICD-10-CM
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal dementia	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G31.83	Dementia with Lewy bodies	Diagnosis	ICD-10-CM
G31.84	Mild cognitive impairment, so stated	Diagnosis	ICD-10-CM
G31.85	Corticobasal degeneration	Diagnosis	ICD-10-CM
G31.89	Other specified degenerative diseases of nervous system	Diagnosis	ICD-10-CM
G91.0	Communicating hydrocephalus	Diagnosis	ICD-10-CM
G91.1	Obstructive hydrocephalus	Diagnosis	ICD-10-CM
G91.2	(Idiopathic) normal pressure hydrocephalus	Diagnosis	ICD-10-CM
G91.3	Post-traumatic hydrocephalus, unspecified	Diagnosis	ICD-10-CM
G91.4	Hydrocephalus in diseases classified elsewhere	Diagnosis	ICD-10-CM
G91.8	Other hydrocephalus	Diagnosis	ICD-10-CM
G91.9	Hydrocephalus, unspecified	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
G93.7	Reye's syndrome	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
	Other Mental Disorders		
300.1	Dissociative, conversion and factitious disorders	Diagnosis	ICD-9-CM
300.8	Somatoform disorders	Diagnosis	ICD-9-CM
302	Sexual and gender identity disorders	Diagnosis	ICD-9-CM
302.0	Ego-dystonic sexual orientation	Diagnosis	ICD-9-CM
302.5	Trans-sexualism	Diagnosis	ICD-9-CM
302.7	Psychosexual dysfunction	Diagnosis	ICD-9-CM
302.8	Other specified psychosexual disorders	Diagnosis	ICD-9-CM
306	Physiological malfunction arising from mental factors	Diagnosis	ICD-9-CM
306.5	Genitourinary malfunctions arising from mental factors	Diagnosis	ICD-9-CM
307	Special symptoms or syndromes, not elsewhere classified	Diagnosis	ICD-9-CM
307.2	Tics	Diagnosis	ICD-9-CM
307.20	Tic disorder, unspecified	Diagnosis	ICD-9-CM
307.21	Transient tic disorder	Diagnosis	ICD-9-CM
307.23	Tourette's disorder	Diagnosis	ICD-9-CM
307.3	Stereotypic movement disorder	Diagnosis	ICD-9-CM
307.5	Other and unspecified disorders of eating	Diagnosis	ICD-9-CM
307.6	Enuresis	Diagnosis	ICD-9-CM
307.7	Encopresis	Diagnosis	ICD-9-CM
307.8	Pain disorders related to psychological factors	Diagnosis	ICD-9-CM
308	Acute reaction to stress	Diagnosis	ICD-9-CM
309.2	Predominant disturbance of other emotions as adjustment reaction	Diagnosis	ICD-9-CM
309.21	Separation anxiety disorder	Diagnosis	ICD-9-CM
309.8	Other specified adjustment reactions	Diagnosis	ICD-9-CM
310	Specific nonpsychotic mental disorders due to brain damage	Diagnosis	ICD-9-CM
310.0	Frontal lobe syndrome	Diagnosis	ICD-9-CM
310.2	Postconcussion syndrome	Diagnosis	ICD-9-CM
310.8	Other specified nonpsychotic mental disorder following organic brain damage	Diagnosis	ICD-9-CM
310.81	Pseudobulbar affect	Diagnosis	ICD-9-CM
310.89	Other specified nonpsychotic mental disorders following organic brain damage	Diagnosis	ICD-9-CM
310.9	Unspecified nonpsychotic mental disorder following organic brain damage	Diagnosis	ICD-9-CM
313	Disturbance of emotions specific to childhood and adolescence	Diagnosis	ICD-9-CM
313.2	Sensitivity, shyness, and social withdrawal disorder specific to childhood and adolescence	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
313.8	Other or mixed emotional disturbances of childhood or adolescence	Diagnosis	ICD-9-CM
313.89	Other emotional disturbance of childhood or adolescence	Diagnosis	ICD-9-CM
313.9	Unspecified emotional disturbance of childhood or adolescence	Diagnosis	ICD-9-CM
315	Specific delays in development	Diagnosis	ICD-9-CM
315.0	Specific developmental reading disorder	Diagnosis	ICD-9-CM
315.00	Developmental reading disorder, unspecified	Diagnosis	ICD-9-CM
315.01	Alexia	Diagnosis	ICD-9-CM
315.02	Developmental dyslexia	Diagnosis	ICD-9-CM
315.09	Other specific developmental reading disorder	Diagnosis	ICD-9-CM
315.1	Mathematics disorder	Diagnosis	ICD-9-CM
315.2	Other specific developmental learning difficulties	Diagnosis	ICD-9-CM
315.3	Developmental speech or language disorder	Diagnosis	ICD-9-CM
315.31	Expressive language disorder	Diagnosis	ICD-9-CM
315.32	Mixed receptive-expressive language disorder	Diagnosis	ICD-9-CM
315.39	Other developmental speech or language disorder	Diagnosis	ICD-9-CM
315.4	Developmental coordination disorder	Diagnosis	ICD-9-CM
315.5	Mixed development disorder	Diagnosis	ICD-9-CM
315.8	Other specified delay in development	Diagnosis	ICD-9-CM
315.9	Unspecified delay in development	Diagnosis	ICD-9-CM
F07.81	Postconcussional syndrome	Diagnosis	ICD-10-CM
F07.89	Other personality and behavioral disorders due to known physiological condition	Diagnosis	ICD-10-CM
F09	Unspecified mental disorder due to known physiological condition	Diagnosis	ICD-10-CM
F66	Other sexual disorders	Diagnosis	ICD-10-CM
F80.89	Other developmental disorders of speech and language	Diagnosis	ICD-10-CM
F81.2	Mathematics disorder	Diagnosis	ICD-10-CM
F81.89	Other developmental disorders of scholastic skills	Diagnosis	ICD-10-CM
F88	Other disorders of psychological development	Diagnosis	ICD-10-CM
F89	Unspecified disorder of psychological development	Diagnosis	ICD-10-CM
F94.8	Other childhood disorders of social functioning	Diagnosis	ICD-10-CM
F95.0	Transient tic disorder	Diagnosis	ICD-10-CM
F98.29	Other feeding disorders of infancy and early childhood	Diagnosis	ICD-10-CM
G44.209	Tension-type headache, unspecified, not intractable	Diagnosis	ICD-10-CM
H93.25	Central auditory processing disorder	Diagnosis	ICD-10-CM
R45.1	Restlessness and agitation	Diagnosis	ICD-10-CM
R48.0	Dyslexia and alexia	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
	Other Psychological Disorders		
290.0	Senile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.10	Presenile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.11	Presenile dementia with delirium	Diagnosis	ICD-9-CM
290.12	Presenile dementia with delusional features	Diagnosis	ICD-9-CM
290.13	Presenile dementia with depressive features	Diagnosis	ICD-9-CM
290.20	Senile dementia with delusional features	Diagnosis	ICD-9-CM
290.21	Senile dementia with depressive features	Diagnosis	ICD-9-CM
290.3	Senile dementia with delirium	Diagnosis	ICD-9-CM
290.40	Vascular dementia, uncomplicated	Diagnosis	ICD-9-CM
290.41	Vascular dementia, with delirium	Diagnosis	ICD-9-CM
290.42	Vascular dementia, with delusions	Diagnosis	ICD-9-CM
290.43	Vascular dementia, with depressed mood	Diagnosis	ICD-9-CM
305.1	Nondependent tobacco use disorder	Diagnosis	ICD-9-CM
307.0	Adult onset fluency disorder	Diagnosis	ICD-9-CM
307.22	Chronic motor or vocal tic disorder	Diagnosis	ICD-9-CM
307.9	Other and unspecified special symptom or syndrome, not elsewhere classified	Diagnosis	ICD-9-CM
313.23	Selective mutism	Diagnosis	ICD-9-CM
315.34	Speech and language developmental delay due to hearing loss	Diagnosis	ICD-9-CM
315.35	Childhood onset fluency disorder	Diagnosis	ICD-9-CM
317	Mild intellectual disabilities	Diagnosis	ICD-9-CM
318.0	Moderate intellectual disabilities	Diagnosis	ICD-9-CM
318.1	Severe intellectual disabilities	Diagnosis	ICD-9-CM
318.2	Profound intellectual disabilities	Diagnosis	ICD-9-CM
319	Unspecified intellectual disabilities	Diagnosis	ICD-9-CM
625.4	Premenstrual tension syndromes	Diagnosis	ICD-9-CM
F01	Vascular dementia	Diagnosis	ICD-10-CM
F01.5	Vascular dementia	Diagnosis	ICD-10-CM
F01.50	Vascular dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F01.51	Vascular dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F02	Dementia in other diseases classified elsewhere	Diagnosis	ICD-10-CM
F02.8	Dementia in other diseases classified elsewhere	Diagnosis	ICD-10-CM
F03	Unspecified dementia	Diagnosis	ICD-10-CM
F03.9	Unspecified dementia	Diagnosis	ICD-10-CM
F06	Other mental disorders due to known physiological condition	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F06.3	Mood disorder due to known physiological condition	Diagnosis	ICD-10-CM
F07	Personality and behavioral disorders due to known physiological condition	Diagnosis	ICD-10-CM
F07.0	Personality change due to known physiological condition	Diagnosis	ICD-10-CM
F07.8	Other personality and behavioral disorders due to known physiological condition	Diagnosis	ICD-10-CM
F07.9	Unspecified personality and behavioral disorder due to known physiological condition	Diagnosis	ICD-10-CM
F10	Alcohol related disorders	Diagnosis	ICD-10-CM
F10.1	Alcohol abuse	Diagnosis	ICD-10-CM
F10.12	Alcohol abuse with intoxication	Diagnosis	ICD-10-CM
F10.15	Alcohol abuse with alcohol-induced psychotic disorder	Diagnosis	ICD-10-CM
F10.18	Alcohol abuse with other alcohol-induced disorders	Diagnosis	ICD-10-CM
F10.2	Alcohol dependence	Diagnosis	ICD-10-CM
F10.22	Alcohol dependence with intoxication	Diagnosis	ICD-10-CM
F10.23	Alcohol dependence with withdrawal	Diagnosis	ICD-10-CM
F10.25	Alcohol dependence with alcohol-induced psychotic disorder	Diagnosis	ICD-10-CM
F10.28	Alcohol dependence with other alcohol-induced disorders	Diagnosis	ICD-10-CM
F10.9	Alcohol use, unspecified	Diagnosis	ICD-10-CM
F10.92	Alcohol use, unspecified with intoxication	Diagnosis	ICD-10-CM
F10.95	Alcohol use, unspecified with alcohol-induced psychotic disorder	Diagnosis	ICD-10-CM
F10.98	Alcohol use, unspecified with other alcohol-induced disorders	Diagnosis	ICD-10-CM
F11	Opioid related disorders	Diagnosis	ICD-10-CM
F11.1	Opioid abuse	Diagnosis	ICD-10-CM
F11.12	Opioid abuse with intoxication	Diagnosis	ICD-10-CM
F11.15	Opioid abuse with opioid-induced psychotic disorder	Diagnosis	ICD-10-CM
F11.18	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.2	Opioid dependence	Diagnosis	ICD-10-CM
F11.22	Opioid dependence with intoxication	Diagnosis	ICD-10-CM
F11.25	Opioid dependence with opioid-induced psychotic disorder	Diagnosis	ICD-10-CM
F11.28	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.9	Opioid use, unspecified	Diagnosis	ICD-10-CM
F11.92	Opioid use, unspecified with intoxication	Diagnosis	ICD-10-CM
F11.95	Opioid use, unspecified with opioid-induced psychotic disorder	Diagnosis	ICD-10-CM
F11.98	Opioid use, unspecified with other specified opioid-induced disorder	Diagnosis	ICD-10-CM
F12	Cannabis related disorders	Diagnosis	ICD-10-CM
F12.1	Cannabis abuse	Diagnosis	ICD-10-CM
F12.12	Cannabis abuse with intoxication	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F12.15	Cannabis abuse with psychotic disorder	Diagnosis	ICD-10-CM
F12.18	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.2	Cannabis dependence	Diagnosis	ICD-10-CM
F12.22	Cannabis dependence with intoxication	Diagnosis	ICD-10-CM
F12.25	Cannabis dependence with psychotic disorder	Diagnosis	ICD-10-CM
F12.28	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.9	Cannabis use, unspecified	Diagnosis	ICD-10-CM
F12.92	Cannabis use, unspecified with intoxication	Diagnosis	ICD-10-CM
F12.95	Cannabis use, unspecified with psychotic disorder	Diagnosis	ICD-10-CM
F12.98	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F13	Sedative, hypnotic, or anxiolytic related disorders	Diagnosis	ICD-10-CM
F13.1	Sedative, hypnotic or anxiolytic-related abuse	Diagnosis	ICD-10-CM
F13.11	Sedative, hypnotic or anxiolytic abuse, in remission	Diagnosis	ICD-10-CM
F13.12	Sedative, hypnotic or anxiolytic abuse with intoxication	Diagnosis	ICD-10-CM
F13.15	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder	Diagnosis	ICD-10-CM
F13.18	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorders	Diagnosis	ICD-10-CM
F13.2	Sedative, hypnotic or anxiolytic-related dependence	Diagnosis	ICD-10-CM
F13.22	Sedative, hypnotic or anxiolytic dependence with intoxication	Diagnosis	ICD-10-CM
F13.23	Sedative, hypnotic or anxiolytic dependence with withdrawal	Diagnosis	ICD-10-CM
F13.25	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder	Diagnosis	ICD-10-CM
F13.28	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorders	Diagnosis	ICD-10-CM
F13.9	Sedative, hypnotic or anxiolytic-related use, unspecified	Diagnosis	ICD-10-CM
F13.92	Sedative, hypnotic or anxiolytic use, unspecified with intoxication	Diagnosis	ICD-10-CM
F13.93	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F13.95	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder	Diagnosis	ICD-10-CM
F13.98	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorders	Diagnosis	ICD-10-CM
F14	Cocaine related disorders	Diagnosis	ICD-10-CM
F14.1	Cocaine abuse	Diagnosis	ICD-10-CM
F14.12	Cocaine abuse with intoxication	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F14.122	Cocaine abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.15	Cocaine abuse with cocaine-induced psychotic disorder	Diagnosis	ICD-10-CM
F14.18	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.2	Cocaine dependence	Diagnosis	ICD-10-CM
F14.22	Cocaine dependence with intoxication	Diagnosis	ICD-10-CM
F14.25	Cocaine dependence with cocaine-induced psychotic disorder	Diagnosis	ICD-10-CM
F14.28	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.9	Cocaine use, unspecified	Diagnosis	ICD-10-CM
F14.92	Cocaine use, unspecified with intoxication	Diagnosis	ICD-10-CM
F14.95	Cocaine use, unspecified with cocaine-induced psychotic disorder	Diagnosis	ICD-10-CM
F14.98	Cocaine use, unspecified with other specified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15	Other stimulant related disorders	Diagnosis	ICD-10-CM
F15.1	Other stimulant abuse	Diagnosis	ICD-10-CM
F15.12	Other stimulant abuse with intoxication	Diagnosis	ICD-10-CM
F15.15	Other stimulant abuse with stimulant-induced psychotic disorder	Diagnosis	ICD-10-CM
F15.18	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.2	Other stimulant dependence	Diagnosis	ICD-10-CM
F15.22	Other stimulant dependence with intoxication	Diagnosis	ICD-10-CM
F15.25	Other stimulant dependence with stimulant-induced psychotic disorder	Diagnosis	ICD-10-CM
F15.28	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.9	Other stimulant use, unspecified	Diagnosis	ICD-10-CM
F15.92	Other stimulant use, unspecified with intoxication	Diagnosis	ICD-10-CM
F15.95	Other stimulant use, unspecified with stimulant-induced psychotic disorder	Diagnosis	ICD-10-CM
F15.98	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F16	Hallucinogen related disorders	Diagnosis	ICD-10-CM
F16.1	Hallucinogen abuse	Diagnosis	ICD-10-CM
F16.12	Hallucinogen abuse with intoxication	Diagnosis	ICD-10-CM
F16.15	Hallucinogen abuse with hallucinogen-induced psychotic disorder	Diagnosis	ICD-10-CM
F16.18	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.2	Hallucinogen dependence	Diagnosis	ICD-10-CM
F16.22	Hallucinogen dependence with intoxication	Diagnosis	ICD-10-CM
F16.25	Hallucinogen dependence with hallucinogen-induced psychotic disorder	Diagnosis	ICD-10-CM
F16.28	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.9	Hallucinogen use, unspecified	Diagnosis	ICD-10-CM
F16.92	Hallucinogen use, unspecified with intoxication	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F16.95	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder	Diagnosis	ICD-10-CM
F16.98	Hallucinogen use, unspecified with other specified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F17	Nicotine dependence	Diagnosis	ICD-10-CM
F17.2	Nicotine dependence	Diagnosis	ICD-10-CM
F17.20	Nicotine dependence, unspecified	Diagnosis	ICD-10-CM
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.21	Nicotine dependence, cigarettes	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.22	Nicotine dependence, chewing tobacco	Diagnosis	ICD-10-CM
F17.220	Nicotine dependence, chewing tobacco, uncomplicated	Diagnosis	ICD-10-CM
F17.221	Nicotine dependence, chewing tobacco, in remission	Diagnosis	ICD-10-CM
F17.29	Nicotine dependence, other tobacco product	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F18	Inhalant related disorders	Diagnosis	ICD-10-CM
F18.1	Inhalant abuse	Diagnosis	ICD-10-CM
F18.12	Inhalant abuse with intoxication	Diagnosis	ICD-10-CM
F18.15	Inhalant abuse with inhalant-induced psychotic disorder	Diagnosis	ICD-10-CM
F18.18	Inhalant abuse with other inhalant-induced disorders	Diagnosis	ICD-10-CM
F18.2	Inhalant dependence	Diagnosis	ICD-10-CM
F18.22	Inhalant dependence with intoxication	Diagnosis	ICD-10-CM
F18.25	Inhalant dependence with inhalant-induced psychotic disorder	Diagnosis	ICD-10-CM
F18.28	Inhalant dependence with other inhalant-induced disorders	Diagnosis	ICD-10-CM
F18.9	Inhalant use, unspecified	Diagnosis	ICD-10-CM
F18.92	Inhalant use, unspecified with intoxication	Diagnosis	ICD-10-CM
F18.95	Inhalant use, unspecified with inhalant-induced psychotic disorder	Diagnosis	ICD-10-CM
F18.98	Inhalant use, unspecified with other inhalant-induced disorders	Diagnosis	ICD-10-CM
F19	Other psychoactive substance related disorders	Diagnosis	ICD-10-CM
F19.1	Other psychoactive substance abuse	Diagnosis	ICD-10-CM
F19.12	Other psychoactive substance abuse with intoxication	Diagnosis	ICD-10-CM
F19.15	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder	Diagnosis	ICD-10-CM
F19.18	Other psychoactive substance abuse with other psychoactive substance-induced disorders	Diagnosis	ICD-10-CM
F19.2	Other psychoactive substance dependence	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F19.22	Other psychoactive substance dependence with intoxication	Diagnosis	ICD-10-CM
F19.23	Other psychoactive substance dependence with withdrawal	Diagnosis	ICD-10-CM
F19.25	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder	Diagnosis	ICD-10-CM
F19.28	Other psychoactive substance dependence with other psychoactive substance-induced disorders	Diagnosis	ICD-10-CM
F19.9	Other psychoactive substance use, unspecified	Diagnosis	ICD-10-CM
F19.92	Other psychoactive substance use, unspecified with intoxication	Diagnosis	ICD-10-CM
F19.93	Other psychoactive substance use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F19.95	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder	Diagnosis	ICD-10-CM
F19.98	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorders	Diagnosis	ICD-10-CM
F20	Schizophrenia	Diagnosis	ICD-10-CM
F20.8	Other schizophrenia	Diagnosis	ICD-10-CM
F25	Schizoaffective disorders	Diagnosis	ICD-10-CM
F30	Manic episode	Diagnosis	ICD-10-CM
F30.1	Manic episode without psychotic symptoms	Diagnosis	ICD-10-CM
F31	Bipolar disorder	Diagnosis	ICD-10-CM
F31.1	Bipolar disorder, current episode manic without psychotic features	Diagnosis	ICD-10-CM
F31.3	Bipolar disorder, current episode depressed, mild or moderate severity	Diagnosis	ICD-10-CM
F31.6	Bipolar disorder, current episode mixed	Diagnosis	ICD-10-CM
F31.7	Bipolar disorder, currently in remission	Diagnosis	ICD-10-CM
F31.8	Other bipolar disorders	Diagnosis	ICD-10-CM
F32	Depressive episode	Diagnosis	ICD-10-CM
F33	Major depressive disorder, recurrent	Diagnosis	ICD-10-CM
F33.4	Major depressive disorder, recurrent, in remission	Diagnosis	ICD-10-CM
F34	Persistent mood [affective] disorders	Diagnosis	ICD-10-CM
F40	Phobic anxiety disorders	Diagnosis	ICD-10-CM
F40.0	Agoraphobia	Diagnosis	ICD-10-CM
F40.1	Social phobias	Diagnosis	ICD-10-CM
F40.2	Specific (isolated) phobias	Diagnosis	ICD-10-CM
F40.21	Animal type phobia	Diagnosis	ICD-10-CM
F40.22	Natural environment type phobia	Diagnosis	ICD-10-CM
F40.23	Blood, injection, injury type phobia	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F40.24	Situational type phobia	Diagnosis	ICD-10-CM
F40.29	Other specified phobia	Diagnosis	ICD-10-CM
F41	Other anxiety disorders	Diagnosis	ICD-10-CM
F43	Reaction to severe stress, and adjustment disorders	Diagnosis	ICD-10-CM
F43.1	Post-traumatic stress disorder (PTSD)	Diagnosis	ICD-10-CM
F43.2	Adjustment disorders	Diagnosis	ICD-10-CM
F44	Dissociative and conversion disorders	Diagnosis	ICD-10-CM
F44.8	Other dissociative and conversion disorders	Diagnosis	ICD-10-CM
F45	Somatoform disorders	Diagnosis	ICD-10-CM
F45.2	Hypochondriacal disorders	Diagnosis	ICD-10-CM
F45.4	Pain disorders related to psychological factors	Diagnosis	ICD-10-CM
F48	Other nonpsychotic mental disorders	Diagnosis	ICD-10-CM
F48.2	Pseudobulbar affect	Diagnosis	ICD-10-CM
F50	Eating disorders	Diagnosis	ICD-10-CM
F50.0	Anorexia nervosa	Diagnosis	ICD-10-CM
F52	Sexual dysfunction not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F52.2	Sexual arousal disorders	Diagnosis	ICD-10-CM
F52.3	Orgasmic disorder	Diagnosis	ICD-10-CM
F60	Specific personality disorders	Diagnosis	ICD-10-CM
F60.8	Other specific personality disorders	Diagnosis	ICD-10-CM
F63	Impulse disorders	Diagnosis	ICD-10-CM
F63.8	Other impulse disorders	Diagnosis	ICD-10-CM
F64	Gender identity disorders	Diagnosis	ICD-10-CM
F64.2	Gender identity disorder of childhood	Diagnosis	ICD-10-CM
F65	Paraphilias	Diagnosis	ICD-10-CM
F65.5	Sadomasochism	Diagnosis	ICD-10-CM
F65.8	Other paraphilias	Diagnosis	ICD-10-CM
F68	Other disorders of adult personality and behavior	Diagnosis	ICD-10-CM
F68.1	Factitious disorder imposed on self	Diagnosis	ICD-10-CM
F70	Mild intellectual disabilities	Diagnosis	ICD-10-CM
F71	Moderate intellectual disabilities	Diagnosis	ICD-10-CM
F72	Severe intellectual disabilities	Diagnosis	ICD-10-CM
F73	Profound intellectual disabilities	Diagnosis	ICD-10-CM
F78	Other intellectual disabilities	Diagnosis	ICD-10-CM
F79	Unspecified intellectual disabilities	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F80	Specific developmental disorders of speech and language	Diagnosis	ICD-10-CM
F80.0	Phonological disorder	Diagnosis	ICD-10-CM
F80.1	Expressive language disorder	Diagnosis	ICD-10-CM
F80.2	Mixed receptive-expressive language disorder	Diagnosis	ICD-10-CM
F80.4	Speech and language development delay due to hearing loss	Diagnosis	ICD-10-CM
F80.8	Other developmental disorders of speech and language	Diagnosis	ICD-10-CM
F80.81	Childhood onset fluency disorder	Diagnosis	ICD-10-CM
F80.82	Social pragmatic communication disorder	Diagnosis	ICD-10-CM
F80.9	Developmental disorder of speech and language, unspecified	Diagnosis	ICD-10-CM
F81	Specific developmental disorders of scholastic skills	Diagnosis	ICD-10-CM
F81.0	Specific reading disorder	Diagnosis	ICD-10-CM
F81.8	Other developmental disorders of scholastic skills	Diagnosis	ICD-10-CM
F81.81	Disorder of written expression	Diagnosis	ICD-10-CM
F81.9	Developmental disorder of scholastic skills, unspecified	Diagnosis	ICD-10-CM
F82	Specific developmental disorder of motor function	Diagnosis	ICD-10-CM
F84	Pervasive developmental disorders	Diagnosis	ICD-10-CM
F90	Attention-deficit hyperactivity disorders	Diagnosis	ICD-10-CM
F91	Conduct disorders	Diagnosis	ICD-10-CM
F93	Emotional disorders with onset specific to childhood	Diagnosis	ICD-10-CM
F93.0	Separation anxiety disorder of childhood	Diagnosis	ICD-10-CM
F93.9	Childhood emotional disorder, unspecified	Diagnosis	ICD-10-CM
F94	Disorders of social functioning with onset specific to childhood and adolescence	Diagnosis	ICD-10-CM
F94.0	Selective mutism	Diagnosis	ICD-10-CM
F94.1	Reactive attachment disorder of childhood	Diagnosis	ICD-10-CM
F94.2	Disinhibited attachment disorder of childhood	Diagnosis	ICD-10-CM
F94.9	Childhood disorder of social functioning, unspecified	Diagnosis	ICD-10-CM
F95	Tic disorder	Diagnosis	ICD-10-CM
F95.1	Chronic motor or vocal tic disorder	Diagnosis	ICD-10-CM
F95.2	Tourette's disorder	Diagnosis	ICD-10-CM
F95.8	Other tic disorders	Diagnosis	ICD-10-CM
F95.9	Tic disorder, unspecified	Diagnosis	ICD-10-CM
F98	Other behavioral and emotional disorders with onset usually occurring in childhood and adolescence	Diagnosis	ICD-10-CM
F98.0	Enuresis not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F98.1	Encopresis not due to a substance or known physiological condition	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F98.2	Other feeding disorders of infancy and childhood	Diagnosis	ICD-10-CM
F98.21	Rumination disorder of infancy	Diagnosis	ICD-10-CM
F98.3	Pica of infancy and childhood	Diagnosis	ICD-10-CM
F98.4	Stereotyped movement disorders	Diagnosis	ICD-10-CM
F98.5	Adult onset fluency disorder	Diagnosis	ICD-10-CM
F98.8	Other specified behavioral and emotional disorders with onset usually occurring in childhood and adolescence	Diagnosis	ICD-10-CM
F98.9	Unspecified behavioral and emotional disorders with onset usually occurring in childhood and adolescence	Diagnosis	ICD-10-CM
V40.0	Problems with learning	Diagnosis	ICD-9-CM
V41.7	Problems with sexual function	Diagnosis	ICD-9-CM
	Persistent Mental Disorders		
294	Persistent mental disorders due to conditions classified elsewhere	Diagnosis	ICD-9-CM
294.0	Amnestic disorder in conditions classified elsewhere	Diagnosis	ICD-9-CM
294.1	Dementia in conditions classified elsewhere	Diagnosis	ICD-9-CM
294.10	Dementia in conditions classified elsewhere without behavioral disturbance	Diagnosis	ICD-9-CM
294.11	Dementia in conditions classified elsewhere with behavioral disturbance	Diagnosis	ICD-9-CM
294.2	Dementia, unspecified	Diagnosis	ICD-9-CM
294.20	Dementia, unspecified, without behavioral disturbance	Diagnosis	ICD-9-CM
294.21	Dementia, unspecified, with behavioral disturbance	Diagnosis	ICD-9-CM
294.8	Other persistent mental disorders due to conditions classified elsewhere	Diagnosis	ICD-9-CM
294.9	Unspecified persistent mental disorders due to conditions classified elsewhere	Diagnosis	ICD-9-CM
F02.80	Dementia in other diseases classified elsewhere without behavioral disturbance	Diagnosis	ICD-10-CM
F02.81	Dementia in other diseases classified elsewhere with behavioral disturbance	Diagnosis	ICD-10-CM
F03.90	Unspecified dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F04	Amnestic disorder due to known physiological condition	Diagnosis	ICD-10-CM
	Personality Disorders		
301	Personality disorders	Diagnosis	ICD-9-CM
301.0	Paranoid personality disorder	Diagnosis	ICD-9-CM
301.1	Affective personality disorder	Diagnosis	ICD-9-CM
301.11	Chronic hypomanic personality disorder	Diagnosis	ICD-9-CM
301.12	Chronic depressive personality disorder	Diagnosis	ICD-9-CM
301.13	Cyclothymic disorder	Diagnosis	ICD-9-CM
301.2	Schizoid personality disorder	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
301.20	Schizoid personality disorder, unspecified	Diagnosis	ICD-9-CM
301.21	Introverted personality	Diagnosis	ICD-9-CM
301.22	Schizotypal personality disorder	Diagnosis	ICD-9-CM
301.3	Explosive personality disorder	Diagnosis	ICD-9-CM
301.4	Obsessive-compulsive personality disorder	Diagnosis	ICD-9-CM
301.5	Histrionic personality disorder	Diagnosis	ICD-9-CM
301.50	Histrionic personality disorder, unspecified	Diagnosis	ICD-9-CM
301.51	Chronic factitious illness with physical symptoms	Diagnosis	ICD-9-CM
301.59	Other histrionic personality disorder	Diagnosis	ICD-9-CM
301.6	Dependent personality disorder	Diagnosis	ICD-9-CM
301.7	Antisocial personality disorder	Diagnosis	ICD-9-CM
301.8	Other personality disorders	Diagnosis	ICD-9-CM
301.81	Narcissistic personality disorder	Diagnosis	ICD-9-CM
301.82	Avoidant personality disorder	Diagnosis	ICD-9-CM
301.83	Borderline personality disorder	Diagnosis	ICD-9-CM
301.84	Passive-aggressive personality	Diagnosis	ICD-9-CM
301.89	Other personality disorder	Diagnosis	ICD-9-CM
301.9	Unspecified personality disorder	Diagnosis	ICD-9-CM
F21	Schizotypal disorder	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F60.0	Paranoid personality disorder	Diagnosis	ICD-10-CM
F60.2	Antisocial personality disorder	Diagnosis	ICD-10-CM
F60.3	Borderline personality disorder	Diagnosis	ICD-10-CM
F60.4	Histrionic personality disorder	Diagnosis	ICD-10-CM
F60.5	Obsessive-compulsive personality disorder	Diagnosis	ICD-10-CM
F60.6	Avoidant personality disorder	Diagnosis	ICD-10-CM
F60.81	Narcissistic personality disorder	Diagnosis	ICD-10-CM
F60.89	Other specific personality disorders	Diagnosis	ICD-10-CM
	Pervasive Developmental Disorders		
299	Pervasive developmental disorders	Diagnosis	ICD-9-CM
299.0	Autistic disorder	Diagnosis	ICD-9-CM
299.00	Autistic disorder, current or active state	Diagnosis	ICD-9-CM
299.01	Autistic disorder, residual state	Diagnosis	ICD-9-CM
299.1	Childhood disintegrative disorder	Diagnosis	ICD-9-CM
299.10	Childhood disintegrative disorder, current or active state	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
299.11	Childhood disintegrative disorder, residual state	Diagnosis	ICD-9-CM
299.8	Other specified pervasive developmental disorders	Diagnosis	ICD-9-CM
299.80	Other specified pervasive developmental disorders, current or active state	Diagnosis	ICD-9-CM
299.81	Other specified pervasive developmental disorders, residual state	Diagnosis	ICD-9-CM
299.9	Unspecified pervasive developmental disorder	Diagnosis	ICD-9-CM
299.90	Unspecified pervasive developmental disorder, current or active state	Diagnosis	ICD-9-CM
299.91	Unspecified pervasive developmental disorder, residual state	Diagnosis	ICD-9-CM
F84.0	Autistic disorder	Diagnosis	ICD-10-CM
F84.3	Other childhood disintegrative disorder	Diagnosis	ICD-10-CM
F84.5	Asperger's syndrome	Diagnosis	ICD-10-CM
F84.8	Other pervasive developmental disorders	Diagnosis	ICD-10-CM
F84.9	Pervasive developmental disorder, unspecified	Diagnosis	ICD-10-CM
	Post-traumatic Stress Disorder		
309.81	Posttraumatic stress disorder	Diagnosis	ICD-9-CM
F43.10	Post-traumatic stress disorder, unspecified	Diagnosis	ICD-10-CM
F43.11	Post-traumatic stress disorder, acute	Diagnosis	ICD-10-CM
F43.12	Post-traumatic stress disorder, chronic	Diagnosis	ICD-10-CM
	Psychotherapy		
8E0ZXY5	Meditation	Procedure	ICD-10-PCS
90810	Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an office or outpatient facility, approximately 20 to 30 minutes face-to-face with the patient;	Procedure	CPT-4
90811	Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an office or outpatient facility, approximately 20 to 30 minutes face-to-face with the patient; with medical evaluation and management services	Procedure	CPT-4
90812	Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an office or outpatient facility, approximately 45 to 50 minutes face-to-face with the patient;	Procedure	CPT-4
90813	Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an office or outpatient facility, approximately 45 to 50 minutes face-to-face with the patient; with medical evaluation and management services	Procedure	CPT-4

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
90814	Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an office or outpatient facility, approximately 75 to 80 minutes face-to-face with the patient;	Procedure	CPT-4
90815	Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an office or outpatient facility, approximately 75 to 80 minutes face-to-face with the patient; with medical evaluation and management services	Procedure	CPT-4
90823	Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an inpatient hospital, partial hospital or residential care setting, approximately 20 to 30 minutes face-to-face with the patient;	Procedure	CPT-4
90824	Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an inpatient hospital, partial hospital or residential care setting, approximately 20 to 30 minutes face-to-face with the patient; with medical evaluation and management services	Procedure	CPT-4
90826	Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an inpatient hospital, partial hospital or residential care setting, approximately 45 to 50 minutes face-to-face with the patient;	Procedure	CPT-4
90827	Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an inpatient hospital, partial hospital or residential care setting, approximately 45 to 50 minutes face-to-face with the patient; with medical evaluation and management services	Procedure	CPT-4
90828	Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an inpatient hospital, partial hospital or residential care setting, approximately 75 to 80 minutes face-to-face with the patient;	Procedure	CPT-4
90829	Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal communication, in an inpatient hospital, partial hospital or residential care setting, approximately 75 to 80 minutes face-to-face with the patient; with medical evaluation and management services	Procedure	CPT-4
90832	Psychotherapy, 30 minutes with patient	Procedure	CPT-4
90833	Psychotherapy, 30 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure)	Procedure	CPT-4
90834	Psychotherapy, 45 minutes with patient	Procedure	CPT-4

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
90836	Psychotherapy, 45 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure)	Procedure	CPT-4
90837	Psychotherapy, 60 minutes with patient	Procedure	CPT-4
90838	Psychotherapy, 60 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure)	Procedure	CPT-4
90839	Psychotherapy for crisis; first 60 minutes	Procedure	CPT-4
90840	Psychotherapy for crisis; each additional 30 minutes (List separately in addition to code for primary service)	Procedure	CPT-4
90845	Psychoanalysis	Procedure	CPT-4
90853	Group psychotherapy (other than of a multiple-family group)	Procedure	CPT-4
90857	Interactive group psychotherapy	Procedure	CPT-4
94.31	Psychoanalysis	Procedure	ICD-9-CM
94.32	Hypnotherapy	Procedure	ICD-9-CM
94.33	Behavior therapy	Procedure	ICD-9-CM
94.35	Crisis intervention	Procedure	ICD-9-CM
94.36	Play psychotherapy	Procedure	ICD-9-CM
94.37	Exploratory verbal psychotherapy	Procedure	ICD-9-CM
94.38	Supportive verbal psychotherapy	Procedure	ICD-9-CM
94.39	Other individual psychotherapy	Procedure	ICD-9-CM
94.43	Psychodrama	Procedure	ICD-9-CM
94.44	Other group therapy	Procedure	ICD-9-CM
GZ2ZZZZ	Crisis Intervention	Procedure	ICD-10-PCS
GZ50ZZZ	Individual Psychotherapy, Interactive	Procedure	ICD-10-PCS
GZ51ZZZ	Individual Psychotherapy, Behavioral	Procedure	ICD-10-PCS
GZ52ZZZ	Individual Psychotherapy, Cognitive	Procedure	ICD-10-PCS
GZ53ZZZ	Individual Psychotherapy, Interpersonal	Procedure	ICD-10-PCS
GZ54ZZZ	Individual Psychotherapy, Psychoanalysis	Procedure	ICD-10-PCS
GZ55ZZZ	Individual Psychotherapy, Psychodynamic	Procedure	ICD-10-PCS
GZ56ZZZ	Individual Psychotherapy, Supportive	Procedure	ICD-10-PCS
GZ58ZZZ	Individual Psychotherapy, Cognitive-Behavioral	Procedure	ICD-10-PCS
GZC9ZZZ	Biofeedback	Procedure	ICD-10-PCS
GZFZZZZ	Hypnosis	Procedure	ICD-10-PCS
GZHZZZZ	Group Psychotherapy	Procedure	ICD-10-PCS
	Psychotic Conditions		
290.8	Other specified senile psychotic conditions	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
290.9	Unspecified senile psychotic condition	Diagnosis	ICD-9-CM
297	Delusional disorders	Diagnosis	ICD-9-CM
297.0	Paranoid state, simple	Diagnosis	ICD-9-CM
297.1	Delusional disorder	Diagnosis	ICD-9-CM
297.2	Paraphrenia	Diagnosis	ICD-9-CM
297.3	Shared psychotic disorder	Diagnosis	ICD-9-CM
297.8	Other specified paranoid states	Diagnosis	ICD-9-CM
297.9	Unspecified paranoid state	Diagnosis	ICD-9-CM
298	Other nonorganic psychoses	Diagnosis	ICD-9-CM
298.0	Depressive type psychosis	Diagnosis	ICD-9-CM
298.1	Excitative type psychosis	Diagnosis	ICD-9-CM
298.2	Reactive confusion	Diagnosis	ICD-9-CM
298.3	Acute paranoid reaction	Diagnosis	ICD-9-CM
298.4	Psychogenic paranoid psychosis	Diagnosis	ICD-9-CM
298.8	Other and unspecified reactive psychosis	Diagnosis	ICD-9-CM
298.9	Unspecified psychosis	Diagnosis	ICD-9-CM
F24	Shared psychotic disorder	Diagnosis	ICD-10-CM
F28	Other psychotic disorder not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F29	Unspecified psychosis not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F44.89	Other dissociative and conversion disorders	Diagnosis	ICD-10-CM
	Schizophrenia		
295	Schizophrenic disorders	Diagnosis	ICD-9-CM
295.0	Simple type schizophrenia	Diagnosis	ICD-9-CM
295.00	Simple schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.01	Simple schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.02	Simple schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.03	Simple schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.04	Simple schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.05	Simple schizophrenia, in remission	Diagnosis	ICD-9-CM
295.1	Disorganized type schizophrenia	Diagnosis	ICD-9-CM
295.10	Disorganized schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.11	Disorganized schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.12	Disorganized schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.13	Disorganized schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.14	Disorganized schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
295.15	Disorganized schizophrenia, in remission	Diagnosis	ICD-9-CM
295.2	Catatonic type schizophrenia	Diagnosis	ICD-9-CM
295.20	Catatonic schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.21	Catatonic schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.22	Catatonic schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.23	Catatonic schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.24	Catatonic schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.25	Catatonic schizophrenia, in remission	Diagnosis	ICD-9-CM
295.3	Paranoid type schizophrenia	Diagnosis	ICD-9-CM
295.30	Paranoid schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.31	Paranoid schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.32	Paranoid schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.33	Paranoid schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.34	Paranoid schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.35	Paranoid schizophrenia, in remission	Diagnosis	ICD-9-CM
295.4	Schizophreniform disorder	Diagnosis	ICD-9-CM
295.40	Schizophreniform disorder, unspecified	Diagnosis	ICD-9-CM
295.41	Schizophreniform disorder, subchronic	Diagnosis	ICD-9-CM
295.42	Schizophreniform disorder, chronic	Diagnosis	ICD-9-CM
295.43	Schizophreniform disorder, subchronic with acute exacerbation	Diagnosis	ICD-9-CM
295.44	Schizophreniform disorder, chronic with acute exacerbation	Diagnosis	ICD-9-CM
295.45	Schizophreniform disorder, in remission	Diagnosis	ICD-9-CM
295.5	Latent schizophrenia	Diagnosis	ICD-9-CM
295.50	Latent schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.51	Latent schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.52	Latent schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.53	Latent schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.54	Latent schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.55	Latent schizophrenia, in remission	Diagnosis	ICD-9-CM
295.6	Schizophrenic disorders, residual type	Diagnosis	ICD-9-CM
295.60	Schizophrenic disorders, residual type, unspecified	Diagnosis	ICD-9-CM
295.61	Schizophrenic disorders, residual type, subchronic	Diagnosis	ICD-9-CM
295.62	Schizophrenic disorders, residual type, chronic	Diagnosis	ICD-9-CM
295.63	Schizophrenic disorders, residual type, subchronic with acute exacerbation	Diagnosis	ICD-9-CM
295.64	Schizophrenic disorders, residual type, chronic with acute exacerbation	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
295.65	Schizophrenic disorders, residual type, in remission	Diagnosis	ICD-9-CM
295.7	Schizoaffective disorder	Diagnosis	ICD-9-CM
295.70	Schizoaffective disorder, unspecified	Diagnosis	ICD-9-CM
295.71	Schizoaffective disorder, subchronic	Diagnosis	ICD-9-CM
295.72	Schizoaffective disorder, chronic	Diagnosis	ICD-9-CM
295.73	Schizoaffective disorder, subchronic with acute exacerbation	Diagnosis	ICD-9-CM
295.74	Schizoaffective disorder, chronic with acute exacerbation	Diagnosis	ICD-9-CM
295.75	Schizoaffective disorder, in remission	Diagnosis	ICD-9-CM
295.8	Other specified types of schizophrenia	Diagnosis	ICD-9-CM
295.80	Other specified types of schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.81	Other specified types of schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.82	Other specified types of schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.83	Other specified types of schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.84	Other specified types of schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.85	Other specified types of schizophrenia, in remission	Diagnosis	ICD-9-CM
295.9	Unspecified schizophrenia	Diagnosis	ICD-9-CM
295.90	Unspecified schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.91	Unspecified schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.92	Unspecified schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.93	Unspecified schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.94	Unspecified schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.95	Unspecified schizophrenia, in remission	Diagnosis	ICD-9-CM
F20.0	Paranoid schizophrenia	Diagnosis	ICD-10-CM
F20.1	Disorganized schizophrenia	Diagnosis	ICD-10-CM
F20.2	Catatonic schizophrenia	Diagnosis	ICD-10-CM
F20.3	Undifferentiated schizophrenia	Diagnosis	ICD-10-CM
F20.5	Residual schizophrenia	Diagnosis	ICD-10-CM
F20.81	Schizophreniform disorder	Diagnosis	ICD-10-CM
F20.89	Other schizophrenia	Diagnosis	ICD-10-CM
F20.9	Schizophrenia, unspecified	Diagnosis	ICD-10-CM
F25.0	Schizoaffective disorder, bipolar type	Diagnosis	ICD-10-CM
F25.1	Schizoaffective disorder, depressive type	Diagnosis	ICD-10-CM
F25.8	Other schizoaffective disorders	Diagnosis	ICD-10-CM
F25.9	Schizoaffective disorder, unspecified	Diagnosis	ICD-10-CM
Sleep Disorder			

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
307.4	Specific disorders of sleep of nonorganic origin	Diagnosis	ICD-9-CM
307.40	Nonorganic sleep disorder, unspecified	Diagnosis	ICD-9-CM
307.41	Transient disorder of initiating or maintaining sleep	Diagnosis	ICD-9-CM
307.42	Persistent disorder of initiating or maintaining sleep	Diagnosis	ICD-9-CM
307.43	Transient disorder of initiating or maintaining wakefulness	Diagnosis	ICD-9-CM
307.44	Persistent disorder of initiating or maintaining wakefulness	Diagnosis	ICD-9-CM
307.45	Circadian rhythm sleep disorder of nonorganic origin	Diagnosis	ICD-9-CM
307.46	Sleep arousal disorder	Diagnosis	ICD-9-CM
307.47	Other dysfunctions of sleep stages or arousal from sleep	Diagnosis	ICD-9-CM
307.48	Repetitive intrusions of sleep	Diagnosis	ICD-9-CM
307.49	Other specific disorder of sleep of nonorganic origin	Diagnosis	ICD-9-CM
327	Organic sleep disorders	Diagnosis	ICD-9-CM
327.0	Organic disorders of initiating and maintaining sleep [Organic insomnia]	Diagnosis	ICD-9-CM
327.00	Organic insomnia, unspecified	Diagnosis	ICD-9-CM
327.01	Insomnia due to medical condition classified elsewhere	Diagnosis	ICD-9-CM
327.02	Insomnia due to mental disorder	Diagnosis	ICD-9-CM
327.09	Other organic insomnia	Diagnosis	ICD-9-CM
327.1	Organic disorders of excessive somnolence [Organic hypersomnia]	Diagnosis	ICD-9-CM
327.10	Organic hypersomnia, unspecified	Diagnosis	ICD-9-CM
327.11	Idiopathic hypersomnia with long sleep time	Diagnosis	ICD-9-CM
327.12	Idiopathic hypersomnia without long sleep time	Diagnosis	ICD-9-CM
327.13	Recurrent hypersomnia	Diagnosis	ICD-9-CM
327.14	Hypersomnia due to medical condition classified elsewhere	Diagnosis	ICD-9-CM
327.15	Hypersomnia due to mental disorder	Diagnosis	ICD-9-CM
327.19	Other organic hypersomnia	Diagnosis	ICD-9-CM
327.2	Organic sleep apnea	Diagnosis	ICD-9-CM
327.20	Organic sleep apnea, unspecified	Diagnosis	ICD-9-CM
327.21	Primary central sleep apnea	Diagnosis	ICD-9-CM
327.23	Obstructive sleep apnea (adult) (pediatric)	Diagnosis	ICD-9-CM
327.24	Idiopathic sleep related nonobstructive alveolar hypoventilation	Diagnosis	ICD-9-CM
327.25	Congenital central alveolar hypoventilation syndrome	Diagnosis	ICD-9-CM
327.26	Sleep related hypoventilation/hypoxemia in conditions classifiable elsewhere	Diagnosis	ICD-9-CM
327.27	Central sleep apnea in conditions classified elsewhere	Diagnosis	ICD-9-CM
327.29	Other organic sleep apnea	Diagnosis	ICD-9-CM
327.3	Circadian rhythm sleep disorder	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
327.30	Circadian rhythm sleep disorder, unspecified	Diagnosis	ICD-9-CM
327.31	Circadian rhythm sleep disorder, delayed sleep phase type	Diagnosis	ICD-9-CM
327.32	Circadian rhythm sleep disorder, advanced sleep phase type	Diagnosis	ICD-9-CM
327.33	Circadian rhythm sleep disorder, irregular sleep-wake type	Diagnosis	ICD-9-CM
327.34	Circadian rhythm sleep disorder, free-running type	Diagnosis	ICD-9-CM
327.35	Circadian rhythm sleep disorder, jet lag type	Diagnosis	ICD-9-CM
327.36	Circadian rhythm sleep disorder, shift work type	Diagnosis	ICD-9-CM
327.37	Circadian rhythm sleep disorder in conditions classified elsewhere	Diagnosis	ICD-9-CM
327.39	Other circadian rhythm sleep disorder	Diagnosis	ICD-9-CM
327.4	Organic parasomnia	Diagnosis	ICD-9-CM
327.40	Organic parasomnia, unspecified	Diagnosis	ICD-9-CM
327.41	Confusional arousals	Diagnosis	ICD-9-CM
327.42	REM sleep behavior disorder	Diagnosis	ICD-9-CM
327.43	Recurrent isolated sleep paralysis	Diagnosis	ICD-9-CM
327.44	Parasomnia in conditions classified elsewhere	Diagnosis	ICD-9-CM
327.49	Other organic parasomnia	Diagnosis	ICD-9-CM
327.5	Organic sleep related movement disorders	Diagnosis	ICD-9-CM
327.51	Periodic limb movement disorder	Diagnosis	ICD-9-CM
327.52	Sleep related leg cramps	Diagnosis	ICD-9-CM
327.53	Sleep related bruxism	Diagnosis	ICD-9-CM
327.59	Other organic sleep related movement disorders	Diagnosis	ICD-9-CM
327.8	Other organic sleep disorders	Diagnosis	ICD-9-CM
347	Cataplexy and narcolepsy	Diagnosis	ICD-9-CM
347.0	Narcolepsy	Diagnosis	ICD-9-CM
347.00	Narcolepsy, without cataplexy	Diagnosis	ICD-9-CM
347.01	Narcolepsy, with cataplexy	Diagnosis	ICD-9-CM
347.1	Narcolepsy in conditions classified elsewhere	Diagnosis	ICD-9-CM
347.10	Narcolepsy in conditions classified elsewhere, without cataplexy	Diagnosis	ICD-9-CM
347.11	Narcolepsy in conditions classified elsewhere, with cataplexy	Diagnosis	ICD-9-CM
780.5	Sleep disturbances	Diagnosis	ICD-9-CM
780.50	Unspecified sleep disturbance	Diagnosis	ICD-9-CM
780.51	Insomnia with sleep apnea, unspecified	Diagnosis	ICD-9-CM
780.52	Insomnia, unspecified	Diagnosis	ICD-9-CM
780.53	Hypersomnia with sleep apnea, unspecified	Diagnosis	ICD-9-CM
780.54	Hypersomnia, unspecified	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
780.55	Disruption of 24 hour sleep wake cycle, unspecified	Diagnosis	ICD-9-CM
780.56	Dysfunctions associated with sleep stages or arousal from sleep	Diagnosis	ICD-9-CM
780.57	Unspecified sleep apnea	Diagnosis	ICD-9-CM
780.58	Sleep related movement disorder, unspecified	Diagnosis	ICD-9-CM
780.59	Other sleep disturbances	Diagnosis	ICD-9-CM
F51	Sleep disorders not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F51.0	Insomnia not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F51.01	Primary insomnia	Diagnosis	ICD-10-CM
F51.02	Adjustment insomnia	Diagnosis	ICD-10-CM
F51.03	Paradoxical insomnia	Diagnosis	ICD-10-CM
F51.04	Psychophysiologic insomnia	Diagnosis	ICD-10-CM
F51.05	Insomnia due to other mental disorder	Diagnosis	ICD-10-CM
F51.09	Other insomnia not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F51.1	Hypersomnia not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F51.11	Primary hypersomnia	Diagnosis	ICD-10-CM
F51.12	Insufficient sleep syndrome	Diagnosis	ICD-10-CM
F51.13	Hypersomnia due to other mental disorder	Diagnosis	ICD-10-CM
F51.19	Other hypersomnia not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F51.3	Sleepwalking [somnambulism]	Diagnosis	ICD-10-CM
F51.4	Sleep terrors [night terrors]	Diagnosis	ICD-10-CM
F51.5	Nightmare disorder	Diagnosis	ICD-10-CM
F51.8	Other sleep disorders not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F51.9	Sleep disorder not due to a substance or known physiological condition, unspecified	Diagnosis	ICD-10-CM
G47	Sleep disorders	Diagnosis	ICD-10-CM
G47.0	Insomnia	Diagnosis	ICD-10-CM
G47.00	Insomnia, unspecified	Diagnosis	ICD-10-CM
G47.01	Insomnia due to medical condition	Diagnosis	ICD-10-CM
G47.09	Other insomnia	Diagnosis	ICD-10-CM
G47.1	Hypersomnia	Diagnosis	ICD-10-CM
G47.10	Hypersomnia, unspecified	Diagnosis	ICD-10-CM
G47.11	Idiopathic hypersomnia with long sleep time	Diagnosis	ICD-10-CM
G47.12	Idiopathic hypersomnia without long sleep time	Diagnosis	ICD-10-CM
G47.13	Recurrent hypersomnia	Diagnosis	ICD-10-CM
G47.14	Hypersomnia due to medical condition	Diagnosis	ICD-10-CM
G47.19	Other hypersomnia	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
G47.2	Circadian rhythm sleep disorders	Diagnosis	ICD-10-CM
G47.20	Circadian rhythm sleep disorder, unspecified type	Diagnosis	ICD-10-CM
G47.21	Circadian rhythm sleep disorder, delayed sleep phase type	Diagnosis	ICD-10-CM
G47.22	Circadian rhythm sleep disorder, advanced sleep phase type	Diagnosis	ICD-10-CM
G47.23	Circadian rhythm sleep disorder, irregular sleep wake type	Diagnosis	ICD-10-CM
G47.24	Circadian rhythm sleep disorder, free running type	Diagnosis	ICD-10-CM
G47.25	Circadian rhythm sleep disorder, jet lag type	Diagnosis	ICD-10-CM
G47.26	Circadian rhythm sleep disorder, shift work type	Diagnosis	ICD-10-CM
G47.27	Circadian rhythm sleep disorder in conditions classified elsewhere	Diagnosis	ICD-10-CM
G47.29	Other circadian rhythm sleep disorder	Diagnosis	ICD-10-CM
G47.3	Sleep apnea	Diagnosis	ICD-10-CM
G47.30	Sleep apnea, unspecified	Diagnosis	ICD-10-CM
G47.31	Primary central sleep apnea	Diagnosis	ICD-10-CM
G47.33	Obstructive sleep apnea (adult) (pediatric)	Diagnosis	ICD-10-CM
G47.34	Idiopathic sleep related nonobstructive alveolar hypoventilation	Diagnosis	ICD-10-CM
G47.35	Congenital central alveolar hypoventilation syndrome	Diagnosis	ICD-10-CM
G47.36	Sleep related hypoventilation in conditions classified elsewhere	Diagnosis	ICD-10-CM
G47.37	Central sleep apnea in conditions classified elsewhere	Diagnosis	ICD-10-CM
G47.39	Other sleep apnea	Diagnosis	ICD-10-CM
G47.4	Narcolepsy and cataplexy	Diagnosis	ICD-10-CM
G47.41	Narcolepsy	Diagnosis	ICD-10-CM
G47.411	Narcolepsy with cataplexy	Diagnosis	ICD-10-CM
G47.419	Narcolepsy without cataplexy	Diagnosis	ICD-10-CM
G47.42	Narcolepsy in conditions classified elsewhere	Diagnosis	ICD-10-CM
G47.421	Narcolepsy in conditions classified elsewhere with cataplexy	Diagnosis	ICD-10-CM
G47.429	Narcolepsy in conditions classified elsewhere without cataplexy	Diagnosis	ICD-10-CM
G47.5	Parasomnia	Diagnosis	ICD-10-CM
G47.50	Parasomnia, unspecified	Diagnosis	ICD-10-CM
G47.51	Confusional arousals	Diagnosis	ICD-10-CM
G47.52	REM sleep behavior disorder	Diagnosis	ICD-10-CM
G47.53	Recurrent isolated sleep paralysis	Diagnosis	ICD-10-CM
G47.54	Parasomnia in conditions classified elsewhere	Diagnosis	ICD-10-CM
G47.59	Other parasomnia	Diagnosis	ICD-10-CM
G47.6	Sleep related movement disorders	Diagnosis	ICD-10-CM
G47.61	Periodic limb movement disorder	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
G47.62	Sleep related leg cramps	Diagnosis	ICD-10-CM
G47.63	Sleep related bruxism	Diagnosis	ICD-10-CM
G47.69	Other sleep related movement disorders	Diagnosis	ICD-10-CM
G47.8	Other sleep disorders	Diagnosis	ICD-10-CM
G47.9	Sleep disorder, unspecified	Diagnosis	ICD-10-CM
Substance Abuse			
291	Alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.0	Alcohol withdrawal delirium	Diagnosis	ICD-9-CM
291.1	Alcohol-induced persisting amnestic disorder	Diagnosis	ICD-9-CM
291.2	Alcohol-induced persisting dementia	Diagnosis	ICD-9-CM
291.3	Alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
291.4	Idiosyncratic alcohol intoxication	Diagnosis	ICD-9-CM
291.5	Alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
291.8	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.81	Alcohol withdrawal	Diagnosis	ICD-9-CM
291.82	Alcohol induced sleep disorders	Diagnosis	ICD-9-CM
291.89	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.9	Unspecified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
292	Drug-induced mental disorders	Diagnosis	ICD-9-CM
292.0	Drug withdrawal	Diagnosis	ICD-9-CM
292.1	Drug-induced psychotic disorder	Diagnosis	ICD-9-CM
292.11	Drug-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
292.12	Drug-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
292.2	Pathological drug intoxication	Diagnosis	ICD-9-CM
292.8	Other specified drug-induced mental disorders	Diagnosis	ICD-9-CM
292.82	Drug-induced persisting dementia	Diagnosis	ICD-9-CM
292.83	Drug-induced persisting amnestic disorder	Diagnosis	ICD-9-CM
292.84	Drug-induced mood disorder	Diagnosis	ICD-9-CM
292.85	Drug induced sleep disorders	Diagnosis	ICD-9-CM
292.89	Other specified drug-induced mental disorder	Diagnosis	ICD-9-CM
292.9	Unspecified drug-induced mental disorder	Diagnosis	ICD-9-CM
303	Alcohol dependence syndrome	Diagnosis	ICD-9-CM
303.0	Acute alcoholic intoxication	Diagnosis	ICD-9-CM
303.00	Acute alcoholic intoxication, unspecified	Diagnosis	ICD-9-CM
303.01	Acute alcoholic intoxication, continuous	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
303.02	Acute alcoholic intoxication, episodic	Diagnosis	ICD-9-CM
303.03	Acute alcoholic intoxication, in remission	Diagnosis	ICD-9-CM
303.9	Other and unspecified alcohol dependence	Diagnosis	ICD-9-CM
303.90	Other and unspecified alcohol dependence, unspecified	Diagnosis	ICD-9-CM
303.91	Other and unspecified alcohol dependence, continuous	Diagnosis	ICD-9-CM
303.92	Other and unspecified alcohol dependence, episodic	Diagnosis	ICD-9-CM
303.93	Other and unspecified alcohol dependence, in remission	Diagnosis	ICD-9-CM
304	Drug dependence	Diagnosis	ICD-9-CM
304.0	Opioid type dependence	Diagnosis	ICD-9-CM
304.00	Opioid type dependence, unspecified	Diagnosis	ICD-9-CM
304.01	Opioid type dependence, continuous	Diagnosis	ICD-9-CM
304.02	Opioid type dependence, episodic	Diagnosis	ICD-9-CM
304.03	Opioid type dependence, in remission	Diagnosis	ICD-9-CM
304.1	Sedative, hypnotic or anxiolytic dependence	Diagnosis	ICD-9-CM
304.10	Sedative, hypnotic or anxiolytic dependence, unspecified	Diagnosis	ICD-9-CM
304.11	Sedative, hypnotic or anxiolytic dependence, continuous	Diagnosis	ICD-9-CM
304.12	Sedative, hypnotic or anxiolytic dependence, episodic	Diagnosis	ICD-9-CM
304.13	Sedative, hypnotic or anxiolytic dependence, in remission	Diagnosis	ICD-9-CM
304.2	Cocaine dependence	Diagnosis	ICD-9-CM
304.20	Cocaine dependence, unspecified	Diagnosis	ICD-9-CM
304.21	Cocaine dependence, continuous	Diagnosis	ICD-9-CM
304.22	Cocaine dependence, episodic	Diagnosis	ICD-9-CM
304.23	Cocaine dependence, in remission	Diagnosis	ICD-9-CM
304.3	Cannabis dependence	Diagnosis	ICD-9-CM
304.30	Cannabis dependence, unspecified	Diagnosis	ICD-9-CM
304.31	Cannabis dependence, continuous	Diagnosis	ICD-9-CM
304.32	Cannabis dependence, episodic	Diagnosis	ICD-9-CM
304.33	Cannabis dependence, in remission	Diagnosis	ICD-9-CM
304.4	Amphetamine and other psychostimulant dependence	Diagnosis	ICD-9-CM
304.40	Amphetamine and other psychostimulant dependence, unspecified	Diagnosis	ICD-9-CM
304.41	Amphetamine and other psychostimulant dependence, continuous	Diagnosis	ICD-9-CM
304.42	Amphetamine and other psychostimulant dependence, episodic	Diagnosis	ICD-9-CM
304.43	Amphetamine and other psychostimulant dependence, in remission	Diagnosis	ICD-9-CM
304.5	Hallucinogen dependence	Diagnosis	ICD-9-CM
304.50	Hallucinogen dependence, unspecified	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
304.51	Hallucinogen dependence, continuous	Diagnosis	ICD-9-CM
304.52	Hallucinogen dependence, episodic	Diagnosis	ICD-9-CM
304.53	Hallucinogen dependence, in remission	Diagnosis	ICD-9-CM
304.6	Other specified drug dependence	Diagnosis	ICD-9-CM
304.60	Other specified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.61	Other specified drug dependence, continuous	Diagnosis	ICD-9-CM
304.62	Other specified drug dependence, episodic	Diagnosis	ICD-9-CM
304.63	Other specified drug dependence, in remission	Diagnosis	ICD-9-CM
304.7	Combinations of opioid type drug with any other drug dependence	Diagnosis	ICD-9-CM
304.70	Combinations of opioid type drug with any other drug dependence, unspecified	Diagnosis	ICD-9-CM
304.71	Combinations of opioid type drug with any other drug dependence, continuous	Diagnosis	ICD-9-CM
304.72	Combinations of opioid type drug with any other drug dependence, episodic	Diagnosis	ICD-9-CM
304.73	Combinations of opioid type drug with any other drug dependence, in remission	Diagnosis	ICD-9-CM
304.8	Combinations of drug dependence excluding opioid type drug	Diagnosis	ICD-9-CM
304.80	Combinations of drug dependence excluding opioid type drug, unspecified	Diagnosis	ICD-9-CM
304.81	Combinations of drug dependence excluding opioid type drug, continuous	Diagnosis	ICD-9-CM
304.82	Combinations of drug dependence excluding opioid type drug, episodic	Diagnosis	ICD-9-CM
304.83	Combinations of drug dependence excluding opioid type drug, in remission	Diagnosis	ICD-9-CM
304.9	Unspecified drug dependence	Diagnosis	ICD-9-CM
304.90	Unspecified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.91	Unspecified drug dependence, continuous	Diagnosis	ICD-9-CM
304.92	Unspecified drug dependence, episodic	Diagnosis	ICD-9-CM
304.93	Unspecified drug dependence, in remission	Diagnosis	ICD-9-CM
305	Nondependent abuse of drugs	Diagnosis	ICD-9-CM
305.0	Nondependent alcohol abuse	Diagnosis	ICD-9-CM
305.00	Nondependent alcohol abuse, unspecified	Diagnosis	ICD-9-CM
305.01	Nondependent alcohol abuse, continuous	Diagnosis	ICD-9-CM
305.02	Nondependent alcohol abuse, episodic	Diagnosis	ICD-9-CM
305.03	Nondependent alcohol abuse, in remission	Diagnosis	ICD-9-CM
305.2	Nondependent cannabis abuse	Diagnosis	ICD-9-CM
305.20	Nondependent cannabis abuse, unspecified	Diagnosis	ICD-9-CM
305.21	Nondependent cannabis abuse, continuous	Diagnosis	ICD-9-CM
305.22	Nondependent cannabis abuse, episodic	Diagnosis	ICD-9-CM
305.23	Nondependent cannabis abuse, in remission	Diagnosis	ICD-9-CM
305.3	Nondependent hallucinogen abuse	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
305.30	Nondependent hallucinogen abuse, unspecified	Diagnosis	ICD-9-CM
305.31	Nondependent hallucinogen abuse, continuous	Diagnosis	ICD-9-CM
305.32	Nondependent hallucinogen abuse, episodic	Diagnosis	ICD-9-CM
305.33	Nondependent hallucinogen abuse, in remission	Diagnosis	ICD-9-CM
305.4	Nondependent sedative, hypnotic or anxiolytic abuse	Diagnosis	ICD-9-CM
305.40	Nondependent sedative, hypnotic or anxiolytic abuse, unspecified	Diagnosis	ICD-9-CM
305.41	Nondependent sedative hypnotic or anxiolytic abuse, continuous	Diagnosis	ICD-9-CM
305.42	Nondependent sedative, hypnotic or anxiolytic abuse, episodic	Diagnosis	ICD-9-CM
305.43	Nondependent sedative, hypnotic or anxiolytic abuse, in remission	Diagnosis	ICD-9-CM
305.5	Nondependent opioid abuse	Diagnosis	ICD-9-CM
305.50	Nondependent opioid abuse, unspecified	Diagnosis	ICD-9-CM
305.51	Nondependent opioid abuse, continuous	Diagnosis	ICD-9-CM
305.52	Nondependent opioid abuse, episodic	Diagnosis	ICD-9-CM
305.53	Nondependent opioid abuse, in remission	Diagnosis	ICD-9-CM
305.6	Nondependent cocaine abuse	Diagnosis	ICD-9-CM
305.60	Nondependent cocaine abuse, unspecified	Diagnosis	ICD-9-CM
305.61	Nondependent cocaine abuse, continuous	Diagnosis	ICD-9-CM
305.62	Nondependent cocaine abuse, episodic	Diagnosis	ICD-9-CM
305.63	Nondependent cocaine abuse, in remission	Diagnosis	ICD-9-CM
305.7	Nondependent amphetamine or related acting sympathomimetic abuse	Diagnosis	ICD-9-CM
305.70	Nondependent amphetamine or related acting sympathomimetic abuse, unspecified	Diagnosis	ICD-9-CM
305.71	Nondependent amphetamine or related acting sympathomimetic abuse, continuous	Diagnosis	ICD-9-CM
305.72	Nondependent amphetamine or related acting sympathomimetic abuse, episodic	Diagnosis	ICD-9-CM
305.73	Nondependent amphetamine or related acting sympathomimetic abuse, in remission	Diagnosis	ICD-9-CM
305.8	Nondependent antidepressant type abuse	Diagnosis	ICD-9-CM
305.80	Nondependent antidepressant type abuse, unspecified	Diagnosis	ICD-9-CM
305.81	Nondependent antidepressant type abuse, continuous	Diagnosis	ICD-9-CM
305.82	Nondependent antidepressant type abuse, episodic	Diagnosis	ICD-9-CM
305.83	Nondependent antidepressant type abuse, in remission	Diagnosis	ICD-9-CM
305.9	Other, mixed, or unspecified nondependent drug abuse	Diagnosis	ICD-9-CM
305.90	Other, mixed, or unspecified nondependent drug abuse, unspecified	Diagnosis	ICD-9-CM
305.91	Other, mixed, or unspecified nondependent drug abuse, continuous	Diagnosis	ICD-9-CM
305.92	Other, mixed, or unspecified nondependent drug abuse, episodic	Diagnosis	ICD-9-CM
305.93	Other, mixed, or unspecified nondependent drug abuse, in remission	Diagnosis	ICD-9-CM
357.5	Alcoholic polyneuropathy	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
425.5	Alcoholic cardiomyopathy	Diagnosis	ICD-9-CM
4320F	Patient counseled regarding psychosocial and pharmacologic treatment options for alcohol dependence (SUD)	Procedure	CPT-2
535.3	Alcoholic gastritis	Diagnosis	ICD-9-CM
535.30	Alcoholic gastritis without mention of hemorrhage	Diagnosis	ICD-9-CM
535.31	Alcoholic gastritis with hemorrhage	Diagnosis	ICD-9-CM
571.0	Alcoholic fatty liver	Diagnosis	ICD-9-CM
571.1	Acute alcoholic hepatitis	Diagnosis	ICD-9-CM
571.2	Alcoholic cirrhosis of liver	Diagnosis	ICD-9-CM
571.3	Unspecified alcoholic liver damage	Diagnosis	ICD-9-CM
94.46	Alcoholism counseling	Procedure	ICD-9-CM
94.53	Referral for alcoholism rehabilitation	Procedure	ICD-9-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.61	Alcohol rehabilitation	Procedure	ICD-9-CM
94.62	Alcohol detoxification	Procedure	ICD-9-CM
94.63	Alcohol rehabilitation and detoxification	Procedure	ICD-9-CM
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.11	Opioid abuse, in remission	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.21	Opioid dependence, in remission	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F12.10	Cannabis abuse, uncomplicated	Diagnosis	ICD-10-CM
F12.11	Cannabis abuse, in remission	Diagnosis	ICD-10-CM
F12.120	Cannabis abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.121	Cannabis abuse with intoxication delirium	Diagnosis	ICD-10-CM
F12.122	Cannabis abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.129	Cannabis abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.150	Cannabis abuse with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.151	Cannabis abuse with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.159	Cannabis abuse with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.180	Cannabis abuse with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.188	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.19	Cannabis abuse with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.20	Cannabis dependence, uncomplicated	Diagnosis	ICD-10-CM
F12.21	Cannabis dependence, in remission	Diagnosis	ICD-10-CM
F12.220	Cannabis dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.221	Cannabis dependence with intoxication delirium	Diagnosis	ICD-10-CM
F12.222	Cannabis dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.229	Cannabis dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.23	Cannabis dependence with withdrawal	Diagnosis	ICD-10-CM
F12.250	Cannabis dependence with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.251	Cannabis dependence with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.259	Cannabis dependence with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.280	Cannabis dependence with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.288	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.29	Cannabis dependence with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.90	Cannabis use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F12.920	Cannabis use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.921	Cannabis use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.929	Cannabis use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.93	Cannabis use, unspecified with withdrawal	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F12.950	Cannabis use, unspecified with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.980	Cannabis use, unspecified with anxiety disorder	Diagnosis	ICD-10-CM
F12.988	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Diagnosis	ICD-10-CM
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	Diagnosis	ICD-10-CM
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Diagnosis	ICD-10-CM
F13.21	Sedative, hypnotic or anxiolytic dependence, in remission	Diagnosis	ICD-10-CM
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium	Diagnosis	ICD-10-CM
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances	Diagnosis	ICD-10-CM
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F14.10	Cocaine abuse, uncomplicated	Diagnosis	ICD-10-CM
F14.11	Cocaine abuse, in remission	Diagnosis	ICD-10-CM
F14.120	Cocaine abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.121	Cocaine abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F14.129	Cocaine abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.14	Cocaine abuse with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.180	Cocaine abuse with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.182	Cocaine abuse with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.188	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.19	Cocaine abuse with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.20	Cocaine dependence, uncomplicated	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F14.21	Cocaine dependence, in remission	Diagnosis	ICD-10-CM
F14.220	Cocaine dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.221	Cocaine dependence with intoxication delirium	Diagnosis	ICD-10-CM
F14.222	Cocaine dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.229	Cocaine dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.23	Cocaine dependence with withdrawal	Diagnosis	ICD-10-CM
F14.24	Cocaine dependence with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.280	Cocaine dependence with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.282	Cocaine dependence with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.288	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.29	Cocaine dependence with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.90	Cocaine use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F14.920	Cocaine use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.921	Cocaine use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.929	Cocaine use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.988	Cocaine use, unspecified with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15.10	Other stimulant abuse, uncomplicated	Diagnosis	ICD-10-CM
F15.11	Other stimulant abuse, in remission	Diagnosis	ICD-10-CM
F15.120	Other stimulant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.121	Other stimulant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F15.122	Other stimulant abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.129	Other stimulant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F15.14	Other stimulant abuse with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.182	Other stimulant abuse with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.188	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.20	Other stimulant dependence, uncomplicated	Diagnosis	ICD-10-CM
F15.21	Other stimulant dependence, in remission	Diagnosis	ICD-10-CM
F15.220	Other stimulant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.221	Other stimulant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F15.222	Other stimulant dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.229	Other stimulant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.23	Other stimulant dependence with withdrawal	Diagnosis	ICD-10-CM
F15.24	Other stimulant dependence with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.282	Other stimulant dependence with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.288	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.90	Other stimulant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.921	Other stimulant use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.929	Other stimulant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.93	Other stimulant use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F16.10	Hallucinogen abuse, uncomplicated	Diagnosis	ICD-10-CM
F16.11	Hallucinogen abuse, in remission	Diagnosis	ICD-10-CM
F16.120	Hallucinogen abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.121	Hallucinogen abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F16.129	Hallucinogen abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.20	Hallucinogen dependence, uncomplicated	Diagnosis	ICD-10-CM
F16.21	Hallucinogen dependence, in remission	Diagnosis	ICD-10-CM
F16.220	Hallucinogen dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.221	Hallucinogen dependence with intoxication with delirium	Diagnosis	ICD-10-CM
F16.229	Hallucinogen dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.90	Hallucinogen use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F16.921	Hallucinogen use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F18.10	Inhalant abuse, uncomplicated	Diagnosis	ICD-10-CM
F18.11	Inhalant abuse, in remission	Diagnosis	ICD-10-CM
F18.120	Inhalant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.121	Inhalant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F18.129	Inhalant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.14	Inhalant abuse with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.17	Inhalant abuse with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.180	Inhalant abuse with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.188	Inhalant abuse with other inhalant-induced disorder	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F18.19	Inhalant abuse with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.20	Inhalant dependence, uncomplicated	Diagnosis	ICD-10-CM
F18.21	Inhalant dependence, in remission	Diagnosis	ICD-10-CM
F18.220	Inhalant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.221	Inhalant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F18.229	Inhalant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.24	Inhalant dependence with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.27	Inhalant dependence with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.280	Inhalant dependence with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.288	Inhalant dependence with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.29	Inhalant dependence with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.90	Inhalant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F18.920	Inhalant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.921	Inhalant use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F18.929	Inhalant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia	Diagnosis	ICD-10-CM
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.988	Inhalant use, unspecified with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F19.10	Other psychoactive substance abuse, uncomplicated	Diagnosis	ICD-10-CM
F19.11	Other psychoactive substance abuse, in remission	Diagnosis	ICD-10-CM
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.121	Other psychoactive substance abuse with intoxication delirium	Diagnosis	ICD-10-CM
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances	Diagnosis	ICD-10-CM
F19.129	Other psychoactive substance abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.20	Other psychoactive substance dependence, uncomplicated	Diagnosis	ICD-10-CM
F19.21	Other psychoactive substance dependence, in remission	Diagnosis	ICD-10-CM
F19.220	Other psychoactive substance dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.221	Other psychoactive substance dependence with intoxication delirium	Diagnosis	ICD-10-CM
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.229	Other psychoactive substance dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.231	Other psychoactive substance dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.239	Other psychoactive substance dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.90	Other psychoactive substance use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F55.0	Abuse of antacids	Diagnosis	ICD-10-CM
F55.1	Abuse of herbal or folk remedies	Diagnosis	ICD-10-CM
F55.2	Abuse of laxatives	Diagnosis	ICD-10-CM
F55.3	Abuse of steroids or hormones	Diagnosis	ICD-10-CM
F55.4	Abuse of vitamins	Diagnosis	ICD-10-CM
F55.8	Abuse of other non-psychoactive substances	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
H0005	Alcohol and/or drug services; group counseling by a clinician	Procedure	HCPCS
H0007	Alcohol and/or drug services; crisis intervention (outpatient)	Procedure	HCPCS
H0008	Alcohol and/or drug services; subacute detoxification (hospital inpatient)	Procedure	HCPCS
H0010	Alcohol and/or drug services; subacute detoxification (residential addiction program inpatient)	Procedure	HCPCS
H0011	Alcohol and/or drug services; acute detoxification (residential addiction program inpatient)	Procedure	HCPCS
H0012	Alcohol and/or drug services; subacute detoxification (residential addiction program outpatient)	Procedure	HCPCS
H0013	Alcohol and/or drug services; acute detoxification (residential addiction program outpatient)	Procedure	HCPCS
H0014	Alcohol and/or drug services; ambulatory detoxification	Procedure	HCPCS
H0015	Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education	Procedure	HCPCS
H0020	Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program)	Procedure	HCPCS
H0022	Alcohol and/or drug intervention service (planned facilitation)	Procedure	HCPCS
H2035	Alcohol and/or other drug treatment program, per hour	Procedure	HCPCS
H2036	Alcohol and/or other drug treatment program, per diem	Procedure	HCPCS
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ41ZZZ	Group Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ42ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ43ZZZ	Group Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ44ZZZ	Group Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ45ZZZ	Group Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ46ZZZ	Group Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ47ZZZ	Group Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ48ZZZ	Group Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ49ZZZ	Group Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ4BZZZ	Group Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ50ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ51ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ52ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ53ZZZ	Individual Psychotherapy for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ54ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ55ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interactive	Procedure	ICD-10-PCS
HZ56ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ57ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ58ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ59ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Supportive	Procedure	ICD-10-PCS
HZ5BZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis	Procedure	ICD-10-PCS
HZ5CZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic	Procedure	ICD-10-PCS
HZ5DZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological	Procedure	ICD-10-PCS
HZ63ZZZ	Family Counseling for Substance Abuse Treatment	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
HZ83ZZZ	Medication Management for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ88ZZZ	Medication Management for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ89ZZZ	Medication Management for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ98ZZZ	Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ99ZZZ	Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
J0570	Buprenorphine implant, 74.2 mg	Procedure	HCPCS
J0571	Buprenorphine, oral, 1 mg	Procedure	HCPCS
J0572	Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine	Procedure	HCPCS
J0573	Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine	Procedure	HCPCS
J0574	Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine	Procedure	HCPCS
J0575	Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine	Procedure	HCPCS
J0592	Injection, buprenorphine HCl, 0.1 mg	Procedure	HCPCS
J1230	Injection, methadone HCl, up to 10 mg	Procedure	HCPCS
J2212	Injection, methylnaltrexone, 0.1 mg	Procedure	HCPCS
J2315	Injection, naltrexone, depot form, 1 mg	Procedure	HCPCS
K29.2	Alcoholic gastritis	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
O35.5XX0	Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified	Diagnosis	ICD-10-CM
O35.5XX1	Maternal care for (suspected) damage to fetus by drugs, fetus 1	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
O35.5XX2	Maternal care for (suspected) damage to fetus by drugs, fetus 2	Diagnosis	ICD-10-CM
O35.5XX3	Maternal care for (suspected) damage to fetus by drugs, fetus 3	Diagnosis	ICD-10-CM
O35.5XX4	Maternal care for (suspected) damage to fetus by drugs, fetus 4	Diagnosis	ICD-10-CM
O35.5XX5	Maternal care for (suspected) damage to fetus by drugs, fetus 5	Diagnosis	ICD-10-CM
O35.5XX9	Maternal care for (suspected) damage to fetus by drugs, other fetus	Diagnosis	ICD-10-CM
O99.310	Alcohol use complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.311	Alcohol use complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.312	Alcohol use complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.313	Alcohol use complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.314	Alcohol use complicating childbirth	Diagnosis	ICD-10-CM
O99.315	Alcohol use complicating the puerperium	Diagnosis	ICD-10-CM
O99.320	Drug use complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.321	Drug use complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.322	Drug use complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.323	Drug use complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.324	Drug use complicating childbirth	Diagnosis	ICD-10-CM
O99.325	Drug use complicating the puerperium	Diagnosis	ICD-10-CM
Q9991	Injection, buprenorphine extended-release (Sublocade), less than or equal to 100 mg	Procedure	HCPCS
Q9992	Injection, buprenorphine extended-release (Sublocade), greater than 100 mg	Procedure	HCPCS
S0109	Methadone, oral, 5 mg	Procedure	HCPCS
T1006	Alcohol and/or substance abuse services, family/couple counseling	Procedure	HCPCS
T1007	Alcohol and/or substance abuse services, treatment plan development and/or modification	Procedure	HCPCS
T1008	Day treatment for individual alcohol and/or substance abuse services	Procedure	HCPCS
T1010	Meals for individuals receiving alcohol and/or substance abuse services (when meals not included in the program)	Procedure	HCPCS
T1012	Alcohol and/or substance abuse services, skills development	Procedure	HCPCS
T40.0X1D	Poisoning by opium, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.0X1S	Poisoning by opium, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.0X3D	Poisoning by opium, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.0X3S	Poisoning by opium, assault, sequela	Diagnosis	ICD-10-CM
T40.0X4D	Poisoning by opium, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.0X4S	Poisoning by opium, undetermined, sequela	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5D	Adverse effect of opium, subsequent encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T40.0X6A	Underdosing of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X6D	Underdosing of opium, subsequent encounter	Diagnosis	ICD-10-CM
T40.0X6S	Underdosing of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1D	Poisoning by heroin, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.1X1S	Poisoning by heroin, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.1X3D	Poisoning by heroin, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.1X3S	Poisoning by heroin, assault, sequela	Diagnosis	ICD-10-CM
T40.1X4D	Poisoning by heroin, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.1X4S	Poisoning by heroin, undetermined, sequela	Diagnosis	ICD-10-CM
T40.1X5A	Adverse effect of heroin, initial encounter	Diagnosis	ICD-10-CM
T40.1X5D	Adverse effect of heroin, subsequent encounter	Diagnosis	ICD-10-CM
T40.1X5S	Adverse effect of heroin, sequela	Diagnosis	ICD-10-CM
T40.5X1A	Poisoning by cocaine, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.5X1D	Poisoning by cocaine, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.5X1S	Poisoning by cocaine, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.5X3A	Poisoning by cocaine, assault, initial encounter	Diagnosis	ICD-10-CM
T40.5X3D	Poisoning by cocaine, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.5X3S	Poisoning by cocaine, assault, sequela	Diagnosis	ICD-10-CM
T40.5X4A	Poisoning by cocaine, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.5X4D	Poisoning by cocaine, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.5X4S	Poisoning by cocaine, undetermined, sequela	Diagnosis	ICD-10-CM
T40.5X5A	Adverse effect of cocaine, initial encounter	Diagnosis	ICD-10-CM
T40.5X5D	Adverse effect of cocaine, subsequent encounter	Diagnosis	ICD-10-CM
T40.5X5S	Adverse effect of cocaine, sequela	Diagnosis	ICD-10-CM
T40.5X6A	Underdosing of cocaine, initial encounter	Diagnosis	ICD-10-CM
T40.5X6D	Underdosing of cocaine, subsequent encounter	Diagnosis	ICD-10-CM
T40.5X6S	Underdosing of cocaine, sequela	Diagnosis	ICD-10-CM
T40.7X1D	Poisoning by cannabis (derivatives), accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.7X1S	Poisoning by cannabis (derivatives), accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.7X3D	Poisoning by cannabis (derivatives), assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.7X3S	Poisoning by cannabis (derivatives), assault, sequela	Diagnosis	ICD-10-CM
T40.7X4D	Poisoning by cannabis (derivatives), undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.7X4S	Poisoning by cannabis (derivatives), undetermined, sequela	Diagnosis	ICD-10-CM
T40.7X5A	Adverse effect of cannabis (derivatives), initial encounter	Diagnosis	ICD-10-CM
T40.7X5D	Adverse effect of cannabis (derivatives), subsequent encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T40.7X5S	Adverse effect of cannabis (derivatives), sequela	Diagnosis	ICD-10-CM
T40.7X6A	Underdosing of cannabis (derivatives), initial encounter	Diagnosis	ICD-10-CM
T40.7X6D	Underdosing of cannabis (derivatives), subsequent encounter	Diagnosis	ICD-10-CM
T40.7X6S	Underdosing of cannabis (derivatives), sequela	Diagnosis	ICD-10-CM
T40.8X1D	Poisoning by lysergide [LSD], accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.8X1S	Poisoning by lysergide [LSD], accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.8X3D	Poisoning by lysergide [LSD], assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.8X3S	Poisoning by lysergide [LSD], assault, sequela	Diagnosis	ICD-10-CM
T40.8X4D	Poisoning by lysergide [LSD], undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.8X4S	Poisoning by lysergide [LSD], undetermined, sequela	Diagnosis	ICD-10-CM
T40.8X5A	Adverse effect of lysergide [LSD], initial encounter	Diagnosis	ICD-10-CM
T40.8X5D	Adverse effect of lysergide [LSD], subsequent encounter	Diagnosis	ICD-10-CM
T40.8X5S	Adverse effect of lysergide [LSD], sequela	Diagnosis	ICD-10-CM
T40.901D	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.901S	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.903D	Poisoning by unspecified psychodysleptics [hallucinogens], assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.903S	Poisoning by unspecified psychodysleptics [hallucinogens], assault, sequela	Diagnosis	ICD-10-CM
T40.904D	Poisoning by unspecified psychodysleptics [hallucinogens], undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.904S	Poisoning by unspecified psychodysleptics [hallucinogens], undetermined, sequela	Diagnosis	ICD-10-CM
T40.905A	Adverse effect of unspecified psychodysleptics [hallucinogens], initial encounter	Diagnosis	ICD-10-CM
T40.905D	Adverse effect of unspecified psychodysleptics [hallucinogens], subsequent encounter	Diagnosis	ICD-10-CM
T40.905S	Adverse effect of unspecified psychodysleptics [hallucinogens], sequela	Diagnosis	ICD-10-CM
T40.906A	Underdosing of unspecified psychodysleptics [hallucinogens], initial encounter	Diagnosis	ICD-10-CM
T40.906D	Underdosing of unspecified psychodysleptics [hallucinogens], subsequent encounter	Diagnosis	ICD-10-CM
T40.906S	Underdosing of unspecified psychodysleptics [hallucinogens], sequela	Diagnosis	ICD-10-CM
T40.991D	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.991S	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.993D	Poisoning by other psychodysleptics [hallucinogens], assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.993S	Poisoning by other psychodysleptics [hallucinogens], assault, sequela	Diagnosis	ICD-10-CM
T40.994D	Poisoning by other psychodysleptics [hallucinogens], undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.994S	Poisoning by other psychodysleptics [hallucinogens], undetermined, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T40.995A	Adverse effect of other psychodysleptics [hallucinogens], initial encounter	Diagnosis	ICD-10-CM
T40.995D	Adverse effect of other psychodysleptics [hallucinogens], subsequent encounter	Diagnosis	ICD-10-CM
T40.995S	Adverse effect of other psychodysleptics [hallucinogens], sequela	Diagnosis	ICD-10-CM
T40.996A	Underdosing of other psychodysleptics [hallucinogens], initial encounter	Diagnosis	ICD-10-CM
T40.996D	Underdosing of other psychodysleptics [hallucinogens], subsequent encounter	Diagnosis	ICD-10-CM
T40.996S	Underdosing of other psychodysleptics [hallucinogens], sequela	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
	Suicidal Behavior		
881	Open wound of elbow, forearm, and wrist	Diagnosis	ICD-9-CM
960	Poisoning by antibiotics	Diagnosis	ICD-9-CM
960.0	Poisoning by penicillins	Diagnosis	ICD-9-CM
960.1	Poisoning by antifungal antibiotics	Diagnosis	ICD-9-CM
960.2	Poisoning by chloramphenicol group	Diagnosis	ICD-9-CM
960.3	Poisoning by erythromycin and other macrolides	Diagnosis	ICD-9-CM
960.4	Poisoning by tetracycline group	Diagnosis	ICD-9-CM
960.5	Poisoning of cephalosporin group	Diagnosis	ICD-9-CM
960.6	Poisoning of antimycobacterial antibiotics	Diagnosis	ICD-9-CM
960.7	Poisoning by antineoplastic antibiotics	Diagnosis	ICD-9-CM
960.8	Poisoning by other specified antibiotics	Diagnosis	ICD-9-CM
960.9	Poisoning by unspecified antibiotic	Diagnosis	ICD-9-CM
961	Poisoning by other anti-infectives	Diagnosis	ICD-9-CM
961.0	Poisoning by sulfonamides	Diagnosis	ICD-9-CM
961.1	Poisoning by arsenical anti-infectives	Diagnosis	ICD-9-CM
961.2	Poisoning by heavy metal anti-infectives	Diagnosis	ICD-9-CM
961.3	Poisoning by quinoline and hydroxyquinoline derivatives	Diagnosis	ICD-9-CM
961.4	Poisoning by antimalarials and drugs acting on other blood protozoa	Diagnosis	ICD-9-CM
961.5	Poisoning by other antiprotozoal drugs	Diagnosis	ICD-9-CM
961.6	Poisoning by anthelmintics	Diagnosis	ICD-9-CM
961.7	Poisoning by antiviral drugs	Diagnosis	ICD-9-CM
961.8	Poisoning by other antimycobacterial drugs	Diagnosis	ICD-9-CM
961.9	Poisoning by other and unspecified anti-infectives	Diagnosis	ICD-9-CM
962	Poisoning by hormones and synthetic substitutes	Diagnosis	ICD-9-CM
962.0	Poisoning by adrenal cortical steroids	Diagnosis	ICD-9-CM
962.1	Poisoning by androgens and anabolic congeners	Diagnosis	ICD-9-CM
962.2	Poisoning by ovarian hormones and synthetic substitutes	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
962.3	Poisoning by insulins and antidiabetic agents	Diagnosis	ICD-9-CM
962.4	Poisoning by anterior pituitary hormones	Diagnosis	ICD-9-CM
962.5	Poisoning by posterior pituitary hormones	Diagnosis	ICD-9-CM
962.6	Poisoning by parathyroid and parathyroid derivatives	Diagnosis	ICD-9-CM
962.7	Poisoning by thyroid and thyroid derivatives	Diagnosis	ICD-9-CM
962.8	Poisoning by antithyroid agents	Diagnosis	ICD-9-CM
962.9	Poisoning by other and unspecified hormones and synthetic substitutes	Diagnosis	ICD-9-CM
963	Poisoning by primarily systemic agents	Diagnosis	ICD-9-CM
963.0	Poisoning by antiallergic and antiemetic drugs	Diagnosis	ICD-9-CM
963.1	Poisoning by antineoplastic and immunosuppressive drugs	Diagnosis	ICD-9-CM
963.2	Poisoning by acidifying agents	Diagnosis	ICD-9-CM
963.3	Poisoning by alkalizing agents	Diagnosis	ICD-9-CM
963.4	Poisoning by enzymes, not elsewhere classified	Diagnosis	ICD-9-CM
963.5	Poisoning by vitamins, not elsewhere classified	Diagnosis	ICD-9-CM
963.8	Poisoning by other specified systemic agents	Diagnosis	ICD-9-CM
963.9	Poisoning by unspecified systemic agent	Diagnosis	ICD-9-CM
964	Poisoning by agents primarily affecting blood constituents	Diagnosis	ICD-9-CM
964.0	Poisoning by iron and its compounds	Diagnosis	ICD-9-CM
964.1	Poisoning by liver preparations and other antianemic agents	Diagnosis	ICD-9-CM
964.2	Poisoning by anticoagulants	Diagnosis	ICD-9-CM
964.3	Poisoning by vitamin K (phytonadione)	Diagnosis	ICD-9-CM
964.4	Poisoning by fibrinolysis-affecting drugs	Diagnosis	ICD-9-CM
964.5	Poisoning by anticoagulant antagonists and other coagulants	Diagnosis	ICD-9-CM
964.6	Poisoning by gamma globulin	Diagnosis	ICD-9-CM
964.7	Poisoning by natural blood and blood products	Diagnosis	ICD-9-CM
964.8	Poisoning by other specified agents affecting blood constituents	Diagnosis	ICD-9-CM
964.9	Poisoning by unspecified agent affecting blood constituents	Diagnosis	ICD-9-CM
965	Poisoning by analgesics, antipyretics, and antirheumatics	Diagnosis	ICD-9-CM
965.0	Poisoning by opiates and related narcotics	Diagnosis	ICD-9-CM
965.00	Poisoning by opium (alkaloids), unspecified	Diagnosis	ICD-9-CM
965.01	Poisoning by heroin	Diagnosis	ICD-9-CM
965.02	Poisoning by methadone	Diagnosis	ICD-9-CM
965.09	Poisoning by opiates and related narcotics, other	Diagnosis	ICD-9-CM
965.1	Poisoning by salicylates	Diagnosis	ICD-9-CM
965.4	Poisoning by aromatic analgesics, not elsewhere classified	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
965.5	Poisoning by pyrazole derivatives	Diagnosis	ICD-9-CM
965.6	Poisoning by antirheumatics (antiphlogistics)	Diagnosis	ICD-9-CM
965.61	Poisoning by propionic acid derivatives	Diagnosis	ICD-9-CM
965.69	Poisoning by other antirheumatics	Diagnosis	ICD-9-CM
965.7	Poisoning by other non-narcotic analgesics	Diagnosis	ICD-9-CM
965.8	Poisoning by other specified analgesics and antipyretics	Diagnosis	ICD-9-CM
965.9	Poisoning by unspecified analgesic and antipyretic	Diagnosis	ICD-9-CM
966	Poisoning by anticonvulsants and anti-Parkinsonism drugs	Diagnosis	ICD-9-CM
966.0	Poisoning by oxazolidine derivatives	Diagnosis	ICD-9-CM
966.1	Poisoning by hydantoin derivatives	Diagnosis	ICD-9-CM
966.2	Poisoning by succinimides	Diagnosis	ICD-9-CM
966.3	Poisoning by other and unspecified anticonvulsants	Diagnosis	ICD-9-CM
966.4	Poisoning by anti-Parkinsonism drugs	Diagnosis	ICD-9-CM
967	Poisoning by sedatives and hypnotics	Diagnosis	ICD-9-CM
967.0	Poisoning by barbiturates	Diagnosis	ICD-9-CM
967.1	Poisoning by chloral hydrate group	Diagnosis	ICD-9-CM
967.2	Poisoning by paraldehyde	Diagnosis	ICD-9-CM
967.3	Poisoning by bromine compounds	Diagnosis	ICD-9-CM
967.4	Poisoning by methaqualone compounds	Diagnosis	ICD-9-CM
967.5	Poisoning by glutethimide group	Diagnosis	ICD-9-CM
967.6	Poisoning by mixed sedatives, not elsewhere classified	Diagnosis	ICD-9-CM
967.8	Poisoning by other sedatives and hypnotics	Diagnosis	ICD-9-CM
967.9	Poisoning by unspecified sedative or hypnotic	Diagnosis	ICD-9-CM
968	Poisoning by other central nervous system depressants and anesthetics	Diagnosis	ICD-9-CM
968.0	Poisoning by central nervous system muscle-tone depressants	Diagnosis	ICD-9-CM
968.1	Poisoning by halothane	Diagnosis	ICD-9-CM
968.2	Poisoning by other gaseous anesthetics	Diagnosis	ICD-9-CM
968.3	Poisoning by intravenous anesthetics	Diagnosis	ICD-9-CM
968.4	Poisoning by other and unspecified general anesthetics	Diagnosis	ICD-9-CM
968.5	Poisoning by other central nervous system depressants and anesthetics, Surface (topical) and infiltration anesthetics	Diagnosis	ICD-9-CM
968.6	Poisoning by peripheral nerve- and plexus-blocking anesthetics	Diagnosis	ICD-9-CM
968.7	Poisoning by spinal anesthetics	Diagnosis	ICD-9-CM
968.9	Poisoning by other and unspecified local anesthetics	Diagnosis	ICD-9-CM
969	Poisoning by psychotropic agents	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
969.0	Poisoning by antidepressants	Diagnosis	ICD-9-CM
969.00	Poisoning by antidepressant, unspecified	Diagnosis	ICD-9-CM
969.01	Poisoning by monoamine oxidase inhibitors	Diagnosis	ICD-9-CM
969.02	Poisoning by selective serotonin and norepinephrine reuptake inhibitors	Diagnosis	ICD-9-CM
969.03	Poisoning by selective serotonin reuptake inhibitors	Diagnosis	ICD-9-CM
969.04	Poisoning by tetracyclic antidepressants	Diagnosis	ICD-9-CM
969.05	Poisoning by tricyclic antidepressants	Diagnosis	ICD-9-CM
969.09	Poisoning by other antidepressants	Diagnosis	ICD-9-CM
969.1	Poisoning by phenothiazine-based tranquilizers	Diagnosis	ICD-9-CM
969.2	Poisoning by butyrophenone-based tranquilizers	Diagnosis	ICD-9-CM
969.3	Poisoning by other antipsychotics, neuroleptics, and major tranquilizers	Diagnosis	ICD-9-CM
969.4	Poisoning by benzodiazepine-based tranquilizers	Diagnosis	ICD-9-CM
969.5	Poisoning by other tranquilizers	Diagnosis	ICD-9-CM
969.6	Poisoning by psychodysleptics (hallucinogens)	Diagnosis	ICD-9-CM
969.7	Poisoning by psychostimulants	Diagnosis	ICD-9-CM
969.70	Poisoning by psychostimulant, unspecified	Diagnosis	ICD-9-CM
969.71	Poisoning by caffeine	Diagnosis	ICD-9-CM
969.72	Poisoning by amphetamines	Diagnosis	ICD-9-CM
969.73	Poisoning by methylphenidate	Diagnosis	ICD-9-CM
969.79	Poisoning by other psychostimulants	Diagnosis	ICD-9-CM
969.8	Poisoning by other specified psychotropic agents	Diagnosis	ICD-9-CM
969.9	Poisoning by unspecified psychotropic agent	Diagnosis	ICD-9-CM
980	Toxic effect of alcohol	Diagnosis	ICD-9-CM
980.0	Toxic effect of ethyl alcohol	Diagnosis	ICD-9-CM
980.1	Toxic effect of methyl alcohol	Diagnosis	ICD-9-CM
980.2	Toxic effect of isopropyl alcohol	Diagnosis	ICD-9-CM
980.3	Toxic effect of fusel oil	Diagnosis	ICD-9-CM
980.8	Toxic effect of other specified alcohols	Diagnosis	ICD-9-CM
980.9	Toxic effect of unspecified alcohol	Diagnosis	ICD-9-CM
981	Toxic effect of petroleum products	Diagnosis	ICD-9-CM
982	Toxic effect of solvents other than petroleum-based	Diagnosis	ICD-9-CM
982.0	Toxic effect of benzene and homologues	Diagnosis	ICD-9-CM
982.1	Toxic effect of carbon tetrachloride	Diagnosis	ICD-9-CM
982.2	Toxic effect of carbon disulfide	Diagnosis	ICD-9-CM
982.3	Toxic effect of other chlorinated hydrocarbon solvents	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
982.4	Toxic effect of nitroglycol	Diagnosis	ICD-9-CM
982.8	Toxic effect of other nonpetroleum-based solvents	Diagnosis	ICD-9-CM
983	Toxic effect of corrosive aromatics, acids, and caustic alkalis	Diagnosis	ICD-9-CM
983.0	Toxic effect of corrosive aromatics	Diagnosis	ICD-9-CM
983.1	Toxic effect of acids	Diagnosis	ICD-9-CM
983.2	Toxic effect of caustic alkalis	Diagnosis	ICD-9-CM
983.9	Toxic effect of caustic, unspecified	Diagnosis	ICD-9-CM
984	Toxic effect of lead and its compounds (including fumes)	Diagnosis	ICD-9-CM
984.0	Toxic effect of inorganic lead compounds	Diagnosis	ICD-9-CM
984.1	Toxic effect of organic lead compounds	Diagnosis	ICD-9-CM
984.8	Toxic effect of other lead compounds	Diagnosis	ICD-9-CM
984.9	Toxic effect of unspecified lead compound	Diagnosis	ICD-9-CM
985	Toxic effect of other metals	Diagnosis	ICD-9-CM
985.0	Toxic effect of mercury and its compounds	Diagnosis	ICD-9-CM
985.1	Toxic effect of arsenic and its compounds	Diagnosis	ICD-9-CM
985.2	Toxic effect of manganese and its compounds	Diagnosis	ICD-9-CM
985.3	Toxic effect of beryllium and its compounds	Diagnosis	ICD-9-CM
985.4	Toxic effect of antimony and its compounds	Diagnosis	ICD-9-CM
985.5	Toxic effect of cadmium and its compounds	Diagnosis	ICD-9-CM
985.6	Toxic effect of chromium	Diagnosis	ICD-9-CM
985.8	Toxic effect of other specified metals	Diagnosis	ICD-9-CM
985.9	Toxic effect of unspecified metal	Diagnosis	ICD-9-CM
986	Toxic effect of carbon monoxide	Diagnosis	ICD-9-CM
987	Toxic effect of other gases, fumes, or vapors	Diagnosis	ICD-9-CM
987.0	Toxic effect of liquefied petroleum gases	Diagnosis	ICD-9-CM
987.1	Toxic effect of other hydrocarbon gas	Diagnosis	ICD-9-CM
987.2	Toxic effect of nitrogen oxides	Diagnosis	ICD-9-CM
987.3	Toxic effect of sulfur dioxide	Diagnosis	ICD-9-CM
987.4	Toxic effect of freon	Diagnosis	ICD-9-CM
987.5	Toxic effect of lacrimogenic gas	Diagnosis	ICD-9-CM
987.6	Toxic effect of chlorine gas	Diagnosis	ICD-9-CM
987.7	Toxic effect of hydrocyanic acid gas	Diagnosis	ICD-9-CM
987.8	Toxic effect of other specified gases, fumes, or vapors	Diagnosis	ICD-9-CM
987.9	Toxic effect of unspecified gas, fume, or vapor	Diagnosis	ICD-9-CM
988	Toxic effect of noxious substances eaten as food	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
988.0	Toxic effect of fish and shellfish	Diagnosis	ICD-9-CM
988.1	Toxic effect of mushrooms	Diagnosis	ICD-9-CM
988.2	Toxic effect of berries and other plants	Diagnosis	ICD-9-CM
988.8	Toxic effect of other specified noxious substances	Diagnosis	ICD-9-CM
988.9	Toxic effect of unspecified noxious substance	Diagnosis	ICD-9-CM
989	Toxic effect of other substances, chiefly nonmedicinal as to source	Diagnosis	ICD-9-CM
989.0	Toxic effect of hydrocyanic acid and cyanides	Diagnosis	ICD-9-CM
989.1	Toxic effect of strychnine and salts	Diagnosis	ICD-9-CM
989.2	Toxic effect of chlorinated hydrocarbons	Diagnosis	ICD-9-CM
989.3	Toxic effect of organophosphate and carbamate	Diagnosis	ICD-9-CM
989.4	Toxic effect of other pesticides, not elsewhere classified	Diagnosis	ICD-9-CM
989.5	Toxic effect of venom	Diagnosis	ICD-9-CM
989.6	Toxic effect of soaps and detergents	Diagnosis	ICD-9-CM
989.7	Toxic effect of aflatoxin and other mycotoxin (food contaminants)	Diagnosis	ICD-9-CM
989.8	Toxic effect of other substances, chiefly nonmedicinal as to source	Diagnosis	ICD-9-CM
989.81	Toxic effect of asbestos	Diagnosis	ICD-9-CM
989.82	Toxic effect of latex	Diagnosis	ICD-9-CM
989.83	Toxic effect of silicone	Diagnosis	ICD-9-CM
989.84	Toxic effect of tobacco	Diagnosis	ICD-9-CM
989.89	Toxic effect of other substances	Diagnosis	ICD-9-CM
989.9	Toxic effect of unspecified substance, chiefly nonmedicinal as to source	Diagnosis	ICD-9-CM
994.7	Asphyxiation and strangulation	Diagnosis	ICD-9-CM
M1A.10X0	Lead-induced chronic gout, unspecified site, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.10X1	Lead-induced chronic gout, unspecified site, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1110	Lead-induced chronic gout, right shoulder, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1111	Lead-induced chronic gout, right shoulder, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1120	Lead-induced chronic gout, left shoulder, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1121	Lead-induced chronic gout, left shoulder, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1190	Lead-induced chronic gout, unspecified shoulder, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1191	Lead-induced chronic gout, unspecified shoulder, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1210	Lead-induced chronic gout, right elbow, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1211	Lead-induced chronic gout, right elbow, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1220	Lead-induced chronic gout, left elbow, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1221	Lead-induced chronic gout, left elbow, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1290	Lead-induced chronic gout, unspecified elbow, without tophus (tophi)	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
M1A.1291	Lead-induced chronic gout, unspecified elbow, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1310	Lead-induced chronic gout, right wrist, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1311	Lead-induced chronic gout, right wrist, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1320	Lead-induced chronic gout, left wrist, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1321	Lead-induced chronic gout, left wrist, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1390	Lead-induced chronic gout, unspecified wrist, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1391	Lead-induced chronic gout, unspecified wrist, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1410	Lead-induced chronic gout, right hand, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1411	Lead-induced chronic gout, right hand, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1420	Lead-induced chronic gout, left hand, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1421	Lead-induced chronic gout, left hand, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1490	Lead-induced chronic gout, unspecified hand, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1491	Lead-induced chronic gout, unspecified hand, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1510	Lead-induced chronic gout, right hip, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1511	Lead-induced chronic gout, right hip, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1520	Lead-induced chronic gout, left hip, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1521	Lead-induced chronic gout, left hip, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1590	Lead-induced chronic gout, unspecified hip, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1591	Lead-induced chronic gout, unspecified hip, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1610	Lead-induced chronic gout, right knee, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1611	Lead-induced chronic gout, right knee, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1620	Lead-induced chronic gout, left knee, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1621	Lead-induced chronic gout, left knee, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1690	Lead-induced chronic gout, unspecified knee, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1691	Lead-induced chronic gout, unspecified knee, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1710	Lead-induced chronic gout, right ankle and foot, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1711	Lead-induced chronic gout, right ankle and foot, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1720	Lead-induced chronic gout, left ankle and foot, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1721	Lead-induced chronic gout, left ankle and foot, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1790	Lead-induced chronic gout, unspecified ankle and foot, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.1791	Lead-induced chronic gout, unspecified ankle and foot, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.18X0	Lead-induced chronic gout, vertebrae, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.18X1	Lead-induced chronic gout, vertebrae, with tophus (tophi)	Diagnosis	ICD-10-CM
M1A.19X0	Lead-induced chronic gout, multiple sites, without tophus (tophi)	Diagnosis	ICD-10-CM
M1A.19X1	Lead-induced chronic gout, multiple sites, with tophus (tophi)	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T36.0X1A	Poisoning by penicillins, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T36.0X2A	Poisoning by penicillins, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.0X3A	Poisoning by penicillins, assault, initial encounter	Diagnosis	ICD-10-CM
T36.0X4A	Poisoning by penicillins, undetermined, initial encounter	Diagnosis	ICD-10-CM
T36.1X1A	Poisoning by cephalosporins and other beta-lactam antibiotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T36.1X2A	Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.1X3A	Poisoning by cephalosporins and other beta-lactam antibiotics, assault, initial encounter	Diagnosis	ICD-10-CM
T36.1X4A	Poisoning by cephalosporins and other beta-lactam antibiotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T36.2X1A	Poisoning by chloramphenicol group, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T36.2X2A	Poisoning by chloramphenicol group, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.2X3A	Poisoning by chloramphenicol group, assault, initial encounter	Diagnosis	ICD-10-CM
T36.2X4A	Poisoning by chloramphenicol group, undetermined, initial encounter	Diagnosis	ICD-10-CM
T36.3X1A	Poisoning by macrolides, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T36.3X2A	Poisoning by macrolides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.3X3A	Poisoning by macrolides, assault, initial encounter	Diagnosis	ICD-10-CM
T36.3X4A	Poisoning by macrolides, undetermined, initial encounter	Diagnosis	ICD-10-CM
T36.4X1A	Poisoning by tetracyclines, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T36.4X2A	Poisoning by tetracyclines, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.4X3A	Poisoning by tetracyclines, assault, initial encounter	Diagnosis	ICD-10-CM
T36.4X4A	Poisoning by tetracyclines, undetermined, initial encounter	Diagnosis	ICD-10-CM
T36.5X1A	Poisoning by aminoglycosides, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T36.5X2A	Poisoning by aminoglycosides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.5X3A	Poisoning by aminoglycosides, assault, initial encounter	Diagnosis	ICD-10-CM
T36.5X4A	Poisoning by aminoglycosides, undetermined, initial encounter	Diagnosis	ICD-10-CM
T36.6X1A	Poisoning by rifampicins, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T36.6X2A	Poisoning by rifampicins, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.6X3A	Poisoning by rifampicins, assault, initial encounter	Diagnosis	ICD-10-CM
T36.6X4A	Poisoning by rifampicins, undetermined, initial encounter	Diagnosis	ICD-10-CM
T36.7X1A	Poisoning by antifungal antibiotics, systemically used, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T36.7X2A	Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.7X3A	Poisoning by antifungal antibiotics, systemically used, assault, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T36.7X4A	Poisoning by antifungal antibiotics, systemically used, undetermined, initial encounter	Diagnosis	ICD-10-CM
T36.8X1A	Poisoning by other systemic antibiotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T36.8X2A	Poisoning by other systemic antibiotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.8X3A	Poisoning by other systemic antibiotics, assault, initial encounter	Diagnosis	ICD-10-CM
T36.8X4A	Poisoning by other systemic antibiotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T36.91XA	Poisoning by unspecified systemic antibiotic, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T36.92XA	Poisoning by unspecified systemic antibiotic, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T36.93XA	Poisoning by unspecified systemic antibiotic, assault, initial encounter	Diagnosis	ICD-10-CM
T36.94XA	Poisoning by unspecified systemic antibiotic, undetermined, initial encounter	Diagnosis	ICD-10-CM
T37.0X1A	Poisoning by sulfonamides, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T37.0X2A	Poisoning by sulfonamides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.0X3A	Poisoning by sulfonamides, assault, initial encounter	Diagnosis	ICD-10-CM
T37.0X4A	Poisoning by sulfonamides, undetermined, initial encounter	Diagnosis	ICD-10-CM
T37.1X1A	Poisoning by antimycobacterial drugs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T37.1X2A	Poisoning by antimycobacterial drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.1X3A	Poisoning by antimycobacterial drugs, assault, initial encounter	Diagnosis	ICD-10-CM
T37.1X4A	Poisoning by antimycobacterial drugs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T37.2X1A	Poisoning by antimalarials and drugs acting on other blood protozoa, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T37.2X2A	Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.2X3A	Poisoning by antimalarials and drugs acting on other blood protozoa, assault, initial encounter	Diagnosis	ICD-10-CM
T37.2X4A	Poisoning by antimalarials and drugs acting on other blood protozoa, undetermined, initial encounter	Diagnosis	ICD-10-CM
T37.3X1A	Poisoning by other antiprotozoal drugs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T37.3X2A	Poisoning by other antiprotozoal drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.3X3A	Poisoning by other antiprotozoal drugs, assault, initial encounter	Diagnosis	ICD-10-CM
T37.3X4A	Poisoning by other antiprotozoal drugs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T37.4X1A	Poisoning by anthelminthics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T37.4X2A	Poisoning by anthelminthics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.4X3A	Poisoning by anthelminthics, assault, initial encounter	Diagnosis	ICD-10-CM
T37.4X4A	Poisoning by anthelminthics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T37.5X1A	Poisoning by antiviral drugs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T37.5X2A	Poisoning by antiviral drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T37.5X3A	Poisoning by antiviral drugs, assault, initial encounter	Diagnosis	ICD-10-CM
T37.5X4A	Poisoning by antiviral drugs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T37.8X1A	Poisoning by other specified systemic anti-infectives and antiparasitics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T37.8X2A	Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.8X3A	Poisoning by other specified systemic anti-infectives and antiparasitics, assault, initial encounter	Diagnosis	ICD-10-CM
T37.8X4A	Poisoning by other specified systemic anti-infectives and antiparasitics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T37.91XA	Poisoning by unspecified systemic anti-infective and antiparasitics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T37.92XA	Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T37.93XA	Poisoning by unspecified systemic anti-infective and antiparasitics, assault, initial encounter	Diagnosis	ICD-10-CM
T37.94XA	Poisoning by unspecified systemic anti-infective and antiparasitics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T38.0X1A	Poisoning by glucocorticoids and synthetic analogues, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T38.0X2A	Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.0X3A	Poisoning by glucocorticoids and synthetic analogues, assault, initial encounter	Diagnosis	ICD-10-CM
T38.0X4A	Poisoning by glucocorticoids and synthetic analogues, undetermined, initial encounter	Diagnosis	ICD-10-CM
T38.1X1A	Poisoning by thyroid hormones and substitutes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T38.1X2A	Poisoning by thyroid hormones and substitutes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.1X3A	Poisoning by thyroid hormones and substitutes, assault, initial encounter	Diagnosis	ICD-10-CM
T38.1X4A	Poisoning by thyroid hormones and substitutes, undetermined, initial encounter	Diagnosis	ICD-10-CM
T38.2X1A	Poisoning by antithyroid drugs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T38.2X2A	Poisoning by antithyroid drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.2X3A	Poisoning by antithyroid drugs, assault, initial encounter	Diagnosis	ICD-10-CM
T38.2X4A	Poisoning by antithyroid drugs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T38.3X1A	Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T38.3X2A	Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.3X3A	Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, assault, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T38.3X4A	Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T38.4X1A	Poisoning by oral contraceptives, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T38.4X2A	Poisoning by oral contraceptives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.4X3A	Poisoning by oral contraceptives, assault, initial encounter	Diagnosis	ICD-10-CM
T38.4X4A	Poisoning by oral contraceptives, undetermined, initial encounter	Diagnosis	ICD-10-CM
T38.5X1A	Poisoning by other estrogens and progestogens, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T38.5X2A	Poisoning by other estrogens and progestogens, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.5X3A	Poisoning by other estrogens and progestogens, assault, initial encounter	Diagnosis	ICD-10-CM
T38.5X4A	Poisoning by other estrogens and progestogens, undetermined, initial encounter	Diagnosis	ICD-10-CM
T38.6X1A	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T38.6X2A	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.6X3A	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, assault, initial encounter	Diagnosis	ICD-10-CM
T38.6X4A	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, undetermined, initial encounter	Diagnosis	ICD-10-CM
T38.7X1A	Poisoning by androgens and anabolic congeners, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T38.7X2A	Poisoning by androgens and anabolic congeners, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.7X3A	Poisoning by androgens and anabolic congeners, assault, initial encounter	Diagnosis	ICD-10-CM
T38.7X4A	Poisoning by androgens and anabolic congeners, undetermined, initial encounter	Diagnosis	ICD-10-CM
T38.801A	Poisoning by unspecified hormones and synthetic substitutes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T38.802A	Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.803A	Poisoning by unspecified hormones and synthetic substitutes, assault, initial encounter	Diagnosis	ICD-10-CM
T38.804A	Poisoning by unspecified hormones and synthetic substitutes, undetermined, initial encounter	Diagnosis	ICD-10-CM
T38.811A	Poisoning by anterior pituitary [adenohypophyseal] hormones, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T38.812A	Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.813A	Poisoning by anterior pituitary [adenohypophyseal] hormones, assault, initial encounter	Diagnosis	ICD-10-CM
T38.814A	Poisoning by anterior pituitary [adenohypophyseal] hormones, undetermined, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T38.891A	Poisoning by other hormones and synthetic substitutes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T38.892A	Poisoning by other hormones and synthetic substitutes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.893A	Poisoning by other hormones and synthetic substitutes, assault, initial encounter	Diagnosis	ICD-10-CM
T38.894A	Poisoning by other hormones and synthetic substitutes, undetermined, initial encounter	Diagnosis	ICD-10-CM
T38.901A	Poisoning by unspecified hormone antagonists, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T38.902A	Poisoning by unspecified hormone antagonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.903A	Poisoning by unspecified hormone antagonists, assault, initial encounter	Diagnosis	ICD-10-CM
T38.904A	Poisoning by unspecified hormone antagonists, undetermined, initial encounter	Diagnosis	ICD-10-CM
T38.991A	Poisoning by other hormone antagonists, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T38.992A	Poisoning by other hormone antagonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T38.993A	Poisoning by other hormone antagonists, assault, initial encounter	Diagnosis	ICD-10-CM
T38.994A	Poisoning by other hormone antagonists, undetermined, initial encounter	Diagnosis	ICD-10-CM
T39.011A	Poisoning by aspirin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T39.012A	Poisoning by aspirin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.013A	Poisoning by aspirin, assault, initial encounter	Diagnosis	ICD-10-CM
T39.014A	Poisoning by aspirin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T39.091A	Poisoning by salicylates, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T39.092A	Poisoning by salicylates, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.093A	Poisoning by salicylates, assault, initial encounter	Diagnosis	ICD-10-CM
T39.094A	Poisoning by salicylates, undetermined, initial encounter	Diagnosis	ICD-10-CM
T39.1X1A	Poisoning by 4-Aminophenol derivatives, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T39.1X2A	Poisoning by 4-Aminophenol derivatives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.1X3A	Poisoning by 4-Aminophenol derivatives, assault, initial encounter	Diagnosis	ICD-10-CM
T39.1X4A	Poisoning by 4-Aminophenol derivatives, undetermined, initial encounter	Diagnosis	ICD-10-CM
T39.2X1A	Poisoning by pyrazolone derivatives, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T39.2X2A	Poisoning by pyrazolone derivatives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.2X3A	Poisoning by pyrazolone derivatives, assault, initial encounter	Diagnosis	ICD-10-CM
T39.2X4A	Poisoning by pyrazolone derivatives, undetermined, initial encounter	Diagnosis	ICD-10-CM
T39.311A	Poisoning by propionic acid derivatives, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T39.312A	Poisoning by propionic acid derivatives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.313A	Poisoning by propionic acid derivatives, assault, initial encounter	Diagnosis	ICD-10-CM
T39.314A	Poisoning by propionic acid derivatives, undetermined, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T39.391A	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T39.392A	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.393A	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], assault, initial encounter	Diagnosis	ICD-10-CM
T39.394A	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], undetermined, initial encounter	Diagnosis	ICD-10-CM
T39.4X1A	Poisoning by antirheumatics, not elsewhere classified, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T39.4X2A	Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.4X3A	Poisoning by antirheumatics, not elsewhere classified, assault, initial encounter	Diagnosis	ICD-10-CM
T39.4X4A	Poisoning by antirheumatics, not elsewhere classified, undetermined, initial encounter	Diagnosis	ICD-10-CM
T39.8X1A	Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T39.8X2A	Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.8X3A	Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, assault, initial encounter	Diagnosis	ICD-10-CM
T39.8X4A	Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, undetermined, initial encounter	Diagnosis	ICD-10-CM
T39.91XA	Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T39.92XA	Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T39.93XA	Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, assault, initial encounter	Diagnosis	ICD-10-CM
T39.94XA	Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.7X1A	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.7X2A	Poisoning by cannabis (derivatives), intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.7X3A	Poisoning by cannabis (derivatives), assault, initial encounter	Diagnosis	ICD-10-CM
T40.7X4A	Poisoning by cannabis (derivatives), undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.8X1A	Poisoning by lysergide [LSD], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.8X2A	Poisoning by lysergide [LSD], intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.8X3A	Poisoning by lysergide [LSD], assault, initial encounter	Diagnosis	ICD-10-CM
T40.8X4A	Poisoning by lysergide [LSD], undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.901A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.902A	Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.903A	Poisoning by unspecified psychodysleptics [hallucinogens], assault, initial encounter	Diagnosis	ICD-10-CM
T40.904A	Poisoning by unspecified psychodysleptics [hallucinogens], undetermined, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T40.991A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.992A	Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.993A	Poisoning by other psychodysleptics [hallucinogens], assault, initial encounter	Diagnosis	ICD-10-CM
T40.994A	Poisoning by other psychodysleptics [hallucinogens], undetermined, initial encounter	Diagnosis	ICD-10-CM
T41.0X1A	Poisoning by inhaled anesthetics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T41.0X2A	Poisoning by inhaled anesthetics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T41.0X3A	Poisoning by inhaled anesthetics, assault, initial encounter	Diagnosis	ICD-10-CM
T41.0X4A	Poisoning by inhaled anesthetics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T41.1X1A	Poisoning by intravenous anesthetics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T41.1X2A	Poisoning by intravenous anesthetics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T41.1X3A	Poisoning by intravenous anesthetics, assault, initial encounter	Diagnosis	ICD-10-CM
T41.1X4A	Poisoning by intravenous anesthetics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T41.201A	Poisoning by unspecified general anesthetics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T41.202A	Poisoning by unspecified general anesthetics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T41.203A	Poisoning by unspecified general anesthetics, assault, initial encounter	Diagnosis	ICD-10-CM
T41.204A	Poisoning by unspecified general anesthetics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T41.291A	Poisoning by other general anesthetics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T41.292A	Poisoning by other general anesthetics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T41.293A	Poisoning by other general anesthetics, assault, initial encounter	Diagnosis	ICD-10-CM
T41.294A	Poisoning by other general anesthetics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T41.3X1A	Poisoning by local anesthetics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T41.3X2A	Poisoning by local anesthetics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T41.3X3A	Poisoning by local anesthetics, assault, initial encounter	Diagnosis	ICD-10-CM
T41.3X4A	Poisoning by local anesthetics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T41.41XA	Poisoning by unspecified anesthetic, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T41.42XA	Poisoning by unspecified anesthetic, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T41.43XA	Poisoning by unspecified anesthetic, assault, initial encounter	Diagnosis	ICD-10-CM
T41.44XA	Poisoning by unspecified anesthetic, undetermined, initial encounter	Diagnosis	ICD-10-CM
T42.0X1A	Poisoning by hydantoin derivatives, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T42.0X2A	Poisoning by hydantoin derivatives, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.0X3A	Poisoning by hydantoin derivatives, assault, initial encounter	Diagnosis	ICD-10-CM
T42.0X4A	Poisoning by hydantoin derivatives, undetermined, initial encounter	Diagnosis	ICD-10-CM
T42.1X1A	Poisoning by iminostilbenes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T42.1X2A	Poisoning by iminostilbenes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T42.1X3A	Poisoning by iminostilbenes, assault, initial encounter	Diagnosis	ICD-10-CM
T42.1X4A	Poisoning by iminostilbenes, undetermined, initial encounter	Diagnosis	ICD-10-CM
T42.2X1A	Poisoning by succinimides and oxazolidinediones, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T42.2X2A	Poisoning by succinimides and oxazolidinediones, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.2X3A	Poisoning by succinimides and oxazolidinediones, assault, initial encounter	Diagnosis	ICD-10-CM
T42.2X4A	Poisoning by succinimides and oxazolidinediones, undetermined, initial encounter	Diagnosis	ICD-10-CM
T42.3X1A	Poisoning by barbiturates, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T42.3X2A	Poisoning by barbiturates, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.3X3A	Poisoning by barbiturates, assault, initial encounter	Diagnosis	ICD-10-CM
T42.3X4A	Poisoning by barbiturates, undetermined, initial encounter	Diagnosis	ICD-10-CM
T42.4X1A	Poisoning by benzodiazepines, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T42.4X2A	Poisoning by benzodiazepines, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.4X3A	Poisoning by benzodiazepines, assault, initial encounter	Diagnosis	ICD-10-CM
T42.4X4A	Poisoning by benzodiazepines, undetermined, initial encounter	Diagnosis	ICD-10-CM
T42.5X1A	Poisoning by mixed antiepileptics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T42.5X2A	Poisoning by mixed antiepileptics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.5X3A	Poisoning by mixed antiepileptics, assault, initial encounter	Diagnosis	ICD-10-CM
T42.5X4A	Poisoning by mixed antiepileptics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T42.6X1A	Poisoning by other antiepileptic and sedative-hypnotic drugs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T42.6X2A	Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.6X3A	Poisoning by other antiepileptic and sedative-hypnotic drugs, assault, initial encounter	Diagnosis	ICD-10-CM
T42.6X4A	Poisoning by other antiepileptic and sedative-hypnotic drugs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T42.71XA	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T42.72XA	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.73XA	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, assault, initial encounter	Diagnosis	ICD-10-CM
T42.74XA	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T42.8X1A	Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T42.8X2A	Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T42.8X3A	Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, assault, initial encounter	Diagnosis	ICD-10-CM
T42.8X4A	Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, undetermined, initial encounter	Diagnosis	ICD-10-CM
T43.011A	Poisoning by tricyclic antidepressants, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T43.012A	Poisoning by tricyclic antidepressants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.013A	Poisoning by tricyclic antidepressants, assault, initial encounter	Diagnosis	ICD-10-CM
T43.014A	Poisoning by tricyclic antidepressants, undetermined, initial encounter	Diagnosis	ICD-10-CM
T43.021A	Poisoning by tetracyclic antidepressants, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T43.022A	Poisoning by tetracyclic antidepressants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.023A	Poisoning by tetracyclic antidepressants, assault, initial encounter	Diagnosis	ICD-10-CM
T43.024A	Poisoning by tetracyclic antidepressants, undetermined, initial encounter	Diagnosis	ICD-10-CM
T43.1X1A	Poisoning by monoamine-oxidase-inhibitor antidepressants, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T43.1X2A	Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.1X3A	Poisoning by monoamine-oxidase-inhibitor antidepressants, assault, initial encounter	Diagnosis	ICD-10-CM
T43.1X4A	Poisoning by monoamine-oxidase-inhibitor antidepressants, undetermined, initial encounter	Diagnosis	ICD-10-CM
T43.201A	Poisoning by unspecified antidepressants, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T43.202A	Poisoning by unspecified antidepressants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.203A	Poisoning by unspecified antidepressants, assault, initial encounter	Diagnosis	ICD-10-CM
T43.204A	Poisoning by unspecified antidepressants, undetermined, initial encounter	Diagnosis	ICD-10-CM
T43.211A	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T43.212A	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.213A	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, assault, initial encounter	Diagnosis	ICD-10-CM
T43.214A	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, undetermined, initial encounter	Diagnosis	ICD-10-CM
T43.221A	Poisoning by selective serotonin reuptake inhibitors, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T43.222A	Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T43.223A	Poisoning by selective serotonin reuptake inhibitors, assault, initial encounter	Diagnosis	ICD-10-CM
T43.224A	Poisoning by selective serotonin reuptake inhibitors, undetermined, initial encounter	Diagnosis	ICD-10-CM
T43.291A	Poisoning by other antidepressants, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T43.292A	Poisoning by other antidepressants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.293A	Poisoning by other antidepressants, assault, initial encounter	Diagnosis	ICD-10-CM
T43.294A	Poisoning by other antidepressants, undetermined, initial encounter	Diagnosis	ICD-10-CM
T43.3X1A	Poisoning by phenothiazine antipsychotics and neuroleptics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T43.3X2A	Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.3X3A	Poisoning by phenothiazine antipsychotics and neuroleptics, assault, initial encounter	Diagnosis	ICD-10-CM
T43.3X4A	Poisoning by phenothiazine antipsychotics and neuroleptics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T43.4X1A	Poisoning by butyrophenone and thiothixene neuroleptics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T43.4X2A	Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.4X3A	Poisoning by butyrophenone and thiothixene neuroleptics, assault, initial encounter	Diagnosis	ICD-10-CM
T43.4X4A	Poisoning by butyrophenone and thiothixene neuroleptics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T43.501A	Poisoning by unspecified antipsychotics and neuroleptics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T43.502A	Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.503A	Poisoning by unspecified antipsychotics and neuroleptics, assault, initial encounter	Diagnosis	ICD-10-CM
T43.504A	Poisoning by unspecified antipsychotics and neuroleptics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T43.591A	Poisoning by other antipsychotics and neuroleptics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T43.592A	Poisoning by other antipsychotics and neuroleptics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.593A	Poisoning by other antipsychotics and neuroleptics, assault, initial encounter	Diagnosis	ICD-10-CM
T43.594A	Poisoning by other antipsychotics and neuroleptics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T43.601A	Poisoning by unspecified psychostimulants, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T43.602A	Poisoning by unspecified psychostimulants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.603A	Poisoning by unspecified psychostimulants, assault, initial encounter	Diagnosis	ICD-10-CM
T43.604A	Poisoning by unspecified psychostimulants, undetermined, initial encounter	Diagnosis	ICD-10-CM
T43.611A	Poisoning by caffeine, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T43.612A	Poisoning by caffeine, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T43.613A	Poisoning by caffeine, assault, initial encounter	Diagnosis	ICD-10-CM
T43.614A	Poisoning by caffeine, undetermined, initial encounter	Diagnosis	ICD-10-CM
T43.621A	Poisoning by amphetamines, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T43.622A	Poisoning by amphetamines, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.623A	Poisoning by amphetamines, assault, initial encounter	Diagnosis	ICD-10-CM
T43.624A	Poisoning by amphetamines, undetermined, initial encounter	Diagnosis	ICD-10-CM
T43.631A	Poisoning by methylphenidate, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T43.632A	Poisoning by methylphenidate, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.633A	Poisoning by methylphenidate, assault, initial encounter	Diagnosis	ICD-10-CM
T43.634A	Poisoning by methylphenidate, undetermined, initial encounter	Diagnosis	ICD-10-CM
T43.691A	Poisoning by other psychostimulants, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T43.692A	Poisoning by other psychostimulants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.693A	Poisoning by other psychostimulants, assault, initial encounter	Diagnosis	ICD-10-CM
T43.694A	Poisoning by other psychostimulants, undetermined, initial encounter	Diagnosis	ICD-10-CM
T43.8X1A	Poisoning by other psychotropic drugs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T43.8X2A	Poisoning by other psychotropic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.8X3A	Poisoning by other psychotropic drugs, assault, initial encounter	Diagnosis	ICD-10-CM
T43.8X4A	Poisoning by other psychotropic drugs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T43.91XA	Poisoning by unspecified psychotropic drug, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T43.92XA	Poisoning by unspecified psychotropic drug, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T43.93XA	Poisoning by unspecified psychotropic drug, assault, initial encounter	Diagnosis	ICD-10-CM
T43.94XA	Poisoning by unspecified psychotropic drug, undetermined, initial encounter	Diagnosis	ICD-10-CM
T45.0X1A	Poisoning by antiallergic and antiemetic drugs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T45.0X2A	Poisoning by antiallergic and antiemetic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.0X3A	Poisoning by antiallergic and antiemetic drugs, assault, initial encounter	Diagnosis	ICD-10-CM
T45.0X4A	Poisoning by antiallergic and antiemetic drugs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T45.1X1A	Poisoning by antineoplastic and immunosuppressive drugs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T45.1X2A	Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.1X3A	Poisoning by antineoplastic and immunosuppressive drugs, assault, initial encounter	Diagnosis	ICD-10-CM
T45.1X4A	Poisoning by antineoplastic and immunosuppressive drugs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T45.2X1A	Poisoning by vitamins, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T45.2X2A	Poisoning by vitamins, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.2X3A	Poisoning by vitamins, assault, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T45.2X4A	Poisoning by vitamins, undetermined, initial encounter	Diagnosis	ICD-10-CM
T45.3X1A	Poisoning by enzymes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T45.3X2A	Poisoning by enzymes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.3X3A	Poisoning by enzymes, assault, initial encounter	Diagnosis	ICD-10-CM
T45.3X4A	Poisoning by enzymes, undetermined, initial encounter	Diagnosis	ICD-10-CM
T45.4X1A	Poisoning by iron and its compounds, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T45.4X2A	Poisoning by iron and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.4X3A	Poisoning by iron and its compounds, assault, initial encounter	Diagnosis	ICD-10-CM
T45.4X4A	Poisoning by iron and its compounds, undetermined, initial encounter	Diagnosis	ICD-10-CM
T45.511A	Poisoning by anticoagulants, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T45.512A	Poisoning by anticoagulants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.513A	Poisoning by anticoagulants, assault, initial encounter	Diagnosis	ICD-10-CM
T45.514A	Poisoning by anticoagulants, undetermined, initial encounter	Diagnosis	ICD-10-CM
T45.521A	Poisoning by antithrombotic drugs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T45.522A	Poisoning by antithrombotic drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.523A	Poisoning by antithrombotic drugs, assault, initial encounter	Diagnosis	ICD-10-CM
T45.524A	Poisoning by antithrombotic drugs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T45.601A	Poisoning by unspecified fibrinolysis-affecting drugs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T45.602A	Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.603A	Poisoning by unspecified fibrinolysis-affecting drugs, assault, initial encounter	Diagnosis	ICD-10-CM
T45.604A	Poisoning by unspecified fibrinolysis-affecting drugs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T45.611A	Poisoning by thrombolytic drug, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T45.612A	Poisoning by thrombolytic drug, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.613A	Poisoning by thrombolytic drug, assault, initial encounter	Diagnosis	ICD-10-CM
T45.614A	Poisoning by thrombolytic drug, undetermined, initial encounter	Diagnosis	ICD-10-CM
T45.621A	Poisoning by hemostatic drug, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T45.622A	Poisoning by hemostatic drug, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.623A	Poisoning by hemostatic drug, assault, initial encounter	Diagnosis	ICD-10-CM
T45.624A	Poisoning by hemostatic drug, undetermined, initial encounter	Diagnosis	ICD-10-CM
T45.691A	Poisoning by other fibrinolysis-affecting drugs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T45.692A	Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.693A	Poisoning by other fibrinolysis-affecting drugs, assault, initial encounter	Diagnosis	ICD-10-CM
T45.694A	Poisoning by other fibrinolysis-affecting drugs, undetermined, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T45.7X1A	Poisoning by anticoagulant antagonists, vitamin K and other coagulants, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T45.7X2A	Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.7X3A	Poisoning by anticoagulant antagonists, vitamin K and other coagulants, assault, initial encounter	Diagnosis	ICD-10-CM
T45.7X4A	Poisoning by anticoagulant antagonists, vitamin K and other coagulants, undetermined, initial encounter	Diagnosis	ICD-10-CM
T45.8X1A	Poisoning by other primarily systemic and hematological agents, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T45.8X2A	Poisoning by other primarily systemic and hematological agents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.8X3A	Poisoning by other primarily systemic and hematological agents, assault, initial encounter	Diagnosis	ICD-10-CM
T45.8X4A	Poisoning by other primarily systemic and hematological agents, undetermined, initial encounter	Diagnosis	ICD-10-CM
T45.91XA	Poisoning by unspecified primarily systemic and hematological agent, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T45.92XA	Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T45.93XA	Poisoning by unspecified primarily systemic and hematological agent, assault, initial encounter	Diagnosis	ICD-10-CM
T45.94XA	Poisoning by unspecified primarily systemic and hematological agent, undetermined, initial encounter	Diagnosis	ICD-10-CM
T50.0X1A	Poisoning by mineralocorticoids and their antagonists, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T50.0X2A	Poisoning by mineralocorticoids and their antagonists, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.0X3A	Poisoning by mineralocorticoids and their antagonists, assault, initial encounter	Diagnosis	ICD-10-CM
T50.0X4A	Poisoning by mineralocorticoids and their antagonists, undetermined, initial encounter	Diagnosis	ICD-10-CM
T50.Z11A	Poisoning by immunoglobulin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T50.Z12A	Poisoning by immunoglobulin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T50.Z13A	Poisoning by immunoglobulin, assault, initial encounter	Diagnosis	ICD-10-CM
T50.Z14A	Poisoning by immunoglobulin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T51.0X1A	Toxic effect of ethanol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T51.0X2A	Toxic effect of ethanol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T51.0X3A	Toxic effect of ethanol, assault, initial encounter	Diagnosis	ICD-10-CM
T51.0X4A	Toxic effect of ethanol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T51.1X1A	Toxic effect of methanol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T51.1X2A	Toxic effect of methanol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.1X3A	Toxic effect of methanol, assault, initial encounter	Diagnosis	ICD-10-CM
T51.1X4A	Toxic effect of methanol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T51.2X1A	Toxic effect of 2-Propanol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T51.2X3A	Toxic effect of 2-Propanol, assault, initial encounter	Diagnosis	ICD-10-CM
T51.2X4A	Toxic effect of 2-Propanol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T51.3X1A	Toxic effect of fusel oil, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T51.3X2A	Toxic effect of fusel oil, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.3X3A	Toxic effect of fusel oil, assault, initial encounter	Diagnosis	ICD-10-CM
T51.3X4A	Toxic effect of fusel oil, undetermined, initial encounter	Diagnosis	ICD-10-CM
T51.8X1A	Toxic effect of other alcohols, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T51.8X2A	Toxic effect of other alcohols, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.8X3A	Toxic effect of other alcohols, assault, initial encounter	Diagnosis	ICD-10-CM
T51.8X4A	Toxic effect of other alcohols, undetermined, initial encounter	Diagnosis	ICD-10-CM
T51.91XA	Toxic effect of unspecified alcohol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T51.92XA	Toxic effect of unspecified alcohol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.93XA	Toxic effect of unspecified alcohol, assault, initial encounter	Diagnosis	ICD-10-CM
T51.94XA	Toxic effect of unspecified alcohol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T52.0X1A	Toxic effect of petroleum products, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T52.0X2A	Toxic effect of petroleum products, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T52.0X3A	Toxic effect of petroleum products, assault, initial encounter	Diagnosis	ICD-10-CM
T52.0X4A	Toxic effect of petroleum products, undetermined, initial encounter	Diagnosis	ICD-10-CM
T52.1X1A	Toxic effect of benzene, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T52.1X2A	Toxic effect of benzene, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T52.1X3A	Toxic effect of benzene, assault, initial encounter	Diagnosis	ICD-10-CM
T52.1X4A	Toxic effect of benzene, undetermined, initial encounter	Diagnosis	ICD-10-CM
T52.2X1A	Toxic effect of homologues of benzene, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T52.2X2A	Toxic effect of homologues of benzene, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T52.2X3A	Toxic effect of homologues of benzene, assault, initial encounter	Diagnosis	ICD-10-CM
T52.2X4A	Toxic effect of homologues of benzene, undetermined, initial encounter	Diagnosis	ICD-10-CM
T52.3X1A	Toxic effect of glycols, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T52.3X2A	Toxic effect of glycols, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T52.3X3A	Toxic effect of glycols, assault, initial encounter	Diagnosis	ICD-10-CM
T52.3X4A	Toxic effect of glycols, undetermined, initial encounter	Diagnosis	ICD-10-CM
T52.4X1A	Toxic effect of ketones, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T52.4X2A	Toxic effect of ketones, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T52.4X3A	Toxic effect of ketones, assault, initial encounter	Diagnosis	ICD-10-CM
T52.4X4A	Toxic effect of ketones, undetermined, initial encounter	Diagnosis	ICD-10-CM
T52.8X1A	Toxic effect of other organic solvents, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T52.8X2A	Toxic effect of other organic solvents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T52.8X3A	Toxic effect of other organic solvents, assault, initial encounter	Diagnosis	ICD-10-CM
T52.8X4A	Toxic effect of other organic solvents, undetermined, initial encounter	Diagnosis	ICD-10-CM
T52.91XA	Toxic effect of unspecified organic solvent, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T52.92XA	Toxic effect of unspecified organic solvent, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T52.93XA	Toxic effect of unspecified organic solvent, assault, initial encounter	Diagnosis	ICD-10-CM
T52.94XA	Toxic effect of unspecified organic solvent, undetermined, initial encounter	Diagnosis	ICD-10-CM
T53.0X1A	Toxic effect of carbon tetrachloride, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T53.0X2A	Toxic effect of carbon tetrachloride, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.0X3A	Toxic effect of carbon tetrachloride, assault, initial encounter	Diagnosis	ICD-10-CM
T53.0X4A	Toxic effect of carbon tetrachloride, undetermined, initial encounter	Diagnosis	ICD-10-CM
T53.1X1A	Toxic effect of chloroform, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T53.1X2A	Toxic effect of chloroform, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.1X3A	Toxic effect of chloroform, assault, initial encounter	Diagnosis	ICD-10-CM
T53.1X4A	Toxic effect of chloroform, undetermined, initial encounter	Diagnosis	ICD-10-CM
T53.2X1A	Toxic effect of trichloroethylene, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T53.2X2A	Toxic effect of trichloroethylene, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.2X3A	Toxic effect of trichloroethylene, assault, initial encounter	Diagnosis	ICD-10-CM
T53.2X4A	Toxic effect of trichloroethylene, undetermined, initial encounter	Diagnosis	ICD-10-CM
T53.3X1A	Toxic effect of tetrachloroethylene, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T53.3X2A	Toxic effect of tetrachloroethylene, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.3X3A	Toxic effect of tetrachloroethylene, assault, initial encounter	Diagnosis	ICD-10-CM
T53.3X4A	Toxic effect of tetrachloroethylene, undetermined, initial encounter	Diagnosis	ICD-10-CM
T53.4X1A	Toxic effect of dichloromethane, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T53.4X2A	Toxic effect of dichloromethane, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.4X3A	Toxic effect of dichloromethane, assault, initial encounter	Diagnosis	ICD-10-CM
T53.4X4A	Toxic effect of dichloromethane, undetermined, initial encounter	Diagnosis	ICD-10-CM
T53.5X1A	Toxic effect of chlorofluorocarbons, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T53.5X2A	Toxic effect of chlorofluorocarbons, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.5X3A	Toxic effect of chlorofluorocarbons, assault, initial encounter	Diagnosis	ICD-10-CM
T53.5X4A	Toxic effect of chlorofluorocarbons, undetermined, initial encounter	Diagnosis	ICD-10-CM
T53.6X1A	Toxic effect of other halogen derivatives of aliphatic hydrocarbons, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T53.6X2A	Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.6X3A	Toxic effect of other halogen derivatives of aliphatic hydrocarbons, assault, initial encounter	Diagnosis	ICD-10-CM
T53.6X4A	Toxic effect of other halogen derivatives of aliphatic hydrocarbons, undetermined, initial encounter	Diagnosis	ICD-10-CM
T53.7X1A	Toxic effect of other halogen derivatives of aromatic hydrocarbons, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T53.7X2A	Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.7X3A	Toxic effect of other halogen derivatives of aromatic hydrocarbons, assault, initial encounter	Diagnosis	ICD-10-CM
T53.7X4A	Toxic effect of other halogen derivatives of aromatic hydrocarbons, undetermined, initial encounter	Diagnosis	ICD-10-CM
T53.91XA	Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T53.92XA	Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T53.93XA	Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, assault, initial encounter	Diagnosis	ICD-10-CM
T53.94XA	Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, undetermined, initial encounter	Diagnosis	ICD-10-CM
T54.0X1A	Toxic effect of phenol and phenol homologues, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T54.0X2A	Toxic effect of phenol and phenol homologues, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T54.0X3A	Toxic effect of phenol and phenol homologues, assault, initial encounter	Diagnosis	ICD-10-CM
T54.0X4A	Toxic effect of phenol and phenol homologues, undetermined, initial encounter	Diagnosis	ICD-10-CM
T54.1X1A	Toxic effect of other corrosive organic compounds, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T54.1X2A	Toxic effect of other corrosive organic compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T54.1X3A	Toxic effect of other corrosive organic compounds, assault, initial encounter	Diagnosis	ICD-10-CM
T54.1X4A	Toxic effect of other corrosive organic compounds, undetermined, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T54.2X1A	Toxic effect of corrosive acids and acid-like substances, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T54.2X2A	Toxic effect of corrosive acids and acid-like substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T54.2X3A	Toxic effect of corrosive acids and acid-like substances, assault, initial encounter	Diagnosis	ICD-10-CM
T54.2X4A	Toxic effect of corrosive acids and acid-like substances, undetermined, initial encounter	Diagnosis	ICD-10-CM
T54.3X1A	Toxic effect of corrosive alkalis and alkali-like substances, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T54.3X2A	Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T54.3X3A	Toxic effect of corrosive alkalis and alkali-like substances, assault, initial encounter	Diagnosis	ICD-10-CM
T54.3X4A	Toxic effect of corrosive alkalis and alkali-like substances, undetermined, initial encounter	Diagnosis	ICD-10-CM
T54.91XA	Toxic effect of unspecified corrosive substance, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T54.92XA	Toxic effect of unspecified corrosive substance, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T54.93XA	Toxic effect of unspecified corrosive substance, assault, initial encounter	Diagnosis	ICD-10-CM
T54.94XA	Toxic effect of unspecified corrosive substance, undetermined, initial encounter	Diagnosis	ICD-10-CM
T55.0X1A	Toxic effect of soaps, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T55.0X2A	Toxic effect of soaps, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T55.0X3A	Toxic effect of soaps, assault, initial encounter	Diagnosis	ICD-10-CM
T55.0X4A	Toxic effect of soaps, undetermined, initial encounter	Diagnosis	ICD-10-CM
T55.1X1A	Toxic effect of detergents, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T55.1X2A	Toxic effect of detergents, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T55.1X3A	Toxic effect of detergents, assault, initial encounter	Diagnosis	ICD-10-CM
T55.1X4A	Toxic effect of detergents, undetermined, initial encounter	Diagnosis	ICD-10-CM
T56.0X1A	Toxic effect of lead and its compounds, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T56.0X2A	Toxic effect of lead and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.0X3A	Toxic effect of lead and its compounds, assault, initial encounter	Diagnosis	ICD-10-CM
T56.0X4A	Toxic effect of lead and its compounds, undetermined, initial encounter	Diagnosis	ICD-10-CM
T56.1X1A	Toxic effect of mercury and its compounds, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T56.1X2A	Toxic effect of mercury and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.1X3A	Toxic effect of mercury and its compounds, assault, initial encounter	Diagnosis	ICD-10-CM
T56.1X4A	Toxic effect of mercury and its compounds, undetermined, initial encounter	Diagnosis	ICD-10-CM
T56.2X1A	Toxic effect of chromium and its compounds, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T56.2X2A	Toxic effect of chromium and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.2X3A	Toxic effect of chromium and its compounds, assault, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T56.2X4A	Toxic effect of chromium and its compounds, undetermined, initial encounter	Diagnosis	ICD-10-CM
T56.3X1A	Toxic effect of cadmium and its compounds, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T56.3X2A	Toxic effect of cadmium and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.3X3A	Toxic effect of cadmium and its compounds, assault, initial encounter	Diagnosis	ICD-10-CM
T56.3X4A	Toxic effect of cadmium and its compounds, undetermined, initial encounter	Diagnosis	ICD-10-CM
T56.4X1A	Toxic effect of copper and its compounds, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T56.4X2A	Toxic effect of copper and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.4X3A	Toxic effect of copper and its compounds, assault, initial encounter	Diagnosis	ICD-10-CM
T56.4X4A	Toxic effect of copper and its compounds, undetermined, initial encounter	Diagnosis	ICD-10-CM
T56.5X1A	Toxic effect of zinc and its compounds, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T56.5X2A	Toxic effect of zinc and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.5X3A	Toxic effect of zinc and its compounds, assault, initial encounter	Diagnosis	ICD-10-CM
T56.5X4A	Toxic effect of zinc and its compounds, undetermined, initial encounter	Diagnosis	ICD-10-CM
T56.6X1A	Toxic effect of tin and its compounds, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T56.6X2A	Toxic effect of tin and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.6X3A	Toxic effect of tin and its compounds, assault, initial encounter	Diagnosis	ICD-10-CM
T56.6X4A	Toxic effect of tin and its compounds, undetermined, initial encounter	Diagnosis	ICD-10-CM
T56.7X1A	Toxic effect of beryllium and its compounds, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T56.7X2A	Toxic effect of beryllium and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.7X3A	Toxic effect of beryllium and its compounds, assault, initial encounter	Diagnosis	ICD-10-CM
T56.7X4A	Toxic effect of beryllium and its compounds, undetermined, initial encounter	Diagnosis	ICD-10-CM
T56.811A	Toxic effect of thallium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T56.812A	Toxic effect of thallium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.813A	Toxic effect of thallium, assault, initial encounter	Diagnosis	ICD-10-CM
T56.814A	Toxic effect of thallium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T56.891A	Toxic effect of other metals, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T56.892A	Toxic effect of other metals, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.893A	Toxic effect of other metals, assault, initial encounter	Diagnosis	ICD-10-CM
T56.894A	Toxic effect of other metals, undetermined, initial encounter	Diagnosis	ICD-10-CM
T56.91XA	Toxic effect of unspecified metal, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T56.92XA	Toxic effect of unspecified metal, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T56.93XA	Toxic effect of unspecified metal, assault, initial encounter	Diagnosis	ICD-10-CM
T56.94XA	Toxic effect of unspecified metal, undetermined, initial encounter	Diagnosis	ICD-10-CM
T57.0X1A	Toxic effect of arsenic and its compounds, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T57.0X2A	Toxic effect of arsenic and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T57.0X3A	Toxic effect of arsenic and its compounds, assault, initial encounter	Diagnosis	ICD-10-CM
T57.0X4A	Toxic effect of arsenic and its compounds, undetermined, initial encounter	Diagnosis	ICD-10-CM
T57.1X1A	Toxic effect of phosphorus and its compounds, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T57.1X2A	Toxic effect of phosphorus and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T57.1X3A	Toxic effect of phosphorus and its compounds, assault, initial encounter	Diagnosis	ICD-10-CM
T57.1X4A	Toxic effect of phosphorus and its compounds, undetermined, initial encounter	Diagnosis	ICD-10-CM
T57.2X1A	Toxic effect of manganese and its compounds, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T57.2X2A	Toxic effect of manganese and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T57.2X3A	Toxic effect of manganese and its compounds, assault, initial encounter	Diagnosis	ICD-10-CM
T57.2X4A	Toxic effect of manganese and its compounds, undetermined, initial encounter	Diagnosis	ICD-10-CM
T57.3X1A	Toxic effect of hydrogen cyanide, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T57.3X2A	Toxic effect of hydrogen cyanide, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T57.3X3A	Toxic effect of hydrogen cyanide, assault, initial encounter	Diagnosis	ICD-10-CM
T57.3X4A	Toxic effect of hydrogen cyanide, undetermined, initial encounter	Diagnosis	ICD-10-CM
T57.8X1A	Toxic effect of other specified inorganic substances, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T57.8X2A	Toxic effect of other specified inorganic substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T57.8X3A	Toxic effect of other specified inorganic substances, assault, initial encounter	Diagnosis	ICD-10-CM
T57.8X4A	Toxic effect of other specified inorganic substances, undetermined, initial encounter	Diagnosis	ICD-10-CM
T57.91XA	Toxic effect of unspecified inorganic substance, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T57.92XA	Toxic effect of unspecified inorganic substance, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T57.93XA	Toxic effect of unspecified inorganic substance, assault, initial encounter	Diagnosis	ICD-10-CM
T57.94XA	Toxic effect of unspecified inorganic substance, undetermined, initial encounter	Diagnosis	ICD-10-CM
T58.01XA	Toxic effect of carbon monoxide from motor vehicle exhaust, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T58.02XA	Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T58.03XA	Toxic effect of carbon monoxide from motor vehicle exhaust, assault, initial encounter	Diagnosis	ICD-10-CM
T58.04XA	Toxic effect of carbon monoxide from motor vehicle exhaust, undetermined, initial encounter	Diagnosis	ICD-10-CM
T58.11XA	Toxic effect of carbon monoxide from utility gas, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T58.12XA	Toxic effect of carbon monoxide from utility gas, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T58.13XA	Toxic effect of carbon monoxide from utility gas, assault, initial encounter	Diagnosis	ICD-10-CM
T58.14XA	Toxic effect of carbon monoxide from utility gas, undetermined, initial encounter	Diagnosis	ICD-10-CM
T58.2X1A	Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T58.2X2A	Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T58.2X3A	Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, assault, initial encounter	Diagnosis	ICD-10-CM
T58.2X4A	Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, undetermined, initial encounter	Diagnosis	ICD-10-CM
T58.8X1A	Toxic effect of carbon monoxide from other source, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T58.8X2A	Toxic effect of carbon monoxide from other source, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T58.8X3A	Toxic effect of carbon monoxide from other source, assault, initial encounter	Diagnosis	ICD-10-CM
T58.8X4A	Toxic effect of carbon monoxide from other source, undetermined, initial encounter	Diagnosis	ICD-10-CM
T58.91XA	Toxic effect of carbon monoxide from unspecified source, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T58.92XA	Toxic effect of carbon monoxide from unspecified source, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T58.93XA	Toxic effect of carbon monoxide from unspecified source, assault, initial encounter	Diagnosis	ICD-10-CM
T58.94XA	Toxic effect of carbon monoxide from unspecified source, undetermined, initial encounter	Diagnosis	ICD-10-CM
T59.0X1A	Toxic effect of nitrogen oxides, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T59.0X2A	Toxic effect of nitrogen oxides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.0X3A	Toxic effect of nitrogen oxides, assault, initial encounter	Diagnosis	ICD-10-CM
T59.0X4A	Toxic effect of nitrogen oxides, undetermined, initial encounter	Diagnosis	ICD-10-CM
T59.1X1A	Toxic effect of sulfur dioxide, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T59.1X2A	Toxic effect of sulfur dioxide, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.1X3A	Toxic effect of sulfur dioxide, assault, initial encounter	Diagnosis	ICD-10-CM
T59.1X4A	Toxic effect of sulfur dioxide, undetermined, initial encounter	Diagnosis	ICD-10-CM
T59.2X1A	Toxic effect of formaldehyde, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T59.2X2A	Toxic effect of formaldehyde, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.2X3A	Toxic effect of formaldehyde, assault, initial encounter	Diagnosis	ICD-10-CM
T59.2X4A	Toxic effect of formaldehyde, undetermined, initial encounter	Diagnosis	ICD-10-CM
T59.3X1A	Toxic effect of lacrimogenic gas, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T59.3X2A	Toxic effect of lacrimogenic gas, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.3X3A	Toxic effect of lacrimogenic gas, assault, initial encounter	Diagnosis	ICD-10-CM
T59.3X4A	Toxic effect of lacrimogenic gas, undetermined, initial encounter	Diagnosis	ICD-10-CM
T59.4X1A	Toxic effect of chlorine gas, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T59.4X2A	Toxic effect of chlorine gas, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T59.4X3A	Toxic effect of chlorine gas, assault, initial encounter	Diagnosis	ICD-10-CM
T59.4X4A	Toxic effect of chlorine gas, undetermined, initial encounter	Diagnosis	ICD-10-CM
T59.5X1A	Toxic effect of fluorine gas and hydrogen fluoride, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T59.5X2A	Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.5X3A	Toxic effect of fluorine gas and hydrogen fluoride, assault, initial encounter	Diagnosis	ICD-10-CM
T59.5X4A	Toxic effect of fluorine gas and hydrogen fluoride, undetermined, initial encounter	Diagnosis	ICD-10-CM
T59.6X1A	Toxic effect of hydrogen sulfide, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T59.6X2A	Toxic effect of hydrogen sulfide, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.6X3A	Toxic effect of hydrogen sulfide, assault, initial encounter	Diagnosis	ICD-10-CM
T59.6X4A	Toxic effect of hydrogen sulfide, undetermined, initial encounter	Diagnosis	ICD-10-CM
T59.7X1A	Toxic effect of carbon dioxide, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T59.7X2A	Toxic effect of carbon dioxide, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.7X3A	Toxic effect of carbon dioxide, assault, initial encounter	Diagnosis	ICD-10-CM
T59.7X4A	Toxic effect of carbon dioxide, undetermined, initial encounter	Diagnosis	ICD-10-CM
T59.811A	Toxic effect of smoke, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T59.812A	Toxic effect of smoke, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.813A	Toxic effect of smoke, assault, initial encounter	Diagnosis	ICD-10-CM
T59.814A	Toxic effect of smoke, undetermined, initial encounter	Diagnosis	ICD-10-CM
T59.891A	Toxic effect of other specified gases, fumes and vapors, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T59.892A	Toxic effect of other specified gases, fumes and vapors, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.893A	Toxic effect of other specified gases, fumes and vapors, assault, initial encounter	Diagnosis	ICD-10-CM
T59.894A	Toxic effect of other specified gases, fumes and vapors, undetermined, initial encounter	Diagnosis	ICD-10-CM
T59.91XA	Toxic effect of unspecified gases, fumes and vapors, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T59.92XA	Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T59.93XA	Toxic effect of unspecified gases, fumes and vapors, assault, initial encounter	Diagnosis	ICD-10-CM
T59.94XA	Toxic effect of unspecified gases, fumes and vapors, undetermined, initial encounter	Diagnosis	ICD-10-CM
T60.0X1A	Toxic effect of organophosphate and carbamate insecticides, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T60.0X2A	Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T60.0X3A	Toxic effect of organophosphate and carbamate insecticides, assault, initial encounter	Diagnosis	ICD-10-CM
T60.0X4A	Toxic effect of organophosphate and carbamate insecticides, undetermined, initial encounter	Diagnosis	ICD-10-CM
T60.1X1A	Toxic effect of halogenated insecticides, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T60.1X2A	Toxic effect of halogenated insecticides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T60.1X3A	Toxic effect of halogenated insecticides, assault, initial encounter	Diagnosis	ICD-10-CM
T60.1X4A	Toxic effect of halogenated insecticides, undetermined, initial encounter	Diagnosis	ICD-10-CM
T60.2X1A	Toxic effect of other insecticides, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T60.2X2A	Toxic effect of other insecticides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T60.2X3A	Toxic effect of other insecticides, assault, initial encounter	Diagnosis	ICD-10-CM
T60.2X4A	Toxic effect of other insecticides, undetermined, initial encounter	Diagnosis	ICD-10-CM
T60.3X1A	Toxic effect of herbicides and fungicides, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T60.3X2A	Toxic effect of herbicides and fungicides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T60.3X3A	Toxic effect of herbicides and fungicides, assault, initial encounter	Diagnosis	ICD-10-CM
T60.3X4A	Toxic effect of herbicides and fungicides, undetermined, initial encounter	Diagnosis	ICD-10-CM
T60.4X1A	Toxic effect of rodenticides, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T60.4X2A	Toxic effect of rodenticides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T60.4X3A	Toxic effect of rodenticides, assault, initial encounter	Diagnosis	ICD-10-CM
T60.4X4A	Toxic effect of rodenticides, undetermined, initial encounter	Diagnosis	ICD-10-CM
T60.8X1A	Toxic effect of other pesticides, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T60.8X2A	Toxic effect of other pesticides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T60.8X3A	Toxic effect of other pesticides, assault, initial encounter	Diagnosis	ICD-10-CM
T60.8X4A	Toxic effect of other pesticides, undetermined, initial encounter	Diagnosis	ICD-10-CM
T60.91XA	Toxic effect of unspecified pesticide, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T60.92XA	Toxic effect of unspecified pesticide, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T60.93XA	Toxic effect of unspecified pesticide, assault, initial encounter	Diagnosis	ICD-10-CM
T60.94XA	Toxic effect of unspecified pesticide, undetermined, initial encounter	Diagnosis	ICD-10-CM
T61.01XA	Ciguatera fish poisoning, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T61.02XA	Ciguatera fish poisoning, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T61.03XA	Ciguatera fish poisoning, assault, initial encounter	Diagnosis	ICD-10-CM
T61.04XA	Ciguatera fish poisoning, undetermined, initial encounter	Diagnosis	ICD-10-CM
T61.11XA	Scombroid fish poisoning, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T61.12XA	Scombroid fish poisoning, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T61.13XA	Scombroid fish poisoning, assault, initial encounter	Diagnosis	ICD-10-CM
T61.14XA	Scombroid fish poisoning, undetermined, initial encounter	Diagnosis	ICD-10-CM
T61.771A	Other fish poisoning, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T61.772A	Other fish poisoning, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T61.773A	Other fish poisoning, assault, initial encounter	Diagnosis	ICD-10-CM
T61.774A	Other fish poisoning, undetermined, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T61.781A	Other shellfish poisoning, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T61.782A	Other shellfish poisoning, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T61.783A	Other shellfish poisoning, assault, initial encounter	Diagnosis	ICD-10-CM
T61.784A	Other shellfish poisoning, undetermined, initial encounter	Diagnosis	ICD-10-CM
T61.8X1A	Toxic effect of other seafood, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T61.8X2A	Toxic effect of other seafood, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T61.8X3A	Toxic effect of other seafood, assault, initial encounter	Diagnosis	ICD-10-CM
T61.8X4A	Toxic effect of other seafood, undetermined, initial encounter	Diagnosis	ICD-10-CM
T61.91XA	Toxic effect of unspecified seafood, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T61.92XA	Toxic effect of unspecified seafood, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T61.93XA	Toxic effect of unspecified seafood, assault, initial encounter	Diagnosis	ICD-10-CM
T61.94XA	Toxic effect of unspecified seafood, undetermined, initial encounter	Diagnosis	ICD-10-CM
T62.0X1A	Toxic effect of ingested mushrooms, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T62.0X2A	Toxic effect of ingested mushrooms, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T62.0X3A	Toxic effect of ingested mushrooms, assault, initial encounter	Diagnosis	ICD-10-CM
T62.0X4A	Toxic effect of ingested mushrooms, undetermined, initial encounter	Diagnosis	ICD-10-CM
T62.1X1A	Toxic effect of ingested berries, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T62.1X2A	Toxic effect of ingested berries, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T62.1X3A	Toxic effect of ingested berries, assault, initial encounter	Diagnosis	ICD-10-CM
T62.1X4A	Toxic effect of ingested berries, undetermined, initial encounter	Diagnosis	ICD-10-CM
T62.2X1A	Toxic effect of other ingested (parts of) plant(s), accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T62.2X2A	Toxic effect of other ingested (parts of) plant(s), intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T62.2X3A	Toxic effect of other ingested (parts of) plant(s), assault, initial encounter	Diagnosis	ICD-10-CM
T62.2X4A	Toxic effect of other ingested (parts of) plant(s), undetermined, initial encounter	Diagnosis	ICD-10-CM
T62.8X1A	Toxic effect of other specified noxious substances eaten as food, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T62.8X2A	Toxic effect of other specified noxious substances eaten as food, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T62.8X3A	Toxic effect of other specified noxious substances eaten as food, assault, initial encounter	Diagnosis	ICD-10-CM
T62.8X4A	Toxic effect of other specified noxious substances eaten as food, undetermined, initial encounter	Diagnosis	ICD-10-CM
T62.91XA	Toxic effect of unspecified noxious substance eaten as food, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T62.92XA	Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T62.93XA	Toxic effect of unspecified noxious substance eaten as food, assault, initial encounter	Diagnosis	ICD-10-CM
T62.94XA	Toxic effect of unspecified noxious substance eaten as food, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.001A	Toxic effect of unspecified snake venom, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.002A	Toxic effect of unspecified snake venom, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.003A	Toxic effect of unspecified snake venom, assault, initial encounter	Diagnosis	ICD-10-CM
T63.004A	Toxic effect of unspecified snake venom, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.011A	Toxic effect of rattlesnake venom, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.012A	Toxic effect of rattlesnake venom, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.013A	Toxic effect of rattlesnake venom, assault, initial encounter	Diagnosis	ICD-10-CM
T63.014A	Toxic effect of rattlesnake venom, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.021A	Toxic effect of coral snake venom, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.022A	Toxic effect of coral snake venom, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.023A	Toxic effect of coral snake venom, assault, initial encounter	Diagnosis	ICD-10-CM
T63.024A	Toxic effect of coral snake venom, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.031A	Toxic effect of taipan venom, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.032A	Toxic effect of taipan venom, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.033A	Toxic effect of taipan venom, assault, initial encounter	Diagnosis	ICD-10-CM
T63.034A	Toxic effect of taipan venom, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.041A	Toxic effect of cobra venom, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.042A	Toxic effect of cobra venom, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.043A	Toxic effect of cobra venom, assault, initial encounter	Diagnosis	ICD-10-CM
T63.044A	Toxic effect of cobra venom, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.061A	Toxic effect of venom of other North and South American snake, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.062A	Toxic effect of venom of other North and South American snake, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.063A	Toxic effect of venom of other North and South American snake, assault, initial encounter	Diagnosis	ICD-10-CM
T63.064A	Toxic effect of venom of other North and South American snake, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.071A	Toxic effect of venom of other Australian snake, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.072A	Toxic effect of venom of other Australian snake, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.073A	Toxic effect of venom of other Australian snake, assault, initial encounter	Diagnosis	ICD-10-CM
T63.074A	Toxic effect of venom of other Australian snake, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.081A	Toxic effect of venom of other African and Asian snake, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T63.082A	Toxic effect of venom of other African and Asian snake, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.083A	Toxic effect of venom of other African and Asian snake, assault, initial encounter	Diagnosis	ICD-10-CM
T63.084A	Toxic effect of venom of other African and Asian snake, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.091A	Toxic effect of venom of other snake, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.092A	Toxic effect of venom of other snake, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.093A	Toxic effect of venom of other snake, assault, initial encounter	Diagnosis	ICD-10-CM
T63.094A	Toxic effect of venom of other snake, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.111A	Toxic effect of venom of gila monster, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.112A	Toxic effect of venom of gila monster, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.113A	Toxic effect of venom of gila monster, assault, initial encounter	Diagnosis	ICD-10-CM
T63.114A	Toxic effect of venom of gila monster, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.121A	Toxic effect of venom of other venomous lizard, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.122A	Toxic effect of venom of other venomous lizard, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.123A	Toxic effect of venom of other venomous lizard, assault, initial encounter	Diagnosis	ICD-10-CM
T63.124A	Toxic effect of venom of other venomous lizard, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.191A	Toxic effect of venom of other reptiles, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.192A	Toxic effect of venom of other reptiles, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.193A	Toxic effect of venom of other reptiles, assault, initial encounter	Diagnosis	ICD-10-CM
T63.194A	Toxic effect of venom of other reptiles, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.2X1A	Toxic effect of venom of scorpion, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.2X2A	Toxic effect of venom of scorpion, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.2X3A	Toxic effect of venom of scorpion, assault, initial encounter	Diagnosis	ICD-10-CM
T63.2X4A	Toxic effect of venom of scorpion, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.301A	Toxic effect of unspecified spider venom, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.302A	Toxic effect of unspecified spider venom, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.303A	Toxic effect of unspecified spider venom, assault, initial encounter	Diagnosis	ICD-10-CM
T63.304A	Toxic effect of unspecified spider venom, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.311A	Toxic effect of venom of black widow spider, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.312A	Toxic effect of venom of black widow spider, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.313A	Toxic effect of venom of black widow spider, assault, initial encounter	Diagnosis	ICD-10-CM
T63.314A	Toxic effect of venom of black widow spider, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.321A	Toxic effect of venom of tarantula, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.322A	Toxic effect of venom of tarantula, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.323A	Toxic effect of venom of tarantula, assault, initial encounter	Diagnosis	ICD-10-CM
T63.324A	Toxic effect of venom of tarantula, undetermined, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T63.331A	Toxic effect of venom of brown recluse spider, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.332A	Toxic effect of venom of brown recluse spider, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.333A	Toxic effect of venom of brown recluse spider, assault, initial encounter	Diagnosis	ICD-10-CM
T63.334A	Toxic effect of venom of brown recluse spider, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.391A	Toxic effect of venom of other spider, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.392A	Toxic effect of venom of other spider, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.393A	Toxic effect of venom of other spider, assault, initial encounter	Diagnosis	ICD-10-CM
T63.394A	Toxic effect of venom of other spider, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.411A	Toxic effect of venom of centipedes and venomous millipedes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.412A	Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.413A	Toxic effect of venom of centipedes and venomous millipedes, assault, initial encounter	Diagnosis	ICD-10-CM
T63.414A	Toxic effect of venom of centipedes and venomous millipedes, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.421A	Toxic effect of venom of ants, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.422A	Toxic effect of venom of ants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.423A	Toxic effect of venom of ants, assault, initial encounter	Diagnosis	ICD-10-CM
T63.424A	Toxic effect of venom of ants, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.431A	Toxic effect of venom of caterpillars, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.432A	Toxic effect of venom of caterpillars, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.433A	Toxic effect of venom of caterpillars, assault, initial encounter	Diagnosis	ICD-10-CM
T63.434A	Toxic effect of venom of caterpillars, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.441A	Toxic effect of venom of bees, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.442A	Toxic effect of venom of bees, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.443A	Toxic effect of venom of bees, assault, initial encounter	Diagnosis	ICD-10-CM
T63.444A	Toxic effect of venom of bees, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.451A	Toxic effect of venom of hornets, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.452A	Toxic effect of venom of hornets, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.453A	Toxic effect of venom of hornets, assault, initial encounter	Diagnosis	ICD-10-CM
T63.454A	Toxic effect of venom of hornets, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.461A	Toxic effect of venom of wasps, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.462A	Toxic effect of venom of wasps, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.463A	Toxic effect of venom of wasps, assault, initial encounter	Diagnosis	ICD-10-CM
T63.464A	Toxic effect of venom of wasps, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.481A	Toxic effect of venom of other arthropod, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T63.482A	Toxic effect of venom of other arthropod, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.483A	Toxic effect of venom of other arthropod, assault, initial encounter	Diagnosis	ICD-10-CM
T63.484A	Toxic effect of venom of other arthropod, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.511A	Toxic effect of contact with stingray, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.512A	Toxic effect of contact with stingray, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.513A	Toxic effect of contact with stingray, assault, initial encounter	Diagnosis	ICD-10-CM
T63.514A	Toxic effect of contact with stingray, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.591A	Toxic effect of contact with other venomous fish, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.592A	Toxic effect of contact with other venomous fish, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.593A	Toxic effect of contact with other venomous fish, assault, initial encounter	Diagnosis	ICD-10-CM
T63.594A	Toxic effect of contact with other venomous fish, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.611A	Toxic effect of contact with Portuguese Man-o-war, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.612A	Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.613A	Toxic effect of contact with Portuguese Man-o-war, assault, initial encounter	Diagnosis	ICD-10-CM
T63.614A	Toxic effect of contact with Portuguese Man-o-war, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.621A	Toxic effect of contact with other jellyfish, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.622A	Toxic effect of contact with other jellyfish, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.623A	Toxic effect of contact with other jellyfish, assault, initial encounter	Diagnosis	ICD-10-CM
T63.624A	Toxic effect of contact with other jellyfish, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.631A	Toxic effect of contact with sea anemone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.632A	Toxic effect of contact with sea anemone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.633A	Toxic effect of contact with sea anemone, assault, initial encounter	Diagnosis	ICD-10-CM
T63.634A	Toxic effect of contact with sea anemone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.691A	Toxic effect of contact with other venomous marine animals, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.692A	Toxic effect of contact with other venomous marine animals, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.693A	Toxic effect of contact with other venomous marine animals, assault, initial encounter	Diagnosis	ICD-10-CM
T63.694A	Toxic effect of contact with other venomous marine animals, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.711A	Toxic effect of contact with venomous marine plant, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.712A	Toxic effect of contact with venomous marine plant, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.713A	Toxic effect of contact with venomous marine plant, assault, initial encounter	Diagnosis	ICD-10-CM
T63.714A	Toxic effect of contact with venomous marine plant, undetermined, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T63.791A	Toxic effect of contact with other venomous plant, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.792A	Toxic effect of contact with other venomous plant, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.793A	Toxic effect of contact with other venomous plant, assault, initial encounter	Diagnosis	ICD-10-CM
T63.794A	Toxic effect of contact with other venomous plant, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.811A	Toxic effect of contact with venomous frog, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.812A	Toxic effect of contact with venomous frog, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.813A	Toxic effect of contact with venomous frog, assault, initial encounter	Diagnosis	ICD-10-CM
T63.814A	Toxic effect of contact with venomous frog, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.821A	Toxic effect of contact with venomous toad, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.822A	Toxic effect of contact with venomous toad, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.823A	Toxic effect of contact with venomous toad, assault, initial encounter	Diagnosis	ICD-10-CM
T63.824A	Toxic effect of contact with venomous toad, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.831A	Toxic effect of contact with other venomous amphibian, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.832A	Toxic effect of contact with other venomous amphibian, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.833A	Toxic effect of contact with other venomous amphibian, assault, initial encounter	Diagnosis	ICD-10-CM
T63.834A	Toxic effect of contact with other venomous amphibian, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.891A	Toxic effect of contact with other venomous animals, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.892A	Toxic effect of contact with other venomous animals, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.893A	Toxic effect of contact with other venomous animals, assault, initial encounter	Diagnosis	ICD-10-CM
T63.894A	Toxic effect of contact with other venomous animals, undetermined, initial encounter	Diagnosis	ICD-10-CM
T63.91XA	Toxic effect of contact with unspecified venomous animal, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T63.92XA	Toxic effect of contact with unspecified venomous animal, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T63.93XA	Toxic effect of contact with unspecified venomous animal, assault, initial encounter	Diagnosis	ICD-10-CM
T63.94XA	Toxic effect of contact with unspecified venomous animal, undetermined, initial encounter	Diagnosis	ICD-10-CM
T64.01XA	Toxic effect of aflatoxin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T64.02XA	Toxic effect of aflatoxin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T64.03XA	Toxic effect of aflatoxin, assault, initial encounter	Diagnosis	ICD-10-CM
T64.04XA	Toxic effect of aflatoxin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T64.81XA	Toxic effect of other mycotoxin food contaminants, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T64.82XA	Toxic effect of other mycotoxin food contaminants, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T64.83XA	Toxic effect of other mycotoxin food contaminants, assault, initial encounter	Diagnosis	ICD-10-CM
T64.84XA	Toxic effect of other mycotoxin food contaminants, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.0X1A	Toxic effect of cyanides, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.0X2A	Toxic effect of cyanides, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.0X3A	Toxic effect of cyanides, assault, initial encounter	Diagnosis	ICD-10-CM
T65.0X4A	Toxic effect of cyanides, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.1X1A	Toxic effect of strychnine and its salts, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.1X2A	Toxic effect of strychnine and its salts, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.1X3A	Toxic effect of strychnine and its salts, assault, initial encounter	Diagnosis	ICD-10-CM
T65.1X4A	Toxic effect of strychnine and its salts, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.211A	Toxic effect of chewing tobacco, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.212A	Toxic effect of chewing tobacco, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.213A	Toxic effect of chewing tobacco, assault, initial encounter	Diagnosis	ICD-10-CM
T65.214A	Toxic effect of chewing tobacco, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.291A	Toxic effect of other tobacco and nicotine, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.292A	Toxic effect of other tobacco and nicotine, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.293A	Toxic effect of other tobacco and nicotine, assault, initial encounter	Diagnosis	ICD-10-CM
T65.294A	Toxic effect of other tobacco and nicotine, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.3X1A	Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.3X2A	Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.3X3A	Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, assault, initial encounter	Diagnosis	ICD-10-CM
T65.3X4A	Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.4X1A	Toxic effect of carbon disulfide, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.4X2A	Toxic effect of carbon disulfide, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.4X3A	Toxic effect of carbon disulfide, assault, initial encounter	Diagnosis	ICD-10-CM
T65.4X4A	Toxic effect of carbon disulfide, undetermined, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T65.5X1A	Toxic effect of nitroglycerin and other nitric acids and esters, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.5X2A	Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.5X3A	Toxic effect of nitroglycerin and other nitric acids and esters, assault, initial encounter	Diagnosis	ICD-10-CM
T65.5X4A	Toxic effect of nitroglycerin and other nitric acids and esters, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.6X1A	Toxic effect of paints and dyes, not elsewhere classified, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.6X2A	Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.6X3A	Toxic effect of paints and dyes, not elsewhere classified, assault, initial encounter	Diagnosis	ICD-10-CM
T65.6X4A	Toxic effect of paints and dyes, not elsewhere classified, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.811A	Toxic effect of latex, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.812A	Toxic effect of latex, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.813A	Toxic effect of latex, assault, initial encounter	Diagnosis	ICD-10-CM
T65.814A	Toxic effect of latex, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.821A	Toxic effect of harmful algae and algae toxins, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.822A	Toxic effect of harmful algae and algae toxins, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.823A	Toxic effect of harmful algae and algae toxins, assault, initial encounter	Diagnosis	ICD-10-CM
T65.824A	Toxic effect of harmful algae and algae toxins, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.831A	Toxic effect of fiberglass, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.832A	Toxic effect of fiberglass, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.833A	Toxic effect of fiberglass, assault, initial encounter	Diagnosis	ICD-10-CM
T65.834A	Toxic effect of fiberglass, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.891A	Toxic effect of other specified substances, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.892A	Toxic effect of other specified substances, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.893A	Toxic effect of other specified substances, assault, initial encounter	Diagnosis	ICD-10-CM
T65.894A	Toxic effect of other specified substances, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.91XA	Toxic effect of unspecified substance, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.92XA	Toxic effect of unspecified substance, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.93XA	Toxic effect of unspecified substance, assault, initial encounter	Diagnosis	ICD-10-CM
T65.94XA	Toxic effect of unspecified substance, undetermined, initial encounter	Diagnosis	ICD-10-CM
T71.111A	Asphyxiation due to smothering under pillow, accidental, initial encounter	Diagnosis	ICD-10-CM
T71.112A	Asphyxiation due to smothering under pillow, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.113A	Asphyxiation due to smothering under pillow, assault, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T71.114A	Asphyxiation due to smothering under pillow, undetermined, initial encounter	Diagnosis	ICD-10-CM
T71.121A	Asphyxiation due to plastic bag, accidental, initial encounter	Diagnosis	ICD-10-CM
T71.122A	Asphyxiation due to plastic bag, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.123A	Asphyxiation due to plastic bag, assault, initial encounter	Diagnosis	ICD-10-CM
T71.124A	Asphyxiation due to plastic bag, undetermined, initial encounter	Diagnosis	ICD-10-CM
T71.131A	Asphyxiation due to being trapped in bed linens, accidental, initial encounter	Diagnosis	ICD-10-CM
T71.132A	Asphyxiation due to being trapped in bed linens, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.133A	Asphyxiation due to being trapped in bed linens, assault, initial encounter	Diagnosis	ICD-10-CM
T71.134A	Asphyxiation due to being trapped in bed linens, undetermined, initial encounter	Diagnosis	ICD-10-CM
T71.141A	Asphyxiation due to smothering under another person's body (in bed), accidental, initial encounter	Diagnosis	ICD-10-CM
T71.143A	Asphyxiation due to smothering under another person's body (in bed), assault, initial encounter	Diagnosis	ICD-10-CM
T71.144A	Asphyxiation due to smothering under another person's body (in bed), undetermined, initial encounter	Diagnosis	ICD-10-CM
T71.151A	Asphyxiation due to smothering in furniture, accidental, initial encounter	Diagnosis	ICD-10-CM
T71.152A	Asphyxiation due to smothering in furniture, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.153A	Asphyxiation due to smothering in furniture, assault, initial encounter	Diagnosis	ICD-10-CM
T71.154A	Asphyxiation due to smothering in furniture, undetermined, initial encounter	Diagnosis	ICD-10-CM
T71.161A	Asphyxiation due to hanging, accidental, initial encounter	Diagnosis	ICD-10-CM
T71.162A	Asphyxiation due to hanging, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.163A	Asphyxiation due to hanging, assault, initial encounter	Diagnosis	ICD-10-CM
T71.164A	Asphyxiation due to hanging, undetermined, initial encounter	Diagnosis	ICD-10-CM
T71.191A	Asphyxiation due to mechanical threat to breathing due to other causes, accidental, initial encounter	Diagnosis	ICD-10-CM
T71.192A	Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.193A	Asphyxiation due to mechanical threat to breathing due to other causes, assault, initial encounter	Diagnosis	ICD-10-CM
T71.194A	Asphyxiation due to mechanical threat to breathing due to other causes, undetermined, initial encounter	Diagnosis	ICD-10-CM
T71.20XA	Asphyxiation due to systemic oxygen deficiency due to low oxygen content in ambient air due to unspecified cause, initial encounter	Diagnosis	ICD-10-CM
T71.21XA	Asphyxiation due to cave-in or falling earth, initial encounter	Diagnosis	ICD-10-CM
T71.221A	Asphyxiation due to being trapped in a car trunk, accidental, initial encounter	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
T71.222A	Asphyxiation due to being trapped in a car trunk, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.223A	Asphyxiation due to being trapped in a car trunk, assault, initial encounter	Diagnosis	ICD-10-CM
T71.224A	Asphyxiation due to being trapped in a car trunk, undetermined, initial encounter	Diagnosis	ICD-10-CM
T71.231A	Asphyxiation due to being trapped in a (discarded) refrigerator, accidental, initial encounter	Diagnosis	ICD-10-CM
T71.232A	Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T71.233A	Asphyxiation due to being trapped in a (discarded) refrigerator, assault, initial encounter	Diagnosis	ICD-10-CM
T71.234A	Asphyxiation due to being trapped in a (discarded) refrigerator, undetermined, initial encounter	Diagnosis	ICD-10-CM
T71.29XA	Asphyxiation due to being trapped in other low oxygen environment, initial encounter	Diagnosis	ICD-10-CM
T71.9XXA	Asphyxiation due to unspecified cause, initial encounter	Diagnosis	ICD-10-CM
T78.1XXA	Other adverse food reactions, not elsewhere classified, initial encounter	Diagnosis	ICD-10-CM
Transcranial Magnetic Stimulation			
90867	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management	Procedure	CPT-4
90868	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent delivery and management, per session	Procedure	CPT-4
90869	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold re-determination with delivery and management	Procedure	CPT-4
Vagus Nerve Stimulation			
61885	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array	Procedure	CPT-4
61886	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to 2 or more electrode arrays	Procedure	CPT-4
61888	Revision or removal of cranial neurostimulator pulse generator or receiver	Procedure	CPT-4
64553	Percutaneous implantation of neurostimulator electrode array; cranial nerve	Procedure	CPT-4
64568	Open implantation of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator	Procedure	CPT-4
64569	Revision or replacement of cranial nerve (eg, vagus nerve) neurostimulator electrode array, including connection to existing pulse generator	Procedure	CPT-4
64570	Removal of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator	Procedure	CPT-4
64585	Revision or removal of peripheral neurostimulator electrode array	Procedure	CPT-4

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
95970	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain, cranial nerve, spinal cord, peripheral nerve, or sacral nerve, neurostimulator pulse generator/transmitter, without programming	Procedure	CPT-4
95971	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with simple spinal cord or peripheral nerve (eg, sacral nerve) neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional	Procedure	CPT-4
95974	Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, with or without nerve interface testing, first hour	Procedure	CPT-4
95975	Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, each additional 30 minutes after first hour (List separately in addition to code for primary procedure)	Procedure	CPT-4
L8679	Implantable neurostimulator, pulse generator, any type	Procedure	HCPCS
L8680	Implantable neurostimulator electrode, each	Procedure	HCPCS
L8681	Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only	Procedure	HCPCS
L8682	Implantable neurostimulator radiofrequency receiver	Procedure	HCPCS
L8683	Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver	Procedure	HCPCS
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension	Procedure	HCPCS
L8686	Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension	Procedure	HCPCS
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension	Procedure	HCPCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
L8688	Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension	Procedure	HCPCS
L8689	External recharging system for battery (internal) for use with implantable neurostimulator, replacement only	Procedure	HCPCS
	Obesity		
278.0	Overweight and obesity	Diagnosis	ICD-9-CM
278.00	Obesity, unspecified	Diagnosis	ICD-9-CM
278.01	Morbid obesity	Diagnosis	ICD-9-CM
278.03	Obesity hypoventilation syndrome	Diagnosis	ICD-9-CM
539.0	Complications of gastric band procedure	Diagnosis	ICD-9-CM
539.01	Infection due to gastric band procedure	Diagnosis	ICD-9-CM
539.09	Other complications of gastric band procedure	Diagnosis	ICD-9-CM
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
O99.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
V45.86	Bariatric surgery status	Diagnosis	ICD-9-CM
V85.3	Body Mass Index Between 30-39, adult	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
V85.30	Body Mass Index 30.0-30.9, adult	Diagnosis	ICD-9-CM
V85.31	Body Mass Index 31.0-31.9, adult	Diagnosis	ICD-9-CM
V85.32	Body Mass Index 32.0-32.9, adult	Diagnosis	ICD-9-CM
V85.33	Body Mass Index 33.0-33.9, adult	Diagnosis	ICD-9-CM
V85.34	Body Mass Index 34.0-34.9, adult	Diagnosis	ICD-9-CM
V85.35	Body Mass Index 35.0-35.9, adult	Diagnosis	ICD-9-CM
V85.36	Body Mass Index 36.0-36.9, adult	Diagnosis	ICD-9-CM
V85.37	Body Mass Index 37.0-37.9, adult	Diagnosis	ICD-9-CM
V85.38	Body Mass Index 38.0-38.9, adult	Diagnosis	ICD-9-CM
V85.39	Body Mass Index 39.0-39.9, adult	Diagnosis	ICD-9-CM
V85.4	Body Mass Index 40 and over, adult	Diagnosis	ICD-9-CM
V85.41	Body Mass Index 40.0-44.9, adult	Diagnosis	ICD-9-CM
V85.42	Body Mass Index 45.0-49.9, adult	Diagnosis	ICD-9-CM
V85.43	Body Mass Index 50.0-59.9, adult	Diagnosis	ICD-9-CM
V85.44	Body Mass Index 60.0-69.9, adult	Diagnosis	ICD-9-CM
V85.45	Body Mass Index 70 and over, adult	Diagnosis	ICD-9-CM
Z68.30	Body mass index [BMI] 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index [BMI] 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index [BMI] 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index [BMI] 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index [BMI] 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index [BMI] 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index [BMI] 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index [BMI] 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index [BMI] 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index [BMI] 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index [BMI] 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index [BMI] 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index [BMI] 50.0-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index [BMI] 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index [BMI] 70 or greater, adult	Diagnosis	ICD-10-CM
	Weight Reduction Surgeries and Procedures		
00HE0MZ	Insertion of Neurostimulator Lead into Cranial Nerve, Open Approach	Procedure	ICD-10-PCS
00HE3MZ	Insertion of Neurostimulator Lead into Cranial Nerve, Percutaneous Approach	Procedure	ICD-10-PCS
00HE4MZ	Insertion of Neurostimulator Lead into Cranial Nerve, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02.93	Implantation or replacement of intracranial neurostimulator lead(s)	Procedure	ICD-9-CM
0312T	Vagus nerve blocking therapy (morbid obesity); laparoscopic implantation of neurostimulator electrode array, anterior and posterior vagal trunks adjacent to esophagogastric junction (EGJ), with implantation of pulse generator, includes programming	Procedure	CPT-3
04.92	Implantation or replacement of peripheral neurostimulator lead(s)	Procedure	ICD-9-CM
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
0DB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
0DB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB64Z3	Excision of Stomach, Percutaneous Endoscopic Approach, Vertical	Procedure	ICD-10-PCS
0DB64ZZ	Excision of Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
0DB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
0DB68ZZ	Excision of Stomach, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DH60MZ	Insertion of Stimulator Lead into Stomach, Open Approach	Procedure	ICD-10-PCS
0DH63DZ	Insertion of Intraluminal Device into Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DH63MZ	Insertion of Stimulator Lead into Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DH64MZ	Insertion of Stimulator Lead into Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
0DH64YZ	Insertion of Other Device into Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DH67DZ	Insertion of Intraluminal Device into Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DH68DZ	Insertion of Intraluminal Device into Stomach, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DL60CZ	Occlusion of Stomach with Extraluminal Device, Open Approach	Procedure	ICD-10-PCS
0DL60DZ	Occlusion of Stomach with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0DL60ZZ	Occlusion of Stomach, Open Approach	Procedure	ICD-10-PCS
0DL63CZ	Occlusion of Stomach with Extraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0DL63DZ	Occlusion of Stomach with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0DL63ZZ	Occlusion of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DL64CZ	Occlusion of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DL64DZ	Occlusion of Stomach with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DL64ZZ	Occlusion of Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DL67DZ	Occlusion of Stomach with Intraluminal Device, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DL68DZ	Occlusion of Stomach with Intraluminal Device, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DV60CZ	Restriction of Stomach with Extraluminal Device, Open Approach	Procedure	ICD-10-PCS
0DV60DZ	Restriction of Stomach with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0DV60ZZ	Restriction of Stomach, Open Approach	Procedure	ICD-10-PCS
0DV63CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0DV63DZ	Restriction of Stomach with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0DV63ZZ	Restriction of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DV64DZ	Restriction of Stomach with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DV64ZZ	Restriction of Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DV67DZ	Restriction of Stomach with Intraluminal Device, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DV67ZZ	Restriction of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DV68DZ	Restriction of Stomach with Intraluminal Device, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DV68ZZ	Restriction of Stomach, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
43.0	Gastrotomy	Procedure	ICD-9-CM
43.41	Endoscopic excision or destruction of lesion or tissue of stomach	Procedure	ICD-9-CM
43.42	Local excision of other lesion or tissue of stomach	Procedure	ICD-9-CM
43.6	Partial gastrectomy with anastomosis to duodenum	Procedure	ICD-9-CM
43.7	Partial gastrectomy with anastomosis to jejunum	Procedure	ICD-9-CM
43.81	Partial gastrectomy with jejunal transposition	Procedure	ICD-9-CM
43.82	Laparoscopic vertical (sleeve) gastrectomy	Procedure	ICD-9-CM
43.89	Open and other partial gastrectomy	Procedure	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
43246	Esophagogastroduodenoscopy, flexible, transoral; with directed placement of percutaneous gastrostomy tube	Procedure	CPT-4
43631	Gastrectomy, partial, distal; with gastroduodenostomy	Procedure	CPT-4
43632	Gastrectomy, partial, distal; with gastrojejunostomy	Procedure	CPT-4
43633	Gastrectomy, partial, distal; with Roux-en-Y reconstruction	Procedure	CPT-4
43634	Gastrectomy, partial, distal; with formation of intestinal pouch	Procedure	CPT-4
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4
43775	Laparoscopy, surgical, gastric restrictive procedure; longitudinal gastrectomy (ie, sleeve gastrectomy)	Procedure	CPT-4
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open	Procedure	CPT-4
44.31	High gastric bypass	Procedure	ICD-9-CM
44.38	Laparoscopic gastroenterostomy	Procedure	ICD-9-CM
44.39	Other gastroenterostomy without gastrectomy	Procedure	ICD-9-CM
44.68	Laparoscopic gastroplasty	Procedure	ICD-9-CM
44.69	Other repair of stomach	Procedure	ICD-9-CM
44.93	Insertion of gastric bubble (balloon)	Procedure	ICD-9-CM
44.95	Laparoscopic gastric restrictive procedure	Procedure	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
44.99	Other operations on stomach	Procedure	ICD-9-CM
45.51	Isolation of segment of small intestine	Procedure	ICD-9-CM
52.7	Radical pancreaticoduodenectomy	Procedure	ICD-9-CM
	Lifestyle Intervention		
0359T	Behavior identification assessment, by the physician or other qualified health care professional, face-to-face with patient and caregiver(s), includes administration of standardized and non-standardized tests, detailed behavioral history, patient observation and caregiver interview, interpretation of test results, discussion of findings and recommendations with the primary guardian(s)/caregiver(s), and preparation of report	Procedure	CPT-3
0360T	Observational behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by one technician; first 30 minutes of technician time, face-to-face with the patient	Procedure	CPT-3
0361T	Observational behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by one technician; each additional 30 minutes of technician time, face-to-face with the patient (List separately in addition to code for primary service)	Procedure	CPT-3
0362T	Behavior identification supporting assessment, each 15 minutes of technicians' time face-to-face with a patient, requiring the following components: administration by the physician or other qualified health care professional who is on site; with the assistance of two or more technicians; for a patient who exhibits destructive behavior; completion in an environment that is customized to the patient's behavior.	Procedure	CPT-3
0363T	Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; each additional 30 minutes of technician(s) time, face-to-face with the patient (List separately in addition to code for primary procedure)	Procedure	CPT-3
0364T	Adaptive behavior treatment by protocol, administered by technician, face-to-face with one patient; first 30 minutes of technician time	Procedure	CPT-3
0365T	Adaptive behavior treatment by protocol, administered by technician, face-to-face with one patient; each additional 30 minutes of technician time (List separately in addition to code for primary procedure)	Procedure	CPT-3
0366T	Group adaptive behavior treatment by protocol, administered by technician, face-to-face with two or more patients; first 30 minutes of technician time	Procedure	CPT-3

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
0367T	Group adaptive behavior treatment by protocol, administered by technician, face-to-face with two or more patients; each additional 30 minutes of technician time (List separately in addition to code for primary procedure)	Procedure	CPT-3
0368T	Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; first 30 minutes of patient face-to-face time	Procedure	CPT-3
0369T	Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; each additional 30 minutes of patient face-to-face time (List separately in addition to code for primary procedure)	Procedure	CPT-3
0370T	Family adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present)	Procedure	CPT-3
0371T	Multiple-family group adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present)	Procedure	CPT-3
0372T	Adaptive behavior treatment social skills group, administered by physician or other qualified health care professional face-to-face with multiple patients	Procedure	CPT-3
0373T	Adaptive behavior treatment with protocol modification, each 15 minutes of technicians' time face-to-face with a patient, requiring the following components: administration by the physician or other qualified health care professional who is on site; with the assistance of two or more technicians; for a patient who exhibits destructive behavior; completion in an environment that is customized to the patient's behavior.	Procedure	CPT-3
0374T	Exposure adaptive behavior treatment with protocol modification requiring two or more technicians for severe maladaptive behavior(s); each additional 30 minutes of technicians' time face-to-face with patient (List separately in addition to code for primary procedure)	Procedure	CPT-3
0403T	Preventive behavior change, intensive program of prevention of diabetes using a standardized diabetes prevention program curriculum, provided to individuals in a group setting, minimum 60 minutes, per day	Procedure	CPT-3
0488T	Preventive behavior change, online/electronic structured intensive program for prevention of diabetes using a standardized diabetes prevention program curriculum, provided to an individual, per 30 days	Procedure	CPT-3
90804	Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an office or outpatient facility, approximately 20 to 30 minutes face-to-face with the patient;	Procedure	CPT-4
90805	Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an office or outpatient facility, approximately 20 to 30 minutes face-to-face with the patient; with medical evaluation and management services	Procedure	CPT-4

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
90806	Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an office or outpatient facility, approximately 45 to 50 minutes face-to-face with the patient;	Procedure	CPT-4
90807	Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an office or outpatient facility, approximately 45 to 50 minutes face-to-face with the patient; with medical evaluation and management services	Procedure	CPT-4
90808	Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an office or outpatient facility, approximately 75 to 80 minutes face-to-face with the patient;	Procedure	CPT-4
90809	Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an office or outpatient facility, approximately 75 to 80 minutes face-to-face with the patient; with medical evaluation and management services	Procedure	CPT-4
90816	Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an inpatient hospital, partial hospital or residential care setting, approximately 20 to 30 minutes face-to-face with the patient;	Procedure	CPT-4
90817	Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an inpatient hospital, partial hospital or residential care setting, approximately 20 to 30 minutes face-to-face with the patient; with medical evaluation and management services	Procedure	CPT-4
90818	Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an inpatient hospital, partial hospital or residential care setting, approximately 45 to 50 minutes face-to-face with the patient;	Procedure	CPT-4
90819	Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an inpatient hospital, partial hospital or residential care setting, approximately 45 to 50 minutes face-to-face with the patient; with medical evaluation and management services	Procedure	CPT-4
90821	Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an inpatient hospital, partial hospital or residential care setting, approximately 75 to 80 minutes face-to-face with the patient;	Procedure	CPT-4
90822	Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an inpatient hospital, partial hospital or residential care setting, approximately 75 to 80 minutes face-to-face with the patient; with medical evaluation and management services	Procedure	CPT-4
90875	Individual psychophysiological therapy incorporating biofeedback training by any modality (face-to-face with the patient), with psychotherapy (eg, insight oriented, behavior modifying or supportive psychotherapy); 30 minutes	Procedure	CPT-4
90876	Individual psychophysiological therapy incorporating biofeedback training by any modality (face-to-face with the patient), with psychotherapy (eg, insight oriented, behavior modifying or supportive psychotherapy); 45 minutes	Procedure	CPT-4
92524	Behavioral and qualitative analysis of voice and resonance	Procedure	CPT-4

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
96115	Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, eg, acquired knowledge, attention, memory, visual spatial abilities, language functions, planning) with interpretation and report, per hour	Procedure	CPT-4
96116	Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, [eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities]), by physician or other qualified health care professional, both face-to-face time with the patient and time interpreting test results and preparing the report; first hour	Procedure	CPT-4
96121	Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, [eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities]), by physician or other qualified health care professional, both face-to-face time with the patient and time interpreting test results and preparing the report; each additional hour (List separately in addition to code for primary procedure)	Procedure	CPT-4
96127	Brief emotional/behavioral assessment (eg, depression inventory, attention-deficit/hyperactivity disorder [ADHD] scale), with scoring and documentation, per standardized instrument	Procedure	CPT-4
96150	Health and behavior assessment (eg, health-focused clinical interview, behavioral observations, psychophysiological monitoring, health-oriented questionnaires), each 15 minutes face-to-face with the patient; initial assessment	Procedure	CPT-4
96151	Health and behavior assessment (eg, health-focused clinical interview, behavioral observations, psychophysiological monitoring, health-oriented questionnaires), each 15 minutes face-to-face with the patient; re-assessment	Procedure	CPT-4
96152	Health and behavior intervention, each 15 minutes, face-to-face; individual	Procedure	CPT-4
96153	Health and behavior intervention, each 15 minutes, face-to-face; group (2 or more patients)	Procedure	CPT-4
96154	Health and behavior intervention, each 15 minutes, face-to-face; family (with the patient present)	Procedure	CPT-4
96155	Health and behavior intervention, each 15 minutes, face-to-face; family (without the patient present)	Procedure	CPT-4
96156	Health behavior assessment, or re-assessment (ie, health-focused clinical interview, behavioral observations, clinical decision making)	Procedure	CPT-4
96158	Health behavior intervention, individual, face-to-face; initial 30 minutes	Procedure	CPT-4
96159	Health behavior intervention, individual, face-to-face; each additional 15 minutes (List separately in addition to code for primary service)	Procedure	CPT-4
96161	Administration of caregiver-focused health risk assessment instrument (eg, depression inventory) for the benefit of the patient, with scoring and documentation, per standardized instrument	Procedure	CPT-4

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
96164	Health behavior intervention, group (2 or more patients), face-to-face; initial 30 minutes	Procedure	CPT-4
96165	Health behavior intervention, group (2 or more patients), face-to-face; each additional 15 minutes (List separately in addition to code for primary service)	Procedure	CPT-4
96167	Health behavior intervention, family (with the patient present), face-to-face; initial 30 minutes	Procedure	CPT-4
96168	Health behavior intervention, family (with the patient present), face-to-face; each additional 15 minutes (List separately in addition to code for primary service)	Procedure	CPT-4
96170	Health behavior intervention, family (without the patient present), face-to-face; initial 30 minutes	Procedure	CPT-4
96171	Health behavior intervention, family (without the patient present), face-to-face; each additional 15 minutes (List separately in addition to code for primary service)	Procedure	CPT-4
97151	Behavior identification assessment, administered by a physician or other qualified health care professional, each 15 minutes of the physician's or other qualified health care professional's time face-to-face with patient and/or guardian(s)/caregiver(s) administering assessments and discussing findings and recommendations, and non-face-to-face analyzing past data, scoring/interpreting the assessment, and preparing the report/treatment plan	Procedure	CPT-4
97152	Behavior identification-supporting assessment, administered by one technician under the direction of a physician or other qualified health care professional, face-to-face with the patient, each 15 minutes	Procedure	CPT-4
97153	Adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with one patient, each 15 minutes	Procedure	CPT-4
97154	Group adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with two or more patients, each 15 minutes	Procedure	CPT-4
97155	Adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, which may include simultaneous direction of technician, face-to-face with one patient, each 15 minutes	Procedure	CPT-4
97156	Family adaptive behavior treatment guidance, administered by physician or other qualified health care professional (with or without the patient present), face-to-face with guardian(s)/caregiver(s), each 15 minutes	Procedure	CPT-4
97157	Multiple-family group adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present), face-to-face with multiple sets of guardians/caregivers, each 15 minutes	Procedure	CPT-4
97158	Group adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, face-to-face with multiple patients, each 15 minutes	Procedure	CPT-4

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
97802	Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes	Procedure	CPT-4
97803	Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes	Procedure	CPT-4
97804	Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes	Procedure	CPT-4
99381	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; infant (age younger than 1 year)	Procedure	CPT-4
99382	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; early childhood (age 1 through 4 years)	Procedure	CPT-4
99383	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; late childhood (age 5 through 11 years)	Procedure	CPT-4
99384	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; adolescent (age 12 through 17 years)	Procedure	CPT-4
99385	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 18-39 years	Procedure	CPT-4
99386	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 40-64 years	Procedure	CPT-4
99387	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 65 years and older	Procedure	CPT-4

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
99391	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year)	Procedure	CPT-4
99392	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years)	Procedure	CPT-4
99393	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years)	Procedure	CPT-4
99394	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years)	Procedure	CPT-4
99395	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 18-39 years	Procedure	CPT-4
99396	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 40-64 years	Procedure	CPT-4
99397	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 65 years and older	Procedure	CPT-4
99401	Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 15 minutes	Procedure	CPT-4
99402	Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 30 minutes	Procedure	CPT-4
99403	Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 45 minutes	Procedure	CPT-4

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
99404	Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 60 minutes	Procedure	CPT-4
99411	Preventive medicine counseling and/or risk factor reduction intervention(s) provided to individuals in a group setting (separate procedure); approximately 30 minutes	Procedure	CPT-4
99412	Preventive medicine counseling and/or risk factor reduction intervention(s) provided to individuals in a group setting (separate procedure); approximately 60 minutes	Procedure	CPT-4
99483	Assessment of and care planning for a patient with cognitive impairment, requiring an independent historian, in the office or other outpatient, home or domiciliary or rest home, with all of the following required elements: Cognition-focused evaluation including a pertinent history and examination, Medical decision making of moderate or high complexity, Functional assessment (eg, basic and instrumental activities of daily living), including decision-making capacity, Use of standardized instruments for staging of dementia (eg, functional assessment staging test [FAST], clinical dementia rating [	Procedure	CPT-4
99484	Care management services for behavioral health conditions, at least 20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales, behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes, facilitating and coordinating treatment such as psychotherapy, pharmacotherapy, counseling and/or psy	Procedure	CPT-4
99492	Initial psychiatric collaborative care management, first 70 minutes in the first calendar month of behavioral health care manager activities, in consultation with a psychiatric consultant, and directed by the treating physician or other qualified health care professional, with the following required elements: outreach to and engagement in treatment of a patient directed by the treating physician or other qualified health care professional, initial assessment of the patient, including administration of validated rating scales, with the development of an individualized treatment plan, review by	Procedure	CPT-4
99493	Subsequent psychiatric collaborative care management, first 60 minutes in a subsequent month of behavioral health care manager activities, in consultation with a psychiatric consultant, and directed by the treating physician or other qualified health care professional, with the following required elements: tracking patient follow-up and progress using the registry, with appropriate documentation, participation in weekly caseload consultation with the psychiatric consultant, ongoing collaboration with and coordination of the patient's mental health care with the treating physician or other qual	Procedure	CPT-4

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
99494	Initial or subsequent psychiatric collaborative care management, each additional 30 minutes in a calendar month of behavioral health care manager activities, in consultation with a psychiatric consultant, and directed by the treating physician or other qualified health care professional (List separately in addition to code for primary procedure)	Procedure	CPT-4
G0270	Medical nutrition therapy; reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition or treatment regimen (including additional hours needed for renal disease), individual, face-to-face with the patient, each 15 minutes	Procedure	HCPCS
G0271	Medical nutrition therapy, reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition, or treatment regimen (including additional hours needed for renal disease), group (two or more individuals), each 30 minutes	Procedure	HCPCS
G0444	Annual depression screening, 5 to 15 minutes	Procedure	HCPCS
G0446	Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes	Procedure	HCPCS
G0447	Face-to-face behavioral counseling for obesity, 15 minutes	Procedure	HCPCS
G0473	Face-to-face behavioral counseling for obesity, group (2-10), 30 minutes	Procedure	HCPCS
G0502	Initial psychiatric collaborative care management, first 70 minutes in the first calendar month of behavioral health care manager activities, in consultation with a psychiatric consultant, and directed by the treating physician or other qualified health care professional, with the following required elements: outreach to and engagement in treatment of a patient directed by the treating physician or other qualified health care professional; initial assessment of the patient, including administration of validated rating scales, with the development of an individualized treatment plan; review by	Procedure	HCPCS
G0503	Subsequent psychiatric collaborative care management, first 60 minutes in a subsequent month of behavioral health care manager activities, in consultation with a psychiatric consultant, and directed by the treating physician or other qualified health care professional, with the following required elements: tracking patient follow-up and progress using the registry, with appropriate documentation; participation in weekly caseload consultation with the psychiatric consultant; ongoing collaboration with and coordination of the patient's mental health care with the treating physician or other qual	Procedure	HCPCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
G0504	Initial or subsequent psychiatric collaborative care management, each additional 30 minutes in a calendar month of behavioral health care manager activities, in consultation with a psychiatric consultant, and directed by the treating physician or other qualified health care professional (list separately in addition to code for primary procedure); (use G0504 in conjunction with G0502, G0503)	Procedure	HCPCS
G0507	Care management services for behavioral health conditions, at least 20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes; facilitating and coordinating treatment such as psychotherapy, pharmacotherapy, counseling and/or psy	Procedure	HCPCS
G0511	Rural health clinic or federally qualified health center (RHC or FQHC) only, general care management, 20 minutes or more of clinical staff time for chronic care management services or behavioral health integration services directed by an RHC or FQHC practitioner (physician, NP, PA, or CNM), per calendar month	Procedure	HCPCS
G0512	Rural health clinic or federally qualified health center (RHC/FQHC) only, psychiatric collaborative care model (psychiatric COCM), 60 minutes or more of clinical staff time for psychiatric COCM services directed by an RHC or FQHC practitioner (physician, NP, PA, or CNM) and including services furnished by a behavioral health care manager and consultation with a psychiatric consultant, per calendar month	Procedure	HCPCS
H0002	Behavioral health screening to determine eligibility for admission to treatment program	Procedure	HCPCS
H0004	Behavioral health counseling and therapy, per 15 minutes	Procedure	HCPCS
H0017	Behavioral health; residential (hospital residential treatment program), without room and board, per diem	Procedure	HCPCS
H0018	Behavioral health; short-term residential (nonhospital residential treatment program), without room and board, per diem	Procedure	HCPCS
H0019	Behavioral health; long-term residential (nonmedical, nonacute care in a residential treatment program where stay is typically longer than 30 days), without room and board, per diem	Procedure	HCPCS
H0023	Behavioral health outreach service (planned approach to reach a targeted population)	Procedure	HCPCS
H0024	Behavioral health prevention information dissemination service (one-way direct or nondirect contact with service audiences to affect knowledge and attitude)	Procedure	HCPCS
H0025	Behavioral health prevention education service (delivery of services with target population to affect knowledge, attitude and/or behavior)	Procedure	HCPCS
H0030	Behavioral health hotline service	Procedure	HCPCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
H1011	Family assessment by licensed behavioral health professional for state defined purposes	Procedure	HCPCS
H2012	Behavioral health day treatment, per hour	Procedure	HCPCS
H2019	Therapeutic behavioral services, per 15 minutes	Procedure	HCPCS
H2020	Therapeutic behavioral services, per diem	Procedure	HCPCS
S3005	Performance measurement, evaluation of patient self assessment, depression	Procedure	HCPCS
S9449	Weight management classes, nonphysician provider, per session	Procedure	HCPCS
S9452	Nutrition classes, nonphysician provider, per session	Procedure	HCPCS
S9470	Nutritional counseling, dietitian visit	Procedure	HCPCS
T1040	Medicaid certified community behavioral health clinic services, per diem	Procedure	HCPCS
T1041	Medicaid certified community behavioral health clinic services, per month	Procedure	HCPCS
T2048	Behavioral health; long-term care residential (nonacute care in a residential treatment program where stay is typically longer than 30 days), with room and board, per diem	Procedure	HCPCS
	Cardiovascular Disease		
00.40	Procedure on single vessel	Procedure	ICD-9-CM
00.41	Procedure on two vessels	Procedure	ICD-9-CM
00.42	Procedure on three vessels	Procedure	ICD-9-CM
00.43	Procedure on four or more vessels	Procedure	ICD-9-CM
00.44	Procedure on vessel bifurcation	Procedure	ICD-9-CM
00.45	Insertion of one vascular stent	Procedure	ICD-9-CM
00.46	Insertion of two vascular stents	Procedure	ICD-9-CM
00.47	Insertion of three vascular stents	Procedure	ICD-9-CM
00.48	Insertion of four or more vascular stents	Procedure	ICD-9-CM
00.66	Percutaneous transluminal coronary angioplasty [PTCA]	Procedure	ICD-9-CM
0210083	Bypass Coronary Artery, One Artery from Coronary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0210088	Bypass Coronary Artery, One Artery from Right Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0210089	Bypass Coronary Artery, One Artery from Left Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021008C	Bypass Coronary Artery, One Artery from Thoracic Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021008F	Bypass Coronary Artery, One Artery from Abdominal Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021008W	Bypass Coronary Artery, One Artery from Aorta with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
0210093	Bypass Coronary Artery, One Artery from Coronary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0210098	Bypass Coronary Artery, One Artery from Right Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0210099	Bypass Coronary Artery, One Artery from Left Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021009C	Bypass Coronary Artery, One Artery from Thoracic Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021009F	Bypass Coronary Artery, One Artery from Abdominal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021009W	Bypass Coronary Artery, One Artery from Aorta with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
02100A3	Bypass Coronary Artery, One Artery from Coronary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02100A8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02100A9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02100AC	Bypass Coronary Artery, One Artery from Thoracic Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02100AF	Bypass Coronary Artery, One Artery from Abdominal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02100AW	Bypass Coronary Artery, One Artery from Aorta with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02100J3	Bypass Coronary Artery, One Artery from Coronary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02100J8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02100J9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02100JC	Bypass Coronary Artery, One Artery from Thoracic Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02100JF	Bypass Coronary Artery, One Artery from Abdominal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02100JW	Bypass Coronary Artery, One Artery from Aorta with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02100K3	Bypass Coronary Artery, One Artery from Coronary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02100K8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02100K9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02100KC	Bypass Coronary Artery, One Artery from Thoracic Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02100KF	Bypass Coronary Artery, One Artery from Abdominal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02100KW	Bypass Coronary Artery, One Artery from Aorta with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02100Z3	Bypass Coronary Artery, One Artery from Coronary Artery, Open Approach	Procedure	ICD-10-PCS
02100Z8	Bypass Coronary Artery, One Artery from Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02100Z9	Bypass Coronary Artery, One Artery from Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02100ZC	Bypass Coronary Artery, One Artery from Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
02100ZF	Bypass Coronary Artery, One Artery from Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
0210483	Bypass Coronary Artery, One Artery from Coronary Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0210488	Bypass Coronary Artery, One Artery from Right Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0210489	Bypass Coronary Artery, One Artery from Left Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021048C	Bypass Coronary Artery, One Artery from Thoracic Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021048F	Bypass Coronary Artery, One Artery from Abdominal Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021048W	Bypass Coronary Artery, One Artery from Aorta with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0210493	Bypass Coronary Artery, One Artery from Coronary Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0210498	Bypass Coronary Artery, One Artery from Right Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0210499	Bypass Coronary Artery, One Artery from Left Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021049C	Bypass Coronary Artery, One Artery from Thoracic Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
021049F	Bypass Coronary Artery, One Artery from Abdominal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021049W	Bypass Coronary Artery, One Artery from Aorta with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104A3	Bypass Coronary Artery, One Artery from Coronary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104A8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104A9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104AC	Bypass Coronary Artery, One Artery from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104AF	Bypass Coronary Artery, One Artery from Abdominal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104AW	Bypass Coronary Artery, One Artery from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104J3	Bypass Coronary Artery, One Artery from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104J8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104J9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104JC	Bypass Coronary Artery, One Artery from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104JF	Bypass Coronary Artery, One Artery from Abdominal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104JW	Bypass Coronary Artery, One Artery from Aorta with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104K3	Bypass Coronary Artery, One Artery from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104K8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104K9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02104KC	Bypass Coronary Artery, One Artery from Thoracic Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104KF	Bypass Coronary Artery, One Artery from Abdominal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104KW	Bypass Coronary Artery, One Artery from Aorta with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104Z3	Bypass Coronary Artery, One Artery from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104Z8	Bypass Coronary Artery, One Artery from Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104Z9	Bypass Coronary Artery, One Artery from Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104ZC	Bypass Coronary Artery, One Artery from Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104ZF	Bypass Coronary Artery, One Artery from Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0211083	Bypass Coronary Artery, Two Arteries from Coronary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0211088	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0211089	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021108C	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021108F	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021108W	Bypass Coronary Artery, Two Arteries from Aorta with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0211093	Bypass Coronary Artery, Two Arteries from Coronary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0211098	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0211099	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021109C	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021109F	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
021109W	Bypass Coronary Artery, Two Arteries from Aorta with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
02110A3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02110A8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02110A9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02110AC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02110AF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02110AW	Bypass Coronary Artery, Two Arteries from Aorta with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02110J3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02110J8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02110J9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02110JC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02110JF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02110JW	Bypass Coronary Artery, Two Arteries from Aorta with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02110K3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02110K8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02110K9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02110KC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02110KF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02110KW	Bypass Coronary Artery, Two Arteries from Aorta with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02110Z3	Bypass Coronary Artery, Two Arteries from Coronary Artery, Open Approach	Procedure	ICD-10-PCS
02110Z8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02110Z9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02110ZC	Bypass Coronary Artery, Two Arteries from Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
02110ZF	Bypass Coronary Artery, Two Arteries from Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
0211483	Bypass Coronary Artery, Two Arteries from Coronary Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0211488	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0211489	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021148C	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021148F	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021148W	Bypass Coronary Artery, Two Arteries from Aorta with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0211493	Bypass Coronary Artery, Two Arteries from Coronary Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0211498	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0211499	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021149C	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021149F	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021149W	Bypass Coronary Artery, Two Arteries from Aorta with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114A3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114A8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02114A9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114AC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114AF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114AW	Bypass Coronary Artery, Two Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114J3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114J8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114J9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114JC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114JF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114JW	Bypass Coronary Artery, Two Arteries from Aorta with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114K3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114K8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114K9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114KC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114KF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114KW	Bypass Coronary Artery, Two Arteries from Aorta with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114Z3	Bypass Coronary Artery, Two Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02114Z8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114Z9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114ZC	Bypass Coronary Artery, Two Arteries from Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114ZF	Bypass Coronary Artery, Two Arteries from Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0212083	Bypass Coronary Artery, Three Arteries from Coronary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0212088	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0212089	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021208C	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021208F	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021208W	Bypass Coronary Artery, Three Arteries from Aorta with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0212093	Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0212098	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0212099	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021209C	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021209F	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021209W	Bypass Coronary Artery, Three Arteries from Aorta with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
02120A3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02120A8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02120A9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02120AC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02120AF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02120AW	Bypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02120J3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02120J8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02120J9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02120JC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02120JF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02120JW	Bypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02120K3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02120K8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02120K9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02120KC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02120KF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02120KW	Bypass Coronary Artery, Three Arteries from Aorta with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02120Z3	Bypass Coronary Artery, Three Arteries from Coronary Artery, Open Approach	Procedure	ICD-10-PCS
02120Z8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02120Z9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02120ZC	Bypass Coronary Artery, Three Arteries from Thoracic Artery, Open Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02120ZF	Bypass Coronary Artery, Three Arteries from Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
0212483	Bypass Coronary Artery, Three Arteries from Coronary Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0212488	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0212489	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021248C	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021248F	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021248W	Bypass Coronary Artery, Three Arteries from Aorta with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0212493	Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0212498	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0212499	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021249C	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021249F	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021249W	Bypass Coronary Artery, Three Arteries from Aorta with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124A3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124A8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124A9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124AC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124AF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02124AW	Bypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124J3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124J8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124J9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124JC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124JF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124JW	Bypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124K3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124K8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124K9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124KC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124KF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124KW	Bypass Coronary Artery, Three Arteries from Aorta with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124Z3	Bypass Coronary Artery, Three Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124Z8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124Z9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124ZC	Bypass Coronary Artery, Three Arteries from Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02124ZF	Bypass Coronary Artery, Three Arteries from Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0213083	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0213088	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0213089	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021308C	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021308F	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021308W	Bypass Coronary Artery, Four or More Arteries from Aorta with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0213093	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0213098	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0213099	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021309C	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021309F	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021309W	Bypass Coronary Artery, Four or More Arteries from Aorta with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
02130A3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02130A8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02130A9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02130AC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02130AF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02130AW	Bypass Coronary Artery, Four or More Arteries from Aorta with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02130J3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02130J8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02130J9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02130JC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02130JF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02130JW	Bypass Coronary Artery, Four or More Arteries from Aorta with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02130K3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130K8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130K9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130KC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130KF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130KW	Bypass Coronary Artery, Four or More Arteries from Aorta with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130Z3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery, Open Approach	Procedure	ICD-10-PCS
02130Z8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02130Z9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02130ZC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
02130ZF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
0213483	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
0213488	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0213489	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021348C	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021348F	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021348W	Bypass Coronary Artery, Four or More Arteries from Aorta with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0213493	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0213498	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0213499	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021349C	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021349F	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021349W	Bypass Coronary Artery, Four or More Arteries from Aorta with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134A3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134A8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134A9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134AC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134AF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134AW	Bypass Coronary Artery, Four or More Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02134J3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134J8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134J9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134JC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134JF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134JW	Bypass Coronary Artery, Four or More Arteries from Aorta with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134K3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134K8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134K9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134KC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134KF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134KW	Bypass Coronary Artery, Four or More Arteries from Aorta with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134Z3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134Z8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134Z9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134ZC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134ZF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021K0Z8	Bypass Right Ventricle to Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
021K0Z9	Bypass Right Ventricle to Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
021K0ZC	Bypass Right Ventricle to Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
021K0ZF	Bypass Right Ventricle to Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021K0ZW	Bypass Right Ventricle to Aorta, Open Approach	Procedure	ICD-10-PCS
021K4Z8	Bypass Right Ventricle to Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021K4Z9	Bypass Right Ventricle to Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021K4ZC	Bypass Right Ventricle to Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021K4ZF	Bypass Right Ventricle to Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021K4ZW	Bypass Right Ventricle to Aorta, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L08P	Bypass Left Ventricle to Pulmonary Trunk with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021L08Q	Bypass Left Ventricle to Right Pulmonary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021L08R	Bypass Left Ventricle to Left Pulmonary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021L09P	Bypass Left Ventricle to Pulmonary Trunk with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021L09Q	Bypass Left Ventricle to Right Pulmonary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021L09R	Bypass Left Ventricle to Left Pulmonary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021L0AP	Bypass Left Ventricle to Pulmonary Trunk with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
021L0AQ	Bypass Left Ventricle to Right Pulmonary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
021L0AR	Bypass Left Ventricle to Left Pulmonary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
021L0JP	Bypass Left Ventricle to Pulmonary Trunk with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
021L0JQ	Bypass Left Ventricle to Right Pulmonary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
021L0JR	Bypass Left Ventricle to Left Pulmonary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
021L0KP	Bypass Left Ventricle to Pulmonary Trunk with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
021L0KQ	Bypass Left Ventricle to Right Pulmonary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
021L0KR	Bypass Left Ventricle to Left Pulmonary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
021L0Z8	Bypass Left Ventricle to Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
021L0Z9	Bypass Left Ventricle to Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
021L0ZC	Bypass Left Ventricle to Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
021L0ZF	Bypass Left Ventricle to Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021L0ZP	Bypass Left Ventricle to Pulmonary Trunk, Open Approach	Procedure	ICD-10-PCS
021L0ZQ	Bypass Left Ventricle to Right Pulmonary Artery, Open Approach	Procedure	ICD-10-PCS
021L0ZR	Bypass Left Ventricle to Left Pulmonary Artery, Open Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
021L48P	Bypass Left Ventricle to Pulmonary Trunk with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L48Q	Bypass Left Ventricle to Right Pulmonary Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L48R	Bypass Left Ventricle to Left Pulmonary Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L49P	Bypass Left Ventricle to Pulmonary Trunk with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L49Q	Bypass Left Ventricle to Right Pulmonary Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L49R	Bypass Left Ventricle to Left Pulmonary Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4AP	Bypass Left Ventricle to Pulmonary Trunk with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4AQ	Bypass Left Ventricle to Right Pulmonary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4AR	Bypass Left Ventricle to Left Pulmonary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4JP	Bypass Left Ventricle to Pulmonary Trunk with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4JQ	Bypass Left Ventricle to Right Pulmonary Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4JR	Bypass Left Ventricle to Left Pulmonary Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4KP	Bypass Left Ventricle to Pulmonary Trunk with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4KQ	Bypass Left Ventricle to Right Pulmonary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4KR	Bypass Left Ventricle to Left Pulmonary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4Z8	Bypass Left Ventricle to Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4Z9	Bypass Left Ventricle to Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZC	Bypass Left Ventricle to Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZF	Bypass Left Ventricle to Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZP	Bypass Left Ventricle to Pulmonary Trunk, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
021L4ZQ	Bypass Left Ventricle to Right Pulmonary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZR	Bypass Left Ventricle to Left Pulmonary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270046	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027004Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0270056	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027005Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0270066	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027006Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0270076	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027007Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02700DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02700E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02700TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02700Z6	Dilation of Coronary Artery, One Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02700ZZ	Dilation of Coronary Artery, One Artery, Open Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
0270346	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027034Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0270356	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027035Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0270366	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027036Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0270376	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027037Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
0270446	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027044Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270456	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027045Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270466	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027046Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270476	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027047Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02704TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271046	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027104Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0271056	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027105Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0271066	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027106Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0271076	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027107Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02710D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02710DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02710E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02710EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02710F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02710FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02710G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02710GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02710T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02710TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02710Z6	Dilation of Coronary Artery, Two Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02710ZZ	Dilation of Coronary Artery, Two Arteries, Open Approach	Procedure	ICD-10-PCS
0271346	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027134Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0271356	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027135Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0271366	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027136Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0271376	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027137Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02713TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0271446	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027144Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271456	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027145Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271466	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027146Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271476	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027147Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02714T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272046	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027204Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0272056	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027205Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0272066	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027206Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0272076	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027207Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02720DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02720E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02720TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02720Z6	Dilation of Coronary Artery, Three Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02720ZZ	Dilation of Coronary Artery, Three Arteries, Open Approach	Procedure	ICD-10-PCS
0272346	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027234Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0272356	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027235Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0272366	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027236Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0272376	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027237Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02723T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0272446	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027244Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272456	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027245Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272466	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027246Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272476	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027247Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02724GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273046	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027304Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0273056	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027305Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0273066	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027306Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0273076	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027307Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02730D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02730DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02730E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02730EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02730F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02730FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02730G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02730GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02730T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02730TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02730Z6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02730ZZ	Dilation of Coronary Artery, Four or More Arteries, Open Approach	Procedure	ICD-10-PCS
0273346	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027334Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0273356	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027335Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0273366	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027336Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0273376	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027337Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02733FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0273446	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027344Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273456	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027345Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273466	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027346Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273476	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027347Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02734F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C00Z6	Extirpation of Matter from Coronary Artery, One Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02C00ZZ	Extirpation of Matter from Coronary Artery, One Artery, Open Approach	Procedure	ICD-10-PCS
02C03Z6	Extirpation of Matter from Coronary Artery, One Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02C03ZZ	Extirpation of Matter from Coronary Artery, One Artery, Percutaneous Approach	Procedure	ICD-10-PCS
02C04Z6	Extirpation of Matter from Coronary Artery, One Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C04ZZ	Extirpation of Matter from Coronary Artery, One Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C10Z6	Extirpation of Matter from Coronary Artery, Two Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02C10ZZ	Extirpation of Matter from Coronary Artery, Two Arteries, Open Approach	Procedure	ICD-10-PCS
02C13Z6	Extirpation of Matter from Coronary Artery, Two Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02C13ZZ	Extirpation of Matter from Coronary Artery, Two Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
02C14Z6	Extirpation of Matter from Coronary Artery, Two Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C14ZZ	Extirpation of Matter from Coronary Artery, Two Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C20Z6	Extirpation of Matter from Coronary Artery, Three Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02C20ZZ	Extirpation of Matter from Coronary Artery, Three Arteries, Open Approach	Procedure	ICD-10-PCS
02C23Z6	Extirpation of Matter from Coronary Artery, Three Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02C23ZZ	Extirpation of Matter from Coronary Artery, Three Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
02C24Z6	Extirpation of Matter from Coronary Artery, Three Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C24ZZ	Extirpation of Matter from Coronary Artery, Three Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C30Z6	Extirpation of Matter from Coronary Artery, Four or More Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02C30ZZ	Extirpation of Matter from Coronary Artery, Four or More Arteries, Open Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
02C33Z6	Extirpation of Matter from Coronary Artery, Four or More Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02C33ZZ	Extirpation of Matter from Coronary Artery, Four or More Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
02C34Z6	Extirpation of Matter from Coronary Artery, Four or More Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C34ZZ	Extirpation of Matter from Coronary Artery, Four or More Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
17.55	Transluminal coronary atherectomy	Procedure	ICD-9-CM
33510	Coronary artery bypass, vein only; single coronary venous graft	Procedure	CPT-4
33511	Coronary artery bypass, vein only; 2 coronary venous grafts	Procedure	CPT-4
33512	Coronary artery bypass, vein only; 3 coronary venous grafts	Procedure	CPT-4
33513	Coronary artery bypass, vein only; 4 coronary venous grafts	Procedure	CPT-4
33514	Coronary artery bypass, vein only; 5 coronary venous grafts	Procedure	CPT-4
33516	Coronary artery bypass, vein only; 6 or more coronary venous grafts	Procedure	CPT-4
33517	Coronary artery bypass, using venous graft(s) and arterial graft(s); single vein graft (List separately in addition to code for primary procedure)	Procedure	CPT-4
33518	Coronary artery bypass, using venous graft(s) and arterial graft(s); 2 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33519	Coronary artery bypass, using venous graft(s) and arterial graft(s); 3 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33520	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Single Graft	Procedure	CPT-4
33521	Coronary artery bypass, using venous graft(s) and arterial graft(s); 4 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33522	Coronary artery bypass, using venous graft(s) and arterial graft(s); 5 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33523	Coronary artery bypass, using venous graft(s) and arterial graft(s); 6 or more venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33525	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Two Coronary Grafts	Procedure	CPT-4
33528	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Three Or More Coronary Grafts	Procedure	CPT-4
33530	Reoperation, coronary artery bypass procedure or valve procedure, more than 1 month after original operation (List separately in addition to code for primary procedure)	Procedure	CPT-4
33533	Coronary artery bypass, using arterial graft(s); single arterial graft	Procedure	CPT-4
33534	Coronary artery bypass, using arterial graft(s); 2 coronary arterial grafts	Procedure	CPT-4
33535	Coronary artery bypass, using arterial graft(s); 3 coronary arterial grafts	Procedure	CPT-4

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
33536	Coronary artery bypass, using arterial graft(s); 4 or more coronary arterial grafts	Procedure	CPT-4
33560	Myocardial Operation Combined With Coronary Bypass Procedure	Procedure	CPT-4
33570	CORONARY ANGIOPLASTY W/BYPASS	Procedure	CPT-4
33572	Coronary endarterectomy, open, any method, of left anterior descending, circumflex, or right coronary artery performed in conjunction with coronary artery bypass graft procedure, each vessel (List separately in addition to primary procedure)	Procedure	CPT-4
33575	CORON ANGIOPLSTY W/BYPASS; COMBO W/VASCULARIZAT	Procedure	CPT-4
35454	Transluminal balloon angioplasty, open; iliac	Procedure	CPT-4
35456	Transluminal balloon angioplasty, open; femoral-popliteal	Procedure	CPT-4
35458	Transluminal balloon angioplasty, open; brachiocephalic trunk or branches, each vessel	Procedure	CPT-4
35459	Transluminal balloon angioplasty, open; tibioperoneal trunk and branches	Procedure	CPT-4
35470	Transluminal balloon angioplasty, percutaneous; tibioperoneal trunk or branches, each vessel	Procedure	CPT-4
35473	Transluminal balloon angioplasty, percutaneous; iliac	Procedure	CPT-4
35474	Transluminal balloon angioplasty, percutaneous; femoral-popliteal	Procedure	CPT-4
35475	Transluminal balloon angioplasty, percutaneous; brachiocephalic trunk or branches, each vessel	Procedure	CPT-4
35600	Harvest of upper extremity artery, 1 segment, for coronary artery bypass procedure (List separately in addition to code for primary procedure)	Procedure	CPT-4
35879	Revision, lower extremity arterial bypass, without thrombectomy, open; with vein patch angioplasty	Procedure	CPT-4
36.03	Open chest coronary artery angioplasty	Procedure	ICD-9-CM
36.04	Intracoronary artery thrombolytic infusion	Procedure	ICD-9-CM
36.06	Insertion of non-drug-eluting coronary artery stent(s)	Procedure	ICD-9-CM
36.07	Insertion of drug-eluting coronary artery stent(s)	Procedure	ICD-9-CM
36.09	Other removal of coronary artery obstruction	Procedure	ICD-9-CM
36.10	Aortocoronary bypass for heart revascularization, not otherwise specified	Procedure	ICD-9-CM
36.11	(Aorto)coronary bypass of one coronary artery	Procedure	ICD-9-CM
36.12	(Aorto)coronary bypass of two coronary arteries	Procedure	ICD-9-CM
36.13	(Aorto)coronary bypass of three coronary arteries	Procedure	ICD-9-CM
36.14	(Aorto)coronary bypass of four or more coronary arteries	Procedure	ICD-9-CM
36.15	Single internal mammary-coronary artery bypass	Procedure	ICD-9-CM
36.16	Double internal mammary-coronary artery bypass	Procedure	ICD-9-CM
36.17	Abdominal-coronary artery bypass	Procedure	ICD-9-CM
36.19	Other bypass anastomosis for heart revascularization	Procedure	ICD-9-CM
36.2	Heart revascularization by arterial implant	Procedure	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
37215	Transcatheter placement of intravascular stent(s), cervical carotid artery, open or percutaneous, including angioplasty, when performed, and radiological supervision and interpretation; with distal embolic protection	Procedure	CPT-4
37216	Transcatheter placement of intravascular stent(s), cervical carotid artery, open or percutaneous, including angioplasty, when performed, and radiological supervision and interpretation; without distal embolic protection	Procedure	CPT-4
37217	Transcatheter placement of intravascular stent(s), intrathoracic common carotid artery or innominate artery by retrograde treatment, open ipsilateral cervical carotid artery exposure, including angioplasty, when performed, and radiological supervision and interpretation	Procedure	CPT-4
37218	Transcatheter placement of intravascular stent(s), intrathoracic common carotid artery or innominate artery, open or percutaneous antegrade approach, including angioplasty, when performed, and radiological supervision and interpretation	Procedure	CPT-4
37220	Revascularization, endovascular, open or percutaneous, iliac artery, unilateral, initial vessel; with transluminal angioplasty	Procedure	CPT-4
37221	Revascularization, endovascular, open or percutaneous, iliac artery, unilateral, initial vessel; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed	Procedure	CPT-4
37222	Revascularization, endovascular, open or percutaneous, iliac artery, each additional ipsilateral iliac vessel; with transluminal angioplasty (List separately in addition to code for primary procedure)	Procedure	CPT-4
37223	Revascularization, endovascular, open or percutaneous, iliac artery, each additional ipsilateral iliac vessel; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed (List separately in addition to code for primary procedure)	Procedure	CPT-4
37224	Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with transluminal angioplasty	Procedure	CPT-4
37225	Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with atherectomy, includes angioplasty within the same vessel, when performed	Procedure	CPT-4
37226	Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed	Procedure	CPT-4
37227	Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with transluminal stent placement(s) and atherectomy, includes angioplasty within the same vessel, when performed	Procedure	CPT-4
37228	Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with transluminal angioplasty	Procedure	CPT-4

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
37229	Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with atherectomy, includes angioplasty within the same vessel, when performed	Procedure	CPT-4
37230	Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed	Procedure	CPT-4
37231	Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with transluminal stent placement(s) and atherectomy, includes angioplasty within the same vessel, when performed	Procedure	CPT-4
37232	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery, unilateral, each additional vessel; with transluminal angioplasty (List separately in addition to code for primary procedure)	Procedure	CPT-4
37233	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery, unilateral, each additional vessel; with atherectomy, includes angioplasty within the same vessel, when performed (List separately in addition to code for primary procedure)	Procedure	CPT-4
37234	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery, unilateral, each additional vessel; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed (List separately in addition to code for primary procedure)	Procedure	CPT-4
37235	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery, unilateral, each additional vessel; with transluminal stent placement(s) and atherectomy, includes angioplasty within the same vessel, when performed (List separately in addition to code for primary procedure)	Procedure	CPT-4
37236	Transcatheter placement of an intravascular stent(s) (except lower extremity artery(s) for occlusive disease, cervical carotid, extracranial vertebral or intrathoracic carotid, intracranial, or coronary), open or percutaneous, including radiological supervision and interpretation and including all angioplasty within the same vessel, when performed; initial artery	Procedure	CPT-4
37237	Transcatheter placement of an intravascular stent(s) (except lower extremity artery(s) for occlusive disease, cervical carotid, extracranial vertebral or intrathoracic carotid, intracranial, or coronary), open or percutaneous, including radiological supervision and interpretation and including all angioplasty within the same vessel, when performed; each additional artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
3E07017	Introduction of Other Thrombolytic into Coronary Artery, Open Approach	Procedure	ICD-10-PCS
3E070PZ	Introduction of Platelet Inhibitor into Coronary Artery, Open Approach	Procedure	ICD-10-PCS
3E07317	Introduction of Other Thrombolytic into Coronary Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E073PZ	Introduction of Platelet Inhibitor into Coronary Artery, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
410.00	Acute myocardial infarction of anterolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.02	Acute myocardial infarction of anterolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.10	Acute myocardial infarction of other anterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.12	Acute myocardial infarction of other anterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.20	Acute myocardial infarction of inferolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.22	Acute myocardial infarction of inferolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.30	Acute myocardial infarction of inferoposterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.32	Acute myocardial infarction of inferoposterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.40	Acute myocardial infarction of other inferior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
410.42	Acute myocardial infarction of other inferior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.50	Acute myocardial infarction of other lateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.52	Acute myocardial infarction of other lateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.60	Acute myocardial infarction, true posterior wall infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM
410.62	Acute myocardial infarction, true posterior wall infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.70	Acute myocardial infarction, subendocardial infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	Diagnosis	ICD-9-CM
410.72	Acute myocardial infarction, subendocardial infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.80	Acute myocardial infarction of other specified sites, episode of care unspecified	Diagnosis	ICD-9-CM
410.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
410.82	Acute myocardial infarction of other specified sites, subsequent episode of care	Diagnosis	ICD-9-CM
410.90	Acute myocardial infarction, unspecified site, episode of care unspecified	Diagnosis	ICD-9-CM
410.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
410.92	Acute myocardial infarction, unspecified site, subsequent episode of care	Diagnosis	ICD-9-CM
411.1	Intermediate coronary syndrome	Diagnosis	ICD-9-CM
411.81	Acute coronary occlusion without myocardial infarction	Diagnosis	ICD-9-CM
411.89	Other acute and subacute form of ischemic heart disease	Diagnosis	ICD-9-CM
413.0	Angina decubitus	Diagnosis	ICD-9-CM
413.1	Prinzmetal angina	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
413.9	Other and unspecified angina pectoris	Diagnosis	ICD-9-CM
414.01	Coronary atherosclerosis of native coronary artery	Diagnosis	ICD-9-CM
414.02	Coronary atherosclerosis of autologous vein bypass graft	Diagnosis	ICD-9-CM
414.03	Coronary atherosclerosis of nonautologous biological bypass graft	Diagnosis	ICD-9-CM
414.04	Coronary atherosclerosis of artery bypass graft	Diagnosis	ICD-9-CM
414.05	Coronary atherosclerosis of unspecified type of bypass graft	Diagnosis	ICD-9-CM
414.06	Coronary atherosclerosis, of native coronary artery of transplanted heart	Diagnosis	ICD-9-CM
414.07	Coronary atherosclerosis, of bypass graft (artery) (vein) of transplanted heart	Diagnosis	ICD-9-CM
414.3	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-9-CM
414.4	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-9-CM
414.8	Other specified forms of chronic ischemic heart disease	Diagnosis	ICD-9-CM
415.11	Iatrogenic pulmonary embolism and infarction	Diagnosis	ICD-9-CM
427.1	Paroxysmal ventricular tachycardia	Diagnosis	ICD-9-CM
427.5	Cardiac arrest	Diagnosis	ICD-9-CM
429.79	Other certain sequelae of myocardial infarction, not elsewhere classified	Diagnosis	ICD-9-CM
430	Subarachnoid hemorrhage	Diagnosis	ICD-9-CM
431	Intracerebral hemorrhage	Diagnosis	ICD-9-CM
432.0	Nontraumatic extradural hemorrhage	Diagnosis	ICD-9-CM
432.1	Subdural hemorrhage	Diagnosis	ICD-9-CM
432.9	Unspecified intracranial hemorrhage	Diagnosis	ICD-9-CM
433.00	Occlusion and stenosis of basilar artery without mention of cerebral infarction	Diagnosis	ICD-9-CM
433.01	Occlusion and stenosis of basilar artery with cerebral infarction	Diagnosis	ICD-9-CM
433.10	Occlusion and stenosis of carotid artery without mention of cerebral infarction	Diagnosis	ICD-9-CM
433.11	Occlusion and stenosis of carotid artery with cerebral infarction	Diagnosis	ICD-9-CM
433.20	Occlusion and stenosis of vertebral artery without mention of cerebral infarction	Diagnosis	ICD-9-CM
433.21	Occlusion and stenosis of vertebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.30	Occlusion and stenosis of multiple and bilateral precerebral arteries without mention of cerebral infarction	Diagnosis	ICD-9-CM
433.31	Occlusion and stenosis of multiple and bilateral precerebral arteries with cerebral infarction	Diagnosis	ICD-9-CM
433.80	Occlusion and stenosis of other specified precerebral artery without mention of cerebral infarction	Diagnosis	ICD-9-CM
433.81	Occlusion and stenosis of other specified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.90	Occlusion and stenosis of unspecified precerebral artery without mention of cerebral infarction	Diagnosis	ICD-9-CM
433.91	Occlusion and stenosis of unspecified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
434.00	Cerebral thrombosis without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.01	Cerebral thrombosis with cerebral infarction	Diagnosis	ICD-9-CM
434.10	Cerebral embolism without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.11	Cerebral embolism with cerebral infarction	Diagnosis	ICD-9-CM
434.90	Unspecified cerebral artery occlusion without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.91	Unspecified cerebral artery occlusion with cerebral infarction	Diagnosis	ICD-9-CM
435.0	Basilar artery syndrome	Diagnosis	ICD-9-CM
435.1	Vertebral artery syndrome	Diagnosis	ICD-9-CM
435.2	Subclavian steal syndrome	Diagnosis	ICD-9-CM
435.3	Vertebrobasilar artery syndrome	Diagnosis	ICD-9-CM
435.8	Other specified transient cerebral ischemias	Diagnosis	ICD-9-CM
435.9	Unspecified transient cerebral ischemia	Diagnosis	ICD-9-CM
436	Acute, but ill-defined, cerebrovascular disease	Diagnosis	ICD-9-CM
437.0	Cerebral atherosclerosis	Diagnosis	ICD-9-CM
437.1	Other generalized ischemic cerebrovascular disease	Diagnosis	ICD-9-CM
437.2	Hypertensive encephalopathy	Diagnosis	ICD-9-CM
437.3	Cerebral aneurysm, nonruptured	Diagnosis	ICD-9-CM
437.4	Cerebral arteritis	Diagnosis	ICD-9-CM
437.5	Moyamoya disease	Diagnosis	ICD-9-CM
437.8	Other ill-defined cerebrovascular disease	Diagnosis	ICD-9-CM
437.9	Unspecified cerebrovascular disease	Diagnosis	ICD-9-CM
438.0	Cognitive deficits due to cerebrovascular disease	Diagnosis	ICD-9-CM
438.10	Unspecified speech and language deficit due to cerebrovascular disease	Diagnosis	ICD-9-CM
438.11	Aphasia due to cerebrovascular disease	Diagnosis	ICD-9-CM
438.12	Dysphasia due to cerebrovascular disease	Diagnosis	ICD-9-CM
438.13	Late effects of cerebrovascular disease, speech and language deficits, dysarthria	Diagnosis	ICD-9-CM
438.14	Late effects of cerebrovascular disease, speech and language deficits, fluency disorder	Diagnosis	ICD-9-CM
438.19	Other speech and language deficits due to cerebrovascular disease	Diagnosis	ICD-9-CM
438.20	Hemiplegia affecting unspecified side due to cerebrovascular disease	Diagnosis	ICD-9-CM
438.21	Hemiplegia affecting dominant side due to cerebrovascular disease	Diagnosis	ICD-9-CM
438.22	Hemiplegia affecting nondominant side due to cerebrovascular disease	Diagnosis	ICD-9-CM
438.30	Monoplegia of upper limb affecting unspecified side due to cerebrovascular disease	Diagnosis	ICD-9-CM
438.31	Monoplegia of upper limb affecting dominant side due to cerebrovascular disease	Diagnosis	ICD-9-CM
438.32	Monoplegia of upper limb affecting nondominant side due to cerebrovascular disease	Diagnosis	ICD-9-CM
438.40	Monoplegia of lower limb affecting unspecified side due to cerebrovascular disease	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
438.41	Monoplegia of lower limb affecting dominant side due to cerebrovascular disease	Diagnosis	ICD-9-CM
438.42	Monoplegia of lower limb affecting nondominant side due to cerebrovascular disease	Diagnosis	ICD-9-CM
438.50	Other paralytic syndrome affecting unspecified side due to cerebrovascular disease	Diagnosis	ICD-9-CM
438.51	Other paralytic syndrome affecting dominant side due to cerebrovascular disease	Diagnosis	ICD-9-CM
438.52	Other paralytic syndrome affecting nondominant side due to cerebrovascular disease	Diagnosis	ICD-9-CM
438.6	Alteration of sensations as late effect of cerebrovascular disease	Diagnosis	ICD-9-CM
438.7	Disturbance of vision as late effect of cerebrovascular disease	Diagnosis	ICD-9-CM
438.81	Apraxia due to cerebrovascular disease	Diagnosis	ICD-9-CM
438.82	Dysphagia due to cerebrovascular disease	Diagnosis	ICD-9-CM
438.83	Facial weakness as late effect of cerebrovascular disease	Diagnosis	ICD-9-CM
438.84	Ataxia as late effect of cerebrovascular disease	Diagnosis	ICD-9-CM
438.85	Vertigo as late effect of cerebrovascular disease	Diagnosis	ICD-9-CM
438.89	Other late effects of cerebrovascular disease	Diagnosis	ICD-9-CM
438.9	Unspecified late effects of cerebrovascular disease due to cerebrovascular disease	Diagnosis	ICD-9-CM
440.20	Atherosclerosis of native arteries of the extremities, unspecified	Diagnosis	ICD-9-CM
440.21	Atherosclerosis of native arteries of the extremities with intermittent claudication	Diagnosis	ICD-9-CM
440.22	Atherosclerosis of native arteries of the extremities with rest pain	Diagnosis	ICD-9-CM
440.23	Atherosclerosis of native arteries of the extremities with ulceration	Diagnosis	ICD-9-CM
440.29	Other atherosclerosis of native arteries of the extremities	Diagnosis	ICD-9-CM
440.30	Atherosclerosis of unspecified bypass graft of extremities	Diagnosis	ICD-9-CM
440.31	Atherosclerosis of autologous vein bypass graft of extremities	Diagnosis	ICD-9-CM
440.32	Atherosclerosis of nonautologous biological bypass graft of extremities	Diagnosis	ICD-9-CM
440.4	Chronic total occlusion of artery of the extremities	Diagnosis	ICD-9-CM
443.81	Peripheral angiopathy in diseases classified elsewhere	Diagnosis	ICD-9-CM
443.89	Other peripheral vascular disease	Diagnosis	ICD-9-CM
443.9	Unspecified peripheral vascular disease	Diagnosis	ICD-9-CM
444.01	Saddle embolus of abdominal aorta	Diagnosis	ICD-9-CM
444.09	Other arterial embolism and thrombosis of abdominal aorta	Diagnosis	ICD-9-CM
444.1	Embolism and thrombosis of thoracic aorta	Diagnosis	ICD-9-CM
444.21	Embolism and thrombosis of arteries of upper extremity	Diagnosis	ICD-9-CM
444.22	Embolism and thrombosis of arteries of lower extremity	Diagnosis	ICD-9-CM
444.81	Embolism and thrombosis of iliac artery	Diagnosis	ICD-9-CM
444.89	Embolism and thrombosis of other specified artery	Diagnosis	ICD-9-CM
444.9	Embolism and thrombosis of unspecified artery	Diagnosis	ICD-9-CM
445.01	Atheroembolism of upper extremity	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
445.02	Atheroembolism of lower extremity	Diagnosis	ICD-9-CM
445.81	Atheroembolism of kidney	Diagnosis	ICD-9-CM
445.89	Atheroembolism of other site	Diagnosis	ICD-9-CM
61630	Balloon angioplasty, intracranial (eg, atherosclerotic stenosis), percutaneous	Diagnosis	ICD-10-CM
61630	Balloon angioplasty, intracranial (eg, atherosclerotic stenosis), percutaneous	Procedure	CPT-4
61635	Transcatheter placement of intravascular stent(s), intracranial (eg, atherosclerotic stenosis), including balloon angioplasty, if performed	Diagnosis	ICD-10-CM
61635	Transcatheter placement of intravascular stent(s), intracranial (eg, atherosclerotic stenosis), including balloon angioplasty, if performed	Procedure	CPT-4
75962	Transluminal balloon angioplasty, peripheral artery other than renal, or other visceral artery, iliac or lower extremity, radiological supervision and interpretation	Procedure	CPT-4
75963	Percutaneous Transluminal Angioplasty, Any Method, Peripheral Artery; Complete Procedure	Procedure	CPT-4
75964	Transluminal balloon angioplasty, each additional peripheral artery other than renal or other visceral artery, iliac or lower extremity, radiological supervision and interpretation (List separately in addition to code for primary procedure)	Procedure	CPT-4
75965	Percutaneous Transluminal Angioplasty, Any Method, Each Additional Peripheral Artery; Complete Procedure	Procedure	CPT-4
92.27	Implantation or insertion of radioactive elements	Procedure	ICD-9-CM
92920	Percutaneous transluminal coronary angioplasty; single major coronary artery or branch	Procedure	CPT-4
92921	Percutaneous transluminal coronary angioplasty; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92924	Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92925	Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92928	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92929	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92933	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
92934	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92937	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single vessel	Procedure	CPT-4
92938	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each additional branch subtended by the bypass graft (List separately in addition to code for primary procedure)	Procedure	CPT-4
92941	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel	Procedure	CPT-4
92943	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; single vessel	Procedure	CPT-4
92944	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; each additional coronary artery, coronary artery branch, or bypass graft (List separately in addition to code for primary procedure)	Procedure	CPT-4
92973	Percutaneous transluminal coronary thrombectomy mechanical (List separately in addition to code for primary procedure)	Procedure	CPT-4
92974	Transcatheter placement of radiation delivery device for subsequent coronary intravascular brachytherapy (List separately in addition to code for primary procedure)	Procedure	CPT-4
92977	Thrombolysis, coronary; by intravenous infusion	Procedure	CPT-4
92980	Transcatheter placement of an intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; single vessel	Procedure	CPT-4
92981	Transcatheter placement of an intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; each additional vessel (List separately in addition to code for primary procedure)	Procedure	CPT-4
92982	Percutaneous transluminal coronary balloon angioplasty; single vessel	Procedure	CPT-4
92984	Percutaneous transluminal coronary balloon angioplasty; each additional vessel (List separately in addition to code for primary procedure)	Procedure	CPT-4

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
92995	Percutaneous transluminal coronary atherectomy, by mechanical or other method, with or without balloon angioplasty; single vessel	Procedure	CPT-4
92996	Percutaneous transluminal coronary atherectomy, by mechanical or other method, with or without balloon angioplasty; each additional vessel (List separately in addition to code for primary procedure)	Procedure	CPT-4
93455	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) including intraprocedural injection(s) for bypass graft angiography	Procedure	CPT-4
93457	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) including intraprocedural injection(s) for bypass graft angiography and right heart catheterization	Procedure	CPT-4
93459	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography	Procedure	CPT-4
93461	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography	Procedure	CPT-4
996.71	Other complications due to heart valve prosthesis	Diagnosis	ICD-9-CM
996.72	Other complications due to other cardiac device, implant, and graft	Diagnosis	ICD-9-CM
997.2	Peripheral vascular complications	Diagnosis	ICD-9-CM
997.79	Vascular complications of other vessels	Diagnosis	ICD-9-CM
B2020ZZ	Plain Radiography of Single Coronary Artery Bypass Graft using High Osmolar Contrast	Procedure	ICD-10-PCS
B2021ZZ	Plain Radiography of Single Coronary Artery Bypass Graft using Low Osmolar Contrast	Procedure	ICD-10-PCS
B202YZZ	Plain Radiography of Single Coronary Artery Bypass Graft using Other Contrast	Procedure	ICD-10-PCS
B2030ZZ	Plain Radiography of Multiple Coronary Artery Bypass Grafts using High Osmolar Contrast	Procedure	ICD-10-PCS
B2031ZZ	Plain Radiography of Multiple Coronary Artery Bypass Grafts using Low Osmolar Contrast	Procedure	ICD-10-PCS
B203YZZ	Plain Radiography of Multiple Coronary Artery Bypass Grafts using Other Contrast	Procedure	ICD-10-PCS
B2070ZZ	Plain Radiography of Right Internal Mammary Bypass Graft using High Osmolar Contrast	Procedure	ICD-10-PCS
B2071ZZ	Plain Radiography of Right Internal Mammary Bypass Graft using Low Osmolar Contrast	Procedure	ICD-10-PCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
B207YZZ	Plain Radiography of Right Internal Mammary Bypass Graft using Other Contrast	Procedure	ICD-10-PCS
B2080ZZ	Plain Radiography of Left Internal Mammary Bypass Graft using High Osmolar Contrast	Procedure	ICD-10-PCS
B2081ZZ	Plain Radiography of Left Internal Mammary Bypass Graft using Low Osmolar Contrast	Procedure	ICD-10-PCS
B208YZZ	Plain Radiography of Left Internal Mammary Bypass Graft using Other Contrast	Procedure	ICD-10-PCS
B20F0ZZ	Plain Radiography of Other Bypass Graft using High Osmolar Contrast	Procedure	ICD-10-PCS
B20F1ZZ	Plain Radiography of Other Bypass Graft using Low Osmolar Contrast	Procedure	ICD-10-PCS
B20FYZZ	Plain Radiography of Other Bypass Graft using Other Contrast	Procedure	ICD-10-PCS
B212010	Fluoroscopy of Single Coronary Artery Bypass Graft using High Osmolar Contrast, Laser Intraoperative	Procedure	ICD-10-PCS
B2120ZZ	Fluoroscopy of Single Coronary Artery Bypass Graft using High Osmolar Contrast	Procedure	ICD-10-PCS
B212110	Fluoroscopy of Single Coronary Artery Bypass Graft using Low Osmolar Contrast, Laser Intraoperative	Procedure	ICD-10-PCS
B2121ZZ	Fluoroscopy of Single Coronary Artery Bypass Graft using Low Osmolar Contrast	Procedure	ICD-10-PCS
B212Y10	Fluoroscopy of Single Coronary Artery Bypass Graft using Other Contrast, Laser Intraoperative	Procedure	ICD-10-PCS
B212YZZ	Fluoroscopy of Single Coronary Artery Bypass Graft using Other Contrast	Procedure	ICD-10-PCS
B213010	Fluoroscopy of Multiple Coronary Artery Bypass Grafts using High Osmolar Contrast, Laser Intraoperative	Procedure	ICD-10-PCS
B2130ZZ	Fluoroscopy of Multiple Coronary Artery Bypass Grafts using High Osmolar Contrast	Procedure	ICD-10-PCS
B213110	Fluoroscopy of Multiple Coronary Artery Bypass Grafts using Low Osmolar Contrast, Laser Intraoperative	Procedure	ICD-10-PCS
B2131ZZ	Fluoroscopy of Multiple Coronary Artery Bypass Grafts using Low Osmolar Contrast	Procedure	ICD-10-PCS
B213Y10	Fluoroscopy of Multiple Coronary Artery Bypass Grafts using Other Contrast, Laser Intraoperative	Procedure	ICD-10-PCS
B213YZZ	Fluoroscopy of Multiple Coronary Artery Bypass Grafts using Other Contrast	Procedure	ICD-10-PCS
B2170ZZ	Fluoroscopy of Right Internal Mammary Bypass Graft using High Osmolar Contrast	Procedure	ICD-10-PCS
B2171ZZ	Fluoroscopy of Right Internal Mammary Bypass Graft using Low Osmolar Contrast	Procedure	ICD-10-PCS
B217YZZ	Fluoroscopy of Right Internal Mammary Bypass Graft using Other Contrast	Procedure	ICD-10-PCS
B2180ZZ	Fluoroscopy of Left Internal Mammary Bypass Graft using High Osmolar Contrast	Procedure	ICD-10-PCS
B2181ZZ	Fluoroscopy of Left Internal Mammary Bypass Graft using Low Osmolar Contrast	Procedure	ICD-10-PCS
B218YZZ	Fluoroscopy of Left Internal Mammary Bypass Graft using Other Contrast	Procedure	ICD-10-PCS
B21F0ZZ	Fluoroscopy of Other Bypass Graft using High Osmolar Contrast	Procedure	ICD-10-PCS
B21F1ZZ	Fluoroscopy of Other Bypass Graft using Low Osmolar Contrast	Procedure	ICD-10-PCS
B21FYZZ	Fluoroscopy of Other Bypass Graft using Other Contrast	Procedure	ICD-10-PCS
C1034	Catheter, coronary angioplasty, surpass superfusion catheter, long 30 surpass superfusion catheter	Procedure	HCPCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
C1100	Guide wire, percutaneous transluminal coronary angioplasty, medtronic ave gt1 guide wire, medtronic ave gt2 fusion guide wire, interventional technologies trackwire, interventional technologies trackwire support, interventional technologies trackwire extra support	Procedure	HCPCS
C1101	Catheter, percutaneous transluminal coronary angioplasty guide, medtronic ave 5f, 6f, 7f, 8f, 9f zuma guide catheter, medtronic ave z2 5f, 6f, 7f, 8f, 9f zuma guide catheter, medtronic ave vector guide catheter, medtronic ave vector x guide catheter. note: only the medtronic ave z2 zuma guide catheters are effective october 1, 2000. the medtronic ave zuma guide catheters were effective august 1, 2000.	Procedure	HCPCS
C1366	Guide wire, percutaneous transluminal coronary angioplasty, hi-torque iron man, hi-torque balance middleweight, hi-torque all star, hi-torque balance heavyweight, hi-torque balance trek	Procedure	HCPCS
C1367	Guide wire, percutaneous transluminal coronary angioplasty, hi-torque cross it, hi-torque cross-it 100xt, hi-torque cross-it 200xt, hi-torque cross-it 300xt, hi-torque wiggle	Procedure	HCPCS
C1500	Atherectomy system, peripheral, rotablator rotational angioplasty system with rotalink exchangeable catheter, advancer, and guide wire	Procedure	HCPCS
C1725	Catheter, transluminal angioplasty, nonlaser (may include guidance, infusion/perfusion capability)	Procedure	HCPCS
C1885	Catheter, transluminal angioplasty, laser	Procedure	HCPCS
C1930	Catheter, percutaneous transluminal coronary angioplasty, coyote dilatation catheter 20mm/30mm/40mm	Procedure	HCPCS
C1933	Catheter, opti-plast centurion 5.5f pta catheter (shaft length 50 cm to 120 cm), opti-plast xl 5.5f pta catheter (shaft length 75 cm to 120 cm), opti-plast pta catheter (5.5 fr), tru trac 5fr percutaneous transluminal angioplasty balloon dilatation catheter, optiplast xt 5 fr percutaneous transluminal angioplasty catheter (various sizes)	Procedure	HCPCS
C1948	Catheter, pursuit balloon angioplasty catheter, cook accent balloon angioplasty catheter	Procedure	HCPCS
C1981	Catheter ,coronary angioplasty balloon, adante, bonnie, bonnie 15mm, bonnie monorail 30mm or 40mm, bonnie sliding rail, bypass speedy, chubby, chubby sliding rail, coyote 20mm, coyote 9/15/25mm, maxxum, nc ranger, nc ranger 9mm, ranger 20mm, long ranger 30mm or 40mm, nc ranger 16/18mm, nc ranger 22/25/30mm, nc big ranger, quantum ranger, quantum ranger 1/4 sizes, quantum ranger 9/16/18mm, quantum ranger 22/30mm, quantum ranger 25mm, ranger lp 20/30/40, viva/long viva, ace - 1cm, ace - 2cm, ace graft, long ace, pivot cobra (10, 14, 18, 30, 40mm in lengths) note: only the bonnie monorail 30mm or	Procedure	HCPCS
C2605	Catheter, spectranetics extreme laser catheter, spectranetics extreme 0.9mm coronary angioplasty catheter (model 110-001)	Procedure	HCPCS
C2623	Catheter, transluminal angioplasty, drug-coated, nonlaser	Procedure	HCPCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
C3551	Guide wire, percutaneous transluminal coronary angioplasty, choice, luge, patriot, pt graphix intermediate, trooper, mailman 182/300 cm, glidewire gold guidewire, platinum plus guidewire, platinum plus guidewire with glidex hydrophilic coating, jagwire single-use high performance guide wire, merit medical systems extender guidewire, merit medical systems tomcat ptca guidewire, platinum plus guidewire (0.014 and 0.018 in diameters)	Procedure	HCPCS
C8526	Optiplast xt 5f percutaneous transluminal angioplasty catheter (various sizes)	Procedure	HCPCS
C9600	Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	Procedure	HCPCS
C9601	Percutaneous transcatheter placement of drug-eluting intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9602	Percutaneous transluminal coronary atherectomy, with drug eluting intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	HCPCS
C9603	Percutaneous transluminal coronary atherectomy, with drug-eluting intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9604	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single vessel	Procedure	HCPCS
C9605	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each additional branch subtended by the bypass graft (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9606	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel	Procedure	HCPCS
C9607	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; single vessel	Procedure	HCPCS
C9608	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; each additional coronary artery, coronary artery branch, or bypass graft (list separately in addition to code for primary procedure)	Procedure	HCPCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
D3450	root amputation - per root	Procedure	HCPCS
G0290	Transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; single vessel	Procedure	HCPCS
G0291	Transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; each additional vessel	Procedure	HCPCS
G45	Transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G9639	Major amputation or open surgical bypass not required within 48 hours of the index endovascular lower extremity revascularization procedure	Procedure	HCPCS
G9641	Major amputation or open surgical bypass required within 48 hours of the index endovascular lower extremity revascularization procedure	Procedure	HCPCS
I20	Angina pectoris	Diagnosis	ICD-10-CM
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.9	Angina pectoris, unspecified	Diagnosis	ICD-10-CM
I21	Acute myocardial infarction	Diagnosis	ICD-10-CM
I21.0	ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.1	ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.2	ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A	Other type of myocardial infarction	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction Type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22	Subsequent ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I24	Other acute ischemic heart diseases	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
I25.11	Atherosclerotic heart disease of native coronary artery with angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
I25.7	Atherosclerosis of coronary artery bypass graft(s) and coronary artery of transplanted heart with angina pectoris	Diagnosis	ICD-10-CM
I25.70	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris	Diagnosis	ICD-10-CM
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.71	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.72	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.73	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.75	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I25.76	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.79	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I46.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM
I46.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM
I46.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
I47.0	Re-entry ventricular arrhythmia	Diagnosis	ICD-10-CM
I47.2	Ventricular tachycardia	Diagnosis	ICD-10-CM
I60	Nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.0	Nontraumatic subarachnoid hemorrhage from carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.1	Nontraumatic subarachnoid hemorrhage from middle cerebral artery	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
I60.3	Nontraumatic subarachnoid hemorrhage from posterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.5	Nontraumatic subarachnoid hemorrhage from vertebral artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61	Nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62	Other and unspecified nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I62.0	Nontraumatic subdural hemorrhage	Diagnosis	ICD-10-CM
I62.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.03	Nontraumatic chronic subdural hemorrhage	Diagnosis	ICD-10-CM
I62.1	Nontraumatic extradural hemorrhage	Diagnosis	ICD-10-CM
I62.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63	Cerebral infarction	Diagnosis	ICD-10-CM
I63.0	Cerebral infarction due to thrombosis of precerebral arteries	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.01	Cerebral infarction due to thrombosis of vertebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.03	Cerebral infarction due to thrombosis of carotid artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
I63.1	Cerebral infarction due to embolism of precerebral arteries	Diagnosis	ICD-10-CM
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.11	Cerebral infarction due to embolism of vertebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.13	Cerebral infarction due to embolism of carotid artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.2	Cerebral infarction due to unspecified occlusion or stenosis of precerebral arteries	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
I63.21	Cerebral infarction due to unspecified occlusion or stenosis of vertebral arteries	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.23	Cerebral infarction due to unspecified occlusion or stenosis of carotid arteries	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid artery	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I63.3	Cerebral infarction due to thrombosis of cerebral arteries	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.31	Cerebral infarction due to thrombosis of middle cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.32	Cerebral infarction due to thrombosis of anterior cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.33	Cerebral infarction due to thrombosis of posterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction due to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.34	Cerebral infarction due to thrombosis of cerebellar artery	Diagnosis	ICD-10-CM
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction due to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.4	Cerebral infarction due to embolism of cerebral arteries	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.41	Cerebral infarction due to embolism of middle cerebral artery	Diagnosis	ICD-10-CM
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.42	Cerebral infarction due to embolism of anterior cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.43	Cerebral infarction due to embolism of posterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.44	Cerebral infarction due to embolism of cerebellar artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.5	Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.51	Cerebral infarction due to unspecified occlusion or stenosis of middle cerebral artery	Diagnosis	ICD-10-CM
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.52	Cerebral infarction due to unspecified occlusion or stenosis of anterior cerebral artery	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.53	Cerebral infarction due to unspecified occlusion or stenosis of posterior cerebral artery	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I63.54	Cerebral infarction due to unspecified occlusion or stenosis of cerebellar artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I65	Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction	Diagnosis	ICD-10-CM
I65.0	Occlusion and stenosis of vertebral artery	Diagnosis	ICD-10-CM
I65.01	Occlusion and stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I65.02	Occlusion and stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I65.03	Occlusion and stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I65.09	Occlusion and stenosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I65.1	Occlusion and stenosis of basilar artery	Diagnosis	ICD-10-CM
I65.2	Occlusion and stenosis of carotid artery	Diagnosis	ICD-10-CM
I65.21	Occlusion and stenosis of right carotid artery	Diagnosis	ICD-10-CM
I65.22	Occlusion and stenosis of left carotid artery	Diagnosis	ICD-10-CM
I65.23	Occlusion and stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I65.29	Occlusion and stenosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I65.8	Occlusion and stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I65.9	Occlusion and stenosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I66	Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction	Diagnosis	ICD-10-CM
I66.0	Occlusion and stenosis of middle cerebral artery	Diagnosis	ICD-10-CM
I66.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I66.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I66.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I66.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I66.1	Occlusion and stenosis of anterior cerebral artery	Diagnosis	ICD-10-CM
I66.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I66.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I66.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I66.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I66.2	Occlusion and stenosis of posterior cerebral artery	Diagnosis	ICD-10-CM
I66.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I66.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I66.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I66.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I66.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM
I66.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
I66.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I67	Other cerebrovascular diseases	Diagnosis	ICD-10-CM
I67.0	Dissection of cerebral arteries, nonruptured	Diagnosis	ICD-10-CM
I67.1	Cerebral aneurysm, nonruptured	Diagnosis	ICD-10-CM
I67.2	Cerebral atherosclerosis	Diagnosis	ICD-10-CM
I67.3	Progressive vascular leukoencephalopathy	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
I67.5	Moyamoya disease	Diagnosis	ICD-10-CM
I67.7	Cerebral arteritis, not elsewhere classified	Diagnosis	ICD-10-CM
I67.8	Other specified cerebrovascular diseases	Diagnosis	ICD-10-CM
I67.81	Acute cerebrovascular insufficiency	Diagnosis	ICD-10-CM
I67.82	Cerebral ischemia	Diagnosis	ICD-10-CM
I67.83	Posterior reversible encephalopathy syndrome	Diagnosis	ICD-10-CM
I67.84	Cerebral vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.85	Hereditary cerebrovascular diseases	Diagnosis	ICD-10-CM
I67.850	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy	Diagnosis	ICD-10-CM
I67.858	Other hereditary cerebrovascular disease	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I67.9	Cerebrovascular disease, unspecified	Diagnosis	ICD-10-CM
I68	Cerebrovascular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
I68.0	Cerebral amyloid angiopathy	Diagnosis	ICD-10-CM
I68.2	Cerebral arteritis in other diseases classified elsewhere	Diagnosis	ICD-10-CM
I68.8	Other cerebrovascular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
I69	Sequelae of cerebrovascular disease	Diagnosis	ICD-10-CM
I69.0	Sequelae of nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I69.00	Unspecified sequelae of nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.01	Cognitive deficits following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.010	Attention and concentration deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.011	Memory deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.012	Visuospatial deficit and spatial neglect following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.013	Psychomotor deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.014	Frontal lobe and executive function deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.015	Cognitive social or emotional deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.018	Other symptoms and signs involving cognitive functions following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.019	Unspecified symptoms and signs involving cognitive functions following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.02	Speech and language deficits following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.020	Aphasia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.021	Dysphasia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.022	Dysarthria following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.023	Fluency disorder following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.028	Other speech and language deficits following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.03	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.031	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.032	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.033	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.034	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.039	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.04	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.041	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.042	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I69.043	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.044	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.049	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.05	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.051	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.052	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.053	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.054	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.059	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.06	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.061	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.062	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.063	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.064	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.065	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage, bilateral	Diagnosis	ICD-10-CM
I69.069	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.09	Other sequelae of nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.090	Apraxia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.091	Dysphagia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.092	Facial weakness following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.093	Ataxia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.098	Other sequelae following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I69.1	Sequelae of nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.10	Unspecified sequelae of nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.11	Cognitive deficits following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.110	Attention and concentration deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.111	Memory deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.112	Visuospatial deficit and spatial neglect following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.113	Psychomotor deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.114	Frontal lobe and executive function deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.115	Cognitive social or emotional deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.118	Other symptoms and signs involving cognitive functions following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.119	Unspecified symptoms and signs involving cognitive functions following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.12	Speech and language deficits following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.120	Aphasia following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.121	Dysphasia following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.122	Dysarthria following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.123	Fluency disorder following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.128	Other speech and language deficits following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.13	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.131	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.132	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.133	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.134	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.139	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.14	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.141	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.142	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I69.143	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.144	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.149	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.15	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.151	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.152	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.153	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.154	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.159	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.16	Other paralytic syndrome following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.161	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.162	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.163	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.164	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.165	Other paralytic syndrome following nontraumatic intracerebral hemorrhage, bilateral	Diagnosis	ICD-10-CM
I69.169	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.19	Other sequelae of nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.190	Apraxia following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.191	Dysphagia following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.192	Facial weakness following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.193	Ataxia following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.198	Other sequelae of nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I69.2	Sequelae of other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.20	Unspecified sequelae of other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.21	Cognitive deficits following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.210	Attention and concentration deficit following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.211	Memory deficit following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.212	Visuospatial deficit and spatial neglect following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.213	Psychomotor deficit following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.214	Frontal lobe and executive function deficit following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.215	Cognitive social or emotional deficit following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.218	Other symptoms and signs involving cognitive functions following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.219	Unspecified symptoms and signs involving cognitive functions following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.22	Speech and language deficits following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.220	Aphasia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.221	Dysphasia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.222	Dysarthria following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.223	Fluency disorder following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.228	Other speech and language deficits following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.23	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.231	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.232	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.233	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.234	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.239	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.24	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.241	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I69.242	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.243	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.244	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.249	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.25	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.251	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.252	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.253	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.254	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.259	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.26	Other paralytic syndrome following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.261	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.262	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.263	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.264	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.265	Other paralytic syndrome following other nontraumatic intracranial hemorrhage, bilateral	Diagnosis	ICD-10-CM
I69.269	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.29	Other sequelae of other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.290	Apraxia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.291	Dysphagia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.292	Facial weakness following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I69.293	Ataxia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.298	Other sequelae of other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.8	Sequelae of other cerebrovascular diseases	Diagnosis	ICD-10-CM
I69.80	Unspecified sequelae of other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.81	Cognitive deficits following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.810	Attention and concentration deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.811	Memory deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.812	Visuospatial deficit and spatial neglect following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.813	Psychomotor deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.814	Frontal lobe and executive function deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.815	Cognitive social or emotional deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.818	Other symptoms and signs involving cognitive functions following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.819	Unspecified symptoms and signs involving cognitive functions following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.82	Speech and language deficits following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.820	Aphasia following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.821	Dysphasia following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.822	Dysarthria following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.823	Fluency disorder following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.828	Other speech and language deficits following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.83	Monoplegia of upper limb following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.831	Monoplegia of upper limb following other cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.832	Monoplegia of upper limb following other cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
I69.833	Monoplegia of upper limb following other cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.834	Monoplegia of upper limb following other cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.839	Monoplegia of upper limb following other cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.84	Monoplegia of lower limb following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.841	Monoplegia of lower limb following other cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.842	Monoplegia of lower limb following other cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I69.843	Monoplegia of lower limb following other cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.844	Monoplegia of lower limb following other cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.849	Monoplegia of lower limb following other cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.85	Hemiplegia and hemiparesis following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.851	Hemiplegia and hemiparesis following other cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.852	Hemiplegia and hemiparesis following other cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
I69.853	Hemiplegia and hemiparesis following other cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.854	Hemiplegia and hemiparesis following other cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.859	Hemiplegia and hemiparesis following other cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.86	Other paralytic syndrome following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.861	Other paralytic syndrome following other cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.862	Other paralytic syndrome following other cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
I69.863	Other paralytic syndrome following other cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.864	Other paralytic syndrome following other cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.865	Other paralytic syndrome following other cerebrovascular disease, bilateral	Diagnosis	ICD-10-CM
I69.869	Other paralytic syndrome following other cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.89	Other sequelae of other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.890	Apraxia following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.891	Dysphagia following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.892	Facial weakness following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.893	Ataxia following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.898	Other sequelae of other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.9	Sequelae of unspecified cerebrovascular diseases	Diagnosis	ICD-10-CM
I69.90	Unspecified sequelae of unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.91	Cognitive deficits following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I69.910	Attention and concentration deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.911	Memory deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.912	Visuospatial deficit and spatial neglect following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.913	Psychomotor deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.914	Frontal lobe and executive function deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.915	Cognitive social or emotional deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.918	Other symptoms and signs involving cognitive functions following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.919	Unspecified symptoms and signs involving cognitive functions following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.92	Speech and language deficits following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.920	Aphasia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.921	Dysphasia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.922	Dysarthria following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.923	Fluency disorder following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.928	Other speech and language deficits following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.93	Monoplegia of upper limb following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.931	Monoplegia of upper limb following unspecified cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.932	Monoplegia of upper limb following unspecified cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
I69.933	Monoplegia of upper limb following unspecified cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.934	Monoplegia of upper limb following unspecified cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.939	Monoplegia of upper limb following unspecified cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.94	Monoplegia of lower limb following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.941	Monoplegia of lower limb following unspecified cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.942	Monoplegia of lower limb following unspecified cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
I69.943	Monoplegia of lower limb following unspecified cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I69.944	Monoplegia of lower limb following unspecified cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.949	Monoplegia of lower limb following unspecified cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.95	Hemiplegia and hemiparesis following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.951	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.952	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
I69.953	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.954	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.959	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.96	Other paralytic syndrome following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.961	Other paralytic syndrome following unspecified cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.962	Other paralytic syndrome following unspecified cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
I69.963	Other paralytic syndrome following unspecified cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.964	Other paralytic syndrome following unspecified cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.965	Other paralytic syndrome following unspecified cerebrovascular disease, bilateral	Diagnosis	ICD-10-CM
I69.969	Other paralytic syndrome following unspecified cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.99	Other sequelae of unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.990	Apraxia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.991	Dysphagia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.992	Facial weakness following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.993	Ataxia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.998	Other sequelae following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I70.2	Atherosclerosis of native arteries of the extremities	Diagnosis	ICD-10-CM
I70.20	Unspecified atherosclerosis of native arteries of extremities	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I70.201	Unspecified atherosclerosis of native arteries of extremities, right leg	Diagnosis	ICD-10-CM
I70.202	Unspecified atherosclerosis of native arteries of extremities, left leg	Diagnosis	ICD-10-CM
I70.203	Unspecified atherosclerosis of native arteries of extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.208	Unspecified atherosclerosis of native arteries of extremities, other extremity	Diagnosis	ICD-10-CM
I70.209	Unspecified atherosclerosis of native arteries of extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.21	Atherosclerosis of native arteries of extremities with intermittent claudication	Diagnosis	ICD-10-CM
I70.211	Atherosclerosis of native arteries of extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
I70.212	Atherosclerosis of native arteries of extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
I70.213	Atherosclerosis of native arteries of extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
I70.218	Atherosclerosis of native arteries of extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
I70.219	Atherosclerosis of native arteries of extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
I70.22	Atherosclerosis of native arteries of extremities with rest pain	Diagnosis	ICD-10-CM
I70.221	Atherosclerosis of native arteries of extremities with rest pain, right leg	Diagnosis	ICD-10-CM
I70.222	Atherosclerosis of native arteries of extremities with rest pain, left leg	Diagnosis	ICD-10-CM
I70.223	Atherosclerosis of native arteries of extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
I70.228	Atherosclerosis of native arteries of extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
I70.229	Atherosclerosis of native arteries of extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
I70.23	Atherosclerosis of native arteries of right leg with ulceration	Diagnosis	ICD-10-CM
I70.231	Atherosclerosis of native arteries of right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.232	Atherosclerosis of native arteries of right leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.233	Atherosclerosis of native arteries of right leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.234	Atherosclerosis of native arteries of right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.235	Atherosclerosis of native arteries of right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.238	Atherosclerosis of native arteries of right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.239	Atherosclerosis of native arteries of right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.24	Atherosclerosis of native arteries of left leg with ulceration	Diagnosis	ICD-10-CM
I70.241	Atherosclerosis of native arteries of left leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.242	Atherosclerosis of native arteries of left leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.243	Atherosclerosis of native arteries of left leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.244	Atherosclerosis of native arteries of left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.245	Atherosclerosis of native arteries of left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.248	Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.249	Atherosclerosis of native arteries of left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.25	Atherosclerosis of native arteries of other extremities with ulceration	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I70.26	Atherosclerosis of native arteries of extremities with gangrene	Diagnosis	ICD-10-CM
I70.261	Atherosclerosis of native arteries of extremities with gangrene, right leg	Diagnosis	ICD-10-CM
I70.262	Atherosclerosis of native arteries of extremities with gangrene, left leg	Diagnosis	ICD-10-CM
I70.263	Atherosclerosis of native arteries of extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
I70.268	Atherosclerosis of native arteries of extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
I70.269	Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
I70.29	Other atherosclerosis of native arteries of extremities	Diagnosis	ICD-10-CM
I70.291	Other atherosclerosis of native arteries of extremities, right leg	Diagnosis	ICD-10-CM
I70.292	Other atherosclerosis of native arteries of extremities, left leg	Diagnosis	ICD-10-CM
I70.293	Other atherosclerosis of native arteries of extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.298	Other atherosclerosis of native arteries of extremities, other extremity	Diagnosis	ICD-10-CM
I70.299	Other atherosclerosis of native arteries of extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.3	Atherosclerosis of unspecified type of bypass graft(s) of the extremities	Diagnosis	ICD-10-CM
I70.30	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities	Diagnosis	ICD-10-CM
I70.301	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.302	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.303	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.308	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.309	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.31	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication	Diagnosis	ICD-10-CM
I70.311	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
I70.312	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
I70.313	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
I70.318	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
I70.319	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
I70.32	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I70.321	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
I70.322	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
I70.323	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
I70.328	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
I70.329	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
I70.33	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration	Diagnosis	ICD-10-CM
I70.331	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.332	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.333	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.334	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.335	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.338	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.339	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.34	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration	Diagnosis	ICD-10-CM
I70.341	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.342	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.343	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.344	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.345	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.348	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.349	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.35	Atherosclerosis of unspecified type of bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM
I70.36	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene	Diagnosis	ICD-10-CM
I70.361	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I70.362	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
I70.363	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
I70.368	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
I70.369	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
I70.39	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities	Diagnosis	ICD-10-CM
I70.391	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.392	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.393	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.398	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.399	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.4	Atherosclerosis of autologous vein bypass graft(s) of the extremities	Diagnosis	ICD-10-CM
I70.40	Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities	Diagnosis	ICD-10-CM
I70.401	Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.402	Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.403	Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.408	Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.409	Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.41	Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication	Diagnosis	ICD-10-CM
I70.411	Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
I70.412	Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
I70.413	Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
I70.418	Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
I70.419	Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I70.42	Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain	Diagnosis	ICD-10-CM
I70.421	Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
I70.422	Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
I70.423	Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
I70.428	Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
I70.429	Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
I70.43	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration	Diagnosis	ICD-10-CM
I70.431	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.432	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.433	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.434	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.435	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.438	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.439	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.44	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration	Diagnosis	ICD-10-CM
I70.441	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.442	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.443	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.444	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.445	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.448	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.449	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.45	Atherosclerosis of autologous vein bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM
I70.46	Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I70.461	Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
I70.462	Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
I70.463	Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
I70.468	Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
I70.469	Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
I70.49	Other atherosclerosis of autologous vein bypass graft(s) of the extremities	Diagnosis	ICD-10-CM
I70.491	Other atherosclerosis of autologous vein bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.492	Other atherosclerosis of autologous vein bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.493	Other atherosclerosis of autologous vein bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.498	Other atherosclerosis of autologous vein bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.499	Other atherosclerosis of autologous vein bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.5	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities	Diagnosis	ICD-10-CM
I70.50	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities	Diagnosis	ICD-10-CM
I70.501	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.502	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.503	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.508	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.509	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.51	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities intermittent claudication	Diagnosis	ICD-10-CM
I70.511	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
I70.512	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
I70.513	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I70.518	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
I70.519	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
I70.52	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain	Diagnosis	ICD-10-CM
I70.521	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
I70.522	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
I70.523	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
I70.528	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
I70.529	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
I70.53	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration	Diagnosis	ICD-10-CM
I70.531	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.532	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.533	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.534	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.535	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.538	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.539	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.54	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration	Diagnosis	ICD-10-CM
I70.541	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.542	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I70.543	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.544	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.545	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.548	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.549	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.55	Atherosclerosis of nonautologous biological bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM
I70.56	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene	Diagnosis	ICD-10-CM
I70.561	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
I70.562	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
I70.563	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
I70.568	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
I70.569	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
I70.59	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities	Diagnosis	ICD-10-CM
I70.591	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.592	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.593	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.598	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.599	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.6	Atherosclerosis of nonbiological bypass graft(s) of the extremities	Diagnosis	ICD-10-CM
I70.60	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities	Diagnosis	ICD-10-CM
I70.601	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.602	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I70.603	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.608	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.609	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.61	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication	Diagnosis	ICD-10-CM
I70.611	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
I70.612	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
I70.613	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
I70.618	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
I70.619	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
I70.62	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain	Diagnosis	ICD-10-CM
I70.621	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
I70.622	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
I70.623	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
I70.628	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
I70.629	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
I70.63	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration	Diagnosis	ICD-10-CM
I70.631	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.632	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.633	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.634	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.635	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.638	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I70.639	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.64	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration	Diagnosis	ICD-10-CM
I70.641	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.642	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.643	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.644	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.645	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.648	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.649	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.65	Atherosclerosis of nonbiological bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM
I70.66	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene	Diagnosis	ICD-10-CM
I70.661	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
I70.662	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
I70.663	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
I70.668	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
I70.669	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
I70.69	Other atherosclerosis of nonbiological bypass graft(s) of the extremities	Diagnosis	ICD-10-CM
I70.691	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.692	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.693	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.698	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.699	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.7	Atherosclerosis of other type of bypass graft(s) of the extremities	Diagnosis	ICD-10-CM
I70.70	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities	Diagnosis	ICD-10-CM
I70.701	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.702	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.703	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I70.708	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.709	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.71	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication	Diagnosis	ICD-10-CM
I70.711	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
I70.712	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
I70.713	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
I70.718	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
I70.719	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
I70.72	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain	Diagnosis	ICD-10-CM
I70.721	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
I70.722	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
I70.723	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
I70.728	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
I70.729	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
I70.73	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration	Diagnosis	ICD-10-CM
I70.731	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.732	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.733	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.734	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.735	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.738	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.739	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I70.74	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration	Diagnosis	ICD-10-CM
I70.741	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.742	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.743	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.744	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.745	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.748	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.749	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.75	Atherosclerosis of other type of bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM
I70.76	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene	Diagnosis	ICD-10-CM
I70.761	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
I70.762	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
I70.763	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
I70.768	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
I70.769	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
I70.79	Other atherosclerosis of other type of bypass graft(s) of the extremities	Diagnosis	ICD-10-CM
I70.791	Other atherosclerosis of other type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.792	Other atherosclerosis of other type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.793	Other atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.798	Other atherosclerosis of other type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.799	Other atherosclerosis of other type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.92	Chronic total occlusion of artery of the extremities	Diagnosis	ICD-10-CM
I73	Other peripheral vascular diseases	Diagnosis	ICD-10-CM
I73.8	Other specified peripheral vascular diseases	Diagnosis	ICD-10-CM
I73.89	Other specified peripheral vascular diseases	Diagnosis	ICD-10-CM
I73.9	Peripheral vascular disease, unspecified	Diagnosis	ICD-10-CM
I74	Arterial embolism and thrombosis	Diagnosis	ICD-10-CM
I74.0	Embolism and thrombosis of abdominal aorta	Diagnosis	ICD-10-CM
I74.01	Saddle embolus of abdominal aorta	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
I74.09	Other arterial embolism and thrombosis of abdominal aorta	Diagnosis	ICD-10-CM
I74.1	Embolism and thrombosis of other and unspecified parts of aorta	Diagnosis	ICD-10-CM
I74.10	Embolism and thrombosis of unspecified parts of aorta	Diagnosis	ICD-10-CM
I74.11	Embolism and thrombosis of thoracic aorta	Diagnosis	ICD-10-CM
I74.19	Embolism and thrombosis of other parts of aorta	Diagnosis	ICD-10-CM
I74.2	Embolism and thrombosis of arteries of the upper extremities	Diagnosis	ICD-10-CM
I74.3	Embolism and thrombosis of arteries of the lower extremities	Diagnosis	ICD-10-CM
I74.4	Embolism and thrombosis of arteries of extremities, unspecified	Diagnosis	ICD-10-CM
I74.5	Embolism and thrombosis of iliac artery	Diagnosis	ICD-10-CM
I74.8	Embolism and thrombosis of other arteries	Diagnosis	ICD-10-CM
I74.9	Embolism and thrombosis of unspecified artery	Diagnosis	ICD-10-CM
I75	Atheroembolism	Diagnosis	ICD-10-CM
I75.0	Atheroembolism of extremities	Diagnosis	ICD-10-CM
I75.01	Atheroembolism of upper extremity	Diagnosis	ICD-10-CM
I75.011	Atheroembolism of right upper extremity	Diagnosis	ICD-10-CM
I75.012	Atheroembolism of left upper extremity	Diagnosis	ICD-10-CM
I75.013	Atheroembolism of bilateral upper extremities	Diagnosis	ICD-10-CM
I75.019	Atheroembolism of unspecified upper extremity	Diagnosis	ICD-10-CM
I75.02	Atheroembolism of lower extremity	Diagnosis	ICD-10-CM
I75.021	Atheroembolism of right lower extremity	Diagnosis	ICD-10-CM
I75.022	Atheroembolism of left lower extremity	Diagnosis	ICD-10-CM
I75.023	Atheroembolism of bilateral lower extremities	Diagnosis	ICD-10-CM
I75.029	Atheroembolism of unspecified lower extremity	Diagnosis	ICD-10-CM
I75.8	Atheroembolism of other sites	Diagnosis	ICD-10-CM
I75.81	Atheroembolism of kidney	Diagnosis	ICD-10-CM
I75.89	Atheroembolism of other site	Diagnosis	ICD-10-CM
M62.2	Nontraumatic ischemic infarction of muscle	Diagnosis	ICD-10-CM
M62.20	Nontraumatic ischemic infarction of muscle, unspecified site	Diagnosis	ICD-10-CM
M62.21	Nontraumatic ischemic infarction of muscle, shoulder	Diagnosis	ICD-10-CM
M62.211	Nontraumatic ischemic infarction of muscle, right shoulder	Diagnosis	ICD-10-CM
M62.212	Nontraumatic ischemic infarction of muscle, left shoulder	Diagnosis	ICD-10-CM
M62.219	Nontraumatic ischemic infarction of muscle, unspecified shoulder	Diagnosis	ICD-10-CM
M62.22	Nontraumatic ischemic infarction of muscle, upper arm	Diagnosis	ICD-10-CM
M62.221	Nontraumatic ischemic infarction of muscle, right upper arm	Diagnosis	ICD-10-CM
M62.222	Nontraumatic ischemic infarction of muscle, left upper arm	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
M62.229	Nontraumatic ischemic infarction of muscle, unspecified upper arm	Diagnosis	ICD-10-CM
M62.23	Nontraumatic ischemic infarction of muscle, forearm	Diagnosis	ICD-10-CM
M62.231	Nontraumatic ischemic infarction of muscle, right forearm	Diagnosis	ICD-10-CM
M62.232	Nontraumatic ischemic infarction of muscle, left forearm	Diagnosis	ICD-10-CM
M62.239	Nontraumatic ischemic infarction of muscle, unspecified forearm	Diagnosis	ICD-10-CM
M62.24	Nontraumatic ischemic infarction of muscle, hand	Diagnosis	ICD-10-CM
M62.241	Nontraumatic ischemic infarction of muscle, right hand	Diagnosis	ICD-10-CM
M62.242	Nontraumatic ischemic infarction of muscle, left hand	Diagnosis	ICD-10-CM
M62.249	Nontraumatic ischemic infarction of muscle, unspecified hand	Diagnosis	ICD-10-CM
M62.25	Nontraumatic ischemic infarction of muscle, thigh	Diagnosis	ICD-10-CM
M62.251	Nontraumatic ischemic infarction of muscle, right thigh	Diagnosis	ICD-10-CM
M62.252	Nontraumatic ischemic infarction of muscle, left thigh	Diagnosis	ICD-10-CM
M62.259	Nontraumatic ischemic infarction of muscle, unspecified thigh	Diagnosis	ICD-10-CM
M62.26	Nontraumatic ischemic infarction of muscle, lower leg	Diagnosis	ICD-10-CM
M62.261	Nontraumatic ischemic infarction of muscle, right lower leg	Diagnosis	ICD-10-CM
M62.262	Nontraumatic ischemic infarction of muscle, left lower leg	Diagnosis	ICD-10-CM
M62.269	Nontraumatic ischemic infarction of muscle, unspecified lower leg	Diagnosis	ICD-10-CM
M62.27	Nontraumatic ischemic infarction of muscle, ankle and foot	Diagnosis	ICD-10-CM
M62.271	Nontraumatic ischemic infarction of muscle, right ankle and foot	Diagnosis	ICD-10-CM
M62.272	Nontraumatic ischemic infarction of muscle, left ankle and foot	Diagnosis	ICD-10-CM
M62.279	Nontraumatic ischemic infarction of muscle, unspecified ankle and foot	Diagnosis	ICD-10-CM
M62.28	Nontraumatic ischemic infarction of muscle, other site	Diagnosis	ICD-10-CM
Q28.0	Arteriovenous malformation of precerebral vessels	Diagnosis	ICD-10-CM
Q28.2	Arteriovenous malformation of cerebral vessels	Diagnosis	ICD-10-CM
S2205	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using arterial graft(s), single coronary arterial graft	Procedure	HCPCS
S2206	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using arterial graft(s), 2 coronary arterial grafts	Procedure	HCPCS
S2207	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using venous graft only, single coronary venous graft	Procedure	HCPCS

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
S2208	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using single arterial and venous graft(s), single venous graft	Procedure	HCPCS
S2209	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using 2 arterial grafts and single venous graft	Procedure	HCPCS
T81.718A	Complication of other artery following a procedure, not elsewhere classified, initial encounter	Diagnosis	ICD-10-CM
T82.817A	Embolism due to cardiac prosthetic devices, implants and grafts, initial encounter	Diagnosis	ICD-10-CM
V45.81	Postprocedural aortocoronary bypass status	Diagnosis	ICD-9-CM
V45.82	Postprocedural percutaneous transluminal coronary angioplasty status	Diagnosis	ICD-9-CM
X2C0361	Extirpation of Matter from Coronary Artery, One Artery using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1	Procedure	ICD-10-PCS
X2C1361	Extirpation of Matter from Coronary Artery, Two Arteries using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1	Procedure	ICD-10-PCS
X2C2361	Extirpation of Matter from Coronary Artery, Three Arteries using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1	Procedure	ICD-10-PCS
X2C3361	Extirpation of Matter from Coronary Artery, Four or More Arteries using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1	Procedure	ICD-10-PCS
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
	Cognitive Impairment		
290.0	Senile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.10	Presenile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.11	Presenile dementia with delirium	Diagnosis	ICD-9-CM
290.12	Presenile dementia with delusional features	Diagnosis	ICD-9-CM
290.13	Presenile dementia with depressive features	Diagnosis	ICD-9-CM
290.20	Senile dementia with delusional features	Diagnosis	ICD-9-CM
290.21	Senile dementia with depressive features	Diagnosis	ICD-9-CM
290.3	Senile dementia with delirium	Diagnosis	ICD-9-CM
290.40	Vascular dementia, uncomplicated	Diagnosis	ICD-9-CM
290.41	Vascular dementia, with delirium	Diagnosis	ICD-9-CM
290.42	Vascular dementia, with delusions	Diagnosis	ICD-9-CM
290.43	Vascular dementia, with depressed mood	Diagnosis	ICD-9-CM
294.0	Amnestic disorder in conditions classified elsewhere	Diagnosis	ICD-9-CM
294.10	Dementia in conditions classified elsewhere without behavioral disturbance	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
294.11	Dementia in conditions classified elsewhere with behavioral disturbance	Diagnosis	ICD-9-CM
294.20	Dementia, unspecified, without behavioral disturbance	Diagnosis	ICD-9-CM
294.21	Dementia, unspecified, with behavioral disturbance	Diagnosis	ICD-9-CM
294.8	Other persistent mental disorders due to conditions classified elsewhere	Diagnosis	ICD-9-CM
331.0	Alzheimer's disease	Diagnosis	ICD-9-CM
331.11	Pick's disease	Diagnosis	ICD-9-CM
331.19	Other frontotemporal dementia	Diagnosis	ICD-9-CM
331.2	Senile degeneration of brain	Diagnosis	ICD-9-CM
331.7	Cerebral degeneration in diseases classified elsewhere	Diagnosis	ICD-9-CM
797	Senility without mention of psychosis	Diagnosis	ICD-9-CM
F01.50	Vascular dementia, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.51	Vascular dementia, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM
F02.80	Dementia in other diseases classified elsewhere, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F02.81	Dementia in other diseases classified elsewhere, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM
F03.90	Unspecified dementia, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM
F04	Amnestic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
F06.1	Catatonic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F06.8	Other specified mental disorders due to known physiological condition	Diagnosis	ICD-10-CM
G13.8	Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere	Diagnosis	ICD-10-CM
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal neurocognitive disorder	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM
R54	Age-related physical debility	Diagnosis	ICD-10-CM
	Traumatic Brain Injury		
310	Specific nonpsychotic mental disorders due to brain damage	Diagnosis	ICD-9-CM
310.0	Frontal lobe syndrome	Diagnosis	ICD-9-CM
310.1	Personality change due to conditions classified elsewhere	Diagnosis	ICD-9-CM
310.2	Postconcussion syndrome	Diagnosis	ICD-9-CM
310.8	Other specified nonpsychotic mental disorder following organic brain damage	Diagnosis	ICD-9-CM
310.81	Pseudobulbar affect	Diagnosis	ICD-9-CM
310.89	Other specified nonpsychotic mental disorders following organic brain damage	Diagnosis	ICD-9-CM
907	Late effects of injuries to the nervous system	Diagnosis	ICD-9-CM
907.0	Late effect of intracranial injury without mention of skull fracture	Diagnosis	ICD-9-CM
907.1	Late effect of injury to cranial nerve	Diagnosis	ICD-9-CM
F07.0	Personality change due to known physiological condition	Diagnosis	ICD-10-CM
F07.81	Postconcussional syndrome	Diagnosis	ICD-10-CM
F07.89	Other personality and behavioral disorders due to known physiological condition	Diagnosis	ICD-10-CM
F48.2	Pseudobulbar affect	Diagnosis	ICD-10-CM
S04.011S	Injury of optic nerve, right eye, sequela	Diagnosis	ICD-10-CM
S04.012S	Injury of optic nerve, left eye, sequela	Diagnosis	ICD-10-CM
S04.019S	Injury of optic nerve, unspecified eye, sequela	Diagnosis	ICD-10-CM
S04.02XS	Injury of optic chiasm, sequela	Diagnosis	ICD-10-CM
S04.031S	Injury of optic tract and pathways, right side, sequela	Diagnosis	ICD-10-CM
S04.032S	Injury of optic tract and pathways, left side, sequela	Diagnosis	ICD-10-CM
S04.039S	Injury of optic tract and pathways, unspecified side, sequela	Diagnosis	ICD-10-CM
S04.041S	Injury of visual cortex, right side, sequela	Diagnosis	ICD-10-CM
S04.042S	Injury of visual cortex, left side, sequela	Diagnosis	ICD-10-CM
S04.049S	Injury of visual cortex, unspecified side, sequela	Diagnosis	ICD-10-CM
S04.10XS	Injury of oculomotor nerve, unspecified side, sequela	Diagnosis	ICD-10-CM
S04.11XS	Injury of oculomotor nerve, right side, sequela	Diagnosis	ICD-10-CM
S04.12XS	Injury of oculomotor nerve, left side, sequela	Diagnosis	ICD-10-CM
S04.20XS	Injury of trochlear nerve, unspecified side, sequela	Diagnosis	ICD-10-CM
S04.21XS	Injury of trochlear nerve, right side, sequela	Diagnosis	ICD-10-CM
S04.22XS	Injury of trochlear nerve, left side, sequela	Diagnosis	ICD-10-CM
S04.30XS	Injury of trigeminal nerve, unspecified side, sequela	Diagnosis	ICD-10-CM
S04.31XS	Injury of trigeminal nerve, right side, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
S04.32XS	Injury of trigeminal nerve, left side, sequela	Diagnosis	ICD-10-CM
S04.40XS	Injury of abducent nerve, unspecified side, sequela	Diagnosis	ICD-10-CM
S04.41XS	Injury of abducent nerve, right side, sequela	Diagnosis	ICD-10-CM
S04.42XS	Injury of abducent nerve, left side, sequela	Diagnosis	ICD-10-CM
S04.50XS	Injury of facial nerve, unspecified side, sequela	Diagnosis	ICD-10-CM
S04.51XS	Injury of facial nerve, right side, sequela	Diagnosis	ICD-10-CM
S04.52XS	Injury of facial nerve, left side, sequela	Diagnosis	ICD-10-CM
S04.60XS	Injury of acoustic nerve, unspecified side, sequela	Diagnosis	ICD-10-CM
S04.61XS	Injury of acoustic nerve, right side, sequela	Diagnosis	ICD-10-CM
S04.62XS	Injury of acoustic nerve, left side, sequela	Diagnosis	ICD-10-CM
S04.70XS	Injury of accessory nerve, unspecified side, sequela	Diagnosis	ICD-10-CM
S04.71XS	Injury of accessory nerve, right side, sequela	Diagnosis	ICD-10-CM
S04.72XS	Injury of accessory nerve, left side, sequela	Diagnosis	ICD-10-CM
S04.811S	Injury of olfactory [1st] nerve, right side, sequela	Diagnosis	ICD-10-CM
S04.812S	Injury of olfactory [1st] nerve, left side, sequela	Diagnosis	ICD-10-CM
S04.819S	Injury of olfactory [1st] nerve, unspecified side, sequela	Diagnosis	ICD-10-CM
S04.891S	Injury of other cranial nerves, right side, sequela	Diagnosis	ICD-10-CM
S04.892S	Injury of other cranial nerves, left side, sequela	Diagnosis	ICD-10-CM
S04.899S	Injury of other cranial nerves, unspecified side, sequela	Diagnosis	ICD-10-CM
S04.9XXS	Injury of unspecified cranial nerve, sequela	Diagnosis	ICD-10-CM
S06.0X0S	Concussion without loss of consciousness, sequela	Diagnosis	ICD-10-CM
S06.0X1S	Concussion with loss of consciousness of 30 minutes or less, sequela	Diagnosis	ICD-10-CM
S06.0X2S	Concussion with loss of consciousness of 31 minutes to 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.0X3S	Concussion with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.0X4S	Concussion with loss of consciousness of 6 hours to 24 hours, sequela	Diagnosis	ICD-10-CM
S06.0X5S	Concussion with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela	Diagnosis	ICD-10-CM
S06.0X6S	Concussion with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela	Diagnosis	ICD-10-CM
S06.0X7S	Concussion with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.0X8S	Concussion with loss of consciousness of any duration with death due to other cause prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.0X9S	Concussion with loss of consciousness of unspecified duration, sequela	Diagnosis	ICD-10-CM
S06.0XAS	Concussion with loss of consciousness status unknown, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
S06.1X0S	Traumatic cerebral edema without loss of consciousness, sequela	Diagnosis	ICD-10-CM
S06.1X1S	Traumatic cerebral edema with loss of consciousness of 30 minutes or less, sequela	Diagnosis	ICD-10-CM
S06.1X2S	Traumatic cerebral edema with loss of consciousness of 31 minutes to 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.1X3S	Traumatic cerebral edema with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.1X4S	Traumatic cerebral edema with loss of consciousness of 6 hours to 24 hours, sequela	Diagnosis	ICD-10-CM
S06.1X5S	Traumatic cerebral edema with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela	Diagnosis	ICD-10-CM
S06.1X6S	Traumatic cerebral edema with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela	Diagnosis	ICD-10-CM
S06.1X7S	Traumatic cerebral edema with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.1X8S	Traumatic cerebral edema with loss of consciousness of any duration with death due to other cause prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.1X9S	Traumatic cerebral edema with loss of consciousness of unspecified duration, sequela	Diagnosis	ICD-10-CM
S06.1XAS	Traumatic cerebral edema with loss of consciousness status unknown, sequela	Diagnosis	ICD-10-CM
S06.2X0S	Diffuse traumatic brain injury without loss of consciousness, sequela	Diagnosis	ICD-10-CM
S06.2X1S	Diffuse traumatic brain injury with loss of consciousness of 30 minutes or less, sequela	Diagnosis	ICD-10-CM
S06.2X2S	Diffuse traumatic brain injury with loss of consciousness of 31 minutes to 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.2X3S	Diffuse traumatic brain injury with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.2X4S	Diffuse traumatic brain injury with loss of consciousness of 6 hours to 24 hours, sequela	Diagnosis	ICD-10-CM
S06.2X5S	Diffuse traumatic brain injury with loss of consciousness greater than 24 hours with return to pre-existing conscious levels, sequela	Diagnosis	ICD-10-CM
S06.2X6S	Diffuse traumatic brain injury with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela	Diagnosis	ICD-10-CM
S06.2X7S	Diffuse traumatic brain injury with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.2X8S	Diffuse traumatic brain injury with loss of consciousness of any duration with death due to other cause prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.2X9S	Diffuse traumatic brain injury with loss of consciousness of unspecified duration, sequela	Diagnosis	ICD-10-CM
S06.2XAS	Diffuse traumatic brain injury with loss of consciousness status unknown, sequela	Diagnosis	ICD-10-CM
S06.300S	Unspecified focal traumatic brain injury without loss of consciousness, sequela	Diagnosis	ICD-10-CM
S06.301S	Unspecified focal traumatic brain injury with loss of consciousness of 30 minutes or less, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
S06.302S	Unspecified focal traumatic brain injury with loss of consciousness of 31 minutes to 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.303S	Unspecified focal traumatic brain injury with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.304S	Unspecified focal traumatic brain injury with loss of consciousness of 6 hours to 24 hours, sequela	Diagnosis	ICD-10-CM
S06.305S	Unspecified focal traumatic brain injury with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela	Diagnosis	ICD-10-CM
S06.306S	Unspecified focal traumatic brain injury with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela	Diagnosis	ICD-10-CM
S06.307S	Unspecified focal traumatic brain injury with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.308S	Unspecified focal traumatic brain injury with loss of consciousness of any duration with death due to other cause prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.309S	Unspecified focal traumatic brain injury with loss of consciousness of unspecified duration, sequela	Diagnosis	ICD-10-CM
S06.30AS	Unspecified focal traumatic brain injury with loss of consciousness status unknown, sequela	Diagnosis	ICD-10-CM
S06.310S	Contusion and laceration of right cerebrum without loss of consciousness, sequela	Diagnosis	ICD-10-CM
S06.311S	Contusion and laceration of right cerebrum with loss of consciousness of 30 minutes or less, sequela	Diagnosis	ICD-10-CM
S06.312S	Contusion and laceration of right cerebrum with loss of consciousness of 31 minutes to 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.313S	Contusion and laceration of right cerebrum with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.314S	Contusion and laceration of right cerebrum with loss of consciousness of 6 hours to 24 hours, sequela	Diagnosis	ICD-10-CM
S06.315S	Contusion and laceration of right cerebrum with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela	Diagnosis	ICD-10-CM
S06.316S	Contusion and laceration of right cerebrum with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela	Diagnosis	ICD-10-CM
S06.317S	Contusion and laceration of right cerebrum with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.318S	Contusion and laceration of right cerebrum with loss of consciousness of any duration with death due to other cause prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
S06.319S	Contusion and laceration of right cerebrum with loss of consciousness of unspecified duration, sequela	Diagnosis	ICD-10-CM
S06.31AS	Contusion and laceration of right cerebrum with loss of consciousness status unknown, sequela	Diagnosis	ICD-10-CM
S06.320S	Contusion and laceration of left cerebrum without loss of consciousness, sequela	Diagnosis	ICD-10-CM
S06.321S	Contusion and laceration of left cerebrum with loss of consciousness of 30 minutes or less, sequela	Diagnosis	ICD-10-CM
S06.322S	Contusion and laceration of left cerebrum with loss of consciousness of 31 minutes to 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.323S	Contusion and laceration of left cerebrum with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.324S	Contusion and laceration of left cerebrum with loss of consciousness of 6 hours to 24 hours, sequela	Diagnosis	ICD-10-CM
S06.325S	Contusion and laceration of left cerebrum with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela	Diagnosis	ICD-10-CM
S06.326S	Contusion and laceration of left cerebrum with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela	Diagnosis	ICD-10-CM
S06.327S	Contusion and laceration of left cerebrum with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.328S	Contusion and laceration of left cerebrum with loss of consciousness of any duration with death due to other cause prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.329S	Contusion and laceration of left cerebrum with loss of consciousness of unspecified duration, sequela	Diagnosis	ICD-10-CM
S06.32AS	Contusion and laceration of left cerebrum with loss of consciousness status unknown, sequela	Diagnosis	ICD-10-CM
S06.330S	Contusion and laceration of cerebrum, unspecified, without loss of consciousness, sequela	Diagnosis	ICD-10-CM
S06.331S	Contusion and laceration of cerebrum, unspecified, with loss of consciousness of 30 minutes or less, sequela	Diagnosis	ICD-10-CM
S06.332S	Contusion and laceration of cerebrum, unspecified, with loss of consciousness of 31 minutes to 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.333S	Contusion and laceration of cerebrum, unspecified, with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.334S	Contusion and laceration of cerebrum, unspecified, with loss of consciousness of 6 hours to 24 hours, sequela	Diagnosis	ICD-10-CM
S06.335S	Contusion and laceration of cerebrum, unspecified, with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
S06.336S	Contusion and laceration of cerebrum, unspecified, with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela	Diagnosis	ICD-10-CM
S06.337S	Contusion and laceration of cerebrum, unspecified, with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.338S	Contusion and laceration of cerebrum, unspecified, with loss of consciousness of any duration with death due to other cause prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.339S	Contusion and laceration of cerebrum, unspecified, with loss of consciousness of unspecified duration, sequela	Diagnosis	ICD-10-CM
S06.33AS	Contusion and laceration of cerebrum, unspecified, with loss of consciousness status unknown, sequela	Diagnosis	ICD-10-CM
S06.340S	Traumatic hemorrhage of right cerebrum without loss of consciousness, sequela	Diagnosis	ICD-10-CM
S06.341S	Traumatic hemorrhage of right cerebrum with loss of consciousness of 30 minutes or less, sequela	Diagnosis	ICD-10-CM
S06.342S	Traumatic hemorrhage of right cerebrum with loss of consciousness of 31 minutes to 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.343S	Traumatic hemorrhage of right cerebrum with loss of consciousness of 1 hours to 5 hours 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.344S	Traumatic hemorrhage of right cerebrum with loss of consciousness of 6 hours to 24 hours, sequela	Diagnosis	ICD-10-CM
S06.345S	Traumatic hemorrhage of right cerebrum with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela	Diagnosis	ICD-10-CM
S06.346S	Traumatic hemorrhage of right cerebrum with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela	Diagnosis	ICD-10-CM
S06.347S	Traumatic hemorrhage of right cerebrum with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.348S	Traumatic hemorrhage of right cerebrum with loss of consciousness of any duration with death due to other cause prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.349S	Traumatic hemorrhage of right cerebrum with loss of consciousness of unspecified duration, sequela	Diagnosis	ICD-10-CM
S06.34AS	Traumatic hemorrhage of right cerebrum with loss of consciousness status unknown, sequela	Diagnosis	ICD-10-CM
S06.350S	Traumatic hemorrhage of left cerebrum without loss of consciousness, sequela	Diagnosis	ICD-10-CM
S06.351S	Traumatic hemorrhage of left cerebrum with loss of consciousness of 30 minutes or less, sequela	Diagnosis	ICD-10-CM
S06.352S	Traumatic hemorrhage of left cerebrum with loss of consciousness of 31 minutes to 59 minutes, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
S06.353S	Traumatic hemorrhage of left cerebrum with loss of consciousness of 1 hours to 5 hours 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.354S	Traumatic hemorrhage of left cerebrum with loss of consciousness of 6 hours to 24 hours, sequela	Diagnosis	ICD-10-CM
S06.355S	Traumatic hemorrhage of left cerebrum with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela	Diagnosis	ICD-10-CM
S06.356S	Traumatic hemorrhage of left cerebrum with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela	Diagnosis	ICD-10-CM
S06.357S	Traumatic hemorrhage of left cerebrum with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.358S	Traumatic hemorrhage of left cerebrum with loss of consciousness of any duration with death due to other cause prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.359S	Traumatic hemorrhage of left cerebrum with loss of consciousness of unspecified duration, sequela	Diagnosis	ICD-10-CM
S06.35AS	Traumatic hemorrhage of left cerebrum with loss of consciousness status unknown, sequela	Diagnosis	ICD-10-CM
S06.360S	Traumatic hemorrhage of cerebrum, unspecified, without loss of consciousness, sequela	Diagnosis	ICD-10-CM
S06.361S	Traumatic hemorrhage of cerebrum, unspecified, with loss of consciousness of 30 minutes or less, sequela	Diagnosis	ICD-10-CM
S06.362S	Traumatic hemorrhage of cerebrum, unspecified, with loss of consciousness of 31 minutes to 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.363S	Traumatic hemorrhage of cerebrum, unspecified, with loss of consciousness of 1 hours to 5 hours 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.364S	Traumatic hemorrhage of cerebrum, unspecified, with loss of consciousness of 6 hours to 24 hours, sequela	Diagnosis	ICD-10-CM
S06.365S	Traumatic hemorrhage of cerebrum, unspecified, with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela	Diagnosis	ICD-10-CM
S06.366S	Traumatic hemorrhage of cerebrum, unspecified, with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela	Diagnosis	ICD-10-CM
S06.367S	Traumatic hemorrhage of cerebrum, unspecified, with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.368S	Traumatic hemorrhage of cerebrum, unspecified, with loss of consciousness of any duration with death due to other cause prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.369S	Traumatic hemorrhage of cerebrum, unspecified, with loss of consciousness of unspecified duration, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
S06.36AS	Traumatic hemorrhage of cerebrum, unspecified, with loss of consciousness status unknown, sequela	Diagnosis	ICD-10-CM
S06.370S	Contusion, laceration, and hemorrhage of cerebellum without loss of consciousness, sequela	Diagnosis	ICD-10-CM
S06.371S	Contusion, laceration, and hemorrhage of cerebellum with loss of consciousness of 30 minutes or less, sequela	Diagnosis	ICD-10-CM
S06.372S	Contusion, laceration, and hemorrhage of cerebellum with loss of consciousness of 31 minutes to 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.373S	Contusion, laceration, and hemorrhage of cerebellum with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.374S	Contusion, laceration, and hemorrhage of cerebellum with loss of consciousness of 6 hours to 24 hours, sequela	Diagnosis	ICD-10-CM
S06.375S	Contusion, laceration, and hemorrhage of cerebellum with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela	Diagnosis	ICD-10-CM
S06.376S	Contusion, laceration, and hemorrhage of cerebellum with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela	Diagnosis	ICD-10-CM
S06.377S	Contusion, laceration, and hemorrhage of cerebellum with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.378S	Contusion, laceration, and hemorrhage of cerebellum with loss of consciousness of any duration with death due to other cause prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.379S	Contusion, laceration, and hemorrhage of cerebellum with loss of consciousness of unspecified duration, sequela	Diagnosis	ICD-10-CM
S06.37AS	Contusion, laceration, and hemorrhage of cerebellum with loss of consciousness status unknown, sequela	Diagnosis	ICD-10-CM
S06.380S	Contusion, laceration, and hemorrhage of brainstem without loss of consciousness, sequela	Diagnosis	ICD-10-CM
S06.381S	Contusion, laceration, and hemorrhage of brainstem with loss of consciousness of 30 minutes or less, sequela	Diagnosis	ICD-10-CM
S06.382S	Contusion, laceration, and hemorrhage of brainstem with loss of consciousness of 31 minutes to 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.383S	Contusion, laceration, and hemorrhage of brainstem with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.384S	Contusion, laceration, and hemorrhage of brainstem with loss of consciousness of 6 hours to 24 hours, sequela	Diagnosis	ICD-10-CM
S06.385S	Contusion, laceration, and hemorrhage of brainstem with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
S06.386S	Contusion, laceration, and hemorrhage of brainstem with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela	Diagnosis	ICD-10-CM
S06.387S	Contusion, laceration, and hemorrhage of brainstem with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.388S	Contusion, laceration, and hemorrhage of brainstem with loss of consciousness of any duration with death due to other cause prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.389S	Contusion, laceration, and hemorrhage of brainstem with loss of consciousness of unspecified duration, sequela	Diagnosis	ICD-10-CM
S06.38AS	Contusion, laceration, and hemorrhage of brainstem with loss of consciousness status unknown, sequela	Diagnosis	ICD-10-CM
S06.4X0S	Epidural hemorrhage without loss of consciousness, sequela	Diagnosis	ICD-10-CM
S06.4X1S	Epidural hemorrhage with loss of consciousness of 30 minutes or less, sequela	Diagnosis	ICD-10-CM
S06.4X2S	Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.4X3S	Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.4X4S	Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours, sequela	Diagnosis	ICD-10-CM
S06.4X5S	Epidural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela	Diagnosis	ICD-10-CM
S06.4X6S	Epidural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela	Diagnosis	ICD-10-CM
S06.4X7S	Epidural hemorrhage with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.4X8S	Epidural hemorrhage with loss of consciousness of any duration with death due to other causes prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.4X9S	Epidural hemorrhage with loss of consciousness of unspecified duration, sequela	Diagnosis	ICD-10-CM
S06.4XAS	Epidural hemorrhage with loss of consciousness status unknown, sequela	Diagnosis	ICD-10-CM
S06.5X0S	Traumatic subdural hemorrhage without loss of consciousness, sequela	Diagnosis	ICD-10-CM
S06.5X1S	Traumatic subdural hemorrhage with loss of consciousness of 30 minutes or less, sequela	Diagnosis	ICD-10-CM
S06.5X2S	Traumatic subdural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.5X3S	Traumatic subdural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.5X4S	Traumatic subdural hemorrhage with loss of consciousness of 6 hours to 24 hours, sequela	Diagnosis	ICD-10-CM
S06.5X5S	Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
S06.5X6S	Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela	Diagnosis	ICD-10-CM
S06.5X7S	Traumatic subdural hemorrhage with loss of consciousness of any duration with death due to brain injury before regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.5X8S	Traumatic subdural hemorrhage with loss of consciousness of any duration with death due to other cause before regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.5X9S	Traumatic subdural hemorrhage with loss of consciousness of unspecified duration, sequela	Diagnosis	ICD-10-CM
S06.5XAS	Traumatic subdural hemorrhage with loss of consciousness status unknown, sequela	Diagnosis	ICD-10-CM
S06.6X0S	Traumatic subarachnoid hemorrhage without loss of consciousness, sequela	Diagnosis	ICD-10-CM
S06.6X1S	Traumatic subarachnoid hemorrhage with loss of consciousness of 30 minutes or less, sequela	Diagnosis	ICD-10-CM
S06.6X2S	Traumatic subarachnoid hemorrhage with loss of consciousness of 31 minutes to 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.6X3S	Traumatic subarachnoid hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.6X4S	Traumatic subarachnoid hemorrhage with loss of consciousness of 6 hours to 24 hours, sequela	Diagnosis	ICD-10-CM
S06.6X5S	Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela	Diagnosis	ICD-10-CM
S06.6X6S	Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela	Diagnosis	ICD-10-CM
S06.6X7S	Traumatic subarachnoid hemorrhage with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.6X8S	Traumatic subarachnoid hemorrhage with loss of consciousness of any duration with death due to other cause prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.6X9S	Traumatic subarachnoid hemorrhage with loss of consciousness of unspecified duration, sequela	Diagnosis	ICD-10-CM
S06.6XAS	Traumatic subarachnoid hemorrhage with loss of consciousness status unknown, sequela	Diagnosis	ICD-10-CM
S06.810S	Injury of right internal carotid artery, intracranial portion, not elsewhere classified without loss of consciousness, sequela	Diagnosis	ICD-10-CM
S06.811S	Injury of right internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of 30 minutes or less, sequela	Diagnosis	ICD-10-CM
S06.812S	Injury of right internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of 31 minutes to 59 minutes, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
S06.813S	Injury of right internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.814S	Injury of right internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of 6 hours to 24 hours, sequela	Diagnosis	ICD-10-CM
S06.815S	Injury of right internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela	Diagnosis	ICD-10-CM
S06.816S	Injury of right internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela	Diagnosis	ICD-10-CM
S06.817S	Injury of right internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.818S	Injury of right internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of any duration with death due to other cause prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.819S	Injury of right internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of unspecified duration, sequela	Diagnosis	ICD-10-CM
S06.81AS	Injury of right internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness status unknown, sequela	Diagnosis	ICD-10-CM
S06.820S	Injury of left internal carotid artery, intracranial portion, not elsewhere classified without loss of consciousness, sequela	Diagnosis	ICD-10-CM
S06.821S	Injury of left internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of 30 minutes or less, sequela	Diagnosis	ICD-10-CM
S06.822S	Injury of left internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of 31 minutes to 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.823S	Injury of left internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.824S	Injury of left internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of 6 hours to 24 hours, sequela	Diagnosis	ICD-10-CM
S06.825S	Injury of left internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela	Diagnosis	ICD-10-CM
S06.826S	Injury of left internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
S06.827S	Injury of left internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.828S	Injury of left internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of any duration with death due to other cause prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.829S	Injury of left internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness of unspecified duration, sequela	Diagnosis	ICD-10-CM
S06.82AS	Injury of left internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness status unknown, sequela	Diagnosis	ICD-10-CM
S06.890S	Other specified intracranial injury without loss of consciousness, sequela	Diagnosis	ICD-10-CM
S06.891S	Other specified intracranial injury with loss of consciousness of 30 minutes or less, sequela	Diagnosis	ICD-10-CM
S06.892S	Other specified intracranial injury with loss of consciousness of 31 minutes to 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.893S	Other specified intracranial injury with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.894S	Other specified intracranial injury with loss of consciousness of 6 hours to 24 hours, sequela	Diagnosis	ICD-10-CM
S06.895S	Other specified intracranial injury with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela	Diagnosis	ICD-10-CM
S06.896S	Other specified intracranial injury with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela	Diagnosis	ICD-10-CM
S06.897S	Other specified intracranial injury with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.898S	Other specified intracranial injury with loss of consciousness of any duration with death due to other cause prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.899S	Other specified intracranial injury with loss of consciousness of unspecified duration, sequela	Diagnosis	ICD-10-CM
S06.89AS	Other specified intracranial injury with loss of consciousness status unknown, sequela	Diagnosis	ICD-10-CM
S06.8A0S	Primary blast injury of brain, not elsewhere classified without loss of consciousness, sequela	Diagnosis	ICD-10-CM
S06.8A1S	Primary blast injury of brain, not elsewhere classified with loss of consciousness of 30 minutes or less, sequela	Diagnosis	ICD-10-CM
S06.8A2S	Primary blast injury of brain, not elsewhere classified with loss of consciousness of 31 minutes to 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.8A3S	Primary blast injury of brain, not elsewhere classified with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
S06.8A4S	Primary blast injury of brain, not elsewhere classified with loss of consciousness of 6 hours to 24 hours, sequela	Diagnosis	ICD-10-CM
S06.8A5S	Primary blast injury of brain, not elsewhere classified with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela	Diagnosis	ICD-10-CM
S06.8A6S	Primary blast injury of brain, not elsewhere classified with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela	Diagnosis	ICD-10-CM
S06.8A9S	Primary blast injury of brain, not elsewhere classified with loss of consciousness of unspecified duration, sequela	Diagnosis	ICD-10-CM
S06.8AAS	Primary blast injury of brain, not elsewhere classified with loss of consciousness status unknown, sequela	Diagnosis	ICD-10-CM
S06.9X0S	Unspecified intracranial injury without loss of consciousness, sequela	Diagnosis	ICD-10-CM
S06.9X1S	Unspecified intracranial injury with loss of consciousness of 30 minutes or less, sequela	Diagnosis	ICD-10-CM
S06.9X2S	Unspecified intracranial injury with loss of consciousness of 31 minutes to 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.9X3S	Unspecified intracranial injury with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela	Diagnosis	ICD-10-CM
S06.9X4S	Unspecified intracranial injury with loss of consciousness of 6 hours to 24 hours, sequela	Diagnosis	ICD-10-CM
S06.9X5S	Unspecified intracranial injury with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela	Diagnosis	ICD-10-CM
S06.9X6S	Unspecified intracranial injury with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela	Diagnosis	ICD-10-CM
S06.9X7S	Unspecified intracranial injury with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.9X8S	Unspecified intracranial injury with loss of consciousness of any duration with death due to other cause prior to regaining consciousness, sequela	Diagnosis	ICD-10-CM
S06.9X9S	Unspecified intracranial injury with loss of consciousness of unspecified duration, sequela	Diagnosis	ICD-10-CM
S06.9XAS	Unspecified intracranial injury with loss of consciousness status unknown, sequela	Diagnosis	ICD-10-CM
S06.A0XS	Traumatic brain compression without herniation, sequela	Diagnosis	ICD-10-CM
S06.A1XS	Traumatic brain compression with herniation, sequela	Diagnosis	ICD-10-CM
	Migraine		
339	Other headache syndromes	Diagnosis	ICD-9-CM
339.0	Cluster headaches and other trigeminal autonomic cephalgias	Diagnosis	ICD-9-CM
339.00	Cluster headache syndrome, unspecified	Diagnosis	ICD-9-CM
339.01	Episodic cluster headache	Diagnosis	ICD-9-CM
339.02	Chronic cluster headache	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
339.03	Episodic paroxysmal hemicrania	Diagnosis	ICD-9-CM
339.04	Chronic paroxysmal hemicrania	Diagnosis	ICD-9-CM
339.05	Short lasting unilateral neuralgiform headache with conjunctival injection and tearing	Diagnosis	ICD-9-CM
339.09	Other trigeminal autonomic cephalgias	Diagnosis	ICD-9-CM
339.1	Tension type headache	Diagnosis	ICD-9-CM
339.10	Tension type headache, unspecified	Diagnosis	ICD-9-CM
339.11	Episodic tension type headache	Diagnosis	ICD-9-CM
339.12	Chronic tension type headache	Diagnosis	ICD-9-CM
339.2	Post-traumatic headache	Diagnosis	ICD-9-CM
339.20	Post-traumatic headache, unspecified	Diagnosis	ICD-9-CM
339.21	Acute post-traumatic headache	Diagnosis	ICD-9-CM
339.22	Chronic post-traumatic headache	Diagnosis	ICD-9-CM
339.3	Drug induced headache, not elsewhere classified	Diagnosis	ICD-9-CM
339.4	Complicated headache syndromes	Diagnosis	ICD-9-CM
339.41	Hemicrania continua	Diagnosis	ICD-9-CM
339.42	New daily persistent headache	Diagnosis	ICD-9-CM
339.43	Primary thunderclap headache	Diagnosis	ICD-9-CM
339.44	Other complicated headache syndrome	Diagnosis	ICD-9-CM
339.8	Other specified headache syndromes	Diagnosis	ICD-9-CM
339.81	Hypnic headache	Diagnosis	ICD-9-CM
339.82	Headache associated with sexual activity	Diagnosis	ICD-9-CM
339.83	Primary cough headache	Diagnosis	ICD-9-CM
339.84	Primary exertional headache	Diagnosis	ICD-9-CM
339.85	Primary stabbing headache	Diagnosis	ICD-9-CM
339.89	Other specified headache syndromes	Diagnosis	ICD-9-CM
346	Migraine	Diagnosis	ICD-9-CM
346.0	Migraine with aura	Diagnosis	ICD-9-CM
346.00	Migraine with aura, without mention of intractable migraine without mention of status migrainosus	Diagnosis	ICD-9-CM
346.01	Migraine with aura, with intractable migraine, so stated, without mention of status migrainosus	Diagnosis	ICD-9-CM
346.02	Migraine with aura, without mention of intractable migraine with status migrainosus	Diagnosis	ICD-9-CM
346.03	Migraine with aura, with intractable migraine, so stated, with status migrainosus	Diagnosis	ICD-9-CM
346.1	Migraine without aura	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
346.10	Migraine without aura, without mention of intractable migraine without mention of status migrainosus	Diagnosis	ICD-9-CM
346.11	Migraine without aura, with intractable migraine, so stated, without mention of status migrainosus	Diagnosis	ICD-9-CM
346.12	Migraine without aura, without mention of intractable migraine with status migrainosus	Diagnosis	ICD-9-CM
346.13	Migraine without aura, with intractable migraine, so stated, with status migrainosus	Diagnosis	ICD-9-CM
346.2	Variants of migraine, not elsewhere classified	Diagnosis	ICD-9-CM
346.20	Variants of migraine, not elsewhere classified, without mention of intractable migraine without mention of status migrainosus	Diagnosis	ICD-9-CM
346.21	Variants of migraine, not elsewhere classified, with intractable migraine, so stated, without mention of status migrainosus	Diagnosis	ICD-9-CM
346.22	Variants of migraine, not elsewhere classified, without mention of intractable migraine with status migrainosus	Diagnosis	ICD-9-CM
346.23	Variants of migraine, not elsewhere classified, with intractable migraine, so stated, with status migrainosus	Diagnosis	ICD-9-CM
346.3	Hemiplegic migraine	Diagnosis	ICD-9-CM
346.30	Hemiplegic migraine, without mention of intractable migraine without mention of status migrainosus	Diagnosis	ICD-9-CM
346.31	Hemiplegic migraine, with intractable migraine, so stated, without mention of status migrainosus	Diagnosis	ICD-9-CM
346.32	Hemiplegic migraine, without mention of intractable migraine with status migrainosus	Diagnosis	ICD-9-CM
346.33	Hemiplegic migraine, with intractable migraine, so stated, with status migrainosus	Diagnosis	ICD-9-CM
346.4	Menstrual migraine	Diagnosis	ICD-9-CM
346.40	Menstrual migraine, without mention of intractable migraine without mention of status migrainosus	Diagnosis	ICD-9-CM
346.41	Menstrual migraine, with intractable migraine, so stated, without mention of status migrainosus	Diagnosis	ICD-9-CM
346.42	Menstrual migraine, without mention of intractable migraine with status migrainosus	Diagnosis	ICD-9-CM
346.43	Menstrual migraine, with intractable migraine, so stated, with status migrainosus	Diagnosis	ICD-9-CM
346.5	Persistent migraine aura without cerebral infarction	Diagnosis	ICD-9-CM
346.50	Persistent migraine aura without cerebral infarction, without mention of intractable migraine without mention of status migrainosus	Diagnosis	ICD-9-CM
346.51	Persistent migraine aura without cerebral infarction, with intractable migraine, so stated, without mention of status migrainosus	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
346.52	Persistent migraine aura without cerebral infarction, without mention of intractable migraine with status migrainosus	Diagnosis	ICD-9-CM
346.53	Persistent migraine aura without cerebral infarction, with intractable migraine, so stated, with status migrainosus	Diagnosis	ICD-9-CM
346.6	Persistent migraine aura with cerebral infarction	Diagnosis	ICD-9-CM
346.60	Persistent migraine aura with cerebral infarction, without mention of intractable migraine without mention of status migrainosus	Diagnosis	ICD-9-CM
346.61	Persistent migraine aura with cerebral infarction, with intractable migraine, so stated, without mention of status migrainosus	Diagnosis	ICD-9-CM
346.62	Persistent migraine aura with cerebral infarction, without mention of intractable migraine with status migrainosus	Diagnosis	ICD-9-CM
346.63	Persistent migraine aura with cerebral infarction, with intractable migraine, so stated, with status migrainosus	Diagnosis	ICD-9-CM
346.7	Chronic migraine without aura	Diagnosis	ICD-9-CM
346.70	Chronic migraine without aura, without mention of intractable migraine without mention of status migrainosus	Diagnosis	ICD-9-CM
346.71	Chronic migraine without aura, with intractable migraine, so stated, without mention of status migrainosus	Diagnosis	ICD-9-CM
346.72	Chronic migraine without aura, without mention of intractable migraine with status migrainosus	Diagnosis	ICD-9-CM
346.73	Chronic migraine without aura, with intractable migraine, so stated, with status migrainosus	Diagnosis	ICD-9-CM
346.8	Other forms of migraine	Diagnosis	ICD-9-CM
346.80	Other forms of migraine, without mention of intractable migraine without mention of status migrainosus	Diagnosis	ICD-9-CM
346.81	Other forms of migraine, with intractable migraine, so stated, without mention of status migrainosus	Diagnosis	ICD-9-CM
346.82	Other forms of migraine, without mention of intractable migraine with status migrainosus	Diagnosis	ICD-9-CM
346.83	Other forms of migraine, with intractable migraine, so stated, with status migrainosus	Diagnosis	ICD-9-CM
346.9	Migraine, unspecified	Diagnosis	ICD-9-CM
346.90	Migraine, unspecified without mention of intractable migraine without mention of status migrainosus	Diagnosis	ICD-9-CM
346.91	Migraine, unspecified, with intractable migraine, so stated, without mention of status migrainosus	Diagnosis	ICD-9-CM
346.92	Migraine, unspecified, without mention of intractable migraine with status migrainosus	Diagnosis	ICD-9-CM
346.93	Migraine, unspecified, with intractable migraine, so stated, with status migrainosus	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
G43.001	Migraine without aura, not intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.009	Migraine without aura, not intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.011	Migraine without aura, intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.019	Migraine without aura, intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.101	Migraine with aura, not intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.109	Migraine with aura, not intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.111	Migraine with aura, intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.119	Migraine with aura, intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.401	Hemiplegic migraine, not intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.409	Hemiplegic migraine, not intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.411	Hemiplegic migraine, intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.419	Hemiplegic migraine, intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.501	Persistent migraine aura without cerebral infarction, not intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.509	Persistent migraine aura without cerebral infarction, not intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.511	Persistent migraine aura without cerebral infarction, intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.519	Persistent migraine aura without cerebral infarction, intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.601	Persistent migraine aura with cerebral infarction, not intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.609	Persistent migraine aura with cerebral infarction, not intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.611	Persistent migraine aura with cerebral infarction, intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.619	Persistent migraine aura with cerebral infarction, intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.701	Chronic migraine without aura, not intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.709	Chronic migraine without aura, not intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.711	Chronic migraine without aura, intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.719	Chronic migraine without aura, intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.801	Other migraine, not intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.809	Other migraine, not intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.811	Other migraine, intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.819	Other migraine, intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.821	Menstrual migraine, not intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.829	Menstrual migraine, not intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.831	Menstrual migraine, intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.839	Menstrual migraine, intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.901	Migraine, unspecified, not intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.909	Migraine, unspecified, not intractable, without status migrainosus	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
G43.911	Migraine, unspecified, intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.919	Migraine, unspecified, intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.A0	Cyclical vomiting, in migraine, not intractable	Diagnosis	ICD-10-CM
G43.A1	Cyclical vomiting, in migraine, intractable	Diagnosis	ICD-10-CM
G43.B0	Ophthalmoplegic migraine, not intractable	Diagnosis	ICD-10-CM
G43.B1	Ophthalmoplegic migraine, intractable	Diagnosis	ICD-10-CM
G43.C0	Periodic headache syndromes in child or adult, not intractable	Diagnosis	ICD-10-CM
G43.C1	Periodic headache syndromes in child or adult, intractable	Diagnosis	ICD-10-CM
G43.D0	Abdominal migraine, not intractable	Diagnosis	ICD-10-CM
G43.D1	Abdominal migraine, intractable	Diagnosis	ICD-10-CM
G44.001	Cluster headache syndrome, unspecified, intractable	Diagnosis	ICD-10-CM
G44.009	Cluster headache syndrome, unspecified, not intractable	Diagnosis	ICD-10-CM
G44.011	Episodic cluster headache, intractable	Diagnosis	ICD-10-CM
G44.019	Episodic cluster headache, not intractable	Diagnosis	ICD-10-CM
G44.021	Chronic cluster headache, intractable	Diagnosis	ICD-10-CM
G44.029	Chronic cluster headache, not intractable	Diagnosis	ICD-10-CM
G44.031	Episodic paroxysmal hemicrania, intractable	Diagnosis	ICD-10-CM
G44.039	Episodic paroxysmal hemicrania, not intractable	Diagnosis	ICD-10-CM
G44.041	Chronic paroxysmal hemicrania, intractable	Diagnosis	ICD-10-CM
G44.049	Chronic paroxysmal hemicrania, not intractable	Diagnosis	ICD-10-CM
G44.051	Short lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT), intractable	Diagnosis	ICD-10-CM
G44.059	Short lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT), not intractable	Diagnosis	ICD-10-CM
G44.091	Other trigeminal autonomic cephalgias (TAC), intractable	Diagnosis	ICD-10-CM
G44.099	Other trigeminal autonomic cephalgias (TAC), not intractable	Diagnosis	ICD-10-CM
G44.1	Vascular headache, not elsewhere classified	Diagnosis	ICD-10-CM
G44.201	Tension-type headache, unspecified, intractable	Diagnosis	ICD-10-CM
G44.209	Tension-type headache, unspecified, not intractable	Diagnosis	ICD-10-CM
G44.211	Episodic tension-type headache, intractable	Diagnosis	ICD-10-CM
G44.219	Episodic tension-type headache, not intractable	Diagnosis	ICD-10-CM
G44.221	Chronic tension-type headache, intractable	Diagnosis	ICD-10-CM
G44.229	Chronic tension-type headache, not intractable	Diagnosis	ICD-10-CM
G44.301	Post-traumatic headache, unspecified, intractable	Diagnosis	ICD-10-CM
G44.309	Post-traumatic headache, unspecified, not intractable	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
G44.311	Acute post-traumatic headache, intractable	Diagnosis	ICD-10-CM
G44.319	Acute post-traumatic headache, not intractable	Diagnosis	ICD-10-CM
G44.321	Chronic post-traumatic headache, intractable	Diagnosis	ICD-10-CM
G44.329	Chronic post-traumatic headache, not intractable	Diagnosis	ICD-10-CM
G44.40	Drug-induced headache, not elsewhere classified, not intractable	Diagnosis	ICD-10-CM
G44.41	Drug-induced headache, not elsewhere classified, intractable	Diagnosis	ICD-10-CM
G44.51	Hemicrania continua	Diagnosis	ICD-10-CM
G44.52	New daily persistent headache (NDPH)	Diagnosis	ICD-10-CM
G44.53	Primary thunderclap headache	Diagnosis	ICD-10-CM
G44.59	Other complicated headache syndrome	Diagnosis	ICD-10-CM
G44.81	Hypnic headache	Diagnosis	ICD-10-CM
G44.82	Headache associated with sexual activity	Diagnosis	ICD-10-CM
G44.83	Primary cough headache	Diagnosis	ICD-10-CM
G44.84	Primary exertional headache	Diagnosis	ICD-10-CM
G44.85	Primary stabbing headache	Diagnosis	ICD-10-CM
G44.86	Cervicogenic headache	Diagnosis	ICD-10-CM
G44.89	Other headache syndrome	Diagnosis	ICD-10-CM
	Epilepsy		
345	Epilepsy and recurrent seizures	Diagnosis	ICD-9-CM
345.0	Generalized nonconvulsive epilepsy	Diagnosis	ICD-9-CM
345.00	Generalized nonconvulsive epilepsy without mention of intractable epilepsy	Diagnosis	ICD-9-CM
345.01	Generalized nonconvulsive epilepsy with intractable epilepsy	Diagnosis	ICD-9-CM
345.1	Generalized convulsive epilepsy	Diagnosis	ICD-9-CM
345.10	Generalized convulsive epilepsy without mention of intractable epilepsy	Diagnosis	ICD-9-CM
345.11	Generalized convulsive epilepsy with intractable epilepsy	Diagnosis	ICD-9-CM
345.2	Epileptic petit mal status	Diagnosis	ICD-9-CM
345.3	Epileptic grand mal status	Diagnosis	ICD-9-CM
345.4	Localization-related (focal) (partial) epilepsy and epileptic syndromes with complex partial seizures	Diagnosis	ICD-9-CM
345.40	Localization-related (focal) (partial) epilepsy and epileptic syndromes with complex partial seizures, without mention of intractable epilepsy	Diagnosis	ICD-9-CM
345.41	Localization-related (focal) (partial) epilepsy and epileptic syndromes with complex partial seizures, with intractable epilepsy	Diagnosis	ICD-9-CM
345.5	Localization-related (focal) (partial) epilepsy and epileptic syndromes with simple partial seizures	Diagnosis	ICD-9-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
345.50	Localization-related (focal) (partial) epilepsy and epileptic syndromes with simple partial seizures, without mention of intractable epilepsy	Diagnosis	ICD-9-CM
345.51	Localization-related (focal) (partial) epilepsy and epileptic syndromes with simple partial seizures, with intractable epilepsy	Diagnosis	ICD-9-CM
345.6	Infantile spasms	Diagnosis	ICD-9-CM
345.60	Infantile spasms without mention of intractable epilepsy	Diagnosis	ICD-9-CM
345.61	Infantile spasms with intractable epilepsy	Diagnosis	ICD-9-CM
345.7	Epilepsia partialis continua	Diagnosis	ICD-9-CM
345.70	Epilepsia partialis continua without mention of intractable epilepsy	Diagnosis	ICD-9-CM
345.71	Epilepsia partialis continua with intractable epilepsy	Diagnosis	ICD-9-CM
345.8	Other forms of epilepsy and recurrent seizures	Diagnosis	ICD-9-CM
345.80	Other forms of epilepsy and recurrent seizures, without mention of intractable epilepsy	Diagnosis	ICD-9-CM
345.81	Other forms of epilepsy and recurrent seizures, with intractable epilepsy	Diagnosis	ICD-9-CM
345.9	Unspecified epilepsy	Diagnosis	ICD-9-CM
345.90	Unspecified epilepsy without mention of intractable epilepsy	Diagnosis	ICD-9-CM
345.91	Unspecified epilepsy with intractable epilepsy	Diagnosis	ICD-9-CM
G40.001	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.009	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.011	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.019	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.101	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.109	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.111	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.119	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.201	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, with status epilepticus	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
G40.209	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.211	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.219	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.301	Generalized idiopathic epilepsy and epileptic syndromes, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.309	Generalized idiopathic epilepsy and epileptic syndromes, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.311	Generalized idiopathic epilepsy and epileptic syndromes, intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.319	Generalized idiopathic epilepsy and epileptic syndromes, intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.401	Other generalized epilepsy and epileptic syndromes, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.409	Other generalized epilepsy and epileptic syndromes, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.411	Other generalized epilepsy and epileptic syndromes, intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.419	Other generalized epilepsy and epileptic syndromes, intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.42	Cyclin-Dependent Kinase-Like 5 Deficiency Disorder	Diagnosis	ICD-10-CM
G40.501	Epileptic seizures related to external causes, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.509	Epileptic seizures related to external causes, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.801	Other epilepsy, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.802	Other epilepsy, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.803	Other epilepsy, intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.804	Other epilepsy, intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.811	Lennox-Gastaut syndrome, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.812	Lennox-Gastaut syndrome, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.813	Lennox-Gastaut syndrome, intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.814	Lennox-Gastaut syndrome, intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.821	Epileptic spasms, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.822	Epileptic spasms, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.823	Epileptic spasms, intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.824	Epileptic spasms, intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.833	Dravet syndrome, intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.834	Dravet syndrome, intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.89	Other seizures	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
G40.901	Epilepsy, unspecified, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.909	Epilepsy, unspecified, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.911	Epilepsy, unspecified, intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.919	Epilepsy, unspecified, intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.A01	Absence epileptic syndrome, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.A09	Absence epileptic syndrome, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.A11	Absence epileptic syndrome, intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.A19	Absence epileptic syndrome, intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.B01	Juvenile myoclonic epilepsy, not intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.B09	Juvenile myoclonic epilepsy, not intractable, without status epilepticus	Diagnosis	ICD-10-CM
G40.B11	Juvenile myoclonic epilepsy, intractable, with status epilepticus	Diagnosis	ICD-10-CM
G40.B19	Juvenile myoclonic epilepsy, intractable, without status epilepticus	Diagnosis	ICD-10-CM
	Chronic Pain		
338.2	Chronic pain	Diagnosis	ICD-9-CM
338.21	Chronic pain due to trauma	Diagnosis	ICD-9-CM
338.22	Chronic post-thoracotomy pain	Diagnosis	ICD-9-CM
338.28	Other chronic postoperative pain	Diagnosis	ICD-9-CM
338.29	Other chronic pain	Diagnosis	ICD-9-CM
338.3	Neoplasm related pain (acute) (chronic)	Diagnosis	ICD-9-CM
338.4	Chronic pain syndrome	Diagnosis	ICD-9-CM
729.1	Unspecified myalgia and myositis	Diagnosis	ICD-9-CM
729.2	Unspecified neuralgia, neuritis, and radiculitis	Diagnosis	ICD-9-CM
780.7	Malaise and fatigue	Diagnosis	ICD-9-CM
780.71	Chronic fatigue syndrome	Diagnosis	ICD-9-CM
G89.21	Chronic pain due to trauma	Diagnosis	ICD-10-CM
G89.22	Chronic post-thoracotomy pain	Diagnosis	ICD-10-CM
G89.28	Other chronic postprocedural pain	Diagnosis	ICD-10-CM
G89.29	Other chronic pain	Diagnosis	ICD-10-CM
G89.3	Neoplasm related pain (acute) (chronic)	Diagnosis	ICD-10-CM
G89.4	Chronic pain syndrome	Diagnosis	ICD-10-CM
M54.10	Radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M54.11	Radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M54.12	Radiculopathy, cervical region	Diagnosis	ICD-10-CM
M54.13	Radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M54.14	Radiculopathy, thoracic region	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
M54.15	Radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M54.16	Radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M54.17	Radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M54.18	Radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M60.80	Other myositis, unspecified site	Diagnosis	ICD-10-CM
M60.811	Other myositis, right shoulder	Diagnosis	ICD-10-CM
M60.812	Other myositis, left shoulder	Diagnosis	ICD-10-CM
M60.819	Other myositis, unspecified shoulder	Diagnosis	ICD-10-CM
M60.821	Other myositis, right upper arm	Diagnosis	ICD-10-CM
M60.822	Other myositis, left upper arm	Diagnosis	ICD-10-CM
M60.829	Other myositis, unspecified upper arm	Diagnosis	ICD-10-CM
M60.831	Other myositis, right forearm	Diagnosis	ICD-10-CM
M60.832	Other myositis, left forearm	Diagnosis	ICD-10-CM
M60.839	Other myositis, unspecified forearm	Diagnosis	ICD-10-CM
M60.841	Other myositis, right hand	Diagnosis	ICD-10-CM
M60.842	Other myositis, left hand	Diagnosis	ICD-10-CM
M60.849	Other myositis, unspecified hand	Diagnosis	ICD-10-CM
M60.851	Other myositis, right thigh	Diagnosis	ICD-10-CM
M60.852	Other myositis, left thigh	Diagnosis	ICD-10-CM
M60.859	Other myositis, unspecified thigh	Diagnosis	ICD-10-CM
M60.861	Other myositis, right lower leg	Diagnosis	ICD-10-CM
M60.862	Other myositis, left lower leg	Diagnosis	ICD-10-CM
M60.869	Other myositis, unspecified lower leg	Diagnosis	ICD-10-CM
M60.871	Other myositis, right ankle and foot	Diagnosis	ICD-10-CM
M60.872	Other myositis, left ankle and foot	Diagnosis	ICD-10-CM
M60.879	Other myositis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M60.88	Other myositis, other site	Diagnosis	ICD-10-CM
M60.89	Other myositis, multiple sites	Diagnosis	ICD-10-CM
M60.9	Myositis, unspecified	Diagnosis	ICD-10-CM
M79.1	Myalgia	Diagnosis	ICD-10-CM
M79.10	Myalgia, unspecified site	Diagnosis	ICD-10-CM
M79.11	Myalgia of mastication muscle	Diagnosis	ICD-10-CM
M79.12	Myalgia of auxiliary muscles, head and neck	Diagnosis	ICD-10-CM
M79.18	Myalgia, other site	Diagnosis	ICD-10-CM
M79.2	Neuralgia and neuritis, unspecified	Diagnosis	ICD-10-CM

Appendix BF. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third

Code	Description	Code Category	Code Type
M79.7	Fibromyalgia	Diagnosis	ICD-10-CM
R53.82	Chronic fatigue, unspecified	Diagnosis	ICD-10-CM
	Antidepressants		
4064F	Antidepressant pharmacotherapy prescribed (MDD, MDD ADOL)	Procedure	CPT-2
80332	Antidepressants, serotonergic class; 1 or 2	Procedure	CPT-4
80333	Antidepressants, serotonergic class; 3-5	Procedure	CPT-4
80334	Antidepressants, serotonergic class; 6 or more	Procedure	CPT-4
80335	Antidepressants, tricyclic and other cyclicals; 1 or 2	Procedure	CPT-4
80336	Antidepressants, tricyclic and other cyclicals; 3-5	Procedure	CPT-4
80337	Antidepressants, tricyclic and other cyclicals; 6 or more	Procedure	CPT-4
80338	Antidepressants, not otherwise specified	Procedure	CPT-4
G8126	Patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase	Procedure	HCPCS
G9194	Patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 180 day (6 month) continuation treatment phase	Procedure	HCPCS

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
Psychiatric drug dispensings	
5-hydroxy-L-tryptophan (oxitriptan)	5hydroxytryptophan(oxitriptan)
5-hydroxytryptophan (5-HTP)	5-HTP
5-hydroxytryptophan (5-HTP)	5-hydroxytryptophan (5-HTP)
5-hydroxytryptophan (5-HTP)	Natrol 5-HTP
5-hydroxytryptophan (5-HTP)/vit B6/ascorbic acid	5-hydroxytryptophan(5HTP)-B6-C
5-hydroxytryptophan/tyrosine/glutamin/phenylal/B6/C/chromium	Appe-Curb
AMITRIPTYLINE HCL	EnovaRx-Amitriptyline
alprazolam	Alprazolam Intensol
alprazolam	Xanax
alprazolam	Xanax XR
alprazolam	alprazolam
amitriptyline HCl	amitriptyline
amitriptyline HCl/chlordiazepoxide	amitriptyline-chlordiazepoxide
amobarbital sodium	Amytal
amoxapine	amoxapine
aripiprazole	Abilify
aripiprazole	Abilify Asimtufii
aripiprazole	Abilify Discmelt
aripiprazole	Abilify Maintena
aripiprazole	Abilify MyCite
aripiprazole	Abilify MyCite Maintenance Kit
aripiprazole	Abilify MyCite Starter Kit
aripiprazole	aripiprazole
aripiprazole lauroxil	Aristada
aripiprazole lauroxil, submicronized	Aristada Initio
asenapine	Secuado
asenapine maleate	Saphris
asenapine maleate	Saphris (black cherry)
asenapine maleate	asenapine maleate
atomoxetine HCl	Strattera
atomoxetine HCl	atomoxetine
brexanolone	Zulresso
brexpiprazole	Rexulti
bromelains/melatonin/herbal complex no.233	MidNite PM
bupropion HBr	Aplenzin
bupropion HCl	Buproban
bupropion HCl	Forfivo XL

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
bupropion HCl	Wellbutrin
bupropion HCl	Wellbutrin SR
bupropion HCl	Wellbutrin XL
bupropion HCl	Zyban
bupropion HCl	bupropion HCl
bupropion HCl	bupropion HCl (smoking deter)
buspirone HCl	buspirone
butabarbital sodium	Butisol
calcium carb,hydroxide/soy isoflavone/black cohosh/melatonin	Estroven Nighttime (cal-meltn)
calcium phosphate, tribasic/melatonin	Alka-Seltzer PM (melatonin)
calcium phosphate/melatonin	calcium-melatonin
carbamazepine	Carbatrol
carbamazepine	Epitol
carbamazepine	Equetro
carbamazepine	Tegretol
carbamazepine	Tegretol XR
carbamazepine	carbamazepine
cariprazine HCl	Vraylar
chlordiazepoxide HCl	chlordiazepoxide HCl
chlordiazepoxide/clidinium bromide	Librax (with clidinium)
chlordiazepoxide/clidinium bromide	chlordiazepoxide-clidinium
chlorpromazine HCl	chlorpromazine
citalopram hydrobromide	Celexa
citalopram hydrobromide	citalopram
clomipramine HCl	Anafranil
clomipramine HCl	clomipramine
clonazepam	Klonopin
clonazepam	clonazepam
clorazepate dipotassium	Tranxene T-Tab
clorazepate dipotassium	clorazepate dipotassium
clozapine	Clozaril
clozapine	FazaClo
clozapine	Versacloz
clozapine	clozapine
daridorexant HCl	Quviviq
desipramine HCl	Norpramin
desipramine HCl	desipramine
desvenlafaxine	Khedezla

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
desvenlafaxine	desvenlafaxine
desvenlafaxine fumarate	desvenlafaxine fumarate
desvenlafaxine succinate	Pristiq
desvenlafaxine succinate	desvenlafaxine succinate
dexmedetomidine HCl	Igalmi
dexmedetomidine HCl	Precedex
dexmedetomidine HCl	dexmedetomidine
dexmedetomidine HCl in 0.9 % sodium chloride	Precedex in 0.9 % sodium chlor
dexmedetomidine HCl in 0.9 % sodium chloride	dexmedetomidine in 0.9 % NaCl
dexmedetomidine in 5 % dextrose in water	dexmedetomidine in dextrose 5%
dexmethylphenidate HCl	Focalin
dexmethylphenidate HCl	Focalin XR
dexmethylphenidate HCl	dexmethylphenidate
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Adderall
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Adderall XR
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mydayis
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	dextroamphetamine-amphetamine
dextroamphetamine sulfate	Dexedrine
dextroamphetamine sulfate	Dexedrine Spansule
dextroamphetamine sulfate	ProCentra
dextroamphetamine sulfate	Zenzedi
dextroamphetamine sulfate	dextroamphetamine sulfate
dextromethorphan HBr/bupropion HCl	Auvelity
diazepam	Diastat
diazepam	Diastat AcuDial
diazepam	Diazepam Intensol
diazepam	Valium
diazepam	Valtoco
diazepam	diazepam
divalproex sodium	Depakote
divalproex sodium	Depakote ER
divalproex sodium	Depakote Sprinkles
divalproex sodium	divalproex
doxepin HCl	Prudoxin
doxepin HCl	Silenor
doxepin HCl	Zonalon
doxepin HCl	doxepin
droperidol	droperidol

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
duloxetine HCl	Cymbalta
duloxetine HCl	Drizalma Sprinkle
duloxetine HCl	Irenka
duloxetine HCl	duloxetine
escitalopram oxalate	Lexapro
escitalopram oxalate	escitalopram oxalate
esketamine HCl	Spravato
estazolam	estazolam
eszopiclone	Lunesta
eszopiclone	eszopiclone
ethyl alcohol/herbal drugs	Lydia Pinkham Herbal
fluoxetine HCl	Prozac
fluoxetine HCl	Prozac Weekly
fluoxetine HCl	Sarafem
fluoxetine HCl	fluoxetine
fluphenazine HCl	fluphenazine HCl
fluphenazine decanoate	fluphenazine decanoate
flurazepam HCl	flurazepam
fluvoxamine maleate	Luvox CR
fluvoxamine maleate	fluvoxamine
guanfacine HCl	Intuniv ER
guanfacine HCl	Tenex
guanfacine HCl	guanfacine
haloperidol	haloperidol
haloperidol decanoate	Haldol Decanoate
haloperidol decanoate	haloperidol decanoate
haloperidol lactate	Haldol
haloperidol lactate	haloperidol lactate
hydroxyzine HCl	hydroxyzine HCl
hydroxyzine pamoate	Vistaril
hydroxyzine pamoate	hydroxyzine pamoate
iloperidone	Fanapt
imipramine HCl	Tofranil
imipramine HCl	imipramine HCl
imipramine pamoate	Tofranil-PM
imipramine pamoate	imipramine pamoate
isocarboxazid	Marplan
lamotrigine	Lamictal

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
lamotrigine	Lamictal ODT
lamotrigine	Lamictal ODT Starter (Blue)
lamotrigine	Lamictal ODT Starter (Green)
lamotrigine	Lamictal ODT Starter (Orange)
lamotrigine	Lamictal Starter (Blue) Kit
lamotrigine	Lamictal Starter (Green) Kit
lamotrigine	Lamictal Starter (Orange) Kit
lamotrigine	Lamictal XR
lamotrigine	Lamictal XR Starter (Blue)
lamotrigine	Lamictal XR Starter (Green)
lamotrigine	Lamictal XR Starter (Orange)
lamotrigine	Subvenite
lamotrigine	Subvenite Starter (Blue) Kit
lamotrigine	Subvenite Starter (Green) Kit
lamotrigine	Subvenite Starter (Orange) Kit
lamotrigine	lamotrigine
lemborexant	Dayvigo
levomilnacipran HCl	Fetzima
lisdexamfetamine dimesylate	Vyvanse
lisdexamfetamine dimesylate	lisdexamfetamine
lithium carbonate	Lithobid
lithium carbonate	lithium carbonate
lithium citrate	lithium citrate
lorazepam	Ativan
lorazepam	Lorazepam Intensol
lorazepam	Loreev XR
lorazepam	lorazepam
lorazepam in 0.9 % sodium chloride	lorazepam in 0.9% sod chloride
lorazepam in 5 % dextrose and water	lorazepam in dextrose 5 %
loxapine	Adasuve
loxapine succinate	loxapine succinate
lumateperone tosylate	Caplyta
lurasidone HCl	Latuda
lurasidone HCl	lurasidone
maprotiline HCl	maprotiline
melatonin	Children's Sleep (melatonin)
melatonin	Kids Melatonin
melatonin	Meladox

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
melatonin	Melatin
melatonin	MelatoninMax
melatonin	VitaJoy Melatonin
melatonin	melatonin
melatonin/5-HTP/valerian/folic acid/dietary combination 28	Hypnosom
melatonin/5-Hydroxytryptophan/tryptophan/B6/magnesium oxide	Somnicin
melatonin/5-hydroxytryptophan/theanine/lemon balm leaf xt	Relax Night Calm
melatonin/GABA/5-HTP/theanine/magnesium citrate,oxide/herbs	Sopordren
melatonin/GABA/tryptophan/valerian root/hops/lemon balm	Sleep Optimizer
melatonin/ascorbic acid/vitamin D3/zinc citrate/elderberry	Kids Sleep Immune Health
melatonin/ascorbic acid/vitamin D3/zinc citrate/elderberry	Sleep Immune Health
melatonin/chamomile flower	melatonin-chamomile flower
melatonin/gamma-aminobutyric acid/herbal complex no.183	Sintralyne-PM
melatonin/gamma-aminobutyric acid/valerian	Medi-Doze
melatonin/genistein/herbal complex no.233	Midnite for Menopause
melatonin/herbal complex no.184	Sleep Caps
melatonin/herbal complex no.184	melatonin-herbal complex #184
melatonin/herbal complex no.233	MidNite
melatonin/lemon balm leaf extract	melatonin-lemon balm leaf extr
melatonin/mag carbonate,glycinate/pot bic/GABA/glycine/lemon	Soothing Night
melatonin/magnesium citrate	SlowMag Mg Calm-Sleep
melatonin/passion flower/lemon balm	Unisom Simple Slumbers
melatonin/pyridoxal phosphate	Melatonin-B6 (pyridoxal phos)
melatonin/pyridoxal phosphate	melatonin-pyridoxal phos (B6)
melatonin/pyridoxine	Melatonin (with B6)
melatonin/pyridoxine	melatonin-pyridoxine (vit B6)
melatonin/pyridoxine HCl (vit B6)	Melatonex
melatonin/pyridoxine HCl (vit B6)	melatonin-pyridoxine HCl (B6)
melatonin/theanine	melatonin-theanine
melatonin/theanine/lemon balm/chamomile flower/lavender	Kids Sleep Calm
melatonin/theanine/lemon balm/chamomile flower/lavender	Sleep Calm
melatonin/tryptophan	Restone
melatonin/tryptophan	Wrestone
melatonin/tryptophan/valerian/chamomile/niacin/inositol/B6	Toprophan
meprobamate	meprobamate
methamphetamine HCl	Desoxyn
methamphetamine HCl	methamphetamine
methylphenidate	Cotempla XR-ODT

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
methylphenidate	Daytrana
methylphenidate	methylphenidate
methylphenidate HCl	Adhansia XR
methylphenidate HCl	Aptensio XR
methylphenidate HCl	Concerta
methylphenidate HCl	Jornay PM
methylphenidate HCl	Metadate CD
methylphenidate HCl	Metadate ER
methylphenidate HCl	Methylin
methylphenidate HCl	QuilliChew ER
methylphenidate HCl	Quillivant XR
methylphenidate HCl	Relexxii
methylphenidate HCl	Ritalin
methylphenidate HCl	Ritalin LA
methylphenidate HCl	Ritalin SR
methylphenidate HCl	methylphenidate HCl
midazolam HCl	midazolam
midazolam HCl in 0.9 % sodium chloride	midazolam in 0.9 % sod chlorid
midazolam HCl in 0.9 % sodium chloride/PF	midazolam (PF) in 0.9 % NaCl
midazolam HCl in 5 % dextrose and water/PF	midazolam in dextrose 5 % (PF)
midazolam HCl in dextrose 5% in water	midazolam in dextrose 5 %
midazolam HCl/PF	midazolam (PF)
milnacipran HCl	Savella
mirtazapine	Remeron
mirtazapine	Remeron SolTab
mirtazapine	mirtazapine
molindone HCl	molindone
naltrexone HCl/bupropion HCl	Contrave
nefazodone HCl	nefazodone
nortriptyline HCl	Pamelor
nortriptyline HCl	nortriptyline
olanzapine	Zyprexa
olanzapine	Zyprexa Zydis
olanzapine	olanzapine
olanzapine pamoate	Zyprexa Relprevv
olanzapine/fluoxetine HCl	Symbyax
olanzapine/fluoxetine HCl	olanzapine-fluoxetine
olanzapine/samidorphan malate	Lybalvi

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
oxazepam	oxazepam
oxcarbazepine	Oxtellar XR
oxcarbazepine	Trileptal
oxcarbazepine	oxcarbazepine
paliperidone	Invega
paliperidone	paliperidone
paliperidone palmitate	Invega Hafyera
paliperidone palmitate	Invega Sustenna
paliperidone palmitate	Invega Trinza
paroxetine HCl	Paxil
paroxetine HCl	Paxil CR
paroxetine HCl	paroxetine HCl
paroxetine mesylate	Brisdelle
paroxetine mesylate	Pexeva
paroxetine mesylate	paroxetine mesylate(menop.sym)
pentobarbital sodium	Nembutal Sodium
pentobarbital sodium	pentobarbital sodium
perphenazine	perphenazine
perphenazine/amitriptyline HCl	perphenazine-amitriptyline
phenelzine sulfate	Nardil
phenelzine sulfate	phenelzine
phenobarbital	phenobarbital
phenobarbital sodium	Sezaby
phenobarbital sodium	phenobarbital sodium
phenobarbital sodium in 0.9 % sodium chloride	phenobarbital in 0.9 % sod chl
phenobarbital/hyoscyamine sulf/atropine sulf/scopolamine Hb	B-Donna
phenobarbital/hyoscyamine sulf/atropine sulf/scopolamine Hb	Belladonna-Phenobarbital
phenobarbital/hyoscyamine sulf/atropine sulf/scopolamine Hb	Donnatal
phenobarbital/hyoscyamine sulf/atropine sulf/scopolamine Hb	Me-PB-Hyos
phenobarbital/hyoscyamine sulf/atropine sulf/scopolamine Hb	Phenohytro
phenobarbital/hyoscyamine sulf/atropine sulf/scopolamine Hb	phenobarb-hyoscy-atropine-scop
pimavanserin tartrate	Nuplazid
pimozide	Orap
pimozide	pimozide
prochlorperazine maleate	Compazine
prochlorperazine maleate	prochlorperazine maleate
protriptyline HCl	Vivactil
protriptyline HCl	protriptyline

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
quazepam	Doral
quazepam	quazepam
quetiapine fumarate	Seroquel
quetiapine fumarate	Seroquel XR
quetiapine fumarate	quetiapine
ramelteon	Rozerem
ramelteon	ramelteon
risperidone	Perseris
risperidone	Risperdal
risperidone	Risperdal M-TAB
risperidone	Uzedy
risperidone	risperidone
risperidone microspheres	Risperdal Consta
risperidone microspheres	Rykindo
secobarbital sodium	Seconal Sodium
selegiline	Emsam
selegiline HCl	Eldepryl
selegiline HCl	Zelapar
selegiline HCl	selegiline HCl
serdexmethylphenidate chloride/dexmethylphenidate HCl	Azstarys
sertraline HCl	Zoloft
sertraline HCl	sertraline
suvorexant	Belsomra
tasimelteon	Hetlioz
tasimelteon	Hetlioz LQ
tasimelteon	tasimelteon
temazepam	Restoril
temazepam	temazepam
theanine/5-hydroxytryptophan (5-HTP)/lemon balm leaf extract	Relaxia Day Calm
thioridazine HCl	thioridazine
thiothixene	thiothixene
tranylcypromine sulfate	Parnate
tranylcypromine sulfate	tranylcypromine
trazodone HCl	Oleptro ER
trazodone HCl	trazodone
triazolam	Halcion
triazolam	triazolam
trifluoperazine HCl	trifluoperazine

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
trimipramine maleate	Surmontil
trimipramine maleate	trimipramine
tryptophan	tryptophan
valerian root extract	valerian root extract
valerian root extract/hops	valerian root extract-hops
valerian root/valerian root extract	valerian root-valerian root xt
valerian rt/passion flower/hops/cherry/magnesium comb/potass	SynovX Calm
valerian/passion flower/hops/lemon balm	valerian-flower-hops-lemon
valproic acid	Depakene
valproic acid	Stavzor
valproic acid	valproic acid
valproic acid (as sodium salt) (valproate sodium)	Depacon
valproic acid (as sodium salt) (valproate sodium)	Depakene
valproic acid (as sodium salt) (valproate sodium)	valproate sodium
valproic acid (as sodium salt) (valproate sodium)	valproic acid (as sodium salt)
venlafaxine HCl	Effexor XR
venlafaxine HCl	venlafaxine
venlafaxine besylate	venlafaxine besylate
vilazodone HCl	Viibryd
vilazodone HCl	vilazodone
vit B/folic acid/calcium/soy xt/black cohosh xt/melatonin	Complete Balance Menopause Rlf
vortioxetine hydrobromide	Brintellix
vortioxetine hydrobromide	Trintellix
zaleplon	Sonata
zaleplon	zaleplon
ziprasidone HCl	Geodon
ziprasidone HCl	ziprasidone HCl
ziprasidone mesylate	Geodon
ziprasidone mesylate	ziprasidone mesylate
zolpidem tartrate	Ambien
zolpidem tartrate	Ambien CR
zolpidem tartrate	Edluar
zolpidem tartrate	Intermezzo
zolpidem tartrate	Zolpimist
zolpidem tartrate	zolpidem
Albiglutide	
albiglutide	Tanzeum
Dulaglutide	

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
dulaglutide	Trulicity
Exenatide	
exenatide	Byetta
exenatide microspheres	Bydureon
exenatide microspheres	Bydureon BCise
Liraglutide	
insulin degludec/liraglutide	Xultophy 100/3.6
liraglutide	Saxenda
liraglutide	Victoza 2-Pak
liraglutide	Victoza 3-Pak
Lixisenatide	
insulin glargine,human recombinant analog/lixisenatide	Soliqua 100/33
lixisenatide	Adlyxin
Semaglutide	
semaglutide	Ozempic
semaglutide	Rybelsus
semaglutide	Wegovy
Tirzepatide	
tirzepatide	Mounjaro
Insulin	
insulin NPH human isophane	Humulin N NPH Insulin KwikPen
insulin NPH human isophane	Humulin N NPH U-100 Insulin
insulin NPH human isophane	Novolin N FlexPen
insulin NPH human isophane	Novolin N NPH U-100 Insulin
insulin NPH human isophane/insulin regular, human	Humulin 70/30 U-100 Insulin
insulin NPH human isophane/insulin regular, human	Humulin 70/30 U-100 KwikPen
insulin NPH human isophane/insulin regular, human	Novolin 70-30 FlexPen U-100
insulin NPH human isophane/insulin regular, human	Novolin 70/30 U-100 Insulin
insulin aspart	Novolog FlexPen U-100 Insulin
insulin aspart	Novolog PenFill U-100 Insulin
insulin aspart	Novolog U-100 Insulin aspart
insulin aspart	insulin aspart U-100
insulin aspart (niacinamide)	Fiasp FlexTouch U-100 Insulin
insulin aspart (niacinamide)	Fiasp Penfill U-100 Insulin
insulin aspart (niacinamide)	Fiasp U-100 Insulin
insulin aspart (niacinamide)/pump cartridge	Fiasp Pumpcart
insulin aspart protamine human/insulin aspart	Novolog Mix 70-30 U-100 Insuln
insulin aspart protamine human/insulin aspart	Novolog Mix 70-30FlexPen U-100

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
insulin aspart protamine human/insulin aspart	insulin asp prt-insulin aspart
insulin degludec	Tresiba FlexTouch U-100
insulin degludec	Tresiba FlexTouch U-200
insulin degludec	Tresiba U-100 Insulin
insulin degludec	insulin degludec
insulin degludec/liraglutide	Xultophy 100/3.6
insulin detemir	Levemir FlexPen
insulin detemir	Levemir FlexTouch U100 Insulin
insulin detemir	Levemir U-100 Insulin
insulin glargine,human recombinant analog	Basaglar KwikPen U-100 Insulin
insulin glargine,human recombinant analog	Basaglar Tempo Pen(U-100)Insln
insulin glargine,human recombinant analog	Lantus Solostar U-100 Insulin
insulin glargine,human recombinant analog	Lantus U-100 Insulin
insulin glargine,human recombinant analog	Semglee U-100 Insulin
insulin glargine,human recombinant analog	Toujeo Max U-300 SoloStar
insulin glargine,human recombinant analog	Toujeo SoloStar U-300 Insulin
insulin glargine,human recombinant analog	insulin glargine
insulin glargine,human recombinant analog/lixisenatide	Soliqua 100/33
insulin glargine-aglr	Rezvoglar KwikPen
insulin glargine-yfgn	insulin glargine-yfgn
insulin glulisine	Apidra SoloStar U-100 Insulin
insulin glulisine	Apidra U-100 Insulin
insulin lispro	Admelog SoloStar U-100 Insulin
insulin lispro	Admelog U-100 Insulin lispro
insulin lispro	Humalog Junior KwikPen U-100
insulin lispro	Humalog KwikPen Insulin
insulin lispro	Humalog Tempo Pen(U-100)Insuln
insulin lispro	Humalog U-100 Insulin
insulin lispro	insulin lispro
insulin lispro protamine and insulin lispro	Humalog Mix 50-50 Insuln U-100
insulin lispro protamine and insulin lispro	Humalog Mix 50-50 KwikPen
insulin lispro protamine and insulin lispro	Humalog Mix 75-25 KwikPen
insulin lispro protamine and insulin lispro	Humalog Mix 75-25(U-100)Insuln
insulin lispro protamine and insulin lispro	insulin lispro protamin-lispro
insulin lispro-aabc	Lyumjev KwikPen U-100 Insulin
insulin lispro-aabc	Lyumjev KwikPen U-200 Insulin
insulin lispro-aabc	Lyumjev Tempo Pen(U-100)Insuln
insulin lispro-aabc	Lyumjev U-100 Insulin

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
insulin regular, human	Afrezza
insulin regular, human	Humulin R Regular U-100 Insuln
insulin regular, human	Humulin R U-500 (Conc) Insulin
insulin regular, human	Humulin R U-500 (Conc) Kwikpen
insulin regular, human	Novolin R FlexPen
insulin regular, human	Novolin R Regular U100 Insulin
insulin regular, human in 0.9 % sodium chloride	Myxredlin
Metformin	
alogliptin benzoate/metformin HCl	Kazano
alogliptin benzoate/metformin HCl	alogliptin-metformin
canagliflozin/metformin HCl	Invokamet
canagliflozin/metformin HCl	Invokamet XR
dapagliflozin propanediol/metformin HCl	Xigduo XR
empagliflozin/linagliptin/metformin HCl	Trijardy XR
empagliflozin/metformin HCl	Synjardy
empagliflozin/metformin HCl	Synjardy XR
ertugliflozin pidolate/metformin HCl	Segluromet
glipizide/metformin HCl	glipizide-metformin
glyburide/metformin HCl	Glucovance
glyburide/metformin HCl	glyburide-metformin
linagliptin/metformin HCl	Jentadueto
linagliptin/metformin HCl	Jentadueto XR
metformin HCl	Fortamet
metformin HCl	Glucophage
metformin HCl	Glucophage XR
metformin HCl	Glumetza
metformin HCl	Riomet
metformin HCl	Riomet ER
metformin HCl	metformin
metformin HCl/blood sugar diagnostic	DM2
pioglitazone HCl/metformin HCl	Actoplus MET
pioglitazone HCl/metformin HCl	Actoplus Met XR
pioglitazone HCl/metformin HCl	pioglitazone-metformin
repaglinide/metformin HCl	Prandimet
repaglinide/metformin HCl	repaglinide-metformin
rosiglitazone maleate/metformin HCl	Avandamet
saxagliptin HCl/metformin HCl	Kombiglyze XR
saxagliptin HCl/metformin HCl	saxagliptin-metformin

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
sitagliptin phosphate/metformin HCl	Janumet
sitagliptin phosphate/metformin HCl	Janumet XR
Alpha-glucosidase Inhibitors	
acarbose	Precose
acarbose	acarbose
miglitol	Glyset
miglitol	miglitol
Thiazolidinediones	
pioglitazone HCl	Actos
pioglitazone HCl	pioglitazone
rosiglitazone maleate	Avandia
Meglitinides	
nateglinide	Starlix
nateglinide	nateglinide
repaglinide	Prandin
repaglinide	repaglinide
repaglinide/metformin HCl	Prandimet
repaglinide/metformin HCl	repaglinide-metformin
Amylin Analogues	
pramlintide acetate	SymlinPen 120
pramlintide acetate	SymlinPen 60
Sulfonylureas	
chlorpropamide	chlorpropamide
glimepiride	Amaryl
glimepiride	glimepiride
glipizide	Glucotrol
glipizide	Glucotrol XL
glipizide	glipizide
glipizide/metformin HCl	glipizide-metformin
glyburide	Diabeta
glyburide	glyburide
glyburide,micronized	Glynase
glyburide,micronized	glyburide micronized
glyburide/metformin HCl	Glucovance
glyburide/metformin HCl	glyburide-metformin
pioglitazone HCl/glimepiride	DUETACT
pioglitazone HCl/glimepiride	pioglitazone-glimepiride
rosiglitazone maleate/glimepiride	Avandaryl

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
tolazamide	tolazamide
tolbutamide	tolbutamide
Bile Acid Sequestrants	
colesevelam HCl	WelChol
colesevelam HCl	colesevelam
Benzphetamine	
benzphetamine HCl	Didrex
benzphetamine HCl	Regimex
benzphetamine HCl	benzphetamine
Combination Naltrexone and Bupropion	
naltrexone HCl/bupropion HCl	Contrave
Diethylpropion	
diethylpropion HCl	diethylpropion
Lorcaserin	
lorcaserin HCl	Belviq
lorcaserin HCl	Belviq XR
Phentermine	
phentermine HCl	Adipex-P
phentermine HCl	Lomaira
phentermine HCl	Suprenza
phentermine HCl	phentermine
Phentermine-topiramate	
phentermine HCl/topiramate	Qsymia
Phendimetrazine	
phendimetrazine tartrate	Bontril PDM
phendimetrazine tartrate	phendimetrazine tartrate
Orlistat	
orlistat	Alli
orlistat	Xenical
orlistat	orlistat
Setmelanotide	
setmelanotide acetate	Imcivree
Analgesic Opiates	
TRAMADOL HCL/GLUCOSAMINE SULFATE	Synapryn
acetaminophen with codeine phosphate	Capital with Codeine
acetaminophen with codeine phosphate	Tylenol-Codeine #3
acetaminophen with codeine phosphate	Tylenol-Codeine #4
acetaminophen with codeine phosphate	acetaminophen-codeine

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
acetaminophen/caffeine/dihydrocodeine bitartrate	Dvorah
acetaminophen/caffeine/dihydrocodeine bitartrate	Panlor(acetam-caff-dihydrocod)
acetaminophen/caffeine/dihydrocodeine bitartrate	Trezix
acetaminophen/caffeine/dihydrocodeine bitartrate	acetaminophen-caff-dihydrocod
alfentanil HCl	alfentanil
aspirin/caffeine/dihydrocodeine bitartrate	Synalgos-DC
aspirin/caffeine/dihydrocodeine bitartrate	aspirin-caffeine-dihydrocodein
benzhydrocodone HCl/acetaminophen	Apadaz
benzhydrocodone HCl/acetaminophen	benzhydrocodone-acetaminophen
buprenorphine	Butrans
buprenorphine	buprenorphine
buprenorphine HCl	Belbuca
buprenorphine HCl	Buprenex
buprenorphine HCl	buprenorphine HCl
butalbital/acetaminophen/caffeine/codeine phosphate	Fioricet with Codeine
butalbital/acetaminophen/caffeine/codeine phosphate	butalbital-acetaminop-caf-cod
butorphanol tartrate	butorphanol
carisoprodol/aspirin/codeine phosphate	carisoprodol-aspirin-codeine
codeine phosphate/butalbital/aspirin/caffeine	Ascomp with Codeine
codeine phosphate/butalbital/aspirin/caffeine	Butalbital Compound W/Codeine
codeine phosphate/butalbital/aspirin/caffeine	Butalbital Compound-Codeine
codeine phosphate/butalbital/aspirin/caffeine	Fiorinal-Codeine #3
codeine phosphate/butalbital/aspirin/caffeine	codeine-butalbital-ASA-caff
codeine sulfate	codeine sulfate
difelikefalin acetate	Korsuva
fentanyl	Duragesic
fentanyl	Subsys
fentanyl	fentanyl
fentanyl HCl	Ionsys
fentanyl citrate	Abstral
fentanyl citrate	Actiq
fentanyl citrate	Fentora
fentanyl citrate	Lazanda
fentanyl citrate	fentanyl citrate
fentanyl citrate in 0.9 % sodium chloride/PF	fentanyl citrate (PF)-0.9%NaCl
fentanyl citrate in dextrose 5% in water/PF	fentanyl citrate in D5W (PF)
fentanyl citrate/PF	fentanyl citrate (PF)
fentanyl citrate/bupivacaine HCl in 0.9 % sodium chloride/PF	fentanyl (PF)-bupivacaine-NaCl

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
fentanyl citrate/ropivacaine HCl/sodium chloride 0.9%/PF	fentanyl-ropivacaine-NaCl (PF)
hydrocodone bitartrate	Hysingla ER
hydrocodone bitartrate	Zohydro ER
hydrocodone bitartrate	hydrocodone bitartrate
hydrocodone bitartrate/acetaminophen	Hycet
hydrocodone bitartrate/acetaminophen	Lorcet (hydrocodone)
hydrocodone bitartrate/acetaminophen	Lorcet HD
hydrocodone bitartrate/acetaminophen	Lorcet Plus
hydrocodone bitartrate/acetaminophen	Lortab 10-325
hydrocodone bitartrate/acetaminophen	Lortab 5-325
hydrocodone bitartrate/acetaminophen	Lortab 7.5-325
hydrocodone bitartrate/acetaminophen	Lortab Elixir
hydrocodone bitartrate/acetaminophen	Norco
hydrocodone bitartrate/acetaminophen	Verdrocet
hydrocodone bitartrate/acetaminophen	Vicodin
hydrocodone bitartrate/acetaminophen	Vicodin ES
hydrocodone bitartrate/acetaminophen	Vicodin HP
hydrocodone bitartrate/acetaminophen	Xodol 10/300
hydrocodone bitartrate/acetaminophen	Xodol 5/300
hydrocodone bitartrate/acetaminophen	Xodol 7.5/300
hydrocodone bitartrate/acetaminophen	Zamicet
hydrocodone bitartrate/acetaminophen	hydrocodone-acetaminophen
hydrocodone/ibuprofen	Ibudone
hydrocodone/ibuprofen	Reprexain
hydrocodone/ibuprofen	Vicoprofen
hydrocodone/ibuprofen	Xylon 10
hydrocodone/ibuprofen	hydrocodone-ibuprofen
hydromorphone HCl	Dilaudid
hydromorphone HCl	Exalgo ER
hydromorphone HCl	hydromorphone
hydromorphone HCl in 0.9 % sodium chloride	hydromorphone in 0.9 % NaCl
hydromorphone HCl in 0.9 % sodium chloride/PF	hydromorphone (PF)-0.9 % NaCl
hydromorphone HCl in dextrose 5 %-water/PF	hydromorphone in D5W (PF)
hydromorphone HCl in sodium chloride, iso-osmotic/PF	hydromorphone(PF)-NaCl,iso-osm
hydromorphone HCl in sterile water/PF	hydromorphone (PF) in water
hydromorphone HCl/PF	Dilaudid (PF)
hydromorphone HCl/PF	Dilaudid-HP (PF)
hydromorphone HCl/PF	hydromorphone (PF)

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
hydromorphone HCl/bupivacaine HCl in 0.9% sodium chloride/PF	hydromorphone-bupiv (PF)-NaCl
hydromorphone HCl/ropivacaine in 0.9 % sodium chloride/PF	hydromorph(PF)-ropiv-0.9% NaCl
ibuprofen/oxycodone HCl	ibuprofen-oxycodone
levorphanol tartrate	levorphanol tartrate
meperidine HCl	Demerol
meperidine HCl	meperidine
meperidine HCl in 0.9 % sodium chloride	meperidine in 0.9 % NaCl
meperidine HCl in 0.9 % sodium chloride/PF	meperidine (PF) in 0.9 % NaCl
meperidine HCl/PF	Demerol (PF)
meperidine HCl/PF	meperidine (PF)
methadone HCl	Diskets
methadone HCl	Dolophine
methadone HCl	Methadone Intensol
methadone HCl	Methadose
methadone HCl	methadone
methadone hydrochloride in 0.9 % sodium chloride	methadone in 0.9 % sod.chlorid
morphine sulfate	Arymo ER
morphine sulfate	Avinza
morphine sulfate	Kadian
morphine sulfate	MS Contin
morphine sulfate	MorphaBond ER
morphine sulfate	morphine
morphine sulfate	morphine concentrate
morphine sulfate in 0.9 % sodium chloride	morphine in 0.9 % sodium chlor
morphine sulfate in 0.9 % sodium chloride/PF	morphine (PF) in 0.9 % sod chl
morphine sulfate in sodium chloride, iso-osmotic/PF	morphine(PF)in iso sod chlorid
morphine sulfate liposomal/PF	DepoDur (PF)
morphine sulfate/PF	Duramorph (PF)
morphine sulfate/PF	Infumorph P/F
morphine sulfate/PF	Mitigo (PF)
morphine sulfate/PF	morphine (PF)
morphine sulfate/dextrose 5 % in water	morphine in dextrose 5 %
morphine sulfate/dextrose 5%-water/PF	morphine (PF) in dextrose 5 %
morphine sulfate/naltrexone HCl	Embeda
nalbuphine HCl	nalbuphine
naltrexone HCl	Lotrexone
naltrexone HCl	Naltrex
oliceridine fumarate	Olinvyk

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
oxycodone HCl	Oxaydo
oxycodone HCl	Oxecta
oxycodone HCl	OxyContin
oxycodone HCl	Roxicodone
oxycodone HCl	RoxyBond
oxycodone HCl	oxycodone
oxycodone HCl/acetaminophen	Endocet
oxycodone HCl/acetaminophen	Nalocet
oxycodone HCl/acetaminophen	Percocet
oxycodone HCl/acetaminophen	Primlev
oxycodone HCl/acetaminophen	Prolate
oxycodone HCl/acetaminophen	Roxicet
oxycodone HCl/acetaminophen	Xartemis XR
oxycodone HCl/acetaminophen	oxycodone-acetaminophen
oxycodone HCl/aspirin	Endodan
oxycodone HCl/aspirin	Percodan
oxycodone HCl/aspirin	oxycodone-aspirin
oxycodone myristate	Xtampza ER
oxymorphone HCl	Opana
oxymorphone HCl	Opana ER
oxymorphone HCl	oxymorphone
pentazocine HCl/naloxone HCl	pentazocine-naloxone
pentazocine lactate	Talwin
sufentanil citrate	Dsuvia
sufentanil citrate/bupivacaine HCl/0.9 % sodium chloride/PF	sufentanil-bupivacain-NaCl(PF)
tapentadol HCl	Nucynta
tapentadol HCl	Nucynta ER
tramadol HCl	ConZip
tramadol HCl	Qdolo
tramadol HCl	Ultram
tramadol HCl	Ultram ER
tramadol HCl	tramadol
tramadol HCl/acetaminophen	Ultracet
tramadol HCl/acetaminophen	tramadol-acetaminophen
tramadol HCl/celecoxib	Seglentis
Antipsychotics	
acepromazine maleate	acepromazine maleate (bulk)
aripiprazole	Abilify

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
aripiprazole	Abilify Asimtufii
aripiprazole	Abilify Discmelt
aripiprazole	Abilify Maintena
aripiprazole	Abilify MyCite
aripiprazole	Abilify MyCite Maintenance Kit
aripiprazole	Abilify MyCite Starter Kit
aripiprazole	aripiprazole
aripiprazole lauroxil	Aristada
aripiprazole lauroxil, submicronized	Aristada Initio
asenapine	Secuado
asenapine maleate	Saphris
asenapine maleate	Saphris (black cherry)
asenapine maleate	asenapine maleate
brexpiprazole	Rexulti
cariprazine HCl	Vraylar
chlorpromazine HCl	chlorpromazine
chlorpromazine HCl	chlorpromazine (bulk)
clozapine	Clozaril
clozapine	FazaClo
clozapine	Versacloz
clozapine	clozapine
fluphenazine HCl	fluphenazine HCl
fluphenazine decanoate	fluphenazine decanoate
fluphenazine decanoate	fluphenazine decanoate (bulk)
haloperidol	haloperidol
haloperidol	haloperidol (bulk)
haloperidol decanoate	Haldol Decanoate
haloperidol decanoate	haloperidol decanoate
haloperidol decanoate	haloperidol decanoate (bulk)
haloperidol lactate	Haldol
haloperidol lactate	haloperidol lactate
iloperidone	Fanapt
loxapine	Adasuve
loxapine succinate	loxapine succinate
lumateperone tosylate	Caplyta
lurasidone HCl	Latuda
lurasidone HCl	lurasidone
molindone HCl	molindone

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
olanzapine	Zyprexa
olanzapine	Zyprexa Zydis
olanzapine	olanzapine
olanzapine pamoate	Zyprexa Relprevv
olanzapine/fluoxetine HCl	Symbyax
olanzapine/fluoxetine HCl	olanzapine-fluoxetine
olanzapine/samidorphan malate	Lybalvi
paliperidone	Invega
paliperidone	paliperidone
paliperidone palmitate	Invega Hafyera
paliperidone palmitate	Invega Sustenna
paliperidone palmitate	Invega Trinza
perphenazine	perphenazine
perphenazine	perphenazine (bulk)
perphenazine/amitriptyline HCl	perphenazine-amitriptyline
pimavanserin tartrate	Nuplazid
pimozide	Orap
pimozide	pimozide
prochlorperazine maleate	Compazine
prochlorperazine maleate	prochlorperazine maleate
quetiapine fumarate	Seroquel
quetiapine fumarate	Seroquel XR
quetiapine fumarate	quetiapine
risperidone	Perseris
risperidone	Risperdal
risperidone	Risperdal M-TAB
risperidone	Uzedy
risperidone	risperidone
risperidone microspheres	Risperdal Consta
risperidone microspheres	Rykindo
thioridazine HCl	thioridazine
thioridazine HCl	thioridazine (bulk)
thiothixene	thiothixene
trifluoperazine HCl	trifluoperazine
ziprasidone HCl	Geodon
ziprasidone HCl	ziprasidone HCl
ziprasidone mesylate	Geodon
ziprasidone mesylate	ziprasidone mesylate

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
Anxiolytics/Hypnotics	
alprazolam	Alprazolam Intensol
alprazolam	Xanax
alprazolam	Xanax XR
alprazolam	alprazolam
amobarbital sodium	Amytal
bromelains/melatonin/herbal complex no.233	MidNite PM
buspirone HCl	buspirone
butabarbital sodium	Butisol
calcium carb,hydroxide/soy isoflavone/black cohosh/melatonin	Estroven Nighttime (cal-meltn)
calcium phosphate/melatonin	calcium-melatonin
chlordiazepoxide HCl	chlordiazepoxide HCl
clonazepam	Klonopin
clonazepam	clonazepam
clorazepate dipotassium	Tranxene T-Tab
clorazepate dipotassium	clorazepate dipotassium
daridorexant HCl	Quviviq
dexmedetomidine HCl	Igalmi
dexmedetomidine HCl	Precedex
dexmedetomidine HCl	dexmedetomidine
dexmedetomidine HCl in 0.9 % sodium chloride	Precedex in 0.9 % sodium chlor
dexmedetomidine HCl in 0.9 % sodium chloride	dexmedetomidine in 0.9 % NaCl
dexmedetomidine in 5 % dextrose in water	dexmedetomidine in dextrose 5%
diazepam	Diazepam Intensol
diazepam	Valium
diazepam	diazepam
doxepin HCl	Silenor
doxepin HCl	doxepin
estazolam	estazolam
eszopiclone	Lunesta
eszopiclone	eszopiclone
ethyl alcohol/herbal drugs	Lydia Pinkham Herbal
flurazepam HCl	flurazepam
hydroxyzine HCl	hydroxyzine HCl
hydroxyzine pamoate	Vistaril
hydroxyzine pamoate	hydroxyzine pamoate
lemborexant	Dayvigo
lorazepam	Ativan

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
lorazepam	Lorazepam Intensol
lorazepam	Loreev XR
lorazepam	lorazepam
lorazepam in 0.9 % sodium chloride	lorazepam in 0.9% sod chloride
lorazepam in 5 % dextrose and water	lorazepam in dextrose 5 %
melatonin	Kids Melatonin
melatonin	Meladox
melatonin	Melatin
melatonin	MelatoninMax
melatonin	VitaJoy Melatonin
melatonin	melatonin
melatonin/5-HTP/valerian/folic acid/dietary combination 28	Hypnosom
melatonin/5-Hydroxytryptophan/tryptophan/B6/magnesium oxide	Somnicin
melatonin/5-hydroxytryptophan/theanine/lemon balm leaf xt	Relax Night Calm
melatonin/GABA/5-HTP/theanine/magnesium citrate,oxide/herbs	Sopordren
melatonin/GABA/tryptophan/valerian root/hops/lemon balm	Sleep Optimizer
melatonin/ascorbic acid/vitamin D3/zinc citrate/elderberry	Kids Sleep Immune Health
melatonin/ascorbic acid/vitamin D3/zinc citrate/elderberry	Sleep Immune Health
melatonin/chamomile flower	melatonin-chamomile flower
melatonin/gamma-aminobutyric acid/herbal complex no.183	Sintralyne-PM
melatonin/gamma-aminobutyric acid/valerian	Medi-Doze
melatonin/genistein/herbal complex no.233	Midnite for Menopause
melatonin/herbal complex no.184	Sleep Caps
melatonin/herbal complex no.184	melatonin-herbal complex #184
melatonin/herbal complex no.233	MidNite
melatonin/lemon balm leaf extract	melatonin-lemon balm leaf extr
melatonin/mag carbonate,glycinate/pot bic/GABA/glycine/lemon	Soothing Night
melatonin/magnesium citrate	SlowMag Mg Calm-Sleep
melatonin/passion flower/lemon balm	Unisom Simple Slumbers
melatonin/pyridoxal phosphate	Melatonin-B6 (pyridoxal phos)
melatonin/pyridoxal phosphate	melatonin-pyridoxal phos (B6)
melatonin/pyridoxine	Melatonin (with B6)
melatonin/pyridoxine	melatonin-pyridoxine (vit B6)
melatonin/pyridoxine HCl (vit B6)	Melatonex
melatonin/pyridoxine HCl (vit B6)	melatonin-pyridoxine HCl (B6)
melatonin/theanine	melatonin-theanine
melatonin/theanine/lemon balm/chamomile flower/lavender	Kids Sleep Calm
melatonin/theanine/lemon balm/chamomile flower/lavender	Sleep Calm

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
melatonin/tryptophan	Restone
melatonin/tryptophan	Wrestone
melatonin/tryptophan/valerian/chamomile/niacin/inositol/B6	Toprophan
meprobamate	meprobamate
midazolam HCl	midazolam
oxazepam	oxazepam
pentobarbital sodium	Nembutal Sodium
pentobarbital sodium	pentobarbital sodium
phenobarbital	phenobarbital
phenobarbital sodium	phenobarbital sodium
phenobarbital sodium in 0.9 % sodium chloride	phenobarbital in 0.9 % sod chl
quazepam	Doral
quazepam	quazepam
ramelteon	Rozerem
ramelteon	ramelteon
secobarbital sodium	Seconal Sodium
suvorexant	Belsomra
tasimelteon	Hetlioz
tasimelteon	Hetlioz LQ
tasimelteon	tasimelteon
temazepam	Restoril
temazepam	temazepam
triazolam	Halcion
triazolam	triazolam
tryptophan	tryptophan
valerian root extract	valerian root extract
valerian root extract/hops	valerian root extract-hops
valerian root/valerian root extract	valerian root-valerian root xt
valerian rt/passion flower/hops/cherry/magnesium comb/potass	SynovX Calm
valerian/passion flower/hops/lemon balm	valerian-flower-hops-lemon
vit B/folic acid/calcium/soy xt/black cohosh xt/melatonin	Complete Balance Menopause Rlf
zaleplon	Sonata
zaleplon	zaleplon
zolpidem tartrate	Ambien
zolpidem tartrate	Ambien CR
zolpidem tartrate	Edluar
zolpidem tartrate	Intermezzo
zolpidem tartrate	Zolpimist

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
zolpidem tartrate	zolpidem
Lithium and Other Mood Stabilizers	
carbamazepine	Carbatrol
carbamazepine	Epitol
carbamazepine	Equetro
carbamazepine	Tegretol
carbamazepine	Tegretol XR
carbamazepine	carbamazepine
clonazepam	Klonopin
clonazepam	clonazepam
divalproex sodium	Depakote
divalproex sodium	Depakote ER
divalproex sodium	Depakote Sprinkles
divalproex sodium	divalproex
lamotrigine	Lamictal
lamotrigine	Lamictal ODT
lamotrigine	Lamictal ODT Starter (Blue)
lamotrigine	Lamictal ODT Starter (Green)
lamotrigine	Lamictal ODT Starter (Orange)
lamotrigine	Lamictal Starter (Blue) Kit
lamotrigine	Lamictal Starter (Green) Kit
lamotrigine	Lamictal Starter (Orange) Kit
lamotrigine	Lamictal XR
lamotrigine	Lamictal XR Starter (Blue)
lamotrigine	Lamictal XR Starter (Green)
lamotrigine	Lamictal XR Starter (Orange)
lamotrigine	Subvenite
lamotrigine	Subvenite Starter (Blue) Kit
lamotrigine	Subvenite Starter (Green) Kit
lamotrigine	Subvenite Starter (Orange) Kit
lamotrigine	lamotrigine
lithium carbonate	Lithobid
lithium carbonate	lithium carbonate
lithium citrate	lithium citrate
oxcarbazepine	Oxtellar XR
oxcarbazepine	Trileptal
oxcarbazepine	oxcarbazepine
valproic acid	Depakene

Appendix BG. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Covariates in this Request

Generic/Nonproprietary Name	Brand/Proprietary Name
valproic acid	Stavzor
valproic acid	valproic acid
valproic acid (as sodium salt) (valproate sodium)	Depacon
valproic acid (as sodium salt) (valproate sodium)	Depakene
valproic acid (as sodium salt) (valproate sodium)	valproate sodium
valproic acid (as sodium salt) (valproate sodium)	valproic acid (as sodium salt)

Appendix CA: Specifications Defining Parameters for Covariates for this Request

Baseline Characteristics

Covariate Number	Covariate	Include in Baseline Table?	Include in Propensity Score model?	Create Subgroup?	Care setting
	Demographics				
	Calendar year	Yes	Yes	No	N/A
	Age (in years) at index date	Yes	Yes	No	N/A
	Sex	Yes	Yes	No	N/A
	Psychiatric history				
1	Previous ISH in any care setting ever	Yes	No	No	Any
74	Psychiatric history overall	Yes	Yes	Yes	N/A
2	Psychiatric drug dispensings	Yes	No	--	N/A
3	Self harm encounter (Patrick algorithm for ICD-9 era)	Yes	No	Yes	Any
4	Any other psychiatric event (inpatient, outpatient, ED; including psychotherapy)	Yes	No	--	Any
5	ADHD (Attention-deficit/hyperactivity disorder)	Yes	No	No	Any
6	Akathisia	Yes	No	No	Any
7	Anxiety	Yes	No	No	Any
8	Behavioral Disorder	Yes	No	No	Any
9	Bipolar Disorder	Yes	No	No	Any
10	Cerebral degenerations usually manifested in childhood	Yes	No	No	Any
11	Conduct Disorder	Yes	No	No	Any
12	Delirium	Yes	No	No	Any
13	Depression	Yes	No	No	Any
14	Electroconvulsive Therapy	Yes	No	No	Any
15	Hallucination	Yes	No	No	Any
16	Obsessive-Compulsive Disorder	Yes	No	No	Any
17	Other Cerebral degenerations	Yes	No	No	Any
18	Other mental disorders	Yes	No	No	Any
19	Other Psychological Disorders	Yes	No	No	Any

Appendix CA: Specifications Defining Parameters for Covariates for this Request

Baseline Characteristics

Covariate Number	Covariate	Include in Baseline Table?	Include in Propensity Score model?	Create Subgroup?	Care setting
20	Persistent mental disorders due to conditions classified elsewhere	Yes	No	No	Any
21	Personality disorders	Yes	No	No	Any
22	Pervasive developmental disorders	Yes	No	No	Any
23	Post-traumatic stress disorder	Yes	No	No	Any
24	Psychotherapy	Yes	No	No	Any
25	Psychotic Conditions	Yes	No	No	Any
26	Schizophrenia	Yes	No	No	Any
27	Sleep disorder	Yes	No	No	Any
28	Substance abuse	Yes	No	No	Any
29	Suicidal behavior	Yes	No	No	Any
30	Transcranial magnetic stimulation	Yes	No	No	Any
31	Vagus nerve stimulation	Yes	No	No	Any
	Medical History				
	Combined comorbidity score	Yes	Yes	No	Any
	Diabetes severity score (aDCSI)	Yes	Yes	No	Any
32	Obesity diagnosis	Yes	Yes	No	Any
73	Weight reduction surgery or procedure	Yes	Yes	No	N/A
53	Lifestyle intervention	Yes	Yes	No	N/A
33	Cardiovascular Disease	Yes	Yes	No	Any
34	Cognitive impairment (Alzheimer's Disease and Related Disorders, Senile Dementia)	Yes	Yes	No	Any
35	Traumatic brain injury (traumatic brain injury and nonpsychotic disorders due to brain damage)	Yes	Yes	No	Any
36	Migraine	Yes	Yes	No	Any
37	Epilepsy	Yes	Yes	No	Any
38	Chronic Pain	Yes	Yes	No	Any
	Drug Use History				

Appendix CA: Specifications Defining Parameters for Covariates for this Request

Baseline Characteristics

Covariate Number	Covariate	Include in Baseline Table?	Include in Propensity Score model?	Create Subgroup?	Care setting
	GLP1-RA Product	No	No	No	N/A
39	albiglutide	Yes	No	No	N/A
40	dulaglutide	Yes	No	No	N/A
41	exenatide	Yes	No	No	N/A
42	liraglutide	Yes	No	No	N/A
43	lixisenatide	Yes	No	No	N/A
44	semaglutide	Yes	No	No	N/A
45	tirzepatide	Yes	No	No	N/A
54	Any anti-diabetic agents	Yes	No	No	N/A
55	insulin	Yes	Yes	No	N/A
56	metformin	Yes	Yes	No	N/A
57	alpha-glucosidase inhibitors	Yes	Yes	No	N/A
58	thiazolidinediones	Yes	Yes	No	N/A
69	meglitinides (nateglinide, repaglinide)	Yes	Yes	No	N/A
70	amylin analogue (pramlintide)	Yes	Yes	No	N/A
71	sulfonylureas	Yes	Yes	No	N/A
72	bile acid sequestrants (colesevelam)	Yes	Yes	No	N/A
59	Other weight loss agents	Yes	Yes	No	N/A
60	benzphetamine	Yes	No	No	N/A
61	combination naltrexone and bupropion	Yes	No	No	N/A
62	diethylpropion	Yes	No	No	N/A
63	lorcaserin	Yes	No	No	N/A
64	phentermine	Yes	No	No	N/A
65	phentermine-topiramate	Yes	No	No	N/A
66	phendimetrazine	Yes	No	No	N/A
67	orlistat	Yes	No	No	N/A
68	setmelanotide	Yes	No	No	N/A
	Other agents	No	No	No	N/A

Appendix CA: Specifications Defining Parameters for Covariates for this Request

Baseline Characteristics

Covariate Number	Covariate	Include in Baseline Table?	Include in Propensity Score model?	Create Subgroup?	Care setting
46	Analgesic opiates	Yes	Yes	No	N/A
47	Antipsychotics	Yes	No	No	N/A
48	Anxiolytics/hypnotics	Yes	No	No	N/A
49	Lithium & other mood stabilizers	Yes	No	No	N/A
50	Antidepressants	Yes	No	No	N/A
	Health Service Utilization Intensity				
	Mean number of ambulatory encounters	Yes	Yes	No	Ambulatory
	Mean number of inpatient encounters	Yes	Yes	No	Inpatient
	Mean number of non-acute institutional stays	Yes	Yes	No	Institutional Stay
	Mean number of ED visits	Yes	Yes	No	Emergency
	Mean number of other ambulatory visits	Yes	Yes	No	Other Ambulatory
	Count of dispensings	Yes	Yes	No	N/A
	Count of unique generic names dispensed	Yes	Yes	No	N/A
	Count of unique class names dispensed	Yes	Yes	No	N/A

Appendix CA: Specifications Defining Parameters for Covariates for this Request

Baseline Characteristics

Covariate Number	Principal diagnosis position	Code Category	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensings	Number of instances the covariate should be found in evaluation period
	Demographics					
	N/A	N/A	0	0	N/A	N/A
	N/A	N/A	0	0	N/A	N/A
	N/A	N/A	0	0	N/A	N/A
	Psychiatric History					
1	Any	Diagnosis	Ever	-1	N/A	1
74	N/A	Drug Code; Procedure Codes; Diagnosis Codes	N/A	N/A	N/A	1
2	N/A	Drug Code; Procedure Codes	-183	0	Dispensing and days supply	1
3	Any	Diagnosis	-183	-1	N/A	1
4	Any	Diagnosis	-183	0	N/A	1
5	Any	Diagnosis	-183	0	N/A	1
6	Any	Diagnosis	-183	0	N/A	1
7	Any	Diagnosis	-183	0	N/A	1
8	Any	Diagnosis	-183	0	N/A	1
9	Any	Diagnosis	-183	0	N/A	1
10	Any	Diagnosis	-183	0	N/A	1
11	Any	Diagnosis	-183	0	N/A	1
12	Any	Diagnosis	-183	0	N/A	1
13	Any	Diagnosis	-183	0	N/A	1
14	Any	Diagnosis	-183	0	N/A	1
15	Any	Diagnosis	-183	0	N/A	1
16	Any	Diagnosis	-183	0	N/A	1
17	Any	Diagnosis	-183	0	N/A	1
18	Any	Diagnosis	-183	0	N/A	1
19	Any	Diagnosis	-183	0	N/A	1

Appendix CA: Specifications Defining Parameters for Covariates for this Request

Baseline Characteristics

Covariate Number	Principal diagnosis position	Code Category	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensings	Number of instances the covariate should be found in evaluation period
20	Any	Diagnosis	-183	0	N/A	1
21	Any	Diagnosis	-183	0	N/A	1
22	Any	Diagnosis	-183	0	N/A	1
23	Any	Diagnosis	-183	0	N/A	1
24	Any	Diagnosis	-183	0	N/A	1
25	Any	Diagnosis	-183	0	N/A	1
26	Any	Diagnosis	-183	0	N/A	1
27	Any	Diagnosis	-183	0	N/A	1
28	Any	Diagnosis	-183	0	N/A	1
29	Any	Diagnosis	-183	0	N/A	1
30	Any	Diagnosis	-183	0	N/A	1
31	Any	Diagnosis	-183	0	N/A	1
	Medical History					
	N/A	N/A	-183	0	N/A	N/A
	N/A	N/A	-183	0	N/A	N/A
32	Any	Diagnosis	-183	0	N/A	1
73	N/A	Procedure	-183	-1	N/A	1
53	N/A	Procedure	-183	-1	N/A	1
33	Any	Diagnosis	-183	0	N/A	1
34	Any	Diagnosis	-183	0	N/A	1
35	Any	Diagnosis	-183	0	N/A	1
36	Any	Diagnosis	-183	0	N/A	1
37	Any	Diagnosis	-183	0	N/A	1
38	Any	Diagnosis	-183	0	N/A	1
	Drug Use History					

Appendix CA: Specifications Defining Parameters for Covariates for this Request

Baseline Characteristics						
Covariate Number	Principal diagnosis position	Code Category	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensings	Number of instances the covariate should be found in evaluation period
	N/A					
39	N/A	Drug Code; Procedure Codes	0	0	Dispensing date only	1
40	N/A	Drug Code; Procedure Codes	0	0	Dispensing date only	1
41	N/A	Drug Code; Procedure Codes	0	0	Dispensing date only	1
42	N/A	Drug Code; Procedure Codes	0	0	Dispensing date only	1
43	N/A	Drug Code; Procedure Codes	0	0	Dispensing date only	1
44	N/A	Drug Code; Procedure Codes	0	0	Dispensing date only	1
45	N/A	Drug Code; Procedure Codes	0	0	Dispensing date only	1
54	N/A	Drug Code	-183	0	Dispensing and days supply	1
55	N/A	Drug Code; Procedure Codes	-183	0	Dispensing and days supply	1
56	N/A	Drug Code	-183	0	Dispensing and days supply	1
57	N/A	Drug Code	-183	0	Dispensing and days supply	1
58	N/A	Drug Code	-183	0	Dispensing and days supply	1
69	N/A	Drug Code	-183	0	Dispensing and days supply	1
70	N/A	Drug Code	-183	0	Dispensing and days supply	1
71	N/A	Drug Code	-183	0	Dispensing and days supply	1
72	N/A	Drug Code	-183	0	Dispensing and days supply	1
59	N/A	Drug Code	-183	0	Dispensing and days supply	1
60	N/A	Drug Code	-183	0	Dispensing and days supply	1
61	N/A	Drug Code	-183	0	Dispensing and days supply	1
62	N/A	Drug Code	-183	0	Dispensing and days supply	1
63	N/A	Drug Code	-183	0	Dispensing and days supply	1
64	N/A	Drug Code	-183	0	Dispensing and days supply	1
65	N/A	Drug Code	-183	0	Dispensing and days supply	1
66	N/A	Drug Code	-183	0	Dispensing and days supply	1
67	N/A	Drug Code	-183	0	Dispensing and days supply	1

Appendix CA: Specifications Defining Parameters for Covariates for this Request

Baseline Characteristics						
Covariate Number	Principal diagnosis position	Code Category	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensings	Number of instances the covariate should be found in evaluation period
68	N/A	Drug Code; Procedure Codes	-183	0	Dispensing and days supply	1
	N/A					
46	N/A	Drug Code; Procedure Codes	-183	0	Dispensing and days supply	1
47	N/A	Drug Code; Procedure Codes	-183	0	Dispensing and days supply	1
48	N/A	Drug Code; Procedure Codes	-183	0	Dispensing and days supply	1
49	N/A	Drug Code	-183	0	Dispensing and days supply	1
50	N/A	Drug Code	-183	0	Dispensing and days supply	1
	Health Service Utilization Intensity					
	N/A	N/A	-183	0	N/A	N/A
	N/A	N/A	-183	0	N/A	N/A
	N/A	N/A	-183	0	N/A	N/A
	N/A	N/A	-183	0	N/A	N/A
	N/A	N/A	-183	0	N/A	N/A
	N/A	N/A	-183	0	N/A	N/A
	N/A	N/A	-183	0	N/A	N/A
	N/A	N/A	-183	0	N/A	N/A

Appendix CB: Specifications Defining Parameters for this Request

This report executed the Cohort Identification and Descriptive Analysis (CIDA) tool (version 13.0.1) to investigate whether there is an increased risk of intentional self-harm among diabetic patients who receive GLP-1 receptor agonists compared to SGLT-2 inhibitors and DPP4 inhibitors. This query includes additional programming to construct the 2+ dispensing cohort and to produce additional plots.

Query Period: 10/1/2015 - 09/30/2023
Coverage Requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 183 days
Enrollment gap: 45 days
Restrictions: None
Age groups: 18-24, 25-44, 45-64, 65-79, 80+
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Distribution of index-defining codes: Y
Freeze data: Y

	GLP-1RA vs. SGLT2i Comparison		GLP-1RA vs. DPP4i Comparison	
Logic				
Group	glp1ra	sglt2i	glp1ra	dpp4i
Drug/Exposure				
Index Exposure/Comparator	GLP-1 receptor agonists	SGLT2 inhibitors	GLP-1 receptor agonists	DPP4 inhibitors
Cohort Definition	First valid exposure episodes during query period		First valid exposure episodes during query period	
Incidence Exposure washout period	(-183, -1)		(-183, -1)	
Incident w/ Respect to:	GLP1RA SGLT2i DPP4i	GLP1RA SGLT2i DPP4i	GLP1RA SGLT2i DPP4i	GLP1RA SGLT2i DPP4i
Exclude evidence of days supply if exposure washout include	Washout lookback period should search for only evidence of a dispensing date		Washout lookback period should search for only evidence of a dispensing date	
Stockpiling	See stockpiling tab		See stockpiling tab	
Build Episodes on Point Exposure?	No		No	
Treatment Episode Gap	30 days		30 days	
Exposure episode extension	30 days		30 days	
Minimum days supplied	1 day		1 day	

	GLP-1RA vs. SGLT2i Comparison	GLP-1RA vs. DPP4i Comparison
Incidence Criteria Care Setting	Any	Any
Principal Diagnosis Position	Any	Any
Forced supply to attach to dispensings	N/A	N/A
Create Baseline Table?	Yes	Yes
Inclusion/Exclusion Criteria		
Inclusion/Exclusion group	Type 2 Diabetes diagnosis *(1 T2DM code AND 1 oral anti-diabetic dispensing)*	Type 2 diabetes diagnosis *(1 T2DM code AND 1 oral anti-diabetic dispensing)*
Type of criteria	Inclusion	Inclusion
Evaluation Period Start	-183	-183
Evaluation Period End	0	0
Care Setting/PDX	Any care setting	Any care setting
Principal Diagnosis	Any	Any
supply if inclusion/exclusion evaluation period includes dispensings	N/A	N/A
Number of instances the criteria should be found in the evaluation period	1	1
Inclusion/Exclusion group		
Type of criteria		
Evaluation Period Start		
Evaluation Period End		
Care Setting/PDX		
Principal Diagnosis		
Exclude evidence of days supply if inclusion/exclusion evaluation period includes dispensings		
Number of instances the criteria should be found in the evaluation period		

	GLP-1RA vs. SGLT2i Comparison		GLP-1RA vs. DPP4i Comparison	
Inclusion/Exclusion group	Other Diabetes diagnosis *(1 insulin code AND no code for antidiabetics)* OR *(1 T1DM code)* OR *(1 GDM/secondary DM code)*		Other Diabetes diagnosis *(1 insulin code AND no code for antidiabetics)* OR *(1 T1DM code)* OR *(1 GDM/secondary DM code)*	
Type of criteria	Exclusion		Exclusion	
Evaluation Period Start	-183		-183	
Evaluation Period End	0		0	
Care Setting/PDX	Any care setting		Any care setting	
Principal Diagnosis	Any		Any	
supply if inclusion/exclusion evaluation period includes dispensings	N/A		N/A	
Number of instances the criteria should be found in the evaluation period	1		1	
Inclusion/Exclusion group	SGLT2i DPP4i	GLP-1 RA DPP4i	DPP4i SGLT2i	GLP-1 RA SGLT2i
Type of criteria	Exclusion		Exclusion	
Evaluation Period Start	-183		-183	
Evaluation Period End	0		0	
Care Setting/PDX	Any		Any	
Principal Diagnosis	Any		Any	
supply if inclusion/exclusion evaluation period includes dispensings	Evaluation period should search for evidence of days supply		Evaluation period should search for evidence of days supply	
Number of instances the criteria should be found in the evaluation period	1		1	
Inclusion/Exclusion group	Pregnancy		Pregnancy	
Type of criteria	Exclusion		Exclusion	
Evaluation Period Start	-183 days		-183 days	

	GLP-1RA vs. SGLT2i Comparison		GLP-1RA vs. DPP4i Comparison	
Evaluation Period End	0		0	
Care Setting/PDX	Any		Any	
Position	Any		Any	
supply if inclusion/exclusion evaluation period includes dispensings	N/A		N/A	
Number of instances the criteria should be found in the evaluation period	1		1	
Inclusion/Exclusion group	GLP-1RA	SGLT2i	GLP-1 RA	DPP4i
Type of criteria	Exclusion		Exclusion	
Evaluation Period Start	-183		-183	
Evaluation Period End	-1		-1	
Care Setting/PDX	Any		Any	
Position	Any		Any	
supply if inclusion/exclusion evaluation period includes dispensings	Evaluation period should search for only evidence of a dispensing date		Evaluation period should search for only evidence of a dispensing date	
Number of instances the criteria should be found in the evaluation period	1		1	
At Risk Time				
Minimum exposure episode duration	1		1	
Maximum exposure episode duration	N/A		N/A	
Risk window interval start	1		1	
Censor treatment episode at evidence of:	*Death; *DP end date; *Query end date; *Initiation of SGLT2i *Treatment end + 30 days *Disenrollment *Hospitalization *Initiation of DPP4i	*Death; *DP end date; *Query end date; *Initiation of GLP1RA *Treatment end + 30 days *Disenrollment *Hospitalization *Initiation of DPP4i	*Death; *DP end date; *Query end date; *Initiation of DPP4i *Treatment end + 30 days *Disenrollment *Hospitalization *Initiation of SGLT2i	*Death; *DP end date; *Query end date; *Initiation of GLP1RA *Treatment end + 30 days *Disenrollment *Hospitalization *Initiation of SGLT2i

	GLP-1RA vs. SGLT2i Comparison	GLP-1RA vs. DPP4i Comparison
Blackout Period	1 (excludes 'same-day' HOIs)	1 (excludes same-day HOIs)
Event/Outcome		
Event/Outcome	Intentional self harm	Intentional self harm
Incident event washout period	None	None
Care Setting	Any care setting	Any care setting
Principal Diagnosis	Any	Any
Exclude evidence of days supply if event washout includes dispensings	N/A	N/A
Event de-duplication	De-duplicates occurrences of the same event group on the same day	De-duplicates occurrences of the same event group on the same day
Forced supply to attach to dispensings	N/A	N/A
Propensity Score Model Parameters		
PS Model Label	glp_sglt_all	glp_dpp_all
Covariates	See covariates tab	See covariates tab
Firth Logistic Intercept Correct (FLIC) Method	No	No
High-dimensional Propensity Score	No	No
Output Kaplan Meier Plot	Yes	Yes
IPTW		
IP Weight	ATES (with stabilization)	ATES (with stabilization)
Weight truncation	0% truncation 1 percentile truncation 2.5 percentile truncation	0% truncation 1 percentile truncation 2.5 percentile truncation
Subgroup Analyses		
Stratifying variable	Psychiatric History	Psychiatric History
Subgroup Categories	Yes, No	Yes, No
Firth Logistic Intercept Correct (FLIC) Method	No	No
Re-estimate Propensity Score within subgroup	Yes	Yes
Stratifying variable	Prior self-harm	Prior self-harm
Subgroup Categories	Yes, No	Yes, No
Firth Logistic Intercept Correct (FLIC) Method	No	No

	GLP-1RA vs. SGLT2i Comparison	GLP-1RA vs. DPP4i Comparison
Re-estimate Propensity Score within subgroup	Yes	Yes

International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology (CPT) codes are provided by Optum360.
National Drug codes (NDC) codes are checked against First Data Bank's FDB MedKnowledge®.

Appendix CB: Specifications Defining Parameters for this Request

This report executed the Cohort Identification and Descriptive Analysis (CIDA) tool (version 13.0.1) to investigate whether there is an increased risk of intentional self-harm among diabetic patients who receive GLP-1 receptor agonists compared to SGLT-2 inhibitors and DPP4 inhibitors. This query includes additional programming to construct the 2+ dispensing cohort and to produce additional plots.

Query Period: 10/1/2015 - 09/30/2023
Coverage Requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 183 days
Enrollment gap: 45 days
Restrictions: None
Age groups: 18-24, 25-44, 45-64, 65-79, 80+
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Distribution of index-defining codes: Y
Freeze data: Y

GLP-1RA vs. SGLT2i IP/ED Comparison		GLP-1RA vs. SGLT2i 15 day Comparison	
glp_iped	sglt_iped	glp_15	sglt_15
GLP-1 receptor agonists	SGLT2 inhibitors	GLP-1 receptor agonists	SGLT2 inhibitors
First valid exposure episodes during query period		First valid exposure episodes during query period	
(-183, -1)		(-183, -1)	
GLP1RA SGLT2i DPP4i	GLP1RA SGLT2i DPP4i	GLP1RA SGLT2i DPP4i	GLP1RA SGLT2i DPP4i
Washout lookback period should search for only evidence of a dispensing date		Washout lookback period should search for only evidence of a dispensing date	
See stockpiling tab		See stockpiling tab	
No		No	
30 days		15 days	
30 days		15 days	
1 day		1 day	

GLP-1RA vs. SGLT2i IP/ED Comparison	GLP-1RA vs. SGLT2i 15 day Comparison
Any	Any
Any	Any
N/A	N/A
Yes	Yes
Type 2 diabetes diagnosis *(1 T2DM code AND 1 oral anti-diabetic dispensing)*	Type 2 diabetes diagnosis *(1 T2DM code AND 1 oral anti-diabetic dispensing)*
Inclusion	Inclusion
-183	-183
0	0
Any care setting	Any care setting
Any	Any
N/A	N/A
1	1
Other Diabetes diagnosis *(1 insulin code AND no code for antidiabetics)* OR *(1 T1DM code)* OR *(1 GDM/secondary DM code)*	Other Diabetes diagnosis *(1 insulin code AND no code for antidiabetics)* OR *(1 T1DM code)* OR *(1 GDM/secondary DM code)*
Exclusion	Exclusion
-183	-183

GLP-1RA vs. SGLT2i IP/ED Comparison		GLP-1RA vs. SGLT2i 15 day Comparison	
0 Any care setting Any N/A 1		0 Any care setting Any N/A 1	
SGLT2i DPP4i	GLP-1 RA DPP4i	SGLT2i DPP4i	GLP-1 RA DPP4i
Exclusion -183 0 Any Any Evaluation period should search for evidence of days supply 1		Exclusion -183 0 Any Any Evaluation period should search for evidence of days supply 1	
Pregnancy		Pregnancy	
Exclusion -183 days 0 Any Any N/A 1		Exclusion -183 days 0 Any Any N/A 1	
GLP-1 RA	SGLT2i	GLP-1 RA	SGLT2i
Exclusion -183 -1 Any		Exclusion -183 -1 Any	

GLP-1RA vs. SGLT2i IP/ED Comparison	GLP-1RA vs. SGLT2i 15 day Comparison
Any Evaluation period should search for only evidence of a dispensing date 1	Any Evaluation period should search for only evidence of a dispensing date 1
1 N/A 1 *Death; *DP end date; *Query end date; *Initiation of SGLT2i *Treatment end + 30 days *Disenrollment *Hospitalization *Initiation of DPP4i *Death; *DP end date; *Query end date; *Initiation of GLP1RA *Treatment end + 30 days *Disenrollment *Hospitalization *Initiation of DPP4i 1 (excludes same-day HOIs)	1 N/A 1 *Death; *DP end date; *Query end date; *Initiation of SGLT2i *Treatment end + 15 days *Disenrollment *Hospitalization *Initiation of DPP4i *Death; *DP end date; *Query end date; *Initiation of GLP1RA *Treatment end + 15 days *Disenrollment *Hospitalization *Initiation of DPP4i 1 (excludes 'same-day' HOIs)
Intentional self harm None *IP *ED Any N/A De-duplicates occurrences of the same event group on the same day N/A	Intentional self harm None Any care setting Any N/A De-duplicates occurrences of the same event group on the same day N/A
glp_sglt_iped	glp_sglt_15gap
See covariates tab	See covariates tab
No	No
No	No

GLP-1RA vs. SGLT2i IP/ED Comparison	GLP-1RA vs. SGLT2i 15 day Comparison
Yes	Yes
ATES (with stabilization) 0% truncation 1 percentile truncation 2.5 percentile truncation	ATES (with stabilization) 0% truncation 1 percentile truncation 2.5 percentile truncation
None	None
N/A	N/A
N/A	N/A
N/A	N/A
None	None
N/A	N/A
N/A	N/A
N/A	N/A

International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology (CPT) codes are provided by Optum360.
National Drug codes (NDC) codes are checked against First Data Bank's FDB MedKnowledge®.

Appendix CB: Specifications Defining Parameters for this Request

This report executed the Cohort Identification and Descriptive Analysis (CIDA) tool (version 13.0.1) to investigate whether there is an increased risk of intentional self-harm among diabetic patients who receive GLP-1 receptor agonists compared to SGLT-2 inhibitors and DPP4 inhibitors. This query includes additional programming to construct the 2+ dispensing cohort and to produce additional plots.

Query Period: 10/1/2015 - 09/30/2023
Coverage Requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 183 days
Enrollment gap: 45 days
Restrictions: None
Age groups: 18-24, 25-44, 45-64, 65-79, 80+
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Distribution of index-defining codes: Y
Freeze data: Y

GLP1RA 2+ dispensing vs. SGLT2i 2+ dispensing Comparison		GLP-1RA vs. SGLT2i Obesity and Diabetes	
glp_2disp	sglt_2disp	glp_obesdm	sglt_obesdm
2+ dispensings of GLP-1 receptor agonists	2+ dispensings of SGLT inhibitors	GLP-1 receptor agonists	SGLT2 inhibitors
2nd valid exposure episode during query period within 45 days of first dispensing		First valid exposure episodes during query period	
(-183, -1)		(-183, -1)	
GLP1RA SGLT2i DPP4i	GLP1RA SGLT2i DPP4i	GLP1RA SGLT2i DPP4i	GLP1RA SGLT2i DPP4i
Washout lookback period should search for only evidence of a dispensing date		Washout lookback period should search for only evidence of a dispensing date	
See stockpiling tab		See stockpiling tab	
Yes		No	
30 days		30 days	
30 days		30 days	
1 day		1 day	

GLP1RA 2+ dispensing vs. SGLT2i 2+ dispensing Comparison	GLP-1RA vs. SGLT2i Obesity and Diabetes
Any	Any
Any	Any
N/A	N/A
Yes	Yes
Type 2 diabetes diagnosis *(1 T2DM code AND 1 oral anti-diabetic dispensing)*	Type 2 Diabetes diagnosis *(1 T2DM code AND 1 oral anti-diabetic dispensing)*
Inclusion -183 0 Any care setting Any N/A 1	Inclusion -183 0 Any care setting Any N/A 1
	Obesity diagnosis
	Inclusion -183 0 Any care setting Any N/A 1
Other Diabetes diagnosis *(1 insulin code AND <u>no</u> code for antidiabetics)* OR *(1 T1DM code)* OR *(1 GDM/secondary DM code)*	Other Diabetes diagnosis *(1 insulin code AND <u>no</u> code for antidiabetics)* OR *(1 T1DM code)* OR *(1 GDM/secondary DM code)*
Exclusion -183	Exclusion -183

GLP1RA 2+ dispensing vs. SGLT2i 2+ dispensing Comparison		GLP-1RA vs. SGLT2i Obesity and Diabetes	
0 Any care setting Any N/A 1		0 Any care setting Any N/A 1	
SGLT2i DPP4i	GLP-1 RA DPP4i	SGLT2i DPP4i	GLP-1 RA DPP4i
Exclusion -183 0 Any Any Evaluation period should search for evidence of days supply 1		Exclusion -183 0 Any Any Evaluation period should search for evidence of days supply 1	
Pregnancy		Pregnancy	
Exclusion -183 days 0 Any Any N/A 1		Exclusion -183 days 0 Any Any N/A 1	
GLP-1 RA	SGLT2i	GLP-1 RA	SGLT2i
Exclusion -183 -1 Any		Exclusion -183 -1 Any	

GLP1RA 2+ dispensing vs. SGLT2i 2+ dispensing Comparison	GLP-1RA vs. SGLT2i Obesity and Diabetes
Any Evaluation period should search for only evidence of a dispensing date 1	Any Evaluation period should search for only evidence of a dispensing date 1
N/A N/A N/A *Death; *DP end date; *Query end date; *Initiation of SGLT2i *Treatment end + 30 days *Disenrollment *Hospitalization *Initiation of DPP4i *Death; *DP end date; *Query end date; *Initiation of GLP1RA *Treatment end + 30 days *Disenrollment *Hospitalization *Initiation of DPP4i 1 (excludes 'same-day' HOIs)	1 N/A 1 *Death; *DP end date; *Query end date; *Initiation of SGLT2i *Treatment end + 30 days *Disenrollment *Hospitalization *Initiation of DPP4i *Death; *DP end date; *Query end date; *Initiation of GLP1RA *Treatment end + 30 days *Disenrollment *Hospitalization *Initiation of DPP4i 1 (excludes 'same-day' HOIs)
Intentional self harm None Any care setting Any N/A De-duplicates occurrences of the same event group on the same day N/A	Intentional self harm None Any care setting Any N/A De-duplicates occurrences of the same event group on the same day N/A
glp_sglt_2dis	glp_sglt_obesdm
See covariates tab	See covariates tab
No	No
No	No

GLP1RA 2+ dispensing vs. SGLT2i 2+ dispensing Comparison	GLP-1RA vs. SGLT2i Obesity and Diabetes
Yes	Yes
ATES (with stabilization) 0% truncation 1 percentile truncation 2.5 percentile truncation	ATES (with stabilization) 0% truncation 1 percentile truncation 2.5 percentile truncation
None	None
N/A	N/A
N/A	N/A
N/A	N/A
None	None
N/A	N/A
N/A	N/A
N/A	N/A

International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology (CPT) codes are provided by Optum360.
National Drug codes (NDC) codes are checked against First Data Bank's FDB MedKnowledge®.

Appendix CC: Design Diagrams for this Request

Type 2 design diagram:
Cohort Def 1: *First valid exposure episodes during query period*



***Exclusion Criteria**
Window 1: *Comparator*
Window 2: *Type 1 diabetes AND NO antidiabetic agents, insulin, gestational diabetes, secondary diabetes*

****Inclusion Criteria**
Window: *Type 2 Diabetes AND oral antidiabetic; Obesity only for the combined diabetes/obesity cohort*

*****Covariates:**
Window I: *Age, year, race, sex, individual GLP-1RA product use (applicable only to GLP-1RA cohort)*
Window II: *Self-harm encounter, use of weight loss procedures*
Window III: *Combined comorbidity score, aDSCI, psychiatric history overall, psychiatric and psychotropic drugs, other psychiatric event, obesity, cognitive impairment, traumatic brain injury, cardiovascular disease, migrane, epilepsy, chronic pain, analgesic opiates, antipsychotics, anxiolytics/hypnotics, lithium and other mood stabilizers, antidepressants, anti-diabetic agents, other anti-obesity agents, mean health service utilization by care setting, count of dispensings*
Window IV: *Previous intentional self-harm encounter in any care setting*

Appendix CC: Design Diagrams for this Request

Type 2 design diagram:
Cohort Def 1: *First valid exposure episodes during query period*



***Exclusion Criteria**
Window 1: *Comparator*
Window 2: *Type 1 diabetes AND NO antidiabetic agents, insulin, gestational diabetes, secondary diabetes*

****Inclusion Criteria**
Window: *Type 2 Diabetes AND oral antidiabetic*

*****Covariates:**
Window I: *Age, year, race, sex*
Window II: *Self-harm encounter, use of weight loss procedures or medications*
Window III: *Combined comorbidity score, aDSCI, psychiatric history, psychiatric and psychotropic drugs, encounter for psychiatric event, other psychiatric disorders, anxiety, sleep disorder, substance abuse, obesity, cognitive impairment, traumatic brain injury, cardiovascular disease, analgesic opiates, antipsychotics, anxiolytics/hypnotics, lithium and other mood stabilizers, antidepressants, anti-diabetic agents, other anti-obesity agents, mean health service utilization by care setting, count of dispensings*
Window IV: *Previous intentional self-harm encounter in any care setting*